<SEC-DOCUMENT>0001193125-20-269768.txt : 20201015
<SEC-HEADER>0001193125-20-269768.hdr.sgml : 20201015
<ACCEPTANCE-DATETIME>20201015065841
ACCESSION NUMBER:		0001193125-20-269768
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		41
FILED AS OF DATE:		20201015
DATE AS OF CHANGE:		20201015

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Praxis Precision Medicines, Inc.
		CENTRAL INDEX KEY:			0001689548
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-249074
		FILM NUMBER:		201240290

	BUSINESS ADDRESS:	
		STREET 1:		101 MAIN STREET, #1210
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
		BUSINESS PHONE:		617-949-2220

	MAIL ADDRESS:	
		STREET 1:		101 MAIN STREET, #1210
		CITY:			CAMBRIDGE
		STATE:			MA
		ZIP:			02142
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>d945651ds1a.htm
<DESCRIPTION>S-1/A
<TEXT>
<HTML><HEAD>
<TITLE>S-1/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>As filed with the Securities and Exchange Commission on October 15, 2020 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right"><B>Registration No. 333-249074 </B></P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>SECURITIES AND EXCHANGE
COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>  <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>Amendment No. 2
</B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>to </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><I>Under </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><I>The Securities Act of 1933
</I></B></P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS
PRECISION MEDICINES, INC. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">47-5195942</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top" ALIGN="center"><B>(State or other jurisdiction of incorporation or organization)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Primary Standard Industrial Classification<BR>Code Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(I.R.S. Employer<BR>Identification Number)</B></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>One Broadway, 16<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Cambridge, MA 02142 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-300-8460</FONT></FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>(Address, including zip code, and telephone number,
including area code, of registrant&#146;s principal executive offices) </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Marcio Souza </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Chief Executive Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>One Broadway, 16<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> Floor </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Cambridge, MA 02142 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">617-300-8460</FONT></FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Richard A. Hoffman, Esq.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Jonathan L. Kravetz, Esq.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Edwin O&#146;Connor, Esq.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>John T. Rudy, Esq.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>William D. Collins, Esq.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Mintz, Levin, Cohn, Ferris, Glovsky&nbsp;&amp; Popeo, P.C.</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Goodwin Procter LLP</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>One Financial Center</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>100 Northern Avenue</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Boston, MA 02111</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Boston, MA 02210</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">542-6000</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(617) <FONT STYLE="white-space:nowrap">570-1000</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL"><B>Approximate date of commencement of proposed sale to the public: </B>As soon as practicable after the effective date of this
registration statement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the
Securities Act of 1933, as amended, check the following box.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL">If this Form is filed to register
additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the
Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large
accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company&#148; and &#147;emerging growth company&#148; in Rule <FONT STYLE="white-space:nowrap">12b-2</FONT> of the Exchange Act. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="bottom">Large&nbsp;Accelerated&nbsp;Filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;Filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="bottom">Non-Accelerated Filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;Reporting&nbsp;Company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging Growth Company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>Title of Each Class&nbsp;of Securities to be
Registered</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>Amount to
be<BR>Registered<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>Proposed&nbsp;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>Maximum</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>Offering&nbsp;Price</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>Per Share<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>Maximum Aggregate<BR>Offering&nbsp;Price<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>Amount&nbsp;of&nbsp;</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>Registration</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:7pt; font-family:ARIAL" ALIGN="center"><B>Fee<SUP
STYLE="font-size:85%; vertical-align:top">(4)</SUP></B></P></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Common Stock, par value $0.0001 per share</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">11,500,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$18.00</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$207,000,000</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$24,654</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Includes 1,500,000 shares that the underwriters have the option to purchase to cover over-allotments.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Estimated solely for the purpose of computing the registration fee in accordance with Rule&nbsp;457(a) under the
Securities Act of 1933, as amended. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Includes the aggregate offering price of 1,500,000 shares that the underwriters have the option to purchase to cover
over-allotments. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Calculated pursuant to Rule 457(a) under the Securities Act of 1933, as amended. $18,782 of this registration fee was
previously paid by the Registrant in connection with the filing of its Registration Statement on Form S-1 on September 25, 2020 and October 9, 2020. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a
further amendment that specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until this registration statement shall become effective
on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#d6284a">The information in this preliminary prospectus is not complete and may be changed. These
securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction
where the offer or sale is not permitted. </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"><FONT COLOR="#d6284a"><B>PROSPECTUS (Subject to Completion)</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT COLOR="#d6284a"><B>Dated October 15, 2020</B></FONT></TD></TR>
</TABLE>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #334998">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>10,000,000 Shares </B></P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g945651g52w82.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P>  <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">This is
the initial public offering of shares of our common stock. We are offering 10,000,000 shares of our common stock. Prior to this offering, there has been no public market for our common stock. We have applied to list our common stock on The Nasdaq
Global Select Market under the symbol &#147;PRAX.&#148; We expect that the initial public offering price of our common stock is expected to be between $17.00 and $18.00 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We are an &#147;emerging growth company&#148; under applicable Securities and Exchange Commission rules and will be subject to reduced public company reporting
requirements for this prospectus and future filings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved
of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Our business and an
investment in our common stock involve significant risks. These risks are described under the caption &#147;<A HREF="#rom945651_4">Risk Factors</A>&#148; beginning on page&nbsp;13 of this prospectus. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><I>Per&nbsp;Share</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><I>Total</I></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; line-height:16.0pt; font-size:10pt; font-family:ARIAL"><B>Public offering price</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; line-height:16.0pt; font-size:10pt; font-family:ARIAL"><B>Underwriting discounts(1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; line-height:16.0pt; font-size:10pt; font-family:ARIAL"><B>Proceeds, before expenses, to Praxis Precision Medicines, Inc.</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">See &#147;Underwriting (Conflicts of Interest)&#148; beginning on page&nbsp;222 of this prospectus for additional
information regarding underwriting compensation. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The underwriters may also purchase up to an additional 1,500,000 shares from us at the
public offering price, less the underwriting discount, within 30 days from the date of this prospectus to cover overallotments. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The underwriters expect to
deliver the shares against payment in New York, New York on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Book-running Managers </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="top"><B>Cowen</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Evercore ISI</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Piper Sandler</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Lead Manager </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:13pt; font-family:ARIAL" ALIGN="center"><B>Wedbush PacGrow
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I><FONT STYLE="white-space:nowrap">Co-Manager</FONT> </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>Blackstone Capital Markets </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom945651_1">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom945651_2">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom945651_3">SUMMARY CONSOLIDATED FINANCIAL DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom945651_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom945651_5">SPECIAL NOTE REGARDING FORWARD-LOOKING
STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom945651_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom945651_7">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">87</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom945651_8">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom945651_9">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom945651_10">SELECTED CONSOLIDATED FINANCIAL DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">95</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom945651_11">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
 AND RESULTS OF OPERATIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">97</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom945651_12">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom945651_13">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom945651_14">EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">190</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom945651_15">DIRECTOR COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom945651_16">CERTAIN RELATIONSHIPS AND RELATED PARTY
TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">201</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom945651_17">PRINCIPAL STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">207</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom945651_18">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">211</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom945651_19">SHARES ELIGIBLE FOR FUTURE SALE</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">216</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom945651_20">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS OF COMMON STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">218</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom945651_21">UNDERWRITING (CONFLICTS OF INTEREST)</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">222</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom945651_22">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">231</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom945651_23">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">231</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom945651_24">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">231</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom945651_25">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</A></P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom945651_26">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Through and including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2020 (25 days after the
commencement of this offering), all dealers effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the obligation of dealers to
deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">You should rely only on the
information contained in this prospectus or in any free writing prospectus we file with the Securities and Exchange Commission, or the SEC. Neither we nor the underwriters have authorized anyone to provide you with information other than that
contained in this prospectus or any free writing prospectus prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may
give you. We and the underwriters are offering to sell, and seeking offers to buy, common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the date on the front
cover page of this prospectus, or other earlier date stated in this prospectus, regardless of the time of delivery of this prospectus or of any sale of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For investors outside of the United States: We have not, and the underwriters have not, done anything that would permit this offering or possession or
distribution of this prospectus in any </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves
about, and observe any restrictions relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The market data and certain other statistical information used throughout this prospectus are based on independent industry publications, governmental
publications, reports by market research firms or other independent sources that we believe to be reliable sources. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from
sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We are responsible for all of the disclosure contained in this prospectus, and we believe that these sources are reliable; however, we
have not independently verified the information contained in such publications. While we are not aware of any misstatements regarding any third-party information presented in this prospectus, their estimates, in particular, as they relate to
projections, involve numerous assumptions, are subject to risks and uncertainties and are subject to change based on various factors, including those discussed under the section entitled &#147;Risk Factors&#148; and elsewhere in this prospectus.
Some data are also based on our good faith estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">-ii- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom945651_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>This summary highlights selected information contained elsewhere in this prospectus and does not contain all of the information that you should
consider in making your investment decision. Before investing in our common stock, you should carefully read this entire prospectus, including our consolidated financial statements and the related notes included elsewhere in this prospectus. You
should also consider, among other things, the matters described in the sections entitled &#147;Risk Factors,&#148; &#147;Business&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; in
each case appearing elsewhere in this prospectus. Unless the context otherwise requires, we use the terms &#147;Praxis,&#148; &#147;Company,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; in this prospectus to refer to Praxis Precision
Medicines, Inc. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Company Overview </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are a
clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal imbalance. Normal brain function requires a delicate balance of
excitation and inhibition in neuronal circuits, which, when dysregulated, can lead to abnormal function and disease. We are applying insights into the genetic mutations that drive excitation-inhibition imbalance in diseases to select biological
targets for severe pediatric epilepsies and more broadly for prevalent psychiatric diseases and neurologic disorders. We apply a deliberate and pragmatic precision approach, leveraging a suite of translational tools including novel transgenic and
predictive translational animal models and electrophysiology markers, to enable an efficient path to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> in patients. We have three product candidates
currently in clinical development. We intend to develop differentiated therapies that can deliver long-term benefits to human health by meaningfully impacting patients and society. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our insights into genetic mutations resulting in neuronal imbalance have enabled us to develop a pipeline addressing prevalent psychiatric and
neurologic conditions and rare diseases, with the ability to expand into additional indications. We have established a broad portfolio, including five disclosed programs across multiple CNS disorders, including depression, epilepsy, movement
disorders and pain syndromes. We expect multiple topline clinical trial readouts from our three clinical-stage product candidates prior to the end of 2021 and anticipate the launch of a new clinical development program in 2021. Below is a summary of
our portfolio of programs, organized by their initial therapeutic focus. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g945651g51s28.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left"><FONT STYLE="white-space:nowrap">PRAX-222</FONT> is a collaboration with Ionis Pharmaceuticals, Inc., or Ionis, and RogCon
Inc., or RogCon. Ionis is eligible to receive royalties as a percentage of net product sales worldwide in the low-20s. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We own global commercialization rights for all of our product candidates, and we are party to
collaboration and license agreements with Purdue Neuroscience Company, Ionis and RogCon, under which we could be obligated to pay certain fees, milestone and other conditional payments and cost reimbursements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">PRAX-114</FONT> </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We
are developing <FONT STYLE="white-space:nowrap">PRAX-114,</FONT> an extrasynaptic-preferring GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A </SUB>receptor positive allosteric modulator, or PAM, for the treatment of patients suffering from
major depressive disorder, or MDD, and perimenopausal depression, or PMD. <FONT STYLE="white-space:nowrap">PRAX-114</FONT> is under development as a potentially differentiated treatment as both a monotherapy and adjunctive therapy for both the acute
and maintenance setting. We have a multi-cohort, three-part Phase&nbsp;2a clinical trial ongoing in Australia, and in Part&nbsp;A of the trial, we observed marked improvements in depression scores in MDD patients within two weeks of treatment. We
expect complete topline data from Part B of the trial in the second half of 2021 and from longer-term dosing in MDD patients in Part C of the trial in the fourth quarter of 2020. We are planning to initiate a Phase&nbsp;2/3 trial in the
United&nbsp;States and Australia in the fourth quarter of 2020, which is intended to satisfy one of two registrational trials required by the U.S. Food and Drug Administration, or the FDA, to support clinical efficacy for the treatment of MDD, and
we expect topline data in the second half of 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">There is significant unmet medical need in MDD and PMD with over 22&nbsp;million individuals
suffering from depressive symptoms in the U.S. Current pharmacological interventions suffer from multiple shortcomings including slow onset of efficacy, low response rates and side effects that limit patient compliance. <FONT
STYLE="white-space:nowrap">PRAX-114</FONT> targets an increasingly well-understood neuronal circuit in the brain that we believe, when properly modulated, can result in a robust antidepressant effect with an advantageous safety and tolerability
profile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe that our <FONT STYLE="white-space:nowrap">PRAX-114</FONT> program has several advantages as compared to currently available
therapies and product candidates in the GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAM therapeutic class: </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Wider Therapeutic Window</B>. We have determined that <FONT STYLE="white-space:nowrap">PRAX-114</FONT> is an
approximately <FONT STYLE="white-space:nowrap">10.5-fold</FONT> more potent PAM of the extrasynaptic form of GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors compared to the synaptic form. By preferentially modulating
extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors, we believe <FONT STYLE="white-space:nowrap">PRAX-114</FONT> has the potential to mediate antidepressant and anxiolytic activity without the significant sedation
observed with less selective neuroactive steroids. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Patient-Centric Dosing.</B> We believe the ability to administer <FONT STYLE="white-space:nowrap">PRAX-114</FONT> with
or without food is key for clinical and commercial success in MDD and is critical for a patient-centric therapeutic, as many patients with depression suffer from appetite disturbance. We have observed fast absorption of <FONT
STYLE="white-space:nowrap">PRAX-114</FONT> within one to three hours of dosing and a robust pharmacokinetic, or PK, profile across multiple trials. Based on clinical findings to date, we believe that <FONT STYLE="white-space:nowrap">PRAX-114</FONT>
does not need to be taken with food to achieve therapeutic exposure, whereas other GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAMs may require food to achieve therapeutic exposure. </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Sustained Administration</B>. After consultation with the FDA and other stakeholders in MDD and PMD therapy, we designed
our Phase&nbsp;2/3 trial of <FONT STYLE="white-space:nowrap">PRAX-114</FONT> to include <FONT STYLE="white-space:nowrap">28-day</FONT> nightly dosing to evaluate patients at both 14 days to assess the rapidity and robustness of response and 28 days
to evaluate durability of effect. We believe that having a dosing paradigm consistent with the duration of depressive episodes will provide the most substantial benefit to patients in controlling their disease, further differentiating <FONT
STYLE="white-space:nowrap">PRAX-114</FONT> from other GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A </SUB>PAMs. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Indication Expansion.</B> Because <FONT STYLE="white-space:nowrap">PRAX-114</FONT> has demonstrated a novel pharmacology
and, to date, has a well-tolerated profile, we believe <FONT STYLE="white-space:nowrap">PRAX-114</FONT> is suitable for potential development across a wide-range of indications in psychiatry and neurology, providing sizable expansion opportunities
to explore in addition to MDD. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">PRAX-944</FONT> </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are developing <FONT STYLE="white-space:nowrap">PRAX-944,</FONT> a potentially differentiated selective small molecule inhibitor of <FONT
STYLE="white-space:nowrap">T-type</FONT> calcium channels, for the treatment of Essential Tremor, or ET. We have evaluated the safety and tolerability of <FONT STYLE="white-space:nowrap">PRAX-944</FONT> in over 150 healthy volunteers in five
separate clinical trials. In these trials, we have studied the safety of PRAX-944 modified release formulation with titration up to 120mg/day and no maximum tolerated dose, or MTD, has been identified. We are currently conducting a Phase 2a
proof-of-concept open-label trial in ET patients. Preliminary site data from five patients of the low dose cohort showed tremor reduction, which seems to compare favorably to the standard of care agents. We plan to announce topline data, including a
high dose cohort, in the first half of 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">There is a large body of clinical, preclinical and genetic evidence that points to the involvement of <FONT
STYLE="white-space:nowrap">T-type</FONT> calcium channels in the cerebello-thalamo-cortical circuit as a main driver of ET. ET is the most common movement disorder, affecting up to seven million patients in the United States, which is seven times
more individuals compared to Parkinson&#146;s tremor. ET is a progressive and debilitating movement disorder with action tremors that significantly disrupt daily living. There is a high unmet need for ET patients given the limited treatment options,
with only one approved pharmacotherapy that is poorly tolerated, resulting in high discontinuation rates and the need for invasive brain surgeries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Successful development of <FONT STYLE="white-space:nowrap">T-type</FONT> calcium channel modulators in ET likely requires a PK profile with a blunted
maximum drug exposure, or Cmax, and thoughtful clinical trial design and endpoint selection. We have designed our development program to include careful selection of clinical endpoints, a modified release formulation and dose titration strategy. We
believe our modified release formulation for <FONT STYLE="white-space:nowrap">PRAX-944</FONT> is positioned to be a differentiated therapy in ET. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Because of the gatekeeper role of T-type calcium channels in regulating neuronal firing patterns in multiple neuronal circuits, we believe <FONT
STYLE="white-space:nowrap">PRAX-944</FONT> is suitable for potential development across a wide-range of indications in psychiatry and neurology, providing sizable expansion opportunities in addition to ET. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">PRAX-562</FONT> </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our
lead rare disease product candidate and third clinical program, <FONT STYLE="white-space:nowrap">PRAX-562,</FONT> is the first selective, persistent sodium current blocker in development for the treatment of a broad range of rare, devastating CNS
disorders, such as severe pediatric epilepsy and adult cephalgia. To date, <FONT STYLE="white-space:nowrap">PRAX-562</FONT> has demonstrated pharmacological activity in <I><FONT STYLE="white-space:nowrap">in-vivo</FONT></I> models with significantly
improved tolerability, suggesting a potentially improved therapeutic index compared to other sodium channel blockers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have initiated a Phase 1
trial of <FONT STYLE="white-space:nowrap">PRAX-562</FONT> in Australia to evaluate the safety, tolerability, PK and effects on an EEG biomarker in up to 129 adult healthy volunteers. We anticipate Phase 1 single ascending dose, or SAD, topline
safety data in the fourth quarter of 2020. The clinical development plan for <FONT STYLE="white-space:nowrap">PRAX-562</FONT> encompasses exploring the broad potential for the mechanism of action in rare diseases through proof-of-concept trials in
Short-lasting Unilateral Neuralgiform headache attacks with Conjunctival injection and Tearing, or SUNCT, and Short-lasting Unilateral Neuralgiform headache with Autonomic symptoms, or SUNA, two rare types of cephalgia, and then expanding into a
range of rare pediatric Development and Epileptic Encephalopathies, or DEEs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Preclinical Programs </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition to our clinical programs, we have one preclinical program and one disclosed discovery program in development for severe genetic epilepsies.
We continue to evaluate additional rare disease program opportunities. We anticipate submitting an Investigational New Drug, or IND, application for one of these programs in the second half of 2021. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Our Approach </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each of our programs is based on four key principles that we believe will both increase the probability of success and allow us to efficiently translate
insights into high-impact therapies for patients and society: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><I>Focus on therapeutic targets identified through human genetics.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><I>Utilize translational tools to validate the potential of our targets and product candidates.</I>
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><I>Pursue efficient, rigorous clinical development paths to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> in humans.</I> </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><I>Apply patient-centric development strategies.</I> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Our Team and Investors </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have attracted a talented team of
scientists and researchers in genetics and biology, chemistry and translational medicine as well as business leaders with established track records of successfully executing innovative drug discovery and development programs. Our Chief Executive
Officer, Marcio Souza, most recently served as Chief Operating Officer at PTC Therapeutics, Inc. and was instrumental in the development and commercialization of multiple approved products while at NPS Pharmaceuticals, Inc., Shire Human Genetic
Therapies Inc. and Sanofi Genzyme Corporation. Our Chief Medical Officer, Bernard Ravina, M.D., previously Chief Medical Officer at Voyager Therapeutics, Inc., is a neurologist and movement disorder specialist who brings decades of neurologic drug
development experience from roles at Biogen, the University of Rochester and the NIH&#146;s Institute of Neurological Disorders and Stroke. Our Chief Financial Officer, Stuart Chaffee, Ph.D., <FONT STYLE="white-space:nowrap">co-founded</FONT> Kymera
Therapeutics, Inc. and has held multiple senior roles in finance, business development and corporate strategy at Biogen Inc., Zafgen, Inc. and Amgen Inc. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To date, we have raised approximately $210&nbsp;million from premier life science investment institutions, including Blackstone Life Sciences, Vida
Ventures, Novo Holdings, Eventide Asset Management, Avoro Capital Advisors, Surveyor Capital (a Citadel company), Point72, Cormorant Asset Management, Qatar Investment Authority (QIA), Irving Investors, Adage Capital Management, Verition Fund
Management, OCV Partners and Ample Plus Fund. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Our Strategy </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our goal is to translate genetic insights into high-impact therapies for millions of people suffering from rare or prevalent CNS disorders characterized
by neuronal imbalance. Key components of our strategy include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Advance <FONT STYLE="white-space:nowrap">PRAX-114</FONT> toward regulatory approval and commercialization as a
potentially differentiated monotherapy and adjunctive therapy for MDD and PMD in both acute and maintenance settings. </I> </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Advance <FONT STYLE="white-space:nowrap">PRAX-944</FONT> toward regulatory approval and commercialization as a
potentially differentiated therapy for ET. </I> </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Advance our three disclosed rare disease programs and build our franchise of candidates addressing rare diseases such as
DEEs based on precision medicine principles. </I> </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Maximize the value of our product candidates through select indication expansion.</I> </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Advance our understanding of genetics and neuronal imbalance to maintain our leadership and continue to build our
pipeline. </I> </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><I>Build a sales and marketing infrastructure to reach prescribers in the United States and maximize the reach of our
products globally, alone or in collaboration with others.</I> </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Risks Associated with Our Business </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our ability to implement our business strategy is subject to numerous risks, as more fully described in the section entitled &#147;Risk Factors&#148;
immediately following this prospectus summary. These risks include, among others: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We are a clinical-stage biopharmaceutical company and we have incurred significant losses since our inception. We
anticipate that we will continue to incur significant losses for the foreseeable future. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to
delay, reduce or eliminate our product discovery and development programs or commercialization efforts. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our business substantially depends upon the successful development of <FONT STYLE="white-space:nowrap">PRAX-114,</FONT> <FONT
STYLE="white-space:nowrap">PRAX-944</FONT> and <FONT STYLE="white-space:nowrap">PRAX-562.</FONT> If we are unable to obtain regulatory approval for, and successfully commercialize, <FONT STYLE="white-space:nowrap">PRAX-114,</FONT> <FONT
STYLE="white-space:nowrap">PRAX-944</FONT> or <FONT STYLE="white-space:nowrap">PRAX-562,</FONT> our business may be materially harmed. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Clinical development involves a lengthy, complex and expensive process, with an uncertain outcome. The outcome of
preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials, which to date have primarily been conducted in Australia and New Zealand, may not satisfy the
requirements of the FDA or comparable foreign regulatory authorities. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The markets for <FONT STYLE="white-space:nowrap">PRAX-114</FONT> for MDD and PMD,
<FONT STYLE="white-space:nowrap">PRAX-944</FONT> for ET, <FONT STYLE="white-space:nowrap">PRAX-562</FONT> for multiple rare neurological conditions and any other product candidates we may develop may be smaller than we expect. </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their
regulatory approval, limit their commercial potential or result in significant negative consequences following regulatory approval, if obtained. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">On May 20, 2020, we received a cease and desist demand letter from Sage Therapeutics, Inc., or Sage, claiming that we
improperly accessed and benefited from Sage confidential information in connection with the in-license of our PRAX-114 development program as a result of our employment or engagement of former Sage employees and consultants. While we believe there
is no merit to these claims and intend to defend our position, an adverse result could harm our business and result of operations. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We face significant competition in an environment of rapid technological and scientific change, and there is a possibility
that our competitors may achieve regulatory approval before us or develop therapies that are safer, more advanced or more effective than ours, which may negatively impact our ability to successfully market or commercialize any product candidates we
may develop and ultimately harm our financial condition. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We expect to depend on collaborations with third parties for the research, development and commercialization of certain of
the product candidates we may develop. If any such collaborations are not successful, we may not be able to realize the market potential of those product candidates. </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our success depends in part on our ability to protect our intellectual property. It is difficult and costly to protect our
proprietary rights and technology, and we may not be able to ensure their protection. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We have entered into, and may enter into, license or other collaboration agreements that impose certain obligations on us.
If we fail to comply with our obligations under such agreements with third parties, we could lose license rights that may be important to our business. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our executive officers, directors and their affiliates and our principal stockholders own a significant percentage of our
stock and will be able to exert significant control over matters subject to stockholder approval. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Corporate Information </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We were incorporated under the laws of the State of Delaware on September&nbsp;22, 2015. Our principal executive office is located at One Broadway, 16<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> Floor, Cambridge, MA 02142, and our telephone number is (617) <FONT STYLE="white-space:nowrap">300-8460.</FONT> Our website address is www.praxismedicines.com. We do not incorporate the information
on or accessible through our website into this prospectus, and you should not consider any information on, or that can be accessed through, our website as part of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Implications of Being an Emerging Growth Company </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are an
&#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act, as amended, or the JOBS Act, enacted in April 2012. As an emerging growth company, we may take advantage of specified reduced disclosure and other
requirements that are otherwise applicable generally to public companies. These provisions include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">only two years of audited financial statements in addition to any required unaudited interim financial statements with
correspondingly reduced &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; disclosure in the registration statement for our initial public offering; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reduced disclosure about our executive compensation arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">no <FONT STYLE="white-space:nowrap">non-binding</FONT> advisory votes on executive compensation or golden parachute
arrangements; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may take advantage of these exemptions for up to five years or such earlier time that we are no longer an emerging growth
company. We would cease to be an emerging growth company on the date that is the earliest of (i)&nbsp;the last day of the fiscal year in which we have total annual gross revenues of $1.07&nbsp;billion or more; (ii)&nbsp;the last day of our fiscal
year following the fifth anniversary of the date of the completion of this offering; (iii)&nbsp;the date on which we have issued more than $1&nbsp;billion in nonconvertible debt during the previous three years; or (iv)&nbsp;the date on which we are
deemed to be a large accelerated filer under the rules of the U.S. Securities and Exchange Commission. We may choose to take advantage of some but not all of these exemptions. We have taken advantage of reduced reporting requirements in the
registration statement of which this prospectus is a part. Accordingly, the information contained herein may be different from the information you receive from other public companies in which you hold stock. Additionally, the JOBS Act provides that
an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This allows an emerging growth company to delay the adoption of certain accounting standards until those standards
would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, while we are an emerging growth company we will not be subject to new or revised accounting standards at the same time that they become
applicable to other public companies that are not emerging growth companies. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom945651_2"></A>THE OFFERING </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Common stock offered by us </P></TD>
<TD>10,000,000 shares. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Common stock to be outstanding immediately after this offering </P></TD>
<TD>36,749,675 shares (38,249,675 shares if the underwriters exercise their option to purchase additional shares in full). </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Underwriters&#146; option to purchase additional shares </P></TD>
<TD>We have granted a <FONT STYLE="white-space:nowrap">30-day</FONT> option to the underwriters to purchase up to an aggregate of 1,500,000 additional shares of common stock from us to cover over-allotments, if any, at the public offering price,
less underwriting discounts and commissions, on the same terms as set forth in this prospectus. </TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Use of proceeds </P></TD>
<TD>We estimate that we will receive net proceeds from the sale of shares of our common stock in this offering of approximately $159.5&nbsp;million, or $183.9&nbsp;million if the underwriters exercise their option to purchase additional shares in
full, assuming an initial public offering price of $17.50 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering
expenses payable by us. The principal purposes of this offering are to create a public market for our common stock and thereby facilitate future access to the public equity markets, increase our visibility in the marketplace and obtain additional
capital. We currently intend to use the net proceeds from this offering along with cash on hand to (i)&nbsp;advance <FONT STYLE="white-space:nowrap">PRAX-114</FONT> into and through the completion of our Phase&nbsp;2/3 trial in MDD, which is
intended to satisfy one of two registrational trials required by the FDA to support clinical efficacy, and to complete Part&nbsp;B (PMD) and Part&nbsp;C (longer-term dosing in MDD) of our ongoing Phase&nbsp;2a clinical trial for PRAX-114;
(ii)&nbsp;complete our ongoing Phase&nbsp;2a clinical trial and a Phase&nbsp;2/3 randomized, controlled clinical trial for PRAX-944 in ET; (iii)&nbsp;complete our ongoing Phase&nbsp;1 healthy volunteer trial and the first patient trial for PRAX-562
and (iv)&nbsp;advance other programs in our pipeline and support working capital and other general corporate purposes. For a more complete description of our intended use of the proceeds from this offering, see &#147;Use of Proceeds.&#148;
</TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Risk factors </P></TD>
<TD>You should carefully read the &#147;Risk Factors&#148; section of this prospectus for a discussion of factors that you should consider before deciding to invest in our common stock. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Conflicts of Interest </P></TD>
<TD>Certain affiliates of Blackstone Securities Partners L.P., an underwriter in this offering, beneficially own more than 10% of our outstanding preferred equity prior to the consummation of this offering. As a result, Blackstone Securities
Partners L.P. is deemed to have a &#147;conflict of interest&#148; within the meaning of Rule 5121 of the Financial Industry Regulatory Authority, Inc., or FINRA Rule 5121. Accordingly, this offering is being made in compliance with the applicable
requirements of FINRA Rule 5121. A qualified independent underwriter is not necessary for this offering pursuant to FINRA Rule 5121(a)(1)(A). See &#147;Underwriting (Conflicts of Interest).&#148; </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Directed Share Program </P></TD>
<TD>At our request, the underwriters have reserved for sale, at the initial public offering price, up to 5% of the shares of our common stock offered by this prospectus (excluding the shares of common stock that may be issued upon the
underwriters&#146; exercise of their over-allotment option), for sale at the public offering price to individuals, including our officers, directors and employees, as well as friends and family members of our officers and directors. If purchased by
persons who are not officers or directors, the shares will not be subject to a lock-up restriction. If purchased by any officer or director, the shares will be subject to a 180-day lock-up restriction. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="49%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The number of shares available for sale to the general public, referred to as the general public shares, will be reduced to the extent
that these persons purchase all or a portion of the reserved shares. Any reserved shares not so purchased will be offered by the underwriters to the general public on the same basis as the other shares offered by this prospectus. Likewise, to the
extent demand by these persons exceeds the number of shares reserved for sale in the program, and there are remaining shares available for sale to these persons after the general public shares have first been offered for sale to the general public,
then such remaining shares may be sold to these persons at the discretion of the underwriters. For further </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="49%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:10pt; font-family:ARIAL">
information regarding our directed share program, see &#147;Certain Relationships and Related Party Transactions&#148; and &#147;Underwriting (Conflicts of Interest).&#148; </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="49%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Proposed Nasdaq Global Select Market symbol </P></TD>
<TD>&#147;PRAX&#148; </TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The number of shares of our common stock after this offering is based on 26,749,675 shares of our common
stock issued as of September&nbsp;30, 2020, including 25,067,977 shares of our common stock issuable upon the automatic conversion of all outstanding shares of our preferred stock upon the closing of this offering and 8,763 shares of unvested
restricted common stock as of September&nbsp;30, 2020, and excludes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">5,814,944 shares of common stock issuable upon the exercise of stock options outstanding as of September&nbsp;30, 2020
under the 2017 Stock Incentive Plan, at a weighted average exercise price of $6.20 per share; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">6,051 shares of common stock reserved for future issuance as of September&nbsp;30, 2020 under the 2017 Stock Incentive
Plan, any unissued shares of which will cease to be available for issuance upon the completion of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">3,271,028 shares of our common stock that will become available for future issuance under the 2020 Stock Option and
Incentive Plan, or the 2020 Plan, upon the effectiveness of the registration statement of which this prospectus forms a part (including 37,615 shares of our common stock issuable upon the exercise of stock options we have agreed to grant under our
2020 Plan upon the effectiveness of the registration statement of which this prospectus is a part, at an exercise price equal to the initial public offering price); and </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">327,102 shares of our common stock that will become available for future issuance under the 2020 Employee Stock Purchase
Plan upon the effectiveness of the registration statement of which this prospectus forms a part. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Unless otherwise indicated, all
information in this prospectus reflects or assumes the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the filing of our amended and restated certificate of incorporation upon the closing of this offering and the effectiveness
of our amended and restated <FONT STYLE="white-space:nowrap">by-laws</FONT> upon the effectiveness of the registration statement of which this prospectus is a part; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the automatic conversion of all outstanding shares of our preferred stock into an aggregate of 25,067,977 shares of common
stock upon the closing of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">no exercise of outstanding options described above; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a one-for-2.14 reverse split of our common stock effected on October&nbsp;8, 2020; and </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">no exercise by the underwriters of their option to purchase up to 1,500,000 additional shares of common stock in this
offering. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom945651_3"></A>SUMMARY CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>You should read the following summary consolidated financial data together with our consolidated financial statements and unaudited interim condensed consolidated
financial statements and the related notes appearing elsewhere in this prospectus and the &#147;Selected Consolidated Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148;
sections of this prospectus. We have derived the consolidated statement of operations data for the years ended December&nbsp;31, 2018 and 2019 from our audited consolidated financial statements appearing elsewhere in this prospectus. The
consolidated statement of operations data for the six months ended June 30, 2019 and 2020 and the consolidated balance sheet data as of June 30, 2020 have been derived from our unaudited condensed consolidated financial statements appearing
elsewhere in this prospectus and have been prepared on the same basis as the audited consolidated financial statements. In the opinion of management, the unaudited data reflects all adjustments, consisting only of normal recurring adjustments,
necessary for a fair statement of the financial information in those statements. Our historical results are not necessarily indicative of the results that may be expected in any future period and our operating results for the six months ended June
30, 2020 are not necessarily indicative of the results that may be expected for the full year ended December 31, 2020 or any other interim periods or any future year or period. </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>YEAR ENDED</B><br><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SIX MONTHS ENDED</B><br><B>JUNE 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(In thousands, except share</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>and per share data)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Consolidated Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">18,820</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">29,557</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">14,512</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">15,918</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,899</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">6,232</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,129</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4,121</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">22,719</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">35,789</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">17,641</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">20,039</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(22,719</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(35,789</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(17,641</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(20,039</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(3,648</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(3,683</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss before provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(26,402</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(35,596</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(17,518</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(19,906</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(84</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(26,535</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(35,512</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(17,518</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(19,898</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accretion and cumulative dividends on redeemable convertible preferred
stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(2,296</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(5,170</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(2,184</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(4,103</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss on conversion of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(392</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Gain on repurchase of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">493</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(29,223</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(40,682</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:ARIAL">$</P></TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">(19,702</P></TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:ARIAL">)&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:ARIAL">$</P></TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">(23,508</P></TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:ARIAL">)&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>YEAR ENDED</B><br><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SIX MONTHS ENDED</B><br><B>JUNE 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(In thousands, except share</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>and per share data)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share attributable to common stockholders, basic and
diluted(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(22.52</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(26.60</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:ARIAL">$</P></TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">(13.38</P></TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:ARIAL">)&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:ARIAL">$</P></TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">(14.37</P></TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:ARIAL">)&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted average common shares outstanding, basic and diluted(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,297,633</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,529,629</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:ARIAL">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">1,472,484</P></TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:ARIAL">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:ARIAL">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right">1,635,913</P></TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE="font-size:0pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:ARIAL">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net loss per share attributable to common stockholders, basic and
diluted (unaudited)(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(2.68</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(1.16</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma weighted average common shares outstanding, basic and diluted
(unaudited)(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">13,270,761</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">17,177,274</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">See Note 13 to our consolidated financial statements and Note 9 to our unaudited interim condensed consolidated financial
statements appearing elsewhere in this prospectus for details on the calculation of basic and diluted net loss per share attributable to common stockholders and unaudited pro forma basic and diluted net loss per share attributable to common
stockholders. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="61%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AS OF JUNE 30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ACTUAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PRO&nbsp;FORMA(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PRO FORMA<BR>AS&nbsp;ADJUSTED(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">19,748</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">129,998</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">289,461</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Working capital(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">12,283</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">122,533</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">282,367</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">22,653</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">132,903</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">291,981</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">118,190</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(104,085</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(104,085</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(104,085</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(104,084</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">124,356</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">283,806</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">We define working capital as current assets less current liabilities. See our consolidated financial statements and
unaudited interim condensed consolidated financial statements and related notes appearing elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The pro forma consolidated balance sheet data give effect to: (i)&nbsp;the sale and issuance of 19,444,453 shares of our
Series&nbsp;C-1 redeemable convertible preferred stock in the third quarter of 2020 for gross cash proceeds of $110.3&nbsp;million and (ii)&nbsp;the automatic conversion of all outstanding shares of our redeemable convertible preferred stock,
including our Series&nbsp;C-1 redeemable convertible preferred stock, into an aggregate of 25,067,977 shares of common stock upon the consummation of this offering. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The pro forma as adjusted balance sheet data give further effect to the issuance and sale of 10,000,000 shares of our
common stock in this offering at an assumed initial public offering price of $17.50 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions
and estimated offering expenses payable by us. The pro forma as adjusted information discussed above is illustrative only and will change based on the actual initial public offering price and other terms of this offering determined at pricing. A
$1.00 increase (decrease) in the assumed initial public offering price of $17.50 per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each
of cash and cash equivalents, working capital, total assets and total stockholders&#146; (deficit) equity by $9.3 million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and
after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. An increase (decrease) of 1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus,
would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, working capital, total assets and total stockholders&#146; (deficit) equity by $16.3&nbsp;million, assuming no change in the assumed initial public
offering price per share and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom945651_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the following risks and uncertainties, together with all
other information in this prospectus, including our consolidated financial statements and unaudited interim condensed consolidated financial statements and related notes and &#147;Management&#146;s Discussion and Analysis of Financial Condition and
Results of Operations,&#148; before investing in our common stock. Any of the risk factors we describe below could adversely affect our business, financial condition or results of operations. The market price of our common stock could decline if one
or more of these risks or uncertainties actually occur, causing you to lose all or part of the money you paid to buy our common stock. Additional risks that we currently do not know about or that we currently believe to be immaterial may also impair
our business. Certain statements below are forward-looking statements. See the section titled &#147;Special Note Regarding Forward-Looking Statements&#148; appearing elsewhere in this prospectus. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Risks Related to Our Financial Position and Need for Additional Capital </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are a clinical-stage biopharmaceutical company and we have incurred significant losses since our inception. We anticipate that we will continue to incur
significant losses for the foreseeable future. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Investment in biopharmaceutical product development is highly speculative because it entails
substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become commercially viable. We have no products
approved for commercial sale and have not generated any revenue to date, and we will continue to incur significant research and development and other expenses related to our clinical development and ongoing operations. As a result, we are not
profitable and have incurred losses in each period since our inception. Since our inception, we have devoted substantially all of our financial resources and efforts to research and development, including preclinical studies and our clinical trials.
Our financial condition and operating results, including net losses, may fluctuate significantly from quarter to quarter and year to year. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future
operating performance. Additionally, net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders&#146; (deficit) equity and working capital. Our net losses were $35.5&nbsp;million and
$26.5&nbsp;million for the years ended December&nbsp;31, 2019 and 2018, respectively, and $19.9 million and $17.5 million for the six months ended June 30, 2020 and 2019, respectively. As of June 30, 2020, we had an accumulated deficit of $104.1
million. We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase as we continue our research and development of, and seek regulatory approvals for our product candidates in our initial and
potential additional indications as well as for other product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We anticipate that our expenses will increase substantially if and as we:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">continue to develop and conduct clinical trials, including in expanded geographies such as the United States or Europe, for
<FONT STYLE="white-space:nowrap">PRAX-114,</FONT> <FONT STYLE="white-space:nowrap">PRAX-944</FONT> and <FONT STYLE="white-space:nowrap">PRAX-562</FONT> for our initial and potential additional indications; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">initiate and continue research and development, including preclinical, clinical, and discovery efforts for any future
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">seek to identify additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">seek regulatory approvals for <FONT STYLE="white-space:nowrap">PRAX-114,</FONT>
<FONT STYLE="white-space:nowrap">PRAX-944</FONT> and <FONT STYLE="white-space:nowrap">PRAX-562,</FONT> or any other product candidates that successfully complete clinical development; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">add operational, financial and management information systems and personnel, including personnel to support our product
candidate development and help us comply with our obligations as a public company; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">hire and retain additional personnel, such as clinical, quality control, scientific, commercial and administrative
personnel; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">maintain, expand and protect our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establish sales, marketing, distribution, manufacturing, supply chain and other commercial infrastructure in the future to
commercialize various products for which we may obtain regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">add equipment and physical infrastructure to support our research and development; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and technologies;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">incur increased costs as a result of operating as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our expenses could increase beyond our expectations if we are required by the U.S. Food and Drug Administration, or the FDA, or other regulatory
authorities to perform clinical trials in addition to those that we currently expect, or if there are any delays in establishing appropriate manufacturing arrangements for or in completing our clinical trials or the development of any of our product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We will need substantial additional funding, and if we are unable to raise capital when needed, we could be forced to delay, reduce or eliminate
our product discovery and development programs or commercialization efforts. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our operations have consumed substantial amounts of cash since
inception. We expect to continue to spend substantial amounts to continue the preclinical and clinical development of our current and future programs. If we are able to gain marketing approval for product candidates that we develop, including any
indication for which we are developing or may develop <FONT STYLE="white-space:nowrap">PRAX-114,</FONT> <FONT STYLE="white-space:nowrap">PRAX-944</FONT> and <FONT STYLE="white-space:nowrap">PRAX-562,</FONT> we will require significant additional
amounts of cash in order to launch and commercialize such product candidates to the extent that such launch and commercialization are not the responsibility of a future collaborator that we may contract with in the future. In addition, other
unanticipated costs may arise in the course of our development efforts. Because the design and outcome of our planned and anticipated clinical trials is highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully
complete the development and commercialization of any product candidates we develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our future capital requirements depend on many factors,
including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the scope, progress, results and costs of researching and developing <FONT STYLE="white-space:nowrap">PRAX-114,</FONT> <FONT
STYLE="white-space:nowrap">PRAX-944</FONT> and <FONT STYLE="white-space:nowrap">PRAX-562</FONT> for our initial and potential additional indications, as well as other product candidates we may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing and uncertainty of, and the costs involved in, obtaining marketing approvals for
<FONT STYLE="white-space:nowrap">PRAX-114,</FONT> <FONT STYLE="white-space:nowrap">PRAX-944</FONT> and <FONT STYLE="white-space:nowrap">PRAX-562</FONT> for our initial and potential additional indications, and other product candidates we may develop
and pursue; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of future product candidates that we may pursue and their development requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of jurisdictions in which we plan to seek regulatory approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">if approved, the costs of commercialization activities for <FONT STYLE="white-space:nowrap">PRAX-114,</FONT> <FONT
STYLE="white-space:nowrap">PRAX-944</FONT> and <FONT STYLE="white-space:nowrap">PRAX-562</FONT> for any approved indications, or any other product candidate that receives regulatory approval to the extent such costs are not the responsibility of any
future collaborators, including the costs and timing of establishing product sales, marketing, distribution and manufacturing capabilities; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">subject to receipt of regulatory approval, revenue, if any, received from commercial sales of <FONT
STYLE="white-space:nowrap">PRAX-114,</FONT> <FONT STYLE="white-space:nowrap">PRAX-944</FONT> and <FONT STYLE="white-space:nowrap">PRAX-562</FONT> for any approved indications or any other product candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the extent to which we <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire rights to other products, product
candidates or technologies; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our headcount growth and associated costs as we expand our research and development, increase our office space, and
establish a commercial infrastructure; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs of preparing, filing and prosecuting patent applications, maintaining and protecting our intellectual property
rights, including enforcing and defending intellectual property related claims; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ongoing costs of operating as a public company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We cannot be certain that additional funding will be available on acceptable terms, or at all. We have no committed source of additional capital and if
we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and
development initiatives. Any of our current or future license agreements may also be terminated if we are unable to meet the payment or other obligations under the agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe that the net proceeds from this offering, together with our existing cash and cash equivalents as of June&nbsp;30, 2020 and the
$110.3&nbsp;million gross cash proceeds from the sale and issuance of our Series&nbsp;C-1 redeemable convertible preferred stock, will enable us to fund our operating expenses and capital expenditure requirements through at least the next 18 months.
Our estimate may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Further, changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster
than we currently anticipate, and we may need to seek additional funds sooner than planned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Raising additional capital may cause dilution to our
stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We expect our expenses
to increase in connection with our planned operations. Unless and until we can generate a substantial amount of revenue from our product candidates, we expect to finance our future cash needs through public or private equity offerings, debt
financings, collaborations, licensing arrangements or other sources, or any combination of the foregoing. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have
sufficient funds for our current or future operating plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To the extent that we raise additional capital through the sale of common stock,
convertible securities or other equity securities, your ownership interest may be diluted, and the terms of these securities could include liquidation or other preferences and anti-dilution protections that could adversely affect your rights as a
common stockholder. In addition, debt financing, if available, may result in fixed payment obligations and may involve agreements that include restrictive covenants that limit our ability to take specific actions, such as incurring additional debt,
making capital expenditures, creating liens, redeeming stock or declaring dividends, that could adversely impact our ability to conduct our business. In addition, securing financing could require a substantial amount of time and attention from our
management and may divert a disproportionate amount of their attention away from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our management&#146;s ability to
oversee the development of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we raise additional funds through collaborations or marketing, distribution, licensing and
royalty arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional
funds when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market
ourselves. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are in the early stages of clinical drug development and have a very limited operating history and no
products approved for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are a clinical-stage biopharmaceutical company with a very limited operating history, focused on translating genetic insights into the development of
high-impact therapies for people with prevalent, as well as rare, CNS disorders characterized by neuronal imbalance. We commenced operations in 2016, have no products approved for commercial sale and have not generated any revenue from product
sales. Drug development is a highly uncertain undertaking and involves a substantial degree of risk. We are conducting Phase 1 or Phase 2a clinical trials for our <FONT STYLE="white-space:nowrap">PRAX-114,</FONT>
<FONT STYLE="white-space:nowrap">PRAX-944</FONT> and <FONT STYLE="white-space:nowrap">PRAX-562</FONT> programs, and have not initiated clinical trials for any of our other current product candidates. To date, our clinical trials have been conducted
only in Australia and New Zealand, and we have not initiated or completed a pivotal clinical trial, obtained marketing approval for any product candidates, manufactured a commercial scale product or arranged for a third party to do so on our behalf,
or conducted sales and marketing activities necessary for successful product commercialization. Our short operating history as a company makes any assessment of our future success and viability subject to significant uncertainty. We will encounter
risks and difficulties frequently experienced by early-stage biopharmaceutical companies in rapidly evolving fields, and we have not yet demonstrated an ability to successfully overcome such risks and difficulties. If we do not address these risks
and difficulties successfully, our business will suffer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Drug development is a highly uncertain undertaking and involves a substantial degree of risk.
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have no products approved for commercial sale. To obtain revenues from the sales of our product candidates that are significant or large
enough to achieve profitability, we must succeed, either alone or with third parties, in developing, obtaining regulatory approval for, manufacturing, and marketing therapies with significant commercial success. Our ability to generate revenue and
achieve profitability depends on many factors, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">completing research and preclinical and clinical development of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtaining regulatory approvals and marketing authorizations for product candidates for which we successfully complete
clinical development and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">developing a sustainable and scalable manufacturing process for our product candidates, as well as establishing and
maintaining commercially viable supply relationships with third parties that can provide adequate products and services to support clinical activities and commercial demand of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">identifying, assessing, acquiring and/or developing new product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">launching and successfully commercializing product candidates for which we obtain regulatory and marketing approval, either
by collaborating with a partner or, if launched independently, by establishing a sales, marketing and distribution infrastructure; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtaining and maintaining an adequate price for our product candidates in the countries where our products are
commercialized; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtaining adequate reimbursement for our product candidates from payors; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">obtaining market acceptance of our product candidates as viable treatment options; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">addressing any competing technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">receiving milestone and other payments under any future collaboration arrangements; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">maintaining, protecting, expanding and enforcing our portfolio of intellectual property rights, including patents, trade
secrets and <FONT STYLE="white-space:nowrap">know-how;</FONT> and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">attracting, hiring and retaining qualified personnel. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Because of the numerous risks and uncertainties associated with drug development, we are unable to
predict the timing or amount of our expenses, or when we will be able to generate any meaningful revenue or achieve or maintain profitability, if ever. In addition, our expenses could increase beyond our current expectations if we are required by
the FDA or foreign regulatory agencies to perform studies in addition to those that we currently anticipate, or if there are any delays in any of our or our future collaborators&#146; clinical trials or the development of any of our product
candidates. Even if one or more of our product candidates is approved for commercial sale, we anticipate incurring significant costs associated with launching and commercializing any approved product candidate and ongoing compliance efforts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Due to the significant resources required for the development of our programs, and depending on our ability to access capital, we must prioritize development of
certain product candidates. Moreover, we may expend our limited resources on programs that do not yield a successful product candidate or fail to capitalize on product candidates or indications that may be more profitable or for which there is a
greater likelihood of success. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We currently have three product candidates in clinical trials. Together, the development of these programs
and product candidates require significant capital investment. Due to the significant resources required for the development of our programs and product candidates, we must focus our programs and product candidates on specific diseases and disease
pathways and decide which product candidates to pursue and advance and the amount of resources to allocate to each. Our drug development strategy is to clinically test and seek regulatory approval for our product candidates in indications in which
we believe there is the most evidence that we will be able to efficiently generate <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> data. We then intend to expand to clinical testing and seek
regulatory approvals in other neurological and psychiatric disease indications based on genetic and mechanistic overlap with the primary indication. However, even if our product candidates are able to gain regulatory approval in one indication,
there is no guarantee that we will be able to expand to other indications, and we may expend significant resources in seeking such approvals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In
addition, we may focus resources on pursuing indications outside of neurology based on the same strategic approach (e.g., human genetics, mechanistic rationale, the availability of translational tools, clinical development path, commercial
opportunity) we utilize in determining on which of our discovery programs to focus. Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular product candidates or
therapeutic areas may not lead to the development of any viable commercial product and may divert resources away from better opportunities. Additionally, we may reprioritize product candidate development plans and activities at any time and delay or
terminate development of any product candidates we identify. For example, we have prioritized developing <FONT STYLE="white-space:nowrap">PRAX-144</FONT> for major depressive disorder, or MDD, ahead of perimenopausal depression, or PMD. Similarly,
our potential decisions to delay, terminate, or collaborate with third parties in respect of certain programs may subsequently also prove to be suboptimal and could cause us to miss valuable opportunities. If we make incorrect determinations
regarding the viability or market potential of any of our programs or product candidates or misread trends in the biopharmaceutical industry, in particular for neurological and psychiatric diseases, our business, financial condition, and results of
operations could be materially adversely affected. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or
other diseases and disease pathways that may later prove to have greater commercial potential than those we choose to pursue or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty arrangements in
cases in which it would have been advantageous for us to invest additional resources to retain sole development and commercialization rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Risks Related to Research and Development and the Biopharmaceutical Industry </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our business substantially depends upon the successful development of <FONT STYLE="white-space:nowrap">PRAX-114,</FONT>
<FONT STYLE="white-space:nowrap">PRAX-944</FONT> and <FONT STYLE="white-space:nowrap">PRAX-562.</FONT> If we are unable to obtain regulatory approval for, and successfully commercialize, <FONT STYLE="white-space:nowrap">PRAX-114,</FONT> <FONT
STYLE="white-space:nowrap">PRAX-944</FONT> or <FONT STYLE="white-space:nowrap">PRAX-562,</FONT> our business may be materially harmed. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We
currently have no products approved for sale and are investing the majority of our efforts and financial resources in the development of our lead product candidates, <FONT STYLE="white-space:nowrap">PRAX-114</FONT> for the treatment of MDD and PMD
and <FONT STYLE="white-space:nowrap">PRAX-944</FONT> for the treatment of Essential Tremor, or ET. We have also commenced a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human</FONT></FONT> trial of <FONT
STYLE="white-space:nowrap">PRAX-562</FONT> in healthy volunteers. We plan to initiate a Phase 2 trial for Short-lasting Unilateral Neuralgiform headache with Conjunctival injection and Tearing, or SUNCT, and Short-lasting Unilateral Neuralgiform
headache attacks with Autonomic symptoms, or SUNA, to demonstrate clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> and then subsequently expand into severe pediatric epilepsies. Successful
continued development and ultimate regulatory approval of <FONT STYLE="white-space:nowrap">PRAX-114,</FONT> <FONT STYLE="white-space:nowrap">PRAX-944</FONT> and <FONT STYLE="white-space:nowrap">PRAX-562</FONT> for our initial and potential
additional indications is critical to the future success of our business. We will need to raise sufficient funds for, and successfully enroll and complete, our clinical development programs of <FONT STYLE="white-space:nowrap">PRAX-114</FONT> for the
treatment of MDD and PMD, <FONT STYLE="white-space:nowrap">PRAX-944</FONT> for the treatment of ET, and possibly other diseases, and <FONT STYLE="white-space:nowrap">PRAX-562</FONT> for the treatment of a broad range of rare, devastating central
nervous system, or CNS, disorders, such as severe pediatric epilepsy and adult cephalgia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Before we can generate any revenue from sales of <FONT
STYLE="white-space:nowrap">PRAX-114,</FONT> <FONT STYLE="white-space:nowrap">PRAX-944,</FONT> <FONT STYLE="white-space:nowrap">PRAX-562</FONT> or any of our other product candidates, we must undergo additional preclinical and clinical development,
regulatory review and approval in one or more jurisdictions. To date, our clinical trials have been conducted exclusively in Australia and, for <FONT STYLE="white-space:nowrap">PRAX-944,</FONT> in New Zealand as well. We are planning to pursue
clinical trials in the United States for all of our clinical programs. We have not submitted Investigational New Drug applications, or INDs, for any of our product candidates with the FDA. In addition, if one or more of our product candidates are
approved, we must ensure access to sufficient commercial manufacturing capacity and conduct significant marketing efforts in connection with any commercial launch. These efforts will require substantial investment, and we may not have the financial
resources to continue development of our product candidates or commercialization of any products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may experience setbacks that could delay or
prevent regulatory approval of our product candidates or our ability to commercialize any products, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">negative or inconclusive results from our preclinical studies or clinical trials or the clinical trials of others for
product candidates similar to ours, leading to a decision or requirement to conduct additional preclinical testing or clinical trials or abandon a program; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">product-related side effects experienced by subjects in our clinical trials or by individuals using drugs or therapeutics
similar to our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays in submitting INDs in the United States or comparable foreign applications or delays or failure in obtaining the
necessary approvals from regulators or institutional review boards to commence a clinical trial, or a suspension or termination of a clinical trial once commenced; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">if the FDA or comparable foreign authorities do not accept the earlier preclinical and clinical trial work, then we may
need to conduct additional preclinical or clinical trials beyond that which we currently have planned and significant preclinical or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize
our drug candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our drug candidates and may harm our business and results of operations; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">conditions imposed by the FDA or comparable foreign authorities regarding the scope or design of our clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays in contracting with clinical sites or enrolling subjects in clinical trials, including due to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays or interruptions in the supply of materials necessary for the conduct of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulators or institutional review boards, or IRBs, or ethics committees may not authorize us or our investigators to
commence a clinical trial or conduct a clinical trial at a prospective trial site; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the FDA or other comparable regulatory authorities may disagree with our clinical trial design, including with respect to
dosing levels administered in our planned clinical trials, which may delay or prevent us from initiating our clinical trials with our originally intended trial design; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays in reaching, or failure to reach, agreement on acceptable terms with prospective trial sites and prospective
contract research organizations, or CROs, which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number of subjects required for clinical trials of any product candidates may be larger than we anticipate or subjects
may drop out of these clinical trials or fail to return for post-treatment <FONT STYLE="white-space:nowrap">follow-up</FONT> at a higher rate than we anticipate; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our third-party contractors for preclinical studies or clinical trials may fail to comply with regulatory requirements or
meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or take actions that could cause clinical sites or clinical investigators to drop out of the trial, which may require that we add
new clinical trial sites or investigators; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">due to the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, we may experience some delays and
interruptions to our preclinical studies and clinical trials, we may experience delays or interruptions to our manufacturing supply chain, or we could suffer delays in reaching, or we may fail to reach, agreement on acceptable terms with third-party
service providers on whom we rely; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">greater than anticipated clinical trial costs, including as a result of delays or interruptions that could increase the
overall costs to finish our clinical trials as our fixed costs are not substantially reduced during delays; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may elect to, or regulators, IRBs, Data Safety Monitoring Boards, or DSMBs, or ethics committees may require that we or
our investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that the participants are being exposed to unacceptable health risks; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may not have the financial resources available to begin and complete the planned trials, or the cost of clinical trials
of any product candidates may be greater than we anticipate; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product
candidates may be insufficient or inadequate to initiate or complete a given clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the FDA or other comparable foreign regulatory authorities may require us to submit additional data such as long-term
toxicology studies, or impose other requirements before permitting us to initiate a clinical trial, including because the FDA has not reviewed our preclinical or clinical data, to date, having been developed outside the United States in Australia
and New Zealand; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">inability to compete with other therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">poor efficacy of our product candidates during clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">unfavorable FDA or other regulatory agency inspection and review of clinical trial sites or manufacturing facilities;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">unfavorable product labeling associated with any product approvals and any requirements for a Risk Evaluation and
Mitigation Strategy, or REMS, that may be required by the FDA or comparable requirements in other jurisdictions to ensure the benefits of an individual product outweigh its risks; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">unfavorable acceptance of our clinical trial data by the patient or medical communities or third-party payors;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">failure of our third-party contractors or investigators to comply with regulatory requirements or otherwise meet their
contractual obligations in a timely manner, or at all; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays related to the impact or the spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> or other pandemics,
including the impact of <FONT STYLE="white-space:nowrap">COVID-19</FONT> on the FDA&#146;s, or similar foreign regulatory agency&#146;s, ability to continue its normal operations; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays and changes in regulatory requirements, policy and guidelines, including the imposition of additional regulatory
oversight around clinical testing generally or with respect to our technology in particular; or </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">varying interpretations of data by the FDA and similar foreign regulatory agencies. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We do not have complete control over many of these factors, including certain aspects of clinical development and the regulatory submission process,
potential threats to our intellectual property rights and our manufacturing, marketing, distribution and sales efforts or that of any future collaborator. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, of the large number of drugs in development in the biopharmaceutical industry, only a small percentage result in the submission of a
marketing application, such as a new drug application, or NDA, to the FDA, and even fewer are approved for commercialization. Furthermore, even if we do receive regulatory approval for <FONT STYLE="white-space:nowrap">PRAX-144,</FONT> <FONT
STYLE="white-space:nowrap">PRAX-944</FONT> or <FONT STYLE="white-space:nowrap">PRAX-562</FONT> for any indication, any such approval may be subject to limitations on the indications or uses or patient populations for which we may market the product.
Accordingly, even if we are able to obtain the requisite financing to continue to fund our development programs, we cannot assure that we will successfully develop or commercialize <FONT STYLE="white-space:nowrap">PRAX-114,</FONT> <FONT
STYLE="white-space:nowrap">PRAX-944</FONT> or <FONT STYLE="white-space:nowrap">PRAX-562</FONT> for any indication. If we or any of our future collaborators are unable to develop, or obtain regulatory approval for, or, if approved, successfully
commercialize <FONT STYLE="white-space:nowrap">PRAX-114,</FONT> <FONT STYLE="white-space:nowrap">PRAX-944</FONT> or <FONT STYLE="white-space:nowrap">PRAX-562</FONT> for our initial or potential additional indications, we may not be able to generate
sufficient revenue to continue our business. In addition, our failure to demonstrate positive results in our clinical trials in any indication for which we are developing <FONT STYLE="white-space:nowrap">PRAX-114,</FONT> <FONT
STYLE="white-space:nowrap">PRAX-944</FONT> and <FONT STYLE="white-space:nowrap">PRAX-562</FONT> could adversely affect our development efforts for <FONT STYLE="white-space:nowrap">PRAX-114,</FONT> <FONT STYLE="white-space:nowrap">PRAX-944</FONT> and
<FONT STYLE="white-space:nowrap">PRAX-562</FONT> in other indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Clinical development involves a lengthy, complex and expensive process, with an
uncertain outcome. The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials, which to date have primarily been conducted in Australia and New
Zealand, may not satisfy the requirements of the FDA or comparable foreign regulatory authorities. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To obtain the requisite regulatory
approvals to commercialize any product candidates, we must demonstrate through extensive preclinical studies and clinical trials that our product candidates are safe and effective in humans. Clinical testing is expensive and can take many years to
complete, and its outcome is inherently uncertain. In particular, in the U.S. where we hope to advance our product development efforts in the future, the general approach for FDA approval of a new drug is dispositive data from two well-controlled,
Phase 3 clinical trials of the relevant drug in the relevant patient population. Phase 3 clinical trials typically involve hundreds of patients, have significant costs and take years to complete. A product candidate can fail at any stage of testing,
even after observing promising signs of activity in earlier preclinical studies or clinical trials. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical
trials. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
completed. There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product candidates in later stages of clinical trials
may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced
clinical trials due to lack of efficacy or emergence of unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence clinical trials are never approved as products and there can be no
assurance that any of our future clinical trials will ultimately be successful or support further clinical development of <FONT STYLE="white-space:nowrap">PRAX-114,</FONT> <FONT STYLE="white-space:nowrap">PRAX-944,</FONT> <FONT
STYLE="white-space:nowrap">PRAX-562</FONT> or any of our other product candidates. Product candidates that appear promising in the early phases of development may fail to reach the market for several reasons, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">preclinical studies or clinical trials may show the product candidates to be less effective than expected (e.g., a clinical
trial could fail to meet its primary endpoint(s)) or to have unacceptable side effects or toxicities; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">failure to establish clinical endpoints that applicable regulatory authorities would consider clinically meaningful;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">failure to receive the necessary regulatory approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">manufacturing issues, formulation issues, pricing or reimbursement issues or other factors that make a product candidate
uneconomical; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the proprietary rights of others and their competing products and technologies that may prevent one of our product
candidates from being commercialized. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, differences in trial design between early-stage clinical trials and
later-stage clinical trials make it difficult to extrapolate the results of earlier clinical trials to later clinical trials. Moreover, clinical data are often susceptible to varying interpretations and analyses, and many companies that have
believed their product candidates performed satisfactorily in clinical trials have nonetheless failed to obtain marketing approval of their products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Additionally, some of our trials may be open-label studies, where both the patient and investigator know whether the patient is receiving the
investigational product candidate or either an existing approved drug or placebo. Most typically, open-label clinical trials test only the investigational product candidate and sometimes do so at different dose levels. Open-label clinical trials are
subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. For example, prior MDD studies have exhibited a high placebo effect. In addition,
open-label clinical trials may be subject to an &#147;investigator bias&#148; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of which patients have received treatment and may interpret the information
of the treated group more favorably given this knowledge. Therefore, it is possible that positive results observed in open-label trials will not be replicated in later placebo-controlled trials. To date, we have conducted some trials as open-label
trials, including with <FONT STYLE="white-space:nowrap">PRAX-114</FONT> and <FONT STYLE="white-space:nowrap">PRAX-944.</FONT> Additionally, the trial design differences and placebo effects that may be possible in clinical research for the
indications we are studying may make it difficult to extrapolate the results of earlier clinical trials to later clinical trials or to interpret the clinical data in any of our trials. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The standards that foreign regulatory authorities and the FDA use when regulating us require judgment and can change, which makes it difficult to
predict with certainty how they will be applied. Although we are initially focusing our efforts on development of small molecule drug products, we intend to develop a potential antisense oligonucleotide candidate for genetic epilepsies and may in
the future pursue development of biological products, each of which could make us subject to additional regulatory requirements. Any analysis we perform of data from preclinical and clinical activities is subject to confirmation and interpretation
by regulatory authorities, which could delay, limit or prevent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
regulatory approval. Our clinical trials have primarily been conducted in Australia and New Zealand. The FDA&#146;s acceptance of data from clinical trials outside of the United States is subject
to certain conditions, including that the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with good clinical practice, that the data must be applicable to the U.S. population and U.S. medical
practice in ways that the FDA deems clinically meaningful, and that the trials are conducted in compliance with all applicable U.S. laws and regulations. If the FDA or comparable foreign regulatory authorities do not accept earlier preclinical or
clinical data, we may need to conduct additional preclinical studies or clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may also encounter unexpected delays or increased costs
due to new government regulations. Examples of such regulations include future legislation or administrative action, or changes in foreign regulatory authority or FDA policy during the period of product development and regulatory review. It is
impossible to predict whether legislative changes will be enacted, or whether foreign or FDA regulations, guidance or interpretations will be changed, or what the impact of such changes, if any, may be. In the United States, where we plan to develop
our candidates in the future, the FDA may also require a panel of experts, referred to as an Advisory Committee, to deliberate on the adequacy of the safety and efficacy data to support approval. The opinion of the Advisory Committee, although not
binding on the FDA, may have a significant impact on our ability to obtain approval of any product candidates that we develop. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we seek to
continue conducting clinical trials in foreign countries or pursue marketing approvals in foreign jurisdictions, we must comply with numerous foreign regulatory requirements governing, among other things, the conduct of clinical trials,
manufacturing and marketing authorization, pricing and third-party reimbursement. The foreign regulatory approval process varies among countries and jurisdictions and may include all of the risks associated with FDA approval described above as well
as risks attributable to the satisfaction of local regulations in foreign jurisdictions. Moreover, the time required to obtain approval may differ
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">jurisdiction-to-jurisdiction</FONT></FONT> from that required to obtain FDA approval. Approval by foreign regulatory authorities does not ensure approval by the FDA and, similarly,
approval by the FDA does not ensure approval by regulatory authorities outside the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Successful completion of clinical trials is a
prerequisite to submitting a marketing application to foreign regulatory authorities or the FDA, for each product candidate and, consequently, the ultimate approval and commercial marketing of any product candidates. We may experience negative or
inconclusive results, or regulators may be unwilling to accept preclinical or clinical data obtained in foreign jurisdictions, which may result in our deciding, or our being required by regulators, to conduct additional clinical studies or trials or
abandon some or all of our product development programs, which could have a material adverse effect on our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our product candidates may cause
undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences following regulatory approval, if obtained. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Undesirable side effects caused by <FONT STYLE="white-space:nowrap">PRAX-114,</FONT> <FONT STYLE="white-space:nowrap">PRAX-944,</FONT> <FONT
STYLE="white-space:nowrap">PRAX-562</FONT> or any future product candidate could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory
approval by the FDA or comparable foreign regulatory authorities. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. In addition, many compounds that have
initially showed promise in clinical or earlier stage testing are later found to cause undesirable or unexpected side effects that prevented further development of the compound. Additionally, the composition of our product candidates or learnings in
preclinical studies or clinical trials may result in contraindications for any product candidates for which we may obtain regulatory approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If
unacceptable side effects arise in the development of our product candidates, we, foreign regulatory authorities, or, in the future, the FDA, the IRBs, DSMBs or independent ethics committees at </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the institutions in which our trials are conducted could suspend or terminate our preclinical studies or clinical trials or foreign regulatory authorities or the FDA could order us to cease
preclinical studies or clinical trials or deny approval of our product candidates for any or all targeted indications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Treatment-emergent side
effects that are deemed to be drug-related could also affect subject recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. Undesirable side effects in one of our clinical trials for
our product candidates in one indication could adversely affect enrollment in clinical trials, regulatory approval and commercialization of our product candidates in other indications. In addition, these side effects may not be appropriately
recognized or managed by the treating medical staff. Any of these occurrences may harm our business, financial condition and prospects significantly. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Moreover, clinical trials of our product candidates are conducted in carefully defined sets of patients who have agreed to enter into clinical trials.
Consequently, it is possible that our clinical trials, or those of any future collaborator, may indicate an apparent positive effect of a product candidate that is greater than the actual positive effect, if any, or alternatively fail to identify
undesirable side effects. Clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients, rare and severe side effects of our product candidates may only be uncovered with a significantly
larger number of patients exposed to the product candidate. If our product candidates receive marketing approval and we or others identify undesirable side effects caused by such product candidates (or any other similar products) after such
approval, a number of potentially significant negative consequences could result, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulatory authorities may withdraw or limit their approval of such product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulatory authorities may require the addition of labeling statements, such as a Boxed Warning or contraindications;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may be required to change the way such product candidates are distributed or administered, or change the labeling of the
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">FDA may require a REMS plan to mitigate risks, which could include medication guides, physician communication plans or
elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools, and regulatory authorities in other jurisdictions may require comparable risk mitigation plans; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may be subject to regulatory investigations and government enforcement actions; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the FDA or a comparable foreign regulatory authority may require us to conduct additional clinical trials or costly
post-marketing testing and surveillance to monitor the safety and efficacy of the product; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we could be sued and held liable for injury caused to individuals exposed to or taking our product candidates; and
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our reputation may suffer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For example, we are developing PRAX-114, an extrasynaptic-preferring GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor positive
allosteric modulator, or PAM, for the treatment of patients suffering from MDD and PMD. There have been documented cases of approved GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor modulators leading to addiction and having
the potential for abuse. To date, there has been no indication of this side effect for PRAX-114 in our clinical trials; however, in any such instance, we would be subject to the risks outlined above, which would impact our ability to achieve or
maintain market acceptance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Any of these events could prevent us from achieving or maintaining market acceptance of the affected product candidates
and could substantially increase the costs of commercializing our product candidates, if approved, and significantly impact our ability to successfully commercialize our product candidates and generate revenues. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we encounter difficulties enrolling patients in our future clinical trials, our clinical development
activities could be delayed or otherwise adversely affected. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may experience difficulties in patient enrollment in our clinical trials for
a variety of reasons. The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Patient enrollment is affected by many factors, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the patient eligibility criteria defined in the protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the size of the patient population required for analysis of the trial&#146;s primary endpoints; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">in the case clinical trials focused on rare disease, the small size of the patient population and the potential of a
patient being undiagnosed or misdiagnosed; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the proximity of patients to trial sites; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the design of the trial; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to recruit clinical trial investigators with the appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">competing clinical trials and clinicians&#146; and patients&#146; perceptions as to the potential advantages and risks of
the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications that we are investigating; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the impacts of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on clinical trial sites, personnel and patient
travel; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to obtain and maintain patient consents; and </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the risk that patients enrolled in clinical trials will drop out of the trials before completion. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product
candidates, and this competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since
the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our
clinical trials in such clinical trial site. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our inability to enroll a sufficient number of patients for our clinical trials would result in
significant delays or might require us to abandon one or more clinical trials altogether. Delays in patient enrollment may result in increased costs, affect the timing or outcome of the planned clinical trials, product candidate development and
approval process and jeopardize our ability to seek and obtain the regulatory approval required to commence product sales and generate revenue, which could prevent completion of these trials, adversely affect our ability to advance the development
of our product candidates, cause the value of our company to decline and limit our ability to obtain additional financing if needed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are also
required to register certain clinical trials and post the results of completed clinical trials on a government-sponsored database, such as www.ClinicalTrials.gov in the United States, within certain timeframes. Failure to do so can result in fines,
adverse publicity and civil and criminal sanctions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Interim, topline and preliminary data from our clinical trials that we announce or publish from time to
time may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">From time to time, we may publicly disclose preliminary, interim or topline data from our clinical trials. These interim updates are based on a
preliminary analysis of then-available data, and the results </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations,
calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. As a result, the topline results that we report may differ from future results of the same
studies, or different conclusions or considerations may qualify such results, once additional data have been received and fully evaluated. Topline data also remain subject to audit and verification procedures that may result in the final data being
materially different from the preliminary data we previously reported. As a result, topline data should be viewed with caution until the final data are available. In addition, we may report interim analyses of only certain endpoints rather than all
endpoints. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Adverse changes between
interim data and final data could significantly harm our business and prospects. Some of our trials may be open-label studies, where both the patient and investigator know whether the patient is receiving the investigational product candidate or
either an existing approved drug or placebo. Open-label clinical trials are subject to various limitations that may exaggerate any therapeutic effect as patients in open-label clinical trials are aware when they are receiving treatment. For example,
prior MDD studies have exhibited a high placebo effect. In addition, open-label clinical trials may be subject to an &#147;investigator bias&#148; where those assessing and reviewing the physiological outcomes of the clinical trials are aware of
which patients have received treatment and may interpret the information of the treated group more favorably given this knowledge. Therefore, it is possible that positive results observed in open-label trials will not be replicated in later
placebo-controlled trials. Additionally, the trial design differences and placebo effects that may be possible in clinical research for the indications we are studying may make it difficult to extrapolate the results of earlier clinical trials to
later clinical trials or to interpret the clinical data in any of our trials. Further, additional disclosure of interim data by us or by our competitors in the future could result in volatility in the price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may
interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate and our company in general. In addition, the information we
choose to publicly disclose regarding a particular study or clinical trial is typically selected from a more extensive amount of available information. You or others may not agree with what we determine is the material or otherwise appropriate
information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or
our business. If the preliminary or topline data that we report differ from late, final or actual results, or if others, including the FDA and comparable foreign regulatory authorities, disagree with the conclusions reached, our ability to obtain
approval for, and commercialize our product candidates may be harmed, which could harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The markets for <FONT STYLE="white-space:nowrap">PRAX-114</FONT> for MDD and PMD, <FONT STYLE="white-space:nowrap">PRAX-944</FONT> for ET, <FONT
STYLE="white-space:nowrap">PRAX-562</FONT> for multiple rare neurological conditions and any other product candidates we may develop may be smaller than we expect. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our estimates of the potential market opportunity for <FONT STYLE="white-space:nowrap">PRAX-114</FONT> for the treatment of MDD and PMD, <FONT
STYLE="white-space:nowrap">PRAX-944</FONT> for the treatment of ET, <FONT STYLE="white-space:nowrap">PRAX-562</FONT> for the treatment of multiple rare neurological conditions, including epilepsy, cephalgias and pain, as well as any other product
candidates, include several key assumptions based on our industry knowledge, industry publications and third-party research reports. There can be no assurance that any of these assumptions are, or will remain, accurate. If the actual market for <FONT
STYLE="white-space:nowrap">PRAX-114,</FONT> <FONT STYLE="white-space:nowrap">PRAX-944</FONT> and <FONT STYLE="white-space:nowrap">PRAX-562</FONT> for these or other indications, or for any other product candidate we may develop, is smaller than we
expect, our revenues, if any, may be limited and it may be more difficult for us to achieve or maintain profitability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may not be successful in our efforts to identify or discover additional product candidates in the future.
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for
clinical development or commercialization for a number of reasons, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our inability to design such product candidates with the pharmacological or pharmacokinetic properties that we desire; or
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that
indicate that they are unlikely to be medicines that will receive marketing approval and achieve market acceptance. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Research
programs to identify new product candidates require substantial technical, financial and human resources. If we are unable to identify suitable compounds for preclinical and clinical development, we will not be able to obtain product revenue in
future periods, which likely would result in significant harm to our financial position and adversely impact our stock price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may in the future conduct
clinical trials for our product candidates in the United States, Europe or other jurisdictions, and the FDA, the European Medicines Agency, or EMA, and applicable foreign regulatory authorities may not accept data from trials conducted outside those
respective jurisdictions. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may in the future choose to conduct one or more of our clinical trials in the United States, Europe or in other
foreign jurisdictions outside of Australia and New Zealand where our trials currently are being conducted for <FONT STYLE="white-space:nowrap">PRAX-114,</FONT> <FONT STYLE="white-space:nowrap">PRAX-944</FONT> and
<FONT STYLE="white-space:nowrap">PRAX-562.</FONT> The acceptance of study data from preclinical studies and clinical trials conducted outside those jurisdictions may be subject to certain conditions for acceptance. For example, in cases where data
from foreign clinical trials are intended to serve as the basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i)&nbsp;the data are applicable to the United
States population and United States medical practice; and (ii)&nbsp;the trials were performed by clinical investigators of recognized competence and pursuant to Good Clinical Practices, or GCP, regulations. Additionally, the FDA&#146;s clinical
trial requirements, including sufficient size of patient populations and statistical powering, must be met. Many foreign regulatory bodies, such as the EMA, have similar approval requirements. In addition, such foreign trials would be subject to the
applicable local laws of the foreign jurisdictions where the trials are conducted. There can be no assurance that the FDA, EMA or any applicable foreign regulatory authority will accept data from trials conducted outside of the United States or the
applicable jurisdiction. If the FDA, EMA or any applicable foreign regulatory authority does not accept such data, it would result in the need for additional trials, which would be costly and time-consuming and delay aspects of our business plan,
and which may result in our product candidates not receiving approval or clearance for commercialization in the applicable jurisdiction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We plan to seek
orphan drug designation for one or more of our product candidates, but we may be unable to obtain or maintain such a designation or the benefits associated with orphan drug status, including marketing exclusivity, which may cause our revenue, if
any, to be reduced. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the United States, under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to
treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that
the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested and granted by the FDA before a new NDA is
submitted. In the United States, orphan drug designation entitles a party to financial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and <FONT STYLE="white-space:nowrap">user-fee</FONT> waivers. After the FDA grants orphan drug
designation, it will disclose publicly the generic identity of the drug and its potential orphan use. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. Such a
designation may also be revoked by the FDA in certain circumstances, such as if the agency finds that the applicant&#146;s request for designation request omitted material information required under the Orphan Drug Act and its implementing
regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If a product that has orphan drug designation subsequently receives the first FDA approval for a particular active ingredient for the
disease for which it has such designation, the product is entitled to orphan product exclusivity. This means that the FDA may not approve any other marketing applications for the same drug and the same indication for seven years, except in limited
circumstances such as a showing of clinical superiority to the product with orphan exclusivity or if FDA finds that the holder of the orphan exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan product
to meet the needs of patients with the disease or condition for which the drug was designated. Furthermore, the FDA can waive orphan exclusivity if the applicant is unable to manufacture sufficient supply of the product subject to a period of orphan
drug marketing exclusivity. Because we are developing <FONT STYLE="white-space:nowrap">PRAX-562</FONT> and <FONT STYLE="white-space:nowrap">PRAX-222</FONT> for indications we believe to be rare, we expect to pursue orphan designations for our
candidates as applicable in the jurisdictions where development activities are planned. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>A Breakthrough Therapy Designation by the FDA may not lead to a
faster development or regulatory review or approval process, and does not increase the likelihood that our product candidates will receive marketing approval. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We do not currently have Breakthrough Therapy Designation for any of our product candidates, but we may seek Breakthrough Therapy Designation for any
product candidate that we plan to develop in the United States if we believe the qualifying criteria for such a designation can be met. A Breakthrough Therapy is defined as a drug that is intended, alone or in combination with one or more other
drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints,
such as substantial treatment effects observed early in clinical development. For drugs that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most
efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as Breakthrough Therapies by the FDA are also eligible for accelerated approval and priority review. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The FDA has discretion to determine whether the criteria for a Breakthrough Therapy has been met and whether to grant a Breakthrough Therapy Designation
to an investigational product. Accordingly, even if we believe a product candidate we develop meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation. In any event, the
receipt of Breakthrough Therapy Designation for a product candidate may not result in a faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval
by the FDA. In addition, even after granting Breakthrough Therapy Designation to our product candidates, the FDA may later decide that the drugs no longer meet the conditions for qualification and withdraw the designation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>A Fast Track Designation by the FDA, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval
process and does not increase the likelihood that our product candidates will receive marketing approval. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We do not currently have Fast
Track Designation for any of our product candidates, but we may seek such a designation for the product candidates we plan to develop in the United States if we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
believe the qualifying criteria for such a designation have been met. If a product is intended for the treatment of a serious or life-threatening condition and preclinical or clinical data
demonstrate the potential to address an unmet medical need for this condition, the product sponsor may apply for Fast Track Designation. The FDA has broad discretion whether or not to grant this designation, so even if we believe a particular
product candidate is eligible for this designation, we cannot assure that the FDA would decide to grant it. Even if we do receive Fast Track Designation, we may not experience a faster development process, review or approval compared to conventional
FDA procedures. The FDA may withdraw the Fast Track Designation if it believes that the designation is no longer supported by data from our clinical development program. Many drugs that have received Fast Track Designation have failed to obtain
regulatory approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in
obtaining regulatory approval of our product candidates in other jurisdictions. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Obtaining and maintaining regulatory approval of our product
candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, but a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the
regulatory approval process in others. For example, even if the FDA grants approval of a product candidate, comparable regulatory authorities in other jurisdictions, including Australia and Europe, must also approve the manufacturing, marketing and
sale of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional preclinical studies or
clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must also be approved for reimbursement
before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to governmental approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs
for us and could delay or prevent the introduction of our products in certain countries. If we or any partner we work with fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals,
our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Any of our current and
future product candidates for which we, or any future collaborators, obtain regulatory approval in the future will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. If approved,
our product candidates could be subject to post-marketing restrictions or withdrawal from the market and we, or any future collaborators, may be subject to substantial penalties if we, or they, fail to comply with regulatory requirements or if we,
or they, experience unanticipated problems with our products following approval. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Any of our product candidates for which we, or any future
collaborators, obtain regulatory approval, as well as the manufacturing processes, post-approval studies, labeling, advertising and promotional activities for such product, among other things, will be subject to ongoing requirements of and review by
the FDA, if approved in the United States, and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, registration and listing requirements, requirements relating to
manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping. We and our contract manufacturers will also be subject to
user fees and periodic inspection by the FDA in the United States and other regulatory authorities, including similar regulatory authorities in foreign jurisdictions, to monitor compliance with these
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
requirements and the terms of any product approval we may obtain. Even if regulatory approval of a product candidate is granted, the approval may be subject to limitations on the indications or
uses for which the product may be marketed or to the conditions of approval, including the potential requirement in the United States to implement a REMS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Regulatory authorities may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or
efficacy of a product. In the United States, the FDA and other agencies, including the Department of Justice, closely regulate and monitor the post-approval marketing and promotion of products to ensure that they are manufactured, marketed and
distributed only for the approved indications and in accordance with the approved labeling. The FDA imposes stringent restrictions on manufacturers&#146; communications regarding <FONT STYLE="white-space:nowrap">off-label</FONT> use of approved drug
products. However, companies may share truthful and not misleading information that is otherwise consistent with a product&#146;s FDA approved labeling. If we, or any future collaborators, do not market any of our product candidates for which we, or
they, receive regulatory approval for only their approved indications, we, or they, may be subject to warnings or enforcement action for <FONT STYLE="white-space:nowrap">off-label</FONT> marketing if it is alleged that we are doing so. In the United
States, violation of the Federal Food, Drug and Cosmetic Act and other statutes relating to the promotion and advertising of prescription drugs may lead to investigations or allegations of violations of federal and state health care fraud and abuse
laws and state consumer protection laws, including the federal False Claims Act, or the FCA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, later discovery of previously unknown
adverse events or other problems with our products or their manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may yield various results, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restrictions on the manufacturing of such products; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restrictions on the labeling or marketing of such products; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restrictions on product distribution or use; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">requirements to conduct post-marketing studies or clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">warning letters or untitled letters; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">withdrawal of the products from the market; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">refusal to approve pending applications or supplements to approved applications that we submit; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">recall of products; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restrictions on coverage by third-party payors; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">fines, restitution or disgorgement of profits or revenues; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">exclusion from U.S. federal health care programs such as Medicare and Medicaid; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">suspension or withdrawal of regulatory approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">refusal to permit the import or export of products; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">product seizure; or </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Even if we, or any future collaborators, obtain regulatory approvals for our product candidates, the terms of approvals and ongoing regulation of our products may
limit how we manufacture and market our products, which could impair our ability to generate revenue. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Once regulatory approval has been
granted, an approved product and its manufacturer and marketer are subject to ongoing review and extensive regulation. We, and any future collaborators, must therefore comply with requirements concerning advertising and promotion for any of our
product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
candidates for which we or they obtain regulatory approval. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be
consistent with the information in the product&#146;s approved labeling. Thus, we and any future collaborators will not be able to promote any products we develop for indications or uses for which they are not approved. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, manufacturers of approved products and those manufacturers&#146; facilities are required to comply with extensive regulatory requirements,
including under FDA authorities ensuring that quality control and manufacturing procedures conform to current Good Manufacturing Practices, or cGMPs, which include requirements relating to quality control and quality assurance as well as the
corresponding maintenance of records and documentation and reporting requirements. We, our contract manufacturers, any future collaborators and their contract manufacturers could be subject to periodic unannounced inspections by regulatory
authorities to monitor and ensure compliance with cGMPs. Despite our efforts to inspect and verify regulatory compliance, one or more of our third-party manufacturing vendors may be found on regulatory inspection to be not in compliance with cGMP
requirements, which may result in shutdown of the third-party vendor or invalidation of drug product lots or processes. In some cases, a product recall may be warranted or required, which would materially affect our ability to supply and market our
drug products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Accordingly, assuming we, or any future collaborators, receive regulatory approval for one or more of our product candidates, we,
and any future collaborators, and our and their contract manufacturers will continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance and quality control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we, or any future collaborators, are not able to comply with post-approval regulatory requirements, we, or any future collaborators, could have the
regulatory approvals for our products withdrawn by regulatory authorities and our, or any future collaborators&#146;, ability to market any future products could be limited, which could adversely affect our ability to achieve or sustain
profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Changes in regulatory requirements or regulatory guidance or unanticipated events during our <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and
clinical trials of our product candidates may occur, which may result in changes to <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and clinical trial protocols or the need for additional
<FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and clinical trials, which could result in increased costs to us and could delay our development timelines. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Changes in regulatory requirements or regulatory guidance or unanticipated events during our <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies
and clinical trials may force us to amend <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies and clinical trial protocols or the applicable regulatory authority may impose additional <FONT STYLE="white-space:nowrap">non-clinical</FONT>
studies and clinical trial requirements. Amendments or changes to our clinical trial protocols would generally require resubmission to the applicable regulatory authority and IRBs for review and approval, which may adversely impact the cost, timing
or successful completion of clinical trials. These decisions may increase costs, and cause us not to meet expected timelines and, correspondingly, our business and financial prospects could be adversely affected. Similarly, amendments to our <FONT
STYLE="white-space:nowrap">non-clinical</FONT> studies may adversely impact the cost, timing or successful completion of those <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies. If we experience delays completing, or if we terminate, any
of our <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies or clinical trials, or if we are required to conduct additional <FONT STYLE="white-space:nowrap">non-clinical</FONT> studies or clinical trials, the development pathway, and
ultimately the commercial prospects, for our product candidates may be harmed and our ability to generate product revenue from resulting products, if any, will be delayed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We could be subject to product liability lawsuits based on the use of our product candidates in clinical testing or, if obtained, following our products&#146;
marketing approval and commercialization. Product liability lawsuits brought against us or any of our future collaborators could divert our </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>
resources and attention, require us to cease clinical testing, cause us to incur substantial liabilities or limit commercialization of our product candidates. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are exposed to potential product liability and professional indemnity risks that are inherent in the research, development, manufacturing, marketing
and use of biopharmaceutical products. Currently, we have no products that have been approved for commercial sale; however, the use of our product candidates by us and any collaborators in clinical trials may expose us to liability claims. We will
face an even greater risk if product candidates are approved by regulatory authorities and introduced commercially. Product liability claims may be brought against us or our partners if any product candidate we develop allegedly causes injury or is
found to be otherwise unsuitable for human use during product testing, manufacturing, marketing or sale. Any such product liability claim may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent
in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted under state consumer protection acts. Such claims could be made by participants enrolled in our clinical trials, patients, health care providers,
biopharmaceutical companies, our collaborators or others using, administering or selling any of our future approved products. If we cannot successfully defend ourselves against any such claims, we may incur substantial liabilities or be required to
limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Regardless
of the merits or eventual outcome, product liability claims may result in: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">decreased demand for any of our future approved products; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">injury to our reputation; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">termination of clinical trial sites or entire trial programs; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">significant litigation costs; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">substantial monetary awards to, or costly settlements with, patients or other claimants; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">product recalls or a change in the indications for which any approved drug products may be used; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">loss of revenue; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">diversion of management and scientific resources from our business operations; and </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the inability to commercialize our product candidates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Although the clinical trial process is designed to identify and assess potential side effects, clinical development does not always fully characterize
the safety and efficacy profile of a new medicine, and it is always possible that a drug, even after regulatory approval, may exhibit unforeseen side effects. If our product candidates were to cause adverse side effects during clinical trials or
after approval, we may be exposed to substantial liabilities. Physicians and patients may not comply with any warnings that identify known potential adverse effects and patients who should not use our product candidates. If any of our product
candidates are approved for commercial sale, we will be highly dependent upon consumer perceptions of us and the safety and quality of our products. We could be adversely affected if we are subject to negative publicity associated with illness or
other adverse effects resulting from physicians&#146; or patients&#146; use or misuse of our products or any similar products distributed by other companies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Although we maintain product liability insurance coverage including clinical trial liability, this insurance may not fully cover potential liabilities
that we may incur. The cost of any product liability litigation or other proceeding, even if resolved in our favor, could be substantial. We will need to increase our insurance coverage if we commercialize any product that receives regulatory
approval. In </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
addition, insurance coverage is becoming increasingly expensive. If we are unable to maintain sufficient insurance coverage at an acceptable cost or to otherwise protect against potential product
liability claims, it could prevent or inhibit the development and commercial production and sale of our product candidates, which could harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We face significant competition in an environment of rapid technological and scientific change, and there is a possibility that our competitors may achieve
regulatory approval before us or develop therapies that are safer, more advanced or more effective than ours, which may negatively impact our ability to successfully market or commercialize any product candidates we may develop and ultimately harm
our financial condition. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The development and commercialization of new drug products is highly competitive. We may face competition with
respect to any product candidates that we seek to develop or commercialize in the future from biopharmaceutical companies worldwide. Potential competitors also include academic institutions, government agencies, and other public and private research
organizations that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing and commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Specifically, we face competition with GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor modulator programs in development
targeting MDD, including that of SAGE Therapeutics, as well as other programs in clinical development targeting other mechanisms of action and approved therapies such as selective serotonin reuptake inhibitors, or SSRIs; <FONT
STYLE="white-space:nowrap">T-type</FONT> calcium channel inhibitor programs in development targeting ET, including that of Jazz Pharmaceuticals, as well as other programs in clinical development targeting other mechanisms of action, and approved
therapies, such as propranolol, and <FONT STYLE="white-space:nowrap">off-label</FONT> therapies, such as primidone; and sodium channel blocker programs in development for DEE, including those of SK-Pharma and Xenon Pharmaceuticals, as well as other
programs in clinical development targeting other mechanisms of action, and approved therapies including other existing ion channel blockers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If any
of these competitors or competitors for our other product candidates receive FDA approval before we do, our product candidates would not be the first treatment on the market, and our market share may be limited. In addition to competition from other
companies targeting our target indications, any products we may develop may also face competition from other types of therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Many of our
current or potential competitors, either alone or with their strategic partners, have: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">greater financial, technical and human resources than we have at every stage of the discovery, development, manufacture and
commercialization of products; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">more extensive experience in preclinical testing, conducting clinical trials, obtaining regulatory approvals, and in
manufacturing, marketing and selling drug products; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">products that have been approved or are in late stages of development; and </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborative arrangements in our target markets with leading companies and research institutions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Mergers and acquisitions in the biopharmaceutical industry may result in even more resources being concentrated among a smaller number of our
competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining
qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could
be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
more convenient or are less expensive than any products that we may develop. Furthermore, currently approved products could be discovered to have application for treatment of our targeted disease
indications or similar indications, which could give such products significant regulatory and market timing advantages over our product candidates. Our competitors also may obtain FDA, EMA or other comparable foreign regulatory approval for their
products more rapidly than we may obtain approval for ours and may obtain orphan product exclusivity from the FDA for indications that we are targeting, which could result in our competitors establishing a strong market position before we are able
to enter the market. Additionally, products or technologies developed by our competitors may render our potential product candidates uneconomical or obsolete and we may not be successful in marketing any product candidates we may develop against
competitors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, we could face litigation or other proceedings with respect to the scope, ownership, validity and/or enforceability of our
patents relating to our competitors&#146; products and our competitors may allege that our products infringe, misappropriate or otherwise violate their intellectual property. The availability of our competitors&#146; products could limit the demand,
and the price we are able to charge, for any products that we may develop and commercialize. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Risks Related to the Commercialization of our Product Candidates
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Any product candidate for which we obtain marketing approval will be subject to extensive post-marketing regulatory requirements and could be subject to
post-marketing restrictions or withdrawal from the market, and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our products, when and if any of them are approved.
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Even if the FDA or a comparable foreign regulatory authority approves any of our product candidates, we will be subject to ongoing
regulatory requirements in the applicable jurisdictions for manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing studies and submission of safety, efficacy and other post-market
information. In addition, we will be subject to continued compliance with cGMP and GCP requirements for any clinical trials that we conduct post-approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Manufacturers and their facilities are required to comply with extensive regulatory authority requirements, including ensuring that quality control and
manufacturing procedures conform to cGMP regulations. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any marketing application, and
previous responses to inspection observations. Accordingly, we and others with whom we work must continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production and quality control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product
may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials and surveillance to monitor the safety and efficacy of the product candidate. In the United
States, the FDA may also require a REMS program as a condition of approval of our product candidates, which could entail requirements for long-term patient <FONT STYLE="white-space:nowrap">follow-up,</FONT> a medication guide, physician
communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product
candidates, we will have to comply with requirements including submissions of safety and other post-marketing information and reports and registration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the United States, the FDA may withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur
after the product reaches the market. Later </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party manufacturers or manufacturing
processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information or other restrictions; imposition of post-market studies or clinical trials to assess new safety risks; or
imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">restrictions on the manufacturing of our products, the approved manufacturers or the manufacturing process;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">withdrawal of the product from the market or voluntary product recalls; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">requirements to conduct post-marketing studies or clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">fines, restitution or disgorgement of profits or revenues; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">warning or untitled letters from the FDA or comparable notice of violations from foreign regulatory authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">suspensions of any of our ongoing clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or
withdrawal of marketing approvals; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">product seizure or detention or refusal to permit the import or export of products; and </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">consent decrees, injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Regulatory authorities strictly regulate marketing, labeling, advertising and promotion of products that are placed on the market. Products may be
promoted only for the approved indications and in accordance with the provisions of the approved label. However, in the United States, companies may share truthful and not misleading information that is not inconsistent with the labeling. The FDA
and other regulatory authorities actively enforce the laws and regulations prohibiting the promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses and a company that is found to have improperly promoted
<FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant liability. Violations of the Federal Food, Drug, and Cosmetic Act relating to the promotion of prescription drugs may also lead to investigations alleging
violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws. Accordingly, to the extent we receive marketing approval for one or more of our product candidates, we and our third-party partners will
continue to expend time, money and effort in all areas of regulatory compliance, including promotional and labeling compliance, manufacturing, production, product surveillance and quality control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The policies of the FDA and of other regulatory authorities may change and additional government regulations may be enacted that could prevent, limit or
delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow
to, or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve
or sustain profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our commercial success depends upon attaining significant market acceptance of our drug product candidates, if approved, among
physicians, patients, third-party payors and other members of the medical community. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Even if any of the product candidates we develop
receives marketing approval, they may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors, such as Medicare and Medicaid programs and managed care organizations in the United States, and others in the
medical community. In addition, the availability of coverage by third-party payors may be affected by existing and future health care reform measures designed to reduce the cost of health care. If the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
product candidates we develop do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The degree of market acceptance of any product candidate, if approved for commercial sale, will depend on a number of factors, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">efficacy and potential advantages compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ability to offer our products, if approved, for sale at competitive prices; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">relative convenience and ease of administration compared to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">perceptions by the medical community, physicians, and patients, regarding the safety and effectiveness of our products and
the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the size of the market for such product candidate, based on the size of the patient subsets that we are targeting, in the
territories for which we gain regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the recommendations with respect to our product candidates in guidelines published by various scientific organizations
applicable to us and our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the strength of sales, marketing and distribution support; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing of any such marketing approval in relation to other product approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any restrictions on concomitant use of other medications; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">support from patient advocacy groups; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ability to obtain sufficient third-party coverage and adequate reimbursement; and </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the prevalence and severity of any side effects. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If government and other third-party payors do not provide coverage and adequate reimbursement levels for any products we commercialize, market
acceptance and commercial success would be reduced. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The successful commercialization of our product candidates in the United States will depend in part on
the extent to which third-party payors, including governmental authorities and private health insurers, provide coverage and adequate reimbursement levels, as well as implement pricing policies favorable for our product candidates. Failure to obtain
or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Significant uncertainty exists as to the coverage and reimbursement status of any products for which we may obtain regulatory approval. In the United
States and in other countries, patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. The availability of coverage and adequacy of
reimbursement for our products by third-party payors, including government health care programs (e.g., Medicare, Medicaid, TRICARE), managed care providers, private health insurers, health maintenance organizations and other organizations is
essential for most patients to be able to afford medical services and biopharmaceutical products such as our product candidates. Third-party payors decide which medications they will pay for and establish reimbursement levels. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the United States, the principal decisions about reimbursement for new medicines are typically made by the Centers for Medicare&nbsp;&amp; Medicaid
Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS. CMS decides whether and to what extent our products will be covered and reimbursed under Medicare and private payors tend to follow CMS to a
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
substantial degree. Factors payors consider in determining reimbursement are based on whether the product is: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">cost-effective; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our ability to successfully commercialize our product candidates will depend in part on the extent to which coverage and adequate reimbursement for our
products and related treatments will be available from third-party payors. Moreover, a payor&#146;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. If coverage and adequate
reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize our product candidates. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to
establish or maintain pricing sufficient to realize a sufficient return on our investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the United States, no uniform policy for coverage and
reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for our products can differ significantly from payor to payor. The process for determining whether a payor will provide coverage for a product may be
separate from the process for setting the reimbursement rate that the payor will pay for the product. One payor&#146;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for
the product. Third-party payors may also limit coverage to specific products on an approved list, or formulary, which might not include all of the <FONT STYLE="white-space:nowrap">FDA-approved</FONT> products for a particular indication. We cannot
be sure that coverage and reimbursement will be available for, or accurately estimate the potential revenue from, our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A
decision by a third-party payor not to cover or not to separately reimburse for our medical products or therapies using our products could reduce physician utilization of our products once approved. Assuming there is coverage for our product
candidates, or therapies using our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require <FONT STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. We
cannot be sure that coverage and reimbursement in the United States will be available for our current or future product candidates, or for any procedures using such product candidates, and any reimbursement that may become available may not be
adequate or may be decreased or eliminated in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Further, increasing efforts by third-party payors in the United States and abroad to cap
or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. In order to secure
coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs
required to obtain FDA or comparable regulatory approvals. Additionally, we may also need to provide discounts to purchasers, private health plans or government healthcare programs. Our product candidates may nonetheless not be considered medically
necessary or cost-effective. If third-party payors do not consider a product to be cost-effective compared to other available therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of
payment may not be sufficient to allow a company to sell its products at a profit. We expect to experience pricing pressures from third-party payors in connection with the potential sale of any of our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Governments outside the United States tend to impose strict price controls, which may adversely affect our
revenues, if any. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The
requirements governing drug pricing vary widely from country to country. For example, in the European Union, Member States can restrict the range of medicinal products for which their national health insurance systems provide reimbursement and they
can control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to
currently available therapies. A Member State may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market.
Approaches between Member States are diverging. For example, in France, effective market access will be supported by agreements with hospitals and products may be reimbursed by the Social Security Fund. The price of medicines is negotiated with the
Economic Committee for Health Products, or CEPS. There can be no assurance that any country that has price controls or reimbursement limitations for biopharmaceutical products will allow favorable reimbursement and pricing arrangements for any of
our product candidates. Historically, products launched in the European Union do not follow price structures of the United States and generally prices tend to be significantly lower. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if we obtain approval of any of our product candidates in the United States or Europe, we may never obtain approval or commercialize such products in other
countries, which would limit our ability to realize their full market potential. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In order to market any products in the United States or
European Union, we must establish and comply with numerous and varying regulatory requirements regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory
approval in one country does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods.
Seeking foreign regulatory approvals outside of where our clinical trials currently have been conducted could result in significant delays, difficulties and costs for us and may require additional preclinical studies or clinical trials which would
be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. Satisfying these and other regulatory requirements is costly, time
consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any product
candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or
to obtain and maintain required approvals, our ability to realize the full market potential of our products will be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We currently have no marketing
and sales organization and have no experience as a company in commercializing products, and we may have to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into
agreements with third parties to market and sell our product candidates, if approved, we may not be able to generate product revenue. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We
have no internal sales, marketing or distribution capabilities, nor have we commercialized a product. If any of our product candidates ultimately receives regulatory approval, we expect to establish a marketing and sales organization with technical
expertise and supporting distribution capabilities to commercialize each such product in major markets, which will be expensive and time consuming. We have no prior experience as a company in the marketing, sale and distribution of biopharmaceutical
products and there are significant risks involved in building and managing a sales </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and
effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may
also choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. We may not
be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, our product revenues and our profitability, if
any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute any products that we develop ourselves. We likely will have little control over such third parties, and any of them may fail to devote
the necessary resources and attention to sell and market our products effectively. If we are not successful in commercializing our products, either on our own or through arrangements with one or more third parties, we may not be able to generate any
future product revenue and we would incur significant additional losses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Risks Related to Ongoing Regulatory and Legal Compliance </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our relationships with healthcare providers and physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other
healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Although we do not currently have any products on the market, upon commercialization of our product candidates, if approved, we will be subject to
additional health care statutory and regulatory requirements and oversight by federal and state governments in the United States as well as foreign governments in the jurisdictions in which we conduct our business. Healthcare providers, physicians
and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare
providers, third-party payors, customers and others may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. In particular, the research of our product candidates, as well as the promotion, sales and marketing
of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may
restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business or financial arrangements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The applicable federal, state and foreign healthcare laws and regulations laws that may affect our ability to operate include, but are not limited to:
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully
soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual, or
the purchase, lease, order, arrangement or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. A person or entity
can be found guilty of violating the statute without actual knowledge of the statute or specific intent to violate it. The term remuneration has been interpreted broadly to include anything of value. Further, courts have found that if &#147;one
purpose&#148; of renumeration is to induce referrals, the federal Anti-Kickback statute is violated. Violations are subject to significant civil and criminal fines and penalties for each violation, plus up to three times the remuneration involved,
imprisonment and exclusion from government </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
healthcare programs. In addition, a claim submitted for payment to any federal healthcare program that includes items or services that were made as a result of a violation of the federal
Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. The Anti-Kickback Statute has been interpreted to apply to arrangements between biopharmaceutical manufacturers on the one hand and prescribers, purchasers and
formulary managers, among others, on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the federal civil and criminal false claims laws, including the FCA, and civil monetary penalty laws which prohibit, among
other things, individuals or entities from knowingly presenting, or causing to be presented, false, fictitious or fraudulent claims for payment to, or approval by Medicare, Medicaid, or other federal healthcare programs; knowingly making, using or
causing to be made or used, a false record or statement material to a false, fictitious or fraudulent claim or an obligation to pay or transmit money or property to the federal government; or knowingly concealing or knowingly and improperly
avoiding, decreasing or concealing an obligation to pay money to the federal government. A claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim under the FCA.
Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#147;cause&#148; the submission of false or fraudulent claims. The FCA also permits a private individual acting
as a &#147;whistleblower&#148; to bring qui tam actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery or settlement. When an entity is determined to have violated the FCA, the government may
impose civil fines and penalties for each false claim, plus treble damages, and exclude the entity from participation in Medicare, Medicaid and other federal healthcare programs; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal
criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, or obtain, by means of false or fraudulent pretenses,
representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private), and knowingly and willfully falsifying, concealing or
covering up by any trick or device a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false fictitious or
fraudulent statement or entry in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of
violating HIPAA fraud provisions without actual knowledge of the statute or specific intent to violate it; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their
respective implementing regulations, which impose, among other things, certain requirements relating to the privacy, security and transmission of individually identifiable health information on certain covered healthcare providers, health plans and
healthcare clearinghouses, known as covered entities, as well as their respective &#147;business associates,&#148; those independent contractors or agents of covered entities that create, receive, maintain, transmit or obtain protected health
information in connection with providing a service on behalf of a covered entity. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave
state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing federal civil actions. In addition, there may
be additional federal, state and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> laws which govern the privacy and security of health and other </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the federal Physician Payments Sunshine Act, created under the Patient Protection and Affordable Care Act, as amended by
the Health Care and Education Reconciliation Act of 2010, or, collectively, the ACA, and its implementing regulations, which require manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare,
Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report annually to CMS information related to direct or indirect payments and other transfers of value made to physicians (defined to include doctors, dentists,
optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by the physicians and their immediate family members. Effective January&nbsp;1, 2022, these reporting obligations will extend to
include transfers of value made in the previous year to certain <FONT STYLE="white-space:nowrap">non-physician</FONT> providers such as physician assistants and nurse practitioners; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that
potentially harm consumers; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">analogous U.S. state, local and foreign laws and regulations, such as state anti-kickback and false claims laws, which may
apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers, and may be broader in scope than their federal equivalents; state and foreign laws that
require biopharmaceutical companies to comply with the biopharmaceutical industry&#146;s voluntary compliance guidelines and other relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to
healthcare providers and other potential referral sources; state and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, marketing
expenditures or drug pricing; state and local laws that require the registration of biopharmaceutical sales representatives; and state and foreign laws governing the privacy and security of health information, some of which may be more stringent
than those in the United States (such as the European Union, which adopted the General Data Protection Regulation, which became effective in May 2018) in certain circumstances, and may differ from each other in significant ways and often are not
preempted by HIPAA, thus complicating compliance efforts. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The distribution of biopharmaceutical products is subject to additional
requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of biopharmaceutical products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If the FDA or a comparable foreign regulatory authority approves any of our product candidates, we will be subject to an expanded number of these laws
and regulations and will need to expend resources to develop and implement policies and processes to promote ongoing compliance. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of
healthcare reform, especially in light of the lack of applicable precedent and regulations. Ensuring business arrangements comply with applicable healthcare laws, as well as responding to possible investigations by government authorities, can be
time- and resource-consuming and can divert a company&#146;s attention from the business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">It is possible that governmental and enforcement
authorities will conclude that our business practices, including our arrangements with physicians and other healthcare providers, some of whom may receive stock options as compensation for services provided, may not comply with current or future
statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to
us, we may be subject to significant sanctions, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, reputational harm, exclusion from participation in federal and state funded healthcare
programs, contractual damages and the curtailment or restricting of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of <FONT
STYLE="white-space:nowrap">non-compliance</FONT> with these laws. Further, if any of the physicians or other healthcare providers or entities with whom we expect to do business are found to be not in compliance with applicable laws, they may be
subject to similar penalties. Any action for violation of these laws, even if successfully defended, could cause us to incur significant legal expenses and divert management&#146;s attention from the operation of the business. In addition, the
approval and commercialization of any product candidate we develop outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. All of these could harm our ability to
operate our business and our financial results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Efforts to ensure that our business arrangements with third parties will comply with applicable
healthcare laws and regulations will involve substantial costs. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#146;s
attention from the operation of our business. The shifting compliance environment and the need to build and maintain robust and expandable systems to comply with multiple jurisdictions with different compliance or reporting requirements increases
the possibility that a healthcare company may run afoul of one or more of the requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may be subject to, or may in the future become subject to, US
federal and state, and foreign laws and regulations imposing obligations on how we collect, use, disclose, store and process personal information. Our actual or perceived failure to comply with such obligations could result in liability or
reputational harm and could harm our business. Ensuring compliance with such laws could also impair our efforts to maintain and expand our customer base, and thereby decrease our revenue. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In many activities, including the conduct of clinical trials, we may be subject to laws and regulations governing data privacy and the protection of
health-related and other personal information. These laws and regulations govern our processing of personal data, including the collection, access, use, analysis, modification, storage, transfer, security breach notification, destruction and
disposal of personal data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The privacy and security of personally identifiable information stored, maintained, received or transmitted, including
electronically, is subject to significant regulation in the United States and abroad. While we strive to comply with all applicable privacy and security laws and regulations, legal standards for privacy continue to evolve and any failure or
perceived failure to comply may result in proceedings or actions against us by government entities or others, or could cause reputational harm, which could have a material adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Numerous foreign, federal and state laws and regulations govern collection, dissemination, use and confidentiality of personally identifiable health
information, including state privacy and confidentiality laws (including state laws requiring disclosure of breaches), federal and state consumer protection and employment laws; HIPAA and European and other foreign data protection laws. These laws
and regulations are increasing in complexity and number, and may change frequently and sometimes conflict. The European Union&#146;s omnibus data protection law, the General Data Protection Regulation, or GDPR, took effect in May 2018. The GDPR
imposes numerous requirements on entities that process personal data in the context of an establishment in the European Economic Area, or EEA, or that process the personal data of data subjects who are located in the EEA. These requirements include,
for example, establishing a basis for processing, providing notice to data subjects, developing procedures to vindicate expanded data subject rights, implementing appropriate technical and organizational measures to safeguard personal data and
complying with restrictions on the cross-border transfer of personal data from the EEA to countries that the European Union does not consider </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
to have in place adequate data protection legislation, such as the United States. The GDPR additionally establishes heightened obligations for entities that process &#147;special categories&#148;
of personal data, such as health data. Nearly all clinical trials involve the processing of these &#147;special categories&#148; of personal data, and thus processing of personal data collected during the course of clinical trials is subject to
heightened protections under the GDPR. Violations of the GDPR can lead to penalties of up to $20&nbsp;million or 4% of an entity&#146;s annual turnover. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As a means to transfer personal data from the EEA to the U.S., <FONT STYLE="white-space:nowrap">U.S.-based</FONT> companies may certify compliance with
the privacy principles of the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Privacy Shield, or the Privacy Shield. Certification to the Privacy Shield, however, is not mandatory. If a <FONT STYLE="white-space:nowrap">U.S.-based</FONT> company does
not certify compliance with the Privacy Shield, it may rely on other authorized mechanisms to transfer personal data. Notably, the Privacy Shield is currently subject to challenge in the EU courts, and it is possible that it will be invalidated,
which was the fate of its predecessor, the <FONT STYLE="white-space:nowrap">EU-U.S.</FONT> Safe Harbor. In the event of invalidation of the Privacy Shield, U.S. companies that currently rely on the Privacy Shield as the basis for cross-border
transfer of personal data will need to establish another basis for cross-border transfer of personal data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">HIPAA establishes a set of national
privacy and security standards for the protection of individually identifiable health information, including protected health information, or PHI, by health plans, certain health care clearinghouses and health care providers that submit certain
covered transactions electronically, or covered entities, and their &#147;business associates,&#148; which are persons or entities that perform certain services for, or on behalf of, a covered entity that involve creating, receiving, maintaining or
transmitting PHI. While we are not currently a covered entity or business associate under HIPAA, we may receive identifiable information from these entities. Failure to receive this information properly could subject us to HIPAA&#146;s criminal
penalties, which may include fines up to $250,000 per violation and/or imprisonment. In addition, responding to government investigations regarding alleged violations of these and other laws and regulations, even if ultimately concluded with no
findings of violations or no penalties imposed, can consume company resources and impact our business and, if public, harm our reputation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In
addition, various states, such as California and Massachusetts, have implemented similar privacy laws and regulations, such as the California Confidentiality of Medical Information Act, that impose restrictive requirements regulating the use and
disclosure of health information and other personally identifiable information. In addition to fines and penalties imposed upon violators, some of these state laws also afford private rights of action to individuals who believe their personal
information has been misused. California&#146;s patient privacy laws, for example, provide for penalties of up to $250,000 and permit injured parties to sue for damages. In addition to the California Confidentiality of Medical Information Act,
California also recently enacted the California Consumer Privacy Act of 2018, or CCPA, which was effective January&nbsp;1, 2020. The CCPA has been characterized as the first &#147;GDPR-like&#148; privacy statute to be enacted in the United States
because it mirrors a number of the key provisions of the EU General Data Protection Regulation. The CCPA establishes a new privacy framework for covered businesses in the State of California, by creating an expanded definition of personal
information, establishing new data privacy rights for consumers imposing special rules on the collection of consumer data from minors and creating a new and potentially severe statutory damages framework for violations of the CCPA and for businesses
that fail to implement reasonable security procedures and practices to prevent data breaches. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The interplay of federal and state laws may be
subject to varying interpretations by courts and government agencies, creating complex compliance issues for us and potentially exposing us to additional expense, adverse publicity and liability. Further, as regulatory focus on privacy issues
continues to increase and laws and regulations concerning the protection of personal information expand and become more complex, these potential risks to our business could intensify. The </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
legislative and regulatory landscape for privacy and data security continues to evolve, and there has been an increasing focus on privacy and data security issues which may affect our business.
Failure to comply with current and future laws and regulations could result in government enforcement actions (including the imposition of significant penalties), criminal and/or civil liability for us and our officers and directors, private
litigation and/or adverse publicity that negatively affects our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Ongoing healthcare legislative and regulatory reform measures may have a material
adverse effect on our business and results of operations. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Changes in U.S. and foreign regulations, statutes or the interpretation of
existing regulations could impact our business in the future by requiring, for example: (i)&nbsp;changes to our manufacturing arrangements; (ii)&nbsp;additions or modifications to product labeling; (iii)&nbsp;the recall or discontinuation of our
products; or (iv)&nbsp;additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the U.S. and in some foreign jurisdictions, there have been, and likely will continue to be, a number of legislative initiatives and regulatory
changes regarding the healthcare system directed at broadening the availability of healthcare, improving the quality of healthcare, and containing or lowering the cost of healthcare. For example, in March 2010, the ACA was enacted, which
substantially changed the way health care is financed by both governmental and private insurers, and significantly impacted the U.S. biopharmaceutical industry. The ACA, among other things, subjects biological products to potential competition by
lower-cost biosimilars, expands the types of entities eligible for the 340B drug discount program; introduced a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled,
infused, instilled, implanted or injected; increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations;
established annual fees and taxes on manufacturers of certain branded prescription drugs; and created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan
Budget Act of 2018, or BBA, effective as of January 2019) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their
coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Since its enactment, there
have been numerous judicial, administrative, executive and legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. Various portions of the ACA are currently
undergoing legal and constitutional challenges in the United States Supreme Court; the Trump Administration has issued various Executive Orders which eliminated cost sharing subsidies and various provisions that would impose a fiscal burden on
states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare providers, health insurers or manufacturers of pharmaceuticals or medical devices; and Congress has introduced several pieces of legislation aimed at significantly
revising or repealing the ACA. Also, in December 2018, CMS issued a final rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program. Since then,
the ACA risk adjustment program payment parameters have been updated annually. It is unclear whether the ACA will be overturned, repealed, replaced or further amended. We cannot predict what affect further changes to the ACA would have on our
business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, on
August&nbsp;2, 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2
trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs, including aggregate reductions of Medicare payments to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
providers of up to 2% per fiscal year. These reductions went into effect on April&nbsp;1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2030,
unless additional Congressional action is taken. However, pursuant to the Coronavirus Aid, Relief and Economic Security Act, or CARES Act, these Medicare sequester reductions will be suspended from May&nbsp;1, 2020 through December&nbsp;31, 2020 due
to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. On January&nbsp;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers,
including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Additionally, the BBA, among other things, amended the ACA, effective
January&nbsp;1, 2019, by increasing the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discount (from 50% under the ACA to 70%) that is owed by pharmaceutical manufacturers who participate in Medicare
Part D and closing the coverage gap in most Medicare drug plans, commonly referred to as the &#147;donut hole&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Moreover, payment
methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment and delivery models, such as bundled payment models. Recently, there has been heightened governmental scrutiny
over the manner in which manufacturers set prices for their products. Such scrutiny has resulted in several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more
transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. For example, on
March&nbsp;10, 2020, the Trump administration sent &#147;principles&#148; for drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part D beneficiary <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> pharmacy expenses, provide an option to cap Medicare Part D beneficiary monthly <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, and place
limits on pharmaceutical price increases. Additionally, the Trump administration previously released a &#147;Blueprint&#148; to lower drug prices and reduce out of pocket costs of drugs that contained proposals to increase manufacturer competition,
increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. HHS has solicited feedback on some of
these measures and has implemented others under its existing authority. For example, in May 2019, CMS issued a final rule that would allow Medicare Advantage Plans the option of using step therapy, a type of prior authorization, for Part B drugs
beginning January&nbsp;1, 2020. This final rule codified CMS&#146;s policy change that was effective January&nbsp;1, 2019. Although a number of these and other measures may require additional authorization to become effective, Congress and the Trump
administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">At the state
level in the United States, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biologic product pricing, including price or patient reimbursement constraints, discounts, restrictions
on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party
payors or other restrictions on coverage or access could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to
determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates that we successfully commercialize or put pressure
on our product pricing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or
administrative action in the United States or in any other jurisdictions. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been
obtained and we may not achieve or sustain profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>In the United States, inadequate funding for the FDA, the Securities and Exchange Commission, or
the SEC, and other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies
from performing normal business functions on which the operation of our business may rely, which could negatively impact our business. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory
and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and
development activities, is subject to the political process, which is inherently fluid and unpredictable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Disruptions at the FDA and other agencies
may also slow the time necessary for new drugs to be reviewed or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, the U.S. government has shut down several times and
certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical employees and stop critical activities. Separately, in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, on March&nbsp;10, 2020, the FDA
announced its intention to temporarily postpone most inspections of foreign manufacturing facilities and along with routine surveillance inspections of domestic manufacturing facilities. On July&nbsp;10, 2020, the FDA announced its goal of
restarting domestic onsite inspections during the week of July&nbsp;20 but such activities will depend on data about the virus&#146; trajectory in a given state and locality and the rules and guidelines that are put in place by state and local
governments. The FDA has developed a rating system to assist in determining when and where it is safest to conduct prioritized domestic inspections. In April 2020, the FDA stated that its New Drug Program was continuing to meet program user fee
performance goals, but due to many agency staff working on <FONT STYLE="white-space:nowrap">COVID-19</FONT> activities, it was possible that the FDA would not be able to sustain that level of performance indefinitely. Regulatory authorities outside
the United States may adopt similar restrictions or other policy measures in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and may experience delays in their regulatory activities. If a prolonged government shutdown
occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews or other regulatory activities, it could significantly impact the ability of the FDA to timely review
and process our regulatory submissions, which could have a material adverse effect on our business. Further, upon completion of this offering and in our operations as a public company, future government shutdowns could impact our ability to access
the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>EU drug marketing and reimbursement regulations
may materially affect our ability to market and receive coverage for our products in the European member states. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We ultimately intend to
seek approval to market our product candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in
those jurisdictions. In some foreign countries, particularly those in the EU, the pricing of drugs is subject to governmental control and other market regulations which could put pressure on the pricing and usage of our product candidates. In these
countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. In addition, market acceptance and sales of our product candidates will depend significantly on the
availability of adequate coverage and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
reimbursement from third-party payors for our product candidates and may be affected by existing and future health care reform measures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Much like the federal Anti-Kickback Statute prohibition in the United States, the provision of benefits or advantages to physicians to induce or
encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. The provision of benefits or advantages to physicians is governed by the national anti-bribery laws of EU
Member States, and in respect of the U.K. (which is longer a member of the EU), the U.K. Bribery Act of 2010. Infringement of these laws could result in substantial fines and imprisonment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of
prior notification and approval by the physician&#146;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry
codes or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, in most foreign countries, including the EEA, the proposed pricing for a drug must be approved before it may be lawfully marketed. The
requirements governing drug pricing and reimbursement vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems
provide reimbursement and to control the prices of medicinal products for human use. Reference pricing used by various EU member states and parallel distribution, or arbitrage between <FONT STYLE="white-space:nowrap">low-priced</FONT> and
high-priced member states, can further reduce prices. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal
product on the market. In some countries, we may be required to conduct a clinical study or other studies that compare the cost-effectiveness of any of our product candidates to other available therapies in order to obtain or maintain reimbursement
or pricing approval. There can be no assurance that any country that has price controls or reimbursement limitations for biopharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our products. Historically,
products launched in the EU do not follow price structures of the United States and generally prices tend to be significantly lower. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or
reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if reimbursement of our products is unavailable or limited in scope or amount, our revenues from sales and the potential
profitability of any of our product candidates in those countries would be negatively affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Legal, political and economic uncertainty surrounding the
exit of the U.K. from the EU may be a source of instability in international markets, create significant currency fluctuations, adversely affect our operations in the U.K. and pose additional risks to our business, revenue, financial condition and
results of operations. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On June&nbsp;23, 2016, the U.K. held a referendum in which a majority of the eligible members of the electorate voted
to leave the EU, commonly referred to as Brexit. Pursuant to Article 50 of the Treaty on EU, the U.K. ceased being a Member State of the EU on January&nbsp;31, 2020. However, the terms of the withdrawal have yet to be fully negotiated. The
implementation period began February&nbsp;1, 2020 and will continue until December&nbsp;31, 2020. During this <FONT STYLE="white-space:nowrap">11-month</FONT> period, the U.K. will continue to follow all of the EU&#146;s rules, the EU&#146;s
pharmaceutical law remains applicable to the U.K. and the U.K.&#146;s trading relationship will remain the same. However, regulations (including financial laws and regulations, tax and free trade agreements, intellectual property rights, data
protection laws, supply chain logistics, environmental, health and safety laws and regulations, medicine licensing and regulations, immigration laws and employment laws), have yet to be addressed. This lack of clarity on future U.K. laws and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
regulations and their interaction with the EU laws and regulations may negatively impact foreign direct investment in the U.K., increase costs, depress economic activity and restrict access to
capital. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The uncertainty concerning the U.K.&#146;s legal, political and economic relationship with the EU after Brexit may be a source of
instability in the international markets, create significant currency fluctuations and/or otherwise adversely affect trading agreements or similar cross-border <FONT STYLE="white-space:nowrap">co-operation</FONT> arrangements (whether economic, tax,
fiscal, legal, regulatory or otherwise) beyond the date of Brexit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">These developments, or the perception that any of them could occur, may have a
significant adverse effect on global economic conditions and the stability of global financial markets, and could significantly reduce global market liquidity and limit the ability of key market participants to operate in certain financial markets.
In particular, it could also lead to a period of considerable uncertainty in relation to the U.K. financial and banking markets, as well as on the regulatory process in Europe. Asset valuations, currency exchange rates and credit ratings may also be
subject to increased market volatility. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If the U.K. and the EU are unable to negotiate acceptable agreements or if other EU member states pursue
withdrawal, barrier-free access between the U.K. and other EU member states or among the European Economic Area overall could be diminished or eliminated. The long-term effects of Brexit will depend on any agreements (or lack thereof) between the
U.K. and the EU and, in particular, any arrangements for the U.K. to retain access to EU markets either during a transitional period from January&nbsp;1, 2021 or more permanently. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Such a withdrawal from the EU is unprecedented, and it is unclear how the U.K.&#146;s access to the European single market for goods, capital, services
and labor within the EU, or single market, and the wider commercial, legal and regulatory environment, will impact our current and future operations (including business activities conducted by third parties and contract manufacturers on our behalf)
and clinical activities in the U.K. In addition to the foregoing, our U.K. operations support our current and future operations and clinical activities in the EU and European Economic Area, or EEA, and these operations and clinical activities could
be disrupted by Brexit. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may also face new regulatory costs and challenges that could have an adverse effect on our operations. Depending on the
terms of the U.K.&#146;s withdrawal from the EU, the U.K. could lose the benefits of global trade agreements negotiated by the EU on behalf of its members, which may result in increased trade barriers that could make our doing business in the EU and
the EEA more difficult. Since the regulatory framework in the U.K. covering quality, safety and efficacy of pharmaceutical products, clinical trials, marketing authorization, commercial sales and distribution of pharmaceutical products is derived
from EU directives and regulations, Brexit could materially impact the future regulatory regime with respect to the approval of our product candidates in the U.K. For instance, in November 2017, EU member states voted to move the EMA, the EU&#146;s
regulatory body, from London to Amsterdam. Operations in Amsterdam commenced in March 2019, and the move itself may cause significant disruption to the regulatory approval process in Europe. It remains to be seen how, if at all, Brexit will impact
regulatory requirements for product candidates and products in the U.K. Any delay in obtaining, or an inability to obtain, any regulatory approvals, as a result of Brexit or otherwise, would prevent us from commercializing our product candidates in
the U.K. and/or the EU and restrict our ability to generate revenue and achieve and sustain profitability. If any of these outcomes occur, we may be forced to restrict or delay efforts to seek regulatory approval in the U.K. and/or EU for our
product candidates, which could significantly and materially harm our business. Even prior to any change to the U.K.&#146;s relationship with the EU, the announcement of Brexit has created economic uncertainty surrounding the terms of Brexit and its
consequences could adversely impact customer confidence resulting in customers reducing their spending budgets on our product candidates, if approved, which could adversely affect our business, financial condition, results of operations and could
adversely affect the market price of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Additional laws and regulations governing international operations could negatively impact or restrict our
operations. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For our operations outside of the United States, we must dedicate additional resources to comply with numerous laws and
regulations in each jurisdiction in which we plan to operate. The U.S. Foreign Corrupt Practices Act, or the FCPA, prohibits any U.S. individual or business entity from paying, offering, authorizing payment or offering of anything of value, directly
or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates
companies whose securities are listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including
international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Compliance
with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the biopharmaceutical industry, because, in many countries, hospitals are
operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals and healthcare providers in connection with clinical trials and other work have been deemed to be improper payments
to government officials and have led to FCPA enforcement actions. Recently the SEC and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all
of our employees, agents or contractors, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> nationals, of information products classified for national security purposes, as well as certain products, technology and technical data relating to those products. If we continue and expand our presence
outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United
States, which could limit our growth potential and increase our development costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Violations of these laws and regulations could result in fines,
criminal sanctions against us, our officers or our employees, the closing down of our facilities, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs and
prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products, if approved, in one or more countries and could materially damage our reputation, our brand, our international
expansion efforts, our ability to attract and retain employees and our business, prospects, operating results and financial condition. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the
FCPA&#146;s accounting provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or
penalties or incur costs that could harm our business. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are subject to numerous environmental, health and safety laws and regulations,
including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials,
including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or
injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees, but this insurance
may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations.
Environmental laws and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Risks Related to Our Intellectual Property </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our success depends in
part on our ability to protect our intellectual property. It is difficult and costly to protect our proprietary rights and technology, and we may not be able to ensure their protection. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our business will depend in large part on obtaining and maintaining patent, trademark and trade secret protection of our proprietary technologies and our
product candidates, their respective components, synthetic intermediates, formulations, combination therapies and methods used to manufacture them and methods of treatment, as well as successfully defending these patents against third-party
challenges. Our ability to stop unauthorized third parties from making, using, selling, offering to sell or importing our product candidates is dependent upon the extent to which we have rights under valid and enforceable patents that cover these
activities and whether a court would issue an injunctive remedy. If we are unable to secure and maintain patent protection for any product or technology we develop, or if the scope of the patent protection secured is not sufficiently broad, our
competitors could develop and commercialize products and technology similar or identical to ours, and our ability to commercialize any product candidates we may develop may be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The patenting process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a
reasonable cost or in a timely manner. In addition, we may not pursue, obtain, or maintain patent protection in all relevant markets. It is also possible that we will fail to identify patentable aspects of our research and development output before
it is too late to obtain patent protection. Moreover, in some circumstances, we may not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from or
license to third parties and are reliant on our licensors or licensees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The strength of patents in the biotechnology and biopharmaceutical field
involves complex legal and scientific questions and can be uncertain. The patent applications that we own or <FONT STYLE="white-space:nowrap">in-license</FONT> may fail to result in issued patents with claims that cover our product candidates or
uses thereof in the United States or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or
held unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our technology, including our product candidates, or prevent others from designing around our claims. If the breadth or
strength of protection provided by the patent applications we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product
candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We cannot be certain that we were the first to file any patent application related to our technology,
including our product candidates, and, if we were not, we may be precluded from obtaining patent protection for our technology, including our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We cannot be certain that we are the first to invent the inventions covered by pending patent applications and, if we are not, we may be subject to
priority disputes. Furthermore, for United States applications in which all claims are entitled to a priority date before March&nbsp;16, 2013, an interference proceeding can be provoked by a third-party or instituted by the United States Patent and
Trademark Office, or USPTO, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. Similarly, for United States applications in which at least one claim is not entitled to a priority date
before March&nbsp;16, 2013, derivation proceedings can be instituted to determine whether the subject matter of a patent claim was derived from a prior inventor&#146;s disclosure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may be required to disclaim part or all of the term of certain patents or all of the term of certain patent applications. There may be prior art of
which we are not aware that may affect the validity or enforceability of a patent or patent application claim. There also may be prior art of which we are aware, but which we do not believe affects the validity or enforceability of a claim, which
may, nonetheless, ultimately be found to affect the validity or enforceability of a claim. No assurance can be given that if challenged, our patents would be declared by a court to be valid or enforceable or that even if found valid and enforceable,
would adequately protect our product candidates, or would be found by a court to be infringed by a competitor&#146;s technology or product. We may analyze patents or patent applications of our competitors that we believe are relevant to our
activities, and consider that we are free to operate in relation to our product candidates, but our competitors may achieve issued claims, including in patents we consider to be unrelated, which block our efforts or may potentially result in our
product candidates or our activities infringing such claims. The possibility exists that others will develop products which have the same effect as our products on an independent basis which do not infringe our patents or other intellectual property
rights, or will design around the claims of patents that may issue that cover our products. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Recent or future patent reform legislation could
increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. Under the enacted Leahy-Smith America Invents Act, or America Invents Act, enacted in 2013, the United
States moved from a &#147;first to invent&#148; to a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system. Under a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> system, assuming the other requirements for patentability are met, the first inventor to file a patent application generally will be entitled
to a patent on the invention regardless of whether another inventor had made the invention earlier. The America Invents Act includes a number of other significant changes to U.S. patent law, including provisions that affect the way patent
applications are prosecuted, redefine prior art and establish a new post-grant review system. The effects of these changes are currently unclear as the USPTO only recently developed new regulations and procedures in connection with the America
Invents Act and many of the substantive changes to patent law, including the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;first-to-file&#148;</FONT></FONT> provisions, only became effective in March 2013. In addition, the
courts have yet to address many of these provisions and the applicability of the act and new regulations on specific patents discussed herein have not been determined and would need to be reviewed. However, the America Invents Act and its
implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial
condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The degree of future protection for our proprietary rights is uncertain because legal means afford
only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">others may be able to make or use compounds that are similar to the compositions of our product candidates but that are not
covered by the claims of our patents or those of our licensors; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we or our licensors, as the case may be, may fail to meet our obligations to the U.S. government in regards to any <FONT
STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications funded by U.S. government grants, leading to the loss of patent rights; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we or our licensors, as the case may be, might not have been the first to file patent applications for these inventions;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">others may independently develop similar or alternative technologies; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">it is possible that our pending patent applications will not result in issued patents; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">it is possible that there are prior public disclosures that could invalidate our or our licensors&#146; patents, as the
case may be, or parts of our or their patents; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">it is possible that others may circumvent our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">it is possible that there are unpublished applications or patent applications maintained in secrecy that may later issue
with claims covering our products or technology similar to ours; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the laws of foreign countries may not protect our or our licensors&#146;, as the case may be, proprietary rights to the
same extent as the laws of the United States; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the claims of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> issued patents or patent applications, if
and when issued, may not cover our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> issued patents may not provide us with any competitive
advantages, may be narrowed in scope, or be held invalid or unenforceable as a result of legal challenges by third parties; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the inventors of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents or patent applications may become
involved with competitors, develop products or processes which design around our patents or become hostile to us or the patents or patent applications on which they are named as inventors; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">it is possible that our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents or patent applications omit
individual(s) that should be listed as inventor(s) or include individual(s) that should not be listed as inventor(s), which may cause these patents or patents issuing from these patent applications to be held invalid or unenforceable;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we have engaged in scientific collaborations in the past, and will continue to do so in the future. Such collaborators may
develop adjacent or competing products to ours that are outside the scope of our patents; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may not develop additional proprietary technologies for which we can obtain patent protection; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">it is possible that product candidates or diagnostic tests we develop may be covered by third parties&#146; patents or
other exclusive rights; or </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the patents of others may have an adverse effect on our business. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have entered into, and may enter into, license or other collaboration agreements that impose certain obligations on us. If we fail to comply with our
obligations under such agreements with third parties, we could lose license rights that may be important to our business. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection with
our efforts to expand our pipeline of product candidates, we may enter into certain licenses or other collaboration agreements in the future pertaining to the <FONT STYLE="white-space:nowrap">in-license</FONT> of rights to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
additional candidates. Such agreements may impose various diligence, milestone payment, royalty, insurance or other obligations on us. If we fail to comply with these obligations, our licensor or
collaboration partners may have the right to terminate the relevant agreement, in which event we would not be able to develop or market the products covered by such licensed intellectual property. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Moreover, disputes may arise regarding intellectual property subject to a licensing agreement, including: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the extent to which our product candidates, technology and processes infringe on intellectual property of the licensor that
is not subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the sublicensing of patent and other rights under our collaborative development relationships; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by our licensors and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, the agreements under which we currently license intellectual property or technology from third parties are complex, and certain provisions
in such agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or
technology, or increase what we believe to be our financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover,
if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected
product candidates, which could have a material adverse effect on our business, financial conditions, results of operations and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In
addition, we may have limited control over the maintenance and prosecution of these <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications, or any other intellectual property that may be related to our <FONT
STYLE="white-space:nowrap">in-licensed</FONT> intellectual property. For example, we cannot be certain that such activities by any future licensors have been or will be conducted in compliance with applicable laws and regulations or will result in
valid and enforceable patents and other intellectual property rights. We have limited control over the manner in which our licensors initiate an infringement proceeding against a third-party infringer of the intellectual property rights, or defend
certain of the intellectual property that is licensed to us. It is possible that the licensors&#146; infringement proceeding or defense activities may be less vigorous than had we conducted them ourselves. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition to patent protection, we rely heavily upon <FONT STYLE="white-space:nowrap">know-how</FONT> and trade secret protection, as well as <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> agreements and invention assignment agreements with our employees, consultants and third parties, to protect our confidential and proprietary information, especially where we do not believe patent
protection is appropriate or obtainable. In addition to contractual measures, we try to protect the confidential nature of our proprietary information using physical and technological security measures. Such measures may not, for example, in the
case of misappropriation of a trade secret by an employee or third-party with authorized access, provide adequate protection for our proprietary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
information. Our security measures may not prevent an employee or consultant from misappropriating our trade secrets and providing them to a competitor, and recourse we take against such
misconduct may not provide an adequate remedy to protect our interests fully. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret can be difficult, expensive, and time-consuming, and the outcome is unpredictable. In
addition, trade secrets may be independently developed by others in a manner that could prevent legal recourse by us. If any of our confidential or proprietary information, such as our trade secrets, were to be disclosed or misappropriated, or if
any such information was independently developed by a competitor, our competitive position could be harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, courts outside the United
States are sometimes less willing to protect trade secrets. If we choose to go to court to stop a third-party from using any of our trade secrets, we may incur substantial costs. These lawsuits may consume our time and other resources even if we are
successful. Although we take steps to protect our proprietary information and trade secrets, including through contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary
information and techniques or otherwise gain access to our trade secrets or disclose our technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Thus, we may not be able to meaningfully
protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of employment or consulting
relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual or entity during the course of the party&#146;s relationship with us is to be
kept confidential and not disclosed to third parties except in specific circumstances. In the case of employees, the agreements provide that all inventions conceived by the individual, and which are related to our current or planned business or
research and development or made during normal working hours, on our premises or using our equipment or proprietary information, are our exclusive property. In addition, we take other appropriate precautions, such as physical and technological
security measures, to guard against misappropriation of our proprietary technology by third parties. We have also adopted policies and conduct training that provides guidance on our expectations, and our advice for best practices, in protecting our
trade secrets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our commercial success depends in part on our ability to develop, manufacture, market and sell our product candidates and use our proprietary
technologies without infringing the proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and biopharmaceutical industries, as well as
administrative proceedings for challenging patents, including interference, derivation, <I>inter partes </I>review, post grant review, and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in foreign
jurisdictions. We may be exposed to, or threatened with, future litigation by third parties having patent or other intellectual property rights alleging that our product candidates and/or proprietary technologies infringe their intellectual property
rights. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and biopharmaceutical industries expand
and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. Moreover, it is not always clear to industry participants, including us, which patents cover various
types of drugs, products or their methods of use or manufacture. Thus, because of the large number of patents issued and patent applications filed in our fields, there may be a risk that third parties may allege they have patent rights encompassing
our product candidates, technologies or methods. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We also may be subject to other third party claims relating to alleged infringement of intellectual
property or other proprietary rights, including breach of nondisclosure, nonuse, noncompetition and non-solicitation provisions, intellectual property assignment and ownership, and misuse or misappropriation of intellectual property, trade secrets
and other confidential information, among others. If a court of competent jurisdiction finds us liable for any such claims, we may be prohibited from using certain intellectual property, trade secrets and confidential information, effectively
blocking our ability to seek patent protection for our inventions and halting the progress of our clinical development and commercialization efforts. For example, on May&nbsp;20, 2020, we received a cease and desist letter from Sage Therapeutics,
Inc., or Sage, in which Sage alleges a claim that we improperly accessed and benefited from Sage confidential information in connection with the in-license of our PRAX-114 development program as a result of our employment or engagement of former
Sage employees and consultants. We believe that there is no merit to these claims and intend to defend our position. However, an adverse result could harm our business and result of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If a third-party claims that we infringe its intellectual property rights, we may face a number of issues, including, but not limited to: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">infringement and other intellectual property claims which, regardless of merit, may be expensive and time-consuming to
litigate and may divert our management&#146;s attention from our core business; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">substantial damages for infringement, which we may have to pay if a court decides that the product candidate or technology
at issue infringes on or violates the third-party&#146;s rights, and, if the court finds that the infringement was willful, we could be ordered to pay treble damages and the patent owner&#146;s attorneys&#146; fees; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a court prohibiting us from developing, manufacturing, marketing or selling our product candidates, or from using our
proprietary technologies, unless the third-party licenses its product rights to us, which it is not required to do; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">if a license is available from a third-party, we may have to pay substantial royalties, upfront fees and other amounts,
and/or grant cross-licenses to intellectual property rights for our products and any license that is available may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> which could result in our competitors gaining access to the same
intellectual property; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">redesigning our product candidates or processes so they do not infringe, which may not be possible or may require
substantial monetary expenditures and time. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Some of our competitors may be able to sustain the costs of complex patent litigation
more effectively than we can because they have substantially greater resources. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have a material adverse effect on our ability to raise the funds
necessary to continue our operations or could otherwise have a material adverse effect on our business, results of operations, financial condition and prospects. Furthermore, because of the substantial amount of discovery required in connection with
intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our collaborators may assert ownership or commercial rights to inventions they develop from research we support or that we develop or otherwise arising from the
collaboration. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We collaborate with several institutions, universities, medical centers, physicians and researchers in scientific matters and
expect to continue to enter into additional collaboration agreements. In certain cases, we do not have written agreements with these collaborators, or the written agreements we have do not cover intellectual property rights. Also, we rely on
numerous third parties to provide us with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
materials that we use to conduct our research activities and develop our product candidates. If we cannot successfully negotiate sufficient ownership and commercial rights to any inventions that
result from our use of a third-party collaborator&#146;s materials, or if disputes arise with respect to the intellectual property developed with the use of a collaborator&#146;s samples, or data developed in a collaborator&#146;s study, we may be
limited in our ability to capitalize on the market potential of these inventions or developments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Third parties may assert that we are employing their
proprietary technology without authorization. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">There may be third-party patents of which we are currently unaware with claims to compositions
of matter, materials, formulations, methods of manufacture or methods for treatment that encompass the composition, use or manufacture of our product candidates. There may be currently pending patent applications of which we are currently unaware
which may later result in issued patents that our product candidates or their use or manufacture may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any
third-party patent were held by a court of competent jurisdiction to cover our product candidates, intermediates used in the manufacture of our product candidates or our materials generally, aspects of our formulations or methods of use, the holders
of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a
license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be
impaired or delayed, which could in turn significantly harm our business. Even if we obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. In
addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop
and commercialize our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful
claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#146; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products,
which may be impossible, or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence
of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In
that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Third parties may
assert that our employees or consultants have wrongfully used or disclosed confidential information or misappropriated trade secrets. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As is
common in the biotechnology and biopharmaceutical industries, we employ individuals who were previously employed at universities or other biotechnology or biopharmaceutical companies, including our competitors or potential competitors. Although we
try to ensure that our employees and consultants do not use the proprietary information or <FONT STYLE="white-space:nowrap">know-how</FONT> of others in their work for us, we may be subject to claims that we or our employees, consultants or
independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of a former employer or other third parties. Litigation may be necessary to defend against
these claims. If we fail in defending any such claims, in addition to paying monetary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation or other legal proceedings relating to intellectual
property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other
interim proceedings or developments, and, if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. This type of litigation or proceeding could
substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be
able to sustain the costs of such litigation or proceedings more effectively than we can because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other
intellectual property related proceedings could adversely affect our ability to compete in the marketplace. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may not be successful in obtaining or
maintaining necessary rights to develop any future product candidates on acceptable terms. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Because our programs may involve additional
product candidates that may require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, <FONT STYLE="white-space:nowrap">in-license</FONT> or use these proprietary rights.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our product candidates may also require specific formulations to work effectively and efficiently and these rights may be held by others. We may
develop products containing our compounds and <FONT STYLE="white-space:nowrap">pre-existing</FONT> biopharmaceutical compounds. We may be unable to acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> any compositions, methods of use,
processes or other third-party intellectual property rights from third parties that we identify as necessary or important to our business operations. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all,
which would harm our business. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights, and may need to seek to develop alternative approaches that do not infringe on such intellectual
property rights which may entail additional costs and development delays, even if we were able to develop such alternatives, which may not be feasible. Even if we are able to obtain a license, it may be
<FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement
technology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Additionally, we sometimes collaborate with academic institutions to accelerate our preclinical research or development under written
agreements with these institutions. In certain cases, these institutions may provide us with an option to negotiate a license to any of the institution&#146;s rights in technology resulting from the collaboration. Regardless of such option, we may
be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to others, potentially blocking our ability to pursue our
program. If we are unable to successfully obtain rights to required third-party intellectual property or to maintain the existing intellectual property rights we have, we may have to abandon development of such program and our business and financial
condition could suffer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies, which may
be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates.
More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities. There can be no assurance that we will be able to successfully complete such
negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be
expensive, time-consuming and unsuccessful. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Competitors may infringe our patents or the patents of our current or future licensors. To
counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid or is
unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question or for other reasons. An adverse result in any litigation or defense proceedings could
put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly, and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial
litigation expense and would be a substantial diversion of employee resources from our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may choose to challenge the patentability of
claims in a third-party&#146;s U.S. patent by requesting that the USPTO review the patent claims in an <I><FONT STYLE="white-space:nowrap">ex-parte</FONT> </I><FONT STYLE="white-space:nowrap">re-examination,</FONT> <I>inter partes </I>review or
post-grant review proceedings. These proceedings are expensive and may consume our time or other resources. We may choose to challenge a third-party&#146;s patent in patent opposition proceedings in the European Patent Office, or EPO, or other
foreign patent office. The costs of these opposition proceedings could be substantial, and may consume our time or other resources. If we fail to obtain a favorable result at the USPTO, EPO or other patent office then we may be exposed to litigation
by a third-party alleging that the patent may be infringed by our product candidates or proprietary technologies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, because some patent
applications in the United States may be maintained in secrecy until the patents are issued, patent applications in the United States and many foreign jurisdictions are typically not published until 18 months after filing, and publications in the
scientific literature often lag behind actual discoveries, we cannot be certain that others have not filed patent applications for technology covered by our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> issued patents or our pending
applications, or that we or, if applicable, a licensor were the first to invent the technology. Our competitors may have filed, and may in the future file, patent applications covering our products or technology similar to ours. Any such patent
application may have priority over our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications or patents, which could require us to obtain rights to issued patents covering such technologies. If another party has filed a
U.S. patent application on inventions similar to those owned by or <FONT STYLE="white-space:nowrap">in-licensed</FONT> to us, we or, in the case of <FONT STYLE="white-space:nowrap">in-licensed</FONT> technology, the licensor may have to participate
in an interference or derivation proceeding declared by the USPTO to determine priority of invention in the United States. If we or one of our licensors is a party to an interference or derivation proceeding involving a U.S. patent application on
inventions owned by or <FONT STYLE="white-space:nowrap">in-licensed</FONT> to us, we may incur substantial costs, divert management&#146;s time and expend other resources, even if we are successful. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of
inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license
rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a <FONT STYLE="white-space:nowrap">non-exclusive</FONT> license is offered and
our competitors gain access to the same technology. Litigation or interference proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other
employees. We may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of
our confidential information could be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If
securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by
governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the
patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other provisions during the patent application process and following the issuance of a patent. While an
inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application,
resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official
actions within prescribed time limits, <FONT STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly legalize and submit formal documents. In certain circumstances, even inadvertent noncompliance events may permanently and
irrevocably jeopardize patent rights. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Any patents, if issued, covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we or one of our licensors initiate legal proceedings against a third-party to enforce a patent covering one of our product candidates, the defendant
could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and
there are numerous grounds upon which a third-party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of
litigation. Such mechanisms include <FONT STYLE="white-space:nowrap">re-examination,</FONT> inter partes review, post grant review, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in
revocation or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we
cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, or if we
are otherwise unable to adequately protect our rights, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business and our
ability to commercialize or license our technology and product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Likewise, our current licensed or owned patents are expected to expire
between 2029 and 2041, without taking into account any possible patent term adjustments or extensions. Our earliest patents may expire before, or soon after, our first product achieves marketing approval in the United States or foreign
jurisdictions. Upon the expiration of our current patents, we may lose the right to exclude others from practicing these inventions. The expiration of these patents could also have a similar material adverse effect on our business, results of
operations, financial condition and prospects. Our current licensed or owned pending patent applications covering our proprietary technologies or our product candidates that if issued as patents are expected to expire from 2029 through 2041, without
taking into </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
account any possible patent term adjustments or extensions. However, we cannot be assured that the USPTO or relevant foreign patent offices will grant any of these patent applications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Changes in patent law in the United States and in foreign jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect
our products. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties
and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability are met, prior to March&nbsp;16, 2013, in the United States, the first to invent the
claimed invention was entitled to the patent, while outside the United States, the first to file a patent application was entitled to the patent. On March&nbsp;16, 2013, under the America Invents Act, the United States transitioned to a first
inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file a patent application will be entitled to the patent on an invention regardless of whether a third party was the first to invent
the claimed invention. A third party that files a patent application in the USPTO on or after March&nbsp;16, 2013, but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made
by such third party. This will require us to be cognizant of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing or
until issuance, we cannot be certain that we or our licensors were the first to either (i)&nbsp;file any patent application related to our product candidates or (ii)&nbsp;invent any of the inventions claimed in our or our licensor&#146;s patents or
patent applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The America Invents Act also includes a number of significant changes that affect the way patent applications will be
prosecuted and also may affect patent litigation. These include allowing third party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity of a patent by USPTO administered post-grant
proceedings, including post-grant review, inter-parties review and derivation proceedings. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States federal courts necessary to invalidate a
patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court
action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Therefore, the America
Invents Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications and the enforcement or defense of our owned or <FONT
STYLE="white-space:nowrap">in-licensed</FONT> issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, the patent positions of companies in the development and commercialization of biopharmaceuticals are particularly uncertain. Recent U.S.
Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and
enforceability of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on
our existing patent portfolio and our ability to protect and enforce our intellectual property in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have limited foreign intellectual property
rights and may not be able to protect our intellectual property rights throughout the world. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have limited intellectual property rights
outside the United States. Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries
do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or
from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and,
further, may export otherwise infringing products to territories where we have patent protection but where enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have
any issued patents and our patent claims or other intellectual property rights may not be effective or sufficient to prevent them from competing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal
systems of certain countries, particularly certain developing countries, do not favor the enforcement of, and may require a compulsory license to, patents, trade secrets and other intellectual property protection, particularly those relating to
biopharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products against third parties in violation of our proprietary rights generally. The initiation of proceedings by
third parties to challenge the scope or validity of our patent rights in foreign jurisdictions could result in substantial cost and divert our efforts and attention from other aspects of our business. Proceedings to enforce our patent rights in
foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not
issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our
intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years
from its earliest U.S. <FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. Various extensions such as patent term adjustments and/or extensions, may be available, but the life of a patent, and the protection it affords, is limited.
Even if patents covering our product candidates are obtained, once the patent life has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of new
product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from
commercializing products similar or identical to ours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we do not obtain patent term extension and data exclusivity for any product candidates we may
develop, our business may be materially harmed. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Depending upon the timing, duration and specifics of any FDA marketing approval of any
product candidates we may develop, one or more of our U.S. patents may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Action of 1984, or the Hatch-Waxman Amendments. The Hatch-Waxman
Amendments permit a patent extension term of up to five years as compensation for patent term lost during the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the
date of product approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to
apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent
term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations and prospects could be
materially harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of
interest and our business may be adversely affected. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our trademarks or trade names may be challenged, infringed, circumvented or declared
generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name recognition by potential partners or customers in
our markets of interest. If we are unable to establish name recognition based on our trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Risks Related to Our Dependence on Third Parties </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We rely on third
parties to assist in conducting our preclinical studies and clinical trials. If they do not perform satisfactorily, we may not be able to obtain regulatory approval or commercialize our product candidates, or such approval or commercialization may
be delayed, and our business could be substantially harmed. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have relied upon and plan to continue to rely on third parties, such as
laboratories, CROs, clinical data management organizations, medical institutions and clinical investigators, to conduct our preclinical studies and clinical trials and expect to rely on these third parties to conduct preclinical studies and clinical
trials of any other product candidate that we develop. Any of these third parties may terminate their engagements with us under certain circumstances. We may not be able to enter into alternative arrangements or do so on commercially reasonable
terms. In addition, there is a natural transition period when a new CRO begins work. As a result, delays may occur, which could negatively impact our ability to meet our expected clinical development timelines and harm our business, financial
condition and prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Although our reliance on these third parties for preclinical and clinical development activities limits our control over
these activities, we remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the applicable protocol, legal and regulatory requirements and scientific standards. Moreover, human
clinical research must comply with GCPs for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial
participants are protected. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators, clinical trial sites and IRBs. If we or our third-party contractors fail to comply with applicable GCPs,
the clinical data generated in our clinical trials may be deemed unreliable and the regulatory authorities may require us to perform additional clinical trials before approving our product candidates, which would delay the regulatory approval
process. We cannot be certain that, upon inspection, a regulatory authority will determine that any of our clinical trials comply with GCPs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
third parties conducting clinical trials on our behalf are not our employees, and except for remedies available to us under our agreements with such contractors, we cannot control whether or not they devote sufficient time, skill and resources to
our ongoing development programs. These outside contractors may not assign as great a priority to our programs or pursue them as diligently as we would if we were undertaking such programs ourselves. These contractors may also have
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities, which could impede their
ability to devote appropriate time to our clinical programs. If these third parties, including clinical investigators, do not successfully carry out their contractual duties, meet expected deadlines or conduct our clinical trials in accordance with
regulatory requirements or our stated protocols, we may not be able to obtain, or may be delayed in obtaining, regulatory approvals for our product candidates. If that occurs, we will not be able to, or may be delayed in our efforts to, successfully
commercialize our product candidates. In such an event, our financial results and the commercial prospects for any product candidates that we seek to develop could be harmed, our costs could increase and our ability to generate revenues could be
delayed, impaired or foreclosed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If our relationships with any third parties conducting our studies are terminated, we may be unable to enter into
arrangements with alternative third parties on commercially reasonable terms, or at all. Switching or adding third parties to conduct our studies involves substantial cost and requires extensive management time and focus. In addition, there is a
natural transition period when a new third party commences work. As a result, delays occur, which can materially impact our ability to meet our desired preclinical and clinical development timelines. Although we carefully manage our relationships
with third parties conducting our studies, we cannot assure that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material and adverse effect on our business, financial condition and
results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We also rely on other third parties to store and distribute drug supplies for our clinical trials. Any performance failure
on the part of our distributors could delay clinical development or regulatory approval of our product candidates or commercialization of any resulting products, producing additional losses and depriving us of potential product revenue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Furthermore, we may also engage third parties to develop companion or complementary diagnostics for use in our clinical trials, as applicable, but such
third parties may not be successful in developing such companion or complementary diagnostics, furthering the difficulty in identifying patients with the targeted eligibility criteria for our clinical trials. If we are required to develop companion
or complementary diagnostics and are unable to do so or unable to obtain any required regulatory clearance or approval of those diagnostics, this could compromise our ability to seek participation in the U.S. in certain of the FDA&#146;s expedited
review and development programs, including those that may accelerate clinical development and regulatory timelines, and could limit our ability to seek regulatory approval for our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>The manufacture of our product candidates is complex, and we may encounter difficulties in production. We currently rely completely on third parties to formulate
and manufacture our preclinical, clinical trial and commercial drug supplies. The development and commercialization of any of our product candidates could be stopped, delayed or made less profitable if those third parties fail to provide us with
sufficient quantities of such drug supplies or fail to do so at acceptable quality levels, including in accordance with rigorously enforced regulatory requirements or contractual obligations, and our operations could be harmed as a result.
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The processes involved in manufacturing our drug product candidates are complex, expensive, highly-regulated and subject to multiple risks.
Further, as product candidates are developed through preclinical studies to late-stage clinical trials towards approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods, are altered
along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives, and any of these changes could require the conduct of bridging studies and could cause our product
candidates to perform differently and affect the results of planned clinical trials or other future clinical trials. We have limited experience in drug formulation or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
manufacturing. Currently, we rely on an extensive network of contract manufacturers, and in some cases sole source suppliers, for the production of our product candidates for current and planned
clinical trials. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In order to conduct clinical trials of our product candidates, or supply commercial products, if approved, we will need to
manufacture them in large quantities. Our contract development and manufacturing organizations, or CDMOs, may be unable to successfully increase the manufacturing capacity for any of our product candidates in a timely or cost-effective manner, or at
all. In addition, quality issues may arise during <FONT STYLE="white-space:nowrap">scale-up</FONT> activities. If our CDMOs are unable to successfully scale up the manufacture of our product candidates in sufficient quality and quantity, the
development, testing and clinical trials of that product candidate may be delayed or become infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our
business. The same risk would apply to our internal manufacturing facilities, should we in the future decide to build internal manufacturing capacity. In addition, building internal manufacturing capacity would carry significant risks in terms of
being able to plan, design and execute on a complex project to build manufacturing facilities in a timely and cost-efficient manner, and the resources associated with ensuring the ongoing regulatory compliance of such manufacturing facilities would
be significant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, the manufacturing process for any products that we may develop is subject to FDA, EMA, and foreign regulatory
authority approval processes and continuous oversight, and we will need to contract with manufacturers who can meet all applicable FDA, EMA and foreign regulatory authority requirements, including complying with current good manufacturing practices,
or cGMPs, on an ongoing basis. Although our agreements with our CDMOs require them to perform according to certain cGMP requirements such as those relating to quality control, quality assurance and qualified personnel, we cannot control the ability
of our CDMOs to implement and maintain these standards. If we or our third-party manufacturers are unable to reliably produce products to specifications acceptable to the FDA, EMA or other regulatory authorities, we may not obtain or maintain the
approvals we need to commercialize such products. Even if we obtain regulatory approval for any of our product candidates, there is no assurance that either we or our CDMOs will be able to manufacture the approved product to specifications
acceptable to the FDA, EMA or other regulatory authorities, to produce it in sufficient quantities to meet the requirements for the potential launch of the product, or to meet potential future demand. Any of these challenges could delay completion
of clinical trials, require bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates, impair commercialization efforts, increase our cost of goods and have an
adverse effect on our business, financial condition, results of operations and growth prospects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If any third-party manufacturer of our product candidates is
unable to increase the scale of its production of our product candidates, and/or increase the product yield of its manufacturing, then our costs to manufacture the product may increase and commercialization may be delayed. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In order to produce sufficient quantities to meet the demand for clinical trials and, if approved, subsequent commercialization of our product candidates
that we may develop, our third-party manufacturers will be required to increase their production and optimize their manufacturing processes while maintaining the quality of the product. The transition to larger scale production could prove
difficult. In addition, if our third party manufacturers are not able to optimize their manufacturing processes to increase the product yield for our product candidates, or if they are unable to produce increased amounts of our product candidates
while maintaining the quality of the product, then we may not be able to meet the demands of clinical trials or market demands, which could decrease our ability to generate profits and have a material adverse impact on our business and results of
operation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We depend on third-party suppliers for key raw materials used in our manufacturing processes, some of which are
our sole source of supply, and the loss of these third-party suppliers or their inability to supply us with adequate raw materials could harm our business. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We rely on our CDMOs to purchase from third-party suppliers the materials necessary to produce our product candidates for our clinical trials. We do not
have, nor do we expect to enter into, any agreements for the commercial production of these raw materials, and we do not expect to have any control over the process or timing of our CDMOs&#146; acquisition of raw materials needed to produce our
product candidates. Any significant delay in the supply of a product candidate or the raw material components thereof for an ongoing clinical trial due to a manufacturer&#146;s need to replace a third-party supplier of raw materials could
considerably delay completion of our clinical trials, product testing and potential regulatory approval of our product candidates. Additionally, if our future manufacturers or we are unable to purchase these raw materials to commercially produce any
of our product candidates that gains regulatory approvals, the commercial launch of our product candidates would be delayed or there would be a shortage in supply, which would impair our ability to generate revenues from the sale of our product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Furthermore, for those third-party suppliers who may be our sole source of supply of certain materials, we may not have arrangements in
place for a redundant or second-source supply of any such materials in the event any of our current suppliers cease their operations for any reason. Establishing additional or replacement suppliers for the raw materials used in our product
candidates, if required, may not be accomplished quickly. If we are able to find a replacement supplier, such replacement supplier would need to be qualified and may require additional regulatory inspection or approval, which could result in further
delay. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We expect to depend on collaborations with third parties for the research, development and commercialization of certain of the product candidates we
may develop. If any such collaborations are not successful, we may not be able to realize the market potential of those product candidates. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may seek third-party collaborators for the research, development and commercialization of certain of the product candidates we may develop. For
example, we have a collaboration with Ionis Pharmaceuticals, Inc. to further our development of product candidates and to enhance our research efforts directed to developing a product candidate for the treatment of epilepsy. Our likely collaborators
for any other collaboration arrangements include large and <FONT STYLE="white-space:nowrap">mid-size</FONT> pharmaceutical companies, regional and national pharmaceutical companies, biotechnology companies and academic institutions. If we enter into
any such arrangements with any third parties, we will likely have shared or limited control over the amount and timing of resources that our collaborators dedicate to the development or potential commercialization of any product candidates we may
seek to develop with them. Our ability to generate revenue from these arrangements with commercial entities will depend on our collaborators&#146; abilities to successfully perform the functions assigned to them in these arrangements. We cannot
predict the success of any collaboration that we enter into. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Collaborations involving our research programs, or any product candidates we may
develop, pose the following risks to us: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators generally have significant discretion in determining the efforts and resources that they will apply to these
collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may not properly obtain, maintain, enforce or defend intellectual property or proprietary rights relating to
our product candidates or research programs, or may use our proprietary information in such a way as to expose us to potential litigation or other intellectual property related proceedings, including proceedings challenging the scope, ownership,
validity and enforceability of our intellectual property; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may own or <FONT STYLE="white-space:nowrap">co-own</FONT> intellectual property covering our product
candidates or research programs that results from our collaboration with them, and in such cases, we may not have the exclusive right to commercialize such intellectual property or such product candidates or research programs; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may need the cooperation of our collaborators to enforce or defend any intellectual property we contribute to or that
arises out of our collaborations, which may not be provided to us; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may control certain interactions with regulatory authorities, which may impact our ability to obtain and
maintain regulatory approval of our products candidates; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or
commercialization of our product candidates or research programs or that result in costly litigation or arbitration that diverts management attention and resources; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may decide to not pursue development and commercialization of any product candidates we develop or may elect
not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#146;s strategic focus or available funding or external factors such as an acquisition that diverts resources or creates
competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial
or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with
our product candidates or research programs if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may restrict us from researching, developing or commercializing certain products or technologies without
their involvement; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators with marketing and distribution rights to one or more product candidates may not commit sufficient resources
to the marketing and distribution of such product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we may lose certain valuable rights under circumstances identified in our collaborations, including if we undergo a change
of control; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may grant sublicenses to our technology or product candidates or undergo a change of control and the
sublicensees or new owners may decide to take the collaboration in a direction which is not in our best interest; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborators may become bankrupt, which may significantly delay our research or development programs, or may cause us to
lose access to valuable technology, <FONT STYLE="white-space:nowrap">know-how</FONT> or intellectual property of the collaborator relating to our products, product candidates or research programs; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">key personnel at our collaborators may leave, which could negatively impact our ability to productively work with our
collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborations may require us to incur short and long-term expenditures, issue securities that dilute our stockholders or
disrupt our management and business; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">if our collaborators do not satisfy their obligations under our agreements with them, or if they terminate our
collaborations with them, we may not be able to develop or commercialize product candidates as planned; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborations may require us to share in development and commercialization costs pursuant to budgets that we do not fully
control and our failure to share in such costs could have a detrimental impact on the collaboration or our ability to share in revenue generated under the collaboration; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaborations may be terminated in their entirety or with respect to certain product candidates or technologies and, if so
terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates or technologies; and </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient
manner or at all. If a present or future collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our development or commercialization program under such collaboration could be delayed, diminished or
terminated. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may face significant competition in seeking appropriate collaborations. Recent business combinations among
biotechnology and pharmaceutical companies have resulted in a reduced number of potential collaborators. In addition, the negotiation process is time-consuming and complex, and we may not be able to negotiate collaborations on a timely basis, on
acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development
programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our
expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further
develop product candidates or bring them to market and generate product revenue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we enter into collaborations to develop and potentially
commercialize any product candidates, we may not be able to realize the benefit of such transactions if we or our collaborator elects not to exercise the rights granted under the agreement or if we or our collaborator are unable to successfully
integrate a product candidate into existing operations and company culture. The failure to develop and commercialize a product candidate pursuant to our agreements with our current or future collaborators could prevent us from receiving future
payments under such agreements, which could negatively impact our revenues. In addition, if our agreement with any of our collaborators terminates, our access to technology and intellectual property licensed to us by that collaborator may be
restricted or terminate entirely, which may delay our continued development of our product candidates utilizing the collaborator&#146;s technology or intellectual property or require us to stop development of those product candidates completely. We
may also find it more difficult to find a suitable replacement collaborator or attract new collaborators, and our development programs may be delayed or the perception of us in the business and financial communities could be adversely affected. Many
of the risks relating to product development, regulatory approval, and commercialization described in this &#147;Risk Factors&#148; section also apply to the activities of our collaborators and any negative impact on our collaborators may adversely
affect us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may acquire businesses or products, or form strategic alliances, in the future, and we may not realize the benefits of such acquisitions or
alliances. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may acquire additional businesses or products, form strategic alliances or create joint ventures with third parties that we
believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies, we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with
our existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
marketing any new products resulting from a strategic alliance or acquisition that delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure that,
following any such acquisition, we will achieve the expected synergies to justify the transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Risks Related to Employee Matters, Managing Our Business and
Operations </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our business is subject to economic, political, regulatory and other risks associated with international operations. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our business is subject to risks associated with conducting business internationally. Some of our suppliers and collaborative relationships are located
outside the United States. Accordingly, our future results could be harmed by a variety of factors, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">economic weakness, including inflation, or political instability in particular
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> economies and markets; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">differing and changing regulatory requirements in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> countries;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not
respect and protect intellectual property rights to the same extent as the United States; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">difficulties in compliance with <FONT STYLE="white-space:nowrap">non-U.S.</FONT> laws and regulations;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulations and customs, tariffs and trade barriers;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in <FONT STYLE="white-space:nowrap">non-U.S.</FONT> currency exchange rates and currency controls;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in a specific country&#146;s or region&#146;s political or economic environment; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">trade protection measures, import or export licensing requirements or other restrictive actions by U.S. or <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> governments; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">negative consequences from changes in tax laws; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">workforce uncertainty in countries where labor unrest is more common than in the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">difficulties associated with staffing and managing international operations, including differing labor relations
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">potential liability under the FCPA, U.K. Bribery Act of 2010 or comparable foreign laws; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">business interruptions resulting from <FONT STYLE="white-space:nowrap">geo-political</FONT> actions, including war and
terrorism, natural disasters including earthquakes, typhoons, floods and fires, or health epidemics such as <FONT STYLE="white-space:nowrap">COVID-19;</FONT> and </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">cyberattacks, which are growing in frequency, sophistication and intensity, and are becoming increasingly difficult to
detect. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">These and other risks associated with our planned international operations may materially adversely affect our ability to
attain profitable operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>A pandemic, epidemic or outbreak of an infectious disease in the United States or worldwide may adversely affect our business.
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If a pandemic, epidemic or outbreak of an infectious disease occurs in the United States or worldwide our business may be adversely
affected. In December 2019, a novel strain of coronavirus named <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">SARS-CoV-2</FONT></FONT> was identified in Wuhan, China. This virus continues to spread globally, including in the
United States and the disease it causes, <FONT STYLE="white-space:nowrap">COVID-19,</FONT> has been declared a pandemic by the World </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Health Organization. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has impacted the global economy and may impact our operations, including the potential interruption of our
clinical trial activities, regulatory reviews and our supply chain. For example, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may delay enrollment in our clinical trials due to prioritization of hospital resources toward the
outbreak or other factors, and some patients may be unwilling to enroll in our trials or be unable to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services, which would delay our ability to
conduct clinical trials or release clinical trial results and could delay our ability to obtain regulatory approval and commercialize our product candidates. Furthermore, the spread of the virus may affect the operations of key governmental
agencies, such as the FDA, which may delay the development or approval process for our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The spread of an infectious disease,
including <FONT STYLE="white-space:nowrap">COVID-19,</FONT> may also result in the inability of our suppliers to deliver components or raw materials on a timely basis or at all. In addition, hospitals may reduce staffing and reduce or postpone
certain treatments in response to the spread of an infectious disease. Such events may result in a period of business disruption, and in reduced operations, or doctors and medical providers may be unwilling to participate in our clinical trials, any
of which could materially affect our business, financial condition and results of operations. We continue to closely monitor the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic as we evolve our business continuity plans, clinical
development plans and response strategy. The extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic impacts our business will depend on future developments, which are highly uncertain and cannot be predicted, including new
information which may emerge concerning the severity of the novel coronavirus and the actions to contain the coronavirus or treat its impact, among others. At present, we are not experiencing significant impact or delays from the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our business, operations and, if approved, commercialization plans. In addition, we have taken steps to mitigate against <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic-related delays,
and may take additional measures,&nbsp;intended to help minimize the risk of the virus to our employees, including temporarily requiring all employees to work remotely, suspending all <FONT STYLE="white-space:nowrap">non-essential</FONT> travel
worldwide for our employees, and discouraging employee attendance at industry events and <FONT STYLE="white-space:nowrap">in-person</FONT> work-related meetings, which could negatively affect our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A significant outbreak of other infectious diseases in the future also could result in a widespread health crisis that could adversely affect the
economies and financial markets worldwide, resulting in an economic downturn that could impact our business, financial condition and results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We depend heavily on our executive officers, principal consultants and others, and the loss of their services would materially harm our business. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our success depends, and will likely continue to depend, upon our ability to hire, retain the services of our current executive officers, principal
consultants and others, including Marcio Souza, our President and Chief Executive Officer, Bernard Ravina, our Chief Medical Officer, and Stuart Chaffee, our Chief Financial Officer. We have entered into employment agreements with Mr.&nbsp;Souza,
Dr.&nbsp;Ravina and Dr.&nbsp;Chaffee, but they may terminate their employment with us at any time. The loss of their services might impede the achievement of our research, development and commercialization objectives. We do not maintain &#147;key
person&#148; insurance for any of our executives or other employees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our ability to compete in the biotechnology and pharmaceuticals industries
depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. Our industry has experienced a high rate of turnover of management personnel in recent years. Replacing executive officers or other key
employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to develop, gain regulatory approval of and commercialize products
successfully. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key
employees on acceptable terms given the competition among numerous </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and
commercialization strategies. Our consultants and advisors may be employed by other entities and may have commitments under consulting or advisory contracts with those entities that may limit their availability to us. If we are unable to continue to
attract and retain highly qualified personnel, our ability to develop and commercialize our product candidates will be limited. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We only have a limited number
of employees to manage and operate our business. If we are unable to hire to retain adequate personnel, then we may not be able to meet our operational goals. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of September&nbsp;30, 2020, we had 50 full-time employees and one part-time employee. Our focus on the clinical development of <FONT
STYLE="white-space:nowrap">PRAX-114,</FONT> <FONT STYLE="white-space:nowrap">PRAX-944</FONT> and <FONT STYLE="white-space:nowrap">PRAX-562</FONT> requires us to optimize cash utilization and to manage and operate our business in a highly efficient
manner. We cannot ensure that we will be able to hire and/or retain adequate staffing levels to develop <FONT STYLE="white-space:nowrap">PRAX-114,</FONT> <FONT STYLE="white-space:nowrap">PRAX-944</FONT> and
<FONT STYLE="white-space:nowrap">PRAX-562</FONT> or to run our operations and/or to accomplish all of the objectives that we otherwise would seek to accomplish. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our employees, independent contractors, consultants, collaborators and contract research organizations may engage in misconduct or other improper activities,
including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory standards and requirements, which could cause significant liability for us and harm our reputation. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are exposed to the risk that our employees, independent contractors, consultants, collaborators and contract research organizations may engage in
fraudulent conduct or other illegal activity. Misconduct by those parties could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violates: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such
authorities; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">manufacturing standards; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced
by comparable <FONT STYLE="white-space:nowrap">non-U.S.</FONT> regulatory authorities; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">laws that require the accurate reporting of financial information or data. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creating
fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of product materials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter
misconduct, and the precautions we take to detect and prevent this kind of activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming
from a failure to be in compliance with such laws, standards or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted
against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of civil, criminal and administrative penalties,
damages, monetary fines, disgorgement, integrity oversight and reporting obligations, possible exclusion from participation in the United States in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm,
diminished profits and future earnings </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
and curtailment of our operations, any of which could have a material adverse effect on our ability to operate our business and our results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We expect to expand our organization, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of regulatory
affairs and sales, marketing and distribution, as well as to support our public company operations. To manage these growth activities, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities
and continue to recruit and train additional qualified personnel. Our management may need to devote a significant amount of its attention to managing these growth activities. Moreover, our expected growth could require us to relocate to a different
geographic area of the country. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion or relocation of our
operations, retain key employees, or identify, recruit and train additional qualified personnel. Our inability to manage the expansion or relocation of our operations effectively may result in weaknesses in our infrastructure, give rise to
operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our expected growth could also require significant capital expenditures and may divert financial resources from other
projects, such as the development of additional product candidates. If we are unable to effectively manage our expected growth, our expenses may increase more than expected, our ability to generate revenues could be reduced and we may not be able to
implement our business strategy, including the successful commercialization of our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Cyber-attacks or other failures in our
telecommunications or information technology systems, or those of our collaborators, contract research organizations, third-party logistics providers, distributors or other contractors or consultants, could result in information theft, data
corruption and significant disruption of our business operations. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We, our collaborators, our CROs, third-party logistics providers,
distributors and other contractors and consultants utilize information technology, or IT, systems and networks to process, transmit and store electronic information in connection with our business activities. As use of digital technologies has
increased, cyber incidents, including third parties gaining access to employee accounts using stolen or inferred credentials, computer malware, viruses, spamming, phishing attacks or other means, and deliberate attacks and attempts to gain
unauthorized access to computer systems and networks, have increased in frequency and sophistication. While we have not experienced any such system failure, accident or security breach to date, if such an event were to occur and cause interruptions
in our operations, it could result in a material disruption of our drug development programs. These threats pose a risk to the security of our, our collaborators&#146;, our CROs&#146;, third-party logistics providers&#146;, distributors&#146; and
other contractors&#146; and consultants&#146; systems and networks, and the confidentiality, availability and integrity of our data. There can be no assurance that we will be successful in preventing cyber-attacks or successfully mitigating their
effects. Similarly, there can be no assurance that our collaborators, CROs, third-party logistics providers, distributors and other contractors and consultants will be successful in protecting our clinical and other data that is stored on their
systems. Any cyber-attack, data breach or destruction or loss of data could result in a violation of applicable U.S. and international privacy, data protection and other laws, and subject us to litigation and governmental investigations and
proceedings by federal, state and local regulatory entities in the United States and by international regulatory entities, resulting in exposure to material civil and/or criminal liability. Further, our general liability insurance and corporate risk
program may not cover all potential claims to which we are exposed and may not be adequate to indemnify us for all liability that may be imposed; and could have a material adverse effect on our business and prospects. For example, the loss of
clinical trial data from completed, ongoing or planned clinical trials for any of our product candidates </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
could result in delays in our development and regulatory approval efforts and significantly increase our costs to recover or reproduce the data. In addition, we may suffer reputational harm or
face litigation or adverse regulatory action as a result of cyber-attacks or other data security breaches and may incur significant additional expense to implement further data protection measures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We rely on a set of cloud-based software services and access these services via the Internet for the vast majority of our computing, storage, bandwidth and other
services. Any disruption of or interference with our use of our cloud-based services would negatively affect our operations and could seriously harm our business. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We use several distributed computing infrastructure platforms for business operations, or what is commonly referred to as &#147;cloud&#148; computing
services and we access these services via the Internet. Any transition of the cloud services currently provided by an existing vendor to another cloud provider would be difficult to implement and will cause us to incur significant time and expense.
Given this, any significant disruption of or interference with our use of these cloud computing services would negatively impact our operations and our business would be seriously harmed. If our employees or partners are not able to access our cloud
computing services or encounter difficulties in doing so, we may experience business disruption. The level of service provided by our cloud computing vendors, including the ability to secure our confidential information and the confidential
information of third parties that is shared with us, may also impact the perception of our company and could seriously harm our business and reputation and create liability for us. If a cloud computing service that we use experiences interruptions
in service regularly or for a prolonged basis, or other similar issues, our business could be seriously harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, a cloud computing
service may take actions beyond our control that could seriously harm our business, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">discontinuing or limiting our access to its platform; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">increasing pricing terms; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">terminating or seeking to terminate our contractual relationship altogether; or </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">modifying or interpreting its terms of service or other policies in a manner that impacts our ability to run our business
and operations. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our cloud computing services have broad discretion to change and interpret its terms of service and other
policies with respect to us, and those actions may be unfavorable to us. Our cloud computing services may also alter how we are able to process data on the platform. If a cloud computing services makes changes or interpretations that are unfavorable
to us, our business could be seriously harmed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our efforts to protect the information shared with us may be unsuccessful due to the actions of
third parties, software bugs or other technical malfunctions, employee error or malfeasance or other factors. In addition, third parties may attempt to fraudulently induce employees or users to disclose information to gain access to our data or
third-party data entrusted to us. If any of these events occur, our or third-party information could be accessed or disclosed improperly. Some partners or collaborators may store information that we share with them on their own computing system. If
these third parties fail to implement adequate data-security practices or fail to comply with our policies, our data may be improperly accessed or disclosed. And even if these third parties take all of these steps, their networks may still suffer a
breach, which could compromise our data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Any incidents where our information is accessed without authorization, or is improperly used, or incidents
that violate our policies, could damage our reputation and our brand and diminish our competitive position. In addition, affected parties or government authorities could initiate legal or regulatory action against us over those incidents, which
could cause us to incur significant expense </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
and liability or result in orders or consent decrees forcing us to modify our business practices. Concerns over our privacy practices, whether actual or unfounded, could damage our reputation and
brand and deter users, advertisers and partners from using our products and services. Any of these occurrences could seriously harm our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are also subject to many federal, state and foreign laws and regulations, including those related to privacy, rights of publicity, data protection,
content regulation, intellectual property, health and safety, competition, protection of minors, consumer protection, employment and taxation. These laws and regulations are constantly evolving and may be interpreted, applied, created or amended in
a manner that could seriously harm our business </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have identified conditions and events that raise substantial doubt about our ability to continue as a
going concern. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may be forced to delay, reduce or eliminate some or all of our research and development programs, product portfolio
expansion or commercialization efforts if we are unable to obtain additional funding to support our current operating plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of June 30, 2020, we
had $19.7&nbsp;million of cash and cash equivalents. To date, we have primarily financed our operations with proceeds from sales of our redeemable convertible preferred stock and the issuance of convertible debt. We have incurred recurring losses
since our inception, including net losses of $35.5&nbsp;million for the year ended December&nbsp;31, 2019 and $19.9 million for the six months ended June 30, 2020. We expect to continue to generate operating losses for the foreseeable future as we
continue to invest significantly in the research and development of our programs. As a result, there is a significant degree of uncertainty as to how long our existing cash and cash equivalents will be sufficient to fund our operations. These
conditions raise substantial doubt about our ability to continue as a going concern for a period of at least one year from the date our consolidated financial statements are issued, and our independent registered public accounting firm has included
an explanatory paragraph relating to our ability to continue as a going concern in its report on our audited consolidated financial statements included elsewhere in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are seeking the anticipated proceeds from this offering to provide additional funding for our operations. Even if the offering is consummated, we may
be required to obtain additional funding whether through private or public equity transactions, debt financings or other capital sources, including collaborations with other companies or other strategic transactions and such additional funding may
not be available on terms we find acceptable or favorable. There is inherent uncertainty associated with these fundraising activities and they are not considered probable. If we are unable to obtain sufficient capital to continue to advance our
programs, we would be forced to delay, reduce or eliminate our research and development programs and any future commercialization efforts. Accordingly, our plans do not alleviate substantial doubt of our ability to continue as a going concern for a
period of at least one year after the date our consolidated financial statements are issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Nevertheless, our consolidated financial statements do
not include any adjustments that might result from the outcome of this uncertainty. We will need to raise additional capital in this offering and/or otherwise to fund our future operations and remain as a going concern. However, we cannot guarantee
that we will be able to obtain sufficient additional funding in this offering or otherwise or that such funding, if available, will be obtainable on terms favorable to us. In the event that we are unable to obtain sufficient additional funding,
there can be no assurance that we will be able to continue as a going concern. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Legislation or other changes in U.S. tax law could adversely affect our
business and financial condition. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The rules dealing with U.S. federal, state and local income taxation are constantly under review by
persons involved in the legislative process and by the Internal Revenue Service and the U.S. Treasury </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many changes have been made to
applicable tax laws and changes are likely to continue to occur in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For example, the Tax Cuts and Jobs Act, or the TCJA, was enacted in
2017 and made significant changes to corporate taxation, including the reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, the limitation of the tax deduction for net interest expense to 30% of adjusted taxable
income (except for certain small businesses), the limitation of the deduction for net operating losses from taxable years beginning after December&nbsp;31, 2017 to 80% of current year taxable income and the elimination of net operating loss
carrybacks generated in taxable years ending after December&nbsp;31, 2017 (though any such net operating losses may be carried forward indefinitely) and the modification or repeal of many business deductions and credits. In addition, on
March&nbsp;27, 2020, President Trump signed into law the &#147;Coronavirus Aid, Relief, and Economic Security Act&#148; or the CARES Act, which included certain changes in tax law intended to stimulate the U.S. economy in light of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> public health emergency, including temporary beneficial changes to the treatment of net operating losses, interest deductibility limitations and payroll tax matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">It cannot be predicted whether, when, in what form or with what effective dates new tax laws may be enacted, or regulations and rulings may be enacted,
promulgated or issued under existing or new tax laws, which could result in an increase in our or our shareholders&#146; tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of
changes in tax law or in the interpretation thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our ability to use our U.S. net operating loss carryforwards and certain other U.S. tax attributes may
be limited. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our ability to use our U.S. federal and state net operating losses to offset potential future taxable income and related income
taxes that would otherwise be due is dependent upon our generation of future taxable income, and we cannot predict with certainty when, or whether, we will generate sufficient taxable income to use all of our net operating losses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Unused losses for the tax year beginning before January&nbsp;1, 2018 and prior tax years will carry forward to offset future taxable income, if any,
until such unused losses expire. Unused losses generated for the tax year beginning after December&nbsp;31, 2017, under new tax legislation will not expire and may be carried forward indefinitely, and generally may not be carried back to prior
taxable years, except that, under the CARES Act, net operating losses generated in 2018, 2019 and 2020 may be carried back five taxable years. Additionally, for taxable years beginning after December&nbsp;31, 2020, the deductibility of such U.S.
federal net operating losses is limited to 80% of our taxable income in any future taxable year. In addition, both our current and our future unused losses may be subject to limitation under Sections 382 and 383 of the Internal Revenue Code of 1986,
as amended, or the Code, if we undergo an &#147;ownership change,&#148; generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a three-year period. We may have experienced such
ownership changes in the past, and we may experience ownership changes in the future as a result of this offering or subsequent shifts in our stock ownership, some of which are outside our control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Risks Related to Our Common Stock and This Offering </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>There has been
no prior public market for our common stock, the stock price of our common stock may be volatile or may decline regardless of our operating performance, an active trading market for our common stock may not develop and you may not be able to resell
your shares at or above the initial public offering price. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Prior to this offering there has been no public market for shares of our common
stock. You may not be able to sell your shares quickly or at the market price if trading in shares of our common stock is not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
active. The initial public offering price for our common stock will be determined through negotiations with the underwriters, and the negotiated price may not be indicative of the market price of
the common stock after the offering. Although our common stock has been approved for listing on The Nasdaq Global Select Market, an active or liquid market in our common stock may not develop upon the completion of this offering or, if it does
develop, it may not be sustainable. As a result of these and other factors, you may be unable to resell your shares of our common stock at or above the initial public offering price. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our ability to enter into
strategic collaborations or acquire companies or products by using our shares of common stock as consideration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The price of our stock may be volatile, and
you could lose all or part of your investment. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The trading price of our common stock following this offering is likely to be highly volatile
and could be subject to wide fluctuations in response to various factors, some of which are beyond our control, including limited trading volume. In addition to the factors discussed in this &#147;Risk Factors&#148; section and elsewhere in this
prospectus, these factors include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the commencement, enrollment, completion or results of our current Phase 2a clinical trials of <FONT
STYLE="white-space:nowrap">PRAX-114</FONT> and <FONT STYLE="white-space:nowrap">PRAX-944</FONT> and current Phase 1 trial of <FONT STYLE="white-space:nowrap">PRAX-562;</FONT> </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any delay in identifying and advancing a clinical candidate for our other programs; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any delay in our regulatory filings for <FONT STYLE="white-space:nowrap">PRAX-114,</FONT>
<FONT STYLE="white-space:nowrap">PRAX-944,</FONT> <FONT STYLE="white-space:nowrap">PRAX-562</FONT> or our future product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory
authority&#146;s review of such filings, including without limitation the FDA&#146;s issuance of a &#147;refusal to file&#148; letter or a request for additional information; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">adverse results or delays, suspensions or terminations in future preclinical studies or clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">adverse regulatory decisions, including failure to receive regulatory approval of
<FONT STYLE="white-space:nowrap">PRAX-114,</FONT> <FONT STYLE="white-space:nowrap">PRAX-944,</FONT> <FONT STYLE="white-space:nowrap">PRAX-562</FONT> or any other product candidate or the failure of a regulatory authority to accept data from
preclinical studies or clinical trials conducted in other countries; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in laws or regulations applicable to <FONT STYLE="white-space:nowrap">PRAX-114,</FONT> <FONT
STYLE="white-space:nowrap">PRAX-944,</FONT> <FONT STYLE="white-space:nowrap">PRAX-562</FONT> or any other product candidate, including but not limited to clinical trial requirements for approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">adverse developments concerning our manufacturers; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our inability to establish collaborations, if needed; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our failure to commercialize our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">additions or departures of key scientific or management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">unanticipated serious safety concerns related to the use of <FONT STYLE="white-space:nowrap">PRAX-114,</FONT> <FONT
STYLE="white-space:nowrap">PRAX-944,</FONT> <FONT STYLE="white-space:nowrap">PRAX-562</FONT> or any other product candidate; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">introduction of new products or services offered by us or our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">announcements of significant acquisitions, strategic partnerships, joint ventures or capital commitments by us or our
competitors; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to effectively manage our growth; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">actual or anticipated variations in quarterly operating results; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our cash position; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the
public; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">publication of research reports about us or our industry, or product candidates in particular, or positive or negative
recommendations or withdrawal of research coverage by securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in the market valuations of similar companies; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in the structure of the healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">overall performance of the equity markets; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">sales of our common stock by us or our stockholders in the future; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">trading volume of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">changes in accounting practices; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">ineffectiveness of our internal controls; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">disputes or other developments relating to proprietary rights, including patents, litigation matters and our ability to
obtain patent protection for our technologies; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">significant lawsuits, including patent or stockholder litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">general political and economic conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">other events or factors, many of which are beyond our control. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, the stock market in general, and the market for biopharmaceutical companies in particular, have experienced extreme price and volume
fluctuations that have often been unrelated or disproportionate to the operating performance of these companies, including as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. Broad market and industry factors may negatively
affect the market price of our common stock, regardless of our actual operating performance. If the market price of our common stock after this offering does not exceed the initial public offering price, you may not realize any return on your
investment in us and may lose some or all of your investment. In the past, securities class action litigation has often been instituted against companies following periods of volatility in the market price of a company&#146;s securities. This type
of litigation, if instituted, could result in substantial costs and a diversion of management&#146;s attention and resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We do not intend to pay
dividends on our common stock so any returns will be limited to the value of our stock. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We currently anticipate that we will retain future
earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Furthermore, future debt or other financing arrangements may contain terms prohibiting or
limiting the amount of dividends that may be declared or paid on our common stock. Any return to stockholders will therefore be limited to the appreciation of their stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our executive officers, directors and their affiliates and our principal stockholders own a significant percentage of our stock and will be able to exert
significant control over matters subject to stockholder approval. </I></B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Based on shares outstanding as of September&nbsp;30, 2020 and
immediately following the completion of this offering, our executive officers, directors and their affiliates and our principal stockholders will beneficially hold, in the aggregate, approximately 48.6% of our outstanding voting stock, excluding any
shares purchased in this offering. These stockholders, acting together, would be able to significantly influence all matters requiring stockholder approval. These stockholders acquired their shares of common stock (including shares of common stock
issuable upon the conversion of preferred stock) for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
less than the price of the shares of common stock being acquired in this offering, and these stockholders may have interests, with respect to their common stock, that are different from those of
investors in this offering and the concentration of voting power among these stockholders may have an adverse effect on the price of our common stock. This concentration of ownership control may adversely affect the market price of our common stock
by: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delaying, deferring or preventing a change in control; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">entrenching our management and the board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">impeding a merger, consolidation, takeover or other business combination involving us that other stockholders may desire;
and/or </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">See the &#147;Principal Stockholders&#148; section of this prospectus for more information regarding the ownership of our
outstanding common stock by our executive officers, directors, principal stockholders and their affiliates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If you purchase our common stock in this
offering, you will incur immediate and substantial dilution in the book value of your shares. </I></B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The initial public offering price will be
substantially higher than the pro forma as adjusted net tangible book value per share of our common stock after this offering. Investors purchasing common stock in this offering will pay a price per share that substantially exceeds the pro forma as
adjusted net tangible book value per share after this offering. As a result, investors purchasing common stock in this offering will incur immediate dilution of $9.79 per share, based on the initial public offering price of $17.50 per share,
representing the difference between our pro forma as adjusted net tangible book value per share after giving effect to this offering and the initial public offering price. Further, investors purchasing common stock in this offering will contribute
approximately 45.8% of the total amount invested by stockholders since our inception, but will own only approximately 27.2% of the shares of common stock outstanding after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This dilution is due to our investors who purchased shares prior to this offering having paid substantially less when they purchased their shares than
the price offered to the public in this offering. To the extent outstanding options are exercised, there will be further dilution to new investors. As a result of the dilution to investors purchasing shares in this offering, investors may receive
significantly less than the purchase price paid in this offering, if anything, in the event of our liquidation. For a further description of the dilution that you will experience immediately after this offering, see the section entitled
&#147;Dilution.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are an emerging growth company, and we cannot be certain if the reduced reporting requirements applicable to emerging growth
companies will make our common stock less attractive to investors. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are an emerging growth company, or EGC, as defined in the Jumpstart
Our Business Startups Act, or the JOBS Act, enacted in April 2012. For as long as we continue to be an EGC, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not EGCs,
including not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended, or the Sarbanes-Oxley Act, reduced disclosure obligations regarding executive compensation in this
prospectus and our periodic reports and proxy statements and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved. We could
be an EGC for up to five years following the year in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
which we complete this offering, although circumstances could cause us to lose that status earlier. We will remain an EGC until the earlier of (i)&nbsp;the last day of the fiscal year
(a)&nbsp;following the fifth anniversary of the completion of this offering, (b)&nbsp;in which we have total annual gross revenue of at least $1.07&nbsp;billion or (c)&nbsp;in which we are deemed to be a large accelerated filer, which requires the
market value of our common stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> to exceed $700.0&nbsp;million as of the prior June 30th, and (ii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt during the prior three-year period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may choose to take advantage of some, but not all, of
the available exemptions. We have taken advantage of reduced reporting burdens in this prospectus. In particular, we have not included all of the executive compensation information that would be required if we were not an EGC. We cannot predict
whether investors will find our common stock less attractive if we rely on certain or all of these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and
our stock price may be more volatile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under the JOBS Act, EGCs can also delay adopting new or revised accounting standards until such time as those
standards apply to private companies, which may make our financial statements less comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new
compliance initiatives. </I></B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As a public company, we will incur significant legal, accounting and other expenses that we did not incur as a
private company. We will be subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which will require, among other things, that we file with the SEC annual, quarterly and current reports with
respect to our business and financial condition. In addition, the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and The Nasdaq Global Select Market to implement provisions of the Sarbanes-Oxley Act, impose significant
requirements on public companies, including requiring establishment and maintenance of effective disclosure and financial reporting controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and
Consumer Protection Act, or the Dodd-Frank Act, was enacted. There are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas
such as &#147;say on pay&#148; and proxy access. Recent legislation permits EGCs to implement many of these requirements over a longer period and up to five years from the pricing of this offering. Stockholder activism, the current political
environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our
business in ways we cannot currently anticipate. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We expect the rules and regulations applicable to public companies to substantially increase
our legal and financial compliance costs and to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have an adverse effect on our
business. The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules and
regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the amount
or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees
or as executive officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If we fail to maintain an effective system of internal control over financial reporting, we may not be able to
accurately report our financial results or prevent fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our common stock. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure
controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any
testing by us conducted in connection with Section&nbsp;404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material
weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported
financial information, which could have a negative effect on the trading price of our stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We will be required to disclose changes made in our
internal controls and procedures on a quarterly basis and our management will be required to assess the effectiveness of these controls annually. However, for as long as we are an EGC, our independent registered public accounting firm will not be
required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section&nbsp;404. We could be an EGC for up to five years. An independent assessment of the effectiveness of our internal controls over financial
reporting could detect problems that our management&#146;s assessment might not. Undetected material weaknesses in our internal controls over financial reporting could lead to restatements of our financial statements and require us to incur the
expense of remediation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon completion of this offering, we will become subject to certain reporting requirements of the Exchange Act. Our disclosure controls and procedures
are designed to reasonably assure that information required to be disclosed by us in reports we file or submit under the Exchange Act is accumulated and communicated to management, recorded, processed, summarized and reported within the time periods
specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the
objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented
by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements or insufficient disclosures due to error
or fraud may occur and not be detected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Substantial amounts of our outstanding shares may be sold into the market when
<FONT STYLE="white-space:nowrap">lock-up</FONT> or market standoff periods end. If there are substantial sales of shares of our common stock, the price of our common stock could decline. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after the <FONT
STYLE="white-space:nowrap">lock-up</FONT> and other legal restrictions on resale discussed in this prospectus lapse, the trading price of our common stock could decline. Based on shares of common stock outstanding as of September 30, 2020, upon the
completion of this offering we will have outstanding a total of 36,749,675 shares of common stock. Of these shares, only the shares of common stock sold in this offering by us, plus any shares sold upon exercise of the underwriters&#146; option to
purchase additional shares, will be freely tradable without restriction in the public market immediately following this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">The&nbsp;lock-up&nbsp;agreements</FONT> pertaining to this offering
will expire 180 days from the date of this prospectus, subject to earlier release of all or a portion of the shares subject to such agreements by the representatives of the underwriters in this offering in their sole discretion. After the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements expire, based upon the number of shares of common stock, on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, outstanding as of September 30, 2020, up to an additional 26,737,873
shares of common stock will be eligible for sale in the public market. Approximately 68% of these additional shares are beneficially held by directors, executive officers and their affiliates and will be subject to certain limitations of
Rule&nbsp;144 under the Securities Act of 1933, as amended, or the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, shares of common stock that are either subject to
outstanding options or reserved for future issuance under our existing equity compensation plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, the <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreements and Rule 144 and Rule 701 under the Securities Act. If these additional shares of common stock are sold, or if it is perceived that they will be sold, in the public market, the trading price of
our common stock could decline. Additionally, the number of shares of our common stock reserved for issuance under our 2020 Stock Option and Incentive Plan, or the 2020 Plan, will automatically increase on January&nbsp;1 of each year, beginning on
January&nbsp;1, 2021, by 5% of the total number of shares of our capital stock outstanding on December&nbsp;31 of the preceding calendar year, or a lesser number of shares determined by our board of directors or compensation committee. Moreover, the
number of shares of our common stock reserved for issuance under our 2020 Employee Stock Purchase Plan will automatically increase on January&nbsp;1 of each year, beginning on January&nbsp;1, 2021, by the lesser of 327,102 shares of common stock, 1%
of the total number of shares of our capital stock outstanding on December&nbsp;31 of the preceding calendar year, or a lesser number of shares determined by our board of directors or compensation committee. Unless our board of directors elects not
to increase the number of shares available for future grant each year, our stockholders may experience additional dilution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">After this offering,
the holders of 25,067,977 shares of our common stock will be entitled to rights with respect to the registration of their shares under the Securities Act as provided under the terms of an investors&#146; rights agreement between us and the holders
of our redeemable convertible preferred stock, subject to the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above. See &#147;Description of Capital Stock&#151;Registration
Rights.&#148; Registration of these shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule&nbsp;144 under the
Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have
broad discretion in the use of our existing cash and cash equivalents and the net proceeds from this offering and may not use them effectively. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our management will have broad discretion in the application of our existing cash and cash equivalents and the net proceeds from this offering, including
for any of the purposes described in the section entitled &#147;Use of Proceeds,&#148; and you will not have the opportunity as part of your investment decision to assess whether such proceeds are being used appropriately. Because of the number and
variability of factors that will determine our use of our existing cash and cash equivalents and the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. Our management might not apply our
existing cash and cash equivalents and the net proceeds from this offering in ways that ultimately increase the value of your investment. The failure by our management to apply these funds effectively could harm our business. Pending their use, we
may invest the net proceeds from this offering in short-term, investment-grade, interest-bearing securities. These investments may not yield a favorable return to our stockholders. If we do not invest or apply the net proceeds from this offering in
ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Affiliates of Blackstone Securities Partners L.P., an underwriter in this offering, will have an interest in
this offering beyond customary underwriting discounts and commissions. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Certain affiliates of Blackstone Securities Partners L.P., an
underwriter in this offering, beneficially own more than 10% of our outstanding preferred equity prior to the consummation of this offering. Therefore, Blackstone Securities Partners L.P. is deemed to have a conflict of interest within the meaning
of Rule&nbsp;5121 of the Financial Industry Regulatory Authority, Inc., or FINRA Rule 5121. Accordingly, this offering is being conducted in accordance with FINRA Rule 5121. See &#147;Underwriting (Conflicts of Interest)&#148; for additional
information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market
price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended
and restated certificate of incorporation and amended and restated bylaws, which are to become effective upon the completion of this offering, contain provisions that could delay or prevent a change of control of our company or changes in our board
of directors that our stockholders might consider favorable. Some of these provisions include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board
will be elected at one time; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a
meeting of our stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a requirement that special meetings of stockholders be called only by the board of directors acting pursuant to a
resolution approved by the affirmative vote of a majority of the directors then in office; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">advance notice requirements for stockholder proposals and nominations for election to our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and,
in addition to any other vote required by law, upon the approval of not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of all outstanding shares of our voting stock then entitled to vote in the election of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a requirement of approval of not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of all outstanding shares of
our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the authority of the board of directors to issue convertible preferred stock on terms determined by the board of directors
without stockholder approval and which convertible preferred stock may include rights superior to the rights of the holders of common stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the General Corporation Law of the State
of Delaware, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and
amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a
merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate
actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about
our business, our stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The trading market for our common stock will depend in part on the research
and reports that securities or industry analysts publish about us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If no securities or industry analysts commence coverage of our
company, the trading price for our stock would likely be negatively impacted. In the event securities or industry analysts initiate coverage, if one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable
research about our business, our stock price may decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading
volume to decline. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our bylaws to be effective upon the consummation of this offering designate certain courts as the sole and exclusive forum for certain
types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our bylaws that will become effective upon the completion of this offering provide that, unless we consent in writing to an alternative forum, the Court
of Chancery of the State of Delaware will be the sole and exclusive forum for any state law claims for (i)&nbsp;any derivative action or proceeding brought on our behalf, (ii)&nbsp;any action asserting a claim of breach of fiduciary duty owed by any
of our directors, officers and employees to us or our stockholders, (iii)&nbsp;any action asserting a claim arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our bylaws (in each case, as they may
be amended from time to time) or (iv)&nbsp;any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery having personal jurisdiction over the indispensable parties named as defendants
therein; provided, however, that this exclusive forum provision will not apply to any causes of action arising under the Securities Act or the Exchange Act. Our bylaws further provide that, unless we consent in writing to an alternative forum, the
United States District Court for the District of Massachusetts will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. We have chosen the United States District Court for the District of
Massachusetts as the exclusive forum for such Securities Act causes of action because our principal executive offices are located in Cambridge, Massachusetts. In addition, our amended and restated bylaws will provide that any person or entity
purchasing or otherwise acquiring any interest in shares of our common stock is deemed to have notice of and consented to the foregoing provisions. We recognize that the forum selection clause in our bylaws may impose additional litigation costs on
stockholders in pursuing any such claims, particularly if the stockholders do not reside in or near the State of Delaware or the Commonwealth of Massachusetts, as applicable. Additionally, the forum selection clause in our bylaws may limit our
stockholders&#146; ability to bring a claim in a forum that they find favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an
action, if successful, might benefit our stockholders. The Court of Chancery of the State of Delaware or the United States District Court for the District of Massachusetts may also reach different judgments or results than would other courts,
including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments may be more or less favorable to us than our stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our issuance of additional capital stock in connection with financings, acquisitions, investments, our stock incentive plans or otherwise will dilute all other
stockholders. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We expect to issue additional capital stock in the future that will result in dilution to all other stockholders. We expect to
grant equity awards to employees, directors and consultants under our stock incentive plans. We may also raise capital through equity financings in the future. As part of our business strategy, we may acquire or make investments in complementary
companies, products or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
technologies and issue equity securities to pay for any such acquisition or investment. Any such issuances of additional capital stock may cause stockholders to experience significant dilution of
their ownership interests and the per share value of our common stock to decline<I>.</I> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom945651_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>This prospectus, including the sections entitled &#147;Prospectus Summary,&#148; &#147;Risk Factors,&#148; &#147;Management&#146;s Discussion and
Analysis of Financial Condition and Results of Operations,&#148; and &#147;Business,&#148; contains express or implied forward-looking statements that are based on our management&#146;s belief and assumptions and on information currently available
to our management. Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown
risks, uncertainties, and other factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by these forward-looking statements.
Forward-looking statements in this prospectus include, but are not limited to, statements about: </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the success, cost and timing of our product development activities and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ability to license additional intellectual property relating to our product candidates from third parties and to comply
with our existing license agreements and collaboration agreements; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ability and willingness of our third-party research institution collaborators to continue research and development
activities relating to our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to commercialize our products in light of the intellectual property rights of others; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to obtain funding for our operations, including funding necessary to complete further development and
commercialization of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the commercialization of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our plans to research, develop and commercialize our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">future agreements with third parties in connection with the commercialization of our product candidates and any other
approved product; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the size and growth potential of the markets for our product candidates, and our ability to serve those markets;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the rate and degree of market acceptance of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the pricing and reimbursement of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulatory developments in the United States and foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the success of competing therapies that are or may become available; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to attract and retain key scientific or management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our expectations regarding the period during which we qualify as an emerging growth company under the JOBS Act, enacted in
April 2012; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our use of the proceeds from this offering; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the development of major public health concerns, including the novel coronavirus outbreak or other pandemics arising
globally, and the future impact of it and COVID-19 on our clinical trials, business operations and funding requirements; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">other risks and uncertainties, including those listed under the caption &#147;Risk Factors.&#148; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In some cases, forward-looking statements can be identified by terminology, such as &#147;may,&#148;
&#147;should,&#148; &#147;expects,&#148; &#147;intends,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential,&#148; &#147;continue,&#148; or the negative of these terms
or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond
our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under &#147;Risk Factors&#148; and elsewhere in this prospectus. If
one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking
statement is a guarantee of future performance. You should read this prospectus and the documents that we reference in this prospectus and have filed with the Securities and Exchange Commission as exhibits to the registration statement, of which
this prospectus is a part, completely and with the understanding that our actual future results may be materially different from any future results expressed or implied by these forward-looking statements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The forward-looking statements in this prospectus represent our views as of the date of this prospectus. We anticipate that subsequent events and
developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should
therefore not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This
prospectus includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and studies
generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We are responsible for all of the disclosure contained in this
prospectus, and we believe that these sources are reliable; however, we have not independently verified the information contained in such publications. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom945651_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We estimate that our net proceeds from the sale of shares of our common stock in this offering will be approximately $159.5&nbsp;million, or
$183.9&nbsp;million if the underwriters exercise in full their option to purchase additional shares, assuming an initial public offering price of $17.50 per share, which is the midpoint of the price range set forth on the cover page of this
prospectus, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A $1.00 increase
(decrease) in the assumed initial public offering price of $17.50 per share would increase (decrease) the net proceeds to us from this offering by $9.3&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of
this prospectus, remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. We may also increase or decrease the number of shares we are offering. Each increase (decrease) of
1,000,000 shares in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the net proceeds to us from this offering by $16.3&nbsp;million, assuming no change in the assumed initial public
offering price per share and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We currently estimate that we will use the net proceeds from this offering, together with our existing cash and cash equivalents, including the proceeds
from our Series&nbsp;C-1 Preferred Stock financing completed in August&nbsp;2020, as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approximately $70 to $80 million to advance <FONT STYLE="white-space:nowrap">PRAX-114</FONT> into and through the
completion of our Phase&nbsp;2/3 trial in MDD, which is intended to satisfy one of two registrational trials required by the FDA to support clinical efficacy, and to complete Part&nbsp;B (PMD) and Part&nbsp;C (longer-term dosing in MDD) of our
ongoing Phase&nbsp;2a clinical trial for PRAX-114; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approximately $30 to $40 million to complete our ongoing Phase 2a clinical trial and a Phase 2/3 randomized, controlled
clinical trial for PRAX-944 in ET; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">approximately $20 to $30 million to complete our ongoing Phase 1 healthy volunteer trial and the first patient trial for
PRAX-562; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the remainder for advancement of other programs in our pipeline and support of working capital and other general corporate
purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Based on our current plans, we believe that the net proceeds from this offering, together with our existing cash and
cash equivalents, will be sufficient to fund our operations for at least the next 18&nbsp;months. We have based this estimate on assumptions that may prove to be incorrect, and we could use our available capital resources sooner than we currently
expect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This expected use of the net proceeds from this offering represents our intentions based upon our current plans and business conditions. As
of the date of this prospectus, we cannot predict with certainty all of the particular uses for the net proceeds to be received upon the closing of this offering or the amounts that we will actually spend on the uses set forth above. The amounts and
timing of our actual expenditures and the extent of clinical development may vary significantly depending on numerous factors, including the progress of our development, the status of and results from preclinical studies or clinical trials we may
commence in the future, as well as any collaborations that we may enter into with third parties for our product candidates, and any unforeseen cash needs. We may also use a portion of the net proceeds to
<FONT STYLE="white-space:nowrap">in-license,</FONT> acquire or invest in additional businesses, technologies, products or assets, although currently we have no specific agreements, commitments or understandings in this regard. As a result, our
management will retain broad discretion over the allocation of the net proceeds from this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pending our use of proceeds from this offering, we intend to invest the net proceeds in a variety of
capital preservation instruments, including short-term, investment-grade, interest-bearing instruments and U.S. government securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom945651_7"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have never declared or paid cash dividends on our capital stock. We intend to retain all available funds and any future earnings to fund the growth
and development of our business. We do not intend to pay cash dividends to our stockholders in the foreseeable future. In addition, any future financing instruments could preclude us from paying dividends. Any future determination to pay dividends
will be made at the discretion of our board of directors subject to applicable laws, and will depend upon, among other factors, our results of operations, financial condition, contractual restrictions and capital requirements. Investors should not
purchase our common stock with the expectation of receiving cash dividends. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom945651_8"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table sets forth our cash and cash equivalents and our capitalization as of June&nbsp;30, 2020: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on a pro forma basis to give effect to: (i)&nbsp;the sale and issuance of 19,444,453 shares of our Series&nbsp;C-1
redeemable convertible preferred stock in the third quarter of 2020 for gross cash proceeds of $110.3&nbsp;million, (ii)&nbsp;the automatic conversion of all outstanding shares of our redeemable convertible preferred stock, including our
Series&nbsp;C-1 redeemable convertible preferred stock, into an aggregate of 25,067,977 shares of common stock upon the consummation of this offering and (iii)&nbsp;the filing and effectiveness of our amended and restated certificate of
incorporation upon the completion of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">on a pro forma as adjusted basis to give further effect to the issuance and sale of 10,000,000&nbsp;shares of our common
stock in this offering at an assumed initial public offering price of $17.50 per share, the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us. </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The pro forma as adjusted information below is illustrative only, and our capitalization
following the completion of this offering will depend on the actual initial public offering price and other terms of this offering determined at pricing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">You should read the information in this table together with our unaudited interim condensed
consolidated financial statements and the related notes appearing elsewhere in this prospectus, as well as the sections of this prospectus captioned &#147;Selected Consolidated Financial Data&#148; and &#147;Management&#146;s Discussion and Analysis
of Financial Condition and Results of Operations.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AS OF JUNE 30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>ACTUAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PRO<BR>FORMA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PRO&nbsp;FORMA<BR>AS&nbsp;ADJUSTED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(In&nbsp;thousands,&nbsp;except&nbsp;share&nbsp;and&nbsp;per&nbsp;share&nbsp;data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">19,748</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">129,998</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">289,461</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Redeemable convertible preferred stock, $0.0001 par value; 36,724,132 shares
authorized, 34,199,861 shares issued and outstanding, actual; no shares authorized, issued or outstanding, pro forma and&nbsp;pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">118,190</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stockholders&#146; (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Preferred stock, $0.0001 par value; no shares authorized, issued or
outstanding, actual; 10,000,000&nbsp;shares authorized, no shares issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Common stock, $0.0001 par value; 50,000,000 shares authorized, 1,670,070 shares
issued and 1,648,165&nbsp;shares outstanding, actual; 150,000,000&nbsp;shares authorized, 26,738,047&nbsp;shares issued and 26,716,142 shares outstanding, pro forma; 150,000,000&nbsp;shares authorized, 36,738,047&nbsp;shares issued and
36,716,142&nbsp;shares outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">228,438</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">387,887</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(104,085</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(104,085</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(104,085</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(104,084</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">124,356</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">283,806</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total </P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">14,106</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">124,356</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">283,806</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A $1.00 increase (decrease) in the assumed initial public offering price of $17.50 per share, the midpoint of
the price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total
stockholders&#146; (deficit) equity and total capitalization by $9.3 million, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, after deducting estimated underwriting discounts and
commissions and estimated offering expenses payable by us. Similarly, an increase (decrease) of 1,000,000 shares in the number of shares offered by us in this offering, as set forth of the cover page of this prospectus, would increase (decrease) the
pro forma as adjusted amount of cash and cash equivalents, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; (deficit) equity and total capitalization by $16.3 million, assuming no change in the assumed
initial public offering price per share, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This table excludes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">3,220,201 shares of common stock issuable upon the exercise of stock options outstanding as of June 30, 2020 under the 2017
Stock Incentive Plan, at a weighted average exercise price of $4.07 per share; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">584,384 shares of common stock reserved for future issuance as of June 30, 2020 under the 2017 Stock Incentive Plan, any
unissued shares of which will cease to be available for issuance upon the completion of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">3,271,028 shares of our common stock that will become available for future issuance under the 2020 Stock Option and
Incentive Plan, or the 2020 Plan, upon the effectiveness of the registration statement of which this prospectus forms a part (including 37,615 shares of our common stock issuable upon the exercise of stock options we have agreed to grant under our
2020 Plan upon the effectiveness of the registration statement of which this prospectus is a part, at an exercise price equal to the initial public offering price); and </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">327,102 shares of our common stock that will become available for future issuance under the 2020 Employee Stock Purchase
Plan upon the effectiveness of the registration statement of which this prospectus forms a part. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom945651_9"></A>DILUTION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the
initial public offering price per share of common stock and the pro forma as adjusted net tangible book value per share of common stock immediately after this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our historical net tangible book value (deficit) as of June&nbsp;30, 2020 was $(104.5)&nbsp;million, or $(62.55) per share of common stock. Our
historical net tangible book value (deficit) is the amount of our total tangible assets less our total liabilities and the carrying value of our redeemable convertible preferred stock. Historical net tangible book value (deficit) per share
represents historical net tangible book value (deficit) divided by the 1,670,070 issued shares of our common stock, which include 21,905 shares of unvested restricted common stock, as of June&nbsp;30, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our pro forma net tangible book value as of June&nbsp;30, 2020 was $124.0&nbsp;million, or $4.64 per share of common stock. Pro forma net tangible book
value is the amount of our total tangible assets less our total liabilities, after having given effect to: (i)&nbsp;the sale and issuance of 19,444,453 shares of our Series C-1 redeemable convertible preferred stock in the third quarter of 2020 for
gross cash proceeds of $110.3&nbsp;million and (ii)&nbsp;the automatic conversion of all outstanding shares of our redeemable convertible preferred stock, including our Series&nbsp;C-1 redeemable convertible preferred stock, into an aggregate of
25,067,977 shares of common stock upon the consummation of this offering. Pro forma net tangible book value per share represents pro forma net tangible book value divided by the total number of issued shares of our common stock as of June&nbsp;30,
2020, after having given effect to the pro forma adjustments described above. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">After giving further effect to the sale and issuance of
10,000,000 shares of our common stock in this offering at an assumed initial public offering price of $17.50 per share, the midpoint of the price range set forth on the cover of this prospectus, and after deducting estimated underwriting discounts
and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value as of June&nbsp;30, 2020 would have been $283.4&nbsp;million, or $7.71 per share. This represents an immediate increase in pro forma as
adjusted net tangible book value per share of $3.07 to existing stockholders and immediate dilution of $9.79 in pro forma as adjusted net tangible book value per share to new investors participating in this offering. Dilution per share to new
investors is determined by subtracting pro forma as adjusted net tangible book value per share after this offering from the assumed initial public offering price per share paid by new investors. The pro forma as adjusted information below is
illustrative only and will depend on the actual initial public offering price and other terms of this offering determined at pricing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table illustrates this dilution on a per share basis to new investors: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">17.50</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Historical net tangible book value (deficit) per share as of June 30,
2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(62.55</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Increase per share attributable to pro forma adjustments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">67.19</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net tangible book value per share as of June 30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4.64</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Increase in pro forma net tangible book value per share attributable to new
investors&nbsp;participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3.07</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma as adjusted net tangible book value per share after this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">7.71</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dilution per share to new investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9.79</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A $1.00 increase (decrease) in the assumed initial public offering price of $17.50 per share, the midpoint of
the price range set forth on the cover page of this prospectus, would increase (decrease) our pro forma as adjusted net tangible book value by $9.3&nbsp;million, or $0.26 per share for an increase and $(0.25) per share for a decrease, and increase
(decrease) the dilution per share to investors participating in this offering by $0.74 per share for an increase and $(0.75) per share for a decrease, assuming that the number of shares offered by us, as set forth on the cover page of this
prospectus, remains the same, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. An increase of 1,000,000&nbsp;shares in the number of shares offered by us, as set forth on the cover page
of this prospectus, would increase our pro forma as adjusted net tangible book value by $16.3&nbsp;million, or $0.23 per share, and decrease the dilution per share to investors participating in this offering by $0.23 per share, assuming that the
assumed initial public offering price remains the same, after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. A decrease of 1,000,000 shares in the number of shares offered by us, as set
forth on the cover page of this prospectus, would decrease our pro forma as adjusted net tangible book value by $16.3&nbsp;million, or $0.23 per share, and increase the dilution per share to investors participating in this offering by $0.23 per
share, assuming that the assumed initial public offering price remains the same and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If the underwriters exercise their option in full to purchase 1,500,000 additional shares of common stock in this offering, our pro forma as adjusted
net tangible book value per share after this offering would be $8.05, representing an immediate increase in pro forma as adjusted net tangible book value per share of $0.34 to existing stockholders and immediate dilution in pro forma as adjusted net
tangible book value per share of $9.45 to investors participating in this offering, assuming an initial public offering price of $17.50 per share, the midpoint of the price range set forth on the cover page of this prospectus, and after deducting
estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes, on the pro forma as adjusted basis described above as of
June&nbsp;30, 2020, the total number of shares of common stock purchased from us on an as converted to common stock basis, the total consideration paid or to be paid and the average price per share paid or to be paid by existing stockholders and by
investors participating in this offering at an assumed initial public offering price of $17.50 per share, the midpoint of the price range set forth on the cover page of this prospectus, before deducting estimated underwriting discounts and
commissions and estimated offering expenses payable by us. As the table shows, new investors purchasing common stock in this offering will pay an average price per share substantially higher than our existing stockholders paid. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SHARES PURCHASED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>TOTAL CONSIDERATION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AVERAGE<BR>PRICE&nbsp;PER<BR>SHARE</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>NUMBER</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PERCENTAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>PERCENTAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center"><B>(In&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Existing stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">26,738,047</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">72.8</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">207,362</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">54.2</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">7.76</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10,000,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">27.2</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">175,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">45.8</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">17.50</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">36,738,047</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$382,362</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">100.0</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10.41</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A $1.00 increase (decrease) in the assumed initial public offering price of $17.50 per share, the midpoint of
the price range set forth on the cover page of this prospectus, would increase (decrease) the total consideration paid by new investors by $10.0&nbsp;million and, in the case of an increase, would increase the percentage of total consideration paid
by new investors by 1.4&nbsp;percentage points and, in the case of a decrease, would decrease the percentage of total consideration paid by new investors by 1.5&nbsp;percentage points, assuming that the number of shares offered by us, as set forth
on the cover page of this prospectus, remains the same. An increase (decrease) of 1,000,000 in the number of shares offered by us, as set forth on the cover page of this prospectus, would increase (decrease) the total consideration paid by new
investors by $17.5&nbsp;million and, in the case of an increase, would increase the percentage of total consideration paid by new investors by 2.3&nbsp;percentage points and, in the case of a decrease, would decrease the percentage of total
consideration paid by new investors by 2.6&nbsp;percentage points, assuming no change in the assumed initial public offering price per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
table assumes no exercise of the underwriters&#146; option to purchase additional shares in this offering. If the underwriters&#146; option to purchase additional shares is exercised in full, the number of shares of our common stock held by existing
stockholders would be reduced to 69.9% of the total number of shares of our common stock outstanding after this offering, and the number of shares of common stock held by new investors participating in the offering would be increased to 30.1% of the
total number of shares outstanding after this offering. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The above discussion and tables are based on issued shares of our common stock, which
include 21,905 shares of unvested restricted common stock, as of June&nbsp;30, 2020 and exclude: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">3,220,201 shares of common stock issuable upon the exercise of stock options outstanding as of June&nbsp;30, 2020 under the
2017 Stock Incentive Plan, at a weighted average exercise price of $4.07 per share; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">584,384 shares of common stock reserved for future issuance as of June 30, 2020 under the 2017 Stock Incentive Plan, any
unissued shares of which will cease to be available for issuance upon the completion of this offering; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">3,271,028 shares of our common stock that will become available for future issuance under the 2020 Stock Option and
Incentive Plan, or the 2020 Plan, upon the effectiveness of the registration statement of which this prospectus forms a part (including 37,615 shares of our common stock issuable upon the exercise of stock options we have agreed to grant under our
2020 Plan upon the effectiveness of the registration statement of which this prospectus is a part, at an exercise price equal to the initial public offering price); and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">327,102 shares of our common stock that will become available for future issuance under the 2020 Employee Stock Purchase
Plan upon the effectiveness of the registration statement of which this prospectus forms a part. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">New investors will experience
further dilution if new options or warrants are issued under our equity incentive plans or we issue additional shares of common stock, other equity securities or convertible debt securities in the future. In addition, we may choose to raise
additional capital because of market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt
securities, the issuance of these securities could result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom945651_10"></A>SELECTED CONSOLIDATED FINANCIAL DATA </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>We have derived the consolidated statement of operations data for the years ended December&nbsp;31, 2018 and 2019 and the consolidated balance sheet data as of
December&nbsp;31, 2018 and 2019 from our audited consolidated financial statements appearing elsewhere in this prospectus. The consolidated statement of operations data for the six months ended June 30, 2019 and 2020 and the consolidated balance
sheet data as of June 30, 2020 have been derived from our unaudited condensed consolidated financial statements appearing elsewhere in this prospectus and have been prepared on the same basis as the audited consolidated financial statements. In the
opinion of management, the unaudited data reflects all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the financial information in those statements. You should read the following selected consolidated
financial data together with our consolidated financial statements and unaudited interim condensed consolidated financial statements and the related notes appearing elsewhere in this prospectus and the &#147;Management&#146;s Discussion and Analysis
of Financial Condition and Results of Operations&#148; section of this prospectus. The selected consolidated financial data contained in this section are not intended to replace our consolidated financial statements and the related notes. Our
historical results are not necessarily indicative of the results that may be expected in any future period and our operating results for the six months ended June 30, 2020 are not necessarily indicative of the results that may be expected for the
full year ended December 31, 2020 or any other interim periods or any future year or period. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>YEAR ENDED </B><br><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SIX MONTHS ENDED</B><br><B>JUNE 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(In thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Consolidated Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">18,820</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">29,557</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">14,512</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">15,918</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,899</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">6,232</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,129</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4,121</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">22,719</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">35,789</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">17,641</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">20,039</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(22,719</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(35,789</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(17,641</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(20,039</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(35</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(3,648</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(3,683</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss before provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(26,402</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(35,596</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(17,518</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(19,906</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(84</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(26,535</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(35,512</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(17,518</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(19,898</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accretion and cumulative dividends on redeemable convertible preferred
stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(2,296</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(5,170</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(2,184</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(4,103</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss on conversion of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(392</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Gain on repurchase of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">493</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(29,223</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(40,682</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(19,702</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(23,508</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="52%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>YEAR ENDED </B><br><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>SIX MONTHS ENDED</B><br><B>JUNE 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(In thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share attributable to common stockholders, basic and
diluted(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(22.52</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(26.60</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(13.38</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(14.37</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted average common shares outstanding, basic and diluted(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,297,633</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,529,629</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,472,484</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,635,913</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net loss per share attributable to common stockholders, basic
and diluted (unaudited)(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(2.68</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(1.16</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma weighted average common shares outstanding, basic and diluted
(unaudited)(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">13,270,761</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">17,177,274</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">See Note 13 to our consolidated financial statements and Note 9 to our unaudited interim condensed consolidated financial
statements appearing elsewhere in this prospectus for details on the calculation of basic and diluted net loss per share attributable to common stockholders and unaudited pro forma basic and diluted net loss per share attributable to common
stockholders. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AS OF DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>AS&nbsp;OF&nbsp;JUNE&nbsp;30,</B><br><B>2020</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Consolidated Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">17,950</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">44,815</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">19,748</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Working capital(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">13,981</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">38,678</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">12,283</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">19,829</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">47,694</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">22,653</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">55,720</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">121,121</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">118,190</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(41,365</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(81,009</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(104,085</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(41,038</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(81,008</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(104,084</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">We define working capital as current assets less current liabilities. See our consolidated financial statements and
unaudited interim condensed consolidated financial statements and related notes appearing elsewhere in this prospectus for further details regarding our current assets and current liabilities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom945651_11"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>You should read the following discussion and analysis of our financial condition and results of operations together with the
&#147;Selected Consolidated Financial Data&#148; section of this prospectus and our consolidated financial statements and unaudited interim condensed consolidated financial statements and related notes appearing elsewhere in this prospectus. Some of
the information contained in this discussion and analysis or set forth elsewhere in this prospectus, including information with respect to our plans and strategy for our business and related financing, includes
<FONT STYLE="white-space:nowrap">forward-looking</FONT> statements that involve risks and uncertainties. As a result of many factors, including those factors set forth in the &#147;Risk Factors&#148; section of this prospectus, our actual results
could differ materially from the results described in or implied by the <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements contained in the following discussion and analysis. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are a clinical-stage biopharmaceutical company
translating genetic insights into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal circuits,
which, when dysregulated, leads to abnormal function and disease. We are applying insights into the genetic mutations that drive excitation-inhibition imbalance in diseases to select biological targets for severe pediatric epilepsies and more
broadly for prevalent psychiatric diseases and neurologic disorders. We apply a deliberate and pragmatic precision approach, leveraging a suite of translational tools including novel transgenic and predictive translational animal models and
electrophysiology markers, to enable an efficient path to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> in patients. Through this approach, we have established a broad portfolio, including five
disclosed programs across multiple CNS disorders, including depression, epilepsy, movement disorders and pain syndromes, with three clinical-stage product candidates. We intend to develop differentiated therapies that can deliver long-term benefits
to human health by meaningfully impacting patients and society. We expect multiple topline clinical trial readouts from all three programs prior to the end of 2021 and anticipate the launch of a new clinical development program in 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our most advanced programs, <FONT STYLE="white-space:nowrap">PRAX-114</FONT> and <FONT STYLE="white-space:nowrap">PRAX-944,</FONT> are currently in
Phase 2 development. <FONT STYLE="white-space:nowrap">PRAX-114</FONT> is being developed for the treatment of major depressive disorder and perimenopausal depression. Together, these conditions affect more than 22&nbsp;million patients in the United
States. <FONT STYLE="white-space:nowrap">PRAX-944</FONT> is a selective small molecule inhibitor of <FONT STYLE="white-space:nowrap">T-type</FONT> calcium channels for the treatment of essential tremor, a progressive and debilitating movement
disorder affecting up to seven million people in the United States. In addition, we have initiated a Phase 1 trial of <FONT STYLE="white-space:nowrap">PRAX-562,</FONT> a persistent sodium current blocker, for the treatment of a broad range of rare,
devastating CNS disorders, such as severe pediatric epilepsy and adult cephalgia. In addition to our clinical programs, we have two disclosed preclinical product candidates in development for severe genetic epilepsies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We were incorporated in 2015 and commenced operations in 2016. Since inception, we have devoted substantially all of our resources to developing our
preclinical and clinical product candidates, building our intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. We employ a &#147;virtual&#148; research and
development model, relying heavily upon external consultants, collaborators and contract research organizations to conduct our preclinical and clinical activities. Since inception, we have financed our operations primarily with proceeds from the
issuance of convertible debt and sales of our Series A redeemable convertible preferred stock, Series B redeemable convertible preferred stock, Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable convertible preferred stock, Series C
redeemable convertible preferred stock and Series C-1 redeemable convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are a development stage company and we have not
generated any revenue from product sales, and do not expect to do so for several years, if at all. All of our programs are still in preclinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
and clinical development. Our ability to generate product revenue sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or
more of our product candidates, if approved. We have incurred recurring operating losses since inception, including net losses of $26.5&nbsp;million and $35.5&nbsp;million for the years ended December&nbsp;31, 2018 and 2019, respectively, and $17.5
million and $19.9 million for the six months ended June 30, 2019 and 2020, respectively. As of June 30, 2020, we had an accumulated deficit of $104.1 million. We expect to incur significant expenses and operating losses for the foreseeable future as
we expand our research and development activities. In addition, our losses from operations may fluctuate significantly from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year,</FONT></FONT> depending on the timing of our clinical trials and our expenditures on other research and development activities. We anticipate that our expenses will increase
significantly in connection with our ongoing activities, as we: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">advance our lead product candidates, <FONT STYLE="white-space:nowrap">PRAX-114</FONT> and
<FONT STYLE="white-space:nowrap">PRAX-944,</FONT> to late stage clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">advance our <FONT STYLE="white-space:nowrap">PRAX-562</FONT> product candidate to Phase 2 clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">advance our preclinical programs to clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">further invest in our pipeline; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">further invest in our manufacturing capabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">seek regulatory approval for our investigational medicines; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">maintain, expand, protect and defend our intellectual property portfolio; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> technology; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">secure facilities to support continued growth in our research, development and commercialization efforts;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">take temporary precautionary measures to help minimize the risk of <FONT STYLE="white-space:nowrap">COVID-19</FONT> to our
employees; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">increase our headcount to support our development efforts and to expand our clinical development team; and
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">incur additional costs and headcount associated with operating as a public company upon the completion of this offering.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, as we progress toward marketing approval for any of our product candidates, we expect to incur significant
commercialization expenses related to product manufacturing, marketing, sales and distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As a result, we will need substantial additional
funding to support our continuing operations and pursue our growth strategy. Until such time as we can generate significant revenue from product sales, if ever, we expect to finance our operations through the sale of equity, debt financings or other
capital sources, including potential collaborations with other companies or other strategic transactions. We may be unable to raise additional funds or enter into such other agreements or arrangements when needed on favorable terms, or at all. If we
fail to raise capital or enter into such agreements as, and when, needed, we may have to significantly delay, scale back or discontinue the development and commercialization of one or more of our product candidates or delay our pursuit of potential <FONT
STYLE="white-space:nowrap">in-licenses</FONT> or acquisitions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Because of the numerous risks and uncertainties associated with product development,
we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or
are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of June 30, 2020, we had cash and cash equivalents of $19.7&nbsp;million. In the third quarter of
2020, we sold and issued shares of Series C-1 redeemable convertible preferred stock for gross cash proceeds of $110.3 million. We believe that our existing cash and cash equivalents, combined with the cash proceeds from the sale and issuance of our
Series C-1 redeemable convertible preferred stock and the anticipated net proceeds from this offering, will enable us to fund our operating expenses and capital expenditure requirements through at least the next 18 months. We have based this
estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See &#147;&#151;Liquidity and Capital Resources.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Without giving effect to the anticipated net proceeds from this offering, based on our current operating plan, we believe we have sufficient cash and
cash equivalents on hand to support current operations into the second half of 2021. We have concluded that this circumstance raises substantial doubt about our ability to continue as a going concern for at least one year from the date that our
unaudited interim condensed consolidated financial statements for the six months ended June 30, 2020 were issued. See Note&nbsp;1 to our unaudited interim condensed consolidated financial statements appearing at the end of this prospectus for
additional information on our assessment. To finance our operations, we will need to raise additional capital, which cannot be assured. If we are unable to obtain additional funding, we could be forced to delay, reduce or eliminate some or all of
our research and development programs, product portfolio expansion or commercialization efforts, which could adversely affect our business prospects, or we may be unable to continue operations. We expect to seek additional funding through private or
public equity transactions, debt financings or other capital sources, including collaborations with other companies or other strategic transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT
STYLE="white-space:nowrap">COVID-19</FONT> Business Update </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">With the global spread of the ongoing
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic in 2020, we have implemented business continuity plans designed to address and mitigate the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our employees and our
business, including our preclinical studies and clinical trials. Our operations are considered an essential business and we are continuing to operate during this period. We have taken measures to secure our research and development activities. While
we are experiencing limited financial impacts at this time, given the global economic slowdown, the overall disruption of global healthcare systems and the other risks and uncertainties associated with the pandemic, our business, financial condition
and results of operations could be materially adversely affected. We continue to closely monitor the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic as we evolve our business continuity plans, clinical development plans and response
strategy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, while we have taken and are continuing to take steps to mitigate against <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic-related delays, our planned clinical trials may be affected by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including (i)&nbsp;delays or difficulties in enrolling and retaining patients in our planned clinical trials,
including patients that may not be able or willing to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services; (ii)&nbsp;delays or difficulties in clinical site initiation, including difficulties
in recruiting and retaining clinical site investigators and clinical site staff; (iii)&nbsp;diversion or prioritization of healthcare resources away from the conduct of clinical trials and towards the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic, including the diversion of hospitals serving as our clinical trial sites and hospital staff supporting the conduct of our clinical trials, and because, who, as healthcare providers, may have heightened exposure to <FONT
STYLE="white-space:nowrap">COVID-19</FONT> and adversely impact our clinical trial operations; (iv)&nbsp;interruption of our future clinical supply chain or key clinical trial activities, such as clinical trial site monitoring, due to limitations on
travel imposed or recommended by federal, state/provincial or municipal governments, employers and others; and (v)&nbsp;limitations in outsourced third-party resources that would otherwise be focused on the conduct of our planned clinical trials,
including because of sickness of third-party personnel or their families, or the desire of third-party personnel to avoid contact with large groups of people. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Financial Operations Overview </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Revenue </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have not generated any revenue since
inception and do not expect to generate any revenue from the sale of products for several years, if at all. If our development efforts for our current or future product candidates are successful and result in marketing approval or collaboration or
license agreements with third parties, we may generate revenue in the future from a combination of product sales or payments from collaboration or license agreements that we may enter into with third parties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Operating Expenses </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Research and Development Expense </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The nature of our business and primary focus of our activities generate a significant amount of research and development costs. Research and development
expenses represent costs incurred by us for the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">costs to develop our portfolio; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">discovery efforts leading to development candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">clinical development costs for our programs; and </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">costs to develop our manufacturing technology and infrastructure. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The costs above comprise the following categories: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">personnel-related expenses, including salaries, benefits and stock-based compensation expense; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">expenses incurred under agreements with third parties, such as consultants, investigative sites and contract research
organizations, or CROs, that conduct our preclinical and clinical studies and <FONT STYLE="white-space:nowrap">in-licensing</FONT> arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">costs incurred to maintain compliance with regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">costs incurred with third-party contract manufacturing organizations, or CMOs, to acquire, develop and manufacture
materials for preclinical and clinical studies; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">depreciation, amortization and other direct and allocated expenses, including rent, insurance and other operating costs,
incurred as a result of our research and development activities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We expense research and development costs as incurred. We
recognize external development costs based on an evaluation of the progress to completion of specific tasks using information provided to us by our vendors and our clinical investigative sites. Payments for these activities are based on the terms of
the individual agreements, which may differ from the pattern of costs incurred, and are reflected in our consolidated balance sheets as prepaid expenses or accrued research and development expenses.
<FONT STYLE="white-space:nowrap">Non-refundable</FONT> advance payments for goods or services to be received in the future for use in research and development activities are deferred and capitalized, even when there is no alternative future use for
the research and development. The capitalized amounts are expensed as the related goods are delivered or the services are performed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A significant
portion of our research and development costs have been external costs. We track direct external research and development expenses to specific programs upon commencement. Due to the number of ongoing programs and our ability to use resources across
several projects, indirect or shared operating costs incurred for our research and development programs, such as personnel, facility costs and certain consulting costs, are not recorded or maintained on a program-specific basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our major programs, <FONT STYLE="white-space:nowrap">PRAX-114,</FONT>
<FONT STYLE="white-space:nowrap">PRAX-944</FONT> and <FONT STYLE="white-space:nowrap">PRAX-562,</FONT> are those for which we have initiated clinical activities. Our discovery-stage programs are those which are at an earlier point in the development
process. The following table reflects our research and development expenses, including direct program-specific expenses summarized by major program, discovery-stage program costs and indirect or shared operating costs recognized as research and
development expenses during each period presented (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended</B><br><B>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">PRAX-114</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4,795</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">7,192</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4,881</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5,060</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">PRAX-944</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,286</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4,035</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,779</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,577</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">PRAX-562</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4,469</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4,276</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,259</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,642</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Discovery-stage programs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,954</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5,909</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">730</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,896</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Personnel-related (including stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,337</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5,398</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,541</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4,345</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other indirect research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,979</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,747</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,322</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,398</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">18,820</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">29,557</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">14,512</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">15,918</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Research and development activities are central to our business model. Product candidates in later stages of clinical
development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect that our research and development expenses will
continue to increase in the foreseeable future as we advance our product candidates through the development phase, and as we continue to discover and develop additional product candidates, build manufacturing capabilities and expand into additional
therapeutic areas. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary
to complete the development of, and obtain regulatory approval for, any of our product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from sales or licensing of our product candidates. This is due to
the numerous risks and uncertainties associated with drug development, including the uncertainty of: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to add and retain key research and development personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the timing and progress of preclinical and clinical development activities; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number and scope of preclinical and clinical programs we decide to pursue; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to successfully complete clinical trials with safety, tolerability and efficacy profiles that are satisfactory
to the FDA or any comparable foreign regulatory authority; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to successfully develop, obtain regulatory approval for, and then successfully commercialize, our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our successful enrollment in and completion of clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs associated with the development of any additional product candidates we identify
<FONT STYLE="white-space:nowrap">in-house</FONT> or acquire through collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to discover, develop and utilize biomarkers to demonstrate target engagement, pathway engagement and the impact
on disease progression of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to establish and maintain agreements with third-party manufacturers for clinical supply for our clinical trials
and commercial manufacturing, if our product candidates are approved; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the terms and timing of any collaboration, license or other arrangement, including the terms and timing of any milestone
payments thereunder; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to obtain and maintain patent, trade secret and other intellectual property protection and regulatory
exclusivity for our product candidates if and when approved; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our receipt of marketing approvals from applicable regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to commercialize products, if and when approved, whether alone or in collaboration with others; and
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the continued acceptable safety profiles of the product candidates following approval. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A change in any of these variables with respect to the development of any of our product candidates would significantly change the costs, timing and
viability associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to delay our planned start of clinical trials or require us to conduct clinical trials or other testing beyond those
that we currently expect, or if we experience significant delays in enrollment in any of our planned clinical trials, we could be required to expend significant additional financial resources and time to complete our clinical development activities.
We may never obtain regulatory approval for any of our product candidates. Drug commercialization will take several years and millions of dollars in development costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>General and Administrative Expense </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">General and
administrative expenses consist primarily of personnel-related costs, including salaries, benefits and stock-based compensation, for personnel in our executive, finance, legal, business development and administrative functions. General and
administrative expenses also include legal fees relating to corporate matters; professional fees for accounting, auditing, tax and administrative consulting services; insurance costs; administrative travel expenses; and facility-related expenses,
which include direct depreciation costs and allocated expenses for office rent and other operating costs. These costs relate to the operation of the business, unrelated to the research and development function, or any individual program. Costs to
secure and defend our IP are expensed as incurred and are classified as general and administrative expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We anticipate that our general and
administrative expenses will increase in the future as we increase our headcount to support the expected growth in our research and development activities and the potential commercialization of our product candidates. We also expect to incur
increased expenses associated with being a public company, including increased costs of accounting, audit, legal, regulatory and <FONT STYLE="white-space:nowrap">tax-related</FONT> services associated with maintaining compliance with exchange
listing and SEC requirements, director and officer insurance costs and investor and public relations costs. We also expect to incur additional <FONT STYLE="white-space:nowrap">IP-related</FONT> expenses as we file patent applications to protect
innovations arising from our research and development activities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Total Other Income (Expense) </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Interest Income </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Interest income consists of interest earned
on our cash and cash equivalents. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Interest Expense </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Interest expense consists of interest incurred on our convertible promissory notes. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Other Expense </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Other expense consists of fluctuations in the
fair value of financial instruments that were measured at fair value, including our Series B redeemable convertible preferred stock tranche obligation, an anti-dilution obligation related to our license agreement with Purdue Neuroscience Company,
and conversion features associated with our convertible notes. All of these financial instruments were settled during the year ended December&nbsp;31, 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Since our inception, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in each year or for our
earned research and development tax credits, due to our uncertainty of realizing a benefit from those items. As of December&nbsp;31, 2018 and 2019, we had U.S. federal and state net operating loss carryforwards which may be available to offset
future taxable income and which would begin to expire in 2035. As of December&nbsp;31, 2018 and 2019, we also had federal and state research and development tax credit carryforwards which may be available to offset future income tax liabilities and
which would begin to expire in 2031. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Income taxes are determined at the applicable tax rates adjusted for
<FONT STYLE="white-space:nowrap">non-deductible</FONT> expenses, research and development tax credits and other permanent differences. Our income tax provision may be significantly affected by changes to our estimates. The income tax provision and
benefit recognized for the years ended December&nbsp;31, 2018 and 2019 and the six months ended June 30, 2020 related to income tax associated with our operations in Australia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Results of Operations </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Comparison of the Years Ended
December&nbsp;31, 2018 and 2019 </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes our consolidated statements of operations for each period presented (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">18,820</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">29,557</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10,737</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,899</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">6,232</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,333</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">22,719</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">35,789</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">13,070</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(22,719</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(35,789</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(13,070</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(127</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(3,648</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,648</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(3,683</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,876</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss before provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(26,402</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(35,596</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(9,194</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(84</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(217</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(26,535</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(35,512</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(8,977</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Research and Development Expense </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes our research and development expenses for each period presented, along with the changes in those items (in thousands):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">PRAX-114</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4,795</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">7,192</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,397</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">PRAX-944</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,286</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4,035</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,749</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">PRAX-562</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4,469</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4,276</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(193</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Discovery-stage programs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,954</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5,909</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,955</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Personnel-related (including stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,337</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5,398</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,061</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other indirect research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,979</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,747</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(232</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">18,820</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">29,557</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10,737</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Research and development expenses increased $10.7&nbsp;million from $18.8&nbsp;million for the year ended
December&nbsp;31, 2018, to $29.6&nbsp;million for the year ended December&nbsp;31, 2019. The increase in research and development expenses was primarily attributable to the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">$4.0&nbsp;million increase in discovery-stage program expense, primarily for our
<FONT STYLE="white-space:nowrap">PRAX-222</FONT> program which commenced during the year ended December&nbsp;31, 2019 and incurred $4.3&nbsp;million of research and development expense, including $2.2&nbsp;million upon our acquisition of the
underlying <FONT STYLE="white-space:nowrap">in-process</FONT> research and development assets in September 2019 and $0.6&nbsp;million of an <FONT STYLE="white-space:nowrap">up-front</FONT> payment and research activity reimbursements under a
collaboration agreement for that program; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">$3.1&nbsp;million increase in personnel-related costs due to increased headcount; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">$2.4&nbsp;million increase in expense related to our <FONT STYLE="white-space:nowrap">PRAX-114</FONT> program, including a
$2.1&nbsp;million increase in outsourced research and development spend and a $0.3&nbsp;million increase in consulting costs, as we started enrolling patients in a Phase 2a clinical trial during the year ended December&nbsp;31, 2019;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">$1.7&nbsp;million increase in expense related to our <FONT STYLE="white-space:nowrap">PRAX-944</FONT> program, driven by a
$1.5&nbsp;million increase in outsourced research and development and CRO spend and a $0.2&nbsp;million increase in consulting costs, as the program progressed into a Phase 2a clinical trial during the year ended December&nbsp;31, 2019;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">$0.2&nbsp;million offsetting decrease in other indirect research and development expenses, driven by a $0.9&nbsp;million
decrease in outsourced research and development and CRO spend as well as consulting costs not allocated to a specific program, offset by a $0.7&nbsp;million increase in facility, office, software and other overhead costs due to increased research
and development headcount; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">$0.2&nbsp;million offsetting decrease in expense related to our <FONT STYLE="white-space:nowrap">PRAX-562</FONT> program,
primarily driven by the timing of our outsourced research and development activities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>General and Administrative Expense </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">General and administrative expenses increased $2.3&nbsp;million from $3.9&nbsp;million for the year ended December&nbsp;31, 2018 to $6.2&nbsp;million for
the year ended December&nbsp;31, 2019. The increase in general and administrative expenses was primarily attributable to the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">$1.5&nbsp;million increase in personnel-related costs driven by increased headcount; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">$0.7&nbsp;million increase in professional fees including legal and consulting services, driven by a $0.4&nbsp;million
increase in legal fees, primarily related to intellectual property filings, as we expand our research and development activities, and a $0.3&nbsp;million increase in consulting costs, primarily in the accounting and business development functions;
and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">$0.1&nbsp;million increase in facilities, office and other general and administrative expenses to support the increase in
our operating activities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Total Other Income (Expense), Net </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Total other income (expense), net for the year ended December&nbsp;31, 2018 was $(3.7) million, compared to $0.2&nbsp;million for the year ended
December&nbsp;31, 2019. The change was primarily attributable to a $3.6&nbsp;million loss recognized during the year ended December&nbsp;31, 2018 as a result of fluctuations in the fair value of financial instruments that were measured at fair
value, including our Series B redeemable convertible preferred stock tranche obligation, an anti-dilution obligation related to our license agreement with Purdue Neuroscience Company and conversion features associated with our convertible notes. All
of these financial instruments were settled during the year ended December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Comparison of the Six Months Ended June&nbsp;30, 2019 and 2020
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes our consolidated statements of operations for each period presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended</B><br><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">14,512</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">15,918</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,406</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,129</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4,121</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">992</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">17,641</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">20,039</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,398</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(17,641</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(20,039</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(2,398</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other income:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss before provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(17,518</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(19,906</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(2,388</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Benefit from income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(17,518</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(19,898</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(2,380</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Research and Development Expense </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes our research and development expenses for each period presented, along with the changes in those items (in thousands):
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended</B><br><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">PRAX-114</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4,881</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5,060</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">179</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">PRAX-944</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,779</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,577</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(1,202</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">PRAX-562</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,259</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,642</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(617</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Discovery-stage programs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">730</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,896</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,166</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Personnel-related (including stock-based compensation)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,541</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4,345</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,804</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other indirect research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,322</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,398</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">76</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">14,512</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">15,918</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,406</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Research and development expenses increased $1.4&nbsp;million from $14.5&nbsp;million for the six months ended
June&nbsp;30, 2019, to $15.9&nbsp;million for the six months ended June&nbsp;30, 2020. The increase in research and development expenses was primarily attributable to the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">$1.8 million increase in personnel-related costs due to increased headcount; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">$1.2&nbsp;million increase in discovery-stage program expense, primarily for our PRAX-222 program which commenced in
September 2019 and incurred $1.4&nbsp;million of research and development expense during the six months ended June&nbsp;30, 2020, primarily driven by outsourced research and development and CRO spend; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">$0.2&nbsp;million increase in expense related to our PRAX-114 program, driven by a $1.1 million increase in outsourced
clinical spend for our ongoing Phase 2a clinical trial for this program, partially offset by a $0.6 million decrease due to a drug product manufacturing campaign completed in the prior year and a $0.2 million decrease related to expenses incurred
during the six months ended June&nbsp;30, 2019 in support of our investigational new drug application; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">$0.1 million increase in other indirect research and development expenses, primarily driven by an increase in facility,
office, software and other overhead costs due to increased research and development headcount; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">$1.2&nbsp;million offsetting decrease in expense related to our PRAX-944 program, driven by a $1.0&nbsp;million decrease in
outsourced research and development and CRO spend, primarily related to toxicology work performed during the six months ended June&nbsp;30, 2019 to prepare for our Phase 2a clinical trial and a drug product manufacturing campaign that was executed
during the six months ended June&nbsp;30, 2019, as well as a $0.2&nbsp;million decrease in consulting costs; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">$0.6&nbsp;million offsetting decrease in our PRAX-562 program, driven by a $0.7&nbsp;million decrease in outsourced
research and development and CRO spend due to expenses incurred during the six months ended June&nbsp;30, 2019 to identify our drug product candidate, offset by a $0.1&nbsp;million increase in consulting spend. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>General and Administrative Expense </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">General and administrative expenses increased $1.0&nbsp;million from $3.1&nbsp;million for the six months ended June&nbsp;30, 2019 to $4.1&nbsp;million
for the six months ended June&nbsp;30, 2020. The increase in general and administrative expenses was primarily attributable to the following: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">$0.5&nbsp;million increase in professional fees including legal and consulting services, driven by a $0.4&nbsp;million
increase in consulting costs, primarily in the accounting and business development functions, and a $0.1&nbsp;million increase in legal fees, primarily related to intellectual property filings, as we expand our research and development activities;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">$0.4&nbsp;million increase in personnel-related costs driven by increased headcount; and </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">$0.1&nbsp;million increase in facilities, office and other general and administrative expenses to support the increase in
our operating activities. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Total Other Income </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Total other income for each of the six months ended June&nbsp;30, 2019 and 2020 was $0.1 million, comprised of interest income on our cash and cash
equivalents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Sources of
Liquidity </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Since our inception, we have incurred significant losses in each period. We have not yet commercialized any of our product
candidates, which are in various phases of preclinical and clinical development, and we do not expect to generate revenue from sales of any products for several years, if at all. To date, we have financed our operations primarily with proceeds from
sales of our redeemable convertible preferred stock and the issuance of convertible debt. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In 2015 and 2016, we raised $1.0&nbsp;million from the
issuance of convertible promissory notes. In October 2016, April 2017 and July 2017, we raised an aggregate of $6.1&nbsp;million from the sale of our Series A redeemable convertible preferred stock, net of issuance costs. In December 2017 and
January 2018, we raised an aggregate of $3.0&nbsp;million from the issuance of convertible promissory notes. In March and October 2018, we raised an aggregate of $36.8&nbsp;million from the sale of our Series B redeemable convertible preferred
stock, net of issuance costs. In June 2019, we raised $9.9&nbsp;million from the sale of our Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable convertible preferred stock, net of issuance costs. In November and December 2019, we raised
an aggregate of $50.3&nbsp;million from the sale of our Series C redeemable convertible preferred stock. In February and March 2020, we repurchased shares of our Series C redeemable convertible preferred stock for an aggregate cash repurchase price
of $30.0 million. In April and May 2020, we raised an aggregate of $23.5 million from the sale of our Series C redeemable convertible preferred stock, net of issuance costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of June 30, 2020, we had cash and cash equivalents of $19.7&nbsp;million. In the third quarter of 2020, we raised an aggregate of approximately
$110.1 million from the sale of our Series C-1 redeemable convertible preferred stock, net of issuance costs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Historical Cash Flows </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table provides information regarding our cash flows for each period presented (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended</B><br><B>June 30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash provided by (used in):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(20,721</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(33,420</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(15,766</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(18,513</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(63</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(103</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(74</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">37,804</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">60,388</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9,997</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(6,554</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net increase (decrease) in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">17,020</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">26,865</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(5,843</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(25,067</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Operating Activities </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our
cash flows from operating activities are greatly influenced by our use of cash for operating expenses and working capital requirements to support the business. We have historically experienced negative cash flows from operating activities as we
invested in developing our portfolio, drug discovery efforts and related infrastructure. The cash used in operating activities resulted primarily from our net losses adjusted for <FONT STYLE="white-space:nowrap">non-cash</FONT> charges and changes
in components of working capital, which are primarily the result of increased expenses and timing of vendor payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the year ended
December&nbsp;31, 2018, net cash used in operating activities of $20.7&nbsp;million was primarily due to our $26.5&nbsp;million net loss, partially offset by $4.4&nbsp;million of non-cash charges and $1.5&nbsp;million in changes in operating assets
and liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the year ended December&nbsp;31, 2019, net cash used in operating activities of $33.4&nbsp;million was primarily due to our
$35.5&nbsp;million net loss, partially offset by $1.3&nbsp;million of non-cash charges and $0.7&nbsp;million in changes in operating assets and liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the six months ended June&nbsp;30, 2019, net cash used in operating activities of $15.8&nbsp;million was primarily due to our $17.5&nbsp;million
net loss, partially offset by $0.6&nbsp;million of non-cash charges and $1.2&nbsp;million in changes in operating assets and liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During
the six months ended June&nbsp;30, 2020, net cash used in operating activities of $18.5&nbsp;million was primarily due to our $19.9&nbsp;million net loss, partially offset by $0.8&nbsp;million of non-cash charges and $0.6&nbsp;million in changes in
operating assets and liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Investing Activities </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the years ended December&nbsp;31, 2018 and 2019 and the six months ended June&nbsp;30, 2019, net cash used in investing activities related to the
purchase of property and equipment. There were no cash flows from investing activities during the six months ended June&nbsp;30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Financing Activities
</I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the years ended December&nbsp;31, 2018 and 2019, net cash provided by financing activities was $37.8&nbsp;million and $60.4&nbsp;million,
respectively, consisting of net proceeds from the issuance of our Series&nbsp;B redeemable convertible preferred stock and proceeds from the issuance of a convertible note during the year ended December&nbsp;31, 2018, and net proceeds from the
issuance of our <FONT STYLE="white-space:nowrap">Series&nbsp;B-1</FONT> redeemable convertible preferred stock and our Series&nbsp;C redeemable convertible preferred stock during the year ended December&nbsp;31, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the six months ended June 30, 2019 and 2020, net cash provided by (used in) financing
activities was $10.0 million and $(6.6) million, respectively, consisting of net proceeds from the issuance of our Series B-1 redeemable convertible preferred stock during the six months ended June&nbsp;30, 2019, and net cash paid for the repurchase
and issuance of shares of our Series C redeemable convertible preferred stock during the six months ended June 30, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Plan of Operation and Future
Funding Requirements </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We expect our expenses to increase substantially in connection with our ongoing research and development activities,
particularly as we advance the preclinical activities and clinical trials of our product candidates. In addition, upon the completion of this offering, we expect to incur additional costs associated with operating as a public company. As a result,
we expect to incur substantial operating losses and negative operating cash flows for the foreseeable future. We anticipate that our expenses will increase substantially if and as we: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">advance the clinical development of our <FONT STYLE="white-space:nowrap">PRAX-114,</FONT>
<FONT STYLE="white-space:nowrap">PRAX-944</FONT> and <FONT STYLE="white-space:nowrap">PRAX-562</FONT> product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">advance the development of any additional product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">conduct research and continue preclinical development of potential product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">make strategic investments in manufacturing capabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">maintain our current intellectual property portfolio and opportunistically acquire complementary intellectual property;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">seek to obtain regulatory approvals for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">potentially establish a sales, marketing and distribution infrastructure and
<FONT STYLE="white-space:nowrap">scale-up</FONT> manufacturing capabilities to commercialize any products for which we may obtain regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">add clinical, scientific, operational, financial and management information systems and personnel, including personnel to
support our product development and potential future commercialization efforts and to support our transition to a public company; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">experience any delays or encounter any issues with any of the above, including but not limited to failed studies, complex
results, safety issues or other regulatory challenges. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of June 30, 2020, we had cash and cash equivalents of
$19.7&nbsp;million. In the third quarter of 2020, we raised an aggregate of approximately $110.1 million from the sale of our Series C-1 redeemable convertible preferred stock, net of issuance costs. Based on our current operating plan, we believe
that our existing cash and cash equivalents, combined with the cash proceeds from the sale and issuance of our Series C-1 redeemable convertible preferred stock and the anticipated net proceeds from this offering, will enable us to fund our
operating expenses and capital expenditure requirements through at least the next 18 months. However, we have based this estimate on assumptions that may prove to be wrong and we could exhaust our capital resources sooner than we expect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are unable to estimate the exact amount of our working capital requirements, but based on our available cash resources, without giving effect to the
anticipated net proceeds from this offering, we expect to have sufficient cash and cash equivalents on hand to support current operations into the second half of 2021. This circumstance raises substantial doubt about our ability to continue as a
going concern for at least one year from the date that our unaudited interim condensed consolidated financial statements for the six months ended June 30, 2020 appearing at the end of this prospectus were issued. We will need to raise additional
capital in this offering and/or otherwise to fund our future operations and remain as a going concern. However, we cannot guarantee that we will be able to obtain sufficient additional funding in this offering or otherwise or that such funding, if
available, will be obtainable on terms satisfactory to us. In the event that we are unable to obtain sufficient additional funding, there can be no assurance that we will be able to continue as a going concern. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Because of the numerous risks and uncertainties associated with product development, and because the
extent to which we may enter into collaborations with third parties for the development of our product candidates is unknown, we may incorrectly estimate the timing and amounts of increased capital outlays and operating expenses associated with
completing the research and development of our product candidates. Our funding requirements and timing and amount of our operating expenditures will depend on many factors, including, but not limited to: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the scope, progress, results and costs of preclinical studies and clinical trials for our programs and product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the number and characteristics of programs and technologies that we develop or may
<FONT STYLE="white-space:nowrap">in-license;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution,
for any of our product candidates for which we receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs necessary to obtain regulatory approvals, if any, for products in the United States and other jurisdictions, and
the costs of post-marketing studies that could be required by regulatory authorities in jurisdictions where approval is obtained; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual
property rights and defending any intellectual property-related claims; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the continuation of our existing licensing arrangements and entry into new collaborations and licensing arrangements;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs we incur in maintaining business operations; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the costs associated with being a public company; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the revenue, if any, received from commercial sales of any product candidates for which we receive marketing approval;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the effect of competing technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the impact of any business interruptions to our operations or to those of our manufacturers, suppliers or other vendors
resulting from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or similar public health crisis; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the extent to which we acquire or invest in businesses, products and technologies, including entering into licensing or
collaboration arrangements for product candidates, although we currently have no commitments or agreements to complete any such acquisitions or investments in businesses. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time consuming, expensive and uncertain process
that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our
commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if ever. Accordingly, we will need to obtain substantial additional funds to achieve our business objectives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Adequate additional funds may not be available to us on acceptable terms, or at all. We do not currently have any committed external source of funds.
Market volatility resulting from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or other factors could also adversely impact our ability to access capital as and when needed. To the extent that we raise additional capital through the
sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a common stockholder. Additional debt
financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends
and may require the issuance of warrants, which could potentially dilute your ownership interest. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we raise additional funds through collaborations, strategic alliances or licensing arrangements
with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds
through equity or debt financings when needed, we may be required to delay, limit or terminate our product development programs or any future commercialization efforts or grant rights to develop and market product candidates to third parties that we
would otherwise prefer to develop and market ourselves. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Contractual Obligations and Commitments </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes our contractual obligations as of December&nbsp;31, 2019 and the effects that such obligations are expected to have on our
liquidity and cash flows in future periods (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payments Due by Period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;Than<BR>1 Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1 to 3<BR>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3 to 5<BR>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More<BR>Than&nbsp;5<BR>Years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating lease commitments(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,574</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">783</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">791</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,574</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">783</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">791</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">We sublease building space in Cambridge, Massachusetts. Our sublease will expire on December&nbsp;30, 2021. The amounts
in the table above represent the fixed contractual lease obligations. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have collaboration and license agreements with Purdue
Neuroscience Company, or Purdue, RogCon Inc., or RogCon, and Ionis Pharmaceuticals, Inc., or Ionis, under which we could be obligated to pay certain fees, milestone payments and cost reimbursements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under our license agreement with Purdue, we are obligated to make future milestone payments of up to $33.0&nbsp;million based on the achievement of
specified development and sales milestones. Furthermore, we will pay Purdue royalties of a <FONT STYLE="white-space:nowrap">low-single-digit</FONT> percentage of annual net sales of licensed products. Either party may terminate the license agreement
for convenience or in the event of a material breach by the other party and failure to cure such breach within a certain period of time. If the agreement is voluntarily terminated by Purdue, our license rights will survive such termination and such
rights will become fully paid, perpetual and irrevocable. As the agreement may be terminated for convenience, the payments are not included in the table above. See &#147;Business&#151;License Agreements&#151;License Agreement with Purdue.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under our license agreement with RogCon, we will reimburse RogCon for its
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs incurred for activities performed under the license agreement. Additionally, we may pay RogCon a milestone payment of $3.0&nbsp;million and profit
share payments. The $3.0&nbsp;million milestone payment will become due when the first profit share payment has become due and payable and certain contingent payments have become due and payable to Ionis under our collaboration agreement with Ionis.
The profit share payments will be based on a <FONT STYLE="white-space:nowrap">low-double-digit</FONT> percentage of net profits, depending on sales volume. Either party may terminate the license agreement for material breach or insolvency of the
other party. Additionally, we may terminate for convenience with prior notice to RogCon. As such, we do not include variable and contingent payments under our agreement with RogCon in the table above as they are not fixed and estimable. See
&#147;Business&#151;License Agreements&#151;License Agreement with RogCon.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under our collaboration agreement with Ionis, we are obligated to
reimburse any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs incurred by Ionis related to research activities, identification of a development candidate and conducting an <FONT
STYLE="white-space:nowrap">IND-enabling</FONT> toxicology study. We also have an exclusive option to obtain the rights and license related to the development candidate following the completion of the
<FONT STYLE="white-space:nowrap">IND-enabling</FONT> toxicology study. If we exercise our development candidate option, we may be required to make additional payments to Ionis </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
including a license fee, development milestone payments, additional milestone payments and sales royalties or sublicense fees. However, we are not obligated to exercise our development candidate
option and are able to terminate our collaboration agreement with Ionis for convenience. Either party may terminate the collaboration agreement upon material breach or insolvency of the other party or if Ionis is unable to identify a development
candidate. Ionis may terminate if we fail to achieve a performance milestone. As such, payments due pursuant to the exercise of our development candidate option are contingent and therefore excluded from the table above as they are not fixed and
estimable. See &#147;Business&#151;License Agreements&#151;Ionis Collaboration Agreement.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have agreements with certain vendors for various
services, including services related to clinical operations and support, for which we are not contractually able to terminate for convenience and avoid any and all future obligations to the vendors. Under such agreements, we are contractually
obligated to make certain payments to vendors to reimburse them for their unrecoverable outlays incurred prior to cancellation. The exact amounts of such obligations are dependent on the timing of termination and the exact terms of the relevant
agreement and cannot be reasonably estimated. We do not include these payments in the table above as they are not fixed and estimable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition,
we enter into indemnification agreements and agreements containing indemnification provisions in the ordinary course of business. Pursuant to these agreements, we agree to indemnify, hold harmless and reimburse the indemnified party for losses
suffered or incurred by the indemnified party, generally our business partners, in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third party with respect to our products. The term of these
indemnification agreements is generally perpetual upon execution of the agreement. The maximum potential amount of future payments we could be required to make under these indemnification agreements cannot be reasonably estimated and therefore is
not included in the table above. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We did not have during the periods presented, and we do not currently have, any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements,
as defined in the rules and regulations of the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Critical Accounting Policies and Significant Judgments and Estimates </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our management&#146;s discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements,
which have been prepared in accordance with generally accepted accounting principles in the United States, or GAAP. The preparation of these consolidated financial statements requires us to make estimates and assumptions that affect the reported
amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, as well as the reported expenses incurred during the reporting periods. Our estimates are based on our
historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from
other sources. Actual results may differ from these estimates under different assumptions or conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">While our significant accounting policies
are described in more detail in the notes to our consolidated financial statements and the notes to our unaudited interim condensed consolidated financial statements appearing elsewhere in this prospectus, we believe the following accounting
policies used in the preparation of our consolidated financial statements require the most significant judgments and estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Fair Value Measurements
</I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Series B Preferred Stock Tranche Obligation </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We
determined that our obligation to issue additional shares of our Series B redeemable convertible preferred stock upon the occurrence of a specified clinical milestone event represented a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
freestanding financial instrument. The resulting tranche liability was initially recorded at fair value, with gains and losses arising from changes in fair value recognized in other income
(expense) in the consolidated statements of operations and comprehensive loss. The tranche liability was remeasured at each reporting period and upon the settlement of the obligation. The tranche liability was valued using a binomial model with
significant inputs including the estimated future value of our Series B redeemable convertible preferred stock, the discount rate, estimated time from the initial closing of our Series B redeemable convertible preferred stock to the tranche closing,
and probability of the tranche closing. The obligation was fully satisfied in October 2018 upon the second closing of our Series B redeemable convertible preferred stock, upon which the tranche liability was remeasured and reclassified to Series B
redeemable convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Anti-Dilution Obligation </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We concluded that our obligation to issue additional shares of our redeemable convertible preferred stock to Purdue to maintain a specified ownership
percentage in our capital stock through issuances of our Series B redeemable convertible preferred stock represented a freestanding financial instrument. The resulting anti-dilution obligation was initially recorded at fair value, with gains and
losses arising from changes in fair value recognized in other income (expense) in the consolidated statements of operations and comprehensive loss. The anti-dilution obligation was remeasured at each reporting period and upon the settlement of the
obligation. The anti-dilution obligation was valued using a discounted cash flow model under the income approach, using significant inputs including the estimated future value of our Series B redeemable convertible preferred stock, discount rates,
estimated time to liquidity and probability of each tranche closing. The anti-dilution obligation was settled in October 2018, upon which it was remeasured and reclassified to Series B redeemable convertible preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Conversion Features </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We issued two separate unsecured
convertible promissory notes to an investor in 2017 and 2018 that would automatically convert, upon an equity financing of at least $2.0&nbsp;million in gross proceeds, into shares of the type of equity securities issued in such financing, at a
discount. We determined that the conversion features represented a derivative instrument which was initially recorded at fair value, with gains and losses arising from changes in fair value recognized in other income (expense) in the consolidated
statements of operations and comprehensive loss. The conversion features were remeasured at each reporting period and upon settlement. The fair value of the conversion features was determined by calculating the fair values of the convertible
promissory notes with and without the conversion features. The difference between the fair values of the convertible promissory notes in the &#147;with&#148; and &#147;without&#148; scenarios was determined to be the initial fair value of the
conversion features. The valuation used significant inputs including the probability of various exit scenarios and discount rates. The conversion features were settled, and the notes converted into shares of Series B redeemable convertible preferred
stock, upon the initial closing of our Series B redeemable convertible preferred stock in March 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Research and Development Expenses and Related Accruals
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Research and development expenses include costs directly attributable to the conduct of research and development programs, including
personnel-related expenses such as salaries, benefits, and stock-based compensation expense; materials; supplies; manufacturing and external costs related to outside vendors engaged to conduct both preclinical studies and clinical trials; and the
allocable portions of facility costs, such as rent, utilities, depreciation, and general support services. All costs associated with research and development activities are expensed as incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As part of the process of preparing our consolidated financial statements, we are required to estimate our accrued research and development expenses.
This process involves reviewing open </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf, and estimating the level of service performed and the associated costs
incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. The majority of our service providers invoice us in arrears for services performed, on a <FONT STYLE="white-space:nowrap">pre-determined</FONT>
schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time.
When evaluating the adequacy of the accrued liabilities, we analyze progress of the studies or trials, including the phase or completion of events, invoices received and contracted costs. Examples of estimated accrued research and development
expenses include fees paid to: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">CROs in connection with performing research services and preclinical and clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">investigative sites or other providers in connection with preclinical and clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">vendors in connection with preclinical and clinical development activities; and </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">vendors related to product manufacturing, development and distribution of preclinical and clinical supplies.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The financial terms of our agreements with CROs are subject to negotiation, vary from contract to contract, and may result in
uneven payment flows. There may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the clinical expense. Payments under some of these contracts depend on factors such as the
successful enrollment of patients and the completion of milestones. In accruing service fees, we estimate the time period over which services will be performed, enrollment of patients, number of sites activated and the level of effort expended in
each period. If the actual timing of the performance of services or the level of effort varies from our estimate, we adjust the accrual or amount of prepaid expense accordingly. Significant judgments and estimates are made in determining the accrued
balances at the end of any reporting period. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing
of services performed may vary and may result in us reporting amounts that are too high or too low in any particular period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Stock-Based Compensation
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We issue stock-based awards to employees and <FONT STYLE="white-space:nowrap">non-employees,</FONT> generally in the form of stock options
and restricted stock awards. We measure all stock-based awards granted to employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> as stock-based compensation expense at fair value in accordance with FASB ASC Topic 718,
Compensation&#151;Stock Compensation, or ASC 718. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For stock-based awards issued to employees, <FONT STYLE="white-space:nowrap">non-employees</FONT>
and members of the board of directors, or the Board, for their services on the Board, we measure the estimated fair value of the stock-based award on the date of the grant. We recognize compensation expense for those awards granted to employees and
members of the Board over the requisite service period, which is generally the vesting period of the respective award. For <FONT STYLE="white-space:nowrap">non-employee</FONT> awards, compensation expense is recognized as the services are provided,
which is generally ratably over the vesting period. We issue stock-based awards with service-based vesting conditions and record the expense for these awards on a straight-line basis over the vesting period. To date, we have not issued any
stock-based awards with performance or market-based vesting conditions. We account for forfeitures as they occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We classify stock-based
compensation expense in our consolidated statements of operations and comprehensive loss in the same manner in which the award recipient&#146;s salary or service payments are classified. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Fair Value of Stock-Based Awards </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We determine the fair value of restricted stock based on the fair value of our common stock less purchase price. We estimate the fair value of our stock
options using the Black-Scholes option pricing model, which requires inputs of subjective assumptions, including: (i)&nbsp;the expected volatility of our stock; (ii)&nbsp;the expected term of the award; (iii)&nbsp;the risk-free interest rate;
(iv)&nbsp;expected dividends; and (v)&nbsp;the fair value of common stock. Due to the lack of company-specific historical and implied volatility data for our common stock, we determine the volatility for awards granted based on an analysis of
reported data for a group of guideline publicly-traded companies that issued options with substantially similar terms. For this analysis, we select companies with comparable characteristics to ours including enterprise value, risk profiles and with
historical share price information sufficient to meet the expected life of the stock-based awards. We determine expected volatility using a weighted average of the historical volatilities of the guideline group of companies. We will continue to
apply this process until such a time as we have adequate historical data regarding the volatility of our own traded stock price. As permitted under ASC 718, we have elected to use the contractual term as the expected term for certain <FONT
STYLE="white-space:nowrap">non-employee</FONT> awards, on an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">award-by-award</FONT></FONT> basis. For all other awards, we determined the expected term utilizing the
&#147;simplified&#148; method whereby the expected term equals the average of the vesting term and the original contractual term of the option, on a weighted basis based on the vesting of each tranche. We utilize this method as we have insufficient
historical exercise data to provide a reasonable basis upon which to estimate the expected term. For the determination of the risk-free interest rate, we utilize the U.S. Treasury yield curve for instruments in effect at the time of measurement with
a term commensurate with the expected term assumption. The expected dividend yield is assumed to be zero as we have never paid dividends, and do not have current plans to pay any dividends on our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Determination of Fair Value of Common Stock </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Given the
absence of an active market for our common stock, the fair value of shares of common stock underlying our stock-based awards was determined on each grant date by the Board with input from management, considering our most recently available
third-party valuations of common stock and the Board&#146;s assessment of additional objective and subjective factors that it believed were relevant and which may have changed from the date of the most recent valuation through the grant date.
Historically, these independent third-party valuations of our equity instruments were performed contemporaneously with identified value inflection points. The third-party valuations were prepared in accordance with the framework of the American
Institute of Certified Public Accountants&#146; Technical Practice Aid, <I>Valuation of Privately-Held Company Equity Securities Issued as Compensation</I>, or the Practice Aid. The Practice Aid identifies various available methods for allocating
enterprise value across classes and series of capital stock to determine the estimated fair value of common stock at each valuation date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In
addition to considering the results of these third-party valuations, our Board considered various objective and subjective factors to determine the fair value of our equity instruments as of each grant date, which may be later than the most recently
available third-party valuation date, including: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the lack of liquidity of our equity as a private company; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the prices of our redeemable convertible preferred stock sold to outside investors in arm&#146;s length transactions, and
the rights, preferences and privileges of our redeemable convertible preferred stock as compared to those of our common stock, including the liquidation preferences of our redeemable convertible preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the progress of our research and development efforts, including the status of preclinical and clinical studies for our
product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our stage of development and business strategy and the material risks related to our business and industry;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the achievement of enterprise milestones, including entering into strategic collaborative and license agreements;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the valuation of publicly-traded companies in the life sciences and biotechnology sectors, as well as recently completed
mergers and acquisitions of peer companies; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any external market conditions affecting the biotechnology industry and trends within the biotechnology industry;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the likelihood of achieving a liquidity event, such as an initial public offering, or a sale of our company, given
prevailing market conditions; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the analysis of initial public offerings and the market performance of similar companies in the biotechnology industry.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">There are significant judgments and estimates inherent in these valuations. These judgments and estimates include assumptions
regarding our future operating performance, the stage of development of our product candidates, the timing and probability of a potential initial public offering or other liquidity event and the determination of the appropriate valuation methodology
at each valuation date. The assumptions underlying these valuations represent management&#146;s best estimates, which involve inherent uncertainties and the application of management judgment. As a result, if factors or expected outcomes change and
we use significantly different assumptions or estimates, our stock-based compensation expense could be materially different. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Once a public
trading market for our common stock has been established in connection with the consummation of this offering, it will no longer be necessary for our Board to estimate the fair value of our common stock in connection with our accounting for granted
stock options and restricted stock, as the fair value of our common stock will be determined based on its trading price on The Nasdaq Global Select Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Valuation Methodologies </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The option-pricing method, or OPM,
treats common stock and preferred stock as call options on the total equity value of a company, with exercise prices based on the value thresholds at which the allocation among the various holders of a company&#146;s securities changes. Under this
method, the common stock has value only if the funds available for distribution to stockholders exceed the value of the liquidation preferences at the time of a liquidity event, such as a strategic sale or merger. The OPM uses the Black-Scholes
option-pricing model to price the call options. Inputs to the model include the anticipated timing of a potential liquidity event and the estimated volatility of the equity securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under the probability-weighted expected return method, or PWERM, the fair value of common stock is estimated based upon an analysis of future values for
the company, assuming various outcomes. The common stock value is based on the probability-weighted present value of expected future investment returns considering each of the possible outcomes available as well as the rights of each class of stock.
Present value is calculated using an appropriate risk-adjusted discount rate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The hybrid method is a PWERM where the equity value in one of the
scenarios is calculated using an OPM. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Third-party appraisals of our common stock were prepared as of March&nbsp;13, 2018, June&nbsp;24, 2019,
May&nbsp;1, 2020, August&nbsp;1, 2020 and September&nbsp;1, 2020. In each appraisal, the value of our equity was calibrated to a contemporaneous transaction in our redeemable convertible preferred stock. For the March&nbsp;13, 2018 and June&nbsp;24,
2019 appraisals, the OPM was used to back-solve to the most recent transaction in our preferred shares. For the May&nbsp;1, 2020, August&nbsp;1, 2020 and September&nbsp;1, 2020 appraisals, the back-solve calculation used a hybrid PWERM. The hybrid
PWERM considered three scenarios: an &#147;early&#148; IPO completed in 2020, a &#147;late&#148; IPO completed in 2021 and a &#147;remain private&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
scenario in which value is allocated using the OPM. An incremental discount for lack of marketability, or DLOM, is applied to the values of the common stock. The DLOM is estimated using a put
option model which considers the expected time to liquidity and the volatility of the common shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">These appraisals resulted in valuations of our
common stock of $2.27 per share as of March&nbsp;13, 2018, $3.30 per share as of June&nbsp;24, 2019, $5.59 per share as of May&nbsp;1, 2020, $8.27 per share as of August&nbsp;1, 2020 and $8.91 per share as of September&nbsp;1, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Grants of Stock-Based Awards </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes
by grant date and type of award, the number of stock-based awards granted between January&nbsp;1, 2018 and the date of this prospectus, the per share exercise price, the fair value of common stock on each grant date and the per share estimated fair
value of the awards, along with the fair value per award on the date of grant: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Type of<BR>Award</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exercise<BR>Price<BR>per<BR>Share(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fair&nbsp;Value&nbsp;of<BR>Common<BR>Stock<BR>per Share<BR>on Grant<BR>Date(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted-<BR>Average<BR>Estimated&nbsp;Fair<BR>Value Per<BR>Share<BR>of Awards(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">October&nbsp;19, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">Options</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,128,318</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2.27</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2.27</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1.65</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">September&nbsp;24, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">Options</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">442,232</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3.30</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3.30</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2.25</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">June&nbsp;5, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">Options</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,683,265</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5.59</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5.59</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4.02</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">August 19, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">Options</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">465,652</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8.27</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8.27</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5.86</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">September 14, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">Options</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,146,701</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8.91</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8.91</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">6.40</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The exercise price per share and fair value of common stock per share represents the fair value of our common stock on
the date of grant, as determined by the Board, after taking into account our most recently available contemporaneous valuation of our common stock as well as additional objective and subjective factors through the date of grant.
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Reflects the weighted-average fair value of options granted on each grant date, determined using the Black-Scholes
option-pricing model. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We did not grant any shares of restricted common stock during this period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>JOBS Act and Emerging Growth Company Status </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In April 2012,
the JOBS Act was enacted. As an emerging growth company, or EGC, under the JOBS Act, we may delay the adoption of certain accounting standards until such time as those standards apply to private companies. Other exemptions and reduced reporting
requirements under the JOBS Act for EGCs include presentation of only two years of audited financial statements in a registration statement for an initial public offering, an exemption from the requirement to provide an auditor&#146;s report on
internal controls over financial reporting pursuant to Section&nbsp;404(b) of the Sarbanes-Oxley Act of 2002, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm
rotation and less extensive disclosure about our executive compensation arrangements. Additionally, the JOBS Act provides that an EGC can take advantage of an extended transition period for complying with new or revised accounting standards. This
allows an EGC to delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of the extended transition period and, therefore, while we are an EGC we will
not be subject to new or revised accounting standards at the same time that they become applicable to other public companies that are not EGCs, unless we choose to early adopt a new or revised accounting standard. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We will remain classified as an EGC until the earlier of: (i)&nbsp;the last day of our first fiscal year in which we have total annual gross revenues of
$1.07&nbsp;billion or more, (ii)&nbsp;the last day of the fiscal year </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
following the fifth anniversary of completion of this offering, (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion of <FONT STYLE="white-space:nowrap">non-convertible</FONT>
debt instruments during the previous three fiscal years or (iv)&nbsp;the date on which we are deemed a &#147;large accelerated filer&#148; under the rules of the SEC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Recently Issued Accounting Pronouncements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have reviewed
all recently issued standards and have determined that, other than as disclosed in Note 2 to our consolidated financial statements appearing elsewhere in this prospectus, such standards will not have a material impact on our financial statements or
do not otherwise apply to our current operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Quantitative and Qualitative Disclosures About Market Risks </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Interest Rate Fluctuation Risk </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are exposed to
market risk related to changes in interest rates. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general level of U.S. interest rates, particularly because our cash equivalents are invested in
short-term U.S. Treasury obligations. However, because of the short-term nature of the instruments in our portfolio, an immediate change in market interest rates of 100 basis points would not have a material impact on the fair market value of our
investment portfolio or on our financial position or results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Foreign Currency Fluctuation Risk </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are not currently exposed to significant market risk related to changes in foreign currency exchange rates; however, we have contracted with and may
continue to contract with foreign vendors. Our operations may be subject to fluctuations in foreign currency exchange rates in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Inflation
Fluctuation Risk </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Inflation generally affects us by increasing our cost of labor. We do not believe that inflation had a material effect on
our business, financial condition or results of operations during the years ended December&nbsp;31, 2018 or 2019 or the six months ended June 30, 2019 or 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom945651_12"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Company Overview </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are a clinical-stage biopharmaceutical
company translating genetic insights into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal imbalance. Normal brain function requires a delicate balance of excitation and inhibition in neuronal
circuits, which, when dysregulated, can lead to abnormal function and disease. We are applying insights into the genetic mutations that drive excitation-inhibition imbalance in diseases to select biological targets for severe pediatric epilepsies
and more broadly for prevalent psychiatric diseases and neurologic disorders. We apply a deliberate and pragmatic precision approach, leveraging a suite of translational tools including novel transgenic and predictive translational animal models and
electrophysiology markers, to enable an efficient path to <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> in patients. Through this approach, we have established a broad portfolio, including five
disclosed programs across multiple CNS disorders, including depression, epilepsy, movement disorders and pain syndromes, with three clinical-stage product candidates. We expect multiple topline clinical trial readouts from all three programs prior
to the end of 2021 and anticipate the launch of a new clinical development program in 2021. We intend to develop differentiated therapies that can deliver long-term benefits to human health by meaningfully impacting patients and society. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our lead clinical program, <FONT STYLE="white-space:nowrap">PRAX-114,</FONT> is an extrasynaptic-preferring GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor positive allosteric modulator, or PAM, for the treatment of patients suffering from major depressive disorder, or MDD, and perimenopausal depression, or PMD. Together, these conditions
affect more than 22&nbsp;million people in the United States, many of whom are not responsive to or are underserved by current treatments. <FONT STYLE="white-space:nowrap">PRAX-114</FONT> is under development as a potentially differentiated
treatment as both a monotherapy and adjunctive therapy for both acute and maintenance settings. We believe that <FONT STYLE="white-space:nowrap">PRAX-114</FONT> has several advantages relative to currently available therapies and product candidates
in the GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAM therapeutic class, including a wider therapeutic window, patient-centric dosing and indication expansion opportunities. We have a multi-cohort, three-part Phase 2a clinical
trial ongoing in Australia, and in Part A of the trial, we observed marked improvements in depression scores in MDD patients within two weeks of treatment. We expect complete topline data from Part B of the trial in the second half of 2021 and from
longer-term dosing in MDD patients in Part C of the trial in the fourth quarter of 2020. We are planning to initiate a Phase 2/3 trial in the United States and Australia in the fourth quarter of 2020, which is intended to satisfy one of two
registrational trials required by the U.S. Food and Drug Administration, or the FDA, to support clinical efficacy for the treatment of MDD, and we expect topline data in the second half of 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our second clinical program, <FONT STYLE="white-space:nowrap">PRAX-944,</FONT> is a potentially differentiated selective small molecule inhibitor of <FONT
STYLE="white-space:nowrap">T-type</FONT> calcium channels, for the treatment of Essential Tremor, or ET. ET is a progressive and debilitating movement disorder with action tremors that significantly disrupt daily living, with an estimated prevalence
of up to seven&nbsp;million patients in the United States. There is a high unmet need for ET patients given the limited treatment options, with only one approved pharmacotherapy that is poorly tolerated, resulting in high discontinuation rates and
the need for invasive brain surgeries. Successful development of <FONT STYLE="white-space:nowrap">T-type</FONT> calcium channel modulators in ET likely requires a PK profile with a blunted Cmax, which we believe positions our modified release
formulation for <FONT STYLE="white-space:nowrap">PRAX-944</FONT> to be a differentiated therapy. In these trials, we have evaluated the safety and tolerability of <FONT STYLE="white-space:nowrap">PRAX-944</FONT> in over 150 healthy volunteers in
five separate clinical trials. We have studied the safety of PRAX-944 modified release formulation with titration up to 120mg/day and no maximum tolerated dose, or MTD, has been identified. We are currently conducting a Phase 2a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> open-label trial in ET patients. Preliminary site data from five patients of the low dose cohort showed tremor reduction, which seems to compare favorably to
the standard of care agents. We plan to announce topline data, including a high dose cohort, in the first half of 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our lead rare disease
product candidate and third clinical program, <FONT STYLE="white-space:nowrap">PRAX-562,</FONT> is the first selective persistent sodium current blocker in development for the treatment of a broad range of rare,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
devastating CNS disorders, such as severe pediatric epilepsy and adult cephalgia. To date, <FONT STYLE="white-space:nowrap">PRAX-562</FONT> has demonstrated pharmacological activity in <I><FONT
STYLE="white-space:nowrap">in-vivo</FONT></I> models with significantly improved tolerability, suggesting a potentially improved therapeutic index compared to other sodium channel blockers. We have initiated a Phase 1 trial of <FONT
STYLE="white-space:nowrap">PRAX-562</FONT> in Australia to evaluate the safety, tolerability, pharmacokinetics, or PK, and effects on an EEG biomarker in up to 129 adult healthy volunteers. We anticipate Phase 1 single ascending dose, or SAD,
topline safety data in the fourth quarter of 2020. In addition to our clinical programs, we have one preclinical program and one disclosed discovery program in development for severe genetic epilepsies and we continue to evaluate additional
programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Below is a summary of our portfolio of programs, organized by their initial therapeutic focus addressing either broad psychiatric and
neurologic conditions or rare diseases. We own global commercialization rights for all of our product candidates. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g945651g51s28.jpg" ALT="LOGO">
 </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left"><FONT STYLE="white-space:nowrap">PRAX-222</FONT> is a collaboration with Ionis Pharmaceuticals, or Ionis, and RogCon Inc.
Ionis is eligible to receive royalties as a percentage of net product sales worldwide in the low-20s. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our company was founded by
scientific innovators Kiran Reddy, M.D., David Goldstein, Ph.D. and Steven Petrou, Ph.D., who have pioneered work to identify and characterize de novo mutations in several dozen genes believed to cause a number of forms of severe pediatric
epilepsies. These genes regulate key neuronal circuits in the brain which, when dysregulated, can result in severe seizure phenotypes as well as comorbid developmental delays, cognitive deficits, sensory-motor issues and often early death. Further,
based on our understanding of a body of preclinical and clinical evidence, we now believe that these genes also play critical roles in the predisposition to other more prevalent neurologic and psychiatric disorders, such as mood disorders, movement
disorders, pain syndromes, autism, migraine and schizophrenia, making them attractive targets for therapeutic intervention for a wide range of CNS disorders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have attracted a talented team of scientists and researchers in genetics and biology, chemistry and translational medicine as well as business
leaders with established track records of successfully executing innovative drug discovery and development programs. Our Chief Executive Officer, Marcio Souza, most recently served as Chief Operating Officer at PTC Therapeutics, Inc. and was
instrumental in the development and commercialization of multiple approved products while at NPS Pharmaceuticals, Inc., Shire Human Genetic Therapies Inc. and Sanofi Genzyme Corporation. Our Chief Medical Officer, Bernard Ravina, M.D., previously
Chief Medical Officer at Voyager Therapeutics, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Inc., is a neurologist and movement disorder specialist who brings decades of neurologic drug development experience from roles at Biogen, the University of Rochester and the NIH&#146;s Institute
of Neurological Disorders and Stroke. Our Chief Financial Officer, Stuart Chaffee, Ph.D., <FONT STYLE="white-space:nowrap">co-founded</FONT> Kymera Therapeutics, Inc. and has held multiple senior roles in finance, business development and corporate
strategy at Biogen Inc., Zafgen, Inc. and Amgen Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Our Approach </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each of our programs is based on four key principles that we believe will both increase the probability of success and allow us to efficiently translate
insights into high-impact therapies for patients and society: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>1.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><I></I><B><I>Focus on therapeutic targets identified through human genetics.</I></B>&nbsp;&nbsp;&nbsp;&nbsp;Numerous CNS
disorders are caused by an imbalance of excitation and inhibition in neuronal circuitry. By applying insights derived from the genetics of pediatric epilepsies, we have identified biological targets that we believe are implicated in determining
neuronal excitability, not only in epilepsies, but also in a variety of more prevalent CNS disorders. For example, human genetics points to the relevance of the GABAergic system where mutations in
GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors are associated with a number of rare pediatric epilepsies. The GABAergic system is also implicated in MDD, where enhancing
GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> activity is believed to be beneficial. As our understanding of the genetic underpinning of these disorders evolves, we plan to continually apply learnings to expand and advance our
portfolio. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>2.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><I></I><B><I>Utilize translational tools to validate the potential of our targets and product
candidates.&nbsp;&nbsp;&nbsp;&nbsp;</I></B>We leverage a number of translational tools to both confirm pharmacodynamic effects of our product candidates in the brain and establish <FONT STYLE="white-space:nowrap">on-mechanism</FONT> effects, which
we believe will result in an increased probability of success in the clinic. Our programs utilize target-specific EEG endpoints to serve as robust markers of pharmacological engagement of the drug target and novel transgenic animal models to assess
the therapeutic activity of our molecules. We expect these tools, along with rigorous preclinical PK and pharmacodynamic characterization of our molecules will position us to more efficiently translate preclinical findings into clinical utility.
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>3.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><I></I><B><I>Pursue efficient, rigorous clinical development paths to <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> in humans</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;Our development strategies are focused on defining efficient paths to demonstrate the safety and therapeutic activity of our programs in humans. We
select indications that we believe will enable the early demonstration of desired effect in a relatively small patient sample and we focus on clinical endpoints that both minimize inter-patient variability and offer a clear connection between
pharmacodynamic effects and clinical measures that are meaningful to patients, physicians and regulatory agencies. Our global network of contract research organizations, or CROs, and scientists affords us the flexibility to conduct research and
development activities in diverse geographic locations to accelerate our development timelines and limit geographic risks. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><I>4.</I></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left"><I></I><B><I>Apply patient-centric development strategies. </I></B>We pursue the development of candidates that address
the treatment needs of patients and the treating community, including targeting the underlying disease pathology versus just symptom management. We intend to develop therapies that provide patients long-term relief from their disorders and
significantly reduce the overall burden to patients and caregivers. Our development strategies are tailored to demonstrate these benefits. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Our Strategy </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our goal is to translate genetic insights into high-impact therapies for millions of people suffering from CNS disorders characterized by imbalance of
neuronal excitation-inhibition. Key components of our strategy include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Advance <FONT STYLE="white-space:nowrap">PRAX-114</FONT> in MDD and PMD toward regulatory approval and
commercialization.</B><FONT STYLE="white-space:nowrap">&nbsp;&nbsp;&nbsp;&nbsp;PRAX-114</FONT> is a potentially differentiated GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A </SUB>receptor PAM currently in Phase 2a development for the
treatment of MDD and PMD. Based on early clinical data where we observed a marked improvement of depression scores in MDD patients within two weeks of treatment, we are planning to initiate a Phase 2/3 trial in the United States and Australia in the
fourth quarter of 2020, which is intended to satisfy one of two registrational trials required by the FDA to support clinical efficacy for the treatment of MDD, and we expect topline data in the second half of&nbsp;2021. We are conducting a
Phase&nbsp;2a trial in Australia in PMD and expect to announce topline data in the second half of 2021. We intend to develop <FONT STYLE="white-space:nowrap">PRAX-114</FONT> in the United States and in other countries as both a monotherapy and
adjunctive therapy for MDD and PMD in both acute and maintenance settings. While we have been diligently pursuing our strategy to efficiently advance PRAX-114 towards regulatory approval and commercialization, there is no assurance that we will be
successful in obtaining regulatory approval in an accelerated manner, or at all. For a detailed description of the risks related to the development and commercialization of our product candidates, please refer to the section entitled &#147;Risk
Factors&#148; in this prospectus. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Advance <FONT STYLE="white-space:nowrap">PRAX-944</FONT> in ET toward regulatory approval and
commercialization.&nbsp;&nbsp;&nbsp;&nbsp;</B><FONT STYLE="white-space:nowrap">PRAX-944</FONT> is a potentially differentiated selective small molecule inhibitor of <FONT STYLE="white-space:nowrap">T-type</FONT> calcium channels in development for
ET. In these trials, we have evaluated the safety and tolerability of <FONT STYLE="white-space:nowrap">PRAX-944</FONT> in over 150&nbsp;healthy volunteers in five separate clinical trials. We have studied the safety of PRAX-944 modified release
formulation with titration up to 120mg/day and no MTD has been identified. We are currently conducting a Phase 2a proof-of-concept open-label trial in Australia and New&nbsp;Zealand in ET patients. Preliminary site data from five patients of the low
dose cohort showed tremor reduction, which seems to compare favorably to the standard of care agents. We plan to announce topline data, including a high dose cohort, in the first half of 2021. While we have been diligently pursuing our strategy to
efficiently advance PRAX-944 towards regulatory approval and commercialization, there is no assurance that we will be successful in obtaining regulatory approval in an accelerated manner, or at all. For a detailed description of the risks related to
the development and commercialization of our product candidates, please refer to the section entitled &#147;Risk Factors&#148; in this prospectus. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Build a rare disease franchise.&nbsp;&nbsp;&nbsp;&nbsp;</B>We are advancing several programs for patients with rare
diseases, such as genetically defined populations suffering from Developmental and Epileptic Encephalopathies, or DEEs, a group of disorders associated with severe and frequent seizures, developmental delays, cognitive decline and high mortality
rates. We have three rare disease programs in our pipeline, including <FONT STYLE="white-space:nowrap">PRAX-562,</FONT> which we believe represents the first selective persistent sodium current blocker in development for the treatment of a number of
rare diseases with limited or no treatment options. We have an ongoing Phase&nbsp;1 trial for <FONT STYLE="white-space:nowrap">PRAX-562</FONT> in healthy volunteers in Australia and anticipate topline from the SAD study by fourth quarter
of&nbsp;2020. We plan to initiate a Phase&nbsp;2 trial for the treatment of Short-lasting Unilateral Neuralgiform headache attacks with Conjunctival injection and Tearing, or SUNCT, and Short-lasting Unilateral Neuralgiform headache with Autonomic
symptoms, or SUNA, cephalgias. If we observe clinical <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept,</FONT></FONT> we will then expand into DEEs. We believe that our additional programs for genetically-defined
pediatric epilepsies will position Praxis as a leader in developing therapies for patients suffering from DEEs. Given the overlapping biology, phenotypic presentation and clinical execution considerations, we believe that we can translate learnings
for the treatment of DEEs across our portfolio in order to more efficiently bring additional treatments to market. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Maximize the value of our product candidates through select indication expansion.&nbsp;&nbsp;&nbsp;&nbsp;</B>All of our
clinical stage product candidates address targets with therapeutic potential beyond their lead indications. As these programs advance through the clinic, we will pragmatically evaluate indication expansion and consider subsequent clinical
development that will expand the labels of our product candidates to encompass other compelling opportunities at a time when we determine to be most efficient. </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Advance our understanding of genetics and neuronal imbalance to maintain our leadership and continue to build our
pipeline.</B>&nbsp;&nbsp;&nbsp;&nbsp;Advances in the field of genetics continue to elucidate new insights into mutations that drive neuronal imbalance. Our team is deeply engaged in these efforts, which we believe will enable us to pursue a pipeline
discovery and development strategy grounded in these learnings and coupled with our drug discovery, translational and clinical experience. As our knowledge base continues to grow, we believe our potential to deliver additional differentiated
medicines for patients will grow as well. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Commercialize our products in the United States and globally.&nbsp;&nbsp;&nbsp;&nbsp;</B>To realize the full potential
of our product candidates, we intend to build a sales and marketing infrastructure to reach prescribers in the United States. In order to capitalize on market opportunities outside the United States, we may pursue collaborations with reputable
pharmaceutical companies that have established presences in key geographies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>BROAD PSYCHIATRY AND NEUROLOGY PROGRAMS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">PRAX-114</FONT> </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are
developing <FONT STYLE="white-space:nowrap">PRAX-114,</FONT> an extrasynaptic-preferring GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A </SUB>receptor positive allosteric modulator, or PAM, for the treatment of patients suffering from major
depressive disorder, or MDD, and perimenopausal depression, or PMD. <FONT STYLE="white-space:nowrap">PRAX-114</FONT> is a potentially differentiated treatment as a monotherapy and adjunctive therapy for both acute and maintenance settings. We have a
multi-cohort, three-part Phase&nbsp;2a clinical trial ongoing in Australia. We observed marked improvements in depression scores in MDD patients in Part&nbsp;A of this trial within two weeks of treatment. We expect complete topline data from
Part&nbsp;B of the trial in the second half of 2021 and from longer-term dosing in MDD patients in Part&nbsp;C of the trial in the fourth quarter of 2020. We are planning to initiate a Phase 2/3 trial in the United&nbsp;States and Australia in the
fourth quarter of 2020, which is intended to satisfy one of two registrational trials required by the FDA to support clinical efficacy for the treatment of MDD, and we expect topline data in the second half of&nbsp;2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">There is significant unmet medical need in MDD and PMD with over 22&nbsp;million individuals suffering from depressive symptoms in the U.S. Current
pharmacological interventions suffer from multiple shortcomings including slow onset of efficacy, low response rates and side effects that limit patient compliance. <FONT STYLE="white-space:nowrap">PRAX-114</FONT> targets an increasingly
well-understood neuronal circuit in the brain that we believe, when properly modulated, can result in a robust antidepressant effect with an advantageous safety and tolerability profile. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe that our <FONT STYLE="white-space:nowrap">PRAX-114</FONT> program has several advantages as compared to currently available therapies and
product candidates in the GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAM therapeutic class: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Wider Therapeutic Window</B>.&nbsp;&nbsp;&nbsp;&nbsp;We have determined that
<FONT STYLE="white-space:nowrap">PRAX-114</FONT> is an approximately <FONT STYLE="white-space:nowrap">10.5-fold</FONT> more potent PAM of the extrasynaptic form of GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors compared to
the synaptic form. By preferentially modulating extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors, we believe <FONT STYLE="white-space:nowrap">PRAX-114</FONT> has the potential to mediate antidepressant and
anxiolytic activity without the significant sedation observed with less selective neuroactive steroids. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Patient-Centric Dosing.</B>&nbsp;&nbsp;&nbsp;&nbsp;We believe the ability to administer
<FONT STYLE="white-space:nowrap">PRAX-114</FONT> with or without food is key for clinical and commercial success in MDD and is critical for a patient-centric </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
therapeutic, as many patients with depression suffer from appetite disturbance. We have observed fast absorption of <FONT STYLE="white-space:nowrap">PRAX-114</FONT> within one to three hours of
dosing and a robust PK profile across multiple trials. Based on clinical findings to date, we believe that <FONT STYLE="white-space:nowrap">PRAX-114</FONT> does not need to be taken with food to achieve therapeutic exposure, whereas other GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAMs may require food to achieve therapeutic exposure. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Sustained Administration</B>.&nbsp;&nbsp;&nbsp;&nbsp;After consultation with the FDA and other stakeholders in MDD and
PMD therapy, we designed our Phase&nbsp;2/3 trial of <FONT STYLE="white-space:nowrap">PRAX-114</FONT> to include <FONT STYLE="white-space:nowrap">28-day</FONT> nightly dosing to evaluate patients at both 14 days to assess the rapidity and robustness
of response and 28 days to measure durability of effect. We believe that having a dosing paradigm consistent with the duration of depressive episodes will provide the most substantial benefit to patients in controlling their disease, further
differentiating <FONT STYLE="white-space:nowrap">PRAX-114</FONT> from other GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A </SUB>PAMs. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><B>Indication Expansion.</B>&nbsp;&nbsp;&nbsp;&nbsp;Based on the novel pharmacology of PRAX-114 and its generally
well-tolerated profile in clinical trials to date, we believe <FONT STYLE="white-space:nowrap">PRAX-114</FONT> is suitable for potential development across a wide-range of indications in psychiatry and neurology, providing sizable expansion
opportunities to explore in addition to MDD. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Major Depressive Disorder </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Major Depressive Disorder, or MDD, is a chronic psychiatric condition causing severe impairments that interfere with the ability to carry out life
activities. An MDD episode is characterized by a period of at least two weeks of persistent depressed mood and/or the loss of interest or pleasure in activities, accompanied by sleep and appetite disturbance, fatigue, concentration difficulty,
cognitive impairment, feelings of guilt, psychomotor retardation or agitation and suicidal ideation. MDD is one of the most prevalent psychiatric disorders. In the United States, approximately 19&nbsp;million adults, or 7% of the adult population
suffer from MDD, with episodes lasting on average six to eight months. It is estimated that MDD affects more than 300&nbsp;million people worldwide. Moreover, the prevalence of depression has increased&nbsp;during the COVID-19 pandemic in the US and
globally. In the United States, depression symptoms have increased by more than 3-fold overall during the COVID-19 pandemic. The most dramatic increases are reported in moderate, moderately severe and severe depression symptoms, with a <FONT
STYLE="white-space:nowrap">2.6-fold,</FONT> 3.7-fold, and 7.5-fold rise, respectively, relative to a pre-COVID-19 pandemic period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">MDD is a chronic
psychiatric condition that requires long-term treatment, with the ultimate goal of achieving remission. MDD is associated with an elevated risk of suicide, underscoring the need for rapid and effective treatment. The most explored pharmacological
mechanisms for treating MDD target monoamine neurotransmitters. Drugs in this class include selective serotonin reuptake inhibitors, or SSRIs, serotonin and norepinephrine reuptake inhibitors, or SNRIs, bupropion and other monoaminergic medications.
SSRIs and SNRIs are associated with significant side effects, including weight gain, sexual dysfunction, drowsiness, nausea, insomnia and discontinuation syndrome, which negatively impact treatment outcomes, quality of life and adherence in MDD
patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Approximately seventy percent of MDD patients fail to respond to current first-line antidepressant treatments. Further, those patients
that are responsive typically require approximately six to eight weeks of treatment to show a clinically meaningful response. Slow onset of action is a substantial unmet need in MDD, with some of the most commonly prescribed antidepressants showing
a reduction in the Hamilton Depression Scale, or HAM-D, of approximately 6- to 8-points and a difference from placebo of approximately 1-2 points at Week 2 (Figure 1). Moreover, approximately 40% of patients on therapy discontinue treatment due to
either a loss of response or adverse side effects. Finally, 33% of patients fail to respond after treatment with three or more different standard of care therapies. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Among the MDD patients who experience a response to treatment, the majority do not achieve remission. Even for patients deemed responsive, disease
burden often persists through the presence of residual depression symptoms that lead to an ongoing negative impact on home, interpersonal and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
occupational functioning, as well as a significantly increased risk of relapse of the full depressive syndrome and worse comorbid outcomes, including suicide. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Despite the numerous and long-standing antidepressant treatment options, there continues to be an unmet need for antidepressants that provide rapid
onset of effect, higher remission rates, efficacy throughout the depressive episode, an improved tolerability profile and patient-centric dosing that is aligned with the clinical care and the course of MDD and its accompanying comorbid symptoms.
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g945651g76h63.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>Figure 1. Reduction of HAM-D from baseline of commonly prescribed antidepressants and placebo at Week&nbsp;2.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Perimenopausal depression </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Perimenopause is
the transition between the onset of hormonal and clinical features of menopause and the <FONT STYLE="white-space:nowrap">one-year</FONT> period after the final menses. Perimenopause can last up to 10 years. Women with no lifetime history of major
depression who have entered the perimenopause period are found to be twice as likely to develop significant depressive symptoms as women who have not entered the perimenopause period. Notably, the increased risk for depression during the
perimenopausal transition has been observed to decline substantially after the final menstrual period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">There are over 30&nbsp;million women in the
United States between the ages of 45 and 59 years who are at risk of developing perimenopause symptoms, with an estimated three million developing mood symptoms such as depression, anxiety, irritability and suicidal ideation and behavior and an
estimated 20&nbsp;million women developing associated vasomotor symptoms or hot flushes. Notably, suicide rates are the highest among women 45 to 59 years of age and have increased by approximately 42% in recent decades. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Although primarily viewed as a reproductive transition, the symptoms of perimenopause are largely neuropsychiatric in nature. Neurological symptoms that
emerge during perimenopause are indicative of disruption in multiple estrogen and progesterone-regulated systems such as thermoregulation, sleep, circadian rhythms and sensory processing and affect multiple domains of cognitive function.
Perimenopausal depression also appears to impact the clinical symptomatology of menopause, with the presence of depression being associated with a greater degree of menopausal hot flushes than in women without perimenopausal depression. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">There is substantial evidence that fluctuations in estrogen and progesterone, the precursor of the endogenous neuroactive steroid allopregnanolone, a
GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A </SUB>receptor PAM, are in part responsible for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the mood changes, hot flushes and other neurologic symptoms of perimenopause. Similar to MDD, SSRIs and SNRIs have shown limited efficacy in treating perimenopausal depression. There remains an
unmet medical need for effective treatment of core depression symptoms and associated physical symptoms of menopause. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A </SUB>receptor PAM, like <FONT STYLE="white-space:nowrap">PRAX-114,</FONT> that potentiates the activity of endogenous neuroactive steroids on GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A
</SUB>receptors, may offer broader therapeutic benefit compared to current standard of care antidepressants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> in depression </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Gamma-aminobutyric acid, or GABA, is the principal neurotransmitter
mediating neuronal inhibition in the brain. Neurons that produce GABA, known as GABAergic neurons, are present throughout the brain, representing between 20&nbsp;percent and 40&nbsp;percent of all neurons depending on the region. Their primary role
is to balance and fine tune excitatory neurotransmission of various neuronal circuits. Whole-exome sequencing has identified GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor mutation as an important cause in a range of
neurological conditions, underscoring their importance as central regulators of excitatory and inhibitory balance in the brain. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">It is well
established that GABAergic signaling is impaired in patients with MDD and other stress-related mood disorders. GABA levels, levels of the GABA synthesizing enzyme GAD67, as well as GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB>
receptor levels, have been shown to be reduced in brains of patients with MDD. In addition, decreased GABAergic neuron function, most notably in the prefrontal cortex, has been documented in MDD patients and in preclinical animal models of
depression. Endogenous neuroactive steroids, such as allopregnanolone and pregnanolone or synthetic derivatives thereof, such as <FONT STYLE="white-space:nowrap">PRAX-114,</FONT> are known to potentiate the activity of GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors. Both human and animal data reveal an important role for neuroactive steroids in these GABAergic deficits and levels of endogenous neuroactive steroids are decreased in individuals with
MDD and PMD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Of particular relevance to the <FONT STYLE="white-space:nowrap">PRAX-114</FONT> program is the more recently established link between
GABAergic signaling, neuroactive steroid levels and stress&#151;a well-established risk factor for MDD and other mood disorders. In preclinical models, exposure to chronic stress leads to reduced neuroactive steroid biosynthesis and reduced
GABAergic inhibition in depression-relevant brain circuits. This ultimately results in increased anxiety and depression-like behaviors. In particular, it has been shown that stress causes long-lasting loss of GABAergic inhibition in the amygdala, a
brain region central to the stress response involved in controlling emotions. This reduced inhibition causes increased activity of the amygdala and is associated with an exaggerated stress hormone response. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe that enhancing modulation of GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors in patients with depression and anxiety
has the potential to restore normal function in these circuits, leading to broad applications in mood and anxiety disorders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors: The target of <FONT STYLE="white-space:nowrap">PRAX-114</FONT> </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><FONT
STYLE="white-space:nowrap">PRAX-114</FONT> is a small molecule neuroactive steroid that acts as a positive allosteric modulator of GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors. Positive allosteric modulators, or PAMs, are
substances that bind to a receptor, such as GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB>, to enhance that receptor&#146;s response to its endogenous ligand (or endogenous agonist). GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAMs bind to a distinct site from endogenous GABA, an allosteric binding site, and do not activate the receptor in the absence of the ligand. Allosteric modulators are believed to have improved
safety profiles and are less likely to result in tachyphylaxis, or decreasing drug response, as compared to agonists. GABA exerts its effects through binding to two types of GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors,
synaptic and extrasynaptic receptors, which differ in their protein subunit composition, physical location on the cell surface and functional role in modulating neuronal circuits. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors are composed of five subunits
which include two alpha, two beta and a fifth subunit (either gamma or delta) that is dependent on the type of receptor. Synaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors, which are located in the synapse of neurons,
contain a gamma subunit while GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors located outside of the synapse, referred to as extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors, contain a
delta subunit. Molecules that act as PAMs of only the synaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor, such as benzodiazepines, bind to sites situated at the interface between the alpha and gamma subunits. Molecules
that act as PAMs of both synaptic and extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors, such as the neuroactive steroids allopregnanolone and <FONT STYLE="white-space:nowrap">PRAX-114,</FONT> bind to sites
situated at the interface between the alpha and beta subunits present in both types of receptors. The figure below displays the synaptic binding site for drugs such as benzodiazepines, and the distinct extrasynaptic and synaptic binding sites for
neuroactive steroids, such as allopregnanolone and <FONT STYLE="white-space:nowrap">PRAX-114.</FONT> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g945651g53m08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>Figure 2. GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> synaptic and extrasynaptic receptors
differ in structure and function. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Synaptic and extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors have
distinct functions. Synaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors are responsible for short-lasting, or phasic, inhibition of neurons in response to GABA release at the synapse. By contrast, extrasynaptic GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors drive continuous, or tonic, <FONT STYLE="white-space:nowrap">low-level</FONT> inhibition of neurons in response to lower ambient levels of GABA outside of the synapse. While synaptic
receptors can respond quickly to stimulation and network demand, extrasynaptic receptors have a broader modulatory role, serving to continuously modulate the overall excitability of neurons. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Molecules that act as PAMs of only the synaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor, such as benzodiazepines and
barbiturates, are used for sedation, sleep induction and anxiolysis, and have anticonvulsant and muscle relaxant properties. These drugs have potent and rapid onset of activity but have not demonstrated antidepressant effects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Allopregnanolone is an endogenous neuroactive steroid and a PAM of both the extrasynaptic and synaptic GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors, which has been associated with antidepressant activity. However, allopregnanolone also has shown significant dose-limiting sedative activity, which we believe is likely mediated at
least partially by its effects on synaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors. Despite this limitation, a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
formulation of allopregnanolone has been approved and is marketed as Zulresso to treat post-partum depression. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The distinct effects mediated by these classes of GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAMs suggest that modulation of
extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors is responsible for the antidepressant effects demonstrated by allopregnanolone. One of the goals for a next generation neuroactive steroids, such as <FONT
STYLE="white-space:nowrap">PRAX-114,</FONT> is to preferentially modulate extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors while minimizing the sedative impact from modulation of synaptic GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">PRAX-114</FONT> preference for extrasynaptic GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To assess the relative potency <I>in-vitro</I> of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PRAX-114-mediated</FONT></FONT> GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor activation for synaptic and extrasynaptic receptors, we measured the peak current
induced by a low concentration of GABA (2 &micro;M) in the presence of increasing concentrations of <FONT STYLE="white-space:nowrap">PRAX-114</FONT> in Chinese Hamster Ovary, or CHO, cells expressing either extrasynaptic (<FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT>4&szlig;3<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT></FONT>) or synaptic
(<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT>1&szlig;2<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>2) human GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors. In this model, <FONT STYLE="white-space:nowrap">PRAX-114</FONT> potentiates the GABA-activated current of both extrasynaptic and synaptic GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors, but was approximately <FONT STYLE="white-space:nowrap">6.4-fold</FONT> more potent in potentiating the extrasynaptic form of the receptor than the synaptic form based on the
concentration that gives half-maximal response, or EC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB>. At a concentration that activates extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors to the
equivalent of full activation by the endogenous ligand GABA (~260 nM, 300% potentiation of 2&micro;M GABA), <FONT STYLE="white-space:nowrap">PRAX-114</FONT> led to <FONT STYLE="white-space:nowrap">10.5-fold</FONT> greater potentiation of
extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors than synaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors (29%) (Figure 3, Table 4). </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g945651g45n70.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>Figure 3. At 300 %&nbsp;extrasynaptic&nbsp;GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor
potentiation (equivalent to ~ 100% activation by endogenous agonist GABA), <FONT STYLE="white-space:nowrap">PRAX-114</FONT> led to 10.5-fold greater potentiation of extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB>
receptors than synaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors (29%). </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the same assay, at the same level of
extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor potentiation (300%), other GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor PAM neuroactive steroids in development, or on the market,
demonstrated only 0.4 to 2.6 fold greater potentiation of extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors, which compares unfavorably to the 10.5 fold observed for
<FONT STYLE="white-space:nowrap">PRAX-114</FONT> (Table 4). Based on these assay conditions, we believe that the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
differentiated preference at extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors by PRAX-114 will allow it to achieve high levels of extrasynaptic GABAergic
activation with improved tolerability. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><FONT STYLE="font-size:10pt"><B>Dosing</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><FONT STYLE="font-size:10pt"><B></B><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT><B></B><B><SUB
STYLE="font-size:85%; vertical-align:bottom">4</SUB></B><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT></FONT><B></B><B><SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB></B><FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT></FONT><B></B><B>&nbsp;%&nbsp;potentiation<BR>(Equivalent of full<BR>activation&nbsp;by&nbsp;GABA)</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><FONT STYLE="font-size:10pt"><B></B><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT><B></B><B><SUB
STYLE="font-size:85%; vertical-align:bottom">1</SUB></B><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT></FONT><B></B><B><SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB></B><FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT><B></B><B><SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB><SUB STYLE="font-size:85%; vertical-align:bottom"></SUB>&nbsp;%&nbsp;
potentiation</B></FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Fold&nbsp;potentiation<BR></B><FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT><B></B><B><SUB STYLE="font-size:85%; vertical-align:bottom">4</SUB></B><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT></FONT>
<B></B><B><SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB></B><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT></FONT><B></B><B>/</B><FONT STYLE="font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT><B></B><B><SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB></B><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#098;</FONT></FONT><B></B><B><SUB
STYLE="font-size:85%; vertical-align:bottom">2</SUB></B><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT><B></B><B><SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">PRAX-114</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"><B>Oral</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right"><B>300</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right"><B>29</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right"><B>10.5</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Zuranolone</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">Oral</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">117</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2.6</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Ganaxolone</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">IV,&nbsp;Oral</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">794</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">0.4</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Zulresso (brexanolone)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">IV</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">300</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">306</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>Table 4. Comparison of the degree of </B><B><I>in-vitro</I></B><B> GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor potentiation achieved by PRAX-114 and other neuroactive steroid GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> PAMs. </B><FONT STYLE="font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT><FONT STYLE="font-family:ARIAL"><B></B></FONT><B>4&szlig;3</B><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#100;</FONT></FONT><FONT STYLE="font-family:ARIAL"><B></B></FONT>
<B>: extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors,
</B><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT><FONT STYLE="font-family:ARIAL"><B></B></FONT><B>1&szlig;2</B><FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#103;</FONT></FONT>
<FONT STYLE="font-family:ARIAL"><B></B></FONT><B>2: synaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT
STYLE="white-space:nowrap">PRAX-114</FONT> clinical development in depression </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have initiated clinical development for <FONT
STYLE="white-space:nowrap">PRAX-114</FONT> in mood disorders. To date, two Phase 1 clinical trials of <FONT STYLE="white-space:nowrap">PRAX-114</FONT> have been completed in healthy volunteers. These studies in 82 healthy volunteers showed <FONT
STYLE="white-space:nowrap">PRAX-114</FONT> to be generally well-tolerated, with dose-dependent pharmacodynamic activities. In our ongoing Phase 2a clinical trial in Australia, we have observed marked improvement in depression scores in MDD patients
within two weeks of treatment, and a pharmacokinetics bridging study in healthy volunteers that is also ongoing. We are planning to initiate a Phase 2/3 trial in the United States and Australia in the fourth quarter of 2020, which is intended to
satisfy one of two registrational trials required by the FDA to support clinical efficacy for the treatment of MDD, and we expect topline data in the second half of 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Phase 1 SAD and MAD trials in healthy volunteers </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We
conducted a Phase 1 randomized, double-blind, placebo-controlled single ascending dose, or SAD, trial of <FONT STYLE="white-space:nowrap">PRAX-114</FONT> in healthy volunteers to evaluate safety and tolerability of
<FONT STYLE="white-space:nowrap">PRAX-114.</FONT> This trial enrolled 36 volunteers who were randomized into cohorts dosed with 1mg, 3mg, 10mg, 30mg or 60mg of <FONT STYLE="white-space:nowrap">PRAX-114</FONT> or placebo. <FONT
STYLE="white-space:nowrap">PRAX-114</FONT> was generally well-tolerated and no serious adverse events, or SAEs, were reported in this trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We
subsequently conducted a Phase 1 randomized, double-blind, placebo-controlled multiple ascending dose, or MAD, trial in healthy volunteers in Australia to evaluate the safety, tolerability and pharmacokinetics of
<FONT STYLE="white-space:nowrap">PRAX-114</FONT> and to assess the effect of food on drug exposure. <FONT STYLE="white-space:nowrap">Thirty-six</FONT> volunteers were randomized to receive daily doses of 15mg, 30mg or 60mg of <FONT
STYLE="white-space:nowrap">PRAX-114</FONT> or placebo for 14 days. Ten additional volunteers in a food effect cohort received 30mg doses of <FONT STYLE="white-space:nowrap">PRAX-114</FONT> when they were in a fasted state or with a <FONT
STYLE="white-space:nowrap">high-fat</FONT> meal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As part of our MAD trial, we measured the effect of
<FONT STYLE="white-space:nowrap">PRAX-114</FONT> on the quantitative EEG, or qEEG, beta power, to understand the pharmacodynamic effect of <FONT STYLE="white-space:nowrap">PRAX-114</FONT> on
GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor activation. An EEG is a real-time <FONT STYLE="white-space:nowrap">non-invasive</FONT> measure of electrical activity of neurons in the brain. The frequency and amplitude of the
detected electrical signals provide insights into brain function and brain state (e.g., awake, deep sleep, etc). qEEG, also called <FONT STYLE="white-space:nowrap">pharmaco-EEG,</FONT> is a quantitative measure of the changes in brain activity in
specific EEG frequency bands in response to treatment with a brain-active compound. Changes in beta power, specifically, are used as a pharmacodynamic biomarker of GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor activation in
response to a brain active compound. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In both the Phase 1 SAD and MAD trials, we observed fast absorption of
<FONT STYLE="white-space:nowrap">PRAX-114</FONT> within one to three hours of dosing and approximately dose-proportional increases in peak concentration and total </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
drug exposure. In the MAD trial, the half-life of the drug was between 12.2 and 14.8 hours, consistent with a once-daily dosing paradigm. Little or no accumulation of the drug was observed in the
multiple dose trial over the ranges of doses tested. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe that the ability to administer <FONT STYLE="white-space:nowrap">PRAX-114</FONT>
with or without food is key for clinical and commercial success in MDD, as many patients struggle with adherence to medication and forcing a dietary regimen would impose further complications in this vulnerable population. In the food effect cohort
of the MAD trial, overall drug exposure as measured by area under the concentration curve, or AUC, of <FONT STYLE="white-space:nowrap">PRAX-114</FONT> increased by only <FONT STYLE="white-space:nowrap">1.17-fold</FONT> in the fed state versus in the
fasted state. The primary&nbsp;effect&nbsp;of&nbsp;food&nbsp;was observed in the maximum drug exposure, or Cmax, which was <FONT STYLE="white-space:nowrap">0.64-fold</FONT> of that observed under fed conditions. These findings indicate that <FONT
STYLE="white-space:nowrap">PRAX-114</FONT> does not need to be taken with&nbsp;food&nbsp;to achieve therapeutic exposures. According to results presented in a published patent application, Zuranolone, a GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB>&nbsp;PAM neuroactive steroid in development for treatment of MDD, exhibited a food effect that resulted in increases in Cmax of approximately <FONT STYLE="white-space:nowrap">2.88-fold</FONT> and
in AUC of approximately <FONT STYLE="white-space:nowrap">1.58-fold</FONT> in the fed versus the fasted conditions (Table 5). We believe this food effect has led to the development of Zuranolone being carried out with a requirement for the compound
to be administered together with a <FONT STYLE="white-space:nowrap">high-fat</FONT> meal. We believe that the absence of a requirement that <FONT STYLE="white-space:nowrap">PRAX-114</FONT> be taken with food creates a potential competitive
advantage. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="11%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2" COLSPAN="5"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="6"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom" COLSPAN="5" NOWRAP ALIGN="center" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1.00pt solid #000000"><B>Statistical Analysis of the Effect of High-fat Meal<BR>for PRAX-114 suspension (30mg)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:2pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1.00pt solid #000000"><B>Statistical Analysis of the Effect of High-fat Meal<BR>for Zuranolone capsules (30mg)</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD>
<TD HEIGHT="2" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>PK</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL"><B>Parameter</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>Fed/Fasted</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>Ratio</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>90%&nbsp;Confidence</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>Interval</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:2pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>PK</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL"><B>Parameter</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1.00pt solid #000000"><B>Fed/Fasted<BR>Ratio</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:2pt ;BORDER-BOTTOM:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>90%&nbsp;Confidence</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>Interval</B></P></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="padding-bottom:6pt ;"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><B>Cmax</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><B>(ng/mL)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:6pt ;"> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g945651g29j24.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:6pt ;"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>(0.46,&nbsp;0.88)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:6pt ;"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><B>Cmax</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><B>(ng/mL)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:6pt ;"> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g945651g26p01.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:6pt ;"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>(2.56,&nbsp;3.28)</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="padding-bottom:6pt ;"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><B>AUC0-t</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><B>(h*ng/mL)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:6pt ;"> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g945651g22c70.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:6pt ;"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>(0.91,&nbsp;1.49)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:6pt ;"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><B>AUC0-t</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL"><B>(h*ng/mL)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:6pt ;"> <P STYLE="font-size:5pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g945651g04r05.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="padding-bottom:6pt ;"> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-bottom:1pt; margin-top:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>(1.45,&nbsp;1.69)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" COLSPAN="13"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="13" ALIGN="right"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL" ALIGN="right"><I>WO2019/051264 Al Patent</I></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>Table 5. Food effect clinical studies of <FONT STYLE="white-space:nowrap">PRAX-114</FONT> and Zuranolone
(WO2019/051264 A1). Subjects were administered a <FONT STYLE="white-space:nowrap">high-fat</FONT> meal 30 minutes prior to administration of the compound in both studies. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the MAD trial, <FONT STYLE="white-space:nowrap">PRAX-114</FONT> was generally well-tolerated, with no SAEs reported. The reported treatment-emergent
adverse events, or TEAEs, were mild to moderate and were consistent with those expected for the mechanism of action. The most common adverse event was somnolence, which is characterized by sleepiness or drowsiness, and was reported by 78% (7/9) of
those subjects receiving the 60mg dose; all events of somnolence were mild in severity. Increases in sleepiness as measured by the Stanford Sleepiness Scale occurred between <FONT STYLE="white-space:nowrap">one-</FONT> and three-hours post-dosing,
consistent with the period of peak drug concentrations; sleepiness ratings at the 60mg dose were similar to placebo within 4 hours post-dose. We did not observe a maximally tolerated dose, or MTD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In our Phase 1&nbsp;multiple ascending dose&nbsp;trial of <FONT STYLE="white-space:nowrap">PRAX-114&nbsp;in</FONT> healthy volunteers in Australia, we
also observed the following TEAEs, all of which were mild to moderate in severity: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">60mg dose (n=9), we observed nervous system disorder TEAEs, of&nbsp;somnolence (77.8% of&nbsp;subjects), headache
(33.3%&nbsp;of subjects), dizziness (55.6%&nbsp;of subjects) and hypoaesthesia, or diminished sense of touch (22.2%&nbsp;of subjects).&nbsp;Other TEAEs observed in more than one subject were euphoric mood&nbsp;(22.2% of subjects), hyperhidrosis, or
excessive sweating&nbsp;(22.2% of subjects) and muscle twitching&nbsp;(22.2% of subjects).</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">30mg dose (n=9), we observed nervous system disorder TEAEs of&nbsp;somnolence (44.4%&nbsp;of subjects) and headache
(22.2%&nbsp;of subjects).&nbsp;Other TEAEs observed in more than one subject were skin irritation (55.6%&nbsp;of subjects) and euphoric mood (22.2% of subjects).</P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">15mg dose (n=9), the only TEAE observed in more than one subject was fatigue (22.2% of subjects). </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Placebo group (n=9), we observed fatigue (22.2% of subjects). </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">TEAEs appearing to be dose related were somnolence, dizziness, headache, euphoric mood and hypoaesthesia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We measured changes in qEEG beta frequency power in these volunteers to assess the effect of <FONT STYLE="white-space:nowrap">PRAX-114</FONT> on GABA<SUB
STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors in the brain on days 1 and 14 of this trial. <FONT STYLE="white-space:nowrap">PRAX-114</FONT> produced increases in the power of the beta-frequency band which were strongly correlated
with dose and <FONT STYLE="white-space:nowrap">PRAX-114</FONT> levels in the blood. In these healthy volunteers at one hour post-dose, <FONT STYLE="white-space:nowrap">PRAX-114</FONT> 30mg resulted in an average increase in qEEG beta power of
approximately <FONT STYLE="white-space:nowrap">1.6-fold</FONT> compared to baseline and 60mg resulted in an increase in this measure of <FONT STYLE="white-space:nowrap">2.8-fold</FONT> compared to baseline (Figure 6). The effects on the qEEG beta
power were sustained at Day 14. These data show that <FONT STYLE="white-space:nowrap">PRAX-114</FONT> engaged GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors in the brain and produced consistent effects on qEEG within the
first hour after dosing. This finding also supports comparison and translation of the pharmacologic activity and qEEG data from the <FONT STYLE="white-space:nowrap">pre-clinical</FONT> studies, where a
<FONT STYLE="white-space:nowrap">1.6-fold</FONT> increase in beta power was associated with robust activity in animal models of anxiety and depression and was used to inform dose selection in subsequent clinical trials. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g945651g14c79.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>Figure 6. <FONT STYLE="white-space:nowrap">PRAX-114</FONT> (30mg and 60mg) showed a robust qEEG signal and target
activation. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Notably, <FONT STYLE="white-space:nowrap">PRAX-114</FONT> showed increases in beta power up to
<FONT STYLE="white-space:nowrap">2.8-fold</FONT> without achieving a MTD or demonstrating any SAEs. In a separate study, another molecule in development in the class resulted in degrees of sedation that were not tolerated at doses that resulted in
increases in beta power by approximately <FONT STYLE="white-space:nowrap">1.7-fold</FONT> compared to baseline. This highlights the unique pharmacological profile of <FONT STYLE="white-space:nowrap">PRAX-114</FONT> and its ability to achieve high
levels of GABAergic activation with improved tolerability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe this improved tolerability profile of PRAX-114 offers the potential for a
wider therapeutic window, increased adherence and a wider dose range for MDD patients. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Phase 2a trial in patients with depression </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Based on the observed pharmacology in the Phase 1 trials, we are currently conducting a three-part, open-label, Phase 2a trial in Australia to assess the
safety and efficacy of <FONT STYLE="white-space:nowrap">PRAX-114</FONT> in patients with moderate to severe MDD or PMD. We have completed Part A of this Phase 2a trial and Parts B and C are ongoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Part A results </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Part A of the open-label
trial included two weeks of treatment and was designed to evaluate the timing and magnitude of the antidepressant effects of <FONT STYLE="white-space:nowrap">PRAX-114</FONT> across a range of doses in patients with MDD. Patients were required to be
between the ages of 18 and 65 and to have moderate to severe MDD for at least one month as defined by the Hamilton Depression Rating Scale, or <FONT STYLE="white-space:nowrap">HAM-D,</FONT> score of 22 or higher. The
<FONT STYLE="white-space:nowrap">HAM-D,</FONT> one of the most widely-used clinical rating scales for depression, was the main assessment used to quantify levels of depression in these patients. The 17 items used for scoring this scale cover a wide
range of symptoms typically found with depression including mood, suicidal thoughts, insomnia, anxiety, loss of appetite and weight loss. Patients with more severe depression have higher scores. The effect of
<FONT STYLE="white-space:nowrap">PRAX-114</FONT> was measured by the change in the <FONT STYLE="white-space:nowrap">HAM-D</FONT> score relative to baseline. Patients who had previously failed to respond to a standard of care antidepressant in their
current episode were eligible for inclusion. In addition to <FONT STYLE="white-space:nowrap">HAM-D,</FONT> other scales used included the Montgomery&#150;&Aring;sberg Depression Rating Scale, or MADRS, the Hamilton Anxiety Rating Scale, or <FONT
STYLE="white-space:nowrap">HAM-A,</FONT> and the Symptoms of Depression Questionnaire, or SDQ. MADRS is a 10 item rating scale designed to assess the severity of symptoms in a depressive illness. <FONT STYLE="white-space:nowrap">HAM-A</FONT> is a 14
item scale widely used to measure the severity of anxiety symptoms, including both psychic anxiety (mental agitation and psychological distress) and somatic anxiety (physical complaints related to </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">anxiety). SDQ is a 44 item self-reported scale designed to measure the severity of symptoms across several subtypes of depression, including irritability, anger attacks
and anxiety. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Based on the Phase 1 data, we selected 3 doses: 45mg, 60mg or 80mg daily of <FONT STYLE="white-space:nowrap">PRAX-114.</FONT> All
three doses were expected to achieve exposures that would show clinical benefit based on the Phase 1 data and qEEG findings. The first week of treatment was conducted in an inpatient setting to facilitate daily efficacy and safety assessments and
then patients were discharged and treated as outpatients for the second week. Patients were instructed to take <FONT STYLE="white-space:nowrap">PRAX-114</FONT> nightly before bed. Patients were not required to take
<FONT STYLE="white-space:nowrap">PRAX-114</FONT> with food. Compliance was carefully monitored throughout the duration of the trial. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Thirty-three
patients were enrolled and completed Part A before the COVID-19 pandemic. At baseline, patients had a mean <FONT STYLE="white-space:nowrap">HAM-D</FONT> total score of 25, ranging from 20 to 33, indicating moderate to severe MDD. <FONT
STYLE="white-space:nowrap">Twenty-six</FONT> of the thirty-three participants had previously received an antidepressant during the current depressive episode but still had moderate to severe MDD. This failure to respond to initial antidepressant
treatment has been associated with more severe and refractory depression. The remaining patients were not being treated with any antidepressant for the current episode before enrolling in the trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Dosing with <FONT STYLE="white-space:nowrap">PRAX-114</FONT> led to a marked improvement in the <FONT STYLE="white-space:nowrap">HAM-D</FONT> score
(Figure 7) within two weeks of treatment. After one week of treatment, least squares, or LS, mean improvements of 15 to 19 points from baseline were noted across the three dose groups. After two weeks of treatment, all 3 dose levels showed
improvements from baseline of greater than 13 points with mean improvements from baseline of 14 to 16 points. Across all dose levels, <FONT STYLE="white-space:nowrap">two-thirds</FONT> of patients were responders (defined as a &gt;=50% reduction in <FONT
STYLE="white-space:nowrap">HAM-D)</FONT> or were clinically in remission (HAM-D&lt;=7) at the end of the 14 day treatment period. Changes in other depression-related scales measured such as MADRS, <FONT STYLE="white-space:nowrap">HAM-A</FONT> and
SDQ were consistent with the changes in <FONT STYLE="white-space:nowrap">HAM-D.</FONT> While the study was not powered to show differences between dose levels, there was no notable dose response observed, which is common amongst trials of
antidepressants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g945651g66t99.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>Figure 7. Reduction in <FONT STYLE="white-space:nowrap">HAM-D</FONT> total score observed in MDD patients treated
with <FONT STYLE="white-space:nowrap">PRAX-114.</FONT> </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">After 14 days of treatment, patients were monitored for an additional 14 days. During
this monitoring period, the core mood symptoms measured by the <FONT STYLE="white-space:nowrap">HAM-D</FONT> generally remained stable with a slight increase in the insomnia item scores post-treatment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">While our Phase 2a trial is not placebo controlled, prior randomized placebo-controlled MDD trials provide important context for the interpretation of
the clinical response. The marked improvements in <FONT STYLE="white-space:nowrap">HAM-D</FONT> scores seen in MDD patients in Part A within two weeks of treatment compares favorably to published reports on changes in
<FONT STYLE="white-space:nowrap">HAM-D</FONT> scale in clinical trials of approved antidepressants such as vortioxetine and duloxetine, among others, which commonly take approximately six to eight weeks to reach a maximal efficacy and often fail to
differentiate from placebo at two weeks. Moreover, mean <FONT STYLE="white-space:nowrap">HAM-D</FONT> changes from baseline at Day 14 for the placebo group of these randomized controlled antidepressant trials are most often between 4-8 points. Even
at the first post-dose assessment on Day&nbsp;3, patients dosed with <FONT STYLE="white-space:nowrap">PRAX-114</FONT> had a mean decrease of over 11 points on the <FONT STYLE="white-space:nowrap">HAM-D</FONT> scale, which compares favorably with the
average changes reported in the placebo groups at Day&nbsp;14 from randomized studies completed for recently approved antidepressants (Figure&nbsp;8), and other common antidepressants after several weeks of dosing. The clinical data that we have
generated to date, and that we expect to generate in the future, from our clinical studies will constitute the bulk of the data needed to support an application for marketing approval of PRAX-114. Unless we conduct head-to-head studies of PRAX-114
against other molecules as part of our future clinical trials and elect to include the resulting data in an application for regulatory approval, we would not expect to rely upon PRAX-114&#146;s potential differentiation from any other molecules in
connection with submissions to the FDA or other regulatory agencies, as applicable, for approval or otherwise. As the data presented above is based on a cross-trial comparison and not a head-to-head clinical trial, such data may not be directly
comparable due to differences in study protocols, conditions and patient populations. Accordingly, cross-trial comparisons may not be reliable predictors of the relative efficacy or other </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">benefits of PRAX-114 compared to other product candidates that may be approved or that are or were in development for MDD. </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g945651g77i66.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>Figure 8. Change from baseline to Day 14 in <FONT STYLE="white-space:nowrap">HAM-D</FONT> total score for the
Placebo arm of selected randomized placebo-controlled studies of recently approved antidepressants. Bubble size is proportional to the sample size of the placebo group in each study. Across studies, the sample size in the placebo group ranged from
89 to 277. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">PRAX-114</FONT> was generally well-tolerated across the dose range, including at the highest 80mg
dose. This is consistent with an expected wider therapeutic window based on the preferential selectivity of <FONT STYLE="white-space:nowrap">PRAX-114</FONT> for extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptors.
TEAEs were generally mild to moderate. Rates of somnolence, which is characterized by sleepiness or drowsiness, increased with dose, demonstrating a pharmacological effect which was somewhat mitigated by dosing at night versus the morning. With
nighttime dosing, 12/33 patients (36%) noted somnolence post-dosing, which was generally time-limited and not experienced during the day time, substantially lower than the 78% reported in the Phase 1 60mg group with morning dosing. There were no
SAEs or discontinuations and study drug cessation at the end of the treatment period was generally well-tolerated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In this MDD part of the trial,
we also observed the following TEAEs in at least 2 subjects per dose level: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">80mg dose (n=7), headache (42.9% of subjects), somnolence (42.9% of subjects), dizziness (57.1% of subjects), feeling drunk
(28.6% of subjects) and diarrhea (28.6% of subjects). </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">60mg dose (n=13), headache (46.2% of subjects), somnolence (53.8% of subjects), dizziness (30.8% of subjects), feeling
drunk (23.1% of subjects) and constipation (23.1% of subjects). </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">45mg dose (n=13), headache (53.8% of subjects), somnolence (15.4% of subjects), fatigue (23.1% of subjects), vessel
puncture site bruise from blood draws (15.4% of subjects), abdominal distension (15.4% of subjects) and upper respiratory tract infection (15.4% of subjects). </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Across all dose levels studied, headache (48.5%), somnolence (36.4%), dizziness (24.2%), fatigue (15.2%), feeling
drunk (15.2%), constipation (12.1%) and vessel site puncture bruise (12.1%) were reported in &gt;10% of subjects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Parts B and C ongoing
</I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are currently conducting Part B of this trial in order to assess <FONT STYLE="white-space:nowrap">PRAX-114</FONT> in PMD patients. We are
dosing up to twelve patients with PMD with 60mg of <FONT STYLE="white-space:nowrap">PRAX-114</FONT> nightly for 14 days on an outpatient basis. The dose for this part of the trial was selected based on the data from Part A. Inclusion criteria for
Part B are similar to Part A and C, except that it requires participants to be females of 40 years of age or older with irregular menses and hot flushes. Part B will help to determine if <FONT STYLE="white-space:nowrap">PRAX-114</FONT> has an effect
on broader menopausal symptoms, like hot flushes, in addition to confirming the antidepressant effect. We anticipate topline results by the second half of 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Part C of this trial is also ongoing. The goal of Part C is to evaluate the impact of four-week dosing on the treatment effect observed in the <FONT
STYLE="white-space:nowrap">two-week</FONT> Part A in a full outpatient setting, a dosing paradigm that more closely parallels the standard of care approach to antidepressant treatment of MDD. We expect to enroll up to thirteen patients with MDD and
dose <FONT STYLE="white-space:nowrap">PRAX-114</FONT> at 60mg nightly for four weeks. Inclusion criteria and efficacy endpoint measurements are the same as Part A. We expect to have complete topline data in the fourth quarter of 2020 that will
inform our planned randomized, placebo-controlled trial, which we anticipate will also use four weeks of dosing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Data from the ongoing Part B and
Part C study indicate that 60mg of PRAX-114 dosed nightly shows a safety profile similar to Part A. The preliminary data show that dosing with PRAX-114 led to a marked improvement in the HAM-D score within two weeks of treatment. We expect complete
topline data from Part B of the trial in the second half of 2021 and from longer-term dosing in MDD patients in Part C of the trial in the fourth quarter of 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Moreover, greater than 70% of participants from the Part A, Part B and Part C study showed they had previously received an antidepressant during the
current depressive episode but still had moderate to severe MDD, and preliminary data show greater than 60% of patients were responders or clinically in remission at two weeks. All Parts demonstrated a well-tolerated profile throughout treatment
schedule. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g945651g25t98.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">As of September 23, 2020, Part B data available for N=4 at Day-8 and N=3 at Day-15, trial ongoing </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>Figure 9. Data from ongoing trial showing reduction of HAM-D total score from baseline in patients with PMD (Part B) and MDD (Part C). </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Pharmacokinetics bridging study </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To date, we have conducted all studies with <FONT STYLE="white-space:nowrap">PRAX-114</FONT> using a liquid, suspension formulation. For our
registrational studies and subsequent potential commercial use of <FONT STYLE="white-space:nowrap">PRAX-114,</FONT> we have developed a tablet formulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In a clinical PK bridging study, <FONT STYLE="white-space:nowrap">PRAX-114</FONT> was administered as a solid dose (i.e., tablet) formulation in single
ascending doses of 40mg, 60mg and 80mg and compared to <FONT STYLE="white-space:nowrap">PRAX-114</FONT> suspension administered at the 60mg dose. The PK of the tablet formulation was found to be comparable to the suspension formulation at the 60mg
dose level (Figure 10). Administration of the 60mg tablet formulation under fasted conditions resulted in a median tmax of ~1.0 hour, Cmax of ~400ng/mL, AUCinf of ~2600 hr*ng/mL and t1/2 of <FONT STYLE="white-space:nowrap">~11-12</FONT> hours,
similar to the 60mg oral suspension. Exposure to <FONT STYLE="white-space:nowrap">PRAX-114</FONT> increased approximately proportional to dose. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g945651g28b20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>Figure 10. <FONT STYLE="white-space:nowrap">PRAX-114</FONT> dose-ranging pharmacokinetic study of tablet
formulation and <FONT STYLE="white-space:nowrap">PRAX-114</FONT> pharmacokinetic bridging study of suspension and tablet formulations. Arithmetic means are displayed with standard deviations at each collection time point. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are currently evaluating the effect of food on the solid formulation, and we expect to observe a similar effect of food to that seen with our
suspension formulation. Like our suspension formulation, we expect that our solid formulation will not need to be taken with food to achieve targeted exposures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Planned <FONT STYLE="white-space:nowrap">PRAX-114</FONT> clinical trials </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We plan to submit an Investigational New Drug application, or IND, to the FDA and then initiate a randomized, double-blinded, placebo-controlled Phase
2/3 trial of <FONT STYLE="white-space:nowrap">PRAX-114</FONT> in the United States and other countries in approximately 200 moderate to severe MDD patients. Patients will be randomized 1:1 to receive nightly doses of
<FONT STYLE="white-space:nowrap">PRAX-114</FONT> or placebo for 28 days in a fully outpatient setting. The primary efficacy endpoint will be change in the <FONT STYLE="white-space:nowrap">HAM-D</FONT> score from baseline at Day 15. Patients will be
required to be between the ages of 18 and 65 and have moderate to severe MDD for at least one month as defined by the <FONT STYLE="white-space:nowrap">HAM-D</FONT> score of 23 or higher, and have at least one prior episode of MDD. We believe
clinical conduct excellence is essential for a study in MDD that appropriately mitigates historical variability in placebo effect, and the current social and environmental changes caused by the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic. Our operational plan, amongst other aspects, includes utilizing sites with a track-record of high quality in the conduct of MDD trials, and a two-level subject quality process that includes independent clinical interviews for eligibility.
A key secondary endpoint will be change in the HAM-D score after 28 days of treatment to assess the durability of effect of <FONT STYLE="white-space:nowrap">PRAX-114.</FONT> In addition, we will also
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
evaluate changes in other depression-related scales. We intend to initiate this trial in the fourth quarter of 2020 with topline data anticipated in the second half of 2021. We believe this trial
could satisfy one of two registrational trials required by the FDA to support clinical efficacy for the treatment of MDD. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon completion of Part B
of our Phase 2a trial, we intend to have a meeting with regulators to discuss further development of <FONT STYLE="white-space:nowrap">PRAX-114</FONT> in PMD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">PRAX-114</FONT> preclinical data </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The goal of our preclinical program was to establish the <I><FONT STYLE="white-space:nowrap">in-vitro</FONT> and
<FONT STYLE="white-space:nowrap">in-vivo</FONT></I> pharmacological profiles, antidepressant potential and tolerability of <FONT STYLE="white-space:nowrap">PRAX-114.</FONT> In addition, we evaluated translational pharmacodynamic biomarkers to inform
clinical development. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Antidepressant activity </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To
determine the antidepressant-like activity of <FONT STYLE="white-space:nowrap">PRAX-114,</FONT> we used the Wistar Kyoto, or WKY, rat model. The WKY rat is an inbred rat strain that has increased sensitivity to stress and displays a depressive-like
phenotype that is resistant to SSRI and SNRI treatment. A common way to assess depressive-like symptoms in animals is a test known as the forced swim test, or FST. The FST is based on the natural behavior of an animal when placed in a container
filled with water from which it cannot escape. The rat will first make efforts to escape by swimming or climbing, but eventually will exhibit floating behavior, which is an indication of behavioral despair and is seen as a surrogate for depression.
WKY rats display longer time inactive (floating) over a given time period than normal rats as an indication of increased behavioral despair. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We
administered oral doses of <FONT STYLE="white-space:nowrap">PRAX-114</FONT> or a placebo to WKY rats and evaluated performance on the FST. At all doses of <FONT STYLE="white-space:nowrap">PRAX-114</FONT> tested, 1mg/kg, 3mg/kg and 10mg/kg, we
observed a significant reduction in immobility time compared to rats that received a placebo, which we believe reflects an anti-depressive-like reaction or activity of <FONT STYLE="white-space:nowrap">PRAX-114.</FONT> Importantly, and as described
below, at these doses, <FONT STYLE="white-space:nowrap">PRAX-114</FONT> did not impair or enhance overall spontaneous activity of the rats in independent assays in the same animals, which we believe indicates that
<FONT STYLE="white-space:nowrap">PRAX-114</FONT> was generally well-tolerated at these doses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Tolerability </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A common model to assess sedation in rats is the measure of spontaneous locomotor activity, or sLMA. Dosing rats with sedatives dose-dependently reduces
their spontaneous movement in this assay. In this model, doses of <FONT STYLE="white-space:nowrap">PRAX-114</FONT> up to 30mg/kg had no significant impact on spontaneous locomotion, while doses as low as 1mg/kg had significant antidepressant-like
effects in the WKY rat model, demonstrating a wide therapeutic window in these models with preclinical activity at doses well below sedative doses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe that the therapeutic window observed in our <I><FONT STYLE="white-space:nowrap">in-vivo</FONT></I> assays is consistent with the preference
of <FONT STYLE="white-space:nowrap">PRAX-114</FONT> for extrasynaptic GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> potentiation observed <I><FONT STYLE="white-space:nowrap">in-vitro</FONT></I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>EEG as a pharmacodynamic biomarker </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In our rat translational
biomarker model, we administered <FONT STYLE="white-space:nowrap">PRAX-114</FONT> to wild-type rats at doses ranging from 1 to 20mg/kg to assess the impact on power in the beta frequency band. We found that
<FONT STYLE="white-space:nowrap">PRAX-114</FONT> dose-dependently increased the power in the beta frequency band and these changes correlated with changes in plasma pharmacokinetics. This EEG biomarker was used to inform dose-selection for <FONT
STYLE="white-space:nowrap">PRAX-114</FONT> clinical studies. In our Phase 1 MAD trial, healthy volunteers administered the 30mg dose of <FONT STYLE="white-space:nowrap">PRAX-114</FONT> displayed an approximately
<FONT STYLE="white-space:nowrap">1.6-fold</FONT> increase in qEEG beta power compared to baseline. In our preclinical studies, doses (and plasma/brain concentrations) that induced a <FONT STYLE="white-space:nowrap">1.6-fold</FONT> increase in the
beta frequency power in rats were associated with both robust preclinical activity in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
animal models of depression and anxiety and good tolerability. Specifically, the <FONT STYLE="white-space:nowrap">PRAX-114</FONT> dose that is estimated to induce a
<FONT STYLE="white-space:nowrap">1.6-fold</FONT> increase in EEG beta power activity in rats was efficacious in the rat WKY model of depression and the window between that dose that increased beta power by
<FONT STYLE="white-space:nowrap">1.6-fold</FONT> increase in EEG and the dose that caused a 50% reduction of spontaneous locomotion in the sLMA sedation assay, or ED<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB>, was <FONT
STYLE="white-space:nowrap">~11-fold,</FONT> based on brain concentrations. In addition, at this well-tolerated brain concentration, <FONT STYLE="white-space:nowrap">PRAX-114</FONT> was efficacious in animal models of anxiety including conditional
emotional response, or CER, punished drinking, or Vogel, and elevated plus maze, or EPM (Figure 11). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the figure below, the lower bound of the
preclinical activity in animal models and EEG bars are determined by the brain exposure at the lowest dose at which significant activity was observed (p &lt; 0.05). The lower bound of the tolerability bar represents the TC<SUB
STYLE="font-size:85%; vertical-align:bottom">50</SUB> in the brain. The upper bound represents the mean brain concentration at the highest dose tested in a given assay. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g945651g08x23.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 11. Summary of <FONT STYLE="white-space:nowrap">PRAX-114</FONT> preclinical data. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Based on our findings in preclinical models, we believe our initial results in humans are supportive of a wide therapeutic window which, in humans,
begins at or below a daily dose of 30mg of <FONT STYLE="white-space:nowrap">PRAX-114</FONT> and extends to higher doses prior to the onset of potential dose-limiting somnolence or sedation. Our clinical studies
<FONT STYLE="white-space:nowrap">to-date</FONT> suggest that <FONT STYLE="white-space:nowrap">PRAX-114</FONT> doses up to 80mg, the highest we have tested in humans, remain generally well-tolerated. We have yet to identify the MTD. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">PRAX-944</FONT> </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are
developing <FONT STYLE="white-space:nowrap">PRAX-944,</FONT> a potentially differentiated selective small molecule inhibitor of <FONT STYLE="white-space:nowrap">T-type</FONT> calcium channels, for the treatment of Essential Tremor, or ET. We have
evaluated the safety and tolerability of <FONT STYLE="white-space:nowrap">PRAX-944</FONT> in over 150 healthy volunteers in five separate clinical trials. In these trials, we have studied the safety of
<FONT STYLE="white-space:nowrap">PRAX-944</FONT> modified release formulation with titration up to 120mg/day and no MTD has been identified. We are currently conducting a Phase 2a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> open-label trial in ET patients. Preliminary site data from five patients of the low dose cohort showed tremor reduction, which seems to compare
favorably to the standard of care agents. We plan to announce topline data, including a high dose cohort, in&nbsp;the first half of 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">There is a large body of clinical, preclinical and genetic evidence that points to the involvement of <FONT
STYLE="white-space:nowrap">T-type</FONT> calcium channels in the cerebello-thalamo-cortical, or CTC, circuit, as a main driver of ET. ET is the most common movement disorder, affecting up to seven million patients in the United States, which is
seven times more individuals compared to Parkinson&#146;s tremor. ET is a progressive and debilitating movement disorder with action tremors that significantly disrupt daily living. There is a high unmet need for ET patients given the limited
treatment options, with only one approved pharmacotherapy that is poorly tolerated, resulting in high discontinuation rates and the need for invasive brain surgeries. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Successful development of <FONT STYLE="white-space:nowrap">T-type</FONT> calcium channel modulators in ET likely requires a PK profile with a blunted
Cmax and thoughtful clinical trial design and endpoint selection. We have designed our development program to include careful selection of clinical endpoints, a modified release formulation and dose titration strategy. We believe our modified
release formulation for <FONT STYLE="white-space:nowrap">PRAX-944</FONT> is well positioned to be a differentiated therapy in ET. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Because of the
gatekeeper role of T-type calcium channels in regulating neuronal firing patterns in multiple neuronal circuits, we believe <FONT STYLE="white-space:nowrap">PRAX-944</FONT> is suitable for potential development across a wide-range of indications in
psychiatry and neurology, providing sizable expansion opportunities in addition to ET. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Essential Tremor </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">ET is the most common movement disorder, characterized by involuntary rhythmic movement in the upper limbs, with or without tremor in other body
locations such as the head, vocal cords, or legs. ET is a <FONT STYLE="white-space:nowrap">day-time</FONT> disease associated with debilitating tremors triggered when a patient voluntarily attempts to move. These tremors significantly disrupt daily
living and are progressive in nature, with increases in tremor severity and amplitude commonly observed over the course of the disease. The upper-limb tremor can range from barely visible to greater than 20cm in amplitude. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Unlike Parkinson&#146;s disease, which is characterized by a rest tremor, the tremor of ET occurs with movement and therefore causes direct disability,
as people are unable to perform basic, <FONT STYLE="white-space:nowrap">every-day</FONT> functions such as writing, typing, drinking or feeding themselves. Given the debilitating physical challenges of the disease, ET has also been associated with
high prevalence of comorbidities, including anxiety, depression and social phobia. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">ET is a clinically well-recognized indication with defined
diagnostic criteria established by The International Parkinson and Movement Disorders Society. ET affects between one and two percent of the worldwide population and approximately five percent of adults over 60 years of age. It is estimated that
there are up to seven million individuals with ET in the United States, up to seven times more than the second most common movement disorder, Parkinson&#146;s disease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Despite the prevalence and significant disease burden of ET, only a fraction of patients (an estimated one million based on claims data) are managed
with pharmacological therapy, though an estimated 80% of those that are treated discontinue these medications due to limitations in efficacy and tolerability. We believe that the treated population will increase with the availability of new
therapies with improved efficacy and tolerability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Currently, there are only two drugs commonly used in ET. Propranolol, approved by the FDA in
1967, remains the only currently approved therapy for ET in the United States. A non-selective beta blocker, Propranolol is contraindicated for individuals with certain respiratory or cardiac issues, which are common comorbidities in the age group
affected by ET. Primidone, an anticonvulsant used <FONT STYLE="white-space:nowrap">off-label,</FONT> requires slow titration over six to eight weeks and can cause sedation and balance issue while accelerating osteoporosis with long-term use. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As a last line therapy, several thousand ET patients in the U.S. opt for invasive surgery each year.
Interventions include gamma knife and focused ultrasound thalamotomy, where part of the thalamus involved in the CTC circuit is ablated, or deep brain stimulation, or DBS, where an electrode is implanted into the brain. These procedures are
generally effective, but are associated with significant side effects and risk. Therefore, many patients who are eligible for surgical therapies do not elect to have these procedures. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A significant unmet need remains for the millions of ET patients that are not currently receiving treatment for their ET, or are underserved by existing
treatment options. We believe that the relatively concentrated ET treatment setting composed of mainly neurology and movement disorder specialists would allow for the rapid adoption of a new treatment option that offered robust response rates and an
improved tolerability profile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Genetics of Essential Tremor </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our rationale for approaching ET through inhibition of <FONT STYLE="white-space:nowrap">T-type</FONT> calcium channels is rooted in the genetics of
epilepsy. CACNA1G, a gene that encodes for a particular isoform of <FONT STYLE="white-space:nowrap">T-type</FONT> calcium channels, is one of the most significantly associated genes for generalized genetic epilepsy, or GGE. Some of these epilepsy
patients also suffer from comorbid movement disorders such as tremor and ataxia. The odds of observing a <FONT STYLE="white-space:nowrap">T-type</FONT> calcium channel mutation in the GGE population is 9 times of that of the healthy population. This
supports the key role of <FONT STYLE="white-space:nowrap">T-type</FONT> calcium channels in maintaining excitation and inhibition balance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Additional human genetic data provide evidence for the role of <FONT STYLE="white-space:nowrap">T-type</FONT> calcium channels in movement disorders.
Whole exome sequencing of early-onset familial ET patients also identified mutations in CACNA1G that segregated with the tremor phenotype in multiple family pedigrees.
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Gain-of-function</FONT></FONT> <FONT STYLE="white-space:nowrap">T-type</FONT> calcium channel mutations have also been reported as causative variants for another phenotypically
overlapping movement disorder called Cerebellar Ataxia. We believe this genetic link, along with the preclinical and clinical evidence, help confirm the role of <FONT STYLE="white-space:nowrap">T-type</FONT> calcium channels in ET. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Role of <FONT STYLE="white-space:nowrap">T-type</FONT> calcium channels in ET </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">T-type</FONT> calcium channels function as the gatekeepers of neuronal firing patterns, controlling the switch between
tonic and burst firing in the CTC circuit. The CTC circuit is a series of brain nuclei or neuron clusters, including the inferior olivary nucleus, cerebellar Purkinje cells, deep cerebellar nuclei, ventral motor thalamus and motor cortex, which work
together in regulating coordinated movements and when disrupted generate tremor. All nuclei in this circuit contain pacemaker cells with inherent burst firing capability and express <FONT STYLE="white-space:nowrap">T-type</FONT> calcium channels,
which are known drivers of oscillatory burst firing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">T-type</FONT> calcium channels are low voltage activated
channels that respond to weak depolarization of neuronal membranes and are quickly inactivated (a closed state where the channel cannot be reopened for some time). The opening of <FONT STYLE="white-space:nowrap">T-type</FONT> calcium channels leads
to membrane depolarization, which activates voltage-activated sodium channels, leading to the formation of an action potential and neuronal firing. When only a small number of T-type calcium channels are activated, leading to small <FONT
STYLE="white-space:nowrap">T-type</FONT> calcium channel mediated membrane depolarizations, the neuron generally generates unitary action potentials, also called tonic firing. When the activity of <FONT STYLE="white-space:nowrap">T-type</FONT>
calcium channels is increased, either due to genetic mutations or other changes in network activity that recruit more <FONT STYLE="white-space:nowrap">T-type</FONT> calcium </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
channels, a longer lasting depolarization is generated, resulting in high-frequency clusters of sodium channel driven action potentials, also called burst firing, as illustrated in the figure
below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g945651g05p78.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 12. <FONT STYLE="white-space:nowrap">T-Type</FONT> calcium channels are gatekeepers of neuronal firing
patterns. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Neuroimaging of ET patients has consistently demonstrated that individual nuclei along the CTC circuit oscillate at tremor frequency
and with strong coherence amongst the brain regions and movement in the affected muscles. Further, intraoperative real-time single-unit recordings of action potentials of individual neurons in the ventral motor thalamus of severe ET patients
receiving DBS implants, in periods with and without tremors, further substantiates the central role of the CTC circuit and <FONT STYLE="white-space:nowrap">T-type</FONT> calcium channels in ET (Figure&nbsp;13). When no tremor was observed at rest,
tonic firing was recorded in neurons of the ventral motor thalamus. During tremor, the same neurons fire in rhythmic bursts that are highly coherent with tremor activity. Furthermore, the emergence of action tremors coincided with the emergence of
burst firing. Lesioning or DBS of the ventral motor thalamus has been shown to silence the oscillatory burst firing activity in the CTC circuit, resulting in significant tremor reduction. The strong temporal coordination between the tremors and
burst firing, a neuronal firing pattern frequently gated by <FONT STYLE="white-space:nowrap">T-type</FONT> calcium channel activity, strongly suggest that pharmacological inhibition of these channels may represent an effective pharmacological
approach in ET. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g945651g49m94.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 13. Thalamic neuron burst firing correlated with tremor activity in ET patients. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The role of the CTC circuit and <FONT STYLE="white-space:nowrap">T-type</FONT> calcium channels has
been further confirmed in animal models. A known pharmacological tremor model utilizes administration of harmaline, an alkaloid toxin, to animals. Harmaline, on administration to experimental animals such as rodents, induces an acute action tremor
as well as rhythmic burst-firing activity in the CTC circuit similar to that observed in ET patients. We believe this model carries clinically predictive value, as compounds that improve tremor in ET patients clinically (e.g.,&nbsp;propranolol,
primidone) have also been shown to reduce harmaline-induced tremor preclinically; in contrast compounds that worsen tremor in patients (e.g.,&nbsp;caffeine) also worsen tremor in this model. Similar to what&#146;s observed in ET patients,
normalizing oscillatory activity in the CTC circuit, for example with DBS, reduces harmaline induced tremor in rodents. Pharmacological inhibition or genetic knockout of <FONT STYLE="white-space:nowrap">T-type</FONT> calcium channels lead to
resistance to harmaline-induced tremor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">PRAX-944</FONT> in Essential Tremor </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are advancing a modified release formulation of <FONT STYLE="white-space:nowrap">PRAX-944,</FONT> a potent and selective small molecule inhibitor of <FONT
STYLE="white-space:nowrap">T-type</FONT> calcium channels, for the treatment of ET. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">PRAX-944</FONT> Clinical Development in
ET </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have evaluated the safety and tolerability of <FONT STYLE="white-space:nowrap">PRAX-944</FONT> in over 150 healthy volunteers in five
separate clinical trials. In these trials, we have studied the safety of PRAX-944 modified release formulation with titration up to 120mg/day and no MTD has been identified. We are currently conducting a Phase 2a proof-of-concept open-label trial in
Australia and New Zealand in ET patients. Preliminary site data from five patients of the low dose cohort showed tremor reduction, which seems to compare favorably to the standard of care agents. We plan to announce topline data, including a high
dose cohort, in&nbsp;the first half of 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Phase 1 trials in healthy volunteers using previous IR formulation </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">An immediate release, or IR, formulation of <FONT STYLE="white-space:nowrap">PRAX-944</FONT> was used in the initial Phase&nbsp;1 trials and reached
maximal plasma concentrations within one to three hours of dosing. Adverse events like nausea were associated with the high peak levels. This prompted the development of modified release, or MR, formulations, which can have slower absorption and
improved tolerability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Phase 1 trials in healthy volunteers using MR formulation </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our current clinical formulation of <FONT STYLE="white-space:nowrap">PRAX-944</FONT> is designed to release 80% of the drug product over seven hours.
This slow release is desirable for diseases like ET where minimum, or trough concentrations, need to be maintained during the day when tremor is present for efficacy and for reducing side effects associated with high peak concentrations which could
limit the ability to treat patients at therapeutic doses. The sustained exposure also enables once daily dosing (Figure 14). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In our Phase 1
multiple dose trial of the MR formulation of <FONT STYLE="white-space:nowrap">PRAX-944</FONT> in England, doses of 20mg and 40mg were generally well-tolerated over 8 days. Adverse events were transient and occurred at a rate similar to placebo. We
observed the following TEAEs all of which were mild to moderate: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">40mg dose (n=6): we observed the nervous system TEAEs of somnolence (33.3%), headache (33.3%) and dizziness (33.3%). The
TEAEs also included fatigue (33.3%) and hot flash (33.3%). We observed ECG application site rash, EEG application site skin reaction, nausea, vision blurred, thermal burn (accidental) and euphoric mood in 16.7% of subject each.
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">20mg dose (n=6): we observed the nervous system disorder TEAEs of somnolence (16.7%) and headache (33.3%). We also observed
nausea (33.3%), fatigue (16.7%), vomiting (16.7%) and dry throat (16.7%). </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Placebo (n=4): we observed the nervous system TEAEs of headache (25%), somnolence (25%) and dizziness (25%). We also
observed fatigue (50%) and nausea (25%). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A single dose of 60mg was not tolerated in the single dose trial due to reports of
nausea in five of six subjects and vomiting in three of six subjects. In the multiple dose 20mg and 40mg groups, three subjects </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
reported nausea with one subject also reporting vomiting; these events were mild in severity and resolved on Day 1 of dosing. No subjects reported nausea or vomiting after Day 1 of dosing (Figure
15). While a single dose of 60mg was not well tolerated, the average peak drug levels (138ng/mL) observed in the 40mg group after eight days of treatment were greater than those seen with the single 60mg dose (130ng/mL) on Day 1. Improved
tolerability at higher concentrations following repeated dosing suggests that titration to higher doses might be a viable strategy to further improve the tolerability profile. To test this hypothesis, we are currently conducting a titration study in
healthy volunteers evaluating up to 120mg of PRAX-944 daily dosing. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g945651g73h11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 14. Sustained exposures were observed for the MR formulation of
<FONT STYLE="white-space:nowrap">PRAX-944.</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g945651g38v62.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 15. TEAEs observed in the <FONT STYLE="white-space:nowrap">PRAX-944</FONT> MAD trial were mild-moderate and
transient. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Quantitative EEG studies in healthy volunteers were used to assess the effect of <FONT STYLE="white-space:nowrap">PRAX-944</FONT> on
<FONT STYLE="white-space:nowrap">T-type</FONT> calcium channels in the brain. One frequency band known to be driven by <FONT STYLE="white-space:nowrap">T-type</FONT> calcium channel activation is the sigma frequency band (11 to 15 Hz) during <FONT
STYLE="white-space:nowrap">non-rapid</FONT> eye movement sleep, or NREM sleep. <FONT STYLE="white-space:nowrap">T-type</FONT> calcium channels expressed in thalamic neurons are critically involved in the generation and modulation of these rhythmic
thalamocortical oscillations during NREM sleep. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In our preclinical studies, dosing of normal rats with
<FONT STYLE="white-space:nowrap">PRAX-944</FONT> led to robust and dose-dependent changes in EEG activity. Because similarly robust sigma frequency band changes after dosing with </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
<FONT STYLE="white-space:nowrap">PRAX-944</FONT> are observed during NREM sleep in rats and humans, our hypothesis is that the inhibition of this EEG signal can be used as a pharmacodynamic
biomarker. Because the doses at which EEG changes observed in rats are similar to those that demonstrated activity in a preclinical model of essential tremor, or the harmaline model, we believe that this EEG biomarker can be used to estimate the
dose of <FONT STYLE="white-space:nowrap">PRAX-944</FONT> that will produce a therapeutic effect in ET. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In our Phase 1 trial, 20mg and 40mg doses of
<FONT STYLE="white-space:nowrap">PRAX-944</FONT> administered to healthy volunteers produced changes in the qEEG recordings of the sigma frequency band during NREM sleep consistent with those observed in rats. This indicated that <FONT
STYLE="white-space:nowrap">PRAX-944</FONT> reached target levels in the brain needed to inhibit <FONT STYLE="white-space:nowrap">T-type</FONT> calcium channels. Based on the overlap of these EEG changes with drug levels showing activity in the
preclinical harmaline model, we believe that 20mg and 40mg doses of <FONT STYLE="white-space:nowrap">PRAX-944,</FONT> which were generally well-tolerated in healthy volunteers without titration, have the potential to reduce tremor in patients with
ET. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g945651g03e59.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 16. Exposures of <FONT STYLE="white-space:nowrap">PRAX-944</FONT> that decreased sigma band activity were
generally well-tolerated in healthy volunteers and were associated with harmaline tremor reduction. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Titration trial in healthy volunteers </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Considering that improved tolerability is the key unmet need in ET and that existing data suggest titration is a viable strategy to further improve
PRAX-944&#146;s tolerability profile, we explored titration in healthy volunteers to dose levels as high as 120mg daily. Participants were randomized to PRAX-944 or placebo in a 3:1 ratio, starting at 20mg daily in the morning and titrated at 20mg
increments up to 120mg daily with up to one week in between each dose increment to achieve steady-state plasma concentration and the collection of safety data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Dosing has completed in this study and the analysis of the safety data to date suggests that with titration, PRAX-944 has been generally well tolerated
up to 120mg. There were no SAEs and no severe AEs. The majority of AEs were mild, transient and resolved without intervention. There were no treatment related ECG or EEG abnormalities. To date, safety laboratory values have generally been within
normal limits and there have been no dose dependent excursion from the normal range. Importantly, no MTD was identified. We believe this provides an advantage to PRAX-944 as it enables a wide dose range for optimizing efficacy and tolerability
profile tailored to the key unmet need in ET as well as individual patient needs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Phase 2a trial in patients with ET </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are currently conducting a Phase 2a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> open-label trial
in up to twelve patients per cohort with ET in Australia and New Zealand. Patients receive 20mg daily dosing of <FONT STYLE="white-space:nowrap">PRAX-944</FONT> for one week followed by 40mg daily dosing for the second week, taken in the morning.
Based on the data from the titration trial in healthy volunteers, we are enrolling an additional cohort of ET patients dosing up to 120mg. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Studies
in movement disorders require careful attention to methods for obtaining and scoring outcome measures. We are measuring changes in tremor with different, complementary approaches including components of the Essential Tremor Rating Scale, or TETRAS,
Performance Scale and accelerometry. TETRAS is a widely used clinical rating scale that measures the severity of ET. It was based on similar clinical scales which have been used to support regulatory approval of neurosurgical treatments for severe
ET. TETRAS has shown good measurement properties and dynamic range compared to other scales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are using change from baseline in the rating of
upper limb, or UL, items of the TETRAS as the primary efficacy outcome in this <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">proof-of-concept</FONT></FONT> trial because all ET patients suffer from UL tremor. As the UL items
drive most of the score on the overall TETRAS and are more reliably rated than other items on the scale, they are therefore expected to have the best signal to noise ratio. UL items have also been the basis of the most recent regulatory approval of
neurosurgical treatments for severe ET. We have established rigorous procedures for training and for blinded scoring of efficacy, including centralized video assessment with randomization of the videos and masking to allow for objective ratings. We
have also included the overall TETRAS performance scale, or <FONT STYLE="white-space:nowrap">TETRAS-PS,</FONT> (both site and central video rating) and Kinesia ONE accelerometer, clinical global impression of severity and improvement (CGI-S and
CGI-I) and the patient global impression of change (PGI-C) as secondary endpoints in the current open-label study to assess consistency of response across different endpoints. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In this trial, we are enrolling participants with well-established ET, as defined by the Movement Disorders Society, or MDS, Task Force for Tremor as an
isolated tremor syndrome of bilateral UL action tremor with at least 3 years&#146; duration. Patients are required to have a combined bilateral score of
<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#179;</FONT></FONT>10 on the TETRAS UL items as confirmed by site investigator and central video review. This baseline severity provides a clear and measurable dynamic range
for detecting a treatment response. Tremor severity will be evaluated before drug administration, after daily morning dosing of PRAX-944 20mg for 7 days (Day 7), following daily administration of <FONT STYLE="white-space:nowrap">PRAX-944</FONT> 40mg
for 7 additional days (Day 14) and one week after administration of PRAX-944 has been stopped (Day 21). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To date, five participants have been dosed
in this trial with 20mg, followed by 40mg of PRAX-944. Preliminary site data of participants in this cohort showed stable tremor severity between screening and baseline visits. In addition, we observed tremor reduction at both dose levels which
seems to compare favorably to the standard of care agents and consistency in response across different endpoint measurements (TETRAS-UL, TETRAS-PS, Kinesia ONE accelerometer score). Over the 14&nbsp;days of dosing, three of the five participants had
greater than or equal to a 4 point reduction in the primary endpoint for the study, TETRAS-UL score, which corresponds to a greater than 50% reduction in upper limb tremor amplitude. Improvement was also observed in the full TETRAS-PS, and
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Kinesia ONE accelerometry scores. Across the three endpoint measures, the scores were also consistent for the two remaining patients that did not demonstrate a notable improvement at 20mg or
40mg. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g945651g41k33.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">* All values displayed are score reduction from baseline </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Source: Praxis Data as of September 23, 2020; Complete Kinesia ONE data on the five participants pending </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 17. Preliminary site data from the Essential Tremor OL study (N=5) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">PRAX-944 has been generally well tolerated in the ET patients dosed to date. There were no SAEs and no severe AEs. The majority of AEs were mild,
transient and resolved without intervention. All five participants that were enrolled completed the full dosing schedule. There were no clinically significant ECG or laboratory abnormalities. There were no changes in the C-SSRS. Based on the
observed safety profile in the titration HV trial and the ET open-label trial, we plan to include a high dose cohort in this on-going ET open-label trial dosing up to 120mg. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We plan to announce topline data, including the high dose cohort, from this Phase 2a trial in the first half of&nbsp;2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Preclinical support for advancing <FONT STYLE="white-space:nowrap">PRAX-944</FONT> </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">PRAX-944</FONT> has been shown preclinically to inhibit all three human <FONT STYLE="white-space:nowrap">T-type</FONT>
calcium channel isoforms, Ca<SUB STYLE="font-size:85%; vertical-align:bottom">V</SUB>3.1, Ca<SUB STYLE="font-size:85%; vertical-align:bottom">V</SUB>3.2 and Ca<SUB STYLE="font-size:85%; vertical-align:bottom">V</SUB>3.3, and has demonstrated high
selectivity against L and <FONT STYLE="white-space:nowrap">N-type</FONT> calcium channels, or Ca<SUB STYLE="font-size:85%; vertical-align:bottom">V</SUB>1.2 and Ca<SUB STYLE="font-size:85%; vertical-align:bottom">V</SUB>2.2, respectively, and other
key ion channels important for normal physiology, such as the cardiac potassium channel human <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Ether-&agrave;-go-go-Related</FONT></FONT></FONT> Gene,
or hERG, and the voltage gated sodium channel Na<SUB STYLE="font-size:85%; vertical-align:bottom">V</SUB>1.5. Robust selectivity and potency have been demonstrated across both exogenously expressed recombinant channels in a human cell line and
na&iuml;ve channels in isolated dorsal root ganglion, or DRG, neurons from rats using electrophysiological techniques. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="4" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>HEK CELLS</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>RAT&nbsp;DRG&nbsp;NEURONS</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>Channel</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>IC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB>&nbsp;(nM)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>Channel</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>IC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB>&nbsp;(nM)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>hCa<SUB STYLE="font-size:85%; vertical-align:bottom">V</SUB>3.1</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>202</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>T-Type</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>50</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>hCa<SUB STYLE="font-size:85%; vertical-align:bottom">V</SUB>3.2</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>240</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">N-Type</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>hCa<SUB STYLE="font-size:85%; vertical-align:bottom">V</SUB>3.3</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>188</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">rCa<SUB STYLE="font-size:85%; vertical-align:bottom">V</SUB><FONT STYLE="white-space:nowrap">1.2&nbsp;(L-Type)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">rCa<SUB STYLE="font-size:85%; vertical-align:bottom">V</SUB><FONT STYLE="white-space:nowrap">2.2&nbsp;(N-Type)</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">hNa<SUB STYLE="font-size:85%; vertical-align:bottom">V</SUB>1.5</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">hERG</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Table 18. <FONT STYLE="white-space:nowrap">PRAX-944</FONT> is a potent and selective inhibitor of <FONT
STYLE="white-space:nowrap">T-type</FONT> calcium channels. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Consistent with the gatekeeper role of
<FONT STYLE="white-space:nowrap">T-type</FONT> calcium channels in neuronal firing patterns, a gain of function mutation of the <FONT STYLE="white-space:nowrap">T-type</FONT> calcium channel
Ca<SUB STYLE="font-size:85%; vertical-align:bottom">V</SUB>3.2 leads to pathological burst firing in thalamic neurons in a rat model known as the GAERS model. Administration of <FONT STYLE="white-space:nowrap">PRAX-944</FONT> resulted in complete
suppression of the pathological burst-firing in thalamic neurons derived from the GAERS model. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We validated the therapeutic potential of <FONT
STYLE="white-space:nowrap">PRAX-944</FONT> to treat ET using the harmaline-induced tremor model in rats. Administration of harmaline triggers <FONT STYLE="white-space:nowrap">ET-like</FONT> tremors in experimental animals as well as pathological
burst firing throughout the CTC circuit. We observed a large and dose-dependent decrease of harmaline-induced tremor in rats treated with <FONT STYLE="white-space:nowrap">PRAX-944</FONT> as compared to vehicle-treated animals, when measured as %
increase of tremor from <FONT STYLE="white-space:nowrap">pre-harmaline</FONT> baseline. This result served to both demonstrate the potential of <FONT STYLE="white-space:nowrap">PRAX-944</FONT> in ET and as independent evidence of the critical role
of <FONT STYLE="white-space:nowrap">T-type</FONT> calcium channels in tremor reduction. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g945651g07z76.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 19. <FONT STYLE="white-space:nowrap">PRAX-944</FONT> led to a dose-dependent inhibition of tremors in the
rat harmaline model. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>EEG as a pharmacodynamic biomarker for dose selection </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">PRAX-944</FONT> robustly and dose-dependently decreased EEG power in the sigma frequency band during NREM sleep in rats.
The effect of <FONT STYLE="white-space:nowrap">PRAX-944</FONT> on the EEG observed in rats when dosed with <FONT STYLE="white-space:nowrap">PRAX-944</FONT> indicates its ability to mediate the blockade of
<FONT STYLE="white-space:nowrap">T-type</FONT> calcium channels in the thalamocortical circuit, suggesting that this effect is a pharmacodynamic biomarker for <FONT STYLE="white-space:nowrap">PRAX-944.</FONT> Because the doses at which the EEG
changes are observed are similar to those that demonstrate tremor reduction in the harmaline model, we believe that this biomarker can be used to estimate the dose that could be effective in treating ET. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g945651g77k55.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 20. <FONT STYLE="white-space:nowrap">PRAX-944</FONT> decreased EEG sigma power during NREM sleep in rats.
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>RARE DISEASE PORTFOLIO </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are advancing several
programs which we believe offer significant therapeutic benefits for rare disease populations over the current standard of care. We believe that all of the programs in our rare disease portfolio have the potential to be differentiated molecules,
have foundational underpinnings in human genetics, utilize translational biomarker tools and have the potential for early clinical signal detection. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our most advanced&nbsp;rare disease candidate is <FONT STYLE="white-space:nowrap">PRAX-562,</FONT> which is currently in a Phase 1 trial in adult
healthy volunteers in Australia. Its mechanism suggests that <FONT STYLE="white-space:nowrap">PRAX-562</FONT> has broad potential to treat many diseases of neuronal hyperexcitability. We are pursuing development in a subset of rare devastating
diseases, initially cephalgias and pediatric epilepsies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The remainder of our current rare disease portfolio consists of precision
medicines&nbsp;approaches to&nbsp;address genetically defined populations suffering from Developmental and Epileptic Encephalopathies, or DEEs. DEEs are rare neurologic diseases characterized by early onset (&lt; 2 years of age), frequent seizures,
abnormal epileptiform electroencephalographic activity, developmental impairment and resistance to available antiepileptic drugs. Additionally, DEEs are associated with a high mortality rate and comorbidities such as developmental delay in addition
to psychiatric and mood disorders, movement disorders, pain and sensory dysfunction and sleep disruptions.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The etiology of DEEs has been revolutionized by recent whole-exome sequencing initiatives that showed
over 60 genetic causes of epilepsy. An underlying pathologic feature of many DEEs is the dysregulated neuronal activity leading to hyperexcitability, seizures and associated comorbidities. This phenomenon is observed in many pediatric DEEs with an
identified genetic cause, such as SCN8A, SCN2A, KCNT1, KCNQ2, KCNQ1 and STXBP1 epilepsy, as well as epilepsies in which a genetic cause remains unclear, such as Lennox Gastaut Syndrome, or Doose Syndrome. Up to 40% of DEEs are caused by single gene
mutations, enabling precision medicine approaches.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Given the overlapping biology, phenotypic presentation and clinical execution considerations, we
believe that developing a portfolio of drugs to treat DEEs creates a differentiated body of knowledge and operational synergies across our rare disease portfolio, positioning Praxis as a leader in developing meaningful therapies for this group of
patients with devastating clinical needs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">PRAX-562</FONT> </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Standard sodium channel blockers, such as Tegretol (carbamazepine), Lidoderm (lidocaine), Lamictal (lamotrigine), Dilantin (phenytoin) and many others
are an important class of medicines in neurology and psychiatry. All standard sodium channel blockers modulate neuronal activity by targeting peak sodium current, which can reverse the pathological neuronal hyperexcitability that underlies many CNS
conditions, but simultaneously affects the physiological cellular action potential firing required for a functioning nervous and cardiovascular system. Hence, this class is widely used for the treatment of epilepsy, pain, migraine and bipolar
disorder, but its efficacy is generally limited by side effects. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">PRAX-562</FONT> is designed as the first
selective, persistent sodium current blocker that has the potential of reducing pathological neuronal hyperexcitability with an improved tolerability profile. PRAX-562 is in development for the treatment of a broad range of rare, devastating CNS
disorders, such as severe pediatric epilepsy and adult cephalgia. We intend to pursue development in a subset of rare diseases, initially Short-lasting Unilateral Neuralgiform headache attacks with Conjunctival injection and Tearing, or SUNCT, and
Short-lasting Unilateral Neuralgiform headache with Autonomic symptoms, or SUNA, two rare types of cephalgia and pediatric epilepsies for which there are currently no FDA-approved treatments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In <I><FONT STYLE="white-space:nowrap">in-vitro</FONT> </I>studies, <FONT STYLE="white-space:nowrap">PRAX-562</FONT> selectively blocks persistent
sodium currents across all subtypes of sodium channels with minimal effects on the peak sodium current that is critical for the normal physiological function of these channels. In line with this selectivity for persistent current, <FONT
STYLE="white-space:nowrap">PRAX-562</FONT> has been shown in <I><FONT STYLE="white-space:nowrap">ex-vivo</FONT> </I>studies to reduce neuronal hyperexcitability without impairing normal neuronal function. This is in contrast to marketed sodium
channel blockers which significantly impact normal neuronal function, leading to a narrow therapeutic index. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To date, PRAX-562 has demonstrated
robust pharmacological activity in an <I>in-vivo</I> seizure model with significantly improved tolerability compared to other sodium channel blockers, suggesting a potentially improved therapeutic index. The characteristics of <FONT
STYLE="white-space:nowrap">PRAX-562</FONT> are expected to make it a versatile molecule that we believe can be broadly applied in diseases of hyperexcitability where sodium channel blockers have demonstrated efficacy but poor tolerability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have initiated a Phase 1 trial of <FONT STYLE="white-space:nowrap">PRAX-562</FONT> in Australia to evaluate the safety, tolerability, PK and effects
on an EEG biomarker in up to 129 adult healthy volunteers. We anticipate Phase 1 SAD topline safety data in the fourth quarter of 2020. The clinical development plan for <FONT STYLE="white-space:nowrap">PRAX-562</FONT> encompasses exploring the
broad potential for the mechanism of action in rare diseases through proof-of-concept trials in SUNCT and SUNA patients and then expanding into a range of rare pediatric DEEs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Voltage-gated sodium channels, persistent sodium current and neuronal excitability </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Voltage-gated sodium channels, or VGSCs, are transmembrane proteins that are required for electrical signaling and therefore communication in neurons.
VGSCs respond to changes in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
membrane potential and are tightly regulated by their biophysical properties. Upon opening of VGSCs, sodium ions can move into the cell leading to a depolarization and therefore excitation of the
neuron. This sodium current is the initiator and driver of neuronal action potentials, or APs, the primary means of electrical signal propagation along the neuron&#146;s axon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The family of VGSCs consists of nine highly related isoforms (Na<SUB STYLE="font-size:85%; vertical-align:bottom">V</SUB>1.1 &#150; Na<SUB
STYLE="font-size:85%; vertical-align:bottom">V</SUB>1.9) with differential tissue distributions and functions. Na<SUB STYLE="font-size:85%; vertical-align:bottom">V</SUB>1.1, 1.2 and 1.6 are the major sodium channels expressed in the central nervous
system. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Isoform</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gene</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Expression</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Na<SUB STYLE="font-size:85%; vertical-align:bottom">V</SUB>1.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">SCN1A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">CNS</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Na<SUB STYLE="font-size:85%; vertical-align:bottom">V</SUB>1.2</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">SCN2A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">CNS</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Na<SUB STYLE="font-size:85%; vertical-align:bottom">V</SUB>1.3</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">SCN3A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">CNS/Pancreas</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Na<SUB STYLE="font-size:85%; vertical-align:bottom">V</SUB>1.4</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">SCN4A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Muscle</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Na<SUB STYLE="font-size:85%; vertical-align:bottom">V</SUB>1.5</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">SCN5A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Heart</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Na<SUB STYLE="font-size:85%; vertical-align:bottom">V</SUB>1.6</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">SCN8A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">CNS/PNS</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Na<SUB STYLE="font-size:85%; vertical-align:bottom">V</SUB>1.7</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">SCN9A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">PNS</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Na<SUB STYLE="font-size:85%; vertical-align:bottom">V</SUB>1.8</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">SCN10A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">PNS</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Na<SUB STYLE="font-size:85%; vertical-align:bottom">V</SUB>1.9</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">SCN11A</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">PNS</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">CNS: Central Nervous
System, PNS: Peripheral Nervous System </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Table 21. Sodium Channel Isoforms and tissue distribution. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">VGSCs undergo conformational changes that alter their ability to conduct sodium ions (Table 21) and are triggered to open upon excitation, or
depolarization, of the cell membrane allowing sodium ions to enter the neuron. Sodium influx further excites, or depolarizes, the neuron, leading to the opening of even more sodium channels. This series of events can lead to a large peak sodium
current underlying the initiation and propagation of neuronal action potentials, or APs, the primary means by which neurons propagate information in the nervous system. To prevent overexcitation of neurons, or hyperexcitability in the form of
excessive high frequency AP firing, the majority of sodium channels only open very briefly after activation <FONT STYLE="white-space:nowrap">(1-2</FONT> ms), followed by a refractory period of inactivation or
<FONT STYLE="white-space:nowrap">non-responsiveness.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">However, at membrane potentials below the AP firing threshold, a small subset of sodium
channels can remain open for hundreds of milliseconds, carrying the <FONT STYLE="white-space:nowrap">so-called</FONT> persistent sodium current. Persistent sodium current is present under physiologic conditions where it modulates excitability of
neurons and can be significantly increased in pathologic states (Figure 22). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g945651g07d59.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 22. Impact of a pathological mutation on sodium channels. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">There are currently more than 15 sodium channel blockers in the market commonly used to treat diseases
such as epilepsy, bipolar disorder and pain. While standard of care sodium channel blockers, such as carbamazepine, lamotrigine and phenytoin, inhibit persistent sodium current, they likely also block peak sodium current at therapeutic
concentrations, which can cause significant adverse events such as ataxia, drowsiness and dizziness, and therefore have a very narrow Therapeutic Index, or TI. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Genetics of persistent sodium current </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In published
whole-exome sequencing studies of diverse patient populations, mutations in all voltage gated sodium channel subtypes have been reported as a likely cause of disease. Furthermore, gain-of-function mutations that are associated with disease can cause
an increase of persistent sodium current, raising the idea that this might be a critical driver of hyperexcitability in neurologic disorders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
specific disease that a patient develops depends on both the sodium channel subtype and where the affected sodium channel is expressed. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Gain-of-function</FONT></FONT> mutations in
SCN2A, or Na<SUB STYLE="font-size:85%; vertical-align:bottom">V</SUB>1.2, and SCN8A, or Na<SUB STYLE="font-size:85%; vertical-align:bottom">V</SUB>1.6, two of the major sodium channels in the brain, cause early onset epileptic encephalopathies with
frequent seizures and developmental delay. <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Gain-of-function</FONT></FONT> mutations in Na<SUB STYLE="font-size:85%; vertical-align:bottom">V</SUB>1.1, Na<SUB
STYLE="font-size:85%; vertical-align:bottom">V</SUB>1.4, Na<SUB STYLE="font-size:85%; vertical-align:bottom">V</SUB>1.5 and Na<SUB STYLE="font-size:85%; vertical-align:bottom">V</SUB>1.7 cause familial hemiplegic migraine, myotonia, cardiac
arrythmia and severe pain disorders, based on their primary expression in the CNS, muscle, heart and pain pathways, respectively. These channelopathies demonstrate the important role persistent sodium current plays as a modulator of cellular
excitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our initial indications for <FONT STYLE="white-space:nowrap">PRAX-562</FONT> </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Developmental and epileptic encephalopathy </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Approximately
100,000 children suffer from DEEs in the United States alone, with over two hundred thousand children affected world-wide. An underlying pathologic feature of many DEEs with both known and unknown genetic causes, is the dysregulated neuronal
activity leading to hyperexcitability and subsequently to seizure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Sodium channel blockers have been a critical component of the pharmacological
management of seizure related conditions, including epilepsy, for decades. However, current standard of care sodium channel blockers are limited by a narrow therapeutic window and inadequate efficacy. We believe these limitations are largely due to
blockage of peak sodium current and disruption of normal neuronal function at or near therapeutic doses and significant <FONT STYLE="white-space:nowrap">off-target</FONT> activity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Given the role of persistent current in modulating excitability, we believe that <FONT STYLE="white-space:nowrap">PRAX-562</FONT> has the potential to
be a broadly efficacious and generally well-tolerated antiepileptic drug for the treatment of DEEs<I> </I>of both genetic and unknown etiology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>SUNCT and SUNA
cephalgias </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">SUNCT and SUNA cephalgias are devastating primary headache disorders that are part of a specific class of cephalgias known as Short
Lasting Unilateral Neuralgiform headaches. These headaches are characterized by severe burning, stabbing and electrical unilateral head pain that is typically 9 to 10 in the Visual Analogue Scale, or VAS, for pain. These headache attacks lasts
between one second and ten minutes in duration and can occur up to 600 times per day. SUNCT and SUNA headaches are rare diseases with a prevalence estimated to be 6.6 per 100,000 based on a recent Australian study. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Increased activation of the posterior hypothalamus during SUNCT and SUNA headache attacks indicates that hyperexcitability of central neurons is core to
the conditions. Moreover, deep brain stimulation of the posterior inferior hypothalamus effectively controls headache attacks. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">SUNCT and SUNA are often refractory to standard migraine and headache treatments, but are highly
responsive to intravenous, or IV, infusion of the sodium channel blocker lidocaine. Response under IV lidocaine requires continuous infusion in an inpatient setting and is associated with side effects such as nausea, vomiting and cardiovascular
effects, with headache attacks returning in majority of patients within days of IV lidocaine withdrawal. Preventative treatment of SUNCT and SUNA often includes oral sodium channel blocker lamotrigine, but this is limited by partial efficacy,
tolerability concerns and the requirement of several weeks of dose-titration to reach therapeutic doses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The absence of FDA-approved treatments
specific to SUNCT and SUNA, combined with high comorbidity and healthcare utilization, substantiates the need for an efficacious, generally well-tolerated and orally bioavailable sodium channel blocker to treat headache attacks in acute and
preventative settings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">PRAX-562</FONT> preclinical data </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">PRAX-562</FONT> is a highly differentiated, potent and selective inhibitor of persistent sodium current designed to
overcome the limitations of currently available sodium channel blockers. <FONT STYLE="white-space:nowrap">PRAX-562</FONT> preclinical studies were designed to test our belief that the block of persistent sodium current is sufficient to demonstrate
robust activity in animal models of hyperexcitation and that the selective block of persistent sodium current over physiological peak current leads to an improved therapeutic index. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Selective inhibition of persistent sodium channels </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In
preclinical studies, <FONT STYLE="white-space:nowrap">PRAX-562</FONT> is a highly potent inhibitor of persistent sodium current as measured in cell-based assays, in which sodium channel isoforms are heterologously expressed and channel activity is
measured via patch clamp electrophysiology. Using electrophysiological voltage protocols, the effect of compounds on a specific channel state (e.g., peak current vs persistent current) can be measured. When compared to other approved sodium channel
inhibitors for various neurological indications, <FONT STYLE="white-space:nowrap">PRAX-562</FONT> was hundreds of times more potent at inhibiting persistent sodium current. <FONT STYLE="white-space:nowrap">PRAX-562</FONT> had an IC50 of 141 nM
compared to SOC sodium channel blockers lamotrigine and carbamazepine which had an IC50 of 78,530 nM and 77,520 nM, respectively &#150; a potency difference of over <FONT STYLE="white-space:nowrap">500-fold.</FONT>
<FONT STYLE="white-space:nowrap">PRAX-562</FONT> was ~60 fold selective for inhibiting persistent current over peak current. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g945651g55m31.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 23. <FONT STYLE="white-space:nowrap">PRAX-562</FONT> is approximately
<FONT STYLE="white-space:nowrap">150-fold</FONT> more potent and two to <FONT STYLE="white-space:nowrap">nine-fold</FONT> more selective for persistent sodium current than standard sodium channel blockers. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The selective block of persistent sodium current reduces neuronal hyperexcitability without affecting the action potential, or AP, amplitude, which is
required for normal neuron function. In mouse </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
brain slice experiments, a hyperexcitable state can be mimicked by artificially depolarizing the neuron using the patch clamp method, which elicits high frequency AP firing. <FONT
STYLE="white-space:nowrap">PRAX-562</FONT> reduced the neuronal AP firing frequency, an indicator of neuronal excitability, without a significant effect on AP amplitude, an indicator of normal neuronal function, suggesting reduction of
hyperexcitability without impacting the ability of the neuron to respond to physiologic stimuli. In comparison, carbamazepine, a SOC sodium channel blocker, at comparable concentrations (relative to the potency in cells heterologously expressing Na<SUB
STYLE="font-size:85%; vertical-align:bottom">V</SUB>1.6), excessively decreased AP firing almost completely and reduced the amplitude of APs, indicating impairment of normal function. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAX-562 Representative AP Traces</B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g945651g12j65.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Carbamazepine Representative AP Traces</B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt" align="left">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g945651g24j64.jpg" ALT="LOGO">
</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAX-562 Average AP Frequency</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>During Increasing Current Steps</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Carbamazepine Average AP Frequency</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>During Increase Current Steps</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g945651g31b86.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g945651g47y96.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAX-562 Average AP Amplitude</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>During Current Step</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Carbamazepine Average AP Amplitude</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>During Current Step</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:1pt" align="left">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="center">


<IMG SRC="g945651g58k64.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">


<IMG SRC="g945651g68b35.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 24. <FONT STYLE="white-space:nowrap">PRAX-562</FONT> reduced neuronal hyperexcitability (AP frequency) without
impairing normal function (minimal effect on AP amplitude). In contrast, carbamazepine significantly reduced the AP amplitude suggesting impairment of normal function. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Preclinical in vivo pharmacological activity, tolerability and EEG pharmacodynamic biomarker </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We investigated the preclinical activity of <FONT STYLE="white-space:nowrap">PRAX-562</FONT> in a maximal electroshock model of epilepsy, or MES model,
that has shown good predictive validity for clinical anti-convulsant activity, and compared it to the effects of SOC sodium channel blockers carbamazepine and lamotrigine. To determine how well <FONT STYLE="white-space:nowrap">PRAX-562</FONT> is
tolerated, we compared its effects on spontaneous locomotor activity, or sLMA, to the effects of carbamazepine and lamotrigine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><FONT
STYLE="white-space:nowrap">PRAX-562</FONT> was able to block seizures completely in mice at a dose that does not impair locomotor function (10mg/kg). In contrast, carbamazepine and lamotrigine only achieve full block of seizures in this model at
doses that also show impairment of locomotion. <FONT STYLE="white-space:nowrap">PRAX-562</FONT> at a dose of 2mg/kg, inhibited the epilepsy response to half of its maximum value, or ED<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB>.
Inhibition of sLMA required an estimated dose of 44mg/kg to obtain 50&nbsp;percent inhibition, or TD<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB>. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g945651g99o66.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 25. Doses of <FONT STYLE="white-space:nowrap">PRAX-562</FONT> resulting in potent anticonvulsant activity
were associated with minimal effects on general locomotor activity. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We calculated the therapeutic index, or TI, of each molecule as the
preclinical tolerability/pharmacological activity ratio. This ratio is calculated by dividing the plasma and brain concentrations at the dose that reduces locomotion by 50% by the concentrations that reduce seizures by 50%. We found that <FONT
STYLE="white-space:nowrap">PRAX-562</FONT> had a significantly improved therapeutic index of ~16 fold (based on brain concentrations) and ~17 fold (based on plasma concentrations) compared to the currently prescribed sodium channel blockers
carbamazepine and lamotrigine, which had a much lower protective index of three to <FONT STYLE="white-space:nowrap">six-fold.</FONT> Notably, standard sodium channel blockers, such as carbamazepine and phenytoin,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
show severe toxicity in humans at exposures that are only about 1.5 to 3 times the target therapeutic exposures, underscoring the need for modulators of sodium channels with an improved
tolerability. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="15%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>Molecule</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>Plasma&nbsp;Therapeutic<BR>Index</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1.00pt solid #000000"><B>Brain&nbsp;Therapeutic<BR>Index</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1.00pt solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>PRAX-562</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right"><B>17.2x</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right"><B>16.4x</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;"><B>&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Carbamazepine</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3.4 x</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5.9 x</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Lamotrigine</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">6.4 x</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4.6 x</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="98%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="5" ALIGN="right" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL" ALIGN="right"><I>Therapeutic Index (TI) = TC<SUB
STYLE="font-size:85%; vertical-align:bottom">50</SUB>/ EC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB></I></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Table 26. Compared to lamotrigine and carbamazepine, <FONT STYLE="white-space:nowrap">PRAX-562</FONT> had an increased
ratio between drug levels that demonstrated preclinical pharmacological activity </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>versus those that caused toxicity. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The auditory steady state response, or ASSR, is a <FONT STYLE="white-space:nowrap">non-invasive</FONT> EEG measure of excitatory/inhibitory balance in
the brain. This response is elicited with short lasting (2sec) auditory stimuli that lead to brain activity changes that are measured as a 40Hz EEG signature and depend on network activity between excitatory and inhibitory cortical neurons. We
believe that persistent current block has the potential to lead to reduced excitability of the network and will be measurable with this endpoint. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Consistent with this hypothesis, dosing normal mice with <FONT STYLE="white-space:nowrap">PRAX-562</FONT> led to a dose-dependent decrease in the ASSR
amplitude (40Hz power). This effect was maximal at doses that have robust anticonvulsant effects in the maximal electroshock model. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g945651g48j89.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 27: <FONT STYLE="white-space:nowrap">PRAX-562</FONT> dose-dependently reduced the 40Hz EEG power of the
auditory steady state response in mice. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Together, our data suggest that the selective effects of
<FONT STYLE="white-space:nowrap">PRAX-562</FONT> on hyperexcitable states without affecting normal neuronal function led to the robust preclinical reduction of seizures and improved tolerability seen in animal models. As shown below, exposures of <FONT
STYLE="white-space:nowrap">PRAX-562</FONT> that led to biomarker change (ASSR amplitude reduction shown in top row) also demonstrated robust anticonvulsant activity (shown in middle row). Moreover, <FONT STYLE="white-space:nowrap">PRAX-562</FONT>
has a ~16.4 fold protective index based on the spontaneous locomotor activity (shown in bottom row), which is a significant improvement over reported effects of approved sodium channel blockers. In the figure below, the lower bound of the
preclinical pharmacological activity range, EEG and tolerability bars is determined by the brain EC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
(preclinical seizure and ASSR assays) or TC<SUB STYLE="font-size:85%; vertical-align:bottom">50</SUB> (tolerability assay) in a given assay and the upper bound represents the mean brain
concentration at the highest dose tested in a given assay. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g945651g49a05.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 28. Summary of <FONT STYLE="white-space:nowrap">PRAX-562</FONT> preclinical data. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe that the profile of <FONT STYLE="white-space:nowrap">PRAX-562</FONT> may translate into therapies with the potential for clinical efficacy
and tolerability across several indications caused by underlying hyperexcitability where standard sodium channel blockers have shown efficacy, albeit with limited tolerability, such as rare pediatric epilepsy and cephalgias like SUNCT/SUNA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">PRAX-562</FONT> clinical development in SUNCT and SUNA cephalgias and DEEs </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have initiated a randomized, double-blinded Phase 1 trial in Australia to evaluate the safety, tolerability and pharmacokinetics of single and
multiple ascending doses of <FONT STYLE="white-space:nowrap">PRAX-562</FONT> in up to 129 adult healthy volunteers between the ages of 18 and 55. In addition, we plan to use ASSR as a pharmacodynamic biomarker in this trial to determine the doses
required to achieve pharmacological blockade of persistent sodium current, which we believe is a potential indicator of efficacy in patients. Preliminary analysis of the first three of six planned cohorts of the Phase 1 SAD trial indicate PRAX-562
appears to be well tolerated at the doses tested. Safety data reviewed included adverse events, vital signs, ECG, C-SSRS, physical examination and safety laboratory data. In the first three cohorts tested there have been no reported SAEs, severe AEs
or any AEs leading to study withdrawal or discontinuation. Dosing has started in the fourth of six planned dose cohorts. We anticipate Phase 1 SAD topline safety data in the fourth quarter of 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The clinical development plan for <FONT STYLE="white-space:nowrap">PRAX-562</FONT> encompasses exploring the broad potential for the mechanism of action
in rare diseases through proof-of-concept trials in SUNCT and SUNA patients and then expanding into a range of rare pediatric DEEs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Along with our <FONT
STYLE="white-space:nowrap">PRAX-562</FONT> program, we are developing a portfolio of sodium channel blockers that we plan to advance in other rare neuropsychiatric disorders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">PRAX-222</FONT> </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><FONT
STYLE="white-space:nowrap">PRAX-222</FONT> is an antisense oligonucleotide, or ASO, that is designed to lower the expression levels of the protein encoded by the gene SCN2A, in patients with <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">gain-of-function,</FONT></FONT> or GOF, SCN2A epilepsy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
This program is ongoing under a <FONT STYLE="white-space:nowrap">three-way</FONT> collaboration with Ionis Pharmaceuticals, Inc., or Ionis, and RogCon Inc., or RogCon. Under the terms of the
collaboration agreement, Ionis is responsible for preclinical and <FONT STYLE="white-space:nowrap">IND-enabling</FONT> toxicology studies and Praxis is responsible for clinical development and commercialization. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">SCN2A is the gene that encodes the voltage-gated sodium channel Na<SUB STYLE="font-size:85%; vertical-align:bottom">V</SUB>1.2 that is primarily found
in excitatory neurons throughout the brain and which plays a critical role in action potential generation and signaling between neurons. Individuals with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">gain-of-function</FONT></FONT> mutations in SCN2A develop early-onset epileptic encephalopathy with severe seizures that begin within the first month of life that are often refractory
to standard of care antiepileptic medications. SCN2A GOF patients also suffer from significant intellectual disability, movement disorders and in some cases early death due to sudden unexpected death in epilepsy, or SUDEP. It is estimated that there
are thousands of patients worldwide with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">gain-of-function</FONT></FONT> changes in SCN2A leading to epileptic encephalopathy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">PRAX-222</FONT> directly targets the cause of disease by down-regulating Na<SUB
STYLE="font-size:85%; vertical-align:bottom">V</SUB>1.2 expression, an effect that has demonstrated disease-modifying activity in animal models of SCN2A epileptic encephalopathy. In transgenic mice carrying a human GOF SCN2A mutation, we observed a
significant, dose-dependent reduction in seizures and increased survival of mice treated with a mouse ASO that down-regulates SCN2A. The survival benefit from the ASO was maintained with repeat dosing. We also observed survival benefits following
administration of a mouse ASO to a group of mice after onset of disease and around the time of onset of mortality. This observation suggests that <FONT STYLE="white-space:nowrap">PRAX-222</FONT> may have the potential to provide clinical benefits
for children after disease onset. The <FONT STYLE="white-space:nowrap">ASO-treated</FONT> disease model animals demonstrated similar behavior and locomotor activity as wild type animals, suggesting SCN2A knockdown is generally well-tolerated and
that the benefits extend beyond seizure control alone. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g945651g26l94.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 29. An SCN2A ASO increased survival in a SCN2A <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">gain-of-function</FONT></FONT> mouse model. </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">PRAX-222</FONT> is currently undergoing
evaluation in <FONT STYLE="white-space:nowrap">IND-enabling</FONT> toxicology studies. We intend to file an IND in the second half of 2021 to pursue clinical development in SCN2A GOF epilepsy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>KCNT1 Program </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are currently identifying small molecule
inhibitors of the sodium-activated potassium channel encoded by the gene KCNT1 for the treatment of KCNT1 GOF epilepsy. Potassium channels encoded by the KCNT1 gene play a key role in regulating neuronal AP firing. <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Gain-of-function</FONT></FONT> KCNT1 mutations promote neuronal hyperexcitability, resulting in severe early onset epilepsy with continuous seizures </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
and severe developmental delay, affecting thousands of patients worldwide. KCNT1 GOF epilepsy is often refractory to conventional treatment approaches. Anticonvulsants, such as stiripentol,
benzodiazepines, levetiracetam and ketogenic diet, have all demonstrated limited efficacy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Genetically lowering KCNT1 expression in transgenic mice
carrying a KCNT1 human GOF mutation has been reported to result in disease modifying preclinical activity including seizure reduction, improved cognitive function and survival benefit. Through chemical optimization of the potency and pharmacokinetic
properties of hits from a high-throughput screen, we have identified novel small molecule inhibitors of KCNT1. These inhibitors restored normal action potential firing <I><FONT STYLE="white-space:nowrap">in-vitro</FONT> </I>in KCNT1 GOF mutant
neurons and reduce seizure and abnormal interictal spikes <I><FONT STYLE="white-space:nowrap">in-vivo</FONT> </I>in transgenic mice carrying a KCNT1 human GOF mutation, recapitulating the reported disease modifying preclinical activity demonstrated
by genetic tools. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g945651g40p25.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Figure 30. A KCNT1 inhibitor eliminated the occurrence of seizures in a KCNT1 transgenic mouse model and suppressed
interictal spikes (or abnormal electrographic discharges observed between seizures) as detected by EEG </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We are continuing to optimize the
chemical structures of our molecules targeting KCNT1 channels and expect to select a development candidate in 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Competition </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The biopharmaceutical industry is characterized by rapidly advancing technologies, strong competition and an emphasis on proprietary products. While we
believe that our technology, knowledge, experience and scientific personnel provide us with competitive advantages, we face substantial competition from many different sources, including large and small pharmaceutical and biotechnology companies,
academic research institutions, governmental agencies and public and private institutions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Any product candidates that we successfully develop and
commercialize will compete with currently approved therapies and new therapies that may become available in the future. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety,
convenience, cost, effectiveness of promotional support and intellectual property protection of our products. Our competitors fall primarily into the following groups of treatment: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor modulator programs in development targeting MDD,
including that of SAGE Therapeutics, as well as other programs in clinical development targeting other mechanisms of action and approved therapies such as SSRIs. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><FONT STYLE="white-space:nowrap">T-type</FONT> calcium channel inhibitor programs in development targeting ET, including
that of Jazz Pharmaceuticals, as well as other programs in clinical development targeting other mechanisms of action and approved therapies, such as propranolol, and <FONT STYLE="white-space:nowrap">off-label</FONT> therapies, such as primidone.
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Sodium channel blocker programs in development for DEEs, including those of SK-Pharma and Xenon Pharmaceuticals, as well as
other programs in clinical development targeting other mechanisms of action and approved therapies including other existing ion channel blockers. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">We are not aware of any development programs targeting SUNCT and SUNA, but we may face competition from <FONT
STYLE="white-space:nowrap">off-label</FONT> therapies such as intravenous lidocaine. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Many of our competitors have substantially
greater financial resources, expertise and capabilities in research and development, the regulatory approval process, manufacturing and marketing than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly
through M&amp;A activity and sizeable collaborative arrangements with established companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Intellectual Property </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We strive to protect and enhance the proprietary technology, inventions and improvements that are commercially important to the development of our
business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. We also rely on trade secrets relating to our proprietary technology platform and on
<FONT STYLE="white-space:nowrap">know-how,</FONT> continuing technological innovation and <FONT STYLE="white-space:nowrap">in-licensing</FONT> opportunities to develop, strengthen and maintain our proprietary position in the field of neuroscience
that may be important for the development of our business. We additionally may rely on regulatory protection afforded through data exclusivity, market exclusivity and patent term extensions, where available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our commercial success may depend in part on our ability to: obtain and maintain patent and other proprietary protection for commercially important
technology, inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> related to our business; defend and enforce our patents; preserve the confidentiality of our trade secrets; and operate without infringing the valid enforceable patents and
proprietary rights of third parties. Our ability to stop third parties from making, using, selling, offering to sell, or importing our products may depend on the extent to which we have rights under valid and enforceable licenses, patents, or trade
secrets that cover these activities. In some cases, enforcement of these rights may depend on third party licensors. With respect to both licensed and company-owned intellectual property, we cannot be sure that patents will be granted with respect
to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents that may be granted to us in the future will be commercially useful in
protecting our commercial products and methods of manufacturing the same. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor positive
allosteric modulators </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We own seven patent families directed to GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> receptor positive
allosteric modulators. One family discloses and claims salts and polymorphs of <FONT STYLE="white-space:nowrap">PRAX-114,</FONT> including the lead clinical candidate citrate salt of <FONT STYLE="white-space:nowrap">PRAX-114.</FONT> A U.S. patent
covering the clinical candidate salt has granted in the U.S. (U.S. 10562930) and PCT, EP, JP and TW applications are pending. Patents issuing from applications in this family would expire in the United States on July&nbsp;19, 2039 and on
August&nbsp;30, 2039 in other countries, not taking into account any potential patent term adjustment or extension that may be available in the future. A second family covers various methods of use, including treatment of the current lead clinical
indication, major depressive disorder, with <FONT STYLE="white-space:nowrap">PRAX-114.</FONT> This patent family has one pending PCT application and two pending U.S. utility applications and two pending U.S. provisional applications. The expected
statutory expiration date of patents issuing from applications in this family is December&nbsp;16, 2039. A third family is directed to methods of treating various perimenopausal symptoms with <FONT STYLE="white-space:nowrap">PRAX-114.</FONT> This
family has one pending PCT application and an expected statutory expiration date of March&nbsp;4, 2040. Four additional </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
U.S. provisional applications have been filed covering combinations of GABA-PAMs (including <FONT STYLE="white-space:nowrap">PRAX-114)</FONT> with NMDA antagonists, NMDA Negative Allosteric
Modulators or NMDA partial agonists (filed Oct. 2, 2019); deuterated forms of <FONT STYLE="white-space:nowrap">PRAX-114</FONT> (filed Feb. 18, 2020); methods of treating adjustment disorder with <FONT STYLE="white-space:nowrap">PRAX-114</FONT>
(filed July&nbsp;2, 2020); and improved methods of treating depression with an evening dose of PRAX-114 (filed September 4, 2020). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I><FONT
STYLE="white-space:nowrap">T-type</FONT> Calcium channel blockers </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We own four patent families directed to
<FONT STYLE="white-space:nowrap">T-type</FONT> Calcium channel blockers. One family discloses and claims certain <FONT STYLE="white-space:nowrap">T-type</FONT> calcium channel modulators, including <FONT STYLE="white-space:nowrap">PRAX-944.</FONT>
This patent family is issued in U.S., AU, CA, CN, EP, HK, IL, JP, KR and ZA and is pending in BR, HK and IL. The statutory expiration for patents issuing from this family in the United States is April&nbsp;8, 2029 and June&nbsp;2, 2029 in foreign
jurisdictions. A second family is directed to methods of use of certain <FONT STYLE="white-space:nowrap">T-type</FONT> calcium channel modulators, including <FONT STYLE="white-space:nowrap">PRAX-944,</FONT> in treating disease such as epilepsy. This
patent family is pending in the United States and the statutory expiration for any patent issuing from this family is December&nbsp;21, 2037. A third patent family is directed to certain pharmaceutical formulations of
<FONT STYLE="white-space:nowrap">PRAX-944</FONT> and methods of use in treating disorders such as essential tremor. This patent family is pending as a PCT, having a 30-month national phase deadline of January 11, 2022 and is also pending in AR, GC
and TW. A fourth family is directed to methods of use of <FONT STYLE="white-space:nowrap">PRAX-944.</FONT> This family is composed of two provisional applications filed respectively on April&nbsp;29, 2020 and July 10, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Persistent sodium current blockers </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We own twenty patent
families directed to persistent sodium current blockers including five patent families that relate to our <FONT STYLE="white-space:nowrap">PRAX-562</FONT> program and fifteen families related to other persistent sodium current blockers.
Additionally, we have <FONT STYLE="white-space:nowrap">in-licensed</FONT> one patent family. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Regarding the five families directed to our <FONT
STYLE="white-space:nowrap">PRAX-562</FONT> program, one family discloses and claims certain persistent sodium current blockers, including <FONT STYLE="white-space:nowrap">PRAX-562,</FONT> and methods of use in treating diseases such as pediatric
epilepsy. This family is pending as a PCT, having a <FONT STYLE="white-space:nowrap">30-month</FONT> national phase deadline of November&nbsp;30, 2020 and is also pending in AR and TW. The statutory expiration for any patent issuing from this family
is May&nbsp;30, 2039. A second family discloses other persistent sodium current blockers and generically claims <FONT STYLE="white-space:nowrap">PRAX-562.</FONT> This family also claims methods of use of the claimed compounds in treating diseases
such as pediatric epilepsy. This patent family is pending in multiple jurisdictions, including US, AU, BR, CA, CN, EA, EP, HK and JP. The statutory expiration for any patent issuing from this family is November&nbsp;28, 2037. A third family is
directed to pharmaceutical formulations of <FONT STYLE="white-space:nowrap">PRAX-562</FONT> and methods of use in treating diseases such as pediatric epilepsy. This family has three provisional applications filed respectively on November&nbsp;27,
2019, March&nbsp;30, 2020 and May&nbsp;21, 2020. A fourth family is directed to methods of making <FONT STYLE="white-space:nowrap">PRAX-562.</FONT> This family is a provisional application filed November&nbsp;27, 2019. A fifth family is directed to
methods of use of persistent sodium current blockers, including <FONT STYLE="white-space:nowrap">PRAX-562,</FONT> in treating diseases such as cephalgia, SUNCT and SUNA. This family is a provisional application filed March&nbsp;30, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The remaining fifteen patent families are directed to a portfolio of sodium channel blockers that we plan to advance in other neuropsychiatric
disorders. Fifteen patent families disclose and claim persistent sodium current blockers of various core structures and methods of use in treating diseases such as pediatric epilepsy, which include eight families pending in the United States (the
statutory expiration for any patent issuing from these families range from November&nbsp;28, 2037 to May&nbsp;29, 2040), one family pending as a PCT, having a <FONT STYLE="white-space:nowrap">30-month</FONT> national phase deadline of March&nbsp;28,
2021 (the statutory expiration for any patent issuing from this family is September&nbsp;27, 2039) and six families pending as provisional applications filed between November&nbsp;26, 2019 and March&nbsp;30, 2020. One family is directed to methods
of use of certain persistent sodium current blockers in treating diseases such as cephalgia, SUNCT and SUNA. This family is composed of two provisional applications filed respectively on March&nbsp;30, 2020 and June 12, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have exclusively <FONT STYLE="white-space:nowrap">in-licensed</FONT> one patent family directed to
additional persistent sodium current blockers. This family is owned by Gilead. This family has claims directed to certain persistent sodium current blockers and methods of use. This patent family is issued in US, AU, BO, CA, CN, EA, EP, HK, MO, NZ
and TW and is pending in PK and VE. The statutory expiration for any patent issuing from this family is between July&nbsp;22, 2030 and July&nbsp;27, 2030, not taking into account any potential patent term adjustment or extension that may be
available in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>KCNT1 blockers </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We own 13
patent families directed to KCNT1 blockers including twelve families related to our KCNT1 program and one family related to antisense oligonucleotides. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Twelve patent families are directed to our KCNT1 program and disclose and claims small molecule KCNT1 blockers and methods of use in treating diseases
such as epilepsy, including epilepsy having certain KCNT1 mutations. Two families are pending as a PCT, having a <FONT STYLE="white-space:nowrap">30-month</FONT> national phase deadline of November&nbsp;3, 2021. The statutory expiration for any
patent issuing from these two families is May&nbsp;1, 2040. Ten families are provisional applications filed between February&nbsp;28, 2020 to March&nbsp;23, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">One family is directed to certain antisense oligonucleotides and methods of use in treating diseases such as epilepsy, including epilepsy having certain
KCNT1 mutations. This family is pending as a PCT, having a <FONT STYLE="white-space:nowrap">30-month</FONT> national phase deadline of June&nbsp;20, 2021. The statutory expiration for any patent issuing from this family is December&nbsp;20, 2039.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>SCN2A downregulation </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have exclusively <FONT
STYLE="white-space:nowrap">in-licensed</FONT> two patent families directed to our <FONT STYLE="white-space:nowrap">PRAX-222</FONT> program. These patent families are owned by RogCon. These families disclose and claim certain antisense
oligonucleotides targeting SCN2A and methods of use in treating diseases such as epilepsy, including epilepsy having certain SCN2A mutations. One family is pending in the United States and the statutory expiration for any patent issuing from this
family is August&nbsp;6, 2039. A second family is pending as a PCT, having a <FONT STYLE="white-space:nowrap">30-month</FONT> national phase deadline of February&nbsp;20, 2021. The statutory expiration for any patent issuing from this family is
August&nbsp;20, 2039. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>License Agreements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>License Agreement with
RogCon </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In September 2019, we and RogCon entered into a Cooperation and License Agreement, or the RogCon Agreement, to collaborate to develop
antisense oligonucleotides for the treatment of epilepsy caused by mutations of the SCN2A gene. RogCon had an existing collaboration arrangement with Ionis and as a result, we and Ionis negotiated a Research Collaboration, Option and License
Agreement, or the Ionis Agreement (described below) in order to complete the license agreement with RogCon. In December 2018, we entered into an agreement with RogCon to advance to them a fully refundable deposit of up to $1.0&nbsp;million while the
RogCon Agreement was being negotiated. Under the RogCon Agreement, RogCon granted us, subject to a concurrent license grant of certain rights to Ionis, an exclusive, worldwide license under RogCon&#146;s intellectual property to research, develop
and commercialize products for the treatment of all forms of epilepsy and/or neurodevelopmental disorders in each case caused by any mutation of the SCN2A gene. Under the RogCon Agreement, we will conduct, at our own cost and expense, the research
and development activities assigned to us under the research plan set out in the Research Collaboration, Option and License Agreement with Ionis. Under the terms of the RogCon Agreement, RogCon is eligible to receive a one-time milestone payment of
$3.0 million as well as profit share payments as a percentage of net profits in the mid-teens. Profit share payments will be calculated and due quarterly on any net profits generated from a product commercialized under the RogCon Agreement. The
$3.0&nbsp;million milestone payment will become due when (i) the first profit share payment has become due and payable and (ii)&nbsp;the Additional </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Milestone, the Initial Interest Amount and the Second Interest Amount (each as defined within the Ionis Agreement as described below) have all become due and payable to Ionis under our
collaboration agreement with Ionis. As part of the RogCon Agreement, we agreed to provide <FONT STYLE="white-space:nowrap">up-front</FONT> consideration of $2.1&nbsp;million, consisting of a $1.0&nbsp;million deposit, $0.7&nbsp;million in cash
reimbursements for certain historical costs previously incurred by RogCon and $0.4&nbsp;million for the retirement of existing loan balances as of September&nbsp;11, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Subsequent to September&nbsp;11, 2019, we will reimburse RogCon for its
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs incurred for activities performed under the RogCon Agreement. We expense these costs as incurred as research and development. Since the acquisition
date, we expensed $0.1&nbsp;million for the reimbursement of RogCon&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs in the year ended December&nbsp;31, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Additionally, RogCon has agreed to certain defined exclusivity obligations. The RogCon Agreement, unless earlier terminated, will continue until the
latest of: (i)&nbsp;the expiration of all patent rights within RogCon patents, (ii)&nbsp;we certify we have abandoned the research, development and commercialization of product with no intention to
<FONT STYLE="white-space:nowrap">re-establish</FONT> such activities and (iii)&nbsp;no third party is obligated to pay any amounts that comprise net sublicense revenue. Either party may terminate the RogCon Agreement for material breach or
insolvency of the other party. Additionally, we may terminate for convenience with prior written notice to RogCon. Upon termination by either party, all rights and licenses granted by RogCon to us will revert back to RogCon. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>License Agreement with Purdue </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In December 2017, we and
Purdue Neuroscience Company, or Purdue, entered into a license agreement, or the Purdue Agreement, pursuant to which we were granted exclusive rights under certain Purdue <FONT STYLE="white-space:nowrap">know-how</FONT> to research, develop and
commercialize pharmaceutical products concerning a GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> positive allosteric modulator. We are obligated to make future milestone payments based on the achievement of specified development and
sales milestones up to $33.0&nbsp;million. Additionally, under the Purdue Agreement, we were obligated to sell to Purdue $0.6&nbsp;million of our Series&nbsp;B Preferred Stock in connection with our Series&nbsp;B financing. In addition, as
consideration for the license obtained, we issued Purdue the anti-dilution obligation to ensure Purdue&#146;s ownership remained at a specified percentage throughout the Series&nbsp;B financing. Further, we are obligated to pay to Purdue a royalty
percentage in the low single-digits of net sales of each licensed product for 12 years from the date of the first commercial sale of such product. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Purdue Agreement will remain in effect until the expiration of our royalty obligation for all licensed products. Either us or Purdue may terminate
the agreement in the event of a material breach by the other party and such party fails to cure such breach within a certain period of time. Either party may voluntarily terminate the agreement with prior notice. If the agreement is voluntarily
terminated by Purdue, our license rights will survive such termination and such rights will become fully paid, perpetual and irrevocable. Purdue may also terminate in the event of our insolvency. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Ionis Collaboration Agreement </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In September 2019, we and
Ionis entered into the Ionis Agreement to discover and develop antisense oligonucleotides to treat forms of epilepsy caused by mutations of the SCN2A gene. Pursuant to the Ionis Agreement, we and Ionis will each conduct certain research activities
and Ionis will be responsible for identifying a development candidate and conducting an <FONT STYLE="white-space:nowrap">IND-enabling</FONT> toxicology study. The design of the IND-enabling toxicology study will be prepared and mutually agreed to by
us and Ionis.&nbsp;We are obligated to reimburse any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs incurred by Ionis related to research activities, identification of a development candidate and
conducting <FONT STYLE="white-space:nowrap">IND-enabling</FONT> studies. We hold an exclusive option, which we may exercise following the results of the IND-enabling toxicology study, to obtain the rights and license to further develop and
commercialize a development candidate in the field of epilepsy and neurodevelopmental disorders, other than Dravet Syndrome. Upon the exercise of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
such option, we will be required to pay Ionis a $2.0&nbsp;million license fee. In addition, after option exercise, Ionis is eligible to receive certain contingent payments from us relating to
development and other milestones, interest payments, royalties as a percentage of net product sales worldwide in the low-20s and any potential sublicense fees calculated as a percentage of sublicense revenue using a rate in the low-to-mid double
digits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Development milestones of $5.0&nbsp;million for each product developed under the agreement are due upon the completion of the first
clinical trial for each product, or the Development Milestone. Ionis will be entitled to receive an additional one-time milestone payment of $5.0&nbsp;million, or the Additional Milestone, upon the earliest to occur of the following (each, a Payment
Trigger): (i)&nbsp;the first acceptance of an NDA filing for a product by the regulatory authority in a major market, (ii)&nbsp;we have both (a)&nbsp;received, in the aggregate, $300.0&nbsp;million in cash since September&nbsp;11, 2019 and
(b)&nbsp;initiated the first clinical study with respect to a product or (iii)&nbsp;the closing of a change of control event affecting Praxis. In addition, upon the occurrence of a Payment Trigger, Ionis is also entitled to certain interest payments
equal to (i)&nbsp;10% simple interest per annum calculated from the effective date of the agreement on the Additional Milestone, or the Initial Interest Amount, plus (ii)&nbsp;10% simple interest per annum calculated from the date the Additional
Milestone is paid on the initial Interest Amount, or the Second Interest Amount, until the earliest to occur of the following: (i) aggregate net sales of $100.0&nbsp;million has been received, (ii)&nbsp;a change in control event affecting Praxis
occurs or (iii)&nbsp;the Ionis Agreement has been terminated. Upon the occurrence of one of these three payment triggers, both the Initial Interest Amount and Second Interest Amount are due and payable to Ionis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Ionis Agreement will continue in full force and effect until the expiration of all payment obligations to Ionis, unless terminated earlier by either
party. Either party may terminate the agreement upon material breach or insolvency of the other party or if Ionis is unable to identify a development candidate. Praxis is able to terminate the Ionis Agreement for convenience with prior written
notice. Ionis may terminate if we fail to achieve certain performance milestones or Ionis&#146; failure to identify a development candidate. Upon termination by us for convenience, we will stop selling all products, subject to certain wind-down
provisions and all products will revert back to Ionis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Manufacturing </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We currently source all of our nonclinical and clinical
compound supply through third-party contract development and manufacturing organizations, or CDMOs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For clinical supply, we use CDMOs who act in
accordance with the FDA&#146;s current Good Manufacturing Practices, cGMP, for the manufacture of drug substance and product. We expect to rely on third parties for our manufacturing processes and the production of all clinical supply drug substance
and drug product and currently expect to continue to do so for commercial supplies of our product candidates, if approved. We use additional contract manufacturers to fill, label, package, store and distribute our investigational drug products and
currently expect to continue to do so for commercial supplies of our product candidates, if approved. It is our intent to identify and qualify additional manufacturers to provide active pharmaceutical ingredient and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">fill-and-finish</FONT></FONT> services prior to submission of an NDA to the FDA for any product candidates that complete clinical development. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Government Regulation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The FDA and comparable regulatory
authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements upon companies involved in the clinical development, manufacture, marketing and distribution of prescription drugs, such as those we
are developing. These agencies regulate, among other things, the research and development, testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion, distribution,
post-approval monitoring and reporting, sampling and export </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
and import of drug products and product candidates. The process of obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local and foreign statutes and
regulations requires the expenditure of substantial time and financial resources. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>U.S. government regulation of drug products </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The FDA also
regulates biological products under the FDCA and the Public Health Service Act, or PHSA. If we advance clinical development of a biologic candidate in the future, these development activities will be subject to additional regulatory requirements
specific to biologics. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions,
such as the FDA&#146;s refusal to approve pending NDAs withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions,
fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties brought by the FDA and the Department of Justice, or DOJ, or other governmental entities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The process required by the FDA before a drug may be marketed in the United States generally involves the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#146;s good
laboratory practice, or GLP, regulations; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Submission to the FDA of an IND which must become effective before human clinical trials may begin; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Approval by an independent institutional review board, or IRB, at each clinical site before each trial may be initiated;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Performance of adequate and well-controlled human clinical trials in accordance with good clinical practice, or GCP,
requirements to establish the safety and efficacy of the proposed drug product for each indication; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Submission to the FDA of an NDA; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Satisfactory completion of an FDA advisory committee review, if applicable; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced
to assess compliance with current good manufacturing practice, or cGMP, requirements and to assure that the facilities, methods and controls are adequate to preserve the drug&#146;s identity, strength, quality and purity; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the
clinical data; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Payment of user fees and securing FDA approval of the NDA, including agreement to compliance with any post-approval
requirements; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and
Mitigation Strategy, or REMS, and the potential requirement to conduct post-approval studies. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Preclinical studies </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Before testing any drug or biological product candidate, including our product candidates, in humans, the product candidate must undergo rigorous
preclinical testing. Preclinical studies generally include laboratory evaluation of product chemistry, formulation and stability, as well as animal studies to assess potential toxicity, which support subsequent clinical testing. An IND sponsor must
submit the results of the preclinical tests, together with manufacturing information, analytical data and any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
available clinical data or literature and a proposed clinical protocol, among other things, to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an
investigational product to humans and must become effective before human clinical trials may begin. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Clinical trials </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in
accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other
things, the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the
IND. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it
initiates at that institution. Information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on their www.clinicaltrials.gov website. Information related
to the product, patient population, phase of investigation, study sites and investigators and other aspects of the clinical trial is made public as part of the registration of the clinical trial. Sponsors are also obligated to disclose the results
of their clinical trials after completion. Disclosure of the results of these trials can be delayed in some cases for up to two years after the date of completion of the trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or
more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result
in the FDA allowing clinical trials to initiate. Additionally, FDA will review any data from clinical trials conducted outside the United States when determining whether to allow an IND to proceed in the U.S. Specifically, FDA&#146;s acceptance of
data from trials conducted outside of the U.S. is subject to certain conditions, including that the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with GCPs; the data must be applicable to
the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful; and that the trials are conducted in compliance with all applicable U.S. laws and regulations. Clinical holds also may be imposed by the FDA at any time
before or during studies due to safety concerns or non-compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Human clinical trials are typically conducted in three sequential phases, which
may overlap or be combined: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Phase 1: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and
tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Phase 2: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to
preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Phase 3: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial
sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for
the labeling of the product. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Progress reports detailing the results of the clinical trials must be submitted at least annually to
the FDA and more frequently if serious adverse events occur. Phase&nbsp;1, Phase&nbsp;2 and Phase&nbsp;3 trials may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a
finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution for a variety of reasons, including if the clinical trial is not being
conducted in accordance with the IRB&#146;s requirements or if the drug has been associated with unexpected serious harm to patients. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Post-approval
trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for
long-term safety follow up. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about the chemistry
and physical characteristics of the drug or biologic as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing
quality batches of the product and, among other things, companies must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and stability studies
must be conducted to demonstrate that the product candidates do not undergo unacceptable deterioration over their shelf life. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Marketing application submission
and FDA review and approval </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Assuming successful completion of the required clinical testing, the results of the preclinical and clinical
studies, together with detailed information relating to the product&#146;s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or
more indications. In most cases, the submission of an NDA is subject to a substantial application user fee. Under the goals and policies agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, the FDA has ten months from the date of
&#147;filing&#148; of a standard NDA for a new molecular entity in which to complete its initial review and respond to the applicant, and six months from the filing date for priority applications. The FDA does not always meet its PDUFA goal dates,
and the review process can be extended by FDA requests for additional information or clarification and a sponsor&#146;s process to respond to such inquiries. This FDA review typically takes twelve months from the date the NDA is submitted to FDA
(for a standard review) because the FDA has approximately two months, or 60 days, after submission to make a &#147;filing&#148; decision on whether to accept an NDA for review. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they
are sufficiently complete to permit substantive review and informs the sponsor by the 74th day after the FDA&#146;s receipt of the submission whether an application is sufficiently complete to permit substantive review. The FDA may request
additional information rather than accept an NDA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the
submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and effective and whether the facility in which it is manufactured, processed,
packaged or held meets standards designed to assure the product&#146;s continued safety, quality and purity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Before approving an NDA, the FDA
typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate
to assure consistent production of the product within required specifications. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Additionally, the FDA may refer any application to an advisory committee, including applications for
novel drug candidates that present difficult questions of safety or efficacy. An advisory committee is a panel of independent experts, including clinicians and other scientific experts, which reviews, evaluates and provides a recommendation as to
whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. The FDA also may require submission of
a risk evaluation and mitigation strategy, or REMS, plan, if it determines that a REMS is necessary to ensure that the benefits of the drug outweigh its risks and to assure the safe use of the drug product. The REMS plan could include medication
guides, physician communication plans, assessment plans and/or elements to assure safe use, such as restricted distribution methods, patient registries or other risk minimization tools. The FDA determines the requirement for a REMS, as well as the
specific REMS provisions, on a case-by-case basis. If the FDA concludes a REMS plan is needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve the NDA without a REMS, if required. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, under the Pediatric Research Equity Act of 2003, or PREA, as amended and reauthorized, certain NDAs or supplements to an NDA must contain
data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe
and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric
data requirements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection
reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue either an approval letter or a complete response letter, or CRL. An approval letter authorizes commercial marketing of the drug with specific prescribing
information and for specific indications. A CRL generally outlines the deficiencies in the submission and contains a statement of specific conditions that must be met in order to secure final approval of the NDA; it may require additional clinical
or preclinical testing and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing in order for FDA to reconsider the application. If a CRL is issued, the applicant may choose to either
resubmit the NDA, addressing all of the deficiencies identified in the letter, or withdraw the application. If and when those deficiencies have been addressed to the FDA&#146;s satisfaction, the FDA will issue an approval letter. The FDA has
committed to reviewing such resubmissions in response to an issued CRL in either two or six months depending on the type of information included. Even with submission of this additional information, the FDA ultimately may decide that the application
does not satisfy the regulatory criteria for approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Even if the FDA approves a product, it may limit the approved indications for use of the
product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase&nbsp;4 clinical trials, be conducted to further assess a drug&#146;s safety after approval,
require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS, which can materially affect the
potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product,
such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Orphan drug designation and exclusivity </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under the Orphan
Drug Act, the FDA may designate a drug product as an &#147;orphan drug&#148; if it is intended to treat a rare disease or condition (generally meaning that it affects fewer than 200,000 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a drug product available in the United States for treatment
of the disease or condition will be recovered from sales of the product). A company must request orphan product designation before submitting an NDA. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its
potential use. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If a product with orphan status receives the first FDA approval for the disease or condition for which it has such designation or for a select
indication or use within the rare disease or condition for which it was designated, the product generally will receive orphan product exclusivity. Orphan product exclusivity means that the FDA may not approve any other applications for the same
product for the same indication for seven years, except in certain limited circumstances. If a drug or drug product designated as an orphan product ultimately receives marketing approval for an indication broader than what was designated in its
orphan product application, it may not be entitled to exclusivity. Orphan exclusivity will not bar approval of another product under certain circumstances, including if a subsequent product with the same active ingredient for the same indication is
shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. Further, the FDA
may approve more than one product for the same orphan indication or disease as long as the products contain different active ingredients. Moreover, competitors may receive approval of different products for the indication for which the orphan
product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Fast track,
breakthrough therapy and priority review designations </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The FDA is authorized to designate certain products for expedited development or review if
they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs include fast track designation, breakthrough therapy designation and priority review designation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or
life threatening disease or condition and demonstrates the potential to address unmet medical needs for the condition. Fast track designation provides opportunities for more frequent interactions with the FDA review team to expedite development and
review of the product. The FDA may also review sections of the NDA for a fast track product on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the application,
the FDA agrees to accept sections of the application and determines that the schedule is acceptable and the sponsor pays any required user fees upon submission of the first section of the application. The sponsor can request the FDA to designate the
product for fast track status any time before receiving NDA approval, but ideally no later than the pre-NDA meeting. Fast track designation may be withdrawn by the sponsor or rescinded by the FDA if the designation is no longer supported by data
emerging in the clinical trial process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, with the enactment of FDASIA in 2012, Congress created a new regulatory program for product
candidates designated by FDA as &#147;breakthrough therapies&#148; upon a request made by IND sponsors. A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or
life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints, such as substantial treatment effects
observed early in clinical development. If the FDA designates a breakthrough therapy, it may take actions appropriate to expedite the development and review of the application, which may include holding meetings with the sponsor and the review team
throughout the development of the therapy; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
providing timely advice to, and interactive communication with, the sponsor regarding the development of the drug to ensure that the development program to gather the nonclinical and clinical
data necessary for approval is as efficient as practicable; involving senior managers and experienced review staff, as appropriate, in a collaborative, cross-disciplinary review; assigning a cross-disciplinary project lead for the FDA review team to
facilitate an efficient review of the development program and to serve as a scientific liaison between the review team and the sponsor; and considering alternative clinical trial designs when scientifically appropriate, which may result in smaller
trials or more efficient trials that require less time to complete and may minimize the number of patients exposed to a potentially less efficacious treatment. Breakthrough therapy designation comes with all of the benefits of fast track
designation, which means that the sponsor may file sections of the NDA for review on a rolling basis if certain conditions are satisfied, including an agreement with the FDA on the proposed schedule for submission of portions of the application and
the payment of applicable user fees before the FDA may initiate a review. Finally, the FDA may designate a product for priority review if it is a drug that treats a serious condition and, if approved, would provide a significant improvement in
safety or effectiveness. The FDA determines at the time that the marketing application is submitted, on a case-by-case basis, whether the proposed drug represents a significant improvement when compared with other available therapies. Significant
improvement may be illustrated by evidence of increased effectiveness in the treatment of a condition, elimination or substantial reduction of a treatment-limiting drug reaction, documented enhancement of patient compliance that may lead to
improvement in serious outcomes, or evidence of safety and effectiveness in a new subpopulation. A priority review designation is intended to direct overall attention and resources to the evaluation of such applications and to shorten the FDA&#146;s
goal for taking action on a marketing application from ten months to six months for an NDA for a new molecular entity from the date of filing. If criteria are not met for priority review, the application for a new molecular entity is subject to the
standard FDA review period of ten months after FDA accepts the application for filing. Priority review designation does not change the scientific/medical standard for approval or the quality of evidence necessary to support approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for
qualification or the time period for FDA review or approval may not be shortened. Furthermore, fast track designation, priority review and breakthrough therapy designation do not change the standards for approval and may not ultimately expedite the
development or approval process. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Accelerated approval pathway </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A drug product may also be eligible for accelerated approval if it is designed to treat a serious or life-threatening disease or condition and provides a
meaningful therapeutic benefit over existing treatments. Such products can be approved on the basis of adequate and well-controlled clinical trials establishing an effect on either a surrogate endpoint that is reasonably likely to predict clinical
benefit or on an intermediate clinical endpoint that can be measured earlier than irreversible morbidity or mortality, or IMM, that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity,
or prevalence of the disease or condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled
post-marketing clinical trials to verify and describe the predicted effect on IMM or other clinical endpoint. Drugs granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional
approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, all promotional materials for products approved under the accelerated approval program are subject to prior review by the
FDA, a requirement that could adversely impact the timing of the commercial launch of the product. FDA may withdraw approval of a drug or indication approved under accelerated approval if, for example, the confirmatory trial fails to verify the
predicted clinical benefit of the product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>U.S. marketing and data exclusivity </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Market exclusivity provisions under the FDCA can delay the submission or the approval of certain follow-on drug applications. The FDCA provides a
five-year period of non-patent marketing exclusivity within the United States to the first applicant to gain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug
containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an Abbreviated New Drug Application, or ANDA, or a 505(b)(2) NDA
submitted by another company for a generic or follow-on version of the protected drug product, respectively, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be
submitted after four years if it contains a certification of patent invalidity or non-infringement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The FDCA also provides three years of data
exclusivity when an NDA or a supplement to an existing NDA, includes new clinical investigations, other than bioavailability studies, conducted or sponsored by the applicant that are deemed by the FDA to be essential to the approval of the
application, for example, new indications, dosages or strengths of an existing drug. This three-year exclusivity covers only the conditions of use associated with the new clinical investigations and does not prohibit the FDA from approving ANDAs or
follow-on 505(b)(2) NDAs if the protected clinical data are not referenced. Five-year and three-year exclusivity will not delay the submission or approval of a stand-alone NDA submitted under section 505(b)(1) of the FDCA. However, an applicant
submitting a stand-alone NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness, if applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pediatric exclusivity is another type of regulatory market exclusivity in the United States. Pediatric exclusivity, if granted, adds six months to
existing regulatory exclusivity periods. This six-month exclusivity may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#147;Written Request&#148; for such a trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Patent term restoration </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Depending upon the timing, duration
and specifics of FDA approval of our drug product candidates, some of our U.S. patents may be eligible for limited patent term extension. These patent term extensions permit a patent restoration term of up to five years as compensation for any
patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the drug product&#146;s approval date. The patent term
restoration period is generally one-half the time between the effective date of an IND and the submission date of an NDA, plus the time between the submission date of an NDA and the approval of that application. Only one patent applicable to an
approved drug is eligible for the extension and the extension must be applied for prior to expiration of the patent. The United States Patent and Trademark Office, or the USPTO, in consultation with the FDA, reviews and approves the application for
any patent term extension or restoration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Post-approval requirements </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Following approval of a new prescription drug product, the manufacturer and the approved drug are subject to pervasive and continuing regulation by the
FDA, including, among other things, requirements relating to monitoring and recordkeeping, periodic reporting, product sampling and distribution, advertising and promotion and reporting of adverse experiences with the product. The FDA strictly
regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs must be promoted by a manufacturer and any third parties acting on behalf of a manufacturer only for the approved indications and in a manner
consistent with the approved label for the product. The FDA and other agencies actively enforce the laws and regulations prohibiting the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
promotion of off-label uses and a company that is found to have improperly promoted off-label uses may be subject to significant liability. After approval, most changes to the approved product,
such as adding new indications or other labeling claims or changes to the manufacturing processes or facilities, are subject to prior FDA review and approval. There are continuing, annual user fee requirements for any marketed products and the
establishments where such products are manufactured, as well as new application fees for supplemental applications with clinical data. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition,
drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and state agencies and are subject to periodic unannounced inspections by the FDA and
these state agencies for compliance with cGMP requirements. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any
deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in
the area of production and quality control to maintain cGMP compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Once an approval of a drug is granted, the FDA may withdraw the approval if
compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or
frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess
new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or
product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Fines, warning letters or other enforcement-related letters or clinical holds on post-approval clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or suspension or revocation of
product approvals; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Product seizure or detention, or refusal to permit the import or export of products; and </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, the distribution of prescription pharmaceutical products is subject to the Prescription Drug Marketing Act, or PDMA, which regulates the
distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical
product samples and impose requirements to ensure accountability in distribution. From time to time, new legislation and regulations may be implemented that could significantly change the statutory provisions governing the approval, manufacturing
and marketing of products regulated by the FDA. It is impossible to predict whether further legislative or regulatory changes will be enacted, or FDA regulations, guidance or interpretations changed or what the impact of such changes, if any, may
be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Other healthcare laws and regulations </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Healthcare
providers, physicians and third party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any drug products for which we obtain marketing approval. Our current and future arrangements with
third party payors, customers, healthcare providers, physicians and others, in connection with the clinical research, sales, marketing and promotion of products, once approved, and related activities, may expose a pharmaceutical
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
manufacturer to broadly applicable fraud and abuse and other healthcare laws and regulations. In particular, the research of our product candidates, as well as the promotion, sales and marketing
of healthcare items and services and certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or
prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business or financial arrangements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The applicable federal, state and foreign healthcare laws and regulations that may affect our ability to operate include, but are not limited to: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the U.S. federal Anti-Kickback Statute, which makes it illegal for any person or entity, including a prescription drug
manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer or pay any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or
reward, or in return for, either the referral of an individual, or the purchase, lease, order, arrangement, or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare
program, such as the Medicare and Medicaid programs. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. The term remuneration has been interpreted broadly
to include anything of value. Further, courts have found that if &#147;one purpose&#148; of renumeration is to induce referrals, the federal Anti-Kickback statute is violated. Violations are subject to significant civil and criminal fines and
penalties for each violation, plus up to three times the remuneration involved, imprisonment and exclusion from government healthcare programs. In addition, a claim submitted for payment to any federal healthcare program that includes items or
services that were made as a result of a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act, or FCA. The Anti-Kickback Statute has been interpreted to apply to
arrangements between biopharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers, among others, on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common
activities from prosecution; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the U.S. federal civil and criminal false claims laws, including the U.S. False Claims Act, or FCA, which can be enforced
through &#147;qui tam&#148; or &#147;whistleblower&#148; actions, and civil monetary penalty laws, which impose criminal and civil penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented,
claims for payment or approval from Medicare, Medicaid, or other federal health care programs that are false, fictitious or fraudulent; knowingly making, using, or causing to be made or used, a false record or statement material to a false,
fictitious or fraudulent claim or an obligation to pay or transmit money or property to the federal government; or knowingly concealing or knowingly and improperly avoiding or decreasing or concealing such an obligation. to pay money to the federal
government. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of these statutes or specific intent to violate them in order to have committed a violation. A claim that includes items or services
resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim under the FCA. Manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are
deemed to &#147;cause&#148; the submission of false or fraudulent claims. When an entity is determined to have violated the FCA, the government may impose civil fines and penalties for each false claim, plus treble damages, and exclude the entity
from participation in Medicare, Medicaid and other federal healthcare programs; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the U.S. federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal
criminal statutes that prohibit knowingly and willfully executing, or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, or obtain, by means of false or fraudulent pretenses, representations, or
promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or
device a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same to contain any materially false fictitious or fraudulent statement or
entry in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating HIPAA fraud provisions
without actual knowledge of the statute or specific intent to violate it; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, and their
respective implementing regulations, which impose requirements relating to the privacy, security and transmission of individually identifiable health information on certain covered healthcare providers, health plans and healthcare clearinghouses as
well as their respective business associates that perform services for them that involve the creation, use, receipt, maintenance or disclosure of individually identifiable health information, relating to the privacy, security and transmission of
individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates and gave state attorneys general new authority to
file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing federal civil actions. In addition, there may be additional federal, state and <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> laws which govern the privacy and security of health and other personal information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus
complicating compliance efforts; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the U.S. federal Physician Payments Sunshine Act, created under Patient Protection and Affordable Care Act, as amended by
the Health Care and Education Reconciliation Act of 2010, or collectively, the ACA, and its implementing regulations, which require manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare,
Medicaid or the Children&#146;s Health Insurance Program to report annually to the Centers for Medicare and Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS, under the Open Payments Program,
information related to direct or indirect payments and other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment
interests held by the physicians and their immediate family members. Effective January&nbsp;1, 2022, these reporting obligations will extend to include transfers of value made during the previous year to certain
<FONT STYLE="white-space:nowrap">non-physician</FONT> providers such as physician assistants and nurse practitioners; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">U.S. federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and
activities that potentially harm consumers; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">analogous U.S. state, local and foreign laws and regulations, such as state and foreign anti-kickback, false claims,
consumer protection and unfair competition laws which may apply to pharmaceutical business practices, including but not limited to, research, distribution, sales and marketing arrangements as well as submitting claims involving healthcare items or
services reimbursed by any third-party payor, including commercial insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and other relevant compliance guidance
promulgated by the federal government that otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to file reports with states regarding pricing and
marketing information, such as the tracking and reporting of gifts, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
compensations and other remuneration and items of value provided to healthcare professionals and entities; state and local laws requiring the registration of pharmaceutical sales representatives;
and state and foreign laws governing the privacy and security of health information, some of which may be more stringent than those in the United States (such as the European Union, which adopted the General Data Protection Regulation, which became
effective in May 2018) in certain circumstances, and may differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of
our business activities could be subject to challenge under one or more of such laws. Efforts to ensure that business arrangements comply with applicable healthcare laws involve substantial costs. It is possible that governmental and enforcement
authorities will conclude that our business practices do not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against
us and we are not successful in defending ourselves or asserting its rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, disgorgement,
imprisonment, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, reporting obligations and oversight if we become subject to integrity and oversight agreements to resolve allegations of
<FONT STYLE="white-space:nowrap">non-compliance,</FONT> contractual damages, reputational harm, diminished profits and future earnings and curtailment of operations, any of which could adversely affect our ability to operate our business and the
results of operations. In addition, commercialization of any drug product outside the United States will also likely be subject to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. Further, if any of the
physicians or other healthcare providers or entities with whom we expect to do business with are found to be not in compliance with applicable laws, they may be subject to similar penalties. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Other data privacy and security laws </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the United States,
numerous federal and state laws and regulations, including state data breach notification laws, state health information privacy laws and federal and state consumer protection laws, govern the collection, use, disclosure and protection of
health-related and other personal information outside of HIPAA and its implementing regulations. For example, in June 2018, the State of California enacted the California Consumer Privacy Act of 2018, or the CCPA, which came into effect on
January&nbsp;1, 2020 and provides new data privacy rights for consumers and new operational requirements for companies, which may increase our compliance costs and potential liability. The CCPA gives California residents expanded rights to access
and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used. The CCPA provides for civil penalties for violations, as well as a private right of
action for data breaches that is expected to increase data breach litigation. While there is currently an exception for protected health information that is subject to HIPAA and clinical trial regulations, as currently written, the CCPA may impact
certain of our business activities. The CCPA could mark the beginning of a trend toward more stringent state privacy legislation in the United States, which could increase our potential liability and adversely affect our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the event we decide to conduct clinical trials or continue to enroll subjects in our ongoing or future clinical trials, we may be subject to
additional privacy restrictions imposed by other countries and jurisdictions. The collection, use, storage, disclosure, transfer, or other processing of personal data regarding individuals in the European Economic Area, or EEA, including personal
health data, is subject to the EU General Data Protection Regulation, or GDPR, which became effective in May&nbsp;2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including
requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches and taking certain measures
when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EEA, including the United States, and permits data protection authorities to impose large penalties for violations of
the GDPR, including potential fines of up to <FONT STYLE="font-family:Times New Roman">&#128;</FONT>20&nbsp;million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer
associations to lodge complaints with supervisory authorities, seek judicial remedies and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR includes restrictions on cross-border data transfers. The GDPR may
increase our responsibility and liability in relation to personal data that we process where such processing is subject to the GDPR, and we may be required to put in place additional mechanisms to ensure compliance with the GDPR, including as
implemented by individual countries. Compliance with the GDPR will be a rigorous and time-intensive process that may increase our cost of doing business or require us to change our business practices and despite those efforts, there is a risk that
we may be subject to fines and penalties, litigation, and reputational harm in connection with our European activities. Further, the United Kingdom&#146;s decision to leave the EU, often referred to as Brexit, has created uncertainty with regard to
data protection regulation in the United Kingdom. In particular, it is unclear how data transfers to and from the United Kingdom will be regulated now that the United Kingdom has left the EU. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Current and future healthcare reform legislation </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
FDA&#146;s and other regulatory authorities&#146; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. For example, in December 2016, the 21st
Century Cures Act, or Cures Act, was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and devices and to spur innovation, but its ultimate implementation is uncertain. More recently, in August
2017, the FDA Reauthorization Act was signed into law to reauthorize the FDA&#146;s user fee programs and included additional drug and device provisions that build on the Cures Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, in both the United States and certain foreign jurisdictions, there have been, and likely will continue to be, a number of legislative and
regulatory changes regarding the health care system directed at broadening the availability of healthcare, improving the quality of healthcare and containing or lowering the cost of healthcare. For example, in March 2010 the ACA was enacted, which
substantially changed the way health care is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. The ACA, among other things, subjects biological products to potential competition by
lower-cost biosimilars, expands the types of entities eligible for the 340B drug discount program; introduced a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled,
infused, instilled, implanted or injected; increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extended the rebate program to individuals enrolled in Medicaid managed care organizations;
established annual fees and taxes on manufacturers of certain branded prescription drugs; and created a new Medicare Part&nbsp;D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the
Bipartisan Budget Act of 2018, or BBA, effective as of January 2019) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries
during their coverage gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part&nbsp;D. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Since its
enactment, there remain judicial, administrative, executive and legislative challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments to the ACA in the future. Various portions of the ACA are
currently undergoing legal and constitutional challenges in the United States Supreme Court; the Trump Administration has issued various Executive Orders which eliminated cost sharing subsidies and various provisions that would impose a fiscal
burden on states or a cost, fee, tax, penalty or regulatory burden on individuals, healthcare </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
providers, health insurers, or manufacturers of pharmaceuticals or medical devices; and Congress has introduced several pieces of legislation aimed at significantly revising or repealing the ACA.
Also, in December 2018, CMS issued a final rule permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program. Since then, the ACA risk adjustment
program payment parameters have been updated annually. It is unclear whether the ACA will be overturned, repealed, replaced, or further amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In
addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, in August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress.
A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic
reduction to several government programs, including aggregate reductions of Medicare payments to providers of up to 2% per fiscal year. These reductions went into effect on April&nbsp;1, 2013, and, due to subsequent legislative amendments, will
remain in effect through 2030 unless additional Congressional action is taken. However, pursuant to the Coronavirus Aid, Relief and Economic Security Act, or CARES Act, these Medicare sequester reductions under the Budget Control Act of 2011 will be
suspended from May&nbsp;1, 2020 through December&nbsp;31, 2020 due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. On January&nbsp;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things,
further reduced Medicare payments to several types of providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.
Additionally, the BBA, among other things, also amended the ACA, effective January&nbsp;1, 2019, by increasing the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discount (from 50% under the ACA to 70%)
that is owed by pharmaceutical manufacturers who participate in Medicare Part D and closing the coverage gap in most Medicare drug plans, commonly referred to as the &#147;donut hole&#148;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, CMS may develop new payment
and delivery models, such as bundled payment models. There also has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has
resulted in several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the
relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. For example, at the federal level, on March&nbsp;10, 2020, the Trump administration sent &#147;principles&#148; for
drug pricing to Congress, calling for legislation that would, among other things, cap Medicare Part&nbsp;D beneficiary <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> pharmacy expenses, provide an option
to cap Medicare Part&nbsp;D beneficiary monthly <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses and place limits on pharmaceutical price increases. Moreover, the U.S. Presidential administration
previously released a &#147;Blueprint&#148; to lower drug prices and reduce <FONT STYLE="white-space:nowrap">out-of-pocket</FONT> costs of drugs that contained proposals to increase manufacturer competition, increase the negotiating power of certain
federal healthcare programs, incentivize manufacturers to lower the list price of their products and reduce the out of pocket costs of drug products paid by consumers. HHS has solicited feedback on some of these measures and has implemented others
under its existing authority. For example, in May 2019, CMS issued a final rule that would allow Medicare Advantage Plans the option of using step therapy, a type of prior authorization, for Part B drugs beginning January&nbsp;1, 2020. This final
rule codified CMS&#146;s policy change that was effective January&nbsp;1, 2019. Although a number of these and other measures may require additional authorization to become effective, Congress and the U.S. Presidential administration have each
indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private
payers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">At the state level, legislatures in the United States have also increasingly passed legislation and
implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures and, in some
cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which
suppliers will be included in their prescription drug and other healthcare programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the European Union and in other foreign jurisdictions,
similar political, economic and regulatory developments may affect our ability to profitably commercialize our products. In addition to continuing pressure on prices and cost containment measures, legislative developments at the European Union or EU
member state level may result in significant additional requirements or obstacles that may increase our operating costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Legislative and regulatory
proposals, and enactment of laws, at the foreign, federal and state levels, directed at containing or lowering the cost of healthcare, will likely continue into the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Rest of world regulation </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For other countries outside of the
European Union and the United States, such as countries in Eastern Europe, Latin America or Asia, the requirements governing product development, the conduct of clinical trials, manufacturing, distribution, marketing approval, advertising and
promotion, product licensing, pricing and reimbursement vary from country to country. Additionally, clinical trials must be conducted in accordance with GCP requirements and the applicable regulatory requirements and the ethical principles that have
their origin in the Declaration of Helsinki. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we fail to comply with applicable foreign regulatory requirements, we may be subject to, among
other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Additionally, to the extent that any of our product candidates, once approved, are sold in a foreign country, we may be subject to applicable
post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or other transfers of value to healthcare professionals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Additional laws and regulations governing international operations </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If we further expand our operations outside of the United States, we must dedicate additional resources to comply with numerous laws and regulations in
each jurisdiction in which we plan to operate. The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering, authorizing payment or offering of anything of value, directly or indirectly, to any foreign
official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are
listed in the United States to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise
and maintain an adequate system of internal accounting controls for international operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Compliance with the FCPA is expensive and difficult,
particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other
hospital employees are considered by U.S. authorities that enforce the FCPA, including the Department of Justice, to be foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be
improper payments to government officials and have led to FCPA enforcement actions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Various laws, regulations and executive orders also restrict the use and dissemination outside of the
United States, or the sharing with certain <FONT STYLE="white-space:nowrap">non-U.S.</FONT> nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we expand
our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of
the United States, which could limit our growth potential and increase our development costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The failure to comply with laws governing
international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the
FCPA&#146;s accounting provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Coverage, pricing and reimbursement </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Significant uncertainty exists as to the coverage, pricing and reimbursement status of any products seeking regulatory approval. Successful
commercialization of new drug products depends in part on the extent to which coverage and reimbursement for those drug products will be available from government health administration authorities, private health insurers and other organizations.
The availability and extent of reimbursement depend substantially, both domestically and abroad, on the extent to which the costs of drugs products are paid for by third-party payors, such as government health care programs (e.g.,&nbsp;Medicare,
Medicaid), health maintenance organizations, managed care providers, pharmacy benefit and similar healthcare management organizations, private health coverage insurers and other third-party payors. These third-party payors decide which medications
they will pay for and will establish reimbursement levels. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the United States, the principal decisions about reimbursement for new drug products
are typically made by CMS. CMS decides whether and to what extent a new drug product will be covered and reimbursed under Medicare, and private payors tend to follow CMS to a substantial degree. Factors payors consider in determining reimbursement
are based on whether the product is: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">cost-effective; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the United States, no uniform policy of coverage and reimbursement for drug products exists among third-party payors and coverage and reimbursement
levels for drug products can differ significantly from payor to payor. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the reimbursement rate that the payor will pay for
the product. One payor&#146;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product. Third-party payors may also limit coverage to specific products on an
approved list, or formulary, which might not include all of the <FONT STYLE="white-space:nowrap">FDA-approved</FONT> products for a particular indication. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Various federal laws may impact the extent of coverage and reimbursement status provided by government health care programs. For instance, the Medicare
Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, established the Medicare Part&nbsp;D program to provide a voluntary prescription drug benefit to Medicare beneficiaries. Under Part&nbsp;D, Medicare beneficiaries may enroll
in prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs. While all Medicare drug plans must give at least a standard level of coverage set by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Medicare, Part&nbsp;D prescription drug plan sponsors are not required to pay for all covered Part D drugs, and each Part&nbsp;D prescription drug plan can develop its own drug formulary that
identifies which drugs it will cover and at what tier or level. However, Part&nbsp;D prescription drug formularies must include drugs within each therapeutic category and class of covered Part&nbsp;D drugs, though not necessarily all the drugs in
each category or class. Any formulary used by a Part&nbsp;D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for drugs
for which we obtain marketing approval. Any negotiated prices for any of our products covered by a Part&nbsp;D prescription drug plan will likely be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug
benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments
from <FONT STYLE="white-space:nowrap">non-governmental</FONT> payors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For a drug product to receive federal reimbursement under the Medicaid or
Medicare Part&nbsp;B programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program. The required 340B discount on a given product is
calculated based on the average manufacturer price, or AMP, and Medicaid rebate amounts reported by the manufacturer. As of 2010, the ACA expanded the types of entities eligible to receive discounted 340B pricing, although under the current state of
the law these newly eligible entities (with the exception of children&#146;s hospitals) will not be eligible to receive discounted 340B pricing on orphan drugs. As 340B drug pricing is determined based on average manufacturer price, or AMP, and
Medicaid rebate data, the revisions to the Medicaid rebate formula and AMP definition described above could cause the required 340B discount to increase. The American Recovery and Reinvestment Act of 2009 provides funding for the federal government
to compare the effectiveness of different treatments for the same illness. The plan for the research was published in 2012 by the Department of Health and Human Services, the Agency for Healthcare Research and Quality and the National Institutes for
Health and periodic reports on the status of the research and related expenditures are made to Congress. Although the results of the comparative effectiveness studies are not intended to mandate coverage policies for public or private payors, it is
not clear what effect, if any, the research will have on the sales of our product candidates, if any such drug or the condition that they are intended to treat are the subject of a trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">It is also possible that comparative effectiveness research, whether conducted by government or private entities, demonstrating benefits in a
competitor&#146;s drug could adversely affect the sales of our product candidate. If third-party payors do not consider our drugs to be cost-effective compared to other available therapies, they may not cover our drugs after approval as a benefit
under their plans or, if they do, the level of payment may not be sufficient to allow us to sell our drugs on a profitable basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition to
the above-mentioned laws, increasing efforts by third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and,
as a result, they may not cover or provide adequate payment for our product candidates. In order to secure coverage and reimbursement for any product that might be approved for sale, we may need to conduct expensive pharmacoeconomic studies in order
to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain FDA or comparable regulatory approvals. Additionally, we may also need to provide discounts to purchasers, private health plans
or government healthcare programs. Our product candidates, if approved, may nonetheless not be considered medically necessary or cost-effective. If third-party payors do not consider a product to be cost-effective compared to other available
therapies, they may not cover the product after approval as a benefit under their plans or, if they do, the level of payment may not be sufficient to allow a company to sell its products at a profit. We expect to experience pricing pressures from
third-party payors in connection with the potential sale of any of our product candidates </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Outside of the United States, the pricing of pharmaceutical products and medical devices is subject to
governmental control in many countries. For example, in the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed.
Some countries may require the completion of additional studies that compare the cost effectiveness of a particular therapy to currently available therapies or <FONT STYLE="white-space:nowrap">so-called</FONT> health technology assessments, in order
to obtain reimbursement or pricing approval. Other countries may allow companies to fix their own prices for products, but monitor and control product volumes and issue guidance to physicians to limit prescriptions. Efforts to control prices and
utilization of pharmaceutical products and medical devices will likely continue as countries attempt to manage healthcare expenditures. Historically, products launched in the European Union do not follow price structures of the United States and
generally prices tend to be significantly lower. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Employees </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of September&nbsp;30, 2020, we had 50 full-time employees and one part-time employee. Of our 51 employees, 24 have Ph.D. or M.D. degrees and 37 are
engaged in research and development activities. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Facilities </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We sublease a facility containing 6,374 square
feet of office space, which is located at One Broadway, Cambridge, Massachusetts 02142. Our sublease expires on December&nbsp;31, 2021. We believe that our current facilities are sufficient to meet our current and&nbsp;near-term&nbsp;needs and that,
should it be needed, suitable additional space will be available. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Legal Proceedings </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of the date of this prospectus, we are not party to any material legal matters or claims. We may become party to legal matters and claims arising in
the ordinary course of business. We cannot predict the outcome of any such legal matters or claims, and despite the potential outcomes, the existence thereof may have an adverse impact on us because of defense and settlement costs, diversion of
management resources and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom945651_13"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Executive Officers and Directors </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table sets
forth the name, age, and position of each of our current executive officers and directors as of September 30, 2020: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="42%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;Age&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Position</B></P></TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"><I>Executive Officers:</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Marcio Souza</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="center">41</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">President,&nbsp;Chief&nbsp;Executive&nbsp;Officer,&nbsp;Director</P></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Bernard Ravina, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="center">53</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Chief Medical Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stuart Chaffee, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="center">47</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Chief Financial Officer</P></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Alex Nemiroff, J.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="center">41</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General Counsel, Secretary</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Nicole Sweeny</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="center">45</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Chief Commercial Officer</P></TD></TR>
<TR STYLE="font-size:1pt" BGCOLOR="#d1fcfc">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors:</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dean Mitchell(2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="center">64</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Chairman, Director</P></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Nicholas Galakatos, Ph.D.(2)(3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="center">62</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Gregory Norden(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="center">62</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Director</P></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Ari Brettman, M.D.(4) </P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="center">38</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Thomas Dyrberg, M.D.(4)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="center">65</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Director</P></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Kiran Reddy, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="center">43</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Director</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stefan Vitorovic(1)(3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="center">35</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Director</P></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">William Young(1)(2)(3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="center">76</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Director</P></TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Member of the audit committee. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Member of the compensation committee. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Member of the nominating and corporate governance committee. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Each of Dr.&nbsp;Brettman and Dr.&nbsp;Dyrberg is expected to resign from our board of directors effective immediately
prior to, and contingent upon, the effectiveness of the registration statement of which this prospectus forms a part. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Executive Officers
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B><I>Marcio Souza</I></B> has served as a director and our President and Chief Executive Officer since April 2020. Prior to joining us,
Mr.&nbsp;Souza was at PTC Therapeutics, Inc., or PTC, where he served as its Chief Operating Officer from May 2017 to April 2020 and its Senior Vice President and Head of Product Strategy from July 2016 to May 2017. Prior to joining PTC,
Mr.&nbsp;Souza served in positions of increasing responsibility at NPS Pharmaceuticals, Inc., Shire Human Genetic Therapies Inc. and Sanofi Genzyme Corporation. From May 2019 to May 2020, Mr.&nbsp;Souza also served on the board of directors of
Clearpoint Neuro, Inc. (NASDAQ: CLPT) (previously MRI Interventions, Inc.). Mr.&nbsp;Souza received a degree in pharmacy and biochemistry with a specialization in toxicology and clinical analysis from the University of S&atilde;o Paulo and an M.B.A.
from Funda&ccedil;&atilde;o Dom Cabral. We believe Mr.&nbsp;Souza is qualified to serve on our board of directors because of his business and leadership experience in the life sciences industry and his scientific background. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B><I>Bernard Ravina, M.D.</I></B>,<B><I> </I></B>has served as our Chief Medical Officer since August 2018. Prior to joining us, Dr.&nbsp;Ravina was at
Voyager Therapeutics, Inc. (NASDAQ: VYGR), where he served as Chief Medical Officer from February 2017 to August 2018 and as Vice President of Clinical<B><I> </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Development from March 2014 to January 2017. Dr.&nbsp;Ravina was also Medical Director in Clinical Development at Biogen Inc. (NASDAQ: BIIB), or Biogen, from 2010 to 2014, where he worked on both
small molecule drugs and biologics for the treatment of neurological disorders. From 2005 to 2010, Dr.&nbsp;Ravina was an Associate Professor of Neurology, Director of the Movement and Inherited Neurological Disorders Unit, Associate Director of
Clinical Trials Coordination Center and Vice Chair of Neurology at the University of Rochester School of Medicine. Dr.&nbsp;Ravina received a B.A. in psychology from Columbia University, an M.D. from Johns Hopkins University School of Medicine and
an M.S.C.E. in clinical epidemiology from the University of Pennsylvania where he completed his residency and fellowship training in Neurology. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B><I>Stuart Chaffee, Ph.D.</I></B>, has served as our Chief Financial Officer since June 2020. Prior to his role as Chief Financial Officer,
Dr.&nbsp;Chaffee served as our Chief Business Officer from November 2017 to June 2020. Dr.&nbsp;Chaffee has an extensive background in drug discovery and development, including as an Entrepreneur in Residence at Atlas Venture from November 2015 to
November 2017 where he was a <FONT STYLE="white-space:nowrap">co-founder</FONT> and the Head of Business Operations at Kymera Therapeutics, Inc. from June 2016 to November 2017. From 2014 to 2015, Dr.&nbsp;Chaffee served as Senior Director of
Corporate Development at Biogen. Dr Chaffee received a B.S. in chemistry from The College of William and Mary, a Ph.D. in chemistry from Yale University and an M.B.A. in finance from the Wharton School of the University of Pennsylvania. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B><I>Alex Nemiroff, J.D.</I></B>, has served as our General Counsel since June 2020. Prior to his role as General Counsel, Mr.&nbsp;Nemiroff served as
our VP of Legal from January 2020 to June 2020.&nbsp;Mr.&nbsp;Nemiroff was also a <FONT STYLE="white-space:nowrap">co-founder</FONT> of RogCon, Inc. and RogCon U.R., Inc., and he has served as both entities&#146; Chief Executive Officer since
inception in November 2015.&nbsp;Mr.&nbsp;Nemiroff has experience working in commercial and securities litigation while at Greenberg Traurig LLP, and served as law clerk to the Honorable Paul C. Huck of the United States District Court for the
Southern District of Florida. Mr.&nbsp;Nemiroff received a B.B.A from the University of Michigan&#146;s Ross School of Business, and a J.D. from Northwestern University School of Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B><I>Nicole Sweeny</I></B> has served as our Chief Commercial Officer since August 2020. Prior to joining us, Ms. Sweeny was at Takeda Pharmaceuticals
(NYSE: TAK) where she served as a Vice President, Franchise Head, Rare Diseases from February 2019 to July 2020. Prior to Takeda, Ms.&nbsp;Sweeny served in several roles at Shire Pharmaceuticals plc (later acquired by Takeda Pharmaceuticals Company
Limited) from August 2010 to January 2019, including Vice President, Head of US Marketing from September 2017 to January 2019 and Vice President, Global Product Strategy Lead from December 2016 to August 2017. Prior to joining Shire, Ms. Sweeny
served in commercial positions of increasing responsibility at AMAG Pharmaceuticals and Sanofi Genzyme Corporation. Ms.&nbsp;Sweeny received her B.S. from Boston College. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B><I>Dean Mitchell</I></B> has served as chairman of our board of directors since September 2020. He served as executive chairman of the board of
directors of Covis Pharma Holdings, a specialty pharmaceutical company, from August 2013 until its sale in March 2020 and was chairman of PaxVax Corporation from January 2016 until its sale in October 2018. Mr. Mitchell served as President and Chief
Executive Officer of Lux Biosciences, Inc., a biotechnology company focusing on the treatment of ophthalmic diseases, from July 2010 to August 2013. Prior to Lux Biosciences, he served as President and Chief Executive Officer of both Alpharma, Inc.,
a publicly traded specialty pharmaceutical company, from 2006 until its acquisition by King Pharmaceuticals, Inc. in 2008, and Guilford Pharmaceuticals, Inc., a publicly traded pharmaceutical company focused in oncology and acute care, from 2004
until its acquisition by MGI Pharma Inc. in 2005. From 2001 to 2004, he served in various senior executive capacities in the worldwide medicines group of Bristol-Myers Squibb Company, a pharmaceutical company. Prior to the Bristol-Myers Squibb
Company, he spent 14 years at GlaxoSmithKline plc, in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
assignments of increasing responsibility spanning sales, marketing, general management, commercial strategy and clinical development and product strategy. Mr. Mitchell currently serves on the
board of directors of Theravance Biopharma, Inc. (NASDAQ: TBPH), ImmunoGen Inc. (NASDAQ: IMGN) and Precigen Inc. (formerly Intrexon Inc.) (NASDAQ: PGEN). Mr.&nbsp;Mitchell holds an M.B.A. from City University London and a B.Sc. in biology from
Coventry University. We believe Mr. Mitchell is qualified to serve on our board of directors because of his management experience in the pharmaceutical and biotherapeutics industries and his experience as a President, Chief Executive Officer and
board member of multiple biotechnology companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B><I>Nicholas Galakatos, Ph.D.</I></B>,<B><I> </I></B>has served as a member our board of
directors since September 2015. Dr.&nbsp;Galakatos is the Global Head of Life Sciences of The Blackstone Group Inc., or Blackstone. Prior to joining Blackstone, Dr.&nbsp;Galakatos was a <FONT STYLE="white-space:nowrap">co-Founder</FONT> and Managing
Director of Clarus Ventures, LLC (acquired by Blackstone in 2018), or Clarus, since the firm&#146;s inception in 2005. Dr.&nbsp;Galakatos is currently the chairman of the board of directors of Anthos Therapeutics, Inc., or Anthos, a private,
clinical-stage cardiovascular biotech founded in 2019, and a member of the board of directors of Talaris, Inc. He is a member of the Director&#146;s Council of the Koch Institute at MIT and a member of the Board of Trustees at Reed College.
Dr.&nbsp;Galakatos received a B.A. in chemistry from Reed College and a Ph.D. in organic chemistry from the Massachusetts Institute of Technology. We believe Dr.&nbsp;Galakatos is qualified to serve on our board of directors because of his business
and leadership experience in the life sciences industry and his scientific background. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B><I>Gregory Norden </I></B>is the former Chief Financial
Officer of Wyeth and has served as a member of our board of directors since March 2019. Mr.&nbsp;Norden currently serves as the Managing Director of G9 Capital Group LLC, which invests in early stage ventures and provides corporate finance advisory
services, since 2010. Mr.&nbsp;Norden currently serves on the boards of directors of Zoetis (NYSE: ZTS), the leading animal health company, NanoString Technologies (NASDAQ: NSTG), a leading provider of life science tools for translational research,
Royalty Pharma (NASDAQ: RPRX), a leading funder of innovation across the biopharmaceutical industry, and Univision Communications, the leading multimedia company serving Hispanic America. Mr.&nbsp;Norden is a former director of Human Genome
Sciences, Welch Allyn and Entasis Therapeutics. Mr.&nbsp;Norden received a B.S. in management and economics from the State University of New York at Plattsburgh and an M.S. in accounting from Long Island University&#151;C.W. Post. We believe
Mr.&nbsp;Norden is qualified to serve on our board of directors because of his background in finance and experience as a senior executive in the global healthcare and pharmaceutical industries, as well as his public company board experience. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B><I>Ari Brettman, M.D.</I></B>, one of our <FONT STYLE="white-space:nowrap">co-founders,</FONT> has served as a member of our board of directors since
March 2018. Dr.&nbsp;Brettman is also currently a Managing Director at Blackstone, a position he has held since January 2020. Previously, Dr.&nbsp;Brettman served as a Principal at Blackstone from January 2017 to December 2019, and as an Associate
from September 2014 to December 2016. Additionally, Dr.&nbsp;Brettman is a <FONT STYLE="white-space:nowrap">co-founder</FONT> of Anthos Therapeutics, Inc., or Anthos, and served as Anthos&#146;s Chief Medical Officer until July 2019.
Dr.&nbsp;Brettman received an A.B. in history and science from Harvard College and an M.D. from Duke University. Dr.&nbsp;Brettman expects to resign from our board of directors effective immediately prior to, and contingent upon, the effectiveness
of the registration statement of which this prospectus forms a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B><I>Thomas Dyrberg, M.D.</I></B>, has served as a member of our board of
directors since March 2018. In December 2000, Dr.&nbsp;Dyrberg joined Novo Holdings A/S, or Novo, then known as Novo A/S, a Danish limited liability company that manages investments and financial assets, where he was employed as Senior Partner.
Since August 2015, Dr. Dyrberg has been employed as a Managing Partner of Novo. From August 2007 to May 2019, Dr.&nbsp;Dyrberg was a member of the board of directors of Ophthotech Corp. (now IVERIC bio, Inc. (NASDAQ: ISEE)). Dr.&nbsp;Dyrberg
previously served on the board of directors of Veloxis A/S, a publicly traded specialty pharmaceutical company. Dr.&nbsp;Dyrberg has held research </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">positions at the
Hagedorn Research Institute in Denmark and at the Scripps Research </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Institute in California. Dr.&nbsp;Dyrberg received a D.M.Sc. and an M.D. from the University of Copenhagen. Dr.&nbsp;Dyrberg expects to resign from our board of directors effective immediately
prior to, and contingent upon, the effectiveness of the registration statement of which this prospectus forms a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B><I>Kiran Reddy,
M.D.</I></B><B></B>,<B></B> has served as a member of our board of directors since September 2015. Prior to his role as our director, Dr.&nbsp;Reddy served as our President and Chief Executive Officer from November 2015 to April 2020. Dr.&nbsp;Reddy
is also currently a Managing Director at Blackstone, a position he has served in since May 2020. Dr.&nbsp;Reddy was a venture partner at Clarus from November 2015 to November 2019 prior to its acquisition by Blackstone. From 2014 to 2015,
Dr.&nbsp;Reddy served as part of Biogen&#146;s Corporate Strategy leadership team, where he focused on sourcing new technologies and product opportunities to support the Company&#146;s growth. Dr.&nbsp;Reddy was previously a Howard Hughes science
fellow and has authored several peer-reviewed scientific papers in the field of epilepsy, neuroimmunology and neurodegenerative diseases. Dr.&nbsp;Reddy received a B.S. in economics, an M.D. and an M.B.A. from Georgetown University. We believe
Dr.&nbsp;Reddy is qualified to serve on our board of directors because of his corporate leadership experience, business background, and perspective and experience as one of Praxis&#146; former executive officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B><I>Stefan Vitorovic</I></B> has served as a member of our board of directors since March 2018 . Mr.&nbsp;Vitorovic is the <FONT
STYLE="white-space:nowrap">co-founder</FONT> and Managing Director of Vida Ventures, LLC, or Vida Ventures, a role he has served in since January 2017. Prior to Vida Ventures, Mr.&nbsp;Vitorovic was a Principal at Third Rock Ventures, where he was
employed from July 2014 to January 2017. Prior to Third Rock Ventures, Mr.&nbsp;Vitorovic was a healthcare private equity investor at TPG Capital from August 2012 to June 2014. Mr.&nbsp;Vitorovic received a B.S. with honors in molecular&nbsp;&amp;
cellular biology and an M.S. in molecular&nbsp;&amp; cellular biology from Stanford University as well as an M.B.A from Harvard University. We believe Mr.&nbsp;Vitorovic is qualified to serve on our board of directors because of his scientific
background and business experience. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B><I>William Young</I></B> has served as a member of our board of directors since December 2016.
Mr.&nbsp;Young is a Senior Advisor with Blackstone. Prior to its acquisition by Blackstone, Mr.&nbsp;Young joined Clarus in March 2010 and held various roles, including Venture Partner, Senior Advisor and portfolio company board member.
Mr.&nbsp;Young currently serves as the chairman of the board of directors of Annexon, Inc. (NASDAQ: ANNX) and NanoString, and as a member of the board of directors of Theravance BioPharma Inc. (NASDAQ: TBPH). Mr.&nbsp;Young also served on the boards
of directors of Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) from May 2015 to June 2020 and BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from September 2010 to November 2015. Mr. Young was elected to the National Academy of Engineering in 1993 for his
contributions to biotechnology. Mr.&nbsp;Young received a B.S. in chemical engineering from Purdue University and an M.B.A. from Indiana University in marketing and finance and holds an honorary doctorate in engineering from Purdue University. We
believe Mr.&nbsp;Young is qualified to serve on our board of directors because of his scientific background, business experience and his service on the board of directors of other life sciences companies </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Family Relationships </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">There are no family relationships
among any of our executive officers or directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Composition of Our Board of Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors currently consists of nine members, each of whom are members pursuant to the board composition provisions of our amended and
restated certificate of incorporation and agreements with our stockholders, which agreements are described under &#147;Certain Relationships and Related Party Transactions.&#148; These board composition provisions will terminate upon the closing of
this offering. Upon the termination of these provisions, there will be no further contractual obligations </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
regarding the election of our directors. Our nominating and corporate governance committee and our board of directors may therefore consider a broad range of factors relating to the
qualifications and background of nominees, which may include diversity, which is not only limited to race, gender or national origin. Our nominating and corporate governance committee&#146;s and our board of directors&#146; priority in selecting
board members is identification of persons who will further the interests of our stockholders through his or her established record of professional accomplishment, the ability to contribute positively to the collaborative culture among board
members, knowledge of our business, understanding of the competitive landscape and professional and personal experiences and expertise relevant to our growth strategy. Our directors hold office until their successors have been elected and qualified
or until the earlier of their resignation or removal. Our amended and restated certificate of incorporation and amended and restated bylaws that will become effective upon the closing of this offering also provide that our directors may be removed
only for cause by the affirmative vote of the holders of at least 66.67% of the votes that all our stockholders would be entitled to cast in an annual election of directors, and that any vacancy on our board of directors, including a vacancy
resulting from an enlargement of our board of directors, may be filled only by vote of a majority of our directors then in office. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Director Independence
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Nasdaq Stock Market LLC, or Nasdaq, Marketplace Rules, or the Nasdaq Listing Rules, require a majority of a listed company&#146;s board
of directors to be comprised of independent directors within one year of listing. In addition, the Nasdaq Listing Rules require that, subject to specified exceptions and phase in periods following the initial public offering, each member of a listed
company&#146;s audit, compensation and nominating and corporate governance committees be independent under the Securities Exchange Act of 1934, as amended, or the Exchange Act. Audit committee members must also satisfy the independence criteria set
forth in <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3</FONT> under the Exchange Act and compensation committee members must also satisfy the independence criteria set forth in <FONT STYLE="white-space:nowrap">Rule&nbsp;10C-1</FONT> under the
Exchange Act. Under the Nasdaq Listing Rules, a director will only qualify as an &#147;independent director&#148; if, in the opinion of the listed company&#146;s board of directors, that person does not have a relationship that would interfere with
the exercise of independent judgment in carrying out the responsibilities of a director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In order to be considered independent for purposes of <FONT
STYLE="white-space:nowrap">Rule&nbsp;10A-3,</FONT> a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors, or any other board committee:
(1)&nbsp;accept, directly or indirectly, any consulting, advisory, or other compensatory fee from the listed company or any of its subsidiaries; or (2)&nbsp;otherwise be an affiliated person of the listed company or any of its subsidiaries. In order
to be considered independent for purposes of <FONT STYLE="white-space:nowrap">Rule&nbsp;10C-1,</FONT> the board must consider, for each member of a compensation committee of a listed company, all factors specifically relevant to determining whether
a director has a relationship to such company which is material to that director&#146;s ability to be independent from management in connection with the duties of a compensation committee member, including, but not limited to: (1)&nbsp;the source of
compensation of the director, including any consulting, advisory or other compensatory fee paid by such company to the director; and (2)&nbsp;whether the director is affiliated with the company or any of its subsidiaries or affiliates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In September 2020, our board of directors undertook a review of the composition of our board of directors and its committees and the independence of
each director. Based upon information requested from and provided by each director concerning his or her background, employment and affiliations, including family relationships, our board of directors has determined that each of our directors, with
the exception of , is an &#147;independent director&#148; as defined under the Nasdaq Listing Rules. In making such determination, our board of directors considered the relationships that each such
<FONT STYLE="white-space:nowrap">non-employee</FONT> director has with our company and all other facts and circumstances that our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
board of directors deemed relevant in determining his or her independence, including the beneficial ownership of our capital stock by each <FONT STYLE="white-space:nowrap">non-employee</FONT>
director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Staggered Board </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In accordance with
the terms of our amended and restated certificate of incorporation and amended and restated bylaws that will become effective upon the closing of this offering, will provide that the number of our directors shall be fixed from time to time by a
resolution of the majority of our board of directors and that our board of directors will be divided into three staggered classes of directors and each director will be assigned to one of the three classes. At each annual meeting of the
stockholders, a class of directors will be elected for a three-year term to succeed the directors of the same class whose terms are then expiring. The terms of the directors will expire upon the election and qualification of successor directors at
the annual meeting of stockholders to be held during the years 2021 for Class&nbsp;I directors, 2022 for Class&nbsp;II directors and 2023 for Class&nbsp;III directors. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our Class&nbsp;I director will be Dean Mitchell; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our Class&nbsp;II directors will be Nicholas Galakatos, Ph.D., Kiran Reddy, M.D., and Stefan Vitorovic; and
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Our Class&nbsp;III directors will be Gregory Norden, Marcio Souza and William Young. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The division of our board of directors into three classes with staggered three-year terms may delay or prevent stockholder efforts to effect a change of
our management or a change in control. See the &#147;Description of Capital Stock&#151;Anti-Takeover Effects of Delaware Law, Our Amended and Restated Certificate of Incorporation and Our Amended and
<FONT STYLE="white-space:nowrap">Restated&nbsp;By-Laws&#148;&nbsp;section</FONT> of this prospectus for a discussion of these and other anti-takeover provisions found in our third amended and restated certificate of incorporation and amended and
restated&nbsp;bylaws,&nbsp;which will become effective immediately prior to the completion of this offering. We expect that additional directorships resulting from an increase in the number of directors, if any, will be distributed among the three
classes so that, as nearly as possible, each class shall consist of one third of the board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Board Leadership Structure and the Role of the Board
in Risk Oversight </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Board Leadership Structure </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The positions of our chairman of the board and chief executive officer are separated, with Mr.&nbsp;Souza serving as our Chief Executive Officer and Mr.
Mitchell serving as the chairman of our board of directors. Separating these positions allows Mr.&nbsp;Souza, as our Chief Executive Officer, to focus on our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT>
business, while allowing the chairman of the board to lead the board of directors in its fundamental role of providing advice to and independent oversight of management. Our board of directors recognizes the time, effort and energy that
Mr.&nbsp;Souza, as our Chief Executive Officer, must devote to his position in the current business environment, as well as the commitment required to serve as our chairman, particularly as the board of directors&#146; oversight responsibilities
continue to grow. Our board of directors also believes that this structure ensures a greater role for the independent directors in the oversight of our company and active participation of the independent directors in setting agendas and establishing
priorities and procedures for the work of our board of directors. Our board of directors believes its administration of its risk oversight function has not affected its leadership structure. Our board of directors believes that having separate
positions is the appropriate leadership structure for us at this time and demonstrates our commitment to good corporate governance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Role of the Board in
Risk Oversight </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Risk is inherent with every business, and how well a business manages risk can ultimately determine its success. We face a
number of risks, including those described under the section titled </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
&#147;Risk Factors&#148; in this prospectus. Our board of directors is actively involved in oversight of risks that could affect us. This oversight is conducted primarily by our full board of
directors, which has responsibility for general oversight of risks. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Following the closing of this offering, our board of directors will satisfy
this responsibility through full reports by each committee chair regarding the committee&#146;s considerations and actions, as well as through regular reports directly from officers responsible for oversight of particular risks within our company.
Our board of directors believes that full and open communication between management and the board of directors is essential for effective risk management and oversight. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Committees of Our Board of Directors </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors
has established an audit committee, a compensation committee and a nominating and corporate governance committee, each of which will operate pursuant to a charter to be adopted by our board of directors and will be effective upon the effectiveness
of the registration statement of which this prospectus is a part. Our board of directors may establish other committees to facilitate the management of our business. Upon the effectiveness of the registration statement of which this prospectus is a
part, the composition and functioning of all of our committees will comply with all applicable requirements of the Sarbanes-Oxley Act of 2002, Nasdaq and U.S. Securities and Exchange Commission rules and regulations. Members will serve on these
committees until their resignation or until otherwise determined by our board of directors. In addition, from time to time, special committees may be established under the direction of our board of directors when necessary to address specific
issues. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Audit Committee </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Effective upon the
completion of this offering, Gregory Norden, Stefan Vitorovic and William Young will serve on the audit committee, which will be chaired by Gregory Norden. Our board of directors has determined that Gregory Norden, Stefan Vitorovic and William Young
are &#147;independent&#148; for audit committee purposes as that term is defined in the rules of the SEC and the applicable Nasdaq rules, and each has sufficient knowledge in financial and auditing matters to serve on the audit committee. Our board
of directors has designated Gregory Norden as an &#147;audit committee financial expert,&#148; as defined under the applicable rules of the SEC. The audit committee&#146;s responsibilities upon closing of this offering include: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">appointing, approving the compensation of and assessing the independence of our independent registered public accounting
firm; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><FONT STYLE="white-space:nowrap">pre-approving</FONT> auditing and permissible
<FONT STYLE="white-space:nowrap">non-audit</FONT> services, and the terms of such services, to be provided by our independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing the overall audit plan with our independent registered public accounting firm and members of management
responsible for preparing our financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and discussing with management and our independent registered public accounting firm our annual and quarterly
financial statements and related disclosures as well as critical accounting policies and practices used by us; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">coordinating the oversight and reviewing the adequacy of our internal control over financial reporting;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establishing policies and procedures for the receipt and retention of accounting-related complaints and concerns;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">recommending based upon the audit committee&#146;s review and discussions with management and our independent registered
public accounting firm whether our audited financial statements shall be included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K;</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">monitoring the integrity of our financial statements and our compliance with legal and regulatory requirements as they
relate to our financial statements and accounting matters; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">preparing the audit committee report required by SEC rules to be included in our annual proxy statement;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing all related person transactions for potential conflict of interest situations and approving all such
transactions; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing quarterly earnings releases. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Compensation Committee </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Effective upon the completion
of this offering, Nicholas Galakatos, Dean Mitchell and William Young will serve on the compensation committee, which will be chaired by William Young. Our board of directors has determined that Nicholas Galakatos, Dean Mitchell and William Young
are independent&#148; as defined in the applicable Nasdaq rules. The compensation committee&#146;s responsibilities upon closing of this offering include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">annually reviewing and approving corporate goals and objectives relevant to the compensation of our chief executive
officer; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">evaluating the performance of our chief executive officer in light of such corporate goals and objectives and determining
the compensation of our chief executive officer; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and approving the compensation of our other executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and establishing our overall management compensation, philosophy and policy; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">overseeing and administering our compensation and similar plans; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">evaluating and assessing potential and current compensation advisors in accordance with the independence standards
identified in the applicable Nasdaq rules; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">retaining and approving the compensation of any compensation advisors; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and approving our policies and procedures for the grant of equity-based awards; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">evaluating director compensation and making recommendations on director compensation to the Board; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">preparing the compensation committee report required by SEC rules, if and when required, to be included in our annual proxy
statement; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing and approving the retention or termination of any consulting firm or outside advisor to assist in the evaluation
of compensation matters. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Nominating and Corporate Governance Committee </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Effective upon the completion of this offering, Nicholas Galakatos, Stefan Vitorovic and William Young will serve on the nominating and corporate
governance committee, which will be chaired by Nicholas Galakatos. Our board of directors has determined that Nicholas Galakatos, Stefan Vitorovic and William Young are &#147;independent&#148; as defined in the applicable Nasdaq rules. The
nominating and corporate governance committee&#146;s responsibilities upon closing of this offering include: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">developing and recommending to the board of directors criteria for board and committee membership; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">establishing procedures for identifying and evaluating board of director candidates, including nominees recommended by
stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">reviewing the size and composition of the board of directors to ensure that it is composed of members containing the
appropriate skills and expertise to advise us; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">identifying individuals qualified to become members of the board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">recommending to the board of directors the persons to be nominated for election as directors and to each of the
board&#146;s committees; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">developing and recommending to the board of directors a code of business conduct and ethics and a set of corporate
governance guidelines; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">overseeing the evaluation of our board of directors and management. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors may from time to time establish other committees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Compensation Committee Interlocks and Insider Participation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">None of the members of our compensation committee has at any time during the prior three years been one of our officers or employees. None of our
executive officers currently serves, or in the past fiscal year has served, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving on our board of directors or compensation
committee. For a description of transactions between us and members of our compensation committee and affiliates of such members, please see &#147;Certain Relationships and Related Party Transactions.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Code of Business Conduct and Ethics </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We plan to adopt a
written code of business conduct and ethics that applies to all of our employees, officers and directors, including those officers responsible for financial reporting, which will become effective upon closing of this offering. Upon the closing of
this offering, our code of business conduct and ethics will be available on the Corporate Governance section of our website at https://praxismedicines.com. We intend to disclose any amendments to the code, or any waivers of its requirements, on our
website or in a Current Report on <FONT STYLE="white-space:nowrap">Form&nbsp;8-K</FONT> as may be required by SEC or Nasdaq rules. We do not incorporate the information on or accessible through our website into this prospectus, and you should not
consider any information on, or that can be accessed through, our website as part of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom945651_14"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Executive Compensation Overview </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following discussion
contains forward looking statements that are based on our current plans, considerations, expectations and determinations regarding future compensation programs. The actual amount and form of compensation and the compensation policies and practices
that we adopt in the future may differ materially from currently planned programs as summarized in this discussion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As an emerging growth company,
we have opted to comply with the executive compensation disclosure rules applicable to &#147;smaller reporting companies,&#148; as such term is defined in the rules promulgated under the Securities Act of 1933, as amended, or the Securities Act. The
compensation provided to our named executive officers for the fiscal year ended December 31, 2019 is detailed in the 2019 Summary Compensation Table and accompanying footnotes and narrative that follow. Our named executive officers for the fiscal
year ended December&nbsp;31, 2019 were: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Kiran Reddy, M.D., our former President and Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Stuart Chaffee, Ph.D., our current Chief Financial Officer and former Chief Business Officer; and </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Bernard Ravina, M.D., our Chief Medical Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In April 2020, Dr.&nbsp;Reddy resigned as our President and Chief Executive Officer and Marcio Souza became our President and Chief Executive Officer.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To date, the compensation of our named executive officers has consisted of a combination of base salary, bonuses and long-term incentive
compensation in the form of stock options. Our named executive officers, like all full-time employees, are eligible to participate in our health and welfare benefit plans. As we transition from a private company to a publicly traded company, we
intend to evaluate our compensation values and philosophy and compensation plans and arrangements as circumstances require. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>2019 Summary Compensation Table
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table sets forth information regarding compensation awarded to, earned by or paid to our named executive officers for services
rendered to us in all capacities during the fiscal year ended December&nbsp;31, 2019. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Salary ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Bonus<BR>($)(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Non-Equity</FONT><BR>Incentive Plan<BR>Compensation<BR>($)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)(3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt" BGCOLOR="#d1fcfc">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Kiran Reddy, M.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><I>Former President&nbsp;and Chief Executive Officer(4)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">385,500</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">190,823</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">576,592</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stuart Chaffee, Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><I>Chief Financial Officer and former Chief Business Officer(5)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">308,250</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">83,228</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">297</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">391,775</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt" BGCOLOR="#d1fcfc">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Bernard Ravina, M.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><I>Chief Medical Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2019</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">75,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">126,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">271</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">551,271</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Amount represents a $75,000 bonus paid to Dr.&nbsp;Ravina pursuant to the terms of his offer letter with us.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Amounts represent annual cash bonuses paid based on achievement of <FONT STYLE="white-space:nowrap">pre-determined</FONT>
corporate performance metrics in 2019, which were paid in March 2020. The corporate performance metrics were achieved at 90% of target. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Amounts represent tax <FONT STYLE="white-space:nowrap">gross-ups</FONT> on taxable long-term disability and commuter
benefits in the following amounts: Dr.&nbsp;Reddy&#151;$65 for long-term disability benefits and $204 for commuter benefits; Dr.&nbsp;Chaffee&#151;$92 for long-term disability benefits and $205 for commuter benefits; and Dr.&nbsp;Ravina&#151;$66 for
long-term disability benefits and $205 for commuter benefits. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Dr.&nbsp;Reddy resigned as our President and Chief Executive Officer effective April&nbsp;20, 2020.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Effective as of May&nbsp;28, 2020, Dr.&nbsp;Chaffee was appointed Chief Financial Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Narrative to the 2019 Summary Compensation Table </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Base Salaries
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each named executive officer&#146;s base salary is a fixed component of annual compensation for performing specific duties and functions,
and has been established by our board of directors taking into account each individual&#146;s role, responsibilities, skills and expertise. Base salaries are reviewed annually, typically in connection with our annual performance review process,
approved by our board of directors and adjusted from time to time to realign salaries with market levels after taking into account individual responsibilities, performance and experience. During 2019, the annual base salaries for Dr.&nbsp;Reddy,
Dr.&nbsp;Chaffee, and Dr.&nbsp;Ravina, were $385,500, $308,250 and $350,000, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Annual Bonus </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For the fiscal year ended December&nbsp;31, 2019, each of our named executive officers was eligible to earn an annual bonus based on the achievement of
certain <FONT STYLE="white-space:nowrap">pre-determined</FONT> corporate performance objectives. During 2019, the target annual bonuses for Dr.&nbsp;Reddy, Dr.&nbsp;Chaffee, and Dr.&nbsp;Ravina, were 55%, 30% and 40% of their base salary,
respectively. The annual bonus earned by each named executive officer with respect to the fiscal year ended December&nbsp;31, 2019 is reported under the <FONT STYLE="white-space:nowrap">&#147;Non-Equity</FONT> Incentive Plan Compensation&#148;
column in the &#147;2019 Summary Compensation Table&#148; above and was determined based upon achievement of the corporate performance objectives at 90% of target. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Equity Compensation </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Although we do not have a formal
policy with respect to the grant of equity incentive awards to our executive officers, we believe that equity grants provide our executives with a strong link to our long-term performance, create an ownership culture and help to align the interests
of our executives and our stockholders. In addition, we believe that equity grants promote executive retention because they incentivize our executive officers to remain in our employment during the vesting period. Accordingly, our board of directors
periodically reviews the equity incentive compensation of our named executive officers and may grant equity incentive awards to them from time to time. Our named executive officers have been granted certain options to purchase shares of our common
stock, as described in more detail in the &#147;Outstanding Equity Awards at 2019 Fiscal <FONT STYLE="white-space:nowrap">Year-end&#148;</FONT> table below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Employment Arrangements with our Named Executive Officers </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We initially entered into an offer letter with each of the named executive officers in connection with his employment with us, which set forth the terms
and conditions of his employment, including base salary, target annual bonus opportunity and initial equity awards. In April 2020, we entered into employment agreements with Dr.&nbsp;Chaffee and Dr.&nbsp;Ravina that replaced the offer letters and
provided for specified payments and benefits in connection with a termination of employment in certain circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We intend to enter into
amended and restated employment agreements with Dr.&nbsp;Chaffee and Dr.&nbsp;Ravina that will be effective as of the closing of this offering, or the New Employment Agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
The New Employment Agreements will replace the employment agreements entered into in April 2020 and will provide for specified payments and benefits in connection with a termination of employment
in certain circumstances. Our goal in providing these specified payments is to offer sufficient cash continuity protection such that the named executive officers will focus their full time and attention on the requirements of the business rather
than the potential implications for their respective positions. We prefer to have certainty regarding the potential severance amounts payable to the named executive officers, rather than negotiating severance at the time that a named executive
officer&#146;s employment terminates. We have also determined that accelerated vesting provisions with respect to outstanding equity awards in connection with a qualifying termination of employment in certain circumstances are appropriate because
they encourage our named executive officers to stay focused on the business in those circumstances, rather than focusing on the potential implications for them personally. The material terms of the offer letter with Dr.&nbsp;Reddy and the New
Employment agreements with Dr.&nbsp;Chaffee and Dr.&nbsp;Ravina are summarized below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Kiran Reddy, M.D.</I> Dr.&nbsp;Reddy resigned as our
President and Chief Executive Officer effective April&nbsp;20, 2020. In connection with the commencement of his employment with us, Clarus Ventures entered into an offer letter with Dr.&nbsp;Reddy to serve as Chief Executive Officer of our company,
which set forth his initial annual base salary, target bonus and initial equity award. In addition, the offer letter provided that, if he transitioned from the position of Chief Executive Officer of our company for good reason, he would have the
opportunity to join Clarus Ventures as a venture partner at his current compensation for a period of one year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Stuart Chaffee, Ph.D.</I> Under
the New Employment Agreement with Dr.&nbsp;Chaffee, Dr.&nbsp;Chaffee will continue to serve as our Chief Financial Officer on an at-will basis. Dr.&nbsp;Chaffee&#146;s current annual base salary is $330,000, which is subject to annual review, and he
is eligible to earn an annual bonus with a target amount equal to 30% of his base salary. Dr.&nbsp;Chaffee is also eligible to participate in the employee benefit plans available to our employees, subject to the terms of those plans. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Bernard Ravina, M.D.</I> Under the New Employment Agreement with Dr.&nbsp;Ravina, Dr.&nbsp;Ravina will continue to serve as our Chief Medical Officer
on an at-will basis. Dr.&nbsp;Ravina&#146;s current annual base salary is $425,000, which is subject to annual review, and he is eligible to earn an annual bonus with a target amount equal to 40% of his base salary. Dr.&nbsp;Ravina is also eligible
to participate in the employee benefit plans available to our employees, subject to the terms of those plans. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pursuant to the New Employment
Agreements, in the event that Dr.&nbsp;Chaffee or Dr.&nbsp;Ravina&#146;s employment is terminated by us without &#147;cause&#148; or Dr.&nbsp;Chaffee or Dr.&nbsp;Ravina resigns for &#147;good reason&#148; (as each term shall be defined in the New
Employment Agreements), subject to the execution and effectiveness of a separation agreement, including a general release of claims in our favor, Dr.&nbsp;Chaffee or Dr.&nbsp;Ravina, as applicable, (i) will be entitled to receive base salary
continuation for nine months following termination, and (ii)&nbsp;subject to the executive&#146;s copayment of premium amounts at the applicable active employees&#146; rate and proper election to continue COBRA health coverage, we will cover the
portion of the premium amount equal to the amount that we would have paid to provide health insurance to the executive had he remained employed with us until the earliest of (A)&nbsp;nine months following termination, (B)&nbsp;the executive&#146;s
eligibility for group medical plan benefits under any other employer&#146;s group medical plan or (C)&nbsp;the end of the executive&#146;s COBRA health continuation period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In lieu of the payments and benefits described in the preceding sentence, in the event Dr.&nbsp;Chaffee or Dr.&nbsp;Ravina&#146;s employment is
terminated by us without cause or Dr.&nbsp;Chaffee or Dr.&nbsp;Ravina resigns for good reason, in either case on or within 12&nbsp;months following a &#147;change of control&#148; (as such term shall be defined in the New Employment Agreements),
subject to the execution and effectiveness of a separation agreement, including a general release of claims in our favor, (i)&nbsp;the executive will be entitled to receive a lump sum in cash equal to one times the sum of (A)&nbsp;the
executive&#146;s then-current </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
annual base salary (or the executive&#146;s annual base salary in effect immediately prior to the change of control, if higher) plus (B)&nbsp;the executive&#146;s target annual cash incentive
compensation for the year of termination (or the executive&#146;s target annual cash incentive compensation in effect immediately prior to the change of control, if higher), (ii)&nbsp;subject to the executive&#146;s copayment of premium amounts at
the applicable active employees&#146; rate and proper election to continue COBRA health coverage, we will cover the portion of the premium amount equal to the amount that we would have paid to provide health insurance to the executive had such
executive remained employed with us until the earliest of (A)&nbsp;12&nbsp;months following termination, (B)&nbsp;the executive&#146;s eligibility for group medical plan benefits under any other employer&#146;s group medical plan or (C)&nbsp;the end
of the executive&#146;s COBRA health continuation period, and (iii)&nbsp;the vesting of 100% of all stock options and other stock-based awards subject solely to time-based vesting held by the executive shall be accelerated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The payments and benefits provided to each of the executives in connection with a change of control may not be eligible for a federal income tax
deduction for the company pursuant to Section&nbsp;280G of the Code and may subject the executive to an excise tax under Section&nbsp;4999 of the Code. If the payments or benefits payable to the executive in connection with a change of control would
be subject to the excise tax on golden parachutes imposed under Section&nbsp;4999 of the Code, then those payments or benefits will be reduced if such reduction would result in a higher net after-tax benefit to the executive. We initially entered
into an offer letter with each of the named executive officers in connection with his employment with us, which set forth the terms and conditions of his employment, including base salary, target annual bonus opportunity and initial equity awards.
In April 2020, we entered into employment agreements with Dr.&nbsp;Chaffee and Dr.&nbsp;Ravina that replaced the offer letters and provided for specified payments and benefits in connection with a termination of employment in certain circumstances.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Outstanding Equity Awards at 2019 Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table sets forth information regarding outstanding equity awards held by our named executive officers as of December&nbsp;31, 2019. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option Awards</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Grant Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Vesting<BR>Commencement<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Exercisable<BR>(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Securities<BR>Underlying<BR>Unexercised<BR>Options (#)<BR>Unexercisable<BR>(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Exercise<BR>Price ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Expiration<BR>Date</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Kiran Reddy, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10/19/2018</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10/6/2015</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">230,928</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2.27</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10/18/2028</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stuart Chaffee, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10/19/2018</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">11/20/2017</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">90,913</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">83,641</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2.27</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10/18/2028</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Bernard Ravina, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10/19/2018</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8/21/2018</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">65,166</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">130,334</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2.27</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10/18/2028</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The stock options vest over four years, with 25% of the total shares vesting on the first anniversary of the vesting
commencement date and the remainder vesting in 36 approximately equal monthly installments. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Compensation Risk Assessment </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We believe that although a portion of the compensation provided to our executive officers and other employees is performance-based, our executive
compensation program does not encourage excessive or unnecessary risk taking. This is primarily due to the fact that our compensation programs are designed to encourage our executive officers and other employees to remain focused on both short-term
and long-term strategic goals. As a result, we do not believe that our compensation programs are reasonably likely to have a material adverse effect on us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Employee Benefit and Equity Compensation Plans </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2017 Stock Incentive Plan </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Praxis Precision
Medicines, Inc. 2017 Stock Incentive Plan, or our 2017 Plan, was approved by our board of directors and our stockholders in May 2017 and was most recently amended in September 2020. Under the 2017 Plan, as amended through the date hereof, we have
reserved for issuance an aggregate of 5,937,763 shares of our common stock. The number of shares of common stock reserved for issuance is subject to adjustment in the event of any stock split, reverse stock split, stock dividend, recapitalization,
combination of shares, reclassification of shares, <FONT STYLE="white-space:nowrap">spin-off</FONT> or other similar change in capitalization or event or any dividend or distribution to holders of common stock other than an ordinary cash dividend.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The shares of common stock underlying awards that are expired, lapsed, terminated, surrendered, canceled without having been fully exercised or
forfeited in whole or in part (including as a result of shares of common stock subject to such award being repurchased by us at or below the original issuance price), and shares of common stock that are withheld upon exercise of an option or
settlement of an award to cover the exercise price or tax withholding are added back to the shares of common stock available for issuance under the 2017 Plan. Following this offering, such shares will be added to the shares of common stock available
under the 2020 Stock Option and Incentive Plan, or the 2020 Plan. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors has acted as administrator of the 2017 Plan. The
administrator has full power to select, from among the individuals eligible for awards, the individuals to whom awards will be granted, and to determine the specific terms and conditions of each award, subject to the provisions of the 2017 Plan.
Persons eligible to participate in the 2017 Plan are those employees, officers and directors of, and consultants and advisors to, our company as selected from time to time by the administrator in its discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The 2017 Plan permits the granting of (1)&nbsp;options to purchase common stock intended to qualify as incentive stock options under Section&nbsp;422 of
the Internal Revenue Code of 1986, as amended, or the Code, and (2)&nbsp;options that do not so qualify. The per share option exercise price of each option is determined by the administrator but may not be less than 100% of the fair market value of
the common stock on the date of grant. The term of each option is fixed by the administrator but may not exceed 10 years from the date of grant. The administrator determines at what time or times each option may be exercised. In addition, the 2017
Plan permits the granting of restricted shares of common stock, restricted stock units and other stock-based awards, including but not limited to stock appreciation rights and awards entitling recipients to receive shares of common stock to be
delivered in the future. Other stock-based awards may be paid in shares of common stock or in cash, as determined by our board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
2017 Plan provides that upon the occurrence of a &#147;reorganization event,&#148; as defined in the 2017 Plan, our board of directors may take one or more of the following actions as to all or any (or any portion of) awards outstanding under the
2017 Plan other than restricted stock awards: (i)&nbsp;provide that awards will be assumed or substituted by the acquiring or successor corporation, (ii)&nbsp;upon written notice to participants, provide that all unexercised awards will terminate
immediately prior to the consummation of the reorganization event unless exercised by the participant within a specified period following the date of such notice, (iii)&nbsp;provide that outstanding awards shall become exercisable, realizable or
deliverable, or that all restrictions applicable to such awards shall lapse, in whole or in part, prior to or upon such reorganization event, (iv)&nbsp;make or provide for a cash payment to the award holder equal to the excess, if any, of the per
share cash consideration in the reorganization event times the number of shares subject to the participant&#146;s award over any aggregate exercise price of such outstanding award and any applicable tax withholdings in exchange for the termination
of such awards, (v)&nbsp;provide that, in connection with a liquidation or dissolution of our company, awards shall convert </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
into the right to receive liquidation proceeds (if applicable, net of the exercise price thereof and any applicable tax withholdings) and (vi)&nbsp;any combination of the foregoing. Upon the
occurrence of a reorganization event other than a liquidation or dissolution of the Company, the repurchase and other rights of the Company under each outstanding restricted stock award shall inure to the benefit of our successor and shall, unless
our board of directors determines otherwise, apply to the cash, securities or other property which the common stock was converted into or exchanged for pursuant to such reorganization event in the same manner and to the same extent as they applied
to the common stock subject to such restricted stock award. Upon the occurrence of a reorganization event involving the liquidation or dissolution of our company (except as otherwise provided for in the award agreement), all restrictions and
conditions on all outstanding restricted stock awards will be automatically deemed terminated or satisfied. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The administrator may amend, suspend or
terminate the 2017 Plan at any time, subject to stockholder approval where such approval is required by applicable law. The administrator of the 2017 Plan may also amend or cancel any outstanding award, provided that no amendment to an award may
adversely affect a participant&#146;s rights without his or her consent. The administrator of the 2017 Plan is specifically authorized to exercise its discretion to reduce the exercise price of outstanding awards under the 2017 Plan or effect the
repricing of such awards through cancellation and <FONT STYLE="white-space:nowrap">re-grants</FONT> without stockholder approval. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The 2017 Plan
will terminate automatically upon the earlier of 10 years from the date on which the 2017 Plan was adopted by our board of directors or 10 years from the date the 2017 Plan was approved by our stockholders. As of September 30, 2020, options to
purchase 5,814,944&nbsp;shares of common stock were outstanding under the 2017 Plan. Our board of directors has determined not to make any further awards under the 2017 Plan following the closing of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2020 Stock Option and Incentive Plan </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our 2020 Plan
was adopted by our board of directors on&nbsp;September 9, 2020, approved by our stockholders on October&nbsp;8, 2020 and will become effective upon the date immediately preceding the date on which the registration statement of which this prospectus
is part is declared effective by the SEC. The 2020 Plan will replace the 2017 Plan as our board of directors has determined not to make additional awards under the 2017 Plan following the closing of our initial public offering. However, the 2017
Plan will continue to govern outstanding equity awards granted thereunder. The 2020 Plan allows us to make equity-based and cash-based incentive awards to our officers, employees, directors and consultants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have initially reserved 3,271,028 shares of our common stock, or the Initial Limit, for the issuance of awards under the 2020 Plan. The 2020 Plan
provides that the number of shares reserved and available for issuance under the 2020 Plan will automatically increase each January&nbsp;1, beginning on January&nbsp;1, 2021, by 5% of the outstanding number of shares of our common stock on the
immediately preceding December&nbsp;31, or such lesser number of shares as determined by our compensation committee, or the Annual Increase. These limits are subject to adjustment in the event of a stock split, stock dividend or other change in our
capitalization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The shares we issue under the 2020 Plan will be authorized but unissued shares or shares that we reacquire. The shares of common
stock underlying awards under the 2020 Plan or the 2017 Plan that are forfeited, cancelled, held back upon exercise or settlement of an award to satisfy the exercise price or tax withholding, reacquired by us prior to vesting, satisfied without the
issuance of stock, expire or are otherwise terminated (other than by exercise) will be added back to the shares of common stock available for issuance under the 2020 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The maximum aggregate number of shares that may be issued in the form of incentive stock options shall not exceed the Initial Limit cumulatively
increased on January&nbsp;1, 2021 and on each January&nbsp;1 thereafter by the lesser of the Annual Increase for such year or 1,635,514 shares of common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The grant date fair value of all awards made under our 2020 Plan and all other cash compensation paid
by us to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director in any calendar year for services as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director shall not exceed $750,000; provided, however, that such amount shall be
$1,000,000 for the calendar year in which the applicable <FONT STYLE="white-space:nowrap">non-employee</FONT> director is initially elected or appointed to the board of directors and $1,500,000 for the non-executive chair of our board of directors.
Notwithstanding the foregoing, the independent members of the board of directors may make exceptions to such limits in extraordinary circumstances. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The 2020 Plan will be administered by our compensation committee. Our compensation committee has full power to select, from among the individuals
eligible for awards, the individuals to whom awards will be granted and the number of shares subject to such awards, to make any combination of awards to participants, to accelerate at any time the exercisability or vesting of any award and to
determine the specific terms and conditions of each award, subject to the provisions of the 2020 Plan. Persons eligible to participate in the 2020 Plan will be those full or part-time officers, employees,
<FONT STYLE="white-space:nowrap">non-employee</FONT> directors and consultants as selected from time to time by our compensation committee in its discretion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The 2020 Plan permits the granting of both options to purchase common stock intended to qualify as incentive stock options under Section&nbsp;422 of the
Code, and options that do not so qualify. The option exercise price of each option will be determined by our compensation committee but may not be less than 100% of the fair market value of our common stock on the date of grant unless the option is
granted (i)&nbsp;pursuant to a transaction described in, and in a manner consistent with, Section&nbsp;424(a) of the Code or (ii)&nbsp;to individuals who are not subject to U.S. income tax. The term of each option will be fixed by our compensation
committee and may not exceed 10 years from the date of grant. Our compensation committee will determine at what time or times each option may be exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our compensation committee may award stock appreciation rights subject to such conditions and restrictions as it may determine. Stock appreciation
rights entitle the recipient to shares of common stock, or cash, equal to the value of the appreciation in our stock price over the exercise price. The exercise price of each stock appreciation right may not be less than 100% of the fair market
value of our common stock on the date of grant unless the stock appreciation right is granted (i) pursuant to a transaction described in, and in a manner consistent with, Section 424(a) of the Code or (ii) to individuals who are not subject to U.S.
income tax. The term of each stock appreciation right will be fixed by our compensation committee and may not exceed 10 years from the date of grant. Our compensation committee will determine at what time or times each stock appreciation right may
be exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our compensation committee may award restricted shares of common stock and restricted stock units to participants subject to such
conditions and restrictions as it may determine. These conditions and restrictions may include the achievement of certain performance goals and/or continued employment with us through a specified vesting period. Our compensation committee may also
grant shares of common stock that are free from any restrictions under the 2020 Plan. Unrestricted stock may be granted to participants in recognition of past services or other valid consideration and may be issued in lieu of cash compensation due
to such participant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our compensation committee may grant dividend equivalent rights to participants that entitle the recipient to receive credits
for dividends that would be paid if the recipient had held a specified number of shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our compensation committee may grant
cash bonuses under the 2020 Plan to participants, subject to the achievement of certain performance goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The 2020 Plan provides that upon the
effectiveness of a &#147;sale event,&#148; as defined in the 2020 Plan, an acquirer or successor entity may assume, continue or substitute outstanding awards under the 2020 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Plan. To the extent that awards granted under the 2020 Plan are not assumed or continued or substituted by the successor entity, upon the effective time of the sale event, such awards shall
terminate. In such case, except as may be otherwise provided in the relevant award certificate, all awards with time-based vesting, conditions or restrictions shall become fully vested and nonforfeitable as of the effective time of the sale event,
and all awards with conditions and restrictions relating to the attainment of performance goals may become vested and nonforfeitable in connection with a sale event in the administrator&#146;s discretion or to the extent specified in the relevant
award certificate. In the event of such termination, individuals holding options and stock appreciation rights will be permitted to exercise such options and stock appreciation rights (to the extent exercisable) within a specified period of time
prior to the sale event. In addition, in connection with the termination of the 2020 Plan upon a sale event, we may make or provide for a payment, in cash or in kind, to participants holding vested and exercisable options and stock appreciation
rights equal to the difference between the per share consideration payable to stockholders in the sale event and the exercise price of the options or stock appreciation rights and we may make or provide for a payment, in cash or in kind, to
participants holding other vested awards. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors may amend or discontinue the 2020 Plan and our compensation committee may amend or
cancel outstanding awards for purposes of satisfying changes in law or any other lawful purpose but no such action may adversely affect rights under an award without the holder&#146;s consent. Certain amendments to the 2020 Plan require the approval
of our stockholders. No awards may be granted under the 2020 Plan after the date that is 10&nbsp;years from the effective date of the 2020 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors has approved the issuance under the 2020 Plan of stock options to acquire an aggregate of 37,615 shares of common stock on the
effective date of the registration statement of which this prospectus is a part. These stock options will have an exercise price equal to the public offering price. No other awards under the 2020 Plan have been made prior to the date of this
prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2020 Employee Stock Purchase Plan </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our 2020 Employee Stock Purchase Plan, or the 2020 ESPP, was adopted by our board of directors on September 9, 2020, approved by our stockholders on
October&nbsp;8, 2020 and will become effective on the date immediately preceding the date on which the registration statement of which this prospectus is part is declared effective by the SEC. The 2020 ESPP is intended to qualify as an
&#147;employee stock purchase plan&#148; within the meaning of Section&nbsp;423 of the Code. The 2020 ESPP initially reserves and authorizes the issuance of up to a total of 327,102 shares of common stock to participating employees. The 2020 ESPP
provides that the number of shares reserved and available for issuance will automatically increase on January&nbsp;1, 2021 and each January&nbsp;1 thereafter through January&nbsp;1, 2030, by the least of (i) 327,102 shares of common stock, (ii) 1%
of the outstanding number of shares of our common stock on the immediately preceding December&nbsp;31 or (iii)&nbsp;such lesser number of shares of common stock as determined by the administrator of the 2020 ESPP. The number of shares reserved under
the 2020 ESPP is subject to adjustment in the event of a stock split, stock dividend or other change in our capitalization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">All employees whose
customary employment is for more than 20 hours per week are eligible to participate in the ESPP. However, any employee who owns 5% or more of the total combined voting power or value of all classes of stock will not be eligible to purchase shares
under the 2020 ESPP. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We may make one or more offerings each year to our employees to purchase shares under the ESPP. Offerings will usually begin
on each May 1 and November 1 and will continue for <FONT STYLE="white-space:nowrap">six-month</FONT> periods, referred to as offering periods. Each eligible employee may elect to participate in any offering by submitting an enrollment form at least
15 business days before the relevant offering date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each employee who is a participant in the 2020 ESPP may purchase shares by authorizing payroll
deductions of up to 15% of his or her eligible compensation during an offering period. Unless the participating employee has previously withdrawn from the offering, his or her accumulated payroll deductions will be used to purchase shares of common
stock on the last business day of the offering period at a price equal to 85% of the fair market value of the shares on the first business day or the last business day of the offering period, whichever is lower, provided that no more than $25,000
worth of shares of common stock may be purchased by any one employee during any offering period. Under applicable tax rules, an employee may purchase no more than $25,000 worth of shares of common stock, valued at the start of the purchase period,
under the 2020 ESPP in any calendar year. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The accumulated payroll deductions of any employee who is not a participant on the last day of an
offering period will be refunded. An employee&#146;s rights under the 2020 ESPP terminate upon voluntary withdrawal from the plan or when the employee ceases employment with us for any reason. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The 2020 ESPP may be terminated or amended by our board of directors at any time. An amendment that increases the number of shares of common stock
authorized under the 2020 ESPP and certain other amendments require the approval of our stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>401(k) Plan </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We participate in a retirement savings plan, or 401(k) plan, that is intended to qualify for favorable tax treatment under Section&nbsp;401(a) of the
Code, and contains a cash or deferred feature that is intended to meet the requirements of Section&nbsp;401(k) of the Code. U.S. employees who are at least 18 years of age are generally eligible to participate in the 401(k) plan, subject to certain
criteria. Participants may <FONT STYLE="white-space:nowrap">make&nbsp;pre-tax&nbsp;and</FONT> <FONT STYLE="white-space:nowrap">certain&nbsp;after-tax&nbsp;(Roth)</FONT> salary deferral contributions to the plan from their eligible earnings up to the
statutorily prescribed annual limit under the Code. Participants who are 50 years of age or older may contribute additional amounts based on the statutory limits <FONT STYLE="white-space:nowrap">for&nbsp;catch-up</FONT> contributions. Participant
contributions are held in trust as required by law. An employee&#146;s interest in his or her salary deferral contributions is 100% vested when contributed. We have the ability to make matching and discretionary contributions under the plan but did
not make any contributions to the 401(k) plan in 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Rule&nbsp;10b5-1&nbsp;Sales</FONT> Plans </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our directors and executive officers may adopt written plans, known as <FONT STYLE="white-space:nowrap">Rule&nbsp;10b5-1&nbsp;plans,</FONT> in which they
will contract with a broker to buy or sell shares of our common stock on a periodic basis. Under a <FONT STYLE="white-space:nowrap">Rule&nbsp;10b5-1&nbsp;plan,</FONT> a broker executes trades pursuant to parameters established by the director or
officer when entering into the plan, without further direction from the director or officer. The director or officer may amend or terminate the plan in limited circumstances. Our directors and executive officers may also buy or sell additional
shares of our common stock outside of a <FONT STYLE="white-space:nowrap">Rule&nbsp;10b5-1&nbsp;plan</FONT> when they are not in possession of material, nonpublic information. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom945651_15"></A>DIRECTOR COMPENSATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table presents the total compensation for each person who served as a <FONT STYLE="white-space:nowrap">non-employee</FONT> member of our
board of directors during the year ended December&nbsp;31, 2019. Other than as set forth in the table and described more fully below, we did not pay any compensation, make any equity awards or <FONT STYLE="white-space:nowrap">non-equity</FONT>
awards to or pay any other compensation to any of the <FONT STYLE="white-space:nowrap">non-employee</FONT> members of our board of directors in 2019 for their services as members of the board of directors. Amounts paid to Dr.&nbsp;Reddy, our former
President and Chief Executive Officer, for his service as employees during 2019 are presented above in the &#147;2019 Summary Compensation Table&#148; above. Dr.&nbsp;Reddy did not receive any compensation for his services as director for the fiscal
year ended December&nbsp;31, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>2019 Director Compensation Table </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Fees<BR>Earned&nbsp;or<BR>Paid in<BR>Cash ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Stock<BR>Awards<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Option<BR>Awards<BR>($)(1)(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>All Other<BR>Compensation<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Nicholas Galakatos, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Thomas Dyrberg, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stefan Vitorovic</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Ari Brettman, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Paul Medeiros(3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Gregory Norden</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">62,815</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">62,815</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Alfred Sandrock(4)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">William Young</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">The amount reported represents the aggregate grant date fair value of the stock option awarded to Mr.&nbsp;Norden during
fiscal year 2019, calculated in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 718. Such grant date fair values do not take into account any estimated forfeitures. The assumptions used in calculating the
grant date fair value of the stock options reported in this column are set forth in Note 11 of our consolidated financial statements included elsewhere in this prospectus. The amounts reported in this column reflect the accounting cost for these
stock options and do not correspond to the actual economic value that may be received by our directors upon the exercise of the stock options or any sale of the underlying shares of common stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Each option grant is subject to the terms of our 2017 Plan. Mr.&nbsp;Norden received an option to purchase 27,928 shares
of our common stock, which vested as to 25% of the total shares on December&nbsp;20, 2019, with the remainder vesting in 36 approximately equal monthly installments over the following three years. As of December&nbsp;31, 2019, Mr.&nbsp;Norden held
options to purchase 27,928 shares of our common stock and Mr.&nbsp;Sandrock and Mr.&nbsp;Young each held options to purchase 27,980 shares of our common stock. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Mr. Medeiros resigned as a director in September 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Mr.&nbsp;Sandrock resigned as a director in March 2020 and continues to serve in an advisory capacity.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Non-Employee Director Compensation Policy </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection with this offering, we intend to adopt a <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy that will become
effective upon the completion of this offering and will be designed to enable us to attract and retain, on a long-term basis, highly qualified <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. Under the policy, each director who is not
an employee will be paid cash compensation from and after the completion of this offering, as set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Annual<BR>Retainer</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Board of Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Members</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Additional retainer for <FONT STYLE="white-space:nowrap">non-executive</FONT>
chair</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Audit Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Retainer for chair</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">16,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt" BGCOLOR="#d1fcfc">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Compensation Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">6,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Retainer for chair</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">12,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Nominating and Corporate Governance Committee:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Members (other than chair)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Retainer for chair</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, the <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy will provide that,
upon initial election to our board of directors, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director will be granted an option to purchase a number of shares equal to 0.1% of the total number of shares of our common stock issued and
outstanding on the grant date, or the Initial Grant. The Initial Grant will vest in equal monthly installments over three years from the grant date, subject to continued service as a director through the applicable vesting date. Furthermore, on the
date of each annual meeting of stockholders following the completion of this offering, each <FONT STYLE="white-space:nowrap">non-employee</FONT> director who continues as a <FONT STYLE="white-space:nowrap">non-employee</FONT> director following such
meeting will be granted an annual option to purchase a number of shares equal to 0.05% of the total number of shares of our common stock issued and outstanding on the grant date, or the Annual Grant. The Annual Grant will vest in twelve equal
monthly installments, subject to continued service as a director through the applicable vesting date. Such awards are subject to full accelerated vesting upon the sale of the company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We will reimburse all reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred by <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors in attending meetings of the board of directors and committees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom945651_16"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Other than the compensation agreements and other arrangements described under &#147;Executive Compensation&#148; and &#147;Director Compensation&#148;
in this prospectus and the transactions described below, since January&nbsp;1, 2017, there has not been, and there is not currently proposed, any transaction or series of similar transactions to which we were, or will be, a party in which the amount
involved exceeded, or will exceed, $120,000 and in which any director, executive officer, holder of five percent or more of any class of our capital stock or any member of the immediate family of, or entities affiliated with, any of the foregoing
persons, had, or will have, a direct or indirect material interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Sales and Purchases of Securities </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Series A Preferred Stock Financing </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">From October 2016
to July 2017, we issued and sold to investors in private placements an aggregate of 6,100,000 shares of our Series A preferred stock at a price of $1.00 per share, for aggregate consideration of $6.1&nbsp;million. In October 2016, we also issued and
sold an aggregate of 1,375,799 shares of Series A preferred stock upon the conversion of a series of convertible promissory notes previously issued to Clarus Lifesciences III, L.P., or Clarus, or the 2016 Notes, at a conversion price of $0.75 per
share. We refer to these transactions collectively as our Series A Preferred Stock Financing. The following table sets forth the aggregate number and purchase price of shares of our Series A preferred stock purchased by related persons: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Purchaser</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;Series&nbsp;A<BR>Preferred<BR>Stock Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;Purchase<BR>Price ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Blackstone(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">7,375,799</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">7,031,849</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">7,375,799</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">7,031,849</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Nicholas Galakatos, Ph.D., a member of our board of directors, was a managing director of Clarus, prior to its
acquisition by The Blackstone Group Inc., or Blackstone, and is a senior managing director of Blackstone. Ari Brettman, M.D. a member of our board of directors, was a principal at Clarus, prior to its acquisition by Blackstone, and is a managing
director of Blackstone. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Convertible Promissory Note Financings </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In December 2017 and January 2018, we issued convertible promissory notes to Clarus, collectively the Convertible Notes, for $2.0&nbsp;million and
$1.0&nbsp;million, respectively. The Convertible Notes were settled in March 2018 upon their automatic conversion into shares of our Series B preferred stock, as described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Nicholas Galakatos, Ph.D., a member of our board of directors, was a managing director of Clarus, prior to its acquisition by Blackstone, and is a
senior managing director of Blackstone. Ari Brettman, M.D. a member of our board of directors, was a principal at Clarus, prior to its acquisition by Blackstone, and is a managing director of Blackstone. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Series B Preferred Stock Financing </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the year
ended December&nbsp;31, 2018, we issued a total of 12,333,333 shares of Series B preferred stock in two separate closings at a purchase price of $3.00 per share for gross cash proceeds of $37.0&nbsp;million, and incurred issuance costs of
$0.2&nbsp;million. We also issued an aggregate of 1,286,185 shares of Series B preferred stock upon the conversion of the Convertible Notes at an average conversion price of $2.40 per share. We also issued 1,294,186 shares of Series B preferred
stock in connection with the anti-dilutive provision within the Purdue License Agreement. The following </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
table sets forth the aggregate number and purchase price of shares of our Series B preferred stock purchased by related persons: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Purchaser</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;Series&nbsp;B<BR>Preferred<BR>Stock Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;Purchase<BR>Price ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Blackstone(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5,052,852</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">14,337,643</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Novo Holdings A/S(2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4,150,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">12,450,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Vida Ventures, LLC(3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4,150,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">12,450,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">13,352,852</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">39,237,643</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Nicholas Galakatos, Ph.D., a member of our board of directors, was a managing director of Clarus, prior to its
acquisition by Blackstone, and is a senior managing director of Blackstone. Ari Brettman, M.D. a member of our board of directors, was a principal at Clarus, prior to its acquisition by Blackstone, and is a managing director of Blackstone.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Thomas Dyrberg, M.D., a member of our board of directors, is employed as a Managing Partner of Novo Holdings A/S, or
Novo. Dr. Dyrberg is not deemed to hold any beneficial ownership or reportable pecuniary interest in the shares held by Novo. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Stefan Vitorovic, a member of our board of directors, is a managing director of Vida Ventures, LLC.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock Financing </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In June 2019, we issued and sold to investors in a private placement an aggregate of 2,666,666 shares of our Series
<FONT STYLE="white-space:nowrap">B-1</FONT> preferred stock at a price of $3.75 per share, for aggregate consideration of approximately $10.0&nbsp;million, or our Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock Financing. The
following table sets forth the aggregate number and purchase price of shares of our Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred stock purchased by related persons: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Purchaser</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Shares&nbsp;of&nbsp;Series&nbsp;B-1</FONT><BR>Preferred<BR>Stock&nbsp;Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;Purchase<BR>Price ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Blackstone(1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,410,477</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5,289,288</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Novo Holdings A/S(2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">551,794</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,069,228</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Vida Ventures, LLC(3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">551,794</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,069,228</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Purdue Neuroscience Company(4)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">133,334</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">500,003</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,647,399</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9,927,747</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Nicholas Galakatos, Ph.D., a member of our board of directors, was a managing director of Clarus, prior to its
acquisition by Blackstone, and is a senior managing director of Blackstone. Ari Brettman, M.D. a member of our board of directors, was a principal at Clarus, prior to its acquisition by Blackstone, and is a managing director of Blackstone.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Thomas Dyrberg, M.D., a member of our board of directors, is employed as a Managing Partner of Novo. Dr. Dyrberg is not
deemed to hold any beneficial ownership or reportable pecuniary interest in the shares held by Novo. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Stefan Vitorovic, a member of our board of directors, is a managing director of Vida Ventures, LLC.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Purdue Neuroscience Company became a holder of five percent or more of our capital stock pursuant to our Series <FONT
STYLE="white-space:nowrap">B-1</FONT> Preferred Financing, but is no longer a holder of five percent or more of our capital stock as of December 2019. Paul Medeiros, a member of our board of directors at the time of this financing who resigned in
September 2020, is a senior vice president of Purdue Pharma L.P., an affiliate of Purdue Neuroscience Company. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Series C Preferred Stock
Financing </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">From November 2019 through May 2020, we issued and sold to investors in a private placement an aggregate of 14,368,935 shares of
our Series C preferred stock at a price of $5.15 per share, for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
aggregate consideration of approximately $74.0&nbsp;million, or our Series C Preferred Stock Financing. The following table sets forth the aggregate number and purchase price of shares of our
Series C preferred stock purchased by related persons: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Purchaser</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;Series&nbsp;C<BR>Preferred<BR>Stock Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;Purchase<BR>Price ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Blackstone (1)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,500,956</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">12,879,923</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Novo Holdings A/S(2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">171,410</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">882,762</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Vida Ventures, LLC(3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">171,410</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">882,762</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Eventide(4)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,883,496</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">20,000,004</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Purdue Neuroscience Company(5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">59,333</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">305,565</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">6,786,605</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">34,951,016</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Ari Brettman, M.D., and Nicholas Galakatos, Ph.D., members of our board of directors, are a managing director and senior
managing director, respectively, of Blackstone, an affiliate of Clarus and BSOF Parallel Master Fund L.P., or BSOF. Kiran Reddy, M.D. a member of our board of directors and our former president and chief executive officer, is a managing director of
Blackstone, an affiliate of Clarus and BSOF. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Thomas Dyrberg, M.D., a member of our board of directors, is employed as a Managing Partner of Novo. Dr. Dyrberg is not
deemed to hold any beneficial ownership or reportable pecuniary interest in the shares held by Novo. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Stefan Vitorovic, a member of our board of directors, is a managing director of Vida Ventures, LLC.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Mutual Fund Series Trust, On Behalf of Eventide Healthcare&nbsp;&amp; Life Sciences Fund, or Eventide Healthcare, and
Mutual Fund Series Trust, On Behalf of Eventide Gilead Fund, or Eventide Gilead, together became a holder of five percent or more of our capital stock pursuant to our Series C Preferred Stock Financing. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Purdue Neuroscience Company is no longer a holder of five percent or more of our capital stock as of December 2019. Paul
Medeiros, a member of our board of directors at the time of this financing who resigned in September 2020, is a senior vice president of Purdue Pharma L.P., an affiliate of Purdue Neuroscience Company. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Series C Repurchase </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On February 2020 and March 2020,
we repurchased from certain holders of five percent or more of our capital stock an aggregate of 5,825,243 shares of our Series C preferred stock at a price of $5.15 per share, for an aggregate consideration of approximately $30.0&nbsp;million, or
the Series C Repurchase. The following table sets forth the aggregate number and purchase price of shares of our Series C preferred stock repurchased by us from related persons: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name of Holder</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;of&nbsp;Series&nbsp;C<BR>Preferred<BR>Stock&nbsp;Repurchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;Purchase<BR>Price ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with RTW</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,912,622</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">15,000,003</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Venrock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,912,621</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">14,999,998</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5,825,243</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">30,000,001</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Series C-1 Preferred Stock Financing </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">From July to August 2020, we issued and sold to investors in a private placement an aggregate of 19,444,453 shares of our Series C-1 preferred stock at a
price of $5.67 per share, for aggregate consideration of approximately $110.3 million, or our Series C-1 Preferred Stock Financing. The following table sets forth the aggregate number and purchase price of shares of our Series C-1 preferred stock
purchased by related persons: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Purchaser</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Shares&nbsp;of&nbsp;Series&nbsp;C-1&nbsp;Preferred</FONT><BR>Stock Purchased</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate&nbsp;Purchase<BR>Price ($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Blackstone <SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">352,734</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,000,002</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Novo Holdings A/S
<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">352,734</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,000,002</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Vida Ventures, LLC
<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">881,835</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5,000,004</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Eventide
<SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,527,337</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">20,000,001</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Marcio Souza <SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">44,092</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">250,002</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5,158,732</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">29,250,011</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Ari Brettman, M.D., and Nicholas Galakatos, Ph.D., members of our board of directors, are a managing partner and senior
managing director, respectively, of Blackstone, an affiliate of Clarus and BSOF Parallel Master Fund L.P., or BSOF. Kiran Reddy, M.D., a member of our board of directors and our former president and chief executive officer, is a managing director of
Blackstone, an affiliate of Clarus and BSOF. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Thomas Dyrberg, M.D., a member of our board of directors, is employed as a Managing Partner of Novo. Dr.&nbsp;Dyrberg is
not deemed to hold any beneficial ownership or reportable pecuniary interest in the shares held by Novo. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Stefan Vitorovic, a member of our board of directors, is a managing director of Vida Ventures, LLC.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Mutual Fund Series Trust, On Behalf of Eventide Healthcare &amp; Life Sciences Fund, or Eventide Healthcare, and Mutual
Fund Series Trust, On Behalf of Eventide Gilead Fund, or Eventide Gilead, together hold five percent or more of our capital stock pursuant to our Series C-1 Preferred Stock Financing. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Marcio Souza serves on our board of directors and is our President and Chief Executive Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Commercial Agreements with Related Parties </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Purdue </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In December 2017, we and Purdue Neuroscience Company, or Purdue, a former holder of five percent or more of our capital stock, entered into a license
agreement, described in the section of this prospectus captioned &#147;Business&#151;Third-Party Licenses.&#148;&nbsp;Paul Medeiros, a former member of our board of directors, serves as a Senior Vice President of Purdue Pharma L.P. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>RogCon </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In December 2018, we entered into an
agreement with RogCon Inc., or RogCon, pursuant to which we agreed to advance RogCon a deposit of up to $1.0&nbsp;million related to the cooperation and license agreement described below. The amounts funded to RogCon under this agreement were
applied towards the purchase price of the license agreement with RogCon described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In September 2019, we entered into a cooperation and
license agreement with RogCon, described in the section of this prospectus captioned &#147;Business&#151;Third-Party Licenses.&#148;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Alex Nemiroff,
our General Counsel and Secretary, is a <FONT STYLE="white-space:nowrap">co-founder</FONT> and chief executive officer of RogCon. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Underwriting Arrangements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Blackstone Securities Partners L.P., an affiliate of Blackstone, is an underwriter in the initial public offering of our common stock and shall be
entitled to commissions and fees on substantially similar terms as our other underwriters. Ari Brettman, M.D., and Nicholas Galakatos, Ph.D., members of our board of directors, are a managing director and senior managing director, respectively, of
Blackstone. For more information regarding our agreement with the underwriters for this offering, see the section titled &#147;Underwriting.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Other
Arrangements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In March 2020, we reimbursed an affiliate of Blackstone approximately $164,000 in third-party expenses related to the recruitment
of our chief executive officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Indemnification Agreements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Prior to the closing of this offering, we intend to enter agreements to indemnify our directors and certain executive officers. These agreements will,
among other things, require us to indemnify these individuals for certain expenses (including attorneys&#146; fees), judgments, fines and settlement amounts reasonably incurred by such person in any action or proceeding, including any action by or
in our right, on account of any services undertaken by such person on behalf of our company or that person&#146;s status as a member of our board of directors to the maximum extent allowed under Delaware law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Agreements with Stockholders </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection with our
Series A preferred stock financing, our Series B preferred stock financing, our Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred stock financing, our Series C preferred stock financing and our Series C-1 preferred stock financing, we
entered into investors&#146; rights, voting and right of first refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> agreements containing registration rights, information rights, voting rights and rights of first refusal, among other things,
with certain holders of our preferred stock and certain holders of our common stock. These stockholder agreements will terminate upon the closing of this offering, except for the registration rights granted under our investors&#146; rights
agreement, as more fully described in &#147;Description of Capital Stock&#151;Registration Rights.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Directed Share Program </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The underwriters have reserved for sale, at the public offering price, up to 5% of the shares of our common stock being offered hereby to individuals,
which may include certain of our officers, directors and employees, as part of a directed share program. The sales will be made by the directed share program administrator. The directed share program will not limit the ability of our officers,
directors and employees to purchase more than $120,000 in value of our common stock. We do not currently know the extent to which these related persons will participate in our directed share program, if at all, or the extent to which they will
purchase more than $120,000 in value of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Policies for Approval of Related Party Transactions </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our board of directors reviews and approves transactions with directors, officers and holders of five percent or more of our voting securities and their
affiliates, each a related party. Prior to this offering, the material facts as to the related party&#146;s relationship or interest in the transaction are disclosed to our board of directors prior to their consideration of such transaction, and the
transaction is not considered approved by our board of directors unless a majority of the directors who are not interested in the transaction approve the transaction. Further, when stockholders are entitled to vote on a transaction with a related
party, the material facts of the related party&#146;s relationship or interest in the transaction are disclosed to the stockholders, who must approve the transaction in good faith. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection with this offering, we intend to adopt a formal written policy that our executive officers, directors, holders of more than five percent
of any class of our voting securities, and any member of the immediate family of and any entity affiliated with any of the foregoing persons, are not permitted to enter into </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
a related party transaction with us without the prior consent of our audit committee, or other independent members of our board of directors in the event it is inappropriate for our audit
committee to review such transaction due to a conflict of interest. Any request for us to enter into a transaction with an executive officer, director, holders of more than 5% of any class of our voting securities, or any of their immediate family
members or affiliates, in which the amount involved exceeds $120,000 must first be presented to our audit committee for review, consideration and approval. In approving or rejecting any such proposal, our audit committee will consider the relevant
facts and circumstances available and deemed relevant to our audit committee, including, but not limited to, whether the transaction will be on terms no less favorable than terms generally available to an unaffiliated third party under the same or
similar circumstances and the extent of the related party&#146;s interest in the transaction. All of the transactions described in this section were entered into prior to the adoption of this policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom945651_17"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table sets forth certain information known to us regarding beneficial ownership of our capital stock as of September 30, 2020, as adjusted
to reflect the sale of common stock offered by us in this offering, for: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each person or group of affiliated persons known by us to be the beneficial owner of more than five percent of our capital
stock; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each of our named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">each of our directors; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">all of our executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To the extent that the underwriters sell more than 10,000,000 shares in this offering, the underwriters have the option to purchase up to an additional
1,500,000 shares at the initial public offering price less the underwriting discount. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Beneficial ownership is determined in accordance with
the rules of the SEC and generally includes voting or investment power with respect to securities. Under those rules, beneficial ownership includes any shares as to which the individual or entity has sole or shared voting power or investment power.
Except as noted by footnote, and subject to community property laws where applicable, we believe, based on the information provided to us, that the persons and entities named in the table below have sole voting and investment power with respect to
all common stock shown as beneficially owned by them. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The percentage of beneficial ownership prior to this offering in the table below is based
on 26,749,675 shares of common stock deemed to be outstanding as of September 30, 2020, including 8,763&nbsp;shares of unvested restricted common stock as of September 30, 2020 and assuming the conversion of all outstanding shares of our preferred
stock upon the closing of this offering, and the percentage of beneficial ownership after this offering in the table below is based on 36,749,675 shares of common stock assumed to be outstanding after the closing of the offering. The information in
the table below assumes no exercise of the underwriters&#146; option to purchase additional shares. Options to purchase shares of common stock that are exercisable within 60 days of September 30, 2020 are deemed to be beneficially owned by the
persons holding these options for the purpose of computing percentage ownership of that person, but are not treated as outstanding for the purpose of computing any other person&#146;s ownership percentage. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of&nbsp;Shares</B><br><B>Beneficially Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name and Address of Beneficial Owner (1)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Beneficially<BR>Owned</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Before<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>After<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>5% Stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Blackstone(2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8,501,487</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">31.8</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">23.1</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Novo Holdings A/S(3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,442,080</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9.1</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">6.6</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Vida Ventures, LLC(4)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,689,329</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10.1</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Entities affiliated with Eventide(5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,463,081</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">12.9</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9.4</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Named Executive Officers and Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Nicholas Galakatos, Ph.D.(2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Ari Brettman, M.D.(2)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Thomas Dyrberg, M.D.(3)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stefan Vitorovic(4)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,689,329</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10.1</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">7.3</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">William Young(6)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">27,397</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Gregory Norden(7)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">13,382</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Kiran Reddy, M.D.(2)(8)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">698,217</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2.6</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1.9</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stuart Chaffee, Ph.D.(9)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">130,915</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Bernard Ravina(10)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">109,968</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Marcio Souza(11)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">20,604</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dean Mitchell</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>All executive officers and directors as a group (13
persons)(12)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right"><B>3,689,812</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right"><B>13.5</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;"><B>%&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right"><B>9.9</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;"><B>%&nbsp;</B></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Represents beneficial ownership of less than one percent. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Unless otherwise indicated, the address for each beneficial owner is c/o Praxis Precision Medicines, Inc., One Broadway,
16th Floor, Cambridge, MA 02142. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of (i) 3,446,711 shares of common stock issuable upon conversion of shares of Series A preferred stock held by
Clarus Lifesciences III, L.P. (&#147;Clarus&#148;); (ii)&nbsp;2,361,198 shares of common stock issuable upon conversion of shares of Series B preferred stock held by Clarus; (iii) 659,116 shares of common stock issuable upon conversion of shares of
Series B-1 preferred stock held by Clarus; (iv)&nbsp;261,318 shares of common stock issuable upon conversion of shares of Series C preferred stock held by Clarus; (v) 164,832 shares of common stock issuable upon conversion of shares of Series C-1
preferred stock held by Clarus; (vi) 700,934 shares of common stock held by Clarus, and (vii) 907,378 shares of common stock issuable upon conversion of shares of Series C preferred stock held by BSOF Parallel Master Fund L.P. (together with Clarus,
the &#147;Blackstone Funds&#148;). Clarus Ventures III GP, L.P. is the general partner of Clarus. Blackstone Clarus III L.L.C. is the general partner of Clarus GP. The sole member of Blackstone Clarus III L.L.C. is Blackstone Holdings II L.P.
Blackstone Strategic Opportunity Associates L.L.C. is the general partner of BSOF Parallel Master Fund L.P. Blackstone Holdings II L.P. is the sole member of Blackstone Strategic Opportunity Associates L.L.C. Blackstone Alternative Solutions L.L.C.
is the investment manager of BSOF Parallel Master Fund L.P. Blackstone Holdings I L.P. is the sole member of Blackstone Alternative Solutions L.L.C. The general partner of Blackstone Holdings I L.P. and Blackstone Holdings II L.P. is Blackstone
Holdings I/II GP L.L.C. The sole member of Blackstone Holdings I/II GP L.L.C. is The Blackstone Group Inc. The sole holder of the Class&nbsp;C common stock of The Blackstone Group Inc. is Blackstone Group Management L.L.C. Blackstone Group
Management L.L.C. is wholly-owned by Blackstone&#146;s senior managing directors and controlled by its founder, Stephen A. Schwarzman. Each of such entities and Mr.&nbsp;Schwarzman may be deemed to
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
beneficially own the shares beneficially owned by the Blackstone Funds controlled by it or him, but each (other than the Blackstone Funds to the extent of their direct ownership) disclaims
beneficial ownership of such shares.&nbsp;Each of Ari Brettman, M.D. Nicholas Galakatos, Ph.D., and Kiran Reddy, M.D. members of our board of directors, is an employee of an entity affiliated with the Blackstone Funds and each disclaims beneficial
ownership of the shares beneficially owned by the Blackstone Funds. The address for each of Clarus and Clarus Ventures III GP, L.P. is c/o Clarus Ventures LLC, 101 Main Street, Suite 1210, Cambridge, MA 02142. The address for each of the other
Blackstone entities and Mr.&nbsp;Schwarzman is c/o The Blackstone Group Inc., 345 Park Avenue, New York, NY 10154. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of (i)&nbsp;1,939,295 shares of common stock issuable upon conversion of shares of Series B preferred stock;
(ii)&nbsp;257,853 shares of common stock issuable upon conversion of shares of Series&nbsp;B-1 preferred stock; (iii)&nbsp;80,100 shares of common stock issuable upon the conversion of Series C preferred stock, and (iv) 164,832 shares of common
stock issuable upon the conversion of Series&nbsp;C-1 preferred stock. All shares are held directly by Novo Holdings A/S, a Danish limited liability company that manages investments and financial assets. Thomas Dyrberg M.D. is employed as a managing
partner at Novo Holdings A/S and is also a member of our board of directors. Dr.&nbsp;Dyrberg is not deemed to hold any beneficial ownership or reportable pecuniary interest in the shares held by Novo Holdings A/S. The address for Novo Holdings A/S
is Tuborg Havnevej 19, DK-2900 Hellerup, Denmark. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of (i) 1,939,295 shares of common stock issuable upon conversion of shares of Series B preferred stock;
(ii)&nbsp;257,853 shares of common stock issuable upon conversion of shares of Series B-1 preferred stock; (iii)&nbsp;80,100 shares of common stock issuable upon conversion of shares of Series C preferred stock, and (iv) 412,081 shares of common
stock issuable upon the conversion of Series C-1 preferred stock. All shares are held directly by Vida Ventures, LLC, a United States limited liability company. Stefan Vitorovic is the Co-Founder and Managing Director of Vida Ventures, LLC and is
also a member of our board of directors. VV Manager, LLC, or VV Manager, is the managing member of Vida. Stefan Vitorovic, Arjun Goyal, Fred Cohen, Arie Belldegrun and Leonard Potter are managers of VV Manager, and may be deemed to share voting and
dispositive power over the shares held by Vida. The address of Vida is 40 Broad Street, Suite 201, Boston, Massachusetts 02109. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of (i) 907,379 shares of common stock issuable upon conversion of shares of Series C preferred stock held by
Mutual Fund Series Trust, On Behalf Of Eventide Healthcare&nbsp;&amp; Life Sciences Fund, or Eventide Healthcare; (ii) 988,994 shares of common stock issuable upon conversion of shares of Series C-1 preferred stock held by Eventide Healthcare; (iii)
907,378 shares of common stock issuable upon conversion of shares of Series C preferred stock held by Mutual Fund Series Trust, On Behalf Of Eventide Gilead Fund, or Eventide Gilead, and (iv) 659,330 shares of common stock issuable upon conversion
of shares of Series C-1 preferred stock held by Eventide Gilead. The address for both Eventide Healthcare and Eventide Gilead is One International Place, Suite 4210, Boston, Massachusetts 02110. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of options to purchase&nbsp;27,397 shares of common stock that are exercisable within 60 days of&nbsp;September
30, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of options to purchase 13,382 shares of common stock that are exercisable within 60 days of&nbsp;September 30,
2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of&nbsp;(i) 467,289 shares of common stock and (ii) options to purchase&nbsp;230,928 shares of common stock that
are exercisable within 60 days of&nbsp;September 30, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of options to purchase&nbsp;130,915 shares of common stock that are exercisable within 60 days of&nbsp;September
30, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of (i) 11,021 shares of common stock and (ii) options to purchase 98,947 shares of common stock that are
exercisable within 60 days of&nbsp;September 30, 2020. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of 20,604 shares of common stock issuable upon the conversion of Series C-1 preferred stock.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Consists of (i)&nbsp;478,310 shares of common stock; (ii) 1,939,295 shares of common stock issuable upon conversion of
shares of Series B preferred stock; (iii) 257,853 shares of common stock issuable upon conversion of shares of Series B-1 preferred stock; (iv) 80,100 shares of common stock issuable upon conversion of shares of Series C preferred stock; (v) 432,685
shares of common stock issuable upon the conversion of Series C-1 preferred stock and (vi) options to purchase 501,569 shares of common stock that are exercisable within 60 days of&nbsp;September 30, 2020. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom945651_18"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following descriptions are summaries of the material terms of our amended and restated certificate of incorporation and amended and restated bylaws
which will become effective immediately upon the closing of this offering. The descriptions of the common stock and preferred stock give effect to changes to our capital structure that will occur immediately upon the closing of this offering. We
refer in this section to our amended and restated certificate of incorporation as our certificate of incorporation, and we refer to our amended and restated bylaws as our bylaws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>General </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon the closing of this offering, our authorized
capital stock will consist of 150,000,000 shares of common stock, par value $0.0001 per share and 10,000,000 shares of preferred stock, par value $0.0001 per share, all of which shares of preferred stock will be undesignated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of September 30, 2020, 26,749,675 shares of our common stock were outstanding and held by stockholders of record. This amount assumes the conversion
of all outstanding shares of our preferred stock into common stock upon the closing of this offering. In addition, as of September 30, 2020, we had outstanding options to purchase 5,814,944 shares of our common stock under our 2017 Stock Incentive
Plan, at a weighted average exercise price of $6.20 per share, 957,214 of which were exercisable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Common Stock </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of the stockholders. The holders of our
common stock do not have any cumulative voting rights. Holders of our common stock are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend
rights of any outstanding preferred stock. Our common stock has no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the event of our liquidation, dissolution or winding up, holders of our common stock will be entitled to share ratably in all assets remaining after
payment of all debts and other liabilities and any liquidation preference of any outstanding preferred stock. The shares to be issued by us in this offering will be, when issued and paid for, validly issued, fully paid
<FONT STYLE="white-space:nowrap">and&nbsp;non-assessable.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Preferred stock </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Immediately prior to the completion of this offering, all outstanding shares of our preferred stock will be converted into shares of our common stock.
Upon the consummation of this offering, our board of directors will have the authority, without further action by our stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series and to fix the rights, preferences,
privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, terms of redemption, liquidation preferences, sinking fund terms and the number of shares constituting, or
the designation of, such series, any or all of which may be greater than the rights of common stock. The issuance of our preferred stock could adversely affect the voting power of holders of common stock and the likelihood that such holders will
receive dividend payments and payments upon our liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing a change in control of our Company or other corporate action. Immediately after
consummation of this offering, no shares of preferred stock will be outstanding, and we have no present plan to issue any shares of preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Registration rights </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon the completion of this offering,
the holders of 25,067,977 shares of our common stock, including those issuable upon the conversion of preferred stock, will be entitled to rights with respect to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the registration of these securities under the Securities Act. These rights are provided under the terms of a third amended and restated investors&#146; rights agreement between us and the
holders of our preferred stock, or the investors&#146; rights agreement. The investors&#146; rights agreement includes demand registration rights, short-form registration rights and piggyback registration rights. All fees, costs and expenses of
underwritten registrations under this agreement will be borne by us and all selling expenses, including underwriting discounts and selling commissions, will be borne by the holders of the shares being registered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Demand registration rights </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Beginning 180 days after
the completion of this offering, the holders of 25,067,977 shares of our common stock, including those issuable upon the conversion of shares of our preferred stock upon closing of this offering, will be entitled to demand registration rights. Under
the terms of the investors&#146; rights agreement, we will be required, upon the written request of holders of at least a majority of the securities eligible for registration then outstanding, and if anticipated aggregate offering price, net of
related fees and expenses, would exceed $5&nbsp;million, we will be required to file a registration statement covering all securities eligible for registration that our stockholders request to be included in such registration. We are required to
effect only two registrations pursuant to this provision of the investors&#146; rights agreement in any twelve-month period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Short-form registration rights
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pursuant to the investors&#146; rights agreement, if we are eligible to file a registration statement on Form
<FONT STYLE="white-space:nowrap">S-3,</FONT> upon the written request of stockholders holding at least a majority of the securities eligible for registration then outstanding, we will be required to file a Form
<FONT STYLE="white-space:nowrap">S-3</FONT> registration restatement with respect to outstanding securities of such stockholders having an anticipated aggregate offering, net of related fees and expenses, of at least $3&nbsp;million. We are required
to effect only two registrations in any twelve-month period pursuant to this provision of the amended and restated investors&#146; rights agreement. The right to have such shares registered on Form <FONT STYLE="white-space:nowrap">S-3</FONT> is
further subject to other specified conditions and limitations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Piggyback registration rights </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon the completion of this offering, the holders of 25,067,977 shares of our common stock, including those issuable upon the conversion of shares of our
preferred stock upon closing of this offering, are entitled to piggyback registration rights. If we register any of our securities either for our own account or for the account of other security holders, the holders of these shares are entitled to
include their shares in the registration. Subject to certain exceptions contained in the investor rights agreement, we and the underwriters may limit the number of shares included in the underwritten offering to the number of shares which we and the
underwriters determine in our sole discretion will not jeopardize the success of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Indemnification </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our investors&#146; rights agreement contains customary cross-indemnification provisions, under which we are obligated to indemnify holders of
registrable securities in the event of material misstatements or omissions in the registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Expiration of registration rights </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The demand
registration rights and short-form registration rights granted under the investors&#146; rights agreement will terminate on the earliest to occur of: (i)&nbsp;on the fifth anniversary of the completion of this offering or (ii)&nbsp;a merger, sale or
liquidation of our company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Anti-Takeover Effects of our Certificate of Incorporation and Bylaws and Delaware Law </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation and amended and restated bylaws include a number of provisions that may have the effect of
delaying, deferring or preventing another party from acquiring control of us and encouraging persons considering unsolicited tender offers or other unilateral takeover proposals to negotiate with our board of directors rather than pursue <FONT
STYLE="white-space:nowrap">non-negotiated</FONT> takeover attempts. These provisions include the items described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Undesignated Preferred Stock
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our amended and restated certificate of incorporation provides for 10,000,000 authorized shares of preferred stock. The existence of
authorized but unissued shares of preferred stock may enable our board of directors to discourage an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise. For example, if in the due exercise of its fiduciary
obligations, our board of directors were to determine that a takeover proposal is not in the best interests of our stockholders, our board of directors could cause shares of preferred stock to be issued without stockholder approval in one or more
private offerings or other transactions that might dilute the voting or other rights of the proposed acquirer or insurgent stockholder or stockholder group. In this regard, our certificate of incorporation grants our board of directors broad power
to establish the rights and preferences of authorized and unissued shares of preferred stock. The issuance of shares of preferred stock could decrease the amount of earnings and assets available for distribution to holders of shares of common stock.
The issuance may also adversely affect the rights and powers, including voting rights, of these holders and may have the effect of delaying, deterring or preventing a change in control. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Exclusive Jurisdiction for Certain Actions </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Our
amended and restated bylaws provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for state law claims for (i)&nbsp;any derivative action or proceeding
brought on our behalf, (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers and employees to us or our stockholders, (iii)&nbsp;any action asserting a claim against us or any
of our current or former directors, officers, or other employees or stockholders arising pursuant to any provision of the Delaware General Corporation Law, or the DGCL, our certificate of incorporation or our bylaws, (iv)&nbsp;any action to
interpret, apply, enforce or determine the validity of our certificate of incorporation or our bylaws or (v)&nbsp;any action asserting a claim against us or any of our current or former directors or officers or other employees that is governed by
the internal affairs doctrine. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Section&nbsp;203 of the Delaware General Corporation Law </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon closing of this offering, we will be subject to the provisions of Section&nbsp;203 of the DGCL. In general, Section&nbsp;203 prohibits a publicly
held Delaware corporation from engaging in a &#147;business combination&#148; with an &#147;interested stockholder&#148; for a three-year period following the time that this stockholder becomes an interested stockholder, unless the business
combination is approved in a prescribed manner. Under Section&nbsp;203, a business combination between a corporation and an interested stockholder is prohibited unless it satisfies one of the following conditions: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">before the stockholder became interested, our board of directors approved either the business combination or the
transaction which resulted in the stockholder becoming an interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">upon consummation of the transaction which resulted in the stockholder becoming an interested stockholder, the interested
stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of determining the voting stock outstanding, shares owned by persons who are directors and also officers,
and employee stock plans, in some instances, but not the outstanding voting stock owned by the interested stockholder; or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">at or after the time the stockholder became interested, the business combination was approved by our board of directors and
authorized at an annual or special meeting of the stockholders by the affirmative vote of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the outstanding voting stock which is not owned by the interested stockholder.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:5%; text-indent:-1%; font-size:10pt; font-family:ARIAL">In general, Section&nbsp;203 defines a business combination to include the following: </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any merger or consolidation involving the corporation and the interested stockholder; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any sale, transfer, lease, pledge or other disposition involving the interested stockholder of 10% or more of the assets of
the corporation; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">subject to exceptions, any transaction that results in the issuance or transfer by the corporation of any stock of the
corporation to the interested stockholder; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">subject to exceptions, any transaction involving the corporation that has the effect of increasing the proportionate share
of the stock of any class or series of the corporation beneficially owned by the interested stockholder; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the receipt by the interested stockholder of the benefit of any loans, advances, guarantees, pledges or other financial
benefits provided by or through the corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In general, Section&nbsp;203 defines an &#147;interested stockholder&#148; as
any entity or person beneficially owning 15% or more of the outstanding voting stock of the corporation and any entity or person affiliated with or controlling or controlled by the entity or person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Provisions of our amended and restated certificate of incorporation and our amended and restated bylaws may delay or discourage transactions involving an
actual or potential change in our control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares or transactions that our stockholders might otherwise deem to be in their best
interests. Therefore, these provisions could adversely affect the price of our common stock. Among other things, our amended and restated certificate of incorporation and amended and restated bylaws: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">permit our board of directors to issue up to 10,000,000 shares of preferred stock, with any rights, preferences and
privileges as they may designate; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that the authorized number of directors may be changed only by resolution adopted by a majority of the board of
directors; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that the board of directors or any individual director may only be removed with cause and the affirmative vote of
the holders of at least 66.67% of the voting power of all of our then outstanding common stock; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that all vacancies, including newly created directorships, may, except as otherwise required by law or subject to
the rights of holders of preferred stock as designated from time to time, be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">divide our board of directors into three classes; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">require that any action to be taken by our stockholders must be effected at a duly called annual or special meeting of
stockholders and not be taken by written consent or electronic transmission; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for
election as directors at a meeting of stockholders must provide notice in writing in a timely manner and also specify requirements as to the form and content of a stockholder&#146;s notice; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">do not provide for cumulative voting rights (therefore allowing the holders of a majority of the shares of common stock
entitled to vote in any election of directors to elect all of the directors standing for election, if they should so choose); </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that special meetings of our stockholders may be called only by our board of directors acting pursuant to a
resolution approved by the affirmative vote of a majority of the directors then in office; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">provide that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for state law claims for
(i)&nbsp;any derivative action or proceeding brought on our behalf, (ii)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers and employees to us or our stockholders, (iii)&nbsp;any
action asserting a claim against us or any of our current or former directors, officers, or other employees or stockholders arising pursuant to any provision of the DGCL, our amended and restated certificate of incorporation or our amended and
restated bylaws, (iv)&nbsp;any action to interpret, apply, enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws or (v)&nbsp;any action asserting a claim against us or any of
our current or former directors or officers or other employees that is governed by the internal affairs doctrine. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The amendment
of any of these provisions included in our amended and restated certificate of incorporation, with the exception of the ability of our board of directors to issue shares of preferred stock and designate any rights, preferences and privileges
thereto, would require the affirmative vote of the majority of all of our then outstanding common stock. The amendment of any of these provisions included in our amended and restated bylaws would require the affirmative vote of the holders of at
least 66.67% of the voting power of our then outstanding common stock. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Nasdaq Global Select Market Listing </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have applied to list our common stock on The Nasdaq Global Select Market under the trading symbol &#147;PRAX.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL">The transfer agent and
registrar for our common stock is Computershare Trust Company, N.A. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">215 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom945651_19"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Prior to this offering, there has been no public market for our shares. Future sales of our common stock in the public market, or the availability of
such shares for sale in the public market, could adversely affect market prices prevailing from time to time. As described below, only a limited number of shares will be available for sale shortly after this offering due to contractual and legal
restrictions on resale. Nevertheless, sales of our common stock in the public market after such restrictions lapse, or the perception that those sales may occur, could adversely affect the prevailing market price at such time and our ability to
raise equity capital in the future. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Based on the number of shares outstanding as of September 30, 2020 upon the completion of this offering,
36,749,675 shares of our common stock will be outstanding, assuming no exercise of the underwriters&#146; option to purchase additional shares and no exercise of outstanding options. Of the outstanding shares, all of the shares sold in this offering
will be freely tradable, except that any shares held by our affiliates, as that term is defined in Rule&nbsp;144 under the Securities Act, may only be sold in compliance with the limitations described below, and shares of our common stock are
restricted shares of common stock subject to service-based vesting terms. These restricted securities were issued and sold by us, or will be issued and sold by us, in private transactions and are eligible for public sale only if registered under the
Securities Act or if they qualify for an exemption from registration under the Securities Act, including the exemptions provided by Rule&nbsp;144 or Rule 701, which rules are summarized below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As a result of <FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;agreements</FONT> referred to below and the provisions of Rule 144 and Rule 701
under the Securities Act, the shares of our common stock (excluding the shares sold in this offering) that will be available for sale in the public market are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">beginning on the date of this prospectus, the 10,000,000 shares of common stock sold in this offering will be immediately
available for sale in the public market; </P></TD></TR></TABLE>  <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">beginning 181 days after the date of this prospectus, 26,737,873 additional shares of common stock will become eligible for
sale in the public market, of which 18,096,460 shares will be held by affiliates and subject to the volume and other restrictions of Rule 144, as described below; and </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the remainder of the shares of common stock will be eligible for sale in the public market from time to time thereafter,
subject in some cases to the volume and other restrictions of Rule 144, as described below. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Rule&nbsp;144 </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In general, a person who has beneficially owned restricted stock for at least six months would be entitled to sell their securities provided that
(i)&nbsp;such person is not deemed to have been one of our affiliates at the time of, or at any time during the 90 days preceding, a sale and (ii)&nbsp;we are subject to the Securities Exchange Act of 1934, as amended, or the Exchange Act, periodic
reporting requirements for at least 90 days before the sale. Persons who have beneficially owned restricted shares for at least six months but who are our affiliates at the time of, or any time during the 90 days preceding, a sale, would be subject
to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of securities that does not exceed the greater of either of the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">1% of the number of shares then outstanding, which will equal approximately shares immediately after this offering,
assuming no exercise of the underwriters&#146; option to purchase additional shares, based on the number of shares outstanding as of September 30, 2020; or </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the average weekly trading volume of our common stock on The Nasdaq Global Select Market during the four calendar weeks
preceding the filing of a notice on Form&nbsp;144 with respect to the sale; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">216 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">provided, in each case, that we are subject to the Exchange Act periodic reporting requirements for at
least 90&nbsp;days before the sale. Such sales both by affiliates and <FONT STYLE="white-space:nowrap">by&nbsp;non-affiliates&nbsp;must</FONT> also comply with the manner of sale, current public information and notice provisions of Rule&nbsp;144.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Rule&nbsp;701 </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Rule&nbsp;701 under the Securities Act,
as in effect on the date of this prospectus, permits resales of shares in reliance upon Rule&nbsp;144 but without compliance with certain restrictions of Rule&nbsp;144, including the holding period requirement. Most of our employees, executive
officers or directors who purchased shares under a written compensatory plan or contract may be entitled to rely on the resale provisions of Rule&nbsp;701, but all holders of Rule&nbsp;701 shares are required to wait until 90 days after the date of
this prospectus before selling their shares. However, substantially all Rule&nbsp;701 shares are subject <FONT STYLE="white-space:nowrap">to&nbsp;lock-up&nbsp;agreements</FONT> as described below and under &#147;Underwriting&#148; included elsewhere
in this prospectus and will become eligible for sale upon the expiration of the restrictions set forth in those agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Lock-Up&nbsp;Agreements</FONT> </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We, all of our directors and executive officers, and the holders of substantially all of our capital stock and securities convertible into or
exchangeable for our capital stock have entered <FONT STYLE="white-space:nowrap">into&nbsp;lock-up&nbsp;agreements</FONT> with the underwriters and/or are subject to market standoff agreements or other agreements with us, which prevents them from
selling any of our common stock or any securities convertible into or exercisable or exchangeable for common stock for a period of not less than 180&nbsp;days from the date of this prospectus without the prior written consent of the representatives,
subject to certain exceptions. See the section entitled &#147;Underwriting&#148; appearing elsewhere in this prospectus for more information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Registration
Rights </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon completion of this offering, certain holders of our securities will be entitled to various rights with respect to registration of
their shares under the Securities Act.&nbsp;Registration of these shares under the Securities Act would result in these shares becoming fully tradable without restriction under the Securities Act immediately upon the effectiveness of the
registration.&nbsp;See the section entitled &#147;Description of Capital Stock&#151;Registration rights&#148; appearing elsewhere in this prospectus for more information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Equity Incentive Plans </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We intend to file one or more
registration statements <FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;S-8&nbsp;under</FONT> the Securities Act to register our shares issued or reserved for issuance under our equity incentive plans. The first such registration statement is
expected to be filed soon after the date of this prospectus and will automatically become effective upon filing with the SEC. Accordingly, shares registered under such registration statement will be available for sale in the open market, unless such
shares are subject to vesting restrictions with us or <FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;restrictions</FONT> described above. As of September 30, 2020, we estimate that such registration statement
<FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;S-8&nbsp;will</FONT> cover approximately 9,413,074 shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">217 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom945651_20"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS OF COMMON STOCK </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following discussion is a summary of certain material U.S. federal
income tax considerations applicable to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders (as defined below) with respect to their ownership and disposition of shares of our common stock issued pursuant to this offering. For purposes of this
discussion, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder means a beneficial owner of our common stock that is for U.S. federal income tax purposes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a <FONT STYLE="white-space:nowrap">non-resident</FONT> alien individual; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a foreign corporation or any other foreign organization taxable as a corporation for U.S. federal income tax purposes; or
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">a foreign estate or trust, the income of which is not subject to U.S. federal income tax on a net income basis.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This discussion does not address the tax treatment of partnerships or other entities that are pass-through entities for U.S.
federal income tax purposes or persons that hold their common stock through partnerships or other pass-through entities. A partner in a partnership or other pass-through entity that will hold our common stock should consult his, her or its tax
advisor regarding the tax consequences of acquiring, holding and disposing of our common stock through a partnership or other pass-through entity, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This discussion is based on current provisions of the U.S. Internal Revenue Code of 1986, as amended, which we refer to as the Code, existing and
proposed U.S. Treasury Regulations promulgated thereunder, current administrative rulings and judicial decisions, all as in effect as of the date of this prospectus and, all of which are subject to change or to differing interpretation, possibly
with retroactive effect. Any such change or differing interpretation could alter the tax consequences to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders described in this prospectus. There can be no assurance that the Internal Revenue
Service, which we refer to as the IRS, will not challenge one or more of the tax consequences described herein. We assume in this discussion that a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds shares of our common stock as a capital
asset within the meaning of Section&nbsp;1221 of the Code, which is generally property held for investment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This discussion does not address all
aspects of U.S. federal income taxation that may be relevant to a particular <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in light of that <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s individual circumstances nor does it
address any U.S. state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> taxes, the alternative minimum tax, the Medicare tax on net investment income, the rules regarding qualified small business stock within the meaning of
Section&nbsp;1202 of the Code or &#147;Section&nbsp;1244 stock&#148; within the meaning of Section&nbsp;1244 of the Code, or any other aspect of any U.S. federal tax other than the income tax. This discussion also does not consider any specific
facts or circumstances that may apply to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder and does not address the special tax rules applicable to particular <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders, such as: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">insurance companies; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> or governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">financial institutions; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">brokers or dealers in securities; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">regulated investment companies; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">pension plans; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#147;controlled foreign corporations,&#148; &#147;passive foreign investment companies&#148; and corporations that
accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">218 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">&#147;qualified foreign pension funds,&#148; or entities wholly owned by a &#147;qualified foreign pension fund&#148;;
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons that elect to apply <FONT STYLE="white-space:nowrap">Section&nbsp;1400Z-2</FONT> of the Code to gains recognized
with respect to shares of our common stock; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons deemed to sell our common stock under the constructive sale provisions of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">persons that hold our common stock as part of a straddle, hedge, conversion transaction, synthetic security or other
integrated investment; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">certain U.S. expatriates. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This discussion is for general information only and is not tax advice. Accordingly, all prospective <FONT STYLE="white-space:nowrap">non-U.S.</FONT>
holders of our common stock should consult their tax advisors with respect to the U.S. federal, state, local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of the purchase, ownership and disposition of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Distributions on Our Common Stock </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As indicated in the
&#147;Dividend Policy&#148; section of this prospectus, we have never declared or paid cash dividends on any of our capital stock and currently intend to retain all available funds and any future earnings to fund the development and growth of our
business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the event that we do make distributions, subject to the discussions below under the sections titled &#147;Backup Withholding and
Information Reporting&#148; and &#147;Withholding and Information Reporting Requirements&#151;FATCA&#148;, distributions paid on our common stock will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or
accumulated earnings and profits, as determined under U.S. federal income tax principles. If a distribution exceeds our current and accumulated earnings and profits, the excess will be treated as a <FONT STYLE="white-space:nowrap">tax-free</FONT>
return of the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s investment, up to such holder&#146;s tax basis in the common stock. Any remaining excess will be treated as capital gain, subject to the tax treatment described below in
&#147;Gain on Sale or Other Taxable Disposition of Our Common Stock.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Subject to the discussion in the following two paragraphs in this
section, dividends paid to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be subject to withholding of U.S. federal income tax at a 30% rate or such lower rate as may be specified by an applicable income tax treaty between
the United States and such holder&#146;s country of residence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Dividends that are treated as effectively connected with a trade or business
conducted by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United States and, if an applicable income tax treaty so provides, that are attributable to a permanent establishment or a fixed base maintained by the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder within the United States, are generally exempt from the 30% withholding tax if the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder satisfies applicable certification and disclosure
requirements. However, such U.S. effectively connected income, net of specified deductions and credits, is taxed at the same graduated U.S. federal income tax rates applicable to United States persons (as defined in the Code). Any U.S. effectively
connected income received by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a corporation may also, under certain circumstances, be subject to an additional &#147;branch profits tax&#148; at a 30% rate or such lower rate as may be
specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder of our common stock who claims the benefit of an applicable income tax treaty between the United States and such holder&#146;s country of residence generally will be required to provide a properly
executed IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or successor form) to the applicable withholding agent and satisfy applicable certification
and other requirements. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders are urged to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">219 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
consult their tax advisors regarding their entitlement to benefits under a relevant income tax treaty. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is eligible for such lower
rate of U.S. withholding tax as may be specified under an income tax treaty may obtain a refund or credit of any excess amounts withheld by timely filing a U.S. tax return with the IRS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Gain on Sale or Other Taxable Disposition of Our Common Stock </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Subject to the discussions below under &#147;Backup Withholding and Information Reporting&#148; and &#147;Withholding and Information Reporting
Requirements&#151;FATCA,&#148; a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will not be subject to any U.S. federal income or withholding tax on any gain realized upon such holder&#146;s sale or other taxable disposition of
shares of our common stock unless: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s conduct of a U.S.
trade or business and, if an applicable income tax treaty so provides, is attributable to a permanent establishment or a fixed-base maintained by such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United States, in which case the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will be taxed on a net income basis at the graduated U.S. federal income tax rates applicable to United States persons (as defined in the Code) and, if the
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a foreign corporation, the branch profits tax described above in &#147;Distributions on Our Common Stock&#148; also may apply; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien individual who is present in the United
States for a period or periods aggregating 183 days or more in the taxable year of the disposition and certain other conditions are met, in which case the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be subject to a 30% tax (or such
lower rate as may be specified by an applicable income tax treaty between the United States and such holder&#146;s country of residence) on the net gain derived from the disposition, which may be offset by certain U.S. source capital losses of the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder, if any (even though the individual is not considered a resident of the United States), provided that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder has timely filed U.S. federal income
tax returns with respect to such losses; or </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we are, or have been, at any time during the five-year period preceding such sale or other taxable disposition (or the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s holding period, if shorter) a &#147;U.S. real property holding corporation,&#148; unless our common stock is regularly traded on an established securities market, as defined by applicable U.S.
Treasury Regulations, and the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds no more than 5% of our outstanding common stock, directly or indirectly, actually or constructively, during the shorter of the
<FONT STYLE="white-space:nowrap">5-year</FONT> period ending on the date of the disposition or the period that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder held our common stock. Generally, a corporation is a U.S. real property
holding corporation only if the fair market value of its U.S. real property interests equals or exceeds 50% of the sum of the fair market value of its worldwide real property interests plus its other assets used or held for use in a trade or
business. Although there can be no assurance, we do not believe that we are, or have been, a U.S. real property holding corporation, or that we are likely to become one in the future. No assurance can be provided that our common stock will be
regularly traded on an established securities market for purposes of the rules described above. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their own tax advisors about the consequences that could result if we are, or
become, a U.S. real property holding corporation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Backup Withholding and Information Reporting </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We must report annually to the IRS and to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder the gross amount of the distributions on our
common stock paid to such holder and the tax withheld, if any, with respect to such distributions. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders may have to comply with specific certification procedures to establish that the holder is not
a United States person (as defined in the Code) in order to avoid backup withholding at the applicable rate with respect to dividends on our common stock. Dividends paid to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders subject to
withholding of U.S. federal income tax, as described above in &#147;Distributions on Our Common Stock,&#148; generally will be exempt from U.S. backup withholding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">220 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Information reporting and backup withholding will generally apply to the proceeds of a disposition of
our common stock by a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder effected by or through the U.S. office of any broker, U.S. or foreign, unless the holder certifies its status as a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder
and satisfies certain other requirements, or otherwise establishes an exemption. Generally, information reporting and backup withholding will not apply to a payment of disposition proceeds to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder
where the transaction is effected outside the United States through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker. However, for information reporting purposes, dispositions effected through a
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a broker with substantial U.S. ownership or operations generally will be treated in a manner similar to dispositions effected through a U.S. office of a broker. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding the application of the information reporting and
backup withholding rules to them. Copies of information returns may be made available to the tax authorities of the country in which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides or is incorporated under the provisions of a
specific treaty or agreement. Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules from a payment to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder can be refunded or credited against the <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s U.S. federal income tax liability, if any, provided that an appropriate claim is filed with the IRS in a timely manner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Withholding and Information Reporting Requirements&#151;FATCA </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Provisions of the Code commonly referred to as the Foreign Account Tax Compliance Act, or FATCA, generally impose a U.S. federal withholding tax at a
rate of 30% on payments of dividends on our common stock paid to a foreign entity unless (i)&nbsp;if the foreign entity is a &#147;foreign financial institution,&#148; such foreign entity undertakes certain due diligence, reporting, withholding and
certification obligations, (ii)&nbsp;if the foreign entity is not a &#147;foreign financial institution,&#148; such foreign entity identifies certain of its U.S. investors, if any or (iii)&nbsp;the foreign entity is otherwise exempt under FATCA.
Such withholding may also apply to payments of gross proceeds of sales or other dispositions of our common stock, although under recently proposed U.S. Treasury Regulations (the preamble to which specifies that taxpayers are permitted to rely on
such proposed U.S. Treasury Regulations pending finalization), no withholding will apply to such payments of gross proceeds. Under certain circumstances, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder may be eligible for refunds or
credits of this withholding tax. An intergovernmental agreement between the United States and an applicable foreign country may modify the requirements described in this paragraph. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should
consult their tax advisors regarding the possible implications of this legislation on their investment in our common stock and the entities through which they hold our common stock, including, without limitation, the process and deadlines for
meeting the applicable requirements to prevent the imposition of the 30% withholding tax under FATCA. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">221 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom945651_21"></A>UNDERWRITING (CONFLICTS OF INTEREST) </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We and the underwriters for the offering named below, have entered into an underwriting agreement with respect to the common stock being offered.
Subject to the terms and conditions of the underwriting agreement, each underwriter has severally agreed to purchase from us the number of shares of our common stock set forth opposite its name below. Cowen and Company, LLC, Evercore Group L.L.C.
and Piper Sandler&nbsp;&amp; Co. are the representatives of the underwriters. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Evercore Group L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Piper Sandler&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Wedbush Securities Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Blackstone Securities Partners L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10,000,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The underwriting agreement provides that the obligations of the underwriters are subject to certain conditions
precedent and that the underwriters have agreed, severally and not jointly, to purchase all of the shares sold under the underwriting agreement if any of these shares are purchased, other than those shares covered by the overallotment option
described below. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may be increased or the underwriting agreement may be
terminated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have agreed to indemnify the underwriters against specified liabilities, including liabilities under the Securities Act of 1933, and
to contribute to payments the underwriters may be required to make in respect thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The underwriters are offering the shares, subject to prior
sale, when, as and if issued to and accepted by them, subject to approval of legal matters by their counsel and other conditions specified in the underwriting agreement. The underwriters reserve the right to withdraw, cancel or modify offers to the
public and to reject orders in whole or in part. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Overallotment Option to Purchase Additional Shares. </I>We have granted to the underwriters
an option to purchase up to 1,500,000 additional shares of common stock at the public offering price, less the underwriting discount. This option is exercisable for a period of 30 days. The underwriters may exercise this option solely for the
purpose of covering overallotments, if any, made in connection with the sale of common stock offered hereby. To the extent that the underwriters exercise this option, the underwriters will purchase additional shares from us in approximately the same
proportion as shown in the table above. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Directed share program</I>. At our request, the underwriters have reserved for sale at the public
offering price up to 5% of the shares of common stock for sale to individuals, including our officers, directors and employees, as well as friends and family members of our officers and directors, who have expressed an interest in purchasing shares
in this offering. The sales will be made by the directed share program administrator. If purchased by persons who are not officers or directors, the shares will not be subject to a lock-up restriction. If purchased by any officer or director, the
shares will be subject to a 180-day lock-up restriction. The underwriters will receive the same underwriting discount on any shares purchased by these persons as they will on any other shares sold to the public in this offering.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">222 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
The number of shares of common stock available for sale to the general public in this offering, referred to as the general public shares, will be reduced to the extent these persons purchase the
directed shares in the program. Any directed shares not so purchased will be offered by the underwriters to the general public on the same terms as the other shares. Likewise, to the extent demand by these persons exceeds the number of directed
shares reserved for sale in the program, and there are remaining shares available for sale to these persons after the general public shares have first been offered for sale to the general public, then such remaining shares may be sold to these
persons at the discretion of the underwriters. We have agreed to indemnify the underwriters against certain liabilities and expenses, including liabilities under the Securities Act, in connection with sales of the directed shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Discounts and Commissions. </I>The following table shows the public offering price, underwriting discount and commissions and proceeds, before
expenses to us. These amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We estimate that the total expenses of the offering, excluding underwriting discounts and commissions, will be approximately $3.3&nbsp;million and are
payable by us. We also have agreed to reimburse the underwriters for up to $30,000 for their FINRA counsel fee. In accordance with FINRA Rule 5110, this reimbursed fee is deemed underwriting compensation for this offering. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Per&nbsp;Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Without&nbsp;Over-<BR>Allotment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>With&nbsp;Over<BR>Allotment</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Underwriting discount</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds, before expenses, to Praxis Precision Medicines, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The underwriters propose to offer the shares of common stock to the public at the public offering price set forth on the
cover of this prospectus. The underwriters may offer the shares of common stock to securities dealers at the public offering price less a concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per
share. If all of the shares are not sold at the public offering price, the underwriters may change the offering price and other selling terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Discretionary Accounts. </I>The underwriters do not intend to confirm sales of the shares to any accounts over which they have discretionary
authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Market Information. </I>Prior to this offering, there has been no public market for shares of our common stock. The initial public
offering price will be determined by negotiations between us and the representatives of the underwriters. In addition to prevailing market conditions, the factors to be considered in these negotiations will include: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the history of, and prospects for, our company and the industry in which we compete; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our past and present financial information; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">an assessment of our management; its past and present operations, and the prospects for, and timing of, our future
revenues; </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the present state of our development; and </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the above factors in relation to market values and various valuation measures of other companies engaged in activities
similar to ours. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">An active trading market for the shares may not develop. It is also possible that after the offering the shares
will not trade in the public market at or above the initial public offering price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">223 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
  <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have applied for the quotation of our common stock on The Nasdaq Global Select Market under the
symbol &#145;&#145;PRAX&#146;&#146;. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Stabilization. </I>In connection with this offering, the underwriters may engage in stabilizing
transactions, overallotment transactions, syndicate covering transactions, penalty bids and purchases to cover positions created by short sales. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Stabilizing transactions permit bids to purchase shares of common stock so long as the stabilizing bids do not exceed a
specified maximum, and are engaged in for the purpose of preventing or retarding a decline in the market price of the common stock while the offering is in progress. </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Overallotment transactions involve sales by the underwriters of shares of common stock in excess of the number of shares
the underwriters are obligated to purchase. This creates a syndicate short position which may be either a covered short position or a naked short position. In a covered short position, the number of shares over-allotted by the underwriters is not
greater than the number of shares that they may purchase in the overallotment option. In a naked short position, the number of shares involved is greater than the number of shares in the overallotment option. The underwriters may close out any short
position by exercising their overallotment option and/or purchasing shares in the open market. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Syndicate covering transactions involve purchases of common stock in the open market after the distribution has been
completed in order to cover syndicate short positions. In determining the source of shares to close out the short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared
with the price at which they may purchase shares through exercise of the overallotment option. If the underwriters sell more shares than could be covered by exercise of the overallotment option and, therefore, have a naked short position, the
position can be closed out only by buying shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that after pricing there could be downward pressure on the price of the shares in the open
market that could adversely affect investors who purchase in the offering. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Penalty bids permit the representatives to reclaim a selling concession from a syndicate member when the common stock
originally sold by that syndicate member is purchased in stabilizing or syndicate covering transactions to cover syndicate short positions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">These stabilizing transactions, syndicate covering transactions and penalty bids may have the effect of raising or maintaining the market price of our
common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock in the open market may be higher than it would otherwise be in the absence of these transactions. Neither we nor
the underwriters make any representation or prediction as to the effect that the transactions described above may have on the price of our common stock. These transactions may be effected on the Nasdaq Stock Market, in the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise and, if commenced, may be discontinued at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Passive Market Making. </I>In connection with this offering, underwriters and selling group members may engage in passive market making transactions
in our common stock on the Nasdaq Stock Market in accordance with Rule 103 of Regulation M under the Securities Exchange Act of 1934, as amended, during a period before the commencement of offers or sales of common stock and extending through the
completion of the distribution. A passive market maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#146;s bid, such bid
must then be lowered when specified purchase limits are exceeded. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">224 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements. </I>Pursuant to certain <FONT
STYLE="white-space:nowrap">&#145;&#145;lock-up&#146;&#146;</FONT> agreements, we and our executive officers, directors and the holders of substantially all of our capital stock and securities convertible into or exchangeable for our capital stock,
have agreed, subject to certain exceptions, not to offer, sell, assign, transfer, pledge, contract to sell, or otherwise dispose of or announce the intention to otherwise dispose of, or enter into any swap, hedge or similar agreement or arrangement
that transfers, in whole or in part, the economic consequence of ownership of, directly or indirectly, or make any demand or request or exercise any right with respect to the registration of, or file with the SEC a registration statement under the
Securities Act relating to, any common stock or securities convertible into or exchangeable or exercisable for any common stock without the prior written consent of Cowen and Company, LLC, Evercore Group L.L.C. and Piper Sandler&nbsp;&amp; Co. for a
period of 180 days after the date of the pricing of the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">This <FONT STYLE="white-space:nowrap">lock-up</FONT> provision applies to common
stock and to securities convertible into or exchangeable or exercisable for common stock. It also applies to common stock owned now or acquired later by the person executing the agreement or for which the person executing the agreement later
acquires the power of disposition. The exceptions permit us, among other things and subject to restrictions, to: (a)&nbsp;issue common stock or options pursuant to employee benefit plans, (b)&nbsp;issue common stock upon exercise of outstanding
options or warrants or (c)&nbsp;file registration statements on Form <FONT STYLE="white-space:nowrap">S-8.</FONT> The exceptions permit parties to the <FONT STYLE="white-space:nowrap">&#145;&#145;lock-up&#146;&#146;</FONT> agreements, among other
things and subject to restrictions, to: (a)&nbsp;make certain gifts, (b)&nbsp;if the party is a corporation, partnership, limited liability company or other business entity, make transfers to any shareholders, partners, members of or owners of
similar equity interests in, the party, or to an affiliate of the party, if such transfer is not for value, (c)&nbsp;if the party is a corporation, partnership, limited liability company or other business entity, make transfers in connection with
the sale or transfer of all of the party&#146;s capital stock, partnership interests, membership interests or other similar equity interests, as the case may be, or all or substantially all of the party&#146;s assets, in any such case not undertaken
for the purpose of avoiding the restrictions imposed by the <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreement and (d)&nbsp;participate in tenders involving the acquisition of 75% or more of our stock. In addition, the <FONT
STYLE="white-space:nowrap">lock-up</FONT> provision will not restrict broker-dealers from engaging in market making and similar activities conducted in the ordinary course of their business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Cowen and Company, LLC, Evercore Group L.L.C. and Piper Sandler&nbsp;&amp; Co., in their sole discretion, may release our common stock and other
securities subject to the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above in whole or in part at any time. In certain circumstances, the release of shares of common stock from the lock-up restrictions described above will
trigger a pro rata release of shares of common stock held by certain other holders. When determining whether or not to release our common stock and other securities from <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, Cowen and Company,
LLC, Evercore Group L.L.C. and Piper Sandler&nbsp;&amp; Co. will consider, among other factors, the holder&#146;s reasons for requesting the release, the number of shares for which the release is being requested and market conditions at the time of
the request. In the event of such a release or waiver for one of our directors or officers, Cowen and Company, LLC, Evercore Group L.L.C. and Piper Sandler&nbsp;&amp; Co. shall provide us with notice of the impending release or waiver at least three
business days before the effective date of such release or waiver and we will announce the impending release or waiver by issuing a press release at least two business days before the effective date of the release or waiver. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Other Relationships. </I>Certain of the underwriters and their affiliates have provided, and may in the future provide, various investment banking,
commercial banking and other financial services for us and our affiliates for which they have received, and may in the future receive, customary fees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Clarus Life Sciences III, L.P., or Clarus, an entity affiliated with Blackstone Securities Partners L.P., purchased (i) an aggregate of 7,375,799 shares
of our Series A preferred stock from October 2016 to July 2017, including shares received upon conversion of convertible promissory notes previously issued, (ii) an aggregate of 5,052,852 shares of our Series B preferred stock from March
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">225 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
2018 to October 2018, including shares received upon conversion of convertible promissory notes previously issued, (iii) 1,410,477 shares of our Series B-1 preferred stock in June 2019; (iv)
559,208 shares of our Series C preferred stock in November 2019; and (v) 352,734 shares of our Series C-1 preferred stock in July&nbsp;2020. In addition, BSOF Parallel Master Fund L.P., or BSOF, an entity affiliated with Blackstone Securities
Partners L.P. purchased 1,941,748 shares of our Series C preferred stock in April 2020. Clarus and BSOF, together the Blackstone Entities, have agreed, pursuant to Rule 5110(g) of the Financial Industry Regulatory Authority, Inc., or FINRA Rule
5110(g), that such shares of Series A preferred stock, Series B preferred stock, Series B-1 preferred stock, Series C preferred stock and Series C-1 preferred stock, or together the Preferred Stock, and the shares of our common stock to be issued to
the Blackstone Entities upon conversion of the Preferred Stock in connection with this offering will not be sold during this offering, or sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale,
derivative, put or call transaction that would result in the effective economic disposition of such shares of the Preferred Stock or common stock by any person for a period of 180 days immediately following the date of effectiveness of the
registration statement of which this prospectus is a part or commencement of sales of common stock in this offering, except as permitted by FINRA Rule 5110(g)(2). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Conflicts of Interest</I>. The Blackstone Entities, which beneficially own more than 10% of our outstanding preferred equity prior to the
consummation of this offering, are affiliates of Blackstone Securities Partners L.P., an underwriter in this offering. As a result, Blackstone Securities Partners L.P. is deemed to have a &#147;conflict of interest&#148; within the meaning of FINRA
Rule 5121. Accordingly, this offering is being made in compliance with the applicable requirements of FINRA Rule 5121. A qualified independent underwriter is not necessary for this offering pursuant to FINRA Rule 5121(a)(1)(A). Pursuant to FINRA
Rule 5121, Blackstone Securities Partners L.P. will not confirm any sales to any account over which it exercises discretionary authority without the specific prior written approval of the account holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Canada</I>. The common stock may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as
defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> <I>Prospectus Exemptions</I> or subsection 73.3(1) of the <I>Securities Act </I>(Ontario), and are permitted clients, as defined in National Instrument <FONT
STYLE="white-space:nowrap">31-103</FONT> <I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>. Any resale of the common stock must be made in accordance with an exemption from, or in a transaction not subject to, the
prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Securities legislation in certain provinces or territories of Canada may provide a purchaser
with remedies for rescission or damages if this prospectus (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the
securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with
a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pursuant to section 3A.3 of National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> <I>Underwriting Conflicts </I>(NI <FONT
STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this
offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Switzerland. </I>The securities will not be offered, directly or indirectly, to the public in Switzerland and this prospectus does not
constitute a public offering prospectus as that term is understood pursuant to article 652a or 1156 of the Swiss Federal Code of Obligations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>European Economic Area and the United Kingdom. </I>In relation to each Member State of the European Economic Area and the United Kingdom (each, a
&#147;Member State&#148;), no shares have been </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">226 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
offered or will be offered pursuant to the offering to the public in that Member State prior to the publication of a prospectus in relation to the shares which has been approved by the competent
authority in that Member State or, where appropriate, approved in another Member State and notified to the competent authority in that Member State, all in accordance with the Prospectus Regulation, except that offers of shares may be made to the
public in that Member State at any time under the following exemptions under the Prospectus Regulation: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A.&nbsp;&nbsp;&nbsp;&nbsp;to any legal
entity which is a qualified investor as defined under the Prospectus Regulation; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">B.&nbsp;&nbsp;&nbsp;&nbsp;to fewer than 150 natural or legal
persons (other than qualified investors as defined under the Prospectus Regulation), subject to obtaining the prior consent of the underwriters; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">C.&nbsp;&nbsp;&nbsp;&nbsp;in any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">provided that no such offer of shares shall require the Company or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus
Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation and each person who initially acquires any shares or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with each of
the underwriters and the Company that it is a &#147;qualified investor&#148; within the meaning of Article 2(e) of the Prospectus Regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In
the case of any shares being offered to a financial intermediary as that term is used in Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares acquired by it in the offer
have not been acquired on <FONT STYLE="white-space:nowrap">a&nbsp;non-discretionary&nbsp;basis</FONT> on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any
shares to the public other than their offer or resale in a Member State to qualified investors as so defined or in circumstances in which the prior consent of the underwriters have been obtained to each such proposed offer or resale. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to shares in any Member State means the communication
in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares, and the expression &#147;Prospectus Regulation&#148; means
Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">References to the Prospectus Regulation includes, in relation to the United Kingdom, the Prospectus Regulation as it
forms part of the United Kingdom domestic law by virtue of the European Union (Withdrawal) Act of 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>United Kingdom. </I>In addition, in the
United Kingdom, this document is being distributed only to, and is directed only at, and any offer subsequently made may only be directed at persons who are &#147;qualified investors&#148; (as defined in the Prospectus Regulation)&nbsp;(i) who have
professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the &#147;Order&#148;) and/or (ii)&nbsp;who are high net worth
companies (or persons to whom it may otherwise be lawfully communicated) falling within Article 49(2)(a) to (d)&nbsp;of the Order and/or (iii)&nbsp;to whom it may otherwise be lawfully communicated (all such persons together being referred to as
&#147;relevant persons&#148;) in circumstances which have not resulted and will not result in an offer to the public of the shares in the United Kingdom within the meaning of the Financial Services and Markets Act 2000. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Any person in the United Kingdom that is not a relevant person should not act or rely on the information included in this document or use it as basis
for taking any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">227 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Hong Kong. </I>The shares have not been offered or sold and will not be offered or sold in Hong
Kong, by means of any document, other than (a)&nbsp;to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (the &#147;SFO&#148;) of Hong Kong and any rules made thereunder; or
(b)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32) of Hong Kong) (the &#147;CO&#148;), or which do not
constitute an offer to the public within the meaning of the CO. No advertisement, invitation or document relating to the shares has been or may be issued or has been or may be in the possession of any person for the purposes of issue, whether in
Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or
are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the SFO and any rules made thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Singapore. </I>Each underwriter has acknowledged that this prospectus has not been registered as a prospectus with the Monetary Authority of
Singapore. Accordingly, each underwriter has represented and agreed that it has not offered or sold any shares or caused the shares to be made the subject of an invitation for subscription or purchase and will not offer or sell any shares or cause
the shares to be made the subject of an invitation for subscription or purchase, and has not circulated or distributed, nor will it circulate or distribute, this prospectus or any other document or material in connection with the offer or sale, or
invitation for subscription or purchase, of the shares, whether directly or indirectly, to any person in Singapore other than: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A. to an
institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act (Chapter 289) of Singapore, as modified or amended from time to time (the &#147;SFA&#148;)) pursuant to Section&nbsp;274 of the SFA; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">B. to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to
Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified in Section&nbsp;275 of the SFA; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">C. otherwise pursuant to, and
in accordance with the conditions of, any other applicable provision of the SFA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Where the shares are subscribed or purchased under
Section&nbsp;275 of the SFA by a relevant person which is: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A. a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of
the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">B. a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary of the trust is an
individual who is an accredited investor, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">securities or securities-based derivatives contracts (each term as defined in Section&nbsp;2(1) of the
SFA) of that corporation or the beneficiaries&#146; rights and interest (however described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under
Section&nbsp;275 of the SFA except: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">(i) to an institutional investor or to a relevant person, or to any person arising from an offer referred to in
Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">(ii) where no consideration is or will be given for the transfer; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">228 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">(iii) where the transfer is by operation of law; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">(iv) as specified in Section&nbsp;276(7) of the SFA; or </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">(v) as specified in Regulation 37A of the Securities and Futures (Offers of Investments) (Securities and Securities-based Derivatives Contracts)
Regulations 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Singapore SFA Product Classification&#151;In connection with Section&nbsp;309B of the SFA and the CMP Regulations 2018, unless
otherwise specified before an offer of shares, we have determined, and hereby notify all relevant persons (as defined in Section&nbsp;309A(1) of the SFA), that the shares are &#147;prescribed capital markets products&#148; (as defined in the CMP
Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA <FONT STYLE="white-space:nowrap">04-N12:</FONT> Notice on the Sale of Investment Products and MAS Notice <FONT STYLE="white-space:nowrap">FAA-N16:</FONT> Notice on
Recommendations on Investment Products). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Israel. </I>In the State of Israel this prospectus shall not be regarded as an offer to the public to
purchase shares of common stock under the Israeli Securities Law, 5728&nbsp;&#150;&nbsp;1968, which requires a prospectus to be published and authorized by the Israel Securities Authority, if it complies with certain provisions of Section&nbsp;15 of
the Israeli Securities Law, 5728&nbsp;&#150;&nbsp;1968, including, inter alia, if: (i)&nbsp;the offer is made, distributed or directed to not more than 35 investors, subject to certain conditions (the &#147;Addressed Investors&#148;); or
(ii)&nbsp;the offer is made, distributed or directed to certain qualified investors defined in the First Addendum of the Israeli Securities Law, 5728&nbsp;&#150;&nbsp;1968, subject to certain conditions (the &#147;Qualified Investors&#148;). The
Qualified Investors shall not be taken into account in the count of the Addressed Investors and may be offered to purchase securities in addition to the 35 Addressed Investors. The company has not and will not take any action that would require it
to publish a prospectus in accordance with and subject to the Israeli Securities Law, 5728&nbsp;&#150;&nbsp;1968. We have not and will not distribute this prospectus or make, distribute or direct an offer to subscribe for our common stock to any
person within the State of Israel, other than to Qualified Investors and up to 35 Addressed Investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Qualified Investors may have to submit
written evidence that they meet the definitions set out in of the First Addendum to the Israeli Securities Law, 5728&nbsp;&#150;&nbsp;1968. In particular, we may request, as a condition to be offered common stock, that Qualified Investors will each
represent, warrant and certify to us and/or to anyone acting on our behalf: (i)&nbsp;that it is an investor falling within one of the categories listed in the First Addendum to the Israeli Securities Law, 5728&nbsp;&#150;&nbsp;1968; (ii) which of
the categories listed in the First Addendum to the Israeli Securities Law, 5728&nbsp;&#150;&nbsp;1968 regarding Qualified Investors is applicable to it; (iii)&nbsp;that it will abide by all provisions set forth in the Israeli Securities Law,
5728&nbsp;&#150;&nbsp;1968 and the regulations promulgated thereunder in connection with the offer to be issued common stock; (iv)&nbsp;that the shares of common stock that it will be issued are, subject to exemptions available under the Israeli
Securities Law, 5728&nbsp;&#150;&nbsp;1968: (a) for its own account; (b)&nbsp;for investment purposes only; and (c)&nbsp;not issued with a view to resale within the State of Israel, other than in accordance with the provisions of the Israeli
Securities Law, 5728&nbsp;&#150;&nbsp;1968; and (v)&nbsp;that it is willing to provide further evidence of its Qualified Investor status. Addressed Investors may have to submit written evidence in respect of their identity and may have to sign and
submit a declaration containing, inter alia, the Addressed Investor&#146;s name, address and passport number or Israeli identification number. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We
have not authorized and do not authorize the making of any offer of securities through any financial intermediary on our behalf, other than offers made by the underwriters and their respective affiliates, with a view to the final placement of the
securities as contemplated in this document. Accordingly, no purchaser of the shares, other than the underwriters, is authorized to make any further offer of shares on our behalf or on behalf of the underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><I>Electronic Offer, Sale and Distribution of Shares. </I>A prospectus in electronic format may be made available on the websites maintained by one or
more of the underwriters or selling group members, if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">229 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
any, participating in this offering and one or more of the underwriters participating in this offering may distribute prospectuses electronically. The representatives may agree to allocate a
number of shares to underwriters and selling group members for sale to their online brokerage account holders. Internet distributions will be allocated by the underwriters and selling group members that will make internet distributions on the same
basis as other allocations. Other than the prospectus in electronic format, the information on these websites is not part of this prospectus or the registration statement of which this prospectus forms a part, has not been approved or endorsed by us
or any underwriter in its capacity as underwriter, and should not be relied upon by investors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">230 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom945651_22"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The validity of the shares of common stock offered by this prospectus will be passed upon for us by Goodwin Procter LLP, Boston, Massachusetts. Certain
legal matters related to this offering will be passed upon for the underwriters by Mintz, Levin, Cohn, Ferris, Glovsky&nbsp;&amp; Popeo, P.C., Boston, Massachusetts. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom945651_23"></A>EXPERTS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
consolidated financial statements of Praxis Precision Medicines, Inc. at December&nbsp;31, 2019 and 2018, and for each of the two years in the period ended December&nbsp;31, 2019, appearing in this Prospectus and Registration Statement have been
audited by Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, as set forth in their report thereon (which contains an explanatory paragraph describing conditions that raise substantial doubt about the Company&#146;s ability
to continue as a going concern as described in Note 1 to the consolidated financial statements) appearing elsewhere herein, and are included in reliance upon such report given on the authority of such firm as experts in accounting and auditing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="rom945651_24"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have filed with the SEC a registration statement <FONT STYLE="white-space:nowrap">on&nbsp;Form&nbsp;S-1&nbsp;(File</FONT>
Number&nbsp;333-249074)&nbsp;under the Securities Act with respect to the common stock we are offering by this prospectus. This prospectus does not contain all of the information included in the registration statement. For further information
pertaining to us and our common stock, you should refer to the registration statement and to its exhibits. Whenever we make reference in this prospectus to any of our contracts, agreements or other documents, the references are not necessarily
complete, and you should refer to the exhibits attached to the registration statement for copies of the actual contract, agreement or other document. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon the completion of the offering, we will be subject to the informational requirements of the Exchange Act and will file annual, quarterly and
current reports, proxy statements and other information with the SEC. You can read our SEC filings, including the registration statement, at the SEC&#146;s website at www.sec.gov. We also maintain a website at www.praxismedicines.com. Upon
completion of the offering, you may access, free of charge, our annual reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-K,&nbsp;quarterly</FONT> reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q,&nbsp;current</FONT> reports on <FONT
STYLE="white-space:nowrap">Form&nbsp;8-K&nbsp;and</FONT> amendment to those reported filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after such material is electronically filed with,
or furnished to, the SEC. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">231 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="index"></A><A NAME="rom945651_25"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Index to Consolidated Financial Statements as of and for the Years Ended December&nbsp;31, 2018 and 2019 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="96%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin945651_1">Report of Independent Registered Public Accounting Firm
</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"><FONT STYLE="white-space:nowrap">F-2</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin945651_2">Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"><FONT STYLE="white-space:nowrap">F-3</FONT></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin945651_3">Consolidated Statements of Operations and Comprehensive
 Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"><FONT STYLE="white-space:nowrap">F-4</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin945651_4">Consolidated Statements of Redeemable Convertible Preferred
 Stock and Stockholders&#146; (Deficit) Equity</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"><FONT STYLE="white-space:nowrap">F-5</FONT></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin945651_5">Consolidated Statements of Cash Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"><FONT STYLE="white-space:nowrap">F-6</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin945651_6">Notes to Consolidated Financial
Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"><FONT STYLE="white-space:nowrap">F-7</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Index to Unaudited Interim Condensed Consolidated Financial Statements as of June 30, 2020 and for the Six Months Ended June 30, 2019
and 2020 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin945651_7">Condensed Consolidated Balance Sheets</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">F-45</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin945651_8">Condensed Consolidated Statements of Operations and Comprehensive
 Loss</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">F-46</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin945651_9">Condensed Consolidated Statements of Redeemable Convertible
 Preferred Stock and Stockholders&#146; (Deficit) Equity</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">F-47</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin945651_10">Condensed Consolidated Statements of Cash
Flows</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">F-48</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#fin945651_11">Notes to Condensed Consolidated Financial
Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">F-49</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin945651_1"></A><A NAME="rom945651_26"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC
ACCOUNTING FIRM </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">To the Stockholders and the Board of Directors of Praxis Precision Medicines, Inc. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Opinion on the Financial Statements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We have audited the accompanying
consolidated balance sheets of Praxis Precision Medicines, Inc. (the Company) as of December 31, 2019 and 2018, the related consolidated statements of operations and comprehensive loss, redeemable convertible preferred stock and stockholders&#146;
(deficit) equity and cash flows for each of the two years in the period ended December 31, 2019, and the related notes (collectively referred to as the &#147;consolidated financial statements&#148;). In our opinion, the consolidated financial
statements present fairly, in all material respects, the financial position of the Company at December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2019, in
conformity with U.S. generally accepted accounting principles. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Adoption of ASU No. 2016-02 </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">As discussed in Note 2 to the consolidated financial statements, the Company changed its method of accounting for leases in 2019 due to the adoption of Accounting
Standards Update (ASU) No.2016-02 Leases (Topic 842) and the related amendments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>The Company&#146;s Ability to Continue as a Going Concern </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the
consolidated financial statements, the Company has suffered recurring losses from operations, has limited financial resources, and has stated that substantial doubt exists about the Company&#146;s ability to continue as a going concern.
Management&#146;s evaluation of the events and conditions and management&#146;s plans regarding these matters are also described in Note 1. The consolidated financial statements do not include any adjustments that might result from the outcome of
this uncertainty. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Basis for Opinion </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">These financial statements are the
responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight
Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about
whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits
we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#146;s internal control over financial reporting. Accordingly, we express no
such opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and
performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used
and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">/s/ Ernst &amp; Young LLP </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">We have served as the Company&#146;s auditor since 2019.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">Boston, Massachusetts </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL">July 22, 2020, except for Note 17, as to which the date is
October 9, 2020 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin945651_2"></A>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONSOLIDATED BALANCE SHEETS </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Amounts in
thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">17,950</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">44,815</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,176</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">681</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">19,126</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">45,496</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,450</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">19,829</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">47,694</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" COLSPAN="8" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><B>Liabilities, redeemable convertible preferred stock and
stockholders&#146; (deficit) equity</B></P></TD>
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:8pt; font-family:ARIAL"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,391</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,667</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,754</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,455</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">696</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5,145</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">6,818</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Long-term liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-current</FONT> portion of operating lease
liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">763</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5,147</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">7,581</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Commitments and contingencies (Note 8)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Series A redeemable convertible preferred stock, $0.0001 par value; 8,075,799
shares authorized; 8,075,799 shares issued and outstanding as of December&nbsp;31, 2018 and 2019; liquidation value as of December&nbsp;31, 2018 and 2019 of $9,284 and $9,932, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9,284</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9,932</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Series B redeemable convertible preferred stock, $0.0001 par value; 14,913,704
shares authorized; 14,913,704 shares issued and outstanding as of December&nbsp;31, 2018 and 2019; liquidation value as of December&nbsp;31, 2018 and 2019 of $46,381 and $49,969, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">46,436</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">49,969</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable convertible
preferred stock, $0.0001 par value; 2,666,666 shares authorized; no shares issued or outstanding as of December&nbsp;31, 2018, and 2,666,666 shares issued and outstanding as of December&nbsp;31, 2019; liquidation value as of December&nbsp;31, 2019
of $10,431</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10,431</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Series C redeemable convertible preferred stock, $0.0001 par value; 11,067,963
shares authorized; no shares issued or outstanding as of December&nbsp;31, 2018, and 9,805,827 shares issued and outstanding as of December&nbsp;31, 2019; liquidation value as of December 31, 2019 of $50,789</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">50,789</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Stockholders&#146; (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Common stock, $0.0001 par value; 46,000,000 shares authorized; 1,670,070 shares
issued and 1,408,677 shares outstanding as of December&nbsp;31, 2018, and 1,670,070 shares issued and 1,621,880 shares outstanding as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">326</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(41,365</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(81,009</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,038</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(81,008</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:8pt; font-family:ARIAL">Total liabilities, redeemable convertible preferred stock and stockholders&#146;
(deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">19,829</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">47,694</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin945651_3"></A>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Amounts in thousands, except share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">18,820</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">29,557</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,899</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">6,232</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">22,719</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">35,789</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(22,719</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(35,789</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(127</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(3,648</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other income (expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(3,683</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">193</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss before provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(26,402</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(35,596</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(84</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(26,535</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(35,512</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accretion and cumulative dividends on redeemable convertible preferred
stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(2,296</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(5,170</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss on conversion of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(392</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(29,223</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(40,682</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share attributable to common stockholders, basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(22.52</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(26.60</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,297,633</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,529,629</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net loss per share attributable to common stockholders, basic and
diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(2.68</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma weighted average common shares outstanding, basic and diluted
(unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">13,270,761</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin945651_4"></A>CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#146; (DEFICIT) EQUITY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Amounts in thousands, except share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt" ALIGN="center">


<TR>

<TD WIDTH="63%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A<BR>Redeemable</B><br><B>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B<BR>Redeemable<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series <FONT STYLE="white-space:nowrap">B-1</FONT><BR>Redeemable</B><br><B>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series C<BR>Redeemable<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional</B><br><B><FONT STYLE="white-space:nowrap">Paid-In</FONT></B><br><B>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>(Deficit)<BR>Equity</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL"><B>Balance at December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8,075,799</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9,031</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,174,547</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(14,438</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(14,437</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Conversion of convertible notes to Series B redeemable convertible preferred
stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,286,185</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,074</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(392</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(392</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Issuance of Series B redeemable convertible preferred stock, net of issuance
costs of $197</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">13,627,519</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">43,362</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Accretion of redeemable convertible preferred stock to redemption
value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">253</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(253</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(253</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Vesting of restricted stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">234,130</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(26,535</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(26,535</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL"><B>Balance at December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8,075,799</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9,284</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">14,913,704</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right"> 46,436</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,408,677</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">326</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(41,365</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(41,038</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Issuance of Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable
convertible preferred stock, net of issuance costs of $61</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,666,666</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9,939</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Issuance of Series C redeemable convertible preferred stock, net of issuance
costs of $165</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9,805,827</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">50,336</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">668</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">668</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Accretion of redeemable convertible preferred stock to redemption
value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">648</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,533</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">492</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">453</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(994</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(4,132</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(5,126</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Vesting of restricted stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">213,203</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(35,512</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(35,512</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL"><B>Balance at December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8,075,799</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">$9,932</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">14,913,704</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">$49,969</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,666,666</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">$10,431</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9,805,827</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">$50,789</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,621,880</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(81,009</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(81,008</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin945651_5"></A>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Amounts in thousands) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(26,535</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(35,512</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Adjustments to reconcile net loss to net cash used in operating
activities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Depreciation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">668</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Change in fair value of financial instruments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,648</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-cash</FONT> operating lease
expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">642</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-cash</FONT> interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(867</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">495</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,667</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(837</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">659</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,742</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(633</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(22</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(20,721</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(33,420</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(63</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(103</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(63</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(103</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Proceeds from issuance of convertible note</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Proceeds from issuance of redeemable convertible preferred stock, net of
issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">36,804</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">60,388</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">37,804</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">60,388</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Increase in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">17,020</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">26,865</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Cash, cash equivalents and restricted cash, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,530</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">18,550</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Cash, cash equivalents and restricted cash, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">18,550</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">45,415</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL"><B>Supplemental disclosures of <FONT STYLE="white-space:nowrap">non-cash</FONT>
activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Issuance of Series B redeemable convertible preferred stock upon settlement of
convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,074</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Settlement of derivative liabilities upon issuance of Series B redeemable
convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5,406</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Issuance of Series B redeemable convertible preferred stock to acquire Purdue
license</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,738</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Accretion of redeemable convertible preferred stock to redemption value</P></TD>

<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">253</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5,126</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Operating lease liabilities recorded upon adoption of ASC 842</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,092</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Interest expense converted into Series B redeemable convertible preferred
stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">127</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Purchases of property and equipment included in accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">41</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:ARIAL">Redeemable convertible preferred stock issuance costs included in accounts
payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin945651_6"></A>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>1. Nature of
the Business </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Praxis Precision Medicines, Inc. (&#147;Praxis&#148; or the &#147;Company&#148;) is a clinical-stage biopharmaceutical company
translating genetic insights into the development of therapies for central nervous system (&#147;CNS&#148;) disorders characterized by neuronal imbalance. The Company has established a broad portfolio, including five disclosed programs across
multiple CNS disorders, including depression, epilepsy, movement disorders and pain syndromes, with three clinical-stage product candidates. The Company&#146;s most advanced programs, <FONT STYLE="white-space:nowrap">PRAX-114</FONT> and <FONT
STYLE="white-space:nowrap">PRAX-944,</FONT> are currently in Phase 2 development. <FONT STYLE="white-space:nowrap">PRAX-114</FONT> is being developed for the treatment of major depressive disorder and perimenopausal depression, and <FONT
STYLE="white-space:nowrap">PRAX-944</FONT> is a selective small molecule inhibitor of <FONT STYLE="white-space:nowrap">T-type</FONT> calcium channels for the treatment of Essential Tremor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Praxis was incorporated in 2015. The Company has funded its operations primarily with proceeds from the issuance of convertible debt, Series A
redeemable convertible preferred stock (the &#147;Series A Preferred Stock&#148;), Series B redeemable convertible preferred stock (the &#147;Series B Preferred Stock&#148;), Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable convertible
preferred stock (the &#147;Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock&#148;) and Series C redeemable convertible preferred stock (the &#147;Series C Preferred Stock&#148;) (the Series A Preferred Stock, Series B Preferred
Stock, Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock and Series C Preferred Stock are collectively referred to as the &#147;Preferred Stock&#148;). From inception through December 31, 2019, the Company raised $107.1 million in
aggregate cash proceeds from these transactions, net of issuance costs. On February&nbsp;19, 2020 and March 3, 2020, the Company repurchased shares of Series C Preferred Stock for an aggregate cash repurchase price of $30.0 million. On April 15,
2020 and May 8, 2020, the Company sold and issued additional shares of Series C Preferred Stock for aggregate cash proceeds of $23.5 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including but not limited to, risks associated with completing preclinical studies and clinical trials, receiving regulatory approvals for
product candidates, development by competitors of new biopharmaceutical products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund
operations. Programs currently under development will require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant
amounts of additional capital, adequate personnel and infrastructure and extensive compliance-reporting capabilities. Even if the Company&#146;s product development efforts are successful, it is uncertain when, if ever, the Company will realize
revenue from product sales. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Going Concern </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In
accordance with the Financial Accounting Standards Board Accounting Standards Update <FONT STYLE="white-space:nowrap">2014-15,</FONT> <I>Disclosure of Uncertainties about an Entity&#146;s Ability to Continue as a Going Concern (Subtopic <FONT
STYLE="white-space:nowrap">205-40)</FONT></I>, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#146;s ability to continue as a going concern within one
year after the date that the consolidated financial statements are issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company has incurred recurring losses since its inception, including
net losses of $26.5&nbsp;million and $35.5&nbsp;million for the years ended December&nbsp;31, 2018 and 2019, respectively. In addition, as of December&nbsp;31, 2019, the Company had an accumulated deficit of $81.0&nbsp;million. The Company expects
to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
The Company&#146;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. There can be no assurance
that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
Company expects that its cash and cash equivalents as of December&nbsp;31, 2019 of $44.8&nbsp;million, together with the $23.5 million aggregate cash proceeds from the sale and issuance of additional shares of Series C Preferred Stock on April 15,
2020 and May 8, 2020, offset by the repurchase of shares of Series C Preferred Stock for an aggregate cash repurchase price of $30.0 million on February 19, 2020 and March 3, 2020, will not be sufficient to fund the operating expenses and capital
expenditure requirements necessary to advance its research efforts and clinical trials for at least the next twelve months from the date of issuance of these consolidated financial statements, and the Company will need to obtain additional funding.
The future viability of the Company beyond one year from the date of issuance of these consolidated financial statements is dependent on its ability to raise additional capital to finance its operations. If the Company is unable to obtain additional
funding, the Company could be forced to delay, reduce or eliminate some or all of its research and development programs, product portfolio expansion, or commercialization efforts, which could adversely affect its business prospects, or the Company
may be unable to continue operations. The Company expects to seek additional funding through private or public equity transactions, debt financings, or other capital sources, including collaborations with other companies or other strategic
transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Although management plans to pursue additional funding, there is no assurance that the Company will be successful in obtaining
sufficient funding on terms acceptable to the Company to fund continuing operations, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Based on its recurring losses and negative cash
flows from operations since inception, expectation of continuing operating losses and negative cash flows from operations for the foreseeable future, and the need to raise additional capital to finance its future operations, management concluded
that there is substantial doubt about the Company&#146;s ability to continue as a going concern for one year after the date that these consolidated financial statements are issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. Accordingly,
the consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in the ordinary course of
business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>2. Summary of Significant Accounting Policies </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Basis
of Presentation </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting
principles in the United States of America (&#147;GAAP&#148;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting Standards Codification (&#147;ASC&#148;) and Accounting
Standards Updates (&#147;ASU&#148;) of the Financial Accounting Standards Board (&#147;FASB&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Principles of Consolidation </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries, Praxis Security Corporation and Praxis
Precision Medicines Australia Pty Ltd. All intercompany transactions have been eliminated in consolidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the
reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant estimates and
assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual for research and development expenses, stock-based compensation expense, the valuation of equity and derivative instruments and the
recoverability of the Company&#146;s net deferred tax assets and related valuation allowance. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which
they become known. Actual results could differ materially from those estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Unaudited Pro Forma Information </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon the closing of a qualified public offering (as defined in the Company&#146;s Amended and Restated Certificate of Incorporation), all of the
Company&#146;s outstanding shares of redeemable convertible preferred stock will automatically convert into shares of common stock. The unaudited pro forma basic and diluted net loss per share attributable to common stockholders in the accompanying
consolidated statement of operations and comprehensive loss for the year ended December&nbsp;31, 2019 was computed using the weighted average number of shares of common stock outstanding, including the pro forma effect of the automatic conversion of
all outstanding shares of redeemable convertible preferred stock into shares of common stock as if the Company&#146;s proposed initial public offering (&#147;IPO&#148;) had occurred on the later of: (i)&nbsp;January&nbsp;1, 2019 or (ii)&nbsp;the
date the equity instruments were issued. The unaudited pro forma net loss attributable to common stockholders used in the calculation of unaudited pro forma basic and diluted net loss per share attributable to common stockholders for the year ended
December&nbsp;31, 2019: (i)&nbsp;excludes the effects of cumulative dividends accrued for redeemable convertible preferred stock from the net loss attributable to common stockholders and (ii)&nbsp;excludes the effects of other accretion recorded for
redeemable convertible preferred stock from the net loss attributable to common stockholders. The unaudited pro forma basic and diluted net loss per share attributable to common stockholders does not include the shares expected to be sold or related
proceeds to be received in the proposed IPO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Segments </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company has one operating segment. The Company&#146;s chief operating decision maker, its Chief Executive Officer, manages the Company&#146;s
operations on a consolidated basis for the purposes of assessing performance and allocating resources. The majority of the Company&#146;s long-lived assets are held in the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Cash, Cash Equivalents and Restricted Cash </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
Company considers all highly liquid investments purchased with original maturities of 90&nbsp;days or less at acquisition to be cash equivalents. Cash and cash equivalents include cash held in banks </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
and amounts held in interest-bearing money market funds. Cash equivalents are carried at cost, which approximates their fair market value. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Restricted cash comprises a letter of credit for the benefit of the landlord in connection with the Company&#146;s lease facility. Restricted cash is
classified as either current or <FONT STYLE="white-space:nowrap">non-current</FONT> based on the terms of the underlying lease arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
following table presents cash, cash equivalents and restricted cash as reported on the consolidated balance sheets that equal the total amounts on the consolidated statements of cash flows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">17,950</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">44,815</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total cash, cash equivalents and restricted cash as shown on the consolidated
statement of cash flows</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">18,550</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">45,415</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Concentrations of Credit Risk and Significant Suppliers and License Agreements </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash, cash equivalents and restricted
cash. The Company maintains deposits in accredited financial institutions in excess of federally insured limits. Bank accounts in the United States are insured by the Federal Deposit Insurance Corporation (the &#147;FDIC&#148;) up to $250,000. As of
December&nbsp;31, 2018 and 2019, the Company&#146;s primary operating accounts significantly exceeded the FDIC limits. The Company deposits its cash in financial institutions that it believes have high credit quality, and has not experienced any
losses on such accounts and does not believe it is exposed to any unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company is dependent on third-party manufacturers to supply materials for research and development activities of its programs, including preclinical
and clinical testing. In particular, the Company relies, and expects to continue to rely, on a small number of third-party manufacturers to produce and process its current and potential product candidates and to manufacture supply of its current and
potential product candidates for preclinical and clinical activities. These programs could be adversely affected by a significant interruption in the supply of the necessary materials. The Company is also dependent on third parties who provide
license rights used in the development of certain programs. The Company could experience delays in the development of its programs if any of these license agreements are terminated, if the Company fails to meet the obligations required under its
arrangements, or if the Company is unable to successfully secure new strategic alliances or licensing agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Risk </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2018 and 2019, the Company had no <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet risk such as foreign exchange
contracts, option contracts, or other hedging arrangements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Fair Value Measurements </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Certain assets and liabilities of the Company are carried at fair value under GAAP. The fair values of the Company&#146;s financial assets and
liabilities reflects the Company&#146;s estimate of the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly
transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Financial assets and liabilities carried at fair
value are to be classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Level 1&#151;Quoted prices in active markets for identical assets or liabilities. </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Level 2&#151;Observable inputs (other than Level&nbsp;1 quoted prices), such as quoted prices in active markets for similar
assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Level 3&#151;Unobservable inputs that are supported by little or no market activity that are significant to determining the
fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">To
the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair
value is greatest for instruments categorized in Level&nbsp;3. A financial instrument&#146;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">An entity may choose to measure many financial instruments and certain other items at fair value at specified election dates. Subsequent unrealized
gains and losses on items for which the fair value option has been elected will be reported in earnings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The carrying amounts reflected in the
consolidated balance sheets for cash, prepaid expenses and other current assets, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Property and Equipment </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Property and equipment are
recorded at cost. Depreciation is calculated using the straight-line method over the following estimated useful lives of the assets: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Estimated&nbsp;Useful&nbsp;Life</B></TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Office furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:3pt ;">5&nbsp;years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:3pt ;">3 years</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="padding-bottom:3pt ;">3 years</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon disposal, retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed
from the accounts and any resulting gain or loss is included in the results of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
operations. Expenditures for repairs and maintenance that do not improve or extend the lives of the respective assets are charged to expense as incurred. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Impairment of Long-Lived Assets </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Long-lived assets
consist of property and equipment. Long-lived assets to be held and used are tested for recoverability whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. Factors that
the Company considers in deciding when to perform an impairment review include significant underperformance of the business in relation to expectations, significant negative industry or economic trends and significant changes or planned changes in
the use of the assets. If an impairment review is performed to evaluate a long-lived asset group for recoverability, the Company compares forecasts of undiscounted cash flows expected to result from the use and eventual disposition of the long-lived
asset group to its carrying value. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of an asset group are less than its carrying amount. The impairment loss would be based on the
excess of the carrying value of the impaired asset group over its fair value, determined based on discounted cash flows. The Company did not record any impairment losses on long-lived assets in either year ended December&nbsp;31, 2018 or 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Leases </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In February 2016, the FASB issued ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT> <I>Leases (Topic 842)</I>. This standard established a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> model that requires all lessees to recognize <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and lease liabilities on their balance sheet that arise from leases as well as provide disclosures with respect to certain qualitative and quantitative
information related to a company&#146;s leasing arrangements to meet the objective of allowing users of financial statements to assess the amount, timing and uncertainty of cash flows arising from leases. The FASB subsequently issued the following
amendments to ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> that have the same effective date and transition date: ASU No.&nbsp;2018-01, <I>Leases (Topic 842): Land Easement Practical Expedient for Transition to Topic 842</I>, ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2018-10,</FONT> <I>Codification Improvements to Topic 842, Leases</I>, ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-11,</FONT> <I>Leases (Topic 842): Targeted Improvements</I>, ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2018-20,</FONT> <I>Narrow-Scope Improvement for Lessors</I>, and ASU No. <FONT STYLE="white-space:nowrap">2019-01,</FONT> <I>Leases (Topic 842): Codification Improvements</I>. The Company adopted these amendments
with ASU <FONT STYLE="white-space:nowrap">2016-02</FONT> (collectively, the &#147;new leasing standards&#148;), effective January&nbsp;1, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
Company adopted the new leasing standards using the modified retrospective transition approach, with no restatement of prior periods and there was no cumulative adjustment to retained earnings. Upon adoption, the Company elected the package of
transition practical expedients, which allowed the Company to not reassess the following: (i)&nbsp;whether any expired or existing contracts are or contain leases, (ii)&nbsp;the lease classification for any expired or existing leases and
(iii)&nbsp;the treatment of initial direct costs for existing leases. The Company made an accounting policy election to not recognize short-term leases with an initial term of twelve months or less within its consolidated balance sheets and to
recognize those lease payments on a straight-line basis in its consolidated statements of operations over the lease term. Upon adopting the new leasing standards, the Company recognized an operating lease <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset of $2.1&nbsp;million and a corresponding operating lease liability of $2.1&nbsp;million, which are included in its consolidated balance sheets. The adoption of the new leasing standards did
not have a material impact on the Company&#146;s consolidated statements of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company determines if an arrangement is a lease at contract inception. Operating lease <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets represent the Company&#146;s right to use an underlying asset for the lease term and operating lease liabilities represent its obligation to make lease
payments arising from the lease. Operating <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and liabilities are recognized at the commencement date of the lease based upon the present value of lease
payments over the lease term. When determining the lease term, the Company includes options to extend or terminate the lease when it is reasonably certain that the option will be exercised. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company uses the implicit rate when readily determinable and uses its incremental borrowing rate when the implicit rate is not readily determinable,
based upon the information available at the commencement date in determining the present value of the lease payments. The incremental borrowing rate is determined using a secured borrowing rate for the same currency and term as the associated lease.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The lease payments used to determine operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT>
assets may include lease incentives and stated rent increases. The Company&#146;s lease agreements may include both lease and <FONT STYLE="white-space:nowrap">non-lease</FONT> components, which the Company accounts for as a single lease component
when the payments are fixed, for all classes of underlying assets. Variable payments included in the lease agreement are expensed as incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
Company&#146;s operating leases are reflected in operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets and in current operating lease liabilities and long-term operating lease liabilities
in its consolidated balance sheets. The Company&#146;s operating lease <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset as of December&nbsp;31, 2019 did not include any lease incentives. Lease
expense for future lease payments is recognized on a straight-line basis over the lease term. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Prior to the adoption of the new leasing standards,
the Company recognized lease costs on a straight-line basis once it gained control of the space, without regard to deferred payment terms, such as rent holidays, that would defer the commencement date of required payments or escalating payment
amounts. Any lease incentives received were treated as a reduction of costs over the term of the lease agreement, as they were considered an inseparable part of the lease agreement. The difference between required lease payments and rent expense was
recorded as deferred rent, which was included in other <FONT STYLE="white-space:nowrap">non-current</FONT> liabilities in the December&nbsp;31, 2018 consolidated balance sheet. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Redeemable Convertible Preferred Stock </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company
records all redeemable convertible preferred stock upon issuance at its respective fair value or original issuance price, less issuance costs and any associated discounts. The Company classifies its redeemable convertible preferred stock outside of
stockholders&#146; (deficit) equity as the redemption of such shares is outside the Company&#146;s control. The Company adjusts the carrying values of the redeemable convertible preferred stock to redemption value when the redemption value exceeds
the carrying value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Research and Development Costs </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Research and development costs are expensed as incurred. Research and development expenses consist of costs incurred in performing research and
development activities, including salaries, stock-based compensation and benefits, facilities costs, depreciation, third-party license fees, and external </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
costs of outside vendors engaged to conduct preclinical development activities and clinical trials as well as to manufacture research and development materials.
<FONT STYLE="white-space:nowrap">Non-refundable</FONT> prepayments for goods or services that will be used or rendered for future research and development activities are deferred and capitalized. Such amounts are recognized as an expense as the
goods are delivered or the related services are performed or until it is no longer expected that the goods will be delivered or the services rendered. Costs incurred to obtain licenses are recognized as research and development expense as incurred
if the technology licensed has no alternative future uses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company has entered into various research and development related contracts with
parties both inside and outside of the United States. These agreements are cancelable, and related payments are recorded as research and development expenses as incurred. The Company records accrued liabilities for estimated ongoing research costs.
When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are
made in determining the accrued balances at the end of any reporting period. Actual results could differ from the Company&#146;s estimates. The Company&#146;s historical accrual estimates have not been materially different from the actual costs.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Patent-Related Costs </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Patent-related costs
incurred in connection with patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying consolidated statement
of operations and comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company accounts for all stock-based awards granted to employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> as stock-based
compensation expense at fair value in accordance with FASB ASC Topic 718, <I>Compensation&#151;Stock Compensation</I> (&#147;ASC 718&#148;). For stock-based awards issued to employees, <FONT STYLE="white-space:nowrap">non-employees</FONT> and
members of the Company&#146;s board of directors (the &#147;Board&#148;) for their services on the Board, the Company measures the estimated fair value of the stock-based award on the date of the grant. The Company recognizes compensation expense
for those awards granted to employees and members of the Board over the requisite service period, which is generally the vesting period of the respective award. For <FONT STYLE="white-space:nowrap">non-employee</FONT> awards, compensation expense is
recognized as the services are provided, which is generally ratably over the vesting period. The Company determines the fair value of restricted stock awards in reference to the fair value of its common stock less any applicable purchase price. The
Company issues stock-based awards with service-based vesting conditions and records the expense for these awards on a straight-line basis over the vesting period. To date, the Company has not issued any stock-based awards with performance or
market-based vesting conditions. The Company accounts for forfeitures as they occur. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company classifies stock-based compensation expense in its
consolidated statement of operations and comprehensive loss in the same manner in which the award recipient&#146;s salary or service payments are classified. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Given the absence of an active market for the Company&#146;s common stock, the fair value of shares of common stock underlying the Company&#146;s
stock-based awards is determined on each grant date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
The Company determines the estimated fair value of its equity instruments based on a number of objective and subjective factors, including external market conditions affecting the biotechnology
industry sector. The Company utilizes various valuation methodologies in accordance with the framework of the American Institute of Certified Public Accountants&#146; Technical Practice Aid, <I>Valuation</I> <I>of Privately-Held Company Equity
Securities Issued as Compensation</I>, to estimate the fair value of its common stock. Each valuation methodology includes estimates and assumptions that require the Company&#146;s judgment. These estimates and assumptions include a number of
objective and subjective factors in determining the value of the Company&#146;s common stock at each grant date, such as the following: (i)&nbsp;prices paid for the Company&#146;s redeemable convertible preferred stock, and the rights, preferences,
and privileges of the Company&#146;s redeemable convertible preferred stock and common stock; (ii)&nbsp;the Company&#146;s stage of development; (iii)&nbsp;the fact that the grants of stock-based awards related to illiquid securities in a private
company; and (iv)&nbsp;the likelihood of achieving a liquidity event for the common stock underlying the stock-based awards, such as an IPO or sale of the Company, given prevailing market conditions. The methodology utilized to estimate the fair
value of the Company&#146;s common stock was the option-pricing method (&#147;OPM&#148;) to back-solve the estimated value of the Company&#146;s equity and corresponding value of the Company&#146;s common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model, which requires inputs of
subjective assumptions, including: (i)&nbsp;the expected volatility of the Company&#146;s stock; (ii)&nbsp;the expected term of the award; (iii)&nbsp;the risk-free interest rate; (iv)&nbsp;expected dividends; and (v)&nbsp;the fair value of common
stock. Due to the lack of Company-specific historical and implied volatility data, the Company determines the volatility for awards granted based on an analysis of reported data for a group of guideline publicly-traded companies that issued options
with substantially similar terms. For this analysis, the Company selects companies with comparable characteristics including enterprise value, risk profiles, and with historical share price information sufficient to meet the expected life of the
stock-based awards. The Company determines expected volatility using a weighted average of the historical volatilities of the guideline group of companies. The Company expects to continue to apply this process until such time as it has adequate
historical data regarding the volatility of its own traded stock price. As permitted under ASC 718, the Company has elected to use the contractual term as the expected term for certain <FONT STYLE="white-space:nowrap">non-employee</FONT> awards, on
an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">award-by-award</FONT></FONT> basis. For all other awards, the expected term of the Company&#146;s stock options has been determined utilizing the &#147;simplified&#148; method
whereby the expected term equals the average of the vesting term and the original contractual term of the option, on a weighted basis based on the vesting of each tranche. The Company utilizes this method as it has insufficient historical exercise
data to provide a reasonable basis upon which to estimate the expected term. The risk-free interest rate is determined by reference to the U.S. Treasury yield curve in effect at the time of grant of the award for instruments with a term commensurate
with the expected term assumption. The expected dividend yield is assumed to be zero as the Company has never paid dividends, and does not have current plans to pay any dividends on its common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Foreign Currency </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The functional currency of the
Company&#146;s wholly owned foreign subsidiary in Australia is the U.S. dollar. Monetary assets and liabilities resulting from transactions denominated in currencies other than the functional currency are remeasured into the functional currency at
exchange rates prevailing at the balance sheet date. <FONT STYLE="white-space:nowrap">Non-monetary</FONT> assets and liabilities denominated in foreign currencies are measured using historical exchange rates prevailing at the date of the transaction
and are not subsequently remeasured. Exchange gains or losses arising from foreign currency transactions are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
included in the determination of net loss. The Company recorded a foreign currency loss of $0.3&nbsp;million for the year ended December&nbsp;31, 2018, which is included in research and
development expense in the consolidated statement of operations and comprehensive loss. There were no material foreign currency gains or losses for the year ended December&nbsp;31, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Income Taxes </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Deferred tax assets and liabilities are
determined on the basis of the differences between the consolidated financial statements and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in deferred tax
assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight of available
evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company accounts for uncertain tax positions recognized in the consolidated financial statements by prescribing a
<FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> threshold for financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. The provision for income taxes includes the effects of any
resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Comprehensive Loss
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Comprehensive loss includes net loss and certain changes in stockholders&#146; deficit that are excluded from net loss. The Company&#146;s
comprehensive loss was equal to net loss for the years ended December&nbsp;31, 2018 and 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Net Loss per Share </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company follows the <FONT STYLE="white-space:nowrap">two-class</FONT> method to compute net loss per share attributable to common stockholders as the
Company has issued shares that meet the definition of participating securities. The <FONT STYLE="white-space:nowrap">two-class</FONT> method determines net income (loss) per share for each class of common and participating securities according to
dividends declared or accumulated and participation rights in undistributed earnings. The <FONT STYLE="white-space:nowrap">two-class</FONT> method requires income (losses) for the period to be allocated between common and participating securities
based upon their respective rights to share in the earnings as if all income (losses) for the period had been distributed. During periods of loss, there is no allocation required under the <FONT STYLE="white-space:nowrap">two-class</FONT> method
since the participating securities do not have a contractual obligation to fund the losses of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Net loss attributable to common
stockholders is equal to the net loss for the period, as adjusted for: (i)&nbsp;cumulative dividends accrued for redeemable convertible preferred stock, whether or not declared, (ii)&nbsp;increases in carrying value recorded for redeemable
convertible preferred stock, including accretion on redeemable convertible preferred stock to redemption value for amounts other than cumulative dividends and (iii)&nbsp;losses resulting from conversions of convertible notes recorded as capital
transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Basic net loss per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders
by the weighted average number of common shares outstanding for the period, which excludes shares of restricted common stock that are not vested. Diluted net loss </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period,
after giving consideration to the dilutive effect of potentially dilutive common shares. For purposes of this calculation, outstanding options to purchase shares of common stock, unvested shares of restricted common stock and shares of redeemable
convertible preferred stock are considered potentially dilutive common shares. The Company has generated a net loss in all periods presented so the basic and diluted net loss per share attributable to common stockholders are the same as the
inclusion of the potentially dilutive securities would be anti-dilutive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Emerging Growth Company Status </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company is an &#147;emerging growth company&#148; (&#147;EGC&#148;), as defined in the Jumpstart Our Business Startups Act (&#147;JOBS Act&#148;),
and may take advantage of certain exemptions from various reporting requirements that are applicable to other public companies that are not EGCs. The Company may take advantage of these exemptions until it is no longer an EGC under Section&nbsp;107
of the JOBS Act, which provides that an EGC can take advantage of the extended transition period afforded by the JOBS Act for the implementation of new or revised accounting standards. The Company has elected to avail itself of the extended
transition period and, therefore, while the Company is an EGC it will not be subject to new or revised accounting standards the same time that they become applicable to other public companies that are not EGCs, unless it chooses to early adopt a new
or revised accounting standard. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Recent Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Recently Adopted Accounting Pronouncements </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In January 2016,
the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-01,</FONT> <I>Financial Instruments&#151;Overall <FONT STYLE="white-space:nowrap">(Subtopic&nbsp;825-10)&#151;Recognition</FONT> and Measurement of Financial Assets and Financial
Liabilities</I>, which has been subsequently amended by ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-03,</FONT> ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2019-04,</FONT> ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2020-01</FONT> and ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2020-03</FONT> (&#147;ASU <FONT STYLE="white-space:nowrap">2016-01&#148;).</FONT> The provisions of ASU <FONT STYLE="white-space:nowrap">2016-01</FONT> make targeted improvements to enhance the reporting model for
financial instruments to provide users of financial statements with more decision-useful information, including certain aspects of recognition, measurement, presentation, and disclosure of financial instruments. The Company early adopted ASU <FONT
STYLE="white-space:nowrap">2016-01</FONT> effective January&nbsp;1, 2019. The implementation of this standard had no impact on the Company&#146;s financial position or results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In February 2016, the FASB issued the new leasing standards to increase transparency and comparability among organizations related to their leasing
activities. The Company early adopted the new leasing standards effective January&nbsp;1, 2019. For additional information on the adoption of the new leasing standards, please read the Company&#146;s policy above entitled <I>Leases</I>, and Note 8,
<I>Commitments and Contingencies</I>, to these consolidated financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In August 2016, the FASB issued ASU <FONT
STYLE="white-space:nowrap">No.&nbsp;2016-15,</FONT> <I>Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments</I> (&#147;ASU <FONT STYLE="white-space:nowrap">2016-15&#148;),</FONT> to address diversity in practice in how
certain cash receipts and cash payments are presented and classified in the consolidated statement of cash flows. The Company early adopted ASU <FONT STYLE="white-space:nowrap">2016-15</FONT> effective January&nbsp;1, 2018. The adoption of <FONT
STYLE="white-space:nowrap">ASU&nbsp;2016-15</FONT> had no impact on the Company&#146;s financial position or results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In January
2017, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2017-01,</FONT> <I>Business Combinations (Topic 805): Clarifying the Definition of a Business</I> (&#147;ASU <FONT STYLE="white-space:nowrap">2017-01&#148;).</FONT> The standard
clarifies the framework for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
determining whether an integrated set of assets and activities meets the definition of a business. The revised framework establishes a screen for determining whether an integrated set of assets
and activities is a business and narrows the definition of a business. The screen requires that when substantially all of the fair value of the gross assets acquired (or disposed of) is concentrated in a single identifiable asset or a group of
similar identifiable assets, the set is not a business. This screen reduces the number of transactions that need to be further evaluated. The Company early adopted ASU <FONT STYLE="white-space:nowrap">2017-01</FONT> effective January&nbsp;1, 2018.
The adoption of this standard did not have a material impact on the Company&#146;s financial position or results of operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In May 2017, the
FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2017-09,</FONT> <I>Compensation&#151;Stock Compensation (Topic&nbsp;718): Scope of Modification Accounting</I> (&#147;ASU <FONT STYLE="white-space:nowrap">2017-09&#148;),</FONT> which
clarifies when to account for a change to the terms or conditions of a share-based payment award as a modification. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of
the award (as equity or liability) changes as a result of the change in terms or conditions. The standard is effective for annual periods beginning after December&nbsp;15, 2017. The Company adopted ASU <FONT STYLE="white-space:nowrap">2017-09</FONT>
effective January&nbsp;1, 2018. The adoption of ASU <FONT STYLE="white-space:nowrap">2017-09</FONT> had no impact on the Company&#146;s financial position or results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In July 2017, the FASB issued&nbsp;ASU No. <FONT STYLE="white-space:nowrap">2017-11,</FONT><I>&nbsp;Earnings Per Share (Topic 260), Distinguishing
Liabilities from Equity (Topic 480), Derivatives and Hedging (Topic 815) I. Accounting for Certain Financial Instruments with Down Round Features II. Replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain
Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception </I>(&#147;ASU <FONT STYLE="white-space:nowrap">2017-11&#148;).&nbsp;Part</FONT> I applies to entities that issue financial instruments such as
warrants, convertible debt or convertible preferred stock that contain down-round features. Part II replaces the indefinite deferral for certain mandatorily redeemable noncontrolling interests and mandatorily redeemable financial instruments of
nonpublic entities contained within ASC Topic 480&nbsp;with a scope exception and does not impact the accounting for these mandatorily redeemable instruments. The Company early adopted ASU <FONT STYLE="white-space:nowrap">2017-11</FONT> effective
January&nbsp;1, 2019. The adoption of ASU <FONT STYLE="white-space:nowrap">2017-11</FONT> had no impact on the Company&#146;s financial position or results of operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In August 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-13,</FONT> <I>Fair Value Measurement (Topic 820): Disclosure
Framework&#151;Changes to the Disclosure Requirements for Fair Value Measurement</I> <FONT STYLE="white-space:nowrap">(&#147;ASU&nbsp;2018-13&#148;).</FONT> The standard eliminates, adds and modifies certain disclosure requirements for fair value
measurements. The Company early adopted ASU <FONT STYLE="white-space:nowrap">2018-13</FONT> as of January&nbsp;1, 2018. The adoption of this standard did not have a material impact on the Company&#146;s financial position or results of operations.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Recently Issued Accounting Pronouncements </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In June 2016,
the FASB issued <FONT STYLE="white-space:nowrap">ASU&nbsp;No.&nbsp;2016-13,</FONT><I>&nbsp;Financial Instruments&#151;Credit Losses (Topic&nbsp;326)&#151;Measurement of Credit Losses on Financial Instruments,</I>&nbsp;which has been subsequently
amended by <FONT STYLE="white-space:nowrap">ASU&nbsp;No.&nbsp;2018-19,</FONT> <FONT STYLE="white-space:nowrap">ASU&nbsp;No.&nbsp;2019-04,</FONT> <FONT STYLE="white-space:nowrap">ASU&nbsp;No.&nbsp;2019-05,</FONT>
<FONT STYLE="white-space:nowrap">ASU&nbsp;No.&nbsp;2019-10,</FONT> <FONT STYLE="white-space:nowrap">ASU&nbsp;No.&nbsp;2019-11</FONT> and <FONT STYLE="white-space:nowrap">ASU&nbsp;No.&nbsp;2020-03</FONT>
<FONT STYLE="white-space:nowrap">(&#147;ASU&nbsp;2016-13&#148;).</FONT> The provisions of <FONT STYLE="white-space:nowrap">ASU&nbsp;2016-13&nbsp;modify</FONT> the impairment model to utilize an expected loss methodology in place of the currently
used incurred loss methodology and require a consideration of a broader range of reasonable and supportable information to inform credit loss estimates. <FONT STYLE="white-space:nowrap">ASU&nbsp;2016-13&nbsp;is</FONT> effective for the Company on
January&nbsp;1, 2023, with early adoption permitted. The Company is currently evaluating the potential impact that this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
standard may have on its financial position and results of operations, as well as the timing of its adoption of this standard. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In December 2019, the FASB issued <FONT STYLE="white-space:nowrap">ASU&nbsp;No.&nbsp;2019-12,</FONT><I>&nbsp;Income Taxes (Topic 740)&#151;Simplifying
the Accounting for Income Taxes</I><FONT STYLE="white-space:nowrap">&nbsp;(&#147;ASU&nbsp;2019-12&#148;),&nbsp;as</FONT> part of its initiative to reduce complexity in the accounting standards. The amendments in
<FONT STYLE="white-space:nowrap">ASU&nbsp;2019-12&nbsp;eliminate</FONT> certain exceptions related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax
liabilities for outside basis differences. <FONT STYLE="white-space:nowrap">ASU&nbsp;2019-12&nbsp;also</FONT> clarifies and simplifies other aspects of the accounting for income taxes. <FONT STYLE="white-space:nowrap">ASU&nbsp;2019-12&nbsp;is</FONT>
effective for the Company on January&nbsp;1, 2022, with early adoption permitted. The Company is currently evaluating the potential impact that this standard may have on its financial position and results of operations, as well as the timing of its
adoption of this standard. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>3. Restricted Cash </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of
December&nbsp;31, 2018 and 2019, the Company had restricted cash of $0.6&nbsp;million, held as a letter of credit for the benefit of the landlord in connection with the Company&#146;s lease in Cambridge, Massachusetts. Restricted cash was classified
as a <FONT STYLE="white-space:nowrap">non-current</FONT> asset on the consolidated balance sheets as the associated lease term expires more than twelve months from each respective consolidated balance sheet date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>4. Fair Value of Financial Assets and Liabilities </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
following tables present information about the Company&#146;s financial assets measured at fair value on a recurring basis and indicates the level of the fair value hierarchy utilized to determine such fair values (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">15,739</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">15,739</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">$15,739</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">$&#150;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">$&#150;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">$15,739</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">44,429</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">44,429</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">$44,429</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">$&#150;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center">$&#150;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">$44,429</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table sets forth a summary of changes in fair value of the Company&#146;s derivative
liabilities for which fair value was determined by Level&nbsp;3 inputs (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series&nbsp;B&nbsp;Preferred</B><br><B>Stock Tranche</B><br><B>Obligation</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B><FONT STYLE="white-space:nowrap">Anti-Dilution</FONT></B><br><B>Obligation</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Conversion</B><br><B>Features</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Balance as of December&nbsp;31, 2017</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,392</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">614</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,006</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Fair value on measurement date</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,185</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">304</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,489</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,221</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,346</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,648</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Settlement of liability</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(5,406</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(3,738</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(999</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(10,143</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Balance as of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the years ended December&nbsp;31, 2018 and 2019, there were no transfers into or out of Level&nbsp;3. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Series B Preferred Stock Tranche Obligation </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
Series B Preferred Stock purchase agreement provided for an initial closing on March&nbsp;13, 2018 and a subsequent closing upon the occurrence of a specified clinical milestone event (the &#147;Milestone Closing&#148;). The Milestone Closing
required the Company to sell, and certain investors to purchase, a total of 7,880,000 additional shares of Series B Preferred Stock at $3.00 per share on the same terms and conditions as the initial closing (the &#147;Preferred Stock Tranche
Obligation&#148;). The Board and Preferred Stock investors determined that the related clinical milestone event was achieved on June&nbsp;25, 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company concluded that the Preferred Stock Tranche Obligation represented a freestanding financial instrument as the underlying shares could be
transferred separately from the tranche right. The freestanding financial instrument was classified as a liability on the Company&#146;s consolidated balance sheet and initially recorded at fair value. The initial fair value of the Preferred Stock
Tranche Obligation recognized in connection with the Company&#146;s issuance of the Series B Preferred Stock in March 2018 was determined using a binomial model with significant inputs not observable in the market, including the estimated future
value of the Company&#146;s Series B Preferred Stock, the discount rate, estimated time from the initial closing to the tranche closing, and probability of the tranche closing. Therefore, the derivative liability represented a Level&nbsp;3
measurement within the fair value hierarchy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A change in the assumptions related to the valuation of the Preferred Stock Tranche Obligation could
have a significant impact on the value of the obligation.&nbsp;The following reflects the significant quantitative inputs used in the valuation of the Preferred Stock Tranche Obligation upon the issuance of the associated shares of Series B
Preferred Stock on March&nbsp;13, 2018: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Future value of Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right"> 3.69</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1.90</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Time from initial closing to tranche closing (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">0.72</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Probability of tranche closing</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">59.10</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company determined the <FONT STYLE="white-space:nowrap">per-share&nbsp;future</FONT> value&nbsp;of
the Series B Preferred Stock by back-solving from the initial proceeds of the Series B Preferred Stock closing. The discount rate was estimated using the capital asset pricing model. The time to tranche closing and probability of tranche closing was
determined using industry data on clinical trial timing and success. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The obligation was fully satisfied in October 2018 upon the second closing of
the Series B Preferred Stock. Upon settlement of the Preferred Stock Tranche Obligation, the Company remeasured the fair value using current assumptions. Upon settlement, the time from the measurement date to the settlement date was zero, and the
probability of closing was 100%. The fair value of the tranche obligation at settlement was determined using a retrospective binomial valuation, driven by the difference between the fair value of the Series B Preferred Stock upon settlement of $3.69
and the exercise price of the forward contract of $3.00. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Anti-Dilution Obligation </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under a license agreement entered into with Purdue Neuroscience Company (&#147;Purdue&#148;) in December 2017, as partial consideration for the exclusive
license provided to the Company under the license agreement, the Company issued Purdue a right to receive additional shares of Preferred Stock, for no additional consideration from Purdue, to ensure Purdue&#146;s ownership remained at a specified
percentage throughout future issuances of the Series B Preferred Stock (the &#147;Anti-Dilution Obligation&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company determined that the
Anti-Dilution Obligation represented a derivative liability as it was a freestanding instrument representing a conditional obligation to issue additional shares of the Company&#146;s optionally redeemable equity securities in exchange for no
additional consideration. The fair value of the Anti-Dilution Obligation was determined using a discounted cash flow model under the income approach, based on significant inputs not observable in the market including the estimated future value of
the Series B Preferred Stock, discount rates, estimated time to liquidity, and probability of each tranche closing. Therefore, the derivative liability represented a Level&nbsp;3 measurement within the fair value hierarchy. A change in the
assumptions related to the valuation of the Anti-Dilution Obligation could have a significant impact on the value of the obligation.&nbsp;The initial fair value of the derivative liability of $2.4&nbsp;million was recorded as research and
development expense in December 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company issued shares of Series B Preferred Stock to Purdue under the Anti-Dilution Obligation upon the
initial and second tranche financing of the Series B Preferred Stock. The Anti-Dilution Obligation was settled in October 2018 upon the final tranche closing of the Series B Preferred Stock. Upon settlement of the Anti-Dilution Obligation, the
Company remeasured the fair value using current assumptions, resulting in an increase in fair value of $1.3&nbsp;million, which was recorded in other expense in the consolidated statement of operations and comprehensive loss for the year ended
December&nbsp;31, 2018. The primary assumption used to determine the fair value upon settlement was the fair value of the Series B Preferred Stock, which was estimated to be $2.39 and $3.69 for shares issued pursuant to the March&nbsp;31, 2018 and
October&nbsp;16, 2018 closings, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Conversion Features </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On December&nbsp;1, 2017 and January&nbsp;29, 2018, the Company issued two separate unsecured convertible promissory notes (the &#147;Convertible
Notes&#148;) of $2.0&nbsp;million and $1.0&nbsp;million, respectively, to an investor. The Convertible Notes would automatically convert, upon the Company&#146;s next equity </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
financing of at least $2.0&nbsp;million in gross proceeds following the issuance of the Convertible Notes, into the type of equity securities issued in such financing (the &#147;Automatic
Conversion&#148;). Pursuant to the terms of the Convertible Notes, the shares received upon conversion would be determined based on the outstanding principal, plus accrued interest, divided by 75.0% of the price paid by investors in the
Company&#146;s next equity financing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company determined that the conversion features represented a derivative instrument as they were based on
a variable number of shares resulting in a fixed dollar amount of value being provided to the lender, and therefore were in substance a redemption feature. Furthermore, the conversion features were not determined to be clearly and closely related to
the debt host contracts, and therefore were required to be separately accounted for. The initial fair value of the derivative was determined by calculating the fair values of the Convertible Notes with and without the conversion features. The
difference between the fair values of the Convertible Notes in the &#147;with&#148; and &#147;without&#148; scenarios was then concluded as initial fair value of the conversion features. The valuation used significant inputs which were not
observable in the market, including the probability of various exit scenarios and discount rates. Therefore, the conversion features represented a Level&nbsp;3 measurement within the fair value hierarchy. The initial fair value of the conversion
features for the $2.0&nbsp;million and $1.0&nbsp;million Convertible Notes was $0.6&nbsp;million and $0.3&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A change in
the assumptions related to the valuation of the conversion features could have a significant impact on their determined fair value.&nbsp;The following reflects the significant quantitative inputs used in the valuation of the conversion features upon
issuance of the 2018 Convertible Note: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>January&nbsp;29,&nbsp;2018</B><br><B>Convertible Note</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Probability of next equity financing scenario</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">75.60</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Probability of contractual maturity scenario</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">24.40</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Time until equity financing scenario (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">0.09</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Discount rate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">15.00</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company estimated the probability of each settlement scenario and time until equity financing using information
obtained from discussions with investors and the Board. The discount rate was calculated based on an average of market rates of return for similar preferred stock financings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The conversion features were settled upon the first closing of the Series B Preferred Stock in March 2018, which triggered the Automatic Conversion and
resulted in the conversion of both Convertible Notes into shares of Series B Preferred Stock. The redemption terms of the 2018 Convertible Note were adjusted such that the discount provided on the effective price of the conversion was decreased from
25.0% to 12.5%. The fair value of the conversion features upon settlement was determined by calculating the fair values of the Convertible Notes with and without the conversion features, which was equivalent to the discount provided to the holders
of the Convertible Notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>5. Property and Equipment, Net </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Property and equipment, net consisted of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Office furniture and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">84</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">113</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">104</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">166</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less: Accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(38</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">103</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Depreciation expense was not material to the years ended December&nbsp;31, 2018 and 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>6. Accrued Expenses </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Accrued expenses consisted of the
following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued external research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">645</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,552</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued personnel-related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">732</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,059</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued license fees</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">363</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">377</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">481</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,754</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,455</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>7. Convertible Promissory Notes </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On December&nbsp;1, 2017 and January&nbsp;29, 2018, the Company issued the Convertible Notes for $2.0&nbsp;million and $1.0&nbsp;million, respectively,
to an investor. The Convertible Notes bore an annual interest rate of 6%. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon issuance, the proceeds were allocated to the Convertible Notes and
the derivative instrument resulting from the conversion features (Note 4). The Company remeasured the conversion features to fair value at each reporting date, and recognized a loss of $0.1&nbsp;million in other expense in the consolidated statement
of operations and comprehensive loss for the year ended December&nbsp;31, 2018. Additionally, the Company incurred interest expense on the Convertible Notes of $0.1&nbsp;million during the year ended December&nbsp;31, 2018, which was reflected in
interest expense in the consolidated statement of operations and comprehensive loss. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In March 2018, both Convertible Notes were settled in full
upon the first closing of the initial tranche of the Series B Preferred Stock, which triggered the Automatic Conversion and resulted in the conversion of both Convertible Notes into 1,286,185 shares of Series B Preferred Stock at a specified
discount. The transaction was accounted for as an extinguishment of debt under ASC <FONT STYLE="white-space:nowrap">470-50.</FONT> As the lender was a related party, the settlement was in substance a capital transaction and therefore the impact upon
extinguishment was recognized as an adjustment to accumulated deficit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>8. Commitments and Contingencies </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Leases </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In October 2018, the Company entered into a
sublease agreement for office space located in Cambridge, Massachusetts which expires on December&nbsp;30, 2021, with no option to renew or terminate early. The base rent increases by approximately 1% annually. The Company issued a letter of credit
to the landlord related to the security deposit, secured by restricted cash, which is recorded in other assets on the accompanying consolidated balance sheets. This lease qualifies as an operating lease. Prior to entering into this sublease
arrangement, the Company rented office space from a related party. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In January 2019, the Company entered into an arrangement with a third party to
sublease a portion of its Cambridge, Massachusetts office space. This sublease was terminated in November 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes the
presentation of the operating lease in the Company&#146;s consolidated balance sheets as of December&nbsp;31, 2019 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,450</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Liabilities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Current operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">696</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Non-current portion of operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">763</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,459</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes total lease costs recognized in the Company&#146;s consolidated statement of operations
for the year ended December&nbsp;31, 2019 (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="93%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating lease cost</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">782</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Variable lease costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Sublease income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(31</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total lease costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">754</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Variable lease costs were primarily related to operating expenses, taxes and insurance associated with the operating
lease, which were assessed based on the Company&#146;s proportionate share of such costs for the leased premises. As these costs are generally variable in nature, they are not included in the measurement of the operating lease <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and related lease liability. Total lease costs are included as operating expenses in the Company&#146;s consolidated statement of operations and
comprehensive loss. Total rent expense for the year ended December&nbsp;31, 2018 was $0.3&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Future lease payments under <FONT STYLE="white-space:nowrap">non-cancelable</FONT> lease agreements as
of&nbsp;December&nbsp;31, 2019 were as follows (in&nbsp;thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Future&nbsp;Lease<BR>Payments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">783</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">791</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total future lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,574</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less: interest</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(115</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Present value of operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,459</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The weighted average remaining lease term and weighted average incremental borrowing rate of the Company&#146;s
operating lease as of December&nbsp;31, 2019 were as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted average remaining lease term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted average incremental borrowing rate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8.0</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under the prior lease accounting guidance, minimum rental commitments under
<FONT STYLE="white-space:nowrap">non-cancelable</FONT> leases as of December&nbsp;31, 2018 were as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Minimum&nbsp;Lease<BR>Payments</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">774</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">783</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">791</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,348</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Legal Proceedings </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
Company, from time to time, may be party to litigation arising in the ordinary course of business. The Company was not subject to any legal proceedings during the years ended December&nbsp;31, 2018 and 2019, and no material legal proceedings are
currently pending or threatened. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Purchase Orders </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company has agreements with third parties for various services, including services related to research, preclinical and clinical operations and
support, for which the Company is not contractually able to terminate for convenience to avoid future obligations to the vendors. Certain agreements provide for termination rights subject to termination fees or wind down costs. Under such
agreements, the Company is contractually obligated to make certain payments to vendors, primarily to reimburse them for their unrecoverable outlays incurred prior to cancelation. The actual amounts the Company could pay in the future to the vendors
under such agreements may differ from the purchase order amounts due to cancellation provisions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Indemnification Agreements </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company enters into indemnification agreements and agreements containing indemnification provisions in the ordinary course of business. Pursuant to
these agreements, the Company agrees to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
indemnify, hold harmless, and to reimburse the indemnified party for losses suffered or incurred by the indemnified party, generally the Company&#146;s business partners, in connection with any
U.S. patent or any copyright or other intellectual property infringement claim by any third party with respect to the Company&#146;s products. The term of these indemnification agreements is generally perpetual upon execution of the agreement. The
maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. The Company has never incurred costs to defend lawsuits or settle claims related to these indemnification
agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>9. Redeemable Convertible Preferred Stock </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2019, the authorized capital stock of the Company included 36,724,132 shares of $0.0001 par value Preferred Stock, of
which&nbsp;8,075,799 shares have been designated as Series A Preferred Stock, 14,913,704 shares have been designated as Series B Preferred Stock, 2,666,666 shares have been designated as Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred
Stock and 11,067,963 shares have been designated as Series C Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the year ended December&nbsp;31, 2018, the Company issued a
total of 12,333,333 shares of Series B Preferred Stock in two separate closings at a purchase price of $3.00 per share for gross cash proceeds of $37.0&nbsp;million, and incurred issuance costs of $0.2&nbsp;million. The Company also issued an
aggregate of 1,286,185 shares of Series B Preferred Stock upon the conversion of the Convertible Notes at an average conversion price of $2.40 per share. The Company also issued 1,294,186 shares of Series B Preferred Stock in connection with the
anti-dilutive provision within the Purdue License Agreement. The issuance of the Series B Preferred Stock resulted in changes to certain rights, preferences and privileges of the Series A Preferred Stock. The Company concluded such changes were not
significant and resulted in a modification, rather than an extinguishment, of the Series A Preferred Stock. The changes to the terms of the Series A Preferred Stock did not result in incremental value to the shareholders, and therefore there was no
impact to the accounting for the Series A Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On June&nbsp;18, 2019, the Company entered into the Series <FONT
STYLE="white-space:nowrap">B-1</FONT> Preferred Stock Purchase Agreement which authorized the sale and issuance of up to 2,666,666 shares of its Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock at a purchase price of $3.75 per
share. During the year ended December&nbsp;31, 2019, the Company issued all 2,666,666 shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock for gross cash proceeds of $10.0&nbsp;million, and incurred an immaterial amount of
issuance costs. The issuance of the Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock resulted in changes to certain rights, preferences and privileges of the Series A Preferred Stock and the Series B Preferred Stock. The Company
concluded that such changes were not significant and resulted in a modification, rather than an extinguishment, of the Series A Preferred Stock and the Series B Preferred Stock. The changes to the terms of the Series A Preferred Stock and the Series
B Preferred Stock did not result in incremental value to the shareholders, and therefore there was no impact to the accounting for the Series A Preferred Stock and the Series B Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On November&nbsp;18, 2019, the Company entered into the Series C Preferred Stock Purchase Agreement which authorized the sale and issuance of up to
5,825,243 shares at $5.15 per share. On December&nbsp;10, 2019, the Company executed Amendment No.&nbsp;1 and Joinder to the Series C Preferred Stock Purchase Agreement which authorized the sale and issuance of an additional 5,242,720 shares at
$5.15 per share. During the year ended December&nbsp;31, 2019, the Company issued 9,805,827 shares of Series C Preferred Stock for gross cash proceeds of $50.5&nbsp;million, and incurred issuance costs of $0.2&nbsp;million. Although there were
multiple closings of the Series C Preferred Stock, there was no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
obligation under the initial closing for investors to purchase, or for the Company to sell to such investors, additional shares of Series C Preferred Stock. The issuance of the Series C Preferred
Stock resulted in changes to certain rights, preferences and privileges of the Series A Preferred Stock, the Series B Preferred Stock and the Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock. The Company concluded that such changes
were not significant and resulted in a modification, rather than an extinguishment, of the Series A Preferred Stock, the Series B Preferred Stock and the Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock. The changes to the terms of
the Series A Preferred Stock, the Series B Preferred Stock and the Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock did not result in incremental value to the shareholders, and therefore there was no impact to the accounting for
the Series A Preferred Stock, the Series B Preferred Stock and the <FONT STYLE="white-space:nowrap">Series&nbsp;B-1</FONT> Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
Preferred Stock consisted of the following (in thousands, except share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="43%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock Issued<BR>and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redemption<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Stock</B><br><B>Issuable</B><br><B>Upon<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8,075,799</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8,075,799</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9,284</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9,284</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9,284</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,773,820</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">14,927,584</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">14,913,704</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">46,436</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">46,381</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">46,381</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">6,969,173</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">23,003,383</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">22,989,503</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">55,720</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">55,665</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">55,665</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10,742,993</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock Issued<BR>and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redemption<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Stock</B><br><B>Issuable</B><br><B>Upon<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8,075,799</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8,075,799</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9,932</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9,932</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9,932</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,773,820</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">14,913,704</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">14,913,704</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">49,969</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">49,969</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">49,969</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">6,969,173</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,666,666</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,666,666</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10,431</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10,431</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10,431</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,246,133</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series C Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">11,067,963</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9,805,827</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">50,789</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">50,789</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">50,789</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4,582,257</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">36,724,132</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">35,461,996</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">121,121</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">121,121</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">121,121</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">16,571,383</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Common stock issuable upon conversion in the tables above represents shares of common stock issuable upon an automatic
conversion in the event of a qualified public offering, pursuant to the Company&#146;s Amended and Restated Certificate of Incorporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Rights, Preferences
and Privileges </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pursuant to the Company&#146;s Amended and Restated Certificate of Incorporation, the Series A Preferred Stock, Series B
Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock have the following rights, preferences and privileges: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Voting Rights </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The holders of outstanding shares of the Preferred Stock are entitled to vote, together with the holders of common stock, on all matters submitted to the
stockholders for a vote, and are entitled to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the number of votes equal to the number of whole shares of common stock into which such holders of the Preferred Stock could convert on the record date for determining stockholders entitled to
vote. Except for the actions requiring the approval or consent of the majority of the holders of the Preferred Stock, the holders of the Preferred Stock will vote together with the holders of common stock and vote as a single class. The holders of
the Series A Preferred Stock, exclusively and as a separate class, are entitled to elect two directors of the Company. The holders of the Series B Preferred Stock and Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock, exclusively
and together as a separate class, are entitled to elect two directors of the Company. The holders of common stock and of any other class or series of voting stock (including the Preferred Stock), exclusively and voting as a single class, are
entitled to elect the balance of total number of directors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Dividends </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The holders of the Series A Preferred Stock, Series B Preferred Stock, Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock and Series C
Preferred Stock are entitled to accrue cumulative dividends at an annual rate of $0.08, $0.24, $0.30 and $0.412 per share, respectively, subject to adjustment in the event of any stock dividend, stock split, combination or other similar
recapitalization with respect to the Preferred Stock. Dividends accrue from day to day whether or not declared by the Board, and are payable only when, as, and if declared by the Board. As of December&nbsp;31, 2019, no dividends have been declared
or paid by the Company since its inception. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company&#146;s cumulative dividends on its Preferred Stock were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,209</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,857</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,639</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5,228</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">431</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series C Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">289</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,848</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">7,805</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">No dividends may be declared, paid or set aside to any other class or series of capital stock (other than dividends on
shares of common stock payable in common stock) unless, in addition to obtaining any consents otherwise required in the Company&#146;s certificate of incorporation, the holders of the Preferred Stock first receive a dividend on each outstanding
share in an amount at least equal to the greater of: (i)&nbsp;all accrued and unpaid dividends and (ii)&nbsp;in the case of a dividend being distributed to common stock or any class or series of capital stock that is convertible into common stock,
the equivalent dividend on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis or (iii)&nbsp;in the case of a dividend being distributed on a series or class not convertible into common stock, an additional dividend equal to a dividend
rate calculated based on the respective original issue price of the Preferred Stock. The original issue price per share is equal to $1.00 for the Series A Preferred Stock, $3.00 for the Series B Preferred Stock, $3.75 for the Series <FONT
STYLE="white-space:nowrap">B-1</FONT> Preferred Stock and $5.15 for the Series C Preferred Stock. The holders of the Series C Preferred Stock, Series B Preferred Stock and Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock are
entitled to receive dividends prior to any dividends on the Series A Preferred Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Liquidation Rights </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the event of any voluntary or involuntary liquidation event, dissolution, winding up of the Company or upon the occurrence of certain events
designated by a majority of the holders of the Preferred Stock, and at least two out of three specific holders, to be a deemed liquidation event, each holder of the then outstanding Series C Preferred Stock, Series
<FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock and Series B Preferred Stock will be entitled to receive, prior and in preference to any distributions to the holders of Series A Preferred Stock and common stock, an amount equal to the
greater of (i)&nbsp;original issuance price (adjusted in the event of any stock dividend, stock split, combination or other similar activity) plus any cumulative accrued dividends, whether or not declared, with any other dividends declared but
unpaid thereon, or (ii)&nbsp;the amount such holder would have received if such holder had converted its shares into common stock immediately prior to such liquidation event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">After the payment of all preferential amounts to the holders of the Series C Preferred Stock, Series <FONT STYLE="white-space:nowrap">B-1</FONT>
Preferred Stock and Series B Preferred Stock, each holder of the then outstanding Series A Preferred Stock will be entitled to receive, prior and in preference to any distributions to the holders of common stock, an amount equal to the greater of
(i)&nbsp;original issuance price (adjusted in the event of any stock dividend, stock split, combination or other similar activity) plus any cumulative accrued dividends, whether or not declared, with any other dividends declared but unpaid thereon,
or (ii)&nbsp;the amount such holder would have received if such holder had converted its shares into common stock immediately prior to such liquidation event. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">After payments have been made in full to the holders of the Preferred Stock, then, to the extent available, the remaining amounts will be distributed
among the holders of the shares of common stock, pro rata based on the number of shares held by each holder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Conversion </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each share of the Preferred Stock is convertible, at any time, at the option of the holder, and without the payment of additional consideration, into
such shares of <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of common stock as is determined by dividing the original issue price by the applicable conversion price in effect at the time of conversion. The applicable conversion
price for the Series A Preferred Stock, Series B Preferred Stock, Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock and Series C Preferred Stock is initially equal to $1.00, $3.00, $3.75 and $5.15, respectively. Each share of the
Preferred Stock will be automatically converted into common stock at the applicable conversion ratio then in effect for each series of the Preferred Stock upon either (i)&nbsp;the closing of the sale of shares of common stock at a price of at least
$10.30 per share in a firm-commitment underwritten public offering pursuant to an effective registration statement resulting in at least $75.0&nbsp;million of gross proceeds and the listing of the Company&#146;s common stock on the New York Stock
Exchange, The Nasdaq Global Select Market, or The Nasdaq Global Market or (ii)&nbsp;the date and time, or the occurrence of an event, specified by vote or written consent of the holders of a majority of the outstanding Preferred Stock, voting
together as a single class and at least two of three specific holders. As of December&nbsp;31, 2019, each share of the Preferred Stock was convertible into one share of common stock and may be adjusted in the event of any stock dividend, stock
split, combination or other similar recapitalization with respect to the Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company accounts for potential beneficial conversion
features at the time of issuance. The Company&#146;s common stock into which each series of the Company&#146;s Preferred Stock is convertible had an estimated fair value less than the effective conversion prices of the Preferred Stock at the time of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
each of the issuances of the Preferred Stock. Therefore, there was no intrinsic value on the respective commitment dates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Redemption </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each series of the Preferred Stock is redeemable
at a price equal to the applicable original issuance price per share (adjusted in the event of any stock dividend, stock split, combination or other similar activity), plus any cumulative accrued dividends, whether or not declared together with any
other dividends declared but unpaid, in three annual installments commencing not more than 60 days on or after November&nbsp;18, 2024 at the written election of at least a majority of the holders of the Preferred Stock voting together as a single
class and at least two out of three specific parties. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>10. Common Stock </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2018 and 2019, the authorized capital stock of the Company included 33,000,000 and 46,000,000 shares of common stock, $0.0001 par
value, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Rights, Preferences and Privileges </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The voting, dividend and liquidation rights of the holders of the Company&#146;s common stock are subject to and qualified by the rights, powers and
preferences of the holders of the Preferred Stock. The Company&#146;s common stock has the following rights, preferences and privileges: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Voting Rights </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Each share of common stock entitles the holder to one vote, together with the holders of the Preferred Stock, on all matters submitted to the
stockholders for a vote. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Dividends </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The holders of
shares of common stock are not entitled to receive dividends. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Liquidation Rights </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, after the payment of all preferential amounts
required to be paid to the holders of the Preferred Stock, the remaining assets of the Company available for distribution to its stockholders will be distributed to the holders of common stock on a pro rata basis based on the number of shares held
by each such holder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Shares Reserved for Future Issuance </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company has reserved the following shares of common stock for future issuance: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,773,820</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,773,820</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">6,969,173</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">6,969,173</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,246,133</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series C Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4,582,257</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Shares reserved for vesting of restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">261,393</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">48,190</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Shares reserved for exercise of outstanding stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,192,454</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,634,686</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Shares reserved for future awards under the 2017 Stock Incentive Plan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">942,691</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">617,101</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total shares of authorized common stock reserved for future issuance</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">13,139,531</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">18,871,360</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>11. Stock-Based Compensation </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>2017
Stock Incentive Plan </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On May&nbsp;9, 2017, the Board adopted the 2017 Stock Incentive Plan (the &#147;2017 Plan&#148;). The 2017 Plan allows
the Company to grant stock options, restricted stock, restricted stock units and other stock-based awards to employees, officers, directors, consultants and advisors of the Company. The 2017 Plan is administered by the Board, which has the authority
to grant awards and determine the terms of awards under the 2017 Plan, provided that generally the exercise price per share of stock options granted may not be less than 100% of the fair market value of a share of the Company&#146;s common stock on
the date of grant, and the term of stock options granted may not exceed ten years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The total number of shares of common stock authorized for
issuance under the 2017 Plan as of December&nbsp;31, 2018 and 2019 was 2,240,285 shares and 2,356,927 shares, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31,
2019, the Company has only issued stock options and restricted stock under the 2017 Plan. Stock options issued comprise service-based awards granted to employees and <FONT STYLE="white-space:nowrap">non-employee</FONT> consultants. Stock options and
restricted stock issued under the 2017 Plan have vesting conditions in which 25% vests upon the first anniversary of a specified vesting commencement date, and the remaining 75% vests in 36 monthly installments over the remaining three years.
Vesting of stock options is subject to the recipient&#146;s continued employment or service. The Company has the right to repurchase any unvested shares of restricted stock held by a recipient during the vesting period if the relationship between
the recipient and the Company has terminated. Stock options issued under the 2017 Plan expire ten years from the date of grant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Shares that expire,
are terminated, surrendered or canceled under the 2017 Plan without having been fully exercised will be available for future awards. In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added
to the number of shares of common stock available for future awards. Upon stock option exercise, the Company issues new shares and delivers them to the participant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2019, the Company did not hold any treasury shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Restricted Common Stock </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Prior to the adoption of the 2017 Plan, the Company granted restricted common stock in 2016 with time-based vesting conditions to certain employees and <FONT
STYLE="white-space:nowrap">non-employee</FONT> founders of the Company pursuant to individual award agreements. The restricted common stock granted pursuant to these agreements vests either: (i) 25% upon vesting commencement or the first anniversary
of a specified vesting commencement date, and the remaining 75% monthly over 36 months thereafter, (ii)&nbsp;monthly over 48 months after a specified vesting commencement date, or (iii)&nbsp;monthly over 12 months from a specified vesting
commencement date. The Company has the right to repurchase the unvested shares held by a recipient during the vesting period if the relationship between the recipient and the Company has terminated. Shares of restricted common stock are not
accounted for as outstanding common stock until they have vested. Unvested shares of restricted common stock may not be sold or transferred by the holder. The Company did not grant any restricted common stock during the years ended December&nbsp;31,
2018 or 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes all of the Company&#146;s restricted common stock activity, including restricted common stock issued
under the 2017 Plan and under individual award agreements prior to the adoption of the 2017 Plan: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Grant&nbsp;Date<BR>Fair Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Unvested as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">261,393</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">0.02</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Issued</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(213,203</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Repurchased</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Unvested as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">48,190</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The total fair value of restricted common stock that vested during the years ended December&nbsp;31, 2018 and 2019 was
$0.6&nbsp;million and $0.6&nbsp;million, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Stock Options </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes the Company&#146;s stock option activity: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Exercise&nbsp;Price<BR>per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Remaining<BR>Contractual<BR>Term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(In years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(In&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Outstanding as of December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,192,454</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2.15</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">442,232</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3.30</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cancelled or Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Outstanding as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,634,686</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2.46</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9.00</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5,107</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Exercisable as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">695,505</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2.18</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8.75</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,372</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Vested and expected to vest as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,634,686</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2.46</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9.00</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5,107</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the
underlying stock options and the estimated fair value of the Company&#146;s common stock for those stock options that had exercise prices lower than the estimated fair value of the Company&#146;s common stock at December&nbsp;31, 2019. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Stock Option Valuation </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The assumptions that the Company used
in the Black-Scholes option pricing model to determine the grant-date fair value of stock options granted to employees, members of the Board and <FONT STYLE="white-space:nowrap">non-employees</FONT> on the date of grant were as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3.10&nbsp;&#150;&nbsp;3.20</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1.55</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">6.00&nbsp;&#150;&nbsp;10.00</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">6.00</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">80.03</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">79.09</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Fair value per share of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2.27</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3.30</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The weighted-average grant-date fair value of the Company&#146;s stock options granted during the years ended
December&nbsp;31, 2018 and 2019 was $1.65 and $2.25, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Stock-based compensation expense was allocated as follows (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">181</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">430</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">398</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">238</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">668</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2019, total unrecognized compensation cost related to unvested stock-based awards was
$1.6&nbsp;million, which is expected to be recognized over a weighted-average period of 2.69 years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>12. Significant Agreements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Purdue License Agreement </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On December 31, 2017, the
Company entered into a License Agreement with Purdue (the &#147;Purdue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">License Agreement&#148;), pursuant to which Purdue granted the Company exclusive rights under
certain Purdue know-how to research, develop and commercialize pharmaceutical products concerning a GABA<SUB STYLE="font-size:85%; vertical-align:bottom">A</SUB> positive allosteric modulator. The Company is obligated to make future milestone
payments based on the achievement of specified development and sales milestones up to $33.0 million. Furthermore, the Company is required to pay Purdue royalties of a low-single-digit percentage of annual net sales of licensed products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under the Purdue License Agreement, Purdue agreed to purchase $0.6&nbsp;million of shares of Series B Preferred Stock. In addition, as consideration for
the license obtained, the Company issued Purdue the Anti-Dilution Obligation to ensure Purdue&#146;s ownership remained at a specified percentage throughout the Series B Preferred Stock financing (Note 4). The Company concluded that the Purdue
License Agreement represented the acquisition of <FONT STYLE="white-space:nowrap">in-process</FONT> research and development assets with no alternative future use. Therefore, the initial fair value of the Anti-Dilution Obligation of
$2.4&nbsp;million was expensed as research and development in December 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Purdue License Agreement will remain in effect until the
expiration of the Company&#146;s royalty obligation for all licensed products. Either the Company or Purdue may terminate the agreement in the event of a material breach by the other party and fails to cure such breach within a certain period of
time. Either party may voluntarily terminate the agreement with prior notice. If the agreement is voluntarily terminated by Purdue, the Company&#146;s license rights will survive such termination and such rights will become fully paid, perpetual and
irrevocable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Anti-Dilution Obligation was settled in October 2018. As of December&nbsp;31, 2019, none of the developmental or sales milestones
under the Purdue License Agreement were achieved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>RogCon and Ionis Agreements </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During 2018, the Company began negotiating a license agreement with RogCon Inc. (&#147;RogCon&#148;) for intellectual property related to treating SCN2A
mutations in epilepsy, which is recognized as the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
second most common genetic cause of epilepsy. <I></I>RogCon had an existing collaboration with Ionis Pharmaceuticals, Inc. (&#147;Ionis&#148;) and as a result the Company needed to negotiate an
agreement with Ionis in order to complete the license agreement with RogCon. On December&nbsp;21, 2018, the Company entered into an agreement with RogCon to advance RogCon a deposit of up to $1.0&nbsp;million on the pending license agreement while
the agreement with Ionis was being negotiated. The deposit was fully refundable to the Company. As of December&nbsp;31, 2018, the outstanding balance was $0.6&nbsp;million and is included within prepaid expenses and other current assets on the
Company&#146;s accompanying consolidated balance sheet. On September&nbsp;11, 2019, the Company entered into both a Cooperation and License Agreement (the &#147;License Agreement&#148;) with RogCon, and a Research, Collaboration, Option and License
Agreement (the &#147;Collaboration Agreement&#148;) with Ionis. The agreements were entered into contemporaneously to enable the parties to advance their collective efforts related to SCN2A.<I> </I>Upon execution of the License Agreement, the
$1.0&nbsp;million outstanding balance of the deposit was applied toward the purchase price of the License Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>RogCon Agreement </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under the License Agreement, RogCon granted to the Company an exclusive, worldwide license under RogCon&#146;s intellectual property to research, develop
and commercialize products for the treatment of all forms of epilepsy and/or neurodevelopmental disorders in each case caused by any mutation of the SCN2A gene. Under the License Agreement, the Company will conduct, at its own cost and expense, the
research and development activities assigned to it under the research plan. In addition, the Company is responsible for reimbursing RogCon for any costs associated with research and development activities RogCon performs at the request of the
Company. As part of the agreement, the Company agreed to provide <FONT STYLE="white-space:nowrap">up-front</FONT> consideration of $2.1&nbsp;million, consisting of the $1.0&nbsp;million deposit, $0.7&nbsp;million in cash reimbursements for certain
historical costs previously incurred by RogCon, and $0.4&nbsp;million for the retirement of existing loan balances as of September&nbsp;11, 2019. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company concluded that the License Agreement represented the acquisition of <FONT STYLE="white-space:nowrap">in-process</FONT> research and
development assets with no alternative future use. Therefore, the aggregate acquisition cost of $2.2&nbsp;million, consisting of the $2.1&nbsp;million of <FONT STYLE="white-space:nowrap">up-front</FONT> consideration and $0.1&nbsp;million of
acquisition costs, was expensed as research and development on September&nbsp;11, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Subsequent to September&nbsp;11, 2019, the Company will
reimburse RogCon for its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs incurred for activities performed under the License Agreement. The Company expenses these costs as incurred as research and
development. Since the acquisition date, the Company expensed $0.1&nbsp;million for the reimbursement of RogCon&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs in the year ended
December&nbsp;31, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Additionally, the Company may pay RogCon a milestone payment of $3.0&nbsp;million and profit share payments. The
$3.0&nbsp;million milestone payment will become due when the first profit share payment has become due and certain contingent payments have become payable to Ionis under the Collaboration Agreement, which are subject to the Company exercising its
option to obtain license rights to a development candidate, as well as other contingent events. The profit share payments will be based on a <FONT STYLE="white-space:nowrap">low-double-digit</FONT> percentage of net profits, depending on sales
volume. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The License Agreement, unless earlier terminated, will continue until the latest of: (i)&nbsp;expiration of all patent rights within RogCon
patents, (ii)&nbsp;the Company and its affiliates certify they have abandoned the research, development and commercialization of product with no intention to <FONT STYLE="white-space:nowrap">re-establish</FONT> such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
activities, and (iii)&nbsp;no third party is obligated to pay the Company or its affiliates any amounts that comprise net sublicense revenue. Either party may terminate the License Agreement for
material breach or insolvency of the other party. Additionally, the Company may terminate for convenience with prior written notice to RogCon. Upon termination by either party, all rights and licenses granted by RogCon to the Company will revert
back to RogCon. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Ionis Collaboration Agreement </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under the
Collaboration Agreement, both parties will participate in research activities related to the downregulation of SCN2A gene products associated with the treatment of any and all forms of epilepsy and/or neurodevelopmental disorders in each case caused
by any mutation of the SCN2A gene, other than one severe type of epilepsy. Ionis will also be responsible for identifying a development candidate and conducting an <FONT STYLE="white-space:nowrap">IND-enabling</FONT> toxicology study. The Company
will reimburse Ionis for any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs incurred related to the research activities, identification of a development candidate and conducting an <FONT
STYLE="white-space:nowrap">IND-enabling</FONT> toxicology study. Additionally, the Company agreed to reimburse $0.3&nbsp;million of costs incurred by Ionis for the performance of research activities prior to the execution of the Collaboration
Agreement, which the Company recognized as research and development expense. The reimbursement of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs is recognized as research and development expense
as incurred. Inclusive of the <FONT STYLE="white-space:nowrap">up-front</FONT> payment of $0.3&nbsp;million, the Company expensed a total of $0.6&nbsp;million as research and development under the Collaboration Agreement for the year ended
December&nbsp;31, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Ionis granted the Company an exclusive option to obtain the rights and license related to the development candidate, which
the Company may exercise following completion of the <FONT STYLE="white-space:nowrap">IND-enabling</FONT> toxicology study. Upon option exercise, the Company will pay Ionis a $2.0&nbsp;million license fee. After option exercise, the Company is
responsible for clinical development and commercialization of the development candidate. If the option is not exercised, the Collaboration Agreement will expire, and the Company will have no further rights to the development candidate. Additionally,
if the option is not exercised, at the request of Ionis, the Company will assign the RogCon License Agreement to Ionis. The Company concluded that there is no accounting recognition for the exclusive option unless and until such option is exercised
because it is a unilateral right of the Company that is priced at an amount that approximates fair value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">If the Company exercises its exclusive
option, Ionis may be entitled to development milestone payments, additional milestone payments, and sales royalties or sublicense fees. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
Collaboration Agreement will continue until the expiration of all payment obligations to Ionis, unless earlier terminated. Either party may terminate the Collaboration Agreement upon material breach or insolvency of the other party or if Ionis is
unable to identify a development candidate. Ionis may terminate if the Company fails to achieve a performance milestone. The Company may terminate for convenience with prior written notice to Ionis. Upon termination by the Company for convenience,
the Company will stop selling all products, subject to certain wind-down provisions, and all products will revert back to Ionis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>13. Net Loss per Share and Unaudited Pro Forma Net Loss per Share </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Net Loss per Share </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Basic and diluted net loss per
share attributable to common stockholders was calculated as follows (in thousands, except share and per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(26,535</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(35,512</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accretion and cumulative dividends on redeemable convertible preferred
stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(2,296</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(5,170</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss on conversion of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(392</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(29,223</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(40,682</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,297,633</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,529,629</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share attributable to common stockholders, basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(22.52</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(26.60</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the
calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have been anti-dilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,773,820</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,773,820</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">6,969,173</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">6,969,173</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,246,133</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series C Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4,582,257</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Outstanding stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,192,454</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,634,686</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Unvested restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">261,393</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">48,190</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">12,196,840</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">18,254,259</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The shares of common stock issuable upon conversion of the Preferred Stock assume automatic conversion in the event of a
qualified public offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Unaudited Pro Forma Net Loss per Share </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Unaudited pro forma basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and
per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year Ended<BR>December&nbsp;31,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(40,682</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accretion and cumulative dividends on redeemable convertible preferred
stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5,170</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(35,512</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,529,629</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma adjustment to reflect the automatic conversion of redeemable
convertible preferred stock into common stock upon the completion of the proposed initial public offering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">11,741,132</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma weighted average common shares outstanding, basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">13,270,761</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net loss per share attributable to common stockholders, basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(2.68</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>14. Income Taxes </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
Company maintains a full valuation allowance on its U.S. net deferred tax assets due to the uncertainty of future taxable income. The Company did not recognize an income tax benefit in the years ended December&nbsp;31, 2018 or 2019 related to its
U.S. operations due to the uncertainty regarding future taxable income. In the years ended December&nbsp;31, 2018 and 2019, the difference between the statutory tax rate in the U.S. and the Company&#146;s effective tax rate was due primarily to the
valuation allowance recorded to offset any potential tax benefit. The income tax provision and benefit recognized for the years ended December&nbsp;31, 2018 and 2019, respectively, related to income tax associated with the Company&#146;s operations
in Australia. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The reconciliation of the U.S. statutory income tax rate to the Company&#146;s effective tax rate is as
follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Year&nbsp;Ended&nbsp;December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2018&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Federal statutory income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">State taxes, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5.1</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">6.0</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Federal and state research and development credits</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">0.7</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2.9</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-deductible</FONT> items</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(3.6</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(0.4</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)%&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Foreign</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(0.1</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">0.2</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(23.1</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(29.6</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)%&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(0.5</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">0.1</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Effective income tax rate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(0.5</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">0.2</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Net deferred tax assets consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="83%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2018</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">6,931</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">14,502</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Amortization</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,776</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,512</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development credits</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">196</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,230</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">340</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Foreign exchange loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Leases</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">396</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total gross deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9,176</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">20,040</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less: Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(9,176</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(19,647</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">393</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating lease
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(393</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total gross deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(393</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2018 and 2019, the Company had U.S. federal net operating loss carryforwards which may be able
to offset future income tax liabilities of approximately $25.6&nbsp;million and $53.4&nbsp;million, respectively. Federal net operating loss carryforwards of $7.7&nbsp;million will expire at various dates through 2037 and approximately
$45.7&nbsp;million may be carried forward indefinitely.&nbsp;As of December&nbsp;31, 2018 and 2019, the Company also had state net operating loss carryforwards of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
approximately $25.1&nbsp;million and $52.0&nbsp;million, respectively, which may be available to offset future income tax liabilities and expire at various dates through 2039. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2018 and 2019, the Company had federal research and development tax credit carryforwards of approximately $0.1&nbsp;million and
$0.9&nbsp;million, respectively, available to reduce future tax liabilities which expire at various dates through 2039.&nbsp;As of December&nbsp;31, 2018 and 2019, the Company had state research and development tax credit carryforwards of
approximately $0.1&nbsp;million and $0.4&nbsp;million, respectively, available to reduce future tax liabilities which expire at various dates through 2034.&nbsp;The Company has generated research credits but has not conducted a study to document the
qualified activity.&nbsp;This study may result in an adjustment to the Company&#146;s research and development credit carryforwards; however, until a study is completed, and any adjustment is known, no amounts are being presented as an uncertain tax
position.&nbsp;A full valuation allowance has been provided against the Company&#146;s research and development credits and, if an adjustment is required, this adjustment would be offset by an adjustment to the deferred tax asset established for the
research and development credit carryforwards and the valuation allowance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Under the provisions of the Internal Revenue Code, the net operating
loss and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities.&nbsp;Net operating loss and tax credit carryforwards may become subject to an annual limitation in the event
of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code, respectively, as well as similar state provisions.
This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on the value of the Company immediately prior to the ownership
change.&nbsp;Subsequent ownership changes may further affect the limitation in future years. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since
inception due to the significant complexity and cost associated with such a study.&nbsp;If the Company has experienced a change of control, as defined by Section&nbsp;382, at any time since inception, utilization of the net operating loss
carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section&nbsp;382, which is determined by first multiplying the value of the Company&#146;s stock at the time of the ownership change by
the applicable long-term <FONT STYLE="white-space:nowrap">tax-exempt</FONT> rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or
research and development tax credit carryforwards before utilization. Further, until a study is completed by the Company and any limitation is known, no amounts are being presented as an uncertain tax position. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">ASC 740 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not
that some portion or all of the deferred tax assets will not be realized. After consideration of all of the evidence, both positive and negative, the Company has recorded a valuation allowance against its deferred tax assets at December&nbsp;31,
2018 and 2019 because management has determined that it is more likely than not that the Company will not recognize the benefits of its federal and state deferred tax assets, primarily due to its history of cumulative net losses incurred since
inception and its lack of commercialization of any products or generation of any revenue from product sales since inception. As a result, a valuation allowance of $9.2&nbsp;million and $19.6&nbsp;million has been established at December&nbsp;31,
2018 and 2019, respectively.&nbsp;Management reevaluates the positive and negative evidence at each reporting period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
The valuation allowance increased by approximately $6.1&nbsp;million and $10.5&nbsp;million during the years ended December&nbsp;31, 2018 and 2019, respectively, due primarily to the generation
of net operating losses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company has not recorded any amounts for unrecognized tax benefits as of December&nbsp;31, 2018 and 2019.&nbsp;The
Company&#146;s policy is to record interest and penalties related to uncertain tax positions as part of its income tax provision.&nbsp;As of December&nbsp;31, 2018 and 2019, the Company had no accrued interest or penalties related to uncertain tax
positions and no such amounts have been recognized in the Company&#146;s consolidated statement of operations and comprehensive loss for either year ended December&nbsp;31, 2018 or 2019.&nbsp;In many cases, the Company&#146;s uncertain tax positions
are related to years that remain subject to examination by relevant tax authorities. The statute of limitations for federal and state tax authorities is open for tax years ended December&nbsp;31, 2016 through December&nbsp;31, 2019.&nbsp;Since the
Company is in a loss carryforward position, the Company is generally subject to examination by the U.S. federal, state and local income tax authorities for all tax years in which a loss carryforward is available. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>15. Related Party Transactions </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the year ended
December&nbsp;31, 2019, the Company reimbursed $0.2&nbsp;million of third-party recruiting costs incurred by a significant shareholder on behalf of the Company. These amounts were recorded in general and administrative expenses during the year ended
December&nbsp;31, 2019 and were within accrued expenses as of December&nbsp;31, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In December 2017 and January 2018, the Company issued the
Convertible Notes to a significant shareholder with Board representation for $2.0&nbsp;million and $1.0&nbsp;million, respectively. The Convertible Notes were settled in March 2018 upon their automatic conversion into shares of the Company&#146;s
Series B Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">A member of the Board is affiliated with Purdue. During the years ended December&nbsp;31, 2018 and 2019, the Company
continued to perform certain research and development activities pursuant to the Purdue License Agreement (Note 12). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the years ended
December 31, 2018 and 2019, related parties participated in each of the </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Company&#146;s offerings of the Preferred Stock (Note 9). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">During the year ended December&nbsp;31, 2018, the Company leased an office space from a significant shareholder. The Company moved out of the space in
December 2018 and recognized $0.1&nbsp;million of rent expense related to this lease during the year ended December&nbsp;31, 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>16. Employee Benefit Plan
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company did not have an employee benefit plan under Section&nbsp;401(k) of the Internal Revenue Code during the year ended December&nbsp;31,
2018. During the year ended December&nbsp;31, 2019, the Company implemented a defined contribution savings plan for eligible employees. The plan covers substantially all employees who meet a minimum age requirement and allows participants to defer a
portion of their annual compensation on a <FONT STYLE="white-space:nowrap">pre-tax</FONT> basis. Under the plan, the Company is not obligated to match any participant contributions. The Company did not make any contributions to the plan during the
year ended December&nbsp;31, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>17. Subsequent Events </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Subsequent Events Through July 22, 2020 </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL"><B><I></I></B>The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the consolidated
financial statements to provide additional evidence for certain estimates or to identify matters that require additional disclosure. The Company has evaluated subsequent events through July 22, 2020, the date these consolidated financial statements
were issued, and identified the following subsequent events: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Series C Redeemable Convertible Preferred Stock Transactions </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On January&nbsp;20, 2020, the Company granted two investors holding 5,825,243 shares of Series C Preferred Stock that were purchased in December 2019 the
option to put their shares back to the Company at the original issuance price. On February&nbsp;19, 2020 and March&nbsp;3, 2020, the investors exercised their put option in full via the execution of Stock Redemption and Release Agreements in order
to effect the repurchase. Pursuant to the Stock Redemption and Release Agreements, the Company agreed to repurchase a total of 5,825,243 shares of Series C Preferred Stock at the original issuance price of $5.15 per share, for an aggregate cash
repurchase price of $30.0&nbsp;million. Under the terms of the Stock Redemption and Release Agreements, the investors waived their right to cumulative dividends that had accumulated from the original issuance date through the date of repurchase.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company determined that the additional put right that was granted to the investors represented a modification of the affected shares of Series
C Preferred Stock, but that it did not result in incremental value to the shareholders. As there was no incremental value associated with the modification, there was no impact to the accounting for the Series C Preferred Stock. The Company also
determined that the put right did not require bifurcation, as it does not contain the characteristics of a derivative instrument. Further, the Company determined that the shares of Series C Preferred Stock that were subject to repurchase did not
become mandatorily redeemable until the execution of the Stock Redemption and Release Agreements because the parties did not have an unconditional legal obligation to complete the redemptions until the associated agreements were finalized. Such
determination was made in consultation with legal counsel. Accordingly, the Company recorded each of the redemptions on the respective date of repurchase and recognized a gain on repurchase equal to the difference between the repurchase price and
the carrying value of the Series C Preferred Stock on the respective date of repurchase. The aggregate gain of $0.5&nbsp;million will be recorded as an adjustment to accumulated deficit in the statement of redeemable convertible preferred stock and
stockholders&#146; (deficit) equity. The gain related exclusively to the dividends accrued on the repurchased shares, which were waived by the investors as part of the Stock Redemption and Release Agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On April&nbsp;15, 2020 and May&nbsp;8, 2020, the Company completed additional closings for the sale and issuance of its Series C Preferred Stock for a
total of 4,563,108 shares at $5.15 per share for aggregate cash proceeds of $23.5&nbsp;million, less an immaterial amount of issuance costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Common Stock
Authorized for Issuance </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On June&nbsp;5, 2020, the Company amended the Company&#146;s Amended and Restated Certificate of Incorporation to
increase the number of shares of common stock authorized for issuance to 50,000,000 shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Amendment to 2017 Stock Incentive Plan </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On June&nbsp;5, 2020, the Company amended the 2017 Stock Incentive Plan to increase the total number of shares authorized for issuance to 3,909,725
shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Related Party Transactions </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">One of the founders
of RogCon became the Company&#146;s General Counsel in June 2020. The Company continues to reimburse RogCon for its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs incurred for activities performed
under the License Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Subsequent Events Through October 9, 2020 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In connection with the re-issuance of these consolidated financial statements, the Company has evaluated subsequent events through October 9, 2020, the
date these consolidated financial statements were re-issued, and identified the following subsequent events: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Common Stock and Preferred Stock Authorized for
Issuance </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On July 24, 2020, the Board amended the Company&#146;s Amended and Restated Certificate of Incorporation to increase the number of
shares of common stock authorized for issuance to 66,000,000 shares. In addition, the Board amended the Company&#146;s Amended and Restated Certificate of Incorporation to increase the number of shares of preferred stock authorized for issuance to
53,644,314 shares, of which 8,075,799 shares are designated as Series A Preferred Stock, 14,913,704 shares are designated as Series B Preferred Stock, 2,666,666 shares are designated as Series B-1 Preferred Stock, 8,543,692 shares are designated as
Series C Preferred Stock and 19,444,453 shares are designated as Series C-1 redeemable convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Series C-1 Redeemable Convertible Preferred
Stock Issuance </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the third quarter of 2020, the Company issued a total of 19,444,453 shares of Series C-1 redeemable convertible preferred
stock at a purchase price of $5.67 per share for aggregate proceeds of approximately $110.1 million, net of issuance costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Common Stock Authorized for Issuance
</I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On September 2, 2020, the Board amended the Company&#146;s Amended and Restated Certificate of Incorporation to increase the number of shares of
common stock authorized for issuance to 70,500,000 shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Amendment to 2017 Stock Incentive Plan </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On September 2, 2020, the Board amended the 2017 Stock Incentive Plan to increase the total number of shares authorized for issuance to 5,937,763 shares.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Reverse Stock Split </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On October 8, 2020, the Board and
the Company&#146;s stockholders approved a one-for-2.14 reverse stock split. Effective on October 8, 2020, the reverse stock split impacted the Company&#146;s issued and outstanding shares of common stock. Stockholders entitled to fractional shares
as a result of the reverse stock split will receive a cash payment in lieu of receiving fractional shares. All shares of common stock, per share amounts and additional paid-in capital amounts for all periods presented in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the accompanying consolidated financial statements and related notes have been retroactively adjusted, where applicable, to reflect the reverse stock split. Shares of common stock underlying
outstanding stock options and other equity instruments were proportionately reduced and the respective exercise prices were proportionately increased, as applicable, in accordance with the terms of the agreements governing such securities. The
respective conversion prices of the Preferred Stock were proportionately increased. The number of shares of common stock authorized for issuance and the par value of common stock were not adjusted as a result of the reverse stock split. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin945651_7"></A>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONDENSED CONSOLIDATED BALANCE SHEETS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Amounts in thousands, except
share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Pro&nbsp;Forma</B><br><B>June&nbsp;30,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">44,815</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">19,748</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">19,748</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">681</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">692</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">692</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">45,496</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">20,440</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">20,440</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Operating lease <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">right-of-use</FONT></FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,450</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,109</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,109</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">396</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">396</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">47,694</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">22,653</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">22,653</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" COLSPAN="12" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL"><B>Liabilities, redeemable convertible preferred stock and
stockholders&#146; (deficit) equity</B></P></TD>
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:0em; text-indent:0em; font-size:7.5pt; font-family:ARIAL"><B>&nbsp;</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,667</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,688</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,688</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,455</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,740</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,740</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">696</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">729</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">729</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">6,818</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8,157</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8,157</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Long-term liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-current</FONT> portion of operating lease
liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">763</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">390</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">390</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">7,581</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8,547</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8,547</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Commitments and contingencies (Note 5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Series A redeemable convertible preferred stock, $0.0001 par value; 8,075,799
shares authorized as of December&nbsp;31, 2019 and June&nbsp;30, 2020; 8,075,799 shares issued and outstanding as of December&nbsp;31, 2019 and June&nbsp;30, 2020; liquidation value as of December&nbsp;31, 2019 and June&nbsp;30, 2020 of $9,932 and
$10,254, respectively; no shares authorized, issued or outstanding, pro forma as of June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9,932</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10,254</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Series B redeemable convertible preferred stock, $0.0001 par value; 14,913,704
shares authorized as of December&nbsp;31, 2019 and June&nbsp;30, 2020; 14,913,704 shares issued and outstanding as of December&nbsp;31, 2019 and June&nbsp;30, 2020; liquidation value as of December&nbsp;31, 2019 and June&nbsp;30, 2020 of $49,969 and
$51,749, respectively; no shares authorized, issued or outstanding, pro forma as of June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">49,969</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">51,749</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable convertible
preferred stock, $0.0001 par value; 2,666,666 shares authorized as of December&nbsp;31, 2019 and June&nbsp;30, 2020; 2,666,666 shares issued and outstanding as of December&nbsp;31, 2019 and June&nbsp;30, 2020; liquidation value as of
December&nbsp;31, 2019 and June&nbsp;30, 2020 of $10,431 and $10,828, respectively; no shares authorized, issued or outstanding, pro forma as of June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10,431</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10,828</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Series C redeemable convertible preferred stock, $0.0001 par value; 11,067,963
shares authorized as of December&nbsp;31, 2019 and June&nbsp;30, 2020; 9,805,827 shares issued and outstanding as of December&nbsp;31, 2019 and 8,543,692 shares issued and outstanding as of June&nbsp;30, 2020; liquidation value as of
December&nbsp;31, 2019 and June&nbsp;30, 2020 of $50,789 and $45,359, respectively; no shares authorized, issued or outstanding, pro forma as of June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">50,789</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">45,359</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Stockholders&#146; (deficit) equity:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Common stock, $0.0001 par value; 46,000,000 shares authorized as of
December&nbsp;31, 2019 and 50,000,000 shares authorized as of June&nbsp;30, 2020; 1,670,070 shares issued and 1,621,880 shares outstanding as of December&nbsp;31, 2019, and 1,670,070 shares issued and 1,648,165 shares outstanding as of June&nbsp;30,
2020; 17,651,659 shares issued and 17,629,754 shares outstanding, pro forma as of June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">118,189</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(81,009</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(104,085</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(104,085</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(81,008</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(104,084</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">14,106</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Total liabilities, redeemable convertible preferred stock and
stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">47,694</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">22,653</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">22,653</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin945651_8"></A>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Amounts in thousands, except
share and per share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">14,512</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">15,918</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,129</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4,121</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">17,641</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">20,039</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(17,641</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(20,039</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other income:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total other income</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">123</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">133</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Loss before provision for (benefit from) income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(17,518</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(19,906</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Benefit from income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(8</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(17,518</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(19,898</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accretion and cumulative dividends on redeemable convertible preferred
stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(2,184</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(4,103</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Gain on repurchase of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">493</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(19,702</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(23,508</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share attributable to common stockholders, basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(13.38</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(14.37</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,472,484</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,635,913</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net loss per share attributable to common stockholders, basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(1.16</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma weighted average common shares outstanding, basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">17,177,274</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin945651_9"></A>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONDENSED CONSOLIDATED STATEMENTS OF REDEEMABLE CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS&#146; (DEFICIT) EQUITY </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Amounts in thousands, except
share data) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7.5pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series A<BR>Redeemable<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series B<BR>Redeemable<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series <FONT STYLE="white-space:nowrap">B-1</FONT><BR>Redeemable<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Series C<BR>Redeemable<BR>Convertible<BR>Preferred Stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common Stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">Paid-In</FONT><BR>Capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Accumulated<BR>Deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total<BR>Stockholders&#146;<BR>(Deficit)<BR>Equity</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL"><B>Balance at December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8,075,799</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9,284</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">14,913,704</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">46,436</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,408,677</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">326</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(41,365</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(41,038</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Issuance of Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable
convertible preferred stock, net of issuance costs of $61</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,666,666</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9,939</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">234</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">234</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Accretion of redeemable convertible preferred stock to redemption
value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">322</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,728</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(560</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(1,578</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(2,138</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Vesting of restricted stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">116,823</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(17,518</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(17,518</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL"><B>Balance at June&nbsp;30, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8,075,799</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right"> 9,606</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">14,913,704</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right"> 48,164</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,666,666</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right"> 10,027</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right"> &#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,525,500</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(60,461</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(60,460</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL"><B>Balance at December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8,075,799</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9,932</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">14,913,704</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">49,969</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,666,666</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10,431</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9,805,827</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">50,789</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,621,880</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(81,009</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(81,008</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Repurchase of Series C redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(5,825,243</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(30,493</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">493</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">493</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Issuance of Series C redeemable convertible preferred stock, net of issuance
costs of $41</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4,563,108</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">23,459</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">432</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">432</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Accretion of redeemable convertible preferred stock to redemption
value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">322</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,780</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">397</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,604</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(432</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(3,671</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(4,103</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Vesting of restricted stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">26,285</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(19,898</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(19,898</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL"><B>Balance at June&nbsp;30, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8,075,799</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right"> 10,254</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">14,913,704</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right"> 51,749</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,666,666</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right"> 10,828</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8,543,692</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right"> 45,359</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,648,165</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(104,085</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(104,084</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL">Conversion of redeemable convertible preferred stock into common
stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(8,075,799</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(10,254</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(14,913,704</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(51,749</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(2,666,666</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(10,828</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(8,543,692</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(45,359</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">15,981,589</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">118,189</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">118,190</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:7.5pt; font-family:ARIAL"><B>Pro forma balance at June&nbsp;30, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">17,629,754</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">118,189</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(104,085</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">14,106</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin945651_10"></A>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Amounts in thousands) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended<BR>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash flows from operating activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(17,518</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(19,898</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Adjustments to reconcile net loss to net cash used in operating
activities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Depreciation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">17</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">234</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">432</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Non-cash</FONT> operating lease
expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">315</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">341</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(520</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(11</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">553</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">912</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,492</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(308</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(340</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(31</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(15,766</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(18,513</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash flows from investing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(74</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(74</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Cash flows from financing activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds from issuance of redeemable convertible preferred stock, net of
issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9,997</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">23,459</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Repurchase of Series C redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(30,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Payment of deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(13</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net cash provided by (used in) financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9,997</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(6,554</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Decrease in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(5,843</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(25,067</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash, cash equivalents and restricted cash, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">18,550</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">45,415</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash, cash equivalents and restricted cash, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">12,707</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">20,348</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Supplemental disclosures of <FONT STYLE="white-space:nowrap">non-cash</FONT>
activities:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accretion of redeemable convertible preferred stock to redemption
value</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,138</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4,103</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Operating lease liabilities recorded upon adoption of ASC 842</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,092</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Purchases of property and equipment included in accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">29</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Deferred offering costs included in accounts payable and accrued
expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">372</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin945651_11"></A>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>1. Nature of the Business </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Praxis Precision Medicines, Inc. (&#147;Praxis&#148; or the &#147;Company&#148;) is a clinical-stage biopharmaceutical company translating genetic
insights into the development of therapies for central nervous system (&#147;CNS&#148;) disorders characterized by neuronal imbalance. The Company has established a broad portfolio, including five disclosed programs across multiple CNS disorders,
including depression, epilepsy, movement disorders and pain syndromes, with three clinical-stage product candidates. The Company&#146;s most advanced programs, <FONT STYLE="white-space:nowrap">PRAX-114</FONT> and
<FONT STYLE="white-space:nowrap">PRAX-944,</FONT> are currently in Phase 2 development. <FONT STYLE="white-space:nowrap">PRAX-114</FONT> is being developed for the treatment of major depressive disorder and perimenopausal depression, and <FONT
STYLE="white-space:nowrap">PRAX-944</FONT> is a selective small molecule inhibitor of <FONT STYLE="white-space:nowrap">T-type</FONT> calcium channels for the treatment of Essential Tremor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Praxis was incorporated in 2015. The Company has funded its operations primarily with proceeds from the issuance of convertible debt, Series A
redeemable convertible preferred stock (the &#147;Series A Preferred Stock&#148;), Series B redeemable convertible preferred stock (the &#147;Series B Preferred Stock&#148;), Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable convertible
preferred stock (the &#147;Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock&#148;) and Series C redeemable convertible preferred stock (the &#147;Series C Preferred Stock&#148;) (the Series A Preferred Stock, Series B Preferred
Stock, Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock and Series C Preferred Stock are collectively referred to as the &#147;Preferred Stock&#148;). From inception through June&nbsp;30, 2020, the Company raised
$100.6&nbsp;million in aggregate cash proceeds from these transactions, net of issuance costs. In the third quarter of 2020, the Company sold and issued shares of Series <FONT STYLE="white-space:nowrap">C-1</FONT> redeemable convertible preferred
stock for aggregate cash proceeds of approximately $110.1&nbsp;million, net of issuance costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company is subject to risks and uncertainties
common to early-stage companies in the biotechnology industry, including but not limited to, risks associated with completing preclinical studies and clinical trials, receiving regulatory approvals for product candidates, development by competitors
of new biopharmaceutical products, dependence on key personnel, protection of proprietary technology, compliance with government regulations and the ability to secure additional capital to fund operations. Programs currently under development will
require significant additional research and development efforts, including preclinical and clinical testing and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel and
infrastructure and extensive compliance-reporting capabilities. Even if the Company&#146;s product development efforts are successful, it is uncertain when, if ever, the Company will realize revenue from product sales. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Going Concern </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In accordance with the Financial
Accounting Standards Board Accounting Standards Update <FONT STYLE="white-space:nowrap">2014-15,</FONT> <I>Disclosure of Uncertainties about an Entity</I><I>&#146;</I><I>s Ability to Continue as a Going Concern (Subtopic <FONT
STYLE="white-space:nowrap">205-40)</FONT></I>, the Company has evaluated whether there are conditions and events, considered in the aggregate, that raise substantial doubt about the Company&#146;s ability to continue as a going concern within one
year after the date that these condensed consolidated financial statements are issued. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company has incurred recurring losses since its
inception, including net losses of $17.5&nbsp;million and $19.9&nbsp;million for the six months ended June&nbsp;30, 2019 and 2020, respectively. In addition, as of June&nbsp;30, 2020, the Company had an accumulated deficit of $104.1&nbsp;million.
The Company expects to continue to generate operating losses for the foreseeable future. The future viability of the Company is dependent on its ability to raise additional capital to finance its operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company&#146;s inability to raise capital as and when needed could have a negative impact on its
financial condition and ability to pursue its business strategies. There can be no assurance that the current operating plan will be achieved or that additional funding will be available on terms acceptable to the Company, or at all. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company expects that its cash and cash equivalents as of June&nbsp;30, 2020 of $19.7&nbsp;million, together with the $110.1&nbsp;million net cash
proceeds from the sale and issuance of shares of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock in the third quarter of 2020, will be sufficient to fund the operating expenses and capital expenditure requirements necessary to
advance its research efforts and clinical trials into the second half of 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The future viability of the Company beyond one year from the date of
issuance of these condensed consolidated financial statements is dependent on its ability to raise additional capital to finance its operations. If the Company is unable to obtain additional funding, the Company could be forced to delay, reduce or
eliminate some or all of its research and development programs, product portfolio expansion, or commercialization efforts, which could adversely affect its business prospects, or the Company may be unable to continue operations. The Company expects
to seek additional funding through private or public equity transactions, debt financings, or other capital sources, including collaborations with other companies or other strategic transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Although management plans to pursue additional funding, there is no assurance that the Company will be successful in obtaining sufficient funding on
terms acceptable to the Company to fund continuing operations, if at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Based on its recurring losses and negative cash flows from operations
since inception, expectation of continuing operating losses and negative cash flows from operations for the foreseeable future, and the need to raise additional capital to finance its future operations, management concluded that there is substantial
doubt about the Company&#146;s ability to continue as a going concern for one year after the date that these condensed consolidated financial statements are issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The accompanying condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.
Accordingly, the condensed consolidated financial statements have been prepared on a basis that assumes the Company will continue as a going concern and which contemplates the realization of assets and satisfaction of liabilities and commitments in
the ordinary course of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Basis of Presentation </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The accompanying condensed
consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America (&#147;GAAP&#148;). Any reference in these notes to applicable guidance is meant to refer to the
authoritative GAAP as found in the Accounting Standards Codification (&#147;ASC&#148;) and Accounting Standards Updates (&#147;ASU&#148;) of the Financial Accounting Standards Board (&#147;FASB&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company&#146;s significant accounting policies are disclosed in the audited consolidated financial
statements for the years ended December&nbsp;31, 2018 and 2019, included elsewhere in this prospectus. Since the date of those financial statements, there have been no changes to its significant accounting policies except as noted below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Unaudited Interim Condensed Consolidated Financial Information </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The accompanying condensed consolidated balance sheet as of June&nbsp;30, 2020, the condensed consolidated statements of operations and comprehensive
loss and statements of cash flows for the six months ended June&nbsp;30, 2019 and 2020 and the condensed consolidated statements of redeemable convertible preferred stock and stockholders&#146; (deficit) equity for the six months ended June&nbsp;30,
2019 and 2020 are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual consolidated financial statements, and in the opinion of management reflect all adjustments, which include only normal
recurring adjustments necessary for the fair statement of the Company&#146;s financial position as of June&nbsp;30, 2020 and the results of its operations and its cash flows for the six months ended June&nbsp;30, 2019 and 2020. Financial statement
disclosures for the six months ended June&nbsp;30, 2019 and 2020 are condensed and do not include all disclosures required for an annual set of financial statements in accordance with GAAP. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The results for the six months ended June&nbsp;30, 2020 are not necessarily indicative of results to be expected for the year ended December&nbsp;31,
2020, any other interim periods, or any future year or period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Unaudited Pro Forma Information </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Upon the closing of a qualified public offering (as defined in the Company&#146;s Amended and Restated Certificate of Incorporation), all of the
Company&#146;s outstanding shares of redeemable convertible preferred stock will automatically convert into shares of common stock. The accompanying unaudited pro forma condensed consolidated balance sheet and condensed consolidated statement of
redeemable convertible preferred stock and stockholders&#146; (deficit) equity as of June&nbsp;30, 2020 have been prepared as if the Company&#146;s proposed initial public offering (&#147;IPO&#148;) had occurred on June&nbsp;30, 2020 to give effect
to the automatic conversion of all outstanding shares of redeemable convertible preferred stock into an aggregate of 15,981,589 shares of common stock upon the consummation of the proposed IPO. The shares of common stock expected to be issued and
the proceeds expected to be received in the proposed IPO are excluded from such pro forma financial information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The unaudited pro forma basic and
diluted net loss per share attributable to common stockholders in the accompanying condensed consolidated statement of operations and comprehensive loss for the six months ended June&nbsp;30, 2020 was computed using the weighted average number of
shares of common stock outstanding, including the pro forma effect of the automatic conversion of all outstanding shares of redeemable convertible preferred stock into shares of common stock as if the proposed IPO had occurred on the later of:
(i)&nbsp;January&nbsp;1, 2019 or (ii)&nbsp;the date the equity instruments were issued. The unaudited pro forma net loss attributable to common stockholders used in the calculation of unaudited pro forma basic and diluted net loss per share
attributable to common stockholders for the six months ended June&nbsp;30, 2020: (i)&nbsp;excludes the effects of cumulative dividends accrued for redeemable convertible preferred stock from the net loss attributable to common
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
stockholders, (ii)&nbsp;excludes the effects of other accretion recorded for redeemable convertible preferred stock from the net loss attributable to common stockholders and (iii)&nbsp;excludes
the effects of the gains on the redemptions of redeemable convertible preferred stock from the net loss attributable to common stockholders. The unaudited pro forma basic and diluted net loss per share attributable to common stockholders does not
include the shares expected to be sold or related proceeds to be received in the proposed IPO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Use of Estimates </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of expenses during the reporting periods. Significant
estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual for research and development expenses, stock-based compensation expense, the valuation of equity instruments and
the recoverability of the Company&#146;s net deferred tax assets and related valuation allowance. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in
which they become known. Actual results could differ materially from those estimates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Cash, Cash Equivalents and Restricted Cash </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table reconciles cash, cash equivalents and restricted cash to the total amounts on the condensed consolidated statements of cash flows (in
thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">12,107</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">19,748</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">600</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total cash, cash equivalents and restricted cash as shown in the condensed
consolidated statement of cash flows</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">12,707</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">20,348</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Deferred Offering Costs </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company capitalizes certain legal, accounting and other third-party fees that are directly associated
<FONT STYLE="white-space:nowrap">with&nbsp;in-process&nbsp;equity</FONT> financings as deferred offering costs until such financings are consummated. After the consummation of the equity financing, these costs are recorded in stockholders&#146;
(deficit) equity as a reduction of <FONT STYLE="white-space:nowrap">additional&nbsp;paid-in&nbsp;capital</FONT> or the associated preferred stock account, as applicable. In the event the offering is terminated, all capitalized deferred offering
costs are expensed. Deferred offering costs as of June&nbsp;30, 2020 were $0.4&nbsp;million. Such costs are classified in <FONT STYLE="white-space:nowrap">other&nbsp;non-current&nbsp;assets</FONT> in the accompanying condensed consolidated balance
sheet. No deferred offering costs were capitalized as of December&nbsp;31, 2019. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Stock-Based Compensation </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company utilizes significant estimates and assumptions in determining the fair value of its equity and equity-based awards. Beginning in the six
months ended June&nbsp;30, 2020, the Company determined the fair value of shares of its common stock underlying stock-based awards granted using a hybrid probability-weighted expected return method (&#147;PWERM&#148;). The fair value of the
Company&#146;s common stock was calibrated to contemporaneous transactions in the Series C Preferred Stock. The hybrid PWERM determined the fair value of the Company&#146;s common stock using a probability-weighted present value of expected future
investment returns considering various outcomes, as well as the rights of each class of stock, with one of the outcomes calculated using an option pricing model (&#147;OPM&#148;). The hybrid PWERM considered three scenarios: an &#147;early&#148; IPO
completed in 2020, a &#147;late&#148; IPO completed in 2021, and a &#147;remain private&#148; scenario in which value is allocated using the OPM. An incremental discount for lack of marketability (&#147;DLOM&#148;) was applied to the values of the
common stock. The DLOM was estimated using a put option model which considered the expected time to liquidity and the volatility of the common shares. The hybrid PWERM used a risk-adjusted discount rate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Other than as noted herein, there were no other changes to the Company&#146;s stock-based compensation policy since the date of the audited consolidated
financial statements for the years ended December&nbsp;31, 2018 and 2019, included elsewhere in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Comprehensive Loss </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Comprehensive loss includes net loss and certain changes in stockholders&#146; deficit that are excluded from net loss. The Company&#146;s comprehensive
loss was equal to net loss for the six months ended June&nbsp;30, 2019 and 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Net Loss per Share </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company follows the two-class method to compute net loss per share attributable to common stockholders as the Company has issued shares that meet the
definition of participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed
earnings. The two-class method requires income (losses) for the period to be allocated between common and participating securities based upon their respective rights to share in the earnings as if all income (losses) for the period had been
distributed. During periods of loss, there is no allocation required under the two-class method since the participating securities do not have a contractual obligation to fund the losses of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Net loss attributable to common stockholders is equal to the net loss for the period, as adjusted for: (i) cumulative dividends accrued for redeemable
convertible preferred stock, whether or not declared, (ii) increases in carrying value recorded for redeemable convertible preferred stock, including accretion on redeemable convertible preferred stock to redemption value for amounts other than
cumulative dividends and (iii) gains on the redemptions of redeemable convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Basic net loss per share attributable to common
stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period, which excludes shares of restricted common stock that are not vested. Diluted net loss
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Unaudited) </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
per share attributable to common stockholders is computed by dividing the net loss attributable to common stockholders by the weighted average number of common shares outstanding for the period,
after giving consideration to the dilutive effect of potentially dilutive common shares. For purposes of this calculation, outstanding options to purchase shares of common stock, unvested shares of restricted common stock and shares of redeemable
convertible preferred stock are considered potentially dilutive common shares. The Company has generated a net loss in all periods presented so the basic and diluted net loss per share attributable to common stockholders are the same as the
inclusion of the potentially dilutive securities would be anti-dilutive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>3. Fair Value of Financial Assets </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following tables present information about the Company&#146;s financial assets measured at fair value on a recurring basis and indicates the level of
the fair value hierarchy utilized to determine such fair values (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">44,429</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">44,429</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">44,429</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">44,429</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June&nbsp;30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Level&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Assets:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cash equivalents:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Money market funds</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">19,361</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">19,361</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">19,361</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">19,361</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>4. Accrued Expenses </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Accrued
expenses consisted of the following (in thousands): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued external research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,552</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,125</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued personnel-related expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,059</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">887</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued license fees</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">363</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued professional services</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">673</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accrued other</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">371</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,455</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,740</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>5. Commitments and Contingencies </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Leases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In October 2018, the Company entered into a
sublease agreement for office space located in Cambridge, Massachusetts which expires on December&nbsp;30, 2021, with no option to renew or terminate early. The base rent increases by approximately 1% annually. The Company issued a letter of credit
to the landlord related to the security deposit, secured by restricted cash, which is recorded in other assets on the accompanying condensed consolidated balance sheets. This lease qualifies as an operating lease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In January 2019, the Company entered into an arrangement with a third party to sublease a portion of its Cambridge, Massachusetts office space. This
sublease was terminated in November 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>6. Redeemable Convertible Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2019 and June&nbsp;30, 2020, the authorized capital stock of the Company included 36,724,132 shares of $0.0001 par value
Preferred Stock, of which&nbsp;8,075,799 shares have been designated as Series A Preferred Stock, 14,913,704 shares have been designated as Series B Preferred Stock, 2,666,666 shares have been designated as Series
<FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock and 11,067,963 shares have been designated as Series C Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On
January&nbsp;20, 2020, the Company granted two investors holding 5,825,243 shares of Series C Preferred Stock that were purchased in December 2019 the option to put their shares back to the Company at the original issuance price. On
February&nbsp;19, 2020 and March&nbsp;3, 2020, the investors exercised their put option in full via the execution of Stock Redemption and Release Agreements in order to effect the repurchase. Pursuant to the Stock Redemption and Release Agreements,
the Company agreed to repurchase a total of 5,825,243 shares of Series C Preferred Stock at the original issuance price of $5.15 per share, for an aggregate cash repurchase price of $30.0&nbsp;million. Under the terms of the Stock Redemption and
Release Agreements, the investors waived their right to cumulative dividends that had accumulated from the original issuance date through the date of repurchase. The 5,825,243 shares of Series C Preferred Stock were retired upon repurchase, and
subsequently authorized for reissuance pursuant to a waiver to the Company&#146;s Amended and Restated Certificate of Incorporation entered into by the Company and the holders of the Preferred Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company determined that the additional put right that was granted to the investors represented a modification of the affected shares of Series C
Preferred Stock, but that it did not result in incremental value to the shareholders. As there was no incremental value associated with the modification, there was no impact to the accounting for the Series C Preferred Stock. The Company also
determined that the put right did not require bifurcation, as it does not contain the characteristics of a derivative instrument. Further, the Company determined that the shares of Series C Preferred Stock that were subject to repurchase did not
become mandatorily redeemable until the execution of the Stock Redemption and Release Agreements because the parties did not have an unconditional legal obligation to complete the redemptions until the associated agreements were finalized. Such
determination was made in consultation with legal counsel. Accordingly, the Company recorded each of the redemptions on the respective date of repurchase and recognized a gain on repurchase equal to the difference between the repurchase price and
the carrying value of the Series C Preferred Stock on </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the respective date of repurchase. The aggregate gain of $0.5&nbsp;million was recorded upon repurchase as an adjustment to accumulated deficit in the statement of redeemable convertible
preferred stock and stockholders&#146; (deficit) equity. The gain relates exclusively to the dividends accrued on the repurchased shares, which were waived by the investors as part of the Stock Redemption and Release Agreements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On April&nbsp;15, 2020 and May&nbsp;8, 2020, the Company completed additional closings for the sale and issuance of its Series C Preferred Stock for a
total of 4,563,108 shares at $5.15 per share for aggregate cash proceeds of $23.5&nbsp;million, less an immaterial amount of issuance costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
Preferred Stock consisted of the following (in thousands, except share amounts): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of December&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock Issued<BR>and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redemption<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Stock<BR>Issuable<BR>Upon<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8,075,799</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8,075,799</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9,932</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9,932</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9,932</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,773,820</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">14,913,704</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">14,913,704</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">49,969</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">49,969</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">49,969</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">6,969,173</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,666,666</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,666,666</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10,431</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10,431</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10,431</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,246,133</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series C Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">11,067,963</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9,805,827</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">50,789</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">50,789</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">50,789</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4,582,257</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">36,724,132</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">35,461,996</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">121,121</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">121,121</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">121,121</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">16,571,383</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of June&nbsp;30, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares<BR>Authorized</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Preferred<BR>Stock Issued<BR>and<BR>Outstanding</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Carrying<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Liquidation<BR>Preference</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Redemption<BR>Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Common<BR>Stock<BR>Issuable<BR>Upon<BR>Conversion</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8,075,799</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8,075,799</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10,254</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10,254</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10,254</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,773,820</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">14,913,704</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">14,913,704</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">51,749</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">51,749</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">51,749</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">6,969,173</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,666,666</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,666,666</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10,828</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10,828</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">10,828</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,246,133</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series C Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">11,067,963</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8,543,692</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">45,359</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">45,359</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">45,359</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,992,463</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">36,724,132</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">34,199,861</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">118,190</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">118,190</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">118,190</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">15,981,589</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Common stock issuable upon conversion in the tables above represents shares of common stock issuable upon an automatic
conversion in the event of a qualified public offering, pursuant to the Company&#146;s Amended and Restated Certificate of Incorporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company&#146;s cumulative dividends on its Preferred Stock were as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;December&nbsp;31,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As&nbsp;of&nbsp;June&nbsp;30,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,857</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,178</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5,228</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">7,008</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">431</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">828</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series C Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">289</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,360</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">7,805</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">11,374</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of June&nbsp;30, 2020, each share of the Preferred Stock was convertible into one share of common stock and may be
adjusted in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Preferred Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>7. Common Stock
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of December&nbsp;31, 2019 and June&nbsp;30, 2020, the authorized capital stock of the Company included 46,000,000 and 50,000,000 shares of
common stock, $0.0001 par value, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Shares Reserved for Future Issuance </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The Company has reserved the following shares of common stock for future issuance: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>December&nbsp;31,</B><br><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>June&nbsp;30,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,773,820</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,773,820</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">6,969,173</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">6,969,173</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,246,133</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,246,133</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series C Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4,582,257</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,992,463</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Shares reserved for vesting of restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">48,190</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">21,905</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Shares reserved for exercise of outstanding stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,634,686</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,220,201</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Shares reserved for future awards under the 2017 Stock Incentive Plan</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">617,101</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">584,384</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total shares of authorized common stock reserved for future issuance</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">18,871,360</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">19,808,079</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>8. Stock-Based Compensation </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2017
Stock Incentive Plan </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The total number of shares of common stock authorized for issuance under the 2017 Plan as of December&nbsp;31, 2019 and
June&nbsp;30, 2020 was 2,356,927 shares and 3,909,725 shares, respectively. As of June&nbsp;30, 2020, the Company did not hold any treasury shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Restricted Common Stock </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes all of the Company&#146;s restricted common stock activity: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Grant&nbsp;Date<BR>Fair Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Unvested as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">48,190</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Issued</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(26,285</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">0.05</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Repurchased</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Unvested as of June 30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">21,905</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">0.06</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The total fair value of restricted common stock that vested during the six months ended June&nbsp;30, 2019 and 2020 was
$0.3&nbsp;million and $0.1&nbsp;million, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Stock Options </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table summarizes the Company&#146;s stock option activity: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of<BR>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Exercise&nbsp;Price<BR>per Share</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Weighted<BR>Average<BR>Remaining<BR>Contractual<BR>Term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Aggregate<BR>Intrinsic&nbsp;Value</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(In years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(In&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Outstanding as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,634,686</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2.46</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,683,265</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5.59</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cancelled or Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(97,750</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3.23</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Outstanding as of June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,220,201</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4.07</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9.23</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4,876</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Exercisable as of June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">890,030</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2.27</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">8.34</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">2,950</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Vested and expected to vest as of June&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,220,201</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4.07</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">9.23</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4,876</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the
underlying stock options and the estimated fair value of the Company&#146;s common stock for those stock options that had exercise prices lower than the estimated fair value of the Company&#146;s common stock at June&nbsp;30, 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Stock Option Valuation </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The assumptions that the Company used in the Black-Scholes option pricing model to determine the grant-date fair value of stock options granted to
employees, members of the board of directors and <FONT STYLE="white-space:nowrap">non-employees</FONT> on the date of grant were as follows for the six months ended June&nbsp;30, 2020: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">0.59&nbsp;&#150;&nbsp;0.91</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">6.00&nbsp;&#150;&nbsp;10.00</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">86.08&nbsp;&#150;&nbsp;88.11</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">0.00</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">%&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Fair value per share of common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">5.59</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The weighted-average grant-date fair value of the Company&#146;s stock options granted during the six months ended
June&nbsp;30, 2020 was $4.02. The Company did not grant any stock options during the six months ended June&nbsp;30, 2019. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Stock-Based Compensation
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Stock-based compensation expense was allocated as follows (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">255</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">234</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">432</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">As of June&nbsp;30, 2020, total unrecognized compensation cost related to unvested stock-based awards was
$7.8&nbsp;million, which is expected to be recognized over a weighted-average period of 3.56 years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>9. Net Loss per Share and Unaudited Pro Forma Net Loss per Share </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Net Loss per Share </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Basic and diluted net loss per
share attributable to common stockholders was calculated as follows (in thousands, except share and per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended&nbsp;June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(17,518</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(19,898</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accretion and cumulative dividends on redeemable convertible preferred
stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(2,184</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(4,103</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Gain on repurchase of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">493</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(19,702</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(23,508</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,472,484</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,635,913</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss per share attributable to common stockholders, basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(13.38</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(14.37</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following potential common shares, presented based on amounts outstanding at each period end, were excluded from the
calculation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have been anti-dilutive: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six Months Ended June&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series A Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,773,820</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,773,820</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series B Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">6,969,173</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">6,969,173</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,246,133</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,246,133</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Series C Preferred Stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">&#150;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,992,463</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Outstanding stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,192,465</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,220,201</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Unvested restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">144,570</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">21,905</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">13,326,161</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">19,223,695</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The shares of common stock issuable upon conversion of the Preferred Stock assume automatic conversion in the event of a
qualified public offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Unaudited Pro Forma Net Loss per Share </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Unaudited pro forma basic and diluted net loss per share attributable to common stockholders was calculated as follows (in thousands, except share and
per share data): </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Six&nbsp;Months&nbsp;Ended<BR>June&nbsp;30,</B><br><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Numerator:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(23,508</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accretion and cumulative dividends on redeemable convertible preferred
stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">4,103</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Gain on repurchase of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(493</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net loss attributable to common stockholders</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(19,898</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Denominator:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Weighted average common shares outstanding, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,635,913</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma adjustment to reflect the automatic conversion of redeemable
convertible preferred stock into common stock upon the completion of the proposed initial public offering</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">15,541,361</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma weighted average common shares outstanding, basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">17,177,274</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Pro forma net loss per share attributable to common stockholders, basic and
diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">(1.16</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>10. Related Party Transactions </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">One of the founders of RogCon Inc. (&#147;RogCon&#148;) became the Company&#146;s General Counsel in June 2020. The Company continues to reimburse RogCon
for its <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs incurred for activities performed under its license agreement with RogCon entered into in September 2019 (the &#147;License Agreement&#148;).
During the six months ended June&nbsp;30, 2020, the Company expensed $0.1&nbsp;million for the reimbursement of RogCon&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs. As of June&nbsp;30,
2020, the Company had accrued expenses of $0.3&nbsp;million due to RogCon under the License Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>11. Subsequent Events </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Subsequent Events Through August 28, 2020 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the condensed consolidated financial statements to provide additional evidence for certain estimates or to identify matters that require
additional disclosure. The Company has evaluated subsequent events through August 28, 2020, the date these condensed consolidated financial statements were issued and identified the following subsequent events: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Common Stock and Preferred Stock Authorized for Issuance </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On
July&nbsp;24, 2020, the board of directors (the &#147;Board&#148;) amended the Company&#146;s Amended and Restated Certificate of Incorporation to increase the number of shares of common stock authorized for issuance to 66,000,000 shares. In
addition, the Board amended the Company&#146;s Amended and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PRAXIS PRECISION MEDICINES, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Unaudited) </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(Continued) </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Restated Certificate of Incorporation to increase the number of shares of preferred stock authorized for issuance to 53,644,314 shares, of which 8,075,799 shares are designated as Series A
Preferred Stock, 14,913,704 shares are designated as Series B Preferred Stock, 2,666,666 shares are designated as Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock, 8,543,692 shares are designated as Series C Preferred Stock and
19,444,453 shares are designated as Series <FONT STYLE="white-space:nowrap">C-1</FONT> redeemable convertible preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Series <FONT
STYLE="white-space:nowrap">C-1</FONT> Redeemable Convertible Preferred Stock Issuance </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the third quarter of 2020, the Company issued a total
of 19,444,453 shares of Series <FONT STYLE="white-space:nowrap">C-1</FONT> redeemable convertible preferred stock at a purchase price of $5.67 per share for aggregate proceeds of approximately $110.1&nbsp;million, net of issuance costs. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Subsequent Events Through October 9, 2020 </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In
connection with the re-issuance of these condensed consolidated financial statements, the Company has evaluated subsequent events through October 9, 2020, the date these condensed consolidated financial statements were re-issued, and identified the
following subsequent events: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Common Stock Authorized for Issuance </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On September 2, 2020, the Company amended the Company&#146;s Amended and Restated Certificate of Incorporation to increase the number of shares of common
stock authorized for issuance to 70,500,000 shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Amendment to 2017 Stock Incentive Plan </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On September 2, 2020, the Company amended the 2017 Stock Incentive Plan to increase the total number of shares authorized for issuance to 5,937,763
shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>Reverse Stock Split </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">On October 8, 2020, the
Board and the Company&#146;s stockholders approved a one-for-2.14 reverse stock split. Effective on October 8, 2020, the reverse stock split impacted the Company&#146;s issued and outstanding shares of common stock. Stockholders entitled to
fractional shares as a result of the reverse stock split will receive a cash payment in lieu of receiving fractional shares. All shares of common stock, per share amounts and additional paid-in capital amounts for all periods presented in the
accompanying condensed consolidated financial statements and related notes have been retroactively adjusted, where applicable, to reflect the reverse stock split. Shares of common stock underlying outstanding stock options and other equity
instruments were proportionately reduced and the respective exercise prices were proportionately increased, as applicable, in accordance with the terms of the agreements governing such securities. The respective conversion prices of the Preferred
Stock were proportionately increased. The number of shares of common stock authorized for issuance and the par value of common stock were not adjusted as a result of the reverse stock split. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">F-62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>10,000,000 Shares </B></P>  <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g945651g52w82.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:60pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>P R O S P E C T U S </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Book-running Managers </I></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="top"><B>Cowen</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Evercore ISI</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Piper Sandler</B></TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I>Lead Manager </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:13pt; font-family:ARIAL" ALIGN="center"><B>Wedbush PacGrow </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><I><FONT STYLE="white-space:nowrap">Co-Manager</FONT> </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>Blackstone Capital Markets </B></P> <P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Until
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, all dealers that effect transactions in these securities, whether or not participating in this offering, may be required to
deliver a prospectus. This requirement is in addition to the dealers&#146; obligation to deliver a prospectus when acting as underwriters and with respect to their unsold allotments or subscriptions. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:3.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B>Information Not Required in Prospectus </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;13.
Other expenses of issuance and distribution. </B></P>  <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The following table sets forth the costs and expenses, other than underwriting discounts and
commissions, to be paid by us in connection with the sale of the shares of common stock being registered hereby. All amounts shown are estimates except for the Securities and Exchange Commission, or SEC, registration fee, the Financial Industry
Regulatory Authority, Inc., or FINRA, filing fee and the Nasdaq Global Select Market initial listing fee. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount&nbsp;to&nbsp;be<BR>Paid</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">24,654</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">31,550</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Nasdaq Global Select Market initial listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">170,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Printing and mailing</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">350,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,650,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Transfer agent and registrar fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Blue Sky fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR BGCOLOR="#d1fcfc" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Miscellaneous</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">23,796</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;">$</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;" ALIGN="right">3,300,000</TD>
<TD NOWRAP VALIGN="bottom" STYLE="padding-bottom:3pt ;">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;14. Indemnification of directors and officers. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Section&nbsp;145 of the Delaware General Corporation Law (DGCL) authorizes a corporation to indemnify its directors and officers against liabilities
arising out of actions, suits and proceedings to which they are made or threatened to be made a party by reason of the fact that they have served or are currently serving as a director or officer to a corporation. The indemnity may cover expenses
(including attorneys&#146; fees) judgments, fines, and amounts paid in settlement actually and reasonably incurred by the director or officer in connection with any such action, suit or proceeding. Section&nbsp;145 permits corporations to pay
expenses (including attorneys&#146; fees) incurred by directors and officers in advance of the final disposition of such action, suit or proceeding. In addition, Section&nbsp;145 provides that a corporation has the power to purchase and maintain
insurance on behalf of its directors and officers against any liability asserted against them and incurred by them in their capacity as a director or officer, or arising out of their status as such, whether or not the corporation would have the
power to indemnify the director or officer against such liability under Section&nbsp;145. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have adopted provisions in our amended and restated
certificate of incorporation and amended and restated bylaws to be in effect upon the closing of this offering that limit or eliminate the personal liability of our directors to the fullest extent permitted by the DGCL, as it now exists or may in
the future be amended. Consequently, a director will not be personally liable to us or our stockholders for monetary damages or breach of fiduciary duty as a director, except for liability for: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any breach of the director&#146;s duty of loyalty to us or our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any unlawful payments related to dividends or unlawful stock purchases, redemptions or other distributions; or
</P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">These limitations of liability do not alter director liability under the federal securities laws and do not affect the availability of equitable
remedies, such as an injunction or rescission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In addition, our bylaws will provide that: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we will indemnify our directors, officers and, at the discretion of our board of directors, certain employees to the
fullest extent permitted by the DGCL, as it now exists or may in the future be amended; and </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman">&#9679;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">we will advance reasonable expenses, including attorneys&#146; fees, to our directors and, at the discretion of our board
of directors, to our officers and certain employees, in connection with legal proceedings relating to their service for or on behalf of us, subject to limited exceptions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We have entered into indemnification agreements with each of our directors and intend to enter into such agreements with certain of our executive
officers. These agreements provide that we will indemnify each of our directors, certain of our executive officers and, at times, their affiliates to the fullest extent permitted by Delaware law. We will advance expenses, including attorneys&#146;
fees (but excluding judgments, fines and settlement amounts), to each indemnified director, executive officer or affiliate in connection with any proceeding in which indemnification is available and we will indemnify our directors and officers for
any action or proceeding arising out of that person&#146;s services as a director or officer brought on behalf of us or in furtherance of our rights. Additionally, certain of our directors or officers may have certain rights to indemnification,
advancement of expenses or insurance provided by their affiliates or other third parties, which indemnification relates to and might apply to the same proceedings arising out of such director&#146;s or officer&#146;s services as a director
referenced herein. Nonetheless, we have agreed in the indemnification agreements that our obligations to those same directors or officers are primary and any obligation of such affiliates or other third parties to advance expenses or to provide
indemnification for the expenses or liabilities incurred by those directors are secondary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We also maintain general liability insurance which
covers certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers, including liabilities under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In the underwriting agreement that we enter into in connection with the sale of shares of our common stock in this offering, a form of which will be
filed as Exhibit 1.1 to this registration statement, there will be provisions for indemnification of us and our directors and officers by the underwriters against certain liabilities under the Securities Act and the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;15. Recent sales of unregistered securities. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The
following list sets forth information regarding all unregistered securities sold by us since January&nbsp;1, 2017. No underwriters were involved in the sales and the certificates representing the securities sold and issued contain legends
restricting transfer of the securities without registration under the Securities Act or an applicable exemption from registration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>(a) Preferred stock
issuances </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">From April 2017 to July 2017, we issued and sold an aggregate of 4,060,000 shares of our Series A preferred stock at a per share
purchase price of $1.00 for aggregate gross consideration of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
$7.1&nbsp;million. From March 2018 to November 2019, we issued and sold an aggregate of 13,627,519 shares of our Series B preferred stock at a per share purchase price of $3.00 for aggregate
gross consideration of $37.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In March 2018, we issued an aggregate of 902,916 shares of our Series B preferred stock at a price per
share of $2.25 pursuant to the conversion of a promissory note. In March 2018, we issued an aggregate of 383,269 shares of our Series B preferred stock at a price per share of $2.625 pursuant to the conversion of a promissory note. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In June 2019, we issued and sold an aggregate of 2,666,666 shares of our Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred stock at a per
share purchase price of $3.75 for aggregate gross consideration of $10.0&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">From November 2019 to May 2020, we issued and sold an
aggregate of 14,368,935 shares of our Series C preferred stock at a per share purchase price of $5.15 for aggregate gross consideration of $74.0&nbsp;million. From February 2017 to March 2020, we repurchased 5,825,243 shares of our Series C
preferred stock at the original issuance price of $5.15 per share for an aggregate cash repurchase price of $30.0 million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">From July to August
2020, we issued and sold an aggregate of 19,444,453 shares of our <FONT STYLE="white-space:nowrap">Series&nbsp;C-1</FONT> preferred stock at a per share purchase price of $5.67 for aggregate gross consideration of $110.3 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>(b) Option issuances </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Since January&nbsp;1, 2017, we have
granted to employees, officers, directors, consultants and other service providers options to purchase an aggregate of 5,930,304 shares of our common stock, with exercise prices ranging from $0.11 to $8.91 per share, pursuant to the 2017 Stock
Incentive Plan, or the 2017 Plan. Since January&nbsp;1, 2017, 11,628 shares of common stock have been issued upon the exercise of stock options pursuant to the 2017 Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>(c) Restricted stock issuance </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">In May 2017, we issued and
sold an aggregate of 105,140 restricted shares of our common stock at a price per share of $0.11 for aggregate gross consideration of $11,500. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">We
deemed the offers, sales, and issuances of the securities described above to be exempt from registration under the Securities Act, in reliance on Section&nbsp;4(a)(2) of the Securities Act, including Regulation&nbsp;D and Rule&nbsp;506 promulgated
thereunder, regarding transactions by an issuer not involving a public offering. All purchasers of securities in transactions exempt from registration pursuant to Regulation&nbsp;D represented to us that they were accredited investors and were
acquiring the shares for investment purposes only and not with a view to, or for sale in connection with, any distribution thereof and that they could bear the risks of the investment and could hold the securities for an indefinite period of time.
The purchasers received written disclosures that the securities had not been registered under the Securities Act and that any resale must be made pursuant to a registration statement or an available exemption from such registration. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;16. Exhibits and financial statement schedules. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>(a) Exhibits
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The exhibits to the registration statement are listed in the Exhibit Index to this registration statement and are incorporated herein by
reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><I>(b) Financial Statement Schedules </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">All schedules have been omitted because they are not required or because the required information is given in the financial statements or notes to those
statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;17. Undertakings. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The undersigned
registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each
purchaser. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling
persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is,
therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful
defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by
controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">The undersigned Registrant hereby undertakes: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">(1)
That for purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the
Registrant pursuant to Rule 424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">(2) That for the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall
be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <I>bona fide</I> offering thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1689548/000119312520266699/d945651dex11.htm">Form of Underwriting Agreement </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d945651dex31.htm">Amended and Restated Certificate of Incorporation of the Registrant, as amended, as currently in effect </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1689548/000119312520254741/d945651dex32.htm">Form of Amended and Restated Certificate of Incorporation of the Registrant (to be in effect upon completion of this offering)
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1689548/000119312520254741/d945651dex33.htm">Bylaws of the Registrant, as currently in effect </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1689548/000119312520254741/d945651dex34.htm">Form of Amended and Restated Bylaws (to be in effect upon completion of this offering) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1689548/000119312520266699/d945651dex41.htm">Specimen Common Stock Certificate </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1689548/000119312520254741/d945651dex42.htm">Fourth Amended and Restated Investors&#146; Rights Agreement among the Registrant and certain of its stockholders, effective as of July 24, 2020
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d945651dex51.htm">Opinion of Goodwin Procter LLP </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1689548/000119312520266699/d945651dex101.htm">Form of Director Indemnification Agreement, as amended </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1689548/000119312520254741/d945651dex102.htm">Form of Officer Indemnification Agreement </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1689548/000119312520254741/d945651dex103.htm">Praxis Precision Medicines, Inc. 2017 Stock Incentive Plan, as amended, and form of award agreements thereunder </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1689548/000119312520266699/d945651dex104.htm">Form of 2020 Stock Option and Incentive Plan </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1689548/000119312520266699/d945651dex105.htm">Form of Incentive Stock Option Agreement under the Registrant&#146;s 2020 Stock Option and Incentive Plan </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1689548/000119312520266699/d945651dex106.htm">Form of Non-Qualified Stock Option Agreement for Company Employees under the Registrant&#146;s 2020 Stock Option and Incentive Plan
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1689548/000119312520266699/d945651dex107.htm">Form of Non-Qualified Stock Option Agreement for Non-Employee Directors under the Registrant&#146;s 2020 Stock Option and Incentive Plan
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1689548/000119312520266699/d945651dex108.htm">Form of Restricted Stock Award Agreement under the Registrant&#146;s 2020 Stock Option and Incentive Plan </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1689548/000119312520266699/d945651dex109.htm">Form of Restricted Stock Award Agreement for Company Employees under the Registrant&#146;s 2020 Stock Option and Incentive Plan
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1689548/000119312520266699/d945651dex1010.htm">Form of Restricted Stock Award Agreement for Non-Employee Directors under the Registrant&#146;s 2020 Stock Option and Incentive Plan
</A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1689548/000119312520266699/d945651dex1011.htm">2020 Employee Stock Purchase Plan </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1689548/000119312520254741/d945651dex1012.htm">Form of Amended and Restated Employment Agreement </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13#*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1689548/000119312520266699/d945651dex1013.htm">Non-Employee Director Compensation Policy </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14&#134;*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1689548/000119312520254741/d945651dex1014.htm">License Agreement, dated December 31, 2017, by and between Purdue Neuroscience Company and the Registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15&#134;*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1689548/000119312520254741/d945651dex1015.htm">Cooperation and License Agreement, dated September 11, 2019, by and between RogCon Inc. and the Registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16&#134;*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1689548/000119312520254741/d945651dex1016.htm">Research Collaboration, Option and License Agreement, dated September 11, 2019, by and between Ionis Pharmaceuticals, Inc. and the Registrant
 </A></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="89%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.17*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1689548/000119312520254741/d945651dex1017.htm">Sublease, dated October 4, 2018, by and between Highland Capital Partners, LLC and the Registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.18*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1689548/000119312520254741/d945651dex1018.htm">Consent to Sublease, First Amendment of Lease and Amendment, dated November 2, 2018, by and among Highland Capital Partners, LLC, MIT One Broadway,
LLC and the Registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1689548/000119312520254741/d945651dex211.htm">Subsidiaries of the Registrant </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d945651dex231.htm">Consent of Ernst &amp; Young LLP, Independent Registered Public Accounting Firm </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d945651dex51.htm">Consent of Goodwin Procter LLP (included in Exhibit 5.1) </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1689548/000119312520254741/d945651ds1.htm#945651_sig">Power of Attorney </A></TD></TR>
</TABLE>  <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:26%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Previously filed. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">#</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Indicates a management contract or any compensatory plan, contract or arrangement. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:ARIAL; " ALIGN="left">Portions of this exhibit (indicated by asterisks) have been omitted in accordance with the rules of the Securities and
Exchange Commission. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, the registrant has duly caused this Amendment No. 2 to the Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-1</FONT> to be signed on its behalf by the undersigned, thereunto duly authorized, in Cambridge, Massachusetts, on the 15th day of October, 2020. </P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="90%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL"><B>PRAXIS PRECISION MEDICINES, INC.</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL">/s/ Marcio Souza</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Marcio Souza</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Chief Executive Officer</P></TD></TR>
</TABLE></DIV>   <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, as amended, this Amendment No. 2 to the
Registration Statement on Form S-1 and Power of Attorney has been signed by the following person in the capacities and on the date indicated. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Name</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">/s/ Marcio Souza</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Marcio Souza</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chief Executive Officer and Director (Principal Executive Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">October 15,&nbsp;2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">/s/ Stuart Chaffee</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Stuart Chaffee, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chief Financial Officer (Principal Financial Officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">October 15,&nbsp;2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">/s/ Lauren Mastrocola</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Lauren Mastrocola</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Principal Accounting Officer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">October 15,&nbsp;2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Dean Mitchell</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chairman of the Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">October 15,&nbsp;2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Nicholas Galakatos, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">October 15,&nbsp;2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Gregory Norden</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">October 15,&nbsp;2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Ari Brettman, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">October 15,&nbsp;2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Thomas Dyrberg, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">October 15,&nbsp;2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Kiran Reddy, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">October 15,&nbsp;2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Stefan Vitorovic</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">October 15,&nbsp;2020</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="13"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD>
<TD HEIGHT="13" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:ARIAL" ALIGN="center">*</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL" ALIGN="center">William Young</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">October 15,&nbsp;2020</TD></TR>
</TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="86%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" STYLE="padding-bottom:3pt ;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">*&nbsp;By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;BORDER-BOTTOM:1px solid #000000">/s/ Marcio Souza</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="padding-bottom:3pt ;"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Marcio Souza</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:ARIAL">Attorney-in-Fact</P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">II-7 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>d945651dex31.htm
<DESCRIPTION>EX-3.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-3.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 3.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">AMENDED AND RESTATED </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CERTIFICATE
OF INCORPORATION </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OF </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PRAXIS
PRECISION MEDICINES, INC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Pursuant to Sections 242 and 245 of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">General Corporation Law of the State of Delaware) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Praxis Precision Medicines, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of
the State of Delaware (the &#147;<B>General Corporation Law</B>&#148;), </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>DOES HEREBY CERTIFY: </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>1.</B> That the name of this corporation is Praxis Precision Medicines, Inc., and that this corporation was originally incorporated pursuant
to the General Corporation Law on September&nbsp;22, 2015 under the name EpiPM Therapeutics, Inc. This corporation filed with the Secretary of State of the State of Delaware an Amended and Restated Certificate of Incorporation on November&nbsp;18,
2019, a Certificate of Amendment to the Amended and Restated Certificate of Incorporation on December&nbsp;10, 2019 and a Certificate of Amendment to the Amended and Restated Certificate of Incorporation on June&nbsp;5, 2020. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>2.</B> That the Board of Directors of the Corporation (the &#147;<B>Board</B>&#148;) duly adopted resolutions proposing to amend and restate
the Certificate of Incorporation of this corporation, declaring said amendment and restatement to be advisable and in the best interests of this corporation and its stockholders, and authorizing the appropriate officers of this corporation to
solicit the consent of the stockholders therefor, which resolution setting forth the proposed amendment and restatement is as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>RESOLVED</B>, that the Amended and Restated Certificate of Incorporation of this corporation be amended and restated in its entirety to
read as follows: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>FIRST: </B>The name of this corporation is Praxis Precision Medicines, Inc. (the &#147;<B>Corporation</B>&#148;).
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SECOND: </B>The address of the registered office of the Corporation in the State of Delaware is 1209 Orange Street, in the City of
Wilmington, County of New Castle, 19801. The name of its registered agent at such address is The Corporation Trust Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>THIRD:
</B>The nature of the business or purposes to be conducted or promoted is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>FOURTH: </B>The total number of shares of all classes of stock which the Corporation shall have authority to issue is (i) 66,000,000 shares
of Common Stock, $0.0001 par value per share (&#147;<B>Common Stock</B>&#148;) and (ii) 53,644,314 shares of Preferred Stock, $0.0001 par value per share (&#147;<B>Preferred Stock</B>&#148;). </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a statement of the designations and the powers, privileges and rights, and
the qualifications, limitations or restrictions thereof in respect of each class of capital stock of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. COMMON STOCK
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. <U>General</U>. The voting, dividend and liquidation rights of the holders of the Common Stock are subject to and qualified by the
rights, powers and preferences of the holders of the Preferred Stock set forth herein. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. <U>Voting</U>. The holders of the Common Stock
are entitled to one vote for each share of Common Stock held at all meetings of stockholders (and written actions in lieu of meetings); <U>provided</U>, <U>however</U>, that, except as otherwise required by law, holders of Common Stock, as such,
shall not be entitled to vote on any amendment to the Corporation&#146;s Certificate of Incorporation (the &#147;<B>Certificate of Incorporation</B>&#148;) that relates solely to the terms of one or more outstanding series of Preferred Stock if the
holders of such affected series are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to the Certificate of Incorporation or pursuant to the General Corporation Law. There shall be no
cumulative voting. The number of authorized shares of Common Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by (in addition to any vote of the holders of one or more series of Preferred Stock that
may be required by the terms of the Certificate of Incorporation) the affirmative vote of the holders of shares of capital stock of the Corporation representing a majority of the votes represented by all outstanding shares of capital stock of the
Corporation entitled to vote, voting together as a single class on an as converted basis, irrespective of the provisions of Section&nbsp;242(b)(2) of the General Corporation Law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">B. PREFERRED STOCK </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8,075,799
shares of the authorized Preferred Stock of the Corporation are hereby designated &#147;<B>S</B><B>eries A Preferred Stock</B>,&#148; 14,913,704 shares of the authorized Preferred Stock of the Corporation are hereby designated &#147;<B>S</B><B>eries
B Preferred Stock</B>,&#148;, 2,666,666 shares of the authorized Preferred Stock of the Corporation are hereby designated &#147;<B>S</B><B>eries <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock</B>&#148; and, together with the Series B
Preferred Stock, the &#147;<B>Series B Stock</B>,&#148; 8,543,692 shares of the authorized Preferred Stock of the Corporation are hereby designated &#147;<B>S</B><B>eries C Preferred Stock</B>,&#148; and 19,444,453 shares of the authorized Preferred
Stock of the Corporation are hereby designated &#147;<B>S</B><B>eries <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock</B>,&#148; each with the following rights, preferences, powers, privileges and restrictions, qualifications and
limitations. Unless otherwise indicated, references to &#147;sections&#148; or &#147;subsections&#148; in this Part B of this Article Fourth refer to sections and subsections of Part B of this Article Fourth. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">1. <U>Dividends</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.1
<U>Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Accruing Dividends</U>. From and after the date of the issuance of any shares of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock, dividends at the rate per annum of
$0.4536 per share shall accrue on such shares of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization
with respect to the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock) (the &#147;<B>Series <FONT STYLE="white-space:nowrap">C-1</FONT></B> <B>Preferred</B> <B>Accruing Dividends</B>&#148;). Series
<FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Accruing Dividends shall accrue from day to day, whether or not declared, and shall be cumulative; <U>provided</U>,<U> however</U>, that except as set forth in
<U>Subsection</U><U></U><U>&nbsp;1.1.1</U>, <U>Subsection</U><U></U><U>&nbsp;2.1.1</U>, <U>Subsection</U><U></U><U>&nbsp;2.3.2</U>, <U>Subsection 4.3</U> or <U>Section</U><U></U><U>&nbsp;6</U>, such Series <FONT STYLE="white-space:nowrap">C-1</FONT>
Preferred Accruing Dividends shall be payable only when, as, and if declared by the Board and the Corporation shall be under no obligation to pay such Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Accruing Dividends. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">1.1.1 The Corporation shall not declare, pay or set aside any dividends on shares of any
other class or series of capital stock of the Corporation (other than dividends on shares of Common Stock payable in shares of Common Stock) unless (in addition to the obtaining of any consents required elsewhere in the Certificate of Incorporation)
the holders of the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock then outstanding shall first receive, or simultaneously receive with the holders of Series C Preferred Stock, Series <FONT STYLE="white-space:nowrap">B-1</FONT>
Preferred Stock and Series B Preferred Stock, a dividend on each outstanding share of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock in an amount at least equal to the greater of (i)&nbsp;the amount of the aggregate Series <FONT
STYLE="white-space:nowrap">C-1</FONT> Preferred Accruing Dividends then accrued on such share of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock and not previously paid and (ii)&nbsp;(A) in the case of a dividend on Common Stock
or any class or series that is convertible into Common Stock, that dividend per share of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock as would equal the product of (1)&nbsp;the dividend payable on each share of such class or
series determined, if applicable, as if all shares of such class or series had been converted into Common Stock and (2)&nbsp;the number of shares of Common Stock issuable upon conversion of a share of Series
<FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock, in each case calculated on the record date for determination of holders entitled to receive such dividend or (B)&nbsp;in the case of a dividend on any class or series that is not
convertible into Common Stock, at a rate per share of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock determined by (1)&nbsp;dividing the amount of the dividend payable on each share of such class or series of capital stock by the
original issuance price of such class or series of capital stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to such class or series) and
(2)&nbsp;multiplying such fraction by an amount equal to the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Original Issue Price (as defined below) for the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock; <U>provided</U> that
if the Corporation declares, pays or sets aside, on the same date, a dividend on shares of more than one class or series of capital stock of the Corporation, the dividend payable to the holders of Series <FONT STYLE="white-space:nowrap">C-1</FONT>
Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;1</U> shall be calculated based upon the dividend on the class or series of capital stock that would result in the highest Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred
Stock dividend. The &#147;<B>Series <FONT STYLE="white-space:nowrap">C-1</FONT> Original Issue Price</B>&#148; for the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock shall mean $5.67 per share, subject to appropriate adjustment
in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.2 <U>Series C Preferred Accruing Dividends</U>. From and after the date of the issuance of any shares of Series C Preferred Stock, dividends
at the rate per annum of $0.412 per share shall accrue on such shares of Series C Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the
Series C Preferred Stock) (the &#147;Series C Preferred Accruing Dividends&#148;). Series C Preferred Accruing Dividends shall accrue from day to day, whether or not declared, and shall be cumulative; provided, however, that except as set forth in
<U>Subsection 1.2.1</U>, <U>Subsection 2.1.1</U>, <U>Subsection 2.3.2</U>, <U>Subsection 4.3</U> or <U>Section</U><U></U><U>&nbsp;6</U>, such Series C Preferred Accruing Dividends shall be payable only when, as, and if declared by the Board and the
Corporation shall be under no obligation to pay such Series C Preferred Accruing Dividends. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">1.2.1 The Corporation shall not declare, pay or set aside any dividends on shares of any
other class or series of capital stock of the Corporation (other than dividends on shares of Common Stock payable in shares of Common Stock) unless (in addition to the obtaining of any consents required elsewhere in the Certificate of Incorporation)
the holders of the Series C Preferred Stock then outstanding shall first receive, or simultaneously receive with the holders of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock, Series <FONT STYLE="white-space:nowrap">B-1</FONT>
Preferred Stock and Series B Preferred Stock, a dividend on each outstanding share of Series C Preferred Stock in an amount at least equal to the greater of (i)&nbsp;the amount of the aggregate Series C Preferred Accruing Dividends then accrued on
such share of Series C Preferred Stock and not previously paid and (ii)&nbsp;(A) in the case of a dividend on Common Stock or any class or series that is convertible into Common Stock, that dividend per share of Series C Preferred Stock as would
equal the product of (1)&nbsp;the dividend payable on each share of such class or series determined, if applicable, as if all shares of such class or series had been converted into Common Stock and (2)&nbsp;the number of shares of Common Stock
issuable upon conversion of a share of Series C Preferred Stock, in each case calculated on the record date for determination of holders entitled to receive such dividend or (B)&nbsp;in the case of a dividend on any class or series that is not
convertible into Common Stock, at a rate per share of Series C Preferred Stock determined by (1)&nbsp;dividing the amount of the dividend payable on each share of such class or series of capital stock by the original issuance price of such class or
series of capital stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to such class or series) and (2)&nbsp;multiplying such fraction by an amount equal
to the Series C Original Issue Price (as defined below) for the Series C Preferred Stock; provided that if the Corporation declares, pays or sets aside, on the same date, a dividend on shares of more than one class or series of capital stock of the
Corporation, the dividend payable to the holders of Series C Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;1</U> shall be calculated based upon the dividend on the class or series of capital stock that would result in the highest
Series C Preferred Stock dividend. The &#147;Series C Original Issue Price&#148; for the Series C Preferred Stock shall mean $5.15 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other
similar recapitalization with respect to the Series C Preferred Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.3 <U>Series <FONT STYLE="white-space:nowrap">B-1</FONT>
Preferred Accruing Dividend</U>. From and after the date of the issuance of any shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock, dividends at the rate per annum of $0.30 per share shall accrue on such shares of Series <FONT
STYLE="white-space:nowrap">B-1</FONT> Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series
<FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock) (the &#147;<B>Series <FONT STYLE="white-space:nowrap">B-1</FONT></B> <B>Preferred</B> <B>Accruing Dividends</B>&#148;). Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred
Accruing Dividends shall accrue from day to day, whether or not declared, and shall be cumulative; <U>provided</U>,<U> however</U>, that except as set forth in <U>Subsection</U><U></U><U>&nbsp;1.3.1</U>, <U>Subsection</U><U></U><U>&nbsp;2.1.1</U>,
<U>Subsection</U><U></U><U>&nbsp;2.3.2</U>, <U>Subsection 4.3</U> or <U>Section</U><U></U><U>&nbsp;6</U>, such Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Accruing Dividends shall be payable only when, as, and if declared by the
Board and the Corporation shall be under no obligation to pay such Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Accruing Dividends. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">1.3.1 The Corporation shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the
Corporation (other than dividends on shares of Common Stock payable in shares of Common Stock) unless (in addition to the obtaining of any consents required elsewhere in the Certificate of Incorporation) the holders of the Series <FONT
STYLE="white-space:nowrap">B-1</FONT> Preferred Stock then outstanding shall first receive, or simultaneously receive with the holders of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock, Series C Preferred Stock and Series B
Preferred Stock, a dividend on each outstanding share of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock in an amount at least equal to the greater of (i)&nbsp;the amount of the aggregate Series
<FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Accruing Dividends then accrued on such share of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock and not previously paid and (ii)&nbsp;(A) in the case of a dividend on Common
Stock or any class or series that is convertible into Common Stock, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
that dividend per share of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock as would equal the product of (1)&nbsp;the dividend payable on each share of such class or series
determined, if applicable, as if all shares of such class or series had been converted into Common Stock and (2)&nbsp;the number of shares of Common Stock issuable upon conversion of a share of Series <FONT STYLE="white-space:nowrap">B-1</FONT>
Preferred Stock, in each case calculated on the record date for determination of holders entitled to receive such dividend or (B)&nbsp;in the case of a dividend on any class or series that is not convertible into Common Stock, at a rate per share of
Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock determined by (1)&nbsp;dividing the amount of the dividend payable on each share of such class or series of capital stock by the original issuance price of such class or series of
capital stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to such class or series) and (2)&nbsp;multiplying such fraction by an amount equal to the
Series <FONT STYLE="white-space:nowrap">B-1</FONT> Original Issue Price (as defined below) for the Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock; <U>provided</U> that if the Corporation declares, pays or sets aside, on the same
date, a dividend on shares of more than one class or series of capital stock of the Corporation, the dividend payable to the holders of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock pursuant to this
<U>Section</U><U></U><U>&nbsp;1</U> shall be calculated based upon the dividend on the class or series of capital stock that would result in the highest Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock dividend. The &#147;<B>Series
<FONT STYLE="white-space:nowrap">B-1</FONT></B> <B>Original Issue Price</B>&#148; for the Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock shall mean $3.75 per share, subject to appropriate adjustment in the event of any stock
dividend, stock split, combination or other similar recapitalization with respect to the Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.4 <U>Series B Preferred Accruing Dividends</U>. From and after the date of the issuance of any shares of Series B Preferred Stock, dividends
at the rate per annum of $0.24 per share shall accrue on such shares of Series B Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the
Series B Preferred Stock) (the &#147;<B>Series B</B> <B>Preferred</B> <B>Accruing Dividends</B>&#148;). Series B Preferred Accruing Dividends shall accrue from day to day, whether or not declared, and shall be cumulative; <U>provided</U>,<U>
however</U>, that except as set forth in <U>Subsection 1.4.1</U>, <U>Subsection</U><U></U><U>&nbsp;2.1.1</U>, <U>Subsection</U><U></U><U>&nbsp;2.3.2</U>, <U>Subsection 4.3</U> or <U>Section</U><U></U><U>&nbsp;6</U>, such Series B Preferred Accruing
Dividends shall be payable only when, as, and if declared by the Board and the Corporation shall be under no obligation to pay such Series B Preferred Accruing Dividends. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">1.4.1 The Corporation shall not declare, pay or set aside any dividends on shares of any other class or series of capital stock of the
Corporation (other than dividends on shares of Common Stock payable in shares of Common Stock) unless (in addition to the obtaining of any consents required elsewhere in the Certificate of Incorporation) the holders of the Series B Preferred Stock
then outstanding shall first receive, or simultaneously receive with the holders of the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock, Series C Preferred Stock and Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred
Stock, a dividend on each outstanding share of Series B Preferred Stock in an amount at least equal to the greater of (i)&nbsp;the amount of the aggregate Series B Preferred Accruing Dividends then accrued on such share of Series B Preferred Stock
and not previously paid and (ii)&nbsp;(A) in the case of a dividend on Common Stock or any class or series that is convertible into Common Stock, that dividend per share of Series B Preferred Stock as would equal the product of (1)&nbsp;the dividend
payable on each share of such class or series determined, if applicable, as if all shares of such class or series had been converted into Common Stock and (2)&nbsp;the number of shares of Common Stock issuable upon conversion of a share of Series B
Preferred Stock, in each case calculated on the record date for determination of holders entitled to receive such dividend or (B)&nbsp;in the case of a dividend on any class or series that is not convertible into Common Stock, at a rate per share of
Series B Preferred Stock determined by (1)&nbsp;dividing the amount of the dividend payable on each </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
share of such class or series of capital stock by the original issuance price of such class or series of capital stock (subject to appropriate adjustment in the event of any stock dividend, stock
split, combination or other similar recapitalization with respect to such class or series) and (2)&nbsp;multiplying such fraction by an amount equal to the Series B Original Issue Price (as defined below) for the Series B Preferred Stock;
<U>provided</U> that if the Corporation declares, pays or sets aside, on the same date, a dividend on shares of more than one class or series of capital stock of the Corporation, the dividend payable to the holders of Series B Preferred Stock
pursuant to this <U>Section</U><U></U><U>&nbsp;1</U> shall be calculated based upon the dividend on the class or series of capital stock that would result in the highest Series B Preferred Stock dividend. The &#147;<B>Series B</B> <B>Original Issue
Price</B>&#148; for the Series B Preferred Stock shall mean $3.00 per share, subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series B Preferred
Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.5 <U>Series A Preferred Accruing Dividends</U>. Subject to <U>Section</U><U></U><U>&nbsp;1.1</U>,
<U>Section</U><U></U><U>&nbsp;1.2</U>, <U>Section</U><U></U><U>&nbsp;1.3</U>, and <U>Section</U><U></U><U>&nbsp;1.4</U> above and from and after the date of the issuance of any shares of Series A Preferred Stock, dividends at the rate per annum of
$0.08 per share shall accrue on such shares of Series A Preferred Stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Series A Preferred Stock)
(the &#147;<B>Series A</B> <B>Preferred</B> <B>Accruing Dividends</B>&#148;). Series A Preferred Accruing Dividends shall accrue from day to day, whether or not declared, and shall be cumulative; <U>provided</U>,<U> however</U>, that except as set
forth in the following sentence of this <U>Section</U><U></U><U>&nbsp;1.5</U> or in <U>Subsection</U><U></U><U>&nbsp;2.1.2</U>, <U>Subsection</U><U></U><U>&nbsp;2.3.2</U>, <U>Subsection 4.3</U> or <U>Section</U><U></U><U>&nbsp;6</U>, such Series A
Preferred Accruing Dividends shall be payable only when, as, and if declared by the Board and the Corporation shall be under no obligation to pay such Series A Preferred Accruing Dividends. The Corporation shall not declare, pay or set aside any
dividends on shares of any other class or series of capital stock of the Corporation (other than Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Accruing Dividends, Series C Preferred Accruing Dividends, Series <FONT
STYLE="white-space:nowrap">B-1</FONT> Preferred Accruing Dividends, Series B Preferred Accruing Dividends or dividends on shares of Common Stock payable in shares of Common Stock) unless (in addition to the obtaining of any consents required
elsewhere in the Certificate of Incorporation) the holders of the Series A Preferred Stock then outstanding shall first receive, or simultaneously receive, a dividend on each outstanding share of Series A Preferred Stock in an amount at least equal
to the greater of (i)&nbsp;the amount of the aggregate Series A Preferred Accruing Dividends then accrued on such share of Series A Preferred Stock and not previously paid and (ii)&nbsp;(A) in the case of a dividend on Common Stock or any class or
series that is convertible into Common Stock, that dividend per share of Series A Preferred Stock as would equal the product of (1)&nbsp;the dividend payable on each share of such class or series determined, if applicable, as if all shares of such
class or series had been converted into Common Stock and (2)&nbsp;the number of shares of Common Stock issuable upon conversion of a share of Series A Preferred Stock, in each case calculated on the record date for determination of holders entitled
to receive such dividend or (B)&nbsp;in the case of a dividend on any class or series that is not convertible into Common Stock, at a rate per share of Series A Preferred Stock determined by (1)&nbsp;dividing the amount of the dividend payable on
each share of such class or series of capital stock by the original issuance price of such class or series of capital stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar
recapitalization with respect to such class or series) and (2)&nbsp;multiplying such fraction by an amount equal to the Series A Original Issue Price (as defined below) for the Series A Preferred Stock; <U>provided</U> that if the Corporation
declares, pays or sets aside, on the same date, a dividend on shares of more than one class or series of capital stock of the Corporation, the dividend </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
payable to the holders of Series A Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;1</U> shall be calculated based upon the dividend on the class or series of capital stock that
would result in the highest Series A Preferred Stock dividend. The &#147;<B>Series A</B> <B>Original Issue Price</B>&#148; for the Series A Preferred Stock shall mean $1.00 per share, subject to appropriate adjustment in the event of any stock
dividend, stock split, combination or other similar recapitalization with respect to the Series A Preferred Stock. The &#147;<B>Applicable Original Issue Price</B>&#148; shall mean (i)&nbsp;the Series A Original Issue Price, in the case of the
Series A Preferred Stock, (ii)&nbsp;the Series B Original Issue Price, in the case of the Series B Preferred Stock, (iii)&nbsp;the Series <FONT STYLE="white-space:nowrap">B-1</FONT> Original Issue Price, in the case of the Series <FONT
STYLE="white-space:nowrap">B-1</FONT> Preferred Stock, (iv)&nbsp;the Series C Original Issue Price, in the case of the Series C Preferred Stock, and (v)&nbsp;the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Original Issue Price, in the case of
the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock. The &#147;<B>Applicable Preferred Accruing Dividend&#148; </B>shall mean (i)&nbsp;the Series A Preferred Accruing Dividend, in the case of the Series A Preferred Stock,
(ii)&nbsp;the Series B Preferred Accruing Dividend, in the case of the Series B Preferred Stock, (iii)&nbsp;the Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Accruing Dividend, in the case of the Series
<FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock, (iv)&nbsp;the Series C Preferred Accruing Dividend, in the case of the Series C Preferred Stock, and (v)&nbsp;the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Accruing
Dividend, in the case of the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">1.6 <U>Certain Distributions</U>.
Subject to <U>Subsection 3.3</U>, and without limiting <U>Section</U><U></U><U>&nbsp;2</U>, in the event that the Corporation determines, to distribute to its stockholders (x)&nbsp;the proceeds (cash or otherwise) resulting from any sale or other
transfer of a significant portion of its assets or (y)&nbsp;the proceeds from any option to acquire securities or assets of the Corporation, the proceeds resulting therefrom (including in respect of any ongoing payments, such as milestone payments)
shall be distributed in accordance with <U>Section</U><U></U><U>&nbsp;2</U> below (and the amounts subsequently distributable pursuant to <U>Section</U><U></U><U>&nbsp;2</U> will be reduced accordingly), and not this
<U>Section</U><U></U><U>&nbsp;1</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">2. <U>Liquidation, Dissolution or Winding Up; Certain Mergers, Consolidations and Asset Sales</U>.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.1 <U>Preferential Payments to Holders of </U><U>Preferred Stock</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.1.1 <U>Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock, Series C Preferred Stock, Series
<FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock and Series B Preferred Stock</U>. In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event (as defined below), the
holders of shares of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock, Series C Preferred Stock, Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock and Series B Preferred Stock then outstanding shall be entitled to
be paid out of the assets of the Corporation available for distribution to its stockholders before any payment shall be made to the holders of Series A Preferred Stock and Common Stock by reason of their ownership thereof, on a pari passu basis, an
amount per share equal to the greater of (i)&nbsp;the Applicable Original Issue Price, plus any Applicable Preferred Accruing Dividends accrued by unpaid thereon, whether or not declared, together with any other dividends declared but unpaid
thereon, or (ii)&nbsp;such amount per share as would have been payable had all shares of the applicable series of Preferred Stock been converted into Common Stock pursuant to <U>Section</U><U></U><U>&nbsp;4</U> immediately prior to such liquidation,
dissolution, winding up or Deemed Liquidation Event (assuming for this purpose the conversion into Common Stock of all shares of each other series of Preferred Stock if such conversion would result in the payment to holders of such series of
Preferred Stock of an amount that is higher than the amounts set forth in <U>Subsections 2.1.1(</U><U>i</U><U>)</U> and <U>2.1.2(</U><U>i</U><U>)</U>, as applicable) (the amount payable pursuant to the first sentence of this <U>Subsection 2.1.1</U>
is hereinafter referred to as the &#147;<B>Series <FONT STYLE="white-space:nowrap">C-1</FONT></B> <B>Liquidation Amoun</B><B>t</B>&#148; with respect to the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock, the amount payable
pursuant to the first sentence of this <U>Subsection 2.1.1</U> is hereinafter referred to as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the &#147;<B>Series C</B> <B>Liquidation Amoun</B><B>t</B>&#148; with respect to the Series C Preferred Stock, the amount payable pursuant to the first sentence of this <U>Subsection 2.1.1</U> is
hereinafter referred to as the &#147;<B>Series <FONT STYLE="white-space:nowrap">B-1</FONT></B> <B>Liquidation Amoun</B><B>t</B>&#148; with respect to the Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock and the amount payable
pursuant to the first sentence of this <U>Subsection 2.1.1</U> is hereinafter referred to as the &#147;<B>Series B</B> <B>Liquidation Amoun</B><B>t</B>&#148; with respect to the Series B Preferred Stock). If upon any such liquidation, dissolution or
winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation available for distribution to its stockholders shall be insufficient to pay the holders of shares of Series <FONT STYLE="white-space:nowrap">C-1</FONT>
Preferred Stock, Series C Preferred Stock, Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock and Series B Preferred Stock the full amount to which they shall be entitled under this <U>Subsection</U><U></U><U>&nbsp;2.1.1</U>, the
holders of shares of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock, Series C Preferred Stock, Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock and Series B Preferred Stock shall share ratably in any
distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were
paid in full. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.1.2 <U>Series A Preferred Stock</U>. In the event of any voluntary or involuntary liquidation, dissolution or winding up
of the Corporation or Deemed Liquidation Event, after the payment of all preferential amounts required to be paid to the holders of shares of Series B Preferred Stock, Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock, Series C
Preferred Stock and Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock pursuant to <U>Subsection 2.1.1</U> hereof, the holders of shares of Series A Preferred Stock then outstanding shall be entitled to be paid out of the assets of
the Corporation available for distribution to its stockholders before any payment shall be made to the holders of Common Stock by reason of their ownership thereof, an amount per share equal to the greater of (i)&nbsp;the Applicable Original Issue
Price, plus any Series A Preferred Accruing Dividends accrued by unpaid thereon, whether or not declared, together with any other dividends declared but unpaid thereon, or (ii)&nbsp;such amount per share as would have been payable had all shares of
Series A Preferred Stock been converted into Common Stock pursuant to <U>Section</U><U></U><U>&nbsp;4</U> immediately prior to such liquidation, dissolution, winding up or Deemed Liquidation Event (assuming for this purpose the conversion into
Common Stock of all shares of each other series of Preferred Stock if such conversion would result in the payment to holders of such series of Preferred Stock of an amount that is higher than the amounts set forth in <U>Subsection
2.1.1(</U><U>i</U><U>)</U> above) (the amount payable pursuant to this sentence is hereinafter referred to as the &#147;<B>Series A </B><B>Liquidation Amoun</B><B>t</B>&#148; for the Series A Preferred Stock). &#147;<B>Applicable</B> <B>Liquidation
Amount</B>&#148; means the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Liquidation Amount with respect to the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock, the Series C Liquidation Amount with respect to the Series C
Preferred Stock, the Series <FONT STYLE="white-space:nowrap">B-1</FONT> Liquidation Amount with respect to the Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock, the Series B Liquidation Amount with respect to the Series B Preferred
Stock and the Series A Liquidation Amount with respect to the Series A Preferred Stock. If upon any such liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, the assets of the Corporation available for distribution
to its stockholders shall be insufficient to pay the holders of shares of Series A Preferred Stock the full amount to which they shall be entitled under this <U>Subsection</U><U></U><U>&nbsp;2.1.2</U>, the holders of shares of Series A Preferred
Stock shall share ratably in any distribution of the assets available for distribution in proportion to the respective amounts which would otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or
with respect to such shares were paid in full. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.2 <U>Payments to Holders of Common Stock</U>. In the event of any voluntary or
involuntary liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event, after the payment of all preferential amounts required to be paid to the holders of shares of Preferred Stock, the remaining assets of the Corporation
available for distribution to its stockholders shall be distributed among the holders of shares of Common Stock, pro rata based on the number of shares held by each such holder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">2.3 <U>Deemed Liquidation Events</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.3.1 <U>Definition</U>. Each of the following events shall be considered a &#147;<B>Deemed Liquidation Event</B>&#148; unless the Investor
Majority (as defined below), including the holders of a majority of each of the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock and the Series C Preferred Stock then outstanding, each voting as a separate class on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> basis, elects otherwise by written notice sent to the Corporation at least ten (10)&nbsp;days prior to the effective date of any such event: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="22%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a merger or consolidation in which </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Corporation is a constituent party or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="26%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">a subsidiary of the Corporation is a constituent party and the Corporation issues shares of its capital stock
pursuant to such merger or consolidation, </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">except any such merger or consolidation involving the Corporation or a subsidiary in which the
shares of capital stock of the Corporation outstanding immediately prior to such merger or consolidation continue to represent, or are converted into or exchanged for shares of capital stock that represent, immediately following such merger or
consolidation, a majority, by voting power, of the capital stock of (1)&nbsp;the surviving or resulting corporation; or (2)&nbsp;if the surviving or resulting corporation is a wholly owned subsidiary of another corporation immediately following such
merger or consolidation, the parent corporation of such surviving or resulting corporation; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) the sale, lease, transfer, exclusive
license or other disposition, in a single transaction or series of related transactions, by the Corporation or any subsidiary of the Corporation of all or substantially all the assets or intellectual property of the Corporation and its subsidiaries
taken as a whole, or the sale or disposition (whether by merger, consolidation or otherwise) of one or more subsidiaries of the Corporation if substantially all of the assets of the Corporation and its subsidiaries taken as a whole are held by such
subsidiary or subsidiaries, except where such sale, lease, transfer, exclusive license or other disposition is to a wholly owned subsidiary of the Corporation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;<B>Investor Majority</B>&#148; shall mean (x)&nbsp;the Corporation stockholders who together hold a majority of the outstanding Series A
Preferred Stock, Series B Preferred Stock, Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock, Series C Preferred Stock and Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock (voting together as a single class, and
not as separate series, on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis) and (y)&nbsp;at least two of the three following parties: Clarus, Novo and Vida. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;<B>Clarus</B>&#148; shall mean Clarus Lifesciences III, L.P. or any transferee, assignee or successor in such stockholder&#146;s interest in
the Corporation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;<B>Novo</B>&#148; shall mean Novo Holdings A/S or any transferee, assignee or successor in
such stockholder&#146;s interest in the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term &#147;<B>Vida</B>&#148; shall mean Vida Ventures, LLC or any transferee, assignee or
successor in such stockholder&#146;s interest in the Corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">2.3.2 <U>Effecting a Deemed Liquidation Event</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) The Corporation shall not have the power to effect a Deemed Liquidation Event referred to in <U>Subsection 2.3.1(a)(</U><U>i</U><U>)</U>
unless the agreement or plan of merger or consolidation for such transaction (the &#147;<B>Merger Agreement</B>&#148;) provides that the consideration payable to the stockholders of the Corporation shall be allocated among the holders of capital
stock of the Corporation in accordance with <U>Subsections 2.1</U> and <U>2.2</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) In the event of a Deemed Liquidation Event
referred to in <U>Subsection 2.3.1(a)(ii)</U> or <U>2.3.1(b)</U>, if the Corporation does not effect a dissolution of the Corporation under the General Corporation Law within ninety (90)&nbsp;days after such Deemed Liquidation Event, then
(i)&nbsp;the Corporation shall send a written notice to each holder of Preferred Stock no later than the ninetieth (90<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day after the Deemed Liquidation Event advising such holders of their
right (and the requirements to be met to secure such right) pursuant to the terms of the following clause; (ii)&nbsp;to require the redemption of such shares of Preferred Stock, and (iii)&nbsp;if the holders of at least a majority of the then
outstanding shares of a series of Preferred Stock so request in a written instrument delivered to the Corporation not later than one hundred twenty (120)&nbsp;days after such Deemed Liquidation Event, the Corporation shall use the consideration
received by the Corporation for such Deemed Liquidation Event (net of any retained liabilities associated with the assets sold or technology licensed, as determined in good faith by the Board, including at least three of the Preferred Directors),<B>
</B>together with any other assets of the Corporation available for distribution to its stockholders, all to the extent permitted by Delaware law governing distributions to stockholders (the &#147;<B>Available</B><B> Proceeds</B>&#148;), on the one
hundred fiftieth (150<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day after such Deemed Liquidation Event, to redeem all outstanding shares of Preferred Stock at a price per share equal to the Applicable Liquidation Amount for each
series of Preferred Stock, unless the Investor Majority, including the holders of a majority of each of the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock and the Series C Preferred Stock then outstanding, each voting as a
separate class on an as-converted basis, requests otherwise by written notice delivered to the Corporation not later than <FONT STYLE="white-space:nowrap">one-hundred</FONT> twenty (120)&nbsp;days after such Deemed Liquidation Event. Notwithstanding
the foregoing, in the event of a redemption pursuant to the preceding sentence, if the Available Proceeds are not sufficient to redeem all outstanding shares of Preferred Stock, the Corporation shall <I>first</I> ratably redeem each holder&#146;s
shares of Series B Preferred Stock, Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock, Series C Preferred Stock and Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock to the fullest extent of such Available Proceeds
based on the respective amounts which would otherwise be payable in respect of the shares to be redeemed if the Available Proceeds were sufficient to redeem all such shares, <I>second</I>, ratably redeem each holder&#146;s shares of Series A
Preferred Stock to the fullest extent of such remaining Available Proceeds after the payment to holders of Series B Preferred Stock, Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock, Series C Preferred Stock and Series <FONT
STYLE="white-space:nowrap">C-1</FONT> Preferred Stock of all amounts owed thereto pursuant to this <U>Subsection 2.3.2(b)</U> based on the respective amounts which would otherwise be payable in respect of the shares to be redeemed if the Available
Proceeds were sufficient to redeem all such shares and <I>then </I>shall redeem the remaining shares as soon as it may lawfully do so under Delaware law governing distributions to stockholders. The provisions of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<U>Section</U><U></U><U>&nbsp;6</U> shall apply, with such necessary changes in the details thereof as are necessitated by the context, to the redemption of the Preferred Stock pursuant to this
<U>Subsection 2.3.2(b)</U>. Prior to the distribution or redemption provided for in this <U>Subsection 2.3.2(b)</U>, the Corporation shall not expend or dissipate the consideration received for such Deemed Liquidation Event, except to discharge
expenses incurred in connection with such Deemed Liquidation Event or in the ordinary course of business pursuant to the Corporation&#146;s budget approved by the Board. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">2.3.3 <U>Amount Deemed Paid or Distributed</U>. The amount deemed paid or distributed to the holders of capital stock of the Corporation upon
any such merger, consolidation, sale, transfer, exclusive license, other disposition or redemption shall be the cash or the value of the property, rights or securities paid or distributed to such holders by the Corporation or the acquiring person,
firm or other entity. The value of such property, rights or securities shall be determined in good faith by the Board, including at least three of the Preferred Directors. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">2.3.4 <U>Allocation of Escrow and Contingent Consideration</U>. In the event of a Deemed Liquidation Event pursuant to <U>Subsection
2.3.1(a)(</U><U>i</U><U>)</U>, if any portion of the consideration payable to the stockholders of the Corporation is payable only upon satisfaction of contingencies (the &#147;<B>Additional Consideration</B>&#148;), the Merger Agreement shall
provide that (a)&nbsp;the portion of such consideration that is not Additional Consideration (such portion, the &#147;<B>Initial Consideration</B>&#148;) shall be allocated among the holders of capital stock of the Corporation in accordance with
<U>Subsections 2.1</U> and <U>2.2</U> as if the Initial Consideration were the only consideration payable in connection with such Deemed Liquidation Event; and (b)&nbsp;any Additional Consideration which becomes payable to the stockholders of the
Corporation upon satisfaction of such contingencies shall be allocated among the holders of capital stock of the Corporation in accordance with <U>Subsections 2.1</U> and <U>2.2</U> after taking into account the previous payment of the Initial
Consideration as part of the same transaction. For the purposes of this <U>Subsection 2.3.4</U>, consideration placed into escrow or retained as holdback to be available for satisfaction of indemnification or similar obligations or otherwise subject
to contingencies in connection with such Deemed Liquidation Event shall be deemed to be Additional Consideration. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3. <U>Voting</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.1 <U>General</U>. On any matter presented to the stockholders of the Corporation for their action or consideration at any meeting of
stockholders of the Corporation (or by written consent of stockholders in lieu of a meeting), each holder of outstanding shares of Preferred Stock shall be entitled to cast the number of votes equal to the number of whole shares of Common Stock into
which the shares of Preferred Stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Except as provided by law or by the other provisions of the Certificate of Incorporation,
holders of Preferred Stock shall vote together with the holders of Common Stock as a single class, on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.2 <U>Election of Directors</U>. The holders of record of the shares of Series A Preferred Stock, exclusively and as a separate class, shall
be entitled to elect two (2)&nbsp;directors of the Corporation (the &#147;<B>S</B><B>eries A Directors</B>&#148;), the holders of record of the shares of Series B Stock, exclusively and as a separate class, shall be entitled to elect two
(2)&nbsp;directors of the Corporation (the &#147;<B>S</B><B>eries B Directors</B>&#148; together with the Series A Directors, the &#147;<B>Preferred Directors</B>&#148;), and the holders of record of the shares of Common Stock, exclusively and as a
separate class, shall be entitled to elect one (1)&nbsp;director of the Corporation. Any director elected as provided in the preceding sentence may be removed without cause by, and only by, the affirmative
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
vote of the holders of the shares of the class or series of capital stock entitled to elect such director or directors, given either at a special meeting of such stockholders duly called for that
purpose or pursuant to a written consent of stockholders. If the holders of shares of Series B Stock, Series A Preferred Stock or Common Stock, as the case may be, fail to elect a sufficient number of directors to fill all directorships for which
they are entitled to elect directors, voting exclusively and as a separate class, pursuant to the first sentence of this <U>Subsection</U><U></U><U>&nbsp;3.2</U>, then any directorship not so filled shall remain vacant until such time as the holders
of the Series B Stock, Series A Preferred Stock or Common Stock, as the case may be, elect a person to fill such directorship by vote or written consent in lieu of a meeting; and no such directorship may be filled by stockholders of the Corporation
other than by the stockholders of the Corporation that are entitled to elect a person to fill such directorship, voting exclusively and as a separate<B> </B>class.<B> </B>The holders of record of the shares of Common Stock and of any other class or
series of voting stock (including the Preferred Stock), exclusively and voting together as a single class, shall be entitled to elect the balance of the total number of directors of the Corporation. At any meeting held for the purpose of electing a
director, the presence in person or by proxy of the holders of a majority of the outstanding shares of the class or series entitled to elect such director shall constitute a quorum for the purpose of electing such director. Except as otherwise
provided in this <U>Subsection</U><U></U><U>&nbsp;3.2</U>,<B> </B>a vacancy in any directorship filled by the holders of any class or series shall be filled only by vote or written consent in lieu of a meeting of the holders of such class or series
or by any remaining director or directors elected by the holders of such class or series pursuant to this <U>Subsection</U><U></U><U>&nbsp;3.2</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.3 <U>Preferred Stock Protective Provisions</U>. At any time when shares of Preferred Stock are outstanding, the Corporation shall not,
either directly or indirectly by amendment, merger, consolidation or otherwise, do any of the following without (in addition to any other vote required by law or the Certificate of Incorporation) the written consent or affirmative vote of the
Investor Majority given in writing or by vote at a meeting, consenting or voting (as the case may be) separately as a class, and any such&nbsp;act or transaction entered into without such consent or vote shall be null and void <I>ab initio</I>, and
of no force or effect:</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.1 liquidate, dissolve or <FONT STYLE="white-space:nowrap">wind-up</FONT> the business and affairs of the
Corporation, effect any merger or consolidation or any other Deemed Liquidation Event, or consent to any of the foregoing; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.2 amend,
alter or repeal any provision of the Certificate of Incorporation or Bylaws of the Corporation; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.3 create, or authorize the creation
of, or issue or obligate itself to issue shares of, any additional class or series of capital stock (unless the same ranks junior to all series of Preferred Stock with respect to the distribution of assets on the liquidation, dissolution or winding
up of the Corporation, the payment of dividends, voting rights and rights of redemption and any other rights, preferences or privileges), or increase the authorized number of any series of Preferred Stock; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.4 create, or authorize the creation of any plan or agreement related to the issuance of stock options or restricted stock, or increase the
total number of authorized shares of Common Stock reserved for issuance pursuant to any stock option plan agreement or similar agreement; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.5 (i) reclassify, alter or amend any existing security of the Corporation that is
<I>pari passu</I> with any series of Preferred Stock in respect of the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of redemption, if such reclassification, alteration or
amendment would render such other security senior to such series of Preferred Stock in respect of any such right, preference, or privilege or (ii)&nbsp;reclassify, alter or amend any existing security of the Corporation that is junior to any series
of Preferred Stock in respect of the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of redemption, if such reclassification, alteration or amendment would render such other
security senior to or <I>pari passu</I> with such series of Preferred Stock in respect of any such right, preference or privilege; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.6
purchase or redeem (or permit any subsidiary to purchase or redeem) or pay or declare any dividend or make any distribution on, any shares of capital stock of the Corporation other than (i)&nbsp;redemptions of or dividends or distributions on the
Preferred Stock as expressly authorized herein, (ii)&nbsp;dividends or other distributions payable on the Common Stock solely in the form of additional shares of Common Stock and (iii)&nbsp;repurchases of stock from former employees, officers,
directors, consultants or other persons who performed services for the Corporation or any subsidiary in connection with the cessation of such employment or service at the lower of the original purchase price or the then-current fair market value
thereof; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.7 create, or authorize the creation of, or issue, or authorize the issuance of any debt security, or permit any subsidiary
to take any such action with respect to any debt security, other than equipment leases or bank lines of credit which have received the prior approval of the Board, including at least three of the Preferred Directors; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.8 increase or decrease the authorized number of directors constituting the Board; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.9 create or hold any capital stock in any direct or indirect subsidiary of the Corporation that is not wholly-owned; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.10 dispose of any of the Corporation&#146;s capital stock in any direct or indirect subsidiary of the Corporation or permit any direct or
indirect subsidiary to sell, lease, transfer, exclusively license or otherwise dispose (in a single transaction or series of related transactions) of all or substantially all of the assets of such subsidiary; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.11 issue any equity interest in any direct or indirect subsidiary of the Corporation (other than to the Corporation itself or one of the
Corporation&#146;s wholly-owned subsidiaries); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.12 create, issue, sell, distribute or sponsor any cryptocurrency, decentralized
application tokens, protocol tokens, blockchain-based assets or other cryptofinance coins, tokens or similar digital assets (&#147;<B>Tokens</B>&#148;), including, without limitation, through a Simple Agreement for Future Tokens, <FONT
STYLE="white-space:nowrap">pre-sale,</FONT> initial coin offering, token distribution event, &#147;airdrop&#148; or crowdfunding; (b)&nbsp;develop computer software or a computer network either incorporating Tokens or permitting the generation of
tokens by network participants; or (c)&nbsp;distribute any software developed by or for the Corporation under an open source license (such as an academic license); or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.3.13 take any action with respect to any direct or indirect subsidiary of the
Corporation, that if taken by the Corporation, would require approval pursuant to this <U>Subsection 3.3</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.4 <U>Series C Preferred
Stock Protective Provisions</U>. At any time when shares of Preferred Stock are outstanding, the Corporation shall not, either directly or indirectly by amendment, merger, consolidation or otherwise, do any of the following without (in addition to
any other vote required by law or the Certificate of Incorporation) the written consent or affirmative vote of the stockholders who together hold at least a majority of the outstanding Series C Preferred Stock, given in writing or by vote at a
meeting, consenting or voting (as the case may be) separately as a class, and any such&nbsp;act or transaction entered into without such consent or vote shall be null and void <I>ab initio</I>, and of no force or effect:</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.4.1 amend, alter, repeal or otherwise waive the rights, preferences or privileges of the Series C Preferred Stock in the Certificate of
Incorporation or bylaws of the Corporation in a manner that is adverse to the holders of the Series C Preferred Stock (it being understood that the authorization of a new series of Preferred Stock on parity with or senior to the Series C Preferred
Stock will not in and of itself be deemed to adversely alter or change the rights, preferences or privileges of the shares of Series C Preferred Stock); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.4.2 pay any dividend on any capital stock of the Corporation prior to the Series B Preferred Stock, Series
<FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock, Series C Preferred Stock and Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock receiving their accrued and unpaid Applicable Preferred Accruing Dividends; provided, the
Corporation may repurchase Common Stock from employees upon termination of employment at the lower of fair market value or the original purchase price thereof; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.4.3 increase or decrease the number of authorized shares of Series C Preferred Stock; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.4.4 any amendment, termination or waiver of Section&nbsp;2.3.1 or Section&nbsp;2.3.2(b) with respect to the requirement that the holders of
a majority of the Series C Preferred Stock then outstanding be included in the elections or requests of the Investor Majority set forth in such sections; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.4.5 any amendment, termination or waiver of Section&nbsp;4.4.2(d); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.4.6 any amendment, termination or waiver of Section&nbsp;5.1(b); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.4.7 any amendment, termination or waiver of the second sentence of Section&nbsp;8; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.4.8 take any action with respect to any direct or indirect subsidiary of the Corporation, that if taken by the Corporation, would require
approval pursuant to this <U>Subsection 3.4</U>.; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.4.9 any waiver of the provisions of <U>Section</U><U></U><U>&nbsp;2</U> if such
waiver would result in an amount of proceeds payable or distributable to the holders of Series C Preferred Stock in connection with a voluntary or involuntary liquidation, dissolution or winding up of the Corporation or Deemed Liquidation Event that
is less than the amount of proceeds that such holders (in such capacity) would have received had such waiver not occurred. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">3.5 <U>Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock Protective
Provisions</U>. At any time when shares of Preferred Stock are outstanding, the Corporation shall not, either directly or indirectly by amendment, merger, consolidation or otherwise, do any of the following without (in addition to any other vote
required by law or the Certificate of Incorporation) the written consent or affirmative vote of the stockholders who together hold at least a majority of the outstanding Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock, given in
writing or by vote at a meeting, consenting or voting (as the case may be) separately as a class, and any such&nbsp;act or transaction entered into without such consent or vote shall be null and void <I>ab initio</I>, and of no force or effect:</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.5.1 amend, alter, repeal or otherwise waive the rights, preferences or privileges of the Series <FONT STYLE="white-space:nowrap">C-1</FONT>
Preferred Stock in the Certificate of Incorporation or bylaws of the Corporation in a manner that is adverse to the holders of the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock (it being understood that the authorization of a
new series of Preferred Stock on parity with or senior to the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock will not in and of itself be deemed to adversely alter or change the rights, preferences or privileges of the shares of
Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.5.2 pay any dividend on any capital stock of the Corporation prior
to the Series B Preferred Stock, Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock, Series C Preferred Stock and Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock receiving their accrued and unpaid Applicable
Preferred Accruing Dividends; provided, the Corporation may repurchase Common Stock from employees upon termination of employment at the lower of fair market value or the original purchase price thereof; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.5.3 (i) reclassify, alter or amend any existing security of the Corporation that is <I>pari passu</I> with the Series <FONT
STYLE="white-space:nowrap">C-1</FONT> Preferred Stock in respect of the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of redemption, if such reclassification, alteration
or amendment would render such other security senior to the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock in respect of any such right, preference, or privilege or (ii)&nbsp;reclassify, alter or amend any existing security of
the Corporation that is junior to the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock in respect of the distribution of assets on the liquidation, dissolution or winding up of the Corporation, the payment of dividends or rights of
redemption, if such reclassification, alteration or amendment would render such other security senior to or <I>pari passu</I> with the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock in respect of any such right, preference or
privilege; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.5.4 increase or decrease the number of authorized shares of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred
Stock; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.5.5 any amendment, termination or waiver of Section&nbsp;2.3.1 or Section&nbsp;2.3.2(b) with respect to the requirement that the
holders of a majority of the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock then outstanding be included in the elections or requests of the Investor Majority set forth in such sections; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.5.6 any amendment, termination or waiver of Section&nbsp;4.4.2(e); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.5.7 any amendment, termination or waiver of Section&nbsp;5.1(b); </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.5.8 any amendment, termination or waiver of the first sentence of Section&nbsp;8; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.5.9 take any action with respect to any direct or indirect subsidiary of the Corporation, that if taken by the Corporation, would require
approval pursuant to this <U>Subsection 3.5</U>; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">3.5.10 any waiver of the provisions of Section&nbsp;2 if such waiver would result in
an amount of proceeds payable or distributable to the holders of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock in connection with a voluntary or involuntary liquidation, dissolution or winding up of the Corporation or Deemed
Liquidation Event that is less than the amount of proceeds that such holders (in such capacity) would have received had such waiver not occurred. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4. <U>Optional</U><U> Conversion</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the Preferred Stock shall have conversion rights as follows (the &#147;<B>Conversion Rights</B>&#148;): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.1 <U>Right to Convert</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.1.1 <U>Conversion Ratio</U>. Each share of each series of Preferred Stock shall be convertible, at the option of the holder thereof, unless
waived by such holder in writing, at any time and from time to time, and without the payment of additional consideration by the holder thereof, into such number of fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of
Common Stock as is determined by dividing the Applicable Original Issue Price by the applicable Conversion Price (as defined below) in effect at the time of conversion. The &#147;<B>Conversion Price</B>&#148; for the Series A Preferred Stock, Series
B Preferred Stock, Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock, Series C Preferred Stock, and Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock shall initially be equal to $1.00, $3.00, $3.75, $5.15 and $5.67
respectively. Such initial Conversion Prices, and the rate at which shares of each series of Preferred Stock may be converted into shares of Common Stock, shall be subject to adjustment as provided below. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.1.2 <U>Termination of Conversion Rights</U>. In the event of a notice of redemption of any shares of Preferred Stock pursuant to
<U>Section</U><U></U><U>&nbsp;6</U>, the Conversion Rights of the shares designated for redemption shall terminate at the close of business on the last full day preceding the date fixed for redemption, unless the redemption price is not fully paid
on such redemption date, in which case the Conversion Rights for such shares shall continue until such price is paid in full. In the event of a liquidation, dissolution or winding up of the Corporation or a Deemed Liquidation Event, the Conversion
Rights shall terminate at the close of business on the last full day preceding the date fixed for the payment of any such amounts distributable on such event to the holders of Preferred Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.2 <U>Fractional Shares</U>. No fractional shares of Common Stock shall be issued upon conversion of the Preferred Stock. In lieu of any
fractional shares to which the holder would otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied by the fair market value of a share of Common Stock as determined in good faith by the Board. Whether or not
fractional shares would be issuable upon such conversion shall be determined on the basis of the total number of shares of Preferred Stock the holder is at the time converting into Common Stock and the aggregate number of shares of Common Stock
issuable upon such conversion. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.3 <U>Mechanics of Conversion</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.1 <U>Notice of Conversion</U>. In order for a holder of Preferred Stock to voluntarily convert shares of Preferred Stock into shares of
Common Stock, such holder shall (a)&nbsp;provide written notice to the Corporation&#146;s transfer agent at the office of the transfer agent for the Preferred Stock (or at the principal office of the Corporation if the Corporation serves as its own
transfer agent) that such holder elects to convert all or any number of such holder&#146;s shares of each series of Preferred Stock held by such holder and, if applicable, any event on which such conversion is contingent and (b), if such
holder&#146;s shares are certificated, surrender the certificate or certificates for such shares of Preferred Stock (or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and
agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate), at the office of the transfer agent
for the Preferred Stock (or at the principal office of the Corporation if the Corporation serves as its own transfer agent). Such notice shall state such holder&#146;s name or the names of the nominees in which such holder wishes the shares of
Common Stock to be issued. If required by the Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by a written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the
registered holder or his, her or its attorney duly authorized in writing. The close of business on the date of receipt by the transfer agent (or by the Corporation if the Corporation serves as its own transfer agent) of such notice and, if
applicable, certificates (or lost certificate affidavit and agreement) shall be the time of conversion (the &#147;<B>Conversion Time</B>&#148;), and the shares of Common Stock issuable upon conversion of the specified shares shall be deemed to be
outstanding of record as of such date. The Corporation shall, as soon as practicable after the Conversion Time (i)&nbsp;issue and deliver to such holder of Preferred Stock, or to his, her or its nominees, a certificate or certificates for the number
of full shares of Common Stock issuable upon such conversion in accordance with the provisions hereof and a certificate for the number (if any) of the shares of Preferred Stock represented by the surrendered certificate that were not converted into
Common Stock, (ii)&nbsp;pay in cash such amount as provided in <U>Subsection</U><U></U><U>&nbsp;4.2</U> in lieu of any fraction of a share of Common Stock otherwise issuable upon such conversion and (iii)&nbsp;pay all accrued or declared, but unpaid
dividends on the shares Preferred Stock so converted, in either (1)&nbsp;shares of Common Stock based on the fair market value in effect at the time of the conversion, or (2)&nbsp;in cash, at the election of such holder of Preferred Stock, but only
to the extent such dividends may lawfully be paid in cash by the Corporation. In the event any dividends may not lawfully be paid by the Corporation on the date of conversion, such dividends shall remain an obligation of the Corporation and shall be
payable to holders of record of Preferred Stock whose shares were converted on the date of conversion as promptly as practicable following the date such obligation may lawfully be paid by the Corporation. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.2 <U>Reservation of Shares</U>. The Corporation shall at all times when the Preferred Stock shall be outstanding, reserve and keep
available out of its authorized but unissued capital stock, for the purpose of effecting the conversion of the Preferred Stock, such number of its duly authorized shares of Common Stock as shall from time to time be sufficient to effect the
conversion of all outstanding Preferred Stock; and if at any time the number of authorized but unissued shares of Common Stock shall not be sufficient to effect the conversion of all then </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
outstanding shares of the Preferred Stock, the Corporation shall take such corporate action as may be necessary to increase its authorized but unissued shares of Common Stock to such number of
shares as shall be sufficient for such purposes, including, without limitation, engaging in best efforts to obtain the requisite stockholder approval of any necessary amendment to the Certificate of Incorporation. Before taking any action which
would cause an adjustment reducing the applicable Conversion Price for a series of Preferred Stock below the then par value of the shares of Common Stock issuable upon conversion of such series of Preferred Stock, the Corporation will take any
corporate action which may, in the opinion of its counsel, be necessary in order that the Corporation may validly and legally issue fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> shares of Common Stock at the adjusted
Conversion Price applicable to such series of Preferred Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.3 <U>Effect of Conversion</U>. All shares of Preferred Stock that
shall have been surrendered for conversion as herein provided shall no longer be deemed to be outstanding and all rights with respect to such shares shall immediately cease and terminate at the Conversion Time, except only the right of the holders
thereof to receive shares of Common Stock in exchange therefor, to receive payment in lieu of any fraction of a share otherwise issuable upon such conversion as provided in <U>Subsection</U><U></U><U>&nbsp;4.2</U> and to receive payment of any
dividends accrued or declared, but unpaid thereon. Any shares of Preferred Stock so converted shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may thereafter take such appropriate action (without
the need for stockholder action) as may be necessary to reduce the authorized number of shares of Preferred Stock accordingly. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.4
<U>No Further Adjustment</U>. Upon any such conversion, no adjustment to the Conversion Price applicable to a series of Preferred Stock shall be made for any declared but unpaid dividends on the Preferred Stock surrendered for conversion or on the
Common Stock delivered upon conversion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.3.5 <U>Taxes</U>. The Corporation shall pay any and all issue and other similar taxes that may
be payable in respect of any issuance or delivery of shares of Common Stock upon conversion of shares of Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;4</U>.<U>4</U>. The Corporation shall not, however, be required to pay any tax
which may be payable in respect of any transfer involved in the issuance and delivery of shares of Common Stock in a name other than that in which the shares of Preferred Stock so converted were registered, and no such issuance or delivery shall be
made unless and until the person or entity requesting such issuance has paid to the Corporation the amount of any such tax or has established, to the satisfaction of the Corporation, that such tax has been paid. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4 <U>Adjustments</U><U> to Conversion Price for Diluting Issues</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.1 <U>Special Definitions</U>. For purposes of this Article Fourth, the following definitions shall apply: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B>Option</B>&#148; shall mean rights, options or warrants to subscribe for, purchase or otherwise acquire Common Stock or
Convertible Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B>S</B><B>eries <FONT STYLE="white-space:nowrap">C-1</FONT> Original Issue Date</B>&#148; shall mean
the date on which the first share of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock was issued. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>Convertible Securities</B>&#148; shall mean any evidences of indebtedness,
shares or other securities directly or indirectly convertible into or exchangeable for Common Stock, but excluding Options. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d)
&#147;<B>Additional Shares of Common Stock</B>&#148; shall mean all shares of Common Stock issued (or, pursuant to <U>Subsection</U><U></U><U>&nbsp;4.4.3</U> below, deemed to be issued) by the Corporation after the Series <FONT
STYLE="white-space:nowrap">C-1</FONT> Original Issue Date, other than (1)&nbsp;the following shares of Common Stock and (2)&nbsp;shares of Common Stock deemed issued pursuant to the following Options and Convertible Securities (clauses (1)&nbsp;and
(2), collectively, &#147;<B>Exempted Securities</B>&#148;): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="67%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(i)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">shares of Common Stock, Options or Convertible Securities issued as a dividend or distribution on Preferred Stock;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(ii)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">shares of Common Stock, Options or Convertible Securities issued by reason of a dividend, stock split, <FONT STYLE="white-space:nowrap">split-up</FONT> or other distribution on shares of Common Stock that is covered by <U>Subsection
4.5</U>, <U>4.6</U>, <U>4.7</U> or <U>4.8</U><B>;</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(iii)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">shares of Common Stock or Options issued to employees or directors of, or consultants or advisors to, the Corporation or any of its subsidiaries pursuant to a plan, agreement or arrangement approved by the Board, including at least
three of the Preferred Directors;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(iv)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">shares of Common Stock or Convertible Securities actually issued upon the exercise of Options or shares of Common Stock actually issued upon the conversion or exchange of Convertible Securities, in each case provided such issuance
is pursuant to the terms of such Option or Convertible Security;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(v)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">shares of Common Stock, Options or Convertible Securities issued to banks, equipment lessors or other financial institutions, or to real property lessors, pursuant to a debt financing, equipment leasing or real property leasing
transaction approved by the Board, including at least three of the Preferred Directors;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(vi)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">shares of Common Stock, Options or Convertible Securities issued pursuant to the acquisition of another corporation by the Corporation by merger, purchase of substantially all of the assets or other reorganization or to a joint
venture agreement, <U>provided</U> that such issuances are approved by the Board, including at least three of the Preferred Directors; or</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="28%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="67%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">(vii)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">shares of Common Stock, Options or Convertible Securities issued in connection with sponsored research, collaboration, technology license, development, marketing or other similar agreements or strategic partnerships approved by the
Board.</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.2 <U>No Adjustment of Conversion Price</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) <U>Series A Preferred Stock</U>. No adjustment in the Conversion Price for the Series A Preferred Stock shall be made as the result of the
issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the holders of a majority of the then outstanding shares of Series A Preferred Stock agreeing that no such adjustment shall be made as
the result of the issuance or deemed issuance of such Additional Shares of Common Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) <U>Series B Preferred Stock</U>. No
adjustment in the Conversion Price for the Series B Preferred Stock shall be made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the holders of a majority of the
then outstanding shares of Series B Preferred Stock agreeing that no such adjustment shall be made as the result of the issuance or deemed issuance of such Additional Shares of Common Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) <U>Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock</U>. No adjustment in the Conversion Price for the Series <FONT
STYLE="white-space:nowrap">B-1</FONT> Preferred Stock shall be made as the result of the issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the holders of a majority of the then
outstanding shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock agreeing that no such adjustment shall be made as the result of the issuance or deemed issuance of such Additional Shares of Common Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) <U>Series C Preferred Stock</U>. No adjustment in the Conversion Price for the Series C Preferred Stock shall be made as the result of the
issuance or deemed issuance of Additional Shares of Common Stock if the Corporation receives written notice from the holders of a majority of the then outstanding shares of Series C Preferred Stock agreeing that no such adjustment shall be made as
the result of the issuance or deemed issuance of such Additional Shares of Common Stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(e) <U>Series
<FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock</U>. No adjustment in the Conversion Price for the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock shall be made as the result of the issuance or deemed issuance of
Additional Shares of Common Stock if the Corporation receives written notice from the holders of a majority of the then outstanding shares of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock agreeing that no such adjustment shall
be made as the result of the issuance or deemed issuance of such Additional Shares of Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.3 <U>Deemed Issue of Additional Shares of Common Stock</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) If the Corporation at any time or from time to time after the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Original Issue Date shall
issue any Options or Convertible Securities (excluding Options or Convertible Securities which are themselves Exempted Securities) or shall fix a record date for the determination of holders of any class of securities entitled to receive any such
Options or Convertible Securities, then the maximum number of shares of Common Stock (as set forth in the instrument relating thereto, assuming the satisfaction of any conditions to exercisability, convertibility or exchangeability but without
regard to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or, in the case of Convertible Securities and Options therefor, the conversion or exchange of such Convertible
Securities, shall be deemed to be Additional Shares of Common Stock issued as of the time of such issue or, in case such a record date shall have been fixed, as of the close of business on such record date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) If the terms of any Option or Convertible Security, the issuance of which resulted in an adjustment to the Conversion Price applicable to
a series of Preferred Stock pursuant to the terms of <U>Subsection 4.4.4</U>, are revised as a result of an amendment to such terms or any other adjustment pursuant to the provisions of such Option or Convertible Security (but excluding automatic
adjustments to such terms pursuant to anti-dilution or similar provisions of such Option or Convertible Security) to provide for either (1)&nbsp;any increase or decrease in the number of shares of Common Stock issuable upon the exercise, conversion
and/or exchange of any such Option or Convertible Security or (2)&nbsp;any increase or decrease in the consideration payable to the Corporation upon such exercise, conversion and/or exchange, then, effective upon such increase or decrease becoming
effective, the Conversion Price for such series of Preferred Stock computed upon the original issue of such Option or Convertible Security (or upon the occurrence of a record date with respect thereto) shall be readjusted to such Conversion Price
applicable to such series of Preferred Stock as would have obtained had such revised terms been in effect upon the original date of issuance of such Option or Convertible Security. Notwithstanding the foregoing, no readjustment pursuant to this
clause&nbsp;(b) shall have the effect of increasing the Conversion Price applicable to a series of Preferred Stock to an amount which exceeds the lower of (i)&nbsp;the Conversion Price applicable to such series of Preferred Stock in effect
immediately prior to the original adjustment made as a result of the issuance of such Option or Convertible Security, or (ii)&nbsp;the Conversion Price applicable to such series of Preferred Stock that would have resulted from any issuances of
Additional Shares of Common Stock (other than deemed issuances of Additional Shares of Common Stock as a result of the issuance of such Option or Convertible Security) between the original adjustment date and such readjustment date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) If the terms of any Option or Convertible Security (excluding Options or Convertible Securities which are themselves Exempted Securities),
the issuance of which did not result in an adjustment to the Conversion Price applicable to a series of Preferred Stock pursuant to the terms of <U>Subsection 4.4.4</U> (either because the consideration per share (determined pursuant to
<U>Subsection 4.4.5</U>) of the Additional Shares of Common Stock subject thereto was equal to or greater than the Conversion Price applicable to such series of Preferred Stock then in effect, or because such Option or Convertible Security was
issued before the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Original Issue Date), are revised after the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Original Issue Date as a result of an amendment to such terms or any other adjustment
pursuant to the provisions of such Option or Convertible Security (but excluding automatic adjustments to such terms pursuant to anti-dilution </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
or similar provisions of such Option or Convertible Security) to provide for either (1)&nbsp;any increase in the number of shares of Common Stock issuable upon the exercise, conversion or
exchange of any such Option or Convertible Security or (2)&nbsp;any decrease in the consideration payable to the Corporation upon such exercise, conversion or exchange, then such Option or Convertible Security, as so amended or adjusted, and the
Additional Shares of Common Stock subject thereto (determined in the manner provided in <U>Subsection 4.4.3(a)</U>) shall be deemed to have been issued effective upon such increase or decrease becoming effective. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) Upon the expiration or termination of any unexercised Option or unconverted or unexchanged Convertible Security (or portion thereof) which
resulted (either upon its original issuance or upon a revision of its terms) in an adjustment to the Conversion Price applicable to a series of Preferred Stock pursuant to the terms of <U>Subsection</U><U></U><U>&nbsp;4.4.4</U>, the Conversion Price
for such series of Preferred Stock shall be readjusted to such applicable Conversion Price as would have obtained had such Option or Convertible Security (or portion thereof) never been issued. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(e) If the number of shares of Common Stock issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or
the consideration payable to the Corporation upon such exercise, conversion and/or exchange, is calculable at the time such Option or Convertible Security is issued or amended but is subject to adjustment based upon subsequent events, any adjustment
to the Conversion Price applicable to a series of Preferred Stock provided for in this <U>Subsection</U><U></U><U>&nbsp;4.4.3</U> shall be effected at the time of such issuance or amendment based on such number of shares or amount of consideration
without regard to any provisions for subsequent adjustments (and any subsequent adjustments shall be treated as provided in clauses (b)&nbsp;and (c) of this <U>Subsection</U><U></U><U>&nbsp;4.4.3</U>). If the number of shares of Common Stock
issuable upon the exercise, conversion and/or exchange of any Option or Convertible Security, or the consideration payable to the Corporation upon such exercise, conversion and/or exchange, cannot be calculated at all at the time such Option or
Convertible Security is issued or amended, any adjustment to the Conversion Price applicable to a series of Preferred Stock that would result under the terms of this <U>Subsection</U><U></U><U>&nbsp;4.4.3</U> at the time of such issuance or
amendment shall instead be effected at the time such number of shares and/or amount of consideration is first calculable (even if subject to subsequent adjustments), assuming for purposes of calculating such adjustment to the Conversion Price
applicable to such series of Preferred Stock that such issuance or amendment took place at the time such calculation can first be made. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.4 <U>Adjustment of Conversion Price </U><U>Upon</U><U> Issuance of Additional Shares of Common Stock</U>. In the event the Corporation
shall at any time after the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Original Issue Date issue Additional Shares of Common Stock (including Additional Shares of Common Stock deemed to be issued pursuant to
<U>Subsection</U><U></U><U>&nbsp;4.4.3</U>), without consideration or for a consideration per share less than the Conversion Price applicable to a series of Preferred Stock in effect immediately prior to such issue, then the Conversion Price
applicable to such series of Preferred Stock shall be reduced, concurrently with such issue, to a price (calculated to the nearest <FONT STYLE="white-space:nowrap">one-hundredth</FONT> of a cent) determined in accordance with the following formula:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">CP<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB> = (CP<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB>* (A + B))
&divide; (A + C). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of the foregoing formula, the following definitions shall apply: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) &#147;CP<SUB STYLE="font-size:85%; vertical-align:bottom">2</SUB>&#148; shall mean the Conversion Price applicable to such series of
Preferred Stock in effect immediately after such issue of Additional Shares of Common Stock </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(b) &#147;CP<SUB
STYLE="font-size:85%; vertical-align:bottom">1</SUB>&#148; shall mean the Conversion Price applicable to such series of Preferred Stock in effect immediately prior to such issue of Additional Shares of Common Stock; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(c) &#147;A&#148; shall mean the number of shares of Common Stock outstanding immediately prior to such issue of Additional Shares of Common
Stock (treating for this purpose as outstanding all shares of Common Stock issuable upon exercise of Options outstanding immediately prior to such issue or upon conversion or exchange of Convertible Securities (including the Preferred Stock)
outstanding (assuming exercise of any outstanding Options therefor) immediately prior to such issue); </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(d) &#147;B&#148; shall mean the
number of shares of Common Stock that would have been issued if such Additional Shares of Common Stock had been issued at a price per share equal to CP<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB> (determined by dividing the aggregate
consideration received by the Corporation in respect of such issue by CP<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB>); and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(e) &#147;C&#148; shall mean the number of such Additional Shares of Common Stock issued in such transaction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.5 <U>Determination of Consideration</U>. For purposes of this <U>Subsection 4.4</U>, the consideration received by the Corporation for the
issue of any Additional Shares of Common Stock shall be computed as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:22%; font-size:10pt; font-family:Times New Roman">(a) <U>Cash and Property</U>: Such consideration shall: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="77%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(i)&#8195;insofar as it consists of cash, be computed at the aggregate amount of cash received by
the Corporation, excluding amounts paid or payable for accrued interest;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(ii)&#8194;&#8201;insofar as it consists of property other than cash, be computed at the fair
market value thereof at the time of such issue, as determined in good faith by the Board, including at least three of the Preferred Directors; and</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(iii)&#8201;&#8201;in the event Additional Shares of Common Stock are issued together with other
shares or securities or other assets of the Corporation for consideration which covers both, be the proportion of such consideration so received, computed as provided in clauses (i)&nbsp;and (ii) above, as determined in good faith by the Board,
including at least three of the Preferred Directors.</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(b) <U>Options and Convertible Securities</U>. The consideration per share received by the
Corporation for Additional Shares of Common Stock deemed to have been issued pursuant to <U>Subsection</U><U></U><U>&nbsp;4.4.3</U>, relating to Options and Convertible Securities, shall be determined by dividing: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="77%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(i)&#8195;The total amount, if any, received or receivable by the Corporation as consideration
for the issue of such Options or Convertible Securities, plus the minimum aggregate amount of additional consideration (as set forth in the instruments relating thereto, without regard to any provision contained therein for a subsequent adjustment
of such consideration) payable to the Corporation upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for Convertible Securities, the exercise of such Options for Convertible
Securities and the conversion or exchange of such Convertible Securities, by</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(ii)&#8194;&#8201;the maximum number of shares of Common Stock (as set forth in the instruments
relating thereto, without regard to any provision contained therein for a subsequent adjustment of such number) issuable upon the exercise of such Options or the conversion or exchange of such Convertible Securities, or in the case of Options for
Convertible Securities, the exercise of such Options for Convertible Securities and the conversion or exchange of such Convertible Securities.</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">4.4.6 <U>Multiple Closing Dates</U>. In the event the Corporation shall issue on more than one date
Additional Shares of Common Stock that are a part of one transaction or a series of related transactions and that would result in an adjustment to the Conversion Price applicable to a series of Preferred Stock pursuant to the terms of <U>Subsection
4.4.4</U> then, upon the final such issuance, the Conversion Price applicable to such series of Preferred Stock shall be readjusted to give effect to all such issuances as if they occurred on the date of the first such issuance (and without giving
effect to any additional adjustments as a result of any such subsequent issuances within such period). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.5 <U>Adjustment for Stock Splits and Combinations</U>. If the Corporation shall at any
time or from time to time after the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Original Issue Date effect a subdivision of the outstanding Common Stock, the Conversion Price applicable to a series of Preferred Stock in effect immediately
before that subdivision shall be proportionately decreased so that the number of shares of Common Stock issuable on conversion of each share of such series shall be increased in proportion to such increase in the aggregate number of shares of Common
Stock outstanding. If the Corporation shall at any time or from time to time after the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Original Issue Date combine the outstanding shares of Common Stock, the Conversion Price applicable to a series
of Preferred Stock in effect immediately before the combination shall be proportionately increased so that the number of shares of Common Stock issuable on conversion of each share of such series shall be decreased in proportion to such decrease in
the aggregate number of shares of Common Stock outstanding. Any adjustment under this subsection shall become effective at the close of business on the date the subdivision or combination becomes effective. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.6 <U>Adjustment for Certain Dividends and Distributions</U>. In the event the Corporation at any time or from time to time after the Series <FONT
STYLE="white-space:nowrap">C-1</FONT> Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable on the Common Stock in additional
shares of Common Stock, then and in each such event the Conversion Price applicable to a series of Preferred Stock in effect immediately before such event shall be decreased as of the time of such issuance or, in the event such a record date shall
have been fixed, as of the close of business on such record date, by multiplying the Conversion Price applicable to such series of Preferred Stock then in effect by a fraction: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(1) the numerator of which shall be the total number of shares of Common Stock issued and outstanding immediately prior to the time of such
issuance or the close of business on such record date, and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(2) the denominator of which shall be the total number of shares of Common
Stock issued and outstanding immediately prior to the time of such issuance or the close of business on such record date plus the number of shares of Common Stock issuable in payment of such dividend or distribution. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing (a)&nbsp;if such record date shall have been fixed and such dividend is not fully paid or if such distribution is not fully made
on the date fixed therefor, the Conversion Price applicable to a series of Preferred Stock shall be recomputed accordingly as of the close of business on such record date and thereafter the Conversion Price applicable to such series of Preferred
Stock shall be adjusted pursuant to this subsection as of the time of actual payment of such dividends or distributions; and (b)&nbsp;that no such adjustment shall be made if the holders of such series of Preferred Stock simultaneously receive a
dividend or other distribution of shares of Common Stock in a number equal to the number of shares of Common Stock as they would have received if all outstanding shares of such series of Preferred Stock had been converted into Common Stock on the
date of such event. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.7 <U>Adjustments for Other Dividends and Distributions</U>. In the event the Corporation at any time or from time
to time after the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Original Issue Date shall make or issue, or fix a record date for the determination of holders of Common Stock entitled to receive, a dividend or other distribution payable in
securities of the Corporation (other than a distribution of shares of Common Stock in respect of outstanding shares of Common Stock) or in other property and the provisions of <U>Section</U><U></U><U>&nbsp;1</U> do not apply to such dividend or
distribution, then and in each such event the holders of Preferred Stock shall receive, simultaneously with the distribution to the holders of Common Stock, a dividend or other distribution of such securities or other property in an amount equal to
the amount of such securities or other property as they would have received if all outstanding shares of Preferred Stock had been converted into Common Stock on the date of such event. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.8 <U>Adjustment for Merger or Reorganization, etc</U>. Subject to the provisions of
<U>Subsection 2.3</U>, if there shall occur any reorganization, recapitalization, reclassification, consolidation or merger involving the Corporation in which the Common Stock (but not the Preferred Stock) is converted into or exchanged for
securities, cash or other property (other than a transaction covered by <U>Subsections 4.4</U>, <U>4.6</U> or <U>4.7</U>), then, following any such reorganization, recapitalization, reclassification, consolidation or merger, each share of Preferred
Stock shall thereafter be convertible in lieu of the Common Stock into which it was convertible prior to such event into the kind and amount of securities, cash or other property which a holder of the number of shares of Common Stock of the
Corporation issuable upon conversion of one share of Preferred Stock immediately prior to such reorganization, recapitalization, reclassification, consolidation or merger would have been entitled to receive pursuant to such transaction; and, in such
case, appropriate adjustment (as determined in good faith by the Board) shall be made in the application of the provisions in this <U>Section</U><U></U><U>&nbsp;4</U> with respect to the rights and interests thereafter of the holders of the
Preferred Stock, to the end that the provisions set forth in this <U>Section</U><U></U><U>&nbsp;4</U> (including provisions with respect to changes in and other adjustments of the applicable Conversion Price) shall thereafter be applicable, as
nearly as reasonably may be, in relation to any securities or other property thereafter deliverable upon the conversion of such series of Preferred Stock. For the avoidance of doubt, nothing in this <U>Subsection 4.8</U> shall be construed as
preventing the holders of such series of Preferred Stock from seeking any appraisal rights to which they are otherwise entitled under the General Corporation Law in connection with a merger triggering an adjustment hereunder, nor shall this
<U>Subsection 4.8</U> be deemed conclusive evidence of the fair value of the shares of such series of Preferred Stock in any such appraisal proceeding. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.9 <U>Certificate as to Adjustments</U>. Upon the occurrence of each adjustment or readjustment of the Conversion Price applicable to a
series of Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;4</U>, the Corporation at its expense shall, as promptly as reasonably practicable but in any event not later than ten (10)&nbsp;days thereafter, compute such adjustment or
readjustment in accordance with the terms hereof and furnish to each holder of Preferred Stock a certificate setting forth such adjustment or readjustment (including the kind and amount of securities, cash or other property into which the Preferred
Stock is convertible) and showing in detail the facts upon which such adjustment or readjustment is based. The Corporation shall, as promptly as reasonably practicable after the written request at any time of any holder of Preferred Stock (but in
any event not later than ten (10)&nbsp;days thereafter), furnish or cause to be furnished to such holder a certificate setting forth (a)&nbsp;the Conversion Price applicable to such series of Preferred Stock then in effect, and (b)&nbsp;the number
of shares of Common Stock and the amount, if any, of other securities, cash or property which then would be received upon the conversion of such series of Preferred Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">4.10 <U>Notice of Record Date</U>. In the event: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(a) the Corporation shall take a record of the holders of its Common Stock (or other capital stock or securities at the time issuable upon
conversion of the Preferred Stock) for the purpose of entitling or enabling them to receive any dividend or other distribution, or to receive any right to subscribe for or purchase any shares of capital stock of any class or any other securities, or
to receive any other security; or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(b) of any capital reorganization of the Corporation, any reclassification of the Common
Stock of the Corporation, or any Deemed Liquidation Event; or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(c) of the voluntary or involuntary dissolution, liquidation or <FONT
STYLE="white-space:nowrap">winding-up</FONT> of the Corporation, </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">then, and in each such case, the Corporation will send or cause to be sent to the holders
of the Preferred Stock a notice specifying, as the case may be, (i)&nbsp;the record date for such dividend, distribution or right, and the amount and character of such dividend, distribution or right, or (ii)&nbsp;the effective date on which such
reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or <FONT STYLE="white-space:nowrap">winding-up</FONT> is proposed to take place, and the time, if any is to be fixed, as of which the holders of record of
Common Stock (or such other capital stock or securities at the time issuable upon the conversion of the Preferred Stock) shall be entitled to exchange their shares of Common Stock (or such other capital stock or securities) for securities or other
property deliverable upon such reorganization, reclassification, consolidation, merger, transfer, dissolution, liquidation or <FONT STYLE="white-space:nowrap">winding-up,</FONT> and the amount per share and character of such exchange applicable to
the Preferred Stock and the Common Stock. Such notice shall be sent at least ten (10)&nbsp;days prior to the record date or effective date for the event specified in such notice. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5. <U>Mandatory Conversion</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.1 <U>Trigger Events</U>. Upon either (a)&nbsp;the closing of the sale of shares of Common Stock to the public at a price per share of at
least 110% of the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Original Issue Price (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the Common
Stock prior to consummation of the public offering) in a firm-commitment underwritten public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, resulting in at least $75,000,000 of gross proceeds
to the Corporation and the Corporation&#146;s shares have been listed for trading on the New York Stock Exchange, NASDAQ Global Select Market or NASDAQ Global Market (a &#147;<B>Qualified IPO</B>&#148;) or (b)&nbsp;the date and time, or the
occurrence of an event, specified by vote or written consent of the Investor Majority, including the holders of a majority of each of the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock and the Series C Preferred Stock then
outstanding, each voting as a separate class on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis (the time of such closing or the date and time specified or the time of the event specified in such vote or written consent is referred to
herein as the &#147;<B>Mandatory Conversion Time</B>&#148;), then (i)&nbsp;all outstanding shares of Preferred Stock shall automatically be converted into shares of Common Stock, at the then effective conversion rate as calculated pursuant to
<U>Subsection 4.1.1</U> and (ii)&nbsp;such shares may not be reissued by the Corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">5.2 <U>Procedural Requirements</U>. All holders
of record of shares of Preferred Stock shall be sent written notice of the Mandatory Conversion Time and the place designated for mandatory conversion of all such shares of Preferred Stock pursuant to this <U>Section</U><U></U><U>&nbsp;5</U>. Such
notice need not be sent in advance of the occurrence of the Mandatory Conversion Time. Upon receipt of such notice, each holder of shares of Preferred Stock in certificated form shall surrender his, her or its certificate or certificates for all
such shares (or, if such holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation against any claim that may
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the Corporation at the place designated in such notice. If so required by the
Corporation, any certificates surrendered for conversion shall be endorsed or accompanied by written instrument or instruments of transfer, in form satisfactory to the Corporation, duly executed by the registered holder or by his, her or its
attorney duly authorized in writing. All rights with respect to the Preferred Stock converted pursuant to <U>Subsection 5.1</U>, including the rights, if any, to receive notices and vote (other than as a holder of Common Stock), will terminate at
the Mandatory Conversion Time (notwithstanding the failure of the holder or holders thereof to surrender any certificates at or prior to such time), except only the rights of the holders thereof, upon surrender of any certificate or certificates of
such holders (or lost certificate affidavit and agreement) therefor, to receive the items provided for in the next sentence of this <U>Subsection 5.2</U>. As soon as practicable after the Mandatory Conversion Time and, if applicable, the surrender
of any certificate or certificates (or lost certificate affidavit and agreement) for Preferred Stock, the Corporation shall (a)&nbsp;issue and deliver to such holder, or to his, her or its nominees, a certificate or certificates for the number of
full shares of Common Stock issuable on such conversion in accordance with the provisions hereof and (b)&nbsp;pay cash as provided in <U>Subsection</U><U></U><U>&nbsp;4.2</U> in lieu of any fraction of a share of Common Stock otherwise issuable upon
such conversion and the payment of any declared but unpaid dividends on the shares of Preferred Stock converted. Such converted Preferred Stock shall be retired and cancelled and may not be reissued as shares of such series, and the Corporation may
thereafter take such appropriate action (without the need for stockholder action) as may be necessary to reduce the authorized number of shares of Preferred Stock accordingly. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6. <U>Redemption</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.1
<U>General</U>. Unless prohibited by Delaware law governing distributions to stockholders, shares of each series of Preferred Stock shall be redeemed by the Corporation at a price equal to the Applicable Original Issue Price per share, plus the
Applicable Preferred Accruing Dividends that have accrued but remain unpaid thereon, whether or not declared, together with any other dividends declared but unpaid thereon<B> </B>(the &#147;<B>Redemption Price</B>&#148;), in three (3)&nbsp;annual
installments commencing not more than sixty (60)&nbsp;days after receipt by the Corporation at any time on or after the five year anniversary upon which this Amended and Restated Certificate of Incorporation is accepted for filing by the Secretary
of State of the State of Delaware, from the Investor Majority, of written notice requesting redemption of all shares of Preferred Stock (the &#147;<B>Redemption Request</B>&#148;). Upon receipt of a Redemption Request, the Corporation shall apply
all of its assets to any such redemption, and to no other corporate purpose, except to the extent prohibited by Delaware law governing distributions to stockholders. The date of each such installment shall be referred to as a &#147;<B>Redemption
Date.</B>&#148; On each Redemption Date, the Corporation shall redeem, on a pro rata basis in accordance with the number of shares of Preferred Stock owned by each holder, that number of outstanding shares of Preferred Stock determined by dividing
(i)&nbsp;the total number of shares of Preferred Stock outstanding immediately prior to such Redemption Date by (ii)&nbsp;the number of remaining Redemption Dates (including the Redemption Date to which such calculation applies); <I>provided</I>,
<I>however</I>, that Excluded Shares (as such term is defined in <U>Subsection 6.2</U>) shall not be redeemed and shall be excluded from the calculations set forth in this sentence. If on any Redemption Date, the Delaware law governing distributions
to stockholders prevents the Corporation from redeeming all shares of Preferred Stock to be redeemed, the Corporation shall ratably redeem the maximum number of shares that it may redeem consistent with such law, and shall redeem the remaining
shares as soon as it may lawfully do so under such law. Notwithstanding the foregoing, in the event of a redemption pursuant to this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<U>Section</U><U></U><U>&nbsp;6</U>, if the amounts available for distribution are not sufficient to redeem all outstanding shares of Preferred Stock, the Corporation shall first ratably redeem
each holder&#146;s shares of Series B Preferred Stock, Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock, Series C Preferred Stock and Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred Stock to the fullest extent of such
available amounts based on the respective amounts which would otherwise be payable in respect of the shares to be redeemed if the available amounts were sufficient to redeem all such shares, second, ratably redeem each holder&#146;s shares of Series
A Preferred Stock to the fullest extent of such remaining available amounts after the payment to holders of Series B Preferred Stock, Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock, Series C Preferred Stock and Series <FONT
STYLE="white-space:nowrap">C-1</FONT> Preferred Stock of all amounts owed thereto pursuant to this <U>Subsection 6.1</U> based on the respective amounts which would otherwise be payable in respect of the shares to be redeemed if the available
amounts were sufficient to redeem all such shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.2 <U>Redemption Notice</U>. The Corporation shall send written notice of the
mandatory redemption (the &#147;<B>Redemption Notice</B>&#148;) to each holder of record of Preferred Stock not less than forty (40)&nbsp;days prior to each Redemption Date. Each Redemption Notice shall state: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(a) the number of shares of Preferred Stock held by the holder that the Corporation shall redeem on the Redemption Date specified in the
Redemption Notice; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(b) the Redemption Date and the Redemption Price; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(c) the date upon which the holder&#146;s right to convert such shares terminates (as determined in accordance with <U>Subsection 4.1</U>);
and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">(d) for holders of shares in certificated form, that the holder is to surrender to the Corporation, in the manner and at the place
designated, his, her or its certificate or certificates representing the shares of Preferred Stock to be redeemed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the Corporation receives, on or
prior to the twentieth (20<SUP STYLE="font-size:85%; vertical-align:top">th</SUP>) day after the date of delivery of the Redemption Notice to a holder of Preferred Stock, written notice from such holder that such holder elects to be excluded from
the redemption provided in this <U>Section</U><U></U><U>&nbsp;6</U>, then the shares of Preferred Stock registered on the books of the Corporation in the name of such holder at the time of the Corporation&#146;s receipt of such notice shall
thereafter be &#147;<B>Excluded Shares</B>.&#148; Excluded Shares shall not be redeemed or redeemable pursuant to this <U>Section</U><U></U><U>&nbsp;6</U>, whether on such Redemption Date or thereafter. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.3 <U>Surrender of Certificates; Payment</U>. On or before the applicable Redemption Date, each holder of shares of Preferred Stock to be
redeemed on such Redemption Date, unless such holder has exercised his, her or its right to convert such shares as provided in <U>Section</U><U></U><U>&nbsp;4</U>, shall, if a holder of shares in certificated form, surrender the certificate or
certificates representing such shares (or, if such registered holder alleges that such certificate has been lost, stolen or destroyed, a lost certificate affidavit and agreement reasonably acceptable to the Corporation to indemnify the Corporation
against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate) to the Corporation, in the manner and at the place designated in the Redemption Notice, and thereupon the Redemption
Price for such shares shall be payable to the order of the person whose name appears on such certificate or certificates as the owner thereof. In the event less than all of the shares of Preferred Stock represented by a certificate are redeemed, a
new certificate, instrument, or book entry representing the unredeemed shares of Preferred Stock shall promptly be issued to such holder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.4 <U>Interest</U>. If any shares of Preferred Stock are not redeemed for any reason on
any Redemption Date, all such unredeemed shares shall remain outstanding and entitled to all the rights and preferences provided herein, and the Corporation shall pay interest on the Redemption Price applicable to such unredeemed shares at an
aggregate per annum rate equal to six percent (6%) (increased by one percent (1%) each three-month period following the Redemption Date until the Redemption Price, and any interest thereon, is paid in full), with such interest to accrue daily in
arrears and be compounded annually; provided, however, that in no event shall such interest exceed the maximum permitted rate of interest under applicable law (the &#147;<B>Maximum Permitted Rate</B>&#148;), provided, however, that the Corporation
shall take all such actions as may be necessary, including without limitation, making any applicable governmental filings, to cause the Maximum Permitted Rate to be the highest possible rate. In the event any provision hereof would result in the
rate of interest payable hereunder being in excess of the Maximum Permitted Rate, the amount of interest required to be paid hereunder shall automatically be reduced to eliminate such excess; provided, however, that any subsequent increase in the
Maximum Permitted Rate shall be retroactively effective to the applicable Redemption Date to the extent permitted by law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">6.5 <U>Rights
Subsequent to Redemption</U>. If the Redemption Notice shall have been duly given, and if on the applicable Redemption Date the Redemption Price payable upon redemption of the shares of Preferred Stock to be redeemed on such Redemption Date is paid
or tendered for payment or deposited with an independent payment agent so as to be available therefor in a timely manner, then notwithstanding that any certificates evidencing any of the shares of Preferred Stock so called for redemption shall not
have been surrendered, dividends with respect to such shares of Preferred Stock shall cease to accrue after such Redemption Date and all rights with respect to such shares shall forthwith after the Redemption Date terminate, except only the right of
the holders to receive the Redemption Price without interest upon surrender of any such certificate or certificates therefor. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.
<U>Redeemed or Otherwise Acquired Shares</U>. Any shares of Preferred Stock that are redeemed or otherwise acquired by the Corporation or any of its subsidiaries shall be automatically and immediately cancelled and retired and shall not be reissued,
sold or transferred. Neither the Corporation nor any of its subsidiaries may exercise any voting or other rights granted to the holders of Preferred Stock following redemption. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8. <U>Waiver</U>. Any of the rights, powers, preferences and other terms of the Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred
Stock set forth herein may be waived on behalf of all holders of such series of Preferred Stock by the affirmative written consent or vote of the holders of a majority of the shares of Series <FONT STYLE="white-space:nowrap">C-1</FONT> Preferred
Stock then outstanding. Any of the rights, powers, preferences and other terms of the Series C Preferred Stock set forth herein may be waived on behalf of all holders of such series of Preferred Stock by the affirmative written consent or vote of
the holders of a majority of the shares of Series C Preferred Stock then outstanding. Except as otherwise provided herein, any of the rights, powers, preferences and other terms of the Preferred Stock set forth herein may be waived on behalf of all
holders of Preferred Stock by the affirmative written consent or vote of the Investor Majority. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9. <U>Notices</U>. Any notice required or permitted by the provisions of this Article Fourth
to be given to a holder of shares of Preferred Stock shall be mailed, postage prepaid, to the post office address last shown on the records of the Corporation, or given by electronic communication in compliance with the provisions of the General
Corporation Law, and shall be deemed sent upon such mailing or electronic transmission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>FIFTH: </B>Subject to any additional vote
required by the Certificate of Incorporation or Bylaws, in furtherance and not in limitation of the powers conferred by statute, the Board is expressly authorized to make, repeal, alter, amend and rescind any or all of the Bylaws of the Corporation.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SIXTH: </B>Subject to any additional vote required by the Certificate of Incorporation, the number of directors of the Corporation
shall be determined in the manner set forth in the Bylaws of the Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>SEVENTH: </B>Elections of directors need not be by
written ballot unless the Bylaws of the Corporation shall so provide. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>EIGHTH: </B>Meetings of stockholders may be held within or
without the State of Delaware, as the Bylaws of the Corporation may provide. The books of the Corporation may be kept outside the State of Delaware at such place or places as may be designated from time to time by the Board or in the Bylaws of the
Corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>NINTH: </B>To the fullest extent permitted by law, a director of the Corporation shall not be personally liable to the
Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director. If the General Corporation Law or any other law of the State of Delaware is amended after approval by the stockholders of this Article Ninth to
authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director of the Corporation shall be eliminated or limited to the fullest extent permitted by the General Corporation Law as so
amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any repeal or modification of the foregoing provisions of this Article Ninth by the stockholders of the Corporation shall not
adversely affect any right or protection of a director of the Corporation existing at the time of, or increase the liability of any director of the Corporation with respect to any acts or omissions of such director occurring prior to, such repeal or
modification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>TENTH: </B>To the fullest extent permitted by applicable law, the Corporation is authorized to provide indemnification
of (and advancement of expenses to) directors, officers and agents of the Corporation (and any other persons to which General Corporation Law permits the Corporation to provide indemnification) through Bylaw provisions, agreements with such agents
or other persons, vote of stockholders or disinterested directors or otherwise, in excess of the indemnification and advancement otherwise permitted by <U>Section</U><U></U><U>&nbsp;145</U> of the General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">Any amendment, repeal or modification of the foregoing provisions of this Article Tenth shall not adversely affect any right or protection of
any director, officer or other agent of the Corporation existing at the time of such amendment, repeal or modification. The rights provided hereunder shall inure to the benefit of any indemnified person and such person&#146;s heirs, executors and
administrators. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>ELEVENTH: </B>The Corporation renounces, to the fullest extent permitted by law, any
interest or expectancy of the Corporation in, or in being offered an opportunity to participate in, any Excluded Opportunity. An &#147;<B>Excluded Opportunity</B>&#148; is any matter, transaction or interest that is presented to, or acquired,
created or developed by, or which otherwise comes into the possession of (i)&nbsp;any director of the Corporation who is not an employee of the Corporation or any of its subsidiaries, or (ii)&nbsp;any holder of Preferred Stock or any of its
affiliates or any of their partners, members, directors, stockholders, employees or agents, other than someone who is an employee of the Corporation or any of its subsidiaries (collectively, &#147;<B>Covered Persons</B>&#148;), unless such matter,
transaction or interest is presented to, or acquired, created or developed by, or otherwise comes into the possession of, a Covered Person expressly and solely in such Covered Person&#146;s capacity as a director of the Corporation while such
Covered Person is performing services in such capacity. Any repeal or modification of this Article Eleventh will only be prospective and will not affect the rights under this Article Eleventh in effect at the time of the occurrence of any actions or
omissions to act giving rise to liability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>TWELFTH: </B>Unless the Corporation consents in writing to the selection of an alternative
forum, the Court of Chancery in the State of Delaware shall be the sole and exclusive forum for any stockholder (including a beneficial owner) to bring (i)&nbsp;any derivative action or proceeding brought on behalf of the Corporation, (ii)&nbsp;any
action asserting a claim of breach of fiduciary duty owed by any director, officer or other employee of the Corporation to the Corporation or the Corporation&#146;s stockholders, (iii)&nbsp;any action asserting a claim against the Corporation, its
directors, officers or employees arising pursuant to any provision of the Delaware General Corporation Law or the Corporation&#146;s certificate of incorporation or bylaws or (iv)&nbsp;any action asserting a claim against the Corporation, its
directors, officers or employees governed by the internal affairs doctrine, except for, as to each of (i)&nbsp;through (iv) above, any claim as to which the Court of Chancery determines that there is an indispensable party not subject to the
jurisdiction of the Court of Chancery (and the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination), which is vested in the exclusive jurisdiction of a court or
forum other than the Court of Chancery, or for which the Court of Chancery does not have subject matter jurisdiction. If any provision or provisions of this Article Twelfth shall be held to be invalid, illegal or unenforceable as applied to any
person or entity or circumstance for any reason whatsoever, then, to the fullest extent permitted by law, the validity, legality and enforceability of such provisions in any other circumstance and of the remaining provisions of this Article Twelfth
(including, without limitation, each portion of any sentence of this Article Twelfth containing any such provision held to be invalid, illegal or unenforceable that is not itself held to be invalid, illegal or unenforceable) and the application of
such provision to other persons or entities and circumstances shall not in any way be affected or impaired thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">*
&nbsp;&nbsp;&nbsp;&nbsp;*&nbsp;&nbsp;&nbsp;&nbsp; * </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>3.</B> That the foregoing amendment and restatement was approved by the holders of the
requisite number of shares of this corporation in accordance with Section&nbsp;228 of the General Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman"><B>4.</B> That this
Amended and Restated Certificate of Incorporation, which restates and integrates and further amends the provisions of this Corporation&#146;s Certificate of Incorporation, has been duly adopted in accordance with Sections 242 and 245 of the General
Corporation Law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Follows</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>IN WITNESS WHEREOF</B>, this Amended and Restated Certificate of Incorporation has been
executed by a duly authorized officer of this corporation on this 24th day of July, 2020. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marcio Souza</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Marcio Souza</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President&nbsp;&amp; Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>C<SMALL>ERTIFICATE</SMALL> <SMALL>OF</SMALL> A<SMALL>MENDMENT</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><SMALL>TO</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>A<SMALL>MENDED</SMALL> <SMALL>AND</SMALL> R<SMALL>ESTATED</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>C<SMALL>ERTIFICATE</SMALL> <SMALL>OF</SMALL> I<SMALL>NCORPORATION</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><SMALL>OF</SMALL> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>P<SMALL>RAXIS</SMALL> P<SMALL>RECISION</SMALL> M<SMALL>EDICINES</SMALL>, I<SMALL>NC</SMALL>. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Praxis Precision Medicines, Inc. (the &#147;<B>Corporation</B>&#148;), a corporation organized and existing under and by virtue of the
provisions of the General Corporation Law of the State of Delaware (the &#147;<B>General Corporation Law</B>&#148;), does hereby certify, </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>O<SMALL>NE</SMALL>:</B> That the name of this corporation is Praxis Precision Medicines, Inc., and that this corporation was originally
incorporated pursuant to the General Corporation Law on September&nbsp;22, 2015 under the name EpiPM Therapeutics, Inc. This corporation filed with the Secretary of State of the State of Delaware an Amended and Restated Certificate of Incorporation
on July&nbsp;24, 2020, as amended by the Certificate of Amendment filed with the Secretary of State of the State of Delaware on September&nbsp;2, 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>T<SMALL>WO</SMALL>:</B> The Board of Directors of the Corporation, acting in accordance with the provisions of Sections&nbsp;141 and 242 of
the General Corporation Law, adopted resolutions amending its Amended and Restated Certificate of Incorporation, as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B></B>That the following is hereby inserted into Article FOURTH immediately before the first sentence therein:
</P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Effective upon the filing of this Certificate of Amendment of the Amended and Restated Certificate
of Incorporation with the Secretary of State of the State of Delaware (the &#147;Effective Time&#148;), every 2.14 shares of Common Stock then issued and outstanding or held in the treasury of the Corporation immediately prior to the Effective Time
shall automatically be combined into one (1)&nbsp;share of Common Stock, without any further action by the holders of such shares (the &#147;Reverse Stock Split&#148;). The Reverse Stock Split will be effected on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">holder-by-holder</FONT></FONT> basis, and any fractional shares resulting from such combination shall be rounded down to the nearest whole share on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">holder-by-holder</FONT></FONT> basis. No fractional shares shall be issued in connection with the Reverse Stock Split. In lieu of any fractional shares to which a holder would
otherwise be entitled, the Corporation shall pay cash equal to such fraction multiplied by the fair market value of a share of Common Stock as determined in good faith by the Corporation&#146;s Board of Directors. The Reverse Stock Split shall occur
automatically without any further action by the holders of the shares of Common Stock and Preferred Stock affected thereby. All rights, preferences and privileges of the Common Stock and the Preferred Stock shall be appropriately adjusted to reflect
the Reverse Stock Split in accordance with this Amended and Restated Certificate of Incorporation.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>T<SMALL>HREE</SMALL></B><SMALL><B></B></SMALL><B>: </B>All other provisions of the Corporation&#146;s Amended and Restated Certificate of
Incorporation will remain in full force and effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>F<SMALL>OUR</SMALL>:</B> Thereafter, pursuant to a&nbsp;resolution of the Board of
Directors, this Certificate of Amendment was submitted to the stockholders of the Corporation for their approval and was duly adopted in accordance with the provisions of Sections&nbsp;228 and 242 of the General Corporation Law. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>[R<SMALL>EMAINDER</SMALL> <SMALL>OF</SMALL> P<SMALL>AGE</SMALL> I<SMALL>NTENTIONALLY</SMALL> L<SMALL>EFT</SMALL> B<SMALL>LANK</SMALL>]
</B></P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>I<SMALL>N</SMALL> W<SMALL>ITNESS</SMALL> W<SMALL>HEREOF</SMALL></B><SMALL></SMALL>, said
corporation has caused this Certificate of Amendment to Amended and Restated Certificate of Incorporation to be signed by its duly authorized officer on October&nbsp;8, 2020. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>P<SMALL>RAXIS</SMALL> P<SMALL>RECISION</SMALL> M<SMALL>EDICINES</SMALL>, I<SMALL>NC</SMALL>.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD COLSPAN="3" VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marcio Souza</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marcio Souza</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">President&nbsp;&amp; Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d945651dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g945651dsp01.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwin Procter <SMALL>LLP</SMALL></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 Northern
Avenue <BR>Boston, MA 02210</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">goodwinlaw.com</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 617 570 1000</P>
<P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="right">October&nbsp;15,
2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Praxis Precision Medicines, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One Broadway, 16<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cambridge, Massachusetts 02142 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Re:&nbsp;&nbsp;&nbsp;&nbsp;<U>Securities Registered under Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT></U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have acted as counsel
to you in connection with your filing of a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-249074)</FONT> (as amended or supplemented, the &#147;Registration
Statement&#148;) pursuant to the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), relating to the registration of the offering by Praxis Precision Medicines, Inc., a Delaware corporation (the &#147;Company&#148;) of up to
11,500,000 shares (the &#147;Shares&#148;) of the Company&#146;s Common Stock, $0.0001 par value per share, including Shares purchasable by the underwriters upon their exercise of an over-allotment option granted to the underwriters by the Company.
The Shares are being sold to the several underwriters named in, and pursuant to, an underwriting agreement among the Company and such underwriters (the &#147;Underwriting Agreement&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinions set forth below. We have
relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinions set forth below, on certificates of officers of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The opinion set forth below is limited to the Delaware General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, upon issuance and delivery against payment
therefor in accordance with the terms of the Underwriting Agreement, the Shares will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Registration Statement and to the references to our firm under the
caption &#147;Legal Matters&#148; in the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations
thereunder. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Goodwin Procter LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GOODWIN PROCTER <SMALL>LLP</SMALL></TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>d945651dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Consent of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Experts&#148; and to the use of our report dated July&nbsp;22, 2020, except for Note 17, as to
which the date is October&nbsp;9, 2020, in Amendment No.&nbsp;2 to the Registration Statement (Form <FONT STYLE="white-space:nowrap">S-1</FONT> <FONT STYLE="white-space:nowrap">No.&nbsp;333-249074)</FONT> and related Prospectus of Praxis Precision
Medicines, Inc. dated October&nbsp;15, 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst &amp; Young LLP </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, Massachusetts </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October&nbsp;15, 2020 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g945651dsp01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651dsp01.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M<T"U\-Z+#IML,A.6<CEV[DT >3_$/P;J\GBZ>[TRTFF@OU#.8UR%;@$'\@:
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ML%PQ18+ABBP7#%%@N&*+!<,46"X8HL%PQ18+ABBP7 #%,0M !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g945651g03e59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g03e59.jpg
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M='BW&3(S<;)UD[&X)D)#15-C@8*8I>7_Q  = 0$!  (# 0$!
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M^D15%N[9O1]%ZL0;WWM_?RMN[O%5=Y/&)^_\-/\ ]UU']-G*O@_U<2_.I?\
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MCHJ2CJS,'!H:UPK(I0S<()!C#2[>(=< 6J[Z$W=_^EK;?Z*.,_JGG)]:H?\
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M/D:QF(2;L-0^JC<R68L?3 -!@C)<-\N!Z2\0#72.>-QP=<6NS>\GH?2-.V#
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M[2-?=U\_CL!SVTO76F0-E*":CS)$5U)X0[RR11Y$$LB.D4!$N-,.% ;.$(4
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M:^>MGIJS%*!SZI['8I'%28C4Q4,>,- O'B8PX4CJMKVMDD>[IG$F3>=*>O\
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M8=AF#/V9H*K!L#P9N%X2RJH8\3?2TS2>GB?/5,GF<^<,B?+),\MF<W>E+BT
M>%;9T&%85M/CNT..8=M&S":[ *2IAKME78M!$W&L/DQ$U=7BOT//"(<1BI)*
M+Z/KL1#</; RH;+)O,=;T!XX5:#N!<X.NIXLI:C>8UPR<D@GQ2ASC2J\,^LI
M)0.U E./H<0X^2"I0)#ZG7@U*&6UO??J9CXZ>&.1K6OCB8QS6 !K2UH;N@-
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M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%Y]>),@O5X<:D=0E5E9:
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ME"-:2G7EWO?DUK6O+O>;#$"2W#B22?HZ+,YG^_5"ZYLT V7:8- :!M/6V
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ML'!!M^&5VJ2_(4&O=/M<\JIF0ESD6JP9%A[@GD3ISEL=.MC@-K!DCP(Y%9%
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M7/B;\K!6VO7F.H_).6G#B5,^N^#KM?3^/<[HB9?FU?.JU=AZ;"URLZ3#5'D
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MK6O:OP:UK6M:U]C%SU=P\DL.OO/FOWW8 ^.V+Y567YUQ<]7</)+#K[SYI[L
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MK:H&?0$6T:]'K?=&==E X<E]<CE_"WC[N-EW[GB1HK!GL\B)N;!X)#0UK%7
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M8*X=9VTRFLK#2P&33>YOF0#;AQY<%B21GKF1:W;;A?D>SO5:1MS?DK\#. ]
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MW_HW\.L(F]:WY/+K6_)ORZ\NO+Y-Z^IO7V-Z^SA%^X1,(F$3")A$PBA_0_W
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MD+MKLE%JEO;%<F8T"R5=BTUAMV"K=EJY DQ"+E8EZ6$D +,04WL63AC8Z2!
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',(F$3"+_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g945651g04r05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g04r05.jpg
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M 0$! 0'_P  1"  : !L# 1$  A$! Q$!_\0 &    P$!
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M\>.@G(1HEQU1$10S:55"J-$Z\  ?IQS_ /4JA1H<X6JM&E4IUEM,JUZE:&O
MJ]PCI$4*)&!KQH+K7&_W9YCLCFN%,L?G,KG,^==AI/<FTE'651=O-#+(R*:S
M) %@F/EB9]8Y"GRO8WZM5$_7150CC2NA1$0LH+%552QU[L0!O_?&Q/37&8VC
IRMCYJ./HTY;4*O:EJU(*\EEU)"M.\,:-,RCP&D+$#P#PU'3WBP./_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g945651g05p78.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g05p78.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[23J4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ),Z^E"(X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   (    X
M0DE-!"4      !#'71?E=+5N]=N^.93 Z7E<.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
M0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O
M;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M        4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U
M8D!OX            $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M                0FQD(%5N=$8C4FQT                4G-L=%5N=$8C
M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE- _(
M      H  /_______P  .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             \(   =D          $                          0
M           '9    \(                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   \(     4F=H=&QO;F<   =D    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   /"
M     %)G:'1L;VYG   '9     -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !#A"24T$#      :20    $   "@    40   >
M )?@   :+0 8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN
M=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M           !  #VU@ !     -,M2% @(
M                                    $6-P<G0   %0    ,V1E<V,
M  &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8    %&=8
M65H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
MB'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,
M    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,
M  0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C
M:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M            $G-21T(@245#-C$Y-C8M,BXQ
M                                          !865H@        \U$
M 0    $6S%A96B                      6%E:(        &^B   X]0
M Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/9&5S
M8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6245#
M(&AT=' Z+R]W=W<N:65C+F-H
M                         &1E<V,         +DE%0R V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%
M0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M                          !D97-C         "Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F
M97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                            =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,
M  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S          $
M                       "CP    )S:6<@     $-25"!C=7)V
M!      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &,
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M9$!DE&3I93UEDF7G9CUFDF;H9SUGDV?I:#]HEFCL:4-IFFGQ
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( 30"70,!$0 "$0$#$0'_Q  >  $  04! 0$!            " 0%!@<)
M P$""O_$ &L0   & 0($ @,)!PT,!@<##0$" P0%!@< $0@2$R$4,14600D7
M(E%389&6T2-7<8&2T_ D,C,W.%18=Z&QM\'7)34V.4)2=GBBM;;A&#1B<W7Q
M)T-%1F-R=":DM!DH1%:"A8>3HZ>RL\3_Q  = 0$  04! 0$
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MZ]4-(K)*1LP_F6[SY]Z=XV.A[/&^VA[>84I:3ZWUK/.9F<ACRXK5G(=CJL]
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M:5TDCM]W/)=;709@&@VTV7T;1TU'11,HZ:GBI*..PCI:.**GA9VB*,1LN>)
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M./X^>C[T-YSC>\OQ))AI8'<PR&1I:%U1@H::-'O7Z;6'5;0CFN(R:2D/!&@
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M3I[<I ,0\A[M=>-^WS>_AWJ;7Y^/=[[Z+P+C>V=)@(Y4L(K+..F\-X&J"F=
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ML=NFB4P\YDB$1("YTSBF4@*G_51SH@!2<9H12/G9'6!S8C<9F9LY<XL !L;
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MFAT=H+'0VY\CIW7 &O:OAI-(A3*'.0I2 8YSB)2E*4"B)C&,(@!0 H"(B(@
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M#\+S'X7S>7S#Y!Y=NP[+2TS#&[:V4 @6N;CZ^/N6+<]PJ(AS-[W]UAS  T_
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MV>=1PT5N6@_#X;>\#;XW7Z)C6SBHR*?*5E$BC=0[T"L:IU#KE*CR&:#Z [(
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M4Z@AOWU2==-[D[#LXZ\CN.Y2M?S!D_#+"L"G2"QB3E 1 >D#L53FVW#N)NN
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M*(B! Y4G3=3<1Y@"K@.\\.QI\GGX*.)[A\W*4C8[\&\. -FA&ZBK-)B@HX4
MZ9A](>)%79 P\KU$ZP&'<W3(X;'3*)A[4WW[.R_#A;M^H[I7X%5ZD1\7PS4
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M$DW3%XHT.!0V;MQCF(I$2 "E 2D%,[@PF$3"HG^N#N K<^WN/N^5_?JB^(F
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M@*X$]I-&0.\V*EO!_P#4T>W^23O^,?;YC^'YN^MIE^U[W?-81FPMR=];_!0
MXS4E%).*Y$U#[/G&_*4Q@#>)B@]@#V_#VWWU6[^(AO\ ]9;;<N.Y^7;R"H81
MUDH.Y#+> 6E^'9)1.1F^=,Y-Y"OB',4Q=]@E=]MP#RW#?XO;K)8?81SW(^P
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MYA[/,-5--NRVMK]G#3E?E<6V-E2Z_+E8Z:<+7T(U-_O!(&D+!6A/SB"??ON
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M;/3D&G?(V:>HE]5?8&:"%T_J\=03EG$/7L+HY&KH="X\Z+(@&1#F'XRB'8
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M;\+5AMAIOIO[OEPUL/BMFQ,=RB4 +[0\@^+V;?$ ]_Q;=]1WZDZJI;6AF?3
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M@$JB#MI1XEM+.&YRB)134G3F,'<YU!WYIS ;-\0XW[[[\U%M[VOW@>&O#8^
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MV+%LX>.UC<J;=HW7<*B1))0Q8S-Y]FQMX[<$L>.G:=M1MV&U^W;0+ 9#W/\
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M;=]MO(!#?YN^EQIJ;\-]^T"WA]ZBV^@L1H=QIO8G:^N_'3M6:L*0!.4.AML
M;[E'F#;R\_+XO/?OJ,X&VVP%M^XWT&U]-/E.6^N8:D^^^^W'?3;W+-&%2Y>7
M[F/L#L7OMY=^P_'OY?@$?;!>?PUTOV\[#@1V[! T VTOV\>X [=YX;+-&-<
MFWP-OB^#\>VX?0/Q_P ^J2[3AOR/'LV!YDW.N_*K+K<F_+A;LT^@'SOFD?!B
M'+L3RV#N'Z 'S[>W8?/<0I.N_P"_O-[\MOWU+.8Z)Z>PB4 $.VXAN'?X@\_P
M>WYQU6 3J=B;'A?GL..W>O-S@=!KQOMMR^?=XC-F+3DV'E\O(!#V[>?\O?M\
M7M#O)-MMB+;_ !M;EQ/ A4C6VH%M1>_,?#<^-[;K+42<B92_-OKS7HW:_/NV
M'=L.RYMS7U5,%2B4?Q?,.BDB_P"Z]QR.WS5E<Q@G$?@[_$)0 ?Q]_GW\]NWG
MW'4WTL1VZ:?AQY<N LO,@CL&QN>7#3?2V@X[;&U@<P/4W 4MP'?S#L/8?8/;
M_P _BU42TCM(VVY:;VU-SQWYZ&+$=X-KW!X^/9IR(MNL?=5(#[_<AWW\^P_&
M(^?,/S;;_-J+ V%^SCS[2.>N@.EP+7*J#CKII8DZ$'Q ^-MN2L#FC<^^R7L'
ML!/Y=QWW^/L'GN'X9 .OM:<3>^N^_9IJ+VT XV9]KCWW\;6VX@:WXJPKX^,8
M^_APV$?B#XOG#;[!_#J;.T-QXW-OCO:^F_RF[2+'APL1;S?Q7A[WAOWL';;_
M "0^GR[[_-\?;V:B[N!N1PL;\N('OO\ 1+,M?A[T][L_[W_D+]GS_CT&8['Y
MZV]W;Q]ZBS/-^/[B@8[-^]_Y _K#YO+\>I.;G\"/_A4V9]-+GY=_TX(&.S[[
M>&W'XN4/L^D/8'TZB[C;7GPV[Q;[_%+,\WU[N?N^H5(OBULY[+,$SB/MY0 1
M_& !O\WQ[[]_/4ASQQ&EM;C7LN/'F-R0GL6VY\#MSY^_O'-0RPSB*.=\4W&F
MR,RW]'2W#X!4P*41)XO$9%S!W[_"-WV\NVXAW#59>ZP(.NM]2=+V!%N X^0J
M-!?46U N#]+:ZC7P4P$,.Q[<?@1Q1$-MN8 _%Y 'Z>S5!<_<FW"YOW6X[:Z'
MMW"J]CAPUM8D=NECOI<]BNQ,<<A0*1H4A0_R2D*4 V';RV_%N/??47=K[7;Q
MVMN-#P/?QX*;,Y<;:7M?D+:>"_7O=GW[M]OQ%[?$'</Z]]N^EW<^/&_*YX7T
M'9R[Q%F<O_%W?/18/DS'^0RX]N9,3M8@,F.Z^_CZ*ZGS%+!Q%EDDQCXNP3*0
MAS/(JM.')9^1C$MG4LTC58QH(.G:(Z7<1J=.5[$CG<[CAQ4G*-M-;7U(T(-N
M_P"[<*#V,N%#B7P0V@<6Q3OUJPC 6:5F($,.R,'C^T1BMKCJPX:-)@N6YR\/
MI2J5>^P^3+W>Q]:W\U;WV7H!*-A)B*IDO69!K;@>(N3M8\#;;?;Q"INWC<'8
M@W/'77>Y^\:7NJ6#X:.,ZKP3_P!2IUM'V>-9UZH-Y#(<O4+.[MC-]?N)F%L%
MH<65"-F9\8"AUW)V(,U4FMRZK-Y*2N.I;'JD36_7*Q.', :7&FHMJ ;:]H4D
MM^!OWW!XW&X[1[E6GP%QF2V79"?LSRP*XJKF::E8ZS4ZW:ZI&3,C5F,AFNI2
MRJ,BO83HSM>=4RS8=LLY"V%O0A.[K5K:15,D;.T0G\@1K]-+=G+OMK]ZF[>8
M]Y[==]MM+=E^"QEAP^^Z#,*7"UB*LC>N6R,H%6B%;!#OL5-\;,89CPU5RKKU
M:I4\*FLO%92B.)I"6O!+([KZN/EL:$7@T'SIJ^A*'5IUU[P2;VV[2;;FYY$]
MP4>SO<<;"PTUWT%^5K]NJG]C/$MP@:LM#W60>3\DQMU_)$2TF[:2$HXI"MYL
M+C'R4J_:M&9'DBRI"T P=.7")I)8[45)5V_E!>/W,^US U))&U^VW=Q ))V*
M#*>T<-#<Z#B-3;6_+3;19][W9OWN'T%_K#^;8/;\>[VM?:';OI?3ES'#;N*F
MS--.[1VO'WKX;'(F 0,V 0]I1*40[AY;"'?L/S_3H2[^E?NOVCEQ[./<@R:V
M]_VOCRV6//\ "D>_W$S(I##W[$ Q?P[=OB'?O\0#[-5![A?46VTOKOSX::FP
MT!U*@AO:-^'/O':+ ;;]JA&I@9DIQW+Q'22$#<(+:3 HDV^'[]KIK^MV[_!]
MOZ!Z"0V^R ;VL"+:ZCC^.NW.FS23O87VO>WPL01RTYJ733AY8("!C()B ;"/
M*3<0\O8.P;[_ ,OSZCK7&]Q8C4D_4V\-"2@:W2UP#P(W]X^/S68,L2-&!0Z+
M$O,'^6)0$?BWVV$ #MY^0>P?C\RYQU%]^ .O>2-?.G*OV!H>7$;"W<+?._:K
MI[W9_P![?R![>_Q?%[?+MJ"7<3R\VM<<;Z;@\0EF'R?-^S=??>Z/^]@^@OX/
MB^/M^'2[C^D-^1&NNFVO=W*/8\YD][L_?9MY>?P0\_P;?;OMV^+2[MKG[[&V
MAMS[OBEF>;]_R7SWNS_O8.WQ@&WX-]MO8/EW\_B[/:O:YTY7MV;#CS2S+7]W
M%/>\-^]P^@ W^D/^7;\.GM<_GQT'#CP[=[%+,Y?^+AOX)[W9_+PW^R'?<?P;
M?1\^_D.EW;W&ONYWW L1Q.G#79+,Y=OZ6W-/>[-^]P^@OM_%^@:7=:]QQX<K
M]G9YNEF<NS]+?DGO=GV_ZM_LAO\ 1R[^P?9\>EW$[\.RP[^'C\QHLSZ?I)[W
M9OWL'M]@?%\P>S^?M\VI&<\?=^ !YZC?:XV2S/.;CLGO=F_>X#^(OT]@[;>?
MQ?'J,SAK??;3X[6^NW"RFS#?3;?[7F_9NH74VBB;W1'B/9 @',EP8\%CKEV#
ML"^;N/9(1\MOA>'#XO(//4W=8:VM?F=+#4[\U2 VYOMH ->-_??3SPFC[W9O
M+P_^R&WT[;?\^VH]H#5P'?W]U^\<.*JLSE_XN_Y)[W9NX>&#?S\@W#^3;V>6
MVAS#<^_AMW:_?MK=1[!\GG^/%/>[/^]P\_8 >WV>7Z>W4^V3:]CV]G#;?6_=
M8\D]CSF3WNS?O<._EV+\?X/T[_%J/;UUV^.MN\W(X_(I9G+_ ,7?\M4][LW;
M]3_@W*']9?Y?ITL_:_/B>&G?Q!Y6-T]CS?O[O=[E]][L_GX;_9#XM_:'Q=_I
MTN[7VM.=KCER/D]Z>QYS+Y[W9P\VW^R'Q_,'G\WGYZ7=_2'#SH#]QX7" ,.W
MU\V[=@GO='_>W^R'S?-\X:>T1OQMQX^[8WT[QMP69YS+[[W9^_ZFWV^(H#_,
M'G\W?S]G;3VCQ/'C;C;LXVMW\-4_-^<RX;^[<5 8FE</IS)BD*UHR 0!  #?
MEB:L;;RV';F =>D;B"0;.M:W9OQLH=8 93H;WU/=MXJQ^X@5(9:/XEA*F*O0
M>XA+N/*(AU$,FC\7MZ?\GGI(2XBVEP1QYCL[?=SU4-MKFVY?N\GW+O'[W9A[
M>'#Z"_@^+7G=PMK>Y[21;>]Q?W*NS.7+^EQV3WNS]OU/Y_\ 9#[/F[?'[-"7
MVO?3LMQ /+M\5%F>'ZR^^]V?;?P_;V=B^7T!\WL^C0EW/?YWM:]M-CQ TXW4
MV9>UM>5G?)0]SOP;91RS?FN0JSE-A1WF.JW6@PY GK+"78I7>*O<7D2S2=NF
M'<>K,QL)>WE,Q[19YM5S'D$Z+&6ANDX5&VOHY-OW\-;;]A(-G#6XMOQX02+Z
M<.78-Q8\ =;Z6'9KK&R\"&8YY.OOCST&K>*C>\AS#'(SS-V<3R-F97O&>9:4
MWN[FIFAUJWCRY5F9O]2DV5,IWCJLO$5DU>C[+7J[&UF BUG6[B #?:QMSY^&
MJ7W OJ-M+F^NXO?3S=5N2>"'B/LS#(477\[/31,_9D#TB/<7*[5*8IU4G(N]
MV2ZJDM\?&6WQEB3R_;X)_4V\E59:.A<68\K]%K;RE2[I"UU][5]^_6WB=+VU
M&Y(L;(2WEOQ]G0WY;>_NU*\&W KG",D,EN8:_P 7'H7:P2%RD$V>1LJ19\@3
M,W*\,DS/P%E-&,$%<?,)9MB#*U$+;*6YFY:+J^5O2,= I%;OJJO%G"_#>^OA
MMMV'B#R4EP[P;:=EKG74'E;GMKJLUH'!=E>"M]<NMER7*.W$"O55(NJL\D95
MGJU6()/(/$19;71T$YMXS97I@C2LJXVQ[#VRXU].<FF>*XB4>QU;&*K<;%3J
M/CL=3H?:O>YY\>(TV,7&YTUXV/$<.%@+'8VL=20IJCCL^XB+8//<>P>WX^W8
M-+NTL;WU%KGLV(O8=ONXI[!\D;?! QV?O^IO(/\ -#Z?(/9[>X:7=SWVL#KW
M&WFUN2$,'D_'E[U;7N)FSXH@NQ+S#YF H .W;S#8 $/C'\/?SU4"]NQ!OQN=
M-+ZFXTMJGL$[G7O/S!/D**O%E@ABTX:>(*1*@0G@<-9)>!S)["!F]0EU0\@'
M;X1.P_'M\8:].L((YDZFW/0:\>7 Z'AH8+6D:'QTVU[+$>>8B-[D_A1I8^$N
M)EU$DC&-?;LW$1)S#]Q>-.W8O?8# /D'GYCH^0@D 7%N-AMO:XUT[]SHH#00
M.>MM#W 7V%S\ -EU.C\)1[ 0$&93B'LY * "'Q^?]6_X=4%[SMQ!''< DBVG
M:-CMJJK,&YX7\?=[[;\]%DA<<B4NQ&I2E#L  4H 'XMNWX1[C\^J+NM]KN[;
MW-M1>_WCFI(9L=QW\!;ARM[M>U?KWNS?O</H+]FEW#2]N^_#O'GCH@##L+_M
M)[W9OWN'Q>0?S[?,/G]FGM[W.QYZ6'=QX'XJ/8\WX^=@GO=F_>_E\P?S;=_T
M]NEW<]C]0#PX7]W@ILSEOV$\_#8I[W9_WO\ [)?,-NWE\_LW^+0YA^EK>UM=
M].8[M2HLSEV_I;:Z^(\Z*K0Q^8NVZ  &_P 0[!] #^+\.P?-%G7!UN=M=>[6
MQ^BF[;: $#LOR WMOW\%=T**)=MT=N_L)^#S'V!MV'^;55R0+N UT.HO;P%A
MIP^.A9P-AIQU'OMS\\-5=D:<!?-(0V^;L'Q]MN^_X1#X^^HX@D[Z\3;4=H.H
MVOK;2U[*,VOLB^PX_N%KZ]ZO*%7(GM]R[_/_ #>8_-MV_!M['LW\+<OB3\;<
M-"%&9QVL!QL.?/CSN1]RO",'R@'W/R]G+O[//R -MP'R\ATS#M)MN>)]YN+&
MQT*!I)-K=][_ "YWXC579&+$FWW,?(/UW;[-_+L'T^>HS'L.@%R._P"^W:$R
M@WU-@3L#;<;#7SV"YNZ34I-A';?XOQ_U_-]'?5*J:TC?3LWUTU]VO#WFP*J]
M%6FB)HB:(O@@ ^8 /X0#118<AIMV+YR$_P TOY(?9HEAR'@OG33^3)^27[-$
ML.0\$Z:?R9/R2_9HEAR'@$Z:?R9/R"_9HEAR'@G33^3)^27[-$L.0\ G33^3
M)^27[-$L.0\ O%RU:N$%FSA),R#A)1!8@AR\Z2I!34)S%Y3!S$,(;E$#!ON
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M@ #N8P!L.H N0-!<VN=AW]BE:;QKE1]<YY6(=!!.TE:^G8$7, =V<D;S.&Z
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M@]8-=H7'4T1-$31$T1-$31$T1-$31$T101HW^,TXG?B_Z#? Y_3Q[H)_RU/
M=Y^35'$]P^;E.[4*4T1-$31$T1-$46<HLJO WJ.=1E=EK1;) "W%Y7 LZ5?J
M:98=RR8MIV:46:R"P/7#L$4XR/8,W!95U'N7+I B+%V\3R] *ZKADHH)F,@T
MSYVDVZS,0S,R-[VM?U;KWLS0@F[@'8?$'8=1S15]3'FG;[,;FF[@&VN0QTC&
MN<T/&UWV-Q<#2+^=B7!Z,EQ(T:2J,13+! Q58OS'(]CBZB^I5@HD_8:\ C.O
M DJ[)5]Q)2"K-PV0>)KL))@>5KY+66U"VB_$TT1/Y/K&U#98)Y71^K1MGZQT
M[86.8Z(S0:$0QN8\.+B'%KF"S2,%T@PFLQV.EK<*Q*"B'56E-1"9(WT]S('-
M.N1["XES7,L;"[FY3FWCPL-Z_'83B6D!D"K9'7-.6^9LD[3)D)FOL[5;++)W
M&9@6*X@BX2)#*SR;,#/8^&?R8%">>PT6YEE&B7G5YQ.\/B? 6LAC;',+2,CA
M@CB87@AI<]\<;7.(:&N>21HM@PRF91X?1TC:@U;:>%L9J"1>=S;YY-"YHS/+
MR&@G*/9X7-RS+1&.3:A,4Z1D)"+1E6;]@$C&&1!ZU3E(Q]#O12!PFJB85X^1
M>-S HF;8JW.02' IR^-/424LK9HPTN:"+. <TAP(-P>P]A'>KR2!M1"Z)Y<&
MN+77:2UP<UP<"".%P+\]0;@V7*&2L&9G-%KV3+)/41>B4J:@\D%<,G4DC9[?
M4Z382S<-,MZ>I!LXRH33R/BXRYH5ES;[HB)D5J.YE6)Y!6U162A;0FN?3LCG
M9/5QAI>"U\4+ZAC)I(FN<<Y:YKC")7 B-QN6S "8<HIXH,*Z0MGEQ.HJHX*R
M6"CHWQPP=3/,7TD?6&,F2J##*61 MC)!$KM6Y#T)Q=Q$4.0G9BI3F2*TZE&5
ME:5V-=N5FD6+R1D6K15K .U$SA$(V%5TY(W81@.&\A*%6;%:,55!YE*,0P\T
M\G\&;-+3]7G=(&E\;' EKP96@,(!#23<6)#2+BRZ50X@VIC:VHZN"J>YV2F<
MYK)I(Q8MD$+R9 ""ZVAT!/$+"LLXHS17+5D.WT%S2WU+O<D2Z2[^S6,]<>5.
M595* K,D6945@9KQU>285E&0C9:*"0FVIGZL"%<*PC&4BZMLM%,R'UGU@/@9
MU3!"QCV2L=-). <\T75/#Y7MS99FEF0Y0YI$FN8_T;Q'%:N.>BQ.*AB>UD=5
M'+3F9X+ 6"2 WR!V0D97!MG9G9SGLV^5?,]FQ73,58(QZR@U)^#QJPF92^WA
MN+NM#!-#-(UF\AZA6+(@Z,YLTNK(A&0![<Q:T^'8%1=/Y50&35U<5U.Z-\U=
M6AS6SSN<(:?VGF6=TLG5E\@ :U@8^\EI2XY0&D/,C,A4XW2872PQP7J#"UE,
MPRR=6W)#&QN=\EG%[G7;86%W7N6VL9'8=XD8VY5FP*WL(J#M%.N3JD2X5T).
M4AIYPA!0=D;V" :%2>RK*.<1%@9#)QKU1\>O2:#^/4EY9DFPFI.T-+(\Q&!L
MDS9X!41CJ\LC8R^2(B1@+@TMDC>P$.(> UPMG#1E,-Q>FQ*A96M<V-ADDA?>
M1KF-EC<6O:V2S0\ BP< -;@@6*DTR>M))FV?L'*#QB]02<M'3=0JS=RW6("B
M2R*I!$BB:A# 8IBB(" ZMB""00002"#N"-"#V@K* @@$&X.H(5,PAHB*,Y/%
MQ4=&G>*=5V=@Q;-#.E>_W1P9NDF*Q^X_#4$QNX]^XZ$DVN2;"PN2;#D+[#L"
M6 O8 7W[>]7+4*4T1-$31%'VT5"OXJB+CEK>?GFV/ZU<[Q&5%-PV*W(O'PLI
M*/&D:<C0')U72(.V4>DZ5<(M1=[@FH)$Q)@8<!PV@KZK&8HI352,E>X!Q> 7
M@OEZJ/2[Y3?V22,Q.4"ZRLF)UM71T^%O?"VG8^-H<6-8YUO9CZZ4:ED=][:-
M'M9K*"](XCLSMKOC%[=+W2+S"Y+M]3J4_1JY4VL2SK2UZ=(1D6]Q[.MY)W..
MVU;DG[-:9/;EY_T]7VTF_9!77)$DB<AZ&>EC'^D/2BDPVLPBDBPC%@\4CH(J
MIE51%M--51B2HEGDBKVY(BR9\5/2M+2ZIC#&1F%_5NE/HKHL$Z,UN+038BVK
MPIL4D\U88125[9*N"D_,P-IXY*9[W3B:&,U%46M887E[GB9N]>)/@OQKE%I8
MK\Q62HF3P<5*QM[0YL=CC*--6*@S<)-UA3(U3CY=M6Y]!<T!&UR0GG42YL:-
M?(S;(NG:<)#,6_3.E70W ^DM-6OJXFTN(S4,])'BT;Y(I(&R1/C8^H9'-##6
MQQ9W#JJMLC6QN>V)T)<'MT#HUTTQ[HX8:6EJII\)-7#4U6$.R]349'L<]L3Y
M(Y7TDK\C7"6GRDRM8^5DH9E.$\.V!\T266JIE_+ TN#A*#&VDM:94^X%NCRU
MV2TQHU]\^<2C>!AV;:GL(I:06:HN#JS<Y,J1;Q_&5T( $9?3_1YZ.*CHKBE9
MC5964D\M122T<(HJJKK&SQSST\[JFHGJ8*6SP:9H;"R.9I=(][IR6,!V_I_T
M^P?I'A5'@V"X3644<59#6U4V(=2)6R4]/44\=+3QPS3@1-]:D<^0NB+BUC1"
M!<B\\07$3$-[W)0E1J-_MX8X\;6<B6*M1=1D(.,=R3&)G7L#$,9^YU>9L]BA
M&1XU]+M8)NX8IE=&AT7<A9FCF#:SZ0>E?1.GKZ7!,6K\2@J87QFJDH:3UFFI
M65362LCK298WF1T;8YVQTT55,R,L>Z*TC [%]$.C/2"II)<5H:3#YH9FO;2Q
M5M2^GGJGP/=&7TF6)[ P2YX'.J9:>&1X>ULGL/+9N8U?5R4QW192GS!+#4Y6
MH5R4K,^F!@3FX"1B&CV'EDRG(D<B<C'KMW:9#)IF(18I#)D$!*'6*41-IJ<0
M2"6 01"&5KQ(V2+(WJY \$AX>VS@X$AP-P;%<]GZSKYNN88I>MDZV,M+#')G
M=G86$ L+'7:6D M(L0++-M>Z\DT1-$31$T1-$31$T1-$31$T1-$31$T1-$31
M$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-
M$31$T1-$31$T1-$4$*-_C-.)[_4:X'/Z>/=!/T\OI]D\!WGY-4<3W#ZJ=^H4
MIHB:(FB*E?/F<8S=2$@Y19L62"CEV[<*%20;MT2B=5550P@4A"% 3&$1\@U(
M!)L 23L!J3[D5H@+7 6@CHT'(D>BQ423>)"BX:N6QET^J@*S5XBW<$373W,B
MJ*0)J\B@$.84S@6N2*6$ALK',+FAP#A:[3L1S'UT*H9)'("8WM> <I+2" 1N
M#;CV=H/%:]RSC2J7%LA8IV?FZBZKC!\F>Q0#B.1<>AESHN7;!^WEHN9CWC;Q
M#5!PV$[ SUJN"I&#A$CY\B[NJ"NJJ&5SJ4C-* QS',#P_7V?9/Z0).4C74C4
M$A66(X;1XE$V*MCZR.-Q>VSWQEI L2'1N:;$?:%[.%KC06BIE^G!,XXQ]&87
MK\O< PSD,+O9L?S:9XVQV-O,UR\,R6--C/IQS*<DF-JL1+<E'J^&;+J,)%2"
M0&Q1T%%J^KS.V>H=62.AEK87@55B[*YTD;GN!A#B&2,8^F>(VDM9*X9"V[3B
M\2I7U.#R4F#>KF2 1,B@>XLB<(K 4\A(?E!LUP+P0YS0'$ EPBSAS+63(+(V
M3<BM\..STH8V,HEECGEA&FW*4L5$F9U2:?PU.F(5RTFG=;0DG< S<V"PT<\C
M)&E89=R#2$CW1IDAI8J>AIG5T;IWNGDC>6SEHBF?'%#"YYB;U3&R0S/99A:#
M.Z0AC']:[6L#KZG V54&. 1RR31O$%,]DT-%&V*Y=*\R>U)('M?((PYK8VL%
MR_,QLHK2YLUZ6B[;14YZ<KUO@ZG8\<V:'EEXV!;P\LQ;R9'DO%*N&8J@[1<E
M?.2RK)<RT>J@S023<D52UZ4YP^*FJ8ZMCA5 R-:PL=GN &L#7;1N8\.#P;:W
MO< !;E4_E!]32FC<PTMV&9Q>!9N8EPL02]KV$=7E-[@:A:WG,&\/3'(C:+L-
M[9Q4G89A&?;X;D[W6&$7/2DE)*/2'9UI\@2[NXF4FTEE1JT?.!3Y$0=0RE?7
MB%GD6K;-JJKJ"6LNV.,0NJ1 TR,BRY!&9PWV3U=HVO(ZUL=HFO$0#%;OZ.X"
M[%6XL^A@.)$YVRN<\$R-!'6B(O$3I0!I)U9>",U[ZJ/V0:7FV.C[5@.)Q8_F
M4[;*VIO#Y"9DC5H"3:7VRRDH-VFGI9-"59S;$98).V-20"CM&P-7RL,NM&K,
M9G7O"RG=-#B#JH--/#$Q]*YQ$CG0P-A,+ ,PDAJ<I=(0]N433M,3K7DU?$<$
MQZ7'XY:>:F9ALM5'4NJ V<UD36R"22$:"$6#1%&YSVVCL00ZS%.[B>D"5JOX
M^E)"%4O,<-M"O%Q^D1HYDK?89J%?DA56$2]4:Q4TY@TFDI,.VDHX91<3'(2%
MP7<M?5=)0M>$/@BK ^HS!C8I#UUP! 6Y']:XN(R@AIC/Z1,@8T.+F@[5CCIF
MX=,Z&2.-X<TVD+VMD:YQ88PZ-CY"\EP+ UCB7- -FEQ&B,&X-Q)FU3($7/PM
MTQ/D*LV%":@X2-E8IK-UBAV>*CV *1+4BMVQK)UJU66M3C]_'MF\V5A-LT9*
M01AY]=N?5SB^)=?4-FI7LGH98PQI<QKHII8[&5Y86M?#.TO:':1SACFOOU=1
M=^%PS",)QK"!38C#!7.$QEG#>NCDAD!<81UOYJ8AL;BT/^R\E[0"&$#9F5JE
M$</L5CS&V$&3DU[MBU]LKZ5M$[RM)&+8I5-K<K?<I0(Y\]?RQ7KRCPM=@8*-
M8,2- ;0T<G UN$;MVEI25\D+IZNH<PPM;%$086OL\YS3Q4\+7P1M(#)'6,D3
M P2N)=*6MDOL4I\-PG"Z:DAA?3P1.+*:GI9!%< %TF>1XDN';O>YKY'R.;K=
MQ*D'PS9*3N-5DJ8_A"5ZU8N4BH&;8-IH;''2#"08"[@K)%S!XJ#<*MIA-%^@
M[8/H>.>1,S&2K J3R-1C9F4L*D9GBH$G6LJ@Z=CS'U3C>1['MDB#I&QO:]C@
M6MDD;ERN:\AP65PC$*?$*,24[2QL#_5I(G.#S%)&QCLA>  _V'L(<0TF_M-:
MZX$E=6ZRB:(FB)HB:(OABE.4Q#E*<ABB4Q3 !BF*8-C%,4=P$H@(@(" @(#L
M/;1%$MKPZ<*O#FO.9U0I3*H(4.'F[&5\YG+I.UB@1K>+>$E'&/,?OYJ8JU(<
M##JO8AFSQY6(AZI'/7%=BT!:2"D>O@8L#Z.X1/5XS%AV'4$XBGGJJYL,<74Q
M!KI:J4/L&4[7@.EJGQ"/KB"^<O-RL]/CW2/%Z6CP6HQ3$\0I620PTF'OJ9IF
M/E+FQTT8B+CUSF$MCIFR9^JN&0A@-EAB/$;6LW3E<QFI3LBXHL]A?JS&/ULF
M1%44@+F_KT8]G'E>6]3[C;7$/+^KK>0L+:+L[6%>';1;IRS1=O(EZR0U*EZ9
M=&^GAKNCV%8A5TM>(Q/%ZU22TQJ88GL>Z2!DI!D9E<QSX)A%4&)QDZG(R1S,
MU5]%,<Z*LIL9Q"DIJJB$G53BFJA-ZO)*U[&LFDC;9CLP<UE1 9Z<2AL9ES21
MB256.:>YID$X8/7;=V]?RKR7= R3.C'ME7@(D%LQ34V.")"H%444,5,SARHN
MX%-,5>0-UP3#/R/AM/A_7NJ.IS_G' M!SO+LK6DNRL;>S1<_%:MB5:,0K):H
M0M@$F4"-IS6#&AH+G6;F>ZUW.RBY*AEE#@JNUDOUTLF-LT,Z)6\C2REAL,'-
M4AW:G]?L3YBS8STI4Y!M<*\T4:S7@4I(L-8(Z10C)YQ(OB.WT2[2KK30^DGH
MLPKI%CK\<=6.I):GU;U^,4D52^5U-&R!DM)/)(T4<Q@CC87/@JH\[&RB(.SA
M_0NB_I1KNC.#?DD8108BZG,QPZKJ7O8^DZU[YLDD;6.]8C9/)),P-DIY 7EA
ME(##'-S'U(@\9T.EXYK!79*Y0JI7J; @_<"\?^AZS$M(:.,^>"1,SMZ9HS2,
M[=&(0SEP*BQBE,<0UTRG@BI8(*6!@C@IH8J>",$D1PPL;'$P%Q+B&,:UH)))
M U)*YG//+4SS5,[S)/42R3S2$ %\LSW22/(  !<]SG$  7.@ 67Z]EY)HB:(
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HBTW;<MO*_>0Q]7\8WO(4XE4V5RD%
M*N^QU&Q\9$R4Q)PC CE>\WRGJKO'+R'?F!&/;O4TD4BG762,JF0Q1<7MQM?W
M*C]]3(G\&G+WUGX??[;=%*>^ID3^#3E[ZS\/O]MNB)[ZF1/X-.7OK/P^_P!M
MNB)[ZF1/X-&7OK/P^_VV_IO^'1$]]3(G\&C+WUGX??[;?Q?\N^B)[Z>1/X-.
M7OK/P^_VVZ(GOJ9$_@TY>^L_#[_;;HB>^GD3^#3E[ZS\/O\ ;;HB>^ID3^#3
ME[ZS\/O]MNB)[ZF1/X-&7OK/P^_VV_IM^#1$]]3(G\&G+WUGX??[;=$3WU,B
M?P:,O?6?A]_MMT1/?4R)_!HR]]9^'W^VWV_^>VB)[ZF1/X-&7OK/P^_VVZ(G
MOIY$_@TY>^L_#[_;;HB>^ID3^#3E[ZS\/O\ ;;HB>^ID3^#3E[ZS\/O]MNB)
M[Z>1/X-.7OK/P^_VVZ(GOJ9$_@TY>^L_#[_;;HB>^ID3^#3E[ZS\/O\ ;;HB
M>^ID3^#1E_ZS\/O]MNB)[ZF1/X-.7OK/P^_VVZ(GOIY$_@TY>^L_#[_;;HB>
M^ID3^#1E[ZS\/O;_ /O;_-HB\&F;7Z%OI51N.(LB8_4O\K)P5<FK#*8IDXA>
M:BZY+VD\<X+3<EVF7;JN8F"DC-5ABC-3.$2(++HF63$Q%O?1$T1-$31$T100
MHW^,TXGO]1K@<_IX]T$U/ =Y^35'$]P^;E._4*4T1-$31%8K/ -K1 2M?>++
MMV\HU.V,X:F*5PW/S%41<(B<IB"=!8B:I2*%.DIR<BI#IF,4:XY'12,D98.8
MX.;<7%VFXN.(5+V"1CF.OE>TM-C8V(L;'@>U10QK=)^-FLA.H#%N7<HJQMKD
MJ!(6QJ\PO7HER\HKYY'OT8J-L678J;,V3E'+_=[(QS,[KX)D&Y&Y4S*7-96O
MK',+HXXFQM+6,C!#1<W<3<DDD^X #M)M**ACH6/8Q\LAD?G>^5V9Q-@T;
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MNH(OO]/NX+9=9X L;51W7RQE_P FGKM?:8%Y*J[7HZ\<_G.'/--@S=CZR/)
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MMIV=Y^946W[?NLM:\3O _D26F;%>.&*55BLC9.3O\!>+'/Y2@*.S@JE?L,8
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ML;X(EY+R[F*"0:0$:1=&M$31$T1-$31$T11QJ/[J+-/\5^&?]Z9)T4#=W?\
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M#54K9F<7P/E F:PW :\LN&.((:[4M(T6[^C_ *+1=,ND3< DE,#ZK#L3?2S
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M:+3V4/\ "S /\<+[^A7,?Z?IOK7\:_S[HM_:"3_AWI MVZ)_R-Z1_P"Q-/\
M\>]!_JMPZV!:2FB)HB:(FB)HB:(FB)HBU"K^WVQ_BAE?^,X;6OG^=3/[/R_W
MC"MU9_HZJ?[:T7]Q5ZV]K8%I2:(FB)HB:(FB*,>=OVTN$K^.RP_T(Y5T4'=O
M?]"I.:*4T1-$31$T100HW^,TXGO]1K@<_IX]T$_3R_Y3P'>?DU1Q/</KY\E3
MOU"E-$31$T1-$7,7(O[FG/O^M!E#^DUWK1O2+_->K_[>E_\ -"['Z!O])&%?
M]TQ/_<Y%")X/_HNQP(>V D?Y<OV+7$'FV#X*?^JE_OJK\]J^S8#;I;TI/_\
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M-]'7O5[X1!WS?B\1\Q:17_X]S[-O/Z/;JYZ#?SFP;?\ BH]>?Y\Z'N^H6/\
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M>ENEOSU6+=T$"[^:^H%^<*:(FB)HB:(N '%>.V:L@>?^'+OR_P##B;_AW_\
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MRW725NF3KWT9&9+BY,DI5V4HH4QVS"U-E4&DI7"NRD,1O*'1>Q9EQ!-PX:E
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MMA'I#I\.?7G!*;$HI3B])5T]=3/PN3$J.)C:R&>L:^D>76;'UGBF=BGEEQD
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M4G"*2RB;M-,KMNV72Q^(85A^*M@9B-+%5QTTQJ(HY@71"4PRP9G1WR26CFD
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M+RE6(<I" 4BR0&#$.ALR:!X5)5%MLV1_4Z*Q2%610^!]R25*0A54T^4BA2$
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8FB)HB:(FB)HB:(FB)HB:(FB)HB:(O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g945651g07d59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g07d59.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2$L4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (1"^A&0X0DE-! 0      !<< 5H  QLE1QP!6@ #&R5'' (   (    X
M0DE-!"4      !#'71?E=+5N]=N^.93 Z7E<.$))300Z      #E    $
M  $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E
M;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L
M  MP<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J
M8P    P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<
M  $     0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X
M0DE-!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P
M !<     0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;
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M4'AL0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M
M %!G4',     4&=00P    !,969T56YT1B-2;'0               !4;W @
M56YT1B-2;'0               !38VP@56YT1B-0<F- 60           !!C
M<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M      QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N
M9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU
M  (  0.__C4  @ !.$))300F       .             #^    X0DE- _(
M      H  /_______P  .$))300-       $    'CA"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             N8   =D          $                          0
M           '9    N8                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   N8     4F=H=&QO;F<   =D    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   +F
M     %)G:'1L;VYG   '9     -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !3A"24T$#      6C     $   "@    /P   >
M '8@   6<  8  '_V/_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN
M=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M           !  #VU@ !     -,M2% @(
M                                    $6-P<G0   %0    ,V1E<V,
M  &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8    %&=8
M65H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
MB'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,
M    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,
M  0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C
M:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M            $G-21T(@245#-C$Y-C8M,BXQ
M                                          !865H@        \U$
M 0    $6S%A96B                      6%E:(        &^B   X]0
M Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/9&5S
M8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6245#
M(&AT=' Z+R]W=W<N:65C+F-H
M                         &1E<V,         +DE%0R V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%
M0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M                          !D97-C         "Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F
M97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                            =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,
M  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S          $
M                       "CP    )S:6<@     $-25"!C=7)V
M!      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &,
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M*6LIG2G0*@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M_N/K;RXBWE\EQ\?U]W?']OU?4O']?[-+:WYGEQY9=>/75-UFN\?<?;O5<_*
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ML^?YOK]?KTME;0>GGI8BWSR3=;GF[+7Z'AY_-%W +\^/[RK[_P#Q+^OZO?\
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MS8HWWE54+($*-PS^%5) @2)["HCRHTK?&>OM^_VY:IND\N/!IM8]!;I;GGS
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M\A^' VD>+AGD>ZA]A1=5OCKWP[^F:;IRT\K#WO;UTTR7V6]ETWYI'=O,^!8
M(Y8?@<?-(K1 KHN)T9"JOH30DYT,B1\#T]/<405OC+NR%IX6]0/INY>Y7/RU
M7BG'9';K/E>F-%(A-JUCR)(8;0"==ZTR)1:Z!=;7H->LT-.V)=#O;;X RS/M
M?KWFEB3P]FD\K:#2WERT6HN+;R6 ^.G?2X^).:JC_A/\*%*Y&2/2^<8DQ-ZO
M&B+2NA\.(VL>5-FO0F'P>,.]$D/.(W"[4IQO-N3TMIRN?G?W&:6/*V9RR/\
MI%\A;+RO\RMNBWJO0*0![=9\)PF@?FBC6.EY>.XAD#J<9'^%ZA;<+H!.XG0J
M***32.-\<;_9"T\+<+$@:D]&]_3A-Z[LBC &W>?$<YLGH"=B@'S+( +AN*JY
M"G8Z6S ^AWI,D-$ 2(30&^WKKR^?>:;KCR]0/;1=9;XV;;#DIS <^"(R^L-Y
M_P I2'VIJ.I'\NK3=^;I)YDA85\!*.BEWU<2(A2!;[;_ *]^O\*=TYD@7O\
M\.?6^[];<UW_ "SWW>.+\G6?>::9&2ZQVL>]B*9& /=U<B1HE,FW!1M#ZA4%
M5SH VC<;XZ]]_P *-TFV@XZ"_P#]O4 G.QOY+2#Q ;D3,_W\\/U5?X_?4V*X
MYB&Z6Y6/1<C;A#%O\TBOX5BM9;L1(\R< 6&)4&27WE''U9F0QRF1^" C7IYM
M\2JJ9N'T%-&2(9ZJ5TUKC?,$;3$UV@+29'/#3>[HVNM=H7</@=A\%3C&,U4C
M6NJJ3#X(Z8$-WHV5<[A4R1YW#]R!D)>!?PYI&7W7N!S:)GKT&1&E1I1-O1'
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MDM7-O<^%*X$<L?XO0%Y4%;5Y"1!R%5D?@4[O#"&7'L(BO?@M-]O5-T\=T^0
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MITF@RA%1Z5[?3QQVU)OCH4A6X(VWT&0 _C,D<-?G>ZI<;>O$Z ^7H?7S6O\
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MV)D;PYHE?<&2-I*^GL6^-FS\.R%7B]$[=Q]L<=/3X)5->'BNG%A(Y[ UL]#
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M?L?<G^?2XYCW";CN7S&7TS\D^3S^07]Q/N_XY_3PN.8]PFX[I[]]CRN^3O\
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M;3/IES''AQ[UJ$VVLE,.X_$[7($XC%6XT\O2740 X]826Q T3H/F.9H"KVS
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MO?X4G+,&RC L"W!V1P&HSO(]\Z/:R]QNGWSGRR/%\FQ+PM9E7Y;MM,R?:;#
MW&OJ2L\5&-Q\LP1AJFNH4G%+V=5%;8V<J_I S^?R%TOW\OU499-_"A[I9)@,
M/,L>KO#GA>+Y7LGXG<L<A8[XBTR3Q [>;A;7[4XKN-B&T=YBV2;&3,%Q#Q+5
M<&XR!W,-E\DKLX"M3&[VS)^RK<2L8%Z12/O3_"KW&SM!N=,F[(4;=SM-N0.S
M]Y$SC=61@M1>[DI%WASQC%<>RB5MQ-H2M+O83;[;S>.@;NI%$S=1M\<)Q*H*
M?E@M4]J3OO\ CRNK"S_"2;H5EYN!:Y=BVWB-[?9/OGC3.&8UN8%=CU)CM9N/
MX5L:VYSWQ)V=[M=<95M;68_B6^#VX^29;CLY[&X6V3&5Y=(Q7*([&/O4Y.^'
MMWRS/.7MJ?X0_.MT,_P>@A[)84N V=AM]09AN/0[R6N15\RRW+W1\3&U&*93
MLJPWM/!J]T]J[:R\.S>65N;6N0X$]:81GM/;5=)-=AI'L2C[_KW]%ZHZ*4T1
M-$31%A<.#T;AY#9<?\IPW$(/5Q[_ "5UFK_3S]7GD7CUXZE]W/J19IHB:(FB
M+4_Q<[6YWN9B&"R,!@0,CL]OMQ86<S,&LYD.!%S*$QB^58ZU$8D6;K%+\,4-
MGD-?EE&U>R(U2[94+*',KIZ5]I TS;W9VNVHV<J,*P^J;35#YZ:<MD(;#5QP
M2;[J69QCF:&NRE9O1/89X8FOW6%TC-LV)QK#L!V@IL0Q6">6B$4\,CZ0--73
M&9H J*</?&TO%C$\;[3X$TI:2X-8[!?"?L5E^!RMQ]R]R,8@8ADV7VD23C^(
MQ;6):NTD:NH&JJPR6[&EG3\9:R[*5;8@3O@R==FWC]!1(]=+(F3JJNQ7PYV)
M?LCA;HZ_P9<0DJ)Y(WLD=.:6EF;!_N[92R-H+Y8Y)Y&Q,$;72D!TCB^1^4^(
M6U-!M)BL;L&95Q89!2PPG\6&1RUE5')4.-5)%$YS6[L4K*>+><7^%$W>#<F-
M\R/"Y_"0;Q_V,.VNX(YMBOC#WDSG;*#GVY&,9#XAO#Y6P]IW</\ #GDN]N:1
M"IO#1X<6\BV^N,LL,:O<7H]O-UJ^]OJVXKV(DG)HH4^1.R>D+GP.6HRU/U[R
M4X1/X1S=;:K$=Q;;<O!\#MJVRW(\23NQ^79CNXY@\:SI<'\:#6Q];ANY\@MJ
M_BKM=&HZ+/\ $8.$Y!(R;)Z_)8^.2ARNXQFQL8LB04W^6:J:[^%CS6;A;6Y\
MCPTU-;M[=XEATO')LS>"Q&[JLORO87PS[\SG]RXJ;3_ N&;0X-0^(B0WG6YE
M??91:453MODN2E@CT)Q(L1V5'GEWUMWQ5#<?PO5O1[AWV"1]C\!W'8QG:G)M
MP'\JV@\15-F-'EJX_M7>[FMYAMJU-P.BN\ZV).34!M]=;IT=/+F4&;-9/$7$
M;.#A]C,E%*W(\"&_V6^(FH\1^6Y-DFW.3U^.^)"3A>%3-G\^8W4VKCXK V'V
M&O'(V";CM8GA3N7T[^69#E-K*GRZ)M^!>65O1!*EQ*F*\1%O=HB:(FB)HB:(
MFB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)H
MB:(FB+X%IL2,A; 2<)#<(0%",T% 0C5$12)!1!0B55041$7A$31%R@ G3P I
MTJJCP*>RJ\\J/IZ*O*\JGJO*\Z(G;#CCH#CJZN.E..K\KCC\;Z_?HB^M$31$
MT1-$31$T1-$31%PJ(2*)(BHJ<*BHBHJ+[T5%]%1?H71%ATS ,5GYSB^XTFLZ
MLMPS%,TPG'; )4IIB!C>X%K@=WE,'X-:>"ND%/L=M,.?:E28KLN -8XS >CM
M3YX22+,.D>5+I'DN%)>$Y51_%55XY7CYN?=\VB+Z1$1.$1$1/<B>B)^K1%@V
M?;@4VW=;66-O"OK1RZO(>.4U3C5/*O+FSMYL:;-:BQ8,5$)4"%73I;SSKC3+
M3$5Q2<ZU; R+!?ES9_P2[Y_S;3O]<T1/ES9_P2[Y_P VT[_7-$3Y<V?\$N^?
M\VT[_7-$3Y<V?\$N^?\ -M._US1$^7-G_!+OG_-M._US1$^7-G_!+OG_ #;3
MO]<T1%WR87T7:7?)?T[:SE^K_P"+^C1%PN^$9>%7:3?%51>4YVTG*J+P@\HO
MF_1>$1.47W)Q]":)Z?3[KCY;XWK_ .Z/?#U)27_W:3?4E144O^5_C$GHJKZJ
MB\+Z:)Z?LB[XQU]^T>^*^J%Z[:S5]I$1$+UE^]$1$1?>B(GT:(GRX1O:7Y(]
M\?:3@O\ W:3O:141%1?XWZ\HB(O/S(B?,FB+E-\8Z<(FTF^2(B(B(FVLY.$'
M\5$_C?H@_,GS?-HBY^7-G_!-OG_-M/\ ];T1/ES9_P $V^?\VT__ %S1$^7-
MG_!+OG_-M._US1$^7-G_  2[Y_S;3O\ 7-$70.]449+LM-I=\^ZZPS')?DUG
M^K<=R0X"?\K_ "I+GOT4>A^7WX?Q==_RYL_X)M\_YMI_^N:*5=L5WDH\HRZ+
MA#F,;@XKD%ACE]E58QF6(3J&-94^,V6,U-X["FNF]&<D0)F88^)Q3<;?<;G*
M\P#K<>231%+NB+Q^Q?\ A58>.2,MO?$3MG)VWVM'*\FPG;;<"JK]QX,'+LYQ
M_<7<7%&]NVI^ZFW^VV$9+D,W#=N;W<DK_;C.<QQ"KJ*RVI[RSJ;@L89RD@S
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M;+PJ[YPQ$ 1L%.HW9\/LIPE410%Z M Y15110N>>%XU@J@ANTV$9?FDP3'V
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M9VL@IF Q4\-#C=12RQU7@S2UUAN?#%:RKRALZ+=/(:"#66^8VDRK9&QD,O\
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'$T1-$7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g945651g07z76.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g07z76.jpg
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M-SA5=G=XEK6VM]88-CE7=9>XU!<B,72T)$$:(R4F)RA16&%Q@=7_Q  < 0$
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MY9C,TY?^PG7[74X7LL5+]0]]^AAM47UA9Y2HBFY=ZHXYQ'JJ==I W$F?7;#
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M#N>,;[316B:LHX'7KL8W@RLO%F?$]];L;6.>#4S14P)J(J&"H/*5M&S$]KF
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M/;CYA]A?8<GF=6>"U'DG^A77;#Z+7_ZKJ_RG+SE^5!>0TX16A>!A_:7]9/\
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ME+9^&O6T/SO%NQ.$3A$X1.$3A$X1.$6):+O356RSI"MTJUH,%X$*84;:6'L
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M4>7F_,<MT6KYKMO\A1_IXUJ^^R6?UFZ@?P+=OVAJ[E;O/&GZI?3&M,]F3O\
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MN0-?8FN2Y,GL!=*D15$#N3?!4LB;)"]N]&U\+&QQSQ!Q)BF#& &1A!=J#D8
MK3ME+6:RWW%G;$-PMD]7)3UL$O(U$D-=4S5530U18T,JJ%\L[W-IYV/#, L<
MUY>]W$2>MN_:MVQL=GI782@5,UOK35Q*6&.*Z_R,5.47U@=U4 9.V:GR=P2!
M=ILI1K9,Y2;'(7#)0HD+ QU9"%-DMY^;Z^>2DBHY")(J=Y?3O> 9H >,<4OR
MFQ$@$QG+ X;S0TX(R8=GK=37>KO5*V2GJKA V&XPQ2%M%<"S>Y.>KI,&)]5&
MUQ8VI:&3&/+'N>US@>7!]!]H5JD[;U4)WYKQ>GML@R:)&J2_7=\Q2:=<#>5/
MF++1AD_<SJZR.F$E8-,5,?(0 #F4MD0,47);\M?UDNM9+/353G@55*UK6U+!
MN32!FC.6>WOI:WN2YX+GLRUY<-%BTVR%DI+?=+1'3N=:+K+++-:IGF:AIC.2
MZ9M# _/:<;Y#RPBA<(X9@)8&1.U4@0.I.UU?'UH-#[-ZV4(KU AU3,9WK8^M
MV:>'PVH42U.2?\:\.-*0VRVI8AOQ0'%)5Y2?\_C1@/?RCWO<.Z>\O.#@9<23
M@8YR3CHT^VPPPMIX88(SB.")D,8.IW(V-8P$DY)#6ZG(R=5";M]X*J\]Y7-0
MO;][0CGI.J1-N'HG4;1K57F&G[8^&D2)3J9>T3@Z+AE8$<CS38]:5M(?PCS+
MLC#K6'4TD-5N\H'@LSNEK@" [&1JT@YW1KC15W:+9*U;4"F-R-2U](V5L$E+
M*(G,$SHG2 A[)6/WN2:!O,R!G&"<JN;9_L>.FZXU7=M@Y[,'2\RA4:]7,F.1
MK&+ C&?:Q7R1P:.&O*O<YT-E]4%$8A+F8.X7AU;L:+&RA+:L8VJCUTE&<8^,
M'<].,LY_'G"KA[%&RQY3!N3=\-#0VK;\41Q,>]"[)=Q=RO*C_9#5WY'L;&C8
M;C8<[36)3N">535-ZKA(:=">5GR8\1M5^<7&,>3C&%$7W9D#RLJS@/C&,)R^
M"J37ONHQWP:'_:'<<3T'(\70/8IV6)<?WB 6;@ JV]P[_>M)A),AYP[>BZ(U
M8?U&\'5MOI-K>RZSTAVAKC0FS[11L*>0MN@<V$FN%ZG$ I %2T;='0TJE0 T
M3+Q&/#CN(D>=<C,QTN80C+IZ>*F:61!V'')WG;Q+L 9T QPR0!CQ!6VP;.V_
M9NDDH[;RW)33=L2&>3E7NEY..(NR QH#F1-RUK6M!R6@#19KW5UF[,;SU7N#
M4-K[04&/5=KC'JWG(WK@['(5ZK$F?1C8J)+5NASTN3.CK<0R2F-NR(BLX<:Q
MX_%A'UD8R1CHW@EKVEK@#@X/'!QI[ZKL:^AAN5%54%5O&GJX9*>81DL>8Y&[
MKMUVI:<$X(X'!\2J'D^QL:%E13T/M+96TJ1%]1XEZN@2%1G<83Z=DTIB]Q,$
MVW<X5Z$@>@*N+A2?2')V49ROKQ:J3N<\J<9S\8.ZSPSW&F.;&/'E4 =BC9<"
M/)N3]PN+MZK8#-O<!)N0- #/]$Q"(G_3+ET2H^QY*+:C^V1&.RUC@LZ^MD2E
M"G5:U@R79Y-_7=!O#A<EC%UC(P-P_<W1[8B(EB7AF"A]1M;CJD(GX)I!N]]Y
MR?C!KJ1N_(X:=?C0=BC9< #-R.[)OY-6S+VZ_%/ @ #!H 6!LNFLBE3UQ\!>
MCJ[NFE;UUKVAD.W*BB;%@,BR:=CE!:;+9:F=I\PB]"C[('Y=#QA]@ERH0AUY
M<M$YF,J28E1L.QW><-OIH)!*P2;[7.+=Y^0 YI;NXW1D $X.<YQDD:+L[1V/
M;!9+A!<Z(UQJJ:262(S5#9&-$T$M.Z(L$3 Z,,E<6%Q,H?NETK@"TVJP=<]N
MV)%<<F]G]9S6!P>9#L$?]&AR/[82SS:DQ"^'6MUX6,Q#<4EST*'Y,9_S>4N)
M\3F?(S].@^?S\WOXU>-?%YCXO'U_<JDMT^ 81V&VL?W/M7M<3GWJ]$U%+])K
M^G!8(;/D1QT,4,S6QOM^FM@L,PQ\1$[$Y9Q,MS#KK"8.5X3C EMU--))*_E-
MZ3!T> &D #0;AXXY\JAW3L<V"\5]9<:Q]?VU6N8^0Q5#&,B<QC8\PL,! WFL
M&\)>5&<EH;G C=8_8\E%K-AU179/96QSWMA7@S6B$V/K6#!:'"Q5$N%W;?@Q
M';K.6LD^BI>K''9,MR(E1',U$/Q1,1)/S^":0[W?1W(QW8T.0,CN>/7D>)8)
M[%.RQ+B/A)N^W<:!6-(C(!^,;O0$EYP,AY?'QPP:8[QGV-C1_(5Y/:>PX=];
M^6A2M50LM8K_ +O_ $JV\7]*U'?^_K5+J!ON>+U#[OCP^"J//"7&[C'*#C_M
M?(X^+Y/B0=BC9;(.;D?B^3([;;@N_P!]I!GE?%GD?^YZ;A->=<^TVJM5UG4M
M*[5T1D%00-(I="GF>M;1,N(I5(!#:[#%E76MP089LE.'C&E3BZH,169*W78L
M:*A;;+/81L;&QD;<EK&-8,G)(:T-!. -=,GI6P*&DCH**DH87.=#14U/20F0
MATABIHF0QF1S0UI>6,&\6M:"[4 #11_[G^#:VEWE PZQM[M""A@JO8X]HH ^
MJ:%0)P"(."' YEDS*?VO/G'X9%EU<AA&)(]Z#*PVI+[T=*XKGRJ*:&I:QLH=
MACB[N78SD8P=.'.,<_'(T74W_9JW;2Q4L%S,YBI9G3L9!((=][HS'B1VZYQ:
M <@,<PY UQD&NT]['!H(D78RS'9^S/-#0,J>,C/ZQ'^=]908CDE[UC(;NZ$2
M![ZFE):CQ(T&4PES'ESI&6\Y=Q/@JDT[Z<$DDR#)',#A@ '4 ?&JH.Q1LN P
M$W(EKRXDU;,R DGDW@0 !@T ,8C?CB\G5<52?8ZM N50J-O3V9LXYFU4$#84
MCE:U'3'8%@."8A/&,S<7.*B4"BYE>:S Q"C$G_(\O!EGRO)2^":0:?&Y#L]\
M'#/R?D</'\KQ\R#L4;+D?*N6LG*9[;9G=_W)^(QR?CQRW_>JQ'I5X+_871%R
MX(TWVA%S1VQH89=X'7'13)AJ6<K3!M@!/!R(>TA4P1"@XL!%;T!^025-5EKS
M\KR4)2G)IZ2&EY3D@_XPM)WG X#<X [D?[1XY.OB5GV>V5MFS(K!;'5&[7/B
M?**B43;G("01LBPQA#1RSR=\O>3C+B IJC-<=OHRJEDEV@UF32);+IM2<=9W
M(GML7+PYZI6E3&ZL9"^J,J1X\#\)Q.\WXY&,^7G&,K373JUX>WW^RR8/2/-Q
M^_W],KN0I3A$X1.$3A$X1.$3A$X1.$6- FTZ^8O.SJ ]'(!#.JXE3+F7S.(,
M8<4K-S#S20>U!I+<U];@/$T+9Z]+D$&1[S!JK&F_,+A-Q9LHBZ74MO:>NT34
M6S29(-2K)L>J$6]5B;\;!UV[&:I=IU>*+8#@'3+CL[%G17*B:3#BHED&&FQK
M$EJ%,S+AXG!\W'W\_F3//T^M<S3=]ZSNEKLE$BV00(NU<N-EIJ:>;.5^':3K
M]5;C.DS5?K[99\N0 >3(5YN=B&VM/HLKTAAC#.<YCWZM<:^_.$]^O3.GOS%9
MFX1<2?.B:N"-64]-:&@JZ)(G31%_RO,#Q(B&\0(S7O(2M?FHL..\^YY"5*\A
MM7DISGQ8RXIP6!J7MRJ;W0?UI:M;W:FXM>MH]H:K&Q6*VRJ\ZKNJ9H%\I"54
M+99L0D>)S ZP 3,@): 2BPSTX7'Q/8<Y)&.<'J3W]_\ 'VKLLC?= ;W>*Z_Q
M'R9.^SJ\>LA+(\<\Z!K,<'%KL[ P\;7EJ$Q8"@ZSBRD #$7,)MB'F"I../'D
M0\@C'O[^9.?'7]V/:LU<(G"*..RNR]6UG8K&&FU*[V(5K\!7+5M>XUR/6G*U
MJVN6J<3B"BMFP9LX8Z22U%#%3YB%3@EG( ZU"49)Q8[4P6U/>_OS*"<:KN-S
MLD#564RZSK6XWJS[.N.%/ Z'$$JF$SL6HLL23Y\W:SU;J5<&P*M3($!4\R?&
M-2WX@L2+CD#1"-$DSQY^ ]?#[TY\=/J]'M*[#K+8@+:]& WZMLDHHH\U-PF"
M9C,Q"XL@*)S0AH038C29L-) .:&D!DQ<"=/'/2(CCPZ?.A.,2WH4\5WSA$X1
M1^VKM[5-*V+IJFVN/--;!M%SB1Z*.$#Y)!^LR; )L=95;C\EMQF  !28#YX!
M&EDWO/%I<F3""PI\F)-7!G7!Z.?SCUXX*"0,9XYT^W3V\?&I \A2G")PBZ!L
MRW1J;4Y)&14K5>G"4T96H52IHZ.0-G)UEG,AHT1*R) .%%0,9EJ?*G+ :# Q
M YF3-($XS;6/+(N$TO>JW>*:IJM5PS3&Z*9):U+TL^@9ZTJ!FE98&/@7I(,Q
M801!B/#Q!?@D YTM"E0),9?I6)/I$=@?3JH'HT\WOIXEEKA2G")PB<(G")PB
M<(G")PB<(G")PBAEV=TA?]AV"NE=9NQ(:;Y6"F@MVR726!4MC2EO-B#9>SB7
M?<>EVBHPAUK"52+%6T^U)V23G86A$53K,@C7/-J.OWX]2XD$\.?0]1]8YNLK
M"._.K^RK-L/;6:L)LYJD;?UMKS7P>)5+3J&H@J9%J,4R*?"W%^]T.TW@-5AK
MA)-MK134:B!R(;F%?, A)2*,//2" !IJ#X_LX$?;G)X<> G![KQC3S>C_%9"
M9ZW6F*LB29K@-1^7W@!;R4;S($X+2J) >"0))B003A#^2>0$4A 4,\O$M<1Y
MV&EGS4E3:HTTZCY]<>I1@YR,<1T9W>?V]7F4^>0N2Q[MNCYV=JG9NMDS4C5;
M"U[=*/@BI*EI@9ME;) <35(1G"UIBY(>?RE&<*5AOQ)SX\XY(."#T'**-M&
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M Q]M54F>,:LPK8A*UP"PJ8XPZIQVQ4]FN029&((L!-I4"SB,S<"GU(9DE!)
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MH1N3C$)<IQ!2L-K[=:V0.?,^U_9:A#-.+;%2232Y.(K^OZU)]#MMP94N6AS
MJK2E,M$(SS;)HDW*C2ZP*/P7DRN% ((SKCI/OS<YX+O#>_J.[:1U:;BV940O
M<3NOQEQ]2+Q2IEQJX0^>LH-!O+^'&7 D2L'8TR?*A,"'2@R<+@D)<Z#-9C$R
M,X\9'VCW^XK'>N^T VSV=RJV6!'$&2@"JW.M!QOI,LLW2;,&EV619;4S(RTT
M #U@*Z"CV O,7&@M'2; 6+YXI/&#I)0#QSC_  QG)/#U>,KDR79L"[6SIVO5
MNU^=":[5N>-'LM>EB&;5J85/@.&SE:>P^XK)66">ER000JW ,IG>KT'!(R-/
MCNNE.>@'T9'/QZ/'CUJ3,>0S*88E1G4/1Y++<AAYO.%-NLO(2XTZA6/<4AQ"
MDK3G'N93G&>%*^[A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A%U
M"\TH/L&NKK)UR:V.69JQQ2Q[S4>5Z;4+2&MXI.'7F)*/,+*@H2)B/-96]#4^
MRVXRXM#S9/?S+YMU*#W5-;087-1BK6X%=1OH3S;.5F*Z\Z_ 1*\XP_YV$I;J
MO2&6_,N.)PG"'V_%G.2@CAXCGW\ZQN5Z[:Z-6Z9:"+!*2/*6L;>S5"?<&R=?
M'+L+K)JILV@K798N0J03DBRT5X@VB<T.GF*Y6CDF"X7&KF228^_FYO?W*_B+
MUQUK M"S\").@!EVJ!>UZY@9%P=;JO(JO0:R-MBZU$%,J64@CAL&3'CKG*#H
M.PX5ER+588$$G&)@?X<PX>S[STKGJQI#7M3%,!QXG$B,*>.)J,J>F(Z:H @Z
M[)>76J)86(D8]7*^*<F3$UV)%)*D 8KZ!PR7'&PAL.$3'OPQXAC"ZT,ZU:Q\
MJ6_>1V-PSI#85AB?M4-3;"X-C5Y%@2+;&PA]6"!X\Q*[797YYY8QVS&G34SU
MV:(MIBMQR8Y^?U>_^*Z^YTWZ[/40/07]:U:1#!#1(F!87ZU5G;<D>'/+LC49
M9Q0+*_,RRD@@X0:;8;:DI*E?_+0[/?=43 QC&B[CMH5%$JU/<A[;<63K_9=2
M&CX#+26HDH/L5].HR0I:6_)Q&C0HESCGX>&$9_\ 4*X-C9PF(](QDAYNL??I
MZU^)SKE07:QFI*E63U7G3MPTAE>",+$OVG7=R$X8D>=]69;]>-J@,^@S?,^B
ML8RYAV!(RK&4DP,8\1'GXJ#61T/8W:0_UO\ 6-LK%6JEGV9L26D(='^J)LB^
M:SLE<-+#BI=?>,@K#,D[3EV"<6E6P]7\F8I*6&I@&0>7('%&>ZQT'T@G_P"<
MYSG.BG@<Z^Z^,VJ5=\L38%G=E5E]@C!5"9Q$@UH*3KF:VAG,'/GZI8J^8)AK
M,!EN/QIT64F3!4,*PAA*"4X]_N]'OE5NZ3/R=JA-F1E$;(-A!:50NIL*&3-0
M[ V&KVT[Y"IY(Y6G6@@.5$2#%M8R$AV9^X61]U$7-CNY],..E!0?4!GHWB!Z
MLZY.5<9%BQX,6-"B-)8BPX[,6,RCQ^0S'CMI:9:3X\YSY+;:$H3X\YSXL8\>
,<\+DOOX1.$3A%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g945651g08x23.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g08x23.jpg
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MDI.5\20G-C=29&5R=):DM=47&$545[;48H;"XB:"TO_:  P# 0 "$0,1 #\
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M?6QT-'0M8+%4SXY=%45\R;#%#C,5)!)ER*6=M.;5037'"H8)42B3*@OU:+I
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M=3G(P5V6EQ21[\IR,M]*]ZC*7I6_.J?310Q1*=(BAE.%QQ*9+<,MO*%Q/:M
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MU<B74TD^354TZ%1R:BGFP3I$V!W2CES9<44N.%M-**&)K)YEQS(W# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M].IO@H9-SR#MC & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 6^$5@
M$7RD:%(T^^%()%$T:;=1N+/4.'E4Q]J<;0EW>QY2!(]HPIQKRD:;VY[5MUM
M%PP"VFB\$ '+'2;BF1H0;.+D'D-N/+:@C8KLR6XAEI*G75-QV7%);;2IQ>]:
M2A.U;UK>,<<,$$4<3M#!#%'$[7M#"FV[+-Y+0T5-1*I*:HJI\3ADTTB;43HE
M"XG#*DRXIDR)0PIQ1-00MJ&%-O1)LYBB40T+&F![BG8!:!#)0G5MK:4Y$GQV
MY49Q33FDN-J6RZA6VUI2M&][2K6E:WK$,2CAACA=X8H5%"]+J))IV>:R>\RD
M3I=3(DU$IN*5/E2YTJ)IPMRYL"C@;A=FFX8DVFDUH\ROS(VC & , 8 P!@#
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M -2#\YGV+[D'NW&O]EI/TTT^N'.^?=A@# & , 8 P!@# & , 8 P!@# & ,
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MF\VFTK;)9N.P, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & 1W1_P"7>K_I$8_Y<<]P"1, C[K7WJNF
M_H^N?^'"6:*KW-4?(3OT<1R.D'O#C?S1B7T*<5G-?O=4'^A55_N*!EI_<\CY
M&5^9";<&]Y\*^;:'Z+*,US<=(8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MM8V,I#IX46'B2@PRXG>EE(!(6-GPYNWX\N!#D-N1V\#(R/ & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@$=T?^7>K_I$8_P"7'/<
MD3 (^ZU]ZKIOZ/KG_APEFBJ]S5'R$[]'$<CI![PXW\T8E]"G%9S7[W5!_H55
M?[B@9:?W/(^1E?F0FW!O>?"OFVA^BRC-<W'2& , 8 P!@# & , 8 P!@# &
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MO?G=V3OPW[_(2[OU)MJVNEE?KO;JT,68,>*0U"NA.-\H=!+3*#=.B/KJ_+P
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MD)G@WO/A7S;0_191FN;CI# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M-M#]%E$CYTSI# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M_P# '1_Z8#_[E:S^@O["C_!#IG_*2D_Y7*/.F;O+]1Z29^U#6, 8 P!@# &
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MD=.Y7C=+/IO"J##)"C<OPT$&VH'%"HG#?9<23M='FS-RWYY=AZ)Y^R#6, 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , LB1Q)AZ6N$1B-,RI2Y7LI UR2XVXXAM+B=
M/-DHJ5(VIOU)U['6TZ5Z=J5O7JV)GQ79^M%Y1I>D(TXI*W-)3I:TIVA*EZUK
MU*2C:W-H2I7GO2=K7M.MZUM:O+SV*<L 8 P!@# & , 8!'='_EWJ_P"D1C_E
MQSW )$P"/NM?>JZ;^CZY_P"'"6:*KW-4?(3OT<1R.D'O#C?S1B7T*<5G-?O=
M4'^A55_N*!EI_<\CY&5^9";<&]Y\*^;:'Z+*,US<=(8 P!@# & , 8 P!@#
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M)?0IQ6<U^]U0?Z%57^XH&6G]SR/D97YD)MP;WGPKYMH?HLHS7-QTA@# & ,
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MW\T8E]"G%9S7[W5!_H55?[B@9:?W/(^1E?F0FW!O>?"OFVA^BRC-<W'2& ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8!YREJ1T[[2;>^4EEI_*7_ !)='+W7G0:D:;OJZ4OMILPS9ZN;D:)S
M2D=F6V-LLF&- ,%B-35/<JAB.78&.3,[K@K[.KS5]FUFM.7"^N5S!I[\U=W7
M!)N[OK^IG?,,=#LG4VQT5CI\058+QVJF6P?,-],E(;I[5"Z>U4I3D*+7*[S"
MB#2!X349G/RU7FDK:5'SQLB?;2!*48TJJR5\LMEIY:WANM[>3=^K@1W;>O\
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M]F/N%?XH/N>_R;HO3&:8_P )^3T(GK/K!B, 8 P!@# & , 8 P!@# & , 8
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M!G/.Q1D=<.$W'%=6SU;SMO4*W=02MPT6E^+>_K-@\Q,BS!_XQ?\ GF9_9Q\
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MTY****5-4$42AF0J);<%]J"*\,242:6J)WB=O7(F+/HYB, 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & 6MX&%DO.2) @8^^\K2G7GH$5QUU6DI1I3CBVMK6K2$I3K:M
M[WZ4IUY^6M:RW?%]I++@NPN2$(:0AMM"6VVTI0VA"=)0A"-:2E"$IUK24I3K
M6DIUK6M:UK6M>6LA3E@# & , 8 P!@# ([HV]?'NK_/_  =$8UO_ /#?R<<\
MWY;_ /TWK?\ [-X'U:DB8!'W6OO5=-_1]<_\.$LT57N:H^0G?HXCD=(/>'&_
MFC$OH4XK.:_>ZH/]"JK_ '% RT_N>1\C*_,A-N#>\^%?-M#]%E&:YN.D, 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & 13SG_Q/W#]*T/_
M )0\GR+6+K^I&B3^^57R\/T:G)6RF\C[K7WJNF_H^N?^'"6:*KW-4?(3OT<1
MR.D'O#C?S1B7T*<5G-?O=4'^A55_N*!EI_<\CY&5^9";<&]Y\*^;:'Z+*,US
M<=(8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M!+3;>D2+@'N JH,3R-8E2+)6QY^O]'B!03$".4IDDB!L0VMW<%86XLY$>3?
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M]0<>)X3\<1_U;.^V'LSTS_B53?[TTG_3A\L7C%_,OK_^]!4/J#CQ/"?CB/\
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MQ25K<.U/T,7OQ[&O2C,LA1@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & ?FDI3M6TI3K:U>I>]:UK:E>E*?4K>OXRO2E*?/?GOTI3K^#6M
M8!^X!'W6OO5=-_1]<_\ #A+-%5[FJ/D)WZ.(Y'2#WAQOYHQ+Z%.*SFOWNJ#_
M $*JO]Q0,M/[GD?(ROS(3;@WO/A7S;0_191FN;CI# & , 8 P#\VE*MIVI*=
M[0KU(WO6M[0K:5(VI.]_.E6T*4GSUY;]*E)_@WO6P/W & , 8 P!@# & , 8
M!Q2E*$I0A*4(0G24(3K24I2G7DE*4ZUK24IUK6M:UK6M:UY:UY8!RP!@# &
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MKH52M-<*ZIL2X1PGP&<:+R(5;7#,RI;J[[*_HXV%\K[O1G;/UW&S&0HP!@#
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!#'<^CE.95<$7$O
M56')-WFK5%92Z2)$6MAXU@EN1GRI)Z-+@N(:AI1I?SRF6][W^_7K65*[W[]-
M<D1NRW;M=,WO-?"7BH-C(LB-).\3;:A=0JM#E=7;L,U_D2(MDHEJM[_O$YTI
M"U!/A)5=B"B([=BEQT)/AWU2&Y,O<!G+96Y1/)O9_A:I<'Z-QCM/>UJE=9K-
M/GR,[K_B'(2Z-UBT/-5"Z-T-T5 I]HYR1ES:1TNP62%%9 UD%.E+EM:,:M1
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B?#@K=_G;\AE#I?B[]NGFL3+D*, 8 P!@# & , 8 P#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g945651g12j65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g12j65.jpg
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M 0$! ?_  !$( $P \ ,!$0 "$0$#$0'_Q  >  $  @(# 0$!
M!P@%!@$"! ,)"O_$ #X0   & @$"! 0"!P0+      $" P0%!@ '$0@2$Q0A
M,146(D$740DR4V%QEM4C,T)2)"4U14948G*!D9/_Q  < 0$  @,! 0$
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MP#3O5/J^ U[FOO[PMH@GY3-ZF0P )QEH@O?W!VG[]MZ.$QA] [3"9^0"% !
MW;SR'<!<]O"ZP&/ &Z%QK\.:'7&5P?Y0?)?F<3I9Q-6W*W7-:]Q>R$:N//\
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M@(CQGR3RWF4>3K%&PQOEF?B>S38HHVN>^63[H\+='&QC07O>][0UK&@N<X@
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%3&(O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g945651g14c79.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g14c79.jpg
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
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M(E%5E-0)%Q@C)#(E,T)2&29A@30U8W%#4U1B<Y'P_\0 '0$!  (# 0$! 0
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , C8'D/.XZX+O8=>TU8]R,G-,N*E9M^' GIL-<=-V*)J[\D[5X:
MRS8#I <S8XF&"FY48PYF0/(;.,2^!). , QF7NE/K\E'0T[:J[#2\OM*8J+E
M9J.CY"1VMS;2-!!E$M$$^][7P4;9;7I;WAI/ES>DYP-3ZKZ7T6_L=*UCJ/0M
M*U/5&EINGZEJUA97M^Y3]E%6EK<UZ=:XWU?T4/90EOJXI1S4:B;*$Y)RC"4H
MQ^\U%M+YM+"_Z<F39WS48 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MIG14QW378>+967\VK52U%OUBJDE&H::<2B&4;-QA;3K"_B+-.-:6PW[4/O\
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MU:4JEU0:7"E;W+JT)Q7W9TY1\BM5A[.I.'[,I)9]$^']5AF89]0:# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M;-VHQM6ORV@M2B4;\I?WMW2]YT%V7R7^>>?Q*K[OY_#_  X_#@J\R8& , 8
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M , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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MO=.C7@WPI4TWPC6G/94A/]F49?-)Y:^JX+?R>U;NW-Z79G5^XV2K\=N53O\
MWLS0S"1)H=S7^Y*V)1@MI25:TO7MUM2=;WXRCX;]1OJSH/I37ZLMUW?Z)82U
M*+^_2U:A0C;ZM0J+O&='4:5S3E&24EMS**;P9K0]G5J0\HR>/W6\Q?UBTR0L
M^W(Q@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@',7UT3]'DK%64"7KATU=.5"-R,ERKH5W=B+'"FS]WY9/UV[U*
M+AJW>)5V\-#5QVJ1H&JSJ8?@.C%%0\F&R2_&V:E<N#<??I.4$\PG+#3<H-2B
ME&3W>ZXI;<XD\-<IV**:4O=FE+A2C'*>%+W7EI;<\MY[QYSY;6>E4.-CN&5P
MZ.F*8="SLK>;C'M4 XLRA5:.M-VL5A13:N9)Q\,;](I*3UUM>C(6OK',BS&M
M5VMLMMP4=/025)/,<2<I8BWLCNDVXQ;2>(MM=ESGB*X4=7.]IIY6%[V-SPDL
MRPWR^_=]^[[O0WU 6KFU_L'?;!#VW@P%>YW(5V<L@!?:N@5J^=?.C^/CCF2%
M2FN>7Z%BJ<#:*7;I#BQ!X59NI=Y*K2H2PCO:JM=#BJM64)2K-2I*,=KEFK.,
MIM4^\7"22S&3IY2ENVX:]U8FIJ45!8GF64O<BXQ6_M)2B\X:4^6E'.5W>>ML
M(H94-$*#!5&"*C %"QJVVVEQXVQ6ML K:96XTVH1K:6%-M+6VC;>TH6I.M;W
M?79<8X7'I\/H5GW>?4N>9,# -?ZIQVU5OJUHZ69TEJPHM4@9\W&2=+"W+1]6
M2V_JO4B$L_UEQV'K=?(4.?\ )Q\6.W,R:#9:5;?EI,H[8&P& 0KZBB'6>*W]
MEA7M>EHD>N,^/SV[:)0"N-HUK[>=K5*:1I/_ %>[Q^N>4>.-:I2\)^M:-*6V
MKJ>F4=!I/UJ=1:A9Z#3CC*SOGJ*ACSW8)[9+V]-OM%N;^4(N?^!=^I]1I_"J
M&NY6U,LW6XE^*B%*AXB0F7V-F.H"#4\S'#OJ&%2K26U%$::'TZID;3FR21F7
M?4J%&G;4*-O2CMI6]*G1I1_9ITH*$(_2,4B!O+;?=\LN]O:F+?S6P-TPTB(F
M[)3SMULTQHN*,"-E8I:XY1+1#31\24A;[:'=O,-F1KVU+6RE]C;>OG>M=/UK
M5ND.I],Z<O?R=KVH:%JEGI%[[25'[-J%Q9UJ5K45>"<[=JK**5S33J6S:KTT
MYTXHWIN,:D)368J<7)8SE)IOCSX\O/L<_O2%1>C\LZ_)0E_:.J;-EJ<P['PL
MB2V^/:Y**DXI3Q$<Z(^3'$FPXKA)#KFB-F_(EK<8;=#=)>:_#_\ !AZ.Z[\.
MO$[4-)ZUI7G35+7^FM4JV6DWUQ"M0ZCO]-U#3I5:]E5MJUQ8W%WI=M4N*U2:
MK_:U:74ZE*%2UJ7%6GT;VI2JT8RIM3<9QS)+F"E&6$\X:W-+C&,K#PTD^GN?
MT'.6, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , Y[6WT_>HK^\9^QTM?"#:\#ZCB?4+!+N$C>1K$](E<F+Y9]#E
M41-9/!8;&#-6:,<&6^^E(88OA+6MZ14E1J[]T?9-*JZJW.6[+I^SP\1:PEZ/
M/")XSI[<2]IET]CPHXQO4N,O/E^/)LYP+GUJYYSHJOWQZLEV6:Z!UV]S#547
M(D5D9SJ'4;AT/<7&KF0P3WQP&[1H)UPH-E3[S3SFTJ2Y[E34H2A!J>W,IU)O
M;G;[\Y2PLI/S\R.I)2EF.<*,8K.$WMBHY>./(AN\73C5-G;C' ^EV6O4!S3Y
M;74+S3.=<I?KE$<(K\;;7ABP9^R5^X6DV,JDS$6.5"H%6MI(D;)"M);>E%JC
M4QRE3BY)4')0^_*,*>(<*6&I2C*3VM-J$9-)KC+-XJ;2?M5%RSMBY3S+#:\D
MTLM-+<US\.3<@,@0H,4H!QEX$D9@@-X?:5#NB/-)<'<84C]C;+C*D*:VG]G:
M-IVG[>,L+&%CMCCY$)4YD# & , @_NW^JB.?0._NW9.Q<VCGV_\ \T6.G4VD
MM&]?EO7RU>=5O6_.M:3[O'VSR/QA_E.F=$Z,^8:]XH]!6-:'^\M[#6(]174,
M>?\ )M#JR??"CG&$R>WXE4E^Q1JM?-QV+^N7U[=V34^,.4WMDIADEG>];VT^
MTAYO>T[\IWM#B5)WO6_OK>]>=;_+/7" ]=:TG6DIUI*4ZUI*=:UK6M:UXUK6
MM?;6M:^VM:^VM8!'/3Z,Y>*\AN+,3$6ZOG,6*D3_ +?*H>RQVEJ$4]XUO;L9
M(-J=BYD127&RHPPE"FEN):VGX3Q!Z0J=7:)"&G74=,ZFT2\HZ[TEK.&WI>OV
M*D[:5513=33[Z$JNG:K;.,X7&GW5>#IRFJ;C+1J>SGSS"2<:D?6$N']5]Z/Q
M2\LE1S:\M7ZLM2CH:HF=CRR8*VU]U7DFO6F*7IB7BGOOO:FT/>T@!_>_!<:0
M&6GQI[VZGZ"ZOI]9]/T]1JVLM,UFQN;C1^IM$JR4J^A]1:=)4=3TVKAO="%1
MQN+.MVNK"O:W,<*MA8JT_9SVYW1:4H2\I0E]V7U[->337D9_GVA&, 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & :)
M][B+K4>G5NUE=;]4L9R2P1ML59 >/5.'Z(FM6]AVH#4J(:K=;Y)=;X!698!Z
MXF%2;0,ZC4V%&C'RT&*^R/*U:RE&<9>TKJFU+<J:WXE[JBMJA*2B\R;:3Y2Y
M2X<T,.+2C3<UC&Y[<KG<\RFHMKCCCCU)X]./XYWRB*5T VYR<PY/7=V*D^C!
MQD7?9&F.W.><HAMPB(B/B@8>=(IZH59D8F-CBA/*$249$R>S(D&6CN]FM[DW
MNGAS24]NY[=R26'MQY+Y+LM*F-WNX7"SM>8YPMV'SE9SYOX-KDTVOG-?4+T*
MQ]<._N,E:NQ;SVHTZ(@/5016^>].$&H59A!)>_0T56'YHADG8[M6GS*H]2)R
M7J,)'P!K9>XP61+K3A6FZC]E*.[AJ-?;"?N))S23?/W9..UN*2YPFY8RA':M
M^<>;IIN/+>(Y>.W*SE*3;XY.F,<PX-'@C.M!L.CABL.,1Z%-@,N-,(;6T"VO
M25MAMJ3M R%)2I+*4)5K6];UEY=E_AV^A7?=_P"/?ZE9@# & , @_H_^OZEP
M2%5^TTBQW6UNH_?^':1)1X[GC_Z9ME%^_C[>[QKQM6MYY%UW_+/$/P9TE^]2
MCKW5?4E6&,_ZBZ1U"RH5'Z>SN]?M^<<.:64VB>EQ2N)<_<A#X>_43>?I!X/Y
MTO[6GU >NCF/K+7'\ROO4:;SBK4.KWV@QW.Y"49KQ4 ,!K\7VB^141MR,EQP
M[<%8H\_\:"E10T&"&A;#8)#JR/0K^K<PN,0G4C",%."@VDUCWI22X>)93W92
M6/4_.OB/K/5UAU0X6%YJ%K8V]G;WEG"RJ5%0E1C!?:;B\ITFZ=2,+F->$_M<
M94HT8132A)N7].5#DY6:HU,F)UV*?FY:J5V3F'X$EHV#>E3X<,J0=AC&''F"
MXIPMUY<<2R\ZT^&IEUMQ:%I5OLQ;<8MXRXIO#RLM<X?FL]GZ'O=G.I5M+6I6
M=-U:EO0G5=&2G2=2=*,INE*+<94W)MPDFU*.&FT\F5YL6#7V_-N<MN3/8(YM
M?X4FDQ\#UX%A&U)8":5H6O\ 0D-(U[MD5M;VHZ>6C3BWJX^E_P"%M44E>O$^
MLZ<_#OJFGXH6,)?FYJT;+1O$ZSI0<HT;2G)6^B];PIP6YU]!G45CK,HQJ3JZ
M%75;V>=-4U8I_I8>Q?WXYE1?J^7*E\I]X^D_WB?VW&WFVWF7$.M.H0XTZVM*
MVW&UITI#C:T[VE:%IWI2%IWM*D[UO6]ZWK>>TTZD*L(5:4X5*=2$:E.I3DIP
MJ0FE*$X3BW&4)1:E&46U)---IE?MW/O-P, 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# .??K3JQ]QN7$X*";H%MMSS=
MIE*;R^\V]%1.DIJK7#DEK*Z!1%'Q,K"3%LIT+#R-?4(9H&8CX2^2DQ R#3 4
MZ#)5+F+E*FELE+$G&$Y;6VI4VYPRFG**6/)I2;3[ISTGA3;W17"E)+.$U-;9
M8:PFWGT;CA]T3_Z7HI<'R9J*<=@VG ;WU8=RO5@V4DZW0GF^FVQ+_-X.2F(R
M%+D([G[^G*FT4S%1T2M<4YJO B5Y,6,U+06*>&UE3GE+.(>^_<3:3:A]W.,<
M<<8(ZCS+//*B\OAR]U>]A=MW?N_B\Y-3_4!ZANL4/LELJH5SFZ@VW$38O+:8
M!R%ZY"WXL?GE0M%6GF)),'(2EFD;'TLNU\P+K=<G(/Z/%Q&S360SC8^PMP5:
MU2%245)Q6);(^SW*6(1E%IXS)RGN@XJ2PDFTFTR6$(.";2?*W/>DU[TE)=\)
M*.)9:?/FUP=*(UTU^. ?D14 R#P0KIX3;R2$!FN,-K*%0^G]E] [ZG&DO)_9
M<TC2]?967%G"RL/"RO1^:*[[O';R*W,@UIHI$E7.X^H!-JOLK,PS-4Y'8Q-V
M0N-CX*HB3$MUQG<7####@1\;&C!QD:R087LB3E"F%'2LB2ZXVA@")(:2/A_4
M4W89"S0]X1>^SVZ@1M?@^B],;F.>-0',CW6]R//BI@2@E1X(E3=7.BJJ*%AR
M-K#N %GE5D@LK WQP"#S_P#B/J+K8ZOVFZOR&S2B=?G\,JTVROQC*_W:^(-7
M3D^?S5[/&OMK>>17C^W>.FA4)>]#I[PPZ@U&*QG9<=1]2Z)84Y?#?;Z%=Q]9
M;7AX3)UQ;2?G.M!?-0A)O\'*/XFOGII ![)U?U;]^FPQ9FMVZZ:]-M!'D!VC
MXXWEG"F9.NVE8VGTK&+A;=U>?Z0Z4SI"Q3AH\+XGQD)2K?J=%>TJ7%5I-2E[
M&/FG"EE2[\-2FY9\G@^)T&$-3U'J36:L8U:%S=_D.S4TIPEI^D*I0N''<G&5
M*YU&M?.44G&:A'.Y)'CZ:3SO3QTR;]%=M,*>K D9)7_TG6*3?=>7.\@08C5@
MY.Z<2I:S++Q"3-8CPV%$/FF\XDJU(:888BS-H46Z4W;2?&'.@V^]/*S3_>IM
M]O.#3[)FNA3EHM_5Z5N92=O&G4O>G:]1MNMIBFO;:<YRRYU])J34(IRE.=C4
MH3PE3D;\Y:/L2F,#%D!"@#AV3 CAGPS!"&TNCE"DM*9('?:7K:'&7FEK;=;7
MK:5H4I*M;UO>L@NK6VO;:XLKRA2N;2[H5K6ZMJ\(U*-Q;7%.5*O0K4YIQJ4J
MM*<J=2$DXSA)Q::;,IM--/#3337=-<I_0@OF1A7/[&5Q*=(>>##$?FN42Q;B
MEN2]*:=2@FLO$.;WM^9HSKK82D^_;Q-?=BS?@H2R0K7CWA_<W/16N7/A+K%>
MK5M;2UK:MX;ZG<SE.>I])4ZD85] JUYN7MM5Z0JU:=I*+G[:XT2KIUW[*,:=
M>2L54JL%<1[MJ-:/I4\IK_AJ=^W$DUYD^Y[05A@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!SE]2E]Y/*WL(:Z1-2L
M\A4(GHE =KC_ '[B= FH1-AE..W*%OPC]AO<!:JI9P9:EHU5"XQR.L4$5'F2
MSFP]%0A#]2M*#DMRC)Q4X8]K3BUETY*?,E*,DX>[C$HXSQP3TXS2S'.&XRSL
MFT\*::X337//D\KXD^^DL9B'X/%F$65^QHD+/U"V2%DE+-0K444]8NC6RQR!
M,G9N:FF4>2*8=/>0<9"N#,_&:=^: C#$D@#24.*2>6\RG)MRC)MN3;Y@W%]_
M+\%V-*N7/MC$8I)*2[)+M+DU-[1U:J$=>D"^<^I#E_IWDBPJ7-R?3K#WZ-L@
M-TAI>IP$O"% >FF3=D:+)@G5LL 1FWRTM1+*4&@<V'>D8Q^/D\@J3BZC<*T*
M.5%N;JJ6Y.*<6J+S%III9;BVL-97>2$);<2IRFO>2BHXPTVG[^5)8?.$FL]_
M,ZCB+TZ*,YHALO3@[*]%-:2EHG2VTJT0VE"EI2V]Y^(C25J3I*M:TI6O&]WE
MV7G\?4KON_+X>A48!0$1,69HW1<;'E:D1V19#1 8[^CQ1E/*'&-TZVKYH=A1
M!"F67_B-M*?>VA*=NKVH"G:K\"S,D6-F$B&K"8*V"7/-1H3<R4$UM&V@R)1+
M.CGQ6]MHVV.Z^II&T(VE&O;KP!=\ T2[SUE_CX?JUZ\$WLJP4'E7/*;10TH2
MZN1O]GW8=TR$;;5Y^(J6N=PJ@?PDI6I6B]J^&O?M3OQ[0:GVKQ>\4=0:W/1>
MFO#_ *;MWWVSK0ZAZ@N*7I[SU:QGA?M)M/*.;U'J3T?IV[OH+=6IT:\K:&,N
MI>5G3M;*FEY^TNITX86>_9]C8/TY<F8X7PKE7)6G=$DTBEP\5-'Z6IS<O:'&
M/G[;...*\J<>GK09+S#[BM[4MXYQ2M[WO>]^NT:?LJ4*??;%)OUEWD_K)M_4
MTT33HZ1I&G::GNE:6M*G5GG/M;AK?<UFWRW6N)5*LGYN;(>]=E3C"^!V3K+5
MA9H]^].#!W=.8W]8KQ:J[:*1&&&OQ1PXB5%R-:O,/H^E6F$;0^B4B9M?@0DP
M8)*8[J*]E*IG;.CFK"7I**SA^L9+W9+S3[92.9U=;4Y:/7U)5E:7FAJ>KV%X
MXRE["XM*<YRIS4/?J6]W2WVMQ12DJM.JUME.,,:^>A#^U/YEZV[C-\R8HM@Y
MKT.'K.[4-'2DF!-PMBBPB(\&;5$R@S(3[!T<;)"NZC"P?B/QKBS&"GMB&M#Q
M6M["YDX;7":CNPVFFEA/#XY3?;';G/?'&Z0\0K#JNYJV"M*UA?4J'VB-.I4A
M6I5Z<'"%5TJD5"2G3G.+]G*&73>]2>V:CU.RZ>@D:]1HY%T@6'(0IN*NM8.:
ML=&G%:WXCK"$A>FF"MI_:<AYD=;T1-BJTMHB.+=4IIQUEGV_!>(?2%?JO1J,
M])N8:;U9T_>4]=Z0UB2;5AK=I":IT;G;[U32]4H3JZ9J]LU.G6L;JHW3G4I4
MMLM*HH2>Y;H26VI'UB_3_B3Q*+\FOF8[SGO%$OKH%>7+A0W0]LDL3=%-=6U*
MQ<U%./C3<6RIU"&#U!$AEK;^5==>= ;2:IEMO:_9P^A?&3H[K.I9Z)+5+32N
MN/97%+5^C[NK*GJ6G:MIM2M;:OIU-U(PI7LK.XM;F</LU2I5J64(WDJ4*3DX
M[5;>I3S+:Y4\K;42]UQ?,9/';*:SGA/C/;,V9ZR0# & , 8!Y.OLL)TM]YIE
M"EI;2IUQ#:5.+W[4(TI>TZVM>_LE.M^Y6_MK6]Y'4JTJ,5*M4ITHRE&"E4G&
M$7.;Q""<FDY2?$8KF3X2;'^?P[GKD@& , 8 P!@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P#1'U=UCHYLC7'^=,6V)CD5:]62?D>:\]HMLL=AL
MU9DZ')QU8ES+51[L_'IFN?L],:J^P@1=R]T8@(E\]XQV&@INM<*IQLW);92>
MR,92<DXO:]T98S#?MPN986<X3GI.*3W8;RDMS:23365B45E2VYSPHY?JR9O2
MSN<WQN(3.D7(]3=FZ"W"S-_JC=#N%@J:;[8_PC.S=+;K5.56BI.M[C']1[U6
M@'W&MMGKB@?G$C-[T,NFLN;YEASCMDX[GM;CB.W*QQM7KCDTJXWO&%Q'*B]R
M3VK*4LO.'\7Z99H+U:=OE'N?9*@#U#UP=%A]RDY]>.JLYZ3JQ&!.P_&:!<+1
M5ZX38* S<TD0]$F8V?0;3@*V^\Z3))@!)>Z1D[/S%6;E"<X^TNIK+W8=!)8I
MPDTLP4N(-/W=OPS)2DYXN+C%N-"+PL;E5;YE)*3Q+:LR37.4O/$6DNN$,L=<
M1%+%<V\*N-!6,[LO<AMT=0K6V7-G[4O9NUM[2K9>UJV3Y^-M2MK\[OQ[+'HO
M["H^[SW\RY9D# & , Y46_?]\'JNHG&VM_,QC'?[/ZC>E-HU[M(I_ILJM.IG
M-(\Y"_\ *<#F>T3D68VRI*_B[I9F]:U\%>E^,^&W\OZ@\5M5E[TKWQ-O;/=^
MU:]*].].Z%0CE]]E[;74,=DZ;2QRCYCJ+^7ZUTMH:YIT95.HK^*SQ0TV;5C&
M>>'&MJ5S;S2YS]ED^RP^J^>S'TYC5RI];Z#4K-1+E$C3U3N,#*UFR0I>W-#R
MD)-A/QTF"ZME;3[22!"'6]/#NM$,J5IUAUIY"'$XE%3C*,EF,DXM/S36&OP(
M+JVH7MM<6=U3C6MKJC4H5Z4L[:E*K!PJ0;336Z,FLQ:DN\6FDSG'RC^Q\]#O
M*G+(]J@S_0"+"XRH4OH=H)D#JFPP\LAL>FGUP:KF0;FG-HUN6T^18-MLH9^L
M::6^AZG"PMH;O<<\_MR;<?W6L-?/[WQ/A].\,^D].=>2LZUY*LUME>W$ISMH
MIY4;6=!6\J33Q^ES*OA8]KC*<O\ ^#.=IO\ F\']5?J2Y.EG]D"M6*W =YY\
M&Q^@C=;[7&V^<8%U_M2W%W"+6A*EJ;=0]M#S<GV=Q_55ZU/':+E[6&/3%12>
M/E)?CR=/\UZUKSI'4.NZ=MXA0KW,-8LXK]E4-5IW56,?A3N:;Y>'G#3X_P#:
M$\[_ .:#Z:_4Q"B?LZ6$5<O3KT.0;U^3BAS$]:H+Q?Y[VE)M?%5OVHU[-;4Z
MA_*X>5&LEZ;J4W\>?:0]?-#/6EEWAH6O4H\>Y*ZT2]FO5J:U*S<O5;Z,7V6.
MZ_G]Y7ZW:U+>I"LU.0Y)W$&PO=/F8N>KE#V[8^@P"039;YOZ"FN!NV6PV&%4
M-MV3!CX  IYH61V,ZA2$;5^#=!_@IZE8>)3Z@N>KZU+IVAJUWJ=G4T:O?V?6
M'M*M2M5H4)7E.E&E:5Z%2I%5]0MKFM5N(TIN%M;2KYH<.W\9[&YK6^E_F[JR
MU*I=.TNK>G&G>1HJG*<:LJ-.BG<W=2"@W*W5M2:]_%26Q;^S/^)[TO1_^7:>
MX^K_ )F2G?\ FB](H?J"JGR_Z;^.=8>5N1*-(WYTOW2._;]]JW[?&\_2W\5U
MJON^)7B_;\8Q/K.]J8\\_P KL*_/[S;_ *SZ3\_- AQ=*YL9><;[0=7M-O[U
M2I91I+T>:G'T3,NKOJ$]']H4EJ#_ +0MMHA>_" Y;N7.(0]2]_;X20+;!!FJ
M=UO\VO@;=3O6_<G6];S:/AG/"]EXO>*]/"PL]2Z'5?I_VOIJNV_C+.2S0ZUZ
M6N&E3UG07)\*%2\HT)M^BA5KTI-\<K:WZ]WF?*Y#0%MTA5)]65PLZ7->YK<)
M<>3V=*]>/.MIV!42/?KQYWY3OQO7_P!LECX9ZU'_ $;QE\4/A[:ZZ+N_QW]&
MK/UY.S0U2PNL?9ZFGW"?;V%=5<_)TZ\L_/\ Z&9?W77]O_X?O_1$^/R^9@>;
M%[_]]KIB//\ [_G_ .^;_P 7G6D/U'C3UQ%^7VC1N@KI?53Z4AG_ #Z%GVM/
MSMZ?PQ*JOQ]_GY#^[KJZ/^5Z@K(KQ_\ J:!S9[]_Y[9KPN]__P!^=^/OF/S&
M\2(_J_&S7Y+R5?HSH&KCYNEH=NWY<_/U'M:/_P -#_YE7_\ ?_#_ *&GWJEX
M/WJV.U0H6T$]3C ]/B?*N#5JHN0\B8^VAI_8#1,='':/3MMA)J=K*84SMEQ+
M;"VU*_,7\(;P7\:NJJW3M:RUZZ\2+&TA<47:*UT+INII5W7J0Q<RL:->RLKN
M%S3VTW>K=<6ZI2IU53H2C-W+6YMJ:GN2H-M<N4I*7DEEY:>6\+SSA99LG0JE
MZDZG2ZS#NW#FDN3'0P0KX=FK]F(D U-,ZTD!VQQ5FTW)+"3[1/G]Q6M.I9TK
M2'->'5^[]&]->/7372G3^EU.J>@=4N+'2[6WK6W4&B=05[VUE"FL6=37=.ZA
MC#4)6D=MK]L>FQ56-)24:G%2=:I.UG.4E"K%.3:<)02?QVN'&>^,\9^AEWUC
MU#Q_W*HW*[&C7Z0M\L<$^K7_ /%,4TYEO>_T3\TYK]Z]?GGTRU3QPLEFYZ0\
M.==BO+2>L]>T>K+_ )>J=*7E*#?=1^TS7DY^9IMMGVJ5H_O4XR_NU%_8A_>-
MU0/]J5X%8EMI_P![E;O%%F__ +_#8/E*^6YKQY\?Z=.][\:WI.]X777B+;<Z
MEX,:Y*FOO5-!ZOZ.U=8]84KW4=#N9_!>P7QP^#/LJ+[7$<^DJ=2/XM*27XGY
M_?>@?_YKR?MD3K7_ #%JH#LTTW^_>W*K(SZ=IU^>U)\Z\??[?EC^-N-'_67A
MMXLZ8E]^4NBZFKTX)-IMSZ;OM;3BL9<EE8Y'V?/:M0?_ #-OT]^,1_B+Y*S]
MI.=F*^YK[+;LE*N\#\/?[G'I2NC#:\?KO3ZDZ_+>_./X\O#6D]NH:QJFBS7W
MX:]TGU=HOL_A.KJ6AV]NL>;59I>;'V:L^T5+]V=.7]DGW\O4OT=W#CDM[= ]
M1H3BU?9++MJAA"%;W^FABRV'][_?K3?V_7.Q8^+GA;J6U6?B)T94G+[M*IU'
MI5O7?RH7-U1K/X_H^.,]S5V]==Z53Z0D_P"M)F>Q\["2^M*BIB*DT[UYTJ/D
M!#=;U^?G6QGG=;UX^_G7VS[.RU?2=22EIVJ:=J$6LJ5E>VUTFO5.A5J+'Q(G
M&2[Q:^::_M+KG1,# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , T ]70#
M,UUKAT(=6>8W..*I?8S%UKM_4YKE7-23093DZ!9 &3@ZK>7I7H(#)9B(>-+J
MQ;2:R7;2QY".6P]HNI<+,Z:Q"7NU,*K-TX9S3Y349;IKR3B^')IKSGI<0GS)
M<QYA%2GVEY-QQ'U:?+23^&SG#XE$+RB#C(JM\VIOP/KWRD#S"X2?0^?1[[TU
M)O)<C+1(5BC2,JDEYSYR7:77XQ0<D^='LNDH&;.?GI+%-+;"+YXA)RAW?:3C
M%OX\</*(IXW/F4NW,DHR[>B<DOARSFWW31)]QNM8Z61QZ4FFFQ+9T.<I/)?5
M(&$ 75*.@,AJ5L'/NRQCK\TSR2[IW<H.&<.D)3EIT>-<PS*XU!"IIU>92C/V
M;:Q*3C"OA;8^;A/E^SD]R6<P:4N-J+,,**E'>EVBG.GYRXXE!K&]>ZWC$N5S
MEG7F+T,F,CM!["V)H 30NXU*41VQM#MZ8V A"EH2%MKV_*I0M:4L?#TE2M:U
MO=]=EC';R[?3X%1]W_CW^I79D# ,"$Z=1Y#HDARJ/GQ#[U$5Y5GFH4+:B5PL
M7\W&B,IEB&M*&!D"=RP)(\6^ZF05'OLR"QD!DB/$ 9;*RT7!1Q<O-R0,1% -
M;?-DI(M@$$1G6])^(042MMAE'N4E.E.+3K:E)3KRI6M;I:CJ.GZ197.I:K?6
M>F:=9TW6N[^_N:-G9VU)-1=2XN;B=.C1ANE&.ZI.*W-+.6D92<FE%-M\))-M
MOT27+.=7H5IYL[T?U1>HB<WM]R\]":Y_0''D[VL7G]7V9=I @)>_'L%GK]T6
MR*>3K7^HU @D>=M_!WGD'@)<VNJ=#W.OV]S0NI=0=7=;ZQ7G0JTZJA/4.K-7
MNJ4:CIRELJ2M*MK.5.>)QA*F]JC*+?$M[*NNH=?U*YA..Y:9I6GJI%K%A8V%
M*XJSIY2]RMJ-[=IM<2="+\D=)<]L.T, 8 P!@$91G%N/0O0)/J\/ROG<7T^9
M:=9ENB1],KH=VDFR$?#)2;9QXYN9)V4WI+1:G3%+*:;:;(4XAEI*-%3IJ3FJ
M<%-]YJ,5)Y[YEC+S\RA3TK3*5Y4U&EI]E3OZJ:J7L+6A&[J*2Q+?<1@JLMRX
MEF;<DDGE)$FYN7S$;%S^AV]*D6VDU&T(7KVK38JW#3:5I_+PI,F$3I6O'V\;
MUO6:N,9?>C&7S2?]J*U>SL[G_2;6VN/+]/0I5>/3])"1 =C]#'HUM:E.37I=
MX4M]>_<LR.YG5((]:O\ O5(049&FJ<U^:7-D;6G>M;2K7C612MK>7>A2^D(I
M_BDF<>OTETO<<U>G](;_ &H6%M1GWSG?1ITYYSY[C#/_  \/2X#^W4Z]T?G)
M*?\ DE<V[WW6D_+[U^6V 8/HHT2CV[\;3YCE>WQX3XUYUO7[)07W5.#\G"K5
MCCY)32_J*OYE=/PYMJ-]8R7W96&L:O:;?W84;Z-)8\O<POD/\%AL=^U4_5_Z
MU*RM'W8;)[+%W\5O>O\ :EUGJE*O+Y#2?RVAPK2]Z^WQ=?GC[-C[MQ<K_F*7
M]^,A^:TX?Z/U+U5;X[)ZI3O(K';*U&TO)->J<N?7MCD'_:A^@WUY=+,Y8JE]
M)Z)ZL:3"M20R8B78YC39RE6(LIKX4D;%56-HD-8!I$'3++5F?!-E(E89@QI
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M<ZO)HJ224I;G^UA1S]%QQV(VTVVEA>F<X^K,IS8P, 8 P!@# & , 8 P!@#
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MZG_&&_Y4[^EP!^.ZG_&&_P"5._I< ?CNI_QAO^5._I< ?CNI_P 8;_E3OZ7
M'X[J?\8;_E3OZ7 'X[J?\8;_ )4[^EP!^.ZG_&&_Y4[^EP!^.ZG_ !AO^5._
MI< ?CNI_QAO^5._I< ?CNI_QAO\ E3OZ7 'X[J?\8;_E3OZ7 'X[J?\ &&_Y
M4[^EP!^.ZG_&&_Y4[^EP!^.ZG_&&_P"5._I< ?CNI_QAO^5._I< ]6+K6"7V
M1F)5MQXAUMAE&AS$[6ZZO3;:/<H9*=>Y:M:\J5I.O/G>]:\[P#*< 8 P!@#
M& , A>&X+1*^5(F0[UK!>(B)V A?@6V<0FD0=GFA+%88JB>TO2JP'+3,=&%O
MH!5[V&8J*C 5B1$8  .!<!>+TH2Y-71/U]\H2Q2UQC((NQRY53B+C.QAD/,6
MF+KKY*P!)<^.DI5E>])4$,]+2QX(0LC)FF/@2Q@# & , 8 P!@# & , 8 P!
M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MW6 A&'-ZVG;C(S+2]I5_N3M:$)5O2O&O.O/C?C[X!ZCC#B,H'$89%':UO3;
M[2&66]*5M6](:;2E"-;4I2MZ2G7E6][W]][W@'M@# & , 8 P"C:CH]C:]L
MAL[<;4TO;0K#>UM+\>]M>T(UM3:O&O<C?E*O&O.M^-8![#CL"LMC"L,C#LIT
MAE@=M#++2-?DAMIM*4(3K]$I3K6OTU@'M@# & , 8 P!@# & , 8 P!@# &
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M@:7K;#XG/$5'MM)KJ;5HD,EF8FXNO56]3]DM(<O(/-%_0!UQKT!'MD".@2E
M>H<R%O8,/8>GU.R<G'O4Q6-=@/W6HB'G'=\I'NC%?(L,4H*H/3<).(/845!-
M@-%B*9AR =R\5)$$@8# ]U[19N;R70=] K%<3$\T].LNL.5@HJ&BBIGK+$,3
M;)(^QR,?+,5XID5TH:GN2@#-3A9PYHJZJ)@&7?D ),YMT:6MT]P.UIDI"5D[
M+.]IYA;7R@JX'J3@*N-.S\=+D.TF=L-,L2JW.56)@@;;7)!$0<[:)QX**KKL
MT; @@;MX P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M&YQEBOT\_+15X C YN:$)LNYL\-Z08+$C]Z=W86Q_P#A[P[Y3*Q5 _$8 A6
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M7]TIN:(AI>,W$GC1Q9\U]0A@/2[\+O=EL73)0:(I+DU/'R\E5.EF6*=C[B%
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MO=+9+$U^'(.E;M*RL&LV5*'DYR3"A1"IDM1O@$0"+Z+Z7[=78V@0I-:Y^&_
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'!@# & ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g945651g22c70.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g22c70.jpg
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M 0$! 0$! 0$! 0'_P  1"  : !L# 1$  A$! Q$!_\0 &@   @(#
M        " H'"0$#!O_$ "<0  $%  $#! ,  P        0! @,%!@<($1(
M$R$B%!4D(R5#_\0 ' $  0,%                !@0'"  ! P4)_\0 +A$
M @("  4# @0'         0(#! 41  82(3$'$T$B410C8:$R,T)2<8&1_]H
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<U(*\EEU)"M.\,:-,RCL&D+$#L#P5'I;PX''_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g945651g24j64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g24j64.jpg
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M(" @(" @(" @(" @(" @(" @(" */#]X<&%C:V5T(&5N9#TB=R(_/O_; $,
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_
M !$( %H!"@,!$0 "$0$#$0'_Q  >  $  @(# 0$!            !0<&" $#
M! D""O_$ $\0   & @$" P,&" 80!P    $" P0%!@ '$0@2$Q0A%C%!"14B
M46&1%R-5<8&5H=,D,C9%4E0E,S4W0D-$1D=R=7:2EK&T8H6&M\+5\/_$ !L!
M 0 # 0$! 0             ! @4#! 8'_\0 3Q$  0," @8%!P4,!@L
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M'2L M<EE=-%3'9ULC1>QNHL=WQK]&:]!'[%03%3>-3F()2F*1PD8Q3'=*LB
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M!F>G4G(CQR938NN4REY^LYC@0 ^(F /CEC_HV<X?78O8XVPZBO\ 7PD=]72
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MJ+I8VM;T?F+BY[ T-;T5\J^DXDFP:&V<2<@US2<B%5OM]K%EBC]L260 [A(
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MJ7/#N'N0:S'#_E-@_P";;4'_ $F<?(M'^6Q;]?X[_$DN>'</<N?9J._K,_\
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-G8.9]B+Z&9")A%__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g945651g25t98.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g25t98.jpg
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M47:V-F%Q@;DD-$)B<W1U=R4X4K2UM[@9<H:1H3=%4V-XAXFQ\/_$ !T! 0$
M @,! 0$            ! @0#!08'" G_Q !D$0 ! P,! P4)" P*!@<'!0$!
M  (#! 41(082,1-!46%Q!Q05(H&1H<'P"!8R59.QT=,7(S-"4U1RDI25TM4D
M-%)6<[*SM.'Q0V)T@J*V-39C=8.$M24F1$6&H\-VA8?"Q,?_V@ , P$  A$#
M$0 _ /ZY&?E P4'J70JG:*U2QU$YG9>T!;O9Z[U&?:[_ ,[K_$Z59;N<Z;UK
MF*.:B!O/^:&(E7D! U@^D8].E66PTL6T&>2=ER0Q7&FF?*, \V <Z_YJ.)WR
MH0!NB<LMC5-YY6R-T">(&=>!_1^U$0X#FY_P^6_FU2.5)5IYOR'KB[*5L^NF
M![+69"0(,=)JZ6)[LE$HI @.$ SSYU T'3VX_P U9KFOB#[#?>O!* 5X76Z)
M6"?'*+VDD2LO5[ WT^L!;ZV?@P:H?Y:GC#86)>@5HK\L):1">H+&C8OJ(PS9
M.:RH)LFG3KV:>?/J63YGXM:+TWQ'=F\.0QF)&.<IB,211A%C%$MWO89%?B=2
MT/ PT[(A&.66:Y4ZHG)!5S_T@>-/L06DH%R5K)C3/-G'T:]>#PZ%:["B81,(
MO&?Y;'_U?.6?^<D7_)-OSVVPO_257_L+O[Q O@ON@O\ JQ9O^_F?^GUR\'N0
M^&[H7;(8R=3GZXTP6ZA6.21?C1*5!7JU6VOV>R"W'M,#IND"4CJF43+F:4IY
MF2J(VB(ZAU;C/T&MNE-0.>V<2DLI):P\FP.'(PR11/ RYOC[TK<-X$ DN& #
M^;K'LI<]H(X9*%U(UL]XH[&SOB5\9%;74M95PEP;%)B 14,P?(,N:\Q@,<'%
MS=NKO@XZ\<(?#"#E5ITIBT=@J1=-O+3QR:^1X=5A%QOLDPJ$()^S&1@AF,\-
MF0]3=$5-O[0VVQIA]_@EOE%&W>:)IVF*BF88&-?RC:^5\-.&;SV9>7L(<T[N
M[IDYR!OTNP=\J)>1E-%0O967VAG%=/+$*679VC@KKD^<QP38A;3SL=#)'RG*
MD.P W=<[YA>#SJI;J=#Y6$)T,Y(Z33I?0*G=Q5G5(YW,I@YL[LE8)EA4.:DB
MX8V56RPZ:V1%QI;!!EJ/N-O4J,MVNO=(RDJ*N1E1&*6<4TT#XL5+9W<GNQMC
M#BUY<)&.:6O(+23G0J1["WF:\VVS4\UMJ'W:A?<Z*XPU9=:Y*"(5/*U3ZHQ-
M?#'$^DGBD$L+)&RM#=SQV%V,Y[X6[?T";T8.Y=>94:P\J<M*KM6[Z?-"#0H=
M2E,M6<WN.-K1IA8D3*=W#D/>\ID>\L/H1%4A*7%Y5-V@IFTSQ!5U$=6(>0EI
MXV/C>Z?)BCR^6,[[P-X#&,$9*XK7L=77.2ZP&X6BW55E-:;A2W*IJ(9X8K>6
MMK*C=AI*AI@@>[DW.+P[?:X!A R<X.\'EZGP'CKU[Y,)J3%%=Z.JZ%K*<8K*
MZIKJ!+D<*<W*8JTF;M16V#=[&M[@)]J,FP9;RX[SKL5G!]ZIVN$8IZQ\QJ!2
M\@R*,R\MWHRL<TM,P;XD+_'.]H]KFC( )V(MA;C+$ZI=<K)!0MMINIKYZNI;
M2&B\,36..0/;1/D)FK8?M3>2&]#)&]Q:YQ8W +\+'0Y5+N71:J7I=]H]$O%6
MH=@LM-+D2(]J?;H R6/+Q_?@HR0[7HDTQ  E)ZV&GXAM[3"8;T36YN<GA>F$
M\%-,R>GGJ()JB.*=C6NW87/#F'=D<!(YL;I&-R0Y@SO Z+5.QMT?;Z^ZT<]O
MN5NMMQHK;4U=!/-+$V6NBA?%.WE*>%[J6.2>*FFE+ YE0[=$;F?;%M>O!I;V
M873YI7JO#P6^.6DC3^APR]LL;,VOEX=I,5"#[=J/3)3:XMA+!92@+J'MKE1'
M(STEJ$MQ3+?#X<A+J1K*.OD[]B;-3.9#$6R,,3)G8)G&L;'CE!C0@@%P&5N^
M\*N;'>))KUL]3> :V6@ND<];5MDI9XZV>@CW@VWO:654]._O9P=E["QSQ&26
MBG^=TO#)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBS->_ML;_W
ME/\ _I6>:VQ_ZKWS_8)?_P"JXI_N,OY#OF5I.>T"R=/MHREU1B*\7)IG/^V(
M36!HL<.%0))4P8+DI2D1AXH0*A3",^6ZKR;C1U^S0Z\IMIS\L0Q/GD;'&!O.
MR<N(:UK6@N<YSCHUK6@DD\P7!9;/77ZY4]KM[(W5-0)7[TTK(*>"&GADJ*FI
MJ9Y"&0T]-3Q2332./BL8=T.<6M,NO^%V]N+&R0%BH%RKA<#T$Y N-4L,LC6G
M'>85UVTVX!(=D!X18?88@=+$F) (B8C1%N;$?ARG8BG9#/.:*7Q2U\4C',F<
M)(WES/M##)(PY:'!X;@@%HSO @XR1Z1^P-W)ADHZVS7.AJ*2\U45SMU;)-0E
MUAHG7"Y4;R^FBJ8:V.F#7Q134T;)Q+&Z*1T9<]O%0/#+<NA;YLW M'/P4GK<
M$K,HD*RFRD"4:=#VPG398U"(8$BVV245%2GF65.>Q7 VT^J0AQ:F$(J.27D0
M'Q,-0'&(/<X%V[(Z(MT8[#MYI('#=USS+&S["7.\^ Q#7V>DDVCAJ9;1%755
M1%)5.I;C/;)( (J.<-G-13R.8TNW3#NO+PXE@S=?\)MJM#/O(7I?&I4.5>HO
M-0,U=M,18=HNLP,*,L @$B75V6WI*FS$6#ZI^Q[7Q%#\?2]MH0\YFR@DD&6S
M4Y!E$+"9' /D+6N#6DQC7Q@/&W?&R.M;5'W.[A7MWZ6^[,21R7:.QTDIN-3'
M%<+I+34]4RDHWR4#6ND(J60YF,#>7#V9W0U[M$A>'SI<WGG1^F)&0V '++!\
MVK5%D34Z-:),3QPTQL9 9;>20B5R68#(L$MJ0EH>V7@/;VZTZM;?$*28PS3;
MH#('[CP3XV\"&NW6\X87-WSH!O#KQU,6QM]FLM[OH@B91[/UG>-PC?*.^N79
M-#!4FGA:UPFCH9*FF%9(UX;"VHA=XS7$MVYKPN6.56Z/9X72>0SXO1;#$JE2
M@Q;(>64*6)XA71L\4B.NJ-LHD@G;0)>-:W)]$>.MU<9<M;>FU\@HGED4@FIR
M)GB.,![]XO)8"W!C&K-]I=KH.&3HNR;L!724-JKX;YLW-'>JV.W6V&.NK#45
M%:^:B@EIPQUN:T24CJ^G=59DPQA<6&0@-/3+>&FP5RM1K+:>A\IK#9!^[QQ(
M<U8C;)LP[0;,8J)O0Z+&K$J,YIXT$E,#MO3&/>$.QG'?=MN+2W'43V,#Y)H&
M;W*[K7/?O.Y*1T;L 1D'QF$#77(X97%4["UE#0LKKA>MGJ 3/NK*>FJJVK;5
MU+K/7U-MJN1CCH)&.WZJDD9!O2,Y0.87;A+@WZ*^%;J0)Z'\937Q@\AR =V^
M&<E$9?P:12)\L#"=]$MH:ZOXR*?L0_988IE*HC.U2$NO,O0ERSJ&=N"[=#33
MBJ#B3NF(E@.#CX3=]N\WFXY.F51W/[_2.B-5WG!!/LU!M7%5R3R=[/M4TE'$
M[$C8''OJG?6P]\P%@,;27ASF.B,F#ZCP8KRD!6K 5O\ S*Q-6^!#,UX;43Q@
MD5(U^;*,0&K"U'G5P4QH0DB"(#W'E2=2$RD(3J,I"MN)QGI70,8]TL+Q( Y@
MC<XN<PEPWP"QHW<M(.N<\V-5JW_9"HV>HZ&MJ+Q8JUMRACJJ*&W5=5/43T<L
ME3"VM:R:BIV=[B:DFA<XR;XD ')EIWA!6:J\DF$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB_M+IG^A]3_PT"_\ A<7/HL?W./\ (;_5"_J%:_\ HVW?[#2?
MW>-;+F:WE%LWBW,254M=&G59F34[S:YUUMX-PD:W$L%A*6&+:2KY+>B6GWAI
M8S#966K_ +5->*#UR@<\7(!SIHZ018)GPV\-8NEGZ WS@'\Y;I7[75K6IQ9%
MX"?!7H-S2NW&"2I[TY=/D?.0#QWF88O*4"]]F"Z@-@NR-QES&Y17)]NK/TE;
M/3>1T"@RQ$^KA940@#YU5>3CB)"P66P$=4*E/D)-:"3"%B,%9A1Z!(*$'W3A
M1^;8"3LE:RA6:I*-I*+#@>!\AJY6K'J_28 H[335_L(,W&FE]&-%NJ3RQ;H<
M@P4617/LS-M,FYQPO!LT@O >/(&G$16RP4-,@$4P81,(F$7C/\MC_P"KYRS_
M ,Y(O^2;?GMMA?\ I*K_ -A=_>(%\%]T%_U8LW_?S/\ T^N7C'X<O$X(X<#$
M""-4)'UC.\T7L*WH1&+#0[!J-)Z!5'PJ4/QW=IES'KG'F,R][VRTU!>:6TI;
MJ%)]O<[2^OE?(R9D>];YZ+#FDX=-/3S"3((T:(2TMXDN!SQ7P/97:Z#9ZFIX
M):*6I,.TMMOI='*R,.CH;?<Z)U. YIP^1U>V1K_@M;&X$$N!$Q ?E I,2M<H
M09IC\OH7.JIVD 5NT:6.<7<BU_Y<(YA2K2;@DH,MJ88K 6NUV(=7/U,38HP9
MEU__ )1*DZWI2;.!TM7N3@4U3-0R,@(>.093U;ZN>%CFN!:R5\LICW<&(O(&
M@&._INZ<^.CLHJ*!S[I:Z*_TTUQ8^(FOGN=H@M%OK*B.6-XDGHZ>EI(Z@R\H
M*IE.TN\9[E$U+\9%L":Z79[R*B=7Z3<Z;7.85\A<TJ14*MS:(8=.6:O1:[6I
M%=7'07F1A"83 :2(A0])+O26YBRC[:]R>R0R=ZPT[S1TD$TM5(R _;I:ES R
M*0R2B4.W&E^\9 ]SLLP6[@71V_;RMI_"U9<867J[5]!2V>EEKP10T=ICG=4U
M=*REI'TI8V>1L C93N@CC G+FR<LX'LV3Q4UZQ=2['U;5#D"C';^!G.=6X8-
MGLMB8_2;0 #";%<A2'T/R6P),@(6<4*E2))),LC*0X1?WY/*D5HEBI**C[X#
MV4%QCJH7.8=\TL4DCXH'X(!D8U^YO@!I#1XHX+DJ]LZ6JO%^O0MKH9]HMFJB
MU5T,4K1"R[5E/3PU=?"'!SQ332P&HY![GRA\KP97?".^<J\:H&AU$%57A730
M$@5P>+Q]5NYK; ]=MD.=%[69ZPHX$GDA!./#C3())-:FQ7XK[KD=R<I+B$OM
M^SUZRQRU$TDH?2R!]P=6\C50ODA<UU"RCY.1K7L+BUS.5:X.&#N]&O8V;;^F
MMM#343H;O3.AV;CL1KK36P4M;')'M!47LU%/+-!,V-DD<PI)&.8YSF&4@C>&
M..N^-V+2",Y845?;P,/]@A7B[;ZO9A1XS?J+.YJW0;?2;3.%B!T27((.;40!
M$TP-(#.#P4I4>1/&)?6DL+IVMWWT\#XZ)U/!WI$^-E/.VJ[YAGB#WO< WX,C
M-[QPZ09#784I>Z&RWS2&G@N5QAJ;['<;AX:JX*J>YVV2TMME=;ZV2&"&.1\I
MS+33"+$!BIGECY80XQ%<O$:*M"?%\EFL$(G\ICHP.\"=NSXSGS6CB>A6"ZK@
M$?0PGXB\]'--P4/1O8(0\PM[:-H6E&MV"V/A\"YE:[P7320/PTCEC)3QP!S=
M?% +-[!SH<+HZ[:J&K&W(;1RL]]UUI[C!F5A[R9#=:JXF*7#1RKG-J!$',W0
M'-+B,$!5.SN%XI,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$6:K
MB5*-CM)3M6]2-*WI.M[WZ4H6I2O+7YDIUM2M_9I.M[WY:UO>>:VQ_P"J]\_V
M"7TEH'I7',"8I0 2>3>=!G0-))[  23S $G17%XMTQOE%Z9LTT)\Y0<X%:*C
M:*^F<H6^6J]SKY"M'8L,HF/*4-()@DG) ^9J-(0S,88V\P\QMUI?Y;IIN0EW
MRSE&ECXWLR6ES)&%C@'#):<$X.#@\Q7+LO?6[/79M=+2=_4DU'7VVX4?+&G=
M4V^Z4<U#5QQ5 9(8)A%.Y\,NX\-E8PN8]F\TV"K?B7YWSQFGTJB4.X/<N&RN
MHS[HW9[4'>N]HF]7H:><%) X@+KT<*"U7:XS'V'9^'3D3YS;KT]327M:;VF5
MD,0CBCBD, ,YD#Y&F1YJ(N1=@M8&LW& ;OBG)R3QPO94.W5ELK;;:K3:+D[9
M^"2_RW1M?<*9UUKY=H;2+)4/AF@HF4M)WE1-9WLT02B:5KG3%H=AN(@^(NEU
MCHOAQ+5"H6;5 \/'M]CX%A-"Y=MLSQ6X&[H;E39HX7 $0/:3C2H8^*S$?3'B
MQ4./27G'MH:@JXV34;HXW\E2?!#W-,CRZ1\KB2UH:W5V  #@#.==->+;:UT%
MZV(J+;;:\6?8O?Y&&MJZ>6XUSJFYU=SJI)98*>&FAS+5&.&-L3PUD8+Y'%V&
MZQ2_$S;^;<E>H- E3:U8Y'52?07;3':#RUM#YM7%@F1L'1 =+EC"4:6.]]05
M'OQ9"4+2VVXA2=[WA'6R0P<E$2Q_?#IN4PTD L:P-&02UP(SO @KK[7MW<K'
MLZ^SV>26AK9-H)[PZX,;32%L$M!!2,@AY:&22"=DD/*BHA?&\ @-<#E212O%
MZ'J-:I//I/,AEBI4:GWFO=)GEY<UR]6DEU.1,=OY0.:;GMBH")K+-88@:*AB
MTQO=9AONS-.[:5&YHZ]D;(H3 'QB.5DQ<X\K(9R>5+7 [HR P-WF.(W!KPQW
MEK[I--;J"U6:2PP5MKCMMVH[Y-4RS.NU?/M ^1UXGI:ELS:>$2L;0LA[XI:B
M5IH8G.D#BTLB:O\ ;!@.N\ !;!3I&^,=?L72IDG4N.WH[!-$Z!.9&1F_9KW"
MEL(IC[;C[JWV5+G-;2G6F5^O794M:RE;ND][U#YB<CQ@XQ'='01R?'4'/4O.
MT6U4%)1;'TG><KSLOM+67V1_*L;WW%4SV>9M.QNZ>2D:+8]KGN+VDRM(&&G,
MXEO%U7CW./F*\_W"IM^\=;7,'T2\U\35[%&Z7>+1;&XUF%SJ_/D3T0X=A2&F
MZ:D,)E1FY.F](T\CT;+[@U\(B_A+,&HR(I6M8\3RR28>TL). _=.NHSTKUE1
MW2**KLG@ES]J[>W?VC,D%INU%3V^M9?;M<+BUE=!-13OF$<5:*67=>P2,:_=
M WACH$/&6@G2>C4*?4)$T/:>24FA5&3)(,+(4H\!I='J%K(0W=1_YP!<TTD6
M1GB4*;VU+%B7T^;Z9;KD-P!BFB,9<U]/'#&21F)S8XHY"#KXLO)-<6_RFMY\
MDZ\W=-$]JO5GEMKY::X;.6FSVZ225AFM=71VNTVVXS1.W-:.Z"U03S4P(W9*
M>F>/'$CG5KZ=T:)?A/(QT89('+YKRL=SR6Z_(;?24E0;9;[&HE'2VA&X\=QJ
MS,QM,.[6XER*XYM>TN)TG4GF$K:=H:6\C (B2<[Q$DC\CH&'@8Z05XF_7R.\
M4VS=/'3O@-BL$5FD<][7BHDCN-QK3.P- +&%M<V,,=EP=&XYP0!$^:Z\XF$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB_M+IG^A]3_PT"_\ A<7/HL?W./\
M(;_5"_J%:_\ HVW?[#2?W>-;+F:WDPB81,(F$3")A$PBI'XZ5^&!'.*EOQ4U
M4];*9N[-:K\*OR[#$E1K/\"->SE/+KEAKDM3&A7Q-K:'Y3\?VCJ-[C[<TVXW
MR1WR>PN-3!,Z%TPY N9%%*2TD28+96N:!F,'(&=,<"5\S[J%9L51V>@DVYHZ
MNMMSKDUE)'1NJFR-K>]:EP>XTE72/W.0$S?&>YF2/$S@CRW]O\CE]S'2OVUU
M+^*6<WV1[C^/3?H=)]6OA_AWW/7Q#?/E+S^^D]O\CE]S'2OVUU+^*6/LCW'\
M>F_0Z3ZM/#ON>OB&^?*7G]])[?Y'+[F.E?MKJ7\4L?9'N/X]-^ATGU:>'?<]
M?$-\^4O/[Z3V_P CE]S'2OVUU+^*6/LCW'\>F_0Z3ZM/#ON>OB&^?*7G]])[
M?Y'+[F.E?MKJ7\4L?9'N/X]-^ATGU:>'?<]?$-\^4O/[Z3V_R.7W,=*_;74O
MXI8^R/<?QZ;]#I/JT\.^YZ^(;Y\I>?WTGM_D<ON8Z5^VNI?Q2Q]D>X_CTWZ'
M2?5IX=]SU\0WSY2\_OI/;_(Y?<QTK]M=2_BEC[(]Q_'IOT.D^K3P[[GKXAOG
MREY_?2>W^1R^YCI7[:ZE_%+'V1[C^/3?H=)]6GAWW/7Q#?/E+S^^D]O\CE]S
M'2OVUU+^*6/LCW'\>F_0Z3ZM/#ON>OB&^?*7G]])[?Y'+[F.E?MKJ7\4L?9'
MN/X]-^ATGU:>'?<]?$-\^4O/[Z3V_P CE]S'2OVUU+^*6/LCW'\>F_0Z3ZM/
M#ON>OB&^?*7G]])[?Y'+[F.E?MKJ7\4L?9'N/X]-^ATGU:>'?<]?$-\^4O/[
MZ3V_R.7W,=*_;74OXI8^R/<?QZ;]#I/JT\.^YZ^(;Y\I>?WTGM_D<ON8Z5^V
MNI?Q2Q]D>X_CTWZ'2?5IX=]SU\0WSY2\_OI/;_(Y?<QTK]M=2_BEC[(]Q_'I
MOT.D^K3P[[GKXAOGREY_?2>W^1R^YCI7[:ZE_%+'V1[C^/3?H=)]6GAWW/7Q
M#?/E+S^^D]O\CE]S'2OVUU+^*6/LCW'\>F_0Z3ZM/#ON>OB&^?*7G]])[?Y'
M+[F.E?MKJ7\4L?9'N/X]-^ATGU:>'?<]?$-\^4O/[Z3V_P CE]S'2OVUU+^*
M6/LCW'\>F_0Z3ZM/#ON>OB&^?*7G]])[?Y'+[F.E?MKJ7\4L?9'N/X]-^ATG
MU:>'?<]?$-\^4O/[Z3V_R.7W,=*_;74OXI8^R/<?QZ;]#I/JT\.^YZ^(;Y\I
M>?WTGM_D<ON8Z5^VNI?Q2Q]D>X_CTWZ'2?5IX=]SU\0WSY2\_OI/;_(Y?<QT
MK]M=2_BEC[(]Q_'IOT.D^K3P[[GKXAOGREY_?2>W^1R^YCI7[:ZE_%+'V1[C
M^/3?H=)]6GAWW/7Q#?/E+S^^D]O\CE]S'2OVUU+^*6/LCW'\>F_0Z3ZM/#ON
M>OB&^?*7G]])[?Y'+[F.E?MKJ7\4L?9'N/X]-^ATGU:>'?<]?$-\^4O/[Z3V
M_P CE]S'2OVUU+^*6/LCW'\>F_0Z3ZM/#ON>OB&^?*7G]]+OC'_DE=3$N57D
M/0XA:.Q,EN/2#'2UM_!(<-^5:&4ID]+DM;>DUADO'C?S6G-2'6ML.QW]-R&M
M>KVWJ+K33T%95334U1$_EHC34\>^R(&8C?B:R1NL8(W7-)(QG!*W*&[=P.IF
MEBI;%>A)WC<Y9-^6\ &EI[=55%<T9O+O&=115#68 <7EH:YKL.&4^>GR2/W3
M=)_:'1OXEYY/E;#^+S?G3?7KK/"GN<_YNWOY6]?OM/GI\DC]TW2?VAT;^)>.
M5L/XO-^=-]>GA3W.?\W;W\K>OWVGST^21^Z;I/[0Z-_$O'*V'\7F_.F^O3PI
M[G/^;M[^5O7[[3YZ?)(_=-TG]H=&_B7CE;#^+S?G3?7IX4]SG_-V]_*WK]]I
M\]/DD?NFZ3^T.C?Q+QRMA_%YOSIOKT\*>YS_ )NWOY6]?OM/GI\DC]TW2?VA
MT;^)>.5L/XO-^=-]>GA3W.?\W;W\K>OWVGST^21^Z;I/[0Z-_$O'*V'\7F_.
MF^O3PI[G/^;M[^5O7[[3YZ?)(_=-TG]H=&_B7CE;#^+S?G3?7IX4]SG_ #=O
M?RMZ_?:?/3Y)'[IND_M#HW\2\<K8?Q>;\Z;Z]/"GN<_YNWOY6]?OM/GI\DC]
MTW2?VAT;^)>.5L/XO-^=-]>GA3W.?\W;W\K>OWVGST^21^Z;I/[0Z-_$O'*V
M'\7F_.F^O3PI[G/^;M[^5O7[[3YZ?)(_=-TG]H=&_B7CE;#^+S?G3?7IX4]S
MG_-V]_*WK]]I\]/DD?NFZ3^T.C?Q+QRMA_%YOSIOKT\*>YS_ )NWOY6]?OM/
MGI\DC]TW2?VAT;^)>.5L/XO-^=-]>GA3W.?\W;W\K>OWVGST^21^Z;I/[0Z-
M_$O'*V'\7F_.F^O3PI[G/^;M[^5O7[[3YZ?)(_=-TG]H=&_B7CE;#^+S?G3?
M7IX4]SG_ #=O?RMZ_?:?/3Y)'[IND_M#HW\2\<K8?Q>;\Z;Z]/"GN<_YNWOY
M6]?OM/GI\DC]TW2?VAT;^)>.5L/XO-^=-]>GA3W.?\W;W\K>OWVGST^21^Z;
MI/[0Z-_$O'*V'\7F_.F^O3PI[G/^;M[^5O7[[3YZ?)(_=-TG]H=&_B7CE;#^
M+S?G3?7IX4]SG_-V]_*WK]]I\]/DD?NFZ3^T.C?Q+QRMA_%YOSIOKT\*>YS_
M )NWOY6]?OM/GI\DC]TW2?VAT;^)>.5L/XO-^=-]>GA3W.?\W;W\K>OWVGST
M^21^Z;I/[0Z-_$O'*V'\7F_.F^O3PI[G/^;M[^5O7[[3YZ?)(_=-TG]H=&_B
M7CE;#^+S?G3?7IX4]SG_ #=O?RMZ_?:?/3Y)'[IND_M#HW\2\<K8?Q>;\Z;Z
M]/"GN<_YNWOY6]?OM=P=9?DF"A" ,B\FZ-[T1F18,;VA+HZ&_;RWT1V?6OZ2
MM^E'M'$^I7EOTI\]^6_+RRB2PN(:*>;)( \:;B3C\.N6&O\ <[5$T4$>SMZW
MYI8XF;TU[#=^1X8W)\-G RX9.#@+WLA0XXZ'$'PV_91(,5B'%:]:W/91XK2&
M&&_:.J6XOT-(2GUN+6M7EZEJ4K>][]0   !H   .H:!?KJ*)D,4<,8W8XHV1
M1MR3NLC:&,&7$N.&@#)))XDDKLY5R+R8D!O&!6;-VWMU='7&:NI]/[M%HE)+
M]1[;<7.VP2HPW2.(T-'!3==8Y3R/G(OH)JF7>9VNDER1)NHT\C++ZAUL[:ID
M0KIS^H8UZ>?3/'R*')(3QY$&*GR2;6.LW*S<7H?BL<FV$]VSL') /8W5E?#7
M;. %7NT<8;K@>T]%@5R[=%YF)J]G,C09<W2+Z<//#6HC!E@KXO9P\G'/.>W.
MO,%<'@G/+8_VFFW>RVKQ(V(6KPK\<M$@KT"T=TH-5/=@,+MX"\D;'PLK;6^=
MT^X3P,<&5/<I?K>HE$+R8\^*%'F=(*O%">(T\@'H/'TJ(/"R6\0NO%G=8]RB
M]L>I<^V^-:&>1<A_B38IT,:-\2_J\.YH9*ZX&:X6P%1RF*\(H\3P[F6I)RNG
M81FS#C,<;*)ARIQCFYL<,\->&O'I7#5O$?XZ;]T"RU 7SE=*K4FY!X]>N]T\
M,W78:ZY7WJ7XQ#1P<;&3;<(K).9!/\;X "CFP5[/"-RNLMNNRMR[C4ZZ$)@8
MY\XZ1KPX<_.=".;ISB0O#UU_Q/=1\1%'>ZO5;9SJKZXAV"?9><)XYU"LU&MV
M:0:\+\KG$PQUBQR'J3<[0=#DNGSA5:&LPS].8U::H2C_ !BJVF3**<W-Q'/K
M]]Y>W_$+9O"*2LDLQ6=7]WQ5+[9)Y:8?\1D:_BN@PO#V/ZRP>J;9.-2%]!'Q
M:?'W&,.VR'R5OPWOKHQCF310UT394@OG9ETA\F,Z<,X\GDSG7/E42?*[_P#[
M#>;_ /FO&_RA:<Z*_P#\6A_IQ_9O7YW]T?\ ]5+'_P#J%G_IMP7D'S6E\Y'<
M@MO:>C ;#=XPOH%9YL$IU?LK51:1-. CUCG6 \;^"'Y2(K$(+J")AQ8C.I)%
M]U<AY;,?;*N@ACA%/)4S,?*!*R%L;'B/5S7O+GNW7G&&X: !DDY.!A?F^Q6N
MR0[-7+:B]T=9=8Z>\T%CI+91U[;<!+5TE972UE75=Z5D@C9#2<E3QQQMWYG.
M+W%K-TRGV#PY4.A5 M80,BQRE2NL\5$@&#$N-LF+I/6.1%NC.!;!&B0V&5V0
M5-;ACMD&FXS4AF.I],!G<SV3/-44D<4;WLWS]OIFL#B,MCGIW3;KPT8WVD-:
M2, \0-0N^VDV)M%HMM16T;ZV0OVAV6IZ-E3)&9X+7M%LW4WMU+6,BB8UU;3R
MMBAY9C8VO8PO$+#)NMV8WRWP]T][Q4Q"7.[G8'/#W<(HT8^SU!(=-A%GNC?,
M\?%E,II9'X?(#PG6WGI:')OQ-]I6ML0=.>:.1T%(SO[,4CN])&M&)MW?#IN3
M /VMVZ6C4G7)Y@-!V%78-C+:[N@QSV2YUKMC;E'!3O;?^]A6P5=[\&PQR-%K
MGY%]-$X.?('2\N]IRR+>T_.E<!XG4^0QS*G?@%RF\9Y%>JI,5UNK'3MTO%W'
M5>::JOT-1Q?SO$B-1BQ:;"L#DQF(PF#%7I4MAU2%)J6FCI][X,AIX)6.-1&Y
MTDL@C+F=[AHD:W#GD/)QAHQG*7S8_96W;-LJB>\[G+LQLY=K?*=HZ"KJ[I=K
MK!0355O][#(/"5/3;E342QUCI61L$49^V,=@]?O7A<K_  "J\ONQBGWTS 'D
MH]*[(-*R953@FKH0I@BVQ)="L3H&<A591*('ZTLDU"(-+*TV6UK_ )\V[DJJ
M)E+'!(Z.5P!$=0''DPZ1T39 8W;I&X"7LR [+HW:Z@KCVOV H]CK=8+K4VV[
MU4,-0RU[305$DENBJKG-;*:Y1R6BM=23#O$235E 9FQ3-,]LD'^F:Y=B[\1X
MEJ]=HI58JML!?11Q(;T-@I/O"3NS9NRS>+/#VG(?S;%I@0PT"\V""\TF3,45
M=7"F[5 ]TW'?LE-3<K4QL9(WO>F;,"9-[><\TY (W&X#1(\'CO9!TQ@YW?9;
M95MVVIM5!;KA2'9W96"],J)KMWWWW55TVR[H6NB[R@Y&*EANU9$YHDE-0XQ2
MYAY/<=N]M\.' H/?ZEQL5 BI@S>Q,4DQ+%]N8L]T^ LQRZI?Q.E:HXSYM2G7
M(L;3TM1HCH?)TW"]E(W,T\SR2T=*VJCIVXW34")Q%2'RAGC9WH^3;N$X&N\[
M' C)!';7'8C8^+;&W;,4\$8BEVE9:ZF2GVK;7W3O1K*DR<O:_!4'>,CG1QAT
MAJI^0?B+=>9-]NE$O#ERSG>^6D+(./\ 0JSUOL1NJ4PZ)M2*NP8YL8#\O*4:
MVM;T!+[T4'[M9\?8A2F6-?&X4H8I^(H6I;W&ZD@A,!>'2LJ*AS(WM?N9A<V!
MT3QXIRX"1P>W^4"W(W3GJI]BMG[*=GYJZGK+S0;1[2UEOME73W#P>VILE33V
M">TW%I[TJ?M\/A&LAK:<M;_"XI*<OC-.2^J'=AE( =2M]5H-=*UP)3CQZHN-
M&++\YY96=7; 6&NG-2]!PNH#1",Q$\A6F9>HCC+B]3Y'M_2WH5+8V3R,B8YC
M8WOC\9^^7%CW#>SNMQD >+@XQQ.5\\VM@M5)?[E;[/0U%#26RKJ[<YM37=_R
M5$U%65$#JOE.]J7D6S1MC_@X9((RUQY9^_AL0YP+S:81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PBVRF;\C$S_"=\U_^=&L6LYZ?21W]!4^FFE"[S9TX
MN%1_W%M0//LU=@M3S@71IA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3"+9J5_IE4O\3 ?_BL3,X_ND?Y;?ZP6]:_^DK=_MU)_>(U_:5G
MT5?U"3"*CCWC%+G]6%[E/'I70(M(H$[L5O5-O(ZHR9'*)-\ZI2*"5H+4D$6B
MVRX]0;XS?+-5*P:G4JO0@<41\[+Y7"!J)#T5QY-<?3YEL0?QW^&@\Q'?$6NV
MSOB3+BJZTQR3K3CMRDQK?4:$1&T/2:3MN]D@UMOU.$G(M1<,[#?'HY BN,*B
M$YT$@!/^8[?4NC,\>WAQ57'[ #MA8@Q\*G2H4LMSSK5<K^SD&@DNI.4DU89G
M/)#-<O:>=B9MTDT4C$^>T2N(9).UOT31Z)9,'V]N'7P669\<OAPD_$$1+)=Y
MDN#/@0&1</C'9Y1H[H@UU5]DC4@C% 66MX1ICA_6WY1NLPRHN.Q12K[DK34H
M.LF3!]M.CZ0I8X_VFK]HB6J;5TOZBU@T"@HDO(D-LFPEPY]2^ITRRCFIT4>2
M:@FZ5?@#LF*1'0Y0JP,'0+B9.Q&YTHHIAPB81>6_RKE=L%EXKSR)7 1D_+8Z
MC'DOQ0HN:5D,Q]5.S-;?=9@L/N-LZ<<;;VZM.D:6XA'J]2DZWTE\8^2GA#&.
M>1-DAC2X@;CQD@ G&2-5\"]T+0UM=LO9HZ*CJJR1E_8]\=+3RU#VL\'5[=]S
M86/<UN\0-X@#) SDA>+O/7_$IRO9?5&J]_$QC[4-HV,E\Z?L 0K\.>6^.>G@
MK)7"X:3+&O.O.CIKL!4R MY_<1]G;SOK\]$*Z#>Y*.9H=C>:82]CL'()8]CF
MD@\"1D<Q"_,%F=MSL_WR+307FGCK&QMJJ>6R/K:2HY%Q? ^:CKJ*II9)8'.<
MZ"5T)EA+G\D]N^[.T KWXOJZ=M5D'P^FOF+L1'E[1).<]<L[)4L(]KH.45 L
MM9+#HI$.AYQD/-@Q(LD5&VF*/=C1VVVDYMDN+'R2!LY?*0Z0NA+PYS<[KBU[
M'-!;D[I !;P;@+?I+OW2:*KN%=#%?GU5UFAJ:]]7975[:BHI]X4U08:Z@J((
MYZ9KG,II88XY*>,\G"YC &C17('B(?CWV-(K'3)3?4)42=?ERZ::ER;/,A'/
MG+&E3YDD0[+3(2<_](N.QGXZWWMJ2^IUI2F]\6[6D2@QU!Y<@RYB>2\AV^"X
MEI.=[7((R>*ZET.VKF7>-]!?9&WZ2.6\&6V54DE?+%5]_1R32R4SI \5?VXN
MC>PO=D/+FDM7[-'^(0E8ZO;)]0Z!+/TR#4QE:GR*!/<T-@4:-#AU6+[FH#N!
M,:$QA\-E*9\65N6AG7O^Y6UN;6+*QSV2&*8OC$88[D7:"( ,&-S!W0 -0<XU
MRDL.V<U=07&:VWF2LM<5N@H9GV>9P@AM+(H[?'R1H^1E;3LAC:!-')R@;]NY
M3+L]F6GQ)$(-Y&$*_P!/GP>DDX1F[1YU-,S$G"PXK*-PB*U2 SCD&8P2FS7T
MR!BX3BFY<J(M2H<AUA=+:TB4&.<B9P=+F)QWG-<7 Y+<@AQ)RW'$@Z$A<D@V
MYFBNT$U%?IHK[/%575DMKJ9!5U$%1)513DOI7&*5D\LKP^ Q.(DDC),;W,/;
MDRO$S+-6RQ2*]T=PS>:S IUKG;H4U*S%:&?-WW$6ZT@ EB.U'^:=>]+\-J/*
M7\-;]H^OVTGV]/?Q=(\QS[TK!'(>1=XS&[F&D;F!C<9J #IQU.>223;N6JN-
M;)17MU5=J"&V7&4V>7-30T_>7(T[FBC#&-9X.HO'B:R1W(-WGG>?O;R5ZCXQ
MC9<=8"(BXN'A1YBSPC;'& 4$N@]&1(0T0?)0*+&FS'/3*?VZU->D1WU+TM]E
MQ;;:D<CI+B]P>Z.7?:\/#Q3-#MX<"7-B!/'@20><+M:B_P#=,JJF"MFIKHZL
MIJQE?%5,V8I(JD5<8>&S/GAM,<LIQ(_>;*Y['DY>UQ#2(]3_ "DT@J-6?F]T
MQ8+FIZ99J*-=I19]FMFI\V*1F2X"G@JW=H?GPV)BH<AQ^"F1IUU$9*I$C;O%
MNUN[$SDY]V%Q?$.2=XCB021XN=2 <$XSS:E=,/?R*2TT/>5]-)8ZN6NM,+K5
M4.;0U4TL<\LD)=2EQ#YHF2&)[GPA^\X1@O?O:B;H79+&:+V$W0>@3S)XH0-%
MYRZ6<:7,)E);TZ?+6U'%-,-JD2GW7E-LM-,HVO:6VT(TE.L'0U+W.>Z&8N>X
MN<>2>,N<22=&@:DDZ#"ZVJL^T];55-;56>\S5-7/-55$IM=6TRSU$CI9I"UE
M.UC2^1[G$-:UH)PT 8"Q?T4]1^[:_?N=8OP[,>]ZC\!-\D_]E<'O>O\ \1WC
M]65OU"?13U'[MK]^YUB_#L=[U'X";Y)_[*>]Z_\ Q'>/U96_4)]%/4?NVOW[
MG6+\.QWO4?@)ODG_ +*>]Z__ !'>/U96_4)]%/4?NVOW[G6+\.QWO4?@)ODG
M_LI[WK_\1WC]65OU"?13U'[MK]^YUB_#L=[U'X";Y)_[*>]Z_P#Q'>/U96_4
M)]%/4?NVOW[G6+\.QWO4?@)ODG_LI[WK_P#$=X_5E;]0GT4]1^[:_?N=8OP[
M'>]1^ F^2?\ LI[WK_\ $=X_5E;]0GT4]1^[:_?N=8OP['>]1^ F^2?^RGO>
MO_Q'>/U96_4)]%/4?NVOW[G6+\.QWO4?@)ODG_LI[WK_ /$=X_5E;]0GT4]1
M^[:_?N=8OP['>]1^ F^2?^RGO>O_ ,1WC]65OU"?13U'[MK]^YUB_#L=[U'X
M";Y)_P"RGO>O_P 1WC]65OU"?13U'[MK]^YUB_#L=[U'X";Y)_[*>]Z__$=X
M_5E;]0GT4]1^[:_?N=8OP['>]1^ F^2?^RGO>O\ \1WC]65OU"?13U'[MK]^
MYUB_#L=[U'X";Y)_[*>]Z_\ Q'>/U96_4)]%/4?NVOW[G6+\.QWO4?@)ODG_
M +*>]Z__ !'>/U96_4)]%/4?NVOW[G6+\.QWO4?@)ODG_LI[WK_\1WC]65OU
M"?13U'[MK]^YUB_#L=[U'X";Y)_[*>]Z_P#Q'>/U96_4)]%/4?NVOW[G6+\.
MQWO4?@)ODG_LI[WK_P#$=X_5E;]0GT4]1^[:_?N=8OP['>]1^ F^2?\ LI[W
MK_\ $=X_5E;]0MGJ7,.E1BLMR3SR\L-JK%U82M^I'VD*?E4T]%BLI4X/2G;T
MF2\S'CMZWZWGW6VFTJ<6E.^:GIYP]V8)0.1J1K&_B:>4 ?!XDX Z\8U7=V"P
M7QE?.Y]ENS&FR;2L!?;JQH+Y-G+K'&T$P@%SY'-8QO%SW-:T%Q 6L?13U'[M
MK]^YUB_#LX>]ZC\!-\D_]E=)[WK_ /$=X_5E;]0GT4]1^[:_?N=8OP['>]1^
M F^2?^RGO>O_ ,1WC]65OU"?13U'[MK]^YUB_#L=[U'X";Y)_P"RGO>O_P 1
MWC]65OU"?13U'[MK]^YUB_#L=[U'X";Y)_[*>]Z__$=X_5E;]0GT4]1^[:_?
MN=8OP['>]1^ F^2?^RGO>O\ \1WC]65OU"?13U'[MK]^YUB_#L=[U'X";Y)_
M[*>]Z_\ Q'>/U96_4)]%/4?NVOW[G6+\.QWO4?@)ODG_ +*>]Z__ !'>/U96
M_4)]%/4?NVOW[G6+\.QWO4?@)ODG_LI[WK_\1WC]65OU"?13U'[MK]^YUB_#
ML=[U'X";Y)_[*>]Z_P#Q'>/U96_4)]%/4?NVOW[G6+\.QWO4?@)ODG_LI[WK
M_P#$=X_5E;]0GT4]1^[:_?N=8OP['>]1^ F^2?\ LI[WK_\ $=X_5E;]0GT4
M]1^[:_?N=8OP['>]1^ F^2?^RGO>O_Q'>/U96_4)]%/4?NVOW[G6+\.QWO4?
M@)ODG_LI[WK_ /$=X_5E;]0GT4]1^[:_?N=8OP['>]1^ F^2?^RGO>O_ ,1W
MC]65OU"?13U'[MK]^YUB_#L=[U'X";Y)_P"RGO>O_P 1WC]65OU"?13U'[MK
M]^YUB_#L=[U'X";Y)_[*>]Z__$=X_5E;]0GT4]1^[:_?N=8OP['>]1^ F^2?
M^RGO>O\ \1WC]65OU"?13U'[MK]^YUB_#L=[U'X";Y)_[*>]Z_\ Q'>/U96_
M4)]%/4?NVOW[G6+\.QWO4?@)ODG_ +*>]Z__ !'>/U96_4)]%/4?NVOW[G6+
M\.QWO4?@)ODG_LI[WK_\1WC]65OU"?13U'[MK]^YUB_#L=[U'X";Y)_[*>]Z
M_P#Q'>/U96_4)]%/4?NVOW[G6+\.QWO4?@)ODG_LI[WK_P#$=X_5E;]0GT4]
M1^[:_?N=8OP['>]1^ F^2?\ LI[WK_\ $=X_5E;]0GT4]1^[:_?N=8OP['>]
M1^ F^2?^RGO>O_Q'>/U96_4)]%/4?NVOW[G6+\.QWO4?@)ODG_LI[WK_ /$=
MX_5E;]0MCIW+>G-6ZJNN\YO;;3=C!N...5"P(0VA!.*I:UK4/TE*$IUM2E*W
MK2=:WO>]:UF<=/.)&$P3 ![228WX R-3XJW;;L_?FW&@<ZR7=K6UM*7.-MK0
M !/&223#@ #4DZ +^P_/?K^E:815';\%_'Y8!BOGOG;*BQ1UMIR7*O>KYS=9
M?DMBN5CMH?D5R10[4#:NU,I3=F(5^L,6)$Q\>&DEF(JXRK3;=G2N?8X.OFY^
M?IY\KYZ/X..86NMQ8-+@QJ!:@)>R'*;96)%WD1:L0N_5N>=?NRH ZJWZA&H*
M#MIYG651G*W;*S.KT.,Z+ 38 &<7"E" X[/\".@])6K4KY/KP^UND5RH6 =:
M+HX+ MPC\TE?.A0A=LMCW.9W)R_1B598M[PK5Z)<^*DJ=JU2-S[2U6780V4?
M(2!< @R3/'KZ/;AU+L=6\#_/[A7A\+G$][EMI%_"H<&W-$.D%)L,&*A]QBLC
MH#U8ZESRQC)27?$-TV5\3&VN(J:V9T'L$4]7&& K1,GV\GGX#0_/JILX;PT!
MPL(;#A"<\RHW,JZW9I)MEM]@51N;TGD]1%-Z:VKS3!J% "/$GO6EHC9IMA-1
MH@N,5:$P2GM[?XJ%_$_XI#_#;K3*D""U?8TK1;O?KK>KS$ZHY3Z,'K)NF!1C
MITCS'G=^17A9'5@L!,M:[@NN5.MCZPMPF7;V08]#V]AD)[>WM\RNDP\W(99?
M:<:>:?:;>:>8<2ZRZVXC2T.,NIWM+C2TJTIMQ.]I6C>E:WY;UA%R:WK>]ZUO
M6]IWY*UK>M[UORTKRW_=OT[UORW]?EO6_LWK"+]PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$6O6?^S8W^(:C_ )K"Y1Q\
MCOF*AX>5OSA;#D53")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A%7_M'"IO84SH3?7>F4 #9*2=YS=ZS4Y-;E K
M34[$KTD7$0;37K BMVUN&Z0%0KA7?<"C8LK+CRTSGX8"4$H./4>CVZU",]G/
MUJ<10N $%C0HJ,B&,$0(8L;#;VM3<6! CMQ(<9O;BEN;0Q':;:3M:U+VE.MJ
M4I7GO<56-"_VE;O\0QO\J5C*>#>SUE0<7=OJ"V'(JF$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%4'Q9^()CBHRE0(+#!(\<
MM(8O*'+WK:T56LEH1,HYK?GY,2"4EB,+@.N)]/DY/?;WMR%O6>JV8V>\-OK'
M3%T=/! ]C)!I_"YFN$'-XS8L&61HUT8TX#U\?[K/=+]X$%DBHV1U-RN-Q@GF
MIGX);9:.9CZ\C.1'+5Y;1TSW# WZB5AWZ?"M0!.#+,$$6(+*1-$'!L(L-EM[
M_)D0I\=N3&<\OKVG:FG$^M&_RFU^I"M:4G>M>:G@EIIYJ>9I9-!(^*5AXM?&
MXM<.O!!P>!&HT7U2WU]+=*&CN5#*V>CKZ:"LI9F\)(*B-LL3\<02QPRTZM.6
MD @A9;.);B81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$6O!?[2MW^(8W^5*QE/!O9ZRH.+NWU!;#D53")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBA+J?&^
M8WJ1$L-NIPH\:1.J@9!"=[TMY MRSP6G(*--R&VT,+1/FZ4E*-;WN2ZKS]2O
M5G:45YN=!$8*.LEIXBY\A9'N@%[F@%YRTDN(:T9)X- YEY*^;"[);25;;A?+
M'1W*L9#'3,J*GEB]M/'(][(F[DK6AC7RR.P&C+GN)R25*%:K0*G@X%;K(U@0
M#%H=:'C8VW5,1&WI#TIQMK;SCKFD;??=7I.U[TCU^A&DH2E.M*IJ9ZN:2HJ9
M'2SRD&21V-YQ:T,!. !D-:!G&N,G75=]:[7066@I[9:Z:.CH*1KVTU-$7F.%
MKY'RN:S?<]VZ9)'N +B!G#<-  SN<"WTPB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(M>"_VE;O\0QO\J5C*
M>#>SUE0<7=OJ"V'(JF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A%KUF_LV-_B&I?_I:PN\HX^0_,5#P\K?G"V'(JF$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M"*@'BEZ)TT9;>F"J9TPIRZ%QSPEW/Q"C7Q@NISXEPN@TL<8&1+=\Z0!MV32:
MQ%J"FSP<#) 3"#%UTZ^9BRH8:5$HYCC.3CGQZ-<^V#S8GJ."!G&GISS>W9>.
ML%7SM;KQR5"6-E&08DK)'.^KVD!\C CS'H3GJTE7KBN/*87ZDI5ZF]^>M;^K
M(LEYA>&3Y2.O];[?TWE%UHBN8$=GYJJ4DM88:29J:&4.K$JK$H!9D,W&M2F8
M#1-L=!DRW%;^(04M+5!;DS/0WNQLL]NH[@ZL9-#,(Q,\1EL,!E;O1R&;><QL
M+GD0MDEY-KI71,:3)*QB^1;&]U2#:;:&Z6&MMS;+-!),VW=\U;>7JWP3<A)1
MR0RQP[M<&_;N0A=*0ULS<?:>4?Z<?'GOT=L/ZM!_$<\\OKF3T'T?2GQY[]';
M#^K0?Q'"9/0?1]*?'GOT=L/ZM!_$<)D]!]'TI\>>_1VP_JT'\1PF3T'T?2GQ
MY[]';#^K0?Q'"9/0?1]*?'GOT=L/ZM!_$<)D]!]'TI\>>_1VP_JT'\1PF3T'
MT?2GQY[]';#^K0?Q'"9/0?1]*?'GOT=L/ZM!_$<)D]!]'TI\>>_1VP_JT'\1
MPF3T'T?2GQY[]';#^K0?Q'"9/0?1]*?'GOT=L/ZM!_$<)D]!]'TI\>>_1VP_
MJT'\1PF3T'T?2GQY[]';#^K0?Q'"9/0?1]*?'GOT=L/ZM!_$<)D]!]'TI\>>
M_1VP_JT'\1PF3T'T?2GQY[]';#^K0?Q'"9/0?1]*?'GOT=L/ZM!_$<)D]!]'
MTI\>>_1VP_JT'\1PF3T'T?2GQY[]';#^K0?Q'"9/0?1]*?'GOT=L/ZM!_$<)
MD]!]'TI\>>_1VP_JT'\1PF3T'T?2GQY[]';#^K0?Q'"9/0?1]*?'GOT=L/ZM
M!_$<)D]!]'TI\>>_1VP_JT'\1PF3T'T?2GQY[]';#^K0?Q'"9/0?1]*?'GOT
M=L/ZM!_$<)D]!]'TI\>>_1VP_JT'\1PF3T'T?2L#8SCRQ\?7P$\WY'JLKU.1
MX6D[]%G$+TC7I(*WZW/3[-O7EK6W%ITI24[VK5''R'YBH2>@\1T=(ZUGOCSW
MZ.V']6@_B.17)Z#Z/I3X\]^CMA_5H/XCA,GH/H^E/CSWZ.V']6@_B.$R>@^C
MZ4^//?H[8?U:#^(X3)Z#Z/I3X\]^CMA_5H/XCA,GH/H^E/CSWZ.V']6@_B.$
MR>@^CZ4^//?H[8?U:#^(X3)Z#Z/I3X\]^CMA_5H/XCA,GH/H^E/CSWZ.V']6
M@_B.$R>@^CZ4^//?H[8?U:#^(X3)Z#Z/I3X\]^CMA_5H/XCA,GH/H^E/CSWZ
M.V']6@_B.$R>@^CZ4^//?H[8?U:#^(X3)Z#Z/I3X\]^CMA_5H/XCA,GH/H^E
M/CSWZ.V']6@_B.$R>@^CZ4^//?H[8?U:#^(X3)Z#Z/I3X\]^CMA_5H/XCA,G
MH/H^E/CSWZ.V']6@_B.$R>@^CZ4^//?H[8?U:#^(X3)Z#Z/I3X\]^CMA_5H/
MXCA,GH/H^E/CSWZ.V']6@_B.$R>@^CZ4^//?H[8?U:#^(X3)Z#Z/I3X\]^CM
MA_5H/XCA,GH/H^E/CSWZ.V']6@_B.$R>@^CZ4^//?H[8?U:#^(X3)Z#Z/I7;
MA%')CWL5"2T+7H4OVTUF*VSYIWK7H]3,Q]?K5Y^:=>CRWK6_/>OJ\R9ZB/-Z
MB5EL*IA$PB81,(F$3"*,>A<7Y5U>2%E]&HE>N$FO(G,"G3,/VZFAY1\=)+!9
M7I6VDE73$D.'DF*V3U, EI D6^1'2G1T-;+)' J$ \?;VZ%)V%5 /1N%<L[M
M7^@T;I=2''0Y&S1IC<E#>H1L0714*TU&/ C4739 2;B)5M+4^*\E;C"G84M,
MD?(DQ'N:.>:%S7Q2.8X,<S0@@QO+@^-S'!S'Q/!(DB>UT<C26O:YI(/37>P6
MB_4<]!=**&H@E>)<[O)S13M8!'4P3LW98:F,8W)HW!X W22PEI\WK/T7Q7?)
MPRFU7UPQXF_",U(:C0>@R=*7T3F ]QQ+,6!>)3+;JVHL;2FHL>PR&Y58F[0A
M&W*I,FP0>_/5EOK:8FIV;EHZ64 F39VZ2RP[.UN,^+;+C'%4U.R54X;K8X70
MW'9EPC;#%061T\E8WY_)<]INY\X,O J]J]D00V.\1-$FT%FCX-;<8_%9<Z=F
MC>^'.CJ#G>,SG<G2N]).%^)CCGB* 1CO,K=!*..L)>E I+C<2P#]^E*G$2AJ
MW%+7IG2T:=?B*DQVE+0AUUMW>V]:5IVLMURN$]BJHJNP[44<0GK=E[[$RCO$
M4!) K*5K)9J.\6MY'VJ\6.KN5IE)W65AD#F-^E6NZVV]T,5SM%;!<*&;1M13
MN)#'@ NAGC<&RTU0S($E/41Q3,)&\P9!,]YZA;Z81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB811_TBT *H&#RK 3C"V"=UHX:$[)5
MM"'R,RTBW&6-*\MZ3Y,1I,EYQ>TM,1HS[[JT-M*5K:I*.IK7R1TT3I7Q4\]1
M(&XRV*%A<]VI&>9K6C+G/<UC07. 74WB]VNQ04U1=:N.CAK+A16RG?+G$E;7
M3"*GB& <9.])(\X9%#')+(YL<;G"0,U5VR81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PBU<Y<ZS7#-5 &BL>"7NI"8+K<-W:M+(S($!
MXC*0A6M;0VEMAI+>G'5(0Y+DPX;>U2);#:]F&CJ:B&JGAB<^*CC9+4/&,1LD
MD;&TD9R27.SAH)#&O><-8XCJJ^]VNV5MIMU=5QT]9?*F:DMD+\[U3-3T[ZF5
MK3C=:&QM:W>>0'32P0M)DFC:=HS67:IA$PB81,(F$3")A$PBUX+_ &E;O\0Q
MO\J5C*>#>SUE0<7=OJ"S,N)%GQ9,&=&CS84V.]$F0Y;+<F++BR6U,R(TF.\E
M;+\=]E:VGF74+;=;6I"TJ2K>MP@$$$9!T(/ CH*CFM>US'M:]CFEKFN <US7
M##FN:<@M()!!!!!P=%XF>(CY-8WRZSS.Y^"1XG6I+4E1BQ\3!3T#TI=0M3T@
MKR1R7-'CHTEM2G)*^<%B(L3,WMQFF66E2O=X<OH-H=F[)M/00VW:&V"ZT5'*
M:FVR15,]NOFS]80 +CLM?J-\=QLM:TAKBVFF;35 !CJ(98W.C=\GNFPU=8J^
M7:+8*IEM=6_QJZTP[CJ2M8"7.:VDF<VEJF9)/>-08L GO&LH9 T/WOPW_*#G
MWXX^N]B'NE'-%5571UB,\)-LV>'ZFIE3)P## EZ/>8+C7IE\\ML.J]#6EQN4
M"B7V!(C&)/C',[H.P\+ZJ$UO==V)IP3+54=-34W=1V;IV:8O%D@Y"W[7T\#0
MT/N%F;0W5X$DLMNJWC)[S9[;^AN;HJ&_0QV"[/F[UCE<Z062OJVY#Z:"IJ&L
MGMEQW@2ZT71L-4W+>]WU43FS'U7J5UJUZ&?%JH:AF(:'-L2=,*6W,'RD^?KA
M%!\A+4\7/:WK>G81"-&E-^7FIK6MZWOV&S6UFSNV%!X2V;NU+=*5LAAG$+G1
MU5%4MR'TEQH9VQ5MNK(R")*2M@@J&??1@$$_07QOC.'M+3Q&>!'2",APZP2%
MM.>B6"81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%1/Q?
M<,ZSVF?5D5LY3A=,KZHC34$N3.1B4NSV HP*40?9@5^?%]UAL/068BO>UR&4
M.$W$-^J0EI7M-EK[:;)%4NJH*R6KJ'!I?!% Z-E/&W+6 R5,3MYSR]TGB@'$
M8R=W*^#]U[N>;9]T"LM<5HK['266V0OD;!7UEPAJ)KE.\MEJ)(Z:VU4)9% R
M*.F/*F1ADJCAHEPK<\\A7 92*R-OTL60N X5'@'2(:3,ECR,J'ZHS9%M^?"'
M2EOSXS3$N=IR$PEN<]);9TMA#;J_+W!]))6U,E"R6.DDE=)!',UC)(VO\8QE
MK'R-#8W%S&8>XE@:3AQ('UW9N"]4MAM5+M#-2U-ZIJ2.GKZFBEFFIZF6#,3:
MELD]/2RNDJ(FQS3AT$8;.^5K YC6N=N>::[M,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB\UO%'Q[L5V[#5+>+N-) #A4@7#Y\Q*+'VB
M >1!?C3Y)TFW'K4J)&>=-K;VMYA^7_R2./:7Z]1G-H^B;-7>T45IJJ26DK9Y
M)FRNKRV* QS->UT;8(R:ECW-$((PYK/&=(1C>&?S)W5=B=MK_MG:KS1WFPV^
MEHGTD.SL<U;<65-') ^.IEKZID5JFABDDKW#+XY)?M,=,UV\(GEOHT*V4V+&
M[-H@MF=P(>R[8QU]\:@GN.W[^@>]*8C27H*97M=1'9$:.^XQIM3K+3FU(3\_
MEY+E9.1+S#RC^2,H:V0Q;QY,R-:YS6O+<;X:YS0[(#B,$_I.C[Z-)2FN$#:X
MT\'?C:5\DE*VJY)O? IGRLBE? )M\0ODBCD='NE[&.):._G&MA,(HDN_9JQ0
MS\>NDAEG*37!;QB8Z $((114- 6X'XNIBG)D9^1,)#*#;GH, 1')S5;#J3(C
MQMS1NYE#2>CB!J>D@>C(RL2X#I\GMU'S*58TEB9&CRXKJ'XTIAJ3'>;WYH>8
M?;2ZRZC?U>:'&U)6G?E]>MZR++BN;")A%%O2>X<;XXL(WUGJ?/\ FKEE2377
MF[Q;0=8<.("['),+$H,38BYZ!:BXI)!<73J8:B4#4C;>Y;&G"*4=;TK6E)WK
M>MZUO6]?7K>MZ\];UO\ /K>OKUA%KX7^TK=_B&-_E2L93P;V>LJ#B[M]06PY
M%4PBIEXD/!O4>U2"%YJ,@7S_ +(\*;$3+,^!B6"G=)!QO2MBE=MHTA3([H54
MWMMM(^8^N+;J?*;BE:?8!4J&EI_!O*PS,JJ29]-5QX+)HG%I./O9 "-YA&A'
M'&@.,@^3VAV3HKVV6>,0T]PDB$,LDD#*BCN$+=6TEVHW_:ZVG! Y-YW:JE<&
MRTL\3V 'SZITWJ/*^@-T.4%LM6ZL*@//1>5+M:)-N/UH3K6Y%A\+'7K/ID'X
MAN>0XJ6Y4GA_7]:Z-3H<?06,8@Z:;?D>2VAV$V9VQN/AIDU5W/\ NB,C#*?;
M;9CDZ22X!F.3AO\ 0<E);K[0.<UO*07*CJF-9D-93.'+M\A:KKM'LM4"U"GE
MN=+&USSLM7U7+5HIHP=ZIV-O=2YHNE+&S+O ]QDCN-*UHB948#6N]"^5^*<;
M80TB=9ELE0PB7\*.W2O"2@^54"K>U-NA^O<W(MJM_+CK"T*1*<FQB%<><]4F
M(4:@;:<5Y6JVMVP[G4K:/NKV9DMGT%-W2ME*:HJ]G)H=&LJ-HK3&ZJK]FW/&
MXZ:MA?<K$)),/K:%K3$WZ79KS:-HZ=]19ZHR/A?R5705#74]PH:@9WZ:KI9F
MQSP3,(<.3EC8]P;O1\HPAQMT.)#B\&*3$SH9,;-:2_#GCY+,R%*87]:'H\F.
MMQEYM7YEMK4G?U_7GT^AKZ&YTE/<+;64MPH*N-LU+6T51%54M3$[X,L%1 ]\
M4L;N9['N:>E=B06DAP((T((((/00=0H]NW8*1SVPU*KV?=P08O4_0JK( \SZ
M7<!Y,I[H3)+&*-T^HG@D @R)"F#<F$3(PY,4"))'9+30B#)FM;?J4SCV\JD_
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBUZS_P!FQO\ $-1_
MS6%RCCY'?,5#P\K?G"V'(JF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(HGN'+DW PHK+L$F,E+#,:-$;A-N-QF6M;WM*5JD)VK;CRW
M7EJVE._4YZ?Z*4YV5+<.]8A&V%KM2YSB\@N)YR-TXP  .SIRO+W79IMVJS53
M5TK,,;''$V)KFQL;DX!+P27/+GN) U<1P  DL=&>A0(<21*5.?BQVF')CC>F
MW)*FD:1[9Q&EKUIQS2=*<WI6]*7M2M>7GY:T)'![WN:T,#G%P8#D-R<X!P-!
MS::#1>BIXWPP1122F9\<;6.F<-UTA: W?< 2-YP&7$'!=D@#.!W<P7,F$5'O
M$*("V'J,"$>V(KT<32PI.$=GT#N%U3:7"1"]A2%>*)Y/T.@!71@(4_+:4%MZ
M;"@C"OAN/'B11\LNV0S;G&1DZXXCFP>!!Y\>;S8.(S@X&FG$YX]!'KX]:NU%
M\M18VD^S].F&?3[)A49KR]FGR]E&6I:X[?E_086M2FD^3:E*VG>]X+-<^$7#
M)U(5'D)AN,LRU,NZBNR67)$=J1MM6F')$=I^*Z^RAWTJ=9;DQW'6]*0A]E2M
M.)(O,OO_ #SO;I&';"".F6_N [CW2:GR+HGA=;C\RY^%NUA.5HP"K]\H=YOM
MY(-Q)Y:M5DH5L5JMQCEA82#F#K)68!""$46NGDYP=>GL^GH/1,'4YUP0.8>G
M/1TX7I.%260&$H/N0GCJ1D!)IT<AQL>Z63%:T2<@(>_GD0ES-/*BH=_G$L;1
MI?Y6MY%5T0O]I6[_ !#&_P J5C*>#>SUE0<7=OJ"V'(JF$3"*+>O<8YSW2I.
M4SI5>:-#$2V"@B?'D21=CJM@A;VL9:*?9!SL8S5[**=W[4>:#S(LQG?K96MV
M*](CNX21LE;NO&1G(/ M(X.:X:M<.8@@^1=?<K70W>F-+70B6,.$D3P71ST\
MS-8ZBEG86RT]1&=62Q.:\:C):7 ^:72J=;^$V$>:[I:+,@*,;:"\^^4 Y^-B
M,WZE#EK;:$TSQB4V'#4 NU-TXF/ <Z%+%RJK.TAAVQPZ.5GOG7-BEN<]#&ZD
MK&,N%KD.'PU +HP':$G=\:GE();WS"0#D<JQPT/S>[VB:W54=9<ZNJIIH6B*
MW[=VR-C;A21 _:J+:NC:TTUQH 0UAJ9H7TS@ 9113/,YDD1=C_*"0Q5WGUWD
M4NTN0WZSV:E:>/>$'LZR:6W1CMD&;EK5Q^U'67&5-O?$H(L@K;\@-:;"AQF%
MOYQ<.Y$VCJ:K:/N-WL[(W.=[JNX[+2P=^[)W>4C>D?7[-Q2P1Q23%H#[ULU+
M;KBP.,E7!6$N:[TE+MA4VU]/1;:PT\$<YCCM^U%"YSK#<.4(Y(25#S(ZT54H
M<'"GKWR4DIWN]:YX(:N'Q 7@1/ZOX;GNI52_5FRT'H"[82W2^EVQBGV&LD:'
MT:BC9];;JMJ 1R;CUBN4(M*=+@XQOX"')528N8+-OQ)7R7:3W1SM@+Y8]D]O
MMA+O;+]<I8FU=1:JZANED=0S5(HX+M9:G>AKJ^&:=DW*6^KHK=7TG)&.1LTA
MB,GOV4@G8989FNC WFYR"?%)P[!+1H00X%S7 YT!*]/,_3BU$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81:#T:S :N&$R3Y.,+8(W2CAX3LI?H
M0^1F6H4MF.E7EO6M^QCR)#JU[2VS&COONK0TTM6MJDI*BL?)'31.E?%!-4/#
M<9;%"PN>[4C.!@ #+G.<UK07. 757>]6RQP4U1=:N.CAJ[A16VG?+G$E973-
MAIXA@'&\XE[WNPR*)DDLCFQQO<-^S57:IA$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3"+635QK5=,5<"9+1H!:YD)@RMPWMJTX2F0(#Q
M*4VVK2=H;2U':TCVCRD(7*D1(C>U29;#2]F&CJ:B&JGAB<^*CC9+4/&,1LDD
M$;2><DN.< $AK7O.&L<1U==>K7;:RU6^MJXJ>LO=3-26R!Y.]4SP4\E5*UI
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M81,(F$3")A%1?Q%>*Y'(^N<YIL!Q#XB%*:+=02VRB2^@,897!@0&=:0IYN;
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M=JHKO3][5L1>&O$L$T;C%4TD[-8ZFDJ&8DIYXSJV1A&=6O#F.<T^*W9AO;O
MM<-7>[.%+GR0C8VBKW;:>)B17HI^7MN"Q<+Q6(:6!%(ZT\SI@5<B,)N%R;Q"
MAMLLGD4KH[4.=/\ /;7;,4NW%LH*"ON#['M+8:COW87;NF8TUNSUSW.3937
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M[_NUO'V4JIG\8[EO=7I^G_W=M%9C]6[15I(ZV@YXIR YIX#P^_</ZS!PY_\
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M;"[;\OLWIST[UOS^KZOKS&U7=@?\#N36%G'6;NF,9Z&[&/6[%=V3?<[5?_\
MQ;?2TW]ZN4./+A2T&Z9XE2_H]\\,D.K>KR\_C_9J=+]GY_G7JL1#WGY?GTWM
MS_5YYR"_]V5_#N;[&P_TW=*K7_V.PI\VO;T]C%,V3&_3UT&?PK*$X[>1N,WH
MRNX9G^+27I7S<KW!@F]Z\T:L!R\6+T;W]FE_"X%<TO>OS^A2=;W]F]93=.[:
M_.YL;W.(>CE=O-H),=O);#-SZ/6LY6./W&J;'_2T)F\GB5\.OH43F:U\HJ8]
M:8/3_"]54*\](4%H%[EOMZW]FU+L1L^PM>OLWOW?2-[UY^SUKZM\3JON[O\
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MV*--S97,N]\ZDUDY= .G4.;@E&G^H$(;"-+-#8[NG6G//55HK*:,U-%4LKZ
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MYYWGO+W: N))])YM>P*WF=JHF$7F3\H-T 9$?YY2H@: 6L Z=\\)LN9#5*3
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M]$9L/ARU1AE+(-;[A!5+W:SIP.XB?J@W_4%N.D173B78;D11-<MYQ3+S,EJ
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M6--:\M^6M:UY9K][9XSU)_\ %+?Z@:MKWKAWW?:#:BHZ<WA]*#TY%OAHQ@]
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MWA5,(H3ZIP#G?6I(\Z7B$JW?@3:DU?J5&(NU;H]85OU?D#;+ 3[:6.5M2_>
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M;(HV##(XV-8QHZ&M: UHZ@ %!7B1_P!!Z?\ ^?\ X8__ *A^9Y%G[>OU*?\
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MT-<SP:C=)"UBP$S1RN!^C5" %N@L.3,EGXL$VQMLE.BN1Y+D/5[?Y*CK]O\
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MA*9KL.9ZMJB)0IT]?T@^I%'M-\,?!N=]*E]8H/+*-2KE,I\>D.2ZG5*Y7(R
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MN-2S/^@!WBV;$)R<X14D399%OP[=M]Y@R+:1?2&.!QT6U/0>QR2"(92!%[#
M@VB'83]OL75*D)M<>0)A5!ZQ-OQZ\5F(IY!OD?>NY^9O,0T8UT)&HQS#)P<
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M%&;X_ .%.AUYV2%NABQH6>L[E@YH'''1X*HUQ^P$I_+2ET"L6Q_?-IY@9(1
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M3(L**WM3\J0RPA;B>KDL]?%&^1\< 9&QSWD5M"\AK07.(:RI<YQ !PUK2X\
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M1S8\B9XZ9UZ]-!IH#_FI1D66\*Z)R.1,.PQ-5M-'M$\K5$ "$%YD[!"!R;I
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MO(1ODCAW<8Y*.1[(\;C'N:T.,JYDMM,(F$6(37@"4"FT@PZ4 9;L\&A(R%I
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MK^ENW_(]*N.9_I;._P 1= _X"0?([X1_WO[F%'_=W_TT_P#R%&OV!_I0&_\
M&>;_ / /+9B>?_<_NA6+/NK/Z2#_ ) D7W4/[1Y?_P"->#[_ ((_4,R'P6?^
M%_=7KDB^Z4?]):/^2:Q<_,OL\//_ (O\F5_PD/$1D;]YVTW]W>N.EX6_\K97
M_E*Y+CX;_4>%_P#\3^2"_P#H&\2^!QC[*;^QF6=O^!:^W9'_ -!N2X/#)_SC
MPJ?^,?(J_P#R6\6^&?Z'\NF_J2+&U\;3V[%?W.\+^@KY-_\ ]0'P8_\ ],_&
@?\B!,W(/N,7Y#?F7T'9O_J_9?^ZZ'^[1JZF<J[I?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g945651g26l94.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g26l94.jpg
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MV_CE5A8?=IA;L=X&Z;UGH'!^EJNY \;HGKR!T"L<S('[>I]8>7L[0I,ZY:P
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MA)J:;8MK+O5%@[C)3&#CUPS\U2'./>?B5_02&7'F5@23/;ILBZ=+_1_,RKU
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M9&2[U790M.0DNGQ!S-=,)R:_\1!B=FXCAVL X'..DV1(-HPTWDS+^.8D2SL
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MRIYF.JI:2YLKXK:*=IHF3^],GJIZ?W::!KFRQ3Q2.;'\;6=$'V<XBQ$8F#7
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MI,)BF8;;ZLMB:#P-)H*R.<6,BJNYVZ]6P@&_4=F-C"'E83!PZ@+'I4&2R =
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M<R'(E8Y/F)\)CAV:ZYXXQR(\1P*?\GRT9%FUV[%9=3]XT<$,T>+-NN$'6*;
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MS'C;$>_RL$<1A%+/"+4Z\<$LEC2-IQ3$AMX<],NMVS89K3T.E$HXV5<LO/\
MGK%"XHK -A&UHM!-0+R$QHA*AV9%8)Q343-I&_AN?ICD>KKZR/!0CZYZNOZ
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MPO8UVB^NC=M](>3V^6B7H_V666> )(QD"6J/:JT"?:6)8&X4[Z.JI"[1RR3
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MU3'21")DTL3-E7LC?(&ASF->X-)P''&5D=PDGXM>Y2_]3>V7_5=R3_Y@.?\
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M'/R:Y^CGX7D>\?1RG,=Q^K5L%Y%5!E^F,=*MLGTH\;;4;GFF9L/XB9I,:/\
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M6U4>HB_3ZAW^+S#@UY^,7R1E;W!^ORU*A./E\S@*L.Q7.EH.Q\;TL-LIB3>
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MOQ]>(6-K_P X^,]@^?YICM/R_)1Q6PDJ%X)/;^TQ%PJ=1BL>G2T%W:\"5#5
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M/QN<K$E;IX4HHPVVX\3&<IG&$.(M1"3$2[;#_='Q#[2"J%IQA,0<P:D#K4.
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ME/4L;!9$$\C!>N8\.KMX?8Y[>29_7L[?/UHL2A]Q,355>^LM/5+)":]6YI#
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M(M<VE:BE+_4\!6X(I]HNE/S^34K%#!T!986]'8$35^1?LN7IV"HY_9T9$I@
M+&F1KQSX8S]1\^]8EV#@CCPX<]/7'EST6#0^XN)JJO>V6GJE<I5;K1.Q@5H/
M8)I+6Y5\0/-3YC JC%X(M"E[FA"P5"M;M\'H["#(D^ ZXMHQY]7=G/EA4'UD
M8\/GY%1_;WG6:K-&&U<512/Y*?/4P-7K QIJJOG/>.VBO%.11D/X[!43OK4
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MGX9SKKG/]F/@1<.11<YSMD8?.V9]2L[9ACSG)6FFL>A.<YU^.9](]-=-9O\
MZ373777&V-<8Q@B_,B";:;1[##[1[YVSO'F&/.F^=]M=M\[:9U^7;.^VFFVV
M<XS\VVFN<_'.N/@1?F0Q,[XDR*-G?7_T=\P19WU_=IK^[;.OQQ_5CCQ^[/\
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MO1K80NL:IQN LE=ZR4'9!M'^54Z1V,ATHWA^2M[L6A,\,\SY:$_;J"F4W9Y
M4BYLPK)FI$[7IT)Z<0D&8Z%=SRVG4WZ(A$Y@RJ=XP;2H/\WD81+M1YG!$9^T
M0$6\Y,Z9.FN/GA8=U[ 20*R)5'.KW@[!:M3"Q;IPXJCH[875?125.;$,YV6E
ML@&YDVD0V#0ES"83Z,KQ6)-NS&*;W'0C',C3.<=?7V^*GW*^B2=&1_E9UL2R
M;*ZHM-1QR9"X?M[52Z_:-8_N)(!\[2A&-3EF<9BTVG@!&89C@U/T@B*@Y\,?
M,9[?JK0\*IX1/")X1/")X1/")X18@E^D"(F$+;+QBA]TD<X\Q4,<T.]E8R**
M_K)'MOC;39TTAE7+,;8QDPR/<>#YY=<ZX(N_J6)N7,!H4/N<,.*60%K-'L6.
M(;(7"$5,/C;,T0Y<R\^(6:336,B0(N.+;?8:;&A%T)!D:@IC8)HURXIA$M$:
M-R-H1I"8 I)X5(I1DVVGQA&G8DZ C[;XCT(/(S#I]8N7,A%W#3@ET.A!Y0X<
M$A8 ,<Q,ND,>YK0X=8M%UWDSKKD@YB6*")%C/SSE$0P1XVDDUUR3UYKZ@-$*
ME-@&)AGF7$ZAGQQ2:[[AE[B"GZ#$:ZYSF*;8(X,K$>_PVS 5!+\/EDUSDBP#
ME[3_ +S%/?MD&#GRXO7].LS L3M%<PC'8O79>1)C8@2<!:XWWUVCVTG$6MI-
M<;PKS=H2+$U^Q<T 6(%M<>5,=4_W'VK8R]DN^W?2V,(BT0$K,ZS9_+S/PY#'
MN#(=B9&WU"C]IB)=YI,E!CEZY_JLTMI]63KL*5:!6"MPP$;?9CB11PY9KY0Y
M@#MM<:_'8D'9<NT"EVSG82  $8?,8X@\49523PBZT80D11)T8\.AAD8T)16-
M-?N)X0_K9$@DE^'S[0C;$D[P0YS].*0DF3377<B;;<B_#B]0 C#MX22- Q2"
M]QPAY"S)]1XMYMH1!8<;3$DRXTSI /%KM)-+MI'IC.VV,>:]74MHZ2JJW15$
M[:6GFJ704D$E353-@C=*8J:FB#I:BHD#2R&"-IDED+8V N< J!D@9 R0,DX
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M]8Y*T*TZ26!*&SKLF=U.=B@1X]@#%4H<R@TA0<M)5,!0CU9BI@"4M,6FABE
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$PB__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g945651g26p01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g26p01.jpg
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M!0$  P        0! @,%!@< "!$2$Q4A(A0)(T/_Q  ; 0 " @,!
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5IWAC1IF4> TA8@> >K4=&]; Z__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g945651g28b20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g28b20.jpg
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M  (1 0,1 ?_$ !X  0 " @,! 0$            '" 4& P0) @$*_\0 2Q
M 00#  $"! $(!0@(! < ! (#!08  0<1"!(3%!4A,0D6(D%159/5%R,RE=,8
M)#0U87%WMC<X4G*!@I&W)28S0B@V0U-B@[7_Q  = 0$  @(# 0$
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MV\3;TA'C-AUN(TQ(P$O*LH%>>)V[)C1MQMKKOOS$#33&-!Y]<+C.>;33.-L
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M9"V& ,G'73&<_'!QCY'MU-",DXSD8U[?4;^7<Z]%;&%"+C8>)CCY%Z8. C
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M----P3J3TQC=4/Z0UU.--==3OC30=\[=M[;Y5756NKV.\0G1V%5>0(EWDUJ
M'@.>#.SX!4G,R!=U;D[,E38&H"?BHAMNOOSH)!SZHP".4HAR'*EX9N<L "#G
MXG30:?'77;?SZ4<3G .XVUSG)U[>_.XW44'7>\-1<NJ(N%S-KP]2M$C3; \T
MZJ4F^SB4CGQU=I+JU1[:Y1@N?D;@^JIO,?)NV-B2J*F6F8!J "G SL-]1Y9=
MGX8QKIC?1 3CX:'SP,:]=<Z:]E?M/NVG7NUK2O&O=K6_.M*\??6M_;SK6_PW
MXUYRBNH"]5+4Z[Z:^\)KLC$Q<@GD717%DS4*9/!J!;J$RN0&2"#/5Q]!90B7
M6 S=R*V0"5ME/@2+32@WI&I [G"@Z GMJM>Y1=:YSOG]@D.J7RCUI;_:.NQ9
M-@F9 "BUZ5GW.A6=UUF)&L<^?L39>QRB0XAR=EC61FUI489\!PA0[_ ?<,?G
MN@VU[N^\JS;3K3[3;[#C;S+S:'67FEI<:=:<3I;;C;B-[0XVXC>E(6G>TJ3O
M2D[WK>MY"E<F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3"*BW1$N#]_K/U$=H\B*FJF77YL?5[.(KD9.W-A$J'
M).NVJ)@&UF+F&P],AMEB@0CXRCHTN*C]1>7'Z)[X.1[/3;IG_7MNN,CVAGN.
M_7IO@8WZ::X.RO3E%R*OGJ$@9B>A(%,2-8#G8LR:E0HV'@6[!&RMC;KLD'6X
MNS"(EXLMB%.-.<9<.U[8\-W;9,C+U[;0DNQ9O77&G?!QD9QYCM]^RJ[IUWQH
M",XTS^<=U$9%8Z$Z>2^=7[/K6K!9"^K,B.290MIKQG>*=.TH"$6EW?YU!0?(
M1;-'$QL.R\4W NO4\D1Z1D&HI4Y&.G3']T@^[VL'MG51@YV.YSYC((]^F1UT
MTQLK/<L"F(^C1 LVT<,2@B=<!#DW5O24=7"+#*DU*+D5NNON_/1=6=AH\Q#S
MSKS1 SC3SKCJ%JW4[_+YXU^O;3LK#;Y_+.GT[Z]UU>RF3<9R;H\O6[!(5>>@
MZ989^)G8L6".,".@8PB88TD2RP\_"D,%K"T$:V9%$*V$21\HL0W0Y@\*5LU-
M9D&*K7T2LY)6615%!O&3DPQ"C24B^2TDA;Q3%=B(&%:4G;OPD(CX@%G33:/<
MVIWXCKA%LN$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB814:O,)*1O>XIT6-GY&%*MU!/=)<TEP<*0D+5&%Z%A5P?.GB@(
MS2-S\_+-G74=)"(.=58O@QTP"F7N#[)U&@/W8UU'D!H>GGCC(]H:;D9TZZ;'
M'Q.NN#LKRY1<B81,(F$5?_5=(OQ7ID[\8,&LUW^B#H NFD:7M+#<A69*/>D"
M---NN_)13)3DF?\ ";6[\D&1\-.U^W,N@IV55;2T\C_#9-/'&YXQD!S@,-YO
M9YW?HLSISD9T6FXBN4UHL5VNE/ *F>@H*FJBA=S\CGQ1N<#+X8,G@LQXDWA@
MO\)K^3VL*B%03(\UF&>1#==C.\P%YMW"^ZF6V.E[#+.TRQR7JUXT,1#K<E[U
M>1$5N\KLLC-5%2"@Y=[\VIY<F].?H'C;"LIJ?U0U4=)44#XZKU0PSR.D\9IA
MD>9&E\<;VR0E@;, #'_"Q\H8?9/7+%=[@Z]BT5-YMO$4-19OM@5UNIHZ7U"1
MM934[:>1L%550R4U>VH?-0.<YM0&T=2)'SMY9&^M^:1=\3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%2OH$_
MO7?8R+/KM3<4]*<L3%-7<'E4B:[J.L4ZTQ9ZL8_UR)O$,ZPF:F&H':J'.D[F
MAR/IL>TZ09\>P&AWZ[9[;'3'OU5"?:'PT..^^<YZZ#'P[74RJNF$3")A%&/;
M/^AGKG_#&^_\JRV$46^DNIU6K\SE=5FM5^NZ,Z5U=DS4%#1T1HMJ(Z9;HR*:
M)U'C#_';C(UAF/CT.^](0++0@VFAVT-Z(K081,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%4*;A+H7WLHJ-5(/",2M )E
MS:UNPP88D P<X^.!9@2/4+4H>R$.A-20Q,N+S"V,;"?^5W'R!(*H1FPQCY[Z
MZXZ>SITTR.BJ?TOEM\\'VAGKT.GN5O<JK)A$PB814N]8OR3<?0BND,W<KTUC
M/W'?>1:$Y9TFK"=KR6JF];6*.\S<C><,%*F?SJ$A5.L++<@79L=^%9.TG=6<
M<QJ64_J_VD\0BA]9$)8?X0^.V+UD&G%0YO((C)@\OB!A#RU=#XX>(6VJ>XFY
MCA:&6M?Q#]DOK63M IA]GRU?V8YEQ=;(Y?'=5MIB0)/5GU#33LD5!_357XKE
MCW0:978&<J_/>H=TXY>^60-N!D(ZY10',/6;2.?6N)LH\PGZNV<&-/T-X0.3
M6J4"CR6DR>MR#A;BMC?IQ6TU+/XK)ZBC=ZK6R1/+X72U%.V=AA/Z/('Q5+<Q
M_P $2W^"]CE76O1U;W</W6ZVX4<UOMU[A?=[%2UD(@N$5%;;A);Y65K2!*9O
M5ZNU2-;4DU;(I&^MDU!D*]:IGL4(Q,7RGUR,G9N^T&J#W"2@Y6KWFJ5TB(-?
M.8CW1NAR=/>II>Y%R)F&P&XF2EB"78B32@?V1Y[HO5,=?S^?].X7L.>GY_/^
MO8K'UKN$/)*YC$6."L,#<.IU?5MA(:(KUNN$"+%*6,I6Y&]1-69K$>^&+(13
M\HU*$QJ@%2(^E?%&=',(*,C('?;X*;\*4PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%4+HTQ887U 5QB('M P<['T
M=DS42-:78>??;NB!/;*R<6P[5X1(-?*LY#K4[[39EJ,:'V2.$P(EZP&6_,[C
ML/+)R<#3R52<.T&X'?74]>F!KL= 5;W*JR81,(F$4-^HB)#G."]EC3_G-"N\
MRNKZ]@24E$%:<!KYYX^VSXDL$]I.B!FMO-M$H;*8^((4AX1]]AQLFZB;T3PE
MDKW'#8F=FX::&"Z7UL>)5%PUDCB6&V^GV]1^Y(^T7N]R4NX4>XZ^(ZX:,X"(
MIL)Y1ZVOG%$5O<(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PBICTF#.+]0,#9FP:X7%P;_-X0N<*A!2":S*SMYKY,8,^\
M[2)<DN3E8^/FX:./$L:/H!%OKQ!3-4;4/.S-Q^B1KU/OT/GL/KCKL*$>UGW#
MW9/NW_S#IJKG9175:.LV_K$5?Z7'T^L6!RNI>G&EF!-5XN+M4X7S3H\C'A2G
MQI=N9C(RNS,/7B->T%M$P8:^WIU+D9'#S-@!@Y/WY R-M,9/YW*J2<C _P!3
M@^>P_.VL-&WN\-Q<NJ(NMM.KX]3L\G3K&ZRA4E.=D#I'/3J]17%;C&_JC)L_
M)6]]534/IIZPL2-1VVTU (@0Y '89TSY-R=?EC7MKYFN>F3MI_:P-,]]]._P
M OVGW;3KW:UI7C7NUK?G6E>/OK6_MYUK?X;\:\Y1<BK3ZQR$C>F#M2U^/8[2
MRPU^?PVB0*$ 4G?X?922=IW_ +\V5GTN=&?U9@_^XUS_ -BZIQQKPG?6?TM$
M8??X\L<.->_/A4QZ6#:[C<^:5ODU7=MO3.>>H[J_9+''D2T77897(H#NRC):
M *GI1Y.AYNW72LU/5;8&$.9T_6SC);0@0J7EY5OCB]1KW5<XIZ6<T]/&\1NF
MD]<C(F:YL3,$L9 9F2.+FX\9H;S$\JUO$E36#B'AV.S6]URNUO9<KA5P&HAH
MH/L2IA?0RQ/JYN8-GGN(H9J:)L4@D-!+XKH6 2*RE Z?7>M6#L%TK^B0FICT
MY\P^:@I78S4[ RD5;/4M%3T',"C$$M-2$)+L/QQNQWWQ5NMH>%(?%('>=UU7
M22T<KX9 #R/(;*T.\*1KF,>Q\;B!EKXW-> 0' . < <A=FLUYH[W105M*3&9
MHBZ6DF=&*NEDCEEIYX*B-CWAKX*B*6%SFN=&YS"8WO86N.U4O_7?I3_X$6W_
M /Q>/9B+:G])O_-]RM/A63")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$52^A)45VZ-B=$IC(X[^BP^:'-ETBM6E^%M
MTM(P*8YI/)K:4E^#/'^(L<;H%3^:?(90^Q%L$+F9*X'LD]L_#09ZC[BJ'',!
M[OCJ=M#]X5M,HKJ!?4%6.C6ZH)AZ$+%R#.]D&2\879CJK(29(2A7H 420$@I
MEIX!H_3LA* OO1'SS@$<(Z>]%O2L:=(P-_A\C]=L?DBKLZ8VR,^>OW=_)1!(
M\VO#\O(E/4DHAG\Y;3(] ^&9 OM]0@)7O=0N-0BV7'Y)DBPL5/E\;/0BH^RC
M1;3 )2Z> R0#)/L)MD=^FF^GLD'IU.-O>HP>PWR<8UU!ZXVUW_:K,<LB)6"H
MT/&3 CD:0R1./!Q#SPY#L#!'6&5/K-<=<#?*#^)7:X3%0:T!$DA-*C]M"$/C
MH:=74G)_._4_$JPT S^>WT]_O*QW<O\ H4[#_P +>@_\IR^0I6B^EO\ Z+Y#
M_BEV?_W5MV$5C,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PBI_?5PV_417$SK,U\9"J']%?@6>2[A?C*F)'Y-%]<MR2+
M6E_4K\3\U5Q*PSUK62U31]V%ITDFX_1.//._TQ[]<^6=,*A_2&?+&W<G7/NT
MQ\-5<#**Z81,(F$50?7JZZUZ2NPZ8VE+Y,?5X]G:U;2CXLG>JO'-Z6K25;2G
M:RDZ5O25;UK>]Z2K?VW=MRALT5;>*ELCZ>T6N[W2H9$&F5T%NME762B(/<QA
MD,<+N0.>UI=@.<T9(ZMQH.;AVKC_ *:JL].,[9J+S;X!T/63LJ@05EJ_80CY
MB'*O_,>EP_7H1@6V4BTN0TB?S7U#^HJI15KJD@6*/M@Q$<S9&W@-&A.N1\X*
M%/PSXCOSPRO!O07^Z/H/2W5<06B'AJ2S55JB@N+:6NJ8KQ25=&9'4S*MD[*6
MA=2UD4CV,FIBQ['QS-Y)ZAK)&Q[6_P#"E-6RTM:ZKN%#6P1RTS*^U5;Z&J--
M4/9)-1RN:)&34[WQLD:)(R^&5GB0.B>7.=HA7&;)QB+]/G,8KD\#QF^C]9D*
M3.^L(\FGS==NL99:W?7"=RR8VSQW0[&5T@-EH;59OH\'"1%J3"18<D\[J%?S
MZN-9%<#<ZB6KDK:9]$)669OC1RP.9)3M'AET+J:(4Q)/C4YDD?%XCG,'M@^)
MMLE;PV.%+;362EL-U@OSZ.?CN5U#4TM?'44UQD)G;#6172K==F,:SU.YLIJ:
M&M%- R5SO5G*;Z-WU%'Z3'5+HSI5GK'II38N3S_<Z%29YWF;4;:Z[R,^I%W(
MP,NQ!52<B%C2$!>6T2IL9!F1[,Q(.1$?([9"TT]F,K*:>C#8C5P.F905-0SU
MSF9)(QP@:YL;IXWMC$D)+6O>'<C1(YN3W>W\;MI:BZ6^^.DK/L6XLHJGB*U6
MRI^Q!%4TU+/"^ODCDJHZ"H@?4FFKF":6&G=%X\KJ>*3E9?#L5SN-%K<1-4V$
MK,\4==J!42Q;-.2D$.PW?[Q7:*&>,1%04\X^N//L8YY S@["7A!GFVGTO+1F
M@&OU^@RO2,_L^JE=/N]J??I.E^W7OTG>]ITKQKW:3O>M;VG6_/C>]:WO7C>]
M:W]L*5]81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A%4NZ #V.VQG2V6?9!Q?1ZIS]4P?50Y*RP)E6OCT/(RU+FTW>-(K
MU5L-M>W1+3K=;.EC6VC9,F+DZDH8QBPT&/(G?N.NFNFHU^JH=\^8&P)T/378
MGR)5M,JKIA$PB811IV=OXW'^JL;9?(T_SB[,*9%4A)#B7ZU)-*2RIQ*T)<]J
M][3O;;GC>OLVYOPA6AXJNU78>&>(;W04#[K76>R72YT=LCYO$KZFAHIZF"C:
M(PZ0FHDB;%B-KY#S8C8]_*TW8T/>QI/*'.:TN[ D GX>>G=>2_*41O<I[DM3
MZ#5GI"*JO;9NPQ<U"SUOK331708/H=UGX*51 SX LJ.;8H")F(IDU#RPF81X
M?RZP0_\ $^:OW-?IPXU]*]?Q30\46RW-@M5/2UM+=+31U%'3P/JIY(OLJI$U
M15-D>^-IGHW![9A%35(G=/F-S,JLIHH1&6..22.5QR3C7F&,;;'/<8QKGVSS
MZS6$F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PBIQ,V*!FK<(4_8H5BZI[9!UZ4Y$'8)(>8FJ]5[PF&K5FDJXQ,(/5,PX;
M(/6_K;<(B"D*2 '$2@AT6*':A[8(&VF-#TUW Z=V^_)&NBH<9\\@8[ZZ$_>#
MVTV5Q\JKIA$PB81>;_Y3:^-1? 2.9H"F/FNFVCGL.[-C"R H<0 UT*MGNNA3
M>PUQ;LZMR-2AB,T7LT85;DD\/\!(_P ?SWT@<:R\'T;61V>"ZLNO#OI)DF=7
MQNEM4$?#OHSXMXF;!7PLY35,N4UIBHG4AE@\6EDK'B9KHFAW6^+8_$L\;.8M
M,G$/!T Y?TCX_%]CB.#@XPQSCGH0-"M"YXW!U_G7.9*/KNH(?K-Y]/*%$O>Y
M]TFZ\Z]3M $F_E2W4Z=1'V:'.3.QT6C2! '(.9;&TI*-N.?._P"YB9:++2<.
MU]%8VV>#TE<,5(?/)S2R5'%G URN%+=O5ZJ0"1E#Q!;*P7F@ML8;2T+K1=HX
M,AI?)W.M+G%X+N8PR-T'2.7E+<CNQPY2=SS-RO3FP0M1ND9)U&TQ5=M</(,:
M:F*S/!1LY'&#H<:<TB1ASVR1WVD.Z9<3H@=24.Z:7KPO2-Y]G12RP2-EAD?%
M(PY9)&]S'M.,9:YI#AH2-#L<+45=)25]/+25U-3UE+.WEFIJJ&.H@E;D'EDA
ME:^-X! (#FD @$:@*F70O1W/)J76:-P;H%=Y5S?K 115AY*KG,81679MZLQM
M8D0JY.PTG"&T>NW2*@XR.M@XD//%#_%DI6NKBI M?G>4UZC\:CJ+A32U=52.
M CK/67B81B5TK72QO;(V>6!\CW0ESXP?89+SM:%Y_<^!*D4-[MO#=SI;-:;W
M&]U59/LJ%U(:AU'%1RQTE33S4\ENI;A!3PQ5K605+V9EGI3#*\YW6;Z9&],X
M_"EHBB*M9ZUW7TZU6^T21<:<EJ+;HSU \H^?@35->&RPU,NCR-?FATZ L5=.
MBYR/WL0]O2=75TKJ6;!>)8I6&6GJ&@AE1"\.Y9&@ZM.06R,/M12-?&[5I7;;
M'=HKO1<XA=1UE)+ZE<K;*X&>W5T(9XM+(1H]G*YDM-.T>'54LD-3%[$HQ;S,
M-;M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PBJJ;-\B1UH. 73ND/VHN]BLN@(5<1Z(S8] 25F NY%.?L U.-8<7 %2
MPMQ%K)KRY@%Z509N2BS2@[X.,Y& #U&<=N_7;X%5TSL<Y^&>^/VX[D9P5:K*
M*RXG7F6-)4^\TRE;C;*-NN(;TMUU6D--)VO>M*<<7O26T:\J6K>DIUO>_&$7
MRHH5/S'N)'3\FC3A?N>;U\JA2-NZ61Y5KX"-MZVYI3OMUM&MKUOVZWO"+F2I
M*TI6A6E)5K2DJ3O2DJ2K7G2D[UYUO6];UO6];WK>M^=814\]<=YEJ+P\AZ.F
M(F$"M%BC:1.E2A<<*Z7%V@22 W#1:9%Q"2I":,V+&Z'"2])*%?)4*TG2721_
M ?W25^X_X;]&\UT]'QJ8:V&YTWVU74,$=376ZP-IJV6KK*:.2.7PVLJ8Z-E5
M51QODI:1\TX\*-LE1!R1344,D?KT\,#)9&00&>5D+):F9P9# PO<T/EE)(BB
M:>:1WLM!. ?)[T5^HJLO==WS5J8"<HM.ZO7;0[;-N)U78^9DJ/U<2:!>G]K4
M$40F5LX;)9"R%?)-KC(Q6VQPF_;XIZ!N,7^CN.S0>DNMM_"T?'-A?)1"Z&*V
MU#JSAVYMH[?<KK3EL;J6HO\ :[R(3<:V.)M7%PY#45,[JB=\DVLHKU37NY7R
MCMTGKL-HGHV>MP#Q*4R55.XU%'#4,!BF?22T_/*UKW.C=5",#E9AOJ-Z?.L\
MVKM<-&+F.R/FVWMO6ZI7=W^O^HJSG&N0-ZMWT2#BR+_$2Q,>W%5$!"R!!W1&
M118>4=DTH(A)=0?W3D$!S2"TM:X$$$$$#4$9&#T^BSA\=,C7.V3CWZ=?FKOX
M4IA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M0(3>NLL=1B:FYRZMC5V1F3QTW+5KL4BHRH" %')E$_)\\3%0DPVZ@=ERM34Z
MA94@M0D:65'*58A[8&,YUQMCK\]?A\>QKDYQC3OKMKY:?'_53WE595G[%8[5
M"V^O:H\I-FV3X0Z=TO6B]1LE'FQ]M':,BHW4+J,GUIFM11ES//L*':;!P<:]
M'#BEV+3$[8#0YV[Z9TQYZ=AIJ2>VE2=1@Z]L]\^1]YSMCS4-G76\MQ<ON(MU
MV-KP]2M$C39]]HI4K-=G$I'/3:[2W5J ;=E!B[!(W!]54?9^GNV-B2J"V6F8
M!F "G ZXSD9QMC)R?+0#7(R#MN54'3()QTR<^UC;N=]L8R,C317[3[MIU[M:
MTKQKW:UOSK2O'WUK?V\ZUO\ #?C7G*+D7EC^4T,**:].%4W7)0D"?[;46E6+
M3L#N%')1+!E;BGAGIINPJ.=8 4[IP:!(C?@.Z0Y((=^(TCK?&T+*C@7CR![&
MO]8X)XJHFAP!P;C9:RVG&A(YFUCHS@:M>X'()!ZQQ3DP61@_G\6\)N_\B_4-
M5]T!/P[X4V^KOBG2NBQE#'Y@*.1#559WQZH&?'P+8I*D"(C)4%HE\"/<^0&9
M)$9:0\V2"E[P RXDLGV?-'[IOT4<?\<4'!L/H\@AFM?#KJT3<.4E;165E/,^
M.GCH+C2,J)J*BD%'31U-)'$V5D](R8MHX9&U-2&=VHYXHS)XIPY^,/(+M!G(
M)&2,G!VP<:G0+%<:%:@9N\]!AH*JVOHHWIBX45)S4EO\V9"=E!;+WANP1T_:
MQZW.V!@QMROBQDJ^7$2!A)\ $W(C:<&0L;WKT3U-55>C3@B:NNC[S7_O?M\-
MPN$OBFHDKZ:%M/6P5?K ;4FMH:J.:AK#5-;5&JIYC4M;.9 ,2<#QY<-Y1DEH
M\B21C&@!&",:8(QIA7%YY8Y:WT:J6N<AXZOR=D@H^=>AHF;)L8,>S*L)-"8:
MFC(&LD'.:!>&64I<($EDM3XS7S+++9A'H*XU1;U,U2DL=ZB[-TV4ZCS_ )S-
M\OC4:MO)$7-A5IZE2+PF?J85V?I$9-$N3-+%^4G>7MR4>AN0E'ID9#YZXL*,
MUV2VOEDMSH:>.CJJB.LY_ KO <(J:2(![X&U#F-#9)&@5#FNS&&QN'(7%Z\N
MXI@I*;B:*NN-5>[/;*JQF$W"P.N,3JVZ4U6YT-/<9+9'-(Y]+2O+[9'+&&5#
MI:N%SI@QD"LIZ5NB2W3.&TN>LTM]5N83)]>NFBA6HNP 6&!D2HYT*XP+;8ZJ
MY<5 ,@&V.#<$$2%(F/?*CH!<%4K6W:F92U\\<3.2 ELD&"7QOCD:UW-!)D^+
M!S%PBD#CEH',>8. [1P9=)KOP[05-7/X]?&V2EN'.QL-5%54TKXC'7TP#325
MYB;%)54Y9'X<LCN1@C+,V'S6KM*81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3"*M&YFMF=/=^L=XYT1,0=Q5'U.IH1S9VTP
MJ)(>."DZ<Z\:._9 IF0,69%.[C21I$N,* &>9^=;<=(G!QL<8UWP?-5TS^D-
M]!IGS&V?KG]ME\A64&=^ITA>*49 1=3=L<@?'SH$=("%U=DZLR4C$OB"R*&;
M:E(.HXU+C\1,R<04S;(F..>?K2='N_. V:<'.<?/4?#_ +=U5PR-L[XVT^?U
MZ_LATKDEZ>DG#2:<(6N.L=GF[4H8ZO?!ZL#.]\I_2X"-#47)M%%[J%,A)>$'
M'O2801DTMF#CB78(LV1:G/GTTWT]DCZG!T^*C![=23MK[0(^F=\=E97ET#(U
MJCQ,1*"HCB&BIXQB';='>;K\7+6&6EH2LMN"..A;1688X" 2D!UV/0F.T@!U
MT-++BJG?Y?'34_$JP&!^?EUVV5$ORG')%=7YOQOYBQ#0,9S_ +6#TIYI4(7*
M&RLC2:'>K''QS)3=ABP8X,X:,DXHYPJ)F2-.281X:Q$QA0,SYKZ81_\ I9Z0
MG@D/9P9Q*(\8UDELU; QNOZSI0 =P[!UV.INMDAO4MF,TSX3:;Y;;S&6MYVR
M.H)N=T,K"YH,<L3I&%X]J-Q;( X-<Q_BOW2NQOY.RQ\7X,]7;-;XWHM-C[I,
M]=?:5&QLM?+9<9P2?!BZVRQ(I2+48E%;8?C&9\B7=9<&+>9;W*#+<^>?W07[
MG]W&<M+Q7;;T:2NL/"SJ2HMU3$TTUS@M9K:Z!E+5NF8RVU#C/+3R231U%-AT
M,[VQ>'*9^A6WB./T:2VSA>>WU%=3WA\=<^] F,"X5]4:>I:*-L<IFBI8F4I,
M3*@5!&F'>+&6^R/(CF[G7?32/7;U)5.1B_4[U^3FJY!/5.;,8$LU%]1-DA$R
M[UEK$L;MI^)9?"#/$9BM'!RTH^MM,H-'OQ'T=Z-N-.">+N'J.+@R^TUVI[/;
M+523T_K'B7.WL]4C92Q7.%X9,R=S(7L?*Z/PYIX9Q&]QCD#?57LJ&B-U3'X4
MK_:D:T\T8D+27M8\M'.UKL@.P"6X<0,A7VY5?ICHD)+3$M4%T_<9:[94VQ'9
MT*=6672[++U*:*2Z".PVR-]:A#DA:<UMT@/X!*T,*<VPCT%1^?S^?BI.PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(JV0L1"
M+Z)9BA^6=>++:Z"ATNR2EIKC55BSE!PI/U.#C">FBRI-2?;<9L'R[%=DEI+/
ME &8]H@=R"!MDXQD8QMC_3?_ +^:K@9S@YSOG_7;\^2LGE59,(F$3"+S7_*$
MLJ,M7HAC$IVK4KZLJF"O6OUI^@3I6O/_ )Q4?^/C--Q(SQ.&[Y"<GUFGH*+
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MC,<DL,D;)!N.1SFAK\C#O9)T.=EL*2[6JOGJ:6AN5!65-&[EJZ>EK*>HGIG
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MT_WH/_A83+OU?\03YV9_<:?[T'_PL)EWZO\ B"?.S/[C3_>@_P#A83+OU?\
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M]16TMO921/D(?51LCJR^%KJ=KQXQEBV%16QS1.C$1/,!J_E(:00X. ]H$M<
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M_3\$^CO?OV;_ (P/\OPF#W/T_!/H[W[]F_XP/\OPF#W/T_!/H[W[]F_XP/\
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M?N_;&3COS$3)6R=W(3Z+S!RXVG@*>8-<;0%7@8IE;(J06S*\,)IMAMUU,A#
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M!+C6GVQY.6  ?<84M;:7D,E$-.*:4XVXC3B4[1M;:TZW[DJUKD9%+("61R/
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M$3")A$PB81,(F$40L=^XD5U<CA8_5**]V$4+9Y'-V[''*MK0Z0M2:TJB=/\
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MNN/ER)H2W5K]V]);;:TR.PVE#;#+2$Z3G#POZ&/1IPG9J2RT/"-EKXJ4R/\
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M_P#30?Y%R?T6\R\:3_1S1/;K\$_FA7_&O]VOI_C7X[QX<?ZC/[K?P3[.M_\
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5$PB81,(F$3")A$PB81,(F$3"+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g945651g29j24.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g29j24.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@ &@ ; P$1  (1 0,1 ?_$ !@   ,! 0                8("@D'_\0
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M"'8#&A-*7DHS*NS&(B*[.=S02#6J<L!N<WTS%YK?9 Y+#-ZNI%N*HE6I'+]
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53O#&C3,H\!I"Q \ ]-1Z>]6!U__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g945651g31b86.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g31b86.jpg
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
M0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M_\  $0@ JP#& P$1  (1 0,1 ?_$ !X  0 " @,! 0$            '" 4&
M @0) P$*_\0 .Q   @(#  $"! ,$" 8" P  ! 4#!@$"!P ($1(3%!55E=0)
M%E/6%R$W5'26M-48(B,D)3$R431AD?_$ !P! 0$  @,! 0             !
M!08" P0'"/_$ #X1  $# P$%!0@! @8" 04   $" P0 !1$A!A(3%#%!46%Q
M\ <5(H&1H;'1P18C""0R,^'Q%T(E0V*"HK+_V@ , P$  A$#$0 _ /[^/%*K
MWZDY+=BDHAJC/8 =C;ND@L+6OCWLR177(0FYY,[(7ETHO2)EAC()4GWS3CUQ
ML!S,$IP9I58+!%+=-?+3SJ'L\_MZ\O/L,*<38]B+NM'WN<?4X7\X:/-S$M ]
MECIL% W]/=%*WF]\@+Z#B\_TXR'PL) !0[KN3)<!)Q(:P! (#3C7&/\ G)Z=
M3C'R\<U!G3K].S'TZ_/PQ5E2&71EEX0(S7U*.362"SSC1BTAZO:+L)M0" ])
MSY>B,1&&=H3-H2=XU:_$LNFL\6@^F<C^<:Y5(/R+#^*)OR([^8_)KWCZ']TI
M\BP_BB;\B._F/QKWCZ']TI\BP_BB;\B._F/QKWCZ']TI\BP_BB;\B._F/QKW
MCZ']TI\BP_BB;\B._F/QKWCZ']TI\BP_BB;\B._F/QKWCZ']TI\BP_BB;\B.
M_F/QKWCZ']TI\BP_BB;\B._F/QKWCZ']TI\BP_BB;\B._F/QKWCZ']TI\BP_
MBB;\B._F/QKWCZ']TI\BP_BB;\B._F/QKWCZ']TI\BP_BB;\B._F/QKWCZ']
MTI\BP_BB;\B._F/QKWCZ']TI\BP_BB;\B._F/QKWCZ']TI\BP_BB;\B._F/Q
MKWCZ']TI\BP_BB;\B._F/QKWCZ']TI\BP_BB;\B._F/QKWCZ']TI\BP_BB;\
MB._F/QKWCZ']TI\BP_BB;\B._F/QKWCZ']TKEK"^QMKG=DHVTQMC.^NJ0W3;
M;7WQ\6-=\V#?&NV<>^,;9TWQKGVSG7;&/;+7O'T/[I67\M*>*4\4IXI4;6/^
MTGFG^ OG^A2>*5)/BE/%*>*4\4IXI3Q2GBE/%*>*4\4IXI3Q2GBE/%*^4T\
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M.3TXE/64'1UCIVS[(X==Y6^H%#6:?HZVE/OB^K<VHDC^LPZ;DUS=Z>82$O\
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M->+];[$AARX)G\.0ZAAM<.U7.Y(#SKS,=AIU5OB24LN2)$AEB,AXH5)=6&V
MXL$"K/3_ %0=$K/0QP*+S,FQ<C4K^=LNG=%L]CZ)3F?)8.BY&W407:F-DPUH
M@8X%+@/9JTZ9RQJ:T@9A<Q4,4NVD64C6F,['*GY2FY:U2$Q8[0:>3*,?.^67
MD.*:*<@I2M:VTNK!2R5XR=4NNV-TBW%+<"T-2;.RW;7;I<I2YD)VSIN6X643
MX3T5,H.E*TK<:89?<AM*2Y.3'2K C?/5/4<UZ"YG*=U9UPB]7GU!<;Y@BD*8
MJ;RTOG+Z]UJ:13>,164?-5I99G.7 (=J#<F/XX5H3*P(JZ+9XYD7HY*W)CH
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M)M=<-<]&W:_$&.FS1);;FP[PW?6VXK^,!Z8\M.^Y"X&SR'*$<$QG>9,[?/\
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M(D!!! ();X@00H8*@4?%J5 DFI;?EM0$C<U&N#;N0UII*M4P:Y1 LCX!Y)1
M3'6 &GVH8J;72&9A]M.P''OM/D6?&F8]MU;"5+0E:BA"E)"E)3OJ2DD J"-Y
M.\0-0G>&>F120MUMAYQAM#SR&G%M-./<!MUQ*24-K?X;O!2M0"5.<)S<!WMQ
M6,5YD7WU"%^H#T]V4YW3N<TROG]EAXJ!>L=M8VNK4JQ"72S4%OT"V'T]70R5
MJ%66L$84K2:P0!7':U5(DTA,M-^I\V-B F#/;2AY]YQ,/G5,<FEIUYLLM2$,
M-!Y3X4XH**7L-E3/"> "U)Q7RZ?M&O:+9V4X_"ML*.N]IL;<_P!^.2HL&2B=
M*MSUQEKALP%-QV7&D.00J0E$TRHBEJ8;7O572S-JDDY+R6=_4*+VVH4JW=8Y
M')32K-TIASWJELGL?-:NL]3E8=PHNE2_+HFT#6&PC&RFR535O>V_/7!K2NBQ
M.,BTAUR7*#;S\-U]F+*#P:C)D16=R0ZNVN(*X^K^\DME..+N,)D(2VXHHUR6
M[#8M-H5)A0+Y#@S+O:#"5*N;EONTM4JV1&=J8SZ6+F0(!2\)*7"M4,/3W[<^
MX[%0'[8+?1BVZ"-QB_'>H)^QT6\XXX%<P1D3C-8[:9S]8N.3V'HZIA9%6]OW
MPUQ,V49N"@MH)J1&*YV910:BZ8M5X1',QA-O;3O2):F25HXL-,A2DK;CK2VK
M@_!A"^"I*#@E 3G-;:UL2[<462X.;1270U;;*B:VAA[E+ZNW--K9DW)EV2T9
MAXN\\SSC*W4;P0\70D($YH/1ER:O=R?^H(<ZVG7FT2/?OPS0FLE5UD%81B@V
M"N=;K5H2<A2"$#B2[ZL,'L1%*41R<S%5BPZ>%R\2W(3< AI+#01PRD.!Q);(
M4E05Q2,[P) W=U)6LH2DJ)K/Q]BK1'OLC:%*Y;D^67Q(2ZJ,N,ZW(2M#C2F^
M5"MPH4E"CQ.(ZAEA#ZW4,MI38"M<UYS3)RBJ?0*55"CH-132:U542*<P;236
M;0<J96 +(1!K+KK+K%+MO'K)KKOC7&V,9QX')$AX .OO.A)RD..K6 <8R I1
MP<:9'96PQK;;H:E+AV^%%4M.ZM4:*PPI:00H)46FT%20H X)(R <9%;GI'I'
MCX8]---??W]M-<:X]_\ []M<8Q[_ -6/Z_\ ]>=.2>IS7L  Z #R&/Q74)6K
MC)-92P BI=-<::R$BP3R:Z8SG;&FN\L>VV-<;;;;8UQG&,9VSGV]\Y\H4H=%
M$>1(_%<%--+(*VVUD# *D)40.N 2"0,ZUW?)793Q2GBE/%*J9RZ#DKCJU^G0
MT=W4["/:+*_PUDN+#":X.5MPLU"M[F&IK;20L7%?O3669! S%(/AN.Q!L'P[
ML#64(-^G\CNUQ^#X'IBIIGM^NG=W_GMSCMJV?DJT\4J-K'_:3S3_  %\_P!"
MD\4J2?%*>*4\4IXI3Q2GBE43_:/\<OG=?2=T6@4CHYG,H)PYW-Y;KIBX3GO/
MT:MF=9*9'@/7&Y UGCT@"8!3%!A,@=2%C&61<:6/-HOM'O%ZV>V/O5_LL6VS
M%6.W7"\7"/<IDJ$EVVVRWRILAJ*Y%AS"N6Z6$---O!E@A2BX\G "L+?[0N^V
MUZV(GOVY,A2$NO1TA2W&<D.1U#?;RTZDX<&]A:06U H6H5G*#QONM8XIP3GM
MGN%3ZM;>6;(V+_H-V=6+9O:SZZ2QC3RS3XKK HDB1,4# >W/FW93EBR3D;FS
M32&2Z_M#8]OK[!V3Q#V*5,LMYAW^;S5UO*XZY5N>E"(Q"<%@<=*'HKS:WY+K
M;3K3X6VVVZ@!Y7OM<5<&!&B2)<B<ZPPEE4M](#S^!HMWXU96!A)45*4O=WEJ
M*E$U<H?)&1X,EZPZ%9ABR3H/)O*/H1G37,VL$LL<,DD.LGQ8BDDBBWWTQKMO
M'IMG.N/JS)=+31D);2^6T%Y+*U.-)=*1Q$M+6AM:VPO>"%K;;4I(!4A))2/7
M7E)!<'?4V7=Z%T#OO<(^*]&YWTY+R"S-^6<P!K5R4+:RR4](;(F%+YPHNCF:
ME&D3,JFME)3;WBL@$L@L69;J49YMI91%1!?CP81FQY$9<MM$F4IQE:G4KC(<
M2](6R@/)&Z\K"PRXH)/"5@5\D3-?NSE_M]PV@OJ;)<K;=&+/+=M5J;BS66XS
MC-R>CNPK8U,>,%:BY$;4IGGXR%.MB4T%KK(^GBF1^HI)W(QC=,\K<6D%'R)^
M@XCR8?G:>;G?-+'U:M5VR2@]GIMZ3LY^L)G)+F#(:O#2I4N&H5R$^ L,HTWC
M<'O=[D((9YI#17+0Y-E&0L2)+45QQK>A/1UI$520@@JW77R\X000$]FSD(;2
M,7Y;DXVE^6VQ9I$>QVA%N9-MM<JZQH\KAWJ%/9<5>&7E/)W&N)$A"'&2XE;:
MW'/0CDW.L\HHB.@QW*U7@"N"P+4[6XCTL9N&F"&'#6)L:42H4A)(&L&'TB&G
ME3;LY<;;['L#),Z[:X&7(YI];_!:84X2I:&2\4%:B5*7_?>?6%*)R0%[H_\
M5*:^B6BV^Z8#%O$V7/1&0EIEZ:F$AY#*$I0TR!;X<%@H:0D)22P73J7'%G42
M1YYJR=/%*>*4\4IXI3Q2GBE/%*>*52N+BEN@]1R[H3^DT8^G8:VEDH:\V3TF
MMNU[LTA=+7+'T:1PE6WIJ2.OELX-@*KW1+,ML;8]2PDY^H'@)WAN=,:_?[=G
MCT[]>_CC7.!YZ>&,^/7&.E3CW.[04&DZ.R+IBD1RNUJO0L10K=V1X6=H5JOK
M%.">S:(=+&Y8:"Z8/>C&I5::%RQ::K019WR@!G/EFN7=ZSH?^_E4)\Q[!TES
MT"M5ZWNJH:R-8BU"S4^K0AD+EOTG :/U)ETA.UTG);%I2[N_*K A$I,Z"=)8
M:E$/I Z&,-<#CL\^O9DCUCQ^4!.>O30C'AGUGRZ]98;-K=-U:@PFU 8(.$+H
M& C=+*,5N;KJ.DTCVW%U71;"?,A]ILZ[RRYTSGY6<YS_ ,WDJU+WUCG\%B_-
M(OTWBE/K'/X+%^:1?IO%*?6.?P6+\TB_3>*4^L<_@L7YI%^F\4I]8Y_!8OS2
M+]-XI40>H"S5VL<0ZM:^GI7^>>5"AV6X7/6H6IXCL^U=J2PBQL]$;2J'H+ *
MQW&6;Z#_ &YTLWGVV^GG+B%FGSYUO% :<4O>W$H4I6Z2%;J05'!24G.!V$=V
M:\%U<BLVV<_-XW*1XKTB1R[CK3W!807EAI;#C3J5E*#C<<1GH5!)->,GI7M_
M&_5!^SYL]S2L+TML='Z#;<MG/7^A62W.#+]5$K)^J3UC]^+A98HXG/.+>O1[
M0U4X"<DO:>0Y<=,%_P!W\!]OULM=^]D&TT>9?A8EQ&7[M#+\EI NT^RQI%S8
ML:6I$EGFC<4,%IMEA:G4OI:DI8?,<LN:OL#+@W6T)EL)EN/L3'VGUSGI$EQM
M]*24K94^_(#:>3E(;46B@*RM*TD_$?6SFEAY5P;FE)HNU\YJ"O'7GE!M6O0*
M@BULII;<XRPNA8IC,13X)L!3').T$YF8"<[CDE3$QR2;?4_9K88UGV'V<LUE
MNR]JH%HMS5O;OD9:)C4U<92VWE)<BNRF4(;>#C+<=,AXQ6VD1E.+4T5':)-P
MM5M4&I4VWV]3JG'DM29,>*I9<<4MUT)=6V5E;JE*6L [RRHDY)JG?0Y:,W]5
M<7<=N*<A?)N97F@<.M)9U@7[]*N73.W'>GQSR_K-91QU(P)V'S5:2I65]B98
M!V[)(VZ$P08A'K4$%C^LQ^81:C"YN6VY)8D3FDI0KEF8\(7!$F(ZYQ4E!DJ"
MUN -E"%HCI<R7"6OF-R]VN[7IOGN:SR(MKN%NL4MUQ]LW2;<[\O9Q^UWF+&$
M5Q#Z+4TIIJ.XN2EYV.]<7(P2F,E,F7N'<EOE2[I9; XXQ=DG/UF7&O&!'O8:
MO9*GRZ*RQ9*OVJ"I@V)F6NS<'.F,IO@"+UK",B>OK,(4Y)8$GCG2V78+;;<M
MER0K<YPHBN-.RBV<,;[RFTA7!0?CR1Q5@.*WU@&LU8+/-B;029$BSSXUM;X_
MN5+]XC2XEJ$H%=PX$)N2XMOG7P.#A+G*,*5'9X#"EMF^GUCG\%B_-(OTWF!K
MZ'3ZQS^"Q?FD7Z;Q2GUCG\%B_-(OTWBE/K'/X+%^:1?IO%*?6.?P6+\TB_3>
M*4^L<_@L7YI%^F\4I]8Y_!8OS2+]-XI3ZQS^"Q?FD7Z;Q2GUCG\%B_-(OTWB
ME<M"V^=]<;IXM-,[:XVWPSBVSKKG.,;;?#@?&=OAQ[Y^'WQ[^WM[X\4K+^*4
M\4K'LE*IR/J(X6+VHNLNL^HS((8X?6;37?32;6$J.6/$NNDDFNLF-?CUUWWU
MQG&-ML94K\&3J I]"@U:X0J, =5&2,"-!/HK$VSL*MTFBBTDU &VVVV'#UVP
M/#MG.8X]<YSGQ2M'L?\ :3S3_ 7S_0I/%*DGQ2GBE/%*>*5PD^/.F^(LZ:RY
MTV^7F37.VF-_;/P9WUUVTVVTQM[9VUUWUSG'OC&VN<^^%#G!QU[,],^->7O+
MO4YT7M1/JUI;@STJ=Q@]/C(BH-N;<Z(M4+>[315ND6@EQ-E@XZ'#"B&-97JA
MQK?W:.E9=!H9:K+59IDO<+3MK)+7]+;4NR[)'VI8M]HGRE[.I:#QO2H44S&X
M :<;DI4J0\T&&QR[RN,D%#:U ).J62\SKG-ND4R;))-ME(B+1#6^AQ>^W%<7
M(*E/20&4%V5&W.'\<J(MLNMC?*,CZ?\ KM&YIZ>;#T"_<8WIO/T;YG(8[I5&
MLMW*:P*%C=^^N5H15^D[XK];JJO7[-I:"6+(+;<4T0F53N/$.5\G_P ,+4+:
M_P!GW$_HFV;/OF^38IYAB,VU?W&EI7&GL*E1V%/*CBX.6AO_ 'RE<)]#;H'$
M::RUYO$>PQGY\]N0(+*"XX["B3)KC#;;3KTAZ4S$C.<O&9:9"C(6HH.<+W#N
M%S6?5=TFMV#?F!6L?/N0(:L@>]KJ)?J%Y185+/I-TH3TM4'P]'67)]'<*B7>
M3)'+$.$9Y8GHCBO,*M5VL.A\V?U98[>B"T_&BLJ4@K$-;%H>81'ALR4\5<T\
M!MQK 42 H<)M*TN\5T$@'YYMA=F)B[8ZLP+4S&C/WR(]M+:I3;]TG6Y]3+=B
M8CR'(+[2GPHO.("7Y#[;T9<2(\D.&ISDXUTJZ=\Y%ZC]:5PNOBUOF\E9T1V>
MMN2.F(E]XDYN\<:RNAA(PQK70LUNT5JI;#YA"#7V^P#RZP:,CXI_.)D9F#+M
MW&FN%V2'>(TZ@1G"P)*$80226G^*VZ[G)*FFR,E*2,X;+=)VT%GVE$*PQTQ;
M8J*&)49]5S8;GFUR'MYY* A$NW\K+BP]TA"&YLA)W0XX%7G\PE;Y3Q2GBE/%
M*>*4\4IXI3Q2GBE/%*>*4\4IXI3Q2GBE1M8_[2>:?X"^?Z%)XI4D^*4\4IXI
M3Q2OG+)\J*67X<[_ "H]Y/@UVCUVW^#7.WPZ[3;Q1:YV]O;&TLL<>,Y]]]]-
M<9VQ%*"4J4H@)2"I1)   &223@  #))T%#T.F? 8R?#4@?4@>->!/HDIO O3
MKT?UL=;0\\Z[QD.VY879-=2KAPWK<E'X\N7T%H^114SF/3>P6/+G;J#.\MMR
M2ZC9$P//EE;W/LRYC 9 3H-CVAV8VSE3K#L;MG:EWN4R7&';'=]G;I/@LH<C
M)6^F+)7<HN ^\EHJEPWF@'VDY2ZMLGYM9(,+95_:2]R[-=K9$45RA)D&+,0Q
M;D-1G'6.!;9DR47><,MXE++J$0VFE+?04N RYT3N7!++Z:![LDZ>3UKB/+NG
M&D= YMUR/?B&G6P8^=WMM/RNK3N*;38[[9(7+A+T$2A%Q-1K))7PE!/TT98&
M)=[]GVP-TV%9.S[E[NUW4XVI=KE3(]D=<LP>F\9YT*L=O@X8?=<?2Y)E<9QC
M?(96AM"D5CMI=K]G;WL^B\1Y+,RS6RYJ-UMEQ,NRIOJ$6N<OW7',]ED3I2%N
M1Y[=OW5MRS&0TX 7&R;!\XXY=NL<3XL94O4%3 J_3[W8>AU?6J"@=YKRR0&_
M7$RCTP#HY=D5R6);S&MM1N>E2_*VV)*KTF-)H(H(H==ED2V8DV8EZ \IQUAN
M.[QB8+B@IAH/O*CAI7"5*<29 &A2'.TDDY"V6:?=['9%PMHX*(T.?*N,7E$(
MO\9LHN$U<&$W<URF3):M49U-N6<'?7&/Q!*0FO1$&(J$(.$XK0XZ(4>(PV,;
M <9A4<6FA!48FLL^!=")L;RZC8FFQ!KOB+$LF-?CSKZB"HE(W4DDA).2!G0$
MX&<#3.!GK@5]';"TH0EQ8<<"$A:PG<"U@ *6$95N!2LD)WE;H.,G&:[7DKG3
MQ2GBE/%*>*4\4IXI3Q2GBE/%*>*4\4IXI3Q2HU'ZO5"K\5SN/+35P*=.F^XR
M+I8T!%E$K2JYF585IMM[3/1:B[76+>'$. Y@-S8Q32#U#D-?<=OKUZ[1F9UQ
MZ]>NPXQ=K>I ^E<SP6X5"YR'?XL8(8"09S+&L4S21X^;-K[R:0P3R[Z8_P";
M6*&63;&-(]\XE6MO-Z!1%H!30ZY589<"'$P+,E?*\00!3CS%CD[[X*SCY)(P
M\\XV^/?!,44F\'S,:9SB@$D :DD #Q.@K@XXVRVXZZM+;32%N.+4<)0VA)4M
M:CV)2D$D]@!-5V1^M[T]O:_<['%9&JX2DP!F&AMZ^Q!;. &;,=*I,KJS;3<E
MGJP;F!+LB;:CLE4YP6[\%0.7!/)H-I]J7L[OMKVBO=GVNM4^T[)%7]1SFQ,;
M9M:4H>6EUP2(K+LJ/(3&?$*3 ;EQK@XRXU =DNI**QQNK* 0\Q,CN*2A<=AY
MC=>EH==;8;+"$K7\1>>9;<9>++\4NMJF-1VUI6?G/ZX?3_#0P;[]^;S1,'QE
M:BJL*:3>XQ.%H@3%E"2IVGT&A"!6LEATSC+'*7?1FN%&83L3Q INI[VK^SB/
MLC%V\?VMMS>R,V6F!%O/+W-8>GJ6^CD4VYN N\"8GEI#CD5=N2^U'9<EN-HB
MI+U471M1X28TM<P.+:5 2AKF4*:;:=<4M2GDQ RAI]A7,<T6%*?::0XI]Q#1
M^MA]</IQKNU3S/=96(UK5"/<F)U)QT%83FSSB1&W"/Y<1B*6,H0V Q1*+,^7
M9"*E8*A1XLS9]MU]HVPED?V8C77:FUPWMLQ'7LN%*D/MW=J6EA462U(BQWX\
M6%)YJ.&)UP=APW5.A*'U*0X$<57B*$EQ")+S;3/,2UMLG_),A;K:E2FW"V\E
MQMQA]+L=IMV4T6EEQA(&3X7:BO\ /[;W/7XP9#/3[M<=DL!80]')0$VK/,\J
MX6PL$%NDP3/OT?X;##=8<26,DK.M8B5Y;2:UKS'_ -<;*CVB'80WJ*-J4PS/
M592EP/)8$#GR5/%OE!)$+_Y$Q.8YX0?\URXCY6/FWN^XC;U5]Y1Y5@$XPP\E
M$8M&8(O+92T)'$(]XZ"8$$JD8B <P1'JY7.[?>^VJ>UT=G;0=2N[T,CIM0FN
M;L%36J_9:^VYE,F*M98BVS1A1"CNE%<G6*5%@KSHBDNJB6=!&$O)+^6?X>E[
M30/:-[49>T>VK&T5MDW[F(<6/#NB%W0\M%:-_MZ;A M[$2(Q:5VZPJCHDAU,
MB(&DM*CVQB0]N%Y>=VBLJ+;$B*CR[Q:%3XZI4B.&(+\>1"6U'G*BF>HGC.E2
M@W'?C/",_'6XE3@%7L]-J;H=29]8NOJ.NW"6/1>A.$<A)/)K$P@J,"7G]=PG
MU$V26I8O9KF:G6><ATQ+=6$@G0V"*>90O6+5\?ZLN4B"ZF*S;TRDQXZ7<)EA
MOC;[KF^H[[3BDJ2< )2$-[F,_&I2E4V8ME^B.W:=M(Y:7KE<GHBBNSJDB&&(
MD?@-(#$MAMUMU.5%;JGY*GM\)WFFVFFQ;#6VU+&VL.EFKF-\S1C:Q:N5F-LD
M3"9/B@UCP3[_ #I0<9-CBQCX]Q,9)UUS#[[^8NMNKCI<JA+K'M':JW)K+J#O
M%MH\6;ZR:-)-H5FT>=2LXWU8RZ;Q [:^^"Y--M!\R;:YQA2F;E4,:;29M=;Q
M'K%//M)EZKQIK ,5@$F;;;)7PXB'-S@.>3.?@B*S@>3;67.-/%*Y;W"I1YDU
MWM-<TVBV-TEUW=K-<Q[K8M9F.DF,E8SIL!#OI,;KM[9%BVUDGQ'IMC.5*:V^
MI[;ZQZVBN[2;30#ZQZNUN=]IRA<FBP:ZX)^+,Q(6,EP1XQG>87&2(]=HL9W\
M4KCK<JAOKIOI:JWOI)&%+'MJ\6;:R1,IMAETFFV"LXVC/(TV@"WUSG4J;7:*
M#,F^N=<*4VN=/TTVDWM=:TCTC)FWWV>J]=-(0B=0C)=MLE8UUC$,VU$)WSG&
ML!.VL$N=)<XTRI5(/4-<>NBWCH W+[0=)7[-Q-=1U&4SA3F*H]%A9=*LUCN:
MJ2<CV7/D=#3X5D2ZZD2XLE@YA&4'D??676Z8\=?X^NOCH =*FN>GK7\??(UT
MK%D>H3U!P9LH6JNDZ;PV:1#7I($UQ=%"![DW&:H'-IQ@\B-H;M5T=><;,*=I
M=\)VCK0%V'7P&9#&FW TU\^GS UZC7KC/9XS)[1J!W$Y/R'0^'3S.!)W.NX=
M*."@L%]BI@P+6E7&Q1H1!&JLBOMDUJ0):8K*/ .N;=IK>PFKD@'"^JDGR2H<
M0*EYY'U,,TP.P]H^XUZXZ'RH">T=A/XQW]1V:FM<Z+UJP63E?/;#.Y+I3R4Q
MJ;<4=-_I'('R0F4' 3JV3*OUQ9U:K!!6.> F-X/SZVU2%BNA2V8=JM:!$%NF
M>A[LX_Y![NO;GLTO7&<_+(^O:._^>F8@ANW2W@71@2[ET"H= ;[R+*[M,9?3
MR:O\\6I%'R13!(Q> %L:XH)<L"YE,D6VTD$Q$0,&DFT6ET\,:]GGCIKCIH3]
MJXX)';G/?V9'RZ=P^6<U9'A'1[I9K?=WO2&4%>6/JGR>:M4\UDMU!K=C^IZ0
MBMBU61I-[,);%-755P!DUEGD*K;^NS1>\6VNVT./GD]_33'7YUR!)[,#L[^W
M/_%6Z\E6GBE/%*AL7CH(W2B+_M8&4P6]E-O(=5W%"U"!N[*@J^9FNHV6D>#Y
M0LU);-$,GD_Z<35V[93%%:2JPU+U]\_+Y?NGK\?JM.MU;].Y5EJ5LL&_$AQ0
MW]QJV=G8U*_\U<S_ (%#!-"49KB.>QKBA60;-?G,K**:4H6>*.3,^F5*S0?.
M?3)<I+-4U5)XD_*2:#IK6D2H*26Q1?*PQ5A!-AU@N3DTPNPS8 #$N!9PYQ&(
MXFT,XA.L5&4D'&H((R 1IKT(((\""#VZ5UNM-OM.L.I#C3K:VG4'HMMQ)0M*
ML$'"DD@X(.#I43I?0/Z?5"*WHYEUD>YMD HT+I\W%,?5,<!B.W!CJ+"!6)A=
MO R#!*(+.@9G.- X 7Y35;B0*3YK9?9![-MGK1M/8+1LK#B6C;'X=HH7-7-Y
M,]E*7TL1TNR)SLB$Q$YF0N$B ]%Y1UTOL*0\EMQ&.-I0YA3\R;)>;2A,:0\M
MCC0PV\U(3P"U':;4I3S#"W526Y"I :0W(+K64'YS>@/T_P M("I^@EE'/#=E
MOLW^!BJQ?BRCQ0P3!#&4J*5/(GG!6K!_LL:&)7%(N&9#BQ.,SL9NM_V.>S:3
ML7$]GSVS#"ME(,X72+;Q.NJ'FKF%/E5P]Y(G)N:Y3B94EEQ;DM:3&>5%"$QV
MV6VJ+6D*XR9DQ,TK6M=P!B\RL.-LLK:4VJ*87!+<:..$F(E 6RA\ 2"MU6H=
M!]&/I4T?<G2%F)J"1MOJA*K>ME6I&O8DX4!L?T;'4O&&[ZQS61XJ^ZV-7*._
M.#92*"#]I9Z_]N]UX]EFP%_?V3D739B%)7L,W%8V82EZ<PS;8D$1Q"A*9CRF
MFIT**8D9;46Y(ELA3:\I4F1+2_P-GCA"FVY$MAM]HL3$-N-GGT*<>=<,AQUE
MQU#SJY,DNR(CD:0OC'+O]MCA2@/Z)/3\+TB'HPU7D'U'+C9CT&'[9%S6!S#K
MCY+6&K:*M<Q20DZZL8ENA^J")KIHRC4:FZZS8]7_ ([V+&VY]H_N&/\ UF8A
MAF]<Q-WRV8/NLN\GS7N[FS;/_CS+Y3F#%R@N;Q*J[1;&@X"'Y(C"1S8@;S/*
M"4'..'A_9YG21_F0US'+\Q_=X6_K4H+?3EZ?4Y+@Q5PWD*XNPS8G>$!\WIX\
MK:7$V2<;G[QI]<D_]UG8OX9<[:Y+WD*SCZB623;?7I<J0AMM^0^\VT,-(==6
MM+8P!\"5*(3H -!T '0 58=HM5N>DR(%M@0GYBM^6]%B,1W9*MY2]Y]QI"5.
M'?4I?QD_&I2O]2B3FM^*\;D^9F3DO,]\RY/S+G>AU;;YF6FNNC/,GQ*L_'EC
MIIIJ?G;W^KUTUU(^9C7&,>>LC44VND^F8G>F3X#X*DVEZ-$.!+.LH0VUBL%7
M),IS:KKI,10Y.? ,I,5DQ?%F<H$V/[*1!H1G4;RX/<:9]>5;E7Z-Z;;$4W65
M:F\1>&U4L-6] 0URBL2:\:J+.B7@-!@ II59*U@$SA#&*T@D#.#810Z1DBE:
MQRE;'GBG&LZ;1YY)S+,>T4\&T>:%5<Z;0$E8.)AVURJ^',1!N,&3QYQ\$I6,
M$2:[2XQOXI7[OQ?CF^9-I.3<SWS)L;)+MO1*MMF3=C%K"QWDSLJSG?8^'36(
MW;;.<E1:ZQSYDTUQC"E0C94OI)L=; 8JR_3>$##T*@_+L,,7-]@9756<HK1^
M[T3 ?X8LN&%17$"""ZSYGU1G?/\ E;J=M_CN#W'IGY=_E3([^G6I*3T;TVNF
MSBN(:;Q%J\JOVT9\C4URBFM*]](21(H@:K1 I"E6!3(2]ET94,&!RX2<CXTG
MCE^&8/=2MCVXIQK?3:/?DG,MX]XB8=]-J%5=M-X32=33(MM<JLZ[1%F:ZEDQ
MYQG6<G76>7&\N,;X4KEMQ?CN^V^^_)^:;[R2%S2;[42K;;22GP:BG2[[959S
MM(8-KJ.7OMG.Q$&NL,V=X\8UPI4)W.O>DQS3;%D>3TXIQ0'"U*?8I!N<Q H;
M"KSMN*N.-CUCT!;"K5[& 866:$L8* S$>F@PY&-+KG3.?O3([ZD5=2/36R?,
M*>JI_#SK*B" E:5A?7:&2[4+QY!&2S<U..'N:"(/*S /"S,/%#!NR"+A^#8T
M>264K9=^*<:DTWCDY)S+?230R*33>A57;22-A/J4?'OKLJSC;0XK30DS3;&=
M29]=9IL;R:XVPI7/;C''MM]I-N3\UVDWE(GWWVHE7SOO.6-@(N;;;*KXMI2@
M]=1"),YSO,-KB"3.T6,:>*5%G2>?>FV*H] 1&JN%4IB-6AUQK9FFHJJ2GE69
M:T049JQVW@%(5[;D8*AK6\D@LQ.PI(RC?.^F^NK![J5-HO0J$<YS70KM4BW^
M%,#[*0:QIYVOV,K0*09Q]OB,W*RLGB9+983\1?2R1L0)-9<Z&#;2J9'?6X>*
M4\4K NE+)I*FD7VAU6]%C89B? H%KA,5B"@SG,R%ML_0NYAU9OOC!$Z&5,[T
MQC'TC<7/OG*E5$L7IBL&E><URE9HRE78$?J/Y]]KQDY$JJU,]0#JJ,HWJ,)2
M@,@+>4V"IP0CU7Y*54VRS)TUM"G473<JYZ?_ (__ *C%<<'_ /H?4Z?0=GRJ
M3N5<EM%,N#!P]+0;J5:Z[)*S(G-8DM'P5WZ<XZ).SM@QBE>,L:*(R0%<$(![
MZ-@60^;[F 8.B71CZ^0'K]U0,?OYD_S^=!5B_)5IXI5=.H\EM%QNH+I(6@T3
MM1.;++-*W,8C-D(O->J@]+%.J@@BE@*T8/M<'*"HSV*"-42*B<QD-?HY%F]!
MT^N/F,=<_P#?2IKG3Y_+T1X=1XV+\E6GBE?FVN-M<Z[8QMKMC.NVN<>^,XSC
MVSC.,_U9QG']6<9_]X\4JE#/TR6(9#'6*EM1U20]?ZAZ44#%L<E$J-+[?UE)
M?%S>G@+$!(DSVI)4F@$=;WU1*RFL@,\%B#%3ZX87)^X/S&?W4(R,# TQY>7Z
M_6#)O&.2VCG[QB982T$P*ZFI>?UN1(8Q*/>*4EMN]BCLEKC-4K(5[HN"T!0;
MJ@27@XQ\;P_5T1JWC&$GK]T ]9)_/KLJQ?BK7P)UDV&(UBA@(EV@EUC@)WVC
M&GDS'MC2$B36$G:."3;.-)=]1Y]M(]MML0RYQ\&RE4*F].O8WB1V<_&Y6/?[
M93^A<YLA(%MLAU1AK70:JBKH9U64?T8HMD /-H:X&!5:%M&=HZ5-G\[R_0/6
M)K4^Y ((SITT [>W]_:IC0^/74X]?3-39S#D%HIMWV<.#DDR)!%V@6LD+SF)
M3RPP]JZX+U4XBU!E*0!%)=3V6BH@, M+#J\W.;.II$F9]%7@G/V^PQ]ZOKUZ
M[35D/)2GBE4B+X)U>2W&] 'CYGJXAR@!!J<EDN,M1.@54+L5$,<BDL*PU8T(
M(@;I2<U9S%*+8*ND^RV;01[LUOCI]'0>H[#\^T'P'9X5QQY>70=H[NF#TUUT
M\]LXUP*S\PL58@-<)FU4H:/H*]$[C*8[7"SD]%.H+,O%D6S+(ERL1"14C1AL
MB/GLCD>5%-+$GD420F,Z?3[ CYYSKTJXUSY_/..OEC'ZZ5;'R5:>*5247TV]
M%K/2FW3E5QKMW8[V&GVT57:1R:K+8G*H?N*-M#:+$F56:2 =77^O!:5$H5&R
MU$UJ:5!JK4J%:Z:*YTQZ[/U4P?7;UT\-3IIT';V1ZQ]%%O>459REA=4JNL+#
M*99]+JERUS;"']8XYS_DD]>VKTP8X$%:(UJ)SZ!GBU3F:12(D>R+755(U)$G
M.1IU[>\D_P TQV'!Z=G;C'3IV=G_ 'Z.>2K3Q2GBE/%*>*4\4IXI3Q2GBE/%
M*>*5&+?HA8EWDI*.FNK.0J75)S:3P#D@4*-5=';M&I)@@:L YG$P>]<<MW8@
MWR90D8>)@<M6I02<E_S]O7[J9UQ^OWG[5K)?J2XV'JJVS9F9OWL->>LT34B_
M/I"!6P5$/4[[Q)*NPE&D:1=-H0ZT<O2 @]G9EZ82*9O@@*"X.OAH?O\ HTSZ
M]>==$;U3\(-E,@"N\ILJ[).S#0.I7<O( (<A413LW(];DU$K ^P)V9K41F.M
MQQ@F3;-<0BS[QL'N]?OPZTWAW_D]_P"C]*RN.^4?%4J%TFC?!)+:J?6+30Y"
MTB<J:W6Q]LM')]?@%)<3QQLR4:: 1:(<8:98E4H4)(<FY&C'EIX^OGW4R-#K
MKZ]8Z]FE8W?U&T0JY5ZCH8V3QU9T=E8+(_DZHY=7R BW"BTX]98ME3Q>^<3\
MYZ7!I@M5&(H(H[(5X0O).41'3'KUU^5,CUU^E3-7'ZNUUY%:$D^2DUD3*WZ@
MG:/>+8E6X!@8@3YBDQK)%F80B*3,<FNN^F=OAVQC;&<>*M9GQ2GBE/%*>*4\
M4IXI3Q2GBE/%*>*4\4IXI3Q2GBE/%*>*4\4IXI3Q2M!L7,*3:GP=E=JBR&XD
M::#>05]8E0+4:NMYWU?$LB=2V!36L)&Y+-9* K, V%6E'L9 X8<L#?GL_P _
M?0T]?2M:0< Y+6<#X3U66+Z0I46+L;8[4WD%D1F4 Y+"/*X>'R0 J9^6T'"Y
M;%OHO#&K8@0XL84YPY3/Z^O_ '3%?0?@O*!=&L456WS Y5OD98L]@LY0<*2S
M:31N4RD,IU,*A4$1D3:0+$<*X%=K)MA; 'CV]E*Z=LX/3+-5U=1&F<UQ6I#L
MJD610U.W81HK9K)*X1P,F!!C )?LSC4-0- B1Y%$]?3"*9 EP>@?ER?7\]]3
M'=ICI\^O_'8.ZNS%P?F0 )T*:NQK6Q;F"SP6B4QDYLX-J#+^YAOX7SPYBUD)
MU<9F:L!)S)%SXQ@\W?",<6)]AC!I5.M2574*NJU]%6$@^1$M<3K$*@7,F\N1
ME:<*!> /F67;:23,(@\4?S)-MM]_A^+?;.V<Y\4K,>*4\4IXI3Q2GBE/%*>*
M4\4IXI3Q2GBE/%*BT3M'-#NE&<B%LX\O0 1MB2$>!#]=?^F'HPF&B8["ZK)S
M1P)-3)PH3)"(H,2[;1XV&)UAT2/[2]B96VTGV=L7QES:Z*P7WK6&)8'P1DS'
M&6YBF!!=E-1%IDNQFI"WFVM\J0"R\EN[IQG&G7[X\ZE+S>ZE5_IGJ9Y3;U13
MHEQM2%8Z.HV>(Z_D)JX";7;WHYWJ;45CLW+7:_>-:\XSHJ,+$?"8"VW8*1(Y
M1]Y;@_G[=:F1^,>.>GKK6^S=<Y2/]T^HZ9S^'[)"M)<_-N->C^U#N-PXU$[#
MXF./HXFDC%?&ND(^7J;(>%H-F38J#$DJU@]N\\F@/<AL;Q6DPJ0@,69V[L"%
M2B.E8UBJW #9.Q-:1:M1S4%Q3&#&!1RB3>Y,>D^=H,?,N#W>LX_.E3([QZ&?
MQ6Z*KY1WKB:NI+E57#\=:.YG2*K I8-H5!8ZXL5I(N$+F+T7D"-U!4)FT.!Y
M!FJR?23,1XF\TJUM?BE5F]2GK"].OI$6T]MZ@NB#4(2^.B$56QNFL+XMD4#&
M+*T)P#6U3<T=6GA-"D:M"((@0OK X9)OJ#!89NEZ0S'"2\O<"SA.BB3CKHD$
MX&F3C R.^L->-H+1841UW66F*F4XIIC^V\ZI:D!)<5NLMN*"&PI)6M0"4[R1
MG>4D&R 1HC(,1BO)@- /&@-",%ETG%+$*BTG&)&GCVVCF@GADTEAECVVTDCW
MUWTVSKG&?.X$$9!R#J".A'?682I*TI6DA25 *2I)!2I*AD$$:$$$$$:$:U'K
M3JM<47U=S\D5Q(P.RG@F<0"B[U]4RL8UF+KBAH7N=&;&P=P5!YL+@5<6&-)&
MN@:%KYWB2)BIG7'H=WUK[I.EIG=YL'/]%KU<Z0+_ +M\UH((.(U5ZL-U,K$&
M*$\AJ&%]RBE&7D6%8CCL<,)#.J9>IQ2F,*K6%,[IS8:W<_IH[Z!LPZ4*V-KQ
MZ:41BEA#5UQ=:XRF[*$KX%PSE*V7$H2-])(&F2QM(9,9)'S+<:$]V/O_ -5,
MZ@=_V\ZU\7U$55O1N?7NKUJYVL3IUL=4ZII%HU95/2&=?!O+)K,=K;[364RX
M(<#GEB(QN4ZT*EQH'#&)L23\B-CQ&G4]GK.FGXJU@D7JMYW8CDD*Q5:MU#QG
M0DD-DFUJ8X(SOI*NOM*NKF1R6W%X*VFTLZ48YDGJ31&OE(G)):Z*E[%B((Q]
M_G@X_@U,YQX_SK_%;#IZD.8_8;#:R368%6J/02>=VJQ' :CJ:^;'#'(!9F!&
M2-MLTAW*6H%3V<.,H.>5VOG(U% T8F ,'ZC(\?6O_=,C&>SUZ^_36LE>>YU7
MGE-IURLJUVNAO3,!.B2-9ZM5G.C)A7G5IC#;R7:SUA C*@25]F02*V>B%Q%0
MZJ]8-VLL866/7_6<_+SZ4S@9P?+M]?SIUK' >H2J.VMN1U=!;;:VI[79&:!7
M(*V=.0U&=F5UN++\RS#Z5B),V6LX"&%^WIZMI"N+.K1ST#30F2>O7G3.O0^?
M9^_K4LU*SJ;M5:S<D,DTR.VU]-9DTQ$&XT\JI\N&:+I)QI,8D'EW$*AVDAWQ
M\<6^=M-OZ]<^.E7K6P>*4\4IXI3Q2GBE/%*>*5&0O&^:A='+ZT-5A(N@'#;#
M$/\ !+#;;.L@>B^6>-?N7LK@,G!CU$G.@"C+E@S)IO-M\^?,NCL>S?8F+MG(
M]H+%ACM[7RF5,/7</2RHA<=,1QU$14@P&I+L5"8[LIJ*B0XUOI6X>*[O\MXX
MW<Z>0[#GKU]#N%2;YO%<:ILC]%='KJ@)0JO?0 HP%M621RKQN<(_KTE35V)2
M"!9!J[SY.'<MR(+(266=<H'YNS(%<5'+'%LV&;4G/W/;V^9J8Z9)..GVZ]^H
MSYUSC]%E AA$@@N-]AB5@U<=4/')485\1]57I%(;ULI%J0RJS/9U27*R1M8
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3%*>*4\4IXI3Q2GBE/%*>*5__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g945651g38v62.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g38v62.jpg
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MAA>!H\;N0@MC>:!S3;+X:=$(*C%$NU\JQ9(\@<\E21L]@WA*$+3+7GD;%A.
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M=*2<>%-NEGR<:8FV347#8L&!1@AOGFQY*#U7SO+]!3A$X1.$3A$X1.$5/=(
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M2YN^ BUBV3L*PFA+,::"KQ,(X-U)!+&R]B4"LIT@RQ70;P\.[HY#>30^@ 4
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M<(G"+EFD[,KVP[!(KM3V/OH@[&+VD$X>E:1-!Z,HK2RQ0%8XK&PS.E(%&E>
MF0I,6T]&L+L<A.BJCC79;CC25ZRW#F?9M56<]YY#V[-%-[#.AUCQ<@KN2[JE
M&6#\@*.% JB>*F\5@1+.FV PH%KTB1*SH@V$^X@? C/SIDC#4"#'DSY$>,[*
M_-'CU5_U'D.BE+=9,NX3V=J71*U,M2,M.P*"S(;:>2M3:GH[M'0^SVL-N?T7
MFT*2IIQ*DX4VO"51H/'JE#J?#HOV[533*%./;5N+3:.SA:W8NO6T(RM6$HPI
M2Z3A*>VI6$IZ\X[2LXQCKSG'%1H/'JE#J?#HO7R/L'K/NWL- ^2.*C0>/5*'
M4^'1/(^P>L^[>PT#Y(XJ-!X]4H=3X=$\C[!ZS[M[#0/DCBHT'CU2AU/AT3R/
ML'K/NWL- ^2.*C0>/5*'4^'1/(^P>L^[>PT#Y(XJ-!X]4H=3X=$\C[!ZS[M[
M#0/DCBHT'CU2AU/AT3R/L'K/NWL- ^2.*C0>/5*'4^'1/(^P>L^[>PT#Y(XJ
M-!X]4H=3X=$\C[!ZS[M[#0/DCBHT'CU2AU/AT3R/L'K/NWL- ^2.*C0>/5*'
M4^'1/(^P>L^[>PT#Y(XJ-!X]4H=3X=%4EXV%5-<G6:Y;=U;'A$U#A1DAD?1A
MU@&UH&=,2:^%/70W7M5E M(!%3,$C!@&;;/##I*A)I]N3F($+R(*OS1X]4I\
MX_\ 'HK;\C[!ZS[M[#0/DCBHT'CU2AU/AT3R/L'K/NWL- ^2.*C0>/5*'4^'
M1/(^P>L^[>PT#Y(XJ-!X]4H=3X=$\C[!ZS[M[#0/DCBHT'CU2AU/AT3R/L'K
M/NWL- ^2.*C0>/5*'4^'1/(^P>L^[>PT#Y(XJ-!X]4H=3X=$\C[!ZS[M[#0/
MDCBHT'CU2AU/AT3R/L'K/NWL- ^2.*C0>/5*'4^'10.C'P.RW;DW0M\6*U)H
M%ODT*V20\:A2H(NW0@@*P3@B2":+X#/DP!MC$^'K&R)<>%/=DB93S14>0AQ6
M7^47OOZJ"]:.-C3=GR4\\C[!ZS[M[#0/DCBHT'CU5H=3X=$\C[!ZS[M[#0/D
MCBHT'CU2AU/AT3R/L'K/NWL- ^2.*C0>/5*'4^'1/(^P>L^[>PT#Y(XJ-!X]
M4H=3X=$\C[!ZS[M[#0/DCBHT'CU2AU/AT3R/L'K/NWL- ^2.*C0>/5*'4^'1
M/(^P>L^[>PT#Y(XJ-!X]4H=3X=$\C[!ZS[M[#0/DCBHT'CU2AU/AT3R/L'K/
MNWL- ^2.*C0>/5*'4^'15)4=A52\VJ13:WNK8\LVTQ994)4RC#0P2Q1*8=B5
MFVRZ?9S6K!]:ND6N'B$ 88D50L89A/SH:W5X8E,/.7U#F=_KX)PVCR'#AQ5M
M^1]@]9]V]AH'R1R5&@\>J4.I\.B>1]@]9]V]AH'R1Q4:#QZI0ZGPZ)Y'V#UG
MW;V&@?)'%1H/'JE#J?#HGD?8/6?=O8:!\D<5&@\>J4.I\.BD@07-%,/-3K"7
ML3CKN'$2"[(5EZ.C",)[EI(00'8RWE6,N9R\RZ[VE9QAS",)3B>JG/ZR5?77
ME]0"W7"*JK_O72FJ2$$3L[;>MM>%"</)$<-NMVKE8G3AZ7W(V9T2(9(PWY$3
M$AIUCPAIM3/?-.-=OMH4G%H3D"?4I4#,@>M:.J=)OHY7JP#JG2M\Z?MMH,./
M-":[6]C5$T;)NQXS\U]N +'%I$V6MF'&D2G4L,K4W'8>>5C#;:U84.AY)4:C
MFM/TBQ]+,B]?"K\9J8FKNW[$DYBUV<16&I(?%.MXN6H;**SQ[CQ&+*,#W6/%
MCN24-Q3<^/EI<;#S?3FQ#<V$V*YC6=[5VV]L.K>[B--"YS22"YOYIVAF,JKX
MSMK!PN9E\&E\8FL.EI!V,;<W[XS\M(-?+>]F)2\0P(DQ&@ET>'$F8+F=PXQX
M3J1F;)A[0Y9JUX\C;*:L1G:>KKT_F_6".S)$;BUJ-G6JMOZ>UY1JM=3K!6SB
M!\:=@C3W/*V$RI<V(0D32-=$D("XK+G1AQ.[>][H\"*3%>!LS$%IB,,O!A0X
MK]I[6AP,.D0"X)<YC2V@/P&'XL,+GIJ=FNT& 8N\XQ.,;$ENTV!0(T_(O[-8
M+A.'XK-LF)^6@LC=]ACO?&$TF+#C/BQY*7C03#8<2G1=<N(ILB][1U81G1+?
M0&[*J3NNJS$2*&$Z,->IY\.^AFU99G"INWAS\DJ'RAUH\_'CF9T>;$;COID(
M0J0C&CP'.#X0>3,L-839)D-[3Y_G-,P"7--=N@<011<6&,P5PPM^+8_V?C18
M>(X.V?,3M3A\4/PB5[!R>&SDL\,Q LBR\7M)!<^/+ .$V]C9J,R+"#'C5U8A
M7!<\4J5L#6[%L3(T=X#LU6\=>SV:R'H2A2+X*G1'+IDU,=L=?ASZUA,$:48L
MN"#3=AF080R),Y(98US28L$1/_&I'\IA.#&PMD16N'>[1+V!S*AKMO:\]P !
M7!(1I&7C2Y?C.!LQ /[*=SCI[5X-&;(2V$&7&+R\:&[%#-173TE#C2 $*!,,
MGN^:)R+"A0(458=/Q750@XBV;9HSC"9.N8^Q5S-UZR9&WR:&L/AMML3: -JD
MF#S$^"B8B86M#X&PGQI9(4G6I,>*UB'(>P0&Q(\*E8(C?^3!V8Q:^L2)YL0O
M?4"[HA:][7;+F&EN+#/(C"EI;$>T>$EH?@K,:,3M3@38&+Q96=[W$9UHE)]\
MS-LC0A%$28Q!\I.S<"8$K,2+V0V]UW^QO'1,9AF-'W%J=IB.TVPRTG8=1[+;
M32,-MMIZS&<]E"$I3CKSG/5C'U\]43,J!03$"@L/\:']I?L+.U?9*&QK&=IN
MSK6,:UC6C&L-HUK0 T#_ ,G(  +U\^^C_7+JG\Q*A\8X\JEOC$#Z:']I:_*[
MLI\I^SW[ZPW[RN8=E[%UK9+I?(0_;NN%M6K7^FH0.;&V?61K;#5-VS9RNQ(2
M"[!V/@7,D ;'7Y"$MRH\PNTRIJ-AW(K/=]*-&@OB10)B%2)"E@TB,QH AQWN
MC#:#ALDL>TBX+A85V;?"8YC6!3N*8O#@]I,$+<0P?LQ"E8L/'Y" &-POM%/S
M&,PVS+9MGD\5\G/2;VAL1D69:PAFUY-YM8VF9KNNB; 2J>W-8 E8-;50IP?N
M(,E>==&8S,JOU6"D4>GD1(J7.9=;A1@\'*JI,GR3D:)%>S)=<X'F"QKG0YB
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MPR.V7CNAN;"C.@.FV",V%$+7NA%[!$#2PN;6HK35]XU%39UW,$]R:$&.W4Q
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M$G=#J*%O!)JA2ZCKHQIW2$2X7<=LC-Q76YX9O%B= !>[AZ^NQ(\,OAZG'JY
MK<]TR)ANKB,R;Y)+?%Y?Z*']FOXT3\B^QOR2[,_N'"OJE2KUU]JWHQ;)J(NX
M@M!ZJB0B#I6%(&E]44.*8"FZ^8(5RR5XQ'C#)D5HO7;$)* RB(<V="Q/'R/
MYLR+W4EV&5E@:>3P/HH?V5!V+[&F_P"279G]PX5]T4S^CGT>_41IK\L*1\#X
M\EEOB\#Z&']E7\BNQOR2[,_N'"ONBINS!^B#4-Q:^TE8-%:P@VG9P&QFZF47
MJ*B9JTF36W8:7JW++X&]["LA6+(F$ 4)Z#B(3C!BK+<]!%$*#->2RWQ>!]%#
M^RI^1?8VM/R2[,_N'"M]?U3@L6KHZ#=E@4N0_0>CM5"^P<9\DJA<JGJ0%<3"
MEGB%:B(@@%H?DSEDC(R5"&I@*E^&R$XC,]J7AR.B^22U_P#QH%B1_P"C#W?Z
M4_(OL;;_ -T^S-P#_P#(<*W_ /VJF1"C="T2):/E*=T8!P-\-BQ1S,ZNZIBB
MY%?R1'ATG&)[T-$5X0HN6%"DDFG5PU$B8^"E[,J;&:=GDLM\6@?0P_LJ_D7V
M-^2?9G]PX5]U6#Y-=!O+E19Q7>BGEV_H:<HC6 ^H\N7-MZ8@<RY548C=JP(>
M(NM#VEB<2TN3G6X:,JDN(:5?))?XM!MG_@P[?\5/R+[&_)/LQ?+_ -@X5?\
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M?OTIQOF@V:D4%J;M?596GIV +V#5YYJ[]'D-JPO&LQT5$KQT  E3)H*))2X
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M^QQUL8+1JX[7-9%1]'ML7M/V*E;6C7:KVFHVF! 4TAB8,B-!YT&P0'9S+-A
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MG")PB<(G")PB<(N8==M64=TH^D&)+WBS6H3)U5T?;:$#&'8#02GJ/W?I,BY
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MX5)N6"=BNF8)A#->K2AXY\JVWVKZ+_BB#U[]^A/C3//+5=W\BJC-Q_U;)_\
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M(H2-% :BNJI/%_J2ZC4+LQN?94L+?#4FMU1F%50DT\6L4"+89I0$W68NM';
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M[]GH?R1PB>1ASUG7OV>A_)'"*2A!4P2P\S,L)FQ+==PXB290&0^PGL)3W#.
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MEW^<K?RQQ[W_ *[B'[3_ &)\')^7OND?Q,S^7I]$A7[3O2[_ #E;^6./>_\
M7<0_:?[$^#D_+WW2/XF9_+T^B0K]IWI=_G*W\L<>]_Z[B'[3_8GP<GY>^Z1_
M$S/Y>GT2%?M.]+O\Y6_ECCWO_7<0_:?[$^#D_+WW2/XF9_+T^B0K]IWI=_G*
MW\L<>]_Z[B'[3_8GP<GY>^Z1_$S/Y>GT2%?M.]+O\Y6_ECCWO_7<0_:?[$^#
MD_+WW2/XF9_+T^B0K]IWI=_G*W\L<>]_Z[B'[3_8GP<GY>^Z1_$S/Y>GT2%?
MM.]+O\Y6_ECCWO\ UW$/VG^Q/@Y/R]]TC^)F?R]/HD*_:=Z7?YRM_+''O?\
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MQ;)M6 Q:S6J?0<RXEUAG:,J07N27++3(-G#$8-ADDFW4J<!1*D\"'>.:Q/\
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M]+',YG\ %67FE[Y('H\9EZZ5R!)L1&'<3.+V,R'FUO&WJN;K#FO 4.PSU5R
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M*:6K3T:\/4KYU-]:ZY"OITXUOFH!7Z)TE%AQ! H7L,*TC7:=$&0)=Y6[7QS
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M$;FT./639<.&""B*U)D 6:S,C5W6$*#AZN$%-0KSW)J]$+!9Y[ 1A38 07-
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M<\NZ!6:F9-*ML ,S>N^ES4[A]>]6]'&^5!:AL-*#>2M,2MF\ZHS8*J-?M1%
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8)PB<(G")PB<(G")PB<(G")PB<(G"+__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g945651g40p25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g40p25.jpg
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M)#A7EK6V"B4R879X&1HF-3E"6'%T)RA#M'*!L?_$ !T! 0$!  (# 0$
M       ! @4& P0'" G_Q !9$0 ! P(#!04& 08)" 8(!P !  (#!!$%(3$&
M$D%181-Q@9'1!Q2AL<'P(A4R-G7A\0@C,S="<K*TM187-%)S=H*V)#53DI33
M0U15=(.BL](8)59B9)7"_]H # ,!  (1 Q$ /P#]_'")PBZ).F?JNWUO#=52
MT5LFR7_4.O8O5#U\QJ_N B/KK4SJR,=/G5_N(55NFC7)]A4M%,INM=0PJV_:
MITX6-V!M0=0;A6:/,A"=>['LI0MN &=OZ+>.EVC,]YOW97U 5W:$F;5V_IK7
M_6A=.LFUZ@/6S:F"A2BV)&OO\G*KT3\MTS7C73F1I1,?7)ZK//#LL:\1?Y5]
M1L9K=DYHU#F30R(^L))0Y?AW03TO>]M?CI;AGS6H0#K;ZD:-JNQUG;VPI+QK
M</60IOI1VRP/&0'R-!K'TF C0^WNF8\O$3R$FXT[6T9^PU66IA!&W:CM1QN
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M4['-MT[SJ+7OD>)&G#OZ+#M1TSL;VMGR!UX]RV>U)8!%AU]6%B;1(N*A <4
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M/XS*C_X%V)_S!J[G\MZ3]#<>_P!YMDO\*VU7)G^4;_4D_M1KN,^CP_@QLO\
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M/^'PEAR'D$]*%^[8'W./^'PEAR'D$]*%^[8'W./^'PEAR'D$]*%^[8'W./\
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M>'8AB7NAK:C>D>\.G-!24%(7,:X1,[&DA'9L9OA\F_(_) )XCN)]5E/2HO\
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MA:*9FEIF"PI#+^! F57!BXCJ4$ATK#V6&OBWL>V?VJVO]F6QSMN<2J<.P./
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MRV^'F-+%"9:<I5%)D$KS$@2$JPIB4\T[C.,IQGE&HX9J'0]QTU\%CKS=5UI
M\.$@)/WBR*?CU:N8>RRA];&&_.&3,E"'%"ZP$2\U(-%5-KRC#D<?!:EER Z#
M*ZEM3M,[!&T>'892#%MJ,:=+#@6#"0Q-F=$&>\XEB4[6R&AP/"VR1S8G7N8X
MM#X:.ECJ,1K**EGT!SO8:D?+O/#ST!6NM%US?1IPK$$[!;GFM,KBUVJC3((9
M'J,X?<:U6[39A<_ Z+]9(K$@@J+#!%,&",X#!'Q/-,'UK(((?'MEMC-JZ'%*
MZ"@VN;5XE[-W0X-@-%B6%T,6S]51[1X+@N.XW0U8HZ?\LP12U;J>GPJN&(5E
M5A-)1T_O$6+N=6-J]D@@$C)QSL<\C8'D; GEX*2UO8<TIM>*<-TFP5J!+@N:
M@DD)$RODQ<?80TB0L$@:R\.+NDY0B3$:6R..K#Q8[\Q3<28P/D96TWS."[8U
M-?M]#B>)[,XO@M+/3.]G<]7-4816T,.U]%5UF+S44<E'B#ZV?#YJ=ACH\5.'
M0Q2U#F4]1%23%T;);\-@0<][PT\^BHK9PZ_[)VK5K]40P:8F":-#]0SR%JFB
MEKSKAN?/,SU#&:T0C.P;4?BSH[<APEEL_7HHIC&!<=[!)SY9MO1;6;:;>X#M
M9L_AN&5(I,2Q.C]GE75X]54#R=C6557B56ZBBP6LA=2X_B\-5 V8UI9BV#4]
M!%:ABD%:_0L&D'H3XY <]-?JM^*I9(%OK0.T"_$Q!.C(A)AIY.42(WF6DK=A
MRVLXPIF9">RY$F,+PEQB4R\RXE*T*3C]88#C-)M%@N%XY0[XI<5HJ>MB9(-V
M:'MHPY]/4,UCJ::3?IZF)P#HIXI(W@.80/&18D<E\[1<*M2A[96W6 37!KLA
M,1N<8FLP8RY*FGGTLI>?4A&7,LQWG>[V_8AI:L_9CF<<VBP+9FD97[08OA^#
M43YA3LJL1J8J6!TQCDF$0DE<UI?V4,LEK_F1N<<@4 )T!/<JXVA>EOZMF$-:
M'XDNSW-M==UK-%^6)8)V:<M^,SY'"\JBY;'HC$)Q&<_A<0/!'3B4U*F(+K:N
ME[=;5/EV$JJO8G%J>HQW:1CL&V*J:'L*X5N.53I88O=0XN@+*-L%75UM5*'4
M^'4M%55M2UT5+(QU SSX9F_+[X<5473V4W54M(:]>/5<5L(*JIBR09RLV*/!
MN,"KR8+4L *="&Q0<"4?@A5Q6$.-VB-)SE"(:VI;K>9C_P \]C];[3=G_9?L
M?)B^!T&U^&NV?H:W#GX)C$-+M'2X'-21U&$8>_"\2H,.PJNFI<-=!$U[,=@G
M.ZVG<RHD8:B6D-).=N\97[[Y+$].'4'%M58MKC.N=BY\+8]Y(]\4!6;BX3:;
M(2M+4-^6RJ,U'(CD%L0YT16%=Q3;4C#G<DX;:]#V,>U^#'\"V@DBV,VR_B]L
M]JJN]#A+L3@#<=QJMQUE-+41NA9%64;,1%-54[@2UT;)0_=F#&'-SU&@U-M!
M;Z+!:_NYO=VY-T4'T"R42H(*P"%QD3$R8=A,CP@P558E16ZTTQBM-V;$5\L1
M>CS))*0#;?&CGHWC/$T<5LCM/BGM.]I'M,V3_)&-[*[/,Q"DJ]HIJEL]-BV)
M4F&4-!@%/L^Z6-D0P5F-^[RU]9)#43UDV%LEHZ.6$RR5S*0 T'4C3/F;WMQ
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M*RIKI*:CAA@8YT4+&]E3P-8<;@#06O;Q('D/F59:/X\G_P"RB)_S?-YW9O\
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MC#C4=EM>,9)MXSC"D(2K&,X^S..W[<?IY^9?X77\RF,_KC9[_$XE[5& )A8
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M3!B J;;^B'<;N)L 2+Y'+0<,M5GM-0R@S3].'&0-Q#FJ?3   @$F.QV)LTB
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MA<QY,C6EK2#8$W.2\T$O92;[FW%B+ YY]X"T4_\ 1YW?_:#5?AY?]CGXT_\
MP-[3?_KS O\ ^JQ#_P ]>[[\S_LW>86W'39HBR:(%6D<0+A+$JPD!\UMV&J?
M 3&3"C2&%-K2]"D9<RYE["L*3E.$X3G&<9[?L_3_ + /8SB/L;PS:.@Q'&Z+
M&G8W74-7%)14L],V!M)3S0N9(V=[R\O,H<TM(  (*]6IG$Q86MMN@WN>=N0/
M);+^(4]C@?$I'RKGZ"7K9\AYGT3Q"GL<#XE(^5<)GR'F?1/$*>QP/B4CY5PF
M?(>9]%TW]6GTR-,Z3=]7/0U@T;9[<5IC%8?DGP]S%0!\W%GJ@6U,)8BS0:Y+
M>8K!IJ([EQ6<+>8<<1V(4G&./GQ!D$KHC&YQ;NW(( .\T.X]]E\QVC]IU'LY
MC%5@\V%5-3)2BG+IHJB)C'^\4T50+->PN&Z)0TW.9!(R*UP_]8>UG_\ 33>O
M]_P'R#GB_*L?_9/_ .\U<'_GIP[_ -AUO_BH/_+7Z&8THG)CL2,0H*</LM/8
M3DE(SE.'4)7A.<X%=F<XPKLSG'Z>SG*K[2UQ<T. %G $7.=B+YY+[>(4]C@?
M$I'RKA7/D/,^B>(4]C@?$I'RKA,^0\SZ*I=\;=<T1IK96Y"M<0?&ZVJ)>VS0
MH\RJ+.)QQ$=4AR'%D21*F&7GL8[J''4Y0G/VJQG'/'+((HWR$$AC2X@:FW!<
M;C&)-PC"Z[%)(C,RAII*E\3'AKY&QMN6M<YM@3P)R"Z.O_6'M9__ $TWK_?\
M!\@YQWY5C_[)_P#WFKY/_GIP[_V'6_\ BH/_ "UO3T*?2<5SKIN=XIM6U(;H
M<FD5B'9I4VP6N 48G,3"K0I,6.V."MN-.H<=PZI;F<HRC&4XQWN>S35C:ESF
MM8YNZ 220;W-N"[;LCMY3;75572T^'ST;J2G;.Y\TT<@>'2"/= 8P$$$WN<K
M+LV\0I[' ^)2/E7/<7?<^0\SZ)XA3V.!\2D?*N$SY#S/HGB%/8X'Q*1\JX3/
MD/,^BZMNN;Z4JL]#>RZMK6TZ?.WN;::-%O+!,!;1XR+$BRCY\ F \R1"..KD
M(= NR,NH5AO+<AM&,=Y"LY]*IK64SVL<QSBYN]<$  7(MGW+Y_M;[0*79.OI
MZ"HPZHK'U%(VK$D,\<;6M=--"&$/827 PEUQE9P&MUI3_P"L/:S_ /IIO7^_
MX#Y!SU_RK'_V3_\ O-75?\].'?\ L.M_\5!_Y:[V-.[+?W#J76.V1P%D,/V=
MK^GW^"(FF%R)@N)<*^/L$8?+D,"4L/R8;)!$=]UE*6G'&U+;QA.<8YR4;Q(Q
MCP+![&O .H#@#8]UU]<PRN&)X;A^(LC,3*^BI:UD3W!SHVU4#)VL<X-L7,#P
MTD9$BX5C^(4]C@?$I'RKFU[V?(>9]%SL=O9CMQC&>S';C&>W&,_RXQG.,9SC
MM_1GLQV_S8_1PJO/")PB<(G")PB<(G")PB<(G")PBT7& H;/5RHT*"-"4)L!
MX<46L'0PN'GI&LLEU.PI,$CBPV!X\2G3;"1)3&G; OQ66EAT@8<XS'U?+4Z=
M;:_8Y>*SQ.E[]+VMY^?"ZWHYE:6JYS<]^%1;+ET93X)&JQ=O668QA)DS"(!-
M7,4R1'K4";F77GVK!8FK?A6#SL%^(/R-D8;K!%*\+;U899G.PY:DCKR6"3GI
ME?F= #;4<_V*9T/9YL[./*/1(+HYFOXM(R)6PYB2;%P\VVWUO(,Q$;G%WS!G
M#=<96AT9 &Y>GM&82!?9";<7"-.\CY9Z"P-^*H))(/[LR+'/7+YK+:M,QCQO
M<)"+%+PVE;'&M89-A2H&=A36I]8X4I0\Q$A34M*[?\VZIC#;N,9RVI6,9X/#
MN^I5&I[_ *!6_P BJKO;Q$B(U1LPJ(+IKY4;0+A.&GUQ)Y!(.=%KY!^*8S %
MLR24WTQ]")N(L!AZ7(RQAJ.TMU:4Y!\49#YM_LFD&3LV%\FX"-[<8 2YUKV%
MC<KPU';=A-[MV7O'9/['MB\0]KNGL^U,8+Q'O6WRP%P;>PNM1U;-VX6SVGNH
M2H4MA6<XS%I/21MC!)C'\O;8-AW"PCI"\?;A+BJ;$1CL[5,K[<XQU+_.I[-X
M]7XT#Q=B&$[24C;\+L=LY3.;J+WF-^!"Z^*#:Z?.?'<)I&Y?@P[ 9G2B_P#_
M ",0Q>JC?T(H6<R%I!H/6,:^[WNE&<V J,";"["B7*Z4()-K&PMZ#S-CC2O$
MODAX$N86GCIBF94B?;7K#,')=)@ZPZ- $)3$OX7L_P"T&L]K^WVTVP46V6+X
M]L1@-2*[%L.Q3!<"PV#$L+H/R73?D.D?A^%46(-H*K'I*VEQ4OEH65VSU/%1
M3TM7-BE1547IX;LO#A]09W"FHZRHIZ^"3$<,DJX\1Q62JJ)9?><1,YDCGGIX
M!%-#)4>^24]5),*.2FI6=G/&VX!\1UH_D:H<7;,*R!-CN[2K^S[_ *)V)=G'
M)S8,F!1,MEP2- -&M7$HSDBM/6V+;QDIQM:*E GQQ\*./5^@(L/QH;;.VEFV
MDV<_)LF LV9?LM2[&8[2UC,$BK9,2B[#'O\ *>3"H\3CKG[WO1P)V'NA;V8H
M6U+C4CJ)A?%C7Y H*'&V5<&-NQ^GVAQ&/W]CJWW-]&36 4-///A$L -.Z1F)
MQ5-S[LR=L$;8%.=]]<753KCJ&I56.:+TX,#:^?$NV:PR]G'G6IT&XB2L<S9@
M$)^O""N0[ ,=/G"QI(7&*Y+Q7@32C+Z&GI/-8GLM!B.,[+8M33RS/P^3')*&
M O\ =WS2S86^FGIZEAI*B)KF1R P/CJPR20L=,::(N+?/B.W6TF%XC/0UF#X
M53Q47Y/-=4^_/FC=#5OD!JZ7>=2S=B(XY).RFIF2M>Q\##4R!I?>?TB8DY,E
M:>MX*SRJQ$GF6=61G'X-1AM3+EL6S5:-09<:?:@1&>Y+'$HLR0RB$IN!$C.R
MYTU>(29\>;^>_;KL1CVT]7LS6X!LGA>T510E\,\U?B[<&DHPW%<)KX(H9Q/'
M)**H4E5 ][8A4439734=92.EJ8ZKZ)B-2VG;!*_%)J".>5E%&(X::5LU36N$
M--)>>"5P="\B1H:>R(!=,UT;3:3]0744%TST^B,[YU_.L=HI@F [8(5MKDVS
MB[0@'69C!.[C2P2+!&O)FRF\-E$JC0Y0F88Q&D!DQ98Z5*WM#CDF(;,8?LMM
M;LSLU%MC11T;H\!VZK756![1S1T;Z)M1LUCP)AQ2KJ:JIAIIH*APQ*C=52-K
MZ0MFI:JI\U?7Q811&LJO>ZB"&.\\U-3F61K61N?)//'"UHC9:-SG%K&L!+0U
MK0;#;'5>Q:WC3%7N2JX3J@!\>Y-:$#:59V<0HLPS)9BNQ04>$2*>!/R\U/0X
MVB0AYF7ZAA>(CGB)^J8#687@&Q>'UTC<*I\*IZ5L[#LI2UM?A'N]95N=!-A=
M/20U59403FICF=)#%*TNDEGOV +Q[5/.*F-DHBGAW[VCJ8G0S-W7%MI&.S:3
M:[03<M(/%3^L;+J-Q!YLM>EDI@'"<N8*R*]8!<1;&(C$[S;2RPR#EZ J'(9D
M(GLI7"6VK.4/J[CF$\K@6U&!;2X4<;P>M-1A-BX5\])6X? ^(4\55[Q&<1IJ
M0RTAIYHY6U<;7TKV$EDQW'AOE.1L0;] 3\KK)B[I6CF7\!2;1C,;#>9.!:5D
M,Q\.]_PLOXB)>\+#OAN>'XG=[_AK[O;W5=GOT.+85B9E&&XGA^(&'<,PH:VF
MJS")-[LS+[O))V>_N/W-^V]N.W;[IM";:AP[VN]%E_5&/9R7PLA^[\Y!+CKY
M'T3U1CV<E\+(?N_"7'7R/HGJC'LY+X60_=^$N.OD?1/5&/9R7PLA^[\)<=?(
M^B>J,>SDOA9#]WX2XZ^1]%BC<F;/%RH@:<2!$GL-8C%?JY(*>5RA]M;N?(RF
M4,/^,REQCL<5CP_%\5/:M"<9]#%*>NJZ&HI\-Q 856R",0UYI(J[W?=E8Z0^
MZSO9%+VD37Q?C< SM.T%W, (.%\P3TLX?11G6P)Z@4\+3Y)@O8X]>@0! B8_
M67AC[ <6/ACX$-YN(TXW)=:1%4XY,7G#KRWLX4G&$)YPFQ>SE5LGLYANSL^+
MOQF'!Z2DP[#ZF6A@H98L.H:.GHZ6FE93O>R:1C8"]]0XM?(Z0@M :+TN!-[$
M>#CGY*=^J,>SDOA9#]WYVI2XZ^1]$]48]G)?"R'[OPEQU\CZ)ZHQ[.2^%D/W
M?A+CKY'T3U1CV<E\+(?N_"7'7R/HGJC'LY+X60_=^$N.OD?1/5&/9R7PLA^[
M\)<=?(^B>J,>SDOA9#]WX2XZ^1]$]48]G)?"R'[OPEQU\CZ)ZHQ[.2^%D/W?
MA+CKY'T3U1CV<E\+(?N_"7'7R/HGJC'LY+X60_=^$N.OD?1?=B:W(7E"&I;>
M<)RKMD0I4=&<8SC'9A;[2$95^=C.$XSWLXQG.,=B<YP2]^?D1\PN7PJL0_7P
M,EUQ^2$$2'W596Z\^-A.NN+S^E;CCC*EK5G^52E9SG^7/"+*H0AI"&VT);;;
M2E#;:$X0A"$8PE"$)3C"4I2G&$I2G&,)QC&,8QC'"+VX1.$3A$X1.$3A$X1.
M$3A$X1.$7X<_IE__ (BF]?ZOU/\ X/4/G6\0_P!+F_\ A_\ TF+\G>T_]-L7
M_J8=_AE&NKOGIKH"_IA"_P#W:.__  8G_P#7;YW!?NV/^3C_ *C?[(7.X6TX
M1:9_2(_ZC?5/_8O=/^&KYZ]7_HT_^S=\EU?;7]$MH?U75?V"OY_?.KK\;K]"
M'_1Z?X\]_P#]DX/_ )PB<Y7"OY27^HW^TOL_L7_ZVQG]70_WEJ_6!SFU^B4X
M1.$7Y%?^D%?ZU6H?_+Z)_P 1MB\X+%/Y>/\ V0_MO7YM]LWZ18;^I8O[]7KH
M9YQB^0K^A?T0_P"IGTF_^6[27^&];YVJG_T>#_8Q?V&K]H[*?HOLY^HL)_N%
M.MH>>9<^G")PB<(G")PB<(G")PB<(G")PB<(M/(&1S?521CSS9^7,;E(>&#F
MRDE%403(Z\ER&G2(!K7K %R\PJ[%)CHIN/=%6-%&:"PBKCD>3F*1UP&7K:_>
M<B>8 OHIQ.O._#/AH+_'OX+</F55@YU8K1/P/4J\#(>6*H.QO/"8$ORYMI.$
MM&6/'CN>$5;3C"4$6^[+0G&,)>QC'"A .H![U]QX(()D$I@H,*&2S,KSIB4/
M'Q(4@K-SE><RR3\9EIV=*SEQS/F)2G7>UQ>>_P#GJ[2JAE(_A3N+^T(1_A-K
M+E.C>[ZE0:N[_H%9'(JJ ZFMR5?2&HC]ILNP1&L))MZ'1:?<C0E5@'A+S<5K
M#UHK+ -RX+A@<!EO*LAR(B6QA%>"EI;KB68SG%G.!#+;UB1O EH(&I +21S
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MZYT^*X9A-56T8K\$=6U<]0P&AKXQ Z9[<*JX)C3N9RD6WF/0;*SXC+@DL]7
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M_9#^V]?FWVS?I%AOZEB_OU>NAGG&+Y"OZ%_1#_J9])O_ );M)?X;UOG:J?\
MT>#_ &,7]AJ_:.RGZ+[.?J+"?[A3K:'GF7/IPB<(G")PB<(G")PB<(G")PB<
M(G"+2  ]5Y_5V<>^M8HK883T^+!C9%T8@:\I'IK;$X.S: .OX-B&"J^0<*0G
M*L=NQ"4@C"DD9B7'94>,QK,-TR/?KW7L<AK;XK-L^.1RTL<CTOE<Z_-;O\RM
M)PBQHXR'+JGH$EAI18N:Z-)H'3HLU0XC'[/''STQG7<Q)K/>3XL61AM]OMQW
MVT]N.$N.:A-(_A3N+^T(1_A-K+E.C>[ZE0:N[_H%9'(JM?>I#6.N=H4JOC=C
MT6IWL>/V;JAZ!"MH 8?BPW2FRJF").1F2<:2VPN>%)$!4Q3:4YD#YLJ([WV'
MG$*TTD'(D9'0VX%1VGB/F%?$*%#&PH@X=%CP1X^+'A0841EN/%APXK2&(T6,
MPTE+3$>.PVAEEEM*6VFT)0A.$IQC&55I5T_=(QG2.]=V[LD6C3Q65O<BDS;H
M5,Z?G-=6%)2-''L1%,7#.U[<IT?+?C3C]G@R 2W;);S$^QO38;Z\1^>K%3F*
M667>C/:F[@V'<-\M'=H[(F[G @[SB77"ZWA6 R8;B>)8D9L/D=BCQ)4-IL*-
M','M#&MM4>_U%V.+7RSM,5YJB5\Q<TG=4B9I?4,GJVD;4<I^F4ZE?UVQJS$]
M&WKNO8B0\2R3[8U:,TM6BFZWDF]-EH%.5K\HGE6(J5$DV5]WL&YUNS>\;^['
MV>X&7[1V_8.+M[=[+=O<VW=_KO<%Y13XM^736FFP[W THHM_\H5)J^S;*Z<3
M^[?DL0[Y>[LS#[YNAOX^W)_ K?MW3YH2_P!IBWF^:0U#=KK"1 ;AW"W:UIED
MM,1 IU4@6B+8#(6:6CH&OJ4] 2U+1B&ZI3D?#:\Y5SR.AA>[??%&]PM9SHVN
M=EI^(@G+AGDN0GPK"ZJ=M358;05-2W<#:B>CIYIVB,W8&RR1ND&X<V6=^$YB
MQ4SLM#H]S7$<N%,JEK6/2\B NRUT0=7"1(RVJ0F(HI#E9C)?RRSEY+.48=RT
MWE>%90GLTYC'?G-:ZVF\T&WF"O8FI::H+344\$Y9<-,T4<I:#:X;OM=:]A>U
MKV%]%\['KZA7 / KUMI%0M( 4['?& ['6@QL..>B1G845Z ,)PI4*&[&AO/1
M([D=AM;,9UUAO*6G%(S2 18@$#0$"P\%)J.DJ8V0U%+3U$,9!9%-!%+&PM:6
MM+&2-<UI:TEH( (:2!D;*N]L=.VL]N:-M73P3$1ZKK.VBT!IHBEAJF.:'0/6
M8YUY(486KARMCI#\]A3^)B0+DR%*?<*BWX!MJ&4BY>P/C?'O.8'M+"6$ [KA
M9S1<$6<TEKA;-I(XKTZ_!Z'$,+GP=\3(*&=@8Z*GBIVM8T2MFO%')!+ QW:-
MW@_L2YCSVD99*&R-T0;^B#Z1:/I,]2:72;.2O 81;I^N=EQSHVK;A!V$B&>0
M(CQ+K1T:O;L2(A=*9(]C8<XI"4N8\-+$DUU+$2#XZ>GCI6.9&9]Q^4K8YC$Z
M>/\ I0R&/<;(QXNTMF:]I#B' MR74Y/9SLY'A<M+!2/DK(8ZE^'X@711XE35
M,D1$3HZFF;1=J8Y+.8*I[VFYC?((0&MU#^BX^C5ZI^GX%N<;MK;^[.GY^TG*
MQ-!1-36/0%A$66*/8L#4DD57:*ON:3".LYF1\/M0H=<C^"\UAPC95H;]&\-/
M!(UKVR25)<99'=I(8+N8Y^\UMVNGEWK[\L@,O9]I,[<;O;\LO7]A=BL=PAF)
MMKZ^OP7WA](88\+FPJ:*81,F:]\GO%-B 9(W?8P".*#\ ;O2S6:RGHWZ/GZ.
M/K*UAUE;=V#>)N[= TZQ [ZR"VN (=+]EL!YTE<0A(>//!3<#;(&-DQ"8>F.
MJ"4 <EAV)AB-/##W'1DGVBQADK7-K,5=VTL#XFSMI1&&,B+7&1W;5 =)"7""
MGW((F]@TN)CWA"W@]C-B]J,/VDJ:RLAGP:F=3X@QF(TDF$5%1*Z6LADCC=#-
M!5PL;4LC,TY93W$H:ULC&[W:8V'T,=5 _P"EC>VH+V/>I0ABWS#,+=UTT)?S
M$&7-76I(K$8YBK:6UYI*8^X[GS3TT(5K-07%>;:A6M-CQE:IV]1[P6#$L2,7
MN#:41OIR8-X2"0TY+)HXO=@\&=LH9<OM$Z(M+G.PW8[&F;?'$F/W@,3DJVXO
M48;6R.+G4[X1++V&$4F&OG+;,>(YH*0Q&\=6)P (#](5$ZGZ]](ITWQ[A$Z;
M-Q'!Z*2_$L$37#NMZ[8X,RR3(K8O;;IZW[2+U!<)AMQ(DP(-0X<9N2T5!"91
MEB0A?6<4V3PK$\1@Q"KJI'32-@;51MQO',*W&X;*:JF:R"AQ P-,SR6MFIZ9
MCJF0F"OBEIVM#M[5UNTE'M=A%/-38-B4D?NSH*EF$T\5/4"HF?"68D^JFK9J
M4PM_$'>\-9'&1/2 S[X&UG6SUS[HTW9*G,ZK-1[GZ8H)2G;0IU.,].5NUILQ
MF\GR4BFNQ7B]JLT,?!13A<%F20D5Q,,5<I1%45?E@\1K,N=R&+81LG65,.)8
MI28O/7'#,0V><UM958;"W!\:=3R8J8JC!L1IJF>H+Z"D]V?42M-$[?GI:=L[
MW3-Y;:/:[:?#988\:I*O9RE=%6FEGP*?#<5=6U\;J<4GO$F)4?8QT<<;YI):
M>-C*B9^XV1T<30)*(^D.I7TA6^ND;70HYT]5@%1AUCIT\34*)J^Q6#>A([#H
MUACY)$ >OSNV15<J#T)TA'40(*IAU92<(&E00=$V1#8]JFP[!\&P<X5L_1OP
MZGIZ"*AADJF4[IJR"G$4;(Q287A;8J>IFBBN9Y)8XVDO9NP]H"SAMLH-O<>P
M7#GXIA5(ZG964]0VCPV@J7XFRJ]TJ&F>4LQ#$6-HF!SVV$=-.Z1\(DB #HQ8
M-#F=9_3Q]';6(VVJ<;C:(I0""?+Q]?5-BI[)$52N;/39;6'N3-G(:SV-JZP'
M&X)=L!>JM3MB*;R4#VLO)J^)4HL)]^M_(M?3B#'\+CQ:F8ZDJ9*AN^ZEFK,.
MEAK*&HFPNKIZ1SF0XA34TSH' 0R&*[F]BXM/DH&;9X'L9 ).VH\*IXM]U/2T
MS*7$Z>A&(F2MIYJLU%-68?4U$!J&05]/2U[V&:*>1T#RZ:.3:B)6+K-T=NFW
MZ:H^]D:4N1N__5_.WMC5>#4*>#ATD, .9L-ZC5#=/51MJT-F!ATQ"IU441J#
M 62$I2++ZHW/:B\8ZBV9J)),4H=E,".,5=0W%*W&:S!Z*25N-1,A@BKZ6G>*
MBE%13P4="6O92-[6> 2NW9'O*]_#6XGM)A.*^YU&T3<!GEK8*&DK,79'34]
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M6C.4Y(M(DSMCX<*L0G]INC8I&TXU/*;1L_+!6P*5JR56V;1FP)=LKP.,_-M
M^:WL&7,K<C,6[SF<Q0D(/""[R'(Z7&76]K&WE;AJ25X\^O&WYVN5KWX=]^-N
M"FSM]Z@8#$TRL2/)LPQ-:+LUYRE%0WFY-@-;$#S SQZ2:<:'M5V!6JJ:(3GX
MW:PH^[*(9AB9@YAB$-ZZVU'GIF.7=KGE;NMP&5],M#D;G*ULSS(\8U-V#M&Z
M +J- RSQ M4%F28\@*J-LUU.*/-:QITJ)5B(Z;B64CR)5CV2HJ,>3%SE0ZLL
MK1&(OPGYTM89:9VXWXG.X/(9]_#)+NS\>%N L+$<SE?6RD\;;VRVSU0&'HF
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MREV)(<B^7?[S&$31LF5$=1X,EQ.0R^/Q%D.?P^!NN(+NH,)E"@^G=CC,MB!
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M$QF8T 7"@M1V$.Q7VVXR8C+/EDM2(,*0SX&6\LR(<1]K*'8S"T$7"I5$JFO
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MBJ4U*GL1HK34)"Y[T9+28J&V\+^&8.733[U2W/D1YZ\U55WZ9+D2M<G-)M,
M#7+2:&6*UV"8^T_8QA(+M39FUA*:R$Q6'64+'F=BS([<[-L'N3FL-N268R!L
MJ-:+?QU'F -;]/GX+9Y?3K?KG?S^.7.]+:*Z5L5UU+/;A6DR>I!Q $W.\K54
M.4#(0?4FVE*#61<2+7 3%GC,C8@^.R;?L>'Y4T66$A; , Z Z9]^=[_?J;K<
MCZ</$FW7/CE:UA:&U&=UD/CYLI$9.+1=9:HUMVALK5 ?CZ]AV8I,*]BAHA#+
MTVSWVRPF(\<?'C>B"0LS#$.1-DC($)^9/G^X< KQOW?"_JMA.1%XSCMQG';G
M';C..W'9VX[<?IQVXSCMQ^G';C..W^3/(1<$7(N+7&HZB]Q?P1:[ZHTX7H)M
MLC.<JK+8^HR:DY-K<.;&+[ DOE()%-UV Y*0A#UF9\E([GANE59EV"Q2O4\,
MS&8;/R'V?^SK$-DL4CK:I^ QLH\ EP%]3@M-50XAM=/+7TM:-IMKGSAK),;C
M%+,&[CZ]WO&+XQ/[\(ZF.FBTYUQE<\<]!KD.F?[%%Z;HFV4014X3,JL7EVKJ
M#$5MVV7+ANERBJ"]2C+$LM%K17*8H);4>32)BPTE<( 4*U#TX7"B#2&?L)<#
M?*U\N=L[\QKQTSSXD+Q;NFAMS[M-.!TZ9<%DPNB"XF[!+4W/J\0>JRC"EOJH
MD7+B5PC #:.9UB&R"%R');8B4(+9(,L15NR&9M0G1(9&=(E@!#+*^5NGC^=?
M7CZ^*ML[]?#\VVG#T\%F7M+/HIFN@HQT(/L5&'V")@Q&;D1D)<.:WM=/=='+
MCQTO-+<+%PD^0\III]<45]BE/-1V52^9//QX@_1 W(<+:V[B+\,].[FN+=]5
M3;F7V.%,CAIL%L#0X"DBWS,9DD%"VJIF[M-?DD(LII]Q"R\JZ58L/?BQ7G5.
MTAZ0_EJ4/%^)0;6Z&_@;>GQ5MD1Q(M?S\!K]V4 MO3Q>S)DO( F@X&$1P%+$
MW47+8,F!>)]<H]4KHNJ6O7LS$VE#!KAVIBR<N^5Q#5AR#@L5_%<=5//D2ZXM
M8]V@RZ\#QTTOG="-;$@GD;>MN^UU*R&CK*?I 6N%R@R$^]M#:.QK6,$&#[89
M;%\&;7<$U^ 0BPP\\JR#LUVK)B7*G0!;).:#FF$CHLER) 3+C/+@ ,ATS\;'
MS2U[=]S\>[0V\E0]KTAMJJE:Z.K[!2\12M@J,D>]BW6F(.H4R O1+-SL[I%R
M0_*?*6634MC&BJ2C344@+.&,H)SCEF-5&SVXSX:__P"K#CT\0.\2QRZ>7 :7
M RSR\=5F2?3ELZIM6&T#;(JS9+CZP]9*6+F%(3)LS":UM,OAR$J(S!DKG;'G
M5:VURWKD>K$6:1;7YM/A,G6#%4O*XY 6O;('6_3A?+A?76X%IU!Y<3IE?._3
M,YGZV?T[TJ]!2.#5J!R:LU]6[;$R,>*RB^'H]DW;L>YTP&F607@FN/K^D$AL
M2"B?&B*ALVYT2W"'2!D\9"&W W\^0N?$Z\<D%^(M^\V'@-+'CIHML^96DX1.
M$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$
M3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X11RTF)@ 2HM&C#GHT*3&D&Y)4ID3"$UQEW#Q\TN1B'-R\L6+;DRVH
M?AMXE.H2VN0PC*G,%#E]>[BJ<IV\I5JL @ ]5)(*4Y-.YLT,PHB,+58.D3,/
M5*:2&%!<"2U**BV(Z#+#J6XHLA(2U!FEH:XTZ12+7S[N1TO;/K^Y0.N0+<[\
M+<OI?AR7Q1U'@'%C$KJEL@I)2Q4=K)!-:1CL-0/''J><8LKS(YM1)Z,%E2B;
MD6'")M$F)3S34!R1ENG/I>_@;?M[DWAE;B0/,>/<5G!.^ZB6%6<S@=88@ZHK
M!H,2'8HZ4UC!DU) NO0GQ10A&)1A,Z%,<F2Q[\F+,A1\S ;Q=MQKOB+<1]B_
M$<>";W0Y>MN?#Y9J)?Y2D(A("( TXU+CF8 TAC).:#$RHR<GJV*L$/+"RLAM
M^:!AV:,2E]C[4%,6&_-1/?&28<YQ;7/3EGSMX$BW0ZJ;X)%N-M<N_/F+Z9=Y
MN%+;%OFK5OT_S@D^^J95:_;);$5 9V:#B6DP. @X9L=DPDC%F32)'",9CQ)<
M1+,$F]B2M,%>%+?7GPS)^\^BI=;AP'$:F^1SZ<+KD5[=X"R%PHJ(!LD7UY;*
M($H@D"QA>7<6!M2L0&CKY=U,2=5; /(9CCW\CW1KDN9AD6_$GR%LKW'=G?AT
MZA-X7MGGH<K=>/"WW<*,JZF*:\\_!@B;&_.\,GF(K$86_!DNQAT^>*PW*C&'
M6WT'_3GFA?@+7F0VJ,1QG 6= *2KNGIZ=_=Q.@TO?)3?'76WWP^*YT;J,ILQ
MN+F,+.27RLZ%!KL6+(JTIVS>J2+5#$3 KC%E7'='E9M1(1H,R4]$8=Q-#RU*
M0/)L2^3=/KTM:]^Z_?JKO#TZZC*W<O9?4536J.9OCXFSL"PQ/(I<-V% 02F/
MH#+L+JH3*B6&5I8#-/D7FGGV9345KQ7(Z4K1G+=-[?N^/V>";PM?[^%_O6R^
MA+>XL-$KA$L%D0H)TK<XSF?5 RY$0+5+F/I:#R6W9\9$N/*DF1!2;%AN2)@T
M:[,7EF5Y-2UW=)TY#XB]OFF\+ \"3Y VOIGW:_%8975#1D0V)C@6UMI?0]G+
M.8@E<AAUFWO4A;,EAHRXZWELXPMMW.$+SY=+TB.B4W!)Y@MT\Q\>5^7+Q3>'
M(W.@RUO:VO/CHO1CJ6K_ &$I\JMV/T.&QF5B;"CCY$F"Q%+BP)1DQ!<)LRFR
M<(@8B/*'"V"3BQF'9C+K^6UM(EC^_J"?D.BF^/#T[_#+6V9Y*0SNH&H#*]6[
M'/$6EF+:)A6# C)&Q'IC3X6PCJ\0Q(;:(*;[&U3W23:6'7W7H0V?':;68\F+
MEW=-R.(]+Z^JN\+ YB^GA]_!87'4S450'26*S=?*QI*XTQ:AXG&8*LD:T)C+
MEH2:4ZC$N=:Q.&VF6WY#<7,B9(9:::QA;=/3X]<M-<BF\.1^ Y6SOU'=Q6<.
M]0%.KLAB.1&6=*G*8-O#_AC8^5Q191F8_&A*:5/0[+,_Z$J(D6-3-D2RLP8(
M&8GD9R8Z( 3RUM\O6_<"4WA\+^>GIWD#BN ]U#U9B="9E09 R"I4QPG.)%ZO
M_H$0:1]#+2%L#CY!UEL296C$B3/Q#A$Q<>:2K4D\VTVER[OCT'47'P%^?"R;
MXRY'CEXZ'A^T76(;ZGJMD^R(D5RT1F'VX:$O>7&3)D>:NS$ZL5CD80TI-6/6
M&(P&DOQ'U>J36I\9X; E-YSG+=/,>?WJ-.&1O:RF^/#[U[OW K)IWLY,AAB(
MJHSYL,U=FJY%:8)U^7-4'R- LN%4KBFU!E/_ %TL0RH.--&78P^0^N20D-.Q
MGH?);KPO]WZ9JAU\[<0/,=+]WSLOA_E*UAV*]*A52X$41HBY\O$)52<\I#74
M'[O!<?<<M3;27IX*"6=;AI6N9%?"%(\]B*ZB&F;=T_=^=CPX'7X73>'(_8OS
MXCQZ+*VS>4.H6@L(GULG)!5]AA1DZ/DCY4F+)>73,.-X"YDM37&(K5]K[[CC
M.7Y4E"I^(4&1B$M:H!?CG?0^/'O%N]"ZQM;O/+P\1]A<I_?%3BURKV22-L##
M-KL#E>@#W(P_!%B0P;9KSTN4WZEY?R+1>5!@+=CR)"TRYT6.XVAU3B6UOE?X
M73>%@1G<V'#Y_?.RC4CJ6K>7H0F)6[*W8C+$= 4:20(9:=)F*J_9ZS#(2(!<
MBJ&@WEA85*T-/O1S+4B$XQE4=Y;=W<KW%NE^=LM+^?S"F^+VL;_?*Y^"Y3W4
MG3O#BN,##:&9@T679F35 8<5$&<8@A)CDGS!]EV+Z.0DRHQ!4I##6<#II* Y
M/"QGR;<W3\^>=L\LN(S\KVN%=X=>'+*_//+QS\BLL:W;%CZZS>P==G$7W7Y,
M6  G31L&=*F"FBY(V.>\M+(*'$H0  3*(ASVF'\Y5"C26HSZY3<1;.WQ[].6
M5R/F+H7?AOQO:W7B%B;EOZ)49DVJ)!R"M\'@F2;L!MQF,$ED(T>MD#(B--;D
M3YB)\<184%(<;,1[,EB.M'C=BF'9% T-\OE>XN=!:XYH7 7'$?L^G3/0+8G'
M;V?;^G^7L_1V\RM)PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB
M<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"
M)PB<(G")PB@M_M9&I"HTL56W;3,F29L9(UN6["QA$0"8,84X^R-*JQF;(&1@
MD1*XJ65DBT%+\AAG+CF* #J;?O4)M:PO?PX$_15/G=YIE\YYC7+J7!KB&FFE
MD9,3):,_ P[')BR,P$W%E@8TC+2[.7,8KD2HBI0^5-\].FMBTK===//B-?*Z
MESGEEE?O]-,S:W'DLV6VN2@-TIA>K3\^7=A+4QV)%[DN,%5*;?8Q%*S&(#\?
M#*S$ROQ%*7AJ1@::G&GX#3($G'XMKF,OC]_LXJWM:XUMX=_C;X^,81OBQN T
MFHVG26/,KA+>COV08PAQ9&'/='=D]D=)@/R<N@B(&7&6^B7&LC8<#':FO%X;
MB;;J/CPUX7^'/DIO<;&WU^^NJEEJV>5KA4LS%UZ0.00<-M<ORN%M$\2%009"
M1'&(:@SX99;\ PKN--RH+#:ZN:;5.DON0(N( .=OVWUY6MGKJ$+K$Y:9\=->
M5L\[:::YJ..;JF,R3Z9]%:GKBI4V*P)<(2HAB!%">OS"40W. P\$0.(C$K*B
M:!42#$DH%15.2U'Q;Z@%[9Z_/@/']N@0NUN-#YVSOGR&?E8YA<&!OFP8<*>K
M:U\'TMXREDZR5<9"KB+.QDAI*>^'DV!(<\#E1WAQW(5K)^R0)X6&%8=9RIBV
MTL;WX9WZ],N_3/BH797MIU%M>?7NU'0J6F;S:H(;7F0U;KA"Q6)+3-C;>S/8
M&!B.2]> V.%#\HQ-?P[!LIO,J>W(D./QA0$U-6U.>@N*;EAGG;E\?H/,A6YR
MR&>OF!;CQ/P*X]7VW),!K(=EZS* (56""C3S:GH\PFM+Z7)!F&D/#'X+,31[
M,>42%Q/)+F'AV8$Y$4?ZN/;>$6Y:Y>O=^WD@-^!RSZWSR'V->JPTC=I;!J,)
M=UP] ',G@$<]*F2<R?2F#;)9$R05CMP([864%.QHBYTQYPE$?%.*,Q5NP"0<
MC+N[EJ+\!Y?0Z:^-P&]8Z6%\SWW^9&NGA8GS'WJ0E=QW&K"D6/F8"9ANDB3$
M24V]8X"IZ\3!2!4DN/G+;7(3#@)@OD#.$N9980J7 ;G2W6^1T%]/H>:@=<Z<
MN//3OU)]%EC.VGA=D.5MO6T]48"^/'/6,@M0NKYBS)\%B2^LED++2V/&H/54
MA)4PU*:<9(&?+8>D54JWQ;*]_#[YY_"^JM\[6TT^7PN/#NLL/G>I&0V)>AT"
M6/=4_"?L\<[B?$2$C$"IJMY:GSV1#GIL\<:C@2I+#D(A)16R;4EL:MV9&=:6
M&=R/#/E]+\A?BF\<LCKQOH;BYRRTZY?#ZS=PV8$U66YU"9G/3J%4CY(8/<DB
MW@AFPQK [*;6\0BNC8=7K4H(.@60M.E1%U[!P3/EM+;DL15VPSST)\LK<LSG
MWV0DC4<!YYW\!E?E=9XIL(KA%,1&'"0,FQ5HM:;$ -")1N:/@1QKA)R1&?&E
M122,J-(:<5@+%'D"YW*NQ;5>;8F3V)\>H_=QX)?,#(9$]VM\[C+CEF>-E'B%
MYVO"<;@X&TPC9&:BLL7BIK9Z*V(./'ZO@0"P]BT$5SW" NPOP8:8RD1"!L&5
MFC2<A< A7(++/77+,:9].8^/BER.6@OD3G<9:]>O%634+A'LU7R8R#=?*][$
MJ97H<.$Q/;:>)OPX'<21(,QY"8R!RHZI\F3 =DO!Y:E#!4QG(6'%;_8[_N_<
M53X[:^QB[\MN%5ZU%E.')N ""H<O%3.B937W>R7.;+O,P)U9#F#$FY$7L(5!
MGBGJVH/$)O.(;U8"U[Z9Y\?(Y'AYK.\<],B;7Y9=<K F_P"^UFZVO<VR>I"3
MXE@4>$0Q\IL;$&NP&9D9^#$EO21[<Z<^^C.9$B(\H=+1$EB8T\-@CG,F9V-0
MCB-#]Y]<CY*@DZCPM8WX\>HY:J($-@[ E6&R@:[6Q0G$7 R(%0?K<PH^V8-*
MJR6UV# .U1H[0[Q;!9)DR0PXVKTROD)PU9M6)33:PRSYW\+Z9<OB=% XW.5A
M\;FVHOUNI!4[^>DW M6KD/$0,Q_,+'%Q@^8S *X];A@(C69<\@\M#[!5,@<W
MEMF1@I(=:RIL$J)'CF65A:]^/A]^%BJ";F^E[#KG;[^EBN+<M@'P]M!5L;7X
M8H/X);,\O80KI&+$2T--Y$'1J0AQKP:_"E"?".R)++*H+!8.R3>KJ"L2:Z %
MB?K^SCP[CR0G,9<\R-.%^[6YZBY%[K!5_8UTG%@,2UU@4R+L_H#$26%$DVR<
M'!J)/6[%*8?,.-PB#BTPR"V!$TLL$&8F%9+LV ^/*86^&O'Q&6GCQ0$Y:6-N
MF9\>-[^'$E9&R;!(:_LC@6%1H<RE!0848*R,8(-%\RHLD7@P,%LLC9<6:D8!
M/!"8T-'0RAZ")MI&68AM!5Q\-1>^=S>_G?Y_!+V-K9</K;NN.'/,665L>Q2M
M,CL-.ZS7()R180V0C"2<9 6!F;-<K<Q<^QRQ(\<A%<5]6&R<E]#3K8,A+(Q8
M[PRMS%J6OQZ"_GIF?+BA-N'*_P M38?7N&:BB-S6E,B/+GZTS"A$YH?#+TI^
M4S("#Y@9N$07;IF1KD4=#"W9DK#F'H2R++-;A.$5!4J\!R;;#.QTOXF_#PMW
MG3I-X\N1[AU/"Q^1R"D5&V^:LEA>#'::]7X?>G807?FYC-M/-F& PR+@<5CP
M"TV(7DO(;&G%0AF)TY4D:T&0X*)R&(1;B/L9],M-;]+*@D\+<[_"W'/J KYY
M%I.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$
M3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X15]LXC9
M1M3FNT])!=D=\5H0@>*]5RX03"ER(3$Q*AY1B# E2V&(LF=*AIB)P\F,^1")
ME>N#:.NG'N4-P,M?OE]\.*JE-WW4TY)<BU-V<PY'=FR&S ">RZ*)I;1*DU\,
MU!R,45&#H:I4:(5E/R'#IX0J+#F8&6<20%6P^/F.>>GQL.&6<N[/NXCC?3+@
M ->)MGFL1G;VSSZ;#FI5..7<K)"/'D1@:'GT22L.V1PQNG.'"3:Q+DA%8EQ[
M<V>'H\!G"UC6X<U4!QXA+#*]Q<7T\OC\.]+G.P!SM;/4'//33,'+E8JR-;[,
MFW.Q6H)-8A); ..1&9 X>8;;R2&G3P<O!F2Y7C0426X,&N6#$7#S,J"W:DA)
M#4B6$ES90BUNOH#];>!\ -[^5QIQ]+^('?#WSFXAD^OKB-V"P,%I!:4@83"#
M8?DH9C$J'5F[.5$U)J)&C@EC1Y"PCH[X4XPY:Y*$32L*O+[[+G\[FVO3/AW#
M(72YRRUY]=+@ 6M87Y7(SRMCIVX=EP90^NRJJ+9MAMI#P$7@>:S(*M.UT88?
MSY5$J7D/D,I9E,^86=]/?(CE5Z$MYZ)/+-K97^_GSMX$'HIO'+(7OR)R.>GG
MQX&W3(#-JWV-:0]/.@8\2>:MY>"&03BR,%#U18,1YC)MM ON0@N8-.ES9CZB
M4?PGB5<>%IRY-(R<AEAPY7/0\NMS\^A5N<KC4FW=SYBPZ<,[77,7LK:V9!E8
M[5TM\:,G250V)0TF+)DXK1ZOC\#8R7GG(*I;PHL1-(/MON"W%"I<1$!3;&9[
MRPRS[\N_]GGJEW7.60TUSME\=1W:9@J4CB^R2=;B$^['B$Y^PQ$;$1VK$X:F
MJ+$.CA9Q>(!:5$(B'B0V"9.0B)EJ6ZQ'(18V("7'8BXK+X<#Y7^NGF@WK9VO
M?D=+V_;?-5O#N.[\(?6D&9G343,20[$ZOJ@ACF"$)#\T>2<S6QI2JAJI*;R&
MAJEN2S)HA-;-M%3%?ARF6UAS'77G;+G?7T4NX"]N[CK<Y\<LAP\5[D]P[,%S
MX0"35!7UC,9><KPS \VB8=CM0X,Y[PX3<N:X(5!%NSR<N63<\GDG"D5&-YF3
M!F'$K>5O+.W7UL0;<$)/(7RR^^'6]A:W5<Z!M2_P+,&J!X''CD#-R,# WJ45
M]).QU.'8("FCT=H5E$,-B/3B$\J]DBRI'G*L\/7WI1K/HEL-1?07Z'QZ\N?3
M,";V/,BY&MCTZ'NRU-\O>%MZ]'B]A9KM<'$ ((B\-FEXHRP%W!LYBUPP4L7F
M,.<[M@FCJZ3AWAYT([X,R*R0KT-&7X^#*EAE]WN#IRS%KG+0Z)O.)TR&NIL;
MVUX\[#49:KQ)V]LE.0\!&MY<0]/CN./CI@H^^C,INO2IS<.'(C,IB.1W3\%@
M*0-YF+#UMBT5^<5D+=8GPE+#GW>=KVU&M[<;'35-YW!OF#K;3AQROIQ6R_,K
M:<(O&$IQE6<)QC*LXRK.,8QE6<8QC&59_3G.,8QC';^C&,8_1PB\\(O'=3E6
M%93CO8PI.%=F.]A*LIRI.,_IQA64IRK&,]F<I3G/Z,=A%YX1>,I2KL[R<9[N
M>\GMQC/=5V9QWL=OZ,]F<X[<?;V9SC^7A%YX1.$3A$X1.$7C*4J[N<IQG*<]
MY.<XQGNJ[,X[R>W]&>S.<=N/M[,YQ^C.>$7GA$X1.$3A$X1.$3A$X1.$3A$X
M1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3
7A$X1.$3A$X1.$3A$X1.$3A$X1.$7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g945651g41k33.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g41k33.jpg
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M];?K[, :/HP?'4EQUYJ^L<YM?04]'_NBA5#;:QEU<#B=7O;XVKMM!G:+0":
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MW*O.BE:U\\;7 .:2<@Z@_A<5IG<6PO<TD$ 8(XC\05*?R@;7_P S6W_%._\
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MG=(=EN23CB<JUADZ:**5NZYLD;) 6DX(>T.!&AT(.FI7(^MN_P#P55_>A?\
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M_P"_#_\ I[D:=9^ ^JG7J'Q/T4=<$[AE3:/I:G-R7+:XYU3&7=6#Q'V;1I5
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M9S '4M/ALSVEH ;-5-=)H1D.9 U@(.-\GA<'2_26:Z S!V1ZPR-32TUE=EZ
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M3T%LNT5#3T]L;(TEHCGFANMPDIHZL.C?3.N#:=S7ME9)(3AL>F*NJZ6:1ET
M9#)(&4]2V)D=,' D />RHJ'QMERTQF<1D$.#G9P!MYA.BD8V2.NH7L>UKV/9
M?'.8]CD1S7-<W/*CFN145KD545%147P7GT ;I ()((R" ""#P(.]J"KO)/ #
MX_V7Z]?I?ZLH_P"_#_\ I[C3K/P'U37J'Q/T52VDM[[R/\P-2CO:R/%$M3'(
MB^M=XHBK3-54_P!BJU/'_8G&G6?@/JFO4/B?HN:OY+I:2V\X=6C?=Q?F5MF6
MYR-]0_Q5K5J6HY43\2*YJ*OV*J?CYM@QTT6#KTC<9&!G(XD$^"US9Z*3(TW'
M9P<G&.0('BL\>8W_ +D7_B9?_:<O_P"9U,^+OHJ?^7UO^#?JKTZ,DN&VE][*
M'6S.4 7SH19%#HU/:'^"M6.J*5RJOCXHK6(B?:BK^+E?<-[=CWL#\3L;N3R'
M'.%VT>,R;N3HW.]@<SC&,]N58A'=N4$[0!Z7(O\ 'Q=GV53)=@Y%UW=*=/7Q
M#D&/>A#<JM<PKV$4D]M;(:RRDKX)#XQ'!M6;GE77VSLN\=A=7Q"[RP&HCHMU
M_2.B#7/)W@.B#^C8Z01&02F)ID#"P;RVFMIA5-HC+&*IS#(V'+MXM +LYW-W
M.ZTNW2[>W1O8W=59WK]+_5E'_?A__3W+;3K/P'U75KU#XGZ+%F!]+6XGUTU!
MV0'EA([S05=;EHLU&OLX=;::^XRT=S+M!]9K<?LJ*%1:OVFT%)Q5\)9E$5I6
M&A2%Y,7@+?M?,ZL-/<XZ5@J*B*.D%,/PQQ2UDU()C6MK*RBKH!N1%TS'T-0R
M1[HG4 P7-HJ>[O,W1U+8ATDC6Q"+@UKII(ND,XFFAFC&&9<#!('.+70#&1$T
M/IVA&I<VQ_7=N1G31::PPZ4EA2DZ$E;;T=\9WM'07E));OL'GRPW-]6P7=6$
MM1(1!2TPL)]P8_UFJGV]C>)YI+=,ZF>V"2@Z"2!U2_IMFZ*_BGG@,QDWRV:H
MB;41,Z$N;! QLDSSG%E]:=]SJ=YB<(W0;CF&0[]NAK]R2/?+LX?(T2-;N$]&
MQH<]Q73@^F]E+&O-LQ<5;J)3UI/OKVO38ZE.%U$:;=HF6!HM%;TVCN#")\)9
M!DP 4SM!5FEC!V&9A*KM+#0],>W5))&^5M#-N11.Z??JJ*"1E6//MVDCIZF:
M"JFD<Z@E8]L<'G$4CVQR4K7QU3:?8V^0N:YXA?NL:[?S+"QPE'3XB;'(]DCR
M3 X$-9TC'.#71@ME$?-R>G6#"_W@G7.E/K[*FSD5%G:X$M^J36KJ_29HMD)9
MJYCO550(7H[FDT:.IA+-Y%@B7<%:.\I])R_\_,!,G\-J9(Y(:5M/31L>:OSP
MU>U$%<R70XACCV;D= #"R4ND_GMB:7F#6;\T'>\WD<US(A'&T'I>F,MSCF:[
MD&-;;7&/\(<2[\88-XLL;NOTBM!B:E#L32!2R_R4"=EO9J*>W,,9[^V^'R.>
MJF4=3:5ADQ<<6AO#;<*,OVIA5?5UPZHZPDG@L[YM)44,._0P,)_A#+H150S/
M>/.*^@HZ:'S>&6.1SPVHJ))HP_?#XHHFZR%S>FNN,D#-Z!C2?-6U.)6/+OYD
M\$,;!&US'%V))'/;D$.:QH](D5I;^D[W1EWY"38Y;(9>NFGL3=.;9T%VRT-S
M3-^/EJ6]GPL6XE[ ZPK+JGDE.&M3<SV?!%;MCK;,6IA>A2U<VU-[I#1FMI*.
MDB+I'U4DM/,)9*47%M)#.Z@;7NN-JBGA)D9-)271HF BE9""'GE?<ZV+H3/%
M#$W\3I7.C>'F/S@1,D,'3^<4K'LRX/=%5#? :\1@Y6O>J-N9O<J7:68HHEO2
M[+L+#6[0&3LKB;+K[<Z#%%65<PB8B>(&V=1)9CC3$DS M+]AG)GF&DE?[*T5
MS[A2/EE8QDT%;<:"81APC=+;J^IH7RQ!Q<X1S&GZ5K2][HP_HW/<YA)N*6=T
M\1>X /9-40/W<[I=3SR0%S<DG=?T>\ 22 <$D@JRN6:Z4X1.$3A$X1.$3A$X
M1?E[&2,?'(QLD<C7,>Q[4<Q['(K7,>UR*US7-54<U45%15145%Y! (((!!&"
M#J"#Q!',%./%8OZ;>_J^Y[2]&<]SF 8^:+L3I]TSE7VOJ+9WCI5IAE>KI)4Z
M^USK/-R.>_QCK"L^QC&QJWGB]F";17739.4D1T+C<['O9_'9*^5[N@:3DN_A
ME:9:4DG(B?3  -P546[-+-4VQQ_#"344>>=',XG<'7YO,71'F&F/3!5Q<]JK
M=5/V7^5I_NS?VA>6MMX3=[/!RKJ[C'W.\6JK^6:X%N;KW]"<U\K@_P";N>>J
M?ZB7VRKJG]3'[/S*[+FA;DX11E=^5M?F;_HPN% XN[_D%)\*5B*\Z?\ 27[$
M[LW8NW[A.S?HT&BA39S-]<&@9W7V3XQPXEH;"\AS_P"$=37S2.MI=$6#HFDV
M;7@C 2#C2OCK/G]18]K+IM!<67"^24FR<C(W4M+:I(Z6NE(:QOFTM0VF-5#$
MXF9U4^.J#Y@8V1%C"1#1OH[G45TXGK71VQP:8HJ9S8IG$ #HW2"/I&-)WS(6
MRY?EH:0-&:CZ^ZQP'55&S.=>9.FRE2CDDGAJQ4838$(BHIMO8S++97-@]%5)
M+"U+,-E\?\X0[GK[;:;;9Z<4MLHH**#.\YL+,.D?_J32N+I9Y3SEF?)([FXJ
MUIZ:GI(^BIXF1,XD-&KC_F>XY<]QYN>YSCS*[KEBMZ<(JU[1ZEQ/<%!'0[*N
MEE<"4RRS]_5DR56IR5W J.$O\I?B^4ZEMQ)&LDC(&?ZJ9&(.; 4(^4>2JN]E
MM]\IA35T1<8WB6EJ8G&&KHJANK*FCJ68D@GC< 0YIW78W9&O87,/-54D%9&(
MYFD[IWHY&G=EAD'"2*0?B8\<B-#P<"W(.$+WN_2>C(Z.F](B<S58PDUU;B^Y
MJ"NBE/MIFI)*VBW^9%D9*#IAPH""VW5-%/5WHHLTR#"6$1,3_(5&TM7L8UE/
MM:^2NMSWB&W;0TL(=+.X N%)=:-A#HJUD;7O;4T[7054;'.+&3-D!JGW"6TA
ML=T+IH''<IZ^-@+GG!/1U,+3ELK6@D21AS)6@G#7AP6F=&<)9XTBR F:2#8
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M@M(&]K[$]'^1ZP.\BC]9;J)J-\Z_8Y).QI55?'^E/L1/Z%Y<>;;>?_NNR_\
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MMAAIZ.2<1[@FJYX)9'RASHW-;NDS14!DDIWW%_G<P():_=-/&1PW(0QD9=@
M.>YCG$@X../UYCC9$QD43&1Q1L;'''&U&,C8Q$:QC&-1&M8UJ(UK6HB-1$1$
M1$YZ$         #  &@  T  T '!>LX<%^^2BC+KX-;?+#_I9>2WB.\>*AW
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MU"[/G:MR_,B/<QZ1N1DBL<C'JWSHQZHJ-<K/,WSHUW@JM\S?,B>'F3Q\>$5
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MX_9/BJ\Y8+A6^\O^C.=^15'\/'YYN;ULOYC_ -Q5['ZN/V&_M"G>:UFG"*,
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M$U&1111,1K(XHV-:R.-C6M8UJ-:B(B)ST+6M8UK&@-:T!K6M #6M:,  #0
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M+Q63L#G4T-,79I\#I:FI:R*!KG;Q;NJ*IX@CH:7+ZZIA<&!KBT4T;LM=52O
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MX_9/BJ\Y8+A6^\O^C.=^15'\/'YYN;ULOYC_ -Q5['ZN/V&_M"G>:UFG"*,
M_.KKYG%_!JGDG@WN^94#B[O^04GR%*<(G")PB<(G"*G[;XG8?KA'[UW"+/?>
M75(F_HH[^IL9<KV-C!SK'$[4%B*773/@=[936D:>"6V6O8FJ'>4I/G@(@?ZZ
M-K"8HW\H[Q8?XL^DJ:.H-NO=OEZ6U72-@<ZGE=Z4%0SA4T-0/P55,_+7L.\
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M3Q;[6SQ%K"6;I+JBMM(JZN&NCJIJ:IIX]R)S Q[!ASG-+HWC\0)>X/;D![2
M2,:UQNNT^P^OI:L'OC)B158S2HQ^V.O(K"VQQD+G0(A&DSLC)]'BIV(D2%2R
M-MZ12)G>HLHX&+Y;"@VGN=@Z2/:VVEM'E@&TEFBFJK4T#> =<:0"2NM1((WI
M'-J*3?)Q.QH7#5U=53EC;C"T, =BLI@Y\#AIK+&=Z6G/#>)WX\G1X'#C=5W3
M32Q 4'59]#V%OM*U64-94VHMC5U0[HHI9M+K2ZZ:?W3GZV B$F1)5C,LY)(
M:^-\LSY8+6Z[9T;FT]!LM/0;07^Y#%!2TM5'44M)&6,>^Y7:6F>_S2@IF2,D
M(>62U3BR"G!>\N9S2UT9#8Z1T=342:1L9(US6#3,LSF$ED3 03_B?HU@R<C?
MOHT=1T_6N%AMY2I]'OMQ&-=;_<V;6NMM%9L8Z(86+\:5N<I!U]@SF?%5@-4"
MWP8QY,Y1,_-:+"VR^=/GJ'W&[U\WG%VNLS0V:MJ<8 :T:04D )BHZ2/$=/"
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M@X%H7FKC:;I:)>ANEOK*&3)#14T\L37XUS$]S>CE;C4/C<]I' E<U[VC_P#
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M (R>/'J/4.Q27OZ+^K+W^YS/\'(P>SXCZJ<CM^!^BI:_[#[BK=X2+2=4SZ3
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MYRD55'71->:FF@J330/>UKXF&I?$V&5DS7YAFB>62%KPW0,<^V??T7]67O\
M<YG^#GUC![/B/JO)Y';\#]$]_1?U9>_W.9_@XP>SXCZID=OP/T536EO&ZR/7
MV&V3Q+(7P=6E(J>,KOL5%9XHJ?TIQ@]8^(^J9[_@?I]\US5_:1NI+9OL5HGF
MKBT\75Y+6IXP/3Q<Y6>"(GXU5?Q)S; ,31'JD;P()XC@ <E:YCF*0<,L=Q!
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MK0,      8 T"F ET["222_)).22<DDDZDDZDGBMW<\\KE.$49=?!K;Y8?\
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M['M>(Z/REVNB/G5LB)Q%%MW9J1CS2[OJCM%:XY+?*>A=6T])--(\>B-HM&U
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M^:9MC&>QH[1R+G<GUD-E]0-J(Y:]YJ=:93K^QF'K8QC;-^6),F&L"S6O=+/
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M4/&3N;XN6G.5*L4X1.$3A$X1.$3A$X1.$3A$X1<3NA-=84EI794EM;*;GM%
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M>'W]1QX<>*['HJB,H^O:UQ>OM=FVZD;>B'VMZ3IEKQC00(EJ:Z],U6W+LJJ
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MW7=)G<^9ZT02QZF[&/L3:VK K2-."-L5VU'E+R^J"2IXS1\J#=STH[QWW-7
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M+79:[MC @+"*C#=H(QK(,XX-#*"1EU7E2#U=7=6GK 3P1CAIZRIL;$,D:$L
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M3RCRQU<../?SZ_?CD@Y]_P A_MSX*KO2FA.T<>=QQ'7\VKSZSCVS[!<-NMY
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M'7R7L@XCZ^X/K5$>NESN3O6&#(&D%E#8YVJF'L8RH&0.ACCFE@_?WDJ1]_>
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M=G%S$X5JE+/7/,.)FCL1*>G)OA"H+2DSUI7%T6B-M\P4(?5POFGHWV0SY ;
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L(CE5?%J(O^U?#FN2>64 2/+@#D9#1@GN 6;(V1YW&AN>..>%T7-2S3A%_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g945651g45n70.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g45n70.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!'@&% P$1  (1 0,1 ?_$ !\
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M_P"ARZF__P#<5Z_Z3<?_ $<RPGA!_P!EOB%_XO< _P#5%2R4O^[4_P#R(?\
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M@/!H-Y+6=DK"3(U)F""3*%#W.-54<LL+Y)ZESWQM=(UK6-;$W2TDMT_K$D#
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MLW#&:C2;S7N6R^@S:D( =5F VB) U*Y_6QU^1O<MO1F T0<'.$H<(AIJX!
M Z9.<D9P#MGO4SC.2>N!@8Y$^_EWCQPL4?\ (GN_':@,L-LMH#HY7IWBA=.W
MUR'*J(^NB:-TJL$^1C&0,+0)V//+\^DN]D'KVP=ED;0VBL.;W8E[++U$8!.
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MHU[EN.+2A"$__E2U;TE.O_\ =[UK/T8][(VN?(]K&-&7/>X-:T=[G.( 'B2
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M=<4ZXE2&MZWPW_RA/1BYKC0W"_W1P'L-M_!G%\O:..S&M?)9(HR7N]AIU8U
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M=:2E*4ZUI*=:UK6M:UK6M:S[,UK6-:QC6L8UH:UK0&M:UHPUK6C #0
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M6DI3K6M:UK6M9^WXXV1,9%$QD<<;&QQQQM#&1L8 UC&,: UK&M :UK0 T
M +4O/,T3")A$PBK[ORT\54R]P%>3/C[J=J1N)N%OLW.=2]2].?#N+N/NR?-J
M1I[^JVSM'R:<_J_;[OV9I]9I\X[>'.<8[5F<\L8U9SG;"ZG[>L8=H-YM.O5I
MT_:-'JU9QIT]MG5G;&,YVYKG^VZ3_2G=#;<2B>-_1S<HM:74[<^J'O\ FATB
MKSTK:TMAQMB3^H*D&X?N4T]I+%W.Q6]J1)7%VFI<3>N?U%'&[Q'K+VGJ/_TF
M$<OZSO$>SY4%_&]6#AS.$*&?.^6GB.LA=MEI =]E4LK>1]FIE:#[1;BGZ^L,
M,16&8T9EJ/&CM-L1X[#:&6&&&4:;:99:;TEMIIIM*4-MH2E"$)TE.M)UK6=C
MRY+WX : UH :       ,  #8 #8 ; +VX53")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3"+F/W"OD8W62PL[P$(4YW&%N%ZI=#GEG=>1J/V.UV>Q6.X
M-I2@LV-WMDE/VZQ7$1'7PD1QEV+.:"SA@<5F,$<]^HTY\.[ZS\<3G/ZH/=DC
M?._7[ONPKF>.L25!X]4XTN+5("D/VA<8?2KL;Z. &#'[@??$#&[S8II K9BP
MT4["@V4FN0B$[9(Y= F&.$MP1\7$\^O3F,=.[HJ.0]_+S]_UT')39D53"+D]
M8F9'(NG5ZP\XEV%T-9.3>09P%VM_I;?37?(ZY1>=[O@D;9 PYYH0,U6I$$V?
MK)MH8\+:B5S=8K[0<:73!DY\]CX# &-(S@\QUVSU)Y\EB<CO/,[]^#\OEX9W
M$;7U^;Q7G-:*\JL]I&3>H> ?2;WT0\FW'BT^?:0Y?QZBC.MR)Y0E.^DN#4/I
MM^?U:8^X\EW3[:]NJ;#P$Q+S)!Z. '+E[6!Y;#93N Z@DC<\R.7/?<[]>OA<
M6C"D<6[[V*@<GKAL[5(W!>,] C<WC6I;[:;L4O77:J0)"R%U.;'B"-HKU;%N
MF%RR<1DR_6FB#ZG"+TF1(@P[3J=C+L%Q!(#=LD@ DZ<YVR3T!*/+FM>6L,A:
MQS@P%H<]P!(8TO<U@+L8!<YK02"X@;KX:+U3IT;I/<#RO&GILH[/(\T@SZ2/
MN'$7S0.#$J,Q4,U.)2NHP:S)A%5..-Q8PHW/)QU,+V0A1$+:6OG^I49D+!=Z
M/3H#NU,%Q#2XN(,>/4B_4  XG3H(( <2"!YK[=O0IA.>#+WVQG=$:1MPX8=,
MV(,:X5)?]NBG,3W.,;6-F,X>QQ=$V,L>ZPL_JMZA3+E';\=^LD8]9UK86>/,
M\;4Q?M;.0!6OQ=J9U2'+B*U F2+%M-NCUCT$C)C'K]Y<@BIF#:2G<V FY4;3
M+^NUS*[-/^C<_P#3$4;@?: B_0F7VWM/Z@<]NZ6]7*.2O:.%;W*RCQZO)%46
M#3<\U,4']#:^]1O81%(ZK(KFT?Z"&1O^\&.%_P"QNM6UTB @O^/?9HC)D,HI
M-*.2.0.CZU+2@DO["=^GZP[.665] PA"@D$R)VLL.THHG6IZH,-'"&2.%QH7
M&-^EK *T/E;['Z2,&C#='M':1T;\,<='ZNHV^5QEI8G<+7]C:BG[:28NL3HJ
M-^)CZM4Z+VZ4S_HV@&GBJ(,SQ S =H8\5ON-IT$B%U^-/D$F3),2Q3E?U%XZ
MX;A1XL.!+0<EI8[&Z*^SS7)SL&(J,5DDMS!I#4@;'C)B29>?J$7:.9]J6X@,
M:\29K>S<2YP+&YH@_6T-#G98&:7-PXG4&ZOYQ5OJ[)SPEQ.'OG?":71875$;
M&1QO%2_3?G0=A(9#&S1.^;M(I-4+6=F^3)SNQFX4FY1]<'[?-14GU,PY<$5S
M]Z-=DI-,"-2*;\G1FI$EA3+VSB=GH]?>^RL/N[9T02@<YBVBC<(3]H4#3,,N
M:Y]2#!^C+\3_ -&(!R.S_1F0=H0,Z?:6V6_5$;Z]HX;XBD%$XMC?%#:W,N %
M0V#709NK7/:6N-2/66TKO5V.<6B4"(^3/9";I(,/7Q#ML9)<"X;=(O *@H:%
M=;A3YGV$R]'O#[S)Y:H*(3<>''G0E39\!O[AIIUYZ.-$P->X5] =$@C#1),'
M/!+1VC :< QC5DEQ:[#7>SD &MOTQFIXCP]Q"P3TQJ'2NI:$PT[A'+)ZM4.9
M<7%M2>S$89&V2,R2Q-[7!<6XW7>)WV<<77P?O[:R!J>'4(W3:\X8'H@QA,A)
MDC%8N+K+(6=LJN- E-27WW9(HLAV*RB.RY)R^SVZW,^T+=[,;7Z^WD#'%Q>.
MS:XP F1NC+@0  ]F'$D@:?YR2=A%.>&^)P9:B6G,'J%*9XA&R!_K$K&U[FMI
MY.V+(GA[G.?#."QH8"[[IG;EPWK>SOCO<9&JC-W#2_#HL>2S:=?>/M'UE0VV
M<]Y>%O7_ ,K\SK<)?V?_ )S;>E?U&8MH-0A/KM .V;JPZH(,/L:],P,?L._J
M8&H:_9SU6V3B$QNKFFQ<1/\ 49#'JCMK7MK/T_8:Z$BHS/&?]MJ(C_0?I" <
M-7L:[:VZ3&#%<I[:SLG77+#]<[SR7H9 TV(G%]A"<QN:XB)8E:@[&MBMZ6M9
M>7!@)<VN2E6H:$ACG^N4)TR"/2*D:W9>UFMK2T9C]K47\@QKG$;*MX@!EBB-
MEXA;VM*:KM'6M_918@DG]7E>V1VBJ/9]B(<$F=\<0=E^1CT]_@J%ABB^3=]:
M29,D R("^26)90:L<T'>42,P6=.N#0TS1A#8\D]OX)CHXPVU^T<_F?V<[6]@
MK+<3&QK]7KD88X.+QI8XX#WMT9<P;M#V?\2U#B>/L:>8V3B9HJ*B6G$1LE49
MH3$('&:HC;J=%3R=N!%*[V9#%.!O$Y?3*[R*B;MGR<U[HYJHST#Y"HO'KI,T
M=4LD\-U+J>HH]U=E@:6SN6N8,2\TV-<9GKVF.XE>8BWO<(2*J@';-+@#6P-,
M>&AV)LN'9.WP&OP2X%HW"S?Q+#'Z]FT<1GU&41/++%7R>LDRF'71:(G&KB!&
MLOA#@(B)?U2"H1\D.YT"=RVQ5.U4?KL:%;:I"(M*+4.\4L/(]\5NSMUQ^YOT
M\^.#6UV..=@LUU\;++/G?AK_ -$W-E)4WU]QO-FX.@COO$%_L=FH(JZ&A;55
MURHF-?5U<PI*:**.6IA,W:R/#M;7B..G;+5RO9302R,ZF_7.&[6RJM3;+Q#4
M.K;>*H1_9-RHXC&R(5SJ>2N-!514U9V<)B;2OB?/)5%E&V/MI6A?6YRD]Y22
M&;AV2'8J1SEJ,K\#Y6Q.>%'Y+,G;3J;3T':/<F,6>0E.QX!#6GPS;BF7WT.Z
ME[)?FRM]'5W]-M<^\>DN&Y<.<'49G@X7X&H;B8:ZL:9&_P#O%Q14TSY(#53B
M,.MUN@!-% \:I]3IS6>ZCD!8Q[6N&MC7XD:YCVAP#@US'8<UPSAS7 %IR" 1
M@69H-*KO,0D2FA"9:1&4[*F0&+&?DFBGQ-MQ&7F83L]U4G[?!0F,E$9A/T\/
MYD^B4?-KU^V<(\)VS@JSQV*TU-UJ***:2:$WBYU5UJH@YD4?815%6]\C*6)L
M;!#3L(BAR[0T:BL'2L[1K'/8)) YS&%P#WAFG6YK2=3@S6W60"&ZFYQD9W[/
M4+),(F$3"+5KO>*?S:IGKW?[*%IU-JX]XK8++82$<6'$P&/32Y$R;*6VTWI2
MU-LL-ZWMZ3)=9C1VW9#S32\7.:QI>]P:UHR7$X 'BM%34T]'!+554T=/3P,,
MDLTK@R.-@YESG$ ;X ',DAH!) 7^>9QZMR_*GSWI88K7*L8K_5N_@9=K!!X#
M'.J/)YK-O4">;9'1AC-877 $BKMK:&:'MC3DQ;T2-#U(L)!IJ3Y*-O;U3 0T
MA\P+@ &-T%P+L#V=(TYQR)Z9<5^3;?"Z^<54\<D,$D-==8C411,%'2NHG5+7
MR!C8VPF&)T PS2&2ORUH)E>,_P"B)7Z^"J8(16*N&%UVMU\;##@@(2!&%APX
MD>PB+ &C!T)IF)!@PXS3;$:+&:;99:0EMM"4IUK/7-:&@-: UK0  !@ #8
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M1+54L-1-1U-OEE9J?15CJ5U33G)&B9U%4U=*78 =^AJ96X(R[5D#!0+X&(]
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M=<'K,3'"!<T5(H$150@\249/D"A9P:%AK=BA16YOVT.P\^T-B14/O)6))YH
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ML)Z=7RX\S#9FL:3M^([)'2)++<IG2T;=CK7IUO2T[6C7NUZD40<^_OT\AO\
M+Y'_ *3)813YA$PBBKM?4X/&>;V#H,\<^8T(3#8ABF'M1E3R)*8Q A,.2E-O
M)B1]/2$NRI.V7E-1FG=LL/O_ !,.>"])O'E)Z->"[OQ?5T<MQ%N;31T]!#((
M75=96U,5)2PNG+)&T\/:S!\\QCD,<+)#''++HB?0,G"A#Q<\JO\ B"EV4&4J
M[5:/U^)'*M_0SG9XT@+D2/I%JTI]AEZ)+B2%L(6VI3R)*'].M*;VVXUKY=Z"
M?3Y_VOSWNUU]B99+M9X(:]GJM5)5T59033=@YP=+%%+3U%/,Z)KV.,C)VRB2
M-S-#XQDYN-QY;JXF?HY8*A/GL"ZX<I50;YS%L9$!'*%%7095FYT@E(4MB!^/
MORH0S2ILL5%4@ON2E+;D5B4[!?DH]R&'6OR;_*SM7I#NO"_#S.#(+S6VF*OK
MG<34-A9535TQ=%2_9$LU-1!U544$#FW#MVM8^&.>2EEF;ED3X\V$ DDX/0K-
M>,%Q(<QXC!8\@KC JA-!<D_7Q]Z.QA]DB513,!(^)+@E)*"VG-3TDW84)UE4
MI@>]#90TVREEI':>@WB*MX&]%U)%Z7^(Z3A^O;<*V6TTG%=U@H[S36!T=(VB
MIZBFKYFUXD%4*U]-321NGBI)*:,,9&V.-APR?9&>_'?O[OP]^5OKWD\&L*]Q
M..4*^]@FJ4IMH@%"2JY36GD^J?;/N-G8'P8S>W=>Q+S$:8VM.G'&U+0C7N]9
M)Z<K;>'&G]''"?%GI%J7$L966VV3V;AJ-^X JN([Y%1TL+"\:1)#!5,< ]["
M\-WFGO('S/7N\N_*J9Y<6_RIK](%&[ 5#TBLV(G)#3:YSEV?*EBVEQM/1&K/
M='FV)+LDAK4N-].%3"$R&V%-O?,MQ+>_SY_*&XC]/=GX6H+I=KA;>%[)>*Z:
MVU5FX,?5SU%!&^'M:>.^<3RMBGDFJP)X.RMC:6@E;&62&1SPPYMT[XW(ZG\!
M^[/BIJ_1^2Y\SB4I<VNCA3<6U$8(\U#%,#9-H@LQH3^YQ%]IIM9>3 FRI@S1
M1Q3FUMQM0U+5(AR%K^F_R1*BLJ?1?,ZJLU';V07ZLI:.Y4U#%13WVEC@II35
MULC&,=<)Z6JJ*FB%>\OULA%.7&6GF<[%_/W=_7\-L?>M-_2>==MW*/&T\V'H
M#-NJ_0HY/GUIL/W]X9)H<@[#TFO&=BV@I)!:!+E-2XCRWIXE$4AH5$^5Y95&
MV/V=PK10UESCUU)AFIBVIAC[,/%0(W?I&:^T;H< 6N'LORW6<8:<_)O3!?:Z
MR<)50@M;:ZCNC)K76U7K+H7VQU3'BEJ#"*>83QOD#XW%TD 9+V+-3C,"S("?
MTA?+*%XV\_\ (KRT) /'L=U*?/U1ZUJ19+P;-!V7-:'SX0@!6G[$0^MB:08?
M?@@W1PT03"R)\R.L@TC?2WN*CM%;+2BK,S82(W2NCTZIL9D8UC'2$B,D,<>C
MPX';!/<67CF";ABW<2<2Q06 75TCZ*D$L];+)3 XAE#8Z9LSS,P=O[$)8R"2
M!SG@R85M.>=RY#U;F07LM Z'6+#R^P179@NZ-D4#PZVX[[T26U,66U ?%3H$
MN/(AD1I9B$1'3([\2=%CR&7&T]>R6.1@D8]I8[D[.!W'GC!!!!!P0=BO84ES
MH*ZBCN-)5PS44K2YE2'AL9 ):X.+])8YK@6O9(&O8X%KFAP(4 ='_2,^#O*W
M/I;3Y,\MFE=O?2IKU%.*ZC:-S-K0VB%NL\TCVT\U+=<<0AJ.\/:<<WO:DZ]B
M%J3J?64L?ZT\9/+#3K=GNTLU'/AA=56<7<,T)TSWJA=)G3V-++Z]/JSC3V%$
M*B4.)V + 2H=5YZ=DZLYN!XG^#O>>A,R4)U#Z3W)B%XW<HTR]K^@9A3;I]5<
M+,.CZ6T\N&)J\:?-3MQJ+M.T*>3K]:DDV@I97_MR@0Q^8+LN<!U :#T77_SH
MN%<=%BX:NE6'8TUES:VST.#_ /$:^I#JB9@R#IC@#G8(;RROG5XG^8GD/_3\
MP/*A-)HTO6MSN ^'4,ISRO3V-[<VL=:NT6%4GI]C'S(ZT0C @<U7ATM#;RHS
MC.I&MH>KU$W^\3Z6GG%3@L:1W.D=E[L\B &CGWK$V+B"['-_OGJU*[]:U</-
M?21.&^6SW&;56S-<"&R1L$+" =)&<B[/$/'CB7C=5$TKAW-*MSBOJ4TY-9 0
M-)(FI3*-MMS[(>EKE'K,32WO;>B9\D2G_'Z-?4?'I*=<F*&*%NB)C6-\!N?%
MQ.2X^+B3XKTELM%ML\'JULHH*.(X+A$S#Y' 8#YI7%TLS\;:Y7O=C;.%,V;%
MV*81,(F$5/O)NU-I,U'G]<ZQ.I73+*++JJ(6!9QM6&"),J>*AQ.L7J9(>9DF
M*_2W&)T0'0'521O2#I5X')#$VX3Y>K9 <SC(Z[?+P\3T^1A\\<_EU/EW'8J1
M37>P@+HC= (#V([BKX&I3A20:C1TM(,<FMW4]&MP5Q?E5'8;JC@'Z?3VMO2)
MJ9B9"?@W#>F.9[OS _%"<$>/CY_ELN?U'[MW&Y4_F/.$V>PQ;D4[1QFXWZX/
M,)8)M<M[*2H?7@G-Q<I3"4-RUUBU7JM;E1D2=CZIQNP")OTSIP3/WD0-_(X]
MV02?AGS(4WVZ;C/WX&3O[ML ^ 5@>Y]0DB^C7,84NEVKC]55QX)S6I4.RUH"
M<*F^BE"<=[H<FO6(H)1TX+L[H32=5-[[R,9^T6!Y(9<R2\0' -N0WSDGD,=/
M#OZ=-T).3SV&PY9[^AST&V^=MLJ/[;Y/W*)9.M]"B2K,+YG*X9W!?'FR(90Z
MHV$[RV!6"=.NP _):2R6(]%F%.@2H+K,M8UVCU^CSV669,PHM<P-AMDD9WW&
M<[8\-O?WH3S.^,'J,'X;Y/PQXK#5OK/18@*_\V"W.RVBU62PU.@UXM0+5-[_
M "*H+&4\.<[+U^MW.6"$3YDV!#M8(*S5I89X+2.@SJ<M6Y0VSS8\:XW!V&Q.
M" WOP,<MSXY(\D!/+F<#D<YVY\P1G[R-SE7_ .%6^??N,<LN)?Y$G+!0JM/L
M33R-MOQ;,L/$;LL*0VK2=MR8)ULA#DM[2G:'V'$;UK>O3,3L3YE4<AU\>65*
MV15,(F$3")A$PB81,(F$3")A$PB81<UO+J<%;[GS)G:CX$HD?S0#8K2)[[TS
MCI*31.I]XK/-)0ZH J 2$1KB2K9,PBU6N:<)1(=;'MUM"V9RC;&X.;1L?>>0
M.X!.^0?(=Y/FL3S'NZD=>F"._?GMW;9MEXTGX=EXS6"0]TQ*AL%+R#8(F[R>
MZ7*-(J_0+36=V&%?+,X\=L]?L2A"CE5)3W%K56" AEG>HS3.M8G8_#ICIW=%
M1]>[ZY]5.^15,(F$58_-'9'7BAY ;&;F:=UR^S_6[@;?U*T#^A5^2;;W%]).
MM:K_ -SV[MC>G=,_)M']+6LK?UAY_P /FH>1^?EU^2BJAJ#CO)/LRO'4+SHL
M(1XY\!>D!@QUBI\\F6QRZ]@0#^YG:?6;>R-*[H.H[K3T2M%9SX-FM,/M-C71
MLID>0SGF[\/QY^:>77'EY_#[@MTY(3ZD_P!2\GI5FIM&$VN.+Y:Z""UWHART
M B1%%/L&X<0A8BO-:7.&1WW6QZ)$IJM$=QDRI*VVI.XB$R6V!W[Y_!7KX;?C
MG\%/$<MT];?+]R:=5F73+"5=;0W<9CJ:-(_%I$U3-15NM(_-VM6Y$<'I^9JK
MJ^U.;,?!\GNA-3;\MOW[?-%Z99?J[8KJ#\.E5*08#/S4\E@.W6:S$N\=NN#Y
M<%VV3=5=:J8[)LSI$2\S%CV%+,&*S.^96GM:V4WW^7[U\5T FKV@%1[/1:P;
MYU:J\:UTQZ3:9[1"OF8B DJM0:W 8!-+/LRB2BBW#:B5;EAE"AY"-'>D2=1V
M>FXBX>LW%=EN'#W$%#'<K1<X1!64<I>ULK&R,EC<V2)[)89H9HXYH)H7LEAF
MC9+&]KV-<*"001_#;RW5-JMXY^0O(!O4Y_$9W-:R1(VR<U3@AAN2<(V*G0RS
M3=?>/74G$FMUZ0@3)FS7A$.M$VM36DLO2WG)2)D/\[<)^@;BST?5M^' '&O#
M_#%NO%>Z5LM1P?)Q'>F6Z*:0T%%45UROD,,@I89':A!!3QS3/DD>TN#'MS+@
M<;<NF< G'O/CX>*F%SE?DW/N\88;\@"+_.W:K-ES;'6:]3JE8H]N;+06(8&-
M7T5XOI8B6$>)3W+ NR;E1)T6-"T+>0]J4CV__9UZ3*LXNWIRO[XR #'8N$.%
M;"0-]6B;L+C.TD$AKC(\L.#DX 4U#.S!RZDG?R(Y>_*XF_I=+IY:^+W(..6N
MOVGHS;MUNW3@/1+#/OLKH]9K441-@(Y9!C(55ZJ %S+U7WBQR8Q, /[C3PSH
MF-)=TP\N3U=R]"ELE:QU^XU])W%<4I<)X+UQI<(:#. -#:*R,M,$3),NRUHU
M$- U<\_-_2-Q'?N'Z.W36<,ACJ):B.KK#3QS]BYK8C31#M6OB:9M4[@7QN+N
MQT@[$'Z?T;"_TAW8N  ^DU?BWA.2B.&3D$#U;R1$]'$WRYQV)VUK.#1-  $
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M \&@UF#NNI1;H<\NZ1@S9TR56G($*+&((B2G)2H3%VWY^&WW[[?-7?\ /?\
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M(A^(B17?O^MUI1_1Y"QZ9C;.Q^_'?CN5SX'X?CR^:C7G_ET)N@>CVNPB7.5
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MY%$^;DQI'ZUNA32TJ.6@]7(O1X@7AE16AT"#1,GDJZ]6C#]DGV4JVV%:#.P
M$XQUSSY#PYY/QR.7>H2<9S\MO?U&-\[_ )*VG6.O/<T*<YKHNBV&_P!FZA8#
M5;K8<!/KHM+4T'4C=QF2RI*S%A$"$,:%@IFWGVWI,O2M)1%@S)*VHSL SG<#
M SOY@?BJ3A50UYBGR?:_'E(T5]HXUT^HFH%]&'XD+=II-^D]$?Y=6W9),;-F
MCG(+'3(4/GDI,.9)@S9EK&E(KSK+:5)NG8]XQ[QN?NW]RFK<=Q^6X'WG!^(\
M9&X)WRY=:\AO(JJRD#$<JIH>AR^3NQHFD$BK&KAU[FMY.SY_NW]9"(WKE)Q%
M>^)/TRP,2 0CN.I)*7L0 !WG.?D1\BJ#N?EY=_QRKGYBJF$3")A$PB81,(F$
M4<=#X[R/KK(N-UCEG..GQP;LM\(QT.CUFZLAWIZ&&YSPMJR"R:![LQ$6,B6Y
M$2RN0B.PE[:],MZ3@^*.3':1LDQG&MC78SSQJ!QGKA<.KM]!7A@KZ&CK1$7&
M,5=-#4B,OP'%@F8\,+@UH<6XS@9S@+E)Y)_H-/$;R"ZL+Z:(?/<.AJCC(=NH
M7(0]/KM-L+ I"([4L2)2"W#J)F9#0W%*3AL65!G;9:GJ$MEG2!"?P)[93S/#
MVDQ; .;&&AIQL"!C#3CG@8//&<D^&O/HSL%VKF5K#+;&X8V>EH(Z>*GE;& T
M&./LM-/(YH#7N8TM=C68^T+GNZ+47Q \5.:2*P0HOCCP^M&Z:T/;K=G&\MI+
M-N&/"XR(D0BU;/LF[$LPEIO2GC#I)PI*?4[(DRW7W7'%<QM-3L+2R")I;C2X
M1LU#'75C5GQSD]2O74O#]CHC ^EL]LADIPP0S,H:85#"QH:UXG[/MC)@;R%Y
M>XY+G$DE6,S<NW51+/XNDBSEJ@ .C1@-4LW;0GD*Z G4G1]_?1*XY6S8H<4)
MKM(QHGS]R]U$#<"E=9%C+!*6S*#P+F)AO1G(66>\9P,<^GPYXS^2A'ESSN.N
M_/EGG\N97A=Z(<C=6*G84*S6"6?\7.KA+ 584?D@R=LC3^80J^-%B9,^=7JU
M/*QXIJ8/ !M0?K7EF""VYDM9*<Y.F.6X_'G@9.$[^I^O@HJE\8_'.2<SZ-VL
M-8.E$N5\"JW,Q7(.=TFPI(E9)LORLL7K]OA!S%MEV^')L7.Z@*.H<'CJ="KK
M%LF6,/-"D)+,"DY)QU.>8\<'ICJ@!VST[L_GO[_DMTY[05R!'C6";KYHJ#KM
MOZ9>K.0< 6.EURHOJFF+6!H4&JWH0$M"*37KV>K/ZL(K@R'J"-Y=69:4-L04
M,8SS\0 /'D"3XD9W\3OWL<NO/[\_#;Y =5B_'LGSNK7>SEA]?NW,A]QDU;F%
M0K-KYUU($9O).MR[A-<Z5>3EFJ\.&?Z!?%2R4Y<V41(GHU-!#R]P+-D9\T+6
M1R1WXW.XVSC8> \-M_B',YVSR\<=?,CISV4SO<*LD'I-_P"ATSL]NIB.DF:P
M<L]8B5CGQL4]-K%3!4UCZ698:R2,1&Y@BOQ/JD-3]:3(<>=8^+>TZ3BJL8WX
MS,1"\R,*ZET$/R\CTASK$[DPS\9BA'+?*M:;X5B1[,@#JZ0J:=O&G;4<J<8Z
MF//(3B8WZQFKD95><N? <L9^CC;R4QXGGG&W/.>[[E3=BDS!)BRP$\]-VJAE
M.A [CVPQ.\?+%5[Q)9F]N(E2U*-R(C)E?<:GMD@R?(MUQ-C'1*M7OJY+LVM6
M8:.8R]^^"!OX<^F,]QWWZ86..?/&<G;<Y)V///B1T[\JX/*N7![IP^O5GH "
MQQ0L.[='.T\#,(V^DF0M)D=&O:^6CI<0>0 V 4R,YF6KX]BM%OA<$,-QH$X=
M'FCD-Q\<[YVY#IGIOS'-9#;Y_?M^Y2L7YZ1'<K+\[Y)9U\V*+#$AE4MI*$0Z
M$]5)A-]^0X8^AL%@CS#LN([+DOP&29WZ=B3N-\B'X,;4!QUW^6!^'X*J'Z!S
M#NO*0-)HM>M/(2=;C65S9TF(YC;JO/@ WJS>2)P\;79>U=(*W^Y6WHTNG$"1
M1PD!GOZ=M90N2)3"3*XHD'O^(\/ 8&.7NZ*<O+Z^.?S)*U^D^*UC14[?0.U7
MZG=6J?0YWY%T$G7*'T;DW3KM<V"P@H,/G>B@N_FW6((M :$+@UNO @(F #@B
MJ\)2,KL!0>52[<$#&.7([?#[TQL1SSS\?AA;ES?QA!<RB]_BA[A="J>YGI);
MWVRX=!N[E7B.\XK-#:BJ<O-YL[M@*HD@IA>5:'G!APD-FAZG.D.AJA7OIIGE
MRV\/'/3'UYIC8COS\_WK93?$$F/&$OXW?DVXR2O!I_$/S+[/IY3"9W/7:'^3
M?C_W1K3NVM._=?L_WIO2]I^B^Z(]?J],[Y\<_/*8VQX86F7KQB3=;O-N6[LH
M9N9OQ+W]NU7-3/C_ .%KM5J["C7U?WV+[_SG=GW75_\ +)_&TPONNOOVY.QK
M ''S^8PA&?E\CE:A4?"P)3C+!B!>9\K8[O ?J@"-.!LNIKG/:R.O;-3XB&<;
M*M*8K-7+])N!4,7=2\]':++&J%+;;:D(I=GITQ[]CGEUP,_>F.6_(Y^\8Y[8
M!_<KMYBJF$3"*#^L^.W*^U3!)*]@Y$HH&9W$B$QQ&6+FN#MO+D;&2W8JTZDP
MM/N.O-(<1MZ*X](5$>C[DR/E^7>D#T.<!>DVIM];Q7:I:BNML?J]/6T=944%
M4ZC,CIC13R0/:)Z7M7R2,:]ID@?+,ZGDB,TNO(.(Y?-2Q7P :JA!=<KP]@4$
M"PF!PP?&TK3,6)&1IMII.UJ6XXKTU[G'GEN//.*6\\XXZM:U?0+1:;;8;906
M:ST<-!:[92PT=#1P B*GIX&!D;&EQ<]YP,ODD<^65Y=)*]\CG..).=RLQG8H
MJ]W_ ,;*-T4A>)10O<!(WI\.I0^DUVN%!PP5=4TEQW8!XI*<#2K% ?;C*C#"
M*JX>!MF1(Z"++MS83;K+]R1[N1[OP^2F/GCY9_-199_'CJTGN?%NGQ^E![H(
MH-SB*=U=:7[[A7J>YRWIX&X/Q#P&X5NM2RE]M-MA_<6PG/0,: EBE.;@SP?.
MT!C-R,$8Y^/B,?#'>>O>F#G.>[W<\_'/A[\;^KF_CD>K'+:!*MC&KST+F,;H
M)^E\YL1>O1N?B;7=';+'>2DL)J3I1^4JMV,M76"!J581X]!PF\W!7O45Z()!
M)QR.-^N-ORSWJ 8'?CEGSV\L[=^,#N61Y9X\E6B)/H%F)W>EWS5WOA*KGE':
M;8NAKI%]K7-AE@KW1I^P=DHYEV58.=B9P9 >$\NOUNMT85&+:D03:)XGP!&/
M'&V?(]>O7*H'WG'?[^?N\AGDISH/*(7.2J4UTX6CT@7SRE<^JO/=R9KH*O(J
M9"TSI]F4N5/E**6>T(/CH9@P^PS.D1Z[!W+DSGGG'40G//GD[_#[E>OP_'Z]
MRP@/QVYS6;7/N%?E=*#D"EP-7PB(@=HZ_&I4VT6(I(-')TGG[=W31WF"A.5(
MES!BZ_L6\XZK2X>T>B=,_=A/KXK"P_&'D]8DO'*M6S#A$1&M<FD5DET:]NT6
MG&+4,*0"K]'J9,N>J'/9!1@N2'?=*S4T/!!I8K%$1&8,^</F,GKX=!G;[_(G
M!ZJ$?CUQS\OO5<JGS;LU1G4XY&YI?SU!YV^L-5.1W+H',[)?!3!7DY&IFB@N
MR2+:W5'J@V80'%#A1.T,FH8V?9R \'!@NPJTYD2"#RR>H! Y@XY;^>% ",;G
M;IMW8Y[;=W+Q'46:I7 Z4KDG&Z/UJCT'HQ_FG-*=37"-HJX2UMLD0U9"B#;X
MF0?&RGV(Q*:*2^XIM+"I26XZWT>]M.DXY.21D9.=BK@8 (!QX?GE;O=^<-6J
MM@@%>M-FY@]5"@@K5RO/G10U0E86)('11+P0F*+5<Q6'ADN0.EULP$FB]QU,
M2(34$H.%$8,^?FKC]WAY*-(7CCH& &Q*IU[J=7MT:W7*\&K] D4V42N)^_N.
M.VA=JJI*GS.=S82U_1*!Q8E0@*K:A(W[0^PA15!2Y[P.0&.['=U^:QT]Q///
MQY[<O ;;=RU6?X=UEVF_JW$=1ZV!YV7H+'-[_3XYFM%1W0J^J4=EFYA-ZPU0
MM,K-DN&[,>BW ]07ZG),PB"4:;B2Q8*:*:NN!G.<[[?/ITSE7'PQC'13[9><
M!K1;.86^7*(19W*31\X B0EQ409DBPTP[1Y3!1#T5Y]R-'%GY4B*F&_#<3-9
MC+===CI<CNSO\?S!_!7N\/R(_%0,OPSYJZ$* GCMS<CD^=] YXB4F>)8("V;
M]U!_KJK.)E1PS2H=JJMQ<CS*H0UI<:!H= =E0ILME4ERY/W?(8^[FL0W&W=G
MYG/Y=WY29S'@=+Y*:08J;Y="6>1\NXTP.FR(C\-JN<H(7HD$)J<1"9FR+ 5E
M= ,.6"?)E.M3W6(DAN-'DJF/2Q)//O)^./EMLKC'UY_GNINR*IA$PB81,(F$
M3"+4_P ]HOY-^%_FE3_,?;[_ ,3_ ",/^3>SXOG]_P!A^L^Z>WX?Z[W?2^GQ
M?UGK[/VYK[6+7V7:1]IS[/6W7CGG1G5RWY+KOMBT^O\ V7]J6[[3QJ^SO7J;
MU_3IU9]3[7UC&GVL]GC3ORW6V9L78IA$PB818^26%PYPT9,)#XA(RJ4@0/DS
M(S$XJN#'W+FH&Q'7$/SE0XB52I28K;NX\=.WGM(;UM60N:"&EP!=G2"0"[ R
M<#F<#<XY#=:9*FGBE@@EGACGJC(*:&25C):@PL,DH@C<X/E,48,D@C:XL8"]
MV&[K(95N6LV>ZTVDQH\RYVVLU&',>W&B2[.>% (TJ1K6M[CQWRLN(T^]K2M;
MVTTM3FM;UOV^F]9@^2., R2,C!. 7O:P$]P+B,GP7 K[K;+4QDMTN-!;8I7]
MG')7UE/1LD?C.ACZB2-KWX(.EI)QT68T3&['?>-$(.Q'T6R7W74MC8[[=IGZ
MG<_Z[Y/IOHM1];D;E?+\&F?ZWY/C_I9ED8U9&G&=61C&,YSRQC?/+"Y7;P=A
MZSVT7JW9=OZQVC.P[#1VG;=KJ[/LM'M]IJT:/:SC=8LE9:F.!L6TN?KL&M--
M0R$:S$BHV*#;9)I1%'SF#,I]$!#1!!!N/#DMR=)EIFH986YJ2E*\3(QK.T<]
M@9@'67 ,P[&DZB<8.1@YWR,<UHFN%!3T8N%174<% 612"NFJ88J,QSE@AD%2
M][82R8R1B)VO3(7L#"2X9\J[;:K;XKLZIV:OVB$P[\#TRNF1IN*R]M/NTR[(
M&R9++;NT_P!+XUKTOV_M]/3#)(Y 3&]CP#@ECFN /<2TD92BN-ON4;IK=74=
M?$UVETM%5054;78SI<^!\C0[&^"0<=%D81462=(,#B4">^(F[&E684R/*=&$
M=1X\O< @VPXXN%-U%EQ9.XLE+3^H\F.]MOXWFU*R#FDD!P):<. ():< X..1
MP0<'?!!ZK=%44\[IF0SPS/II>PJ&Q2LD=!-H9)V,S6.)BE[.2.3LWAK]$C'X
MTN:3]^5;EI)3I?.0AK=<-7^DB+#I4=&P)2U H!K2Y;:'HJ=BY<]J=I4EEUMV
M.G;'J\VXA;>E)6G>];IH6NT.EC:_;V'2-#M^7LD@[]-MUU<]\LE+5>HU5XM=
M-6C0#1SW"DAJ@9&AT8]7DF;+[;7-<SV/::06Y!"W;^W^S-B[1,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A%S5="A*)27CI4'1NQ< +]?_+HW4*V1FUGL]1LEAZVF3$)E-+B*_+9=7NLY
ML!))AK'7["H)#V/< 2VF9$-_IRUL49>YL512.G+Q,PN94QO?4?K' _2&.0AA
M<U['EHP6G!!^&NIJ6TVIU944EIXEX.J>)/M%E_H9I:'B>VUU;Q'KCJ)P8C]H
MR4%UE;125%-74=8:2/L74<C&/B?(U9ZCTLCU,=P>59'UVJC]-Z/9KV;^VB-3
M#/$!H:&?YTV^T@<D?&^^3NC4VL/D(#$2;(<I=D^-W4E$QQ>YD\SIVTI?[<<T
MKY7 -)=3-:'Q C3@%YFB82W!_1OP>:[RAO\ ?9^((.$9*YYN%JOU[KKO5=A3
M=K4\*04T=990YH@$#/6Y;W:[>^6%D<SC;*[#A()7'6.17_J4:!XI76X]9.6N
M-W&KV-=V"F@--A5P0H5R\S?!I<$W7JX(-1)L-\%M@JJ69(1RK<V6XW%@);@Q
MXF%/)/IH99)W/%0QYE:YD88W$+I&N9H8UP(T@.RXAV20&[ <#AR\7]D7H]NE
MRXBJKA'Q705QNM+54=LBHJ<TUAJ;M!4T;:*BIJJ*6-])HJ#)53,J6RR.;'"!
M"R+&4OKW5&[1SJ:_:.A'ZKUOG/3[-",7@#R8 !+.5ZKQ+36+1SFK4^>6N53%
M? _IO0>^D"<F4*GP'":EFF9#JL8ZB<20DOE<RHAG>#*R!C7:(Q(Q\+(W.D8W
M?]64N.EPU9<N-;.).(6U]EE?<+U66_B.QWZNBJ;M1\.4=)4NHK?%<*"X62WV
MR:INENIPQ^DTUXFGDD@FA=.7537.6;H-CZL]#\6IQCM5ML*_)2ARF[3!6&YU
M$>J)3?)7^@1;?0_H*6RB"X$(04@B3%C;LHR>LU%D28B)2&6U9Q/G_H1=4O>:
MR-VL%L(T.[ S!\6(QIT$:"'!X.H$C(7,M%;Q"Z/@"6IXIN-:>.+1*+A$:6R1
MNMU0>''WF*Y6CL;6T1.I9HO5)F5K:^"8U43Y(Q(&@Z5Q:P6.A\V\1OIRY*U1
MS-?[2?D#3 ^MR)B45_GI,D+KP*?!K\,B.A)GP5/)<0^\5ENSY4>>1FP-QH4?
M53.?%#;\.=('LG>0X,)]F N#&.# 0-0)YZB20YQ& .JX5K*VT6+T<:*F>X,J
MJ+B>L?!4PT+Y *.RSSP4-'-%113P1":$N#@]]3(Z:2.:>6'1$RP_%I=](0>-
MW^Q]QCV-'6Z9JPFZ$<@T\>/>(%:W$L\-KDS880*/M-51+KL,K%,%+,J:#2X2
MGK8),;DKY=.92*>5]3J[>/6Z%XC +G,#P(-+6O'9Y(<'.?ENYP1E>SX7EN\T
M7#-XK>*V5PXCM?KM59ZN*V00NGJ*&.OC;PZVFIJ>L:VW!SHJB.IJ*XRTFJ>8
MMG9K..<BLD?)SL[I>LC+C9J_Q7F+O*ZX=>@Q6I0(F8OZ;HH-))1Y<6#HA8(H
M2 ?))C.*2B.&C2MJ9^!O<.#65&6-DD;30F%CB!EA=*)-)((&IX:'NP>3 5I=
M&R?CSB=U30P7.OH^%[$[A^AJW11M?1U%3>!=#323QR1P]M6QTL-9.&.(#*6.
M0EFAJA8[>:]_P_1.4U6B6>JMWOMMXY"9H58>)="+A:N N9@EVQ57CA(JI3U?
M2$A'PPB&-C-P0S9\8TPVQ":2AOC/E;ZJ(&1/C,U3) Z)A=,YK&R.=4Z-(R6Z
M ]K0T8;K &&C;R]7=J+^9T?#UOM%PMPNW%5UX;JK/0.GO%52T%'<ZFHXI-!'
M2QF1]&*2*LI:>*"-L5*VL@:P,A: -6+V-<OQAZ!RJ$()#YW*>Z<>!U(%?@9>
MM3'.=V3N5&.\P2:$$H2"481$&R9%,^34%6Y$:J2'X[+J5HTO!S\T,\ :08*B
MG9&R5KF$POJH70ZVN&H-P3'G&X82 NOJ:XR<!WGA^&FGAEX>XLX:I+;27BDJ
M:&4V6NXKM578154T\0G931PODM>H1'7';I'L:X$9E0(>=X[V_KUNZB)HU9E0
M?'*%<HX_E6Y**Y/JU*LYK[E(L_W,>*(2+O(*F(HRM*1 W#?$;?AQ7GY;4EIO
M<UQIZJHDF;$PBD;(&P9T%D;WY+\AKC)J<&L.G!;L#G('H*6K=PSQ7Q)<K_3V
MF@DBX)AN3(>'NT%%+;[77U7;R5XGAIYGW5]14QT] 1"8W4VN*-SY1(UNJ>,I
M^=1^H5^#8@'0 )7R$J90Y?Y%QI5HJXI??!I,Y>ID4'.L,&)%G-SJ@?/@XZ(#
MN]Z$\V!IU&2A:%YA1.,4S ]DK75;"Z4R1O8WUII=*0TO !S&Y[1C^K"W/,+K
MN!*V6U7ZBAK:.\TE1QE;JBKO#[G:J^WTQXOAGJ[M+'22UD4<<HEMU95TC!"X
MGU:R4GL '*Z#UVWUJV+L#=<,12RZM8I]3L"8NW-_:[$+;C.D!3^W&T:5(B(E
MQ]/;:VXTE:U-?)MUIU".U9(R36&.#NS>8WX_JO;@EI\1D97V6BN5#<36"BJ8
MZ@V^MFMU8(]7Z"MIVQNFIWZFMR^,2LU%NIH)TZM0<!SHZB6,@K]YIEHW&ZCT
M\##'<UW8"-E+,LJK@][E@N/-(?84U4^1-BQ$%Y\^68&RX4U4(=(;AH<EJ95K
MJ9BYLMQ=V$<S V'6Y[A[ [ 9.C0XO:T9<X @X!QOA?%+]45-)>?2C4LX9MM^
MHXH+$:V:NJ6M-#"ZP0,EG]4%OJYJJGIXG/JZAL$L,O90/$8,A:5]TBP]E%3!
MW%N;FNEV*-R/@'*I82U<W_4BMNY60T*-PX5NN+O8K#!DSZ.K5:C,1!M3^9Z3
M\QAPP=;DI#^ZE]0W33PNF>(*6 MDA]6.M[FN#9)/6' F/V-@S.<NU.R&K>^L
MXGIY(>%['57VM9PYP?P_)2W&R?S4<+G755/51Q7*Y.XFK8I);2?48V1P6[6Z
M0NJC4U8>*8&21]GZ_P!((=&65Z=KA97D]!YF3=#PX]')5%JUV?GS%WLQR_$S
M8T\LG2QI1Z56$?CU@"PD#P)HA',/S5,3H>X/J)C-JF]6,$4+BT",L#WQ=I(Z
M4O:[,;7$L]A[1ACCJSR[N&OXDOD][-1?OYI5'#MGL<[J:)EJGMK;A7V9EUKZ
MN[SU<%8:BUP5#Y*!OJ5;2Q"&CJIF53I2R:+1K/U;R&M%NZQ(YN.NY)[EM@K0
M*L"JC)X7&Y2;5^)56V&)70)O0[.,Z'(@6U!Z4R')5A$$>(!)&3Q<LH8260C5
M)45;Y)^Q;(XP/8U@C]6$+OT<<CNU,L@E(DUD-+-(:S2YI<[4NJK^(.-+A<>(
M7V.&ZSNL%90TE!3VZ3A)G#]4?LZWW&JDO,MYKX+T^&Y-JY&TL] (8::D[":G
MDJ*D5&G[;=?NL#J]Y$]9A=8.1?U*]DD@*USK86D.5,X!A1*'*>JYMQ=:<M,T
MA8%626+$S85D@R8$UV [&2^[MWYZ^6<-JYQ.\>K5!8R$MB[-S0V(ECSH,A+R
M\M!#P0<86RXWCB*&BXUXBBXBJX_YK<3R45!932VHVVKHX8[3(Z@JW>H&X2S5
MIKI*>"6*NBDBE="Z/4[5KQL\O<.56#S0MH*]G9Q9/3.*U6#)L\2JRPE?<Z#5
M^.AE7.;%'5P.Y(71A=C<;'QWI>A+P@1&^_1",Y<\R_BYTD#KC(V5^H34T;2\
M,+6=JRG;VI :W)C#SC?3I:-0)RY:)JFY\/UGI0N-)=JN6I%]X7M\,E?%;Y:6
MB=>;?PU3?:DL<%%3.>;33UKA"QTGJ[Z:FC%7'/,9JE^8ZW?>J\;;ZQ2Q'4CM
MNE0^. >DUVV6D/39%EIAQ_HD&G38<E &N 09(-88TIZ>)BD0VY<1\4998FN1
M=L(A9SRSTXGC;,^0BG;,R1[8R^-_:B,@Z6-:0X'+0YI(TG!/3E<17?B'AD<1
M6NFO]7<I(N&:2^45QN%+:WUUKJWWJ*VR12"CH*.DJ*:LCD=+31STQDC=35+&
MRNCT"*\U1!DJX A""]K.78C'5*<E66QL@XQ8@Y+F/R_:['K8<$'CQXFG]0H#
M$08SMF!'C-R'94E+LI[LF-<QH:Y[I'#)+W!H)R2>3&M: ,X: -@!DDY)^KVV
MDGH:.*FJ;A5W69AD=)75S:1E1,Z25\F',H::DIF,C#^RA9' W3"QC7ND>'2.
MV3,USDPBI/Y0CTF>J>.8=^A3>G0IBNN.2:5$-# >B2HE: NQY;LLR6"C%:&.
M;W*0A^:ES>];TPA;F_;OK:UNJHHVF,S ^L$Q!P9JPQF#ESFM]GGN>FV^%\LX
M^A]9XAX)IG6B6_12?SD<^U1U5/2"<QT-$YDCI*JII:<^KDF0!\N<_J N7E=.
MAR?%_E]9O<#EHVF4'[P;A7GG$@T(?ML$X:2[!I94+88UFF5B1%GEAX^-88>W
M9CL(*:0<V_"17"T619)310,E$ CBU.$L.IID:YV1&YKP\L(+@T/'M$-=KVT.
M!RNEZDX#L%!=HN'X+7:/6:N*[61U52ON,575!T5KJ*6LCKI*!\<U1#"RMCU2
MNBIJH56J,453&_Z(!+NVO(7C0FU7FH,12O#[W9;?4ZY6;%JNO%!EBYG'(LPG
MY'0'8\R?&?.)C5NT2Q2UC1C9EEP3.W84N"J'50JZ=LDD8#J:5\D;&/T:FOA!
MP3+N1KPQY&P#LM)=EN<,W%O\\^&*:X7:VLCJ.%;O77*W4-!6BB=/!6V&.=D3
MWWES)9HWU>BAKY*<F" 53332^N T^ J_;>S$.'\XZ59K/R@,:Z[+K?V$<(YU
MTFSS@HV:#+E)\4!2ZZ=-V7I=MFI@,3&AT9ZK"ZX-T6GSYI>,)]9^+*BH=3Q3
M/? UT[FZ0V*9Y8TM<2&QM<]\TAT@Z1H#!J)+@W?AT'%7$\W"MDOE=7\/4U5Q
M')1>J04UDOE?-2P2TE3/-'1VNAJZNNOMQE[%DK8&.M]/10"HEFEJ64_Z7RA>
M076S?-81D>&88(#.OV[FU]O,3DW0SR*Y7JU%(R8%P5Q*,6C="BR3+^@HHD+?
M*S$U:3+F$)WU4)IMI,%5.Z$.:W=M1)#+**>5VAC 7"3U8.[4%WLM<"3H))((
MV5BXQXCJK%%504K&30<27*R7>[1\.WJL%%14,<\D-R/"K*F.\Q253Q2T\\#Z
MF46^226:;7$&L;E8WDN<K RB6Z^D>=G*!9:=V!<VUT+1EJ$Y=N8IFV0;'92<
MF*D!562C ;2J=4"+$TQ7[8"EAU&)^D:T[?77,;%)*8G1/CJ27Q:L=I!E[0-9
MRW7$U^6.!<V1I;J/7>SCJJH(+1<KQ/9:JS5UMXE,MPLXJVQ&Z6$2UU.QOK<I
M?2^O6FDN!EML[):FCN-))3&JFP [$:ZQY*$=V,8A_E%5/43Q^Y[U^T12E,M1
MGZBUVA%_E$:7&98O@K8T6QJI,CWC+KQ"=">:D/-#Y^IZ$BYV]8[6W]!&^*DA
MJ'@QO=F1XE+HQB4 -'9XU;D') .1IXXXBXXG]>@#N'K?66G@VS<25\<]LN%3
MKN->+Q)-:V-9=Z?L*=GV<V%U4Y\TL3VO<V&83 0>GHWDM>X%;A6VH3JE!3'X
MA7>P2J>CG'4.J'I<@V'('-B[47IBA-?Y56'8T#<$59CTHK()2/N))<"&-!OH
MGI:V01B6,Q@"F94&/LIIWG4TNTO='I9 S& U[R2?:<0UK3G"]\=7:&ACN-ME
MMT09PI0\2OM@LE_X@K)7U=-/5^KW"IM9IJ+A^A<R'LJ>OK)*ATS^WG=#%!2/
M$VP$>O=LM1KIJN=RN;  _.N9\XZ-%&VVM6$\2L4FYUH_8I%;E&1MPK\,)#0@
M(J,DTT))OLKD-N;'N-LN?+D:BID=-V)A:V*"&8-D8][GF5CW:"YLC T>SC5I
M.#C;&<\R;B7BFX55^^Q7V.CIK)8K'>XX+C05M9/6R72AK*U]%)507.CCI8P*
M0QBI;33/:Y[7=DX-<':4UT7H=KN?0K:NPAY/.2_AI4>L#^;$0![Z=ABVQ>F2
MH@^3.CWEF(DTF3 2U8[%#"Q'CH- P)&@A9 E)F7J[:9\LKRYIB-N9.(7,=CV
MQ-AI(ETZLM]MX;E[<, ;IU'K&WJ]7"YWBY&MIGV2I]&-NXAAL<U'5Z&,N,=]
MDCADE9=FQ^MA\0;6UT5+$ZKI!!2,AI7TXJI-WJG0NOW9AJL<E3SFL(YYR#DU
MBG0;0 L)QBT6.\5>47&U,0]%MX=ZJ5R .&,Q7+!.7:2*I4]OTANH%RMD-L<T
M\@T0")G8T\#R'M>X/?*PN;&TB0%C UN"]VLY(V.DY[2WWKB2ZM%!PX+)0"R\
M-\.ULT5?1UM4ROKKK025,%NIG1W*F=;Z*&"!D;JR4U\VN9OZ)X@D[7=_(PS8
M=<NI@QR1.J$CH?2N.T*Y2 Q9;1 "#NUP"#+7 '6"%N.N,](C/R:\T9B[8<0F
M?N3$4P\IE:-M6Y_81M),9FFIXI-+L%K9'M$@#P6D9&6!P(.^1OA=KQK55@L%
MLIW/EMSKU?.&K1<WTU0YLU'272YTL%QA@K(M!8Y\;I*(5498X"8R1%CRPC6Z
M>-Y7S#NS%4J(>]<X?*TNU_4!7H3T;E=XCUB369\RW1I4XC*1^0UE!=N"\8CM
M1'R$4W*9*KE_317&<(VP0U(CC;+#F.3+<$02Z>S)D!).7LS@N !(<=1.Q7!M
ML/#]AXN;;K=2W>R.J+7<-=,Z(LX?NS*!]#-)<6/EGDS6T J1$ZI8R-\S*J1M
M0Z3LXW-@+@O=:X9[U&MZ.BP#+?DK/NHA=*T82\]1TT!_>N+K^UJ7M Q=HH0V
MQR#:$-M+>L987'>6[(6A&<2EJF/JA()0[UPR-[+4,Q"$_P!');OI+XP\NY9<
MX9W7C^$.+:&JXO9<A>X:H<<RW2F-J%4U[[2+.[_W8<8,D0&OM$%:^J :QSJZ
MIIV/+I"&B-78D\?7+_?XO/CH*<&\IKVX1\C8ESCMZJ-9&^0,Z.4>D5(>=W9#
MPJ(%;>K,L(Z%6+>@RW),G7VZ*MW6DY:R>40N865\N:L2#]&QM60?T8=K<T-R
MPMTZ<')V;E=(^.6&BO%X99JJDEI?2!=G3\;1W.,?9M#!QE+'4/?;H:HUU73Q
MTK74$M*ZE-.Z&1TCQV,9<I5\HNT!Q/8%RV.@0:_.\905;O$:IK,MP)/0K3;2
M\.9:*MJ#MQ*B3L+CPTG"',;]O_S'0QZT)<<CIUK?6U#6U'^V##1MCE$9=@S/
MD<"]F-]6*=K@, ^U,T\PN_X^XHIJ;B4R-O$-%+P+24-UCMQJFPR7JX7*IBDK
M[>(2X=N8N&H*B*%G/UB]0N +F +HM"L8$C& RH9<<\S:(39&N;^K90X;A.04
M$DR!C+BT/3$:'N(F.? VO;496GG-(1Z[SMP]I#2' AXRS?\ 6&,Y YG;?;HO
MM<5;1S,I)(JF%S:^(347Z1K35Q.B$X? QQ#Y0(2)7:6DM8=3@!NJL>8FH;@;
MAL0F ,6P3.\@ZK$*U8$E+A*PP5TGHCBQC+#A 4S)^1UII[;#\^.TK;&E;7[D
M)UOA5^"RG#F.D::I@+&XU.'9R[#+FCXN"^?^DOLC3<)QST=3<:>7C*WQU%OI
M '3UL1M5Z<8&L=-3LDRYK7ECYF-.C.<@*"JOU:7RT'V2XT&LV"M4LKU'G/'J
M!SBY(L%L(4OHVGY@OH=BG4:J$K/8X(9V*0#E!U+KTO9.TJ#MS1D<:W98LUWB
MLG,#:B2-CF1.GA@BADU2.CFR6S.,4;GN#<%KFQ,)+](+0W6%Y.@XADL%)Q-<
M[105E#:ZCB"R<,V>R7,5EQFM=[#Y*>]5LMIMT]?614KHYJ:>"V4,AGN!I6RP
M,@%='(Z21?D/U23&54FQ<659S_4J9SRB=)LW(NG\MJA&#:JQ9;47,3N>WF8/
ML4TC4(M,L$!Z +LS(\Q+F5US1 8B5*:1N;5S$=GIS(Z>.*.9]//!&X2,>]SC
M%(0\NC$;P0'AKB6;C)"[RGXSX@>PVX4\<E?6<06NRVF^5_#=^X?MT\5PH*ZX
M5-3+9KM+#6S3VV.V5L3X8*]D-3)+1.$U.)'M&P]#[%U_E<*LU.V(K$FV73H$
MZMUSH%8Y[?;@)=I@NH.VLE9Y'(J>3L%S=L<21&?KB04,\Z,6][;1()PPK,J$
MUG-43P!D<@87R2N8R5D4LC3&(^T+^PC+Y-8(+- =I)&LN#<@<V]<2\2</Q4-
MNN(H7W&Z7F:AH;Q06:[W.G=:Z>VNN$]>_ARVSUET=6QO8^B%)%5NIR[%?)41
M4K7Q-P0+N?;+<_SFHCH==JU@M5\Z?3YMQN?*NC ()@#2:I!M86ZUOG%H/52S
M0-%XL](V2-+F),1@Q$(_3D9$:(EI_!M542&&,!K'233Q]I)!*P.9'&)&R-BD
M>Q[=0."'$@/!P2T;\*EXLXJN,ECML,5%;ZRXW>_VV2YW3A^]T<531VJWPW&E
MNM#9*^KMU?"*F.;L)(*FI?&VJBGT3OCC#7ZV3Z9V^TGN."T6^J58U7_)RV<=
MO.@U8L<D#<)5?YU=;+#,;AIOXUY-=) /M[DBGSWR*QUN3$*I/2& :1<_ SU+
MWT[>T8QS:V2GETL?ID+(9'AV.U'L%NDZ"78?@ZR&Z3PY[[Q5<*OAF 7*WT%5
M1<>7#AF[>JT%:^DN<E'9+K715/9B\0.%%-1B%S[9,^<PW(1U K'LI!!-NY+N
MG5&:_:^SPTT?7)ZAU(G07Z/("&5W<M7:]T%/-3]L:N";*R+'FM&VIQ416':?
M(COB(S,*2520GHDQ-KJJ<,DJ1V?81SNB,6EW:EC)A"Z3M-8:UP<'.#.S(+
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M7 ;MU@@AN_LM]H^RW#=SME=-'P1PS1F6:VV:@H:TP5D-/511$.IA6P302LA
M=B*G+9Y"::(,@!<YS8VO.I?+Q3QWY]QT#3-#ZX!<O%=H8*G%+?#A.LO$'((T
M?'.31T>2_(0';L92#LL4:@I8<(2EZ?).2Y*=N[4U)#3MCTL9VC8FQND QG &
MH@$G2'N&IP&,G<Y.ZPX7X,LW#5);.QH:,W:BM%);*BY11.:Z9T4$+*N2!CW/
M%,VMJ(O69VQ!AFD(?.9'C4MXKO(N:U-X:_7*>($.!C-@L ?Z1#R6Q)>U0T#[
M!*&,K>6R/23A-ICOQ8C;,-#?N^&.UM:]JV,IX8R"R-K=+WO;@?JND&'EHY-U
M#8@8'<%VM%PY8[<Z!]#;::F--55E;3=F'!M/4W",0UDD#"XLA$\0#'QQM;$!
MG0QI)SZ:MQOEM(/2K-4Z+7P)R6W-9W/@0M-KB1R4I,TE&%,J4J,%BDIB$2B$
M4.S!CSI#;;TIIUQM"DF4\$;R^.)C7$$9 Y G)#1R:"=R&@ G&>06-OX9L%JJ
MY*^W6FCI*N42M,T,6DQLGD$L\=,PDQTD<\H$DT=*R%DSVM?(USF@C[;QROGO
M2-C7+M5!9^2&5(V((/H>C%1B9B4(FLP"\!Z*3B1IJ6VDS8K$M$>9IIK4EIWX
MF_;98(IL=I&UY;^J3LYN>>'##@#U .#U6R[</V6^=@;K;J>L?2EYIIGAS*BG
M$H#96PU,+HZB-DH#1-&R01RAK1(UVD8\P'+^>59VN/5NG  :ZB,-"*SH8/9B
M-A8%CE09M@:@-,Z2TRZ;F#H4DK+]FYD]YC3DJ0ZI;FUF0Q,T:(V-[-KFLTM
MTAY!< !L-1 +CS)YG<K*CL%EMYH74-LHZ0VV"JIJ 00MC;2PUKXI:QL+6X:U
MU5)!$^HEQVLSF9D>XEV?3:^3\YO"S+ELJ(@XY8A@(,<7+:=THH,JYMVQUV),
M4RZUMY 4X^^2'+5OY8LEYW;3B4N*3M)!#+J[2-KM;6M=D?K-8[6P''/2XES>
MXDXYK&X\/62[&J-QMM-5FMIZ2EJS*UV:B"@JG5M%'(6N;J%+5O?/"?UHWO<6
MD!Q!PHK@G&P@HT%%\ZK,0=9'A+U@;3!^1\VH#/9)AFBLYY;DZ?%&SX[4F'"D
MR7(;+GR>UC27GDN8MI:=K7-;"P->6EXTY+M)#FZB=R&D @$D#NW*XM/PAPS2
MT]52T]DH(X*YU,^L:(=3ZHTDK)Z5M1,XNFFC@EC:^**21T33JPS#WAVYVVMP
M["/C.K#ARYNN3M6:G:-KD,P1]O'PIK 8@Y*ALR)<-"%3'XLJ1%CR'DP)<MO4
M:0EQ3#F<C ]H]EKG,.N/7D 2-!TG(!(YD$@$X)V/)=G<:&*MAC<ZFIJFJH9A
M7VP59>V*&Y01RMI9C)$U\L0!E?'(^-CW=C)*W0\.+'1!R#CEEY4;W(>N&K6*
M-TV#!M2B$.$-GJNH<K)(L'Q[ D5%CS]6+=EM3ED(EI7W;;L&M-(W-9T^J#HI
MZ=\#LF3M&NC D) !,C7$AP#6@'7KD+W.=JR&#<9QYOAOAJNX?JM;KG]H4]5;
M(HK@9HXH)C=*:I?.RLA93T\;)A6^O7!U=/42>LET5"T&9NLPS1&JE;B$;*6C
MA8#9&X_0ZM,K;"5K.Z&C4AX*2*7/>W(1'%H3!0A2/9N/KXUI5K>_7D"-@<]P
M:,R8UG_BTC2,]#ANWDO3QVZABGKJEE+")[GV7VA)H!-6((!30B<.R'M9 !$&
MD8T9!!R<Q\5\?^,G!U<$E>>5^9 J0?\ '*\RMF0VH?7/5&]UO4AF0W)E5W?Q
MHUL#->D"=I0E.X>TIUK6IU+3N#&F)A$;=+!C&EG_  ;$$L_8.6^"Z>HX.X8J
MX:&GJ+-1R16VF]2HFEKVF&BV_H.MCVR246PS1RN?3$  Q$!??9>(\DN$\62L
MO/:P5EAA\,/!4^-:;9T%'/?4#@<R)'^&(3!P)'J]"#$V)@R(ZI:X\1M3B]JK
MZ:GD+2^%CBP!K<C;2-PT@;.:#N&N!:.@6VNX5X<N<M//76:@J)*:"*EB+X&A
MGJL+@^&DEC9ICGI(7C5#2SLD@B<7&.-I<[/E9>*\HN%A9M5FH5=,GVFQ[+A"
M7"UM4]D2]]0*8,1VUHB'&!C^_E',F8\YJ"O]L5#65]-!(\/DB8YPQN1STG+=
M0Y.TGEJ!QT5KN%N'KE6MN%?:**IK&B%KII(MYFTSM=.VJ8"(ZMM.[VH&U3)F
MPG_9AJCVL>,]!@W"[WBW :_:[#8NJ2^C Y\F ]IP.C0P#%"PYC#CZX928"("
MIA(7-E1W?MLB>IX<F-(^1U>EE%$))99&,>]\YF82#[(TL#0=\.+2TN!(."=L
M'==-;^!;/#<KK=;E24=QK:WB&6]TDSX7!U,TP4D=+%*QSS'42TDU/+/3RR,=
MV$DQ? (WZG&59?+N>3S5IL,ZH!)I:[@FZU<'Y<34EBS@V66XS4 X/>VL<20B
M*RS#T]*BN2?HF68>WMQ6FVD[S#$7/<8VETK0R0D9#V@8 <.3L#;)&< #.  O
M0R6"RRU5PK9;;2RU-UI&T-S?)'K;7TC&M8V&KA<3#.!&UL6J2-S^R:V+5V;0
MT843PSD8,#8*R+H8*.%M7T.K)%6R])=-MBU)6+CDITM]\A*B"]HU]LAN2MQ1
MZ=K1#990XXE6+::G8Q[&Q,#9,:QC]<-_5#B=R&_U03AO3"XM-PGPY24E90T]
MHI(Z6X=B*Z,M=(ZK;3D&G9/-(]\TD=/@=A$Z0QP@N$36!S@97S>O0IA$PBBS
MHG(Z_P!))50T2,6ZOFJ6LVH 7IUAD5XC&38HD6$6:<D1VG5.M28T-EK:%:UI
M.O?Z?]6\T34[)G1N<Z1CHM6AT;RQPU@!PR =B %Y^]<.4=\J+=5SU5RHZJUF
MK-'4VRM?13,%;''%4-<]C7%S7LB:W!V&_>L2WPBGR5U_=J)V[H359=LSXN)?
M["]9H>I-K#HKY*1,BR6$-$'6 BB P7]8EYL9&-&_I$(=(O.9B*6,Z-;I)>SU
MEHE>7C,C0TEP(PXAN0W/ZH<[&Y*XXX2MLAHS<)[C>6T+J]]/'>*QU=%KN-,V
MCG?+'(P-F<RE[:"G[4.$$=55]F&NG>Y>8WA=0#R^8SQQ.W1YW)@I6KUJ9NQR
M7I,VIEW13TBK61Z0VZHZ&:4"!ZBHE;U-:T)B;W-6K<E4BBEC:8"TR T[2QA#
MSO&[3EC\_K-]AN,[^R-^>;3\)VVEDL,T$]Q9+P[2U%!0R>NO<^2W5+J=[[?6
MN>UQJZ9IHZ3LQ)^E;ZO'^E)UE_R2?'RAN4;G=$@2;2 B\H5%70+#7[#*&6RO
M.1A,T M;!EI"M243PI*>,)1IT:3#FQ92]/1]N(9<;AI8C%%$"]@AP8GL>6R,
M(:6[.ZY:XAP(((.XV&-;^#;0;39;3"^OHX^'C&;/6T=9)!<:-S*:6C<6530=
M8FI9YH)V2QOBECD(<S(:6XJ'XS\^&!F!@@K?A)&'<SM^'VZ)=C#MRA66T#VQ
MMDD_?ISDQXE%/1D+V3'FVRD.2^\J1ME+K,14;$44+6AK3*UPD=*)!([M0]X
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>@D'VA<:JZ5/:/+\U=86NG+,@:(R6-TL&0W??=?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g945651g47y96.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g47y96.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "M ,H# 1$  A$! Q$!_\0
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M/M)7?O\ 2_B@/_/XI3[25W[_ $OXH#_S^*4^TE=^_P!+^* _\_BE/M)7?O\
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MQ('UKC<>9:(#KK;9.H#CB4$@<R-XC./*H%M_JLY?1>FI^06"SWG-\L6!I*\
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M/QD**4*95$+#SLAU4^5+C)9+2EMK0XV"WJOBC=JE_1/45:<?HN%GJKO/K;M
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MXI9Y/AQ:;2;_  X(-))YM_=US[D4,<DLFWLTCTVWSC7*H2 "3G !)P"3@:Z
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MI)R")Y-(8(((=-I)9II9-M8XHHH]=MY)-]M=---=MMML:XSGQ2M9#84!#:1
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LRP:<C4:* ;6:6$73>30>"$?3?;.L$,46---9SJ\JZ?Q2GBE/%*>*4\4K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g945651g48j89.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g48j89.jpg
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MMM+4%S$U5Y.4EK6WT]8B&251N!@:(R1!5EB'US)287B7_\0 '0$!  $$ P$
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M[)C9_P 9K'V*K>?(7NF/GORZ\]@7X7P15F>".?K*J]FB5R3"+)SR:7JCVO\
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M'LY5LBL[AZM(QRBBC!^T<"#=XMU77=4KT%B*)DZLE;2Q/=')*&O;8.&:\VN
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MS3>VB]F,KJ]+_)=+KT%D 550%9)1(%D# 1='K"&)UJ)Q*8"*I\_33,)3 4X
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M/2TY8)Q6=]'^JPPAX=WF,C/#BVQL0"5GMRZ+:281,(F$3")A$PBQZ\>4%"2
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M++OS%GT,T;ST#M5+3N'2>Q>??RN K&Y1CBB%PFDDL-OKO3315,NF4?R?5#F
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MJA&!3]Z:3?+^^.;]56_]$V3'[7%O[7!_)\ZY(/!O^&[G+S[ZW2( *?3 &5)
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MG(U_X7Z+H?S:_L4Z:@<2+O4VKW4P%E"6<Z[I+B4"YD*G< D5JU&*/0M:9/\
M0G90<F5"=(3_ $EE.U%+Z0!@ZSJU[-7-Q(-0]NOG4B9")A$PBH+N>*N==N'%
M(^US)[!<VF9X.;+8:LW1LMKG2LMA)N;XT@@HD*^D7L56Y0JC2**QCJNQC2N7
MQ&[MP@X>KJ.%9W?G\Z]JC1IWGCT]MNI2%PQNZBYL.Y2:IE1F=-(2M"+4';.8
MD9VO%L9Z2S/=F\!)2+IZ8PE,-?6L3=LX,1&VKSIY(A+&M.@([+Z_\;>RUM0
M"#;NV='Y-SI-^<VXR%*81,(F$3")A$PB81,(F$3")A$PBZ%*U>W/9!TZC]ES
MD,S6.!D(MM7Z<[09E A2BFFXD(%T]5*8Y3*=)PX5. G$H&Z(% "+C_0;>OUO
M6/\ A>@_XUA$]!MZ_6]8_P"%Z#_C6$3T&WK];UC_ (7H/^-81/0;>OUO6/\
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D@B9&TO.<]V:T OD< ,Z21UWR/L,Y[G.(TKO.<EV4PB81?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g945651g49a05.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g49a05.jpg
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MQ:7^"=<^!V>;M!\I#[F'O(^V;+Z6L_\ <2?S<)=F9'G& , 8 P!@# & , 8
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MP#VD(1,I2$*4A"%*0A"% I2$*  4I2@  4I0  *4       Y8!]8 P!@# &
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M%!U9P3!JMCPYRL0%;=7"@4LFO=OI/9ZVO(2;B9BH'@[!;=7R+UNXE*+?8J4
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M4BZBTSHOF@(@HDY:Q4N85$E"%YI';$*<AS&[,4Q *<"K1BLNJFH,PPCF"P'
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M$*6Z;=*MD/9GL 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
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M\[2=HR36,>&9N7*;Z#6C9-%\W9K"=4KJ(7=1#\CE-,%6*CJ/<@=(5VQS@5G
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , A_3OJ78WOP;$^& P"8, 8 P!@# & , 8 P!@# & , 8 P!@
M# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8!#^G?4NQO?@V)\,!@$P8 P!@# & , 8 P!@# & , 8 P!@#
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
M8 P!@# & , 8 P"'].^I=C>_!L3X8# )@P!@# & , 8 P!@# & , 8 P!@#
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M# ,_/(Y?HX67WKYS^5%,SZX^0Q^FCEO\1<J?KW-HPCP6_P"!FZS/TX/$, 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MO/:5>CK%#*S&P]NS,#2U;ZTV"I5]=T77&D]8WD:ZAKHM]91:MPF7&PV8OCQ
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MH9%ZS (>@87O>:_:KQ\/Z[]T'Z*=4TIZ)=RIZ=>S[9]FBBV:KUM5'_12Q7J
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MR@;IIE$Y^F0.?(3<PY& 0Y8!4L 8 P!@$/Z=]2[&]^#8GPP& 3!@# & , 8
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M]CM,+RG,CLUJE129\N"T97M\^2YDJ-*.!QR9D$Q*))[F).EYGUG G80P!@#
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MLG_N[N<H\DR]AL]/@SG'\9#@.(TP#S^1%QC_ /XW\1/QC!QUL7KO)7OED_\
M=P\D_P#\-GI\&<X_C(<_FCAZO0BXQ^HHA]+?Q$>OTOV1?W?7YCX!#JY.MJ]=
MY*]\LG_N[N\@\DR]AL]/@SG'\9!^:.'J]"+C'ZBB'TM_$1Z_2_9%_=]?F/@$
M.KDZVKUWDKWRR?\ N[N\@\DR]AL]/@SG'\9#@.(TP>Q%QC]X0^EOXB?7 0_5
M&#_WWA >O'6Q>NLE>^63_P!W#R3+V&ST^#.<?QD <1I@]B+C'[PA]+?Q$^N
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M$^& P"8, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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MQ/E'<3?OMEZ?\1UT^,+@7ZUQ/E'<3?OMEZ?\1UT^,+@7ZUQ/E'<3?OMEZ?\
M$==/C"X%^M<3Y2[-?NKJ[K1#[!;Q*%I;SENCW!X./<1,5(1,5;IR,K$TSC'<
M[9G4>6?J[2&FU&:\[(*MEI!1(ZB0E[72%6WG_,O3 & , 8 P!@# & , 8 P!
M@# & , 8 P!@&!G#A?[_ #<_H*2L=TG+0GQ"<,]OW;<8&6[F'C:-<X6P:6,P
MB:JBRC63B#AV[3;,]57$4Z7<BY&GQ;U4#31+ _D*]*U.G?WJ\6_H1%??7%+G
M2^G\#//(48 P!@# & , A?B#=W9MJ:QHZYDV4-=I=_4JW7Y)]8(>K@U<VBYU
M^NN#L9N>;/HUM,C'R;LL"B>.E'3^:%A'QT5*2+IK'N:N'3ASXR.M+L=NUF'M
M9N=[MUQ;Z,E-A[(UW*4F)X@I+8%B\M]:MTFM>* QX=).FIP5Z4H=;9SE"8U;
M>J5L>1KZFP3US,-4X2PL5&,3+L'K;35=?337O:]=+U=*:*N[35;+G=MT]ZA1
MM=[OVO>JY ;HF+7,0\RUVWP@:U6U<R2C6U2?5[>6M.':>OR\G$KQRLFXFV\K
MN^SV./E4I)):*8TF%CVW8F25D0EJU2ZFAO;<WP:+^'91>W6NI7)X4KA6ZM<7
MA1:S:'F)D, 8 P!@# /,]!X+-V$>=LF_%LN#%1ZFJLS3>"D<&QW:*"J"RK8J
MW0,NFBNBJHD!RIJIG$#@!KYK-NVQ-L:!KRW[.EEI.X\66[]<6R]5:-85%^YK
ME!J>U;?#U>IH'&;-56CE_3XI! 2OY2=)68N38J3;N1>.)D+2FVY/CIWJ[/ \
M:NZF%8D]=U<*[V'@(L3W3MZ9HNUK6ML>?:2_#II-E=JNE'(0+1KMNPQFY.(B
ME]UKFS+#BVFF-]K^D:S%(1T.2*8,WUMGY.'09R*]?<1)TT4O[ERVX5;QU8A5
MQ=;EAKX-=RX[B;M?7^_/+_K.T/[K.RB&U.(#B@U'8*"Y[EC6*S5=2O\ <S>F
MR$,P1CD9",EX;Y$D%'3<D>06"<D+Q*JR)%B>5U*)<G)O^#P%U<]>]WN4STR%
M& , 8 P!@&->]9G8L%<M!.*U;F<%39C;]?K%P@$((',W:4Y:)LCA)HI87$@+
M>)@6G<]-PZ8,H4\I*/@:&[ML(]H[CI>K3L7A0,1-B;@W/J8NVMC3\W*OFMB)
MQ0M-(JP6PZG<:%#26J:U?I^N$MU CZ6U<Q;=A6J!)R\@Z)L&Q.VMI8R%8M$/
M7WKAL@%NNNU:[Z\>S!:;MN+N;=7@]-VO!T5<>!7XLON6L>P(#<T1PZ-]IWF3
MJ-HO.JR/K\^>PREYC&5ET_Q)WJ?J4=9&D*W09!-3VBJH^(OVD$C&1EZF(V!=
MQS96NI1<V[^-=G \<'=KQ0>JK6%]==537HWVWJ,H^'.T6"VZJ8O[/*+3LO#W
M3;5&&PN46B#NR1FMMMWC7D#97I(]NSCQ?6*"J\;-/E6#1JQ<.WRR[-L@V423
M*?)SOY[7B58:^>SGL6!..0HP!@# & 63L@ZR5"MRR-Y;ZR[! R+A?83IO%.D
M*:Q;H&7D;$9.<.2%(>+8)N72+F7!:,9K)INW[1XU05:+ 8.U:8VA9;/2J4K?
M-IUW4NT+[?9G7ECL"C&*VW*T6F:OKZS..=2$C IRT-$6F^/+)>:\UG&"=T5J
ML"U;RBK2!DEJZTRHEJ;25>/DHKM>PQON5ZO:UMT6VO'C=MNCRH[OV[;J(ZVC
M)7^9:S>M&?"W'QU>C6T&RK>RODAV:(CK=9)V)+%G,_-M%I+J0U?+'N&C*N/8
M]N[JR3-Z9Z=T:2NN_P!J^^ZE:+'9IKCQDV[[Z7:,:XO!:\5==787A6=S;2@2
MZQV :>G[Z]W%6]SS-AUP^*Q4AZP[J.Q:A&0!*NTCHYK(PS>DQ<X[IDRD9VX[
MMNW#*2GA7G$1=K2F->.^G<UXJZ_OJNZBKC=5)\UAWZFRO(9# & , 8 P!@#
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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)@# & , 8!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g945651g49m94.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g49m94.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X=#Z:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/E-4,#<\+W)D9CIL:3X*(" @(" @
M(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @
M(" \9&,Z9&5S8W)I<'1I;VX^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @
M(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+7)E<&%I<B(^1FEL92!.
M86UE.B @(" @(" @(" @(" @(%-4,#<N86DF(WA!.U5S97)N86UE.B @(" @
M(" @(" @(" @<G(R,#8P,S0F(WA!.TQO8V%L(%1I;64Z(" @(" @(" @(" @
M(#(Q+4IU;"TR,#(P(# X.C$S.C,U)B-X03M%4U0@5&EM93H@(" @(" @(" @
M(" @(#(P+4IU;"TR,#(P(#(R.C0S.C,U)B-X03M38W)I<'0@5F5R<VEO;CH@
M(" @(" @(" R+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I;VXZ(" @(#$V+C N
M,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X03LF(WA!
M.^* HB V(')A<W1E<B!I;6%G97,@:&%V92!A(')E<V]L=71I;VX@8F5L;W<@
M,C8U+B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P<F5S96YT
M(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!!<FEA;$U4)B-X03L@
M(" @(" @(" @07)I86Q-5"U)=&%L:6,F(WA!.R8C>$$[5&AE(&9O;&QO=VEN
M9R!C;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @
M(" @(" @($)L86-K)B-X03L@(" @(" @(" @0TU92R8C>$$[)B-X03M4:&4@
M9F]L;&]W:6YG(&ET96US(&AA=F4@8F5E;B!F;&%G9V5D(&9O<B!#4SHF(WA!
M.R8C>$$[16UB961D960@:6UA9V4@:7,@;&]W(')E<R8C>$$[+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&
M:6QE($YA;64Z(" @(" @(" @(" @(" @4U0P-RYA:28C>$$[57-E<FYA;64Z
M(" @(" @(" @(" @("!R<C(P-C S-"8C>$$[3&]C86P@5&EM93H@(" @(" @
M(" @(" @,C$M2G5L+3(P,C @,#DZ,34Z,S4F(WA!.T535"!4:6UE.B @(" @
M(" @(" @(" @,C M2G5L+3(P,C @,C,Z-#4Z,S4F(WA!.U-C<FEP="!697)S
M:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @
M,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!
M.R8C>$$[XH"B(#8@<F%S=&5R(&EM86=E<R!H879E(&$@<F5S;VQU=&EO;B!B
M96QO=R R-C4N)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R
M97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($%R:6%L350F
M(WA!.R @(" @(" @("!!<FEA;$U4+4ET86QI8R8C>$$[)B-X03M4:&4@9F]L
M;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X
M03L@(" @(" @(" @0FQA8VLF(WA!.R @(" @(" @("!#35E+)B-X03LF(WA!
M.U1H92!F;VQL;W=I;F<@:71E;7,@:&%V92!B965N(&9L86=G960@9F]R($-3
M.B8C>$$[)B-X03M%;6)E9&1E9"!I;6%G92!I<R!L;W<@<F5S)B-X03LM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TF
M(WA!.T9I;&4@3F%M93H@(" @(" @(" @(" @("!G-#EM.30N86DF(WA!.U5S
M97)N86UE.B @(" @(" @(" @(" @<G(Q.3(Q,#0F(WA!.TQO8V%L(%1I;64Z
M(" @(" @(" @(" @(#(Q+4IU;"TR,#(P(#$Q.C,T.C Q)B-X03M%4U0@5&EM
M93H@(" @(" @(" @(" @(#(Q+4IU;"TR,#(P(#$T.C,T.C Q)B-X03M38W)I
M<'0@5F5R<VEO;CH@(" @(" @(" R+C8F(WA!.TEL;'5S=')A=&]R(%9E<G-I
M;VXZ(" @(#$V+C N,"8C>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W
M;W)K)B-X03LF(WA!.^* HB V(')A<W1E<B!I;6%G97,@:&%V92!A(')E<V]L
M=71I;VX@8F5L;W<@,C8U+B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S
M(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!!
M<FEA;$U4)B-X03L@(" @(" @(" @07)I86Q-5"U)=&%L:6,F(WA!.R8C>$$[
M5&AE(&9O;&QO=VEN9R!C;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M
M96YT.B8C>$$[(" @(" @(" @($)L86-K)B-X03L@(" @(" @(" @0TU92R8C
M>$$[)B-X03M4:&4@9F]L;&]W:6YG(&ET96US(&AA=F4@8F5E;B!F;&%G9V5D
M(&9O<B!#4SHF(WA!.R8C>$$[16UB961D960@:6UA9V4@:7,@;&]W(')E<R8C
M>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM)B-X03L\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@
M(" @(" @(" \+V1C.F1E<V-R:7!T:6]N/@H@(" @(" \+W)D9CI$97-C<FEP
M=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @
M(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q
M+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'26UG/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @(" @(" @/'AM<#I-971A9&%T
M841A=&4^,C R,"TP-RTR,50Q,3HS-#HQ,"TP-SHP,#PO>&UP.DUE=&%D871A
M1&%T93X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C M,#<M,C%4,3$Z
M,S0Z,3 M,#<Z,# \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \>&UP.D-R
M96%T941A=&4^,C R,"TP-RTR,50Q,3HS-#HP.2TP-SHP,#PO>&UP.D-R96%T
M941A=&4^"B @(" @(" @(#QX;7 Z0W)E871O<E1O;VP^061O8F4@26QL=7-T
M<F%T;W(@0U,V("A7:6YD;W=S*3PO>&UP.D-R96%T;W)4;V]L/@H@(" @(" @
M(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @
M(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z=VED=&@^,C4V/"]X;7!'26UG
M.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SIH96EG:'0^,3(T
M/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T/@H@(" @(" @(" @(" @(" @
M(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K6DI29T%"06=%0FIW1U!!040O
M-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML3D$K,$%!04%!04)!0FIW04%!
M045!)B-X03M!44=004%!04%104(O*S1!1&M&:V(R2FQ!1U1!04%!04%F+V)!
M25%!0F=114)!545"9U5&0F=K1T)164I#=V='0F=G3$1!;TM#=V]+)B-X03M$
M0D%-1$%W341!=U%$031014$X3T1"351&0E%417AW8D=X<V-(>#AF2'@X9DAX
M.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(>#AF)B-X03M(>#AF2'@X9DAX
M.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X
M9DAX.&8O.$%!15%G069!14%!=T52)B-X03M!04E205%-4D%F+T5!84E!04%!
M2$%114)!445!04%!04%!04%!05%&07=)1T%104A#06M+0W=%04%G241!445"
M05%%04%!04%!04%!)B-X03M!44%#07=11D)G8TE#46],14%!0T%1341!9U%#
M0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%1T4R16EC645537!':$)X5WA1
M:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I25&MQ2WE9,U!#3E51;FLV3WI.
M:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P5G1.5DM"<GDT+U!%)B-X03LQ
M3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7-799,U(Q9&YD-&58<#=F2#$K
M9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E66U:)B-X03MQ8FY*,F5N-4MJ
M<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"455%0E%914-!341B445!06A%
M1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO8DAW1DU(4C133D-&5DII8W9%
M>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X9%5K=V=*0VAG6DIJ6D9':61K
M9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-5%4U4%)L9%E75G!B6$8Q95@Q
M4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F2#$K9C-/16A984AI26U+:31Y
M3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K<4]K<&%A;G%+;7%Q-GET<G$K
M=B]A04%W1$%104-%44U2040X03E5-'$W1EA9<3=&6%EQ-T9867$W)B-X03M&
M6%EQ-T9867$W1EA9<3=&6%EQ-T953D@O=T%D2V8X031W=R\X5&QW9%=!*V\K
M-&9P4D]&;3=&6%EQ-T9867$W1EA9<6AR5"]!2&]V)B-X03MF*TUW+W=#5$UE
M04U).'HW+W="05)/1FTW1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1EA9<3=&)B-X03M867%H;R\X06IP5"]!4$='2"]I
M8W5$<7=(,4@S1#E,2&1E9E5M,5,U:C O-C9K.&1V2WE356Y.=7IM0F=K55%6
M9E)R>4EC=35R>6]O)B-X03LY;U-U,T-Z;5A'4DAI=6HS,7DR039E9&XS2F1Q
M2"M)=G%&>#E7*W8K=G=K+U)F2#9X6# O5W5/6'$Q,S4K:#9F2#%0:7)3;GA6
M=T<R)B-X03MN2C1N0V$T<F\X4%!V;'HX-G)N=CAB4C$S<69M;3%V-40Y6#1#
M5DQ614-26$XY06]R2UI8<D=S2E9Q8V%G2V$O1#AW4U,R>GDU;WDU)B-X03MF
M>F5K<$1R9DMV>%-V<D@V42]48BMH.6,U8V),-G V6'(O5C9E<R\Q<FYX+V,O
M,U90=#<Y2V(T5&1S.#-&-&TS1B]$6$]U6C1V3&PS)B-X03LO0DIR2"]%1&%C
M0DXY96HT;3%A45 Y9FM,4#95;VQ$165L8TQ6*TI0<&-L0G Q1F-G3&-82#1N
M0G9X9% U,V-B-W!F-E=X.7%E6$IU)B-X03MZ8F%58C!8>3(S,59V<E,R-6QA
M8UA01U P>$EB8TLU,CE496=7=EAT:WHP8W581E5E3&ER:#-Q-W9B;G<O2'E6
M3D)V=DUB6$5.='%C)B-X03M!15EH-'9,-F)+,W%P1D%Z1G!/4E)U8GEU4&A5
M9EI/35-E<6104$Q917@P*S)O+T1Q9FMM.7 O=E)E+SA::"]Y6FIY46-M4$TK
M+SA!)B-X03M1151H6G5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X
M5D1V<49O;#E(675X1GI+=D].940X4T)8.75N0W9W;F%T8U975SDU)B-X03M(
M4&8S16-5<7E2>%)X16A31T-S>E-!,7 S*T59<6DX5E='84UC9FDK,GA29F1H
M5V\O=T-&3TMT3F-2<4A,5D%29VA*.%=P4VXO0EEQ)B-X03LR2FQ->GA524M+
M<FQJ.6XT:7=P.4A(9D96*TMT8S$K2&8W6#)F9F%U2W5$;U)64T-+:V)(=4YI
M4&]P:7%3835O.&UR=F17:U8W3%I-)B-X03M966%V0U)V.%5V=W5/<$AS0TUH
M2TYU3&YW;DIC451(66-V:6U-5FIC2D=I9EA:=FA!2%-(<U X06I(:W%B>$$Y
M-2MZ.5,W-FY+9G18)B-X03MK-T1W+V1R*TMO<'AP944Y-6$K;V8X=D4O=T1W
M9CEM3DQW95ID.5$O-65*+RM$+W-X<&5$>DQV<4@O3'A0+W=F.6U.3'=E6F0Y
M42\U)B-X03ME2B\K1"]S>'!E1'I+0C%F>3-(<55%550S;'I&-E5Q>6E22D-(
M2$5%55AS1'8Q<&M41S)R3G!X359:1S9-,#9)4DYD4D)M8TI+<3AN)B-X03M*
M6FI30U!C<V1Y8VM'>4%Q>"M/45)M1G-A6FQ55EDP1E%0<$IO3595,G5!3V9W
M;CDR-GAM=$M(;'@S2%@K9D96+W%X,5IE5S95-41W)B-X03MR,'A64FUU9E1J
M;6(O9E1+1#E012]W1$<R2W1Y4$M8;FI1.%-);$M.='-Z8VA88V5W>%9D2F-#
M4#%3>6YH16=K3$1V.7%O+S181E5-)B-X03MM=39->7IV.6-I4DQA8S)S-U--
M27=S=S9P5BM.5#AS5E=Z95ET0VAH858Y471Y:6E1+T1)<FLK:T]59U962EII
M;S9G1$96-V$W;VES)B-X03M68E5,64UP9%=";6IQ1$5+>4$W.55'-V5'2W)2
M-6<P07EP14Y3=%1,2G@T4FEE4&LS3VA79S564$MO<&EQ,69-96=S+T)D471Z
M.$MU)B-X03M(.5)E0E8S6D)2-CA4.%-%54)X5F1C83EO.$5B4U!D27E)-WAY
M1T]S=D9O:TQY0FA(>30X1D97<C!X5E9T.51S8FDX=4Q/1U5.8S)T)B-X03M0
M6%-J0VY)5C)*1D<Y*TI.3RM+<6-L=G!9,65'-&MK0S9K,&)2=TE:;4)A36)T
M>&DU8U0T:SAC5F)346I76C!P.% Q945S>%!1.#5A)B-X03M$.65+<6ES<7E7
M+THO56MO,$IC9T%K,'%446)#<&E/2W)&:E-E0TEW3E%#5EIJ6"]!0WHV:$@S
M4&EQ-C14,31*;U9.2$Y$565)66=F)B-X03LX47A6,#AL57555"LX0W14-6A&
M4"]'*TMT>#A&34)*-4UO845-97!)-B\X04IV1E9#,D5I<EI2=#%8,4-F.591
M45 X06E1>%9T;E5,)B-X03M(-D]Y<F-!=%1V-F\U3B]Y8WA65&I22DY2=7HP
M-4,S8S!*1SAC<VDO.'DX2%9G4'%0=4@V57=384M1<T5D5TM-5EE!9S!99%%F
M8U9W)B-X03MS,GI,1W969TYW=35(53E".'I81E8R2W5X5C)+=7A6,DMO5S):
M5FYV4WA!2')Q2VYB8WA29T0V5&=$0U!-*R\Y058U2E9J-$)Q:W5W)B-X03M6
M44)88S<O=W=S,$]F4UEK37AD6EIW57 K>3!1<E0O9V]J:7)C-5@V=DLT3S1B
M:V8K96)F.#)9<6@W,C%U2F9R:V-48T=M.49K9G=))B-X03MA:"]"8U9A=E$T
M5RM(-TQ#2G@X>65*+S1H:7%..5I!,'!/,T8P:DHY,C0P+S1N:7)B0T]1>4EF
M,FPT35!A;B].,DMS5EA19DM!;&5Z)B-X03MH,6)J8S=I-&DK<W=Y>4TV4GEP
M2WIX>6E3:$M3>6-W1D$Y:%1#<4=N.'(K4S4P5EI.8F)H-D%Q1G5B9$$X0TM)
M-#)92V]$3$=&041()B-X03LV4V-53'AO9FMZ5&]:8GE45T@Y2S1J9$E:2DQM
M3U-I>'E*2E-!55!)>'9%2T-H.$-$:7$K6%%02E@Q85=/8E9L.4UY=4IN831H
M52MS)B-X03LU:&0Q2F]/3$4R;S(R-G0Y0W%'4&QF>6)Y=7)2.6)N5V5!,'94
M2F12<DHX2T5667-T95!P>FQ$5&)E:#-X5DY19DQA6$YQ:U=Q5VMK)B-X03MC
M5%AA,T5-='A'5TLS:$US9T%"-FAX5"]!1F$W*TML53AV5U=K=S-I1%1R*TLW
M:71,67AJ:DUS,'I.4$PV<G9+52\Q5C1N-3E/-G%A)B-X03MZ-E)B5&%P0G%,
M331M='A254)(0G1N549G450X4'%T4VA(6&9!<4=E>E58.#9),&A6;S122E9N
M:V%J;61.:7A.2V-Q-'%I>D1(1DDX)B-X03MQ3'I)6D%E+T5S-T9J.4%L2BM7
M2W1Q<V1V2$I$0U%B:C K66IR=CA!0V=11VYH.$EX5F)#5FEM54UA=F---%@S
M5E=D-B]W1$19<7-4)B-X03MH>%=E4V]-.45),W%':T-)45(T,51&5W!P:$5L
M=TDQ3%!B<TA.4B]V>&E7<"]S5WA65FMJ9$IM;$94=T1-:7%+;6Q%<6\O,75*
M>%9W)B-X03LT>$HY5FIP-GE20C%*-D5Q3TE0-%EQ9T),3VUO>5!B24HT<')B
M;GI89F9N33A:0CA'<F<V<T(Y4CEW+U-M4#90=#)64DMV<5551#1Q)B-X03M%
M,4%O4U0Q4$E!0G%N8UE78F8Q0T-T5G%P-&M#:#9(<W=R5VA7=$(W8EEQ=49L
M8D)E4$-Q:T)30U119V1J=G8W*T]+="]6660V9VMS)B-X03M!0U-Z16M$<'98
M=&ER4G1)0V$P4&I4:S%!9D5#=7@Y.%983&)22TM+0W%G04)66F=O03)!04)O
M359C8F5-.5,K+V<W:G(X:C<T<6A,)B-X03MA,6E.>F5F831I54M5-4AG45E)
M>%%R,#<T07=J>E!V+T%%0E5A,&5.2E=J9&YB9S-!13%*8VIQ5#AG04U,3EEY
M4RML2E-I=3A*94M,)B-X03MQ=VM0278X06DT1TMQ3&MZ,T5C54)(;U-1=$XY
M379)03$O,E=+;WDS=30U56E9+T,P+TEX2V5P56)G+V141E=G56U5.&A14T5O
M0C0K)B-X03MM>F(O044P>%9:.$QY54)&2C)76F9F,"]4+W!I<6YB;#%%9#-)
M,SDO=S12.7@V<7A#;C!&0V-6449X-4LP:6536C-E87,U:TPP6E(O)B-X03ME
M+U=/6#=.9BM0="]U2#!T<6<O*U9C-E964S$Y9E!1<WA$>5)U1VMF;'EK64Y'
M950O2#%/1S%8+T%02W9D24M1>'9D6%1X5SAC.&--)B-X03MB3D=1;W552WET
M6# K4EIU4F)C.69B8D<Q54Y9.&EE<T-D4&Y:2&U6-&)L-5A',%5S:GET>$%J
M979X4VYB8F]0:4<Y5S!*<&,K561/)B-X03MU2CE3;DTQ>$9.<5IG85=32G=R
M4G1B14=.;VIX<7!Q;T\Y8T-52V9)1VE(4S0Y3DUK+S%A2DAJ2'A,>4EK;5-C
M,5!(*V%)064R1S%4)B-X03M44G1$='1+1C$V36MK<C-K>EA.>$I+5C5'4G=/
M4BM"54%Q4E=L34-Q47-T64]V<F1Y5$ED4%)'5EDT,VQ1-R]:1'A(;D=X1F9T
M,4(V)B-X03ME1S9Q2719<$DY4W51.'IZ5FAH;UA#06HT-68U1EA&55A*1DA*
M1SAB1#1*05$T1S%14E$W:F9P:7)::E%Y0U%J-#%"54=P-DU15'0O)B-X03MS
M4FER4W=X2T5#<E0P>'A4,D9+57A6>7=X<6Y';%)Y3#<O>D9U6#8X5F)A3D=6
M;$DR8C=72W)Q0W!08VEN,UEQ,7A7=DMG-55P6'94)B-X03M&54Y%04Y2;D$V
M0T-%1"]G<&-(5F=0<5!U2#955FA:=7A6,DMU>%8R2W5X5C)+;V$P+S-O=F8X
M06I-4"M4365!34DX>C<O,$)%-%=B)B-X03MU27)7;30R0C<P3TMT2VE+0495
M04M+2T%+54AG359C1E55;T]G;U!L:7%L.59I1%%K5DAO5D-B:S=%8V0V,7)I
M<F8Q5T%.17EO1CE))B-X03MS>6-244%U1'DR2&I81E9Y>$%+069I-&MS<$Y.
M<3$V53A!85EQ=GA6,DMU>%8R2W5X5C)+=7A6,DMU;TMK,#-/>%!E9WA6,DMU
M>%8R)B-X03M+=7A6,DMU>%8R2V]A4#A!-#9C+R]'1T@O:6-U1'%W2#%(,T0Y
M2TIQ34Q.,5)I<G%J1EA61TMU<4U69%59<39O>%9$5VA(,6DY+S1Z)B-X03M,
M+WE::G=":$AM9F8K9TEM;W=S,U9'2W1C:&ER94MU<4U69%59<39O>%8R2V](
M6$Y48E1.3FMV1FDY9&ME2D9I<7=Q6EI6:D@R1FMB)B-X03MB;EA:4V-64V5$
M>C-9=EIX4W9A>F5V3&1R64,S:C1%;60Q1$-H:TU0=S=J-U%59SE2:'!7,3@W
M,CAQ,T1W5V-Z4C(Q=F,S16YQ1D5A)B-X03MT<TEZ>&]'86=94V<W-RLR3DMH
M-T@X=UDW:'A&2G!S-E1Q-W=326IX3U!85V%+25)X<WI2:'0U,7%7-&=E*TY+
M:G)B>G)P3G=*;5=/)B-X03MD631,43-R>4UQ531,2$A+>6=":6515V1E,5!F
M0E-O:E-F34(Q3%5,:3)3,&5'3S)11U-35FLU97 V<VM42G=1=4YM:&(T=5@Y
M8U94)B-X03MF1E5Q.# K6DQ$>3-O8RMS6#595W1U,$M/54)9,6YM4T).:"]L
M4T1&579L.#EA5D1C5U5%;E!N97AA:E!%47!P>#!T,5-A=B]!05<R)B-X03M+
M<&8U8R].4%%D970U2G)54TM)-V$X=DM/:$99<D=F,$I$.4IO44U+<FXO3DA1
M,%AY.%=%9U!M3S!K=F)-1E1T2$=I3V563VXY-$U#)B-X03MR-W8X>DY%='(K
M97E):V%E,FUT;UI60TAR9%0R,$-M<&].;795>%91,4@X,DY!<T4X>%!-:W9(
M>3-D,FQN9D5,5W)8:G%I379I05@S)B-X03MX5D529FU8;VMT*TQ*4R]Q;31A
M,3-1,#5R8S-.<68X06@W2CA+;RLS.#5A9$YC879%;V8O04A$,G=U<FQI=3-!
M>EA53D8X84Y9=F=6)B-X03LU:#5T+W=#8VA9.4I4>7IQ;6QA84QY>CAZ=VMN
M,6UA2C1L9VY-5W=!87!Q-V9D9S9S45!59F-0,'9B5U!'3714;TLP*U%W<VMQ
M6%<R)B-X03LO=T%6=&]8<&9!=&=,-S%Q-VMT35EU3E Y:EA&53-P:7%!=DY3
M3G9Q=6Y746HU0RLY648V+UHY2D]F-#1Q:C99<6]7.'AK;'552S Y)B-X03M#
M44E$-#%J4C8O.$%$-'%R,'A6:3-M8GI:8BM764QI.'5)2&Y74V$T-')'45 Y
M-61,:W9J5W9I;'%62'5C05E2-6XS+T%+06AT3B]-)B-X03MA>78O0410<&9L
M.4Q35DID53!I1%=9<'EY;%939C%+4G-/=DEE;#%W<S)/-F0K9E=J6#-K<E5V
M3E-A6F-,0G!P:5=7,DQO6%EY>&5O)B-X03M/3&1.=6U&53(X>"]M>'!U:#9&
M<C)R>E=-,'-E:&%K9$ML:59L0FMK145C,TY396=P34(Y1T)6=7%F;3=P=&@U
M-'4O2VI737IZ,F1V)B-X03MC6$5T>4=8:5)B,F%8:%92,2M*2D%0;FEQ,WED
M*V-/;&5A27)E4S)S6F]0<DAO14Q)5DY0<D5P:$A4=UE6=S!Q=DHK865N>#)7
M;C-:)B-X03MS<%-U;UA&.6)O=DIA<6)#,VQU1UDO-G=H;U!N:E-Q3W9F;3=P
M;6M(>DMS;&A.32]L<$,X-$1+0DPO8V)+93,K.5,Y9D1!<DET8C@R)B-X03MR
M<$]O:3%E>FMN:451;FML:EI!>7)W;F1Q2S57=$9T:65V-#!"5E,K-C@Y*U@W
M;WI7:SEO8FDQ4TUY5'!,-DQ!9U12>'@O05=+9D4X)B-X03ML9FI+;&%B:D13
M14Q.-7 X<'A7:6%N1&]F2DEK6C=/-$U.<V=P0DE)>'A)6G!&06MD45!H,G)7
M;EA&56)*<G9L;3,P.3=W84\S;TTX)B-X03MI0E5G9T)K4U=&<%I*1G%W56\X
M8THU5DY44VA'2UA.-6PX;U%Y,TI3>55V87EY1U)O-&]A;5)"2DMZ:6I61$4R
M6BLQ46MH5#!O8U91)B-X03MC5W-E5W)7-UA5,# V-C5A;D)"8GA7+W R,T%2
M,T95:&I#:'AT24QC;6A*07 R<G5O6E9O,S9.:S K,W4W0S)3,V=U65DS:E95
M5TUI)B-X03M-9W5Q:TQT.%!--V4U=TI2,DMS0B]08B]!36QH<68X07I%860O
M=T(Q1S-X5FI/<"\X9%AY-R]Z065B+RM4.&5&5TLO;$HO>'IR:B]T)B-X03MG
M-CDO,U52:7$K*S8O;% O04YS1S4O-4U166A3:6194"]/,S9Z+WI'850O,U5D
M2'A63%!/2"LX=C5V9CET;E)0*U0X94MP;G O=T1Y)B-X03ML22\W83!V+T%(
M5SE:>$-L;&UL+S<R*V9V*S)2+W=":BMT67$K979.=B]+2&9L6B]Z1#-8+V11
M3U(V<U(Y4CDS-C,R>$HO8W0O<6XY)B-X03M71FMX;&8X07EA56XO8D14+W%,
M8D97531Q:V5R+W=$2U1A0C@W=CA!-4TT5E1Z07%%<W8Y-F(O+T%)>FHO:WA&
M:7%,>%8U:BMC9CA!)B-X03MX>%<O-'HV;B]W0TEZ9EE!=VIZ4'8O445H.'$O
M*U1A.&]F.$%G1C)0-C=J2DTS;5!L8B]Y42]M=B]8='8K;U4T<C%::"MA2"]!
M2DQZ)B-X03LX>% O04%+:B]W0E%.<FEQ:C5T+SAN,7)F+V)/,4@O=6@R*TMQ
M4#5'+W=#.%=M+TQ4+SA!<4YB1E-M='HO=T%O+W=#5W8K,FAR+SA!)B-X03LS
M5$QV1D-"+TU4*RLO3E O04EW2"]U,UEP9E$X*VYA9F-3:5<T=%EP<%%P:D5K
M:V%S,T)G47DQ24IO47A"2'9G5E%(;#=10GIP<'1Q)B-X03M05D9*9C-%9GA$
M:T=O,W<W+T5!9FYI<3@V3F\U9U<S3FIB*V=O2W)$-E-C07)-2$E#,'!1<V]0
M>D=+=&I33DI73C1X6E%#3U)M:V1")B-X03M%;D9N9%-J35)48VQ724HX3597
M>6%*;W-G:T5L:&)/2EA%:V]A1TTX;D911V%O,UEC:G9I<3ET2C!P;6A:<DM!
M=&)Q1F=9>$E41W%M)B-X03MQ:$YV:$%)<4M9<6E);V]O66MI:5)9-&M!5DDP
M059603)!04=W1TMR<U93,WI(-64P=GI&;S@R:V%P1S!T:D\P5'E)<D9#5V=L
M5UI0)B-X03MI1R\R-'AI<41L.&QA1DY.87IY4DU:3$]/*VAG*TUG0DY364YC
M9VIV>4MI;FAI<40P5#AT4$MM:7=V1EE7.&E+.79C,F@U4T9V,TXU)B-X03M,
M-C!Y-RM,.5!$1EA39FQR-59F.4-C;TI$+V@K,F5Z,# K;S-W=WE+<4U'+VU.
M14<U>%9F8V9L,35:;G9*<GE30B]R1GA*1$Q+-&-I)B-X03MR5S!S13!F+T%!
M.7!&.3)+<58W*U8O;$<Y6%<Q=4QE4C$X=S-&=F0V;U!666,U3%)G,%A(*U5!
M<G5",7A65FHO04,W.'-2,VXQ=$QD)B-X03MX3TIJ8S$Y4FE056$T;G53868X
M04=7.&Q0,"LR2V]Y2'EJ;S!5=7!32D5W8E9O9G$Q-U9Y43!F<5A%=$%/,W@S
M:W8X06U-5EDW1BM5)B-X03M(:TDO;S=4<&1085<R,$-"4#!8>FUL0FI-:S!K
M<FML1UAN5GA8-'$T3W)!9E5F8U P<SE)0D9$,'=S,$],0S$K=F98=4@K;$=,
M,%1*)B-X03M5+S-98FQ3;E1R:7%)>%93:W1O6DHT<#)7<VM(3# R.$]1;V9W
M>%96>%9A:U-)6%I247E(:S-U84)F,41&5C)+<V8Q;GDQ<#)V<&17)B-X03MT
M*W)'2DIP94I5,$DK<V%E8E(O*U-6>2M!34DX>C<O,$)3<V9);6E797575W12
M2R\Q,U0Y3VDP;3-*3E%,945V=S(X9C-H,W=S,&]T)B-X03M0>6(X;E=V;&4X
M.'1X4D].3W9V5#EF9C1Y63 Y3E1Y.&509D-Q4#%N.'0O3&5R-E1R1VPS8V).
M839Z94<O=DM(8U1M1DEE4V5(=WA$)B-X03MP,W=+-BLO3%AY,V5E84HO36MS
M5$A58FE'5S-L3S-&:VYG4S)E;SAF5&I!>%8S;#,X=&9,5V=247A715)665!3
M0T5G9C=P9C%&+S1B)B-X03M$87(S+TQV>2LY=EI7-TDS<#)%,3%C46HO3'9)
M6DE:82M)-%1';4MR3EDO3%AY>G%O,6]8351!-C9H:G8R5V=99RML=4-.-B]U
M17=+)B-X03MY,T9867$W1EA9<3=&6%EQ-T9867$W1EA9<7A,>DY:96):3E9E
M9E)Z2T570U P0W-O5TU3<5I#,TI';59.-G Y<4HV*TLY8TMR6B\X)B-X03MF
M4U-'94@Q26LY66-,52]5+W=#-F%A66M/,W@P2WAI2596:C,R2C-#<6ID5TAN
M:&)F4FYT2DIZ8U<Q<&-*97$X<U9$4#9:151-2SA:)B-X03M+=C U5F]/=$18
M1D,R8B]',FTR,3%C5%AK:E<X9#5+;TUV,55K5V)66EIG>$%O+TQ90G9H6'5O
M56)+<3!R96),=4QY.697.&-S>7!!)B-X03MK,39Q4W!!2DAK0W-227!:0G-"
M<T]*1S5(=SEC5EIJ9U-H;R\K3VQ0+W=!65EF.$%I8W5$<7=(,4@S1#E+2G=S
M,DQE8G),>DQ04'DP)B-X03MF,39I1&I(-F-W:FHY4FDS27-05FEO=U=L0U9F
M+UEF87=Q9S1O=GI%5SE%2'A*671/959Z-FQU-TQ!.7E72D-Y2S=C>$=D="M)
M6&%N)B-X03M,1D16>$0K66LP,FXX6&MH-'9$.6-:1&$X06AH4EI7,TY78T]:
M0U9+;&9S.&5M2W$R;F%H-7%/=#-7;3-%=V5A2S)U2&=6:$-%2E8Q)B-X03M7
M,FMK-$1K1V-.5G8R9D%61%564G9L,C$X>69P3V4V,6538C!"07-D=$9).% R
M:3=&>DEK2#=V;4M,>%EF<VYX<FEL:V5"54YA9C<P)B-X03M8=CA!>&U(+T%#
M6FIW0FA(;69F*V=);D-Z64UB5'HU8C-6,TYA:5IG>EA00EAL:F--2$UN;T9&
M;&UK44)#67IS<V1!2U5B0VA7=7)F)B-X03MZ.# T06ML93-D*V)Q:'152TML
M,55"1V]R171!;S)B8F,Q4&)&5W18,'9Z;S)Q6&-L:&,S0S)S+S%O3%-A24%,
M.5=J34-O<F99<D]R)B-X03M,>55"9TXV:71C5E$R=#9P-3 P,4A-<S=)2GI)
M3%!I3%5U6F95:T5C635#:%0P=VA),V-K-V0V2W O8GAA.&YM,C5M:VIK9E-*
M63%3)B-X03M*=E=4,&M+;W U0TMV2W!A;S9F9E@T46Q0<U9D:7)S5F1I<G-6
M9&ER<U9D:7)S5F1I<G-69&EQ438O<#)R4UAA,U=M=DU*171,:F=Q)B-X03MZ
M<VMF,6MC4'$Y66DT:E W9E9A9GID<U93,E)0>D)R9'AO>D)9-4<K<7HX<E%T
M26EX>D9#4G=!54]W:$161F$X:4M$649#*T-0>C1:)B-X03LU67!:6%=(,75#
M5&HV<%@P4%AI0WE+3THO965J-G!B:W10<S!&86I&3$QC0W5X5D12+SA!2%-N
M+T%/34U0+T4U8TA69U!Q4'5(-E54)B-X03MH6G-2,5)04$57<%AJ-EE*6'1(
M85)O,%IR6FPS=#!32#!V55!*94TS2FY$549"=%=P<55,3"LR."M34GE2>'EY
M1EIO-W--1DYQ;D)Q)B-X03MY0S-#=4%(,U52+V5A=#1+<4]S-E@U-&LQ835M
M,#8T=55T6C0U54,K<D-!;T9S:&I#;U121V%F:W!:9"]C9&-65S8S9BMD3DYT
M2DI7)B-X03MN6E1.3'=T.7):;41&<FYH1VYW,$E:5F=*-59B8V='=3)+<'A(
M1#5H5'IJ3$\P8W(V4$I(-E-N,6PY2E!G4F<T:4Q63&,Q2R]:2%=T)B-X03M3
M3F=P6D1G5D17;BLY1C<O04U::"]W06U9.$%94C5N,R]O0TIW<S-9<7AA.#!Z
M>DI$8S-K=6U3>D%Y5',P2'%4*W%N<$,P-4MV0V-Y)B-X03M+;V$V1D110G%D
M0T)H5D0X9GI$94)*3U11>6E.=C-.8E(V=5!R1$M(8F=+;C191DI8:4YZ4VY:
M46IT1E1Z93)Q9S9M-W!926MH6F8Y)B-X03M';S@Q5D-Q3T%,*VQ1<U5R4G1V
M:3A-57-J=TLW1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T953D@O=T%D)B-X03M+9CA!-'=W+SA4;'=D5T$K;RLT9G!23T9M;%!M
M1S(Q:65/>B]!15A+67!O<FM3>71Y;W!267!+3$E+:FMJ4V-145!N,GA63'1*
M:#@S)B-X03MP3&%W,V)/3&1B5D9N9&UH8T-4,&%-4S-X4VU8,74K-F-F9D-Q
M5T-(.'ER9E%R2T]%=$QQ1DI&;D1V82]U*TI666%K<6592T)I9FER)B-X03MY
M24I.05%60TMA3#AW26\U,5=:-7E74&]U4F%"9T%B:%4W2W9&<5%-.60V13AD
M.%9:1F]K97!*<%9S3E1K85<O2T)R:W-)>%)Y2W-O)B-X03LY24MT1D\R0DM/
M>%9$5VXK.48W+T%-6F@O=T%M63A!65(U;C,O;T-*=W,S67$W1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W)B-X03M&6%EQ-T9867$W1EA9<3=&6%EQ
M-T961EE71C5,35-/3'AX;T(S<6I/5"]X35E'3F(R<EE75'-69&ER<U9D:7)S
M5F1I<6I"0S!C='<U)B-X03M)<$Q)2%=N9TDP5&8V5G=":4)22W1H6D]X5C)+
M=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%9$+T%+4C O
M=T-S)B-X03MV82]7;W9R369(,4E/83@Q-491=%9R559,<E0U:D954FEQ>#4T
M235)-#-K5DI*:5)%:D5";DMG<U%O4%=G1F1S5E@T<6AN,5!454MH)B-X03LW
M=493>&-+1VM116U*=4UG1E0K=S)Z94)X5D4T<3!844])>7=$<T-Y<EAC:&%!
M:T0R-41&54XK;&1,.50P+W)K2'%E<#9(1#%%-65R)B-X03LO=G5L9G1F-5!8
M1E8P1V\V9E!-64E,<4M76E%784I*1EIG1F)I4U9"<E%.=#@X5E)'2W)8;&I4
M:GIC3'I01D]207%X-T-V9D984U12)B-X03M2;%))-F]82E9!>$$U14M7249E
M=G=Q5#AH:7%$:C$S4DI':E=054Q:,FUB:$-&;6I*9'1V:%=H,U!X1%E9<6I*
M2DDT-#)K:UE*1V=,)B-X03M/-T5"46]&4U-4,$%X5G1(4U)&:VI93VIG37)+
M86=G-V=G:D97;S5)-4DQ:VI94$<T1$DV:T93<$9145(Q0GA69&EQ;DAC,CAS
M:VM5)B-X03MC<5!*0U%*559G5U%N8T)G3VQF9D965$9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867%W9GI&+VAY:S-0,5 P:CEE+S!I)B-X03MN
M;V5V>#E-,34X=CDP*VHY:FXX3F503&%U1D-45V8X06A(-G)B+UAV<F9Q9E9Z
M5&@V2&]F5U!Q169R96A4-'5F2&A3=3-0:E1&57EV)B-X03LO=T1",S9,,$0Q
M+W)F,6(V<F0O54LK;GEP-EDU*W!Z+T%.,E9P-F9(.75M2W).32]W6BMM<E P
M=G)0,3<Q1BMR*W V1E!S>%5P>"\S)B-X03M8>39C3G$X*U!W-'%L<VXK0V9R
M8V9Q9G!B-G@V>3AF-W9R>5!0<"MX-G1E9% R=F]X5EIC+W=#0BM%=G$O<$]N
M;T1N-E@Q6&IW.5IE)B-X03MN<&9".75N=%@O2WA633E/+W=!22]P>5 P4'(S
M<F9753E0,2]3.4AN-CAN2&@V=GAF,VY,-U!X+SA.:7%0:2]1=C9:2')F6'9R
M9C%L)B-X03LO5CE8-G0P*W-18V581#0O4CEF,"M02#-R='EX5D0V4"]H1W5S
M9E4O<F9Q9E5P9E=P-E!0,'5+*W(V2' W,355-B]$>2MZ,WA6,FEF)B-X03LT
M52MR-GHY4BMT97 Y5W50<G9(-G9Z-"]T*VPV6#=U=CAL4&@X3RM+<&%N*T,O
M46@Y4#A!4T@R;U!2<CE6.51L.59.4'0W.&%D82]$)B-X03MZ*WIT6$955&\S
M*T9U9#,Y5R]39G)E:4]F<F5J>C4O5DIA8U K3&94.51R=%@R>%9K2&PW.4,X
M9$XK<3@K3DHO<3,K.'9(;'A4;'HK)B-X03MQ+T)Z-&10871D-EEP65I$+VA,
M-G!A9E@O<B\Q<6MN<BMN.5<Y3#$O4E0Q<2]S9EIP,3,O04IV:7A1<5<O=T1G
M1#DO=R]31D]38T]F)B-X03MO,#5E<VYP*VQY,G)4;%0O04-/6'1I<6%A-2]H
M1#8U<&8Q:C8W-B\Q93$K;R]69E1P-E!X*VQ4:"]L5G)X-S!P=&EQ9U X1RMI
M+U V)B-X03LU-E Q9&5F2#9T>#E0-C%(+W9N86YR8V5N=R]A<'9Y>%9!>68T
M2SE'5#!F<FXQ,S!:9E-R.5<U535T>31E:CA.83%P>"]66$95*SAG)B-X03MF
M;VXV.6,O5B]8*W9E:5!8-65H.5@T*W$Q9E,Y2&(K.#5E,VAT5$5Q>FI!;#)+
M=B\R43T]/"]X;7!'26UG.FEM86=E/@H@(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+WAM<#I4:'5M
M8FYA:6QS/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP
M34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @
M(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O
M<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN<SIS=$5V=#TB
M:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E<V]U<F-E179E
M;G0C(CX*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HW0T9#
M1D5&0S=&0T)%03$Q0C P13A".$5%1$(U,$(T-3PO>&UP34TZ26YS=&%N8V5)
M1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HW0T9#1D5&
M0S=&0T)%03$Q0C P13A".$5%1$(U,$(T-3PO>&UP34TZ1&]C=6UE;G1)1#X*
M(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C5$,C X
M.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]X;7!-33I/<FEG:6YA;$1O
M8W5M96YT240^"B @(" @(" @(#QX;7!-33I296YD:71I;VY#;&%S<SYD969A
M=6QT/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @(" @(" @/'AM<$U-.D1E
M<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HW0D9#1D5&0S=&0T)%03$Q
M0C P13A".$5%1$(U,$(T-3PO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @
M(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HW0D9#1D5&0S=&0T)%03$Q
M0C P13A".$5%1$(U,$(T-3PO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @
M(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C5$,C X.3(T.3-"
M1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]S=%)E9CIO<FEG:6YA;$1O8W5M96YT
M240^"B @(" @(" @(" @(#QS=%)E9CIR96YD:71I;VY#;&%S<SYD969A=6QT
M/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*(" @(" @(" @/"]X;7!-33I$97)I
M=F5D1G)O;3X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @
M(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO
M;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.D1!-#%#,D8U1D)#045!,3%!.$0V.4(T
M-C,W-#8R,#$V/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z=VAE;CXR,#(P+3 W+3(Q5# X.C$S.C(Y*S U.C,P/"]S=$5V
M=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N
M=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T
M=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO
M/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^
M>&UP+FEI9#HW0T9#1D5&0S=&0T)%03$Q0C P13A".$5%1$(U,$(T-3PO<W1%
M=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^
M,C R,"TP-RTR,50Q,3HS-#HQ,"TP-SHP,#PO<W1%=G0Z=VAE;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@26QL=7-T
M<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @
M(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E
M9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F
M.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" \+W)D9CI$
M97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70]
M(B(*(" @(" @(" @(" @>&UL;G,Z:6QL=7-T<F%T;W(](FAT=' Z+R]N<RYA
M9&]B92YC;VTO:6QL=7-T<F%T;W(O,2XP+R(^"B @(" @(" @(#QI;&QU<W1R
M871O<CI3=&%R='5P4')O9FEL93Y0<FEN=#PO:6QL=7-T<F%T;W(Z4W1A<G1U
M<%!R;V9I;&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F
M.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX
M;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]T+W!G+R(*(" @
M(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P
M+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @(" @(" @(" @>&UL;G,Z<W1&
M;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]&;VYT(R(*
M(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+V<O(CX*(" @(" @(" @/'AM<%109SI(87-6:7-I8FQE3W9E<G!R
M:6YT/D9A;'-E/"]X;7!44&<Z2&%S5FES:6)L94]V97)P<FEN=#X*(" @(" @
M(" @/'AM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/D9A;'-E/"]X;7!4
M4&<Z2&%S5FES:6)L951R86YS<&%R96YC>3X*(" @(" @(" @/'AM<%109SI.
M4&%G97,^,3PO>&UP5%!G.DY086=E<SX*(" @(" @(" @/'AM<%109SI-87A0
M86=E4VEZ92!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(#QS=$1I;3IW/C4Y-2XR.# R-S,\+W-T1&EM.G<^"B @(" @(" @(" @(#QS
M=$1I;3IH/C@T,2XX.#DV-#@\+W-T1&EM.F@^"B @(" @(" @(" @(#QS=$1I
M;3IU;FET/E!O:6YT<SPO<W1$:6TZ=6YI=#X*(" @(" @(" @/"]X;7!44&<Z
M36%X4&%G95-I>F4^"B @(" @(" @(#QX;7!44&<Z1F]N=',^"B @(" @(" @
M(" @(#QR9&8Z0F%G/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O
M;G1.86UE/D%R:6%L350M271A;&EC/"]S=$9N=#IF;VYT3F%M93X*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI;'D^07)I86P@350\+W-T1FYT
M.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C
M93Y)=&%L:6,\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z9F]N=%1Y<&4^5'EP92 Q/"]S=$9N=#IF;VYT5'EP93X*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^,# Q+C P,SPO<W1&
M;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F-O
M;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/F%R:6E?7U]?+G!F8CL@87)I:5]?
M7U\N4$9-/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @(" @(" @(" @(#PO
M<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1.86UE
M/D%R:6%L350\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z9F]N=$9A;6EL>3Y!<FEA;#PO<W1&;G0Z9F]N=$9A;6EL>3X*(" @
M(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/E)E9W5L87(\+W-T1FYT
M.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^
M3W!E;B!4>7!E/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.G9E<G-I;VY3=')I;F<^5F5R<VEO;B W+C P/"]S=$9N=#IV97)S
M:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z8V]M<&]S:71E
M/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @(" @(" @(" @(#QS
M=$9N=#IF;VYT1FEL94YA;64^87)I86PN='1F/"]S=$9N=#IF;VYT1FEL94YA
M;64^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D
M9CI"86<^"B @(" @(" @(#PO>&UP5%!G.D9O;G1S/@H@(" @(" @(" \>&UP
M5%!G.E!L871E3F%M97,^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @
M(" @(" @(" \<F1F.FQI/D-Y86X\+W)D9CIL:3X*(" @(" @(" @(" @(" @
M/')D9CIL:3Y-86=E;G1A/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D^665L;&]W/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^0FQA
M8VL\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \
M+WAM<%109SI0;&%T94YA;65S/@H@(" @(" @(" \>&UP5%!G.E-W871C:$=R
M;W5P<SX*(" @(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \>&UP1SIG<F]U<$YA;64^1&5F875L="!3=V%T8V@@1W)O=7 \+WAM
M<$<Z9W)O=7!.86UE/@H@(" @(" @(" @(" @(" @(" \>&UP1SIG<F]U<%1Y
M<&4^,#PO>&UP1SIG<F]U<%1Y<&4^"B @(" @(" @(" @(" @(" @(#QX;7!'
M.D-O;&]R86YT<SX*(" @(" @(" @(" @(" @(" @(" @/')D9CI397$^"B @
M(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS
M=V%T8VA.86UE/E=H:71E/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\
M+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P
M,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0FQA8VL\+WAM
M<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'
M.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N
M=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,3 P+C P
M,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIS=V%T8VA.86UE/D--64L@4F5D/"]X;7!'.G-W871C:$YA;64^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT
M>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P,"XP,# P,# \
M+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z>65L;&]W/C$P,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB
M;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T
M8VA.86UE/D--64L@665L;&]W/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%
M4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N
M=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ
M,# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @
M(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#35E+
M($=R965N/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXQ,# N
M,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C$P,"XP,# P,# \
M+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D--64L@0WEA;CPO>&UP
M1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,3 P+C P,# P,#PO>&UP
M1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E
M;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P
M,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G-W871C:$YA;64^0TU92R!";'5E/"]X;7!'.G-W871C:$YA;64^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO
M>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT
M>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8WEA;CXQ,# N,# P,# P/"]X;7!'.F-Y86X^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 P+C P,# P
M,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB
M;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T
M8VA.86UE/D--64L@36%G96YT83PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#
M15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ,# N,# P,# P/"]X;7!'.FUA
M9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO
M=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @
M(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STQ
M-2!-/3$P,"!9/3DP($L],3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T53
M4SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIC>6%N/C$T+CDY.3DY.#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G
M96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W
M/CDP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F)L86-K/C$P+C P,# P,CPO>&UP1SIB;&%C:SX*(" @
M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]
M,"!-/3DP(%D].#4@2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\
M+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIM86=E;G1A/CDP+C P,# P,#PO>&UP1SIM86=E;G1A
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^.#4N
M,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @(" @
M(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TX
M,"!9/3DU($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'
M.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^
M,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6%G96YT83XX,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/CDU+C P,# P
M,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T]-3 @63TQ
M,# @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P
M,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM86=E;G1A/C4P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P,# P,#PO
M>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],S4@63TX-2!+
M/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P
M/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUA9V5N=&$^,S4N,# P,# T/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXX-2XP,# P,# \+WAM<$<Z
M>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C
M:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-2!-/3 @63TY,"!+/3 \+WAM
M<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C4N,# P,# Q/"]X;7!'
M.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N
M=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z>65L;&]W/CDP+C P,# P,#PO>&UP1SIY96QL;W<^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P
M,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G-W871C:$YA;64^0STR,"!-/3 @63TQ,# @2STP/"]X;7!'.G-W
M871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO
M9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXQ.2XY.3DY.3@\+WAM<$<Z8WEA
M;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP
M+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIY96QL;W<^,3 P+C P,# P,#PO>&UP1SIY96QL;W<^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P
M/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL
M:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54
M>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G-W871C:$YA;64^0STU,"!-/3 @63TQ,# @2STP/"]X;7!'.G-W871C
M:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^
M0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8WEA;CXU,"XP,# P,# \+WAM<$<Z8WEA;CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P
M,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIY96QL;W<^,3 P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X
M;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G-W871C:$YA;64^0STW-2!-/3 @63TQ,# @2STP/"]X;7!'.G-W871C:$YA
M;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU9
M2SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z8WEA;CXW-2XP,# P,# \+WAM<$<Z8WEA;CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P
M,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIY96QL;W<^,3 P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0STX-2!-/3$P(%D],3 P($L],3 \+WAM<$<Z<W=A=&-H3F%M
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+
M/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIC>6%N/C@U+C P,# P,#PO>&UP1SIC>6%N/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C$P+C P,# P
M,CPO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIY96QL;W<^,3 P+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C$P+C P,# P,CPO>&UP
M1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS
M=V%T8VA.86UE/D,].3 @33TS,"!9/3DU($L],S \+WAM<$<Z<W=A=&-H3F%M
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+
M/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIC>6%N/CDP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C,P+C P,# P
M,CPO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIY96QL;W<^.34N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,S N,# P,# R/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0STW-2!-/3 @63TW-2!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X
M;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y
M<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIC>6%N/C<U+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X
M;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.GEE;&QO=SXW-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C
M:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.
M86UE/D,].# @33TQ,"!9/30U($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z
M;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y0
M4D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F-Y86X^.# N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,3 N,# P,# R/"]X;7!'
M.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE
M;&QO=SXT-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*
M(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE
M/D,]-S @33TQ-2!9/3 @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%
M4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8WEA;CXW,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XQ-"XY.3DY.3@\+WAM<$<Z;6%G
M96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W
M/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \+WAM<$<Z8FQA8VL^"B @(" @
M(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3@U
M($T]-3 @63TP($L],#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X
M;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y
M86X^.#4N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUA9V5N=&$^-3 N,# P,# P/"]X;7!'.FUA9V5N=&$^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P
M,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STQ,# @33TY
M-2!9/34@2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z
M='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXQ
M,# N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUA9V5N=&$^.34N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXU+C P,# P
M,3PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STQ,# @33TQ,# @
M63TR-2!+/3(U/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z
M='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXQ
M,# N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUA9V5N=&$^,3 P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,C4N,# P
M,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^,C4N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @
M(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STW-2!-/3$P
M,"!9/3 @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z
M='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXW
M-2XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6%G96YT83XQ,# N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P
M,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STU,"!-/3$P,"!9
M/3 @2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP
M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXU,"XP
M,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6%G96YT83XQ,# N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO
M>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STS-2!-/3$P,"!9/3,U
M($L],3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C,U+C P
M,# P-#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM86=E;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C,U+C P,# P-#PO
M>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F)L86-K/C$P+C P,# P,CPO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @
M(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],3 @33TQ,# @63TU
M,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C$P+C P
M,# P,CPO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM86=E;G1A/C$P,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C4P+C P,# P,#PO
M>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T].34@63TR,"!+
M/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P
M/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUA9V5N=&$^.34N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXQ.2XY.3DY.3@\+WAM<$<Z
M>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C
M:SXP+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],C4@33TR-2!9/30P($L],#PO
M>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,C4N,# P,# P/"]X
M;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA
M9V5N=&$^,C4N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXS.2XY.3DY.38\+WAM<$<Z>65L
M;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP
M+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIS=V%T8VA.86UE/D,]-# @33TT-2!9/34P($L]-3PO>&UP
M1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,SDN.3DY.3DV/"]X;7!'
M.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N
M=&$^-#4N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.GEE;&QO=SXU,"XP,# P,# \+WAM<$<Z>65L;&]W
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXU+C P
M,# P,3PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIS=V%T8VA.86UE/D,]-3 @33TU,"!9/38P($L],C4\+WAM<$<Z
M<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C4P+C P,# P,#PO>&UP1SIC
M>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A
M/C4P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIY96QL;W<^-C N,# P,# T/"]X;7!'.GEE;&QO=SX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,C4N,# P
M,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G-W871C:$YA;64^0STU-2!-/38P(%D]-C4@2STT,#PO>&UP1SIS
M=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM
M;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^-34N,# P,# P/"]X;7!'.F-Y
M86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^
M-C N,# P,# T/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.GEE;&QO=SXV-2XP,# P,# \+WAM<$<Z>65L;&]W/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXS.2XY.3DY
M.38\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z<W=A=&-H3F%M93Y#/3(U($T]-# @63TV-2!+/3 \+WAM<$<Z<W=A
M=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D
M93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIC>6%N/C(U+C P,# P,#PO>&UP1SIC>6%N
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C,Y
M+CDY.3DY-CPO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIY96QL;W<^-C4N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,"XP,# P,# \
M+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z<W=A=&-H3F%M93Y#/3,P($T]-3 @63TW-2!+/3$P/"]X;7!'.G-W871C
M:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^
M0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z8WEA;CXS,"XP,# P,#(\+WAM<$<Z8WEA;CX*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XU,"XP
M,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z>65L;&]W/C<U+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C$P+C P,# P,CPO
M>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIS=V%T8VA.86UE/D,],S4@33TV,"!9/3@P($L],C4\+WAM<$<Z<W=A=&-H
M3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#
M35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIC>6%N/C,U+C P,# P-#PO>&UP1SIC>6%N/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C8P+C P
M,# P-#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIY96QL;W<^.# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,C4N,# P,# P/"]X
M;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G-W871C:$YA;64^0STT,"!-/38U(%D].3 @2STS-3PO>&UP1SIS=V%T8VA.
M86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--
M64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F-Y86X^,SDN.3DY.3DV/"]X;7!'.F-Y86X^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^-C4N,# P
M,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.GEE;&QO=SXY,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXS-2XP,# P,#0\+WAM
M<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M<W=A=&-H3F%M93Y#/30P($T]-S @63TQ,# @2STU,#PO>&UP1SIS=V%T8VA.
M86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--
M64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F-Y86X^,SDN.3DY.3DV/"]X;7!'.F-Y86X^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^-S N,# P
M,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.GEE;&QO=SXQ,# N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^-3 N,# P,# P/"]X
M;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G-W871C:$YA;64^0STU,"!-/3<P(%D].# @2STW,#PO>&UP1SIS=V%T8VA.
M86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--
M64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F-Y86X^-3 N,# P,# P/"]X;7!'.F-Y86X^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^-S N,# P
M,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.GEE;&QO=SXX,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXW,"XP,# P,# \+WAM
M<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(" @(" @
M(" @(#PO>&UP1SI#;VQO<F%N=',^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE/D=R87ES
M/"]X;7!'.F=R;W5P3F%M93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O
M=7!4>7!E/C$\+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @(" @(" @(" \
M>&UP1SI#;VQO<F%N=',^"B @(" @(" @(" @(" @(" @(" @(#QR9&8Z4V5Q
M/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y
M<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+/3$P,#PO>&UP1SIS=V%T8VA.
M86UE/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--
M64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P
M,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \
M>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXQ,# N,# P,# P/"]X;7!'
M.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G-W
M871C:$YA;64^0STP($T],"!9/3 @2STY,#PO>&UP1SIS=V%T8VA.86UE/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\+WAM
M<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z='EP
M93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO>&UP
M1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIY
M96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIB;&%C:SXX.2XY.3DT,#4\+WAM<$<Z8FQA8VL^
M"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M
M93Y#/3 @33TP(%D],"!+/3@P/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%
M4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA9V5N
M=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXP
M+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.F)L86-K/C<Y+CDY.#<Y-3PO>&UP1SIB;&%C:SX*(" @(" @
M(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @
M(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-
M/3 @63TP($L]-S \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @
M(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP
M1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N
M/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @
M(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P
M/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z8FQA8VL^-CDN.3DY-S R/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @
M/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],"!9/3 @
M2STV,#PO>&UP1SIS=V%T8VA.86UE/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIM;V1E/D--64L\+WAM<$<Z;6]D93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F-Y86X^,"XP,# P
M,# \+WAM<$<Z8WEA;CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6%G96YT83XP+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z
M>65L;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C
M:SXU.2XY.3DQ,#0\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D],"!+/34P/"]X
M;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP
M1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E
M;G1A/C N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C4P+C P
M,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3 @63TP($L]-# \+WAM<$<Z<W=A
M=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D
M93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X;7!'.F-Y86X^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP
M,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @(" @(" @(" @(" @(" @
M(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'.GEE;&QO=SX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA8VL^,SDN.3DY-# Q/"]X
M;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D9CIL:3X*
M(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.G-W871C:$YA;64^0STP($T],"!9/3 @2STS,#PO>&UP1SIS=V%T8VA.86UE
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM;V1E/D--64L\
M+WAM<$<Z;6]D93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z
M='EP93Y04D]#15-3/"]X;7!'.G1Y<&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F-Y86X^,"XP,# P,# \+WAM<$<Z8WEA;CX*(" @(" @
M(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6%G96YT83XP+C P,# P,#PO
M>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIY96QL;W<^,"XP,# P,# \+WAM<$<Z>65L;&]W/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXR.2XY.3@X,#(\+WAM<$<Z8FQA
M8VL^"B @(" @(" @(" @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H
M3F%M93Y#/3 @33TP(%D],"!+/3(P/"]X;7!'.G-W871C:$YA;64^"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM
M;V1E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!2
M3T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8WEA;CXP+C P,# P,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/C N,# P,# P/"]X;7!'.FUA
M9V5N=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.GEE;&QO
M=SXP+C P,# P,#PO>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.F)L86-K/C$Y+CDY.3<P,3PO>&UP1SIB;&%C:SX*(" @
M(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,]
M,"!-/3 @63TP($L],3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @
M(" @(" @(" @(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO
M>&UP1SIT>7!E/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC
M>6%N/C N,# P,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P
M,# P/"]X;7!'.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z8FQA8VL^.2XY.3DQ,#,\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @
M(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z<W=A=&-H3F%M93Y#/3 @33TP(%D]
M,"!+/34\+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P
M,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUA9V5N=&$^,"XP,# P,# \+WAM<$<Z;6%G96YT83X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z>65L;&]W/C N,# P,# P/"]X;7!'
M.GEE;&QO=SX*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8FQA
M8VL^-"XY.3@X,#,\+WAM<$<Z8FQA8VL^"B @(" @(" @(" @(" @(" @(" @
M(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" @(" @(" \+W)D9CI397$^
M"B @(" @(" @(" @(" @(" @(#PO>&UP1SI#;VQO<F%N=',^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$<Z
M9W)O=7!.86UE/D)R:6=H=',\+WAM<$<Z9W)O=7!.86UE/@H@(" @(" @(" @
M(" @(" @(" \>&UP1SIG<F]U<%1Y<&4^,3PO>&UP1SIG<F]U<%1Y<&4^"B @
M(" @(" @(" @(" @(" @(#QX;7!'.D-O;&]R86YT<SX*(" @(" @(" @(" @
M(" @(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIS=V%T8VA.86UE/D,],"!-/3$P,"!9/3$P
M,"!+/3 \+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @
M(" @(" @/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P
M,# P/"]X;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX
M;7!'.FUA9V5N=&$^,3 P+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P,# P,#PO
M>&UP1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.F)L86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T]-S4@63TQ,# @
M2STP/"]X;7!'.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*
M(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXP+C P,# P
M,#PO>&UP1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP
M1SIM86=E;G1A/C<U+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P,# P,#PO>&UP
M1SIY96QL;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L
M86-K/C N,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @
M(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL
M:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G-W871C:$YA;64^0STP($T],3 @63TY-2!+/3 \
M+WAM<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M/'AM<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C N,# P,# P/"]X
M;7!'.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA
M9V5N=&$^,3 N,# P,# R/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(#QX;7!'.GEE;&QO=SXY-2XP,# P,# \+WAM<$<Z>65L
M;&]W/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP
M+C P,# P,#PO>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIS=V%T8VA.86UE/D,].#4@33TQ,"!9/3$P,"!+/3 \+WAM
M<$<Z<W=A=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM
M<$<Z;6]D93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" \>&UP1SIC>6%N/C@U+C P,# P,#PO>&UP
M1SIC>6%N/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E
M;G1A/C$P+C P,# P,CPO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" \>&UP1SIY96QL;W<^,3 P+C P,# P,#PO>&UP1SIY96QL
M;W<^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N
M,# P,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(#QX;7!'.G-W871C:$YA;64^0STQ,# @33TY,"!9/3 @2STP/"]X;7!'
M.G-W871C:$YA;64^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'
M.FUO9&4^0TU92SPO>&UP1SIM;V1E/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIT>7!E/E!23T-%4U,\+WAM<$<Z='EP93X*(" @(" @(" @
M(" @(" @(" @(" @(" @(" @/'AM<$<Z8WEA;CXQ,# N,# P,# P/"]X;7!'
M.F-Y86X^"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.FUA9V5N
M=&$^.3 N,# P,# P/"]X;7!'.FUA9V5N=&$^"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(#QX;7!'.GEE;&QO=SXP+C P,# P,#PO>&UP1SIY96QL;W<^
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(#QX;7!'.F)L86-K/C N,# P
M,# P/"]X;7!'.F)L86-K/@H@(" @(" @(" @(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G-W871C:$YA;64^0STV,"!-/3DP(%D],"!+/3 \+WAM<$<Z<W=A
M=&-H3F%M93X*(" @(" @(" @(" @(" @(" @(" @(" @(" @/'AM<$<Z;6]D
M93Y#35E+/"]X;7!'.FUO9&4^"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(#QX;7!'.G1Y<&4^4%)/0T534SPO>&UP1SIT>7!E/@H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" \>&UP1SIC>6%N/C8P+C P,# P-#PO>&UP1SIC>6%N
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIM86=E;G1A/CDP
M+C P,# P,#PO>&UP1SIM86=E;G1A/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" \>&UP1SIY96QL;W<^,"XP,#,P.3D\+WAM<$<Z>65L;&]W/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" \>&UP1SIB;&%C:SXP+C P,S Y.3PO
M>&UP1SIB;&%C:SX*(" @(" @(" @(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @(" @
M(" @(" @/"]X;7!'.D-O;&]R86YT<SX*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z
M4W=A=&-H1W)O=7!S/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL
M;G,Z<&1F/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9B\Q+C,O(CX*(" @(" @
M(" @/'!D9CI0<F]D=6-E<CY!9&]B92!01$8@;&EB<F%R>2 Q,"XP,3PO<&1F
M.E!R;V1U8V5R/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z
M4D1&/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP
M86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ N@%_ P$1  (1 0,1 ?_$ !X  0 !
M! ,! 0             '! 4&" $" PD*_\0 6A   00! P(#! 0&"@P*"P
M P$"! 4&  <1$B$($Q0)%3%!%B)182,R-W%VD0HD,T)2>(&TM;87.#DZ<G5W
MH;&WT? F)S0V<X*ELKC!&"4J-41)5'1YX?'_Q  ; 0$! 0$! 0$!
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M4Z5\Z3C^3UM/=#K;!T64VOLG0/03G19+8L@SHYD9FSMK.U<01%X6>&*&."(
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M2:3++T5O$(;"VB-C%>!#96D1L((88X[<""(FQ@@C,,$45H/<AACBAAB,0$1
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MV]Y2C"TT03GC.I5"CNQ2#3ER=-H8X+U#:"RM+2$V$4'^S$):+VD,0!WHH0'
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M&O<PYR-1B-;VD/3\6ZH(<XHCS]>*\UP>4[ZBYKF"QU5B.CK8Q>XU:B21>I2
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MK:"%3#AW=Q<C*_FWCU021E8B#&6L;+&LACN>ISY 9 !/1R(C6Q!=/=7<=#R
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M:(FB)HB:(FB)HB:(FB)HB:(H9R;\NVT?Z [S?TEM+KFM/I5W_57GQL%YB_\
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MX>08B"\1KWTA(S^8MM-&U15T9SN4\I\=RM<R,'I(@,.) K/QX9K4S)Z&(O\
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M1G:QGH(/FM$_"5_;X>UB_3W=?^MM9K0^*+^'P7RC^&S^SYK;WP[_ )<=^?\
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M4>@NZ<%C&NY46OK&XM>,=8R)LB]KPS(: ]XF/+,&")LYD$SJ ]<ZJD.,*$:
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M2YWN>;&[29C5_&KKV/,RFM-$-4S3US(]D,P>'(^$0S'.1_EJYK>=:%2<VX$
M89S?IHOG$088,Q"7%?TFGDXG-;8;![6[E5^\F]5C-PV_C0K3QZ>%;(X$@U)<
MB%)Q^IQW86/;VPBD@L&6% +66+)$L3WQ .BD0YQN&5K!D(SF"!SW?EZP@(!A
M9W 8\R:<CU6K_BCVJW-E?L<?=G!(>W^9S\UF>(K'K.+B,'%[R5DIJ]-[\2EK
M*'1"@.LWA'%&204K(KA, QYE>@VJJ8(- Y]W*?Q/33%?>R,(M 20 (C,D ?
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M>1$<KWK%()'"=YJJKE5BK^_<[J<O/=55?CQHA R\JL]."IY-%4RVQQ2JR%)
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MC\4LO!,.RXM;D%I2D"P[8_I*V18FA!>8"(@T F>-).]2**$D@-4EF%:S8^=
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MW)JB@][F@X9*9BF,V]/%,L-DETJJRS<[%)OJXD6/.DQZ62 8&CE'CN"%]['
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BQC4:UC&HB-:UJ(B-:U$1&M1$1$1$1.-86UVT1-$31%__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g945651g51s28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g51s28.jpg
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M#,,$V RM^'";66^PD8VV&6ZZEK%'!21.W*9((8>)<<,(D  D^/U>CWY-03G
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M*MG.QNW9)V+4R2VV](OG-QMQT..9(]'+'3/UU.[/49Y 'T\\]<?556QX.LG
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M^GH/>M_@WE7^4'@S _\ 2"RZ]XN!X^,-.PE/\@^TJ/B:L/X0'#?^?T/^(?\
MU/,_XP.#?R@LO=/^IJ?)YOYG_P"9?]5/X0'#?^?T/^(?_4\?Q@<&_E!9>Z?]
M33R>;^9_^9?]5=M<_</*UTIO<2K7J=.FI#>NGV/,%DCC[@X\QKUF1XA;@_\
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M:5I3:E>3N["))$-W$]J+J"VN=-SY19RQQS/J"+<1%;FU2:(U?R4C:#(N6;:
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M&V^HE*.KU4ZUKS1HVD#5#K8TO3QK+0"U;519VXU%K88Q ;WL_*3#@ =F9-N
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M>4B &6:VAED(M9))K8;W1FQ;RS2RP#.(9)9'CVL[$U#,!@,0.?($@<\ \O2
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M(;;0E"=:UK6L]V""&VAAMK>)(+>WBC@@AB4)'##$@CBBC10%1(T5415 "J
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MFN3Y*H^3B(9N (K]#XXYOJ5:AH>[A0]QB)*]VMQ5AK9TA7I0>",Y+'4.-O0
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M8['R2&[(<WT=T9IS)/E,N2?-Y@#H3R'=S)R/^;..6W&!CTD/!VXX5'MQBV[
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M;_Z1'QY"S19'X6/J/Y:^/KI@^!]QK'^\#Z]5]GWU'[V:^46XZSP_I4_U4P?
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MO.S0XN@&8T@UHYHJ/*&9F3GHV*6\&:P.6C4@<PZ*+K;'6>=3I*-;TM&U=O\
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MX(Z?DOHWB?\ ^SIY5<?CY?[;??4KYD'%'VM:)_NG!_U'(_BE^2W_ ,..!O\
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M-UT?=RR@$X/A]U2'(Z #U"H7E(__ #=%?DJ_ELOL'B?J^ZF\^ ^O[Z>4C_\
M-T5^2K^6QL'B?J^ZF\^ ^O[Z>4C_ /-T5^2K^6QL'B?J^ZF\^ ^O[Z>4C_\
M-T5^2K^6QL'B?J^ZF\^ ^O[Z>4C_ /-T5^2K^6QL'B?J^ZF\^ ^O[Z>4C_\
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MV_65'\*+;^J.)O\ +NJ_[>N-^$)!IUT[XUY\Z/N<'\B*W[B83>_Z,?-DA_\
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MECDQ9[PKJL1 .RJ8(Q]8$C%1Q(H$F(3_ "V6BK<>0.VHAD(I#L._1IN,DQC
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M7LPA(B$NOO(2&EC<@\DBKW=]-;);E2T)6*,,L"AY$M@_8QM*J;W6$%]HW$@
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M, (7#]]>>=>+\7*&[RZZXX]UUK5O=VN[IQ*&N;AA-M[8--(PEV@!>U!8]IM
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M*F])2C>^NE2.CK:WK01N5+!'*CJP4E1W\SC Y<^=#-"'$9FB$A. AD0.3DC
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M 2[3@EO)(G GFS4/!$OO-".,BN+8W9=4OT&T7!*9)[-XXI(^< MCF.1&C(:
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M"<.2L9EQY2HHJ$*?$[ A;PVM./N=KIG3Z=Z0XE.O2BALGC5I;UH9#G=&+5Y
MN"0//$B@Y !Y 8SCJ*\&\O\ 78;F2.ST".]MUV]G<MJ]O;&3**6S ]N[)M<L
MG-CNV[A@$ 47EYSM]H&._/! ?W<S3R?3OZR?^XR?KJYOG/B;\EHO\?M?]I3R
M\YV^T#'?G@@/[N8\GT[^LG_N,GZZGSGQ-^2T7^/VO^TIY><[?:!COSP0']W,
M>3Z=_63_ -QD_74^<^)OR6B_Q^U_VE/+SG;[0,=^>" _NYCR?3OZR?\ N,GZ
MZGSGQ-^2T7^/VO\ M*>7G.WV@8[\\$!_=S'D^G?UD_\ <9/UU/G/B;\EHO\
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M/$W%EHL/(4O.>%14%M\@'TJ^<CQ+4Y4XO3-6K%ZI-UXM.@Y.+M,=/5AB*I:
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M4%L-Y$U=](F3-FF1(4/"EUM(]<8TR994&R3.R@ -MRR8N/?9.,Y;EG6XC12
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MJ!BY+3*["Z'&UQMH\R?*F[*X?<GX)]J,(V.[.!@Q]H#G=E Y= <;RJQX)O\
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MKK?3FQ&00>A!'OJCJKHR,,JZLK#)&58$$9',9!/,<ZPZ3X]JTL@U!8+G5D6
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MY.NSVST)+VWWA.NR4IKHTYK79[VCZ'>]8P,YP,^.!GPZ]>G*AM[<S"X,$)G
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M5.:C^3K]$7:I51ZE)Y#HMKBXZR6:L3#C3\I"V YJ%,KLJ\?(U;<RZY'104S
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MUVQRW*SD:B+H\D=+G2+UV,/F.87ZU5SHBSSZGB<\QSY^C'I[O9X#//'UIQK
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MIME'$8RDUO##V4$L:NY.?<?>#7$4:V"7@Z_7F\VD>QWJT$S-K34$G2TE?HF
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M2-^I%1A;#/5ZMR<Q-@YUJ._T_5^_[^%?FQSA7? ^YV\*KA+PK[9X4E!XEO\
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)4Q2F*4Q2O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g945651g52w82.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g52w82.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[22P4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ))2^DV0X0DE-! 0       \< 5H  QLE1QP"   "KK, .$))300E
M   0W;/F]A$TE(R)U-=F*+S[8#A"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!M$8$
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              -    ((          $
M                 0             ""    -
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   -      4F=H=&QO;F<   ((
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   #0     %)G:'1L;VYG   ""     -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $    !3A"24T$#      :+@
M  $   "@    0    >   '@    :$@ 8  '_V/_B#%A)0T-?4%)/1DE,10 !
M 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94
M     $E%0R!S4D="               !  #VU@ !     -,M2% @(
M                                                        $6-P
M<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($
M%')865H   (8    %&=865H   (L    %&)865H   )     %&1M;F0   )4
M    <&1M9&0   +$    B'9U960   -,    AG9I97<   /4    )&QU;6D
M  /X    %&UE87,   0,    )'1E8V@   0P    #')44D,   0\   (#&=4
M4D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q
M.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="
M($E%0S8Q.38V+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M
M  !865H@        \U$  0    $6S%A96B                      6%E:
M(        &^B   X]0   Y!865H@        8ID  +>%   8VEA96B
M   DH   #X0  +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H
M               6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                             &1E<V,
M+DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@              +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R
M('-P86-E("T@<U)'0@                            !D97-C
M "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M               L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%
M0S8Q.38V+3(N,0                                  =FEE=P
M$Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %    !7
M'^=M96%S          $                        "CP    )S:6<@
M $-25"!C=7)V        !      %  H #P 4 !D '@ C "@ +0 R #< .P!
M $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X
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M:4-IFFGQ:@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$!_\  $0@ 5@#7 P$1  (1 0,1 ?_$ !\  0 !!0$
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MU8Z0"B0*]WW5SY9R)YI7/F*-+(DF*..)DE+.+FF**FEGEDD=EHBQJ$0<JJ,
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M2NK*T6<VP/-(B&$"#%C=,0241*YL<,$,372222.:QC457*B<A( ))  W))
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MU_#?]O['JIWNNNLNQ9"Z'$>S/MUI95EL]X7Z-;MPPJTDP;ZP4CPHY]D5/D6
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MI]_]'WXI6K3N1H6_P?(6=G-,2D4U_2$LL\S%JT\21OC1L7Z4BC^UT<T;XO\
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M6VG1MF6X; >X91EX[?F_.QQRLV"$S@'/3VW7^+>%_8SH2<-</Q1:AQ"\7O3
MV68W4RJG_):Q)$,@R8!MK*-A(T:K#&(H0)#=;JKIC*A)C=[[I(*N-P9P.CAT
MLE19,2QHAD;Q:P45K4'KRRXVL<2,/'$E>&D%>V.&9;!LV3Q#J=LX72-*40Z9
M:-A@A8BZG4GFE=FP752!R$]3ECT%;WV9<(ZK"TW&W&4DEYQ;K<($?X@*&TG3
M'//%:0PKF.WEE4@S)&%]S%[NWV(F4YN\ZMZ^M>Q5R[/61_E@NUG]=N)_V5PC
MBJ>@\!X]Y^5=0*G_ (IJ_P#-P7^S1<5Q'0>0J/5Z^?I)9WZ@N#X%N/KZE>9V
M$TK57-%%AEF<+4#;/P"S)2W_   "ZL9H*RLRC'[AI1V/-M)P:FRBN[D,^P%G
M2ND2'^NI'KSZU0<=^YST!.0#C;;/=@?>H<FF^XWJ<>DSEMOK3',@VAH9S;28
MJ^TWM3#([+"[,YCF-).%Q;-*PNN'>;[8TFR+#9@"K&!(7-MR(/E+QTQU_;YG
M'[URQGSWQ@ 9[M@0?/8_:MX?6OXL?8M?9UE/VUZW8KDE#))%!8YMHRSLL:R(
M"'PB2&?H-F5G>U%^0YRN<Z$?+\5B8Q/,37N\,6Y[/7G4QYCOSMOCI]-^S/ZR
MW^I7<7K[W=U.!N7KKG0N98D20ZNM!989:S)L3O88V2%8YEV.F(P^CN1FO;(D
M<S) [ 5\-E4&V-62,;,J5!U^*L_E'-:^?R_N0M;*O^1-K[T5?^%^W[_MQ5 R
M?79Z_P!56G6/X8C8O97KOI+L%7]N<*Q,'=&L<,V6'C!FIKVV+H!LQHP[R&I)
MLX,W!A/G!C,:/*5$&-'.]BR,AC:Y&H]?Q4]?S6:^IOA(\0!O S=X]Q<@R7'H
M2(WF8_J[5U?B%H= U4<^&/*<JRG,1Z]7>/8LB8H<Y6N56I&Y$=R>O7=\L;[U
M?7KIFI0W5/I_U[Z5:MK]0=<]>UF!XD+(AEG+$KSLARJZ=$V*?(<OR(Q9+7(;
MLAC4C^J.(?$&.V,"L'!KH!Q(K4]>O7[56W8C_%_WG_4[LW^Q5WQ2N6SZ7_4#
M$>]_=75'6#.<LR/"<:V"#L$H_),4@K"+P!V'ZZRG- VB16XY5>]I9M! $3\Z
M!ZM&(E?&K)6QKR=OW[?7W/EVU>S/RZ ]WTZCL^=2;-\?"AZUHM/;"O- ]A=J
M97N*EQJPML!Q3.JW"A,7RF]KH_K(L;L#JJL!,KY;V&&:KKK!"$&!LR1"3FO"
MC(;QOW^7[>O+QRV[1].O9X^L^6(ZOI>9AU>T+WGQ6C[_ .CJ',=;/NC]>9,/
MLL&V2#36>0VL00.5Y+B$Q0U3=U]#=B24V84F6U5F-5UA9MS"&XZG00MYX_CK
MOV>73OH<#H?[&V._[_KM74TIH*@6HJQJ"&N'HAZ\.&F@J(QX:J&KC'C8!%61
M"-:)%7QBI$T.,5K1F#)&V!$B1B<M2OU%EC "DG&D0B!ACS%EE$2-B'&&'C=-
M.1/*]6LCAAB8^261[FM8QKG.5$15XI^]<KGU'>QNQ/4P]0C:N<:TQ[+]D0W&
M0V& Z'PG#:&XRC(R]7:^99MH'TN-THEA:3SV]:';Y]="A#$M#)N+@ASU&'?,
M@^O7\50,#L'SP=^X>.>ZLF,([!_$&ZUP[%M?8'2=^,5PK"*"IQ7$\:I^MF:#
M5=#CU$#!65-4 .FK%6,4$$:$>%'.>]49[Y'OD<YZP>OX[.GB*?3KC'E\^WP/
M[58OM%8>LEVAQ&L#[6:S[H;(P[79-IEU:1GG7?.@JW$GI620W5RMQ#KJL=7
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M4XI3BE.*4XI5)9C67=W5OI:6RDHG6B.$/R 96NL:FND]J&2T\;V/B2WGA5T
M)<[5@KI'K821E/%B")^]N\44BRRQB81GF2)LA)''Y1+@@F('=U!RX^#(!++K
MM3MKJ\M7M+2Y-DUP#%+>( 9[>!MI3:@@JMTZDI!*X*0,??E9&C2*3%??.[M6
M=)M3C5M%55[[X]I(^#X0-.OU][;2N12[NZ(<^:PE#B)D:5<W);IBC2'-%CE>
M61$C<75-4D=VN;J0S7$@(08 Z#"JB+A8XU&P2-54 849KH?$G$7#OLKX<BM[
M&UC$[B2/2=)B<M<7UTYS)=7,KL\\H:4^\N[R=I)IY7"AWDD%8<];.EV9[MS%
MW93MO]79F7Y++R@U]:L?&XN%Z.EK)LC!=X;68\%$^)*?$H4C26!D2VJ-&=,
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5<9.-SCID]N.ROZXJTXI3BE.*5__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g945651g53m08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g53m08.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2324&AO=&]S:&]P(#,N,  X0DE-! 0
M    )+:^DY@X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
M   0S<_Z?:C'O@D%<':NKP7#3CA"24T$.@     !"P   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4    % !# &$ ;@!O &X ( !4 %, -0 Q #  ,  @ ', 90!R
M &D 90!S       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F
M "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T
M   ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M     $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N
M=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M    4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L
M("!D;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD
M(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'+            *
M=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P
M  !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M       $    'CA"24T#\P      "0           0 X0DE-)Q        H
M 0         !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ !
M *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M   !.$))30/X      !P  #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@  #A"24T$"
M    $     $   )    "0      X0DE-!!X       0     .$))300:
M  ,U    !@             $+P  !V0          0
M       !              =D   $+P                     !
M                 !     !        ;G5L;     (    &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   $+P    !29VAT;&]N9P  !V0    &<VQI
M8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$
M;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,
M15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *
M15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P  !"\     4F=H=&QO;F<   =D     W5R;%1%6%0    !
M;G5L;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$58
M5     $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$58
M5     $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@
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M       ! 0 X0DE-!!0       0    #.$))300,     !HI     0   *
M  !;   !X   JJ   !H- !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI
M;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#
M('-21T(               $  /;6  $     TRU(4" @
M                                               18W!R=    5
M   S9&5S8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@
M A@    49UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD
M9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4
M;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P
M  @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W
M;&5T="U086-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y
M-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR+C$
M                                                     %A96B
M      #S40 !     1;,6%E:(                     !865H@
M;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /
MA   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M     !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                    9&5S8P         N245#(#8Q
M.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M       N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@
M+2!S4D="                             &1E<V,         +%)E9F5R
M96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M     "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M
M,BXQ                                  !V:65W       3I/X %%\N
M !#/%  #[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M         0                        */     G-I9R      0U)4(&-U
M<G8        $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\
M5 !9 %X 8P!H &T <@!W 'P @0"& (L D "5 )H GP"D *D K@"R +< O #!
M ,8 RP#0 -4 VP#@ .4 ZP#P /8 ^P$! 0<!#0$3 1D!'P$E 2L!,@$X 3X!
M10%, 5(!60%@ 6<!;@%U 7P!@P&+ 9(!F@&A :D!L0&Y <$!R0'1 =D!X0'I
M ?(!^@(# @P"% (= B8"+P(X D$"2P)4 ET"9P)Q GH"A *. I@"H@*L K8"
MP0++ M4"X +K O4#  ,+ Q8#(0,M S@#0P-/ UH#9@-R WX#B@.6 Z(#K@.Z
M \<#TP/@ ^P#^00&!!,$( 0M!#L$2 15!&,$<01^!(P$F@2H!+8$Q 33!.$$
M\ 3^!0T%' 4K!3H%2058!6<%=P6&!98%I@6U!<4%U07E!?8&!@86!B<&-P9(
M!ED&:@9[!HP&G0:O!L &T0;C!O4'!P<9!RL'/0=/!V$'= >&!YD'K >_!]('
MY0?X" L('P@R"$8(6@AN"(((E@BJ"+X(T@CG"/L)$ DE"3H)3PED"7D)CPFD
M";H)SPGE"?L*$0HG"CT*5 IJ"H$*F JN"L4*W KS"PL+(@LY"U$+:0N "Y@+
ML O("^$+^0P2#"H,0PQ<#'4,C@RG#, ,V0SS#0T-)@U #5H-= V.#:D-PPW>
M#?@.$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/LP_/#^P0"1 F$$,0
M81!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#
M$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5-!56%7@5FQ6]%> 6
M Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA &&48BABO&-48^AD@
M&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;LAO:' (<*AQ2''L<
MHQS,'/4='AU''7 =F1W#'>P>%AY 'FH>E!Z^'ND?$Q\^'VD?E!^_'^H@%2!!
M(&P@F"#$(/ A'"%((74AH2'.(?LB)R)5(H(BKR+=(PHC."-F(Y0CPB/P)!\D
M321\)*LDVB4))3@E:"67)<<E]R8G)E<FAR:W)N@G&"=))WHGJR?<* TH/RAQ
M**(HU"D&*3@I:RF=*= J BHU*F@JFRK/*P(K-BMI*YTKT2P%+#DL;BRB+-<M
M#"U!+78MJRWA+A8N3"Z"+K<N[B\D+UHOD2_'+_XP-3!L,*0PVS$2,4HQ@C&Z
M,?(R*C)C,ILRU#,-,T8S?S.X,_$T*S1E-)XTV#43-4TUAS7"-?TV-S9R-JXV
MZ3<D-V WG#?7.!0X4#B,.,@Y!3E".7\YO#GY.C8Z=#JR.N\[+3MK.ZH[Z#PG
M/&4\I#SC/2(]83VA/> ^(#Y@/J ^X#\A/V$_HC_B0"- 9$"F0.=!*4%J0:Q!
M[D(P0G)"M4+W0SI#?4/ 1 -$1T2*1,Y%$D5519I%WD8B1F=&JT;P1S5'>T?
M2 5(2TB12-=)'4EC2:E)\$HW2GU*Q$L,2U-+FDOB3"I,<DRZ30)-2DV33=Q.
M)4YN3K=/ $])3Y-/W5 G4'%0NU$&45!1FU'F4C%2?%+'4Q-37U.J4_940E2/
M5-M5*%5U5<)6#U9<5JE6]U=$5Y)7X%@O6'U8RUD:66E9N%H'6E9:IEKU6T5;
ME5OE7#5<AES672==>%W)7AI>;%Z]7P]?85^S8 5@5V"J8/QA3V&B8?5B26*<
M8O!C0V.78^MD0&249.EE/6629>=F/6:2
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                         /_A
M/JQH='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I
M;CTB[[N_(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM
M<&UE=&$@>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E
M(%A-4"!#;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C Q,B\P,B\P-BTQ-#HU
M-CHR-R @(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O
M=W=W+G<S+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @
M/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL
M;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @
M(" @(" @(" @('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA
M<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS
M.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S
M;W5R8V52968C(CX*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I
M9#HQ,C(V.3="0T4U,#E%0C$Q0D5%-$5&,$)&034S0D8U-SPO>&UP34TZ1&]C
M=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HQ
M0T(U0S,R144V,#E%0C$Q0D5%-$5&,$)&034S0D8U-SPO>&UP34TZ26YS=&%N
M8V5)1#X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @(" @(" @(" @(#QR
M9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYD
M97)I=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IP87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&EM86=E+VIP96<@=&\@87!P
M;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<#PO<W1%=G0Z<&%R86UE=&5R
M<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR
M9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z,3(R-CDW
M0D-%-3 Y14(Q,4)%131%1C!"1D$U,T)&-3<\+W-T179T.FEN<W1A;F-E240^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C M,3 M,#A4,C$Z
M,38M,#<Z,# \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.FEN<W1A;F-E240^>&UP+FEI9#HQ0D(U0S,R144V,#E%0C$Q0D5%-$5&,$)&
M034S0D8U-SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @
M/'-T179T.G=H96X^,C R,"TQ,"TP.%0R,3HQ-CHU.2TP-SHP,#PO<W1%=G0Z
M=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^
M061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E
M06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T
M179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @
M(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYC;VYV97)T960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E<G,^
M9G)O;2!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P('1O(&EM86=E
M+V5P<V8\+W-T179T.G!A<F%M971E<G,^"B @(" @(" @(" @(" @(#PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYD97)I
M=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IP
M87)A;65T97)S/F-O;G9E<G1E9"!F<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B
M92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @
M(" @(" @(" @(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z,4-"-4,S,D5%
M-C Y14(Q,4)%131%1C!"1D$U,T)&-3<\+W-T179T.FEN<W1A;F-E240^"B @
M(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C M,3 M,#A4,C$Z,38Z
M-3DM,#<Z,# \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM
M<$U-.DAI<W1O<GD^"B @(" @(" @(#QX;7!-33I/<FEG:6YA;$1O8W5M96YT
M240^,C(X13<U14(S03A$,C(T.3,Y-T4P,S9",$,Y,C5"1#$\+WAM<$U-.D]R
M:6=I;F%L1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F
M.FEN<W1A;F-E240^>&UP+FEI9#HQ0D(U0S,R144V,#E%0C$Q0D5%-$5&,$)&
M034S0D8U-SPO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F
M.F1O8W5M96YT240^>&UP+F1I9#HQ,C(V.3="0T4U,#E%0C$Q0D5%-$5&,$)&
M034S0D8U-SPO<W12968Z9&]C=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F
M.F]R:6=I;F%L1&]C=6UE;G1)1#XR,CA%-S5%0C-!.$0R,C0Y,SDW13 S-D(P
M0SDR-4)$,3PO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/@H@(" @(" @(" \
M+WAM<$U-.D1E<FEV961&<F]M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*
M(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @
M(" @>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O
M(CX*(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^
M"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T
M:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ]
M(FAT=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @(" @
M(" \<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-;V1E
M/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP
M=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O(CX*(" @(" @(" @/'AM<#I#<F5A
M=&5$871E/C(P,C M,3 M,#A4,C Z,# Z-#4M,#<Z,# \+WAM<#I#<F5A=&5$
M871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R,"TQ,"TP.%0R,3HQ
M-CHU.2TP-SHP,#PO>&UP.DUO9&EF>41A=&4^"B @(" @(" @(#QX;7 Z365T
M861A=&%$871E/C(P,C M,3 M,#A4,C$Z,38Z-3DM,#<Z,# \+WAM<#I-971A
M9&%T841A=&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI2
M1$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!5P)= P$1  (1 0,1
M ?_$ !X  0 !! ,! 0             &! 4'" $#"0(*_\0 :1    8! @0#
M P@&! 4+#PD) 0(#! 4&!P 1"!(A,1-!411A<0D5%B*!D:'P(S*QP='A%T)2
M8A@S57+Q&20E)C=#1E.2F-8G5E=866>"AY67HK+2T]@H-#9$8V;"U^(X2'>#
MDY:FQLC_Q  > 0$  04! 0$!            ! $" P4&!P@)"O_$ &,1  (!
M P(#! <%! 0(" D'#0$" P $$04A$C%!!A-1810B<8&1H? ',K'!T2-"4N$(
M%6+Q%B0S1%-RDI0E0U2"E:*RU DT572$M,+2TQ<U159C9).DU49E=8.%L^+C
M<Z/%_]H # ,!  (1 Q$ /P#]_&E*:4II2FE*:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2FE*:4II2FE*:4J(Y <.&E#NSIG:XZB.VU1LCAK>)=)H
MO$TUPC#/5$+7)H2"J#!:.KJI2R[U)ZNBT4;,U2.54T3'."E>"7#QQX$X;L9W
M":NZDCF.!Q=8\3,^)S.55XNKEQAXGDT\K8NR ?&F0<*6ZR\JM8G<@9:JU(K%
MYP$G!U1K16V9,?6:"0?P,I&.)12MA&7RBV>Z?;5_Z=,68@I=#K>9)3AZR">N
MVB^6"V5C(5>^3N#CNM-G211K*[64IE?<QD_C,(J/9.[-,H>Q6MD""Z!JW(J5
MBFC_ "M>1[J]AJB]2X4,8S$ED/(]27REE;+2,-B=&-IV%</YFB%41J5HNS(U
MDE2Y+D*J[KSS(;%VR:P@VUX6/E4W>."/KZ^C3Y5<H#CSR_EEN]L%K5JM%J=R
MQY\F;E>C8@J]PF:QF6N(\2?$U7<>VB95LB32.EK1CTZY7C.1=*P$=%VB 4KD
M(LU@OI/8FHJIOO\ I[//W>VMZ>"+BPL'%3$3]IG9+!$216.8S3#$-&OC^PYR
MP^1Q9KC7'51X@ZP^;M0KEN8+U@&,B5LSBTF%P97*G@Q>%JI)^857Z\*WRTI3
M2E-*4TI32E-*4TI32E-*4TI32E-*5X6XXS9*N>/7B[B;UF>BQC#&O$>^KU&B
MLA\>UZQTZJE99\(^$[HQC6'!LU@TZ3D.CA<+%/SDC9)&Y0[E4\I9'@-_&J#(
MCVNV.N?9M\<_E5"<'F![3[<;?S&:^L?_ "DN;\T2G"C.-6V&L P-YXL66#LJ
MTC(<G/NK%*UZ;X2+?F>HST;(6.%I[B)K>7;##NK!@1^E&M)FZU<,;KS:<1.3
MV0,:UBE/P^?3^=6ZV_*NY@H/#MP[YNM="P<2RYXH<UG=CC./N,PS61PI#_T7
M1Q6[>VW5]2XU>^.YB]K@Y8UV/NDJS7>UJ%A*-;VYIFTLZX!. >NQ/U]>5.0R
M>GY?7N\ZFK;Y5Z0KEIXAW63:[C".QOPTYDA(3*SRD6MQ>IFF8$N%XS+B:FY8
M<V"J.[%2IB3>9"HM'^E5/<O*I;:#'S=^C;556+BC,)BTTIX>_/N\QMSZ?I4S
MK''QQ$,K!'/LPXAQ7CVD0&1,6XGRW"MK/=IG(M,N.2^$B"XEI%1@BVKRL/)Q
M^.I>:0H\NS325D[.@$C,Q2<4YB&D18U-_+Z\OY^>W*M?:7\KUD.Z.*+6U&?"
MW0WE^RLWIC/+&0LI$C<20M9FN'RQYRKSZ2+7K395"65VXK9ZJS@)NVU28E$Y
MF&EI*#I\HL>K:?0IGXCG\/KYUU(?*"YERBE=IBS2-$IM#L?#-P3Y=Q_CFB7N
M9@,C.Y?*?%-?L2W:[X^R(E'Q$[<<931*<QF6<P2 :,)?'$SCPQXZ"=7&QE=5
M]QY_0]M/>,8!^CRY?K[?1/A!XK9WB5FK\K+2N"H9K#R]UCX[$%9O3V8XA\;E
MI.3+/CQ9OG&GN4TD:_*2(0"+YZV:-6*-<FW:]737LJ+5*QO*56M[=*4TI32E
M-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4T
MI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E
M8,SSGNMX$@:H^E*];KW;<C7>.QMB[&6/V<0_O.1[U)1,W8_F&O)V&:K=<9IQ
M-3K%IN5CF[)8H* K]3K$[-2<F@BR BJE8]M7%@EC7 >1<[9=P9FG&9L>3*%<
M2Q;(ML<6S(^0YZ9D*Y!TB*Q@ACO(MOJEI>9$M-KA:A4&R]IB73BSKK1TJWBD
MVYG)E*Q9E[Y1W$&+J]CZY1%&R9E^C9!X<[3Q7)6[&A\7%B(+!503I"\Q;I,F
M0\FT%]*+BROT(]95ZI,[)8'R";Y-O&G=(I-UU*MV8+[PI6[-O#OP>69"UQ3G
M)#J$X@86KU"&9UC%\_/5-Y+9.Q95<PJ(MFDDG+7=]B#(.1*74Q;M$K:.![PS
MM+D[%B$!85/KZ^/UO6Z64+75,58YR)EBR0YGD)C>HV[)T^C%1S!S,NVM0JDC
M(2JL:F[59-W$XX@8]Q&-#NGK0JR9TV2[Q!H8YBJ5H)5,W\+>2;TI<<NTV3X5
M'_#1C*$L<C5\^OL$57'#[&O%@^(SH]PDIRJ7B]T4Y9&?P;*14)&/[7 6&)EX
MU<9*OJ-Y2ONW YY^WWG;]:I^7U]>VMXY')N D;K3ZS+9!P^ED6]UL)B@U^1M
ME+)=;E4&*@3@2M/BG+\)VPUMFLP"8!]"MWD6W49!(>*0S?QB*K44;\2'"7$U
M23RLTSUPZQE&DIYY#S.26^4L:,ZH_M$,F@20BY.XI3J<.ZGHI)RV(\9.I%20
M8IKH%722*JF!E/KZ^5=\7Q7\-<SD>]8DC,XXP=Y!QGCFN9;O5>3N4%XU;QQ:
M4I%S%6^1=&>@Q3AR1\>G+RSDKDP0,).5.:F@81=QJ[N64J3QW$!@:7C:',1.
M;<12D1E-VJPQA*QV2::]C<COF\JP@UV5#?-II5K;W:,W*Q<.JVKRLBLG*R3"
M/.0KMXW144K+FE*:4II2FE*:4II2FE*:4II2M0;UQ:G@\D7K&&+^'_-W$--X
MG95UQEB0Q0&*&$'1)2U1C6Q0E,6D,J92QN%DOZ]0?Q=S<U.I)3;R+K,Y6WTL
MJQ6LL$UD%4^>^_E];4OO$#P[U+B?Q7PVVNLI.LNYIKLU.Q<U]#X:0A(8[:'L
MSVMUZ[V54_M43/Y*@<>Y65Q\R,W>M["UQ-?6AW316.8-Y-5:@>*.-#$F;LP-
ML3CAC(5;=ST]G6*HEYN41BJ1J=\E.$?*3O%N05XQ*J9"MUWKA*Y;07<U1]?Z
M?3T'[-<%XIPG(.D6*ZE9)X;.(G _&#5[38\:0:CN%Q7D2=QRBG:ZO%L1533@
MX>;KMXI2(+2"+K'.4<>6FMW3']F9';)62FV%DJJU9N >Q[5^?SI^7RK%'&Q)
MXS9?T68?GL,Y@RNOF2[RMZ>8YP2\Q35OZ0RX2:1E\DF659+(]XQLQF*D=P2%
M>/H1K8TWUG4CTH24]JK[F5C7]??TZ_AUJGZ_'Z_+PK.6(N)_AOSA"X>G:9D"
MBA/9\QG5L[XXH%AEZ[!Y8GJ18J\C)Q5J_H^>O_I2<&,2!V;V1;L739@9B[:@
M^,BU,8*<JK6(KS*<"=VD,69BE\YX CZIP^9/N-=:+1^2\0-L:+Y*O%$LE#DL
M?WA5PY7BSV5O&6:2E(ZJ _BYU.8(B\6;.$2K-U5-OQ_G_.L]S6:N&)A<GU0L
M66L#LL@UFNS4E)5>:OF/F]RK]3KK)M9;$_?0CZ5)-Q-=@XYNSGYITX;-XV,9
M(-I5\H@@FDN52HU0.*3A'N=1QIEVEYIPH2O\1JD:CC6QKVZI5N2RE,F0;E;U
MN,;RSR,FYNY1(O$HV2J"C=6SU^1,I#R<6Q?IJM2*;<_'KXUFJMY'QY<IFSUR
MH7RF6JPTERFRN<#6[1!SDS47BLC-1"32SQ<6^=/H%RI+5NQ1::$J@T5/(P$T
MR*07,4^204J9Z4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*
M:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II
M2FE*:4II2FE*:4II2M;.)# 4GFMMBJQTN\I8SR]@;)J>6<17A]62W:O1UC<4
MFYXRLL)<J7\]UA>T4^X8YR)<ZM,QT?:*U,,SRC.=A)Z-F(=BN#Z-/H5I16/D
MQ'RUPE;'?\P0,) VGB3=\4]LH'#%C><X<*Z]RA%8=J^)* \CY"/RE<I]H$.[
MC;/E6WO#R"KN[Y3G8BR*_,YZX8DN/]V?"J8^//(V_7IM[*QA:?D?UW[6JU>&
MR?ABST#'M8XC,=8PB.(CAI<9[L6+<>Y^O5)R,Q&CV=YF:G+1^1L56&OS\?1;
M^Y9N54*M+0<0O$>T5Q21F%5^OK^ZLMS'R81Y="W7.0XELM2.>5<FXHR5CC)\
ME(SKFOU!7A^85J$PY%V;&;6U,X._BS@8*;2R!(N7<.YN\KDK)4FW2KY;+[&U
M53&_,^SI]?7A6R,7(7WBPP5Q&XPO]&L>$7%^KN0L>TR4L%;?D<.L:Y/I3Z+I
MUV>0[I^F4EEC"2LBSM5,5EV,I'2D& OT(1M-1H:54>?G^.WRK3F5^2)K$&1D
MQPKD*!Q)6('+M%S_ %BE5ZC6JJ0++*\=@ZX8!R6X>2F&LLX?NPU&\5BPQEPK
ME?A+7!NZ'D5I9I LO9*G=I.GMF:5(X3Y+M6J4F_8CJF4J9$8IS)A.#Q+DQNY
MQ9<+!DRNO(3#MEQ"29P%D^S9RFIG&, 9K.I6"+J%L;93"NR1[22.G%"W.059
ML[Y]]*Q43Y/;+6+<F<.$U3+/CFTWYOE6UVBRY%L^*<XY-QQ 0M<X8K9BNK-[
M15,I<4^0;+'O78SDI'P4W5,F4A)@#^#K!HV6B8@[>4KGG]=<^_\ N\!5,;@C
MSS]>X<O?RK)<5\E>I7Z3*X^A<SPOS%-8!X:L:/EY7$:;QP.1>%[/M]X@:;92
M1S2^QT$.'+-.Y!D*A;\%*1QRJ4"(A*O"9!B6C8QQI5:SGA+@52QUG,G$/>[=
M3+O?Y"4X@[1,QM<Q6A2J5#6_.+'A+KC>5QK#2%MN<G2TZ_4N%*-0G57,Y/S5
MWMF0+?:W4Q#).A@U*YVQ];9_6J8WS[?GC]*]!]4JM-*4TI32E-*4TI32E-*4
MTI7FGQ&<!MPRRKQ-PU"R;BN&QKQ@0\.KF7'6;,"+9OB8O)D!18#&47F'&3AC
ME+&AJ]:D:53:"E\V6%O:HAC:<?U:XUX("6^D 3RJ8'AY[[U$['\F(6S#D"Z/
M>(;(C;-\ID'$=YQ7>8Q2;C:1C5'AW8UME@RNR.*6MO)"7F-KQH:Q2-L4D9..
M7M3_ "9D,&QH%E-(M&BJ^_W;?IGYUB]G\D]<HF?R'8*CGG&.+)ZV3O%C)L<C
M8BX; I>;;!'\6=YNMDG(?-N3U,NRYLML<7P][?HXL;!7*FC!W2LX]N;@KE&I
MFKLLI67B<,$GP-34UE+A1:Y)R6>X8IQW@X, 664L5]C'CO%$FY?8RL\=;YZS
MM$<<PE#Q@[R73EV+DI8FPKR&/(I%\Q=0<;%3:J?7N^'3I65>*O@JQ1Q]1V(G
MV5V@KT*!IN4]JE8Z9R69)[F.A1T#"66.//B@]H%[QVLF29CU7,(ZDV<N4S%R
MDQ%)TFJJOY5K@V^2L?3&0#W/(V;6UI;V?^C^R7]M6X#+F-ET<ET/A]B, HV;
M$T!3>(AAB*@0B["OQ=JB:_9,3Y'=UUZ_M=;2G9&KS<9'UQ3Q\_K:ONT_)E9
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M-U*S2NNBV16<N5DF[=NDHNNNLH5)%!%(@J*K+*G$I$TDR%,=10Y@*0A1,80
M!'2E:=XZD3Y4M*O$#.)J?-;U@[A,%0SE-9(L!C)\JW6<7APQ=)IJ(V[+JK-G
M/.%7!$G,+0&U*K1641-%NXSDV&$A>(CUCRSM@? G)Z\N51Y)!G Q@>6=_B-N
M6-SOSQ@5GOYV+VYOP#?[1[_<(ZS\!WW]G\]OG\JQ!@-R!D8_='3'AG.?,#F3
MFH1D?+=,Q+1[-D:_S[&MT^H1#R;GIJ1/X;5DP9)&55.;E RRRA]@2;MD$U73
MIPHDV:HJN%4DSU6)F*JH)9L  9)+$X4  9.3R R2=@":PW%S#:02W,\L4-O!
M&\TTLI6..&*)2\DLCN0J(B!F=V8*B L2 #CQ6M=MXNN/AFA;E;E.<)_":K,1
MTC!UJOS1JCF_(%,9OT'BM[L=\;,W;V@)$9H!*UZ%JSZ*V,0Z4W8+'%2"+B.V
MTD%EIGJ7""_OP07M>-EM+0[$QW,D+++/.!M)%!)%'$2R/*[ JO@C]L^U?V@2
M22=E;N3LEV*=9DM.T)L8;GM-VDRKQQWFAV.H0SZ?H^C2EA+::EJ=E?7NH(L<
M]MI]G!(D\N)[;PM?)SQK4B84L<NV)4P)R-A--W;(<C+& A_&<RUP:2@5]62!
M7<5P-)HN?'45,L@4YA$NCU/MYHW9^01ZSK79K0W54D%G-#I8O55@&CD-BMO<
M:FR.I#)+)"P=<,KD8KS_ %71>S<_>)'J_P!H?:J^+SVMU<6_;#MS>P%DXX[F
M%[FSUBST"SEC?BCFLK8V@C?CC:V4Y OT!=*IC92)4Q7*6"IC5SMUH2I76J.'
ME>2]C5*JFG'V&$CI9_#N%!W4.]LZECCEQ*":R+,JRK]*+;?:-V%UV4J_:G1)
M9K@X-P;UK"1V;;!CU06<,PVX0EN89 3MQGAC/+6UO/V4%J_9FUUG2DTPI)9Z
M/K&C/=V""!N\46^H:7!?75E(V2W?ZJVI6TA'"\<7&]PDWI5WD<]RDF_JBD2#
M@5G3ZXVF37:#6ZHN1P)9$LB$2LBA(S8J JNA"1CMNW=([2+B8CHERTDG/6RV
MHLD1KCB,;JAM4BR9+M'4-&\)=?5@*E<S.I*D\"QR2*\:W:-KUQV[NKJ72#:B
M59)I=9U.[DB.FZ1(DA6X2Z%K)&MS?<0=X["UFC26,"XDO+:TF@N99Q.XKX++
M0R<0.6<FX]RP)Q\)T6S9*A(B+ Q@$#MV\#7)N"9(- YCI)I2@2,AX(BD[D79
MC'55I'+KD/$UG87-JCJR,J63SF2,[$2&XBF[P,!ZRJJQDYQ&H&!OI-#^R*:2
M(:_VPT?7;^VGBGANY^UEMI)L[F-@\<EC#HNH:<;-HY,=P\CS7D8"A[N5BSM
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M7&B]HK.W($][H%Y.D<SM;!U>_P!)NU74=/21)3Z7:'TT^JH2X#L/.&P]=P*
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M%VTUS;:=!VDU/LY"D)D;NH[#LSV-FTZ>YM;?A$*3WZZK,67-Q?/*2XQ_7O\
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MT-&R;5,D5&NWND3\;9:E:XB/GJ_/1#A%Y&RL3*-DWC%\S<HF,15!PW5343,
M]0-L(%, E#2&)@<-L1S!V(_N/3GT.#7T5%/'/''-$Z2QR('21"KI(C@,K(ZD
MJ592"&4D$$$9!!J5_.Q?[?\ Z(?;_(/V:<&_/;X'\#_/RJ\MGH![@=_'?QZ\
M^58.IDL3#&4V])$3)XHS3-R[^F 8%SMZ#F)TD_L=CJ*9P%1!A4\GM6TO;JVB
MH1JTA[^PML0#UPI?:9!1T.>+@/$/NMS'@?<!L>E2(G#>J>8R1YC/X^\UM]J/
M6:FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE
M*:4II2FE*:4II2FE*:4II2N!*!N_<.P@(@(? 0Z_9V'STI70<JA>H?7+Y^1P
M^P V-YB.VQNO0!'51@^7T?,8Z#P\:QD,#D9_'\2<UU@H40W^/EY^8>NX;;"
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MAJ33PL&=Y%J+ <IC(2LNT2.F9(Z;=/F!12]+.1@(Q:JSL3PG)$L@ZB).\"R
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M01S0I#+ID:6[:JS<&-.LY9GN)%#18XEDSWB*3Z[R(>WPBJID5D#*,R/ 0<$
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MM7#Y4#+JMV+5(YQ(B0 CW-]?W[VQO;J6Y]'1((!*Y810K(SK%&,!50.[MP@
M98FI=W>7%TI-Q)+*RQLBE]^%<,<#H!DDG;Q-3W$CT$J@R52V Z4S: $=]MU$
M[3,$4,( ']=0IA]X#O[]?H#V%9).S.F+E<'2>SH(!&P/970B!YXW4DG(*D'<
M;>+64QCC,B##+JG:#.?5]=.TFKHQQRP[ OYA@W(FMMD<SR!Z-(UQV9-PJNNV
M0*JX<OE) 61TS JB@;<S<&B?LQ$E"J+)F CD")(G(902[MM+!<X;*DY)Y8(Z
M'?8G/+?ES%>A0]MIUTF6TD :4R1JK-)*TQCP<JG.,1*8U5@SJ2K@*C#B(T<P
M9P_8FX=J;!4O&=7CH]*#K\965+.YBX$EVL47#%,G%A;;)$0T0XL+EFB((I.'
MB7,4A"!R@;<1VL4:Q+PKOXDXXB03DG'09V'3)Y9KEM6UR_UFZDN;R5F$DC2K
M ))/1XF< MW43NXC#8RW">?AL*R1:G!0C4R]-SND@Z^Y-8P^@AV]_O\ +6>,
MY;H<#F#^0_ _E7+:M)BU P,M*H&2.BN3[#M\^G.L(W_(++&-!N%[?.4FA:U&
MQ\LV64.!">VQUD@I%!,QQ'8 4*S5 X[_ %4@5./U2&VVVEVXN+KN6QP/%*)&
M8[)%P_M'/^HA+>)QO7,WNIR:5H>O7\"LUY!:Z7_5T4>\ESJ1[3:"UG9Q@9S)
M=R(8549V+-@!36JO#WCB9KF%*>\4G+% VB<9NKC+1[F34/&Q<K>)5Y;):,-%
M.R+1Q3Q[F:<L"J*M53>(D*NWBB54GK-@(Q:0BXM8B9>.XE'!P3+)<2-<.AD7
MA<]V\A3!('"H4C KZ=[.:4_9KL_H>@V]SQKH>CZ;I*R85HYCIUE#:/<$<(.9
MVB:8L&!+MDD@8/LMA[%B53QU6W]7NMN0>6=&)DK&O(S[R5:NUI0$4G:+&/E3
M/&44JW*H1BBM&HM9$R31(B<@DX'VD>6U*YBGO)DN+*V98&>. 1Q=TRA"2G&\
M95Y58Y9A(SJ2Q/"0 *[*W:ZBA4Q73$R<(D[U490S#'$B\*A63]T?=)!#*<UE
MIQ37[%9@A'7:XHMI%THWDRR%C=R3I=,&;EW_ +'.I$7#N/7$[7J:)68N0 ?&
M,X,V05:N(/>6[@F2QM"T:@Q]W"L*@\0'[58BJRKZV0)5?)V//(S][=H55;MR
M)#PL9!&[J,%LQ'@&&('#PE64*Q8 %=LS<!ZQH1+B*QB1T]>1V/<YOW,6YDGJ
MTA(+AE&FU#,TN=V\<;KN%BSN1) HJJG44.F*0G4,;<=>9ZX -4NR$C0.ZN$B
M18XUXXT8A44!5'$3L !GEM7;:4S/80%F+L Z%V(+-P.R@D@#.P &PVQ6_NM3
M6QII2FE*\UN*)28L'$3$,XN9?5];%>"RRC5XU4; W>J9NR"Z9O$7S9XD\9NO
M84,!-S- >,5DFYY%91$IG(IJM>N[)I"TUVT\"3Q\$4>&#!@6+MZCHRNI)1>+
MA/K+L3@D'G>T,TT4=N()5C;BD=E< QN%" !\C(QQ$@JR[C?(VJ"O*=)L$TW$
M5=[:@\<.F;9X>2G74JS50=N46RQ&C&7,_:L5!!7]"9JF1X4I009O&BYRNB=F
M)+9\++8VI15)3NHNY<%1E>.2(H\@)&&XV8;EB#C!YMI+Q!E+MF9BH;O5C*8D
M]7B10JE74GB0!B&(56# [<KTU^R59HQMWN**,BZ,WDRR5B=2BRZ(-7#DQ8Y:
M2]I7CG!C-P$%(I1D[('Z4KLJ**[=R[RWDR9;"T9HUS&8X1"H.0O[18B@D7#'
M:0."< C?(&2[1E5;MR')5S*(W9=N+BC' H#''#@AEX26QE<UXU?*;TF1B8^S
MO:[,V1ZO"LJI>BLY.37FGTC(T6096DH-G;XCF0*=TSA5(U))FLV*=91))<5T
MA(DETUFB76C32"W@$ULWI$0@C[H%;>9)FB[J(JA:4*R E22)#R.#7"]NM+FU
M[0->[/&8L=:TJ]T^&27@XX+VXM9H[&X60*N!;W9MYB6#</= @KO5^LU]3R;8
M%,E(*HJ%R%7J%<"BW$3(IG=T2MQ#M) Y3&*9-I+0<DQYR&,'BM%1$PG PAZ-
M]E:QV_9JXL"<^A:QJ,).Q#1OW,T;]>(2)(K#/-3MD8)_.#[4M8DUSM4O:"2,
MQ2Z]H?9_5)(R&5H+D:5;6-Y;D$#@:UO;"ZM7&3B2%@Q$@8 -IL M/81EGHM-
MMO!\8XAR[;;<V_/MMMV-Y!KNOZLTSO>_]%A[TD$MP ;Y&^.1\\CS(KDCVEUL
MVPLSJ5WZ/CA[OOFQ@#[O%@-C;QW]]56%'1"95M2:I@%1S5H\S<!$=]FSI,7>
MPCWW%PVYNHCT+OMT'7E?VTQM_5.ARJ"(A<7"^0(.#GEC_*)C..0P/'LOL$N4
M';OME"_#WSZ5I;H.(\10!.(X8@;,"<C=B0#RKT7QIE%]37R*)E$C1ZH*IJHO
M%WA(\IE$^0KE9)H5505DN4@$4*W5,)?J& "_6+\PW-@L[]XN V,\.<@GD<;C
MV[XP>1Z5]S=G.U,VDRI&Y3N&X@5E>00*2N [+$'?B&  1&Q(V(P,C ]DK%.L
M.8)G.BT*(9%GJ9"8_D9I20DEDE*I7+'9+7!QR42N\6BVZT?-VV>7)*(LR2JR
M+T&KAZJU;MDDLMK:);?O!F.1SV&_3.^3[-O'Q@:OVDO-4C[AFX+;TF6Z$8"A
MA+,J(^7WD*<$<:A&8J.#.,G)KY!<A&+TQMM@:.!ZCO\ [T?8![=QV#8=M^VI
MPW(P?9C<^W\/9XUS-Q(%@F)  [F3?.?W&QRY;D>^L4-C'5<-TT]A447233 -
M]Q.=0I2 &P[[B80U) W'F1X?I^.:Y2V$DMQ;QQ =[)/%'& Q+&1Y%5   =^(
MC&*T1J9TLU\0N1+VWE99I5\<4JF8EJ:L').HI5)^=H2T6YJNLT43%9N0CBI.
M6R(?HB X5$1.;MZAH5N;=YS)%%(R<8?O464">ZD,\V V<%K=;!N+&=B-NOIG
MV0<%_:=H^U%J7BM-8U2VTK29%"CO=$[,6K6UL\996 C76]0[11!4PG[+J2<>
ME7"OBEM.RMBLDW<+8K.5A1HVKWS589");,V[TTJV,L_:Q:S-.56]G:>R+$?"
MLH=-9PD]7=K\CDN;7;F.&.*"*SMA%<<9F$L0E+%> @(TG$8QEN)>#!&%Q@9!
M]PLO2'=W:YD$D>!&8U0+@EAQ.I0ARPW8$A<Y"@#GNLVJ$L[8IRCR\VM2=%$R
MR;EK.*-H4%2@;P3*P3%-I7W!" 5/Q0^:TVRXI@9=LMS+>/S1DM5S$EA:B#D5
M>+BGP?O 7#EKA#S Q+E<G!V&-D)+UQWINB),<01%0PCP!0J2P(_>+%CDX(JF
MQ\W<4[B<X>K3(STU,NK?!Y-QR[._E#N(T)*RQM2N#<\?'%!*/8%]FH,J/+&-
MVC93GYB-$DBI)(<IVK[HP6O<P0PI%/(B\" 2L'0$=Y*<R2X[O;C9L$G<DDG>
MZ!+,TTPFF:0R0JY7"B-"K\HPHV4=YC+$EL;[YQZWZXBNIII2FE*:4II2FE*:
M4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2
MFE*:4II2FE*X,4#%$I@ 2F 2F >H" AL("'H(=!TY<J5%D1%$YT3"(BDJHEN
M/<W(82@80_OD #B =/K=.P:FXXU4[ D ^//F/=_+J:B,"C'&X.3[P,[Y\?[N
M0JM$2B'8!W[;AN(=??VZ=0#KL(^0!JT*V? >((Y>[ZZU0LI7&Y))Y\A_/GUV
M_#I,8  2AYAL/IL/E^>FLF <8QC.?>#T_,]:QU&7C006 X)J'#J!@2,!1.4-
MA*!S#]8H (;"!=^<HB ]!$-7<_'E@X/, Y'0XQ\,=.=5SMC;8Y'P.?RZYV&/
M*K9)*%!114H%,J;F$@=BAL  4/4   #?8!';3\]^GGX<N?*GGG/7?Y\^>^WY
M8KX=( <# (#MOU\^_4/O_#KMUVU>AR>>_,_RWQC)\O9X6G!Y9W!V/,@?#',?
MW<NJ*G#0QRLGPF-&[\J2WZQH_?;8A@[F8=Q*(<QV?ZH 9KL#6R:V[S+QCU^9
M7HXR=P?X_$;<?,>M][+#-CU7.PP 3TW(P>OQQ[,;C(A#D4(51,Q3D.4#$.0P
M&(<I@W*8IBB(&*8! 0$!$! =P';6NY<ZF5&[3( QCTR[@!G+E-( WV$2$ RQ
MQ#X"0A1_S@U>@R<^'X_6:@W\PAA7?'&X7W %B?=@>W->+&&'4@GC7'*AE5$Y
M9IB"+0;',8#JFE209'K\RH'*9,RY'82)CE5)RG.R1\4#&)MKUK2D5M(L,C*L
MUOWN  0O J<^8SE=P<^NV.9KSN_D8:G>,I*LL=P83XL2TF<8(P/6VQCU!GE6
M4S2;A%[,3 /%4_';4I<')>50Z$4_,W4?@@DH10A0,HFL0J0)B!166.0H**<V
MIXC#)#"$#,K7BE1D<4B*>#B(QDCU#SWQ@[5'$C*\T_$02MD>+GP12E>\X0<@
M9PVV#@ECCBKY&2E8Y:R.!7*BNK.1Q4C$,18'3E1T90&1?$*KXC,\ <RH\P)&
M022;>"8##RD&**1+8*"<0RELY7A51CC."-Q-D=0Q._C5.\EC:Y8L QGB"<FX
MF9L\ V/J& YWX>' X=\8\.>-G%\O7WUX2K)%@L=%M(Y+QNZ 1,\.O!RCF29L
MF;D?TB:\E'%E*>LZ+]8A7CL0*8.@]FZC5- BD5%DGBB5^#&>*:)?VD6-@HN8
MFDA8\Q'<'G7"=K="CU[3=<T"29K==3@EAM[KFUI>1RK<Z7?CGDZ=J4%I?(O5
M[5 :R_A>^1U^QY V., GL3UJDNT*@(F;),7J*4C&MVJANJ[=G'O6S$%M@$5F
MJR9P!1-0H?E=]NO9E^SWVD:T4 -GKG==H+*4(#WR:B&-W(=N$%]2BO6"@D=V
MT;;!P*X7[,M;DU3LG:1W$+6M[I$]SHU]9L#_ (E/92D1V:D@%A96SPV;,0/V
MUO,A''&P&3UW  BL.P]$E!\NFQ##OV\M>0I&>)=OWACU1X^./9OY;5WTDW[.
M3<;(QS@[84[[?&OC$LP5!:TUY50>=!\VL#%$!'E3CII#P%RDWVW-\^1LN[7
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M"5(A'/@,"T=OW8QDN3C.Q)SQ3#A8 X&#@; UG,DIE@+$$+-<"3. $"[$# &
ML!#(V['.#RK+?!%(IR%^XEET')G2:U_J0KJJ$(FX,\;X$P.FJ+I(@ 1)P *
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MP,DUUMY5#Q8IPL]%-7YUE9Z26 A3G0%PGX!8DI#AR+*/VS R)P.!$2$D$2D
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M0&"D.'PW?!E"!9"S9 4*,#A"D# P?9@7BS-S/8Y!8.8" F<JHAW1!843>.(
M0PB0/!\$_P!7D3!?VA3]$@8II QE@>,*0R,8R0X5LY*%3E2IP05]88)&XP,"
MG#;\)PRD C()7U@&SMCR.QW!VSB%MT (DB[=K(Q[%CN4D@4R)4G#$YR&$?;3
MCX2;DXD.0RR2B:1R+ )#"4!14C&&0E.*2-%@=HTD#O---9LG"$:5GCFBN6DC
MAEFD D#D<.7+N4D&10& #.9 &*E51(YAS98PK(T2JS*B^JPR3ZO",W&JN59:
M9E9=(AR1QB)M&1CD43%=)(3',MRJ !P!5PJX.B!RD4*W,D"Q"J@<I9@W+-C
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M,&C0&1 O,R6/!'G ]9'WSYEN AN6 1G(VE.PC9F VBOR\@QD\++ZA&-L</>
MJ3D$\A4>M$ZUH==D+-*%*LSHQ;DJ^(0>8[VO0L.:<=QR9!,47#]ZU=OVD6B
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M]0_Y0_QUX_PG^%?B?UKW;O<=3S^N?0?W"M6N(JC+6^IO6\4W*XG()XC::^U
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M(TD<B'AE?)[Y0/4E)=5+\8&1)PX=65UR"M8GC8/(DB*KHVZ@C",=BF%)X<;
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M%X&RP/>-GF"K$HK(.N>%G#*H[L#BKND.,BN!.Q!F%:GUH8B3HLDX%%)-0#K
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M/P\,UO.F)8)T)CEB970D,*\9L.T5AJ5K'=6LCNCC#1\*B6&1=I()XR0T,\3
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M&YR?#;W#VYTH6[U;4(;6RMIKJ\NY8K:RLH$[R>:21PD44: G,DC'D/5!8DG
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M+XB@,TTR))@"+-)($4Q55.Z=NNITV M;0Y14CC#1I&H' HXFX0  .G",8"X
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M@=GS=!8[M]+M;BXO=0O=4NHP+6\[2:W?WVM7=A'%9++9V0DM9/64]H9V!RK
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MQZT;<*RKL.:$[CS4LO\ :VKE&@92=@P4X8J!A2<X5P0&C;GZCJC[<L5B;/?
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MN;687=RFQ*R;?OI@^'-"NW7[I.V-ZV\6OW"@":UAG_MPRO;N3_:$@N(RWDG
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M-'HD=&IP,*V35:,6J#5PLDB8[1!)$A$D&""::3.-023 $TTH]LV*5,"D$!*
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MCU_N\Z^_H5\IQ_VRG I_S)L^_P#Q]Z;>!^(_2J[_ $/YUS]"OE./+B4X%?\
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M>@=[UCY\_#?F>?C@;9^&VVU802-P<8\#^7NW^>U0<T)6V:PN$&#<5N^Y2 !
MVWV$1 .H!OT*7</4?(:K;HIV4 Y\AX=#O64RR$8+'&.9&?83SW.V^,C.1SJF
M?S*#<H&65*F7J5,OO !'D12+N8YM@'8A"F,/?4E5(QCEML-SL1D9V'Y[;9WK
M%D=.9ZD[[\]N7CXGKG:H'*3#Q^FJDDHI'-U"F("P;"^4$P#RB0H")6Y0$0$
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MI%W85I%$XE$A+6[!A*L31NA28@@(Y.$W)&1OABX$+&0295"8BO!@3 @QF3O
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M67^3EQC,#G$R][OJ9LZXXXBL:3YD@K>\)$\2+O&[VTOH03PA_P#7\$KC.)"
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M]8//J(AW]![_ ("'4-24@.VQY^SVX Y>_P#"LZQ'..77&^?,8 SSP03@#/M
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MY"M;BDPV)8O&D.TSDSE(W&V/[:WGY?,#UW!6*;:L8>%,YL%IJYE!_(?A^?\
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M'1ONNK(?8P(/R->7CHQT5ED%!$#HJJ(G*&V_,D<2& >VP@)?/KW\]=PD>0&
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M?\1_"M6\,T*BP"<E(6%C>F=RI%[LKKVAK)6"PR:,C/Q*@"H]E'#44ZL%EB6
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MFF0H%(0A"@!2D(4 *4I0 "@     :\8))))))))))R23N22=R2>9KTP
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MB:%X9'C? >,R)(87*,I:-V5O4)KYGZ'7D9:"*[8A,2+EPX!HO8'DE9W3)))
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M-"H>$JO[$MX\9 ,BLV3Q!3GA((!4L!PL0>? 648QQYV7IC&&Y#A!W!(YYY$
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MC9T4I3':.UHIVZ*T>)@8OBLW/A.41$ 52(/37#W=E>6$IAO;2YLYAOW5S!)
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MF_DX/@1L1!E[=W;9$%C;QG8 O)),1XY"B(;G.-MN6YWK%,QQ#\6^1$CMK1Q
MY"38+!L9G3C06-/! W<&\OC>#J=D O4=A7G'!P#ZHJ&  $-U;]B>Q]@0T>D1
M3N!L]Y+-=\1!.,PS2/ <XY"+A/@=JUTO:C6[@8]*6 -GU8(HTV(Y!B#(K#H>
M/(.^>50ECC-C+2"$U80<V6<3-SA/VAX]LMA,H._,=6P3SB0F5U!WZJK/CG,(
M[B8=;8-;6:=W:6UM:QXP$MX8X$QC;"1HB^ QC&U:Z2XN;DEIKB:9N($][(TF
M#RR S$+CP4 #?'6LXP5-:(\GZ(H!TW$ Z[A]GQ[]-NX=!UK[B\=L[D?'ED?#
MD>7RJ]0O@2=LYY>9P-L>.VY.^!RS%"UYFF!!$A.FW3;81#SZ[^_L/O .G36F
MGF<YWY_6>7S&V=_*I"M@$<O/GOYCP.#RZ>>]97B&+1$I! A>@!Y (]=OQ\@^
MSS[ZF9V.=]\GQQMD>SV[_*I4>!C.-^9Z9Y8WQMMR!WWY<ZFR":0%#E*&^P^7
MEYB'O />(==OCKR3DYSG.1Y]-]CC<8Y#EMR-2A\.F,\C_//X;>%S1, AMMMW
M[!L ;"'7< 'S["&_IK"PP3U]O/'3/G5:K04  Z@/3N(%$0$NW<! !W$-NW?R
M]^K<;Y^O[O'S \\YE.>O+GGY'RSOD=/F:5Y\W.D%&K]%)RV5#E51=-C*H& H
M@8!."B9D_JF #%$=N4P (#N'2X YVY^T9_&A*\B?Y>_I5I9GJT0J8R,@S([7
M*5(SF1F5'\BJD40%-N5Y*/'+X6R9MS)-2K"W2,8XIIE$QA&[@D89".1SV0X^
M0 Z_A5J]TF0O N2<XX1OYXQ\?'GO6-LH4EU9K3C*T(*I2;2F2\P[-6CD0\=Z
MYEH5=@:6B'CER@U2DF,.$K'^SN!(1S'3$B5LZ17,9K)0[NS-Y$45@CQL)5XP
M2AP0A#<*LRD*[<+!3N</A3Q) U.WCNHH(I"IA].L'G4L<-!'=1M,G"/O]Y&&
M4(WJL_ 3@C(K,SV$\KC]Y!PE6MTS*3;N,:IM2TVRH%CT6SU&2=23U5U%))HH
M-V[%1!NJB*P*23E@0>1HHX=M_-NT'9G5[[1]3L(+&.ZN+FV>WMXS>6"H;B4A
M(I3--=)"@MG(NF9Y P$)"!IBB-SVN17<MG';6MJ]Q+=7EK'G*K'#'%,MS/-*
MSE6P8X6@B,:R,;FX@1@L32S14?#K4)C'V$<=U.U,VT//L(ERH^KZ+MH]0K(R
M<K)2[6J-G+%=PR6:UAB\0@V0M#@B#*-1%-!JF -D>^T6SFT[1]+T^XE[^>QT
M^RM)IP6*RS06\<4CJSJK,I=3ABHXN8R"#770(8X(8G;C:.*.-W8@EV10I=MS
M@N5+D$EAGUCG-2C(^.X/)<*RA)24EHE!E+(2P.(12-3<JF2:/F)VYQDXV312
M(=N_6.B[:HMY-@\2;/8Y\U70W-H^VO8O3NW6F66E:GJ&O:=!8ZYI&O1S=G]9
MO=$NY;K1KI;NVMKFZLI(Y9]/FD4"[LW8QS@*QX9(XY$WVA:[/V?NY[RTM].N
M9+BPN]/=-1M([R%8KM%222..0@).@4".0'92\;J\<CHTZ,BR,(B)4^HB/0=N
M_ET\@\@UV(9AU/OWK283R^/Z'^7A4'FF$BT?O5V,<:;AY>.(R>,&+UFSE&CL
M@+)^.F2278Q[MDX04*1<1?MG;-5$ID6\@1R;V*QE+NQ9_5:!X2N-_78'B##.
M" 67D=B,$8WTFJZ7+>-');7*PR*O=MQ%@.#B+<2L@)XU8@J.'!WR1C?6^[X3
MHM0Q&R;RMDCZ!6JH0&JC5>'6R4T392K" J<;#Q#&0*VEI:YOW<=$QU>>1C-6
M6?RTW(PD;!R2D^#97Q?[8OL9TC[6NR6B]E]1[3=INS&GZ#VATWM(+KLYJ3V%
MU<R:8\TD=M<3>M((A+,LT#Q.L\-U! Z,Z]Y#+[;;?:UKX[:]INWVM0:9KNN]
MJ1?2:G+?P1PP]]>,CR3+%;]W#%$L<?=36X46[6V5/=E%E2L/Q-T.MI-VLQCW
M++&*CFS,CR;>M*/-R#2/*3P2RDI5X"^S&1EU0(B*\@S0ICB>;;J'?1#=0#D#
MU&?M)IFGP127UZME;LZ01W-\QMXY'(]4"2<H9'8 DA>-L!F.P8CQ,]HNS[7H
ML$U:PEO&XB;>WF67N\,05D:(&&WP=L2NB@<&#ZRDY'R3-6!]2:W9L-@2U,9Y
M9E(%EJH>MS"[NNRD,\=0LM"#-KEA)"+?R*L.+IZBHZ4"+<F6;)H-U%YF)X/[
M9-4^V"P[')<?8CH_9K7^V,FK:;&UMVHOFM--BT60RF^O(BDMNEU/&PM@+=KN
MT#VLMU+#.;B*".3T;L9;=CKC6&3MK?7UAI LKADEL(WDF:]4Q"&*3NX;B2-#
M&;AE98''I"0I(.Z9Q678-DJI#1"L\@P:SBD9'J339@H*K%O+F:(FDD&2BFZB
MS-%Z*Z3950>=1 I#F^L(Z]2@ENF@A-SW:7!AC-PD+L\23E%[U8I&5&:-7X@C
M,BLRX) .PY61(1)((G9H@[B)GX5D,88]VSJI*JY7!906 )(!.,G3?CA9U>5Q
MXG#(LA5R%64GF4,?RXKQK1C#2E93^:W;:04?R+%5]'6V'G):HS3*,0DWC*"E
MI*<;-T9R,K@K^3?:=]OG9/[$-4[!#M(FNS7W;+M%'HFBIHVF-J(61Y[*SNI]
M1Q-$\>GQ_P!9VR7)MUN[M(I6N8;.2.VF>+K.S'V?ZKVYM=<&FR620:59K/>&
M[N#"S%TN)K=+;ABE'?DV<KQM,T-OQ((I9T$N#&N "0CY>G9PE$8Q=C8$LSD@
MY2$G2%C;! #!XJQBW?5>5;@5P9H]KMK6N#%TS,<[9*P%FD4G7AB=QKW#6+Y-
M1U2>\C=C!-%:& D#B1!;('C8 [-%<FXCD7/J.)  ?WN%LK9K2RB@<+WJ&?O"
M&]5W,\G"ZDC!5X.Y9&_>0H3C.W9A*K7+&V,*]C>WTZ8;6.":1JM@G8Z-D+*W
MLEA]A%M+OR3T2U?$D'#V3(_FG2CAP+QVM-%=.TB/U'8:^9.QGV1]H-!^T3[0
M^WNKWK:C+VGEM;#1(1/&\=AH<!6ZE4<4W&HO-1,EWP310SPRO.C\<30$<GVD
MNM0N[2/0;?2>&*WU2]UB;4(WB=[^:\>:*T5U#&6+T&SQ"58F)D>$H Z2$TU;
MP<ED7,9\ML)/)T=\UQMJQU+IJYVRICRO,&*!:2_01J=&I-NCW,2^7G E']S(
M:+KBMG=QM:4DWBYVB+EI[78:<%F>>:; $(MVCM)Q)(9A*7!DDMY.Y1!$%0\<
MK2J1CN"H#'L]/[/ZSV5TG2;75[86TVL:?;=I+*&YL)[9DTW4VNX[9R;VUB-V
MMP+<7<-U8^DV,B7#\%T9_2 LNQ+P]T)IDSB?71F\K-R2&6::Y?.8SB#SO'N9
M"83X?,+H.G,TLRR6F\DY(&"421%W-.9"01B0C(])V$:R8-6TJ*UC,MR.*< 2
M*,B>4%CW:,>(A@6(! XFWP H]516PDG8QP B(CNVQF&$C_+2YX04( SG90!D
MD[EB:S[_ $&4?_KHS=_SE^(K_P#-+4CT2/\ TEQ_O$W_ +]8^_/_ -C_ /@P
M?_#K4OBHP774QPW(-I7-\U7H?)Y5;DP)G?/L\X914W2[A6HR>0;O,@R"W@,I
MN691,LI%D3<Q\3/.Y>17;0C"16#R3[<M'[>WOV8=ID^S!6N.V:6IDTBVF O%
MN9U5@D:V]PEQ"\JRM%-%WT$D(DB4S PB13C>6T>2W34D673#<0'488K6&22X
ML1,AN80@C!97CRTBH>\9%9(AWKI5HHUT+3\1R]IBTK<[BJ7;\GHPKV=4L3M>
M,@ZSEFV1-69V&W3J;\R18J)CXR.<+S+]RZ.V:"F<7*G0_1]GK/61V<TBZU^"
M.ROOZHLSJZW92VCAOVM$2^B,0#2+W5T98RD$4AC*X4845R_9#L#>=N_M)T'L
MOV<LK^TM]?U6RL]*2RLK5+Z..:V2:%;73[RZTNVDNPBDK;2W5G$\H*//"I+C
M=_$5=2JU33:ISK>1C%Y:TR<%'1?LPU^OPUAM<S8F$'$KI-DEY)I"-)1O!QCX
M_LC4T1&L@91,>4ZQ5>\MEB2UM4@?O8EA0I,05:92@*L$XF$:!?NH"S#DSMPC
M'53PW%I//:WL4EM>6LTMI=6TJE'M[FV<P7$4JL PE2:-UD# <+!@!SJ)&KM;
MA<GRMLIDY*GMUGDCOK)$Q;:/G(M[+MJ["5449E$OS66)55@(2N_HW]DB$5%:
MQ&.#@JN"GM.2;2[:[AE:YB,?&J?MA(T3,$(970,)58HJ\&8X6/ Q&V<UHKZT
MMWO[._RWI$$=Q:!D=0&@N 9.XE^[Q1>DK',J!U;OE1CQ*&1I=9ZHTDIVFRU\
M]FGY--V8D+&*LFZ,'$N2E3EE%THXRD@H^D$7D7'K>*[D7C-)1FBZ2:@LT;N4
MM>FEZ5:7=LT5HC74:7+VUY.3-<0ED6.8PL52.!GC_9F6**.?NW:(2".61'@P
MM!)J=M(85>58)TBE;+&)7,9D"(257O#'&6?&6"JI)V FZZHCN<YA,<X\QC"(
MF$1'J.XFWYA'L.X]/7OK< #90-ATY8P<# &.9&<_J,= 2=S\SU/B3X#]?+,2
MDCIG*?F*40'F].@>?D/7IT#U'OZS8@1@>SXG/X'KG'EX1I&#9QR&Q..9Z#\S
M@<AC:L7S3!HN4X\I=QWW'IL;UW#S[]!\^F^_;6UB=@1@GG^GQ]OEO43)&1G(
MZ#J.?PY#;GX8-89GZPT7 ^Y"B4V^WU=_V>0_9MTWW#ONK>Y=2-\?/8$\L\CM
MRY'R&:CR%<;KEB1@C; SL3CH<#Q ZC.*P)-8Z;M94M@ASOH&PMR FTLM>?/J
M]969 'F &%CA7$?-Q_+UV,R?H&+N;8>O7:EX+N/N+NW@N8CSBN(4GB)QUCD5
MD)Y[E3[=ZMCGN+5N.">6!\YS'(48XY%L$<1Y8!!&, ^%9%@>*OC#QL1!O!9K
MF+%&,Q*",/DJ%@[ZV4*0-A*]L$BR;9!>B< ^L=>\^)N/-X@#WT5UV![(:AEO
MZO>RD<#U[">6'!/40,9+9>?)85&VP'([2'M9K-OLTD=T!C:>)>+&Y^]$48GS
M)8[BLRQ_RJ_$7")A])<28CMRI0_2!"/;ECX@[#W!5\]R5L)@V#_%; (\P!ML
M36BF^Q[3)"?1=<O(0<X$]M!<XWY$QO:D^WA'+EOD;*+M[* !-IT;'J8YWCSM
MOPJ\3_O#EQ[ @9)&3=P^6*R8F79;A,J:I]^ADN(F81*(>7U#\/JX@(B C_C!
MV =NHAN:,?L77]WM,,8ZZ1^/_"8_#R]F4=OD)_\ FI\>5XA/G_FX\1]';Y-\
MLGD,H@(\(D#X8K)MO: XAYP6A72R2ZZ+11X'#F+5-XNW;.7"#118KE=!LX61
M2.F@J8G.W/8+LU9]HM.[(7?VBZ%:]JM8L;O4M)[.7$=I%K>I:?8'%[>6.F/K
M O+JVM<'OYH87CB"N78!&(VD7:>]GTVYUF'LYJ<NDV<\=K=ZE&&>QMKF;A[F
M">Z6$PQ2R<2!4=PQ+Q@ F1 >[_5CLA?]J36O^<=*_P#P[ZWW_P C#?\ UDC_
M .BC_P#G&H?^'EI_Y/NO_P 2']?[O9O3_5CLA=/_ ))-;_YQTKT]_P#^SQ^_
M3_Y&'_\ K)'_ -%G_P#.-/\ #RT_\GW7_P")#^M89XCOE@,H2F!,N5^'X5H5
MC.W&A6&A5QXRX@))^[:6;(#%6E5IR@S5P&Q1<'1G9Z/4!)5ZU3,!1YUTB;G"
M)??9')96LMRNNI<R)W:Q6XTTQF>:61(88>]].E$8DED1#)W<G "6X&X2*RV_
M;:UN)5B]#FB#!RTC2Q$1JD;2.Y4$%N%%+<((+8P#UJ'X$^4,D.%?'3.!@N$*
MMV_(-LD(%I:[0PSL^C[!DR\OS(1$2U;-E\#N_F*K1 +!'5:OKR[J(HU2:**.
MY%R9":G7\S5?LLN9WEO9^T7?SRLD<,$>E'+.[+'!;0\>I!$4$JH+,$1 TLC!
M5=JUG^'FD:18R2RVDEM96<,EQ=7#S1D(D:\<LK\"EGD8[*@7CD<I%&I)5:WB
M?\;G%*Y3;2<3"XIC6CI4JKN+-BZS6]M!)&,GXC1K:$.(6F3MQ;(>*<@3R&*J
MN]=)M1=)4PBK@(YOYSJ/9:32KR6PNM1L&NH,"5+5YYD23?BA:9K>*)94P RE
MPJL>%V5E8#C5^W."ZACN].[):Y<6,CMBYN9-.MCW(9 EQ':Q7EU?31."[XCM
M6EX$S%',66L<Y#^4PO+IQ><(9BX+L>6 "1K)G8XAWGI_)U"]5&R-#KPUIA6C
M_A_7.[K%@*W>HMBNP%W%SL/,PRJBDA!K.C;_ +.=@;?M!9&\@U\VLT$QAN+9
MM-XWMY5PRD2C4(PZ.I#1R<*9(8$*R,!Z%)VVB6.&0:<TD5S"LJ.+I.!@R^NN
M3"0>'.XZHR.0 X%>1,UQKW3&5IF,?.<*-I1C')I3E0>2F;9:2E@HLR^E$*_%
MS,X]Q&H\L4U7#Q3ZO/Y]^"<I.(1\?.S'BRDLZ<+^KZ3V3N)%ELY]7CFN+..!
MFG:S*&X@F5Q%,R"Z?AD,D,T3@.^>[68D=\%7E;W5;8,MQ';20PSM)PQ!E<1.
MG"716PN5X71U/" .,H">[)-K?_*+VADW(H3A[9R#QRY;1\9%1V7G;B2F)5^N
MFTC8F-0-B-,BKV0>*HMD 55103,H*SE=!LDLNG/N^R8LK>2YFU)2D8&$2S9I
M)7=@D<,2^D -++(RQQ@D*78<3*N6$:#5([B5(HXGXFSEF("HJCB>1SN0B*"S
M'<X!QDX%>E'#=QXW# V-YPLAP_8^G+K*6V"<W^0_P@YIG-R\O9UVL=#,:U"C
M@%V 4NEQKN-@HH5Y1HI(J,['/*-#SSR:.^^,OM%^TK1NSOV__9Y]B.JVG:R^
MU_[1-.%]!K6E=G#<=G- AD_K1;2&XNI=1@-W$)M(NTOY[8++8B6UNY[4PW$K
M6WM_9G0;B\[ :[VQLGL8K#L_/+%+;7-X$O;YX8[22X<A8G6WE=+N$6L+]X+A
ME:%9481&;:9'Y4V^+;;<,]<+N/\ V=I0>P]>HX.+U#T]P]=>^G[*5'_Z0'RS
MI('_ /TSCVUP@[:Q_P#DY_\ >E//V09^7MJYI_*;9"6ZDX<JNF40Z ?-TL<W
MWAA<@#YCV#;MU[CC/V71KSUYR?+2U^?_  EMM@U>.V2GEIQ]]T ?'D;??;^=
M7!'Y2;(2GZW#U5B=MMLT2P]_CAT/W>>K#]F,0_\ IUSC_P#5B_\ YQ/O_6KO
M\,%/*PSCG_C6X_\ R;\^AJXI?*+9 4'_ '!JL7?L 9:EC;;[;!S?T5D 1#?O
MRAOZ!OMJP_9K",YUN3('_DU0/_7_ 'U4=KN(X&G],@FZ&/AZ/OMY_G5R2^4'
MOJP;?T'UE,1\_P"E*55V#?OR_P!&B0FW#^\7UW';8<1^SJ$<M9D/_P##E^'_
M (\<GQJ[_"P=;'_\HVY]3W/E[C\[DCQZWQ3;?#59+OZ9&E!VZ=NM!#X?'RUC
M;[/81RU>0_\ H"G8'&?_ !S\,^W<5>O:GB_S''F;C_\ L\_?5T2XX;ZML(8E
MK*8>@WN55'?N/UOH:B';;IRCZ[COTQ'L';CGJTO^Y*.O/'I1.,9]^-ZN_P )
M_P#[GOO_ ,?_ /V?9\>=71'C/O2P?[E]9((]A^F4JH >6_+]%4]_@!P^(=]8
MF[$0+_\ 2<I_]#0>/7THXY=1UJ]>TC-G_$\<O^/S@GED"+/Y\@-S5T0XN[TK
MMOCNM%W]+-*C\.HP(!^(_?L&L+=CK<?_ $C+Y'T5<?\ \^L@[0'K:CIC]L??
MG]F?PJ]M^*:Z+!N:B5Y/W!/2:GV[C$I[_#E[>NL1[)6Z_P#TA*?9;H#\._)_
M#Y5=_7QY^C >V4_$?LQMN-\>VKRAQ)VY?8!IT"F([#N$M(*; .W]7V%/[^;M
MUY1[:PMV7A7_ #V0[;_L$&/#)[TXZ?6!60:VQY6X&^V93N.N/4'UU\+PAG^U
M*[<U8A W$ '9^_V#KMYH=_=]O76!NSL(_P ZDY9_R2_@&_,5D75G.Y@4?\\_
M^[RY?.KNWS79U?UX*%*'N5?>?8.I^_Y\]8FT&)?\XD_V$_7/RK(-38_\4N>O
MKG;WXQ[ZNZ.6;$J(;Q,00!#L O3#O\16+T'L'3[1UB;1H1RFD)S_  J.OGU'
MP-9?3V.XC7'^L<^_:KXVR+.+[<T?&%]=@=#M]ZX?MZ=O+?6!M+C4$]Z_LPOP
MSG?X#EGKM=Z:<C]F-_[1//EMCP]_ER)D+6VRJ^W,U9%W]"K^[KU7[=QZ;_OU
M'>RC782,>?ATSD<N?(>WY91<,<>J-_,G'/GMY8]OLJ0M99VL)0.FW#?IL4J@
M#Z_UEAZ?MW#4=H%7/K-MX@?#^?\ ><@F)Z#.<8S[\]-OKKM?43F4)S&  W[;
M;_O$=_+KJ.P . <_7*LJDG.<;'P/Y^^N[5M74TI32E-*4TI7Y("U-F [^$G^
M/7\>GPZ_'KK[1])?QS[0OY?R]M?._=$\^+RY>WK@[]3SZ>5=Y:PR+M^B3_Y.
M^W;M]8.OGY>>_75#<.>I^/\ ?RY >'SKW1\SGGD_#D=_[_*JDE>9$Z^&GOOY
M$#]HA_(/(-4,[^)^/\OKSH(O$?,_J:N[&.;(FVY"[!L(!L&_3S#H'4!Z[^7?
MW#ADD8CF?Q'/F:NX># VQGF.8\B#D$'?(WSS.>5:[\0] G<C7_"%<A8Z#D(X
MT;EQU+%M:=N-5FZZ<93D8ET^^ATM /R2R"B[L80QY5H8!^<!:JI+_IDN2UNU
MGN[O3HHU1T*7K/W_ '_< A;?@9C Z-W@)/=Y=<^N =LC<Z?<1V\-Y([.K<5J
M%[KNC(P+3<0 E1U"D@!\(V/5!R-JCM.R;G[%U@K^(5ITEY>8]D*%BIO%VC&E
M[D+/EFF,\25Z2L?$O*Y*BY>7:1S1M;U)U.6CBQ<^"BM<>4U>2D<@VF&=):4W
M&I6DD=BTAG:U:"T1)K:=I+R%;.-GU-[I68*HEXPR<+G$31$M/(C5L.ZLKB-[
MI5[D3K-<$QSQ".V=KAU2P6$J&8F/@X&RFSB3A6&-P:K$?$%Q#6^7Q+.6>WMX
MAHF^RW4;0W_H?GF..[S<V%0Q[;JLTK$_$6JPRDS6UUI>Q0D#9%8.&L17E;M5
M??TX;1%/O&UL-[J$S6TDLI0!KN&7-I(MO/,L,,L01UD<M&2[+%)W:.#'(AC,
M@.9<MM9QB9(X^+*P2)_C"--'$TDL<G>*410X"J[)Q.A#QLLG RU):7Q@\2?T
M!I;E[%1$];,D72?X>ZY*CC64A*DWSS88ND6C'UNA736YRBURP3 5UUE-:V6%
MRWI\\1Y0_HS)14+864LHZBC4+]H8F9%>2::2S5O1V1%NV6.2&12)&[VU5#/Q
MR%8WS$$(5PQK(UC:":10Q2.*-+IE[]7D-LK2)*C!D'!<LXAX4S(N) ZLR$8S
MXXXA^)*F(7&SV4S"2K$K&<3:%3C:YA>87F,>O<2\350PSC6<GWK[(L>QM$/:
M:/<E[]:G;SZ*,&$!5G]LB?&A(V50>X9Y[Z/O'D(9&%\J+';,3";:]CMH7=N]
MPXDCD[UR> !4+KZH8&L<%JXC1.(,#:%V><8D$]G)<2<([HE"DD?=H 6)9PC'
M)4C%2/')Q- P6CG<Y2:]<*]AW(E]K\,G@/)MZ=9SN=2S9D_']!IT$A"SL"]A
M$,IUFI5YU&+,(AQ(6-W).K126Q:ZQ=QJ6J>^N]@717$+RKBVED,[I/-$B@*5
M*]ZJ*PPH+DED'"2*V"VMO_"S(94C),\:")'@AD=FR&#=TSMGU@% X)#Q;C*S
MG)G$/&7.\K2\3(9BM]$XM[5*X^Q@-;M=9<U2KFX <LY!I,?&6"'L 0T]!6K(
M;1MC5G*RS*6J_P!(G-B=)L@LLK")UJTRW/>2\0,KQW;LD7"Z\"^@R2* RMPL
MK.!&-BO$2?O,  2'NXPI$:R6R!Y.)6XW]-CC<E2N598SWA P>$*/NA@V_?"]
M?Y[(>/EYVQY,A,GRAI1#QI2$Q!:\-(5Y=U!P\D\J3NNV^?GY%T]@WSUPDLLJ
MJTD(LJB=<L#=2PPTF[<3;21I8RSRB4D](6AX,@'@*L225SC)P<8!WS42X012
M +&8QCD95EXP"0'XD  # <MQ^\IP1C+V1<BP6,JNO9YU-\\W>1\3$0<.D@XG
M;)89AVDPA:_!MG;EDU5D9-ZLFF55Z]8QL<V*YE9F0C89A(2+7)+(EO&\LAQ&
M@XC@98DD *HVXF8D*H)W)&2 ":P/-%#&TLLB11QKQ.\C!410-RS$;*!UW9B>
M%06*J=;93//$(+59U"8)H,VR07<I.2MLC9;>$0%ML86DG*EX;$*LS6(@)C2#
MJ/GIYC'.D%F:1Y(3-EG.AONT<6GVTMY<VQ6"",S-PS&XN3%G'$+.T@N;G.,%
ML(RJH:1F$:NR\I)VTTUV*V%GK>I@3/;R2VNB7:6L4B$<9:^NVMK)D XB3WZ$
M</ P$K)&^2\1WRBYMAGSM.L'J-PJ4H6.MU9*NHPEH*679J&:OXZ=AOFM6>J\
M]'KK.J]8&_@(R+0SEG),(BQ1DY Q&PT'M)8=HM/34M)O#<6SL\+JP/%%*F"\
M,T$P/ X#(X#(.)&1UV85TEM-:ZA D\05XV*N-@&5T8, X4Y22-@.)<G! *EX
MV1WRC*U>1>>#[%9GJ)$#IF3:RC1M+- !-=NX HJ)&BY=43';$(8[N6=@*1CE
M,F;F'6[$RY4O&#PDG,;&)B2"OK;.A !) $8P>1%8VTRW,L4REU:$LR N60%A
MC)!.3C8CUL@@5K9F?$5WO+Y@^64:MFK:/5B5G,;$)W-S#H*.P=DL552<+04[
M7;6)RD355AHZ;,86T.Y]N*$*+>0\,^V+[$5^U_6OLVU6+[0NT_8M/L_[21]H
M9+#1288]>DCGLIXXIKF*YA>TGA]#>WCNFDE@:TOKZVN+&>.<A?1NQO;<]C[+
MM%:OV>T[6CKMB+-)[IR#9C@GC8/$89!=6SF=9'MAW3&2")UG0C(N>4LUK5:-
MBXNIIQDCD.XV-I3ZE"3IW3!JTF'<;+V!_)V)D5-&5;QM<JE>LEI=QXE8O)="
M$-#L7;5[(-G"?NE^RV%HURRAQLD(5LI)*QPJAU)4JH#.Q4_=1@/6(QYG>7JV
M5M/=2\1CMX^-U7AXSETC51Q#8O))&F2#P\7&P*J15IEL=<2"-8A[-7,TS;I^
MG&J34RVL43C,T8[*9$'A$&]288JAY1LR2(!N5B;*#>5*S,5FYE5I(#R6N%NN
MTE[9Q7<Q5[R6W5F2RAMH!WQC.6CCE,\;<1P54,S<?(/DJ3HY-8UTQ0W4.D:6
MMLR][<"XU2\CO(82O$ L(LGMC)P99B\Z<+84Q#A8"JQ#F1_DZIV%K/)E@;I5
M)N1I-K&'*JBQ"3+&1\O%62N@].]418SM;G8*Q-&2[F4/!/'KFNO)"4=PSIVX
MZ'LQK5EVPT&'6-/,L$=R)K>1&X1<6MS$3'*I&98PZY66+)D4J\?%Q#.=]9WR
M7,4%T@!1PLG=R$$95BKQ.5*D@.K(2. NF' 3C4#'EYJ-L1B<-LDY.2OC2DY3
MEKE9W#YRZ,Z58NL>Y,B(%-&+?/9-W*-86WV.K/&K1Y+OUF*K7YZ9>"M"Q;9+
M5]GNQ>I=G.R6G=G;GM-K?;&^LKFXEN.T':26WDUC4H[F[O;P1W,EI!;VQ%KZ
M3%:VJ"&-([6U@3BRBU*[;:@O:(ZM=:?I5AHRW5O;"#2M+5HK-&MC9K(D?>-F
M,W*02R2,,!YI74J%=VK9C)UQ@IO&<Y#P438GTB^BFZ<1'A2[,W2;.Q7;"V56
M<.X9O'-$V _ZX5%5TB I('11.94Y"FT.K=CM3U6PU'3WL8IN_MKE(EDO+- U
MPL;FV9'>X!5EN!&ROC*,.)A@&N9UJVG?3+J#3XU,F(4M@1W42*9XU65N\X%6
M*&/,KIE9)(T>- TCJK:Z80L3O%=9@\;6H6C!4;%:WL<FP1EY5M'1U^R';IFC
MP3^18Q7T<KJI&3QM!QT>:6=I*K,R,F?@I*1P.;K+MEV-[#ZAV"^ROM5VMTJV
M^T'M#I930]#>68SZIZ#!<RR"UE>%5PL%E=I;>DFV:[-E<K:+.8)%3M])[-]H
M;WL]<:Y:Z=/<:3HT=M!J5\IC*02K%;H^%,@FE56EB>9H8Y!"DT;S&)7!.SHV
M5$H"8RG*4 $1$P@4  /41  #UZB'NWZ[>J^B^P^>_M/7H.7LWQSK4][UXA\/
M#W?7LJR2Y:M9#1J\]"0<\>)<^W1*LM%Q\H:-=[IF!W'*/&ZXLW F11,"[8R:
MG,DD;GW3()8=WHFGW[VKW]A97CV-PEW9->6L-PUI=(&5+JU:9':WN$5F"S1%
M)%!(5ADYDP7]U;+,MK>3VZW$307 @G>(7$+?>AF$;*)8B1DQN&0G<@X&,&34
M!_1CE"R9XH,1(RB5_BH2*S?1X,H+/K$%51>(5;)M6B>4"25[K;%XM7K'#ME&
MDA>:2+#V-:4LU$J=8LE9+)H96N(E+APJSQ*=V5>(K)&N=W3B(9!@R*<@LZJK
M%N%DC6"1T0JS-%*>2DXXXW/1&X058C"/GDCNZS^!S/69UV\E:U+DLU<5%%J_
M=UU-::=UZPMP\)[#V>#8IK3T!()M@8@NRDHU!S&KINF\PA&K$1*O<G$TT4D)
M2:$1R12J&''&^>-<H2&!SQ*PP)%.,KC)',ZW97[2)/;(681%'CXA&7'%E'C9
MN%'&"02&W&"O$.6O#[-^(N'U>SQE(C9F=MMOM<Y-1N+()*5G;O:+[<DTW[E^
MYK45&RT]2*:C'U1],K3$Y%%768-+0_A(>3)'Q4?+ZI8;#1([QE?!NK@7'<\?
M&RR2+@!@H<HKD$JO"78#$:$\*CT;6^V7:CMG8=D'[6W<4\O8SL3I/8BQO'2&
M#N>SG9V>_DTFWN)E=(KJ:QM;\637)*EXX(._D>037#\4/B)#'==\6QXXR+(D
MEIB5LMZO<8RIT@[DK#,2"BDQ8B4RNW2S6DE8C")(PU>@$%+#>("IP\%!NX5<
M(SVC6GO>UW9W0I;2WUBYN+%K^5UCN;FTE2VDE(5F9W4,T$:AE ,P4J@7B'"&
M8>?P]J]$U"[>VLM1MKCNP$$D+&2VPK-$(UN@/1V<NC!G5Q$6XG[P!ESN1$7F
M'GXJ,G(23:2T-,Q[.5B96.<(NX^2C9!NFZ8OF3M$QT7+1VV527;N$3G2614(
MH0PD, Z[5;<,H965E90RL&X@RL 5964E2K Y# D$;C((K<=X<G< @X((Q@@X
M((.X.0<CF*X4O4:1R>/2=*/)$I.8\5%H.966\,W3G&*BT';\4Q["?V?DV'ZQ
M@U<;3 XFX53^-V")Y89V5<\^N<YQF@D8G"DD@<E&3\@?EX>VL2XDA[=<<>VJ
MNRM9BBU>4R?GMBN:Y.Q?B]BW6:<@^(1Q6FR3A9VH!U%6CQA*RD(H(HF5!90%
M0(&K5+9XKR"X[NZMYY9U$*)D F:595=V"H$8A7C,:R@=0-ZBQV>KVFLVNKZ7
MJUWH]S8RZ=?Z;?:?//;:CI]]:1V\L%U9W,$D<MK<V\\2303QR+)%(H9>%@"<
MX06+H>(8HQ[Y_(2C%NFQ1;0B:RL56F;>-BV$,S9(0[-<57<>1A&M2"SL$C.E
M45!1PH8RZJBAKH76WAC@M8E@AA18X]S)*$7E^U?)4@G9HPF1L-L5O]2O;O5M
M0U'5]5N7O=1U6_O-3O[F0*C7-]?W,MW=SND2I&#+<322$*H0<6%4*%%2E_!Q
M*S%I'I-PCD8Y4B\::(,:+4C%B%43*HP,R!$K<!355141*46ZZ"RS9PBJW552
M/3+,3DEB^>(L22V1ODYSGSSGSJ"=\;#8@@$ @$$,I"D%?58!AD;, >8S5L1A
M3 _;RTS,2ECD&*2R$:YEOFQ(D:DN7D<&9L8>.BHXCIP3=)>14:*R!T!.U*[*
MS.9N-P50W$ "^" Q!X@#@G<DD*Q52V, D+D948P16T$)8PQK&2,%ADM@G) 9
MBQ .WJAL#"G&PK[>NR[&'<-@'<?[P]MM@_._W:DQ(3C.3[OGSY>'RZ55WQZH
MV)&/8,;YSU P>O@/&M:;//9&R$P>GQNW?5&DQ5@E8ZSY>D1JX&485D7S&=2Q
MQ!39Y<TB]2M#0M>6L%IK2==(S96"0A4)\"PCMUH]0[0)#(]E9<1N%?NVF**R
M(1GC$8/%QR<6%R4X!ZQR< '5ZO=-IMA/=*(Y)88Q((Y6(2-&(+RSL&C "1^O
MW:R!SE.+A]8#'H5[.#!T67Q[(R^<:^DBJE9:A8)&@0UACE#)'6CI2G6)&/IS
M!RX=JMG3*2@K0]=-U_:&CZ*DX4D8Z83&/3>TS6<^-5>>>VD5@&@BA,T4@(PP
M4F!)(\$B12P<'@9&V*OHM UB76O2$E%J.X5'6YB[U4)=BHAD6,RA<J&=)$C
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MCQ@F./'&8O2''" Q19 '(.V]%OH3=6B(6"N$F,? 0[(>-45L<<F3&)#$IR>
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M]AW'?WA^0]P#TU,C@ Z;[ [;$>7/KX<]NE8I'Y 9&_(>\'<CJ>I]N<5$GTT
M[[GV#8?/UZ;CU#MTZ]/=Y"$I(L=/9[1[!MG./B#G&#B9P@P"2Y WV./9T/LZ
M^51%[."<QBD,/<0#J'4 \Q\A[=.G3MV'4E8POWL;C.3MCV>!&VV_GX5@9P-@
M=NI)W/OS\<>[:K(9V<YA,8^XCYB;\//X!U^.LV5&,$?$;;FL?$/$<_KY;9\?
MA7S[0/78WGZAU#U_EID>(^(^A[Z9'BN ??GQ'\@<^.]3'#KC#:N96*.=RUYW
M6TJ//OJ+#6U@G,5J9NK9]'GF#N(ARV=LI2T0U7*=U48X[1T\58.KI)L6IU87
MVIEYMV_LM>U:32-,T>VN;N*Y:Y:6&U&>\GB5'03MQ!5CCB$LBF0K'GC9B2B\
M-\^OZ-V:TF^UK6=0M],MK62W6:[F<@I'*71$@$8::62:4A#'"CRL>[55]8YR
MY0<R8NS+E>Z8H<5HHX@4*_KB97\)(14%+1<E!-6J]950!LS)#1:(NY%$0D4X
M@@Q18IM'D>%>*.F_FVL:#JF@JMKJ-O)::@L2,\#LO&J,6X)D969)@Z %6@>1
M0_'DH4*UXAV,^TSL]VM[87+:5<=[H<=\\ECJ)AGB2:X5(7:&7O8HS:"VNVF+
M"]BMG:-($5)!*9AJ?8X6EXUXA<NXQQG.N9BAPCZ.,R9+S3NP_1&P'@H-U8:<
M6<DG4A)2?S0_>KN%59"0>/8Q63"KN5@/7000]C[!:EJ6J=FA/JDDL\EM?S6M
MM=3DF6XM5BA8<4K>M/W4S21B5F8[&-F+(:]YU&.**YB,:)$9[<32QH%5 _>.
MJR"-<+%WL0!X5"@X$@&)!4C]H-WYOQ#]NWN_#W:Z_*^(^(J%D;;CY<SUW(\\
MCGO6*)#'4@K?']ZA<BVNLJR[.NL9J CHVB/X:32K1Y,S(RBU@I\Q.M#KIRSE
M!W\VS#(IDRI'1!%<IE3:Z2P+7C7D=]<6YD6%)88TLGBD$)<KGO[6692P=E;@
ME3;&.$[F4MTH@$#V]O*%,C)([7 =3*$#8$=Q'&<% 1QQMOGBXA@"%P?#=5ZT
M$06N6RYQPQE_')RQEG,)*FE;I+5.QTV^33\9.#<\BV1HJS2#ZRHQ_L+1M8=Y
MRNMX1T[D2O8*Z);PA%AN+I EWZ:3Q12%[F2":VNY6XXF]:]2>1I^'A42XEA6
M)B_'-.HR2AS+' Q-OZ, !(@2!98Y8(UX7&ULT:K$6R>[_9R-(H3'>[X9J@_>
M8Z74L=G!IC2M8ZKD!'+(5*00(3&3U1Y"2*"TO6)%U#2$J*I6]L&OKQ3>R-6$
M0TD$#-(XK=;%+H=K(UF6GN ME%9PPH5@< V3%HI 9('9&?/#<=R46=5C5QPH
M :+JDJBX'<PYN9+F1V5I5/\ C*A74A)0&5,9A[P.8BSE2&;(L$%PT(URV8O*
MPE7DA4Z-9;!=I5[(.(6,]O5>,:VG"X[A:-5*K U: I[&WTNC90.>(+&)I6^H
M@JE'+_2.653CQZ%W-Q9!6:2WMYIKJ61VB0L72(1VD5K##%#% D]O;7I*! )X
M<A#WKXS-J1EBN251)9XXX450[%<-*7N'FEE>5YFAFGMP'XR8I=W'=(*F3CA@
MICB%K<*TLEK8H5JEXUHB',%8EF4K XQ2NJ,.G8X*:K<E7YXSP+W*/'S>2BUH
MY.8C:],,&+-]$)**9)-!MWC@C6>>/N(+2V48A=98K3OP@ECEA:*7C](=F#H5
MXTCD5%:,58NJ3!I7:.%N\FN)21WRE7N&B+F-T=9(PHA5597#%6=&9@YQ0XNX
M:RT%VYBCW6RN,?05KQ=,52F^+7EVLN7$N(<24.J35JD?HHVL"$RUG\=A+NH^
M"FVD)(#&P:ZK5)%Q,13O!9:%Z(SQM<S&TCN+22"V!A8.ME8V-M!)/)W(F619
M;4NZ1R+&_#&>$ NK9;G4C.JN(8A.\-PDLO[0%#=7=U-*D2]X4X#'/P*9$,B\
M3CB)".+W!<,<!7V53"(OUX:V"@05"KE%M)DZ>O(5V(QO&Y2KE;;#'*U4\#+F
M/3\NVNKRJTQ%/57S0(^43,TGFOSH:^/0HHD@[NZN1+:QVL5M.1 7ACLTNX85
MX##W4G["]EA<R(2PX7!60<54?4I7,O'!"8YWGDGB F59&N&MY)#Q=[WB 36T
M4BA'7!)7=#PUM7&"LU9,FCB0=R:[5JV07DGY69'LBLBDFFJ_>$CFD?'E=O#E
M,X<$8,63(JJAP:M&R )HDVJ*4159B[*H4NX4.Y"X+L%5$!8C+%$49)P -JAY
MR2>$*"20H+84$G"@,2V%&P+,2<;DG>K\BJ/<!$ [ '7KZ;] ';R_9[L+NOC^
M/GT_/'3GX7A"02,;D[;;],^'X>-=QV)'+AN_;N7D7*M"&(WDXY<J3HB9S"8Z
M"R2J2[*1:&, ',QDVCQIX@ L5 %R)JDA7,4<Z%9.(*0 2K%3L<C[I]8!AD9X
MEX@#C(!JDMK;W,7=W$4<J <G!# DYRCC$B'D"496*C!.-JOK!B;VL)*2DY":
MD2@=-%Y)G;@5HF<I2G38,&#9E&,#*E*4KA=JR3=O"E3*\<."(H%3@100VP(C
M7+$?>;=B#G;.P SN0 ,YWS@8D6T4-O"MO BQ0H2X12Q!=ANSL[.\CX !9V8A
M0%! 4 3%JH&X=Q'U^ ;?AY=?/[KF)Z@]3[/'&^>?AUK..>V!OMY;GGY>.U7U
MLKL8/3?KUWZ#OU[=1]/7;WZCN.>/=CSW&Y_'X5G7IRY9QL/;X8J2-%1*!1WW
M[;#[A\OY].P=>NH[G?8'8YYDD@$>?Z^>^]7; Y'/?QWWP!S/3)R#U\=ZD;9<
M!$HAON&_;8.FW?T]1[#UVZZBN-V)Y'..>.9 Y>W&0>>3BI"DG)SC'(^0/+SR
M <=,9'G4A;+#N #[AW[#^'0/?Y>G< U$;ED>."H.?'',^6V>F/#)E(,J=\Y'
MT<>/EM^%29DH.X==]^O<0Z==@VV]VX;>FHTF#U(P.8.//QWY^0_$90<DCE[>
M7M_'SYU)6RG;T'8![;=1W]_IT\^O3TU#<[8ZG./+Q]FW\]LUE3._AGX;<M]]
MMO'E4F9&[!N'0 [[;]>@]_=^S?N'2)+_ '^8'/RY9'COTV-2$',9'/GY\OR'
MASJ3LC= Z^G?UWV']OO_ '!$..N/?4A?NC?R.3C'7;SQOS]O(8E+0P@8OH&X
M@._D'P]>VWNZ=]]1I=L]<\O?OX_1J4FX]@_#;^?D/94F;&'<0\]AZ=-_4/,=
MNNHS=,=3L1XG;WC!/RJ0O(>!\#[!MD>77D?&I6R.!BAWV 0'KY!OT#SZ=?AJ
M*_N.1@^>X/(^S\CTJX#!QUY;8&2!C/M)&^^]3%B(@8!WZ"7S\@\@'N(ATZ^?
MEK72\SX@X\!L<D^S?&/ 'RQ-3KG .^0-QG'/;;)V'D02.M3!@/4OQ]/+8O\
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MP2%'3%5:MCY2E33$")D*!"%+T*0I0V*4I?U0 H   4O0 #8 #RDK:CJ>OO\
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M#;OMOV$.OKO_  ^W45N1/,\]_;S]N_MJ0O@!UQCP)]^.N1T%2IJ.QBCN'3<
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M@Q-L)>_IW[;>GIO^ ]>O;4:4 J<^SX@_1S@;;FKE(#>XCS^CRQYXWJ:QYA$
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MB(2",\B#@XYG.:^#U*NAN'SWD8/_ !PY7$1^/^W3J._H'V]-7#38?]+>G_\
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M7+_!;?[E9_\ P*?0. Z?[+9 _P#.KD_MU_\ O=U\_N[]-/0(/]+?>7_"M_\
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MC5N/KH*Y^FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4JM0ZD
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M&\?4&4?"OY6/-#CL)KNUE]2)%E@OHR[SRR&Z>61NX[^-H@(U@9<JX:9D&%B
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M ^(^?Z4!=,>V_P!WY[@._P"WKH8V'/'Q\\>'E3@/B/G^E/'3Z]1Z=^G;IO\
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5S4E.1]OZ55:LJ^FE*:4II2FE*__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g945651g55m31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g55m31.jpg
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ML? 4,L%BX?$5%R-"4E2"E);3U21R,Y('-(.$HK*STA8V0U.%PN+_V@ , P$
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M*I@<%@6UR.,!@Z""SI?W,EKU'+0222'DX+V:-9:U95 PCMWN\%%E3JI=+#7
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M3+0%"T?,N1UZP,< *#,\TA,^81!8XH(LS$32SRYTCU]2:627?V[[[;9K6M:
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M#_Z0/98@@XGQ2""/_P M>TW/_P#AUB-1V#XV(=%H:>U]P+D@.E8W)KP?7/=
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M#=\=2=Q[5!*M4H:<*R0_N#R-IM*Z)[I'>6"QB]>72WP%)5E72UUX"66BUI)
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M')D<]>44"9#[WIE!DSC3Z[P32:;<JQ(98Q\=,>AJ,!'J+'HNE( ON)^%^?\
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M*E4]I41S"61 _@!B7P"3L-GPYM;^ V,L-GJD0ANK\9;L,QUL5.L:F==-C0V
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M$3A$X1.$3A$X1:U=AT7M1FR?-ZT^<:Q%W%?N.G$MCY='O2H.N8%V!EP@-FK
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MWYR8Y#*0I\76;9D1UF.6D3KFIG&9VFCJWJ*E32P,SG370 >P[+IFH@$=(*B
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MIPB>\_\ ZE/_ 'DW_*<(GO/_ .I3_P!Y-_RG")[S_P#J4_\ >3?\IPB>\_\
MZE/_ 'DW_*<(GO/_ .I3_P!Y-_RG")[S_P#J4_\ >3?\IPB>\_\ ZE/_ 'DW
M_*<(GO/_ .I3_P!Y-_RG")[S_P#J4_\ >3?\IPB>\_\ ZE/_ 'DW_*<(GO/_
M .I3_P!Y-_RG")[S_P#J4_\ >3?\IPB>\_\ ZE/_ 'DW_*<(GO/_ .I3_P!Y
M-_RG")[S_P#J4_\ >3?\IPB>\_\ ZE/_ 'DW_*<(GO/_ .I3_P!Y-_RG")[S
M_P#J4_\ >3?\IPB>\_\ ZE/_ 'DW_*<(GO/_ .I3_P!Y-_RG")[S_P#J4_\
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M1ASL)VN21BMOA1M<C^EOC;._LPV$.)HUW,XG5F5,+2I4VQ_2/Q%1U,-(B9D
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MQJ/N1O\ *N+:G8=T^/\ 9^:>H^_L:C[D;_*N+:G8=T^/]GYIZC[^QJ/N1O\
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M,T[#H5POJ8[]W6F0-Q/#@.\AJ%(UA$J<N\]F0/=IR6OSCJ!YQK]DZ+,'BSY
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MN5Z:37]LZ] &SRBXS$V.?E&9STU7,\749&;YD"V6O6+PL_W*VX87BH+J\\N
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MOL*P7I6S9LRF)&KX-LJ]5;&KTKR4ACE]0>9T^_1;8<*)PB<(L<LI^Q<W<,2
M<."ARC9Q&R4PA'N-&?P16=]K)ARR7:KD^A.8-08:VJL; XG6/<\U*%Z^DEM'
M7[RZ^=E+STZ9SUZ>7K98&V,[)"U1!GM+^>R%L5O$KAOP+&/%@8"=]$JHM[?&
MD6B)<*9NN=0YP(V 8*'2NE.7:>"'Y4*<LU\/3*^5AP\IYSYFU^N?B&4G3.YX
MN?2-3!Y9*2U-E>:C=%5<?DV.Z*S"&*,9W[&D0N&, 52V>-2-"\--6$$A<F&
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MVG -,!FS(*61#(16&'K'K\<G)4-121R>V/,4>H>OPHN-"!"]M  <YR$OC)-
M ..B!''C8' !&G:$%"#RQTDFQ/W^L28TDJ0-!_'/?FJ"#I[K(?072*FJ,8$E
MEFBVWTGEDDS.&B73QERRS;RGC3@5FO!3AG;D"3"I5L$L.\0D.NKB-[YIPBUL
MKA5^W6=!VVWWS55.LF\V"=IHX=HI\$X9(W&I.D\>^LT9&K6MHF6D\>^LNAJT
M<G3?6;&^^Z3KRCTOW*0!R^[=@OBMT"NJ*LSKLHWSD2U%.W%JG;0+]B;*SM,T
MI3LQMHN!7 2;E8GP)IH,$-# ".*)!%'$/'C"3,Z1'2,LT@1&<Y]97C)U/US-
MKKI-454VF RP9=9])IL%PG2.)BI6'JS;_,CY9[#8"/FC#XEGH2]<DQEZ3M#I
M)TG7[^^70:!(&@^]=3U-\]5=#J!3&3"-J=7%A+"-CAK@K>'/J2':PH8-92,:
M[:Z%1ZZ56L;ZC$ZS"ZD5U&5K#@E4#- D_?WY[G5('W]^6PT5$'UAU^ $2O$J
M:B((Q>P4D#^AM)INI9@#JBU>/4WWVC6_*Q1U@P$6V@@"V'0 "$83'H\2=>OK
MK]YI '(<_FJLSK^F'M8WA==7S-HV,3;)N=)-)2& ^R>04@W$<FFA_P '-7D1
B(41NA$(9:986+'$4"-+&DY??/N=T@3,7^]U,>15.$7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g945651g58k64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g58k64.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #! .$# 1$  A$! Q$!_\0
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MW/Q'<FJR,QK(*5*R\OQ-EVFVWW+;*YK1L+CW+G_W2,:^9DA]*?M.(.[MA[
M&KLBYLQM47';S0Z.%B@XU)8IBQTF<'+DW(<!L(T_!(/1D-EWIRF7QGKOR&<N
M./3O$]DN7]O3,A[2;WM-QDMG$X2I:LXNC'6QU>67+033.BQ>"?2C$L].Q5AD
MB8;IGD[UM=S7F8W.U[-'C3AK*6:M3'WV3RV:4^0+@US8ZM6N(G2/N/D#6PD"
M4=20.R>T0UT9=<W0G=*)LZG;>M5O"#1*=4BQ-EE1:O.^)RIH \V=4,2F!+D8
M?3*=> 28\>>X['&3UN94G,-$21G&/LM_X@[G%W"/M XMXLX:=A:/ [66G28L
M6)V7X9(;DKZ$++A9VLG4-6*.<F:.!QNUWRMIL#B=G[<3I!&R5CI.PR0L#VN>
MV.0N$<I:T]H1R%D@8[LZ<6.#2XM.I?UIVBUQL'6ECVE,7-I=?J))0RQ9L"$N
MJAO*1"<AKCK&^[S/Q.^(16(T>,TJ:Y-5F*B*M2F%O[KP1[=>#.,.",SQY8=:
MX:P_#UUU',G+M:\U9"VJ^NZ%U'W@VVVA<KQ0101FT^RXUVUW.,3I<BP@@#GO
MIX?7?\Z4LU?9-$N518OE=LXR947\._\ ?'W5C(D=3#_MGFIR2J(3XYYI_P &
MULSV8SN,K;SY/*ZWE7T'!<:\*\2\/1<5X;.4;/#THD(RDKW4:\1BE,,K+0OM
MK2TY(Y?['Q6HX9 7-/9T]A="T@ZUS\AS^FM[^2[1EYF2RU(CNM/QWVT/,/LN
M)=9>9=3A;;K3J,J0XVXA6%H6A64K3G"DYSC.,\V6.2.:..:&1DL4K&R12QO:
M^.2-[0YCXWM):]CVD.:YI+7-(()!47TYFB<(G")PB<(G")PB<(G")PB<(G")
MPB\X.VH417;<=LB6:5$!VC708?LJ+*-:S&78F!#6*V3\RJ%!L@A^QP[2Y@R1
M\IL6HU,+RV!<6MB8UJ"Q)DG(=/$=='PV>H)]>0^?-8GD>6N?4>/(D[ ^OG\%
MZ/\ ,5DG")PBB7?O]"=U?VEV/_LXSRMZCXC\HI:Y$3A$X1.$3A%^9QA6,I5C
M"DJQG"DYQC.,XSCPSC.,_P ,XSC^&<9_AG'"=>JJ-8.D'761KS>%$H>N*IJJ
M5OFDV6E6ZTTH##@ED0;'#D,N8C)1EIMH8Q+>1/=KT-< /-<92AYA/BEQ'HG)
MVI7P&W(^Y#"\.,$[B62C78>)".;G/CW'WKNU(UIY.Y:6I3<$\/MH9JGC<?5Q
M$N;IV*=BY1@CCG8V<.([O_RMB9*X2FLSL0/<T=IG0CRWK?V4-SZN]=>US6F;
M<MS:.X*%6M?PF-<1[,Y+ATJ)<QI*]E1,>VW)4LK<IE16:C5:NQC AJ-EA =)
MPJ0,K*L]63%\.7J=K!NJ&/&Y6.W%D'9$Q6V3=_4GKP5IXQ"(GT&OF<++'QO=
M8CFE[S30 -%AX&SG#F*SMW'7&2Y:S4ITZ\.)CM1.93COP3Y*Q +5UTDF2EJ-
ME;3A;-"R)T;(A-(^9THKT"J';+JUT-[)UZ;$OF[[)MK;>H*_I"/L?7UIIIMV
M[D?45=)0V@V,U$MS0QL)5:V,J7O8P1ZRWO+L& #,0GX[ASY[E?8SP;-[/\MP
M!4Q6.9B[[9\ED:&![NK%$Z&U0EKVZT]5I$N1@DKBTZ1SIAW4,,$K)(HS [CI
M9OBS!8C*7+']2R$M[)XJA@WYFC:K67W)HYS=W0M3-M1U#%#7KU YE=T]Y[^Z
MC>'-?+R5D[5[4UG]E^-(;FU7'J-]H_:]6M+Q3I*3M2-FB!NG/[" J]F\D\T-
M*C*Z86S8!1[$)P<Y7AD9^'%+RDI3\NXM_P"'[%2^Q['>SK#7;G#M/^J,S]>Y
M,'Y&Q;LMGNPODR\'>4Q/'9[3RQC'UXXG04I8HR(1$[U:_M$R-3!39++8V(WJ
M.;.&NT_]2DYSY:<61B%?;;/=RP03!MADP[33$Z-X9(_8L01[56=/V;G5W:S*
M;P% VDW8D3)FO$&IPH6TS>I]0"5VVVB0\">AFV+/)?A"AK4=0@K'@.DH2VVA
M<9.=9XW]DW'D7LCX(X(]G_%EJO/P[9+LC:GO7,*_+5Y9+,C#[S3,\L$-*W8+
MJN.=(^'W9L6II)J<'>;)4XUK'"4L]?J3L@OOE:T46.LQU2RQ[JR"Q+)W&IW2
M L[08&R%KGM#6;U:+L1WI-:,HG7 =*V. UQ=+12XI>V!=P8K5>V$2S!DHK\4
MB;K=EFO21@"P$A!]]LVRXV[+PSEQPD/=3EMWL>U+,>W?A' >S/&\#-=G\G'0
MKU.+\K%CJV3GOY6I7H5V.MLOL+ZF,R$HNSS9'LUY2YH=/;I.T)O:?Q%A:[8G
M9"[!BY+$1GCJY.6.G:$/>/C#S"Z3?-S'=G1<"!L;YZL7M?N?-I5PT@(J(BHW
M&M[7J],M;!Z$:5,C6.#=">!HUNCSHDMN&^T]E<5\>1DMD&"6"<!IIAKS8==]
M/VG>VCC+@3C3@+AC'<%PYFOQ+5QTV2LL]]E=8MV[SZ=K&8.:N1"RQ1:QMA\M
MN.R'QVJ_:@A8#-)Z<-FI-%'-'9A=%-'%-#(V5G8DAFUW,K3L]IDI(#' Z<>3
M225-=K[1T*H;I Z1(#[ \?-R@8Y1:+%BJ#CR=ERS@)#?RY*;F/8D>ZB>XDQH
MSC$3W37F4YE$K$;;,_[=N$N'?:9B?9?<J9>7+Y2?%TSD(((#C:=[-&,8RM,7
MV&69.^[ZOWTT,#XJXL1]IS^S.(.?L$CM>A/R&]_A?./VEHDC>SFA4#+!@ZB0
M\-2=5'C?!EF8XQ99Z#A'N?B"64QVUL)G9B^DN:GR8;Q#RF<K"'V[\*3>U9_L
MF;2RXRS99:8RAA@_ICLE#1=D9*@;W_O8C$#'Q"T:_=NLM[ ;[N6VC>P>SO8Z
M;UZ?SX_#QWR79U??VJ[CL([J^OV3$VX5Y4]$V%F#.8BOO"7L1BS \@\PB)->
M&O\ BB2AEW/G2AUZ-F0PP^ZWLN"]K? 7$G&&6X%Q&:%GB/#&VVU5-6U%!+)C
MY1#D(J=R2)M:U)2E)9.V*0EP;))#WT,4DC(6D#?+7+Q'CT_?#QTMI1=TZOV6
M9/U^CV^!8"]86I)B'&8GL9:;2_F*J3$>FQ(S!2"B3C#"IPMV9#2XMG&7_!]C
M+O?X5]IG O&V2R^(X6XBJ9?(X-Q;DJT$5N(QM$I@,]>2S7AAO56S#NG6J$EF
MNU[HP91WL1?"TCJ-?OV^:D6$1'DD.N#I\.>W'?<BOKA2F)2&93.<8>C.J86X
MEM]K.<8<97E+B,YQYDX\<<W&M<J7&R/IVJUID4KX)75IXIVQ3QD"2&1T3GAD
ML9(#XW$/82.TT*+,YV43A%JC)X'7(625A,B@([#K3&9YDC#%PL/O9REEG,J<
M\PQAUU6,X:;RYYW,XSA.,YQSH9+*XO#5C=R^2H8JF)&1&WDKE>C6$LIU'&9[
M4D40DD((8SM]IYY-!*H!/0$_#FL(W;ZG6F1\FQV>O (Y:0W$%OFC0T6R2E.I
MPMJ/ =G26$3'W$*2I#4=3BU)SA24YQG&>=;*<18#"15)LSG,/B8<A,RO0ER>
M2IT8[L\@#HX:C[4T3;$KVD.;'"7N<"" 0=H 3T!.NNAM91&P@!$P:/+' XR>
M:>S&#P2).%"F%I"?+A3 V-)?:>GO)RM&,M14.KQYT^*?YL>//<S&)Q]BE4OY
M3'4;>2D,..JW+U:M8R$P[.XJ4,TK)+4@[;-QP-D<.TW8_N&VB=Z!.NOI\5N.
M>BHO,#<,VVR]TE'69>W'HI1Z+5DCHHG<@@6)0$/63&,T*Q@.@NP748(AB40Q
M,LM8VM#F02;KT8;:ECP(6Q9RY:\-_+\=K_'R\%CSWX]?77+_ /7Y]1S\?%>G
M_,5DG")PBB7?O]"=U?VEV/\ [.,\K>H^(_**6N1$X1.$3A$X1.$3A$X1<S<:
M94MA5LI3KU6@=OJIME$<M7K&,B& Y!IMYN0SB5 G-/1W%1Y++,J,[E'JQI3+
M,EA;;[+;B>2&:6O(R:"1\4K#MDD;BQ[3K1TYI!Y@D$=""0=@D+JW:-/)59:6
M0JU[M2=H;-6LQ,FAD (<.U'('-):X!S3K;'M:]I#@"*,]J/L[--=@]3Z[U:!
MJ])IU>U;<I=RK]*=$6B#K8Z^5&3QIJ!:A.M+GK:SNKG+F-%VC@RUPRC)F$T_
M,R3BRB$.5V'6(KCYAEVV;T<[&M>6VY89F.C<'1O:X%T<@8 6B*:-\8#B6!CV
MM<-/S_ ^/R6,Q^/Q<./QL>+MOM5ZCJDAQT_?1OCL168J-G'V@92\3>\5[<4W
M?,!D,T;Y8W^-'VD71QW6/7?J=U+U\]A .#=-R[2)78I<:K1==PK#+EUUR53A
MV-U[9##X*8-8/G9-)'F-A';/)A5:7']P165LQT7U;N,=E('C%T;9;4=69#7B
MG%MT<):Z-SI>_E%B0N<-M=7B%>%SNPYL37Q!WSGBW _T3%\-\.FU7;')8S&2
ML9">2#'4?>B^N\U(/ZA>C@B$=>>9U9EJ_/=ECK'^^=SK4\4==VMN;OKW4W[*
MX#1]V5O19D#7:B]/I%OO@8=>6#%.='T_5&];!E:"SKNMEP*X=,,D<Y>!P_C"
MHZ8]@PQXC/.RM2>O+%4AD; :SV1NCM6J;)V/ #6.E<R=T3@PM>V1T;W,8[D_
MLD]EN.;S&2'#7 1@R,6.E]V@D=7?*X3]NL604,K('1O>*3XX9)HW/'8U+IK9
M];9Z_=C_ +,W4W>S:'7+M!:-R&'9U,H]$BD9.M7@Y.D[3KH@M*O <I532)#^
M ,(P2L!22R<$N%F9X*; S":C28[9%U-29:DAF=(=M:S?8T6O /:!:?#9)YC8
M(UH>*^CY?@ZAQ-=Q&:FR$A=7K56O=3,;ZUV&.1UF-\$H)[ILCYGD2L+PZ)S.
MR&N';/G/VVI&_IWVM=-+5?7&T"?6-Z^:?G[0E!.N&Y;%KV>V.9#8O:;!-#:X
M(CKF;+QXZF1ML RRP4:MROH(%QRZW.7!U')<'<.W^+*'%%KAW&VLUCQ"RKF9
M<8R6Y78SM:#;!A<YSXNV\P2[<ZN9'&)\9+RM;S;\\.-(H*K,D>'I;>/DR$4.
M,R4E&7LB(VQ-W=1T=B24-[(GB+XA_H]Y(WN7%G9 M^W&1]MP1T(LKOOX(T?G
MH3.=@Z'Q)]>'6I5^=5-2UUY9LN-)2Z]B-11Z6[HU>TUO,8^[LB4_*2&8Y&<,
M<--XR?Q*W XYO$;XC [.BA2_J9C[GNR#;]U[_LFL!4[SO>_-4"$S&'_2'8CS
M^2=Q^[ >^9DTFSN(B+L;V YL3KI[3!BA+_33'J!C18%D1ZG-MSW=@7BT+MP.
M9[B[DI-?ZS5 +M6CC9)K8\T+V>I5P)BF[/%-$&< Z)B! \A0P;&#!%H;4^-;
MI\BT"?BLB!$)X8E>+P_[+N!>'^-<QQIB.'XZO$N5][DNVQD+$\44F0D,]Z2I
M2EE=6JRWI@#8=#&PL$CV1]U%+)&_;:7$MN[E;>(_IE=LM!@DL]UEZDTK6N9(
M80V!L;'.<7LCCE!<P0.FB=,1VF[Q.L=WJ<NX=GQ]'ZL[?JQK7T.PTK8SHG;&
MCKZ< 6)^N!KA&U]2 ==V*Y*?(EXIJ'\,)NOR!$:PAI=?('X1$,3AQ?'X/]BW
M O!=OBVYPU0RF.N\24;N,M6!DQ/+BZES_6DJ8=O]IK,$QAFC?,ZQ*V6M"WOP
MV,L/)0XEL7YK\/\ 1;;#BRYEH1V\99D]Y;#'.RNR*&X3(^5DH:UP(A$C7Q/D
M:]CPV)],;!AZ\ZW]Q[D$C[XUY HX>SIL=XV%K.NC18R7J4T2"7BFU@54MQ&B
MLG93Z'38.*6<ECP@$HF 6<D$X@]V'/T3V=^PG(^SO@_VD8?%<:77Y7BVB^I0
MRK:#\=#AY*<%^"M89#%D+<_O\CKKA8M0RQO@;'$:_:?&'N#BJ":ED+_N.2IU
M\5W[K4ERM YKS3G#+E2%D-TN=:TR2)CG%L+).S(\O8TL?#/7G;=7[:=#=ZG6
M[)>BP&C;+K#0ZHDO=UFS@;(F,TN>079X5E.,F*F3$V"*4;!AV!!(80KIZ5+F
M.L%F'X6GU\%[1/8[[!>,+%OC"S<XAI9BOD\4W$SPWX:5>>6G3GKB;B3%VW3U
M'-DGR]VK5HUI6^ZO[BS'WUJ9W%B<OA^.:EA[(;)HP3Q1.KV&OJ66V&M=)WIF
MIW'M=$]DL;(VA[7,<R4R=H.C#-\;O]>ZG?9^0=E0;YM&@Q"^](U>*.BSA6R/
M''B5>D#6,/D%(E6L8+:A $REN9,+>DE(,GUUS<%(S*.+A^_[6?:7_P /DU_"
M<4Y./C*YQ*]LEE]O&8>:SB:A$4E/%V\/0QC\:R=W=S%UR9\\Q@M1^^"I;AB;
MSW)L%P;3CLR>\U:+K+8G!CK-T.GFB<UKYN^?/.6-9"XCL.Y/T2U[^:Y#L9VJ
MI2/L_P#K1V'NVW;O:AM^N%QB5NJEZ@X0M=M*QK6NKSI#1Z27$8  M?5NLV6<
ME9V#8B%L*&8$=DJ+C36EQMRX@]CN<]H7LDX&X<X\XOMP\4X2>2Y<RL4)S+;4
MDDEJ%M>X)K-)UR>ICI(:YONG,DEF*6;MSLG>Y_E9'C?'8[%T^((9)[-')33Q
M5J4D'=6)9&3,ADDCFWJM!6;!9E$<D4SIS-&P/B'9#?CWC[(:/TOI/HO9;5?M
ME[=&[*J0UZK2*;4@-5!-Z8BRQA,[;V@-CGS38[8N:[9:C7HP(E;R(J?)J^5R
MXE5<S+=(=[VA>P'AWC+ASV=X.QQ%FZL?!.-CQ-6W'%!9?D,9W%"&P9XIW,9!
M=D;1@,,\9?%%_=&^M)&V)L?%EN.JN!JXB[,Z;)MS;&V(Q7A95BBI-D,K[#8Y
M723"R(;<,/<2V'MD=!LFLXO,GR^T)['ZSTIOKJ'12<_>VQ86PM8ZT(OW9IRG
M0#(2@3R;];KANH0(]''1C.R"10<4L]E%DA\>&Q-G#DPHT6+)B@XG)[3?81A^
M.>)N"<U)Q%F<:SAK&XW&/JQ11V7W,=CK<EFJ:]ITL#Z.2=)+*+%TPW.\:("(
M&/B!=,UQO!P]<QF.=#>R(RE>O9]\[=>)]>&<^[1RPPMJ!EBP]\3IY('-B:U[
MP&D,>V)G^A?[FFO_ '-OG_V*!]"<_2O9/_K=]&?_ !6Z^[R?^]M?2I_]54@[
M0U4I;=PDP]<!C#)DGJ.D#GBY?6.LK9/U\AZY[&6)M5"M5\[*:1, ;&Y,1*D3
M,U,!8I(N57ZN8^(,$\"XR>0=.OCTWR.M>&B#\RNP>NO3GZ#F">H\-]!_"]!@
M;)R.('LV4B)+'FXZ4E"0,-,KPB9+QG/G>'A)YZSS!L=6/+A,:18"SB,XSG,M
M>,XPG%9+:\(G"*)=^_T)W5_:78_^SC/*WJ/B/RBEKD1.$3A$X1.$3A$X1.$3
MA$X1:XH'$G(F8!H6.,05.M/9A%(48A$R\PO#C#N8TMIYG+K+F,+:<RCS-KQA
M2,X5C&>9->]A[3'.8[1'::XM.CU&P0='Q7'+##.SNYXHYH]AW8EC;(SM-.VG
MLO!;MIY@ZV#S"JIN[K79]@; 5LG7=\J%+L)G6C>HK8U>M60]I#7:G$-&SP<Q
M4XKMFJJZ[;P<ZS6##4F6\; %F9T5HN"D?"XJL^A5N560""Y3-ID=@VH3',('
MB4L8Q[)7&&;O(7B-A+6B-[2'%D@[;EJN;X<O7L@<EB\G6Q\\^,&'N-NXMN4B
M=4CFGG@FJ,-NI[M=KOM6.R]YGKS-D8V:N[N6%0S9^QICJP&L.G-:==;QMO7/
M4O3>N46^]0+Y4!6057@5#/L&YPTPA@J7+CJP 6<,L@(9!UD=EN<J+'1+B,.=
M^'&QY)T5J?(04Y\I;L""N:\K@^0R@$-='MD;'22"./MEH+MM!/9)7A6^)9N%
M(;.&QG#F0S&-X1PN.-W(,R%.,P58Z9[ DCG[,T\\=6N;$XKLE<(R)"UO;8T^
MB@R<V3&CR37DPT0@Q)S>&GD2&_3EQVY"/3D-_P#IOH\KF/(\W_(ZGP6C^56.
M> ]O9<YIWMKBT[&CR)','F#RZ'HOH\4@EBCE&M21LD&G!PT]H<-.')PT>3AR
M/4<EX7BM$OL]MXFR4ENU^>S3G;0GDW4I%FW=G1;?5=K9!@^/?1:W9":I*UVQ
M3WXEN&51RZ.!G=CRWZ$J@-A5N@(_M.Q>+$3K@9#W1QK'MM?U&<VSD^PUY@-/
MWOLAOO1?&8O=>Y;6_P!5KB=./QB*M>_[3-F,_$O_ &A/%D@FHF/(#!#A09":
M2*49 Q"!U-N/++<<7]0(=DW.H&D(2Z!O+=3.H,K3OVB>[NT,OKQVW UN\INY
MFF3+5*T01"U\W=\V.T;-<L\>G[BL-M-#Y<^- #:NAB!9XC*?/9^\L=J4/BEL
M:;7K]W<EG[FPUKNT6]KNB&EW:=)VNS(YSAO0C#0XG?\ =T!7KX+ NQ_%F2S3
ML3GHH;/O,E=TYQ;XXI;/?3W3.*^1FGE:Y[6QTFQ,E>XR_P"L 6"1<M]F1U3.
M]:]Y]N+I4:IV758[G6K0'T8K>>I#>OZ.;"8A5V[#YFP['))2&W;B_?G'ZA'P
MI,!UT(#,V1G+:K7\-#2E 89;#FB;M.#A$98RQI&@[;SO_F[?]OAR!/\ YM#B
MX-P<N'R6=LP09DS6(9H\;_4J,E6M+'V8;+76YG2.!LFT75QOL$QQ23 CWCL1
M]K]ER([F[STEW-UUV9D/:V$VC<=MAC;7'I.J2I[&PK#<;3*[*U9ZG6FLW&@'
MJNZ72R E,V*J$A[23Y^ "E2,0XS@3*B+$L=EDQ[ =(X ]F,GMESN^;V7-<PM
MWH$.:1S('IS\%1\0Y/&\15,PXTXY\A8:R<5J,DOO<UB=V9A->>&Q5E@,FHG"
M:![ )961./9!CNWI_P"S4UKJG1Y_KTK:.T#NMB]I@7*#$$,:[U4;#'F4E4%9
MGWEU%1J2>L:[ P0A0R&;B0L.88VO@1@3(H? 3'7PW>'L1E*1QV6HU,K1,S)Q
M5R-2K;@;-&'!LO=30.89 '$->YKG-!TTM!(6SXOA2#%X^7&19+(^[23-G::[
MJV-GC?\ WB0^\8VO5FF$P<QK_>'RZ9#"R/L,9V3E7_[/4 4ZU6[K!K/916L4
MB_OS$6V=MH"[V$*9&OUQD#!9JSEOLP7-4*@9$,:>KYZ*[,FB3D!HC$0W,RF0
MC#'\-X?"TY:&#QN.P]6>4S3PT*%:M%)*8VQ=ZZ*NR!AE#&, E(+P&-&]-&L\
MAPVZUB9L1#DK'<6>TV:3*"3-2B,Q=VUM=UNPPUWQ.#9H9&N<8YF]XT!Q[2C[
ML1]G]L/>'6K7'6Z=;NN1P-12\<BP<L'7T]6,5^* EB,U4=KH!K[:X<;46?@C
M)^L6O*W"39T,9PF$P'EQ\2%>A+4?+"R$NA<&G>S"6ZT1V0QK) &\MM=Y@\M%
M>?EN%;>2P]3$.GQ$D=:0/$LN*E@$+8G1]PRG%4O,; .Z$L,^R\2QR#LB,MV=
MKO?HML[>] Z\T8H?ZC@QFB)=7-00$CJO9+?5VBM0*.)'5VJ0BF]QSU>U@5JD
M.N5RS4E_XD^9R(=D+/-0WX T4FJOE9"PFN!$6D-,!<W;3R:T&7E&6AK7,\==
M=$ <F3X9N9.KBJKY<#%'C#!(V(X26Q"'UY#V88&R9-ABI20-AAGKGMF41DF4
M-+&1R?MGI,8WE;]/[*O78F_UZ^:=CCRE7;UIK_14&D@;ZJL2ZW9+74PVS]7[
M9M@V(;P0ESHE>L5[ML,%-9#D1[V#0(45B\DE8ROCD=,X.CYM[#(@UKNR6N<T
M/9(X;WL!SW=D@$<V@CNWN'),E8Q]RSEK45K'AKX/<ZN,96BM& PSSP1W:5^=
MC9>T7-BFM6&Q.$;V'O(F2"V_W0L/_NC>/T[6_P#_ #_G8[)_];OHS_XKW/=I
M?_?6_I3_ /J+S_[:&A=7WO#L/P$67ELZYI+!V1906IRHV +%S]XW4>\%>O(X
MK9(Y!(JHWR22; L1F):X8&% 25L$IB)'S WX#GRWS]/+XCZKLD]?QR]?/SUS
MUSY+T\Y%DG"+R_%;?V:T:B5JQ[+4^WLVX "B;Q2KU4[96Z%K\_MHJ : (B/:
MKJSU /D7'06N0;QDI>72"\V!Z&4'V:OYD+RU\/GL;^Y\-'PZZY\MX@GEU.];
MUX>'YWRV=:)]%)Q79UV.]5]F9)4R[WQI5)W]7H^S!TG5T0.=KE<,[$J-9N,Z
M-)NE;)/K-5,,'M!&37ZED?/P27*K\-]A^/%3!_S#EXCE^_YZ>*H^O[^^A\%=
M3XP0_"I[\Q6/J/D53XP0_"I[\Q6/J/A$^,$/PJ>_,5CZCX1/C!#\*GOS%8^H
M^$3XP0_"I[\Q6/J/A$^,$/PJ>_,5CZCX1/C!#\*GOS%8^H^$3XP0_"I[\Q6/
MJ/A$^,$/PJ>_,5CZCX1/C!#\*GOS%8^H^$3XP0_"I[\Q6/J/A$^,$/PJ>_,5
MCZCX14KW3TWKF[;;?K42NW9JBM;0JP&G7ZJ:UO.L*Y4+4"KK$R-!CG!4T29D
ME7'HQ&=#G/$)\I<L;+>#N> =7P_'LT\U-2B@B;4H3FM+)-!+9AEDFB?(07%C
MFSL#0"UI:&M&G /']_\ <M(S? M+.7,A;ES'$% 96I7I9"IC+M6M3MUZS7MC
M;/"^C,Z4ELLC)'22/+XGNA/^@>[6\LV^][4[<E,TD!ZX + .M->LIVJ6HEO0
M57I\RJ:[>H(JUD2E9'ZR)C112+)OHA(\-$./12*&I"VI8]M.&FI%2I3TI[TE
MZ:)\,D3)86TN\ ELBPZ)K)77&ES2*[^T]S06[')QV5R6\[G*.<HX&O@:5F*Y
M6M6*EZ3.&LY]3&NQT-N2:JS#2-AF8[(Q=U R5S)0QY#XAV6JW'Q@A^%3WYBL
M?4?/'6YI\8(?A4]^8K'U'PBT%I<M!JMG!%?:M5-.$A<V&(M8^-02\VND)#"V
MXAB*+/&" 4@] >4B0B&4A284C*/2D,K;5G'(X$M(#BTD$!P ):? Z((.NNB-
M%<4[))(98XIG5Y7L<V.=C(Y'0O((;(UDK7QO+#H]E[2TZT1I5PZV:(V#U_DW
M5)?:FS=L!;M9[?>Y8&QU+2-;CPKS?;._:[79(T^GY$DUJ)$9<Q+8AV7D+ 9D
MJ1"@LX:8]+@AA=#VMRND#G.>06L;I[W=ISMM /,^&]#P"\C#XBQBC9$F4GO1
MV9[%IT4U:I"&V;4SIYYFNKQ,>>V]SM1EW=L!TUHT-6N^,$/PJ>_,5CZCYV%[
MB?&"'X5/?F*Q]1\(GQ@A^%3WYBL?4?")\8(?A4]^8K'U'PBRH9"7)>]-X&4'
MH\BE>XF/!5L^.,XQAORP"\Y_SJ\<Y3GT/)X)SYEISY<9(MIPBJQ7=M0MA[.D
M4RUZ]IB:L[,VDBDV.=8(Y\])+:&V+7*78<V"JD:I"AUI4BT%,EZ9*&6:Q.O0
MPV2$Y <@_%BHI&OMOYC8^RF]_<?'7(_OB%:?D53A%SF:?4LL'HV:M7,QK2ZM
M^SQ\A!F6+&^XG*''CS7M?3+NN(SE*W""9"U)SE*E9Q_#A%P.](T:%H'<4.''
M8B1(FG]A1HL6,TVQ&C1V*67:8CQV&DH:999;2EMIIM*6VT)2A"<)QC&*WJ/B
M/RBF'D1.$3A$X1.$3A$X1.$3A$X1.$3A$X1>0NY@U^=[-%HGPG<DKL<8O ,Q
MU0NE>MDN%IJM=? [NH&]O03X1FSPJ^@;'(NE$[8%6:K%SMLDD:3]W79./@&1
M&V4WP#&M/:IC',@>S*PR0M=<DOO][]T=&\QF3M%O9-1\<K(X@V<2:_O#_CF:
MAOGBF9AAS;^)9[T$W"-VM<?'A:O#L)PS<S'/ +3*PB;*93EXK52:Q<?)1]V+
MO^[]SZ]<U-?8TX1.$3A$X1.$3A$X1.$3A%YA[AUL1(;D@3;KHRF5#6Q/8S[I
MK9VMM%4/:-P-@<@3Y&#8K7>98BUW"JDBUNC5H=84(T["8KP\F0)1=P/JC*)P
M,M\B-GITZ?'TUK?EOR4V=CRY^'T\?AOEYG:]/.8JIPB<(HEW[_0G=7]I=C_[
M.,\K>H^(_**6N1$X1.$3A$X1.$3A$X1.$3A$X1.$3A%5*Y=<;K:]T MRP^QN
MQ*U)JL"P ZO5AM-U!-#!*Q<9-,FW&OM2S%!(%Y[%@F44$^HB6FSS OTG6A,^
M&T^^EWU(<C#%3DIG'UY!,Z-\LKIK8>^2$3"&0AD[6-,8GDTUC6L=L=MKM#6I
M7>&KMO.5\VSB3)57TX[,%2I%2PSX(*MUU)]VN'S8^2:1MA]"NXR32231:<(9
M&!S@;6\\M;:G")PB<(G")PB<(G")PB<(G")PB<(G"*)=^_T)W5_:78_^SC/*
MWJ/B/RBEKD1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X11+OW^A.ZO[2['_ -G&>5O4?$?E%+7(B<(G")PB<(G")PB<
M(G")PB<(G")PB<(JW]LI%W9TF2C:WM,RE7<UL#2%7K]F@K\CHN5;MX:ZJ[RG
M<>5>'H$F&7DPB<92<IEC9,N*K^5[.>4=?D?L"H?\C\A4S>[9[(>MQC:(%B;B
ME7"H:PKM/JMA4+9KE(E+NZZO>;A98)RUZ^'8.PKV_;=>OME+Q5H4^0 JD=)6
M(F0KW%UST?MX[Z://?@?KH;ZS?+8\===\N?E_M\=!=PGNA<_BVJ8#P^BLO6<
M]J@%9A+3@&=((Q=G;W/:?'V>MF8VX<Q6A\L(&^_ R!11F]V(W_7!K%80X^(Q
M:9KLCGU\?L-ZZ=>O77F!X(';\C\/CK?P\?'KY<U//73<>P=F.#L7MBFI39M(
MZBW0$Q4A)L2H.SLEZX1YE:*J,6*PX-.C?NW#DQC41 -#OOI4-T3GVC4Z5#K0
M/J?MK^5=\]>F_OS73:J[ 0-HWO8-(9JTL(NF$%LP"C]OUB<:.CF!%4D29K0V
MIWJPFV?(7L,T;B4T+E X^12X10T.LRI%<B-$ 'S]#_M]% [9_P!O\$^?_54>
MM^W[!7RVWW1VUR-AL,P9VH9$.53:9&48JV:A3MDV>N"-A=>+. '+U#$UPBO"
M (+9=*G2W[@;:K$ZPJ5&V%&4J@=/4CKZZZ$'GX<M<M_-.8!^?3X<N6N7GUZ_
M%9,V[7:5K2*YJG95?([%D7W5[P^'1^UUI[$K,.PH5IL#=9LT:U5H FE!KB5$
M0Z^7CCV9Z38Z7/9>>CK$1<//$;&OD!R^G/Z<O!3?3LG9/J3O0)Z$\O#Q^*L9
MUOVH=VSM_=%J0?*SM9677ND[AJBOSDJ8C! $VT[\H\XQ%C*;1G"KU)URQ;$R
M,Y6IX1/"LY5G$5/(1H>NR#\M?RLM\R/+7^=_C\JZ/(JG")PB<(G"*%=XV$\#
M T^"!.2:JJX;/HE**6N"P*?G5\38"WI/N0,'!Y4.T0.2F8=2@2)XZ8F/,L+#
ML1G)!,-2:/AOK^%#_D?=5TL>V;@4ZI[7=,4R]WY^/1^PE=3?0<:@,#K('J!C
M8U, VI^-FSUS.95@KH 799^05=CB9#A-;H&)B&Y&BMAR(^(_E =C8YJ7RW8T
M@#BXFENO/8"%$45HP5M]T3K#*'2-_+000=AOT]JK5GV1<G!@&UY3A U^0CS*
M=;PI:8JOY)=D)X=T2T3Z\=@XBC9LO7AJEA=9N(?)C&7WXS2E,;3=]%JP-QGO
MN_(>\C,[+><.KBYRGQ(OB1[*SA+P2+/ZZ=B&)EC=$1 D3X%K1Q^>3*#"II\2
MCTMJ.-,SP88&6)G42G&&(,:$M+<B1)=CL/$64YV+GLV,=57>OF_6S)95K<@,
MJ%:Q])\93<!4%CON,;4RT@.[+L04>.DN*2[-FD&FFX^$)>=;?OP18O\ S*D,
MS) Q'7+L0X8BU,1<7PZ NK\D6QIHO-#1(F6L[7PWDLW)'3794##V5,1(ZW\N
M9\4I419T?L1/EV G68_7_?3I0.4'#B2<"M9XC1(Y:!-G#CBY*MI):6"E_#YD
M-$UI3CB)S.6'8S:5MN+(M:,[,SC&#J!_7'L8]+K3+F#@_(#6;4V 53 #%V:Z
MIMW:J&WSDL+80YF+&BNOQG($S'GEMRF9$5DBSA'8R<>Q(<$=?-_3HD:URJ>[
M/;$:S;B8)C)Q 2<DI7(VDRXH4!-"B <J02UEIN?'SB+B5&<:D./W]^/@BQA/
M96<<!Q;$+Z[=A98J:(/&([Z VL$J<9 RW8BHOI+VLE>)Y532W@L;.,>_CXP[
MYV?'R\(L23VD3$J4J]O:$W]]SX@():'3S036[\55;,B,G7#;++.T%S7X007C
M,DZEJ*J5"\/2:C27<X1FZ\$6<7[(S@$-D@8Z\=A(,-\F^'0^L)K1W&"&3$
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M[)B<;%Z@V7#GOK@C$&(QQJ)(@PH5A(PH=V-:]/3_ /+^1^Z5USWX?_SK\%9
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M/:C-RU^9=2(K:ZY:!<1C7,21:H8R<0,2:6G7NK:W*7(%Y:8!$=@SP[#DR<U
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M_AUW.QW-J2MLZ]LQ,$0C'H7_  TA#M9!1^TKC1I2"&U2<.YV)C:M5)T>JC3
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;BJ<(G")PB<(G")PB<(G")PB<(G")PB<(O__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g945651g66t99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g66t99.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!6 (# P$1  (1 0,1 ?_$ !X
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M&L-BO(Z*:)RM5T<C%T<U5:KFJJ+R7153O,1E98& , 8 P!@# & , 8 P!@#
M& , 8 P!@# & , 8!-%+_H@A_P"LDY_I=9SP/PL_]-8[_=;?^+LE[(?]$8S_
M 'AE_P#A\,3G3M([:V!!/++2]?V2QP;)=RU4D(Q@99)R\9-@>O6,6F8Q%YF0
M9M#$<NF$0D^>-T5$E%D"%53$WF4=:Q,U7QQ/>U-4WD3DJHFJHW7Z2HBHJHW5
M41=50G&;*[19FI)>Q>'O7JD3Y(UF@A5S9)8H^++#7151UJ:*-4?)#6;+)&QS
M7/8B.:JX5GK2^2"D BRJ\JY5M-<G;=7DTTB":6K59"<&?F&@"H'.9Q7<W.];
M.;FF)V6ZX$-S YU*0RJK41CE5['2-3K<QF]ON3N;N/U_LKV&-'@LO,ZFV+'V
M'NOT;>2IM:U%6Q1H>-^.68TUYQU_$;?$5=%3Q>31%T37?%>3-O=%A#29]:3W
M4+"^BHR#<E-'*$E7\V^91D6T8E3?&.NN[?R+%J4A"B*:KE(%NC 1$+GB5K1K
MN"_1ZM1J\OG*Y4:U$Y\U5SD33M5-3;.V%VM;#5L.P=M(;LM>"H_6!4L36Y8H
M*\42)*JO?+-/%&C435'2-1V[J:_/:/VY6+#5:K.T"QQ\_>'9&%0CU&8*C8WQ
MGJ,:+.(<MSK-'KE%\X;MG2*3@RC0[A#K142K)F-2^M88^-CXGM?*ND:*GTUU
M1NC5Z%7541=%Y*O,P[FRFT>/N8_'W,/=@MY61(<;"Z+>6]*LK8%CK/8KHY7M
ME>QDC6O5T:O9Q$:CFJO8K>A-PV^6M$%7*!.2<S2I%S$VN,3(U0>P4BR,\*\:
MOV[IR@HF=J,>]ZR)0.1 K94RARE !&65;$CGL9$]SHU5KVZ)JU4UU1454Z-%
MU[-"Y1V0VER5G(4Z.'MSVL5,^OD:[4C;+4FB65)(YF22,5%C6&7?5$5&HQRN
M5$YG:C^3QNJ5D!BX_7DZZ? PFY04D^I 3LZN63N0G'O6#NRMA;QUF$(5=0%N
M;UT2IIB<I@,)*EE5W4A<J[KG<M/HL?PW+KKIHU_S5['<BN'8O:FQ-XO#A;<D
MO!M6-U.%IP:-[X-MR[ZR(Q607_\ -7NWM.*J-375%,/*Z8VG" Y/)TB;;I,K
M5$4AVN5)%PV;VV?C&\S#0*KEJLLW(_D8QVW=MDQ4YIR*@3G@J!B!2ZM.W76)
MZ:2-B5=-4XCVHYK-4U3><U45$[S&L;+[054D6?%6F-BR%;%2/1K7L9D;D#+-
M6FZ2-SF)-/!(R2--[14<B:[VJ)G?XN6[NY^5M(Z[FRU^$/+)R\H8\>5O'JP:
M\BVE477.>@HDNS7B9),Z(I]*H+)<42* 3B-7BEG<=)PG;C=Y'.Y:(K55'(O/
MI3==R[E,OXD[5>)6,@N%MI2J+82S85849 ZH^9EALFLJ.:^)]>=JL5-Y5B?N
MHY$(3S'.6& , 8 P!@# & , 8 P!@# & , 8 P"R?([_ .M)HC_VDUS_ .K#
M,S'_ -.J_P"V9^\[CP:?^G^R/^_*/_FH?K=SO#]&!@# & , 8 P!@'X9-5VR
M)H>^=<7F>%R$'3-NT^V3(LT0<O B:[<HZ8D1:MQ.F"[GJ;-;H$143!57FD$Y
M.=S@][N0OLXZU7CTXD]*>&/>71N_+ YC=Y=%T3><FJZ+HG/0_.3"W8,;M+B<
MC9W_ !;'YVA=L<-N_)P*N0BGEW&:IO/X<;MUNJ;SM$U374]"Z[RX-4-8F#IU
MDC+!+5J"UYOQ:M/DXI%.3IVW-B6O?*<6_9 +L#O*[:==[380]L;BH )2\?!O
M")'&O@HOS4F!N*^2:-T;)9+..25JO56STZT./5[7<M&R0V:CI(5TYL=(U5_G
M$1/4ZOA%P;(:]"W%:GIUL7M,ZI(D+4FH9S*7MI4@EC3?UDJW<5F8X+K==&S1
MUI$36JJNA>[<JFI7!S3-=(0\17=5SNNN3AKO=MWCJH[4VE8:_J^%I/=1"(/'
M,ZX8GCF<[6C+081;&%<R)&$85^[Z S@A\^#$30-GLJ]\MR.SD[-"!TR)4CDM
MOGX4BM;&CD<Z.723?<]&JY^ZFNFF@R&VM&_)C\4V""IA;6*V3Q>T61BI2+F;
M5;#UL?XY6;(ZR^-8F6:BK7X$4#I4CBXC]U7HO-RE.5)JOE#UR$>-ZA9:1<J'
MM5])U1N^FT+5&O-86=%(\E -7#:%K_<VUJDA7H!2MULZ,NW;MI:<*C+B<1*K
M&+Q-S&RR-6:*>"Q3:R96L6)S;<2Z-D5'22<59FR2))+JQ55D>K$3HG:W;/";
M55*\C:-S'9#&9N2:DR6PV[%)A[C46:LQS*]9*C*<M6JZI45L[6-FL(VPJKHN
MZU7E9ZGA]Z;UV$\-9>Y[8?*OT9N.O"E#$.]&G:]V?:;;8!?-NNE!M*!$R[06
M+$%52N7/2HBND!.>:Q-A[C\?CZS4BXM;$9"E+K)HWCV:T,,>ZN[S9OL=O.Y:
M)HNBZZ&QI;;X.OM)M+E)%M^*Y7;79O/55;7UD\0Q>7NW;2R,XB;DW GCX<>K
MM]^\W>335>)ERHM=:UV+/;/US:89S8W.N-F0M="J\GJ U,DRL\Y+5:5K86@(
MJPR:5O9.QCI!K).'Z275FQ7"1DG*<NL1*78JU:K1U+,+VQ)9JODXV2?<5T4;
M)F2\+?C8L+F[S5:C57>71=4W-5ICVRQ.(RUG,XF[6?;?B<Q7J)2V6KX1L=RS
M/3GJ>.\*U*EYDBQ2LF=(B;C$>BHY)U1,-:.4WI-_O*HW^H0,]4Z/%\E>_:M4
MJY62;HU;NESHVUXTD#$&!R7KE5BK!>F+"/DU!27+"H LLUZ9$Z9ZX<5?90FK
MS21S3OR]>XDN]IQ8()Z;ED?R^;,^.NYSF)JF^NB+HIC7-L-G9-I*.4HUK-'&
MP[&9/#+32-'K4R%_&YJ)*L&CDXE*&UD8HHIET<E=J.<S>:J+YQ9TYY., 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@$T4O^B"'_ *R3G^EUG/ _"S_T
MUCO]UM_XNR7LA_T1C/\ >&7_ .'PQ?C6>V]1IU[D\N;O8KO5I[DVVB=GFL+6
M:RUG&VPF<A=D[\R*QF%+##EK$Z=^0U=E',BR>M30Z,6[0655:'8#Y[#/7W*B
MRODC?3>YR-8Q')*BR\5-UV\U&/5WS%5VJ;J-7FJ:+VN"VCV<;2V+DRMW+8^Y
ML/D+=R.K0HQVX\S%-E6YB)(;+KM9*%M9D6E8DFBEC6LRO*QSG1K";7'<H;4[
MUI6=A2[NQPU_I.M=\T)GKV-K#=] S;W;$CL]Y R+6V#-M"Q43#I[,.E*MW,*
MH\#L3@P1<E=$ E;;4"[DSG/9+'!:BX38T5CEG=.YBM?O)NHWC\T5J_1Y:Z\L
M^#;/9V6.AF;,MZKF,7@MKL/'AH*#)JEJ3:&;/R5)H\BMN)*\%9,ZK;#'U72?
MYK_,L?Q$1(XUYNNE5D.2$$F,L'N*;5M5PNO5V!5>$/,6RF3+,8GBX)U]UU."
M?=*@;JX$5!%,#FZ3G%M168V?!^]O?YM.^27EK\UTD3DW>?-=&+RY<]#28;:C
M%T?Y-^.MA/BMM#?R>4W(4=_FUC)8NW'XM\].-)PJDV\Q=S1VZFJH[5-EIW*G
M@&]J)8K948N.@=;0&QUM1T77+->L-UKULQ6/A)>S2<]*.+.]82;:O@O*H2;@
MDH1G+0\,2.C$AZ4^5QWF))OR1M:R%LRUXH46-%EFW6N>YR[ZHY&:N1R[VCFM
MT1#/QGA J1Y!+F1QM>&GA*>;=LYB<)$Z@QV7SKH*MB_/<L/ORPSLI[]AEAZ6
M$BL5:R0P-57./J8WYJV5W0]V^QC[%"FNFA[Y4[C#.03F7;/94WK.SZ[9NTY5
M-.,2F&<[SJ_-2TQU".5[1?S"ZL>4Q !4ZU ZPZPB.;Q:LL<C53>5)GPOA3YR
M(U'([YCW.W6\U=RZ$%K:_ 6=J)=I(H;M5<KLCE\=DZTF[:DBSEO!9#"Q2)8:
MV!+,5O6E:LV>#"Y)YK+EAU:F]L&I.4)JZOZYK5)LCQ5B[9:3OM ?NI;7S'8-
M?1G;!OR-V5&BYK,A)L6DW'FKS(Y3G751!G*F0,0BAD"G&N"W V%D3UW5;5EA
M571)*S??;2=NK%<B.3<3GKIH[3DNAF[.;9X"GA*&*O2NBEBV5S&'FDL8:+,T
MVV[NV$&=@WZ,T\4=N%:42HY7N9PK"L5J.5B*9:@<IS5^O"/*B[*:X4.T[A86
M6YLX*@1^OXX]53J57)'S=:J[63?L82RTR\03:9BVR*XIR18Y?I5D$9QRBG,5
MV&'^;_21OL)))N1)"W<X<:(YC-Y4:^.1F\U.AVBZJF\IDX?;S X5LF.D1<EB
M<AM-#?RD=3#P8>!<>W'4$AM4:$=B:*K>QF6J1VJS&OW9^ _>>QEN1J0%<-LU
M.;I7* @60R77]D\H& V36^F9E31&MQI=H@Y%^ITYNJO^-NB.C:@54#\7/\J'
M0?#Q))XW166HJ[TMMDS$5/ZC4G1=5Z$7^<;R\_9SX[)[18ZWC-L:D7'XV<VR
MIYRCO1(UOB,";0(_C.WUX<W_ -)5M(T1R+_.?.^9SK'F&<(, 8 P!@# & ,
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M$Q7"0%[Y3YYSME*FT]^K;KHM9M>HE9S)EWG.<DTLN\BLY(FDB)HO/5%*[/\
MD]9J>E5JMVAQ;75[-V=7K6MZ.2U%1C:U$3FBL6HY55>2H]NG0IG_ 'H#9/TP
M4?[#GO6SC_@"?ZQ%[+_<:[Y-N=^TF)^ZW![T!LGZ8*/]ASWK8^ )_K$7LO\
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MF"C_ &'/>MCX G^L1>R_W#Y-N=^TF)^ZW![T!LGZ8*/]ASWK8^ )_K$7LO\
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MZB?=-+_#)_\ 85=#]HOQ]H6CO?'_ 'A_S# ,[TB?SA/K%^_ '2)_.$^L7[\
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MT%6QUT$5C-EP J[<RJ93F06*43 55(3"FH "( <I@ 1#OX*CGP!@# & , 8
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M_!JN\08V1$565FN;JQ[%6]^=*=B, 8 P!@# & , 8 P!@# & , 8 P!@# &
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MLDX(JBFH5=#AT*Y3D*8JR/ Z@=$H @=/@HH',,' Y_VA%1S8 P!@# & , 8
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MEDBE:A%T=Y 3,>[YJ\,_@X.TW6$,NB@HW=(RL/9Y>,F6+MG),G1T'),!.?\
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MHB_GTGHXU5!=LW6 Y5 6015!0ADSE4!1,IP.4Z1C)&*;CSBF2,9,P" D,)1
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M6YQ.U=LZ#O\ 4+6M)0-IY/F^Y1@[20B5#(D4O/)CZ=FJ!&7,!9%8PI+\XO.
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M_=EW"V*4:MG;2N;$9N*C(.D'1"F2<L%)8B#5ZQ5YP"W>IK%1=$$JJ/.(;CG
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MQOC71[5:JIJFJ=*=R]"^@L#G4% P!@# & , 8 P!@# ,$W_I-+_X%7?]0M&
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MEV:?X_P_CK<?!)$^U-+47;[*.+9FCYA8:^N=[3[Y6'ZM?OU(DSEYO:-5M#(
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M,U.)$JM54;W>"V@?=GFP^7KLQNT=&-)+5%'.=7N5][<9E,1,]$6UCIG<E_\
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M(0\4B[.LG'M"HB.M>2="=7/KZ_03M@D8 P!@# & , 8 P!@# & , 8 P!@#
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M?_FN$^'_ !X8_E5Q[OT>QGA1D_\ VZVFAU^\TH=/3H. OE(/VS/><I=MF/\
ML:NV\/\ XJ<BE_YTNGD_RH1N_1[ >%"3L3XF6H=?O-F!$]*H.!_UL'[1/<<Y
M=I.S_L:KVP/_ (H"$2^7A_Z:RI\/^/R9'\IEE?H>#/PHO_\ T_BHO^(S\/XZ
M$<%/+0^;>=_\G^'><ONDRH_L:FVD<?DXL:<E_P ^GNB7#_X_W8_E(RJ_H_!/
MX4).S6EL="B_>-M8=/23P6^7@]<G]T?SW0K,?^9T[L0W_P"L[U^V_P#GO \,
MG^4#:5_Z'P/^$-W^VM>#ZO\ ^+;EVGG(X3.N>+T)*O\ \(_H7B\G_F],VT ^
M05K+KE+_ )@6WJF#_D/R8^.^V[OT?@;VNY]<VT?@ZB]:-VOE<GL\^K4GA1==
MB/T,F7_X: ;EL,?V-/3 #_\ G7&DD#_CT4LX_P#@.1\<?""[Z/@@S#?]MMAL
M4SU\'+6/PU'#B^L-]$<O\6H<9K?L[O\ 1Z?5'^SI;Y64^/\ W]&5?A__ #D_
M&OPE.3YG@H5J]D^W6 9_Y,%GS$;D/E_5&_\ #H_'0X!M^VOZFG6G_P"YLB&)
M_P"7#K?_ .^3(^,OA3=]'P78IO9QO")49Z^#LW8T]"*3N0>77T1+R];T_/4<
M(VW<P_L:=A"_WJ;19?\ RIU4WQ_^+'Q@\+COH>#792/OG\)EGEWJV'8*7\'#
M<K^6?^Q__P!3@&S[R-QYFJJHEQ^+I=D=)P_[^CK)>/\ PX8^%?#&_P"CL5X/
MH/\ ;>$'.RZ>?@^#Y.C_ ):C=K^4E_9-_O?SJ?SM_?!O_P /:,E_WW5VOP__
M *9OQ_YA_P!^/&_#2[HP'@OB\^UVU<^GJV)@U\VJ<^L:5OUYE\T;$_?)^>TQ
MLK<=Q0C0[^;A-:03%/CTCV5M)FS1/@ B//<NW3!$O  XCSCEX  CA9O#2J<Z
M7@NA[URNU<Z)_P#T];7K_5+<DE.)JOEE?&U.E\BQ,:GG5ST3\>_JYU\M'+=H
M=.4%"Q[VY*T4] _1]EDV979B9,<1YH$3A(R]'EE3B;X(%39B)CB!0 3=[+3I
MO#%UVO!7"O8L>U5ER:]')+%95Y=R&EL;4;*5%W9\YCV/UTX?PA3?+KW11O?(
MO9R9^[GIY>7L65$$Z3&6W9:YQ^ 36?):Y0MW:F+Q$.D+-L.JUT4N]_.FF")@
M'PS& @@;*=[PR/UW<KX,FK_J;,[864]:;25FKU_UD,;XW;/OY58\WD7<M$Q^
M'REENB]?%9C^!N]ZRHG694G*6Y6MA*!:/R4=I2*APXE=6ZC:^UA&$*(]XRIK
MSRF64Z7A\9B%KBBP /P4CFXE!XMX:I/_ *P>#J+O9L/M&[3TS^$)BKI_83S:
MD?&&>7E3V3VDF7]>S+B,='IIR7_.[C)O.G WD[#NQEX_A*9ASP4T1H6KL1,
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M!"U>>AEH8 P!@# .J\>LHYLJ\D';5BT0+SEG3QPDU;(E_P!Y5=<Y$DR_WG,
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M2OU]IZFZJX'!T=/$L-B:>G1XKCJ=?3S<&%FGH)'  * %*  4         #@
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M!2\X>'$>!2AQ$>  '>P5'U@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
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MC?VF .U8OQDP],;^TP#Z))1RARIIOV1SG,!2$(Z0,<YC#P*4I2J")C&$0
M!$1'@ << [N 0U<-":[O4\ZLMA-L$)5XFV27" W+N.GQG,:-TVJ/00-0OD%
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M*K$*B%3H[EU_A_$EW!(P!@&";_TFE_\  J[_ *A:, SN , 8 P!@# & , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@#
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , P3?^DTO_@5=_U"T8!G< 8
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M@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P
M!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# &
M , 8 P!@# & , 8 P!@&"F[36*T#8;'8X&O@]%8&8S<O'Q0.Q;]'TX-A?N&_
M3BATR/3=%S^CZ5/G\WI"\;D<4LNO"BDDW=-[AL<_37737=1=-=%TUZ=%[#&L
M7:=3<\;MUJO$WN'XQ/%#O[NF]N<1[=[=WF[VFNF\FNFJ%!MN_P *=R/=*[JA
MM&6Z[2CRQ2)X9.8LU9BFT[1*8I/D06C"6JPMY,BJ0J-'31\Z-"1TXG&LW*2L
MD=GP5*GASVHZTWB\R/9(F[OHYBIP]Y$5N^CM%35JH[H7YJHO0IR&1\(>R^-R
M<.+GN.EEEX?$LUF,GI5N+IN>,3LDY:HJ.=P63)&U4616<]+TQE^HDT\3CH:Z
MU*6D%2JG28QECAW[Q4B"1UUSIMFKQ58Y444SK*F*0032(=0X@0HB&<^O8C:K
MY()F-335SXGM:FJZ)JJM1$U541.?-5T.KAR6.L2-AKWZ4\KM5;%#:@ED<C45
MSE:QDCG+NM1571.2(JKR0KQ(<JN,['G9:#JAWB+3;3+5U8<S4PZB8RU(/-9,
MMI)W1)S#URTR3.O/H%5ZI @WAI5S-M$HR13*V0F$TVMDR][EJG;ISY=^OFT[
MO/RYF\)<I'6")(-I)3+AS-R[*N*=!1ZU?=B5]23L];&TQ$9"VNM4U6-G#RT0
MDY?0(I)M'LTS;F60C4EN>U3$ZI^==/0NG/IY=:F78\H#4\F[KK..L;U\-I&K
MIQ#UK4[BO#]<NC).2K$3*SB=?-#5^=E(]9!\2!GW\9,MFCALX>L6R3EN94-4
M_*+^=>[ITY]!,N"1@&H3M_IE;C)26E[+#MVD,U=.WX$?MG#I--H0QEDDV2"B
MCI=UQ(*:;5%$[A582HIIF4,!1Y3,;<[(8&AD<EE-H\/7K8JO9LW6MOUIK,;*
MK7.FC94AE?9FL(K%C96BB?/)+I$R-TCD:MQL4CE1$8[YRHB*J*B<^CFO)$[]
M=#0-<\H/6^S DR14BYA'<2*)G#"TE91#E9LY%0J#UF8K]TU=-SG14(H5-R+I
MJ;HP>-F_3H"KPO@_\//@Y\(S,C\$923%SXQ\:3U-HTJXFQ)#,LC8;555N3U[
M$#W1/:Y(YUL0+N>,P0I+"LER6K-%IO-WD7716:N3EU+RU3IZTY\]-=%,;MW?
MT%K$*VV9]S4W(V9A;9EB,S<V=4@AAZ0E#C8#EG^S)U(TDFXL,,BV9J,T6"3=
M:0EIN7A(6'D)!+URI=IWX4LT;=:[7<YS6SU)XK,+G,71S4EA>]BN:O)R([5J
M\ET4QW:MY.147IT75.7?RU[-.7/4Q;CE(P\4\=RMEA"P&LV\K=*Z%Z5FBR;Q
M.>U[19?85M*^K41&/2$@F$'5[B@UF(N>F7,A)5IPBC#E9R$8_=9)&O/GHGIY
M]&J\NK3S_O-A1Y2&GU%Y%NYL$U#GB FBRJEDH6P:NUC7=>K8W*5BGSVQU:+:
M-9U&G\+6W@%ER33^MJ(SC!@YC5T7*@:IZNG5%3]YOU+V#5[^E-GK3B5,K6Y=
M."GV$Y6;/4I>)EEH>*GT6;Z&MD/"2J)UH6;B9)%468H+-7R"B2I^<(%$ZZ_G
MTFZX!BIB=A*\T!_/S,5!L3+$;E>S$@TC&AG"A3G30!P]601%8Y$U#$2 _/,5
M,YBE$"F$*V1R2.W8V/D=IKNL:Y[M$Z5T:BKHFJ<^\LSV:]5G%LSPUXU<C4DG
ME9"Q7*BJC=^1S6[RHBJB:ZJB*J)R4@&Z<I^FUV?"L4RL7?=TZTK_ '6V-EII
MI7+26I5@SMTQ;2DX]D;/!1XNI)TPDDHBO1+N4L\H$:]4:0RB215%-C!BIY8^
M+/+!0C=)P8G75EBXTNC7*R-K8I':-1[%?(]&1,WF[ST5>7,W]L*%6SXGCZ>1
MVALQU4O6X\"RI<2C361\3)K,DMRM$KY7Q3)!5@?-<GX,BQUW(W59$J&Z=3WN
M(K<U5]A5&3:6UA%2,"@$]&H2;Q*9017CVXQ#ARE)MY!4'"21XUPU3?(.1,U6
M;D<$,F&+-1N5WRLFK3,6%SVR+PWJQJQJJ.7?1-U6IHJHY%5JIS1=.9M*.T&$
MR4%2Q3RE&:.]%#+6:EF%LTC;#6NB;P'O;,V5V\C5A>QLK7ZL<Q'HJ$+)\JZ.
M6L%TKK>JMWDC79A[6HM@RM2*\J-C+MZ$TI 1U\CQA4@H"5UM-ACIFH.B.K0,
MG2D9.P*MVB[$D4YQ3;ZISZ-47337T?O7O[^?(VU+E,4*(0=M-@F>U*T0TG.Q
M=BA8F'MMYCHD(&:CX5>;//UZJ&20K+M2:@'+69G6$ *2,TS3D6C!R5=!(-4_
M?T:K^Y/7V&8=\I#4#%B:0=S\XBBW)+*2J!J!L,9&MHPDH$+(.+=$$JII6GM@
MDQZJS<6AE$HR8@=:,.\;)*K$#5.W^.GG[/23G@D8 P!@# & , 8 P!@# & ,
M 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!IE
MNUSKW8'4.[RATR[=E=9[+[KJO!V3LWKO0=<ZAVRQ>]3ZWU5MUGJ_1]/U=#I>
M?T*?-OPVK-;>\7L3P;^F_P &62+>W==-[<<W>TU737735=.DU][$XO)\+X2Q
MN/R'!W^#X]3KV^%Q-WB<+QB.3A[^XS?W--[<;O:[J:>=FX?X(7D?;EW7#;IE
MH&?JBK0T,>PZ\HB]?K>N+B:!(@BR&7@T*ZJ[CBNVC9NQFB5R2ABRK9$%3 A)
M+/)!U@6:[;=E;5B2669VZLCGR*]9%8B-:KW/WGNT:U&_23YJ(G)$.-O^#+9:
M_DX<CXM)3;'P^+CZ"5ZN/L<+3=WX&5]8]]$1LR0/B25$WETD<][KVL=":.BE
M%UX?3NKX5TYCY**5?0E#J\-(#'3#!Q%2K-.0BXMH]11D(UVZ8NRHN$^F:N%D
M#B*:ABCLI;UV=BQS7+4T;M-Z.6Q-(Q=%14U:]ZM71414U3DJ(J<T.KJ[/X&C
M.RS2PF(IV8T<D=BKC:=>=B/:YCT9+#"R1J/8YS'(CDWFN<U=454-8AN3K5:>
MK8G6N+%<M=/[):8>TNW%>DH]\W2-"TI"C-H'LJS14]$OJ\:.2/)BRE63]PA/
MJ)23-ZV+'139CBFVTZ>_W:'/5^3Q2*B6#)$/[)T<!8*G96A73Z/7%>2J-+>T
M=H9ZH$4119.18/W,E+ F9%1:7/TS11DR#J.!HB<D[47U:>XBUGR;++7+=4X^
MHV S#5T-9M?6V<;O;$T7D[#+:_K[6$9N)*O%UN*JTJ[0@:Q'J2$7L.O0@1T:
MV<JU-:38*+3(A$T7EKIIW=*:)SY=:=BER\%0P"/)_4VM[)'2T;)4NM@29;NF
M[QZTA8UG*%,\*<%';:2;M2.V[XBAQ72=IJ@L1<"J\X3 /'@<UX+?!YGZ.3HW
M]C=F],M!:AMW*V%QE7)(ZVUZ2VH,A#5;:ANH]ZS1VF2<5LR))O*[76ZV>5BM
M5LC_ )NFB*YRIRZM-=-.K3HTY$?ZYY,^LM>=IJ]14N+R3%%,7ET:PLN=DU;F
M5.DU8-THIHS; <RHG=+@W,Y<G*F!U012113X3P?_ .3EX,]@&9%8\8NU-C(O
MBWK.U];%9A]2"%7K'7I0IC:]6NURR*Z>5L"SV'-9OR)'''$RY+;FETU=N(G5
M&KFZKVKSU7NYZ)U&QW#2]<LP0ZL(_D=>/X6+ME?:R%(8U=J<U>O2<22UQ!V,
MU7IN(*G*+P,%(%>HQZ4BVD(9BJD[%J9\S>^U8W%8O#56T</C:&)I->^1M/&T
MZ]&JV21=9'MKU8XHD?(O-[D8CG+S<JJ8SE5ZZN<Y5TTU555=.S5=>1HTAR6*
M(_BIBL!.V]G2Y"+MC.*I[1U!]E5:5NFOWFM)RRP;QS .9P\L:L2DX#1&9E9:
M(0DK#-OSQBYG#--AGD;J=_7UZ]/2O/K_ ,>U3)[$Y/E>N<;=%".9%:8LMDL%
M[;M'LFG'Q'=5*Z1]P]JU5>,(=S*,(5&"2;2I5V@.Y5G/E&126=,TR0Q@5-?S
MW*G\3,:3H5VIB6P938$\6>L5[NS>SG4"38S!F#%A1Z936C):2BZ-K>,<K'&J
MK/Q!A3(=!ND]1:J#(NT'4L_!.OO7^")_ F[!)K=IIM0O,:2&NU4K=PB$G:3]
M**M,%%V"-3?()K(HO2,99J[:D=HHN7"23DJ0+)IKK$(<"JG UV&>:N_B032P
M/5%:KX9'QOW55%5N\Q6KHJHBJFNBJB=AB7:%'(Q)7R%*I?@1Z2I#=K0VHDD:
MCFMD2.=DC$>UKW-1Z-WD1SD1='+K7NP<E.KHV!:S:9M,SR<)67KR51N!=/UZ
M@Q<7;:Z@\>OF0O8:7J<M&1]GB%Y.2"$N$4V:3C!"0<ME5G;<C1-KL8\O*L:1
M7HF9-C)%FA\=DL/?#*K6M=NR,F8]T3T8S?A>JQN5J+HB[V]R]K8NFVTZY@+M
MC92:>JE&^F"JXR&&]5;)))'Q()Z4\,5R!TTWB]Z%C+$;97M<LC48C-UI?)FT
M!0(^K,:WI[7+=S3VL.A"3SJF5M[:$G$&F@5A+N+(XC#S#J=*JV3>*S*KL9!5
M_P YX9?IS<_+,^5R-ETKI;MI4F5ZR1I/*V%4DUWF)$C]Q(]%5J,1NZC?FZ:&
MPQ^R.S&,BIQU,%BFOH,@97LOQ]22XCJS6I%.^VZ%9WV45B/=8<_BNDUD5V\N
MI@5>3+5%U%>GM5S4;,!L"]*:@K6$PH#^Q[&K>V'<G!.4ZP5Y*O65ZJ%;EHSN
MQ<69L@E%D:.6SQ-R^,ZUYT6G>O7^*HO\/X=!W0Y.-36;S02-AMDE)V:-FV-B
MFUUX)%]+.)^V1EN>22B+.!;Q[9T@YAXZ(CT6C)%BT@FJ+06BKHG7A#3^/XKJ
MI'&T.3;99N4LY]=V T&UV:WDV&Q9!]8FC-PK'RDZE)"R)#'UO:"S<9&MW<\:
M+9L+#198%Y1XRD+&^92"*L*(5.:]BIS[=>CU)T]J^;D7+P5# & , 8 P!@#
M& , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8
M P!@# & 82RS):Y7)^PF;B[+!0DK,F:E5!$SDL6P7?"W*L)%02%8$!3!44U
M3$W/$A^'-$" J7RFJ[;VE+='K5BC5;!0[W:[-#-X^5LMFI4Y0)G5D-)U%>M5
MB'E9B></#;08RL9)Q+4R+^O-F$^R:NHF=:NVXC7N_P"?YZS:+'O&,B8"NV&&
MI]\FF<]L:D:]<#*U&Q:_/ FN-OK%3[H99KL&)KDL>(9+VED9J,9%R*DR^ \>
MSYB367D(D%73UHGK_/4=IIM9[[KR>JY:LLHQ23A;%8(!TE:V$I8'$+6W4*P5
MGIVJM&/,KU?G'TJNUK3XT_(OY!6-=)OXB)6*LBW#7GIW:]/FZO3^!,V"1@#
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M@:=:S,:54B\.Y P=:\NCK[?S^>@ES!(P!@# & , 8 P!@# & , 8 P!@# &
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* , 8 P!@# /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g945651g68b35.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g68b35.jpg
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MO _G!#]#X1.]9_EX'\X(?H?")WK/\O _G!#]#X1.]9_EX'\X(?H?")WK/\O
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MKL/8+$N4RO+V#[-5<CX%C(TE5SP\/OU] !\LJ8X^)SKKZ:]=58;-T4&;/6[
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MTS-JL0QKE5JTV>UK:U;/LQ<!&PWB*J4@?@%)"1&UJQYQV6$#&WV51\M8(LJ
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MNAN5]ND5S D@&+F:\;8<FMY'Y><FAY()]L9+P[A]E@X7:4XI+Z<)(K<_TA:
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MX)=)""2GPY$SQYY_M[\.7 )CARQ_?WX\^)4'IZ:M^MT:#1VKM3HF7:F126L
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MV7';B2G2+6&NW.<DQ6FHTA<E+JGH[;;+F5-H2G!%AD?4.IH@2)68NK]=QJY
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<U?!M/X<0)@8CLGJ4P%(/(JG")PB<(G")PB__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g945651g73h11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g73h11.jpg
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M%Q@S-4)1<7:!MADD4Y$E)C1#4F)R<X*ALL$G*+,V1(2%I*6TQN'_Q  < 0$
M 04! 0               0(#! 4&!PC_Q !7$0 ! P," P4$!0<(!P4$"P !
M  (#! 41!B$2,4$346%QD0<4@=$B,J&QP0@5%B-"<O D,U)38I*RX1=#@I.B
MTO$T-7.#HRA%5.(V8V1T=82%E<+#Q/_:  P# 0 "$0,1 #\ _=M==LZRURZ(
M->KY5JL8>VIX".F)D(64.90K*7'PHM3N9$L=I6,I=?'&<9:5\G%ISG') )Y
ME02!S*S-2N]-OT9F:I%IK]MBDO*&</KLL#+C,%-XQET0EP%][ QC7?&'A"/*
M)9SGPNM(S\N""-B"#W$80$'D5M/(4K1)C9-/@[O4]=&RF%7&Y>M<B(89IPEY
MH,&)G)A<C*+;QEJ+!*8KLL/&NF+;7*&!&,Q[1*8^3<"G&Q/=_'XJ,[@=_P#G
M\EJH^\:H_'V:;7$W$6N5E^6#58R:X_B(GI")LN:C[MJ[C+SQ<T?*3^/00H[
MB52BU-J&SE+K>5SPG;<$GIG?EE.(;\\#K@X[OO6[TZYQ=T#DB !I.--@Y@BO
MV"#FQ$A3$%-#B R.8^18:>*&RMZ+E(N5$("+,",C9($P4EUI].>01C[]D!SW
M_'FO:Q_SQ0O[V&?Y%NG Y.\OQ"'FWS_ K;.0I3A$X1.$3A$X1.$3A$X1.$3A
M$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.
M$3A$X1.$3A$X1.$3A$X1.$3A$X1.$5?Y3<?3OKJU68"2M%0K-P)-:=M><1[S
M,P:;D4=0ZY<X:/6\<XV$H5L?+Y#V!Q4LCL^6TTAM-0:XC(&W3<*GB:,C/GS_
M (^7)?71D[$[$"LNS$"PQQYETOU7A;6##CQYTK1(:UEL5H=\M PY<@&V&*,\
M.Z9EQ65Y<>1X5/O97!VV[L?#(R?M08._B?OVS\,<_P 5/?(52CVWU*1G[7JF
M="=!:%HUPF9^702X^@DD&0US>*B.U'I:&>;>)1)V8)]QLEX1I(39CJ'EOH:&
M?D=?$?B#^"@]/ _@1^*K YTWVL@IPZ,KNI]?G0\>E]#E()G!H[:=JAMI479=
M4E+R$] I,A0H]ZD/A*61)7Z:CUW*>1'2#@(BT6"KB'B?/&PP00///<!L-CTI
MX3OR!\,[X.02#U]>:LCK2KV&$?V!8K4U$A3NQ+NW;2HB$D2IB-A!P*53:)&@
M-RQD7"/R)#T=3!90Y_,4&VR;(D L8('#9+(I)Y> Q]I/XJH [DXR3T[L;+*3
M\8,W::1*)=D<DOV<ME;2Y>6=CDHQ1+>G&68=PU<2.[V91G+XX+3ZE9=4IS*G
MW\N =B/#N'>.O-"-P?'O/<>G);YR%*<(G")PB<(G")PB<(G"+B%'@ J&0::(
M&HQ](HB2B61U%$KQG*!QL.K1E]]>,9REEK"G%8QG.$Y[<D-<[):TD-&7$ G
M[SCD/$[*A\D<?"))&,+W!C ][6\;SR8WB(XG'HT9)Z!<OD*M.$3A$X1.$3A$
MX1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$
M3A$X1.$3A$X1.$3A%5??LK84WG6-;B$[;EHZ5KVQYB5J^F9:!KMH+=@C-?"1
MUAD)RQR]< Q7X14\7&$Q+-A#..D;+%F- R0\64H*IN,$[;8^MXYY =?N />J
M79R!OUY;'SSRQZ?%3'JMHIFF@MF1NQ8E_!,AE06U)F(GKDWC);F4J.DH.>LL
M<Z,XGLL!#4L\MD3+;;K;#B5-)@\^GPY*1RZ_'FI%Y"E.$3A$X1:G8_YXH7][
M#/\ (MTY(Y.\OQ"@\V^?X%;9R%*<(G")PB<(G")PB<(G"+I=WVQ [<ZDNH$0
MS1%YZL(F UU4M8T NE.-)K>E=J/"V VRU\V3E)F$B8F8,+)@)J>N4*Y*R=2]
M,)#'L(?<<&:[BW&2CM=N<VX4]G?)4S5=0)\]K74@=&V*1K61R/>QK6R,C@?P
M,FRYX.,$^ :F937O5NIV2::N6M8:6U4-GM<EO<WW33]Z<RJDJZ62::HIH8*A
M[WTM155].9YZ'@C@E:''@;<+I@WTW'P-#Z>=[.6"A=1=6JL3 G1.Q5#M*V:Y
M#!L@.6B@6UDLV#OXYR6<.E*CI-^>24DQ<@!XFGB5Z2ZV_BDJ+E;^SJ+9+,^1
MKZ;)]U$CBX0U$):V2F+<X;Q,$>.$-=N .[T?J41TUMTMJ0U5MU7144%-+!=2
MQIO#J=@B-;;*YKY*:YLEX>)YBE=4A_&98L@O-X.:)>B)PB<(G")PB<(G")PB
M<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G"
M)PB<(G")PBICU&BP@,[5Y?8UNUOZ!),XG7\%8+]LO1MB96^'%)L;(=[H=FDF
M;"K#3(;N!2Z0TL-AW+7KD-DD/JJ'(X!\< .'AMC;U5#L9&<8WQS!Z9W&?N"D
MSIWV!K2WU%Z+U[+B$Y@"WO>41G:+.U90/!S[KK,BN?>L]FFW8B1?06B*7,O1
MY&,"$#HC0T#X:Q!!'/[L?@%+2"-ML'EG^/\ KE6"Y"J3A$X1.$6IV/\ GBA?
MWL,_R+=.2.3O+\0H/-OG^!6V<A2G"+\P'M7O:"=7_3CU;26M=,;@(I-('H%*
MF681JE:YG$XDI9@]R0+]?9JA-2B\D+:;[MJ-RPUX,)9:;QXL9TU=53Q3\$<A
M:W@:<<+#N<YYM)[NJ\#]HFL]2V/4<E#:[FZEI!1TLHB%)0S#M) _C=QU%-+)
M](@;<>!C8!;U?O;JW'3_ ,"5&7Z9++.SR]5ZYG;%/['L'\&4U8)^<K )TK/1
MM:BJA/Q2ZQ-%K<DZ]+1L@D.2CRFW6@H_PJ"8K?<G1\+3"XG@827G@)):"2&A
MI&#S!!^ Y++K/:W4VSW.FEL,\TQMU#-/-73>X2S32P,?)-'!'331FGE=F2"1
MCPU[' AD>"P?H0UK;E; UU0;XL!,4N[4JJVY46DG)B8U5D@@)E0"3,L"Y+2'
MDW(^"<C#Y?PWYN6&LK\M.T:>)K78QQ-!QSQD9PO9Z&I-90T=86=F:NEIZDQA
MW$&&>%DO!Q8;Q</'P\7"W.,X&<+=>5+*3A$X15"Z@MJW"3LD7TV:(-;9W)=X
MW,E9[AAKU<?HS6KKOI9&_P PVE24.V60\2X[7\"XXTY(3"TR12V(\).3-S;J
M2%L3[G<&DT4#N"*'/"ZOJ@,MIV=T3?K5$F,,9]$9<[ X74]ZKIJR'26FY V_
MW&'MJRNQQQ:<M)/!+<YP-C62C,5KIB6F6<B5Y;%'].=M3:JI^EJ%!:[HX3@L
M+",KRX46[ZJ6G)4MS)$O8I^04E+LG/3A[CQ\H>[C&7B'LI:0R,VPPU@5E7-7
M5$E3.X&20C :,,C8T89%&W<,CC: UC1R WR22>DLEEH-/VRFM5NC+*>G:27R
M.XYZF=Y+YZNJE(#IJFIE+I9I7;N>XAH:P-:UM'4>N=SUEZH[,JD9:H5;F"1D
M&H6U(1)Z,=F96!EQ%L2L#+C_ /W>4B# S6L94A+WEK6A44E94T,HFI9GQ/ P
M>$Y:]IYLD8<LD8>K'M<T]V<)>;':K_1NH+O10UM.2'L$@+98)1]6>FG86STT
M[/V)H)(Y&[@.P2#U;W6S;8TOLJ_:9L77#):HHNO=: ;*U%8]GU>@SMMV!B17
M)"O523M=E!RY>@:6="^C=" 89NDYB>::5ZM,:P[CJX(:2NI::MBL+*N>IJG4
MM9'22U,<--PAA$S(8G8IW3M>7!SB8(^SR.$O(/C=QK+WI^[7.P57M$ELEMM5
MHBNUBJ[S1VRIK;IVSIF.HIJVLC)N45ODIQ&YD;&W"H%2 XO$32>Q3I@W!G>^
MAM:;/*?@US=DK$<[:1:^:R8!&VEEA#,Y'^!H@IR.>:-2MU428\HZ-0\V*4I;
MK>7%\W=:+\WW"JI0)!'%*\0F1I:Y\)),;LD .!;L'M'"[!(VV7JFCK[^DNFK
M1>7NIS45='$ZL932-DBAK6M#:F+ <\Q.;("3 ]QDA#@QY+ADSWS7KIDX1.$3
MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1
M.$3A$X1.$3A$X1.$57-^2\S7KEK:;HKL@=LH>!V$'$5EC7IFPXV2J!I=#7;)
M60%"ME'=@'HB4%J X,SBQH\W,N3%9BI))RGH^IHSG/+;KC??'0^/3XA4NVP>
MN^-L]V>H\.O5<C1NNY,(P'84X7,#2;D1>X]^!F:8)3#DS=^V#\;VV46 )9K.
MT/!.& 1 U/A<F$%1(B9J0E)F=D[$4^,<>FW3D<\@!_U_R4-!YG/(@@C&Y.?3
M^/!6;Y2JTX1.$3A%J=C_ )XH7][#/\BW3DCD[R_$*#S;Y_@5MG(4IPBH#>Q!
M;Y[1[1U=(&'?&TGTQ[;VH1YC+;J<R^T[G4]902",*2KQ+Q%5RW+#\SY-H2;Y
M?;+JN^,[Z57$.D<,C_(O<U@^.&N^&>_?CJMK:S7%IA<UI;:K#<K@<@'];<*J
MFH(0[;GV<%269Y /QC._-ZD_9M])O5-/V*\[-H)KVS)NK(K =]B[A=HTV"2#
M'/@0,D'7@;&+42RH-3R"1V9&"*$-6PAF29+84M"DU)!.2Y["7EO"'<3P1L<$
M .#=LYW&#URJK[H;3FH)IZNOHWFOEIO=V5D=35L="&,<R%[(&3MIG.A+N)H?
M"YKB 'AP66Z)-FS1])E>G;9@H4+O/I<3!ZPO,6&E;(%FJP,6V/K7:M::=SEQ
MRL["JH0QZ,]D+CYT::C'AQ<##MKFG>2TQ/VDAPQW0.;CZ$C?[+P,^#@X=%=T
MK7ROI)+)7M;'=M/]C;ZMC1PLJ*=D8%#<8 =S3UM.UKQR+)FRQEK>%H-J[-L.
M@4HN( N5YI]2.GW\BP(5FLT+ ES9.%(1D>(&E31'I)_"W&T9:#0\YA2T)\/=
M2<9SHJ:HG#W04\TS8QF1T44D@C&YR\L:0T8!.78&Q6[K+I;+>^".ON-!0R5+
MN"FCK*RGIGU#\@<$#)I&.E=D@<,8<<D#&X68G;%7ZO'/3%FG8>NQ ^.Y$I.R
M841',8[9SW>.D'QQFL=L9SW6ZGY8SGZ8SRB..25P9%&^5YY,C8Y[CY-:"3\
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MU51&?I4\PR/U<F [FQSM\9U@U93W6HDM-QI9;'J2F9QU5DK7-,CXQD&KMM2
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M4.XTGPI(36H(&(47GOC"E.&."+*><7CS'77EN.9RM:LYN1MX&,8/V&M;M_9
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M[5/[]\I_A"UATP;*[YS\_P!=[^T<SDCY_7QYQE7VYYDLJ+G%_,W>Y1^50[\
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M3IHV#Y2:1U!:7M3SW;"!(/9M,D#\*5]$.1X\RLYES/\ LGAVW/ZT\N-FA?\
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MTB[Y4KD=34KJ2VS:KC8X]YRFT/T= B'HXE8"[C/PQ9!UE+-+9QA]Z(AR"\0
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MLX/_ (C_ -%_X$JOO45OKJ"HU4C30-<8UJ@R5]*1:%3=<O:4>%E2V0$#L@O
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M;_2(:89[>\M<=5,-_P!+WGTJ;S:\';Z^+T],)^G[N_*O>X^K)QYP2?@TJ_\
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MV'6Z>:>%'#BG.1M;I4G6E@QCY#3B@QC9&3D6!,M,F2IY"'"W<EM*, 22SR8
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M"P4''!0\-#10C $9%14:,V''QL<"*AH8,$(1EH844=MMEAAIMII"4(2G%8
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M'''';0RPPPRA+;++++:4MM---I2AMM"4H0A*4I3A.,8Y<6S #0&M :UH :T
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M:_QY>/S%QD^'H/DF!X^I^:?!D1]\M?X\O'YBXR?#T'R3 \?4_-/@R(^^6O\
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M6$XSGA%&)N[]:1TD+%&3D@P^0F R04JIW%4-!.VAH-^OAVZPMP"X&E24JU(
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M\AUM;8TDRAV/(6A2&"7%8SCF756^NH0PU=+-3B3ZAE86AQ !+<\@X @EA(<
M=P%IK/J;3^H'5#++=Z"Y/I2!4,I)V2/C!)#7E@(<8G$$,F:#$\@AKR5*4A(
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MVG*^3@^IQ\5&1Z#/P7-JESKMV",.KIA)"(X]<5)B2,3,0$O%22!1#\!2L%8
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M4]C5&]P*=8SL9B#@AQS-QZ]M<X\S,/")%(%3*4^E3<S,5!J!"$FX<X-E<>!
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g945651g76h63.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g76h63.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X6,':'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O<'5R;"YO<F<O
M9&,O96QE;65N=',O,2XQ+R(^"B @(" @(" @(#QD8SIF;W)M870^87!P;&EC
M871I;VXO<&]S='-C<FEP=#PO9&,Z9F]R;6%T/@H@(" @(" @(" \9&,Z=&ET
M;&4^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F
M.FQI('AM;#IL86YG/2)X+61E9F%U;'0B/E18,3(U/"]R9&8Z;&D^"B @(" @
M(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SIT:71L93X*(" @(" @
M(" @/&1C.F1E<V-R:7!T:6]N/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @
M(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UR97!A:7(B/D9I;&4@
M3F%M93H@(" @(" @(" @(" @("!46#$R-2YA:28C>$$[57-E<FYA;64Z(" @
M(" @(" @(" @("!R<C$Y,C$P-"8C>$$[3&]C86P@5&EM93H@(" @(" @(" @
M(" @,#@M3V-T+3(P,C @,3 Z,S Z,3@F(WA!.T535"!4:6UE.B @(" @(" @
M(" @(" @,#@M3V-T+3(P,C @,3,Z,S Z,3@F(WA!.U-C<FEP="!697)S:6]N
M.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N
M,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C
M>$$[XH"B(#$P(&AA:7)L:6YE(')U;&5S(&-H86YG960@=&\@,"XR-2XF(WA!
M.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@
M9&]C=6UE;G0Z)B-X03L@(" @(" @(" @36]N='-E<G)A="U296=U;&%R)B-X
M03L@(" @(" @(" @07)I86Q-5"8C>$$[(" @(" @(" @(%)O8F]T;RU296=U
M;&%R)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@8V]L;W)S(&%R92!P<F5S96YT
M(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!";&%C:R8C>$$[(" @
M(" @(" @($--64LF(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03M&:6QE($YA;64Z(" @(" @
M(" @(" @(" @9S<V:#8S+F%I)B-X03M5<V5R;F%M93H@(" @(" @(" @(" @
M(')R,3DR,3 T)B-X03M,;V-A;"!4:6UE.B @(" @(" @(" @(" P."U/8W0M
M,C R," Q,SHU,CHP,R8C>$$[15-4(%1I;64Z(" @(" @(" @(" @(" P."U/
M8W0M,C R," Q-CHU,CHP,R8C>$$[4V-R:7!T(%9E<G-I;VXZ(" @(" @(" @
M,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N.B @(" Q-BXP+C F(WA!.T=R
M87!H:6,@='EP93H@(" @(" @(" @07)T=V]R:R8C>$$[)B-X03LJ*BI4:&4@
M<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E+B!0;&5A<V4@96YS=7)E(&UA
M;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P97(@<')O8V5S<RXJ*BHF(WA!
M.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A<F4@<')E<V5N="!I;B!T:&4@
M9&]C=6UE;G0Z)B-X03L@(" @(" @(" @36]N='-E<G)A="U296=U;&%R)B-X
M03L@(" @(" @(" @07)I86Q-5"8C>$$[(" @(" @(" @(%)O8F]T;RU296=U
M;&%R)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@8V]L;W)S(&%R92!P<F5S96YT
M(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!";&%C:R8C>$$[(" @
M(" @(" @($--64LF(WA!.R8C>$$[+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM)B-X03L\+W)D9CIL:3X*(" @(" @
M(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.F1E<V-R:7!T:6]N/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O(@H@(" @(" @(" @("!X;6QN<SIX;7!'
M26UG/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O9R]I;6<O(CX*(" @
M(" @(" @/'AM<#I-971A9&%T841A=&4^,C R,"TQ,"TP.%0Q,SHU,CHQ,RTP
M-SHP,#PO>&UP.DUE=&%D871A1&%T93X*(" @(" @(" @/'AM<#I-;V1I9GE$
M871E/C(P,C M,3 M,#A4,3,Z-3(Z,3,M,#<Z,# \+WAM<#I-;V1I9GE$871E
M/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R,"TQ,"TP.%0Q,SHU,CHQ
M,BTP-SHP,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @(#QX;7 Z0W)E871O
M<E1O;VP^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO>&UP.D-R
M96%T;W)4;V]L/@H@(" @(" @(" \>&UP.E1H=6UB;F%I;',^"B @(" @(" @
M(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S
M951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M=VED=&@^,C4V/"]X;7!'26UG.G=I9'1H/@H@(" @(" @(" @(" @(" @(" \
M>&UP1TEM9SIH96EG:'0^,38T/"]X;7!'26UG.FAE:6=H=#X*(" @(" @(" @
M(" @(" @(" @/'AM<$=);6<Z9F]R;6%T/DI014<\+WAM<$=);6<Z9F]R;6%T
M/@H@(" @(" @(" @(" @(" @(" \>&UP1TEM9SII;6%G93XO.6HO-$%!45-K
M6DI29T%"06=%05-!0DE!040O-U%!<U5':'9D1SEZ84<Y=TE$375-04$T46ML
M3D$K,$%!04%!04)!05-!04%!045!)B-X03M!44))04%!04%104(O*S1!1&M&
M:V(R2FQ!1U1!04%!04%F+V)!25%!0F=114)!545"9U5&0F=K1T)164I#=V='
M0F=G3$1!;TM#=V]+)B-X03M$0D%-1$%W341!=U%$031014$X3T1"351&0E%4
M17AW8D=X<V-(>#AF2'@X9DAX.&9(=T5(0G=C3D1!,%E%0D%91VA54D92;V9(
M>#AF)B-X03M(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&8O.$%!15%G07!!14%!=T52)B-X03M!
M04E205%-4D%F+T5!84E!04%!2$%114)!445!04%!04%!04%!05%&07=)1T%1
M04A#06M+0W=%04%G241!445"05%%04%!04%!04%!)B-X03M!44%#07=11D)G
M8TE#46],14%!0T%1341!9U%#0F=C1$)!24=!;DU"06=-4D)!049)4DEX459%
M1T4R16EC645537!':$)X5WA1:5!")B-X03M5=$AH37A::3A#4GEG=D5L47I2
M5&MQ2WE9,U!#3E51;FLV3WI.:&156DA41#!U24E*;TU*0VAG6FA*4D92<5,P
M5G1.5DM"<GDT+U!%)B-X03LQ3U0P6EA71FQA5S%X9%AL.5=:,FAP86UT<V)7
M-799,U(Q9&YD-&58<#=F2#$K9C-/16A984AI26U+:31Y3FIO*T-K-5-6;'!E
M66U:)B-X03MQ8FY*,F5N-4MJ<$M7;7 V:7!Q<75S<F$V=F]204%)0T%1241"
M455%0E%914-!341B445!06A%1$)#15--545&55).:$EG6GAG6D5Y)B-X03MO
M8DAW1DU(4C133D-&5DII8W9%>DI$4D1G:&%357E7:5DW3$-",U!33F5*16=X
M9%5K=V=*0VAG6DIJ6D9':61K9$95,SAQ3WIW>6=P)B-X03LP*U!Z:$I3:W1-
M5%4U4%)L9%E75G!B6$8Q95@Q4FQ:;61O85=P<F)',75B,E(Q9&YD-&58<#=F
M2#$K9C-/16A984AI26U+:31Y3FIO)B-X03LK1&Q*5U=L-6E:;7!U8VY:-F9K
M<4]K<&%A;G%+;7%Q-GET<G$K=B]A04%W1$%104-%44U2040X04]S=S-H;EEQ
M-T9867$W1EA9<3=&)B-X03M867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M:FLP)B-X03MA*VLP;V%N1VYQ5S5U4'%V1F%L>$IX5F@X3D]H-6=!*U P66$R
M='1'0U)H>&IL9$EM-CAQ87IB>E123D=J=$)4;59K4VA*:E=69VY))B-X03MQ
M6#1)-$PX46%D96TK17A,8E!2-4%32S5E9FQF.7$Q4$Q'<U!Y2WAX96UO42MT
M.5ET>$5227I+=D=1>6-'<3!B1%DY4FIW;&E.2FM0)B-X03MD.'A8>G9Y478V
M375H8E14=4%G9VY3,FQJ86]C4U-">4YQ9'933F-&3F9G>6]N=4YF9CA!<5),
M*UA.45).45EM36I4<&I"3E)J5FU6)B-X03LK1$=-52M)2V%6.6IJ=W1V-5=F
M<2]O;6PQ,35:,5<R:S%*2FM64G!153-$,5!%.#-#<'=.3BM83&M+,#)W;4I7
M5VMN17EV.$%G-7),)B-X03M,45IR=3)H;5,T:&IE-6QE0S%T,SE4,4I:14-%
M<7!61U%6.5)13U1$04%J2'!Z24$R3GI11RLO,E8Q43A';#-K.7,Q>6EQ2599
M<GED)B-X03LP46QL04Q"1EEH;DMG9VYI1%1';75/1U5H635)>30X<39X1&5.
M86-96&M$=$=H5V5(:3=Q,T%O;%=&6'(K>#ER,G<X2F):85!)2E9T)B-X03LX
M>"M0:'I5679,,G)Y,CA6>$9!2&IM04U916MF4&E72V,R5&QZ5F53:V-M04=#
M:7AJ<&-H04E(4#-+9SAS83!3;U=&2$1Q2&I:2F]7)B-X03M6*U1-<7%J2S56
M;5IO,D%65'E.3VU(:$MF>6U4=2LP9G)D62M83"LY<U!R:T1W8U,W>'!%.'%2
M=3-P2C9K:F9%46]61C-9<U)I27)J)B-X03LP<W!X-&A8>C=U9GEA2&QN5U-6
M06A3<')Y<DY#3TA&1$EF5G$O=T,W*T)#,W@P-EE/17(K57ED,S)J,S<W-V9&
M4W9T13%+>&E-='I')B-X03MI;T=61S13>%-&4S1,2GE#37A53W%K<50Q1S1X
M27!J:S X-$-Z.316-S-Y=G%T<&1.8GDK:%9(84UY:31H15E:97I->DQW2DA1
M4%%N)B-X03MW=VU*6GHP8S1M:EAZ2#0K87HO1&5S0FQ6;U934FDV:4HU66QF
M.3)Z2S=&1V--155X=%9Y3TEP,7=C2E(K5GED,S)J.68R<7%E53E9)B-X03MD
M3FQ4,5-X5DEE64Q-96-#1&EW<6A$9E=K2VYL46HV2VYH3$EA4$HX9BMK9F@O
M149,+T1M<BMV-E!P2GDT:'<O<E$K;5%835EP3'HY)B-X03M-;FUP5V=A=%)G
M-%-X+TLU3'%V=$AU-3-3:F-A3G%&<S!+5&]K8VLU54I%6EEU635G1F5A8W55
M9%%A+T=":E1'5T-C879R-6HX1#1Q)B-X03LQ>#5E,4LR<UIB,F(P4D1%,&%F
M1$Y%-6(Q45-P5&=Z8W@X2BMZ-R]Y=%(T57HP,#1X-&I693AD9G@K3C%'-#!T
M;W)&3'AB:4MA3FU7)B-X03M/4EEY+TM.,EAM1F)K<7%D9V9S:S0P>&QH<5!&
M64MO+VPW5U5B:3%Q,65C,&5X56=T8C Y44%G.7%I;C@S875.1FMD3&LW=2\W
M3V8T)B-X03LV.494+T,K=&QI<7=+,U%";&QH6E-X2D%J5F<O1G!+<69G0C5E
M,E!#5U@U4$HS9F%0,3@O3&TW+T%!>G%X05I547AM2T]B,5=K4TI!)B-X03MS
M<V%Y0W)3;$(X26-"=7=*03=J2&A++VQ-;E!P5C@V-E@Q4WE73F\U2&IA;DI#
M5F)I47=Q1%1:;$I"*UEW3T]24G!B:6@R2W5X5C)+)B-X03MU>%8R2W5X5DUB
M3%AT4G-R6DE,5GA%1656=S1(>%9M5D906&(T9E-6;#(R3RM',B](<5IW1E(X
M+W1R.5--:C@T-G%K2FE#>&Q+249&)B-X03M:5D$T4DI$=7%U<75'4TIA:'=W
M-C!P6$1X1G1'=6U"6#8K-$1V.'5Q;G%F;6DK,4-$,$I9;VMJ<D=11DUR2#DP
M,'),.%5R>4XQ;F)V)B-X03LT57!I6E=X>39Y57A2039D+U,K."MA;5!-*W)P
M2F535SAX='!,-C1&,4\X1%!',TE&>G="1&99+V5(62LR4$559FTU:7E$6$5B
M,B]()B-X03M,9%AB>FAQ:&1Z-F1U16QE95-A4#!68FLQ>7AA6#0R<DET45%V
M=W-.;$AZ>#1I>2]05'9P,39D+U!Z*S-O<VTX,C8Q2S W1U5,-GAC)B-X03MJ
M:%941UI*,75#55E(;%5/9S0Q2F]-94EO;')C:'9F;BMK,G-T+TUL-49&1TAI
M:G5,;4=:-VU#.&U-<E1*3$E%<2\R=W)(.3)P*TI4)B-X03MJ>$EJ<7!!0W=#
M46)S,V0O4'DV;V%(5DAJ<W9Q:G=25&]R=DI#.&Y0;$<X9U982SA75E15278R
M9V9B0F)#3UEI3E5$*VA--UAZ<G%D)B-X03MV33AQ=W=--S--=#-5:59A4U1-
M<DU!56M2=5!W1#1384AV6$-*=#A.9D]*=6AZ2C8Y9FEO-F0U;75B95=.6$-I
M1#9V.51L2V]767=.)B-X03M-6FU&0WEG;&EX53=J-&9F9D534FDQ6FED*U96
M.$QT1U0K8U!Q=VIT.4II.4\P:FE607 Y844X,6ML:T1R-F,W=4ME<U)2<$="
M-BM!)B-X03M"-'4U<VQR=4=H065M=DUD5#-3."LX<%)A-C%D,C%Q3%I&46]0
M<D<W06LO-EA#25I/+UI6,CDX:F)I=WIY:D=V9B]S:%-+8GI496Q*)B-X03MG
M<TU+4UA19C8U2T$O2UIN:65(;3E82VAG<W)(-%%"53%)3TAI8D1R2F(W1&9N
M-3=%9"]M:&)R5V)Q-6AM:&M607,S,6)M5D)R+V]K)B-X03M2:&IP=C-6=FDY
M.$9T8S@X<$%G.6$O,DEO2F<S;D<Y3GI,8TQA5S!B6$1M5S574#%L.5-19V=0
M>45V3E=7<'!W6F5P.&-013,O;G!7)B-X03M443,U."\Q+V-V6'IV<6E/-W!$
M0W)Y>5-3=6%Z.5I3,TU+1$Q22V@V8VM!8C-X-#!J=$-9-D0W979X,BM'-FUN
M;DQ656U%;U--<W(K)B-X03MO=DUY>4=V3T)W3U1U>FM!,FE$8SE++U$X4EEJ
M6%1"=F(W9C90;B]20VY996).5'-O,&EI0VU*22]4-$)P639G4W9-0U=I94XV
M:'!7)B-X03LV1VQ/=4EL4TUE=&Y%55 P.3DY0T\Y8F-E84PR9C9P-FM55$YA
M4W)/<E-'5U5U>3<P8C%:2E!H63=S1F]$:GA);')*4W%W3FIF52]E)B-X03M3
M,W%F;6TY,4LS83-U25EJ1U9I5D176FU1=VU1<7=D-4A9;CDX=RM):U5X37)8
M3')*6D)2039D+U,O4'HV<4QA+V-I,W19<E=*3$M7)B-X03LQ1DDW;3)A84]5
M,49(3&9V0W18+T%':49R,$A48D)B139M5D%$,#$Q1B]R5C(X,V%W66A'1$=T
M16=J5G=V>$0V<S-.5T939FE:=#,X)B-X03MC4$579C4W2E9E-S=0>'5I5S@Y
M87E3,U%+,41X.6$V,F-&:4A5*W1Y0BM-+T18:C=B665-<R\U4GEF9WDO=T-+
M+UEO>&5C3E14,$]A)B-X03M2>6DR:E-+,G$P>4=.56I%6C1.1DI'=S5H45A&
M844T3TIJ2%A41F-J6$QN=#AI3V962C=U-&4U=7!R;#%62&UD<$=60GA51FI7
M:6IS)B-X03M..&DT<S4X56EE.5-X675X5C)+=7A6,DMU>%8R2W5X5C)+=7A6
M,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X)B-X03M6
M,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W9O8CE'86(O>7E1+SAI,"]P;5A193(X
M3U!C2&9O>E1F*U=32"]!2D9P+U1'9W9H>#=G-SE')B-X03MA8B]Y>5$O.&DP
M+W!J45AW-#EW9"MJ3DXO=T-74T@O:U=N.4UA0RM(2'5$=C!:<'8O3$I$+W=!
M:3 O<&I16'<T.7=D*VI.3B\U6DEF)B-X03LK4F%F,'AO3#1C931/+U)M;2\X
M04Q*1"]!36DP+W!J45AW-#EW9"MJ3DXO-5I)9BM2868P>&],-&-E-$\O4FUM
M+W=$3$I$+WE,5"MM)B-X03M.0F9$:C-",S9-,#,O;&MH+W=#4F%F,'AO3#1C
M931/+U)M;2\X<VM0+TET4#99,$8X3U!C2&9O>E1F.$%L:V@O-49P+U1'9W9H
M>#=G)B-X03LW.4=A8B]Y>5$O.$%)=% V63!&.$]08TAF;WI49BM74T@O:U=N
M.4UA0RM(2'5$=C!:<'8O04-Y42]W1$ET4#99,$8X3U!C2&9O>E1F)B-X03LK
M5U-(+VM7;CE-84,K2$AU1'8P6G!V.$%Y>5$O.&DP+W!J45AW-#EW9"MJ3DXO
M-5I)9CA!:U=N.4UA0RM(2'5$=C!:<'8O3$I$+WE,)B-X03M4*VU.0F9$:C-"
M,S9-,#,O04I:268K4F%F,'AO3#1C931/+U)M;2\X<VM0+T%#3%0K;4Y"9D1J
M,T(S-DTP,R]L:V@O-49P+U1'9W9H)B-X03MX-V<W.4=A8B]W07-K4#A!>4Q4
M*VU.0F9$:C-",S9-,#,O;&MH+S5&<"]41V=V:'@W9S<Y1V%B+T%-<VM0+TET
M4#99,$8X3U!C2&9O)B-X03MZ5&8K5U-(+T%*1G O5$=G=FAX-V<W.4=A8B]Y
M>5$O.&DP+W!J45AW-#EW9"MJ3DXO=T-74T@O:U=N.4UA0RM(2'5$=C!:<'8O
M3$I$)B-X03LO=T%I,"]P:E%8=S0Y=V0K:DY.+S5:268K4F%F,'AO3#1C931/
M+U)M;2\X04Q*1"]!36DP+W!J45AW-#EW9"MJ3DXO-5I)9BM2868P)B-X03MX
M;TPT8V4T26Y#>F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5E-B>3=Q
M5C-E,U=U4C-$0FQS=%)A,G1W04)325<X36=',U@T)B-X03MP1S-/2W!Z:7)S
M5F1I<E)K:D5G:DQ!4TU#>7!88VAA06M$=TA)63)R94MU>%8R2W5X5C)+=7A6
M,DMU>%8R2W5X5C)+=7A6,DMU>%8R)B-X03M+=7A6,DMU>%8R2W!2-75T.61N
M.'58-F%"8WE7=7-I2FYS6DEH05-:5D9542]756MI-'-D:E5F4TU667-T>BMC
M<V5U4$-T=%I484U$)B-X03LV8V1X37%E<C9A,TQ1<DDS<'IX,6MA0FQU2&]G
M6&)G<4LR*TMS9G0W;B]N26$X1FQ.939F0EEZ,C!6-'-S9'9*83A*;DYQ0F)0
M27)4)B-X03M41&PV.65N=VHU8FMQ;E=O5&9M<F4V2' X:E%N5$YC+S Q:D9:
M<D59+UA33W1O<W9+5S9J.4M2031F;3%&8W%!86A72W%:82MV-6ME)B-X03MP
M<D0V8U=72F\W4#E'43)R,FMJ<59U;D8P63)U;S1L.5)R8F=X179*061L2C8T
M1EEP<FYN9C@U9DQF;#8W,5A7-T13;V\W8U1Q:FA1)B-X03M35VI%6G1Z5#8W
M1TI$4%8Q-$QX86\K145L63)65%!5=%0O3W5/2T,V,&I424QW>6%C,7ET<F1E
M:$="93-6.&I,8E1F=F](2#%7>DQ+)B-X03M#=E5G;&U9,$=+<79K-WI"*UI/
M<C9L4&0V;'!S3G0Y6&DQ0S)7,$1443)S:SA%.$MW8S5M13E'1&5V2'EI4F=E
M0F)D5VI!5E1Z>4$K)B-X03MO3S-M2CE2:&ET-W<V=DHV,$YV2S X4VXV<F(P
M-'EV2$%Z8F5+1$975C1Q-T953G%5;"](<#EX2G X2UA&-FMB1S-H:V)G<G5"
M.$ML)B-X03MU,RMF5')K6FLP835S;S%E+TIJ='!C-C=,<4=J,T]O5VM55W-T
M<$]O=DIA235%9G$K=%HX5C5(;'AR=%AR5#-Z2&I+4DU34C9U1U@K)B-X03LY
M8E-),%%$=%DO4VTS;&DW,38W,&5+9EAB4T]Y,49I,W%14DU754M$.$HS3&-3
M4C(U2"M!='=Y;5DS25571U%20CE*<TIR;')7-T95)B-X03MQ,#-465ID371N
M;&4V16MT=$=S9V$X;F1H54)Z.&%U;TPQ-G5O0E!Y,G="04-J6EAN;&)58G4T
M<S=(5FMU-W5&>#E:=')F54AK:VIA)B-X03M%;4UH:U-5<VQ'<4A&0E4O83-W
M,'1)=35T9$]S-V53.'5:-6]B93(Y4S5M;&4U;D-);U=R;'%V5&=Q<EAI9FA(
M65DP=$Y3-F9:4E=R)B-X03M3:#=H,&EH8T-L,6-%;%16:CA8<6)T=G-X,TA9
M-$1S16E.;T<Q=E!,;#%.0EI(541(<58W85)4<'!X=C528RMH44985TU3:"\R
M3C-!)B-X03LS,W%E=4-*<T%R2TY':S!/;#)X671Z=4ML,6M.3&UC1&MO24%P
M>BMZ=G5V43EX:W%25%$P<3%(1VHS2'=L,D9B;31/.&=!3F%Y8FIB)B-X03M9
M2#=086U#;'!B<&%E:SDW07-S<VMC3317351&;DMG=WAT>$5J<S=/2W-456YQ
M861S46]2,D9,<U9D:7)S5F1I<G-69&ER<U9D:7)S)B-X03M69&ER<U9D:7)S
M5F1I<G-6634U42]W0C=V32\O04<Q,R]W0V]3,GA6:V5+=7A6,DMO4GIP>#%E
M15!4.4I*8GEM169&55%/.&9Q+S5/)B-X03LW;VYV:T181C4P>3-R>5)E5%EU
M>%8R2V],4D]0-D=S3TEJ0R]6;V5):4Q'341G4'-&<71X.$LW-$%G8VYN=7)F
M:VA&9D,X;%175U<X)B-X03MV23=M0G!:-U-'-&E31V954G%+4G)#,T9'5TXR
M:T@W>FM7-58R04,T56]#.2])0U,W,$LS,' Y9E941$TP<VQY=&E#,#5A<#5Z
M.'!M)B-X03M,5$M7-')+<%4X0G=.4E=P=%4W,&8X<E1O=#5$<6=V-#58<S=+
M-70O<3A&<C9#56UM=7!X2$-"3$HV54LO6$ME;E%K.$503#1C:%!K)B-X03M5
M>#5H4C%8.')"-6UB4W)Y-W9K:G-9-#E+;6TP.3=B,41)*VYR4#A!03=T24(V
M8VE8:G$V*VXY3DMQ4FDK:V4U32]Q2U<V5"M63W,V)B-X03M*-30P2RM35DY3
M<V)76&Q*94=#3TDR,$U';G1:>%)G=&-02GIK;VYQ1DDK3&XK5&IV67AE=#1&
M46QK2$9Z9FQL:U5'9%-P:TY6665H)B-X03M%2WAI9V]T9'4O>%9X4458:6PR
M2W5X5C)+=7A6,DMU>%8R2W-C.#,V3C5H,4=85&TP;35%561V23=815)U<#=/
M<%!(,#5E5G5R;5@P)B-X03LV3BLU9C1(<CA85$971WDK5&9Z<C57.75N;5<P
M:W-&83)K=5!86C-L-7=*870X1$Q!:CAF5V=L,DUN>$LS>&)K,$MO=7IS4'IJ
M:S%U)B-X03M+,&XQ:4]+>G19<E=3.6XT47-S=D\Y;6%625@K<%)H-5)A;VE-
M,4552#EI<F-L0W%N;&YY+W=$;EI"2EIZ95EF33%N9'1(3U1D,G-%)B-X03M5
M46AE,SE31VDX=G%K56Y0,'97,T1+3UA$='EQ<6=8.&EF;5DY.7$Y>$AR:7!:
M,U5L>4Q85%9L;G,Y;C%.3'%/53-51%138VYT9552)B-X03MB9W!104EO-&)L
M5D-A-5DO;FAO4&PV-W5X<C4Q5S515'!B5S%P87AY>D=O:BMQ8T%T:DLS3&M(
M5GDT6F%%5EID-4965%!5=DQ(-7=3)B-X03M245A':V$W0EHS6C U9S!D>DDP
M<7AA:F18>5A.=V5*9VU74TM/1&Q$1E4O0TM"5E=T8U98*U5D2R].1V953&DK
M,38Y:FEU-#1D47-R)B-X03MA-F%#4#!T-31F<3=M0TIO;FU13DA-54QL5#9:
M5#EP,W=Q;FXU97<V;$-034UE<%A-9#5F3'$P;G)834U*=#0S4#%7,V]6:4QZ
M1F1Q)B-X03M$-UIW2WDS1EA9<6AT4VIV-4Y0=4DY4&U3,W98:EE7.#!I.#%2
M>5!H67(S+T%-*W9427I";S%Z6E)Q.2M413=A>3AY>%@Q;F%81CE&)B-X03M*
M<C8V3F1*.68T1F\O5BMS4F-7-"]$>6]+8C S-C W6FE#37=10V96=VYF-&AV
M2FI23F5N:5I0;V-'<5<K:U=S3W$S0UA7;WAX:&)M)B-X03LT:DA&5V)X05 V
M-D-V5V<V6FQ9>$E206MB3%)-9VLQ>5(R5%EU>%9,<D]Z,6DS=&)E0G)U,F8P
M67I'-TQA=$AY25AI:$-R3GA7:#-))B-X03M!;V5G-#1%0495.4Q794HO,'$R
M-65M040Y6&5N<6-T,G V+S)E3S-(>#-R,GA89'-X878X5DQM,T93;D-T=35O
M;T(U9R]V='EX-DAT)B-X03LW-')U,G-7<F-W5W5B8W V;%=!9V-(,'8U82MS
M9FDO>7%5+WEC2S=R5FDQ;FEV2S9T:3-&=WA&=31"8S$T140Q>E%$86\W*TEW
M3'4T)B-X03MX87IX86PQ8D)U0VA38F1Y031)-4U2-BLV:U9O=F)X3TLW<FI&
M<3-),'5B8TQZ57%$03EF5$%02F$K=#EO-U5B=#1(0W4W9&A:>3(U)B-X03MU
M6&UD2DIB;5@Q6&%.1VI'>4I'=7I02G9X:DAF-DU605)72UA9<3=&6%EQ-T98
M67$W1EA9<3=&5VYD149864M#46]*3DXR3D%0<$IP)B-X03MI<F5+=7A66D90
M1$M8155I>4=.:6MG56<X6$%"2W14;V0K;4MR.%9D559P,WA66C8X4')'1#%&
M.6-+2$U64GHT13!$8V5T2VEL8U99)B-X03LO=T-54#DW=DTO.$$R,3,O04]O
M4S)X5FME2W5X5C)+;T=Z,4-Z=3E2=G)E3TUI-3 Q,&=M:UI6,SE72DIG14E*
M4$=J:71A8C5#37=:)B-X03M%9%(O87E-4T%03DA:3FDW1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T951'(R;"]P8E$Y4C!R,691
M+U-&)B-X03MR3F$K<T)Y-&5T1S!F3&I683AE5F%6>%8U.7!N-5%A.7!L>%E#
M=S@Q4U=7;%=-2W=R;W1P2&5X5VA)8W-:1E@V*WIH:5=R.%1-0S,R)B-X03MU
M4R]$:7%J+T%-<58Q-5=G:FDX-3-K5FA%,$1Y,F9P3S9/.75L<45A:VQW-DM6
M:W1/83!4-&563S(U5E=(-6)E9'!T4DU-=FUY*V=S)B-X03M,93)T>$AC>%,S
M5EIP9G)C.#AQ8U=V2&165TUX>#AN3$]W<#AD07EK2VEF3%@U5RM:=$MK<S4W
M-WIV<5=Q6$9R3UI8858W:U)Y>&5R)B-X03M%-&EE1G)M4TUG26MQ5DE0.358
M.6QC5EAY+VQ/6G)F6%DS=31&;#%E5EA,4&(K=D=Y>#9N4'%+979(>6@Y5&$U
M.45R>2]:-59Q84)6)B-X03M).6,O2R]Z,7!N;#8W1VAE6CE6,5A55T4V5S%S
M8FUA26-:4D@V035095%R1TE':DHU25%A3CEL;$AP<W%M97!F;$QR,35&1$IA
M*V%:)B-X03LY2W9H<'I7<W,Q<6MV=S-L>F9*9EAT,4-6;6DT*W4V<VA&2S!)
M<5-">'A61654=DE8;7EY=DIR<EAD8W5,=5E*<49R83-,5$=3-%-+)B-X03LU
M;6=-8G@X,65/3W8Q67EC9FEP>E9/:UEQ<6Y8:T<Q93!B>D9B=F-3,V)2-G9)
M1&-4;%1).6)7,TY7-$MI+V-U2W-Q>%8R2V]B5DY0)B-X03MG,4A4<FUW;G%)
M<FU.;S-+-TU/47!Y52M)-FI)>F=*06<Y5U5:56)91C56+TQU,'-V36LP-U-4
M1F1);FI%5$YY0S-,4%I1,6M/+S=-)B-X03MV2G1Q-S=:9UED24)/+S5V,C="
M>7-U;TIJ-R\Q=E)S,DQH=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+
M=7A6,DMU>%8R2W5X)B-X03M61#9H<4]N-F):>5AU;UA55FY:=V='835U2%=+
M2D%304-Z=5%O,TY.>FER5FAQ;6YA:D<X;&AC>#-555I65VMH64]T6&I35F9I
M5V].)B-X03M9-49953=(1E9E5U=+2TYP6EA73TI!5V0R2596039K:SE-5F%H
M;6AN:%-A1C%L:&Q54$A):$1+>7-+:&Q),DE)-DA&57!U4$]N;$<Q)B-X03MU
M8FTQ=3E:<W)7-'1$+W!%5GA02$-Y:C1F:2]E1F%R5G=V26)C=F@V9VI&551E
M*UEV3#EG2S,R<#)L;U!3*W-6;FYJ:B]C;&Q4,69I)B-X03M99D)Z9%8U9$MK
M1'9I<5!2,&1&9$=$27=$2WEM;TE/-$E)>%9$<G%E;D]99VPQ0WAN;&MT-%%R
M<65C,%!0,5DQ;V0S:CE**U,Y4GA.)B-X03ME;4MR:F8R:3,V5T1305AC:U14
M>'A%149O,%I59&Q.2TAI>G%'<# U0W9567%K9FQ$+V4W>E X03ET9"\K;U,R
M>%9K94MU>%92=3=Q)B-X03M/,FAA4GE/5D<Y3D-1<&1L579X2'9X56Y)>6Q1
M4T)A:'!'<5$V;' Y=&1,>%-384-+95-!34AA4#%K1&A7-F50:'9G>'I%9T-M
M8V%.)B-X03M),TIS6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<6PS;411<E!89$MK,'DX95=/,VQE1U)N=#5':&Q")B-X03MG
M;5-:94UI+T5N>%)J9%-$-$5(9D97239Z*U,O;'969%-U<C9A+S%"4')K;'9.
M3F)C-V5A27E7<U)H:5IV<DU%-W8X04%X-4(R64Y8)B-X03LT9V-6454S+T%$
M:B]!3U-P<GEA-FQU8CDS;E,W4FME4T8P2#$R37AU=U9O5#A39F%6:E5L=#(U
M16UQ<78O=T%Q2SAO0E%&=7(Y5#8Q)B-X03MH8TU6;&E(2CE-:&%#1&PK-F]F
M9V,X<3DK;$U64G5O9FQ663,Y+V-8575R,W-%8GIT8U<Q=F)I,D-X4U-43&--
M.5IO6FU:+U=$54YA)B-X03M"1'@T+V%,2W)B>CAN=DQC.7A$8U$S;6]7:W1V
M8E%7<U1X>G)+46QT35IO:GEU16YA:7-X+V0Q.5 O27%&2599-7(O+T%$:C5O
M839$)B-X03ME5S-L=C1.4W5V<D%%;#8X9G P=794-65O4F)41C%I84E/:6QE
M=%-'5G%/<7%A*UE0>4HX<F593%=Y:#%+.'90571B84LR:VUT+W$V)B-X03M0
M2S!B>5-V2WI01$LV=$Q*33=/1EE+4V5L441I<4DX;69L2%EE6#5,;' W;')Y
M3S0K=7AE:S-,:UEB=5=.;#5Y1G528FIB:&TT:%(V)B-X03MJ>4XS1D95,CAG
M,D9R64XU:71,4E!4=#1D6&-2<%5T44<Q='HQ66LY.%9:5FER<U933'I4-5=T
M.6-&<$Y*4&-25&%C>GI7<5%/<7$P)B-X03MP030X=WET6'!4-E1L1V9!2C%Z
M,F)C5UAH*TM&.&TK5# P5E)F4&-83%@Y,V$R.%8Y8GEY23A3=D1'<6=+1E@O
M04A847%V>$AB239F)B-X03M4.$<Y;7E"8DQ.;31T=6QS;GI*84A9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867%X,D0X>&9)<W-9
M:T]T)B-X03LR;'5R26MI+U=P0F%K:5-*2GAT4#9:<4DU55IL-G)58W%9<7!0
M*UIN:T]05#-V-4YB=%9G6&U62'%"-4A23&<R,W%24DIY:VM2<%8T)B-X03MO
M>4M1,V)&55-F4'9K:CDP4G(K;G5S-GE01S98351R=VA6;FMK3$MX0V]G:F)K
M>#)(4W1C5EAZ961F2S8R5GID5S)P5SDO.$%663!L)B-X03ME0WIM:6YL26U)
M5T5+<70O=3%M0W!79TI06$952'!V-6QE5'13,4]F4S=7-VTO4T9T1DIC5#(P
M,6YE44]S551-:G-F5VAJ-DY'>2]-)B-X03M9<7!4+VUN-4AT-U=7-G5,-F%#
M0T97858U8D\X:F]5=55T2%-J46<X,&YM4E=4-U,X9U-!3CA64C,K4'9)=T5X
M8GI$<'-:='=48W)*)B-X03MD=V\P6$9G:D-65UE.1U9D9W!$055/>#-X5EIF
M+VU(-4DP+U5',"LO,7$Q=$QT2E!294]E45)C4UE23T=,4'A89U591&Y8:GDK
M0W9,)B-X03MB1E9E4'IN-5EL=FUT2712=#5E344Q>3EX2$Y%.$M*8E-,1DU(
M:U9I15I(8T$X<60V9EIA:7%!.&DS;'!E4RM9-VTP;FIU8F%45C--)B-X03MC
M.%1+-DU"83(T*T9L2D(S1TMS<'A6,DMP5'(S;7I13D)E,516<G(V<S$T5U<R
M2'!Y4V-I;D5.+V1Q.4MC>#%Y<DQN:$-U23%B6D1&)B-X03M+6$I+22]0,FQ7
M158P*W8S2S)W1V\S5FY:;%EP6#5,8G-!2RMM<C<P8G%C<$=Q:D<K33$V:5!K
M,DA!5%A$,T)L=5IB:G5X5C)+=7A6)B-X03LR2W5X5C)+=7A6,DMU>%8R2W5X
M5C)+=7A6,DMU>%8R2W5X5FE:+TMN.'9J<45';VI2-#%V8F$T;'9)6FMK;5%I
M86%B-G<W14LT1$0Q)B-X03M254LQ4791041B1E9+2#AN+W=!=6]B>7AV23E)
M0S-/;4MQ,DUN<C-*.4U,33%W2T%Y,"]V6D=B9CE635975VXU3V9L>EIW>%$R
M*VQ-)B-X03MS54U5<T5A1S9U,T%J;3E4;71';5!8-GA*5'<U1VQ+-'%I,"],
M4'EB0DIQ<SEN6D<P=3E:*TLK=6\U6D,U:T5N<DQ+<7E-.&%U<V=$)B-X03M$
M-&5W-V)9<6E:9DE(;$M784M787@Y5F]69%EH2DY--D)P2DAM85AG>FQ435I*
M6&8Q4T]D5#ER1E5.0BM74&LV,VAA1T<S=6MJ83-3)B-X03MZ<"MK3#AK45)Y
M*W-Q2U105F%38C%'+S!9<6Q8;4@X;79+.3EO9'AP,FI2<F\Y>$]:>70T<'5*
M5$@Y8E95=4-I<E!$47-K86=F1G@R)B-X03MO5DML;%I62&%P*U5N:U!6,%ID
M57-*3'=/-U-30C=M-5%-5VUK;DA*67!),6)G,#=Q<$EQ1E!(-T\R2W%N;$PX
M<R],=FQM5U=7>59M)B-X03M-:EA25TYG=G!R2&101V5(1VQ7-'@R,$UF2GE3
M94YE<DY65E@X;5)X>#-F;59),4-)=7)V4E9!04@K:5<S65EQ>5A&6%EQ;&US
M*U=D)B-X03M#,7 W6CE5=$9U;71#>'1Y>%EC0R]%=%1I4C$T1')L5U1$1V1C
M475M8TUK;SAI;&-8:U13<G%/-517<F5/.40S.7IE,G4W:F=,:&=A)B-X03M'
M:%AF8F9+>'!O;2M)6'54.#)W-7E0<#(R<&LK6DQ1-T9867$W1EA9<3=&6%EQ
M-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ)B-X03LW1EA9<3=&6%EQ
M-T9867$W1EA9<7=44V9+;FQZ571A.'A3;E8U<FDV8E5$2E!B-EAR3B]$.5A"
M:&IJ0UA%1G)C4DI(2GEI8G%T860Y)B-X03MT;%4R+W=#5F9A1"]!3717<R\X
M06-C,6HO<W)X5C,O2W9T0B\U871:+W=#-#5R2"]!1U8T<6M7<V54.49S9DUE
M:D=F>D)E,D]L6$LS)B-X03M&=$I:6%!M1%9)-7)Q.&QA2#9O<TA/-G%X5VMG
M2W%W<GE'>#=+<#<O04UQ*S!(+VQQ,6XO04QJ;7-F.$%:6&ER=BM69F%$+WDQ
M87HO)B-X03M!3GAZ5U X07-R>%9++TUF:V93271/.4LP,6Y58D158G%33T=X
M;'5D93%:5F%2;DAW2T=U;35->6=G04M4:7%,<U!+6&LW55DU2DY0)B-X03LQ
M8E5R>4]'4F]*;G0O34=R4W%K<V8R-#)+6&AO>3DQ3S1X5D4O=T1+=G1"+S5A
M=%HO=T,T-7)(+T%'5C1Q=&LX:&5866\R:VMV9%A3)B-X03M.05=D,C$S5T%Q
M<4)5:VLS97='2W)V2T8O<#%P65=/:7IA,V(V:'%C<V-T,V%,.6,K=%1Z5U5K
M.&I14W$P<DY.2V=J;W908V)D5&ER)B-X03M*8U9D:7)S5F1I<G-69&ER<U9D
M:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5EEX-58X;'9O5W(V
M<F9T94QC<&9K<F)W)B-X03MP1#92:6IA.'5R,&E2>DI*-G(K<&9U3U9&1D%.
M<3%*5EI0:7)S5EEX-6HX;E@R<F$S<&UQ46%Z4%HO;S9E2U99079W:4Y(5G!O
M-#)I)B-X03MA0G8Y259/16YR*W%V2#=+2V0X5EI0:7)S5E-46'9,4#98;G0U
M6DQX,%,R=4Q/-6ET,FII94Y(=$QL6C):1'A755!+1CE.=C-H541O)B-X03MT
M83%655!*4&Q&=DQ&:F17:EAN,7HQ-6QE3GA'675-555%9'9%:D%V2GEC2D-/
M8C=C:G9X1TMS:7A61#,Y;3$S0W-)=4AT,#5Q,'9P)B-X03MR13-Q2416;VY%
M>5-R=VM(=W110G%D0T1V:7)&9DPS-653-DIQ,FLS<T=P;C!.3S!Q1%-P-V1%
M:U0V=W1T-FYP330Y67=H54UR36\Y)B-X03M)=40P9FE3=4MS>7A6,DMU>%8R
M2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMS2SAY
M-F(U;&TX,5(S1G9")B-X03MF,TYH-DYO=&<Y;&9#>F=T<#0W:59R>#=Y27ER
M-C9Y=W1%1DAO>69:24AP:S@X5EE20D0O04TU1U=6;EHR35%L=4)$6GE+8G57
M6%1*)B-X03M*1$UD355O<WI/3U5J2F9N:6IJ.6QA>65P>359<6<Y53AY+VY2
M82M:,CAT,D8W2F9A<VML-EE,6FIP369Q-F-O;DYT8U-(,'<V6$1F)B-X03MU
M=4QI35%6;W)$;'I81E4X=6)8.#EP-U-#948U3$Q52# Q0F-+:W1H34)D=W@V
M:S9)-&Q1=V-P2D1:3$TX56%G,5!%:%8R5E1,>C%P)B-X03MN-7-Y,SDY9656
M-6Q715)A43%V6D\O2#%:-$QU5U,V5T]4,30Q:%@P>6=M-5)V-G$O0T]M2W-7
M,6)Y-R]!335!439&6F%B<#@P:SDW)B-X03M:,C)P,DYZ9D1547AU23=J,%I,
M4V-34T<S8WIX,65-4TY'<D%Q5'-'0DMR2V14,#,X>')N>FY&8R]68FE#>FI'
M;7@R3GI:-FUZ,E-2)B-X03MW6#!K;"LY-V%U.7)Y;&YT1T-"4D1-06%58V9A
M0W%8-FQP2#5Y,B]M=GI2939F9EAZ-DIC5#)J851A=WEA9$DU:4U*12]W0EA3
M.$)J)B-X03MI36-Q;TM.>$1+5U!X4%$T<6IV2W1T*V1#87I9>BM93'!P3$DS
M0B]31F]O,"]W0D%1=CA!6'=F5$UC83-&13E/>5I0:C5F1S-+=$1X)B-X03M6
M66)P;6UF.#5$-E)P-$YN8C-T,61T1&)#9$QM.71:3U9X17-X;%EM.74Y5$AP
M3U=13C98;VQT<4I(4W)+;S-622\X06Y*3V92;S=+)B-X03M+1C-U2F],=4]A
M-T9X<'1R24A934DS9%EL67(R.4@P6E%19#5'4%%+<7AH+S5Y2W-T26=3,E=3
M-VU&=D1&3D,Q>'!O;5)O<F5Z<3A-)B-X03LX>51";FMN834Y47IC-FAF:#1K
M<5-Q.6@P;S9I,FPR8F%M<4IQ2F=J3C9K4G)'2BM!.5%)938X-C!X5D99<3=&
M6%EQ-T9867$W1EA9)B-X03MQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&
M6%EQ)B-X03LW1EA9<3=&6%EQ-T950G)&-7$Q<71O9$XP-SE)=$YD47<S4RMS
M:TAO5S!J56QU4&I"-2MK=2]!8G0R>%9)=GI!,51Z9F$R.6YB959D)B-X03M0
M;G9.4FYD-7!8:5=$,#!I='='.4XS=5I)66PY85(P:E!X8RM"9&M"2S=+<V4Q
M>GIB*UI:=#-V=$MS9E)S2C=U,VAT-%I.3'4U8GE#)B-X03LS84-#-FUU2FM%
M=TUQ9TY,0UEK:59U97=B:TM9<6PR;RM:=GI'-'<R,71P,7I',&5P<DEL<6QJ
M<51Y6&1U=6]/-U X05AN;&%',6I:)B-X03M&04U5;U!W2#1E2T910W%L;W8U
M<&9M4&8V:3%P4&]Z5W-S8V--<U9N3F\K;U)Z6$EL:TM-<G-S.'-6:T9+<W%Y
M>7-Y='@U8F9:54MI)B-X03MB<CAW9GI7=$=T8F0Y04TP.'5N<&1Z,T5E;#-R
M5S9Y4W=T2U9(<%A%>BMP0R]'13(W049Z5BMA1#1C5E=3+VU8*UEQ>%A,<F]D
M.'I,)B-X03MA=WHR>7(U974R8FY)2753>4)T46I(4&LW:C!K6G5!1E,U24M9
M<6E4-70O3G%F4T5V>G P5FHY83E35DQC86)D>EA&;VQV93(X6E=:)B-X03M0
M5W)/6F)A5U9W<4EJ9D(X3E-D;%919FU$-3=B>71Q3W!R<$9W3"LR=FMH:&<O
M470O=T%M=&U"671"8E!02$YC:T-G-78V0S$V:GA6)B-X03MD6F594'I*,#)X
M55A&=3%X0F546'-Q6%5M;3-T>%!9>$QF<W%#94-+9#5,;FY(279P2DAW2V]0
M,FQ&8U962B]/+W=#85594DEV3&%Z)B-X03M.2DAY5V8P3&A&0G55.4<P3%)L
M:7=P8V\P;'=H26%+1FQR=G53<4YG.'HK9C103$8W96%J66E45DDW5W=U-U57
M5VU81#!A.&)J3F)')B-X03LP939$>7E7+T=R,&U466=K0VTT5D-7=FYJ>CE0
M66TT;C Q<D<V3G!:>6UX8E-.4G5#:&Y7,DYZ4#9S8VEO+V].3DU0<6=!;5!$
M<G9I)B-X03MR;#@W*V9L:S5F;S S55-E;3EX175K-FIB=71S1VI-;'EJ>4\T
M:V5337-6=%98,55.03-)<6%Q<4XO-78O3D\U,&TK=CE+,'1946M.)B-X03M,
M3WIM,#8V1C-).7AD6$U%36=-:W%"4%)J:FAM:U(T:G-X<GA"1D969EAR+T%-
M.&989$,Q:7EE4U<S9S R5U,W:EA4.5)J:BMS5%0R)B-X03LP3'EY5TM4<$Q)
M631:2DI%=#-$3CA,8V9I25I6530X;S8S-3@Q3S,Q0S4Q2W=T-V8P4D5M;E<P
M<TYZ6DY/-6E34C5N95%Z=$=J1C9#)B-X03M0,&EY14972DE/2W!B-6DX>2]M
M9&)8:W-.<C5B;6],4V1,5V5Y;'1R=3%E.$U%:W-C:G1)66)J:$=9,%%+66LU
M3WI#<&]N3E9*<#EE)B-X03LO3D]'84\U<V9R=6]A1UAA3EIB:7DY0R]A,U-5
M2S@X;'-,2D=76FYK0U(P569U,4UH:&)R:%9/9GI!.'DK931%;'1F3#%H2W!U
M9$]-)B-X03ML=CA!-D1C6$5X;FMJ;35G6$5,:4,S93,T4G-%:T1'471X5&9!
M<7I7.4\X.39B83)A859R1V]/8F92<C)A4T='0TLT:FMV<E9):F)O)B-X03M7
M=DDW,C9R33!J+T,P-TUE4'=N631Q<S!0>D@K64U&.6)73C-9,S%X8E18=VEU
M8FY5<E--,TYV8DY(8D533RMN*VYA4T(U6DI)>#98)B-X03M,9T-(:U W=5)C
M5E)T;G)0;G505C555WA69$AH=FA(2D9,8C-C='A+;#%Q9#%!6EER;5-C<6E1
M=W!&358Y3FQ#3CA01F5.1E5*<F9M)B-X03M$>G1W;C V>BMU5S)O5W0U9E-8
M5C9U;E-Z42]O*VMP<R]2:U<S;6IL:R]E46EK87E/0T-74G%%1E9L;FMU.3%#
M.3AT5V1X<4,S4S-J)B-X03ME;W-P=E5%8S=C2E=53WEI0WEO<FA1>59G:F)J
M5&MO3F-65'9&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$W)B-X03M&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ+R]:/"]X;7!'26UG.FEM86=E/@H@(" @(" @(" @(" @
M(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \
M+WAM<#I4:'5M8FYA:6QS/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @
M(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @
M>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B
M"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O8F4N8V]M
M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @("!X;6QN
M<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+U)E
M<V]U<F-E179E;G0C(CX*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP
M+FEI9#I%,T,Q1C@R,T$X,#E%0C$Q044W,#@T-34P1#DY.4-%,SPO>&UP34TZ
M26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I
M9#I%,T,Q1C@R,T$X,#E%0C$Q044W,#@T-34P1#DY.4-%,SPO>&UP34TZ1&]C
M=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YU
M=6ED.C5$,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]X;7!-33I/
M<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I296YD:71I;VY#
M;&%S<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S<SX*(" @(" @(" @
M/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*
M(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#I%,D,Q1C@R
M,T$X,#E%0C$Q044W,#@T-34P1#DY.4-%,SPO<W12968Z:6YS=&%N8V5)1#X*
M(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#I%,D,Q1C@R
M,T$X,#E%0C$Q044W,#@T-34P1#DY.4-%,SPO<W12968Z9&]C=6UE;G1)1#X*
M(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YU=6ED.C5$
M,C X.3(T.3-"1D1",3$Y,31!.#4Y,$0S,34P.$,X/"]S=%)E9CIO<FEG:6YA
M;$1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIR96YD:71I;VY#;&%S
M<SYD969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*(" @(" @(" @/"]X
M;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM<$U-.DAI<W1O<GD^"B @
M(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C-#,#@P-D5#.$(P.45"
M,3%!13<P.#0U-3!$.3DY0T4S/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(P+3$P+3 X5#$P.C,P.C$R+3 W
M.C P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F
M='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S
M=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V
M960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN
M<W1A;F-E240^>&UP+FEI9#I%,T,Q1C@R,T$X,#E%0C$Q044W,#@T-34P1#DY
M.4-%,SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.G=H96X^,C R,"TQ,"TP.%0Q,SHU,CHQ,RTP-SHP,#PO<W1%=G0Z=VAE
M;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O
M8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!
M9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%
M=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @
M(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R
M9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z:6QL=7-T<F%T;W(](FAT
M=' Z+R]N<RYA9&]B92YC;VTO:6QL=7-T<F%T;W(O,2XP+R(^"B @(" @(" @
M(#QI;&QU<W1R871O<CI3=&%R='5P4')O9FEL93Y0<FEN=#PO:6QL=7-T<F%T
M;W(Z4W1A<G1U<%!R;V9I;&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SIX;7!44&<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]T
M+W!G+R(*(" @(" @(" @(" @>&UL;G,Z<W1$:6T](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]S5'EP92]$:6UE;G-I;VYS(R(*(" @(" @(" @(" @
M>&UL;G,Z<W1&;G0](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP
M92]&;VYT(R(*(" @(" @(" @(" @>&UL;G,Z>&UP1STB:'1T<#HO+VYS+F%D
M;V)E+F-O;2]X87 O,2XP+V<O(CX*(" @(" @(" @/'AM<%109SI(87-6:7-I
M8FQE3W9E<G!R:6YT/E1R=64\+WAM<%109SI(87-6:7-I8FQE3W9E<G!R:6YT
M/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^1F%L
M<V4\+WAM<%109SI(87-6:7-I8FQE5')A;G-P87)E;F-Y/@H@(" @(" @(" \
M>&UP5%!G.DY086=E<SXQ/"]X;7!44&<Z3E!A9V5S/@H@(" @(" @(" \>&UP
M5%!G.DUA>%!A9V53:7IE(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @/'-T1&EM.G<^-C,P+C P,# P,#PO<W1$:6TZ=SX*(" @(" @
M(" @(" @/'-T1&EM.F@^.#$P+C P,# P,#PO<W1$:6TZ:#X*(" @(" @(" @
M(" @/'-T1&EM.G5N:70^4&]I;G1S/"]S=$1I;3IU;FET/@H@(" @(" @(" \
M+WAM<%109SI-87A086=E4VEZ93X*(" @(" @(" @/'AM<%109SI&;VYT<SX*
M(" @(" @(" @(" @/')D9CI"86<^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1&;G0Z9F]N=$YA;64^07)I86Q-5#PO<W1&;G0Z9F]N=$YA;64^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%M:6QY/D%R:6%L/"]S=$9N=#IF
M;VYT1F%M:6QY/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^
M4F5G=6QA<CPO<W1&;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS
M=$9N=#IF;VYT5'EP93Y/<&5N(%1Y<&4\+W-T1FYT.F9O;G14>7!E/@H@(" @
M(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SY697)S:6]N(#<N
M,# \+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @(" @(#QS
M=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @(" @
M(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93YA<FEA;"YT=&8\+W-T
M1FYT.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^4F]B;W1O+5)E
M9W5L87(\+W-T1FYT.F9O;G1.86UE/@H@(" @(" @(" @(" @(" @(" \<W1&
M;G0Z9F]N=$9A;6EL>3Y2;V)O=&\\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @
M(" @(" @(" @(" @(#QS=$9N=#IF;VYT1F%C93Y296=U;&%R/"]S=$9N=#IF
M;VYT1F%C93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/D]P
M96X@5'EP93PO<W1&;G0Z9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS
M=$9N=#IV97)S:6]N4W1R:6YG/E9E<G-I;VX@,BXP,#$Q,#$[(#(P,30\+W-T
M1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC
M;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @
M(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93Y2;V)O=&\M4F5G=6QA<BYO=&8\
M+W-T1FYT.F9O;G1&:6QE3F%M93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^
M"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R
M8V4B/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$YA;64^36]N='-E
M<G)A="U296=U;&%R/"]S=$9N=#IF;VYT3F%M93X*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.F9O;G1&86UI;'D^36]N='-E<G)A=#PO<W1&;G0Z9F]N=$9A
M;6EL>3X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86-E/E)E9W5L
M87(\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z
M9F]N=%1Y<&4^3W!E;B!4>7!E/"]S=$9N=#IF;VYT5'EP93X*(" @(" @(" @
M(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^5F5R<VEO;B W+C(P,#M0
M4R P,#<N,C P.VAO=&-O;G8@,2XP+C@X.VUA:V5O=&8N;&EB,BXU+C8T-S<U
M/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @(" @(" @(" \<W1&
M;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I=&4^"B @(" @(" @
M(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^36]N='-E<G)A="U296=U
M;&%R+F]T9CPO<W1&;G0Z9F]N=$9I;&5.86UE/@H@(" @(" @(" @(" @(" \
M+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z0F%G/@H@(" @(" @(" \+WAM
M<%109SI&;VYT<SX*(" @(" @(" @/'AM<%109SI0;&%T94YA;65S/@H@(" @
M(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:3Y#>6%N
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D^36%G96YT83PO<F1F
M.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/EEE;&QO=SPO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI/D)L86-K/"]R9&8Z;&D^"B @(" @(" @
M(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!44&<Z4&QA=&5.86UE<SX*
M(" @(" @(" @/'AM<%109SI3=V%T8VA'<F]U<',^"B @(" @(" @(" @(#QR
M9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!.86UE
M/D1E9F%U;'0@4W=A=&-H($=R;W5P/"]X;7!'.F=R;W5P3F%M93X*(" @(" @
M(" @(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C \+WAM<$<Z9W)O=7!4>7!E
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z
M4V5Q/@H@(" @(" @(" \+WAM<%109SI3=V%T8VA'<F]U<',^"B @(" @(#PO
M<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B
M92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/D%D;V)E
M(%!$1B!L:6)R87)Y(#$P+C Q/"]P9&8Z4')O9'5C97(^"B @(" @(#PO<F1F
M.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#  $!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1
M" #V 8@# 1$  A$! Q$!_\0 '@ !  (" P$! 0            8'!0@#! D"
M 0K_Q  ^$  " @(#   ""0$&!0,#!0 $!0,& @<  0@3% D1$A46&%>5U!<9
M(3%9E]<B(SAWN"0E,B9%@2=!46%Q_\0 ' $!  (# 0$!              $"
M P0%!@<)_\0 1A$  0," P,%#P,#! ( !P   0 " P01!1(A$S%!!A0B46$'
M%1=45G&!D9*3H;'2X? RP=$C8O$D0E*"%B4S-4-3=7:V_]H # ,!  (1 Q$
M/P#9#GS=?E>G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(
MG")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")P
MB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G
M")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB
M<(G")PB<(G"*9:\I^>P+S5*3&S$2YVAX EQ;GQS2A+>SIL8>S2XQ^NY\QANL
MNY9NH<<I/AXY?8QRR^K'O)#'M98X@X-SN#<QN0VYM<VUL.Q=/!L-=C&+8?A3
M9XJ5U?5PTHJ9@YT,&V>&;64,!>8X[YGY0790; G13"F:3M=MV&ZUW/F(A85F
M%T19&1^?4RU7$H^N"/+&8;++ [ITTF6J$68F><+(QNNDBF^3FR)PR1TTCY71
M&S2P.+R=0T-TW@V.9UFLL;.+FV-C==+"^2V(XCC-5@KC'1S4#:I]=/,<T%.V
MFZ#2'L)$O.JAT%-1NC+F5$M3 YC]D_:"* ZWO+*O96D&MGD).A&#&(G'X&)!
MBQ1E-@W;+EN<V+1FG3Y#%8MVRX,I:KR$+Z/*'[%(^%C$,A9G#"6V+@=+EK20
MYP;?,YK2#F< 0VQN18KGQ8'BT]&:^*AF?2[.:9KQD#Y*>F+Q4U,$!<*B>FIC
M'(*FIABD@IS'()I&;-^7\*UQ=@ZW^+B*^5@@Q% /G+QF#EG"7-988%31BLA)
MD:+%+2<D6%:U8!#+SY3 XQ"9LRQL91AD#,Y8<M@XFXN&NME<6WS-:[, UQ :
MXD $J),$Q2*A[XOHY!1B.&9\@=$Y\4%0YC*>HG@:\U$%/4/DC;!4311PS.DC
M;&]QD8'9!SJ/9%?4%O7-29@+0!@3C\YNQ>R@%K.0:%:V.6QD9L@TK"<P,<%R
M2)$K+)+%&@+DG(ACSDP2M:7.C<  ";VN&NL&N+;Y@TD@!Q&4D@ W6:IY.8W1
MTTE74X=/#!"R*68NR;2&"H<QD%3- 'F>*EF?)''%521MIY))(XV2N>]K3A0Z
MK,91K%=\3(L!Z];*9590.XLNYB9KDGOC> R.;K+K".('"B$0RQ989939L(<\
M,L.H,^LX$9,3Y;Z,DCCMQ)D;*X&_9LB#UW'4M:+#W2X36XJ)6AE%B.%X>Z$M
M)=([$Z;%ZEDH?>S6Q#"'L<T@EQF:00&$'+=ZY<D=ZM&4YX-6FU@<B$:V*/N&
M2 O*]6*BC 3329]QR9D'(,B_C_\ *BBA+PPDZ^N'.3*=BX[ -Z3IQ=K=UCM7
MQ $G34LO?< 5L'!*I_>!E.145'*&$R4D#1E<V0XM6X3'"YSCE)?-1F3/T6M9
M(T._2XJ88Z3EGVU7]9A7%"6JM<0A]=V%U";%66*0Q>09TZ^Q)AT;"($2$P5-
M,.X\Y@&*UB/EA)F+ECED%/>=D(D:6OL62V(86D$YNNP(+7<0YK@=05T?_%R[
ME%1X'%B=')38@V*6BQH-E;034LL+Y.=6<!*V*&2.:GJ18NAG@G80YT9!Q=+T
MO:[;<K52R/@5TVD*[2RM)+3_ (AU6=8&*^M=_P C++YHYLVA&3+(Q<I<99S,
M#.\NEPY14-8Z>1\DD9LPQ-D=)F_V[,&[=+W+G68+7U(.X$C!AG)C$,1Q/$,,
M?DHI<*I\0GQ!]1JRG=A\<EX#D)VDM14L920",N#GRB0G8LD>V(4"I]WJZUBG
M8GXJN[&Y"4]LLQLC,0<2I>L,B>Q,9A\B/A8_7GU#U/#W)WUUC\7#Z_M=4BCV
MLK([Y<[@W-:]KG?;2]NJX7.P?#SBV*4&&"84_/JJ*FVY89!$)'!ID,8<PORB
MYR![<UK9A>ZE,^OJXW3O&E NTEF*K*W-TYK[NLSU5[FD@F@@.;I8X6MB5MAU
M/S$1#47ML$U&!^,R'7&+P6105S$QS7.BD+RP9G,>S9ORWL7- <]K@VX+AF#@
M+NREH<1ONP:BJ:6KJ,'Q1U=)0P&JJ:*KH78?6&D:]K):FE:RHKJ>H939VOJ(
M^<Q5#(2Z=D$D$-1)#&*MK^X72(PBM(R&(H$PHI1N4X8 $9QW4V0"S$YD2&',
MV88CD9+U,,\C([J"?L06;J&3O&C(I)+Y&D@$ FX NZ^5MR0,SK'*T&YL; V6
MA08/B6*-E?0TKYHX71QR2E\4,+99LVQ@$T[XHG5,^1^PIFO,\V1^RC?E=:>8
M:&OI]:J[U$D:M2WTUE!+3Y"0KS0W-<<SJID"\<TN(U\^DQ@^8E2+0Y&X_>>$
M784GV\,\\HI97,8YK'.+R]I;:Q#V.(+&@D%S[:EC07#J77')'%Y:'#ZNDI:B
MHDK'UT,E*8FPRQU5%5/IW4<+)9&RU=8X-SNI((G5++AIB-P3"5&N+N^2D6!1
M7RCE8T#(ON2*4/$L@1-#(2X,7JY"<&K0-0/#-.U+6A%CKH8")39(,!YLL,38
M9'M+VL): X\+D-U<0V^9P:-7%H(: 22+%<JGP3%*NEDK:>CDEIXV3R%S71B1
M\5,TOJ98:=SQ45$5,QKGU$D$4C(&,>Z5S&L<1WP]1[(/0P68.I,YTIBHYZO*
MQ[%ZE:)U>1?35BH!S(Q8-Q5/0!DC:5:*5TK@'D(8?+P==2=R()2S.&'*6EP.
MG2:V^8M%[N#;$NR@Y0+NL-5FCY.XW-2,KH\.G=2R4TM7#(,@=44M.914STT1
M>)JF.F$,KJET$<@IF,=)/LV=)?==T_LNV!JCJ[4&;2%[-W"CBA[%C.=XX&9+
MYRTZR<B)BT6AFQS#,&P I"Q=*,7B<6/\H3W%+*>:0-+(W.S_ * +9GZV):TG
M,X @YG $-L2X@ J:+DWCF(QT\M%AM14-JW%M(UFS$U4!(87RTT#WMGJ*>*5K
MV35,,;Z>!T<@FE9LWY<:LUM>7"'.S+*V>6FQ@8E1$Q_ QG.#3XR9N3E2Z2;!
MDW 38139N#E8A@BK""?)A,-C!-WA40RN;G#"6V<0=+D-_46B^9S6ZYBT$-L;
MD66&#!,5J:0UT%#-)2AD\K7C('RQ4P)JIJ>%SA/4PTH:XU4U/'+'3ACS,Y@8
MZTHU5JS^H@]V;&M)%2.BUX9VRD"[KL[4N4^P):^&&$#8;/51>\.I'&1Q)DC#
M&'"(+L&/[;%@!#+D@@VHD<7%K(F!SB,A<;O8P !\D8_W7)OPM^IS0=_D_P G
MSC4>*U,M0::DPFB95SNCYD^HD=-64M'%%%%6U^'QVS5)FDE=,&-;%L1>:>%K
ML+GJ38\95?"SJ+7 JTK,G:$>3&#"8Y%@L%<YO^X\I^LA4."LR(Z1V;\NJC@C
M+RS,Z[ .Z'IL)@6 QN!>,S1I<MRAV>U_T93?.;-L#KH;:IY.XVV2CB=AU0),
M0@-721D,#Y:04\=4:S*7WCHVT\K9G5<N2G:QLI=*-C-D1ZEV/,[GKT%29D-8
M$F-ERB&^6(%DK>1L"_NQ"LH)Y%AB",PC"&=T(9.M'^&3).5'$&7G V$Q<6"-
MQ<&Y]+$%E[9P02TLN?U EHUUT-C>3N-NJGT;,.G?4,I!7EL>1\;J$RLAY['.
MQY@EHVR/#7U44CX&99'/D:V*4LR,^CML#1$SS4EKU".).?%+AF#-&V!% Q:&
M&UO.$N3&U"!+<L3SB:UVVA"$[^8*SABZ[RY8TTXO>)VXD;ND ,Q+-?Z@ -R6
M9@!J;!9W\E.4,;9'NPJHR,C?,UP,3FU,,<0GEEH2V0C$8HH")II*#G+(8SGD
M+&ZK&Z\UVSV+E;Q4W14[2M5&6T"+A!.BI&G<-CK:2<:23N>'  885[.V+8R_
M$@$&6RYDXQ#]RE#UBB=+M VY<R/. !>]GL:1OT #BXG< W72Y&O@V#5&-'$H
MZ42/J*'#C7QP11[1T^6NH:1['',T0QQQU;ZF6=UV1QP.,F5F:1G')JR_0NX:
M_+79XCR%7;X>:0Q9@GG18D9!Y/(;'D;U7I4V)V&:_)K@TR Q8X9K\B.C<,H.
MA@E#@TLU+<X-VY2R]LV>^3+?3-FM?2]U!P#%VU3:-U$]LSZ<U;'NE@%*^D#S
M$:MM<911.I1*#":EM081,##GVH+%RP:EV).T<)_PP4,:@^Z_O;)B4N5@B=O1
M<CD&/WJR,$53YV$##,^OX#&S9O0(Y#5.)@N&<O4BGF+G-R$%N7-F+6@9Q=G2
M<0TYQJRQ.<:MNK,Y.XR^>IIN821RT?-^<F>2&GBC-7&9:,<XGECIWNK809J)
MK)7.K(09:82Q@N'7 U?L!FL+;@U9E."'*TARR^S#$45(CQRD>8JE\TT;!U]R
M1XY2N<E IV*J+'*5AV/'UWEU AE<"0QQ S><Y?U96[W9-[\H.4:NL%2' <8G
M@DJ(L/G?%&:AIT:V20T@)JQ3PN<V:JYHT%U4::.44S1FFR-U65/US& @'=_/
M-C.R=7 [%[P 3"S"+LS-E8Z_Z"<ESNQ)0E77>4<T3@,-F5(X-6*,DT0A1+D&
MQA 8'W<;P";1H(!V^QLXYA9O', XYBUN6Q+AL2X*V*C95;6IESX!%C5H:6-\
M<!EQT8-LJJ1]5&Z*GU#VU,44\CJF6GIC2MCD?51=.Q:CV14UQ[2Q5)FK#53P
M#MOC]BY%*>RI_E@B&R^$B5@L 8S]X1+&9PHZYGG,/T 43\Q!\2KX)HP2^-S0
MVV:]KMN; N -VAQ_27 !VF4FX6.MY.8WAT,U16X=/3QT[V,J<YC,E/M'Y(7U
M$+7NF@AG>0VGGEC9!4%S-C(_.V_"=JK8JX, TNHN,8V1:H >"&# MC&<^QZS
M0A'J1))VBHQ[AWUFD&:!ASM\/^-=&3A_?P8)0 =FZQ+0 !<@N_0'-%W-+_\
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M/64\T$HW?0_3IZZMOPT/IOKU=2K:NR3=.DVA<.;G9S9 S-TML-KF<XLT!86
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M! (-UJ!OS2JBM^7.]2:/UZ*J3IKKI4A%2J8JZCA&7J-[Z]L]@,A#&Q[DE['
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M?==.HUGWS+&*V=W;9C,1(?YZQ0U]NCU'68K+7+7ZLVFFWV+?%N)=J<GF4?S
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M?VM]2UAUAY)WM9O3/J;6MI]T_2)KM7ZN6:$)U38NM@Z]7Y64J^52TM=@1YV
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ME<O0*!I3/Z:5EC:C;"ILR?*P)G,6,. P:E(6EQZ.Z=6(Y,JQRF"7=F?>S-8
M83X*L!O7^I&\=>RJ0&S;[.YJ@%Z:K*/JN\V)[1:FQL%AJ4#*^U\1-T\KS'*U
M5"XUV.G=KRKV:VIUM'6U<WJLNY 2FW%=PCUGJ4/*YL#([_!1J')?0[!M;#6U
MT-UE@YU?.T#OB$&S+DYG9[%"T2MZ]%,.%DIL%N7D4FK,WEQZP19DM^>?4?G#
MC9<J3U3K%JY'J[0*^4JY$V"BH(Z;>Z.\K-C[PV9E9\*(^P%,@R&GKE@FIEH#
MQ9BF$=J&B1@FL ZAP-*!@46_/5_(7';_ %?JZH6>6D=AWRT77K83;5H55I='
M>61LSNB36-5W R7C9"0XKQ0!J%<4S65^W.6((9NR5\[.(V'J&0IM\KK!TWUW
M4-A;6H.MJ;2-BN%E]UW<;WA>IJ_DE3U<RAWB+7MKIMP3/95MF06:MVS$^O61
M>:JP*1V /I02+G+++**2V_L^-^K^5"'OKL^M>AMG:_L59=J-<:S4ZX2!2A:[
M>6VW[3V?M"4R2NHZ,>@M>7<&'RT4,<"66@M^R1 ;7;'UKIM9JQDTY+:7X^?<
M.W33UZ]2L,/V#J8YY4J@,!LC.^VVW66A]:__ *<6C\75>UTY73+%9E]W Z"[
M%J@2VI7ZJW.&R-#HJJ[J;A8[KKQP,Y1_>A+'X7]%[?/TJT[=O'3U!L>-1N^S
M*74[+(CQL<26PV!>I.F3R9-<8"H8C9H?C2&=(7T@ <7>9S"%"\G!&(@3LI!B
MBQZE7I'I6J1[$N5>ZF4CT+7*2T0VJ^'MNH<F^R*LIPMEAUYKU+@/)-<2M?4@
M-L^VDW$)C"JS,E'4@,'EB%OP=#*;'\[>OS\.OU7HN7U]MBLJJ \V3IRFU59N
MZFX6[5\R_939WW3\^SJ7.<GWCG)0E@E<CK5#MYFR;59J@7:ZZG4T+8*J0O*)
M57;';"FV^Q.G9;]^NPZ]?0K7TOZF1[=ML-,CSIRUJ KL,;CN&YB$YV*R+; 6
M,FZU>L)&";7.I-Z(L[VD59^A PU]1NFM\P>WDKA_)6RBW'AU_EU)[%ZDU;6+
MDVJ##&Y3P5NVU;7UNNZVDV%AKNGW^[QUZ2I4ZQW </)<&U;]6ZJX3%P?-(J[
M-8DP]L<()SX(\BBW\_&RKO0>\-V[YUEL/8"BF5NM,X-IWZG:ZJ>P$MAIPXU>
MU_LJR4(XBT6=38+Y/9&QPE<E933IJG50DKZ8JK=B.!%V-I8%) &XWT_/S_ K
M"G>IO2-LHGFFQXZTT@$\]/6_)%50,MA7R936%2[3^VMK.3+ ;UK[ PIA_P#I
MP"F6"K@NQI?O<LPHJ#Y&& LEAKJ=.SM Z^W\X6.@]KTA.LL4.[Q0M<6:IWS8
M&LBY:R>XV%0;C>: FJ]ESJ6L[9#64#*VWNR(K:'&@UIC6!+RTMU>V%2J\JLC
M"A.#,R6ZC\AZ]?S16CM[T!6M,2K'EV8Q(*B%J+=.XK>(2@;-+(/5].(:S8["
M2NF4F2+1ITBYU/DQ63P,2W$T@L"67#L4K.8HWK.ZRWS3=I6&Q5-6IOE7LU=1
MUVV2H=AT6Q45HTIEM*> 5RVIQ7X8LA2Q@=6W018$W0MDKA8D0UK1(9F*K XI
M(M^>O\]6BK+\S1O]$OZN?A 7YC\SOY>ON/[YE^#\I^=?\I/XI^?^[?M_,?(?
M_7'W3\K\+YO_ -A^?^#_ .Z\);6W9?X76)TOZ:L.VMK6RC3B:8K'55M&QJ^V
MUJPVFXC]'U]+2;0YK""]O-5F4,*+NO[ [6K["FD@<1(8JI85#Q-<;?'/".20
MC]O-J+V\X6YO"A.$3A$X1.$3A$X1.$3A$X1.$3A%&+;2:9?E<2.]5*L71+ S
M5NX$]M0JK&KA<I#8F*5O$O<"&"1LU#"" ]6?A#T4O-AB*$EAGCPDZ(I'-A))
M#+A%+W!+G')A%/UAC)W#)ECWUA+U'G]>&?<>7?6?6&?7V<OJ^SE_=WWPBTQK
M7@W0M-6ZMGJZMBIV)JNWUZ^KMPQSCR[%L5O',*DV(_M1\HN2IDSW:K?7M#M,
MJ!2'*W V);9U62=F4$<"4W_CCNX#T:6\P67,\9ZV::EU;IAJ\MY=2U=YTMWF
M8*7 Q6*W>46Z:UKNK7#)J7$I^#%8^D%<'*$+7"B P,RB9LE\L'4(T9+G7M-_
M4;Z+C=>1P[09U:;-M[8S#:(J#5:M/M (#7R=\C<Z?O.S;I5;, C$IF5-E+,'
MVI8:;9%;"N&I'50[^4D A9EEMI27]6O7QMV]@/G4 L/T?=&NF+UU?=B6S8.Q
M'6W(-S8W>]4_3MI#76+#4M?TN16Q=>-]<$Z\RHA-+K:R+I1+7,GX[4:"Q0VK
M&SX2O)R7Z@!I;2_7>^^]UCD'D2S5/;I\NMMV6;4M<6^===:XBGU[3M)J#73'
MK:>][G:';&C]:<ZU@B81E700ZJ-JM7E^$#<NRR6!"WB,DS8DOV<2>/$#C>_Q
M5A2^%M)R:CO>D,<'N&OKE%I# %83FC?9U"7SM7-:(=3E*HK8CL*FP95XO4U-
ML!0-]4VY)8&890ED5-T1YBB8ES>_'^=ZB3+P#1&FN<]<RV=..L/LK*RNXQ/.
MODV%,>6:D7(%Q E:[T7FK6.ZH($<95;/CT2]%96)YTY,>I,*^CKY+F]^/G/\
M_EEBG_T<^O;.S/8N]F[")(GJLE1@<05_3P%V:I^EZI8"JV=?@=8CV;>%;5!)
M@1XZGMXRWU^Q8=22[ "NAN(I@I+_  [3_/I4\U)XAU[J-JM=IK TE. ]$'>E
M.PE=6UQ1JSU<6'F5CY;F1 56@4ZM)EM5CI;*1[%%"/)82+1%@<VL+2*4N$DE
MS\+?&ZE0WE=6EN-=OE0V3>JE9$5CW\T(* $I#6%N@]'[$J.S]@U0D2R5)R,,
M+#:*%4NZ^V#BA;KEP!@9!)V3*:>,E_V^ L%PZ3\GU[1\NU3Z[='/WSMA.B4-
M3DM)T_0U:HFN?C',*Y@4JBZY04$_8[2>ZF3VVW6&KN.K1@CJ:L]5BAKH:CA"
M2?CU\?.2HKJOP[0M6VVNW5?:7)#:N["@V*.I2536>NJ1.X&U7MC4OQY*+K6E
M52MQ.&R7;SUK:K5"%A9K,V3504YGC6ZVG0!DN3ZK?$'CYO-U!9J/R,(@;GV?
M66XMF:LMSQGM>:S6*N!:Y=ROTNUMMVW<LJ<I9>:+:DT$]"MEXM'>O' P$92T
M1TR'L<5J@*[AP)?L'#X"WY\++%=^#='X30##96P6K!^9AO+H-,P=83(PZN D
MGJ:R_0S%!SN.]MK:62331;Y*RD9?A^;(27&3+'"3$ESZC?TZ?PK0U7YTJ^J6
MU3>K+!97KJMZLGUHP:/LU&9EP-;6_._6S8=FR6JET,]XNER*:V.QE+X5ZDAF
MY8S"J1,9(XXB7_;X7M\U!;+XYH]BT9H'1,EA;Y5_SL#1P*H2^046Z@V>&C:R
M;ZJ PV!3[A5W-.LD<R)V2[CQP2KY%=P"2O54PF*[($HE];]M_C?S_NH[KSQ&
MLTXO2!:?W9M/74XM4AHUH8)TNG3<KC65NP=B[(KO4R9QJX^JU5W6'&U;PN4'
MTJO5]5(A=?=K9 SZ252:NDOU@'6^M^/I^=U)"?(JPM+>=?R[=VA%IF[F;%<9
M:H$BUY !7'^S'K>W-F-=N>5#FV$'!7;N[/NU& DL\^%:?9#!?&/J"Q-55A+_
M .?S3L^ZZ3/Q_'8YVMIMV[MHV7;4I>L"*KM6=;J]8UHT&H;$_L]57HJJFU^!
M12A'#&UV?&^R.ZXS/LXCT@(4U$(GJ,%9)?L'QU\^M^"S>NO**:B76+8K/9-_
MO]RSV3=]I,W%JPJ(W;.P7O5U'U0Q!R"K%8KX 2%2@H:G.O@!#0S@Y99P%FL8
MH\.^$OV#=;CUWZ^M=VJ>7D]'O57OE4OUS5&HW7H,]VLR&J9ZRWJ?1.[S=_61
M S^?KA!RR"NW4OL*M,$!JQCU7)"P7$[5A*(V7D)O\/@++MWGS'6;K9+;=8;=
M<:I=7UBUC<:_:*]G7LSZ):=5JWR-.S0"/4#I0= \06>P5VTK+&N<A,T3ID&-
M&O(F@-&*%U]?^7D%(V 'M=A=[E=MCS--@OK79K!A60\;8ZV#6-34F6>=/6Z^
MD3I5]7INEJ)6:PM1!@X8@KR&%AGL-D9-'QQ%L@4K6'=X]FK@3.\" B\>RA!R
M.\2ULWS*XK'N6//OH@ C_GA3=?5(+-_S8,H\_P#BX1:B,_ _ELZ]46^!ZN0)
M#J19;I;L52@7 =)8GM[$:X/#; OR^)&1+.T<L+#+D/\ +9&NB)RF/9F)$\<A
M3<]9X<>K=\-.KX+/ZS\MCZZ=5)N;MO9.PXM641SKC2RJ\84J</6M;=Q(Q"2>
MRD%20-[Q:H5-:1UL6VWED\<QUP,L?.>1Q9KF]LI">P#KM^?#^ NX@\L5"M6^
MFVM79K9]57A1E-EIG: K*\6ROR;5,ANUG==H\'OX@>.]SWRRV[M0>L"L+TH"
M;(4-=V_66$A-_P _-.KJ6/LWE%-9+1:C/ZE["4ZZV#L.J;4V#IY?'2LZC:;K
M4.ZCF-+]\GU$V\I*]8IZ-62[K64EH"76$L K*/[M@L5N'L1+]@W$>O\ #;_"
MNO5NMU.J*EE3TAS%@!E;=BW#LEID-D7\_LG8=IV.W&Z[$'%A^4!;6PT%=U\+
MXV*X<7$F8DGJ8B4H5%&^+=,/Z#YWUG>% ^QZ7YQ?3V*MU^_H:I:TUH/DUS?-
M;P96Y.W1%*C/D%]_8N 9  @)AW:]81A)U!'./.4@D7MQ4?E\*:LSI55U@-8;
MHEUCK5[=;=IZDUHM-75VJ+G9''W_ $^UU4A6EA)E8Z2:&/Y-- .,F5?K$3SK
MINFL95?JAB(ES^Q/7_G[[U9&ZO-5;WPDD47.SV0>8K26Z]('LDF*8.<M/O:L
MU^LVVP=#SK#!1W@,->@-2811=*QRB2,"P#!^H8HR@:$'J5G1:Y4Q;6.VYB:Q
M[>'Z]5:YE7=Y#?=."E19'-F@-CPZ'Z,^\9#'9$$N61>0W8T4/6 ^$O6<F93?
M2W;=4-CY'68N?D^MK['_ *0_UI[]!]:1^7H7X8ZV=WM'^N/Q?Q7^#/ZD?A+K
M=/U[3ZK/XO\ M=63_P!D^]?Z<]?@/A+_ "M?X>;=I]]5(\O.AS?9]"V+>=R7
M^_B:HN=IONMJJ\0:J6#URP6NGV^A$1$V*J:]K]H;)4M2O+].D6S-8)B8I B[
;>=;F( YN)1^_Y^RV8X1.$3A$X1.$3A$X1?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g945651g77i66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g77i66.jpg
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MV"&'."(D,7@C)3-"42@RP?_$ !@! 0$! 0$                ! @,$_\0
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M)=[,Y1+H>]ZI6T?M"GJ8K2<V1W9ZJQSLK:T1FU,U@*I]G=M=2 P:8LR9N5Q
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M^(S$(WV"J#L!6LAL>IK(?P .ZC$.L$0]ATW@\LA,X'PYPE"I GPM)HK,HN+
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MVXP8G6>_T?/NU/P3]G/S7TS_ +<8,3K/?Z/GW:GX)^SGYKZ9_P!N,&)UGO\
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M^220*;!5W#F-=;CK+@BK&*3@=)V"'+78_'#BZ@N-/WE.?]:XPN3A# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8'AL[&NY&0[1=JWLQV<;RI7LS>#
M4AN\YWV>\A U@&@-<)J\J^A7EDVJ@5 VD?Y4UTXVC#<)NCKPWV1])R_]/Y=L
M<./.9OOE!<@3$J@329_9),'N)(ZF5%]^4T4Q?+1;SZBJO'/'*2:;7VN^ZFO/
M&R?&O.^O/'.O'.&>',LQOF8\7N9ZS/YR4ZW]?2=G\/>++(TC5#^P^"6NVA'B
M<O(&!<2W@AIOQQMH]X/J$/-:[<<;:K^TXVXXYXYP[W>XVY)NP& P& P& P&
MP& P& P& P& P& P& P-8_C(?9O]C?\ 4/[\5?AK@_E//XJT72__ (=]3O\
MUIHG]KHKA.+>^-^5EL(8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8'GN\7NH.GHZ8#[,,V\:J3L_,0+396&P6 ?-U:V0 1/D*&DDZKM"1
MP=*.NA3<?S%@%J&+%K\619C$HJ7=3+X8C@@ +)9_EM-KG%G632Y[R2]?&C/A
MZ5!T[MJZH@(["7)*WDKU.LWM>41-*C'53!['D0U7AZ,&2&;C+4NJ-SW;ATV2
M(,*MTE$%(RA1JLQ*@IQ&=# E4G#P\,UX;^5DWSK)UDLE\]<=LQZ]\*8# 8#
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M81PH9X&.F>O+;UW[8VUV95U_\0:06 +JH+,X;%A\HG=7%9Z8F967J06N(T5
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MLWW Y\U>^3>)_P#W&KORRJOEW.G_ .:"WJ*Z_P#Y:<8'98# 8# 8# 8# 8#
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M(D=XZ3(ZLE=^=-^-4W/*6^W.NW'''/J\^@)$P*2]WND4)[IP:/ARLA>0"Q(
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MWM&"ON2T*?I>7+1LI'XA9 %24(QC:-+R2)(,XL9EB;L^K$A9C/;[QRROKA#
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MB%Y)A1#U349[\<$VY!DR)^^G_4^8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M\SGC%]G9G,+?==3(Z;(!JG@T7CQ6VA@MVNQYLF<3-IN<80Z5;M]TE7\'BL+6
MCAI:.**[AI66FFW$B8.TXL+T4,\7%>&3&EN=><G;QUF>U:6%(X!4;L6O(<<F
MB*6;NA/#9HBU4#O&>^JC)\&7;:HKB7[%;1-=@_'*-7C%PFFX:+HK)Z;ZG*<7
M%-9;ZUZF?")[43F^:FGE96J>?RZP*$+QI@VF9=?=Z?EM93=B57@9*6$5/_D)
MRL64B\UB) LO[4B=&QH+(CKM_(3!=ZN=I?RDO72XZS?^KYZ-N.%,!@,!@,!@
M,!@,!@,!@,!@,!@,!@,!@,!@,!@:Q_&0^S?[&_ZA_?BK\-<'\IY_%3OTWA$:
M==;.H\]<#_;2=MT^IR$)/=W+K9#X:+P*!F2 ]0=RM[O5\P0$,%>7*C;9UIHE
MLAHMJ@LJGN2[\7C?[^W1,/#PZN!XNSAH"*RR.Q]B@^'H,0%FV$*TV D'%8N7
M,6=>4D:?!",+[4Y7:;T(_P!7+,PF%>^_-":DGEBAP9N<\]]I^\_W$2#KT^H?
ME^5+.XV:)F#NJ?OLN5FDO($BZ^D-MV!;O7[IP:WW7?.8U>EG-7;O_I6<NI#H
M25VV("1#EB3._?\ ZZ$5T:ZX@_FOP)BI]BG=X:41RSDFT]FZ2<I 3'B=;G!+
MWC0]KSPV5=61+GC-33;5V-6=B41[ELQBL39@RYNFNVW;]PDYIU]KA.05G+2B
M,GE4LJ!W,GD!DTQFTLE!L1O/AC<1)D7#PN7<\F&CMBT::M&AC5^W%KM&SP8F
MT=H)KZD8%#>DO6"#.D'0>IP;[5L!2C2#"5."<T#I!D!U3,&[-()+7ID2CJW7
MI.!GV^Z+-/="7I269);:2F;3 L;+FXDSMM[_ '\=(ZE7HCUEVT=^7@Y4<[>,
MH<QW*"YS.!Y9%*OP8>/0Y5F0;2#1RR= AH$9Y5TUW27W>(J$'&ZSURY75&;[
M6<MJS#Z2Z'Y%.F:D-4<R!X:9R5>S")X^7N+:1CI''I8-,<VV7)/[!V5'G8C%
MEF0[>0;!&XR.A8TF+XBXYJ%3)G]Q$C0JHH!7B@)2(A%!6T;KR.58']8H6(<M
MH3%%W3D(,5W)/GBCYT@X>.5G)E]NY-$55MU2)!TISSOR/W]]$E8# 8# 8# 8
M# 8# 8# 8# 8# 8# 8# 8# \QOC'=;I; [H==K10EZ0J&Q8U&A=FGF;=5TVK
M>PH>R^'&1^8*I:[>YH;,H8UBH=A(7.B8,)((BZ8G23)W+(TW>&>/A_*2S6S3
M'6<L=\YTYYT:;GAH0P9)$7I-BV8N-VZ;9TJY1U1=*N]M=&B#3?U^>';AXIOH
MFS;M_:K.E=]$F^BBF^NO)RDMN)+GP^>CU"^#_P!8)S253V!:]H1\E#YK?A:+
MN1<.-LUQDCCE7P1D93@R<L$.=='(:3G#$NF\I7#/=$"H4$=CP<^R%R1@9%,C
MM)^,DWWMO>].TDD]6W["F P& P& P& P& P& P& P& P& P& P& P& P-8_C
M(?9O]C?]0_OQ5^&N#^4\_BI0ZMW)!(7UPZ3UX95ECJ7S#JU214,*BU;V1.=$
MQ+."0 &[+GBD)B<A$1,0W*&QK98K*WX4>GPNHXV<\-6CQ9N2[\7C?[^EBB78
M&BPY%F+*W#6@YX09RE\UX>36/-VV[>$&8U'9;Z[]4AJP0<1\[,8R)),W#E)X
M@_,-6_*'*GM>$QB_O?;X<K:\J;22U7=VC QB"J:KAHL:E @(D18(^7])<2H7
M=,M# -3S3?RQX7R[#._;:>5?+>G"8O3;?LY4DN2JHD)G1H]8$5:LJR&$B\^2
M;%VI0I%F8B.EI:^X* A.[XVD^TC0$T;0%ICU"CT>+>N&+-QJW4] QMWV?N06
MY7D6+' 1Z1ICR\<:5N]+#]QQ==PDA;TQ+5]6W#75J/7U*.);-09.-C68O9Z\
MT)M]$7:#;5TTW7&/[]M:PZM>S=%V^[KUC6]@,)0]M.KSESP=HU%R%HY*5M&Y
M''(B:D3U$F(9*1U1C)Y6'![@Y-J'D2Q'WLW;B5MX[(O=1<77M<7QU^F'N.['
M6)O'(3*^+.T>![(8SDC!>1,0GQLI)V];3$+7\ST%QX/%GT@5>"9G(@L>2&[B
M]")=^02X"-2*6JJJ8Q>G[X[8[[)$2[ U#M6DLMU]+](] H'L82FY.8!))"2L
M/=@M45" R3Q*7APDP!&>470]P."DP+4L9:E@CH.R?MS8E5Z,6W'[^_#G1V[J
MPE<Z?5L DN[^8CQ')MR.]Q2-HRV8IBH6<=)M3[T0VCK\F/#6-!"A8&P+.38A
MA+ 3HH/:(D$-MB8Y_O/ZJ5L!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@>;CQ@
M^VDY-6<ZZB061%8Q7<9BH4K=JX!^Z%%9_(IFU5)BJS)%&2K=^UA0>'*")%*@
M[1?1"=<S04$,[\QX0:#2,SQ<5X9,;W/E)S\;<R=,7GBS0VSJZM!RZ#L97\+$
MOFJJ"[,@)C(8428N6BJ:[-V/(CV;9ZP>,G"*+ED\9KH.F;E%%PU527234U.?
MY\?_ -N+UOV]0GA =O)]<4?L+K_;TD)S284^-C4D@\[D+M5_*)96<D<%1'N>
M4E5]E'<CDM>G VC%Y+"*GO4]'93#^3BYF3LY#(BYUE_*9VNUQ\SU]<[3#=/A
M3 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8&L?QD/LW^QO^H?WXJ_#7!_*>
M?Q6;]7* K.=TIT?N*8QL-)I1 >G]01J'>_000MK%W)>'UM(]Y1''S\>N6C\H
M:.XXQ29E@S]BX02YVWUV]NF@JD2[\4[_ !G[8I&_#8C,*B36+1"\K:%;-XJ5
MKMP:?* #Y<C6Y5E1 9Q$W1 L.7)-N74<Z_1>/O"X<@*=M1Q^4MXII%&VL2;1
M09SRFNO/OTO?]USEW/AY50Z)F31,^:=D3S8>B^T:@X:+$M=A];]BJV1U"AF@
M#AH&8(L>R4L*CQ;7_LQA #&4F6B;)N_;OAG?O_KZ?UCT#C#-O>3-:V[,)LKU
MA$VKLXV+[@2B<;BLU6MM\NA$$B(MTTCSX62N$XHT<B&K!H[9A0B94<_+/9B;
ME@SMI-+GX^O>II=]<FTDFM3V'8$]D4OE55NI$MZZ8N-QT'.&I14>1C;*:@A(
MS5L3TKR2BF$O@ZZ"K5</)D=R6N^^SA?109WY2\M?OR\+8AZH?#VJ6GRH0F'F
M%JOM8[7KFLPK=O-B4+6%Q5X0JF4O1[ Y7.\/DB#5_9%=26R";38RHU*2"W[$
M&D4G455CX &,Z8Q/[N^_K[>.<72\-:L!^J2P2P[%%D6#&"M@+GGX5>LX^X@;
M$ FT>C!+B/\ #)+<^< ZRN5H\\<I'3Y!\[7XTXV1U2$MGGGKS\UA G6"-L!5
MF^^YO8THF%P,Y<A8$M?2EZ)8F'4MB8."\D$ZUC>X>J47T<AT6B\9C!1Q"GA]
MB( MM'QLF^>F'Y,9UEZ;37#D0?K5'H+:CJSF4IDA#C<>42'15^F&X#BS<AB5
M1PF0GDG;4:@6<*O0=+1;EFQ</=F@\@9F3KGAVB5#-(X3]^?O]U61P& P& P&
M P& P& P& P& P& P& P& P&!Y6/&!I"25EVB<WDJP<J5EV"&1!'B4>SVV'A
MK>B$<90=Y#BSG77V Q61PB,PTO#-72FJDA>LIJT:Z\*A=-71CCF9+.69=]LZ
M7UMV:M>>>...>>>>.....>>>>>?1QQQQ_GGGGGG_ !QQQQ_GGGG_ ,8<F^7P
M0Z/DO#FU^TAD>Y80V7QT'6%0.W">Z'$N$CS+V06%-1NN^O\ WT3?%V\1CT7,
M)[:)$WT9ECMIJY$+""3T[\,O#PXNEMS9TTTSWWOACO'H,PK#YS8< J^/KRRR
MYS#Z\BS51-%U)9S)@L2C[99;UO9)+F3[T>.145]3?V::CG7;?U=O5XY]7GT!
MB59=@:&NO=^G35VU%;>XI/54II65DPV>[C4M]^$]%'^L5-%>6:>ZG/">N[CA
M/7;?GC7CGG;GCC!BS>82[@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#6/XR'V
M;_8W_4/[\5?AK@_E//XJ7^K5MU;!>KG2N(S2Q(7%)5,>M-&?"<<D$E$"3DDX
M2KR#C%-@@MZ[1>D]4R)0:PWV9HJZZ/'[-OMSPJY1TW)Q;WQOS5S%"8U(DT#J
MD&29=^R($V(I1VAH2>#1*XQJ5(-&.RG#IPR&.C0=L0=HI;H,URPQ%RHFH_:Z
MJD?UF18$/->0>M7GD7BXYYY5=-?RK]MZOF&3CV>VWL72'KZ>V04]51/UM?6U
MX]/&!QSAP-&0IB22,L. QZ/"R!P\<,/6XT0%#"6BS\H6*D7BB+1@.',6Z[Q\
M]=*I-VK9%5==31)/;;@.I)3F%AG19B7EL;%O0+6-/C;,@:',W0AE,RS\#$'9
M)NX<)JLVTI."B@:.K.-$TS14<^'#MG+MHNBF'31>W*KF^\03AEDP26;V##"%
MCP32-RP$;WF=?"7L>&E)O%]1SYSL=B8XC+8LP?2$9PY%-7DB"-5W>BQ-GHL&
M.ONQ5 C 064$+LJEE&Y(RDQ*/'G-@19$0='PLPPCLP>AR&Y3AJ3:Q8^4& Y"
MNS563#%R#(:0V;O'2".Y<7I7?-+BJ9_!%+08V; 7M;(K[M%9ZTEP%S$$WJ1C
M6.J,5)$B_P!Q6C].0[:@-V.SKAWJ<VU$<H\$=N&W)'VC=LU9,CBD8B%D0.52
M-$"/E"@*.2T";+:1HLP"E1A_D>-?N77N9^+DL:)M"7"7+-<=(X^^36V:FQBK
MH8O3MY]$@X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# QR7PZ)6#&3,+GD7CTU
MA\C9*#9!%96&'2&.G!ZO.NRC$L%+-G8XBTWVTTWV;NVRJ7.^FF_J^MKKSP%(
M!?A8= Q,@UD277*.DE-''#G2/264V)+J^TWUWYW32TJZ53 S6VK1#;_+9AK%
M.&+;CC75NW2UUUXX'/.DO622^LU_<;+]M6K5BU;,F39!FR9H(M6C1JBFW:M6
MK=/5%NV;-T==$D$$$M-$D44M-4TD]==--===>.. P:V;)CM-5;9%NR_9QK%:
MM@<NL.2<LT]57G(.& "$B*Z,D=]T]5WBC(<LFT0YWU]NXV22XVXYWXP36R=7
MB+N.WK*[*6.\N6[R?)R:OU72H()LZ4?1>J CW?A1""UPR6XU:AQ QMJW8DC+
M-JU,S9\TYD,G</23GCAN<N+BS;)_'E.N-K>_QR8"UY=C#@66 "96,3*,.^"$
M5FL9(. <NBQ'7_'#Z/R!AND0'+;:\[(NDDEN6A%HHN/)MGHYTZ:+&9Q7AVOE
MO+XS9Z_/#?[3'>V'6UC*YQRS4M*O)45J>U'8UJBQ'&99'A8(^.E+-BWXT;#^
M9E!Y5$):1%-$TV ,V:*@1_M&0M!90[[R6<YG^K[R^2^V P& P& P& P& P&
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MK'\9#[-_L;_J']^*OPUP?RGG\5:+I?\ \.^IW_K31/[717"<6]\;\K+80P&
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M#_/TA:1-"* &Q[1ZE(V@UNSE2)3T^^$):SU\K*VYSUO_ ).#Z$B2)HG>%_\
MN>"^CWAU_P!QPKAQX_Y<7C?2[8[8QCL3;5OO#I4FZ3<K(*QXPBH@RU5W?./;
M,%TM&[!-OQRY4?KJ;ZHL4FW'+E1WNCHWXY6VTXY'#G\N'&^9\O?+7*<J1KV"
M)3I356;I0R+IS%779/;525:!&.LA4UV1YY1VUW+\/-N-DN>4^>.>.=.?5YXP
M[>#,L!@,!@,!@,!@,!@,!@,!@,!@,!@,!@:Q_&0^S?[&_P"H?WXJ_#7!_*>?
MQ5HNE_\ P[ZG?^M-$_M=%<)Q;WQORLMA# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8'1RB31^%1J0S*6F!\>BL3!EI-)CY9QHT%@X^"8."
MADP2=J\\)MF T<U<O7CA3GC1%NBHIMSQKKS@>7#L3XNO96W)$12Z^'%.O%3(
MN%4HP_2B<6/W#+AW&^VB1V5KV $E4:A34NW]1RQAH:+?% %/;10O,]R*ZX,*
M8XN.2XDELWMSC/28OOG7ISNGV;,K5,26;V.-L961SF;EG4GD3&>A8]Q&#TD=
MI)\$2NJ4'"Q!T ,'G"7#TT5:>>;$B[A\?*AB)LD1(.C/Y3BL_.=L\.EQKOG.
M?ZQIW]#?AC^'S1-@QRLNW$JM5Y>CH:0U+QBN]X$WK.+5I9L4)[(/F]@1929V
M.4E,^KF2,=^0+A66HP;5Z@-G 0"<4XALJ9G2<,X=N<WSG,NNFDF+,<L^M>A+
M"F P& P& P& P& P& P& P& P& P& P-8_C(?9O]C?\ 4/[\5?AK@_E//XKK
MJOD]Y1KK9T;"5CJ9>!;@ZLT762!09%F![2H)YM$ZZ)\VD[74$/6J IG4BUKG
M7'QTLO"W<SKJMH8T:Z&; 59'1<?E<ZZW3;G^^^S!A?:OM^)DV[M[6LN-C?AV
MNM64!/U-*U7TF,R.(T&^ESP)-(E#(^-C+B"+3JQ9+(&,D1+:%](+(XX&8AUD
MU7$.)B69VUO/ERTWN;IE*:W:KLFQ,NX,8K*.L3,>'04S.K"'0:S)'&(N"MJ*
M(2"ORK2OH^_+30[LVEL2MFHIB.:D]"<=-M:^L$HQ'1>1.@J(Q/&;3EGQMVY7
M:[XRZW2X+]=1JHW4\E]OP-P]H&.R-P[J[KOM*STTOU4/#7<@KR? )!74E9AU
MFJI#AP.$1Y2K6LEX/2MDQE 3FO2;L,68[;]<3%Z<_G$WC]&[\LDS&JR%OYS>
MM<E6?8FY(C<LD@/7EV?DS""#FG8E6JV[ 9)J'L8"^#DW$0KQ%O(XQ&"*Y+90
M,DX-<JRC3WL3'AM,:]YOKIIGISZ/E4W83N$YGM?$K(HVTB4#*U-&(!)08.(U
MV!\SV+1JT%;<@F+5S)YA'Y%%P;Q\K-*=?LI3NRK4;-8_'&@F:."1A71X+)U]
M^]G37KRTY.N)3_MK,%+5" I3<<!D:\V3C<>Y;U17.[&JWDB[)3:K*_6;.I)5
M4J"6!"T*->1N\[-]@?D3_76*C>0T^AX:<H,G8Q.LNWGIKWFNDSC=DO8NV>PH
M&5D!D&VON%D(_4E@+UA'1U5US9(*_;EC9\(S@:4Q-1*$V?\ "$&GG"WEWJ2L
MHH\\)!/#ITQK#$!;<J,$QSZSRFN?ZO/EX,IHXUW+0.RV<6,S/SR!$9G<\5C5
M?><JP7*!B3*]#86LI@U'O:UHU6+P(!685;@ZF9L>ZI;-T#,:/QUL@JQ([R47
M'Q\:^_\ >4#P&^.RQ16G0LAF%SM)%*;"@"9%V;Z\L@L3W$:Q'KS(KOC]@DT:
MA\P $QB3GK*K.N&@#0')S,M.O$CTWY U+,):&+CPTFNLZWOK<=//?%V_X9,!
M@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#6?XOQ$R/\/^X^ ^RVFA63T3'3NR
M'.WK;Q:2=@*O!25BJGK_ /?8& Y!T#+([\<I;B"3_P!OQRCPIQ@Y7MP\5].&
MO)_AYS W]^!41,^Z>UH'797:(MYI5LD:\<\[<M])V=B)D++=$^>?^G5Q\)P^
ML57">O/'/"2K57;7CVW&VQVX/XSM;)X;_-O[AOUPT8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8# UC^,A]F_V-_U#^_%7X:X/Y3S^*M%TO_X=]3O_ %IHG]KHKA.+
M>^-^5EL(ZQ@%#"W1A\,$C!SZ0OTBI]XP8-6CHX40&L R)(PX;I)K$WZ(<4+%
M)/'NZ[A,:-8,=%.&K-NDF'9X# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8
M# 8# 8# 8$=6[5D/N^KY[4,_9*D(;8T5,1*0(-5O*OTV!AFHUY?"GW&BFXTT
M,5W2)!"J.O+D66:,B+;G5PV2VX#QX]B>E?9'JO(B(:=0*6SV#M7"NL=N^NX>
M:D\+D@;3?GAH2EC.,,R[VK#_ +#9OJ<#R] > T+*+MXE))0.2U>\'/B_\[OP
MZSIG6=M=_+7K(C&J**O>^CC2-TM3T\FSUZNFWVD+F.G(Q683C?;C55[*;0.B
MV\0$-&*?.SIVP9O2\M=M45]8Y%I 1U2&K$G!;O\ XSGG?TSG/QSP]<G2#J@'
MZ=T2,K% LC)YB9,OYU:<S0:;L&\LL,XT',2#P>Q4W448@ 84.!AT5:+J*ODH
MO&@^Q9R^,J$2#LZZ;3:;>'[K>ZPUDV1!J?@<JLVRI(/B,%A0AP<DDA)\K<MF
M#!OZNO'";=LDX>D'[QPH@P%"1K9V5,E'3,4*9/"3QJU6#058/CES9V><:4QU
MN!IPQ!QM[O-6_/R(N7'FFNWJ\+.(5$(V7'Q'1QQKRNS\Q-9&1\LLC[T#"'Z;
M@:D9O'PSG;X33UME]EX>E?BD5UVGE;:IIO#%Z2NL@T>OHW&W$D1F$(L) 6S5
M(%FT"F_(:+O7DD$#&[@P4B,ABD=,;!VQ$K&^92( R0D'++.+-G+?,Q9X[STM
M[XS&TO"F P& P& P& P& P& P& P& P&!K'\9#[-_L;_ *A_?BK\-<'\IY_%
M=?5]NV76?6SHW%XF.&$4[JZLT57M</G0=Z^UC5T\Q.NN4W1I-F\2Y-QY"K2L
M^M<F*XV$;MP%$2E!(ORZD#31J+OQ=K<^&?WKOV8*,\1V<#Y+MJ:@<:*@=HY7
M3A&,N99M&K&+F)M$:$.NG,%#:1<HA-&$7VMPD5F[/VH56+Q2-&I-YQ\DSU#Z
MDQ,;]?233UNG/V2^[[Y2H4\^&Y)3$:B$I9,X>2E)F3W \#U!"PUGQ1A*ZJD)
M^S"-4LW*8.;K"K4KYL]3AWH9VW7"$(5U59S(/)6PQIG/WW\YI<9Y[Z5'$U[M
M6.%JVO)H7E-:5XY(=> =IJ*H-H[*7-EVF^#PA^2JX..GMB4]'H\7BK:0N9-*
M*P2FKNQ9/&C,=^ ) F3'DV3\N)MKG.->4SC>9SG;IG/9U!WO!V!&*F1!(%!X
M9L;D/9DI6T[E<:E32%?+>J+>=54/;3LBBY>MX?.H0\:)$I@1.[#X+O'95#Y>
M^)#8^*L=:*$QIWTT\<Z[>&/^,DKWN1,I>M&TI%;M?5R.1%"WD;+2F "3KOL7
M)'-YV771Z"U\A75L2\!+2$2B<0A.CLG2I^8K&99:,<DNX2,"VBU;/BV8_OMF
M3%MLTUNUZ>;.[ [BV'&+?8A0T#-/1.[-)-M2;R#F][JE Q:N+VE"]D#6P1\9
M)MHJWG]:PFO-%&,1-M!Z,C)D"*KTH;BPQ@23/[IO)TY2YK'D.X4Z*4YUDD$F
MD0FE25GSA6.6?<4^K,M!ZO"MF< O0WLF$%VE((^_!/"4PK.-B&C:5/.5/=I]
M#R;@@Y*#76Q<3-WLFV.>LDY7KT<"D^RO;BSI?N7W@B!2NHD_ )S)V"A0,<"D
ML06JS:5JRF%Z&+9VM9M*YZ2=1Z15]%-(++HZWCTD&QP]+."6A"1#27$SOS]=
M-_?6>D=9/>\<MBQV9\'YM":T#ME9DWYC,BA2+FQ*U) IO6,8J6)R- S8L;C[
M>5]CPLU/S"-DYP[B<-BD=C1,V[(.XS%I7(VQ9)WSXZ8US=KI/'7DV:UX5.'8
M!!CDF7B[J2&8=&2L@=0=\J4A;DX1"LG99>($EU%EB,76?K.% #Y9555V)V:.
M%%-]U.=N3+,,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,!@,#1CXZ$E.M
MJHZ[0ANHNWB<MN<B8DWJ<[\-2Y&#P4\5B4?(:^GV+AOJ6>JS1HW5UVV3,P<4
M30]54;QOJ3BTX>+&^)/*W%^O-YW<.#\Z20["'X2?Q-5="8UW(0%@0U5MSMPX
M^+8879R*/-M-=>>-ETB),>W%O&/_ %)E&#UT+736;O5D5#7!<<4Z6XOA=*]^
M6'8P& P& P& P& P& P& P& P& P-8_C(?9O]C?]0_OQ5^&N#^4\_BK1=+_^
M'?4[_P!::)_:Z*X3BWOC?E9;".@%Q:.A2\D/BP[%D;E[L>]DQ5%'CA^:7%#6
MX@9YUSMSLJHB/'-M&[-KKMJU;<J.ED4='#UXJN'?X# 8# 8# 8# 8# 8# 8#
M 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8%2NZW5,%W#HLM5C\OK%I0-+CYO6,
MUY9<DM8;88%N0:"RCH;PNVV)!"H@L<B,J'(NF;Q]$I*=;#" LJHQ*,AIM=9=
MY^^L[O*;8'3GM]5)YQ&9IUIMXJ^07V0;'*C@LMNZ$G4=-^4]2P60UH!/.F0M
MSMQSNU;S8-#)+HCSKN1C@_?GE/@Y7_SN?\<6=[)ZYQKX+Z=#?#%N&;6A"+@[
M(0E]5M45W(@TYC]?RI1EQ/[/EL:?MS,04.1UBZ>*0J" C[1A("(^4+,9=)B(
MAM'R,4'Q=T_=ES?#P_CK<6XO+;_?EIX[>G/#1@,!@,!@,!@,!@,!@,!@,!@,
M!@:Q_&0^S?[&_P"H?WXJ_#7!_*>?Q4^Q3I['81%XW"XI=G94+%X@ #Q>-AFM
MNO=FPD  '-A(<8WV<"UE]D& YHV:I;+*JJ\II:\J*;[\[;<DS>WI/IW_ -,N
MGW_=G/U<<?PV#-[>D^CZ9=/O^[.?JXX_AL&;V])]'TRZ??\ =G/U<<?PV#-[
M>D^CZ9=/O^[.?JXX_AL&;V])]'TRZ??]V<_5QQ_#8,WMZ3Z/IET^_P"[.?JX
MX_AL&;V])]'TRZ??]V<_5QQ_#8,WMZ3Z/IET^_[LY^KCC^&P9O;TGT?3+I]_
MW9S]7''\-@S>WI/H^F73[_NSGZN./X;!F]O2?1],NGW_ '9S]7''\-@S>WI/
MH^F73[_NSGZN./X;!F]O2?1],NGW_=G/U<<?PV#-[>D^CZ9=/O\ NSGZN./X
M;!F]O2?1],NGW_=G/U<<?PV#-[>D^CZ9=/O^[.?JXX_AL&;V])]'TRZ??]V<
M_5QQ_#8,WMZ3Z/IET^_[LY^KCC^&P9O;TGT?3+I]_P!V<_5QQ_#8,WMZ3Z/I
MET^_[LY^KCC^&P9O;TGT?3+I]_W9S]7''\-@S>WI/H^F73[_ +LY^KCC^&P9
MO;TGT?3+I]_W9S]7''\-@S>WI/H^F73[_NSGZN./X;!F]O2?1],NGW_=G/U<
M<?PV#-[>D^CZ9=/O^[.?JXX_AL&;V])]'TRZ??\ =G/U<<?PV#-[>D^CZ9=/
MO^[.?JXX_AL&;V])]'TRZ??]V<_5QQ_#8,WMZ3Z/IET^_P"[.?JXX_AL&;V]
M)]'TRZ??]V<_5QQ_#8,WMZ3Z/IET^_[LY^KCC^&P9O;TGT?3+I]_W9S]7''\
M-@S>WI/H^F73[_NSGZN./X;!F]O2?1],NGW_ '9S]7''\-@S>WI/H^F73[_N
MSGZN./X;!F]O2?1],NGW_=G/U<<?PV#-[>D^CZ9=/O\ NSGZN./X;!F]O2?1
M],NGW_=G/U<<?PV#-[>D^CZ9=/O^[.?JXX_AL&;V])]'TRZ??]V<_5QQ_#8,
MWMZ3Z/IET^_[LY^KCC^&P9O;TGT?3+I]_P!V<_5QQ_#8,WMZ3Z/IET^_[LY^
MKCC^&P9O;TGT?3+I]_W9S]7''\-@S>WI/H^F73[_ +LY^KCC^&P9O;TGT?3+
MI]_W9S]7''\-@S>WI/H^F73[_NSGZN./X;!F]O2?1],NGW_=G/U<<?PV#-[>
MD^CZ9=/O^[.?JXX_AL&;V])]'TRZ??\ =G/U<<?PV#-[>D^CZ9=/O^[.?JXX
M_AL&;V])]'TRZ??]V<_5QQ_#8,WMZ3Z/IET^_P"[.?JXX_AL&;V])]'TRZ??
M]V<_5QQ_#8,WMZ3Z/IET^_[LY^KCC^&P9O;TGT?3+I]_W9S]7''\-@S>WI/H
M^F73[_NSGZN./X;!F]O2?3 +0Z)UW=,%.5G:=K]C9G Y+[L]^QHI;Y--B2]S
M&!\@&>WW8CVCKCR9D4/?I>R<)^E9JGQOZZ?.^FP_*]O2?2[>$,!@,!@,!@,!
M@,!@,!@0E*;>:DQU@QNAR]5VQ>$*20:JU@[M,0#]QEG9-N+]I8;H(RE\BAP@
M5RLX(%-N8F1+KH#W \4+>%%VS?8N.N9+V_XHB#[(]AICTFZW]GY%;]#4!'9!
MU_3M&^K%.P"23MUM8I@?$M8%!JPK/23@4W@*4F2LE1>H[RPM/B9!C#8)!P)$
MY,G$@CQ<3-F+=<2>NN>WACKMKL#H:56%.J/IV;6W"]*XM27U= I/9-?)[K;I
MP>=GHL**2V):<N55W/&L>.NGXGC1PNX73\I[-9==7797<ETMF<XN_7NEC"&
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M<<F.5.2GW$6=QD; E*Z?%X*-/[VW!RB!4U>'3G=)=YSQ=9OC7?SVK;WADP&
MP&!\'3ILQ;.'KUP@S9LT%G3MVZ63;MFK9NGLJNX<+J[:)((():;JK+*[ZIII
MZ[;[[:ZZ\\\!K#[T^( RJCK994QZDR2K;GMT555M6<%=L)*,F5>0F&TY&N9%
M.9Q-GL5*KIJ)M%' 2'Q*-I/DR,EG\MCK51%&+#YB; &N'AS9+F2V3OK>7[]7
M:#KMKOKKOIMKOIMQQMKMKSQMKMKSQZ>-M=N.>>.>.>/\\<\<\\<\?YXPR_6
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M<YJY*WDR\4!S*4!S\SE0F&)&2CZ'L6;/G1 (KJL9:OBH >5$X<XU_EI-]_\
MOR[:Y_$H:5XEV#DE:=<[3ORL>J,$%3:_[$A1^O@#:,*G*P87*TC<5CLQD0@[
M.3(&LCL8G$[T'-V2<;C\D')C.9-)=74:0'XZR73-Q/7'SI.\NTU=%:7BJ02!
M2&?C(U4DEL0/1U?P.Q+^+L[&J&&DX2RGT#8VDSBD&B4[F0 _;D]"5N2&S(Z
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M^Q\C[GC/M/.:$SOWF/>7^G:-?#J .:WZ)5;*[%WD<7Z;T'*Z"DK=.'["M[G
M3'K)IUL,$--]):\WKS=4=RYDNK/3>9[:\K\!M7^O*?!C<MXM>*[9MOAKGS8/
MU7\."2=>9W394S8M!G87U\C!B,P7:N.G\%JBYK'X>1A2% C=^7#S+YGO(S,:
MC2[KVZU7Q.I=9?)W"LCD?M&&ZD84%LN;BYMSFW/]3WRVMX9,!@,!@,!@,!@,
$!@?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>g945651g77k55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g77k55.jpg
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M P$1  (1 0,1 ?_$ !X  0 " @,! 0$            '" 8) P0% @H!_\0
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MK8]:]H,&]VRQQ-&W29.1=M56ZRW)RRK=MUQ4R\T\_P#A\2;-1$$-^<I#3??
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M>1,2[9;3+NP(GR+?$#"'&UO)4L)2[(>::YBU--H7P*3)&U=(T?;E6C5<XT1
MY%V$3;J[8:=)9 66KVL$MU0FQ 2*(LAF.3AH?D,MN28<MG+4AU*F<J\"T>S\
M9I] 0H%'"M+B%MG@6A:?]JDG!&1N-P1@],X(SFH-*VK4=O;@2DOP^[S8URA3
M+8XF'.@7&(5&/-B/!M:4/M!:TI4MMQ/"M0X<X(BY73O6*Z(JGJ.;!4<7L=O;
MV=J*LL=6T<;*93AAJV)/*%9&)E-P4X'(@I!X$)B9SE(_$S/J^>'X>P6N65/<
M7.$CG\8Y_.&P<X^'AS@8QP</CC.]8 ]FEA-I-M,N\F6;VG4G^H#.0;_^.)'
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MV6V2KH[#N<]N&TEQ4.S6Z5=KF_Q.I;"(ENA-NRI3@*PI2&FU%+:5N*PA"E"
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MDG8*!/D"#7DW)C/*X&I##JL$\+;K:U8& 3A*B< D9.,;BJ4_#D__ &4V;_\
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MJ+%?4I_+R9&?)4TJEI;C<*.IML.D,H*@7 W@! ).2E63MC&*\K3,G0='6"1
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M&WDO1"E9$EI32DNI<9*T%M25A7"0:U>Z(6=2Z66$**&T7T+4$DI050XX2%J
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ME)24H)'MHY$*'IIB<B,@*"KB7G(D0O276V[G,"$!$5I<A\A(2&VT)6<!(2G
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MI3%JBBT.M2[G(@PFH\FQKLKB6X$5+JTI(6A*TO):4%QILS>=9[(T32^CNO\
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M8)(>>E1UMU.ZNCRUH1*A.HC?W1(2AQF0J2AQOE<E:2U%"6^$E7&%EQ*TME!
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M>*0CG.8".$'C.<X&,YV3IS4^XX(T9MC6U(V./#2W9XF'=:R(LC R8^SZ=^3
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MVPZVDH;<0Q)G/,<3:5$-DM'@."G! (MUS$UN-?"6VTY^:4(3G_\ JE*<9_\
M\XQQ48'D/M7WQ4TXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*5"^G/]UN'_ )HM?_3UGDGHGZ?N:@=5?7]A4T<BIIQ2L%V1K:H;:J4^CWJ"
M1(UHF]!?FPQ5DLU3F.N#IC,Z)E!NH& 1R.A$IAIQQJ.2::D)3EF2AYE2VU>\
M:2]$=2^PI*7$A025M-/ !0*3^1Y#B"2"1DI)'4$&K"YVR'>(;D">VZY%=4VI
M:&94J&X2TM+B"'X3T>0G"T@D(=2% <*@4D@Z0/B/_#>TF/T;4:WU[K9:A;!V
M;M^@Z?AR']F;#+ RPR^V*49? 'F+C8;="BA9-Q'"+1*D01F)6#8]D@KS75.Y
M5L,>8[?FI]OO4A:X"H:I3JHT>(U);5"6RZAQE28X25A""UA84.4M2!PG!'%=
M=Z M%JMEN7I6(J#=9MYA69GO%SNLB(\U='G5+CR42IDE*&%2PU,4II 7WEI#
MIXOS T7ZU=>]F="R?:CK%M@C7X5AV1J[2&^Z;*K%GF3,FQE-VJ6H,J#B2TV%
M1+R-DVPE.(B)0I]25L 345;/H%.*^3OZIHD"!V0:M7;)EV:Y-QTO)M[QDKB&
M0E-Y@1Y#$I,4M(DF.Y*YZ65E37'W24&4/Q6G!D^S.V7G3%[N-BO8MZ9,ZU1[
MHD0W5O!0CRY$9!;4LH(3PN.\QM316%)"@LH.*L;?K*.N&CXEG[!3[?M>@4_L
MSHE^W54J5/VLZ4I$@9L9=A&TYB5*D.#RKSK XB5>A3@DDI6A)@$@LRHBAA_5
M_P"A?4.J=2N=HLF\ZHU%>9\:):X=M7>[_<[E%A&0F>ZMQ+$Z4^RVIQ3*$<Y+
M96%<O.4)(K-=K2;<FR69ZZQ>^6R/J>UNW&*VR7)4B$&Y0>:BE("T.9*'70AU
M@NQFGV0ZDN 'O:JW#T;8WAN@!6NH]BV#HG8BM/PM8ZZ):!!W 4?[ CH5ZB2O
MID)?E>FI4NP5:>^@6DJL6,<C5JZ%UR!+6'FR/W7=;-.GVZ$+G*@NR8BY3K[D
ME]*PS#/*"5KX4+#JFUE25*;2IP<YIL<>=N<6+46BHE_OC5LTM/E6*YBS,VRW
MIL3<A$G4#:)X<3&:FJ2(2I$5?]I+RFF2(DU\J9 (<V.ZKTET3[#0+O02O2+6
MFKK9KH]6Y>P=3VW3&MZF>%32@DNY3+(Y)H:9@*R!"HR38FJ^8@FI['S09CK:
MB2$.MJTR=9F8B65\,.3&DA2F),9']IQ31X7$$*;;<0XT5@+0M ("P1D&NK6=
MG2VH4SH+FEF+5.MKT<W"TSK;"C2&5/MNJAR>*$IV/)COM\\1WVGW$GA>00A2
M5)JQM/Z6=1J$*( ZIULTJ+#E2$4J0&JUW62,.42A1I$.).6P4'S48DQHLN5'
M9=1A*D-27T)SC#KF%6*8T=((2RT 3DC@2=QTZCU-;''TW8(K:VF+-;4-N+2X
MM!B,K2I:4E*5$.(4.()4H CH%'S-4)^*9U0UQ?.K;FG]8=;-ARCY6U/;"I;G
M6#6^NHPL/LJGUDP&KC^U8#YVEY<JY^!;"P-<X;'-%(#:I)"/'R\/BPB%K.80
MI@MH97Q$\:.2A. M*2$\S=/Y2%$9 )&Y\ #J^M[##E60V^%9Y9=<?,N/^"0X
MB4-S([+C;)G(+L;+#J7UM%2$NK0,K2GB0E*]1VR=6]L.G?PV+B&T=#[(5S6]
MS?E4GL[K'>VG=7N20J;S2UIOVU=7&JB8LAZOZXF11\77I=ZT9G/0_7-'HLFO
MD\>K9QZVY$>&L-<Y*%'A?0ZVC(XD86MLI4HA! "%<6>N00<FM"FPK[I_1TEJ
MV(O#,.051KU"NEOA%38E1B)4Z"Y'<>=:AJ"4Q7"_Q%)4'4J:7N-A'43XHMRJ
MO2T+9=XZAV+L[8&F YMO<:-=C]?U@]K[7 2(&FZYNM^I%TME&,1HMTJ95EX"
M7J=?)@3K(2=,:?CS''(2;R/.4F,%.MK6ML'F< 0DH0,<"EI4I!PI)_*4@@X/
MCM6UV#6TAC3C3]S@2YLNWMN_B AHBL.Q(;26U0Y,J-)D15A,EA8+3C#2VG0V
MI0(42FN;XEG<>QT?K57=RR#W;WIYMLR?.4;4VHH4W2^8U_E1XU;/$K[>4"E[
M$2FI"!DQT5!<A6\$<07>\K-=DPI+9%:9)*60YF1'<)*&V_[6%G 45JQQ_E .
M-E!6?_*1O56L=0O1;,U<5.7_ $_/<>=BP;>%6W$M02TZN5)".^8CMH44)*9#
M3O,VY*DJ"SJ"^(KV=B[SZVZ>@:MN&[+C0'#M@MY?9W:HOI )N"^HENB0<6ET
M ?46:]9K'KS6MJ%6!BSRA@=\(]<9*U8G&(U<9FCL?,?YK+8075(XBHN2"T'%
M] $H",%2$*!XL CC\2$@CG^K[V+G9K>B#)N4B(77I#DV^.6QFX2\EMI,:(B.
M&7GHD-]#H?*&RV9"B>)Q+(4B\'7#X2>M^[W5K3.R+UV@LY2\8%$1U[S2"]+V
M56@9^"9).#:V$*.,/LU@@)J<ZOQ;R.KTYR'9+4U(L!>48E*AS\7+,!$EAM:W
MU%6"%<)2M(()P 3G!"2D+ .%*'$<G!K9;/H.'J:QVZ9*O3RY/+4B5W9R-,9:
M>0XLMLMK(4&%MQUM)DH964/OY><+BN%=;!15;[D=?K-KSI1U1V1J"[#M::)8
MOA@[O/6\:H-A 4^YV"L4P&+>U*L?")O$<A9S"\/T[)%IX60L%DMI>:?CQ8F[
MVF#:(]J[S=._.#OBHL<Q%L)4H(:;=7Q-J;2E(:#B25EPJ<*P C*2HY&2K6EK
MND+2&D9UDDH@6!%RDNWZ Y'#+3DV3$B--.VQQ*75/%A:2DPPILLN/ORG5R$H
M11,?W5#3]P.7WO\ ]=W-L?/41O7-0%5:C!;E5 %IJ.TKX$OTT/4++8"E>&.V
M0D-33Y5F;L,JQ/-T>&17!&5^QQ(L3,3W;9:T_AT2_0;$2['GB1=;K"MQG,26
M4\MMI:GFYCIAA"7W4+B-Q1WUM#+S[S3Z6^>1]7]YNWXGKW2SU]_]$RK7$8M]
MK3<8D.9"NLYBX+;B2'GH;7?'$=R,E,MV6H6Y+JVF(TIH#^Z=H%ZK&O\ 7>W]
M8]M6NK)K;>O[-"+A+)2=J[*LDVF#-E74+1J\\_9'K+7!PK7-:'P:Y2)U;KE5
M)Q&DE24:3*8+,2U\WUKV_P#91HN:S:M=S1!?D\RX6ILQW9K4R$V^Y"_%V).F
M(MUBJ8N[T5R8VU)G&2([C"9<6)(2[';S&F-#ZJDVR#?-,ZE&GEW&"_'EM28U
MQER1'1.E"%;UB[.J;;1:(O+AQ'8D**4J2^ZR\\V\AU7QMKIU>MIAM01M=3;W
M<:SK[5D>@*M&O-4& E3L4K-ELIVP/P9=I:+W2P0;#,-Y*VM%G,3QQ*VR3K\&
M!#&+B0(W"M4?U(ZM?O;]W[(>RW4NO=-76VML+U$^-;6^W/OH>D<0LT"*8<%"
MX;:T1TWMBVP[H5MF)WMUB%'6-ED=D0N$"SQ9]^[LY:H0A\-NMD'E.@O.OOJ=
MD3!)N,AN8XX7Y<:7+?B.25O.MLMI=+:<0[0T+0>K#^I*KV8[;$J-L*!I35QD
M54[C$W=%GUD7&#SP Y@4"U'JXE2ZHP'D0#8&+!A/,F<YBSB);'K"\AU_'3K9
MVPW-$2ZV<=F5GCZ@TA:(MSM/:!IAS5FJ(L><Q%N5UTQ=K[>+#=+U=+5%O"%+
M3#OETN3ZY,<2I2R_PH9]KU:]&6YVW0M2ZEOR)\"/%?BIB3;G;8K7=T/0XLN'
M;K(TU;+<\EE+L=)A,L+".,D9=6I?5O6R';$NHR=):.[H;YU[ H56#"MKUW2.
MZKY4;A)%PUQB1&G6>Z#H=B(5K,U+K<)4V!!;2\B5Z.,F'EAQSB7:A_3CVAZT
MU'&OMJ<T\$O62V,3VDS+K'M<>Z,H=$UC3T#\)4W;+ A:@;=;8[<:/$2IQMF,
MTGKLL/6%NBQ8\>!:]7W>&RTAN/<D6J?/$QM*0 \9LM:9$E9.0MYT<2UA1R1@
MFM?:SLQ=M$[:<UY9M-U^S6&%3Z07+/5.UV@>D0[8:W!,0P%E&7$#8CXJ["Q<
MN W;!LDJY&A&%R&!L: .3%@Q]QNW]&NH;Z]%N-MU%<+3&<M=K9,.'9;I=VDR
MHT%B/.=-RG:B;D2UOS6Y#W$68[;2%HCM,-MM)36HW[M:C:?N+ELGVN!*EM-M
M.NJ1<#&6TF2@/L,2([L*0XQ):CN-)?;+RP'.(IPDA(E^U=/NWO9 CNK=&C^R
MH>9K.A>UQ3$[8YF"3LEAF0-14?9I*57%5;6J@2ZJD=:H0^G#W9F'84&#&ARY
M\M3.2DGZ.?\ Z=^SR=^#R-81EW/4\NVVY%PN M\N.'YD=E-I<?,=%_:$,N*B
M**HZ$N%E"@VIYY04M6&<FZYO2[_<M,7B)^!VQXI!G7!MQ]](MD.[J5',:QNL
MN1@U-0B+Q.@X0 HX'&>9KJ,&[;Z_VMW4U]0J#0:'0P[DHS1!>U+]5<R"&K-0
MU&P6MT77:O0<5C,\_)Q*D$93TF$X:LTHJ2*N>=-?GO\ 3G.S+0UME6^S/6\A
MP,PH;!9@6]3#;#9$"(DJD<V00AEEOB*W'5D;E2E9K",FYZLM=XUK;HELB6^"
MAYY^&;M=&'5NVZU1IDTMLQ(*8A6\M2^)1+7-D%Q;A'$5GC(_#\U%VKUEVB^(
M&FY&-/6:JF-Q7.H:<JE2I]=J@MG452:,U(,X&=$#9<9R9@5#CFWL#8\DC,7,
M)OLYG37\JO)VDH+5[@04J>2W)_#D.%DM!I!>4VRZ6@EM20DD%P +(!40" !@
MU:(NH[!J?7/>/PR3!<OLN':FHK+#2$6F,7X;*VE!M:5*#:&WE<I*G%!3BD\:
MU9V&5BI]LB74K=FHBW4$A<[OOR3NNUP=K5J_Z2'4Q<C>A M91Y># LMX'W."
M+A*/I>Q#FC(Y.,PG#.8^'T93S9W';2F[0I:+LEEF (;*HKL>:I[$%*6E(4IM
MA3*EGEXX@LI)WSC>LW%AZO=T??+,]HUR;.U"J^3$7:+<;$W"*K\X]*;=;:E3
MVIR&4&0#P.-)=2G;@XA@Y\,ZO]TZMU=V;U%"U#2EAJMZE;2BP]I67<UL:M;8
MW8]G+'4$S5?9U5-CS#(]DIA)%+9I2)\QI]YM]*74YYX*N=F=N<:[+=F-NL",
M3%;AM%KBCM)04(<,I)"%%/Y<H_*" 0<5DFM*ZWB:4NFCF(5CDQ)ZKLA%VDWN
M8F6&KG*>D!U^,FT+2M]M+V'0'\.+"E!6"*DJ-\/#:HW2A?K2$[6,AM EY5D1
MFC(T172!J "M-QGW0B$C7>3=&R#KC) E(8B%71J%):2UE4##:<Q^6QU!$5-1
M<EVLKG(#?][OSB4*6TREE*RP&"D92D%20O!.=_&LFGLXNS5C?TO'U:EC3KZY
M0[@+!&<D-QY<UR:['1/5.#A(<=4E#Q9R!C^W@<-2^CX=^F$#$U=%][#IUR@\
MD\G4R=WV].KTJ3:<7%(I-02[B"D/@_C$[$7"L/X?_P#4XE8F_P#JN6G^H)A5
MS3'M_>.7P=[[DUWK_P +D\?-Z\?!MG&,;</#M69'9O9 T(HN&I!;1($@6@7Z
M:+4,2N^AGN05RPSWC^YPC\W%^?CYGYZOIS!5T"G%*<4IQ2G%*<4IQ2G%*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*A?3G^ZW#_S1:_\
MIZSR3T3]/W-0.JOK^PJ:.14TXI3BE5G[5Z#L?8;7H"K4[9SNH+=4]C4_958O
MC%5CW)X.<IK\N3 6V"EF@420YEV5A:'),MUAI36/,AR$J\*<E:I[=OD..O1A
M+9=CO1G6"Z60M#P 5E80L@8&,  G.RA6KZMT_)U';8\2%=#9ID2Y0KG$N"8B
M9JF)$):EMD1UOQT*.59!6LI!&Z%5H'[7T;8'6O;]HWEVAWQ(WQ=-!TK2%[UN
MZ;UZ.K C<6E#VXLT/=.JYPD+-*CH)""3N Y^!ZUHFN.7G5*R2"P4>A]E&.[0
M+'I/6&E835STQ;9UMAWDR7X%P0FX,MRRREIEP(?;("GXZG AT! 2IM2-P5*K
MD+K-]TIJ>X7*_P"IW[Q<+=:+/*MKY@H@HNEF<NZHMVMZFH[KC:7&'Y392E8=
M(6]%D%UE&4C8OK+MIU#M4(SV"Z>%T%*WK0G5J1O"J#*/9Z4P5 7V3.< RH,2
MU!@,:19PD\7*F0I4)>8\F(F6,)3H[3T16?F+6L+2W8H8/:CHRTQ+3:X,B'8-
M:Z?M,-N,S?+'=9B41Y<9DEEA%[L\XHD1'5*93*C.2(4E]#9;*>VV/4EHU&B0
M;5*5)3%+8>*H\A@MJ=2X6Q_?::*N(-KR4E03P[X)3FR) A3^\U.@D=:V*[:I
MNVE]B +O0[T1K]?(R %RCB#(]MR37/>B(^S5PF ,F@QT+-G#?5QYV%,R6'V&
M7T=9[(>V?37:;%O4_3MOO"8,!QJUW*->V(D)Q_O3?>6S&5!GW#AY992H.**%
M)6  A:2:\M16$WJ/##,YRVW"V3FKG;+@RTW(,:6TV\P2[&=X6Y,=Z/(?9>84
MM'&A>0M"DI4*G;[ZFW6I6&M;MVU?]Q]BP=SO(41VRJVJ@$RH!CFHJ[6SJ-<Q
M!NI*/.)V,I5J)>)$0G:(<.QGC904<L$MZ'):<DYC=T@75EUMV%$8B6];+"U6
MIV4XEY:);CB.\%4M]*&TNR&04-$MMH0M#8!&V>9:@TA.AR8M\O%QO6I&)T]A
MC5\2TQEPV'[-&BR!;4-6> X[)=B0)ZT.RT(DR)#S,B2LH4"KA\_2>]+/HR_6
M_6VE^MFZRVK=YV\>YT_I>P)^-<UN-+JM/]?NV4])V'-)7W7%!4MAJUUT=-I\
MV/-2@FL$.BO$TP43-@M3F&I,RXPD2H32_P 7>83WAPAQ[AA) CI2Q(D;EIQ0
M=24Y2%K(1FO*QW^58+C-M=CTQ?';5?YC9T9!N+GX9%2Y$A<R^J4JXK=N%KMV
M4B7';7"6E8#ICMI4Z&ZV1Z%WF3VR_L.J72@2M6[6U+8!E?O]'=L$*WC8R;"$
MBV2KV"N6T=#'1CU>L0:5Y\-]X8*)1)<6? (#(SL9*WM=G0DQ1'=9?$J++;4Y
M'?#:FE'EK+;K;C2BHMN-K&% *6DA25)603CING[\[=U7*).MR[3=K/):C7&
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M5$DDDDDDG)))W))W).Y-;@A"&T(;;2E#:$I0A" $H0A("4I2D !*4I "0
M  ,5S\BJJ<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4I
MQ2G%*<4IQ2G%*<4JE>W;M?\ :JZ*"T0_<@JHEMM4F[,'%GNO-F-"ZY4Y;$<;
M7G]JZO*F#P-T_80DZ4;J-,.B,3!PZ!/.B8DY^4FH #.?3'CU^A'ETS49.=O7
M.=O+^9W%0D+W?;KE53&VZK>;X+%ZXQU4&5.F'G*\\[;H&QI%+^LW=A-Q!KK%
MCLEPQ:Y]0CE0\UD8.,UY@Q4,,/2)KD^<8V( _P!V>NV/+IT^I]1T%1GJ1DX
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MY N1$E/1VILB6M[I[5CMD&UVZ5>H4Y^9< \X<2$LE#:$1EHX@_&<624OA)W
M24$#/^XX;3,:3J^3<&(?X&Y)M,6V_BTS4EMG7FYR+I*>NC$EI;HNT;N[4;\-
M2EEC@SRG$+4$J4H&P_5+:8;=1&[U[<W90_U%KFH*MK?7^LJ!JG;%<T)KD@.
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M4..Y[4>K;3HU,!B5$EEJ4AY,9NW,1BVTB(&$E!0[)C);2 ^V&TMA0 2H'A
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M-)3'X7W(LH0&D.):<:=2M+;K;B5(WUV;)^';K^W@-T]2"E/Z>]:;F)&Z2W&
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M%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*A?3G^ZW#_S1:_^GK/)/1/T_<U
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M_GVS4;5CK#MFETU[4;,*OG0VP8_76=;KY&/)A1::6U>NJQ]C0HH29$08*0B
MRHQ5ZY=@-JRLH4D-61%?B0&YD^20?TXOUXOC)_AVC!^^/H,#P'CGH=ZOO;Z3
M#N3<!N6>N0/ ]<A:%5"W'*HY)S)2RE29ZPDR(J<AKR<9CHD96EA2WLM83EU?
MSISCR_4 _P":JJMFJ=)C79.U//NNY(N&]MV5IC+6U;S$S)82*KV42G<H*H]6
M\XI2TJF+\;CN&THRO.&\8Q)/3IT\@?$^?3Z5 \?K^P_Z5F]9T-.C1RR;3LW;
M9"0[9+!(#K'[>OK:(U8?)/N5V!*QF;#\4^$+4Q'G.>%_"Y"%J]7*^?G*@GR
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MIX^F_P"V/WI)T-.5;P\N-L[;;=,9K=DCFA;FWKYDI*L\@I5':Q/BN^M7X8$
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MI3BE.*4XI5>KM?-D@M]:7ID.%5HNLKNNY1"Q!<J=-N!4T%I1VPQXK$',",+
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MD5EV<_7Z;7UDWGEP 0MTE+6GQ*?*3_\ TB2Y(BD:,3#DG./3W]3ZFHQCV]O
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M*>OZ'_!J#T_4?Y'^?']ZJM=M';!K1S3E>F4_5BQVR>RQ*?7]".;'O9S3]>&
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M-,,-(0TTTA+;:4H3C&*P !@# &P Z >57B4I2E*4I"4I 2E*0 E*0,!*0,
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MU /KC]*]2L]>MO\ 78I'EZ5L3FU8I72HW4\N#LMZH5R& /T,A&QJJY3<U*M
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M++M2?_-_\IJE7_E_^8?O4X<IJJG%*<4K3=\18X;&=C.KM=&F"@^O[$D0JML
M%"(2X@>]5E.P:XRFNW$8P\W"LX)+)HRTD0;8G#\-EB:,1_#/E8=J'^U7IC'I
MD[U2?]R?7.?7 VK<CRFJJTR'CQQSXK/T*LR672$C&KNFG+(S%55-TBZ4=1%M
MZ:]E[(C%HC(890P?Q#P692RTEN6G#:,8]/\ R9\?_P#JJ/\ S'ZC_P#I56S;
MKJVVWH'2>4(0C,C5&OYK^4)2G+TR?51<V=+>SC&,N29LV0_+EOK\3LF4^](>
@6MUQ:U4*ZGZFJD]!]!4R\BIIQ2G%*<4IQ2G%*<4K_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>g945651g99o66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g945651g99o66.jpg
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M"B(V-SA1D9.UMK<9(S(Y07B7&B0S-%AS=7:SUR4F6;0G0V%TF$)2<9FQ_\0
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M),+Q"KP\3TU-XQ04T=8*F,RU<T,0$@D;"1I%WURX:0'6@B,T_/N]6<1E%H/
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M,%V#X>'RL?KM6VP'[>X+\[8=],A7TI^]7_N9F_C%<^T&=FOLFYW'J[4[U?\
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M.225O**AH\.IXZ2AIXZ6FB+S'!"W1C89'F1Y:W9I/<YQY23M6=I: JJ74?\
MG3>2G4-I%M_.\0&Y3]=WBX07Z]?_ ,[!UCECU'4QROD[*W673 I^LYA5?O8+
M*MRGI[?;EU*%MR>#UX9>(6,A8?=T+L;9T?6TBC7VUOW;N"62AY R"K9U-LD5
M[L*(3$@@H1%^Z6263<IMFQ3H "7WUN2*.8 2QL> 20'-!L3KLM=B.$89BS(H
M\3HH*UD+B^)E0W3:QSAHES03DXC(G790(;P*'@V#"H(</BQ .NW5*4NT=N""
M2:(I"HU3Z=Y.84'?5G!P94RCDH+J]E<-A! 4;7B=+^#Q?F!:KZB^"OXAP[]
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M;*^K77;,ZUO77!/LJ=B;R1>V)(=%=F9%KUY2KHO$Z3\'B_,'?<H^HO@K<?\
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MUP>D/?3I/RZS^DPB>N#TA[Z=)^76?TF$7Y-Q :-.)!/M&CG%,W3()IMB82'
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M;]2S>(UU3(22;3;&OQQ)YL@"(3@MTPDU1%GV%555<@% RKAOTB+"4A2F Y@
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M)M"R$>2,;$5<O$UI!-[3?D!U:[[!8;55;GV]>M8-9^&]NXA):/J=LG8T@-+
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MM9J!QU'ATLLG<%KHU<TU[#S'&O!\3K5PF\<KJNJ,TX<X;5S,Y3!$&14LP3S
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MD;HQ/C&GV+D1GP.05)"',F!BBH4D.](<Q.8=(I#FG%"D,)>8%,*9P*(@(D,
M=$>9RW'I'8O6,]XZ#VKKRXM%;1;;C"+:_K>WXBV4%U'QKF84X=[#M37EJAF6
MP-9[6;IQSJ$NM)DF[AO9M:0")Y..EQ;/(U>;BGT<H\&'EX*1YK'E .HC;SG8
MH)W7!_JD^SDYNJUNN'>$- ZBK39?QE&1DI"Y6F?5MU5\1IUS:;K>+)<+8\6I
MW:GWBQ'O;+.RKN#A!?R QT$O&MA?OA3%TM!U[/-G[2I'?*RFO(4IA$PB811-
MKG\,-^?"S#?P+TMA%+.$3"*$[5Q&Z2I,](5BT[#A8B>BCHIR$:LE)++-%%VZ
M3I)-4[5BNB!S-UTE!("HF(!P*<"F 2AYCCWAE\&'!C%JO L>X8X7AV+4#HV5
ME%*VLDEIWS0QU$;9'04TL8<Z&6-Y:'DM#@' .! J#2<P.L+"I?B9X5[ W3:S
MU\IDVU25!PDVEX5])-TEP(=,%DT7D*LF14$U%" H4H' ASE W1,(#S.(>&_P
M"XO"RGQ7A9P9Q.".02L@Q##JFMA9*&N8)61U.&RL;(&/>T/#0X-<YM[.(+1<
M-0MYQVK'O5LX+/;75?S+)]G,T_\ &=_!F_&' '_VW'_^G4V?R]/[5&NGMM\)
MD3K.GQUJDM<)V%I%BG*DD:F1T]*Y[4X-R<N!@EQ54ZLR?WPJG^]Y!S\G(.*\
M'/A"_@^T' C@Y1X_7<"F8Q3T&A7MK,!94539N.F-IICA<O&/T"SWW&/RL+Y6
M%3PXN)%[$W%C^U3!$<17"17UU74#;Z#".5DA06<1%<<1JZJ G*H**JK*"144
M2%0A#BF8PDZ9"FZ/2* AZ+AWAD_@]81*^?">$?!'"YI8^*DFP[!Y:*62+2:_
MBWR4V%Q/?'IM:[0<2W2:UUK@$4Z+SKN?/^U9(EQ9<.JRJ:*>U:_TU5")DZ:$
MNF7IG,!2])12-(FF7F(<SJ&*0H<S&,!0$0W4?\('P-RR,C9P^P<OD>UC=)E>
MQND]P:W2>^C:Q@N1=SW-:T9N( )4:#MW6.U6(SV)4IA$PB81,(F$3")A$PB8
M1,(F$3")A$PBABXZ.JUVW%IW=<G)3[:S:3;WUM68Y@XCDX*2)L.!3KTP,ZW<
M1CF07.T9I@M&C'R4:"3D1,Z*[2Y)!FPU\L%%6T+&QF*N-.97.#C(TTTAD9Q9
M#PT:3C9^DQ]QJT3FN?K^#E'B./8!PAFFJ65G!UN)LHXHG1"FE&*THI*@U+7P
MOE<61@.AXJ6'1?F_C&^]4-['X,8._;<LFYXG=F^]56RVU^#K$\35=MKU:9/8
MB 1!%DB91U49:3 XB'7G.,B8"./YU B7( #.IL;DIZ**A?0X=5PPR22QFKAD
ME<U\ANXY3,9R6T=61NM#BO "FQ/'*OA!!PAX38+6UU+34=2,%KJ2DCD@I6Z,
M;29*">:_W1/&D!WOFAM@H9WMPL42B:3UKK.CU/9\[6JK>K/>5QKM)I>ZY6P;
M"D:1;(^-L.SZ[?HN=:V5O,2DR9JO($J\@TBG1XU0QZPR8,)6-S:#%JBHKZJJ
MJ)J6.6:GBIQQD\U"V.F;/"Y\=)+3OC,18QEPWCFN>W2 $KG.:[0\).!F&X;P
M>PC!\-HL7J*.BQ*LQ%WBN'8?PAFJ<4EPZNAAJL8I<3AJ&5;)YJ@L?**.5D+S
M$2ZCCCCGAC_56I=P-.(36]@M^J%:U=FUSIURLMZKT(R;4" U4WX1V&OYK54)
M.,E3MFL?&[;*X81U":&.B@9!&RMFZC A)4V365E$<-J8X:L2P&":"*GD>75$
ME6<9=4LJY(W"Y<ZCLYU0[,Z1B)TO>+68+@F/,X48355V"NI,09B%!7U>(TM/
M&S#*;!6\!X\+J,%IZB,EC(H<=#F18:QQ:TM;6,8Z,"8]F.LJ$IK:IH55:[7O
M81T)"7?C9=D3I;':%PEI%Q( Q7E"M&0'CXPK@&$4WZ@!:QZ"#<3J=7TQY:JJ
M!53&804],"UC>*I8^*A&@T-T@PN=9S[:3S?-Q)L-2]<PC#3A-$VB=B&)8H6R
MSR^-XM4BKK'">5\O%NF$<8,4(?Q4+= :$36,N;7,%V+@AX;)R\:SO3+5U(J3
MS64S+3;:&I]%H4) 6US)QY&+=*ZL4JL=6:;PBQ"RD$5-RS4CI4 >$4,8 *&P
MCQW%(X*J!U7/,*IC(S)-45$DD(:[2)@<9@(S(/>2$AP<SWI"YNJ\'?!*HQ'"
M,1CP;#J%^#SSU#*>APW#*>EKGS1")K<0C;1DU#*8CCJ8!\9BGM("2++^6_@@
MX:[;:]>VTFK:15W>OK*YLX1]2HE"AXJY.'#,[4(^\-@JRRD[%ME3A(-6W7MC
MI2)".@6$P<L0X[B<,-3":N>45,0BTIJBH>^ !P=I4YXT"-YMHN-B"V[;)7>#
MO@E75N%UPP;#J-^%UCZSBJ'#<,@AKWNC+!%B+?$W&IA8X\:QFDPB4!^E<*4M
MQ:3K&ZR:Q)9I*>C@U5M^E;H@1@G$>W%]9:+WGW5'2_>$;) M!NN]5^\$&0,7
MZG01[-(M>1^GB45=+0FJ,38W>-T<]#)Q@<=&*HT=-S-%[+2#1&B7:31G=I6X
MQ[@]1\(1A K)JF'W%QW#^$%-XLZ)O&5>&\=Q$4_&Q2Z5,_CG<:V/BY39NA*S
M.\3V[@SUM<H+B0@)*PWANTXG9NK3UX58OH%-S"NZD:-/'I50SBNN$FC=<8M
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M&D/I,_>I8R=Y1WG[+XTA])A%6OC.D6!N#WBN*1\T,<W#7O0"%*Y1$PF'5]I
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M]W1MOE(%N8:N3]@&^^OD6<:DJZL98MZLC6FU2AD=M18B^E9!FX?+=9I#32H
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MUQEHSK"(*G61*/B[#\@(JHD@<X='D(B9(@@(B'(0 !'\>OX1G\M7#SYPH/\
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MZ+T _G/*+,WD=>;CY%N@.$7\[RCN0CW@RY 1JH(]J0Y 1\;H,CB/6<@(\/\
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M1,(F$3")A$PB81,(OR<Y$R'44.5--,ICJ*',!"$(0!,8YS&$"E*4H")C"(
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M-@M47&3)DF:P1RYU3.NC)B])%$%-%)7HN)A:-?M85J80<S+UHNRC$G;M,R(
M"<P,AW[[D+@#:^??O9<:.XM>$;GD%[+%I1)TXI6/DB/$G991.6BWDRF9JR9B
MXD2E:QD>]?/17:) U9,WCQ<4VK-TJDL=WLY/3ESY*-(7/( =][\V[ODL@B[]
M3)N:5KT19(J2ETD57'96;DJY5DFY&BCOLCH@"S?*,22# \@BR<+K1Y7S,SU-
M '2 J""-84@@ZCW[E9?D*4PB81,(F$3")A$PB81,(OR<A%"F(<I3D.4Q#D.4
M#%.0P"!BF*("!BF 1 Q1 0$!$!#EA%BOB%1?<74_FY#_ %/")XA47W%U/YN0
M_P!3PB>(5%]Q=3^;D/\ 4\(GB%1?<74_FY#_ %/"*J>P+_)0^YK!IW5_"[1]
MG/JEJNB;4L4K(6^IT $F-_M.SJQ$0T2SDJ9,(2#\BVK9=RLN[E(ED7M[%)15
M$@+."V'RO$ACCBXPM8R1Q,@98/<]H NTW/ULWS&L+156*UD>(RX?0X:VM=3T
M-+6S2/K8Z2S:N:MABCC:^&0/?>AD)+GQM&DT$C,B,ZCQ(-=N$5E='<*]-NE9
M::AU-M]^_M]SJ.N)="-VW"6">B8-*,<TJPQ"DG%MJX^;R+QS9V4*+HR1DI$6
M!A?A;;4NDSBBTF\7'(2Z0,-I&EP%BTBX S-P.6V:PX.$517W?AF&"I@;04%>
M]]171T<@97QRRQQACH98R]C87![G3MCTK6?H>_6163BBT1"T7AEV&QU(VDX#
MB1CJA;TR+5^MQLAK?5UG&E,9'8]N;&:NTSPU/L6S=>0UD38.#I-D;$K+H/UF
M$<<SFIU4P-@>&N(G#7;!H,.B"]V>IKGL#K7^ROJ"O3<):6.EP:K9!,^+&&4]
M0 2UCZ.AF\68^LJ&^^!CIY:VDCF#7$-$QD#RUAODNW-Z:BTG<Y^D7C4$<G+O
M:A%6+22$5"U]\ZWY8G\VSJ3S65*;*1S0K78<5;)NI,W,,]<*M1K]NB[>:01A
MHVTFK\R5#8WECVD$M#HK&_'.)T3&W(>_#BT6OJ<'7L':-ZOQV'#:F6FJ8)!(
M^GCEPT,<USL4F?*V!U%3-(;HU;)Y(&F-Q(,4[*C2$<<_%2#N>ST?26G'6T;)
MJJD.)1JYH$(>KD6K$;'C:]A6^LT2,BCW&6AV<<UBFMCM#0CNQ/V#1LC&(+R;
MAJW3*=-.N27BH^,<,_>#1TA;2>YK -(@"P<[-UK6!-EEXCB'N;AYK9HFEX=2
M1&$3-8WCZNHAI6,\8>UK QLT[=*5S6@,!>6@9"%);B!JL55=>O1T=I]Q<ME-
M;M88"*2VMJX==IT2A.ZS%S%L>;?)"J5X>VV"YU*K0<1'QK]T_L5@9MEUF,:V
ME96.MFH(#/>-+I YP'&MT QA:"XR6T<W/:T  DEVP D:V3'WQPTCO%:=U16"
MIEB8,3IO%!2TKH625#J_1,/OIJF""*-K'.?-*T$M8V21G,6K=,756\7:)'A/
MD(K6Z"&H"WBT6J/J-:G*W+[BDX2(8P=>JBD>_2OCVCR%BB&FP#15A9),7J[B
M*JIK?-LG,80Z=S;.,+@SZWI.<0T@RD !K<],M+@'V<,[AND197)\<F@#)WX7
M51T0;A_C,\\D<,D,F(/CC;%% =,5+J9TT;:OBYFAKR8X/&)&EBG>[/\ 6M-M
M&NZ@- J<A,[ D;"8I!B(1DW@*E3H!S/6VYR:IXQP8T7#G-!01444A4<3]LK[
M555FR7=R#.\Z0-<QNLO+MMK-:V[G'D'O1SN;J%R-G4UK*>>DI]'3DJWS?=!H
MB@IX72SU+S8DLC/%16 N99XFDM:7/;&3/B1X%I R1&.TN'IT9=U#M$@0D*@H
M"@V!<[2(>%$J8@,0]?)JQQ9WGW*E)HK1B[])^BHV+;%33G5-&;VM[X;=1YKY
M7U7R)ODL-O"+ GVT<6H77,8&C41F_&N+8W9'X-SP6<;\&) 8R\/!:LZ]4/A8
M]44NH^_].#LQ22-#)4@"5@;"M,I1 V!Q#(L 0%1:79P75S#^+2Z;^/C'#1\]
M;MVSUHHM7QL6GQ?&-T]6C<:5[7(MO S(U@6)UA9/NKAOC?B'CU-XZ7\6*;C6
M<<9!'QKHPR]S(V*TCV"[F,+7. :YI,6ZYWQI*ZV&U0\[0*518^'2H;BL3DP2
MNKM[VCM+:FZ];ZY3@6@0S1PI(6]IJ%M:HJ.;]N<KL[BR9) J:+<O'-ME0QSG
M ^]L&$$D>^XR26-@;M)=Q>D!_2 &JZPZ3':>HEFCE:*5K!2NADDE:14BNKL1
MHZ,1-T6N+Z@4#9V,&D2VH:T7T'.,I5S8?"Q<+N]UM5I_3D_?8Y>:;NJG%$K+
MR:*M6G)F5C*BT10,=V6OR":L9.*-.O3B)5%:+D#MY!%5L2XV:)SBQLC2\$@M
M!!-VY.Y]$BQMJ.1S6;#BN&U%2ZC@KJ:6J:9 8(Y6.DO"=&:S0??<4\%DI;<1
MR QOL\%HXG?EDKNG8*E.ZYI2H; LE_V76-95^OK*0%0:#*V9O+.4'KZ=<5R<
M(U:-DXA8% +'+'4,H0"B7D(Y$TAC:TM9IN>]K W2T<W7UFQW;E;Q2ODP^*G=
M#3"KFJJR&CBA,XIVZ<P>0YTICE#6M$9O[PDW4)!Q%5ID[G=?3?#%&->()CL.
MJZVK^I8B2HLW%6N5N=#E]F14\SV%W7'L8NIQ-)K-LG+>_F(%G,0:%:=H,H";
M>2E:;SEKQDB[#$1-IMC;&'-(<7,+P0_4&AC7.<2 1HD $EH.M^J"1IDI9<-D
M;BK:N"BBH(ZF&6.>2HI9*UDK:NS&LIXZ:&HDJ'R1-DB$+@V*5SX6R<_ZMM8K
M4=M5IM;AZK="O&EJ]4MD7BOL'M<MM=>:6L4Q)L9;:E*MJ-7AG%ACJ>PK-T>6
M"O258K=@;O*P+#LA6T[7Y61GQ@M$G&1Z#XFM>]H=I Q$D&1C@T$AH:XEI:UP
M+;6L03=]W'PLKFU]$:2IPV&"LJ8F5#:B%V&RR/:^NIJ@11NF93MAJ72PO@AF
M:Z#1T0V6&1]P2T2AG*4Y*;43D.4#$.6O0QBF*8.93%,#,0,4P" @("(" \P'
MEF2N@UZE^O$*B^XNI_-R'^IX1/$*B^XNI_-R'^IX1/$*B^XNI_-R'^IX1<U&
M0T/"I*(0T5&Q*"RG6JHQC%JP255Z($ZU1-JDD0ZG0*4G3, FZ)0+SY  81<E
MA$PB811)/ZUD7T[8I.MWJ7IJ-W:1[>W-(MBP7?.5(MH$42:K<LOT'=;GUH;L
MD0XDP3E$$D&$6Y8,6$FV,^7F^K*]M78=XW:LR;W4$<MKZ_V;COU[-2X='2QS
MNUVDI<)"0IBM_D-CEJ*<4P9BO/.K O:62$E/%.O).XV)L"J$LS0:A&N5'D='
M@Z=KM4W+5U-Q;(9VM?7E:VK8HT>4VO>W+SZ^]UFHZ]@FXT0D89>,8Z_M$C:&
M#,'"[TKES)5.X59PV=.I!=RZ*B"5R=ORFZXQBK-D$2@5 QBA%R;WVBW6.Q38
M9 ;#V]J]"9UI'3%H<6164=(NG3_7TD+0B2!DP'7<E.R+,A3&_G!3?*V!5-T8
M?*B"2(I<C'-S7]O6+);,G?;J[]*P6.T"G .V\Q6KE(1=@9]:BTDG$1'R;=-D
M\923&0;GCE5$4U55 ?(/&;D%B&:/HUJ*J;R/6?QSRHO)R(RY,MW.J0RQN#GR
MY\]]2Y.FZ+B*9<#VEK,*R!"/;/+MD7\/$J3 S-Q<F>3SQ]82H@LJ@=XYDUV3
M6,8PQD"R:[1VXD&#=BU:TDDBWMRRU6';<DYWUJH"V?/G87S._JV=DYB8H"4!
M$ $P]$H"( )C=$3<B@/LCT2F-R#R]$HC[ #D*5_<(F$3")A$PB81,(F$3")A
M$PB81,(F$5,[QPATK;/$C<ML;8K-?N-+D]&ZFUK6XAU+6%!^WG*C>]X62W'E
MXF//'Q+V"E(O8-5;,@>/9,SE=E,-W,:R;D25DL9].V29TDC0YIBC8T7<#=KY
M7.N!8$$/:!<G4;@;>=J< IZ[&*FOKH8JBFDPV@HX8W23![9*>IQ.6H,D;-"-
MT3XZN!K=)SRXMD!8T %\;[)\'MJK<-QW:]NU,H#:!M6K=0:^TO+14$P<6'5#
MC7+"YH"M$P[N(2@6<&P=RM848U@%)*NV".BG,'88@88YV+NA]''(Z4N:P!S(
MV1$ :4>@'#(6L "6V;FT@6(MDL.LX)T.(5.)/J::E$4]#A])ATC(FF6A-&RI
M%XXW1B)L3'20EL/OX96,,4T9CNQW&N.#"\[U/8I#B<M2=67?Z!JO#^PK7#Y<
M9>)J"L(M'R#W:TH[92=4AC(,;I:'D22,K1$G#6)K],K:)W:CL%A)'BSY=(SN
MT?K+80V%S@VUB9#8M&3G$6;G8-&95)X.U.)F9^-3B OPJ#"6PX3421P&(L>Z
MN>YKX(]%M3.Y@CA <(XJ:'WVE>WK3'"OQ(;<AZ;8MO[)JT#MS0E#IP</\Q1Y
M>Q2E;-OR(CX]>Z;HV0S?0M?6E8Z\+1P4 U$[/*MHC7$]?Q2E%YRXHFKXP3R!
MKI7M$D36\26%Q:90 72O%FDAQ&AH9@1N?]T[WM,F!XO7QTTV(5D$5?A5+3^Y
M4E-)-)#[J1L8:G$:QKHX3(RI+/%/%;/$='+5?7#+4#B9SNVD;S-0+ZX-NYKS
ML&<?:[LDYI?<5PF+OP_,I.M3]=L$_%4,CZK.#U"6:K13HU&V"%+?.HF92CY=
MU64P5<-V]UT3BTNR<]V@YT4CB^$%I:7!MVG1(L=!^ADZQ+=BV=3AM3)$ZH:(
MJJKD=232X=B%1)4X4U\,L,TK*72@=XO(TQN\5J_%G.9)HR.@%R&UJ;\&E^B[
MA'[L5U;H*[6EY:^(&2>Z"LEBD&^K*9#;SAM.Q)'%5MBNKIPKNQL'.F@E[><^
MNHIE-.=M;,%@L91!@,[8%,\.$O%PN<72DPN<=!@E;&/>.XMWO@8KN]X >,DM
MLOIQP>JF5#,2-%A53.Z?%7NPN:9XH::/$X\/CTH)S0RWF:<.#ZC_ (.-LAKZ
MW0-PWC>2J_#QQ15*<T/4YZOZBW+ISA\H>I8.D,IO==UU^<VQJO!,F5GVQ9*6
MEHS82-OE:R[*9IIZ"E;TWBZPVC4;&ZZ5R>Q\S5Y;#.TPM+8Y(H6QAMY7,]^U
MH#I',$3](M/P;2X!M@XW?9S:X,)QNGDPRGEBP_$</PJDH(J9LN(U-(3601-;
M-7S4PPRK%0^%PT</B?5-CA#!,[_B',D@L?N:M2@;ZTA=443+0TIK/B&T$Y<"
M18[2$L6V$]5WJJ3$FJDFJ#"+<K:/DZN=ZH3HJ35DK\:GTG4@V16O2M/&QN&H
MQS0WSL#)Q;VD[A>(MOO+1F2%M\1AD]U<-J0"8WT6+84YV>C%-7^(U4$C[ Z+
M''#7P%YR,DT3![Y[0:]ON#'8JVGYJA-'M!0FWO@^-9\*,>Y!]+)Q[:_4U&SA
M)O1<)UL7*-+56EX]1B^1:FE%3(*'7@6QD4>LM>+/XLLNRYHXZ<9FP>T.N?L?
ML;D6.O+4M2[@[5G#Y*5KJ42NX)T>!,=IR!C:JG;.'NN(=(4Y,C"QX;IFQ)B;
M87@>P!M<VUX'1>IX^C3T[3N+/B;WC#SDV7849?:[([ USQ&66'D+[ R&M4JQ
M7M>QU\V?%U&M[-C+_9$[E6'5/C8*N"\6ED(NT>,XP11AI+:B>4$AX<TO9,07
M@QZ(8'R!K9 ]VDW1 :;D#62^/>/Q890-II9:?'<:Q..645;*J)]71XQ-&ZJB
M=1B"&D955K*>&M953"H@-.R*'2=(([#/."BT5?>%$W3K.8@P=:7UKPW:PUO7
MK'.3:4).577_ *LE1VY'VF+;Q$G'1<U(Z]V3$N]=W9@WE;!%VB'>Q3@T;5)R
MS-K#=\5<V5LL9;];C@CC#BZQ:SC6R!P (!+'C0<+D.!!LTNTML[@Y-!B5+B-
M%)%?#:/!Z*CAFDE$4D%(<1@KV3,$;V,E?1UC'4E2T22LGC=&XL@EG;-7_3,Q
ML6)V!J>FU&I52]->$_3W%.R8.F)=F1MWF90RU:C:7";6B)K53 FK[5=7T:DD
MXAH&4VC)7AXVF;M7T%H6*;)R-F,O#XVM:U_B\=0 ;R!Q.36B0.C'%N>1J:9"
M[-S;@9ZK#I*N.KH:>"""J;@5!CC&O;XXRID?>%E-%71R4+!13U+F .CB?6OJ
M7-DJH@8F-T^P3B,T>]XB*II^OS,=$)QE?V_0-B7Z!DYB4: M 049.IS4-%R4
M$AVES*$>2K=-H8J\8V<IH+*&?MPZ!%,R:+CFQM(%A(Q[P2=3;W +=N>6H<H7
M5XOAIQ:"@AE9'Q<5?2U=5$^1[;Q1,DXR-CXA<O#GMT<V-< 27#4<5N'"M#TQ
MAKBQ\,E3H-/O&J=HO]I,X.>6E8NO;+<V*@6#5]OA;M;V4?9K,TD9.GV G<EQ
M6B[2]A).MUQNK%R$$DZC5*70!H8Z%K&OC>7@&X#[L,;@YUG.!+2+.LX@M;D6
MW"QZC XZ=M'-@T%+3U-!6OK6Q2E\<-89J66BJ(JFH:R>9KWT\OUNH+)WQ/AA
M!8^(.C,8;-U_MU_4.)G<.S*_4(_8^S]#-N&K4>IZ'89B\14::R/;3&P:MEN4
MG4Z>K)R]VV!L.)3G#-*LT@:758!LX%]*B,S(Y0]DA;-)(UH?)$(8XVDO TM(
M#2<6MN7/> ZPLUK0;G,K#K:6O?3XSB%9#3MK*W"VX/04%++)4L89G3LB,U2^
M"F+WU-75L$I; V*F@B:[3?:1YO\ UB&\7*U7J]VE1[W#!Q,-VQ4!!5WW6P;L
M>TJ )C""B_4=:<!,80,<?OA]D<MHT6ANNP N=9L+9KJ88^)AAATB[BHHX](Z
MW:# W2.O,VN<USF2KJ81,(F$3")A$PBK38DK?(;(LS&(D)F*>K3VJX]1]"H,
M5GC+5SJ+M+E^Y0-),)%JR*]MR-B9OI!-L#PI6;#HK)G:LCI596&5]>TZ[CV6
M5!O?:,QF!?*Q]M]8RU\WDK<7O1Z-.D9&=?I1[(6C>RM7\_6H5_)(1<X\;NG;
MRN!HJPN7#J5AD&SA8D;>*XE(*+F!AXN]81T0='.WH.[^MOW@^=2 [?E?>-5_
MZN[EZ%#$)5HJ1=(V$NL+-7J8E9ZHA;=:.]<6]9Q+4R!C+^A$V&VDDX55?9MU
M=W2P5VQ6(C#QF>1K"':*K/IUVB]E'=5]FEG8YW&LVN =@M<; 538:[97&5CJ
ML<S?6;G.U[<JYJ*0NM8C*>[F#VBGQ:<C Z_41CF31]<F501J]]OC-M6H]TPF
M5GJA7TE0JO8F\-'RK]FTHDT=0B4;&24BS@V-P,]9SRSN!R#>0=6=DS N;C98
M:[ $\N?6.1*3-[CL%1K=TF+-L)2!ED=:EE30E>@'<J-4E]=1TU.VB"BX>LR+
MZ1EWMX-'Q<J:'2D4HV">V!6!CT'"+=\U>]!M87SUDVO<V&O=OUY7Y9N3M-LM
M0&T9D9;]=M7HR&+M>ZVQ&D;,L;DJ]D9C7CJ*D355OU)*6G<IMM9'EH?,(PD+
M"6!W4&\$ZLL0N9B\:/I%92&C6S5N[%C%AO&0-\]MMG)GES=*[@#>]]8-M0Y=
M@U=8\V,5&R7NQZ_K5AD).WS)GR7#3+P,K;(%I R:FR)^UD2V*T@$FL/"'=55
M:JO6";]ZP1>0H0DC8>[9=\U[U!K-A<C^M>V>6R^>P\VQ!<CHM???.UMENKF*
MO+E"K3")A$PB81,(F$3")A$PB81,(F$3")A$PB81?DYR)D,HH8I"$*8YSG,!
M2$(4!,8QC&$ *4H (F,(@   B(\@PB <AA.4IBF,F8"G*!@$2&$I3@4X /,I
MA(8IP >0B4Q3>P(")%^O8]G"+Q]:EU77=8GU/0ZWKNF7JNKZ/2ZSK.?0Z'1^
M^Z?/H]'R\^7EPB_?2+S O,.D("8 YAS$I1 !$ ]D0 3% 1#R )@Y^R&$7]PB
M_AC%*',Q@* B4H"80 !,<P$(7F/+RF,8"E#V3&$ #F(@&$0#%$PE P"8H )B
M@(=( -SZ(B'L@!NB/(1]GD/+V!PB 8I@YE$#!S,7F @(=(IA*8.8?VE, E,'
ML@8! ?* X1?W")A$PB81,(F$3")A$PB81,(J\WG=L'3MPTJB+*U8G>J42QLK
MN1DVC2RLC7E_)1%";U]B=<CB50>V:#59V!NFDIW:A)PLDH*22@"K4!<$Y\P&
M[,WW6!N#SA4D@. WC7Y\NO9Y]ZP>/XG'B#)H:SUQK&R:-LOQ'[)FHX7"9UW6
M*;M^T1-HK(JJ$%1\L^UF-;FF+DRO=\H1Z<4TV4G .W#1ZP/,21D>FZC2U\A/
MG !SZK+)IW9>UZC'Q+Z8B*;8'-JKDW/PL)66DVB]BY"M1"=LD*HJZ=R[Q.U*
M2M:;3+*)LS9I5D4;$VBR.:\LSEA!D !WY6'3D#TZQ<Y;4TB-V8)&O98Z^:^P
M9KC]F;>AEZY;UBLM>SE92E-=U&H.[XLV)59N]6M!*QOG,HO(*D8>+E:J4M 6
M$7"(IO%5FL^R26(\9HIX#3EKOF3;6 /;K4DY'41D!?42<^BUC[5[4IO%[*5B
M@S.M$*^+6WQ.NW*JTPV<RC6M*;&V+3:) M7#.(E8@KD6J;V\=>U1?MN<A52-
MB+HI"L(M&U[WR)'0"=OFSY4N<K6SM?;:Y WC>>A9/#[;<1L_9:/?&C5>QUPD
MD^[TJK-9&#F(-A5XJSG==WRLF[>0\EU4BM'C$GD9=(YV:3X9))&0(@V@C41M
MU#;?;WRUH#F0;9;>^KKU'DOPZW$!0X^/6?*TVV-J]664RXBY4D/6ACQ?UN@A
M<7D' ,4+$>60DR4UT[(T5&*8PZ@)/HDDL54005DM-[7S.O7M-KGS^?D32!SL
M<N;7:YV[KK]S_$U1JJ9PSLL18X&<8/)UM+5R4=4=K*QJ%>AZG//WO7'NG<LR
M"D3>*R[CXFLR\[9)(9!1LQA%W<=)MV8-)U$=>VXW<B%P&N^W=LMR\HU77(U#
M<\C:M@I4[Q*D&48X4VH#>QGD819LLUUW,4.+:2!&R,LH^[)->.(F.11FD]9K
M]W)@S6;'D7K 6V%[[NL$^S]V5P=<D6U7ZK=JGO*54F$3")A$PB81,(F$3")A
M$PB81,(F$3"+%;O2Z[L2ISM(MC-60K=D8GC9ADB]>1RSEDH<AU$DG\<NUD&1
MS"F7HNF+IL[0$ 4;KHK%(H4BJSM'6[;6TK1W&JX#9 N-G[0CXO8L;K2T,(:;
MF86I:'VL$ ",A:IR$@JXS:S,%57<DJREX$9=['M$W9I19XXC92=8YL^D@;L^
M_,H(W;=W,=5SD>_*N+LVGN(>?J J7.YL]DOW]+J*,Y2&4DO1HUM*1K&NK;(K
M#"/BP9T[9,?LU5A8H5LOL0L"WJ[>=*=H\(R!5)-<7RRY_/8[Q8'9M%T(-CKY
M+9'FOWUKV@UM;@UPTK9]3O5:VANEULI74_:]<&CU*(YO4H^;40K4]M"I&DV3
MI=GLD\0=^6I)F2+#M9U:22*T!MU^?T^;O9,_W^SEO8^@E9%J;3EDJ=MTK:9:
M,=-5JWHS9]#G6RED/(,*F$]=]46&C4R.B"RKF'3-#P<%-0KV9K;$S9Z6N,$7
M\FZ:I5\ ';OOK].[7E:_[PR []5\O-EK7 ;"JO$V]D[\UK\W.A5XF99N: I
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G$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$7__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
